PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	PASRICHA, PJ; RAVICH, WJ; HENDRIX, TR; SOSTRE, S; JONES, B; KALLOO, AN				PASRICHA, PJ; RAVICH, WJ; HENDRIX, TR; SOSTRE, S; JONES, B; KALLOO, AN			TREATMENT OF ACHALASIA WITH INTRASPHINCTERIC INJECTION OF BOTULINUM TOXIN - A PILOT TRIAL	ANNALS OF INTERNAL MEDICINE			English	Note							DILATATION; DISORDERS				PASRICHA, PJ (corresponding author), JOHNS HOPKINS UNIV HOSP, 600 N WOLFE ST, BLALOCK 4, BALTIMORE, MD 21287 USA.		Kalloo, Anthony/AAY-9380-2020					COCCIA G, 1991, GUT, V32, P604, DOI 10.1136/gut.32.6.604; CSENDES A, 1989, GUT, V30, P299, DOI 10.1136/gut.30.3.299; ECKARDT VF, 1992, GASTROENTEROLOGY, V103, P1732, DOI 10.1016/0016-5085(92)91428-7; JANKOVIC J, 1991, NEW ENGL J MED, V324, P1186, DOI 10.1056/nejm199104253241707; PASRICHA PJ, 1993, GASTROENTEROLOGY, V105, P1045, DOI 10.1016/0016-5085(93)90947-B; RICHTER JE, 1991, TXB GASTROENTEROLOGY, P1083; ROBERTSON CS, 1989, GUT, V30, P768, DOI 10.1136/gut.30.6.768; STUART RC, 1989, BRIT J SURG, V76, P1111, DOI 10.1002/bjs.1800761104; VANTRAPPEN G, 1980, GASTROENTEROLOGY, V79, P144; WONG RKH, 1992, ESOPHAGUS, P233	10	128	135	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1994	121	8					590	591		10.7326/0003-4819-121-8-199410150-00006	http://dx.doi.org/10.7326/0003-4819-121-8-199410150-00006			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL486	8085691				2022-12-24	WOS:A1994PL48600006
J	BRITTBERG, M; LINDAHL, A; NILSSON, A; OHLSSON, C; ISAKSSON, O; PETERSON, L				BRITTBERG, M; LINDAHL, A; NILSSON, A; OHLSSON, C; ISAKSSON, O; PETERSON, L			TREATMENT OF DEEP CARTILAGE DEFECTS IN THE KNEE WITH AUTOLOGOUS CHONDROCYTE TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RABBIT ARTICULAR-CARTILAGE; PERICHONDRIAL GRAFTS; PERIOSTEAL GRAFTS; OSTEO-ARTHRITIS; REPAIR; RECONSTRUCTION; SURFACES	Background. Full-thickness defects of articular cartilage in the knee have a poor capacity for repair. They may progress to osteoarthritis and require total knee replacement. We performed autologous chondrocyte transplantation in 23 people with deep cartilage defects in the knee. Methods. The patients ranged in age from 14 to 48 years and had full-thickness cartilage defects that ranged in size from 1.6 to 6.5 cm(2). Healthy chondrocytes obtained from an uninvolved area of the injured knee during arthroscopy were isolated and cultured in the laboratory for 14 to 21 days. The cultured chondrocytes were then injected into the area of the defect. The defect was covered with a sutured periosteal flap taken from the proximal medial tibia. Evaluation included clinical examination according to explicit criteria and arthroscopic examination with a biopsy of the transplantation site. Results. Patients were followed for 16 to 66 months (mean, 39). initially, the transplants eliminated knee locking and reduced pain and swelling in all patients. After three months, arthroscopy showed that the transplants were level with the surrounding tissue and spongy when probed, with visible borders. A second arthroscopic examination showed that in many instances the transplants had the same macroscopic appearance as they had earlier but were firmer when probed and similar in appearance to the surrounding cartilage. Two years after transplantation, 14 of the 16 patients with femoral condylar transplants had good-to-excellent results. Two patients required a second operation because of severe central wear in the transplants, with locking and pain. A mean of 36 months after transplantation, the results were excellent or good in two of the seven patients with patellar transplants, fair in three, and poor in two; two patients required a second operation because of severe chondromalacia. Biopsies showed that 11 of the 15 femoral transplants and 1 of the 7 patellar transplants had the appearance of hyaline cartilage. Conclusions. Cultured autologous chondrocytes can be used to repair deep cartilage defects in the femorotibial articular surface of the knee joint.	GOTHENBURG UNIV, SAHLGRENS UNIV HOSP, DEPT CLIN CHEM, ENDOCRINOL & METAB RES CTR, S-41345 GOTHENBURG, SWEDEN; UNIV GOTHENBURG, SAHLGRENS UNIV HOSP, DEPT ORTHOPED SURG, GOTHENBURG, SWEDEN; GOTHENBURG UNIV, SAHLGRENS HOSP, DEPT INTERNAL MED, S-41345 GOTHENBURG, SWEDEN	Sahlgrenska University Hospital; University of Gothenburg; Sahlgrenska University Hospital; University of Gothenburg; Sahlgrenska University Hospital; University of Gothenburg			Lindahl, Anders/H-9550-2014; Ohlsson, Claes/AGP-3544-2022	Lindahl, Anders/0000-0003-2871-5166; Ohlsson, Claes/0000-0002-9633-2805				AMIEL D, 1985, J BONE JOINT SURG AM, V67A, P911, DOI 10.2106/00004623-198567060-00013; AMSTUTZ HC, 1986, CLIN ORTHOP RELAT R, V213, P92; ASTON JE, 1986, J BONE JOINT SURG BR, V68, P29, DOI 10.1302/0301-620X.68B1.3941138; BENYA PD, 1982, CELL, V30, P215, DOI 10.1016/0092-8674(82)90027-7; BRITTBERG M, 1989, 1989 BAT SHEV SEM ME, V1, P28; BUCHWALTER JA, 1990, ARTICULAR CARTILAGE, P19; CHESTERMAN P J, 1968, Journal of Bone and Joint Surgery British Volume, V50B, P184; COLETTI JM, 1972, J BONE JOINT SURG AM, VA 54, P147, DOI 10.2106/00004623-197254010-00014; DANDY DJ, 1975, J BONE JOINT SURG BR, V57, P346, DOI 10.1302/0301-620X.57B3.346; DAVIS MA, 1989, AM J EPIDEMIOL, V130, P278, DOI 10.1093/oxfordjournals.aje.a115334; ELVES MW, 1974, J BONE JOINT SURG BR, VB 56, P178; ENGKVIST O, 1979, SCAND J PLAST RECONS, V13, P361, DOI 10.3109/02844317909013084; ENGKVIST O, 1979, SCAND J PLAST RECONS, V13, P269, DOI 10.3109/02844317909013069; FICAT RP, 1979, CLIN ORTHOP RELAT R, V144, P74; FURUKAWA T, 1980, J BONE JOINT SURG AM, V62, P79, DOI 10.2106/00004623-198062010-00012; GRANDE DA, 1989, J ORTHOP RES, V7, P208, DOI 10.1002/jor.1100070208; GREEN WT, 1977, CLIN ORTHOP RELAT R, V124, P237; GYLYSMORIN VM, 1987, AM J ROENTGENOL, V148, P1153, DOI 10.2214/ajr.148.6.1153; Hunter W., 1743, PHILOS T R SOC LOND, V42, P514, DOI [DOI 10.1098/RSTL.1742.0079), 10.1098/rstl.1742.0079]; INSALL J, 1974, CLIN ORTHOP RELAT R, P61; Johnson L, 1991, OPERATIVE ARTHROSCOP, P341; JOHNSONNURSE C, 1985, J BONE JOINT SURG BR, V67, P42, DOI 10.1302/0301-620X.67B1.3968141; KAWABE N, 1991, CLIN ORTHOP RELAT R, V268, P279; KLARESKOG L, 1986, ARTHRITIS RHEUM, V29, P730, DOI 10.1002/art.1780290605; LANDON GC, 1985, CLIN ORTHOP RELAT R, V192, P69; LANGER F, 1974, J BONE JOINT SURG AM, VA 56, P297, DOI 10.2106/00004623-197456020-00007; MITCHELL N, 1976, J BONE JOINT SURG AM, V58, P230, DOI 10.2106/00004623-197658020-00012; MUCKLE DS, 1990, J BONE JOINT SURG BR, V72, P60, DOI 10.1302/0301-620X.72B1.2404987; NIEDERMANN B, 1985, ACTA ORTHOP SCAND, V56, P457, DOI 10.3109/17453678508993034; NOYES FR, 1980, J BONE JOINT SURG AM, V62, P687, DOI 10.2106/00004623-198062050-00001; ODRISCOLL SW, 1986, CLIN ORTHOP RELAT R, V208, P131; OUTERBRIDGE RE, 1961, J BONE JOINT SURG BR, V43, P752; PETERSON L, 1984, 30TH T ANN ORTH RES, P218; PRAEMER A, 1992, MUSCULOSKELETAL COND, P125; RADIN EL, 1978, CLIN ORTHOP RELAT R, P288; RADIN EL, 1992, OSTEOARTHRITIS DIAGN, P341; ROTHWELL AG, 1990, ORTHOPEDICS, V13, P433; RUBAK JM, 1982, ACTA ORTHOP SCAND, V53, P175, DOI 10.3109/17453678208992197; WAKITANI S, 1989, J BONE JOINT SURG BR, V71, P74, DOI 10.1302/0301-620X.71B1.2915011; WOJTYS E, 1987, AM J SPORT MED, V15, P455, DOI 10.1177/036354658701500505	40	4005	4278	14	368	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 6	1994	331	14					889	895		10.1056/NEJM199410063311401	http://dx.doi.org/10.1056/NEJM199410063311401			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ419	8078550				2022-12-24	WOS:A1994PJ41900001
J	HASHIMOTO, L; HABITA, C; BERESSI, JP; DELEPINE, M; BESSE, C; CAMBONTHOMSEN, A; DESCHAMPS, I; ROTTER, JI; DJOULAH, S; JAMES, MR; FROGUEL, P; WEISSENBACH, J; LATHROP, GM; JULIER, C				HASHIMOTO, L; HABITA, C; BERESSI, JP; DELEPINE, M; BESSE, C; CAMBONTHOMSEN, A; DESCHAMPS, I; ROTTER, JI; DJOULAH, S; JAMES, MR; FROGUEL, P; WEISSENBACH, J; LATHROP, GM; JULIER, C			GENETIC-MAPPING OF A SUSCEPTIBILITY LOCUS FOR INSULIN-DEPENDENT DIABETES-MELLITUS ON CHROMOSOME 11Q	NATURE			English	Article							BB RAT; REGION; MARKER; RT6	LOCI in the major histocompatibility complex (MHC) on chromosome 6 and the insulin (INS) region on chromosome 11 have been implicated in susceptibility to insulin-dependent diabetes mellitus (IDDM) through candidate gene investigations(1-5), but they may account for less than 50% of genetic risk for the disease(6). Genome-wide linkage studies have led to localization of more than 10 susceptibility loci for insulin-dependent diabetes in the non-obese diabetic (NOD) mouse(7) and the BB rat(8). Similar studies are now possible in humans through the development of dense genetic maps of highly informative microsatellite loci obtained using polymerase chain reaction analysis(9). We have applied microsatellite markers from recent Genethon maps(10,11), and other highly informative markers, in a genome-wide linkage study in IDDM. Here we report evidence for the localization of a previously undetected susceptibility locus for IDDM in the region of the FGF3 gene on chromosome 11q. Our result shows the potential of genome-wide linkage studies to detect susceptibility loci in IDDM and other multifactorial disorders.	HOP ST LOUIS,INSERM,U358,F-75010 PARIS,FRANCE; WELLCOME TRUST CTR HUMAN GENET,OXFORD OX3 7BN,ENGLAND; HOP ST LOUIS,INSERM,U93,F-75010 PARIS,FRANCE; CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE; HOP PURPAN,CTR IMMUNOPATHOL & GENET HUMAINE,CNRS,UPR 8291,F-31300 TOULOUSE,FRANCE; HOP NECKER ENFANTS MALAD,SERV ENDOCRINOL & DIABET ENFANT,F-75015 PARIS,FRANCE; CEDARS SINAI MED CTR,DIV MED GENET,LOS ANGELES,CA 90048; UNIV CALIF LOS ANGELES,SCH MED,LOS ANGELES,CA 90048; GENETHON,F-91002 EVRY,FRANCE; HOP ST LOUIS,SERV ENDOCRINOL,F-75010 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Oxford; Wellcome Centre for Human Genetics; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CHU de Toulouse; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite			JULIER, Cécile/M-9824-2017; FROGUEL, Philippe/O-6799-2017	JULIER, Cécile/0000-0002-1538-0240; FROGUEL, Philippe/0000-0003-2972-0784	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAIN SC, 1992, NAT GENET, V2, P212, DOI 10.1038/ng1192-212; BELL GI, 1984, DIABETES, V33, P176, DOI 10.2337/diabetes.33.2.176; BLACKWELDER W C, 1985, Genetic Epidemiology, V2, P85, DOI 10.1002/gepi.1370020109; GOSH S, 1993, NAT GENET, V4, P404; GREINER DL, 1987, J EXP MED, V166, P461, DOI 10.1084/jem.166.2.461; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HODGE S E, 1984, Genetic Epidemiology, V1, P109, DOI 10.1002/gepi.1370010203; HYER RN, 1991, AM J HUM GENET, V48, P243; JACOB HJ, 1992, NAT GENET, V2, P56, DOI 10.1038/ng0992-56; JAMES M, IN PRESS NATURE GENE; JULIER C, 1991, NATURE, V354, P155, DOI 10.1038/354155a0; KOCH F, 1990, P NATL ACAD SCI USA, V87, P964, DOI 10.1073/pnas.87.3.964; LANG F, 1989, EUR J IMMUNOL, V19, P1785, DOI 10.1002/eji.1830191004; LATHROP GM, 1994, NAT GENET, V6, P327; PROCHAZKA M, 1991, IMMUNOGENETICS, V33, P152, DOI 10.1007/BF00210829; QUACKENBUSH E, 1987, P NATL ACAD SCI USA, V84, P6526, DOI 10.1073/pnas.84.18.6526; RISCH N, 1988, AM J HUM GENET, V40, P1; THOMSON G, 1988, AM J HUM GENET, V43, P799; TODA T, 1994, HUM MOL GENET, V3, P465, DOI 10.1093/hmg/3.3.465; VADHEIM CM, 1992, INT TXB DIABETES MEL, P31; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; 1989, SAGE STATISTICAL ANA	22	384	392	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 8	1994	371	6493					161	164		10.1038/371161a0	http://dx.doi.org/10.1038/371161a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF191	8072544				2022-12-24	WOS:A1994PF19100065
J	HOGE, CW; REICHLER, MR; DOMINGUEZ, EA; BREMER, JC; MASTRO, TD; HENDRICKS, KA; MUSHER, DM; ELLIOTT, JA; FACKLAM, RR; BREIMAN, RF				HOGE, CW; REICHLER, MR; DOMINGUEZ, EA; BREMER, JC; MASTRO, TD; HENDRICKS, KA; MUSHER, DM; ELLIOTT, JA; FACKLAM, RR; BREIMAN, RF			AN EPIDEMIC OF PNEUMOCOCCAL DISEASE IN AN OVERCROWDED, INADEQUATELY VENTILATED JAIL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SICK BUILDING SYNDROME; RESISTANT STREPTOCOCCUS-PNEUMONIAE; POLYSACCHARIDE VACCINE; OUTBREAK; TUBERCULOSIS; TRANSMISSION; CARRIAGE; FAMILIES; SYMPTOMS; EFFICACY	Background. In the United States many correctional facilities now operate at far over capacity, with the potential for living conditions that permit outbreaks of respiratory infections. We investigated an outbreak that was identified in an overcrowded Houston jail after two inmates died of pneumococcal sepsis on the same day. Outbreaks of pneumococcal disease have been rare in the era of antibiotics. Methods. We assessed risk factors for pneumococcal disease in both a case-control and a cohort study. Ventilation was evaluated by measuring carbon dioxide levels and air flow to the living areas of the jail. The extent of asymptomatic infection was determined by culturing pharyngeal specimens from a random sample of inmates. Type-specific immunity was determined with an enzyme immunoassay. Results. Over a four-week period, 46 inmates had either acute pneumonia or invasive pneumococcal disease due to Streptococcus pneumoniae serotype 12F. The jail's capacity had been set at 3500 inmates, but it housed 6700 at the time of the outbreak; the inmates had a median living area of only 34 ft(2) (3.2 m(2)) (interquartile range, 28 to 56 ft(2) [2.6 to 5.2 m(2)]) per person. There were significantly fewer cases of disease among inmates with 80 ft(2) (7.4 m(2)) per person or more (P = 0.030). Carbon dioxide levels ranged from 1100 to 2500 ppm (acceptable, <1000), and the ventilation system delivered a median of only 6.1 ft(3) of outside air per minute per person (interquartile range, 4.4 to 8.5 ft(3); recommended, greater than or equal to 20 ft(3)). The attack rate was highest among inmates in cells with the highest carbon dioxide levels and the lowest volume of outside air delivered by the ventilation system (relative risk, 1.94; 95 percent confidence interval, 1.08 to 3.48). Of underlying medical conditions, intravenous drug use was most strongly associated with disease (odds ratio, 4.50). The epidemic strain (serotype 12F) was cultured from 7 percent of the asymptomatic inmates. Of 11 case patients tested with the enzyme immunoassay, 9 (82 percent) lacked preexisting immunity to this strain. Conclusions. Severe overcrowding, inadequate ventilation, and altered host susceptibility all contributed to this outbreak of pneumococcal disease in a large urban jail.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,RESP DIS BRANCH,ATLANTA,GA; VET AFFAIRS MED CTR,HOUSTON,TX 77030; BAYLOR COLL MED,HOUSTON,TX 77030; HARRIS CTY HLTH DEPT,HOUSTON,TX; TEXAS DEPT HLTH,AUSTIN,TX	Centers for Disease Control & Prevention - USA; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; Texas Department of State Health Services			Dominguez, Edward A./AAL-6119-2020					AUSTRIAN R, 1992, INFECTIOUS DISEASES; BERK SL, 1985, SOUTHERN MED J, V78, P159, DOI 10.1097/00007611-198502000-00010; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; BROOME CV, 1991, NEW ENGL J MED, V325, P1506, DOI 10.1056/NEJM199111213252109; BROOME CV, 1981, REV INFECT DIS, V3, P277; BURGE S, 1987, ANN OCCUP HYG, V31, P493, DOI 10.1093/annhyg/31.4A.493; BUTLER JC, 1993, JAMA-J AM MED ASSOC, V270, P1826, DOI 10.1001/jama.270.15.1826; CHERIAN T, 1994, JAMA-J AM MED ASSOC, V271, P695, DOI 10.1001/jama.271.9.695; Dallal GE, 1988, AM STAT, V42, P272; DEAN AG, 1990, EPIINFO VERSION 5 WO; DOWLING JN, 1971, J INFECT DIS, V124, P9, DOI 10.1093/infdis/124.1.9; ERDMAN DD, 1990, J CLIN MICROBIOL, V28, P2744, DOI 10.1128/JCM.28.12.2744-2749.1990; Facklam RR, 1991, MANUAL CLIN MICROBIO, P238; FINNEGAN MJ, 1984, BRIT MED J, V289, P1573, DOI 10.1136/bmj.289.6458.1573; GLASER JB, 1993, ANN INTERN MED, V118, P139, DOI 10.7326/0003-4819-118-2-199301150-00010; GOULD FK, 1987, J INFECTION, V15, P77, DOI 10.1016/S0163-4453(87)91576-3; Heffron R, 1979, PNEUMONIA SPECIAL RE; HENDLEY JO, 1975, J INFECT DIS, V132, P55, DOI 10.1093/infdis/132.1.55; HODGES RG, 1946, AM J HYG, V44, P183, DOI 10.1093/oxfordjournals.aje.a119088; HUGHES RT, 1986, AM IND HYG ASSOC J, V47, P207, DOI 10.1080/15298668691389630; JORGENSEN JH, 1991, J INFECT DIS, V163, P644, DOI 10.1093/infdis/163.3.644; KING L, 1977, JAMA-J AM MED ASSOC, V237, P791, DOI 10.1001/jama.237.8.791; MACKENZIE GM, 1940, T ASSOC AM PHYSICIAN, V55, P199; MENDELL MJ, 1990, AM J PUBLIC HEALTH, V80, P1193, DOI 10.2105/AJPH.80.10.1193; MENZIES R, 1993, NEW ENGL J MED, V328, P821, DOI 10.1056/NEJM199303253281201; MERCAT A, 1991, CHEST, V99, P147, DOI 10.1378/chest.99.1.147; MOORE EP, 1988, J INFECTION, V16, P199, DOI 10.1016/S0163-4453(88)94147-3; MUSHER DM, 1990, J INFECT DIS, V161, P728, DOI 10.1093/infdis/161.4.728; QUICK RE, 1993, AM J MED, V94, P149, DOI 10.1016/0002-9343(93)90176-P; REICHLER M, 1991, 31ST INT C ANT AG CH, P107; RIEDO F, 1991, 31ST INT C ANT AG CH, P106; SAMET JM, 1988, AM REV RESPIR DIS, V137, P221, DOI 10.1164/ajrccm/137.1.221; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; Smillie WG, 1938, AM J PUBLIC HEALTH N, V28, P293, DOI 10.2105/AJPH.28.3.293; Smillie WG, 1936, AM J HYG, V24, P522, DOI 10.1093/oxfordjournals.aje.a118281; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; STEAD WW, 1978, JAMA-J AM MED ASSOC, V240, P2544, DOI 10.1001/jama.240.23.2544; THOMAS JC, 1991, AM J EPIDEMIOL, V133, P286, DOI 10.1093/oxfordjournals.aje.a115873; 1989, MMWR-MORBID MORTAL W, V38, P635; 1992, ANN INTERN MED, V117, P71; 1981, ASHRAE551981 AM SOC; 1989, MMWR-MORBID MORTAL W, V38, P64; 1989, ASHRAE621989 AM SOC; 1985, MMWR-MORBID MORTAL W, V34, P615; 1988, AM C GOVT IND HYGIEN; 1981, STANDARDIZED DIAGNOS; 1989, MMWR-MORBID MORTAL W, V38, P73; 1992, MMWR-MORBID MORTAL W, V41, P927; 1989, MMWR-MORBID MORTAL W, V38, P733; 1992, MMWR-MORBID MORTAL W, V41, P507; 1989, MMWR-MORBID MORTAL W, V38, P641	51	185	188	0	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 8	1994	331	10					643	648		10.1056/NEJM199409083311004	http://dx.doi.org/10.1056/NEJM199409083311004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE382	8052273				2022-12-24	WOS:A1994PE38200004
J	SOUMERAI, SB; MCLAUGHLIN, TJ; ROSSDEGNAN, D; CASTERIS, CS; BOLLINI, P				SOUMERAI, SB; MCLAUGHLIN, TJ; ROSSDEGNAN, D; CASTERIS, CS; BOLLINI, P			EFFECTS OF LIMITING MEDICAID DRUG-REIMBURSEMENT BENEFITS ON THE USE OF PSYCHOTROPIC AGENTS AND ACUTE MENTAL-HEALTH-SERVICES BY PATIENTS WITH SCHIZOPHRENIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ECONOMIC COSTS; PAYMENT; THERAPY; POLICY; NEED; CARE; ILL	Background. We examined the effects of a three-prescription monthly payment limit (cap) on the use of psychotropic drugs and acute mental health care by noninstitutionalized patients with schizophrenia. We hypothesized that reducing access to such drugs would increase the use of emergency mental health services and the rate of partial hospitalizations (full-day or half-day treatment programs) and psychiatric-hospital admissions. Methods. We linked Medicaid claims data for a period of 42 months with clinical records from two community mental health centers (CMHCs) and the single state psychiatric hospital in New Hampshire, where Medicaid imposed a three-prescription limit on reimbursement for drugs during 11 months (months 15 through 25) of the study. For comparison, we used Medicaid claims for a period of 42 months in New Jersey, which had no limit on drug reimbursement. The study patients (n = 268) and the comparison patients (n = 1959) were permanently disabled, noninstitutionalized patients with schizophrenia, 19 through 60 years of age, who were insured by Medicaid. We conducted interrupted time-series regression analyses to estimate the effects of the cap on the use of medications and mental health services. Results. The cap resulted in immediate reductions (range, 15 to 49 percent) in the use of antipsychotic drugs, antidepressants and lithium, and anxiolytic and hypnotic drugs (P<0.01). It also resulted in coincident increases of one to two visits per patient per month to CMHCs (range of increase, 43 to 57 percent; P<0.001) and sharp increases in the use of emergency mental health services and partial hospitalization (1.2 to 1.4 episodes per patient per month), but no change in the frequency of hospital admissions. After the cap was discontinued, the use of medications and most mental health services reverted to base-line levels (measured in the first 14 months of the study). The estimated average increase in mental health care costs per patient during the cap ($1,530) exceeded the savings in drug costs to Medicaid by a factor of 17. Conclusions. Limits on coverage for the costs of prescription drugs can increase the use of acute mental health services among low-income patients with chronic mental illnesses and increase costs to the government, even aside from the increases caused in pain and suffering on the part of patients.	HARVARD UNIV,SCH MED,DEPT PREVENT & SOCIAL MED,BOSTON,MA; HARVARD COMMUNITY HLTH PLAN,BOSTON,MA; INT ORG MIGRAT,GENEVA,SWITZERLAND	Harvard University; Harvard Medical School; International Organization for Migration	SOUMERAI, SB (corresponding author), HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE,BOSTON,MA, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH044881] Funding Source: NIH RePORTER; NIMH NIH HHS [R01MH44881] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDREWS G, 1985, ARCH GEN PSYCHIAT, V42, P537; BALDESSARINI RJ, 1988, ARCH GEN PSYCHIAT, V45, P79; Cook T.C., 1979, QUASIEXPERIMENTATION; CRANE GE, 1973, SCIENCE, V181, P124, DOI 10.1126/science.181.4095.124; DAVIS JM, 1984, TREATMENT CARE SCHIZ; ELLENBROEK BA, 1993, PHARMACOL THERAPEUT, V57, P1, DOI 10.1016/0163-7258(93)90036-D; ENNA SJ, 1983, NEUROLEPTICS NEUROCH, P1; GILLINGS D, 1981, AM J PUBLIC HEALTH, V71, P38, DOI 10.2105/AJPH.71.1.38; HAAIJERRUSKAMP FM, 1991, DRUGS MONEY PROBLEM; JABLENSKY A, 1988, SCHIZOPHRENIA MAJOR, P19; JOHNSON DAW, 1988, SCHIZOPHRENIA MAJOR, P158; KANE JM, 1993, SCHIZOPHRENIA BULL, V19, P287, DOI 10.1093/schbul/19.2.287; LIEBERMAN AA, 1986, COMMUNITY MENT HLT J, V22, P104, DOI 10.1007/BF00754549; Lohr K N, 1986, Med Care, V24, pS1; LURIE N, 1992, HOSP COMMUNITY PSYCH, V43, P69; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; MCGUIRE TG, 1991, SCHIZOPHRENIA BULL, V17, P375, DOI 10.1093/schbul/17.3.375; MECHANIC D, 1992, HEALTH AFFAIR, V11, P128, DOI 10.1377/hlthaff.11.1.128; Mohr L., 1992, IMPACT ANAL PROGRAM; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; ROSSDEGNAN D, 1993, JAMA-J AM MED ASSOC, V270, P1937, DOI 10.1001/jama.270.16.1937; SCHROEDER SA, 1991, NEW ENGL J MED, V325, P1099, DOI 10.1056/NEJM199110103251510; SHAPIRO S, 1985, MED CARE, V23, P1033, DOI 10.1097/00005650-198509000-00002; SHARFSTEIN SS, 1992, HEALTH AFFAIR, V11, P84, DOI 10.1377/hlthaff.11.3.84; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; SOUMERAI SB, 1993, MILBANK Q, V71, P217, DOI 10.2307/3350399; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P831, DOI 10.1001/jama.263.6.831; SOUMERAI SB, 1987, NEW ENGL J MED, V317, P550, DOI 10.1056/NEJM198708273170906; Torrey EF, 1990, CARE SERIOUSLY MENTA; 1979, SCHIZOPHRENIA INT FO; 1973, INT PILOT STUDY SCHI, V1; 1984, MED CARE S, V22, pS1	32	403	404	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 8	1994	331	10					650	655		10.1056/NEJM199409083311006	http://dx.doi.org/10.1056/NEJM199409083311006			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PE382	8052275	Green Published			2022-12-24	WOS:A1994PE38200006
J	CROWLEY, KS; LIAO, SR; WORRELL, VE; REINHART, GD; JOHNSON, AE				CROWLEY, KS; LIAO, SR; WORRELL, VE; REINHART, GD; JOHNSON, AE			SECRETORY PROTEINS MOVE THROUGH THE ENDOPLASMIC-RETICULUM MEMBRANE VIA AN AQUEOUS, GATED PORE	CELL			English	Article							SIGNAL RECOGNITION PARTICLE; ESCHERICHIA-COLI; LIPID BILAYER; TRANSLOCATION; INSERTION; SEQUENCE; BINDING; ER; FLUORESCENCE; RIBOSOMES	The environment of secretory proteins undergoing translocation across the ER membrane was determined by incorporating fluorescent probes into nascent chains during translation. Dyes were positioned at various locations across the entire bilayer and inside the ribosome, and in each case the probes were in an aqueous milieu, as shown both by their fluorescence lifetimes and by collisional quenching of their fluorescence by iodide ions introduced into the ER lumen. The nascent chain therefore occupies an aqueous pore that spans the entire membrane. Since the pore is sealed off from the cytoplasm, cotranslational translocation is effected topographically. This pore is not open to the lumen after targeting is completed; it opens only after the nascent chain length reaches about 70 residues.			CROWLEY, KS (corresponding author), UNIV OKLAHOMA,DEPT CHEM & BIOCHEM,NORMAN,OK 73019, USA.		Johnson, Arthur E/G-3457-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033216, R01GM026494] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM 33216, R01 GM 26494] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS DW, 1988, J BIOL CHEM, V263, P15791; ANDREWS DW, 1992, J BIOL CHEM, V267, P7761; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; CRANNEY M, 1983, BIOCHIM BIOPHYS ACTA, V735, P418, DOI 10.1016/0005-2736(83)90156-6; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GILMORE R, 1993, CELL, V75, P589, DOI 10.1016/0092-8674(93)90476-7; HIGH S, 1991, J CELL BIOL, V113, P35, DOI 10.1083/jcb.113.1.35; JOHNSON AE, 1976, BIOCHEMISTRY-US, V15, P569, DOI 10.1021/bi00648a018; JOHNSON AE, 1993, TRANSLATIONAL APPARATUS, P359; KENNER RA, 1971, BIOCHEMISTRY-US, V10, P4433, DOI 10.1021/bi00800a013; KILLIAN JA, 1990, BIOCHEMISTRY-US, V29, P8131, DOI 10.1021/bi00487a021; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; LEWIS BA, 1983, J MOL BIOL, V166, P211, DOI 10.1016/S0022-2836(83)80007-2; LIU J, 1993, P NATL ACAD SCI USA, V90, P10653, DOI 10.1073/pnas.90.22.10653; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; MCKNIGHT CJ, 1991, BIOCHEMISTRY-US, V30, P6241, DOI 10.1021/bi00239a023; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; NICCHITTA CV, 1989, J CELL BIOL, V108, P789, DOI 10.1083/jcb.108.3.789; OJCIUS DM, 1991, TRENDS BIOCHEM SCI, V16, P225, DOI 10.1016/0968-0004(91)90090-I; OKUN MM, 1990, J BIOL CHEM, V265, P7478; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SASAVAGE NL, 1982, J BIOL CHEM, V267, P678; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1015, DOI 10.1073/pnas.84.4.1015; THRIFT RN, 1991, J CELL BIOL, V112, P809, DOI 10.1083/jcb.112.5.809; TWETEN RK, 1988, INFECT IMMUN, V56, P3228, DOI 10.1128/IAI.56.12.3228-3234.1988; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WICKNER W, 1979, ANNU REV BIOCHEM, V48, P23, DOI 10.1146/annurev.bi.48.070179.000323; WIEDMANN M, 1989, FEBS LETT, V257, P263, DOI 10.1016/0014-5793(89)81549-2; WIENER MC, 1992, BIOPHYS J, V61, P434, DOI 10.1016/S0006-3495(92)81849-0; WOLIN SL, 1993, J CELL BIOL, V121, P1211, DOI 10.1083/jcb.121.6.1211	42	299	303	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 12	1994	78	3					461	471		10.1016/0092-8674(94)90424-3	http://dx.doi.org/10.1016/0092-8674(94)90424-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PC405	8062388				2022-12-24	WOS:A1994PC40500012
J	KIM, SG; UGURBIL, K; STRICK, PL				KIM, SG; UGURBIL, K; STRICK, PL			ACTIVATION OF A CEREBELLAR OUTPUT NUCLEUS DURING COGNITIVE PROCESSING	SCIENCE			English	Article							MOTOR CORTEX; ARCUATE PREMOTOR; EYE-MOVEMENTS; MENTAL SKILLS; CELL ACTIVITY; BRAIN; DISCHARGE; NEURONS; MONKEY; ORGANIZATION	Magnetic resonance imaging was used to examine the involvement of the dentate nucleus of the cerebellum in cognitive operations. All seven people examined displayed a large bilateral activation in the dentate during their attempts to solve a pegboard puzzle. The area activated was three to four times greater than that activated during simple movements of the pegs. These results provide support for the concept that the computational power of the cerebellum is applied not only to the control of movement but also to cognitive functions.	VET ADM MED CTR, RES SERV 151, SYRACUSE, NY 13210 USA; SUNY HLTH SCI CTR, DEPT PHYSIOL, SYRACUSE, NY 13210 USA; SUNY HLTH SCI CTR, DEPT NEUROSURG, SYRACUSE, NY 13210 USA; UNIV MINNESOTA, SCH MED, DEPT RADIOL, CTR MAGNET RESONANCE RES, MINNEAPOLIS, MN 55455 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Minnesota System; University of Minnesota Twin Cities			Ugurbil, Kamil/AAD-6058-2022		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024328] Funding Source: NIH RePORTER; NCRR NIH HHS [RR08079] Funding Source: Medline; NINDS NIH HHS [NS24328] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKSHOOMOFF NA, 1992, BEHAV NEUROSCI, V106, P731, DOI 10.1037/0735-7044.106.5.731; BANDETTINI PA, 1992, MAGNET RESON MED, V25, P390, DOI 10.1002/mrm.1910250220; BLOEDEL JR, 1992, BEHAV BRAIN SCI, V15, P666; BRACKETOLKMITT R, 1989, BEHAV NEUROSCI, V103, P442, DOI 10.1037/0735-7044.103.2.442; Brooks VB, 1981, HDB PHYSL NERVOUS SY, V2, P877; DAVIS R, 1984, CEREBELLAR STIMULATI; DECETY J, 1990, BRAIN RES, V535, P313, DOI 10.1016/0006-8993(90)91615-N; Dow RS, 1942, BIOL REV CAMB PHILOS, V17, P179, DOI 10.1111/j.1469-185X.1942.tb00437.x; DRAYER B, 1986, AM J ROENTGENOL, V147, P103, DOI 10.2214/ajr.147.1.103; FIEZ JA, 1992, BRAIN, V115, P155, DOI 10.1093/brain/115.1.155; GARDNER EP, 1975, J NEUROPHYSIOL, V38, P627, DOI 10.1152/jn.1975.38.3.627; GILBERT PFC, 1977, BRAIN RES, V128, P309, DOI 10.1016/0006-8993(77)90997-0; Holmes G, 1939, BRAIN, V62, P1, DOI 10.1093/brain/62.1.1; HU XP, 1994, MAGN RESON MED, V31, P495, DOI 10.1002/mrm.1910310505; Ito M, 1984, CEREBELLUM NEURAL CO; Ivry R B, 1989, J Cogn Neurosci, V1, P136, DOI 10.1162/jocn.1989.1.2.136; KIM SG, 1993, J NEUROPHYSIOL, V69, P297, DOI 10.1152/jn.1993.69.1.297; KIM SG, 1993, SCIENCE, V261, P615, DOI 10.1126/science.8342027; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LEINER HC, 1987, ITAL J NEUROL SCI, V8, P425; LEINER HC, 1989, BEHAV NEUROSCI, V103, P998, DOI 10.1037/0735-7044.103.5.998; LEINER HC, 1986, BEHAV NEUROSCI, V100, P443, DOI 10.1037/0735-7044.100.4.443; LEINER HC, 1991, BEHAV BRAIN RES, V44, P113, DOI 10.1016/S0166-4328(05)80016-6; LEINER HC, 1993, TRENDS NEUROSCI, V16, P444, DOI 10.1016/0166-2236(93)90072-T; LYNCH JC, IN PRESS EXP BRAIN R; MCCORMICK DA, 1984, SCIENCE, V223, P296, DOI 10.1126/science.6701513; MILES FA, 1981, ANNU REV NEUROSCI, V4, P273, DOI 10.1146/annurev.ne.04.030181.001421; MUSHIAKE H, 1993, J NEUROPHYSIOL, V70, P2660, DOI 10.1152/jn.1993.70.6.2660; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; ORIOLI PJ, 1989, J COMP NEUROL, V288, P612, DOI 10.1002/cne.902880408; PASSINGHAM RE, 1975, BRAIN BEHAV EVOLUT, V11, P73, DOI 10.1159/000123626; Petersen S E, 1989, J Cogn Neurosci, V1, P153, DOI 10.1162/jocn.1989.1.2.153; PETERSEN SE, 1993, ANNU REV NEUROSCI, V16, P509, DOI 10.1146/annurev.ne.16.030193.002453; RYDING E, 1993, COGNITIVE BRAIN RES, V1, P94, DOI 10.1016/0926-6410(93)90015-W; SCHELL GR, 1984, J NEUROSCI, V4, P539; SCHIEBER MH, 1985, J NEUROPHYSIOL, V54, P1228, DOI 10.1152/jn.1985.54.5.1228; SCHMAHMANN JD, 1991, ARCH NEUROL-CHICAGO, V48, P1178, DOI 10.1001/archneur.1991.00530230086029; STONE LS, 1990, J NEUROPHYSIOL, V63, P1262, DOI 10.1152/jn.1990.63.5.1262; STRICK PL, 1993, INT CONGR SER, V1024, P171; STRICK PL, 1983, J NEUROSCI, V3, P2007; THACH WT, 1993, REV NEUROL, V149, P607; THACH WT, 1975, BRAIN RES, V88, P233, DOI 10.1016/0006-8993(75)90387-X; THACH WT, 1978, J NEUROPHYSIOL, V41, P654, DOI 10.1152/jn.1978.41.3.654; THACH WT, 1970, J NEUROPHYSIOL, V33, P527, DOI 10.1152/jn.1970.33.4.527; THACH WT, 1968, J NEUROPHYSIOL, V31, P785, DOI 10.1152/jn.1968.31.5.785; THOMPSON RF, 1986, SCIENCE, V233, P941, DOI 10.1126/science.3738519; VANKAN PLE, 1993, J NEUROPHYSIOL, V69, P57, DOI 10.1152/jn.1993.69.1.57; WETTS R, 1985, J NEUROPHYSIOL, V54, P231, DOI 10.1152/jn.1985.54.2.231; WIESENDANGER R, 1985, EXP BRAIN RES, V59, P105; WOOTEN GF, 1981, J NEUROSCI, V1, P285; YEO CH, 1985, EXP BRAIN RES, V60, P99, DOI 10.1007/BF00237023	51	409	418	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 12	1994	265	5174					949	951		10.1126/science.8052851	http://dx.doi.org/10.1126/science.8052851			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052851				2022-12-24	WOS:A1994PB49900041
J	WILSON, KP; BLACK, JAF; THOMSON, JA; KIM, EE; GRIFFITH, JP; NAVIA, MA; MURCKO, MA; CHAMBERS, SP; ALDAPE, RA; RAYBUCK, SA; LIVINGSTON, DJ				WILSON, KP; BLACK, JAF; THOMSON, JA; KIM, EE; GRIFFITH, JP; NAVIA, MA; MURCKO, MA; CHAMBERS, SP; ALDAPE, RA; RAYBUCK, SA; LIVINGSTON, DJ			STRUCTURE AND MECHANISM OF INTERLEUKIN-1-BETA CONVERTING-ENZYME	NATURE			English	Article							RECEPTOR ANTAGONIST PROTEIN; COLLAGEN-INDUCED ARTHRITIS; DEATH GENE CED-3; CELL-DEATH; 3-DIMENSIONAL STRUCTURE; MOLECULAR-CLONING; SIDE-CHAIN; PAPAIN; RESOLUTION; IL-1-BETA	Interleukin-1 beta converting enzyme (ICE) processes an inactive precursor to the proinflammatory cytokine, Interleukln-1 beta, and may regulate programmed cell death in neuronal cells. The high-resolution structure of human ICE In complex with an inhibitor has been determined by X-ray diffraction. The structure confirms the relationship between human ICE and cell-death proteins in other organisms. The active site spans both the 10 and 20K subunits, which associate to form a tetramer, suggesting a mechanism for ICE autoactivation.			WILSON, KP (corresponding author), VERTEX PHARMACEUT INC,40 ALLSTON ST,CAMBRIDGE,MA 02139, USA.							BENDER PE, 1989, A REP MED CHEM, V25, P185; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; Blundell T.L., 1976, PROTEIN CRYSTALLOGRA; BREITNER JCS, 1994, NEUROLOGY, V44, P227, DOI 10.1212/WNL.44.2.227; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHAPMAN KT, 1992, BIOORG MED CHEM LETT, V2, P613, DOI 10.1016/S0960-894X(01)81209-9; DINARELLO CA, 1992, IMMUNOL REV, V127, P119, DOI 10.1111/j.1600-065X.1992.tb01411.x; DINARELLO CA, 1993, JAMA-J AM MED ASSOC, V269, P1829, DOI 10.1001/jama.269.14.1829; Drenth J., 1987, BIOL MACROMOL, V3, P312; EKLUND H, 1976, J MOL BIOL, V102, P27, DOI 10.1016/0022-2836(76)90072-3; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GEIGER T, 1993, CLIN EXP RHEUMATOL, V11, P515; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; HAMMERBERG C, 1992, J CLIN INVEST, V90, P571, DOI 10.1172/JCI115896; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; HOLMGREN A, 1975, P NATL ACAD SCI USA, V72, P2305, DOI 10.1073/pnas.72.6.2305; HOWARD AD, 1991, J IMMUNOL, V147, P2964; KAMPHUIS IG, 1985, J MOL BIOL, V182, P317, DOI 10.1016/0022-2836(85)90348-1; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; MANDRUPPOULSEN T, 1993, CYTOKINE, V5, P185, DOI 10.1016/1043-4666(93)90003-N; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MARX J, 1993, SCIENCE, V259, P760, DOI 10.1126/science.8430327; MENARD R, 1991, BIOCHEMISTRY-US, V30, P8924, DOI 10.1021/bi00101a002; MENARD R, 1991, BIOCHEMISTRY-US, V30, P5531, DOI 10.1021/bi00236a028; MILLER DK, 1993, ANN NY ACAD SCI, V696, P133; MILLER S, 1987, NATURE, V328, P834, DOI 10.1038/328834a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NETT MA, 1992, J IMMUNOL, V149, P3254; NETTGIORDALISI MA, 1993, J CELL BIOCH B, V17, P117; NORONHA IL, 1993, KIDNEY INT, V43, P682, DOI 10.1038/ki.1993.98; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; POLGAR L, 1973, EUR J BIOCHEM, V33, P104, DOI 10.1111/j.1432-1033.1973.tb02660.x; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SANDBERG JO, 1993, DIABETES, V42, P1845, DOI 10.2337/diabetes.42.12.1845; SHIVERS BD, 1993, J CELL BIOCH B, V17, P119; SINGER II, 1988, J EXP MED, V167, P389, DOI 10.1084/jem.167.2.389; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WOOLEY PH, 1993, ARTHRITIS RHEUM, V36, P1305, DOI 10.1002/art.1780360915; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; 1979, SUITE PROGRAMS PROTE; 1992, QUANTA VERSION 4 0B	45	734	779	1	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 28	1994	370	6487					270	275		10.1038/370270a0	http://dx.doi.org/10.1038/370270a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ229	8035875				2022-12-24	WOS:A1994NZ22900055
J	TOYOSHIMA, H; HUNTER, T				TOYOSHIMA, H; HUNTER, T			P27, A NOVEL INHIBITOR OF G1 CYCLIN-CDK PROTEIN-KINASE ACTIVITY, IS RELATED TO P21	CELL			English	Article							CELL-CYCLE; RETINOBLASTOMA PROTEIN; TGF-BETA; DEPENDENT KINASES; G(1); PHASE; PHOSPHORYLATION; PROLIFERATION; SUPPRESSION; FIBROBLASTS	Using a yeast interaction screen to search for proteins that interact with cyclin D1-Cdk4, we identified a 27 kDa mouse protein related to the p21 cyclin-Cdk inhibitor. p27 interacts strongly with D-type cyclins and Cdk4 in vitro and more weakly with cyclin E and Cdk2. In mouse fibroblasts, p27 is associated predominantly with cyclin D1-Cdk4. Recombinant p27 is a potent inhibitor of cyclin D1-Cdk4 and cyclin A-Cdk2 protein kinase activity and a weaker inhibitor of cyclin B1-Cdc2. Overexpression of p27 in Saos-2 cells causes G1 arrest. p27 protein levels do not change as serum-stimulated quiescent mouse fibroblasts progress through the cell cycle. p27 is identical to p27(Kip1), a cyclin-Cdk inhibitor present in TGF beta-treated cells. p27 has the hallmarks of a negative regulator of G1 progression and may mediate TGF beta-induced G1 arrest.			TOYOSHIMA, H (corresponding author), SALK INST BIOL STUDIES, MOLEC BIOL & VIROL LAB, 10010 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NCI NIH HHS [CA14195, CA39780] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014195, R35CA039780] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	44	1957	2040	0	61	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 15	1994	78	1					67	74		10.1016/0092-8674(94)90573-8	http://dx.doi.org/10.1016/0092-8674(94)90573-8			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033213				2022-12-24	WOS:A1994NX32800009
J	COTE, J; QUINN, J; WORKMAN, JL; PETERSON, CL				COTE, J; QUINN, J; WORKMAN, JL; PETERSON, CL			STIMULATION OF GAL4 DERIVATIVE BINDING TO NUCLEOSOMAL DNA BY THE YEAST SWI/SNF COMPLEX	SCIENCE			English	Article							TRANSCRIPTION FACTOR ACCESS; XENOPUS-LAEVIS OOCYTES; TUMOR VIRUS PROMOTER; SACCHAROMYCES-CEREVISIAE; ASSEMBLY INVITRO; GLUCOCORTICOID RECEPTOR; HISTONE COMPLEXES; GENES; PROTEINS; ACTIVATORS	The SWI/SNF protein complex is required for the enhancement of transcription by many transcriptional activators in yeast. Here it is shown that the purified SWI/SNF complex is composed of 10 subunits and includes the SWI1, SW12/SNF2, SWI3, SNF5, and SNF6 gene products. The complex exhibited DNA-stimulated adenosine triphosphatase (ATPase) activity, but lacked helicase activity. The SWI/SNF complex caused a 10- to 30-fold stimulation in the binding of GAL4 derivatives to nucleosomal DNA in a reaction that required adenosine triphosphate (ATP) hydrolysis but was activation domain-independent. Stimulation of GAL4 binding by the complex was abolished by a mutant SWI2 subunit, and was increased by the presence of a histone-binding protein, nucleoplasmin. A direct ATP-dependent interaction between the SWI/SNF complex and nucleosomal DNA was detected. These observations suggest that a primary role of the SWI/SNF complex is to promote activator binding to nucleosomal DNA.	UNIV MASSACHUSETTS, MED CTR, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA; PENN STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, University Pk, PA 16802 USA; PENN STATE UNIV, CTR GENE REGULAT, University Pk, PA 16802 USA; UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of Massachusetts System; University of Massachusetts Worcester			Cote, Jacques/I-8901-2014; Quinn, Janet/AAR-9957-2021	Cote, Jacques/0000-0001-6751-555X; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049650, R01GM047867, R37GM049650, R37GM047867] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM049650, GM47867-02, GM49650-01, R37 GM049650] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; CHEN H, 1994, EMBO J, V13, P380, DOI 10.1002/j.1460-2075.1994.tb06272.x; COTE J, 1991, MOL CELL BIOL, V11, P655; CROSTON GE, 1992, GENE DEV, V6, P2270, DOI 10.1101/gad.6.12a.2270; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; FINLEY RL, 1990, MOL CELL BIOL, V10, P5663, DOI 10.1128/MCB.10.11.5663; GINIGER E, 1988, P NATL ACAD SCI USA, V85, P382, DOI 10.1073/pnas.85.2.382; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; JUAN LJ, IN PRESS COLD SPRING; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KLADDE MP, 1994, P NATL ACAD SCI USA, V91, P1361, DOI 10.1073/pnas.91.4.1361; KLEINSCHMIDT JA, 1990, EMBO J, V9, P1309, DOI 10.1002/j.1460-2075.1990.tb08240.x; KLEINSCHMIDT JA, 1985, J BIOL CHEM, V260, P1166; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; KRUGER W, UNPUB; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LI BY, 1994, J BIOL CHEM, V269, P7756; LI Q, 1993, GENE DEV, V7, P2471, DOI 10.1101/gad.7.12a.2471; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; LORCH Y, 1992, GENE DEV, V6, P2282, DOI 10.1101/gad.6.12a.2282; Maxam A M, 1980, Methods Enzymol, V65, P499; MCMURRAY CT, 1986, P NATL ACAD SCI USA, V83, P8472, DOI 10.1073/pnas.83.22.8472; MORSE RH, 1993, SCIENCE, V262, P1563, DOI 10.1126/science.8248805; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; PETERSON C, UNPUB; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; RANDAZZO FM, 1994, DEV BIOL, V161, P229, DOI 10.1006/dbio.1994.1023; RHODES D, 1989, METHOD ENZYMOL, V170, P575; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SEALY L, 1989, METHOD ENZYMOL, V170, P612; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMPSON RT, 1991, PROG NUCLEIC ACID RE, V40, P143; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; TRAVERS AA, 1992, CELL, V69, P573, DOI 10.1016/0092-8674(92)90218-2; TREMETHICK D, 1990, J BIOL CHEM, V265, P5014; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; VETTESEDADEY M, 1994, MOL CELL BIOL, V14, P970, DOI 10.1128/MCB.14.2.970; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; WORKMAN JL, 1993, TRENDS BIOCHEM SCI, V18, P90, DOI 10.1016/0968-0004(93)90160-O; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WORKMAN JL, 1992, SCIENCE, V258, P1780, DOI 10.1126/science.1465613; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	57	728	740	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 1	1994	265	5168					53	60		10.1126/science.8016655	http://dx.doi.org/10.1126/science.8016655			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV301	8016655				2022-12-24	WOS:A1994NV30100024
J	GONCZY, P; THOMAS, BJ; DINARDO, S				GONCZY, P; THOMAS, BJ; DINARDO, S			ROUGHEX IS A DOSE-DEPENDENT REGULATOR OF THE 2ND MEIOTIC DIVISION DURING DROSOPHILA SPERMATOGENESIS	CELL			English	Article							MATURATION-PROMOTING FACTOR; CDC2 PROTEIN-KINASE; CELL-CYCLE; M-PHASE; FISSION YEAST; TYROSINE PHOSPHORYLATION; ACTIVATES P34CDC2; STERILE MUTATIONS; GENETIC-ANALYSIS; MITOTIC CONTROL	During spermatogenesis, germ cells execute two meiotic divisions, then withdraw from the cell cycle and initiate postmeiotic differentiation. We show that the gene roughex (rux) is a dose-dependent regulator of meiosis II during Drosophila spermatogenesis. rux mutant germ cells execute the two meiotic divisions, but then undergo an additional M phase resembling an extra meiosis II. Conversely, germ cells with excess rux function fail to undergo meiosis II. rux does not appear to act directly at meiosis II. Rather, rux appears to act through cyclin A during premeiotic G2 to regulate meiosis II. We propose that cyclin A-cdc2 kinase at the G2 to M transition of meiosis I activates a target necessary for meiosis II, thereby coupling the two meiotic divisions.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	GONCZY, P (corresponding author), ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021, USA.			Gonczy, Pierre/0000-0002-6305-6883; DiNardo, Stephen/0000-0003-4131-5511				ALPHEY L, 1992, CELL, V69, P977, DOI 10.1016/0092-8674(92)90616-K; ASHBURNER M, 1989, DROSOPHILA LABORATOR; Bellve A.R., 1979, Oxford Reviews of Reproductive Biology, V1, P159; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BONACCORSI S, 1988, GENETICS, V120, P1015; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CASTRILLON DH, 1993, GENETICS, V135, P489; Cooper KW, 1950, BIOL DROSOPHILA, P1; COURTOT C, 1992, DEVELOPMENT, V116, P405; DOREE M, 1983, DEV BIOL, V99, P489, DOI 10.1016/0012-1606(83)90298-1; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FERELL JE, 1991, MOL CELL BIOL, V11, P1965; FRITZNIGGLI H, 1972, CYTOBIOLOGIE, V5, P12; FULLER MT, 1993, DEV DROSOPHILA MELAN, V1, P71; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOLDSTEIN LSB, 1980, CHROMOSOMA, V78, P79, DOI 10.1007/BF00291909; GONCZY P, 1992, DEVELOPMENT, V114, P89; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HACKSTEIN JHP, 1991, EUR J CELL BIOL, V56, P151; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HUNT T, 1993, CELL CYCLE, P167; KEMPHUES KJ, 1982, CELL, V31, P655, DOI 10.1016/0092-8674(82)90321-X; Kimble J, 1988, NEMATODE CAENORHABDI, P191; KNOBLICH JA, 1993, EMBO J, V12, P65, DOI 10.1002/j.1460-2075.1993.tb05632.x; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LETWIN K, 1992, EMBO J, V11, P3521, DOI 10.1002/j.1460-2075.1992.tb05435.x; LIFSCHYTZ E, 1977, DEV BIOL, V58, P276, DOI 10.1016/0012-1606(77)90092-6; LIFSCHYTZ E, 1977, CHROMOSOMA, V64, P371, DOI 10.1007/BF00294944; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NURSE P, 1980, GENETICS, V96, P627; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; RONCHI E, 1993, CELL, V74, P347, DOI 10.1016/0092-8674(93)90425-P; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SCHUPBACH T, 1991, GENETICS, V129, P1119; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; STERN B, 1993, DEVELOPMENT, V117, P219; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; Tates AD, 1971, THESIS RIJKSUNIVERSI; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5; WHITECOOPER H, 1993, J CELL SCI, V106, P1035; WHITFIELD WGF, 1989, NATURE, V338, P337, DOI 10.1038/338337a0; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	75	49	50	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					1015	1025		10.1016/0092-8674(94)90441-3	http://dx.doi.org/10.1016/0092-8674(94)90441-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	8020092				2022-12-24	WOS:A1994NV42500010
J	WEYAND, CM; HICOK, KC; HUNDER, GG; GORONZY, JJ				WEYAND, CM; HICOK, KC; HUNDER, GG; GORONZY, JJ			TISSUE CYTOKINE PATTERNS IN PATIENTS WITH POLYMYALGIA-RHEUMATICA AND GIANT-CELL ARTERITIS	ANNALS OF INTERNAL MEDICINE			English	Article						CYTOKINES; TEMPORAL ARTERITIS; POLYMYALGIA RHEUMATICA; VASCULITIS; INFLAMMATION	TEMPORAL ARTERITIS; RESPONSES; DISEASE; INTERLEUKIN-2; LYMPHOCYTES; MACROPHAGES; VASCULITIS; MECHANISMS; INDUCTION; IMMUNE	Objective: To analyze temporal artery specimens from patients with giant cell arteritis and polymyalgia rheumatica for the presence of inflammatory cytokines and to ascertain whether a specific cytokine pattern exists for the two conditions. Design: Case series of patients having temporal artery biopsy procedures. Setting: The outpatient clinic and the research laboratories of the Division of Rheumatology, Mayo Clinic. Patients: 34 patients having temporal artery biopsy procedures: 15 patients had giant cell arteritis, 9 had polymyalgia rheumatica without evidence of vasculitis, and 10 had neither polymyalgia rheumatica nor vasculitis. Measurement: Temporal artery specimens were analyzed for in vivo presence of cytokine messenger RNA (mRNA) by polymerase chain reaction with cytokine-specific primer sets. Results: Vasculitic lesions in giant cell arteritis samples were characterized by in situ production of interleukin-1 beta, interleukin-6, and transforming growth factor-beta 1 mRNA (indicative of macrophage activation) and by interferon-gamma and interleukin-2 mRNA (indicative of selective T-cell activation). However, macrophage- and T-cell-derived cytokines were also detected in temporal artery biopsy specimens from patients with polymyalgia rheumatica. Tissue-infiltrating T cells in giant cell arteritis and polymyalgia rheumatica samples each had distinctive lymphokine profiles. Although interferon-gamma was found in 67% of giant cell arteritis samples, polymyalgia rheumatica samples had only interleukin-2. Conclusions: Patients with polymyalgia rheumatica have vascular involvement. Patients with polymyalgia rheumatica and giant cell arteritis share in situ production of mRNA specific for macrophage-derived cytokines. T cells recruited to vasculitic lesions in patients with giant cell arteritis predominantly produce interleukin-2 and interferon-gamma. Patients with polymyalgia rheumatica do not have interferon-gamma production, suggesting that interferon-gamma may be involved in the progression to overt arteritis.			WEYAND, CM (corresponding author), MAYO CLIN & MAYO FDN, 401 GUGGENHEIM BLDG, 200 1ST ST SW, ROCHESTER, MN 55905 USA.		Weyand, Cornelia/AAH-3343-2021	Goronzy, Jorg/0000-0001-7670-1856				ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BANKS PM, 1983, ARTHRITIS RHEUM, V26, P1201, DOI 10.1002/art.1780261005; BETZ M, 1991, J IMMUNOL, V146, P108; Boros D.L., 1980, BASIC CLIN ASPECTS G, P1; CALAMIA K, 1920, CLIN RHEUM DIS, V6, P389; CHENSUE SW, 1989, J IMMUNOL, V142, P1281; CHUANG TY, 1982, ANN INTERN MED, V97, P672, DOI 10.7326/0003-4819-97-5-672; Dinarello C A, 1992, Semin Immunol, V4, P133; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; FAUCI AS, 1978, ANN INTERN MED, V89, P660, DOI 10.7326/0003-4819-89-5-660; GOLD KN, 1994, ARTHRITIS RHEUM, V37, P925, DOI 10.1002/art.1780370623; HUNDER GG, 1985, CLIN RHEUM DIS, V11, P471; HUNDER GG, 1993, ARTHRITIS RHEUM-US, V36, P757, DOI 10.1002/art.1780360604; HUSTON KA, 1978, ANN INTERN MED, V88, P162, DOI 10.7326/0003-4819-88-2-162; LIE JT, 1990, ARTHRITIS RHEUM-US, V33, P1074; MATHEW RC, 1986, INFECT IMMUN, V54, P820, DOI 10.1128/IAI.54.3.820-826.1986; MCINNES A, 1988, J EXP MED, V167, P598, DOI 10.1084/jem.167.2.598; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MOST J, 1990, EUR J IMMUNOL, V20, P1661, DOI 10.1002/eji.1830200807; NOVAK TJ, 1990, P NATL ACAD SCI USA, V87, P9353, DOI 10.1073/pnas.87.23.9353; POSTLETHWAITE AE, 1982, J EXP MED, V155, P168, DOI 10.1084/jem.155.1.168; ROCHE NE, 1993, ARTHRITIS RHEUM, V36, P1286, DOI 10.1002/art.1780360913; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; SHAW J, 1988, J IMMUNOL, V140, P2243; WAGNER AD, 1994, IN PRESS J CLIN INVE; WAHL SM, 1992, J CLIN IMMUNOL, V12, P61, DOI 10.1007/BF00918135; WEYAND CM, 1992, J CLIN INVEST, V90, P2355, DOI 10.1172/JCI116125; WEYAND CM, 1994, ARTHRITIS RHEUM, V37, P514, DOI 10.1002/art.1780370411; WEYAND CM, 1994, J EXP MED, V179, P951, DOI 10.1084/jem.179.3.951; YAMAMURA M, 1991, SCIENCE, V254, P277, DOI 10.1126/science.1925582; YOKOTA T, 1990, PEPTIDE GROWTH FACTO, P576	31	314	327	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1994	121	7					484	491		10.7326/0003-4819-121-7-199410010-00003	http://dx.doi.org/10.7326/0003-4819-121-7-199410010-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ102	8067646				2022-12-24	WOS:A1994PJ10200003
J	HELD, PJ; KAHAN, BD; HUNSICKER, LG; LISKA, D; WOLFE, RA; PORT, FK; GAYLIN, DS; GARCIA, JR; AGODOA, LYC; KRAKAUER, H				HELD, PJ; KAHAN, BD; HUNSICKER, LG; LISKA, D; WOLFE, RA; PORT, FK; GAYLIN, DS; GARCIA, JR; AGODOA, LYC; KRAKAUER, H			THE IMPACT OF HLA MISMATCHES ON THE SURVIVAL OF FIRST CADAVERIC KIDNEY-TRANSPLANTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RENAL-TRANSPLANTATION; GRAFT-SURVIVAL; CYCLOSPORINE; RECIPIENTS; EXPERIENCE; THERAPY	Background. The benefits of HLA-A, B, and DR matching of cadaveric kidney grafts and recipients remain controversial when viewed from the perspective of social equity and graft survival. Methods. We estimated graft survival using proportional-hazards techniques, adjusting for patient and donor characteristics, for a series of 30,564 Medicare patients receiving a first cadaveric kidney transplant between 1984 and 1990. The effects of minimal achievable HLA mismatches and maximal matching on graft survival were estimated by simulated allocation of a sample of organs to a sample of 20,000 candidates for transplantation. Results. The adjusted one-year graft survival was 84.3 percent for grafts with no mismatches and 77.0 percent for grafts with four mismatches. National rationing of donor organs to achieve minimal mismatching and maximal matching could potentially decrease the average number of HLA mismatches from 3.6 to 1.2, with a corresponding increase in the number of matches, As a consequence, projected five-year graft survival could potentially increase from 58.5 percent to 62.9 percent. This would be associated with a decrease in the proportion of kidneys allocated to black recipients from 22.2 to 15.0 percent. Conclusions, Under ideal circumstances, a policy of maximal matching of cadaveric renal transplants would increase five-year graft survival by a comparatively small 4.4 percentage points, but the actual benefit is likely to be smaller.	UNIV MICHIGAN,SCH PUBL HLTH,DEPT HLTH SERV MANAGEMENT & POLICY,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH PUBL HLTH,DEPT EPIDEMIOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH PUBL HLTH,DEPT BIOSTAT,ANN ARBOR,MI 48109; UNIV TEXAS,SCH MED,DIV IMMUNOL & ORGAN TRANSPLANTAT,HOUSTON,TX 77030; UNIV IOWA HOSP & CLIN,DEPT INTERNAL MED,IOWA CITY,IA 52242; URBAN INST,CTR HLTH POLICY,WASHINGTON,DC 20037; NIDDKD,BETHESDA,MD 20892; PRINCETON UNIV,WOODROW WILSON SCH,PRINCETON,NJ 08544; UNIFORMED SERV UNIV HLTH SCI,SCH MED,DEPT PREVENT MED,BETHESDA,MD 20814; UNIFORMED SERV UNIV HLTH SCI,SCH MED,DIV BIOMETR,BETHESDA,MD 20814	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Texas System; University of Iowa; Urban Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Princeton University; Uniformed Services University of the Health Sciences - USA; Uniformed Services University of the Health Sciences - USA	HELD, PJ (corresponding author), UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,315 W HURON ST,SUITE 240,ANN ARBOR,MI 48103, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [N01DK082234] Funding Source: NIH RePORTER; NIDDK NIH HHS [N01-DK-8-2234] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER JW, 1987, TRANSPLANT P, V19, P672; BAILEY RC, 1977, TRANSPLANTATION, V24, P309, DOI 10.1097/00007890-197711000-00001; BARGER B, 1992, TRANSPLANTATION, V53, P770, DOI 10.1097/00007890-199204000-00013; BRYNGER H, 1988, TRANSPLANT P, V20, P261; CARPENTER CB, 1989, TRANSPLANT P, V21, P663; Cicciarelli J, 1991, Clin Transpl, P325; COX DR, 1972, J R STAT SOC B, V34, P187; ELLISON MD, 1992, AM J KIDNEY DIS, V20, pA3; FESTENSTEIN H, 1986, NEW ENGL J MED, V314, P7, DOI 10.1056/NEJM198601023140102; GAYLIN DS, 1993, JAMA-J AM MED ASSOC, V269, P603, DOI 10.1001/jama.269.5.603; Gjertson D W, 1991, Clin Transpl, P225; HUI SL, 1983, J AM STAT ASSOC, V78, P753, DOI 10.2307/2288179; KAHAN BD, 1985, SURGERY, V97, P125; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; OPELZ G, 1988, LANCET, V2, P61; PERSIJN GG, 1989, TRANSPLANT P, V21, P656; PORT FK, 1991, AM J KIDNEY DIS, V17, P519, DOI 10.1016/S0272-6386(12)80492-6; SANFILIPPO F, 1984, NEW ENGL J MED, V311, P358, DOI 10.1056/NEJM198408093110603; TERASAKI PI, 1991, KIDNEY INT, V39, P557, DOI 10.1038/ki.1991.64; 1993, NIH1993 NAT I DIAB D; 1983, E ENGL J MED, V309, P809; 1992, NIH923176 NAT I DIAB; 1991, SAS USERS GUIDE STAT	24	174	176	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 22	1994	331	12					765	770		10.1056/NEJM199409223311203	http://dx.doi.org/10.1056/NEJM199409223311203			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG301	8065404				2022-12-24	WOS:A1994PG30100003
J	WIBLE, BA; TAGLIALATELA, M; FICKER, E; BROWN, AM				WIBLE, BA; TAGLIALATELA, M; FICKER, E; BROWN, AM			GATING OF INWARDLY RECTIFYING K+ CHANNELS LOCALIZED TO A SINGLE NEGATIVELY CHARGED RESIDUE	NATURE			English	Article							POTASSIUM CHANNEL; FUNCTIONAL EXPRESSION; ION CHANNELS; RECTIFICATION; CONDUCTANCE; DEPENDENCE; BLOCKING; MG-2+; CELLS	INWARDLY rectifying K+ channels (IRKs) conduct current preferentially in the inward direction. This inward rectification has two components: voltage-dependent blockade by intracellular Mg2+ (Mg-i(2+))(1-7) and intrinsic gating(8,9). Two members of this channel family, IRK1 (ref. 10) and ROMK1 (ref. 11), differ markedly in affinity for Mg-i(2+) (ref. 12). We found that IRK1 and ROMK1 differ in voltage-dependent gating and searched for the gating structure by large-scale and site-directed mutagenesis. We found that a single amino-acid change within the putative transmembrane domain M2, aspartate (D) in IRK1 to the corresponding asparagine (N) in ROMK1, controls the gating phenotype. Mutation D172N in IRK1 produced ROMK1-like gating whereas the reverse mutation in ROMK1-N171D-produced IRK1-like gating. Thus, a single negatively charged residue seems to be a crucial determinant of gating.	BAYLOR COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030; UNIV NAPLES FEDERICO II,SCH MED 2,DEPT HUMAN COMMUN SCI,PHARMACOL SECT,I-80121 NAPLES,ITALY	Baylor College of Medicine; University of Naples Federico II			Taglialatela, Maurizio/K-1840-2013; Taglialatela, Maurizio/AAB-8621-2022; Taglialatela, Maurizio/ABH-4262-2020; Taglialatela, Maurizio/A-2062-2019	Taglialatela, Maurizio/0000-0002-8202-0560; Taglialatela, Maurizio/0000-0002-8202-0560; 				ALDRICH R, 1993, NATURE, V362, P107, DOI 10.1038/362107a0; ANUMONWO JMB, 1991, CARDIOVASC DRUG REV, V9, P299, DOI 10.1111/j.1527-3466.1991.tb00418.x; CATTERALL WA, 1993, TRENDS NEUROSCI, V16, P500, DOI 10.1016/0166-2236(93)90193-P; CIANI S, 1980, BIOPHYS J, V30, P199, DOI 10.1016/S0006-3495(80)85089-2; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; HILGEMANN DW, 1989, PFLUG ARCH EUR J PHY, V415, P247, DOI 10.1007/BF00370601; HILLE B, 1992, IONIC CHANNELS EXCIT, V2, P83; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ISHIHARA K, 1989, J PHYSIOL-LONDON, V419, P297, DOI 10.1113/jphysiol.1989.sp017874; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; KIRSCH GE, 1992, BIOPHYS J, V62, P136, DOI 10.1016/S0006-3495(92)81800-3; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KUGLER JL, 1994, BIOPHYS J, V66, pA427; LEECH CA, 1981, J PHYSIOL-LONDON, V319, P295, DOI 10.1113/jphysiol.1981.sp013909; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MATSUDA H, 1991, MG2PLUS EXCITABLE ME, V53, P289; PENNEFATHER P, 1992, BIOPHYS J, V61, P448, DOI 10.1016/S0006-3495(92)81850-7; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; SHIMONI Y, 1992, J PHYSIOL-LONDON, V448, P709, DOI 10.1113/jphysiol.1992.sp019066; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; STANFIELD PR, 1994, J PHYSIOL-LONDON, V475, P1; TAGLIALATELA M, 1994, SCIENCE, V264, P844, DOI 10.1126/science.8171340; TAGLIALATELA M, 1993, PFLUG ARCH EUR J PHY, V423, P104, DOI 10.1007/BF00374967; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687	27	216	218	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 15	1994	371	6494					246	249		10.1038/371246a0	http://dx.doi.org/10.1038/371246a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG290	8078584				2022-12-24	WOS:A1994PG29000052
J	FEHLING, HJ; SWAT, W; LAPLACE, C; KUHN, R; RAJEWSKY, K; MULLER, U; VONBOEHMER, H				FEHLING, HJ; SWAT, W; LAPLACE, C; KUHN, R; RAJEWSKY, K; MULLER, U; VONBOEHMER, H			MHC CLASS-I EXPRESSION IN MICE LACKING THE PROTEASOME SUBUNIT LMP-7	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; ANTIGEN PRESENTATION; VIRAL PEPTIDES; MOLECULES; GENE; REGION; CELLS	Proteasomes degrade endogenous proteins. Two subunits, LMP-2 and LMP-7, are encoded in a region of the major histocompatibility complex (MHC) that is critical for class I-restricted antigen presentation. Mice with a targeted deletion of the gene encoding LMP-7 have reduced levels of MHC class I cell-surface expression and present the endogenous antigen HY inefficiently; addition of peptides to splenocytes deficient in LMP-7 restores wild-type class I expression levels. This demonstrates the involvement of LMP-7 in the MHC class I presentation pathway and suggests that LMP-7 functions as an integral part of the peptide supply machinery.	UNIV COLOGNE,INST GENET,D-50931 COLOGNE,GERMANY	University of Cologne	FEHLING, HJ (corresponding author), BASEL INST IMMUNOL,GRENZACHERSTR 487,CH-4058 BASEL,SWITZERLAND.		Kühn, Ralf/U-1278-2017	Kühn, Ralf/0000-0003-1694-9803; Rajewsky, Klaus/0000-0002-6633-6370; Fehling, Hans Joerg/0000-0002-4580-1990				ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; DRISCOLL J, 1993, IMMUNOL TODAY, V365, P262; GACZYNSKA M, 1993, IMMUNOL TODAY, V365, P264; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; Kaer LV, 1992, CELL, V71, P1205; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; MONACO JJ, 1986, HUM IMMUNOL, V15, P416, DOI 10.1016/0198-8859(86)90019-4; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; VANBLEEK GM, 1990, NATURE, V348, P213; YANG Y, 1992, J BIOL CHEM, V267, P11669; ZANELLI E, 1993, IMMUNOGENETICS, V38, P400, DOI 10.1007/BF00184520	25	460	471	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 26	1994	265	5176					1234	1237		10.1126/science.8066463	http://dx.doi.org/10.1126/science.8066463			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD422	8066463				2022-12-24	WOS:A1994PD42200038
J	SCHACHTMAN, DP; SCHROEDER, JI				SCHACHTMAN, DP; SCHROEDER, JI			STRUCTURE AND TRANSPORT MECHANISM OF A HIGH-AFFINITY POTASSIUM UPTAKE TRANSPORTER FROM HIGHER-PLANTS	NATURE			English	Article							ARABIDOPSIS-THALIANA; SALT TOLERANCE; BARLEY ROOTS; K+ CHANNELS; EXPRESSION; MEMBRANE; CDNA	POTASSIUM is the most abundant cation in higher plants and is crucial for plant nutrition, growth, tropisms, enzyme homeostasis and osmoregulation(1-4). K+ accumulation can be rate-limiting for agricultural production(2-4). K+ uptake from soils into roots is largely mediated by high-affinity K+ uptake (K-m approximate to 10-40 mu M) (refs 1, 2, 5-7). But although K+ channels allow low-affinity K+ uptake(8-10), both the transport mechanism and structure of the high-affinity K+ nutrition pathway remain unknown. Here we use expression cloning to isolate a complementary DNA encoding a membrane protein (HKT1) from wheat roots which confers the ability to take up K+. The substrate affinity, saturation and cation selectivity of HKT1 correspond to hallmark properties of classical high-affinity K+ uptake in plants(1,2,11). The transport mechanism of HKT1 uses K+-H+ co-uptake. Expression of HKT1 is localized to specific root and leaf regions which represent primary sites for K+ uptake in plants(2,3). HKT1 is important for plant nutrition and could possibly contribute to environmental alkali metal toxicities(11-13).	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego				Schachtman, Daniel/0000-0003-1807-4369; Schroeder, Julian/0000-0002-3283-5972				ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; DREW MC, 1984, PLANTA, V160, P490, DOI 10.1007/BF00411136; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; EPSTEIN E, 1963, P NATL ACAD SCI USA, V49, P684, DOI 10.1073/pnas.49.5.684; EPSTEIN E, 1966, NATURE, V212, P1324, DOI 10.1038/2121324a0; FERNANDO M, 1992, PLANT PHYSIOL, V100, P1269, DOI 10.1104/pp.100.3.1269; FROMMER WB, 1993, P NATL ACAD SCI USA, V90, P5944, DOI 10.1073/pnas.90.13.5944; GASSMANN W, IN PRESS PLANT PHYSL; GREENWAY H, 1980, ANNU REV PLANT PHYS, V31, P149, DOI 10.1146/annurev.pp.31.060180.001053; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; KO CH, 1991, MOL CELL BIOL, V11, P4266, DOI 10.1128/MCB.11.8.4266; KOCHIAN LV, 1988, ADV BOT RES, V15, P93; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LESTER HA, 1994, ANNU REV PHARMACOL, V34, P219; MAATHUIS FJM, 1993, PLANTA, V191, P302, DOI 10.1007/BF00195686; MAATHUIS FJM, IN PRESS P NATN ACAD; NEWMAN IA, 1987, PLANT PHYSIOL, V84, P1177, DOI 10.1104/pp.84.4.1177; POOLE RJ, 1978, ANNU REV PLANT PHYS, V29, P437, DOI 10.1146/annurev.pp.29.060178.002253; RAINS DW, 1967, PLANT PHYSIOL, V42, P314, DOI 10.1104/pp.42.3.314; RAINS DW, 1965, SCIENCE, V148, P1611, DOI 10.1126/science.148.3677.1611; RODRIGUEZNAVARRO A, 1986, J GEN PHYSIOL, V87, P649, DOI 10.1085/jgp.87.5.649; SCHACHTMAN DP, 1991, CROP SCI, V31, P992, DOI 10.2135/cropsci1991.0011183X003100040030x; SCHACHTMAN DP, 1992, SCIENCE, V258, P1654, DOI 10.1126/science.8966547; SCHROEDER JI, 1991, P NATL ACAD SCI USA, V88, P11583, DOI 10.1073/pnas.88.24.11583; SCHROEDER JI, 1994, ANNU REV BIOPH BIOM, V23, P441, DOI 10.1146/annurev.bb.23.060194.002301; SCHROEDER JI, 1987, P NATL ACAD SCI USA, V84, P4108, DOI 10.1073/pnas.84.12.4108; SHEAHAN JJ, 1993, PLANT J, V3, P647, DOI 10.1111/j.1365-313X.1993.00647.x; SPANSWICK RM, 1981, ANNU REV PLANT PHYS, V32, P267, DOI 10.1146/annurev.pp.32.060181.001411; WELCH RM, 1968, P NATL ACAD SCI USA, V61, P447, DOI 10.1073/pnas.61.2.447	30	460	528	4	115	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 25	1994	370	6491					655	658		10.1038/370655a0	http://dx.doi.org/10.1038/370655a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD310	8065452				2022-12-24	WOS:A1994PD31000052
J	NAKANO, T; KODAMA, H; HONJO, T				NAKANO, T; KODAMA, H; HONJO, T			GENERATION OF LYMPHOHEMATOPOIETIC CELLS FROM EMBRYONIC STEM-CELLS IN CULTURE	SCIENCE			English	Article							IMMUNOGLOBULIN HEAVY-CHAIN; COLONY-STIMULATING FACTOR; HEMATOPOIETIC DEVELOPMENT; YOLK-SAC; INVITRO; DIFFERENTIATION; GENE; INTERLEUKIN-7; EXPRESSION; INVIVO	An efficient system was developed that induced the differentiation of embryonic stem (ES) cells into blood cells of erythroid, myeloid, and B cell lineages by coculture with the stromal cell line OP9. This cell line does not express functional macrophage colony-stimulating factor (M-CSF). The presence of M-CSF had inhibitory effects on the differentiation of ES cells to blood cells other than macrophages. Embryoid body formation or addition of exogenous growth factors was not required, and differentiation was highly reproducible even after the selection of ES cells with the antibiotic G418. Combined with the ability to genetically manipulate ES cells, this system will facilitate the study of molecular mechanisms involved in development and differentiation of hematopoietic cells.	OHU UNIV,SCH DENT,DEPT ANAT,FUKUSHIMA 963,JAPAN		NAKANO, T (corresponding author), KYOTO UNIV,FAC MED,DEPT MED CHEM,SAKYO KU,KYOTO 606,JAPAN.		Honjo, Tasuku/N-4470-2016					BORZILLO GV, 1990, MOL CELL BIOL, V10, P2703, DOI 10.1128/MCB.10.6.2703; BURKERT U, 1991, NEW BIOL, V3, P698; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHEN U, 1992, P NATL ACAD SCI USA, V89, P2541, DOI 10.1073/pnas.89.7.2541; Chen U, 1992, Dev Immunol, V2, P29, DOI 10.1155/1992/79518; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; GUTIERREZRAMOS JC, 1992, P NATL ACAD SCI USA, V89, P9171, DOI 10.1073/pnas.89.19.9171; HAYASHI SI, 1990, J EXP MED, V171, P1683, DOI 10.1084/jem.171.5.1683; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; JACKS T, 1992, NATURE, V359, P328; KAWAKAMI T, 1980, NUCLEIC ACIDS RES, V8, P3933, DOI 10.1093/nar/8.17.3933; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KINCADE PW, 1988, J IMMUNOL, V18, P97; KODAMA H, 1984, J CELL PHYSIOL, V118, P233, DOI 10.1002/jcp.1041180303; KODAMA H, 1991, J EXP MED, V173, P269, DOI 10.1084/jem.173.1.269; KODAMA H, IN PRESS EXP HEMATOL; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKANO T, UNPUB; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; OGAWA M, 1988, EMBO J, V7, P1337, DOI 10.1002/j.1460-2075.1988.tb02949.x; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; ROLINK A, 1991, EMBO J, V10, P327, DOI 10.1002/j.1460-2075.1991.tb07953.x; Sambrook J., 1989, MOL CLONING LAB MANU; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; SHIMIZU A, 1982, CELL, V28, P499, DOI 10.1016/0092-8674(82)90204-5; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; SUDA T, 1989, BLOOD, V74, P1936; SUDA T, 1985, J CELL PHYSIOL, V124, P182, DOI 10.1002/jcp.1041240203; SUDO T, 1989, J EXP MED, V170, P333, DOI 10.1084/jem.170.1.333; WILES MV, 1991, DEVELOPMENT, V111, P259; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	32	641	686	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 19	1994	265	5175					1098	1101		10.1126/science.8066449	http://dx.doi.org/10.1126/science.8066449			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC539	8066449				2022-12-24	WOS:A1994PC53900038
J	CHOI, KY; SATTERBERG, B; LYONS, DM; ELION, EA				CHOI, KY; SATTERBERG, B; LYONS, DM; ELION, EA			STE5 TETHERS MULTIPLE PROTEIN-KINASES IN THE MAP KINASE CASCADE REQUIRED FOR MATING IN SACCHAROMYCES-CEREVISIAE	CELL			English	Article							SIGNAL-TRANSDUCTION PATHWAY; PHEROMONE RESPONSE PATHWAY; SACCHAROMYCES-CEREVISIAE; THREONINE KINASE; YEAST; FUS3; COMPONENTS; CLONING; FAR1; PHOSPHORYLATION	Ste5 is a Zn2+ finger-like protein thought to function before three kinases, Ste11 (a MEKK), Ste7 (a MEK), and Fus3 (a MAPK), in a conserved MAP kinase cascade required for mating in S. cerevisiae. Here, we present evidence that Ste5 forms a multikinase complex that joins these kinases for efficient Fus3 activation. By two-hybrid analysis, Ste11, Ste7, and Fus3 associate with different domains of Ste5, while Kss1, another MAPK, associates with the same domain as Fus3, thus implying that Ste5 simultaneously binds a MEKK, MEK, and MAPK. Ste5 copurifies with Ste11, Fus3, and a hypophosphorylated form of Ste7, and all four proteins cosediment in a glycerol gradient as if in a large complex. Ste5 also increases the amount of Ste11 complexed to Ste7 and Fus3 and is required for Ste11 to function. These results substantiate a novel signal transduction component that physically links multiple kinases within a single cascade.			CHOI, KY (corresponding author), HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115, USA.				NIGMS NIH HHS [R01 GM46962-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046962] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BRILL JA, 1994, MOL BIOL CELL, V5, P297, DOI 10.1091/mbc.5.3.297; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; DOLAN JW, 1990, GENE DEV, V4, P492, DOI 10.1101/gad.4.4.492; ELION EA, 1991, P NATL ACAD SCI USA, V88, P9392, DOI 10.1073/pnas.88.21.9392; ELION EA, 1993, MOL BIOL CELL, V4, P495, DOI 10.1091/mbc.4.5.495; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ERREDE B, 1993, NATURE, V362, P261, DOI 10.1038/362261a0; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; HASSON MS, 1994, MOL CELL BIOL, V14, P1054, DOI 10.1128/MCB.14.2.1054; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KRANZ JE, 1994, GENE DEV, V8, P313, DOI 10.1101/gad.8.3.313; KURJAN J, 1992, ANNU REV BIOCHEM, V61, P1097; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEBERER E, 1993, MOL GEN GENET, V241, P241, DOI 10.1007/BF00284675; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; MACKAY VL, 1983, METHOD ENZYMOL, V101, P325; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MATSUDA S, 1993, J BIOL CHEM, V268, P2377; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MUKAI Y, 1993, MOL CELL BIOL, V13, P2050, DOI 10.1128/MCB.13.4.2050; NEIMAN AM, 1993, TRENDS GENET, V9, P390, DOI 10.1016/0168-9525(93)90139-9; NIEMAN AM, 1994, P NATL ACAD SCI USA, V91, P3398; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PINES J, 1990, New Biologist, V2, P389; PINES J, 1992, J CELL BIOL, V115, P1; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; SEGER R, 1992, J BIOL CHEM, V267, P25628; SKALHEGG BS, 1994, SCIENCE, V263, P84, DOI 10.1126/science.8272870; Sprague G. F., 1993, MOL CELLULAR BIOL YE, P657; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHOU ZQ, 1993, MOL CELL BIOL, V13, P2069, DOI 10.1128/MCB.13.4.2069	48	441	452	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 12	1994	78	3					499	512						14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PC405	8062390				2022-12-24	WOS:A1994PC40500015
J	IMBALZANO, AN; KWON, H; GREEN, MR; KINGSTON, RE				IMBALZANO, AN; KWON, H; GREEN, MR; KINGSTON, RE			FACILITATED BINDING OF TATA-BINDING PROTEIN TO NUCLEOSOMAL DNA	NATURE			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR; CHROMATIN STRUCTURE; CRYSTAL-STRUCTURE; MINOR-GROOVE; TFIID BINDS; BOX COMPLEX; MAJOR LATE; YEAST; INVITRO	BINDING of the TATA-binding protein (TBP) to the TATA box is required for transcription from many eukaryotic promoters in gene expression. Regulation of this binding is therefore likely to be an important determinant of promoter activity. Incorporation of the TATA sequence into nucleosomes dramatically reduces transcription initiation(1-3), presumably because of stereochemical constraints on binding of general transcription factors. Biochemical and genetic studies imply that cellular factors such as yeast SWI/SNF are required for activator function and might alter chromatin structure(4-11). One step that could be regulated during the activation process is TBP binding in chromatin(12,13) We show here that binding of TBP to the TATA sequence is severely inhibited by incorporation of this sequence into a nucleosome. Inhibition can be overcome by ATP-dependent alterations in nucleosomal DNA structure mediated by hSWI/SNF, a putative human homologue of the yeast SWI/SNF complex. Additionally, the orientation of the TATA sequence relative to the surface of the histone core affects the access of TBP. We propose that the dynamic remodelling of chromatin structure to allow TBP binding is a key step in the regulation of eukaryotic gene expression.	MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; UNIV MASSACHUSETTS,MED CTR,HOWARD HUGHES MED INST,PROGRAM MOLEC MED,WORCESTER,MA 01605	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester								ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CROSTON GE, 1992, GENE DEV, V6, P2270, DOI 10.1101/gad.6.12a.2270; HAHN S, 1989, P NATL ACAD SCI USA, V86, P5718, DOI 10.1073/pnas.86.15.5718; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LORCH Y, 1992, GENE DEV, V6, P2282, DOI 10.1101/gad.6.12a.2282; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MATALLANA E, 1992, MOL GEN GENET, V231, P395, DOI 10.1007/BF00292708; MATSUI T, 1987, MOL CELL BIOL, V7, P1401, DOI 10.1128/MCB.7.4.1401; MEISTERERNST M, 1990, P NATL ACAD SCI USA, V87, P9153, DOI 10.1073/pnas.87.23.9153; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; WECHSLER DS, 1994, MOL CELL BIOL, V14, P4097, DOI 10.1128/MCB.14.6.4097; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; WORKMAN JL, 1988, CELL, V55, P211, DOI 10.1016/0092-8674(88)90044-X; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; WORKMAN JL, 1991, METHOD CELL BIOL, V35, P419; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	30	527	535	1	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 11	1994	370	6489					481	485		10.1038/370481a0	http://dx.doi.org/10.1038/370481a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	8047170				2022-12-24	WOS:A1994PB40700062
J	STREETLY, A; GRANT, C; BICKLER, G; ELDRIDGE, P; BIRD, S; GRIFFITHS, W				STREETLY, A; GRANT, C; BICKLER, G; ELDRIDGE, P; BIRD, S; GRIFFITHS, W			VARIATION IN COVERAGE BY ETHNIC-GROUP OF NEONATAL (GUTHRIE) SCREENING-PROGRAM IN SOUTH LONDON	BRITISH MEDICAL JOURNAL			English	Article							CONGENITAL HYPOTHYROIDISM; PHENYLKETONURIA; PREVALENCE	Objectives-To determine whether coverage of the neonatal (Guthrie) screening programme in Britain is different for groups at highest risk of sickle cell disease and to identify possible reasons for incomplete coverage. Design-Descriptive study of coverage of screening programme and its variation by mobility, district of residence, and ethnic group. Subjects-1727 infants born between 1 October and 31 December 1991. Setting-Former West Lambeth and Camberwell District Health Authorities, London. Main outcome measure-Proportion of infants with an identifiable screening test result. Results-Screening covered 1663/1727 (96.3%) infants overall (745/786 (94.8%) in West Lambeth; 918/941 (97.6%) in Camberwell). The relative odds ratio of an African infant not having been tested compared with a white infant was 3.05 (95% confidence interval 1.30 to 7.14) (2.08 (0.86 to 5.01) after adjustment for mobility and district of residence). For infants whose families moved into the districts after the birth compared with those born and resident in the districts the relative odds ratio of having been tested was 10.16 (4.85 to 21.29). The odds ratio of locally delivered infants in West Lambeth not having been tested compared with those in Camberwell was 2.12 (1.08 to 4.16) after adjustment for ethnic group. Conclusion-Coverage of the screening programme is incomplete and poorer in infants of African ethnic group than in white infants. Poorer coverage is also associated with mobility of the family around the time of birth. The findings have implications for using the neonatal programme for testing for sickle cell disease and other disorders. Arrangements for monitoring the existing screening programme are inadequate and an improved system should be established, similar to the scheme that monitors the immunisation programme.	UNITED MED & DENT SCH,ST THOMAS HOSP,DEPT PUBL HLTH MED,LONDON SE1 7EH,ENGLAND; LAMBETH SOUTHWARK & LEWISHAM HLTH COMMISS,LONDON SE1 7RJ,ENGLAND; LEWISHAM HOSP NHS TRUST,DEPT CLIN CHEM,LONDON SE13 6LH,ENGLAND; GUYS HOSP,DEPT CLIN BIOCHEM,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust				Bickler, Graham/0000-0001-8935-2368				ADES AE, 1991, LANCET, V337, P1562, DOI 10.1016/0140-6736(91)93260-G; Dean A. G., 1990, EPI INFO VERSION 5 W; DHONDT JL, 1991, J INHERIT METAB DIS, V14, P633, DOI 10.1007/BF01797933; ELLIMAN D, 1991, BRIT MED J, V303, P471, DOI 10.1136/bmj.303.6800.471; FERNHOFF PM, 1987, LANCET, V2, P490; FISHER DA, 1987, PEDIATR CLIN N AM, V34, P881; GRIFFITHS PD, 1987, ADV NEONATAL SCREENI, P513; HENDERSON SJ, 1993, BRIT J HAEMATOL, V84, P20; HUNTER R, 1989, HEEL HEAL SCREENING; PASS KA, 1991, AM J PUBLIC HEALTH, V81, P22, DOI 10.2105/AJPH.81.Suppl.22; PHAROAH POD, 1992, ARCH DIS CHILD, V67, P1073, DOI 10.1136/adc.67.9.1073; POLLITT RJ, 1993, J CLIN PATHOL, V46, P497, DOI 10.1136/jcp.46.6.497; RATTENBURY JM, 1978, LANCET, V2, P482; SMITH I, 1991, BRIT MED J, V303, P333, DOI 10.1136/bmj.303.6798.333; STREETLY A, 1993, BRIT MED J, V306, P1491, DOI 10.1136/bmj.306.6891.1491; 1981, SCREENING EARLY DETE; 1989, SAS STAT USES GUIDE, V2; 1969, SCREENING EARLY DETE	18	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 6	1994	309	6951					372	374		10.1136/bmj.309.6951.372	http://dx.doi.org/10.1136/bmj.309.6951.372			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB316	8081135	Green Published			2022-12-24	WOS:A1994PB31600017
J	BRUNNER, D; DUCKER, K; OELLERS, N; HAFEN, E; SCHOLZ, H; KLAMBT, C				BRUNNER, D; DUCKER, K; OELLERS, N; HAFEN, E; SCHOLZ, H; KLAMBT, C			THE ETS DOMAIN PROTEIN POINTED-P2 IS A TARGET OF MAP KINASE IN THE SEVENLESS SIGNAL-TRANSDUCTION PATHWAY	NATURE			English	Article							RECEPTOR TYROSINE KINASE; FUNCTIONS DOWNSTREAM; GENETIC DISSECTION; DROSOPHILA EYE; GROWTH-FACTOR; ACTIVATION; EXPRESSION; CELLS; LOCALIZATION; PATTERN	The fate of the R7 photoreceptor cell in the developing eye of Drosophila is controlled by the Sevenless (Sev) receptor tyrosine kinase(1,2). Sev activates a highly conserved signal transduction cascade involving the proteins Ras1 and Raf and the Rolled/mitogen-activated protein (Rl/hlAP) kinase(3). Here we show that the ETS domain protein encoded by the P2 transcript of the pointed (pnt) gene is a nuclear target of this signalling cascade which acts downstream of RI/MAP kinase. The PntP2 protein is phosphorylated by Rl/MAP kinase in vitro at a single site and this site is required for its function in vivo. Furthermore, we present genetic and biochemical data suggesting that MAP kinase controls neural development through phosphorylation of two antagonizing transcription factors of the ETS family, Yan and PntP2.	UNIV ZURICH,INST ZOOL,CH-8057 ZURICH,SWITZERLAND; UNIV COLOGNE,INST ENTWICKLUNGSBIOL,D-50923 COLOGNE,GERMANY	University of Zurich; University of Cologne			Brunner, Damian/F-2024-2011; Scholz, Henrike/ABE-1063-2020	Brunner, Damian/0000-0001-5250-492X				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BASLER K, 1990, GENE DEV, V4, P728, DOI 10.1101/gad.4.5.728; BASLER K, 1989, DEVELOPMENT, V107, P723; BASLER K, 1989, EMBO J, V8, P2381, DOI 10.1002/j.1460-2075.1989.tb08367.x; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN T, 1992, DEV BIOL, V151, P176, DOI 10.1016/0012-1606(92)90225-6; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DICKSON B, 1993, DEV DROSOPHILA; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JURGENS G, 1984, W ROUXS ARCH DEV BIO, V193, P183; KLAMBT C, 1993, DEVELOPMENT, V117, P163; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MAYER U, 1988, GENE DEV, V2, P1496, DOI 10.1101/gad.2.11.1496; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; SCHOLZ H, 1993, GENETICS, V135, P455; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x	30	318	320	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 4	1994	370	6488					386	389		10.1038/370386a0	http://dx.doi.org/10.1038/370386a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA304	8047146				2022-12-24	WOS:A1994PA30400060
J	NELLEN, D; AFFOLTER, M; BASLER, K				NELLEN, D; AFFOLTER, M; BASLER, K			RECEPTOR SERINE/THREONINE KINASES IMPLICATED IN THE CONTROL OF DROSOPHILA BODY PATTERN BY DECAPENTAPLEGIC	CELL			English	Article							TGF-BETA FAMILY; POSTERIOR COMPARTMENT BOUNDARY; DORSAL-VENTRAL PATTERN; POLARITY GENE HEDGEHOG; 2ND CHROMOSOME; GERM LAYERS; II RECEPTOR; CYTOGENETIC ANALYSIS; SPATIAL EXPRESSION; BICOID PROTEIN	Members of the TGF beta superfamily of secreted signaling molecules regulate growth and cellular patterning during development and interact with specific type I and type II membrane receptors possessing a cytoplasmic serine/threonine kinase domain. We describe two members of the type I receptor family in Drosophila and demonstrate that they are encoded by the genes saxophone (sax) and thick veins (tkv). Further, we show that mutations that abolish sex or tkv activity cause phenotypes similar to partial or complete loss of activity, respectively, of the TGF beta homolog decapentaplegic (dpp). We propose that specification of distinct cell fates in response to different concentrations of dpp may be achieved combinatorially by the sax and tkv receptors.	UNIV BASEL,BIOZENTRUM,CH-4056 BASEL,SWITZERLAND	University of Basel				Basler, Konrad/0000-0003-3534-1529; Affolter, Markus/0000-0002-5171-0016				AFFOLTER M, 1993, DEVELOPMENT, V117, P1199; ARORA K, 1992, DEVELOPMENT, V114, P1003; ASHBURNER M, 1989, DROSOPHILA LABORATOR; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BAUMGARTNER S, 1987, GENE DEV, V1, P1247, DOI 10.1101/gad.1.10.1247; BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; CHASAN R, 1993, DEV DROSOPHILA MELAN, V1, P387; CHOU TB, 1993, DEVELOPMENT, V119, P1359; CRICK F, 1970, NATURE, V225, P420, DOI 10.1038/225420a0; DEFRUTOS R, 1990, METHODS MOL CELL BIO, V2, P32; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEITZLER P, 1993, GENETICS, V135, P105; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; JURGENS G, 1986, ROUX ARCH DEV BIOL, V195, P359, DOI 10.1007/BF00402870; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LAWRENCE PA, 1972, DEV SYSTEMS INSECTS, V2, P157; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MLODZIK M, 1988, EMBO J, V7, P2569, DOI 10.1002/j.1460-2075.1988.tb03106.x; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; POSAKONY LG, 1990, MECH DEVELOP, V33, P69, DOI 10.1016/0925-4773(90)90136-A; RAFTERY LA, 1991, DEVELOPMENT, V113, P27; RAMAIN P, 1993, DEVELOPMENT, V119, P1277; RAY RP, 1991, DEVELOPMENT, V113, P35; Rushlow C, 1990, Adv Genet, V27, P277; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUPBACH T, 1989, GENETICS, V121, P101; SEGAL D, 1985, GENETICS, V109, P119; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; SPRENGER F, 1992, CELL, V71, P987, DOI 10.1016/0092-8674(92)90394-R; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON RD, 1987, EMBO J, V6, P2785, DOI 10.1002/j.1460-2075.1987.tb02574.x; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; SZIDONYA J, 1988, GENET RES, V51, P197, DOI 10.1017/S0016672300024290; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; TOROK T, 1993, GENETICS, V135, P71; WHARTON KA, 1993, DEVELOPMENT, V117, P807; Wieschaus E., 1986, P199; WINICK J, 1993, DEVELOPMENT, V119, P1055; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837; XU T, 1993, DEVELOPMENT, V117, P1223	69	249	253	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 29	1994	78	2					225	237		10.1016/0092-8674(94)90293-3	http://dx.doi.org/10.1016/0092-8674(94)90293-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	8044837	Green Accepted			2022-12-24	WOS:A1994NZ24200007
J	BODEN, G; MURER, E; MOZZOLI, M				BODEN, G; MURER, E; MOZZOLI, M			GLUCOSE-TRANSPORTER PROTEINS IN HUMAN INSULINOMA	ANNALS OF INTERNAL MEDICINE			English	Article							BETA-CELL LINE; GENE-EXPRESSION; MESSENGER-RNA; RAT; SEQUENCE; LIVER	Objective: To determine the reason patients with insulinoma are unable to cease insulin secretion during hypoglycemia. Patients: Five patients with insulinoma. Design: All patients fasted for up to 25 hours, during which blood was obtained serially for determination of glucose and insulin concentrations. Insulinomas were surgically removed from all patients and Glut 1 and Glut 2 transporter proteins were measured in solubilized tumor membranes by immune blotting. Results: in all patients, serum insulin concentrations failed to decrease to less than 30.0 pmol/L (<5.0 mu U/mL) and C-peptide concentrations to less than 0.08 nmol/L during hypoglycemia (glucose concentration, <2.2 mmol/L) that was induced by fasting. The islet cell tumors from all five patients contained Glut 1, a low-K-m glucose transporter protein, which is not normally present in beta-cells. Glut 2, a high-K-m glucose transporter protein, which is normally prevalent in beta-cells, was undetectable in one patient and was present in what appeared to be low concentrations in the remaining four patients. Conclusions: Our data are compatible with the concept that continued glucose transport, mediated by the low-K-m Glut 1 glucose transporter, was responsible for continued insulin release during hypoglycemia in these patients.			BODEN, G (corresponding author), TEMPLE UNIV HOSP & MED SCH, 3401 N BROAD ST, PHILADELPHIA, PA 19140 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007988] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00349] Funding Source: Medline; NIA NIH HHS [R01 AG-07988] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BIRNBAUM MJ, 1987, SCIENCE, V235, P1495, DOI 10.1126/science.3029870; BODEN G, 1989, GASTROENTEROL CLIN N, V18, P831; CHEN L, 1990, P NATL ACAD SCI USA, V87, P4088, DOI 10.1073/pnas.87.11.4088; CHICK WL, 1977, P NATL ACAD SCI USA, V74, P628, DOI 10.1073/pnas.74.2.628; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; GERSGIBU, 1990, METHOD BIOCHEM ANAL, V33, P1; GORUS FK, 1984, J BIOL CHEM, V259, P1196; HARRIS V, 1979, METHOD HORM RADIOIMM, P643; INAGAKI N, 1992, DIABETES, V41, P592, DOI 10.2337/diabetes.41.5.592; JOHNSON JH, 1990, J BIOL CHEM, V265, P6548; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; ORCI L, 1989, SCIENCE, V245, P295, DOI 10.1126/science.2665080; PRAZ GA, 1983, BIOCHEM J, V210, P345, DOI 10.1042/bj2100345; RASTOGI GK, 1970, DIABETOLOGIA, V6, P445, DOI 10.1007/BF01212080; SALTIS J, 1991, J BIOL CHEM, V266, P261; SEINO Y, 1993, J CLIN ENDOCR METAB, V76, P75, DOI 10.1210/jc.76.1.75; SOELDNER JS, 1965, DIABETES, V14, P771, DOI 10.2337/diab.14.12.771; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; THORENS B, 1990, DIABETES CARE, V13, P209, DOI 10.2337/diacare.13.3.209; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; YASUNAMI Y, 1987, J CLIN ENDOCR METAB, V65, P110, DOI 10.1210/jcem-65-1-110	24	31	34	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1994	121	2					109	112		10.7326/0003-4819-121-2-199407150-00005	http://dx.doi.org/10.7326/0003-4819-121-2-199407150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW186	8017722				2022-12-24	WOS:A1994NW18600005
J	ONEILL, EM; REBAY, I; TJIAN, R; RUBIN, GM				ONEILL, EM; REBAY, I; TJIAN, R; RUBIN, GM			THE ACTIVITIES OF 2 ETS-RELATED TRANSCRIPTION FACTORS REQUIRED FOR DROSOPHILA EYE DEVELOPMENT ARE MODULATED BY THE RAS/MAPK PATHWAY	CELL			English	Article							ACTIVATED PROTEIN-KINASE; SUBSTRATE RECOGNITION; TYROSINE KINASE; DOMAIN PROTEIN; GENE; PHOSPHORYLATION; RAS1; IDENTIFICATION; PHOTORECEPTOR; EXPRESSION	We show that the activities of two Ets-related transcription factors required for normal eye development in Drosophila, pointed and yan, are regulated by the Ras1/MAPK pathway. The pointed gene codes for two related proteins, and we show that one form is a constitutive activator of transcription, while the activity of the other form is stimulated by the Ras1/MAPK pathway. Mutation of the single consensus MARK phosphorylation site in the second form abrogates this responsiveness. yan is a negative regulator of photoreceptor determination, and genetic data suggest that it acts as an antagonist of Ras1. We demonstrate that yan can repress transcription and that this repression activity is negatively regulated by the Ras1/MAPK signal, most likely through direct phosphorylation of yan by MAPK.			ONEILL, EM (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.			Rubin, Gerald/0000-0001-8762-8703	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033135, R01GM033135] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33135] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIGGS WH, 1992, P NATL ACAD SCI USA, V89, P6295, DOI 10.1073/pnas.89.14.6295; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CHEN T, 1992, DEV BIOL, V151, P176, DOI 10.1016/0012-1606(92)90225-6; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DIEDERICH RJ, 1994, DEVELOPMENT, V120, P473; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; KARPEN GH, 1992, GENETICS, V132, P737; KLAMBT C, 1993, DEVELOPMENT, V117, P163; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MELNICK MB, 1993, DEVELOPMENT, V118, P127; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; ONEILL EM, 1994, THESIS U CALIFORNIA; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHOLZ H, 1993, GENETICS, V135, P455; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; TEI H, 1992, P NATL ACAD SCI USA, V89, P6856, DOI 10.1073/pnas.89.15.6856; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; XU T, 1993, DEVELOPMENT, V117, P1223; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	39	584	590	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 15	1994	78	1					137	147		10.1016/0092-8674(94)90580-0	http://dx.doi.org/10.1016/0092-8674(94)90580-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033205				2022-12-24	WOS:A1994NX32800016
J	STOLTZFUS, A; SPENCER, DF; ZUKER, M; LOGSDON, JM; DOOLITTLE, WF				STOLTZFUS, A; SPENCER, DF; ZUKER, M; LOGSDON, JM; DOOLITTLE, WF			TESTING THE EXON THEORY OF GENES - THE EVIDENCE FROM PROTEIN-STRUCTURE	SCIENCE			English	Article							TRIOSEPHOSPHATE ISOMERASE GENE; MULTIPLE SEQUENCE ALIGNMENT; INTRON-DEPENDENT EVOLUTION; ALCOHOL-DEHYDROGENASE GENE; PYRUVATE-KINASE GENE; ASPERGILLUS-NIDULANS; MOLECULAR ANALYSIS; SPLICE SITES; IN-PIECES; CHICKEN	A tendency for exons to correspond to discrete units of protein structure in protein-coding genes of ancient origin would provide clear evidence in favor of the exon theory of genes, which proposes that split genes arose not by insertion of introns into unsplit genes, but from combinations of primordial mini-genes (exons) separated by spacers (introns). Although putative examples of such correspondence have strongly influenced previous debate on the origin of introns, a general correspondence has not been rigorously proved. Objective methods for detecting correspondences were developed and applied to four examples that have been cited previously as evidence of the exon theory of genes. No significant correspondence between exons and units of protein structure was detected, suggesting that the putative correspondence does not exist and that the exon theory of genes is untenable.	WASHINGTON UNIV,CANADIAN INST ADV RES,INST BIOMED COMP,PROGRAM EVOLUT BIOL,ST LOUIS,MO 63110; INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405	Washington University (WUSTL); Indiana University System; Indiana University Bloomington	STOLTZFUS, A (corresponding author), DALHOUSIE UNIV,CANADIAN INST ADV RES,DEPT BIOCHEM,PROGRAM EVOLUT BIOL,HALIFAX B3H 4H7,NS,CANADA.		Logsdon, John M/B-7812-2009; Stoltzfus, Arlin/D-8551-2011	Stoltzfus, Arlin/0000-0002-0963-1357; Doolittle, W. Ford/0000-0002-4675-8832	NIGMS NIH HHS [GM-35087] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035087] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLAKE C, 1983, NATURE, V306, P535, DOI 10.1038/306535a0; BLAKE CCF, 1978, NATURE, V273, P267, DOI 10.1038/273267a0; BOLTON W, 1970, NATURE, V228, P551, DOI 10.1038/228551a0; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P142; BURKE J, 1987, PROTEINS, V2, P177, DOI 10.1002/prot.340020303; CAVALIERSMITH T, 1991, TRENDS GENET, V7, P145, DOI 10.1016/0168-9525(91)90102-V; COLE KP, 1992, GENE, V122, P255, DOI 10.1016/0378-1119(92)90213-9; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; COUTURE M, 1994, MOL GEN GENET, V243, P185, DOI 10.1007/BF00280316; CRABB DW, 1989, GENOMICS, V5, P906, DOI 10.1016/0888-7543(89)90133-X; CRAIK CS, 1983, SCIENCE, V220, P1125, DOI 10.1126/science.6344214; DARNELL JE, 1978, SCIENCE, V202, P1257, DOI 10.1126/science.364651; DEGRAAFF L, 1988, CURR GENET, V14, P553, DOI 10.1007/BF00434080; DENNIS ES, 1984, NUCLEIC ACIDS RES, V12, P3983, DOI 10.1093/nar/12.9.3983; DIBB NJ, 1989, EMBO J, V8, P2015, DOI 10.1002/j.1460-2075.1989.tb03609.x; DOOLITTLE RF, 1985, TRENDS BIOCHEM SCI, V10, P233, DOI 10.1016/0968-0004(85)90140-9; DOOLITTLE RF, 1991, SCIENCE, V253, P677, DOI 10.1126/science.1871603; DOOLITTLE WF, 1993, NATURE, V361, P403, DOI 10.1038/361403a0; DOOLITTLE WF, 1987, AM NAT, V130, P915, DOI 10.1086/284755; DOOLITTLE WF, 1978, NATURE, V272, P581, DOI 10.1038/272581a0; DORIT RL, 1990, SCIENCE, V250, P1377, DOI 10.1126/science.2255907; DUESTER G, 1986, NUCLEIC ACIDS RES, V14, P1931, DOI 10.1093/nar/14.5.1931; DUESTER G, 1986, J BIOL CHEM, V261, P2027; EKLUND H, 1984, BIOCHEMISTRY-US, V23, P5982, DOI 10.1021/bi00320a014; GILBERT W, 1986, CELL, V46, P151, DOI 10.1016/0092-8674(86)90730-0; GILBERT W, 1987, COLD SPRING HARB SYM, V52, P901, DOI 10.1101/SQB.1987.052.01.098; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GILBERT W, 1994, GENE, V135, P137; GO M, 1987, COLD SPRING HARB SYM, V52, P915, DOI 10.1101/SQB.1987.052.01.100; GO M, 1983, P NATL ACAD SCI-BIOL, V80, P1964, DOI 10.1073/pnas.80.7.1964; GO M, 1981, NATURE, V291, P90, DOI 10.1038/291090a0; GWYNNE DI, 1987, GENE, V51, P205, DOI 10.1016/0378-1119(87)90309-X; HICKEY DA, 1989, J THEOR BIOL, V137, P41, DOI 10.1016/S0022-5193(89)80148-1; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; KERSANACH R, 1994, NATURE, V367, P387, DOI 10.1038/367387a0; LONBERG N, 1985, CELL, V40, P81, DOI 10.1016/0092-8674(85)90311-3; MICHELSON AM, 1985, P NATL ACAD SCI USA, V82, P6965, DOI 10.1073/pnas.82.20.6965; MOENS L, 1993, FEBS LETT, V320, P284, DOI 10.1016/0014-5793(93)80604-S; MUIRHEAD H, 1986, EMBO J, V5, P475, DOI 10.1002/j.1460-2075.1986.tb04236.x; NAKANO T, 1991, BIOCHIM BIOPHYS ACTA, V1090, P273, DOI 10.1016/0167-4781(91)90118-6; Palmer JD, 1991, CURR OPIN GENET DEV, V1, P470, DOI 10.1016/S0959-437X(05)80194-7; PATTHY L, 1991, BIOESSAYS, V13, P187, DOI 10.1002/bies.950130408; Patthy L, 1991, CURR OPIN STRUC BIOL, V1, P351, DOI 10.1016/0959-440X(91)90033-P; POHAJDAK B, 1993, FEBS LETT, V320, P281, DOI 10.1016/0014-5793(93)80603-R; PRESS WH, 1992, NUMERICAL RECIPES C, P282; STEPHENS RM, 1992, J MOL BIOL, V228, P1124, DOI 10.1016/0022-2836(92)90320-J; STOLTZFUS A, 1993, CURR BIOL, V3, P215, DOI 10.1016/0960-9822(93)90336-M; STONE EM, 1985, NATURE, V313, P498, DOI 10.1038/313498a0; STRAUS D, 1985, MOL CELL BIOL, V5, P3497, DOI 10.1128/MCB.5.12.3497; TITTIGER C, 1993, NATURE, V361, P470, DOI 10.1038/361470a0; WATSON JD, 1987, MOL BIOL GENE, P1145; ZUKER M, UNPUB; [No title captured]	56	194	198	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 8	1994	265	5169					202	207		10.1126/science.8023140	http://dx.doi.org/10.1126/science.8023140			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV957	8023140				2022-12-24	WOS:A1994NV95700027
J	HARRISON, MR; ADZICK, NS; ESTES, JM; HOWELL, LJ				HARRISON, MR; ADZICK, NS; ESTES, JM; HOWELL, LJ			A PROSPECTIVE-STUDY OF THE OUTCOME FOR FETUSES WITH DIAPHRAGMATIC-HERNIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							EXTRACORPOREAL MEMBRANE-OXYGENATION; INITIAL CLINICAL-EXPERIENCE; PRENATAL-DIAGNOSIS	Objective.-To establish the natural history and outcome of isolated congenital diaphragmatic hernia (CDH) diagnosed before birth. The mortality of CDH with currently available postnatal care, including extracorporeal membrane oxygenation (ECMO), reported in retrospective studies ranges from less than 25% to greater than 75%. This variation is attributable to a ''hidden mortality (infants who die with CDH that is not recognized) of unknown magnitude. Design.-Prospectively followed case series. Setting.-Patients were referred from practitioners in 18 slates and evaluated and followed up by the University of California, San Francisco, Fetal Treatment Center. Arrangements were made for planned delivery at tertiary perinatal centers with ECMO capability. Patients.-All 83 fetuses with isolated, potentially correctable CDH diagnosed prior to 24 weeks' gestation referred to the University of California, San Francisco, Fetal Treatment Center between January 1989 and October 1993. Main Outcome Measures.-Survival beyond 2 months after optimal postnatal care. Results.-Fifty-eight percent (48 of 83) died despite optimal postnatal care (95% confidence interval, 41% to 75%). Of the 48 nonsurvivors, seven suffered intrauterine fetal demise, four were too premature for ECMO, 16 died before ECMO could be started, and 21 died despite ECMO therapy. Twenty-two of the 35 survivors received ECMO, and nine of these have severe chronic illness attributable to the intensive management. Conclusions.-In this study, the mortality for potentially correctable CDH diagnosed before 24 weeks' gestation is 58%, despite optimal care presently available after birth. Infants who die in utero and soon after birth constitute a substantial hidden mortality.			HARRISON, MR (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT SURG,DIV PEDIAT SURG,513 PARNASSUS AVE,ROOM 1601-HSW,SAN FRANCISCO,CA 94143, USA.		Harrison, Michael/GYD-8608-2022					ADZICK NS, 1985, J PEDIATR SURG, V20, P357, DOI 10.1016/S0022-3468(85)80219-0; ATKINSON JB, 1991, J PEDIATR SURG, V26, P791, DOI 10.1016/0022-3468(91)90140-O; BENJAMIN DR, 1988, J PEDIATR SURG, V23, P899, DOI 10.1016/S0022-3468(88)80380-4; BUTLER N, 1962, LANCET, V1, P659; CRAWFORD DC, 1989, BRIT J OBSTET GYNAEC, V96, P705, DOI 10.1111/j.1471-0528.1989.tb03286.x; FLEISS JL, 1981, STATISTICAL METHODS, P13; HARRISON MR, 1990, J PEDIATR SURG, V25, P47, DOI 10.1016/S0022-3468(05)80163-0; HARRISON MR, 1990, NEW ENGL J MED, V322, P1582, DOI 10.1056/NEJM199005313222207; HARRISON MR, 1993, J PEDIATR SURG, V28, P1411, DOI 10.1016/S0022-3468(05)80338-0; HARRISON MR, 1990, LANCET, V336, P965, DOI 10.1016/0140-6736(90)92420-M; HARRISON MR, 1979, J PEDIATR SURG, V13, P227; Harrison MR, 1991, UNBORN PATIENT PRENA, P328; HEISS K, 1989, ANN SURG, V209, P225, DOI 10.1097/00000658-198902000-00014; KAMATA S, 1992, PEDIATR SURG INT, V7, P109, DOI 10.1007/BF00183914; NAKAYAMA DK, 1985, J PEDIATR SURG, V20, P118, DOI 10.1016/S0022-3468(85)80282-7; SHARLAND GK, 1992, AM J OBSTET GYNECOL, V166, P9, DOI 10.1016/0002-9378(92)91817-T; STOLAR C, 1988, J PEDIATR SURG, V23, P207, DOI 10.1016/S0022-3468(88)80723-1; THORPE-BEESTON J G, 1989, Fetal Therapy, V4, P21; TORFS CP, 1992, TERATOLOGY, V46, P555, DOI 10.1002/tera.1420460605; VANMEURS KP, 1990, J PEDIATR-US, V117, P954, DOI 10.1016/S0022-3476(05)80144-1; WENSTROM KD, 1991, AM J OBSTET GYNECOL, V165, P838, DOI 10.1016/0002-9378(91)90425-Q	21	264	272	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	1994	271	5					382	384		10.1001/jama.271.5.382	http://dx.doi.org/10.1001/jama.271.5.382			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR983	8054005				2022-12-24	WOS:A1994MR98300034
J	HARLOS, K; MARTIN, DMA; OBRIEN, DP; JONES, EY; STUART, DI; POLIKARPOV, I; MILLER, A; TUDDENHAM, EGD; BOYS, CWG				HARLOS, K; MARTIN, DMA; OBRIEN, DP; JONES, EY; STUART, DI; POLIKARPOV, I; MILLER, A; TUDDENHAM, EGD; BOYS, CWG			CRYSTAL-STRUCTURE OF THE EXTRACELLULAR REGION OF HUMAN TISSUE FACTOR	NATURE			English	Article							FACTOR-VII; PROTEIN CRYSTALLOGRAPHY; HUMAN CD4; DOMAINS; RECEPTOR; FRAGMENT; COMPLEX; BINDING	TISSUE factor is a cell-surface glycoprotein receptor which initiates the blood coagulation cascade after vessel injury by interacting with blood clotting factor VII/VIIa and which is implicated in various pathological processes(1). When bound to tissue factor, factor VII is readily converted to the active protease factor VIIa by trace amounts of factors Xa, IXa or VIIa. Human tissue factor consists of 263 residues, the first 219 of which comprise the extracellular region(2). We have determined the crystal structure of the extracellular region at a resolution of 2.2 Angstrom. Tissue factor consists of two immunoglobulin-like domains associated through an extensive, novel, interdomain interface region. The binding site for factor VII lies at the interface region and involves residues from domain 1 and an extended loop (binding 'finger') of domain 2. This is the first reported structure of a representative of the class 2 cytokine receptor family, which also includes interferon-alpha, interferon-gamma (refs 2, 3) and interleukin-10 (ref. 4) receptors.	UNIV EDINBURGH, SCH MED, DEPT BIOCHEM, EDINBURGH EH8 9XD, SCOTLAND; UNIV OXFORD, MOLEC BIOPHYS LAB, OXFORD OX1 3QU, ENGLAND; OXFORD CTR MOLEC SCI, OXFORD OX1 3QU, ENGLAND; MRC, CLIN RES CTR, HAEMOSTASIS RES GRP, HARROW HA1 3UJ, MIDDX, ENGLAND	University of Edinburgh; University of Oxford; University of Oxford; Medical Research Council Clinical Trials Unit			Jones, Yvonne/J-2293-2016; Tuddenham, Edward/AAS-6196-2020; Jones, Yvonne/N-8111-2019; Martin, David/C-2984-2009; Polikarpov, Igor/D-2575-2012	Jones, Yvonne/0000-0002-3834-1893; Tuddenham, Edward/0000-0001-8955-2909; Jones, Yvonne/0000-0002-3834-1893; Polikarpov, Igor/0000-0001-9496-4174; Stuart, David/0000-0002-3426-4210; Martin, David/0000-0002-8732-204X				BACH R, 1988, BIOCHEMISTRY-US, V27, P4227, DOI 10.1021/bi00412a004; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOYS CWG, 1993, J MOL BIOL, V234, P1263, DOI 10.1006/jmbi.1993.1678; BRADY RL, 1993, SCIENCE, V260, P979, DOI 10.1126/science.8493535; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; GIBBS CS, 1993, BLOOD, V82, pA451; HO ASY, 1993, P NATL ACAD SCI USA, V90, P11267, DOI 10.1073/pnas.90.23.11267; HOLDEN HM, 1991, ARCH BIOCHEM BIOPHYS, V291, P187, DOI 10.1016/0003-9861(91)90122-Y; JONES EY, 1993, CURR OPIN STRUC BIOL, V3, P846, DOI 10.1016/0959-440X(93)90147-D; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MARTIN DMA, 1993, BIOCHEMISTRY-US, V32, P13949, DOI 10.1021/bi00213a026; OBRIEN DP, 1993, BIOCHEM J, V292, P7, DOI 10.1042/bj2920007; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PABORSKY LR, 1989, BIOCHEMISTRY-US, V28, P8072, DOI 10.1021/bi00446a016; REHEMTULLA A, 1991, J BIOL CHEM, V266, P10294; ROY S, 1991, J BIOL CHEM, V266, P22063; RUF W, 1992, J BIOL CHEM, V267, P6375; RUF W, 1992, J BIOL CHEM, V267, P22206; RUF W, 1994, FASEB J, V8, P385, DOI 10.1096/fasebj.8.6.8168689; RUF W, 1994, BIOCHEMISTRY-US, V33, P1565, DOI 10.1021/bi00172a037; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0	29	211	220	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 25	1994	370	6491					662	666		10.1038/370662a0	http://dx.doi.org/10.1038/370662a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD310	8065454				2022-12-24	WOS:A1994PD31000054
J	ZARRINKAR, PP; WILLIAMSON, JR				ZARRINKAR, PP; WILLIAMSON, JR			KINETIC INTERMEDIATES IN RNA FOLDING	SCIENCE			English	Article							GROUP-I INTRON; TETRAHYMENA-THERMOPHILA RIBOZYME; RIBOSOMAL-RNA; CONFORMATIONAL-CHANGES; TERTIARY STRUCTURE; ACTIVE-SITE; SUBSTRATE; CATALYSIS; BINDING; SEQUENCE	The folding pathways of large, highly structured RNA molecules are largely unexplored. Insight into both the kinetics of folding and the presence of intermediates was provided in a study of the Mg2+-induced folding of the Tetrahymena ribozyme by hybridization of complementary oligodeoxynucleotide probes. This RNA folds via a complex mechanism involving both Mg2+-dependent and Mg2+-independent steps. A hierarchical model for the folding pathway is proposed in which formation of one helical domain (P4-P6) precedes that of a second helical domain (P3-P7). The overall rate-limiting step is formation of P3-P7, and takes place with an observed rate constant of 0.72 +/- 0.14 minute(-1). The folding mechanism of large RNAs appears similar to that of many multidomain proteins in that formation of independently stable substructures precedes their association into the final conformation.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)			Williamson, James R/B-2891-2009; Williamson, James/AAL-2104-2021	Williamson, James R/0000-0002-8772-468X; Williamson, James/0000-0002-8772-468X				BANERJEE AR, 1993, BIOCHEMISTRY-US, V32, P153, DOI 10.1021/bi00052a021; BEVILACQUA PC, 1992, SCIENCE, V258, P1355, DOI 10.1126/science.1455230; CECH TR, 1993, RNA WORLD, P239; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; CHRISTIAN EL, 1993, BIOCHEMISTRY-US, V32, P4475, DOI 10.1021/bi00068a001; CLOAD ST, 1993, J AM CHEM SOC, V115, P5005, DOI 10.1021/ja00065a008; COLE PE, 1972, BIOCHEMISTRY-US, V11, P4368, DOI 10.1021/bi00773a025; COUTURE S, 1990, J MOL BIOL, V215, P345, DOI 10.1016/S0022-2836(05)80356-0; CROTHERS DM, 1974, J MOL BIOL, V87, P63, DOI 10.1016/0022-2836(74)90560-9; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DOUDNA JA, 1993, P NATL ACAD SCI USA, V90, P7829, DOI 10.1073/pnas.90.16.7829; EMERICK VL, 1993, BIOCHEMISTRY-US, V32, P14062, DOI 10.1021/bi00213a040; FELDEN B, 1994, RNA WORLD, V235, P508; Garel Jean-Renaud, 1992, P405; GUO QB, 1992, GENE DEV, V6, P1357, DOI 10.1101/gad.6.8.1357; HERSCHLAG D, 1992, BIOCHEMISTRY-US, V31, P1386, DOI 10.1021/bi00120a015; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10172, DOI 10.1021/bi00496a004; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; JAEGER JA, 1990, BIOCHEMISTRY-US, V29, P10147, DOI 10.1021/bi00496a002; JAEGER L, 1993, J MOL BIOL, V234, P331, DOI 10.1006/jmbi.1993.1590; LAGGERBAUER B, 1994, EMBO J, V13, P2669, DOI 10.1002/j.1460-2075.1994.tb06557.x; LECUYER KA, 1994, P NATL ACAD SCI USA, V91, P3373, DOI 10.1073/pnas.91.8.3373; LYNCH DC, 1974, BIOCHEMISTRY-US, V13, P1841, DOI 10.1021/bi00706a012; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MURPHY FL, 1993, BIOCHEMISTRY-US, V32, P5291, DOI 10.1021/bi00071a003; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; NIKONOWICZ EP, 1993, J MOL BIOL, V232, P1141, DOI 10.1006/jmbi.1993.1466; Pan  T., 1993, RNA WORLD, P271; PORSCHKE D, 1971, J MOL BIOL, V62, P361, DOI 10.1016/0022-2836(71)90433-5; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; RESTELAND RF, 1993, RNA WORLD; RUDINGER J, 1992, P NATL ACAD SCI USA, V89, P5882, DOI 10.1073/pnas.89.13.5882; SCHEFFLE.IE, 1968, J MOL BIOL, V36, P291, DOI 10.1016/0022-2836(68)90156-3; SCHIMMEL PR, 1980, ANNU REV BIOPHYS BIO, V9, P181, DOI 10.1146/annurev.bb.09.060180.001145; STEIN A, 1976, BIOCHEMISTRY-US, V15, P160, DOI 10.1021/bi00646a025; STERN S, 1988, J MOL BIOL, V204, P447, DOI 10.1016/0022-2836(88)90588-8; TSUCHIHASHI Z, 1993, SCIENCE, V262, P99, DOI 10.1126/science.7692597; UHLENBEC.OC, 1970, NATURE, V225, P508, DOI 10.1038/225508a0; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WANG JF, 1993, SCIENCE, V260, P504, DOI 10.1126/science.7682726; WANG JF, 1994, J AM CHEM SOC, V116, P4178, DOI 10.1021/ja00089a005; WELLER JW, 1992, BIOCHEMISTRY-US, V31, P2748, DOI 10.1021/bi00125a015; WESTHOF E, 1992, STRUCTURAL TOOLS ANA, P255; WOODWARD CK, 1994, CURR OPIN STRUC BIOL, V4, P112, DOI 10.1016/S0959-440X(94)90068-X; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	46	307	315	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 12	1994	265	5174					918	924		10.1126/science.8052848	http://dx.doi.org/10.1126/science.8052848			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052848				2022-12-24	WOS:A1994PB49900032
J	LI, YZ; HUNTER, RL; MCIVER, RT				LI, YZ; HUNTER, RL; MCIVER, RT			HIGH-RESOLUTION MASS-SPECTROMETER FOR PROTEIN CHEMISTRY	NATURE			English	Article							ASSISTED LASER-DESORPTION; ION-CYCLOTRON RESONANCE; BIOLOGICAL MOLECULES; SEQUENCE DATABASES; MATRIX; PEPTIDES; SPECTROSCOPY; FIELD	Matrix-assisted laser desorption/ionization is an accurate and sensitive method for measuring the molecular weights of peptides and proteins. Usually time-of-flight mass spectrometry is used to detect the laser-produced ions, but a new method called Fourier transform mass spectrometry offers greater sensitivity and much higher mass measurement accuracy.	IONSPEC CORP,IRVINE,CA 92714		LI, YZ (corresponding author), UNIV CALIF IRVINE,DEPT CHEM,IRVINE,CA 92717, USA.							ARNOTT D, 1993, CLIN CHEM, V39, P2005; Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P432, DOI 10.1002/rcm.1290031207; BEAVIS RC, 1991, CHEM PHYS LETT, V181, P479, DOI 10.1016/0009-2614(91)90384-L; BIEMANN K, 1992, ANNU REV BIOCHEM, V61, P977, DOI 10.1146/annurev.bi.61.070192.004553; BILLECI TM, 1993, ANAL CHEM, V65; CHAIT BT, 1993, SCIENCE, V262, P89, DOI 10.1126/science.8211132; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; CHAMBERS DM, 1993, ANAL CHEM, V65, P14, DOI 10.1021/ac00049a005; COMISARO.MB, 1974, CHEM PHYS LETT, V26, P489, DOI 10.1016/0009-2614(74)80397-0; COMISAROW MB, 1978, J CHEM PHYS, V69, P4097, DOI 10.1063/1.437143; COTTER RJ, 1992, ANAL CHEM, V64, pA1027, DOI 10.1021/ac00045a002; EKSTROM P, 1980, SCI AM, V243, P105, DOI 10.1038/scientificamerican0880-104; HENZEL WJ, 1993, P NATL ACAD SCI USA, V90, P5011, DOI 10.1073/pnas.90.11.5011; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; KARAS M, 1987, INT J MASS SPECTROM, V78, P53, DOI 10.1016/0168-1176(87)87041-6; KARAS M, 1989, INT J MASS SPECTROM, V92, P231, DOI 10.1016/0168-1176(89)83030-7; Karas M., 1988, ANAL CHEM, V60, P2291; LEBRILLA CB, 1989, J AM CHEM SOC, V111, P8593, DOI 10.1021/ja00205a006; LEBRILLA CB, 1989, INT J MASS SPECTROM, V87, pR7, DOI 10.1016/0168-1176(89)80014-X; LI YZ, 1994, ANAL CHEM, V66, P2077, DOI 10.1021/ac00085a024; MANN M, 1993, BIOL MASS SPECTROM, V22, P338, DOI 10.1002/bms.1200220605; MARSHALL AG, 1985, ACCOUNTS CHEM RES, V18, P316, DOI 10.1021/ar00118a006; MCIVER RT, 1990, INT J MASS SPECTROM, V98, P35, DOI 10.1016/0168-1176(90)85046-5; MCIVER RT, 1994, P NATL ACAD SCI USA, V91, P4801, DOI 10.1073/pnas.91.11.4801; MCIVER RT, 1994, INT J MASS SPECTROM, V132, pL1, DOI 10.1016/0168-1176(94)85003-8; MCIVER RT, 1981, INT J MASS SPECTROM, V39, P65, DOI 10.1016/0020-7381(81)80122-2; MCIVER RT, 1994, RAPID COMMUN MASS SP, V8, P237, DOI 10.1002/rcm.1290080303; MCIVER RT, 1985, INT J MASS SPECTROM, V64, P67, DOI 10.1016/0168-1176(85)85037-0; MEIVER R, 1985, Patent No. 4535235; PAN Y, 1992, ORG MASS SPECTROM, V27, P3, DOI 10.1002/oms.1210270103; SCHWARTZ JC, 1993, RAPID COMMUN MASS SP, V7, P27, DOI 10.1002/rcm.1290070107; SPENGLER B, 1991, RAPID COMMUN MASS SP, V5, P198, DOI 10.1002/rcm.1290050412; STRUPAT K, 1991, INT J MASS SPECTROM, V111, P89, DOI 10.1016/0168-1176(91)85050-V; WINELAND D, 1973, PHYS REV LETT, V31, P1279, DOI 10.1103/PhysRevLett.31.1279; ZHOU J, 1992, RAPID COMMUN MASS SP, V6, P671, DOI 10.1002/rcm.1290061109	35	11	11	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 4	1994	370	6488					393	395		10.1038/370393a0	http://dx.doi.org/10.1038/370393a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA304	8047148				2022-12-24	WOS:A1994PA30400066
J	JAMES, AF; XIE, LH; FUJITANI, Y; HAYASHI, S; HORIE, M				JAMES, AF; XIE, LH; FUJITANI, Y; HAYASHI, S; HORIE, M			INHIBITION OF THE CARDIAC PROTEIN-KINASE A-DEPENDENT CHLORIDE CONDUCTANCE BY ENDOTHELIN-1	NATURE			English	Article							GUINEA-PIG ATRIA; AUTONOMIC REGULATION; MYOCYTES; CELLS; CONTRACTION; ACTIVATION; MECHANISM; RECEPTOR; SUBUNITS; ISOZYME	ENDOTHELIN-1 is a peptide hormone constitutively secreted by vascular and endocardial endothelial cells(1-3). Secretion of endothelin-1 is increased under certain pathophysiological conditions, including coronary vasospasm, cardiac ischaemia and myocardial infarction. We have examined the effect of endothelin-1 on the protein kinase A (PKA)-dependent chloride current in voltage-clamped guinea pig ventricular myocytes. This conductance, induced by catecholamines through beta-adrenergic receptors, counteracts the simultaneously increased L-type calcium current by shortening the action potential duration(4-6). We report here that endothelin-1, acting through ET(A) (endothelin-1-selective) receptors, inhibited the current through a pertussis toxin-sensitive mechanism, analogous to muscarinic receptors, by reducing the intracellular cyclic AMP concentration. This effect of endothelin-1 should help protect the ventricle against potentially arrhythmogenic shortening of the action potential during ischaemia when the circulating levels of catecholamines are increased.	KYOTO UNIV,FAC MED,DEPT INTERNAL MED 3,KYOTO 606,JAPAN; CIBA GEIGY JAPAN LTD,INT RES LABS,TAKARAZUKA,HYOGO 665,JAPAN; NATL INST PHYSIOL SCI,DEPT CELLULAR & MOLEC PHYSIOL,OKAZAKI,AICHI 444,JAPAN	Kyoto University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)			Horie, Minoru/ABG-7128-2020					BAHINSKI A, 1989, NATURE, V340, P718, DOI 10.1038/340718a0; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; HARVEY R D, 1990, Journal of Cardiovascular Electrophysiology, V1, P309, DOI 10.1111/j.1540-8167.1990.tb01072.x; HARVEY RD, 1990, J GEN PHYSIOL, V95, P1077, DOI 10.1085/jgp.95.6.1077; HARVEY RD, 1989, SCIENCE, V244, P983, DOI 10.1126/science.2543073; HAYNES WG, 1993, CLIN SCI, V84, P485, DOI 10.1042/cs0840485; HILALDANDAN R, 1992, J BIOL CHEM, V267, P10620; HORIE M, 1992, J PHYSIOL-LONDON, V455, P235, DOI 10.1113/jphysiol.1992.sp019299; HWANG TC, 1992, J GEN PHYSIOL, V99, P465, DOI 10.1085/jgp.99.4.465; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; ISHIKAWA T, 1988, AM J PHYSIOL, V255, pH970, DOI 10.1152/ajpheart.1988.255.4.H970; JAMES AF, 1993, CARDIOVASC DRUG REV, V11, P253, DOI 10.1111/j.1527-3466.1993.tb00190.x; JONES LG, 1992, AM J PHYSIOL, V263, pH1447, DOI 10.1152/ajpheart.1992.263.5.H1447; KIM D, 1991, CIRC RES, V69, P250, DOI 10.1161/01.RES.69.1.250; KOHMOTO O, 1993, AM J PHYSIOL, V265, pH793, DOI 10.1152/ajpheart.1993.265.3.H793; LAUER MR, 1992, J PHYSIOL-LONDON, V448, P729, DOI 10.1113/jphysiol.1992.sp019067; MASAKI T, 1992, MED RES REV, V12, P391, DOI 10.1002/med.2610120405; MEBAZAA A, 1993, AM J PHYSIOL, V265, pH1841, DOI 10.1152/ajpheart.1993.265.5.H1841; ONO K, 1994, NATURE, V370, P301, DOI 10.1038/370301a0; REID JJ, 1989, EUR J PHARMACOL, V168, P93, DOI 10.1016/0014-2999(89)90637-7; SOKOLOVSKY M, 1992, NEUROCHEMISTRY, V59, P809; TAKAI M, 1992, BIOCHEM BIOPH RES CO, V184, P953, DOI 10.1016/0006-291X(92)90683-C; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TOHSE N, 1990, BRIT J PHARMACOL, V99, P437, DOI 10.1111/j.1476-5381.1990.tb12944.x; VOGELSANG M, 1994, J CARDIOVASC PHARM, V23, P344, DOI 10.1097/00005344-199402000-00025; WANG JX, 1993, AM J PHYSIOL, V265, pH2168, DOI 10.1152/ajpheart.1993.265.6.H2168	26	83	84	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 28	1994	370	6487					297	300		10.1038/370297a0	http://dx.doi.org/10.1038/370297a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ229	8035878				2022-12-24	WOS:A1994NZ22900065
J	DJERASSI, C; LEIBO, SP				DJERASSI, C; LEIBO, SP			A NEW LOOK AT MALE CONTRACEPTION	NATURE			English	Editorial Material							UNITED-STATES MEN; PROSTATE-CANCER; VASECTOMY; SPERM; CRYOPRESERVATION; OLIGOSPERMIA; COHORT		UNIV GUELPH, ONTARIO VET COLL, GUELPH N1G 2W1, ON, CANADA	University of Guelph	DJERASSI, C (corresponding author), STANFORD UNIV, DEPT CHEM, STANFORD, CA 94305 USA.							ANDERSON NG, COMMUNICATION; ANDERSON NG, Patent No. 5092466; ASHWOODSMITH MJ, 1977, CIBA F S, V52, P251; BARWIN BN, 1986, ANDROLOGY MALE FERTI, P461; BELKER AM, 1987, UROL CLIN N AM, V14, P597; DJERASSI C, 1981, POLITICS CONTRACEPTI, pCH5; GIOVANNUCCI E, 1993, JAMA-J AM MED ASSOC, V269, P873, DOI 10.1001/jama.269.7.873; GIOVANNUCCI E, 1993, JAMA-J AM MED ASSOC, V269, P878, DOI 10.1001/jama.269.7.878; GLENISTER PH, 1990, GENET RES, V56, P253, DOI 10.1017/S0016672300035357; HEALY B, 1993, JAMA-J AM MED ASSOC, V269, P2620, DOI 10.1001/jama.269.20.2620; IRITANI A, 1980, 9TH INT C AN REPR AI, V1, P115; IRVINE DS, 1986, HUM REPROD, V1, P539, DOI 10.1093/oxfordjournals.humrep.a136470; LEIBO SP, UNPUB; LELANNOU D, 1989, HUM REPROD, V4, P757; LI HH, 1988, NATURE, V335, P414, DOI 10.1038/335414a0; LIU DY, 1992, FERTIL STERIL, V58, P465; MARTIN RH, 1991, MOL REPROD DEV, V30, P159, DOI 10.1002/mrd.1080300213; MUMFORD SD, 1977, VASECTOMY COUNSELING; Ross John A., 1993, FAMILY PLANNING POPU; SALAMON S, 1974, J REPROD FERTIL, V37, P433, DOI 10.1530/jrf.0.0370433; SHERMAN JK, 1977, TECHNIQUES HUMAN AND, P399; Short R.V., 1985, P24; SHULMAN S, 1986, ANDROLOGY MALE FERTI, P399; SILBER SJ, 1989, HUM REPROD, V4, P318, DOI 10.1093/oxfordjournals.humrep.a136896; SOKOL RZ, 1987, FERTIL STERIL, V47, P356; Triazolam's status in European Community, 1991, LANCET, V338, P1586; VANSTEIRTEGHEM AC, 1993, HUM REPROD, V8, P1061, DOI 10.1093/oxfordjournals.humrep.a138192; 1988, ARTIFICIAL INSEMINAT	28	8	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 7	1994	370	6484					11	12		10.1038/370011a0	http://dx.doi.org/10.1038/370011a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV711	8015592				2022-12-24	WOS:A1994NV71100024
J	STEIMLE, V; SIEGRIST, CA; MOTTET, A; LISOWSKAGROSPIERRE, B; MACH, B				STEIMLE, V; SIEGRIST, CA; MOTTET, A; LISOWSKAGROSPIERRE, B; MACH, B			REGULATION OF MHC CLASS-II EXPRESSION BY INTERFERON-GAMMA MEDIATED BY THE TRANSACTIVATOR GENE CIITA	SCIENCE			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; GUANYLATE-BINDING-PROTEIN; TRANS-ACTING PROTEIN; TYROSINE PHOSPHORYLATION; IFN-GAMMA; TRANSCRIPTION; INDUCTION; CELLS; ALPHA; ACTIVATION	Major histocompatibility complex (MHC) class II genes are expressed constitutively in only a few cell types, but they can be induced in the majority of them, in particular by interferon-gamma (IFN-gamma). The MHC class II transactivator gene CIITA is defective in a form of primary MHC class II deficiency. Here it is shown that CIITA expression is controlled and induced by IFN-gamma. A functional CI ITA gene is necessary for class II induction, and transfection of CIITA is sufficient to activate expression of MHC class II genes in class II-negative cells in the absence of IFN-gamma. CIITA is therefore a general regulator of both inducible and constitutive MHC class II expression.	UNIV GENEVA,SCH MED,DEPT GENET & MICROBIOL,MOLEC GENET LAB,CH-1211 GENEVA 4,SWITZERLAND; HOP NECKER ENFANTS MALAD,INSERM,U132,F-15015 PARIS,FRANCE	University of Geneva; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			, Mühlethaler-Mottet/H-2848-2019	, Mühlethaler-Mottet/0000-0001-8274-0907				ALLEN JM, 1988, NUCLEIC ACIDS RES, V16, P11824, DOI 10.1093/nar/16.24.11824; AMALDI I, 1989, J IMMUNOL, V142, P999; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; BLANAR MA, 1988, P NATL ACAD SCI USA, V85, P4672, DOI 10.1073/pnas.85.13.4672; BONO MR, 1991, P NATL ACAD SCI USA, V88, P6077, DOI 10.1073/pnas.88.14.6077; CELADA A, 1989, EUR J IMMUNOL, V19, P1103, DOI 10.1002/eji.1830190621; CHARRON DJ, 1979, P NATL ACAD SCI USA, V76, P6567, DOI 10.1073/pnas.76.12.6567; CHENG YSE, 1986, J INTERFERON RES, V6, P417, DOI 10.1089/jir.1986.6.417; COGSWELL JP, 1991, CRIT REV IMMUNOL, V11, P87; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LISOWSKAGROSPIE.B, IN PRESS HUM MOL GEN; MAFFEI A, 1987, J IMMUNOL, V139, P942; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SINGER DS, 1990, CRIT REV IMMUNOL, V10, P235; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, UNPUB; TSANG SY, 1990, MOL CELL BIOL, V10, P711, DOI 10.1128/MCB.10.2.711; WATSON AJ, 1983, NATURE, V304, P358, DOI 10.1038/304358a0; ZIEGLER A, 1986, IMMUNOBIOLOGY, V171, P77, DOI 10.1016/S0171-2985(86)80019-5	30	685	704	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 1	1994	265	5168					106	109		10.1126/science.8016643	http://dx.doi.org/10.1126/science.8016643			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV301	8016643				2022-12-24	WOS:A1994NV30100037
J	VANDENBROUCKE, JP				VANDENBROUCKE, JP			SHOULD YOU EAT MEAT, OR ARE YOU CONFOUNDED BY METHODOLOGICAL DEBATE	BRITISH MEDICAL JOURNAL			English	Article											VANDENBROUCKE, JP (corresponding author), LEIDEN UNIV HOSP,POB 9600,2300 RC LEIDEN,NETHERLANDS.		Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				BRESLOW NE, 1987, STATISTICAL METHODS, V2, P151; BRESLOW NE, 1987, STATISTICAL METHODS, V2, P136; BRESLOW NE, 1987, STATISTICAL METHODS, V2, P92; DOLL R, 1956, BRIT MED J, V2, P1071, DOI 10.1136/bmj.2.5001.1071; Feinstein A.R., 1985, CLIN EPIDEMIOLOGY; MONSON RR, 1990, OCCUPATIONAL EPIDEMI, P53; Rothman KJ, 1986, MODERN EPIDEMIOLOGY, P45; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; THOROGOOD M, 1994, BRIT MED J, V308, P1665	9	2	2	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 25	1994	308	6945					1671	1671						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU483	8025459				2022-12-24	WOS:A1994NU48300018
J	CLELAND, WW; KREEVOY, MM				CLELAND, WW; KREEVOY, MM			LOW-BARRIER HYDROGEN-BONDS AND ENZYMATIC CATALYSIS	SCIENCE			English	Article							TRANSITION-STATE ANALOGS; DELTA-5-3-KETOSTEROID ISOMERASE; TRIOSEPHOSPHATE ISOMERASE; OROTIDYLATE DECARBOXYLASE; CARBOXYPEPTIDASE-A; INHIBITOR-BINDING; CRYSTAL-STRUCTURE; ACTIVE-SITE; MECHANISM; DEHYDROGENASE	Formation of a short (less than 2.5 angstroms), very strong, low-barrier hydrogen bond in the transition state, or in an enzyme-intermediate complex, can be an important contribution to enzymic catalysis. Formation of such a bond can supply 10 to 20 kilocalories per mole and thus facilitate difficult reactions such as enolization of carboxylate groups. Because low-barrier hydrogen bonds form only when the pK(a)'s (negative logarithm of the acid constant) of the oxygens or nitrogens sharing the hydrogen are similar, a weak hydrogen bond in the enzyme-substrate complex in which the pK(a)'s do not match can become a strong, low-barrier one if the pK(a)'s become matched in the transition state or enzyme-intermediate complex. Several examples of enzymatic reactions that appear to use this principle are presented.	UNIV MINNESOTA,DEPT CHEM,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities	CLELAND, WW (corresponding author), UNIV WISCONSIN,INST ENZYME RES,MADISON,WI 53705, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018938, R37GM018938] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 18938] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUDARI K, 1979, J AM CHEM SOC, V101, P3688, DOI 10.1021/ja00507a059; ADAMS MJ, 1973, P NATL ACAD SCI USA, V70, P1968, DOI 10.1073/pnas.70.7.1968; ALBRECHT G, 1984, Z NATURFORSCH A, V39, P986; BIRKTOFT JJ, 1983, J BIOL CHEM, V258, P472; BLANCHARD JS, 1980, BIOCHEMISTRY-US, V19, P4506, DOI 10.1021/bi00560a019; BRANT DA, 1963, J AM CHEM SOC, V85, P2204, DOI 10.1021/ja00898a003; BUEHNER M, 1974, J MOL BIOL, V90, P25, DOI 10.1016/0022-2836(74)90254-X; CLELAND WW, 1992, BIOCHEMISTRY-US, V31, P317, DOI 10.1021/bi00117a001; FREY PA, 1994, SCIENCE, V264, P1927, DOI 10.1126/science.7661899; GERIT JA, 1993, BIOCHEMISTRY-US, V32, P11943; GERIT JA, 1993, J AM CHEM SOC, V115, P11552; GILLI P, 1994, J AM CHEM SOC, V116, P909, DOI 10.1021/ja00082a011; Hibbert F., 1990, ADV PHYS ORG CHEM, V26, P255, DOI DOI 10.1016/S0065-3160(08)60047-7; HOLDEN HM, 1987, BIOCHEMISTRY-US, V26, P8542, DOI 10.1021/bi00400a008; KAPLAN AP, 1991, BIOCHEMISTRY-US, V30, P8165, DOI 10.1021/bi00247a011; KARPUSAS M, 1990, BIOCHEMISTRY-US, V29, P2213, DOI 10.1021/bi00461a002; KIM H, 1990, BIOCHEMISTRY-US, V29, P5546, DOI 10.1021/bi00475a019; KIM HD, 1991, BIOCHEMISTRY-US, V30, P8171, DOI 10.1021/bi00247a012; KINTANAR A, 1991, J BIOL CHEM, V266, P17222; KREEVOY MM, 1980, J AM CHEM SOC, V102, P3315, DOI 10.1021/ja00530a002; KULIOPULOS A, 1991, BIOCHEMISTRY-US, V30, P3169, DOI 10.1021/bi00227a003; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; LI YK, 1993, BIOCHEMISTRY-US, V32, P1816, DOI 10.1021/bi00058a016; LODI PJ, 1991, BIOCHEMISTRY-US, V30, P6948, DOI 10.1021/bi00242a020; NEIDHART DJ, 1991, BIOCHEMISTRY-US, V30, P9264, DOI 10.1021/bi00102a019; NICKBARG EB, 1988, BIOCHEMISTRY-US, V27, P5948, DOI 10.1021/bi00416a019; PORTER DJT, 1980, J BIOL CHEM, V255, P4772; REMINGTON J, 1992, CURR OPIN STRUCT BIO, V2, P730; SCHLOSS JV, 1980, BIOCHEMISTRY-US, V19, P2358, DOI 10.1021/bi00552a012; SHOSTAK K, 1992, BIOCHEMISTRY-US, V31, P12155, DOI 10.1021/bi00163a026; SMILEY JA, 1992, BIOCHEMISTRY-US, V31, P12162, DOI 10.1021/bi00163a027; TRONRUD DE, 1986, EUR J BIOCHEM, V157, P261, DOI 10.1111/j.1432-1033.1986.tb09664.x; USHER KC, IN PRESS BIOCHEMISTR; VIOLA RE, 1984, ARCH BIOCHEM BIOPHYS, V228, P415, DOI 10.1016/0003-9861(84)90005-5; WERST MM, 1990, BIOCHEMISTRY-US, V29, P10526, DOI 10.1021/bi00498a015; ZENG BF, 1991, J AM CHEM SOC, V113, P3838, DOI 10.1021/ja00010a028	36	1028	1037	3	150	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1887	1890		10.1126/science.8009219	http://dx.doi.org/10.1126/science.8009219			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	8009219				2022-12-24	WOS:A1994NT84700034
J	BENNETT, DH; TAMBEUR, LJMT; CAMPBELL, WB				BENNETT, DH; TAMBEUR, LJMT; CAMPBELL, WB			USE OF COUGHING TEST TO DIAGNOSE PERITONITIS	BRITISH MEDICAL JOURNAL			English	Article									ROYAL DEVON & EXETER HOSP,DEPT SURG,EXETER EX2 5DW,DEVON,ENGLAND	University of Exeter								DIXON JM, 1991, BRIT MED J, V302, P386, DOI 10.1136/bmj.302.6773.386; LIDDINGTON MI, 1991, BRIT J SURG, V78, P795, DOI 10.1002/bjs.1800780710; MOORE SW, 1958, SURG CLIN N AM, V38, P371; PROUT WG, 1970, BRIT J SURG, V57, P508, DOI 10.1002/bjs.1800570706	4	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 21	1994	308	6940					1336	1336						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM989	8019222				2022-12-24	WOS:A1994NM98900023
J	MURPHY, FL; WANG, YH; GRIFFITH, JD; CECH, TR				MURPHY, FL; WANG, YH; GRIFFITH, JD; CECH, TR			COAXIALLY STACKED RNA HELICES IN THE CATALYTIC CENTER OF THE TETRAHYMENA RIBOZYME	SCIENCE			English	Article							GROUP-I INTRON; PHENYLALANINE TRANSFER-RNA; PERMUTED TRANSFER-RNAS; SECONDARY STRUCTURE; RIBOSOMAL-RNA; TERTIARY STRUCTURE; TARGET SEQUENCE; REV PROTEIN; ACTIVE-SITE; DNA	Coaxial stacking of helical elements is a determinant of three-dimensional structure in RNA. In the catalytic center of the Tetrahymena group I intron, helices P4 and P6 are part of a tertiary structural domain that folds independently of the remainder of the intron. When P4 and P6 were fused with a phosphodiester linkage, the resulting RNA retained the detailed tertiary interactions characteristic of the native P4-P6 domain and even required lower magnesium ion concentrations for folding. These results indicate that P4 and P6 are coaxial in the P4-P6 domain and, therefore, in the native ribozyme. Helix fusion could provide a general method for identifying pairs of coaxially stacked helices in biological RNA molecules.	UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31819] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baserga S., 1993, RNA WORLD, P359; BEAUDRY AA, 1990, BIOCHEMISTRY-US, V29, P6534, DOI 10.1021/bi00479a027; BHATTACHARYYA A, 1990, NATURE, V343, P484, DOI 10.1038/343484a0; BURKE JM, 1987, NUCLEIC ACIDS RES, V15, P7217, DOI 10.1093/nar/15.18.7217; BURKE JM, 1986, CELL, V45, P167, DOI 10.1016/0092-8674(86)90380-6; CECH TR, 1988, GENE, V73, P259, DOI 10.1016/0378-1119(88)90492-1; CECH TR, 1994, NAT STRUCT BIOL, V1, P273, DOI 10.1038/nsb0594-273; CECH TR, 1993, RNA WORLD, P239; CELANDER DW, 1990, BIOCHEMISTRY-US, V29, P1355, DOI 10.1021/bi00458a001; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; CHASTAIN M, 1992, BIOCHEMISTRY-US, V31, P12733, DOI 10.1021/bi00166a004; CHASTAIN M, 1993, BIOCHEMISTRY-US, V32, P14220, DOI 10.1021/bi00214a022; DAYTON ET, 1989, SCIENCE, V246, P1625, DOI 10.1126/science.2688093; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; FELDSTEIN PA, 1993, NUCLEIC ACIDS RES, V21, P1991, DOI 10.1093/nar/21.8.1991; FLOR PJ, 1989, EMBO J, V8, P3391, DOI 10.1002/j.1460-2075.1989.tb08503.x; Gold L., 1993, RNA WORLD, P497; GREEN R, 1994, J MOL BIOL, V235, P140, DOI 10.1016/S0022-2836(05)80022-1; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; GROSSHANS CA, 1991, NUCLEIC ACIDS RES, V19, P3875, DOI 10.1093/nar/19.14.3875; HAGERMAN PJ, 1990, ANNU REV BIOCHEM, V59, P755, DOI 10.1146/annurev.biochem.59.1.755; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; JARRELL KA, 1993, P NATL ACAD SCI USA, V90, P8624, DOI 10.1073/pnas.90.18.8624; JOYCE GF, 1989, NUCLEIC ACIDS RES, V17, P7879, DOI 10.1093/nar/17.19.7879; KIM SH, 1987, P NATL ACAD SCI USA, V84, P8788, DOI 10.1073/pnas.84.24.8788; KIM SH, 1973, SCIENCE, V179, P285, DOI 10.1126/science.179.4070.285; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAGGERBAUER B, 1994, EMBO J, V13, P2669, DOI 10.1002/j.1460-2075.1994.tb06557.x; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; LATHAM JA, 1990, METHOD ENZYMOL, V181, P558; MALIM MH, 1990, CELL, V60, P675, DOI 10.1016/0092-8674(90)90670-A; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1992, GENE DEV, V6, P1373, DOI 10.1101/gad.6.8.1373; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MICHEL F, 1983, EMBO J, V2, P33, DOI 10.1002/j.1460-2075.1983.tb01376.x; MURPHY FL, 1993, BIOCHEMISTRY-US, V32, P5291, DOI 10.1021/bi00071a003; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; MURPHY FL, 1992, THESIS U COLORADO; MURPHY FL, UNPUB; NOLAN JM, 1993, SCIENCE, V261, P762, DOI 10.1126/science.7688143; NOLLER HF, 1981, SCIENCE, V212, P403, DOI 10.1126/science.6163215; OLSEN HS, 1990, SCIENCE, V247, P845, DOI 10.1126/science.2406903; PAN T, 1991, SCIENCE, V254, P1361, DOI 10.1126/science.1720569; PRICE JV, 1985, NUCLEIC ACIDS RES, V13, P1871, DOI 10.1093/nar/13.6.1871; PUTTARAJU M, 1992, NUCLEIC ACIDS RES, V20, P5257; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TANG RS, 1990, BIOCHEMISTRY-US, V29, P5232, DOI 10.1021/bi00474a003; TULLIUS TD, 1985, SCIENCE, V230, P679, DOI 10.1126/science.2996145; TULLIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469, DOI 10.1073/pnas.83.15.5469; WANG JF, 1993, SCIENCE, V260, P504, DOI 10.1126/science.7682726; WANG YH, 1994, J MOL BIOL, V236, P64, DOI 10.1006/jmbi.1994.1118; WARING RB, 1983, J MOL BIOL, V167, P595, DOI 10.1016/S0022-2836(83)80100-4; WOESE CR, 1993, RNA WORLD, P91; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZAUG AJ, 1993, BIOCHEMISTRY-US, V32, P7946, DOI 10.1021/bi00082a016	58	61	62	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 16	1994	265	5179					1709	1712		10.1126/science.8085157	http://dx.doi.org/10.1126/science.8085157			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG284	8085157				2022-12-24	WOS:A1994PG28400031
J	MCGARRY, GW; GATEHOUSE, S; HINNIE, J				MCGARRY, GW; GATEHOUSE, S; HINNIE, J			RELATION BETWEEN ALCOHOL AND NOSE BLEEDS	BRITISH MEDICAL JOURNAL			English	Article							EPISTAXIS		GLASGOW ROYAL INFIRM,MED RES COUNCIL,INST HEARING RES,GLASGOW,SCOTLAND; GLASGOW ROYAL INFIRM,DEPT BIOCHEM,GLASGOW G4 0SF,SCOTLAND	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Glasgow; University of Glasgow	MCGARRY, GW (corresponding author), GLASGOW ROYAL INFIRM,DEPT OTOLARYNGOL,GLASGOW G4 0SF,SCOTLAND.							DIGHT S, 1976, SCOTTISH DRINKING HA; HART MJ, 1974, AM J MED, V56, P22; JACKSON KR, 1988, ARCH OTOLARYNGOL, V114, P862; KLATSKY AL, 1977, NEW ENGL J MED, V296, P1194, DOI 10.1056/NEJM197705262962103; STELL PM, 1977, CLIN OTOLARYNGOL, V2, P263, DOI 10.1111/j.1365-2273.1977.tb01365.x	5	16	16	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 10	1994	309	6955					640	640		10.1136/bmj.309.6955.640	http://dx.doi.org/10.1136/bmj.309.6955.640			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG020	8086988	Green Published			2022-12-24	WOS:A1994PG02000021
J	RADMACHER, M; FRITZ, M; HANSMA, HG; HANSMA, PK				RADMACHER, M; FRITZ, M; HANSMA, HG; HANSMA, PK			DIRECT OBSERVATION OF ENZYME-ACTIVITY WITH THE ATOMIC-FORCE MICROSCOPE	SCIENCE			English	Article								The height fluctuations on top of the protein lysozyme adsorbed on mica were measured locally with an atomic force microscope operated in tapping mode in liquid. Height fluctuations of an apparent size of 1 nanometer that lasted for about 50 milliseconds were observed over lysozyme molecules when a substrate (oligoglycoside) was present. In the presence of the inhibitor chitobiose, these height fluctuations decreased to the level without the oligoglycoside. The most straightforward interpretation of these results is that the height fluctuations correspond to the conformational changes of lysozyme during hydrolysis. It is also possible, however, that the height fluctuations are, at least in part, the result of a different height or elasticity of the transient complex of lysozyme plus the substrate.	UNIV CALIF SANTA BARBARA,INST MARINE SCI,SANTA BARBARA,CA 93106	University of California System; University of California Santa Barbara	RADMACHER, M (corresponding author), UNIV CALIF SANTA BARBARA,DEPT PHYS,SANTA BARBARA,CA 93106, USA.		Radmacher, Manfred/A-3956-2012	Radmacher, Manfred/0000-0001-8744-4541				AMDUR I, 1966, CHEM KINETICS PRINCI; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P378, DOI 10.1098/rspb.1967.0035; DRAKE B, 1989, SCIENCE, V243, P1586, DOI 10.1126/science.2928794; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FLORIN EL, 1994, SCIENCE, V264, P415, DOI 10.1126/science.8153628; FRITZ M, 1994, BIOPHYS J, V66, P1328, DOI 10.1016/S0006-3495(94)80963-4; GOLANDER CG, 1990, COLLOID SURFACE, V50, P113, DOI 10.1016/0166-6622(90)80257-5; HANSMA HG, 1994, ANNU REV BIOPH BIOM, V23, P115, DOI 10.1146/annurev.bb.23.060194.000555; HANSMA PK, 1994, APPL PHYS LETT, V64, P1738, DOI 10.1063/1.111795; HENDERSON E, 1994, PROG SURF SCI, V46, P39, DOI 10.1016/0079-6816(94)90006-X; HENDERSON E, 1992, NUCLEIC ACIDS RES, V20, P445, DOI 10.1093/nar/20.3.445; Imoto T., 1972, ENZYMES, V7, P665; ISHIJIMA A, 1991, NATURE, V352, P301, DOI 10.1038/352301a0; JACKSON MB, 1993, J CHEM PHYS, V99, P7253, DOI 10.1063/1.465418; KARRASCH S, 1994, P NATL ACAD SCI USA, V91, P836, DOI 10.1073/pnas.91.3.836; KEATON A, 1994, MAR P NATO ADV STUD; KELLER D, 1992, P SOC PHOTO-OPT INS, V1639, P91, DOI 10.1117/12.58194; LEE GU, 1994, LANGMUIR, V10, P354, DOI 10.1021/la00014a003; OHNESORGE F, 1993, SCIENCE, V260, P1451, DOI 10.1126/science.260.5113.1451; RADMACHER M, 1992, SCIENCE, V257, P1900, DOI 10.1126/science.1411505; RUGAR D, 1990, PHYS TODAY, V43, P23, DOI 10.1063/1.881238; RUPLEY JA, 1967, PROC R SOC SER B-BIO, V167, P416, DOI 10.1098/rspb.1967.0038; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; WENZEL M, 1961, Z PHYSIOL CHEM, V327, P13; YANG J, 1993, J MOL BIOL, V229, P286, DOI 10.1006/jmbi.1993.1033; YANG Y, 1980, J BIOCHEM-TOKYO, V87, P1003; [No title captured]	28	329	335	1	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 9	1994	265	5178					1577	1579		10.1126/science.8079171	http://dx.doi.org/10.1126/science.8079171			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF336	8079171				2022-12-24	WOS:A1994PF33600034
J	HARLAN, JE; HAJDUK, PJ; YOON, HS; FESIK, SW				HARLAN, JE; HAJDUK, PJ; YOON, HS; FESIK, SW			PLECKSTRIN HOMOLOGY DOMAINS BIND TO PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE	NATURE			English	Article							ADRENERGIC-RECEPTOR KINASE; PHOSPHOLIPASE C-DELTA-1; SIGNALING PROTEINS; PH DOMAIN; EXPRESSION	THE pleckstrin homology (PH) domain is a new protein module of around 100 amino acids found in several proteins involved in signal transduction(1-5). Although its specific function has yet to be elucidated, the carboxy-terminal regions of many PH domains bind to the beta gamma subunits of G proteins(6,7). On the basis of structural similarities between PH domains and Lipid-binding proteins, we have proposed that PH domains may be binding to lipophilic molecules(8). indeed, many of the proteins that contain this domain associate with phospholipid membrane(6,9,10), and disruption of this domain can interfere with membrane association(6,11). Here we report that PH domains bind to phosphatidylinositol-4,5-bisphosphate and show that the lipid-binding site is located at the Lip of the beta-barrel. This suggests that PH domains may be important for membrane localization of proteins through interactions with phosphatidylinositol-4,5-bisphosphate.	ABBOTT LABS,DIV PHARMACEUT DISCOVERY,NMR RES,ABBOTT PK,IL 60064	Abbott Laboratories			Yoon, Ho Sup/A-2193-2011	Yoon, Ho Sup/0000-0002-8243-3904				CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; DAVIS LH, 1994, J BIOL CHEM, V269, P4409; GIBSON S, 1993, BLOOD, V82, P1561; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; MANO H, 1993, ONCOGENE, V8, P417; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SHAW G, 1993, BIOCHEM BIOPH RES CO, V195, P1145, DOI 10.1006/bbrc.1993.2164; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0	19	672	681	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 8	1994	371	6493					168	170		10.1038/371168a0	http://dx.doi.org/10.1038/371168a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF191	8072546	Green Accepted			2022-12-24	WOS:A1994PF19100067
J	COLEMAN, DE; BERGHUIS, AM; LEE, E; LINDER, ME; GILMAN, AG; SPRANG, SR				COLEMAN, DE; BERGHUIS, AM; LEE, E; LINDER, ME; GILMAN, AG; SPRANG, SR			STRUCTURES OF ACTIVE CONFORMATIONS OF G(I-ALPHA-1) AND THE MECHANISM OF GTP HYDROLYSIS	SCIENCE			English	Article							ELONGATION-FACTOR TU; H-RAS P21; ALPHA-SUBUNITS; G-PROTEINS; ADENYLATE-CYCLASE; CRYSTAL-STRUCTURE; TRIPHOSPHATE CONFORMATION; STEREOCHEMICAL COURSE; REGULATORY COMPONENT; SIGNAL TRANSDUCTION	Mechanisms of guanosine triphosphate (GTP) hydrolysis by members of the G protein alpha subunit-p21(ras) superfamily of guanosine triphosphatases have been studied extensively but have not been well understood. High-resolution x-ray structures of the GTP gamma S and GDP.AlF4- complexes formed by the G protein G(i alpha 1) demonstrate specific roles in transition-state stabilization for two highly conserved residues. Glutamine(204)(Gln(61) in p21(ras)) stabilizes and orients the hydrolytic water in the trigonal-bipyramidal transition state. Arginine 178 stabilizes the negative charge at the equatorial oxygen atoms of the pentacoordinate phosphate intermediate. Conserved only in the G(alpha) family, this residue may account for the higher hydrolytic rate of G(alpha) proteins relative to those of the p21(ras) family members. The fold of G(i alpha 1) differs from that of the homologous G(t alpha) subunit in the conformation of a helix-loop sequence located in the alpha-helical domain that is characteristic of these proteins; this site may participate in effector binding. The amino-terminal 33 residues are disordered in GTP gamma S-G(i alpha 1), suggesting a mechanism that may promote release of the beta gamma subunit complex when the a subunit is activated by GTP.	UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Berghuis, Albert M/A-6495-2008; Linder, Maurine/AAU-9999-2021	Linder, Maurine/0000-0003-2202-9712; Berghuis, Albert/0000-0002-2663-025X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM034497] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 46371] Funding Source: Medline; NIGMS NIH HHS [GM34497] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONELLI M, 1994, FEBS LETT, V340, P249, DOI 10.1016/0014-5793(94)80148-7; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CASSEL D, 1977, P NATL ACAD SCI USA, V74, P3307, DOI 10.1073/pnas.74.8.3307; CHUNG HH, 1993, SCIENCE, V259, P806, DOI 10.1126/science.8430333; COLEMAN DE, 1994, J MOL BIOL, V238, P630, DOI 10.1006/jmbi.1994.1320; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; Doublie S., 1992, CRYSTALLIZATION NUCL, P311; ECCLESTON JF, 1982, J BIOL CHEM, V257, P5046; FEUERSTEIN J, 1989, J BIOL CHEM, V264, P6188; FRECH M, 1994, BIOCHEMISTRY-US, V33, P3237, DOI 10.1021/bi00177a014; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P3396; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; JONES DT, 1987, J BIOL CHEM, V262, P14241; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; KLEUSS C, IN PRESS P NATL ACAD; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE E, 1994, METHOD ENZYMOL, V237, P146; LEE E, 1992, J BIOL CHEM, V267, P1212; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1990, J BIOL CHEM, V265, P8243; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MIXON M, UNPUB; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMITH JL, 1991, ISOMORPHOUS REPLACEM, P96; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; VANDOP C, 1984, J BIOL CHEM, V259, P696; 1991, CCP4 SERC UK COLLABO	61	740	755	1	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 2	1994	265	5177					1405	1412		10.1126/science.8073283	http://dx.doi.org/10.1126/science.8073283			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	8073283				2022-12-24	WOS:A1994PE73300037
J	BRITTENHAM, GM; GRIFFITH, PM; NIENHUIS, AW; MCLAREN, CE; YOUNG, NS; TUCKER, EE; ALLEN, CJ; FARRELL, DE; HARRIS, JW				BRITTENHAM, GM; GRIFFITH, PM; NIENHUIS, AW; MCLAREN, CE; YOUNG, NS; TUCKER, EE; ALLEN, CJ; FARRELL, DE; HARRIS, JW			EFFICACY OF DEFEROXAMINE IN PREVENTING COMPLICATIONS OF IRON OVERLOAD IN PATIENTS WITH THALASSEMIA MAJOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHELATION-THERAPY; CARDIAC-FUNCTION; DESFERRIOXAMINE; STORES; ANEMIA; SURVIVAL	Background. To determine whether deferoxamine prevents the complications of transfusional iron overload in thalassemia major, we evaluated 59 patients (30 were female and 29 male; age range, 7 to 31 years) periodically for 4 to 10 years or until death. Methods. At each follow-up visit, we performed a detailed clinical and laboratory evaluation and measured hepatic iron stores with a noninvasive magnetic device. Results. The body iron burden as assessed by magnetic measurement of hepatic iron stores was closely correlated (R = 0.89, P < 0.001) with the ratio of cumulative transfusional iron load to cumulative deferoxamine use (expressed in millimoles of iron per kilogram of body weight, in relation to grams of deferoxamine per kilogram, transformed into the natural logarithm). Each increase of one unit in the natural logarithm of the ratio (transfusional iron load to deferoxamine use) was associated with an increased risk of impaired glucose tolerance (relative risk, 19.3; 95 percent confidence interval, 4.8 to 77.4), diabetes mellitus (relative risk, 9.2; 95 percent confidence interval, 1.8 to 47.7), cardiac disease (relative risk, 9.9; 95 percent confidence interval, 1.9 to 51.2), and death (relative risk, 12.6; 95 percent confidence interval, 2.4 to 65.4). All nine deaths during the study occurred among the 23 patients who had begun chelation therapy later and used less deferoxamine in relation to their transfusional iron load (P < 0.001). Conclusions. The early use of deferoxamine in an amount proportional to the transfusional iron load reduces the body iron burden and helps protect against diabetes mellitus, cardiac disease, and early death in patients with thalassemia major.	CASE WESTERN RESERVE UNIV, DEPT MED, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, DEPT PHYS, CLEVELAND, OH 44106 USA; MOORHEAD STATE UNIV, DEPT MATH, MOORHEAD, MN 56560 USA; ST JUDE CHILDRENS RES HOSP, MEMPHIS, TN 38105 USA; NHLBI, CLIN HEMATOL BRANCH, BETHESDA, MD 20892 USA; NHLBI, CARDIOL BRANCH, BETHESDA, MD 20892 USA	Case Western Reserve University; Case Western Reserve University; Minnesota State Colleges & Universities; Minnesota State University Moorhead; St Jude Children's Research Hospital; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)					NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM025105] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K06DK014370] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM-25105] Funding Source: Medline; NIDDK NIH HHS [DK-14370] Funding Source: Medline; FDA HHS [FD-U-000532] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); FDA HHS		BARRY M, 1974, BMJ-BRIT MED J, V2, P16, DOI 10.1136/bmj.2.5909.16; BORGNAPIGNATTI C, 1985, J PEDIATR-US, V106, P150, DOI 10.1016/S0022-3476(85)80488-1; BRITTENHAM GM, 1988, ANN NY ACAD SCI, V526, P199, DOI 10.1111/j.1749-6632.1988.tb55506.x; BRITTENHAM GM, 1982, NEW ENGL J MED, V307, P1671, DOI 10.1056/NEJM198212303072703; BRITTENHAM GM, 1993, AM J HEMATOL, V42, P81, DOI 10.1002/ajh.2830420116; BRITTENHAM GM, 1992, BLOOD, V80, P569; BRITTENHAM GM, 1994, IRON METABOLISM HLTH, P31; BRONSPIEGELWEINTROB N, 1990, NEW ENGL J MED, V323, P713, DOI 10.1056/NEJM199009133231104; COHEN A, 1984, BRIT J HAEMATOL, V58, P369, DOI 10.1111/j.1365-2141.1984.tb06096.x; COHEN A, 1990, J PEDIATR-US, V117, P326, DOI 10.1016/S0022-3476(05)80556-6; COX DR, 1972, J R STAT SOC B, V34, P187; DESANCTIS V, 1988, ARCH DIS CHILD, V63, P58, DOI 10.1136/adc.63.1.58; EHLERS KH, 1991, J PEDIATR-US, V118, P540, DOI 10.1016/S0022-3476(05)83374-8; Fleiss JL, 1981, STAT METHODS RATES P; FOSBURG MT, 1990, BLOOD, V76, P435; FREEDMAN MH, 1990, AM J DIS CHILD, V144, P565, DOI 10.1001/archpedi.1990.02150290059028; FREEMAN AP, 1989, CLIN LAB HAEMATOL, V11, P299, DOI 10.1111/j.1365-2257.1989.tb00227.x; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P740; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LUCARELLI G, 1993, NEW ENGL J MED, V329, P840, DOI 10.1056/NEJM199309163291204; MARCUS RE, 1984, LANCET, V1, P392; Modell B., 1984, CLIN APPROACH THALAS; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PIOMELLI S, 1993, BAILLIERE CLIN HAEM, V6, P287, DOI 10.1016/S0950-3536(05)80073-3; Pippard M J, 1989, Prog Clin Biol Res, V309, P85; POOTRAKUL P, 1988, BLOOD, V71, P1124; PROPPER RD, 1977, NEW ENGL J MED, V297, P418, DOI 10.1056/NEJM197708252970804; PROPPER RD, 1976, NEW ENGL J MED, V294, P1421, DOI 10.1056/NEJM197606242942603; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; SMITH RS, 1962, BMJ-BRIT MED J, P1577, DOI 10.1136/bmj.2.5319.1577; WOLFE L, 1985, NEW ENGL J MED, V312, P1600, DOI 10.1056/NEJM198506203122503; ZURLO MG, 1989, LANCET, V2, P27, DOI 10.1016/S0140-6736(89)90264-X	32	648	668	1	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 1	1994	331	9					567	573		10.1056/NEJM199409013310902	http://dx.doi.org/10.1056/NEJM199409013310902			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD699	8047080	Bronze			2022-12-24	WOS:A1994PD69900002
J	NICOLAIDES, NC; PAPADOPOULOS, N; LIU, B; WEI, YF; CARTER, KC; RUBEN, SM; ROSEN, CA; HASELTINE, WA; FLEISCHMANN, RD; FRASER, CM; ADAMS, MD; VENTER, JC; DUNLOP, MG; HAMILTON, SR; PETERSEN, GM; DELACHAPELLE, A; VOGELSTEIN, B; KINZLER, KW				NICOLAIDES, NC; PAPADOPOULOS, N; LIU, B; WEI, YF; CARTER, KC; RUBEN, SM; ROSEN, CA; HASELTINE, WA; FLEISCHMANN, RD; FRASER, CM; ADAMS, MD; VENTER, JC; DUNLOP, MG; HAMILTON, SR; PETERSEN, GM; DELACHAPELLE, A; VOGELSTEIN, B; KINZLER, KW			MUTATIONS OF 2 PMS HOMOLOGS IN HEREDITARY NONPOLYPOSIS COLON-CANCER	NATURE			English	Article							DNA MISMATCH REPAIR; COLORECTAL-CANCER; SEQUENCE	HEREDITARY nonpolyposis colorectal cancer (HNPCC) is one of man's commonest hereditary diseases(1). Several studies have implicated a defect in DNA mismatch repair in the pathogenesis of this disease(2-8). In particular, hMSH2 and hMLH1 homologues of the bacterial DNA mismatch repair genes mutS and mutL, respectively, were shown to be mutated in a subset of HNPCC cases(9-16). Here we report the nucleotide sequence, chromosome localization and mutational analysis of hPMS1 and hPMS2, two additional homologues of the prokaryotic mutL gene. Both hPMS1 and hPMS2 were found to be mutated in the germline of HNPCC patients. This doubles the number of genes implicated in HNPCC and may help explain the relatively high incidence of this disease.	JOHNS HOPKINS ONCOL CTR,BALTIMORE,MD 21231; HUMAN GENOME SCI INC,ROCKVILLE,MD 20850; INST GENOM RES,GAITHERSBURG,MD 20878; WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD 21205; UNIV HELSINKI,DEPT MED GENET,SF-00290 HELSINKI,FINLAND	Johns Hopkins University; Johns Hopkins Medicine; GlaxoSmithKline; Human Genome Sciences Inc; J. Craig Venter Institute; University of Edinburgh; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Helsinki			Dunlop, Malcolm G/F-1973-2011; Papadopoulos, Nickolas/K-7272-2012	Dunlop, Malcolm G/0000-0002-3033-5851; Fraser, Claire/0000-0003-1462-2428				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JOHNSON CV, 1991, METHOD CELL BIOL, V35, P73; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LIU B, INPRESS CANCER RES; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; NYSTROMLAHTI M, 1994, P NATL ACAD SCI USA, V91, P6054, DOI 10.1073/pnas.91.13.6054; PALOMBO F, 1994, NATURE, V367, P417, DOI 10.1038/367417a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PEINADO MA, 1992, P NATL ACAD SCI USA, V89, P10065, DOI 10.1073/pnas.89.21.10065; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; PROLLA TA, IN PRESS SCIENCE; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, J BIOL CHEM, V269, P14367; VANDERLUIJT R, 1994, GENOMICS, V208, P1	29	1384	1440	1	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 1	1994	371	6492					75	80		10.1038/371075a0	http://dx.doi.org/10.1038/371075a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE381	8072530				2022-12-24	WOS:A1994PE38100055
J	ABRAHAMS, JP; LESLIE, AGW; LUTTER, R; WALKER, JE				ABRAHAMS, JP; LESLIE, AGW; LUTTER, R; WALKER, JE			STRUCTURE AT 2.8-ANGSTROM RESOLUTION OF F1-ATPASE FROM BOVINE HEART-MITOCHONDRIA	NATURE			English	Article							ATP SYNTHASE; BETA-SUBUNIT; OXIDATIVE-PHOSPHORYLATION; ELECTRON-MICROSCOPY; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; F1-ATPASE; PROTEIN; BINDING; MECHANISM	In the crystal structure of bovine mitochondrial F-1-ATPase determined at 2.8 Angstrom resolution, the three catalytic beta-subunits differ in conformation and in the bound nucleotide. The structure supports a catalytic mechanism in intact ATP synthase in which the three catalytic subunits are in different states of the catalytic cycle at any instant. Interconversion of the states may be achieved by rotation of the alpha(3) beta(3) subassembly relative to an alpha-helical domain of the gamma-subunit.	MRC, MOLEC BIOL LAB, CAMBRIDGE CB2 2QH, ENGLAND	MRC Laboratory Molecular Biology			Abrahams, Jan Pieter/AAE-4319-2020; Abrahams, Jan Pieter/G-7287-2016	Abrahams, Jan Pieter/0000-0001-8216-1868; Abrahams, Jan Pieter/0000-0001-8216-1868; Walker, John/0000-0001-7929-2162				ABRAHAMS JP, 1993, EMBO J, V12, P1775, DOI 10.1002/j.1460-2075.1993.tb05825.x; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BIANCHET M, 1991, J BIOL CHEM, V266, P21197; BOEKEMA EJ, 1986, BIOCHIM BIOPHYS ACTA, V851, P353, DOI 10.1016/0005-2728(86)90071-X; BOEKEMA EJ, 1992, BIOCHIM BIOPHYS ACTA, V1098, P131, DOI 10.1016/S0005-2728(05)80328-7; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1993, XPLOR VERSION 3 1 MA; BULLOUGH DA, 1989, BIOCHIM BIOPHYS ACTA, V975, P377, DOI 10.1016/S0005-2728(89)80346-9; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; COLLINSON IR, IN PRESS BIOCH J; COLLINSON IR, IN PRESS J MOL BIOL; COX GB, 1986, BIOCHIM BIOPHYS ACTA, V849, P62, DOI 10.1016/0005-2728(86)90096-4; COX GB, 1984, BIOCHIM BIOPHYS ACTA, V768, P201, DOI 10.1016/0304-4173(84)90016-8; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; CROSS RL, 1981, ANNU REV BIOCHEM, V50, P681, DOI 10.1146/annurev.bi.50.070181.003341; DREYFUS G, 1993, J BACTERIOL, V175, P3131, DOI 10.1128/JB.175.10.3131-3138.1993; ESCH FS, 1978, J BIOL CHEM, V253, P6100; ESCH FS, 1981, J BIOL CHEM, V256, P9084; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; GANN J, 1986, BIOCHEMISTRY-US, V25, P4431; GARIN J, 1994, BIOCHEMISTRY-US, V33, P3772, DOI 10.1021/bi00178a038; HOLLEMANS M, 1983, J BIOL CHEM, V258, P9307; ISSARTEL JP, 1992, EXPERIENTIA, V48, P351, DOI 10.1007/BF01923429; JACKSON PJ, 1986, BIOCHEM J, V235, P577, DOI 10.1042/bj2350577; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KJELDGAARD M, 1993, STRUCTURE, V1, P350; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; LUTTER R, 1993, J MOL BIOL, V229, P787, DOI 10.1006/jmbi.1993.1081; MACNAB RM, 1992, ANNU REV GENET, V26, P131, DOI 10.1146/annurev.ge.26.120192.001023; MILLBURN MV, 1990, SCIENCE, V247, P939; MITCHELL P, 1985, FEBS LETT, V182, P1, DOI 10.1016/0014-5793(85)81142-X; Mitchell P, 1966, BIOL REV, V41, P455; MUELLER C W, 1992, Journal of Molecular Biology, V224, P159; NICOLLS A, 1991, PROTEINS, V11, P281; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAI EF, 1977, J MOL BIOL, V114, P37, DOI 10.1016/0022-2836(77)90281-9; PENEFSKY HS, 1991, ADV ENZYMOL RELATED, V64, P173; PERLIN DS, 1984, BIOCHEMISTRY-US, V23, P4998, DOI 10.1021/bi00316a026; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; WALKER JE, 1990, PHILOS T ROY SOC B, V326, P367, DOI 10.1098/rstb.1990.0018; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; WILKENS S, 1994, BIOL CHEM H-S, V375, P43; ZHUO SQ, 1993, BIOCHEMISTRY-US, V32, P2219, DOI 10.1021/bi00060a013; 1979, SERC4 DAR LAB COLL C	50	2713	2775	8	225	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 25	1994	370	6491					621	628		10.1038/370621a0	http://dx.doi.org/10.1038/370621a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD310	8065448				2022-12-24	WOS:A1994PD31000041
J	WIESEN, AR; HOSPENTHAL, DR; BYRD, JC; GLASS, KL; HOWARD, RS; DIEHL, LF				WIESEN, AR; HOSPENTHAL, DR; BYRD, JC; GLASS, KL; HOWARD, RS; DIEHL, LF			EQUILIBRATION OF HEMOGLOBIN CONCENTRATION AFTER TRANSFUSION IN MEDICAL INPATIENTS NOT ACTIVELY BLEEDING	ANNALS OF INTERNAL MEDICINE			English	Note							UNITED-STATES; BLOOD; COLLECTION		WALTER REED ARMY MED CTR, WASHINGTON, DC 20307 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center								Barnes A, 1993, HEMATOLOGY CLIN LAB, P1653; GREENFIELD RH, 1989, ANN EMERG MED, V18, P51, DOI 10.1016/S0196-0644(89)80312-9; GROVERASMUSSEN M, 1961, NEW ENGL J MED, V264, P1034, DOI 10.1056/NEJM196105182642006; HUBER H, 1964, BRIT J HAEMATOL, V10, P567, DOI 10.1111/j.1365-2141.1964.tb00733.x; Johnston M, 1985, TRANSFUSION THERAPY, P35; Jones J, 1993, BLOOD TRANSFUSION CL, P423; KEELING RP, 1987, FUNDAMENTALS CLIN HE, P932; MCCULLOUGH J, 1993, JAMA-J AM MED ASSOC, V269, P2239, DOI 10.1001/jama.269.17.2239; MOLLISON PL, 1947, CLIN SCI, V6, P137; NADLER SB, 1962, SURGERY, V51, P224; OCONNELL B, 1988, TRANSFUSION, V28, P66, DOI 10.1046/j.1537-2995.1988.28188127957.x; Rovin BH., 1989, MANUAL MED THERAPEUT, P221; Sekhsaria S, 1991, J Perinatol, V11, P161; Simon TL, 1991, PRINCIPLES TRANSFUSI, P97; SIMPSON MB, 1984, LABORATORY HEMATOLOG, P1149; SURGENOR DM, 1990, NEW ENGL J MED, V322, P1646, DOI 10.1056/NEJM199006073222306; WALLACE EL, 1993, TRANSFUSION, V33, P139, DOI 10.1046/j.1537-2995.1993.33293158046.x; WIDMANN FK, 1985, TECHNICAL MANUAL AM, P7; WINTROBE MM, 1981, CLIN HEMATOLOGY, P8	19	64	69	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1994	121	4					278	280		10.7326/0003-4819-121-4-199408150-00009	http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00009			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB102	8037410	Green Submitted			2022-12-24	WOS:A1994PB10200009
J	PENDERGRAST, PS; EBRIGHT, YW; EBRIGHT, RH				PENDERGRAST, PS; EBRIGHT, YW; EBRIGHT, RH			HIGH-SPECIFICITY DNA CLEAVAGE AGENT - DESIGN AND APPLICATION TO KILOBASE AND MEGABASE DNA SUBSTRATES	SCIENCE			English	Article							GENE ACTIVATOR PROTEIN; TRIPLE-HELIX FORMATION; SITE-SPECIFIC CLEAVAGE; ESCHERICHIA-COLI; SINGLE-SITE; DUPLEX DNA; CRYSTAL-STRUCTURE; TRANSCRIPTION ACTIVATION; NUCLEASE ACTIVITY; RECEPTOR PROTEIN	Strategies to cleave double-stranded DNA at specific DNA sites longer than those of restriction endonucleases (longer than 8 base pairs) have applications in chromosome mapping, chromosome cloning, and chromosome sequencing-provided that the strategies yield high DNA-cleavage efficiency and high DNA-cleavage specificity. In this report, the DNA-cleaving moiety copper:o-phenanthroline was attached to the sequence-specific DNA binding protein catabolite activator protein (CAP) at an amino acid that, because of a difference in DNA bending, is close to DNA in the specific CAP-DNA complex but is not close to DNA in the nonspecific CAP-DNA complex. The resulting CAP derivative, OP(26)CAP, cleaved kilobase and megabase DNA substrates at a 22- base pair consensus DNA site with high efficiency and exhibited no detectable nonspecific DNA-deavage activity.	RUTGERS STATE UNIV, DEPT CHEM, NEW BRUNSWICK, NJ 08855 USA; RUTGERS STATE UNIV, WAKSMAN INST, NEW BRUNSWICK, NJ 08855 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick			Ebright, Richard/O-3321-2019	Ebright, Richard/0000-0001-8915-7140	NIGMS NIH HHS [GM41376] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041376] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATTAGLIA LP, 1977, ACTA CRYSTALLOGR B, V33, P3886, DOI 10.1107/S0567740877012321; BERG OG, 1988, J MOL BIOL, V200, P709, DOI 10.1016/0022-2836(88)90482-2; CHEN CHB, 1987, SCIENCE, V237, P1197, DOI 10.1126/science.2820056; CHEN CHB, 1993, P NATL ACAD SCI USA, V90, P4206, DOI 10.1073/pnas.90.9.4206; COREY DR, 1989, J AM CHEM SOC, V111, P8523, DOI 10.1021/ja00204a038; EBRIGHT RH, 1990, NUCLEIC ACIDS RES, V18, P1457, DOI 10.1093/nar/18.6.1457; EBRIGHT RH, 1989, NUCLEIC ACIDS RES, V17, P10295, DOI 10.1093/nar/17.24.10295; EBRIGHT RH, 1990, P NATL ACAD SCI USA, V87, P2882, DOI 10.1073/pnas.87.8.2882; EBRIGHT RH, 1987, P NATL ACAD SCI USA, V84, P6083, DOI 10.1073/pnas.84.17.6083; FERRIN LJ, 1991, SCIENCE, V254, P1494, DOI 10.1126/science.1962209; FRANCOIS JC, 1989, P NATL ACAD SCI USA, V86, P9702, DOI 10.1073/pnas.86.24.9702; GUNASEKERA A, 1992, J BIOL CHEM, V267, P14713; KANG C, 1993, BIOTECHNIQUES, V15, P659; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KOOB M, 1988, SCIENCE, V241, P1084, DOI 10.1126/science.2842862; KOOB M, 1990, SCIENCE, V250, P271, DOI 10.1126/science.2218529; KOOB M, 1992, NUCLEIC ACIDS RES, V20, P5831, DOI 10.1093/nar/20.21.5831; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; PEI D, 1990, J AM CHEM SOC, V112, P4579, DOI 10.1021/ja00167a085; PEI D, 1991, J AM CHEM SOC, V113, P9398, DOI 10.1021/ja00024a072; PEI DH, 1990, P NATL ACAD SCI USA, V87, P9858, DOI 10.1073/pnas.87.24.9858; POVSIC TJ, 1992, J AM CHEM SOC, V114, P5934, DOI 10.1021/ja00041a005; SAXE SA, 1979, BIOCHEMISTRY-US, V18, P255, DOI 10.1021/bi00569a003; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SHANG ZG, 1994, P NATL ACAD SCI USA, V91, P118, DOI 10.1073/pnas.91.1.118; SIGMAN DS, 1986, ACCOUNTS CHEM RES, V19, P180, DOI 10.1021/ar00126a004; STROBEL SA, 1991, NATURE, V350, P172, DOI 10.1038/350172a0; STROBEL SA, 1991, SCIENCE, V254, P1639, DOI 10.1126/science.1836279; STROBEL SA, 1988, J AM CHEM SOC, V110, P7927, DOI 10.1021/ja00231a082; STROBEL SA, 1990, SCIENCE, V249, P73, DOI 10.1126/science.2195655; SUTTON CL, 1993, BIOCHEMISTRY-US, V32, P4225, DOI 10.1021/bi00067a009; TAKAHASHI M, 1979, NUCLEIC ACIDS RES, V7, P1699, DOI 10.1093/nar/7.6.1699; VIPOND IB, 1993, MOL MICROBIOL, V9, P225, DOI 10.1111/j.1365-2958.1993.tb01685.x; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WEBER IT, 1984, NUCLEIC ACIDS RES, V12, P8475, DOI 10.1093/nar/12.22.8475; Winkler F. K., 1992, CURR OPIN STRUC BIOL, V2, P93; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZHANG XP, 1991, J BIOMOL STRUCT DYN, V9, P463, DOI 10.1080/07391102.1991.10507929; ZHANG XP, 1992, J BIOL CHEM, V267, P8136; ZHANG XP, 1990, P NATL ACAD SCI USA, V87, P4717, DOI 10.1073/pnas.87.12.4717; ZHOU YH, 1993, P NATL ACAD SCI USA, V90, P6081, DOI 10.1073/pnas.90.13.6081	45	51	52	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 12	1994	265	5174					959	962		10.1126/science.8052855	http://dx.doi.org/10.1126/science.8052855			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052855				2022-12-24	WOS:A1994PB49900045
J	NICOLL, A; MCGARRIGLE, C; HEPTONSTALL, J; PARRY, J; MAHONEY, A; NICHOLAS, S; HUTCHINSON, E; GILL, ON				NICOLL, A; MCGARRIGLE, C; HEPTONSTALL, J; PARRY, J; MAHONEY, A; NICHOLAS, S; HUTCHINSON, E; GILL, ON			PREVALENCE OF HIV-INFECTION IN PREGNANT-WOMEN IN LONDON AND ELSEWHERE IN ENGLAND	BRITISH MEDICAL JOURNAL			English	Article									CENT PUBL HLTH LAB,HEPATITIS & RETROVIRUS LAB,LONDON,ENGLAND; PUBL HLTH LAB SERV,STAT UNIT,LONDON,ENGLAND	Public Health England; Public Health England	NICOLL, A (corresponding author), PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON NW9 5EQ,ENGLAND.		McGarrigle, Christine/J-8331-2017	McGarrigle, Christine/0000-0001-5814-5673				COUTURIER E, 1993, B EPIDEMIOL HEBDOM, V38, P175; Gilbart V L, 1992, Commun Dis Rep CDR Rev, V2, pR55; NICOLL A, IN PRESS COMMUNICABL; PARKER S, 1992, AIDS, V6, P1031; PERUCCI CA, 1993, 9TH P INT C AIDS BER	5	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 6	1994	309	6951					376	377		10.1136/bmj.309.6951.376a	http://dx.doi.org/10.1136/bmj.309.6951.376a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB316	8081138	Green Published			2022-12-24	WOS:A1994PB31600020
J	SEAGROATT, V; GOLDACRE, M				SEAGROATT, V; GOLDACRE, M			MEASURES OF EARLY POSTOPERATIVE MORTALITY - BEYOND HOSPITAL FATALITY RATES	BRITISH MEDICAL JOURNAL			English	Article							DISCHARGE	Objective-To quantify the short term risk of postoperative mortality in ways which take account of deaths after discharge and the background risks of death in patients who come to operation. Design-Analysis of linked abstracts of hospital admission records and death certificates for common operations. Setting-Six health districts in the Oxford region. Subjects-Records of 223529 operations performed in 1980-6. Main outcome measures-In hospital fatality rates, case fatality rates, and standardised mortality ratios at selected time periods during the year after operation and the ratio of early ( < 30 days) to late (90-364 days after operation) fatality rates. Results-Fatality rates throughout the year after operations performed after emergency admissions were generally higher than those for similar operations performed after elective admissions and higher than expected from population rates. Examples were prostatectomy, hip arthroplasty, inguinal herniorrhaphy, and cholecystectomy. Common elective operations such as inguinal herniorrhaphy and cataract operations showed no early peak in mortality, but others did. These included transurethral prostatectomy (ratio of early to late mortality 2.0; 95% confidence interval 1.3 to 2.6), hysterectomy (3.2; 1.5 to 6.6), hip arthroplasty (3.8; 2.5 to 5.4), and cholecystectomy (6.9; 4.3 to 11.1). Conclusions-Temporal profiles of death rates in the year after operation show which operations have early peaks in mortality and which do not. Emergency and elective operations have very different profiles and should be analysed separately. For elective operations for conditions which pose no immediate threat to life the ratio of early to later fatality rates provides a measure of increase in mortality after operation while allowing for the background risk of death in the patient groups.			SEAGROATT, V (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,HLTH CARE EPIDEMIOL UNIT,OXFORD OX3 7LF,ENGLAND.							Acheson E.D., 1967, MED RECORD LINKAGE; ALDERSON MR, 1975, THEORY PRACTICE PUBL, P29; Breslow N. E., 1987, STATISTICAL METHODS, VII; Buck N, 1987, REPORT CONFIDENTIAL; GARDNER MJ, 1989, STATISTICS CONFIDENC; GOLDACRE M, 1993, LANCET, V342, P283, DOI 10.1016/0140-6736(93)91822-4; Goldacre M J, 1981, Community Med, V3, P60, DOI 10.1007/BF02549440; Iezzoni L I, 1990, Int J Technol Assess Health Care, V6, P272; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; LOFT A, 1991, BRIT J OBSTET GYNAEC, V98, P147, DOI 10.1111/j.1471-0528.1991.tb13360.x; Lubitz J, 1985, Health Care Financ Rev, V6, P103; MACKAY D, 1951, HOSPITAL MORBIDITY S, P7; SEAGROATT V, 1991, BRIT MED J, V303, P1431, DOI 10.1136/bmj.303.6815.1431; VERHEUL HA, 1993, LANCET, V341, P872, DOI 10.1016/0140-6736(93)93073-A; 1975, CLASSIFICATION SURGI; 1840, LANCET, P597; 1993, LANCET, V341, P1183	17	35	36	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 6	1994	309	6951					361	365		10.1136/bmj.309.6951.361	http://dx.doi.org/10.1136/bmj.309.6951.361			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB316	8081132	Green Published			2022-12-24	WOS:A1994PB31600013
J	WANG, YH; AMIRHAERI, S; KANG, S; WELLS, RD; GRIFFITH, JD				WANG, YH; AMIRHAERI, S; KANG, S; WELLS, RD; GRIFFITH, JD			PREFERENTIAL NUCLEOSOME ASSEMBLY AT DNA TRIPLET REPEATS FROM THE MYOTONIC-DYSTROPHY GENE	SCIENCE			English	Article							FRAGILE-X; MUTATIONS; SEQUENCE; INSTABILITY; EXPANSION; DISEASE	The expansion of CTG repeats in DNA occurs in or near genes involved in several human diseases, including myotonic dystrophy and Huntington's disease. Nucleosomes, the basic structural element of chromosomes, consist of 146 base pairs of DNA coiled about an octamer of histone proteins and mediate general transcriptional repression. Electron microscopy was used to examine in vitro the nucleosome assembly of DNA containing repeating CTG triplets. The efficiency of nucleosome formation increased with expanded triplet blocks, suggesting that such blocks may repress transcription through the creation of stable nucleosomes.	UNIV N CAROLINA,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27599; TEXAS A&M UNIV,INST BIOSCI & TECHNOL,HOUSTON,TX 77030	University of North Carolina; University of North Carolina Chapel Hill; Texas A&M University System					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030822, R01GM031819] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30822, GM31819, GM42342] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMIRHAERI S, UNPUB; CARANGO P, 1993, GENOMICS, V18, P340, DOI 10.1006/geno.1993.1474; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; HAYES JJ, 1991, BIOCHEMISTRY-US, V30, P8434, DOI 10.1021/bi00098a022; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HSIEH CH, 1988, CELL, V52, P535, DOI 10.1016/0092-8674(88)90466-7; Kang S.-G., UNPUB; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MUZARD G, 1990, EMBO J, V9, P1289, DOI 10.1002/j.1460-2075.1990.tb08238.x; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; RICHARDS RI, 1992, NAT GENET, V1, P7, DOI 10.1038/ng0492-7; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SHRADER TE, 1990, J MOL BIOL, V216, P69, DOI 10.1016/S0022-2836(05)80061-0; Sinden Richard R., 1992, Current Opinion in Biotechnology, V3, P612, DOI 10.1016/0958-1669(92)90005-4; STELLWAGEN NC, 1983, BIOCHEMISTRY-US, V22, P6186, DOI 10.1021/bi00295a023; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WANG Y, UNPUB; 1993, CELL, V72, P971	25	203	208	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 29	1994	265	5172					669	671		10.1126/science.8036515	http://dx.doi.org/10.1126/science.8036515			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	8036515				2022-12-24	WOS:A1994NZ53800035
J	LIAO, H; LI, G; YEN, TJ				LIAO, H; LI, G; YEN, TJ			MITOTIC REGULATION OF MICROTUBULE CROSS-LINKING ACTIVITY OF CENP-E KINETOCHORE PROTEIN	SCIENCE			English	Article							TAU-PROTEIN; MAP2; SEQUENCE; MITOSIS; TUBULIN; CELLS; DNA	CENP-E is a kinesin-like protein that is transiently bound to kinetochores during early mitosis, becomes redistributed to the spindle midzone at anaphase, and is degraded after cytokinesis. At anaphase, CENP-E may cross-link the interdigitating microtubules in the spindle midzone through a motor-like binding site at the amino terminus and a 99-amino acid carboxyl-terminal domain that bound microtubules in a distinct manner. Phosphorylation of the carboxyl terminus by the mitotic kinase maturation promoting factor (MPF) inhibited microtubule-binding activity before anaphase. Thus, MPF suppresses the microtubule cross-linking activity of CENP-E until anaphase, when its activity is lost.	FOX CHASE CANC CTR,PHILADELPHIA,PA 19111	Fox Chase Cancer Center				JOHNSON, HEATHER/0000-0001-7468-0705; Yen, Tim/0000-0003-2159-0997	NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044762] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927] Funding Source: Medline; NIGMS NIH HHS [GM-44762-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; LEE G, 1989, NEURON, V2, P1615, DOI 10.1016/0896-6273(89)90050-0; LEWIS SA, 1988, SCIENCE, V242, P936, DOI 10.1126/science.3142041; MCINTOSH JR, 1989, SCIENCE, V246, P622; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; PASCHAL BM, 1989, NATURE, V342, P569, DOI 10.1038/342569a0; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; Sawin K E, 1991, Trends Cell Biol, V1, P122, DOI 10.1016/0962-8924(91)90117-R; SERRANO L, 1984, BIOCHEMISTRY-US, V23, P4675, DOI 10.1021/bi00315a024; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0	15	117	120	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 15	1994	265	5170					394	398		10.1126/science.8023161	http://dx.doi.org/10.1126/science.8023161			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023161				2022-12-24	WOS:A1994NW81600040
J	BERO, LA; GLANTZ, SA; RENNIE, D				BERO, LA; GLANTZ, SA; RENNIE, D			PUBLICATION BIAS AND PUBLIC-HEALTH POLICY ON ENVIRONMENTAL TOBACCO-SMOKE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To examine the tobacco industry's claim that publication bias against negative studies invalidates the risk assessment of environmental tobacco smoke (ETS) conducted by the US Environmental Protection Agency and other reviews of the health effects of ETS. Design.-Determination of the number of published original research articles that tested the hypothesis that ETS exposure is associated with adverse health effects and that reported statistically significant (''positive'') or nonsignificant (''negative'') results; the number of articles that concluded that ETS is a health risk; and unpublished studies on the effects of ETS on health. Participants.-Articles identified by a computerized search of the medical literature supplemented with material obtained from the tobacco industry and hand searching. Articles were classified as peer-reviewed journal articles or articles from sponsored symposia. Main Outcome Measure.-The statistical significance of results reported in the article and whether or not the article concluded that ETS exposure is a health risk. Results.-More symposium articles than journal articles were reviews (46% vs 6%; P=.0001). More original journal articles than original symposium articles reported the use of statistical tests (96% vs 54%; P=.0001). Of articles with statistical analyses, similar proportions of journal articles and symposium articles reported statistically significant results (57% vs 47%; P=.329). The conclusions of 80% of the original journal articles were positive, compared with 51% of the original symposium articles (P=.006). Conclusions.-There is no publication bias against statistically nonsignificant results on ETS in the peer-reviewed literature. The high proportion of articles in symposia that reach the conclusion that ETS is not harmful primarily results from the inclusion of review articles.	UNIV CALIF SAN FRANCISCO, SCH MED, DIV CARDIOL, SAN FRANCISCO, CA USA; UNIV CALIF SAN FRANCISCO, SCH PHARM, DIV CLIN PHARM, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	BERO, LA (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, INST HLTH POLICY STUDIES, 1388 SUTTER ST, 11TH FLOOR, SAN FRANCISCO, CA 94109 USA.							[Anonymous], 1986, ENV TOBACCO SMOKE ME; ARMITAGE AK, 1993, J SMOKING RELATED DI, V4, P27; BERO LA, 1994, JAMA-J AM MED ASSOC, V271, P612, DOI 10.1001/jama.271.8.612; BERO LA, 1993, TOB CONTROL, V2, P103; BROWNSON RC, 1987, AM J EPIDEMIOL, V125, P25, DOI 10.1093/oxfordjournals.aje.a114509; BUTLER TL, 1988, THESIS U CALIFORNIA; CALDWELL ADS, 1992, J SMOKING REL DISORD, V4, P1; CATANOSO J, 1992, NEWS REC        0926, pA1; CHALMERS TC, 1990, JAMA-J AM MED ASSOC, V263, P1392, DOI 10.1001/jama.263.10.1392; CHALMERS TC, 1982, T AM CLIN CLIMAT ASS, V8, P388; COOK DJ, 1993, JAMA-J AM MED ASSOC, V269, P2749, DOI 10.1001/jama.269.21.2749; DAVIDSON RA, 1986, J GEN INTERN MED, V1, P155, DOI 10.1007/BF02602327; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; DICKERSIN K, 1990, JAMA-J AM MED ASSOC, V263, P1385, DOI 10.1001/jama.263.10.1385; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; FEUER G, UNPUB ASSESSMENT HLT; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; HUBER GL, 1991, CONSUMERS RES    JUL, P10; HUMBLE CG, 1987, AM J PUBLIC HEALTH, V77, P598, DOI 10.2105/AJPH.77.5.598; KILPATRICK SJ, 1992, INT SURG, V77, P131; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; Lam W. K., 1985, THESIS U HONG KONG; LEE PN, 1992, ENV TOBACCO SMOKE MO; MANTEL N, 1989, INT CONGR SER, V860, P155; MCNAMEE R, 1989, BRIT J IND MED, V46, P143; OLDAKER GB, 1989, J NATL CANCER I, V81, P1424, DOI 10.1093/jnci/81.18.1424; OLDAKER GB, UNPUB ETS PASSENGER; POCOCK SJ, 1990, STAT MED, V9, P657, DOI 10.1002/sim.4780090612; RENNIE D, 1992, JAMA-J AM MED ASSOC, V267, P411, DOI 10.1001/jama.267.3.411; ROTHMAN KJ, 1986, ANN INTERN MED, V105, P445, DOI 10.7326/0003-4819-105-3-445; STEENLAND K, 1992, JAMA-J AM MED ASSOC, V267, P94, DOI 10.1001/jama.267.1.94; STERLING T, UNPUB COMP RISK CHRO; STERLING TD, 1959, J AM STAT ASSOC, V54, P30, DOI 10.2307/2282137; STERLING TD, 1992, EPIDEMIOLOGY, V3, P11, DOI 10.1097/00001648-199201000-00004; STERLING TD, UNPUB BIAS DIAGNOSIS; SUGITA M, 1992, JPN J CLIN ONCOL, V22, P354; SVENSSON C, 1988, SMOKING PASSIVE SMOK; SZKLO M, 1991, J CLIN EPIDEMIOL, V44, pS109; VANDENBROUCKE JP, 1988, BRIT MED J, V296, P391, DOI 10.1136/bmj.296.6619.391; VARELA LR, 1987, THESIS YALE U; WEETMAN DF, 1992, INDOOR ENVIRON, V1, P197; WELLS AJ, 1988, BRIT MED J, V296, P1128, DOI 10.1136/bmj.296.6629.1128-a; WOODWARD A, 1991, EUR J CANCER, V27, P1472, DOI 10.1016/0277-5379(91)90034-B; WU AHT, 1988, CASE CONTROL STUDY L; 1990, MAILING TOBACCO ACTI; 1984, CIGARETTE SMOKE NONS; SMOKING RESTRICTIONS; 1986, DHHS CDC878398 US DE, P332; 1990, HLTH EFFECTS PASSIVE; 1990, SCI DOES NOT SUPPORT; ENV TOBACCO SMOKE HL; SMOKERS RIGHTS WORKP; SMOKING WORKPLACE SO; 1992, RESPIRATORY HLTH EFF; 1986, TOBACCO SMOKE NONSMO	55	45	46	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 13	1994	272	2					133	136		10.1001/jama.272.2.133	http://dx.doi.org/10.1001/jama.272.2.133			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV424	8015124				2022-12-24	WOS:A1994NV42400014
J	POOLE, CJM; MILLER, S; FILLINGHAM, G				POOLE, CJM; MILLER, S; FILLINGHAM, G			IMMUNITY TO HEPATITIS-B AMONG HEALTH-CARE WORKERS PERFORMING EXPOSURE PRONE PROCEDURES	BRITISH MEDICAL JOURNAL			English	Article									HAMMERSMITH HOSP,OCCUPAT HLTH SERV,LONDON W12 0HS,ENGLAND	Imperial College London	POOLE, CJM (corresponding author), DUDLEY HLTH AUTHOR,CENT CLIN,OCCUPAT HLTH SERV,DUDLEY DY2 7BX,W MIDLANDS,ENGLAND.							ALEXANDER G, 1986, BRIT MED J, V293, P956, DOI 10.1136/bmj.293.6552.956-a; BOXALL EH, 1993, BRIT MED J, V306, P652, DOI 10.1136/bmj.306.6878.652-c; Gupta H L, 1989, J Assoc Physicians India, V37, P618; 1992, IMMUNISATION INFECTI, P114; 1993, PROTECTING HLTH CARE	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					94	95		10.1136/bmj.309.6947.94a	http://dx.doi.org/10.1136/bmj.309.6947.94a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038675	Green Published			2022-12-24	WOS:A1994NW71600018
J	JAMESON, SC; HOGQUIST, KA; BEVAN, MJ				JAMESON, SC; HOGQUIST, KA; BEVAN, MJ			SPECIFICITY AND FLEXIBILITY IN THYMIC SELECTION	NATURE			English	Article							T-CELL-RECEPTOR; TRANSGENIC MICE; POSITIVE SELECTION; PEPTIDE BINDING; BETA-2-MICROGLOBULIN; THYMOCYTES; EXPRESSION; DEFICIENT; TOLERANCE; ANTIGEN	DURING positive selection, developing thymocytes are rescued from programmed cell death by T-cell receptor (TCR)-mediated recognition of major histocompatibility complex (MHC) molecules(1-3). MHC-bound peptides contribute to this process(4-8). Recently we identified individual MHC-binding peptides which can induce positive selection of a single TCR(9). Here we examine peptide fine specificity in positive selection. These data suggest that a direct TCR-peptide interaction occurs during this event, and strengthens the correlation between selecting peptides and TCR antagonists(9,10). Certain positively selecting peptides are weakly antigenic(9). We demonstrate that thymocytes 'educated' on such a peptide are specifically non-responsive to it and have decreased CD8 expression levels. Similar reduction of CD8 expression on mature T cells converts a TCR agonist into a TCR antagonist. These data indicate that thymocytes may maintain self-tolerance towards a positively selecting ligand by regulating co-receptor expression.			JAMESON, SC (corresponding author), UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT IMMUNOL,SEATTLE,WA 98195, USA.		Jameson, Stephen C/D-9892-2013	Jameson, Stephen C/0000-0001-9137-1146; Hogquist, Kristin/0000-0001-9963-5687	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019335] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIAID NIH HHS [R01 AI019335, R01 AI019335-19] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDER J, 1993, J IMMUNOL, V150, P1; ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; AUPHAN N, 1992, INT IMMUNOL, V4, P1419, DOI 10.1093/intimm/4.12.1419; BERG LJ, 1990, CELL, V60, P1043, DOI 10.1016/0092-8674(90)90352-F; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; EVAVOLD BD, 1993, IMMUNOL TODAY, V14, P602, DOI 10.1016/0167-5699(93)90200-5; GREGOIRE C, 1991, P NATL ACAD SCI USA, V88, P8077, DOI 10.1073/pnas.88.18.8077; HAMMERLING GJ, 1991, IMMUNOL REV, V122, P47, DOI 10.1111/j.1600-065X.1991.tb00596.x; HOGQUIST KA, 1993, J EXP MED, V177, P1469, DOI 10.1084/jem.177.5.1469; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; LEE NA, 1992, J EXP MED, V175, P1013, DOI 10.1084/jem.175.4.1013; MOLLER G, 1993, IMMUNOL REV, V135; ROBEY EA, 1992, CELL, V69, P1089, DOI 10.1016/0092-8674(92)90631-L; ROTHENBERG EV, 1992, ADV IMMUNOL, V51, P85, DOI 10.1016/S0065-2776(08)60487-3; SEBZDA E, 1994, SCIENCE, V263, P1615, DOI 10.1126/science.8128249; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; SPRENT J, 1987, ADV IMMUNOL, V41, P39, DOI 10.1016/S0065-2776(08)60030-9; VITIELLO A, 1990, SCIENCE, V250, P1423, DOI 10.1126/science.2124002; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZUGIC JN, 1990, NATURE, V344, P65	25	209	209	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 30	1994	369	6483					750	752		10.1038/369750a0	http://dx.doi.org/10.1038/369750a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU581	8008067	Green Accepted			2022-12-24	WOS:A1994NU58100062
J	AUSTOKER, J; SANDERS, D; FOWLER, G				AUSTOKER, J; SANDERS, D; FOWLER, G			CANCER PREVENTION IN PRIMARY-CARE - SMOKING AND CANCER - SMOKING CESSATION	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Smoking is the single most important cause of cancer. The risk of developing cancer is reduced by stopping smoking and decreases substantially after five years. Reduction in smoking must be central to any programme aimed seriously at the prevention of cancer. An individual approach, based in primary care, has the potential to bring about modest but important reductions in risk. Many randomised trials have shown the effectiveness of various smoking cessation interventions in primary care. Given resource limitations in primary care, individual effort should be focused on those at highest risk who are motivated to stop smoking. A population strategy has considerable advantages over the high risk approach as the potential for reducing morbidity and mortality in the whole population is much greater. The government must acknowledge its major responsibility; the outstanding example of its failure to do this is its persistent refusal to ban outright all forms of advertising and promotion of tobacco. There is clear evidence that a ban would contribute to a reduction in smoking prevalence and especially in the uptake of smoking by children.	UNIV OXFORD, WARNEFORD HOSP, DEPT PSYCHIAT, OXFORD OX3 7JX, ENGLAND; UNIV OXFORD, DEPT PUBL HLTH & PRIMARY CARE, IMPERIAL CANC RES FUND, GEN PRACTICE RES GRP, OXFORD OX2 6PE, ENGLAND	University of Oxford; University of Oxford	AUSTOKER, J (corresponding author), UNIV OXFORD, DEPT PUBL HLTH & PRIMARY CARE, CANC RES CAMPAIGN, PRIMARY CARE EDUC RES GRP, OXFORD OX2 6PE, ENGLAND.							DICLEMENTE CC, 1991, J CONSULT CLIN PSYCH, V59, P295, DOI 10.1037/0022-006X.59.2.295; FOWLER G, 1993, PREVENTION GENERAL P, P106; FOWLER G, IN PRESS PREVENTIVE; KOTTKE TE, 1988, JAMA-J AM MED ASSOC, V259, P2882, DOI 10.1001/jama.1988.03720190050031; RAW M, 1994, GUIDELINES SMOKING P; SANDERS D, 1992, PHP DEP PUBLICATION, V6; SILAGY C, 1994, LANCET, V343, P139, DOI 10.1016/S0140-6736(94)90933-4; TANG JL, 1994, BRIT MED J, V308, P21, DOI 10.1136/bmj.308.6920.21; WALD N, 1991, UK SMOKING STATISTIC; 1992, STOPPING SMOKING MAD; 1993, GIVING UP SMOKING DO; [No title captured]; 1993, EUROPEAN CODE CANCER; [No title captured]; 1992, 11 CANC RES CAMP FAC; 1992, EFFECT TOBACCO ADVER	16	37	37	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 4	1994	308	6942					1478	1482		10.1136/bmj.308.6942.1478	http://dx.doi.org/10.1136/bmj.308.6942.1478			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ229	8019283	Green Published			2022-12-24	WOS:A1994NQ22900020
J	GREENGOLD, NL				GREENGOLD, NL			BY THE NUMBERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 23	1994	271	12					890	890		10.1001/jama.271.12.890	http://dx.doi.org/10.1001/jama.271.12.890			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA743	8080507				2022-12-24	WOS:A1994NA74300002
J	DZIK, WH				DZIK, WH			BLOOD USAGE REVIEWS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							TRANSFUSION				DZIK, WH (corresponding author), HARVARD UNIV,SCH MED,BOSTON,MA, USA.							BABINEAU TJ, 1992, AM J SURG, V164, P22, DOI 10.1016/S0002-9610(05)80640-3; DZIK WH, 1992, CURRENT ISSUES CREAT; GOULD SA, 1986, NEW ENGL J MED, V314, P1653, DOI 10.1056/NEJM198606263142601; LACKRITZ EM, 1992, LANCET, V340, P524, DOI 10.1016/0140-6736(92)91719-O	4	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 21	1994	272	11					896	896		10.1001/jama.272.11.896	http://dx.doi.org/10.1001/jama.272.11.896			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG182	8078172				2022-12-24	WOS:A1994PG18200034
J	SZERSZEN, JB; SZCZYGLOWSKI, K; BANDURSKI, RS				SZERSZEN, JB; SZCZYGLOWSKI, K; BANDURSKI, RS			IAGLU, A GENE FROM ZEA-MAYS INVOLVED IN CONJUGATION OF GROWTH-HORMONE INDOLE-3-ACETIC	SCIENCE			English	Article							ENZYMATIC-HYDROLYSIS; ENZYMIC-SYNTHESIS; BOUND AUXINS; 6-O-INDOL-3-YLACETYL-BETA-D-GLUCOSE; PURIFICATION; EXPRESSION; SEQUENCE; CLONING; ESTERS; FAMILY	Plants contain most of the growth hormone indole-3-acetic acid (IAA) in conjugated forms believed to be inactive in promoting growth. The iaglu gene, which controls the first step in the biosynthesis of the IAA conjugates of Zea mays, encodes (uridine 5'-diphosphate-glucose:indol-3-ylacetyl)-beta-D-glucosyl transferase. Protein synthesized by Escherichia coli that contained cloned 1-O-beta-D-indol-3-ylacetyt-glucose complementary DNA (cDNA) was catalytically active. The predicted amino acid sequence of the cDNA was confirmed by amino-terminal sequencing of the purified enzyme. Homologous nucleotide sequences were found in all plants tested. The blockage or enhancement of iaglu expression may permit regulation of plant growth.	MICHIGAN STATE UNIV, DEPT BOT & PLANT PATHOL, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, DEPT ENERGY, PLANT RES LAB, E LANSING, MI 48824 USA	Michigan State University; Michigan State University								BANDURSK.RS, 1974, PLANT PHYSIOL, V54, P257, DOI 10.1104/pp.54.3.257; BANDURSKI RS, 1988, PLANT GROWTH SUBSTAN, P341; BANDURSKI RS, 1991, PROGR PLANT GROWTH R, P1; COHEN JD, 1982, ANNU REV PLANT PHYS, V33, P403, DOI 10.1146/annurev.pp.33.060182.002155; COHEN JD, 1978, PLANTA, V139, P203, DOI 10.1007/BF00388631; FURTEK D, 1988, PLANT MOL BIOL, V11, P473, DOI 10.1007/BF00039028; GEORGE DG, 1990, METHOD ENZYMOL, V183, P333; JACKSON MR, 1986, NUCLEIC ACIDS RES, V14, P779, DOI 10.1093/nar/14.2.779; JAKUBOWSKA A, 1993, J PLANT PHYSIOL, V142, P61, DOI 10.1016/S0176-1617(11)80108-2; KEGLEVIC D, 1971, CARBOHYD RES, V20, P293, DOI 10.1016/S0008-6215(00)81383-X; KESY JM, 1990, PLANT PHYSIOL, V94, P1598, DOI 10.1104/pp.94.4.1598; KOWALCZYK S, 1991, BIOCHEM J, V279, P509, DOI 10.1042/bj2790509; KOWALCZYK S, 1990, PLANT PHYSIOL, V94, P4, DOI 10.1104/pp.94.1.4; LEZNICKI AJ, 1988, PLANT PHYSIOL, V88, P1481, DOI 10.1104/pp.88.4.1481; MICHALCZUK L, 1982, BIOCHEM J, V207, P273, DOI 10.1042/bj2070273; NOWACKI J, 1980, PLANT PHYSIOL, V65, P422, DOI 10.1104/pp.65.3.422; Reinecke D. M., 1987, Plant hormones and their role in plant growth and development., P24; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; Sambrook J., 1989, MOL CLONING LAB MANU; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P758; SZERSZEN JB, UNPUB; TUKEY RH, 1993, J BIOL CHEM, V268, P15260; WOOSTER R, 1991, BIOCHEM J, V278, P465, DOI 10.1042/bj2780465	23	165	180	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 16	1994	265	5179					1699	1701		10.1126/science.8085154	http://dx.doi.org/10.1126/science.8085154			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG284	8085154				2022-12-24	WOS:A1994PG28400028
J	MINOR, DL; KIM, PS				MINOR, DL; KIM, PS			CONTEXT IS A MAJOR DETERMINANT OF BETA-SHEET PROPENSITY	NATURE			English	Article							HELIX-FORMING TENDENCIES; STREPTOCOCCAL PROTEIN-G; OCCURRING AMINO-ACIDS; STABILITY; PARAMETERS; ALANINE; GLYCINE; PEPTIDE; WATER	RESIDUES in B-sheets occur in two distinct tertiary contexts: central strands, bordered on both sides by other beta-strands, and edge strands, bordered on only a single side by another beta-strand(1). The Delta Delta G values for beta-sheet formation measured at an edge beta-strand of the IgG-binding domain of protein G(GB1) are suite different from those obtained previously(2,3) at a central position in the same protein. In particular, there is no correlation at the edge position with statistically determined beta-sheet-forming preferences(4). The differences between beta-sheet propensities measured at central and edge beta-strands, Delta Delta Delta G values, correlate with the values of water/octanol transfer free energies(5) and side-chain non-polar surface area for the amino acids(6). These results strongly suggest that, unlike alpha-helix formation, beta-sheet formation is determined in large part by tertiary context, even at solvent-accessible sites, and not by intrinsic secondary structure preferences.	MIT,WHITEHEAD INST BIOMED RES,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute	MINOR, DL (corresponding author), MIT,WHITEHEAD INST BIOMED RES,HOWARD HUGHES MED INST,DEPT CHEM,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.							ALEXANDER P, 1992, BIOCHEMISTRY-US, V31, P3597, DOI 10.1021/bi00129a007; BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; CHAKRABARTTY A, 1991, NATURE, V351, P586, DOI 10.1038/351586a0; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FAHNESTOCK SR, 1990, BACTERIAL IMMUNOGLOB; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; FRICK IM, 1992, P NATL ACAD SCI USA, V89, P8532, DOI 10.1073/pnas.89.18.8532; GRATHWOHL C, 1981, BIOPOLYMERS, V20, P2623, DOI 10.1002/bip.1981.360201209; GRONENBORN AM, 1993, J MOL BIOL, V233, P331, DOI 10.1006/jmbi.1993.1514; GRONENBORN AM, 1991, SCIENCE, V253, P657, DOI 10.1126/science.1871600; HOROVITZ A, 1992, J MOL BIOL, V227, P560, DOI 10.1016/0022-2836(92)90907-2; KIM CWA, 1993, NATURE, V362, P267, DOI 10.1038/362267a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIFSON S, 1980, J MOL BIOL, V139, P627, DOI 10.1016/0022-2836(80)90052-2; LIVINGSTONE JR, 1991, BIOCHEMISTRY-US, V30, P4237, DOI 10.1021/bi00231a019; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; MCGREGOR MJ, 1987, J MOL BIOL, V198, P295, DOI 10.1016/0022-2836(87)90314-7; MCINTOSH LP, 1990, BIOCHEMISTRY-US, V29, P6341, DOI 10.1021/bi00479a003; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PADMANABHAN S, 1990, NATURE, V344, P268, DOI 10.1038/344268a0; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; SERRANO L, 1992, NATURE, V356, P453, DOI 10.1038/356453a0; SMITH CK, 1994, BIOCHEMISTRY-US, V33, P5510, DOI 10.1021/bi00184a020; WOJCIK J, 1990, BIOPOLYMERS, V30, P121, DOI 10.1002/bip.360300113; Wuthrich K., 1986, NMR PROTEINS NUCL AC	29	321	335	1	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 15	1994	371	6494					264	267		10.1038/371264a0	http://dx.doi.org/10.1038/371264a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG290	8078589				2022-12-24	WOS:A1994PG29000058
J	WILSON, P; WATSON, R; RALSTON, GE				WILSON, P; WATSON, R; RALSTON, GE			METHADONE-MAINTENANCE IN GENERAL-PRACTICE - PATIENTS, WORKLOAD, AND OUTCOMES	BRITISH MEDICAL JOURNAL			English	Article							INJECTING DRUG-USERS; HIV-INFECTION; PRACTITIONERS; MISUSE; GLASGOW; CLIENTS; LONDON	Objective-To assess recruitment to and workload associated with methadone maintenance clinics in general practice; to investigate the characteristics of patients and outcomes associated with treatment. Design-Study of case notes. Setting-Methadone maintenance clinics run jointly by general practitioners and drug counsellors in two practices in Glasgow, Participants-46 injecting drug users receiving methadone maintenance during an 18 month period, 31 of whom were recruited to clinic based methadone maintenance treatment and 15 of whom were already receiving methadone maintenance treatment from the general practitioners. Mean (SD) age of patients entering treatment was 29.6 (5.5) years'; 29 were male. They had been injecting opiates for a mean 9.9 (5.1) years, and most had a concurrent history of benzodiazepine misuse. Average reported daily intake of heroin was approximately 0.75 g. Participants in treatment had high levels of preexisting morbidity, and most stated that they committed crime daily. Results-2232 patient weeks of treatment were studied. Mean duration of treatment during the study period was 50.7 (21.1) weeks and retention in treatment at 26 weeks was 83%. No evidence of illicit opiate use was obtained at an average of 78% of patients' consultations where methadone had been prescribed in the previous week; for opiate injection the corresponding figure was 86%. Conclusions-Providing methadone maintenance in general practice is feasible. Although costs are considerable, the reduction in drug use, especially of intravenous opiates, is encouraging. Attending clinics also allows this population, in which morbidity is considerable, to receive other health care.	LANSDOWNE CLIN,DEPT CLIN PSYCHOL,GLASGOW,LANARK,SCOTLAND; THE SURGERY,GLASGOW G72 8RW,LANARK,SCOTLAND	University of Glasgow	WILSON, P (corresponding author), THE SURGERY,GLASGOW G42 9JT,LANARK,SCOTLAND.		Wilson, Philip/V-6519-2019	Wilson, Philip/0000-0002-4123-8248				Ball J.C., 2012, EFFECTIVENESS METHAD; BELL J, 1990, BRIT J ADDICT, V85, P1599; BENNETT T, 1986, BRIT J ADDICT, V81, P757; CHALMERS J W T, 1990, Health Bulletin (Edinburgh), V48, P62; COHEN J, 1992, BRIT MED J, V304, P1158, DOI 10.1136/bmj.304.6835.1158; COOPER JR, 1989, JAMA-J AM MED ASSOC, V262, P1664, DOI 10.1001/jama.262.12.1664; FRISCHER M, 1992, AIDS, V6, P1371, DOI 10.1097/00002030-199211000-00022; FRISCHER M, 1992, BRIT J ADDICT, V87, P235; GLANZ A, 1986, BRIT MED J, V293, P543, DOI 10.1136/bmj.293.6546.543; GLASS RM, 1993, JAMA-J AM MED ASSOC, V269, P1995, DOI 10.1001/jama.269.15.1995; GREENWOOD J, 1992, DRUGLINK         JUL, P8; KIDD BA, 1992, BRIT J GEN PRACT, V42, P441; KIDD BA, 1993, BRIT MED J, V306, P1414, DOI 10.1136/bmj.306.6889.1414; KING MB, 1989, BMJ-BRIT MED J, V299, P713, DOI 10.1136/bmj.299.6701.713; LEAVER EJ, 1992, BRIT J GEN PRACT, V42, P465; MCLELLAN AT, 1993, JAMA-J AM MED ASSOC, V269, P1953, DOI 10.1001/jama.269.15.1953; NOVICK DM, 1988, JAMA-J AM MED ASSOC, V259, P3299, DOI 10.1001/jama.259.22.3299; ROBERTSON JR, 1989, BRIT J ADDICT, V84, P377; ROZEWICZ L, 1992, BRIT MED J, V304, P1442, DOI 10.1136/bmj.304.6839.1442; STARK MJ, 1990, AM J DRUG ALCOHOL AB, V16, P67, DOI 10.3109/00952999009001573; TANTAM D, 1993, BRIT J GEN PRACT, V43, P470; WARD J, 1992, BRIT J ADDICT, V87, P447; 1993, SCOTTISH DRUG MISUSE, P8; 1990, GAOHRD90104 GEN ACC	24	64	64	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 10	1994	309	6955					641	644		10.1136/bmj.309.6955.641	http://dx.doi.org/10.1136/bmj.309.6955.641			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PG020	8086989	Green Published			2022-12-24	WOS:A1994PG02000022
J	KAMINER, RK				KAMINER, RK			CHILDREN WITH DISABILITIES - MY PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Freud S, INTERPRETATION DREAM	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 7	1994	272	9					652	652						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PE327	8064976				2022-12-24	WOS:A1994PE32700002
J	TACCIOLI, GE; GOTTLIEB, TM; BLUNT, T; PRIESTLEY, A; DEMENGEOT, J; MIZUTA, R; LEHMANN, AR; ALT, FW; JACKSON, SP; JEGGO, PA				TACCIOLI, GE; GOTTLIEB, TM; BLUNT, T; PRIESTLEY, A; DEMENGEOT, J; MIZUTA, R; LEHMANN, AR; ALT, FW; JACKSON, SP; JEGGO, PA			KU80 - PRODUCT OF THE XRCC5 GENE AND ITS ROLE IN DNA-REPAIR AND V(D)J RECOMBINATION	SCIENCE			English	Article							STRAND BREAK-REPAIR; RAY-SENSITIVE MUTANTS; COMBINED IMMUNE-DEFICIENCY; PRE-B CELLS; IONIZING-RADIATION; PROTEIN-KINASE; HUMAN CHROMOSOME-8; SCID MUTATION; BINDING; COMPLEMENTATION	The radiosensitive mutant xrs-6, derived from Chinese hamster ovary cells, is defective in DNA double-strand break repair and in ability to undergo V(D)J recombination. The human XRCC5 DNA repair gene, which complements this mutant, is shown here through genetic and biochemical evidence to be the 80-kilodalton subunit of the Ku protein. Ku binds to free double-stranded DNA ends and is the DNA-binding component of the DNA-dependent protein kinase. Thus, the Ku protein is involved in DNA repair and in V(D)J recombination, and these results may also indicate a role for the Ku-DNA-dependent protein kinase complex in those same processes.	UNIV SUSSEX,MRC,CELL MUTAT UNIT,BRIGHTON BN1 9RR,ENGLAND; CHILDRENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA; UNIV CAMBRIDGE,WELLCOME CRC INST,CAMBRIDGE CB2 1QR,ENGLAND; UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 1QR,ENGLAND	University of Sussex; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; University of Cambridge; University of Cambridge			demengeot, jocelyne/K-8072-2014; Jackson, Stephen Philip/R-4548-2019; Dry, Kate/I-2328-2014	demengeot, jocelyne/0000-0002-4761-614X; Jackson, Stephen Philip/0000-0001-9317-7937; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020047, R01AI020047] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 20047] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission)		AKROYD JE, 1986, NUCLEIC ACIDS RES, V14, P6901, DOI 10.1093/nar/14.17.6901; ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; CAI QQ, 1994, CYTOGENET CELL GENET, V65, P221, DOI 10.1159/000133635; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; FINNIE N, 1993, BIOCHEM SOC T, V21, P930, DOI 10.1042/bst0210930; FROELICHAMMON SJ, 1994, J BIOL CHEM, V269, P7719; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GELLERT M, 1992, ANNU REV GENET, V22, P425; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GIACCIA A, 1985, SOMAT CELL MOLEC GEN, V11, P485, DOI 10.1007/BF01534842; GIACCIA AJ, 1990, AM J HUM GENET, V47, P459; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GOTTLIEB TM, UNPUB; HAFEZPARAST M, 1993, SOMAT CELL MOLEC GEN, V19, P413, DOI 10.1007/BF01233246; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; HISEH CL, 1993, J BIOL CHEM, V268, P20105; ITOH M, 1993, RADIAT RES, V134, P364, DOI 10.2307/3578198; JEGGO PA, 1991, MUTAT RES, V254, P125, DOI 10.1016/0921-8777(91)90003-8; JEGGO PA, 1983, MUTAT RES, V112, P313, DOI 10.1016/0167-8817(83)90026-3; JEGGO PA, 1989, MUTAT RES, V218, P75, DOI 10.1016/0921-8777(89)90013-X; JEGGO PA, 1992, P NATL ACAD SCI USA, V89, P6423, DOI 10.1073/pnas.89.14.6423; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; KIRCHGESSNER CU, 1993, CANCER RES, V53, P6011; KNUTH MW, 1990, J BIOL CHEM, V265, P17911; KOMATSU K, 1993, HUM MOL GENET, V2, P1031, DOI 10.1093/hmg/2.7.1031; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MIMORI T, 1986, J BIOL CHEM, V261, P2274; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; PRUZAN R, 1992, NUCLEIC ACIDS RES, V20, P5705, DOI 10.1093/nar/20.21.5705; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; TACCIOLI GE, 1994, J BIOL CHEM, V269, P7439; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; THACKER J, 1991, MUTAT RES, V254, P135, DOI 10.1016/0921-8777(91)90004-9; THACKER J, 1994, MUTAGENESIS, V9, P163, DOI 10.1093/mutage/9.2.163; THALER DS, 1987, EMBO J, V6, P3171, DOI 10.1002/j.1460-2075.1987.tb02628.x; WHITMORE GF, 1989, INT J RADIAT BIOL, V56, P657, DOI 10.1080/09553008914551881; ZDZIENICKA MZ, 1988, MUTAT RES, V194, P239; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2	48	584	592	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 2	1994	265	5177					1442	1445		10.1126/science.8073286	http://dx.doi.org/10.1126/science.8073286			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	8073286				2022-12-24	WOS:A1994PE73300047
J	ARNOW, PM; BLAND, LA; GARCIAHOUCHINS, S; FRIDKIN, S; FELLNER, SK				ARNOW, PM; BLAND, LA; GARCIAHOUCHINS, S; FRIDKIN, S; FELLNER, SK			AN OUTBREAK OF FATAL FLUORIDE INTOXICATION IN A LONG-TERM HEMODIALYSIS UNIT	ANNALS OF INTERNAL MEDICINE			English	Article						HEMODIALYSIS UNITS, HOSPITAL; FLUORIDE POISONING; HEMODIALYSIS; DEIONIZATION SYSTEMS; WATER	HYPERKALEMIA	Objective: To determine the cause of an outbreak of acute illness and death in a long-term hemodialysis unit. Design: A retrospective cohort and case-control study of patients receiving hemodialysis and a laboratory study of a model deionization system to purify water for hemodialysis. Setting: An outpatient hemodialysis unit of a university hospital. Patients: 12 patients who became severely ill after hemodialysis treatment and 20 patients who did not become ill after receiving hemodialysis treatment in the same unit. Measurements: Medical and dialysis unit records were reviewed to identify and characterize cases. Fluids for dialysis were tested for toxic substances, and fluoride was measured in patients' serum. Resistivity and fluoride were measured in effluent from a model deionization system operated in the same way as the system associated with illness. Results: During five consecutive hemodialysis shifts, 12 of 15 patients receiving dialysis treatment in one room became acutely ill, with severe pruritus, multiple nonspecific symptoms, and/or fatal ventricular fibrillation (3 patients). None of 17 patients treated in the adjacent room became ill (P < 0.0001). Death was associated with longer hemodialysis time and increased age compared with other patients who became ill. Serum concentrations of fluoride in the sick patients were markedly increased to as high as 716 mu mol/L, and the source of fluoride was the temporary deionization system used to purify water for hemodialysis only in the affected room. Operation of a model deionization system showed how fluoride was adsorbed and then displaced in a massive efflux. Conclusions: Because deionization systems are used widely in hemodialysis and can cause fatal fluoride intoxication, careful design and monitoring are essential.	CTR DIS CONTROL & PREVENT, HOSP INFECT PROGRAM, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA	ARNOW, PM (corresponding author), UNIV CHICAGO HOSP & CLIN, DEPT MED MC5065, 5841 S MARYLAND AVE, CHICAGO, IL 60637 USA.							ABUELO JG, 1993, SEMIN DIALYSIS, V6, P59, DOI 10.1111/j.1525-139X.1993.tb00257.x; ABUKURAH AR, 1972, J AMER MED ASSOC, V222, P816; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; Arduino MJ, 1989, DIALYSIS TRANSPLANT, V18, P655; ARMSTRONG W D, 1964, J Clin Invest, V43, P555; BALTAZAR RF, 1980, CHEST, V78, P660, DOI 10.1378/chest.78.4.660; BERMAN L, 1973, NEW ENGL J MED, V289, P922; Clifford D., 1990, WATER QUALITY TREATM; FLAHERTY JP, 1993, ANN INTERN MED, V119, P1072, DOI 10.7326/0003-4819-119-11-199312010-00003; FUCHS C, 1975, CLIN CHIM ACTA, V60, P157, DOI 10.1016/0009-8981(75)90121-7; HANES CM, 1990, J DENT RES, V69, P282, DOI 10.1177/00220345900690S110; JOHNSON WJ, 1974, KIDNEY INT, V5, P451, DOI 10.1038/ki.1974.64; KESHAVIAH PR, 1989, REPLACEMENT RENAL FU, P189; KUO HC, 1975, ARCH ORAL BIOL, V20, P235, DOI 10.1016/0003-9969(75)90117-X; LEVIN NW, 1990, CLIN DIALYSIS, P172; LUEHMAN DA, 1989, MANUAL WATER TREATME, P109; MCIVOR M, 1983, AM J CARDIOL, V51, P901, DOI 10.1016/S0002-9149(83)80153-2; MCIVOR ME, 1987, ANN EMERG MED, V16, P1165; MCIVOR ME, 1987, ANN EMERG MED, V16, P777; Murray J. J., 1986, APPROPRIATE USE FLUO, P131; PARSONS V, 1975, BMJ-BRIT MED J, V1, P128, DOI 10.1136/bmj.1.5950.128; SCHIFFL HH, 1980, NEPHRON, V26, P69, DOI 10.1159/000181954; SIDDIQUI JY, 1970, P EUR DIAL TRANS, V7, P110; SNEDECOR GW, 1980, STATISTICAL METHODS, P107; TAVES DR, 1968, T AM SOC ART INT ORG, V14, P412; TEPPERMAN PB, 1980, J OCCUP ENVIRON MED, V22, P691, DOI 10.1097/00043764-198010000-00018; Tokars J I, 1993, ASAIO J, V39, P966, DOI 10.1097/00002480-199310000-00027; VLCHEK DL, 1991, QUALITY ASSURANCE GU; YOLKEN R, 1976, PEDIATRICS, V58, P90; 1993, ANSIAAMI RD51992 ASS, P5; 1980, MMWR-MORBID MORTAL W, V29, P134	31	47	48	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1994	121	5					339	344		10.7326/0003-4819-121-5-199409010-00005	http://dx.doi.org/10.7326/0003-4819-121-5-199409010-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD701	8042823				2022-12-24	WOS:A1994PD70100005
J	AKIYAMA, KY; YOKOTA, KY; KAGAWA, S; SHIMBARA, N; TAMURA, T; AKIOKA, H; NOTHWANG, HG; NODA, C; TANAKA, K; ICHIHARA, A				AKIYAMA, KY; YOKOTA, KY; KAGAWA, S; SHIMBARA, N; TAMURA, T; AKIOKA, H; NOTHWANG, HG; NODA, C; TANAKA, K; ICHIHARA, A			CDNA CLONING AND INTERFERON-GAMMA DOWN-REGULATION OF PROTEASOMAL SUBUNIT-X AND SUBUNIT-Y	SCIENCE			English	Article							LINKED LMP GENE; CLASS-II REGION; ANTIGEN PRESENTATION; YEAST PROTEASOME; HUMAN MHC; PROTEINASE; PROTEOLYSIS; DISTINCT; CODES	Proteasomes are the proteolytic complex responsible for major histocompatibility complex (MHC) class I-restricted antigen presentation. Interferon gamma treatment increases expression of MHC-encoded LMP2 and LMP7 subunits of the proteasome and decreases expression of two proteasome subunits, named X and Y, which alters the proteolytic specificity of proteasomes. Molecular cloning of complementary DNAs encoding X and Y showed that their proteins are proteasomal subunits with high amino acid similarity to LMP7 and LMP2, respectively. Thus, interferon gamma may induce subunit replacements of X and Y by LMP7 and LMP2, respectively, producing proteasomes perhaps more appropriate for the immunological processing of endogenous antigens.	UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN; UNIV TOKUSHIMA,SCH MED,DEPT UROL,TOKUSHIMA 770,JAPAN; SUMITOMO ELECT IND LTD,DEPT BIOMED RES & DEV,SAKAE KU,YOKOHAMA 244,JAPAN	Tokushima University; Tokushima University; Sumitomo Electric Industries			Nothwang, Hans G/C-5847-2011; Tamura, Tomohiro/M-4732-2018	Tamura, Tomohiro/0000-0003-2409-6556; Nothwang, Hans Gerd/0000-0001-7695-6437				AKI M, 1994, J BIOCHEM, V115, P257, DOI 10.1093/oxfordjournals.jbchem.a124327; AKIYAMA K, 1994, FEBS LETT, V343, P85, DOI 10.1016/0014-5793(94)80612-8; BEY F, 1993, MOL GEN GENET, V237, P193, DOI 10.1007/BF00282801; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; BROWN MG, 1993, J IMMUNOL, V151, P1193; DEMARTINO GN, 1991, BIOCHIM BIOPHYS ACTA, V1079, P29, DOI 10.1016/0167-4838(91)90020-Z; DICK LR, 1992, BIOCHEMISTRY-US, V31, P7347, DOI 10.1021/bi00147a020; DRISCOLL J, 1993, NATURE, V365, P262, DOI 10.1038/365262a0; ENENKEL C, 1994, FEBS LETT, V341, P193, DOI 10.1016/0014-5793(94)80455-9; FRUH K, 1992, J BIOL CHEM, V267, P22131; GACZYNSKA M, 1993, NATURE, V365, P267; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HILT W, 1993, J BIOL CHEM, V268, P3479; HUANG J, COMMUNICATION; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; LARSEN F, 1993, HUM MOL GENET, V2, P1559; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; NISHIMURA C, 1993, FEBS LETT, V336, P462, DOI 10.1016/0014-5793(93)80856-P; NOTHWANG HG, IN PRESS BIOCH BIOPH; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; SKOOG B, 1986, TRAC-TREND ANAL CHEM, V5, P82, DOI 10.1016/0165-9936(86)80045-0; TAMURA T, 1991, BIOCHIM BIOPHYS ACTA, V1089, P95, DOI 10.1016/0167-4781(91)90090-9; TANAKA K, 1992, NEW BIOL, V4, P173; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4978; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	30	185	192	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 26	1994	265	5176					1231	1234		10.1126/science.8066462	http://dx.doi.org/10.1126/science.8066462			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD422	8066462				2022-12-24	WOS:A1994PD42200037
J	SADEGHNASSERI, S; STERN, LJ; WILEY, DC; GERMAIN, RN				SADEGHNASSERI, S; STERN, LJ; WILEY, DC; GERMAIN, RN			MHC CLASS-II FUNCTION PRESERVED BY LOW-AFFINITY PEPTIDE INTERACTIONS PRECEDING STABLE BINDING	NATURE			English	Article							ANTIGENIC PEPTIDE; INVARIANT-CHAIN; HISTOCOMPATIBILITY MOLECULES; MICE LACKING; HLA-DR; EXPRESSION; COMPLEXES; HLA-DR1	MAJOR histocompatibility complex class II molecules and their peptide ligands show unusual interaction kinetics, with slow association and dissociation rates that yield an apparent equilibrium constant of similar to 10(-6)-10(-8) M (refs 1-5). However, there is evidence for a specific, rapidly formed, short-lived complex(6). The altered migration on SDS-polyacrylamide gel electrophoresis of class II molecules upon stable peptide binding(7-9) has led to the hypothesis that the two kinetically distinguishable types of class II-peptide complexes correspond to different structures. In accord with this model, we demonstrate here that insert cell-derived HLA-DR1 class II molecules show fast, almost stoichiometric occupancy with rapidly dissociating peptide while remaining sensitive to SDS-induced chain dissociation. The same DR1 molecules slowly and quantitatively form long-lived complexes resistant to SDS-induced denaturation. Surprisingly, low-affinity interaction with peptide protects class II from denaturation at physiological temperature, a finding that has implications for understanding the role of invariant chain in the intracellular behaviour of class II molecules.	NIAID,IMMUNOL LAB,LYMPHOCYTE BIOL SECT,BETHESDA,MD 20892; HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Harvard University; Howard Hughes Medical Institute			Germain, Ronald/ABE-7090-2020; Germain, Ronald N./Z-1945-2019	Sadegh-Nasseri, Scheherazade/0000-0002-8127-1720				BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; BONNEROT C, 1994, EMBO J, V13, P934, DOI 10.1002/j.1460-2075.1994.tb06338.x; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; FAIRCHILD PJ, 1993, INT IMMUNOL, V5, P1151, DOI 10.1093/intimm/5.9.1151; GERMAIN RN, 1993, NATURE, V363, P725, DOI 10.1038/363725a0; HAMMER J, 1993, CELL, V74, P197, DOI 10.1016/0092-8674(93)90306-B; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; KOZONO H, 1994, NATURE, V369, P151, DOI 10.1038/369151a0; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; NELSON CA, 1993, P NATL ACAD SCI USA, V90, P1227, DOI 10.1073/pnas.90.4.1227; ROCHE PA, 1990, J IMMUNOL, V144, P1849; ROMAGNOLI P, IN PRESS J EXP MED; ROOF RW, 1990, P NATL ACAD SCI USA, V87, P1735, DOI 10.1073/pnas.87.5.1735; Sadegh-Nasseri S, 1994, ANTIGEN PROCESSING P, P170; SADEGHNASSERI S, 1989, NATURE, V337, P274, DOI 10.1038/337274a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; TAMPE R, 1991, P NATL ACAD SCI USA, V88, P4661, DOI 10.1073/pnas.88.11.4661; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219	22	130	130	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 25	1994	370	6491					647	650		10.1038/370647a0	http://dx.doi.org/10.1038/370647a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD310	8065450				2022-12-24	WOS:A1994PD31000049
J	BITHELL, JF; DUTTON, SJ; DRAPER, GJ; NEARY, NM				BITHELL, JF; DUTTON, SJ; DRAPER, GJ; NEARY, NM			DISTRIBUTION OF CHILDHOOD LEUKEMIAS AND NON-HODGKINS-LYMPHOMAS NEAR NUCLEAR INSTALLATIONS IN ENGLAND AND WALES	BRITISH MEDICAL JOURNAL			English	Article							WEST-BERKSHIRE; POWER STATION; YOUNG-PEOPLE; LEUKEMIA; CANCER; VICINITY; MORTALITY; CHILDREN; CUMBRIA; SITES	Objective-To examine the relation between the risk of childhood leukaemia and non-Hodgkin's lymphoma and proximity of residence to nuclear installations in England and Wales. Design-Observed and expected numbers of cases were calculated and analysed by standard methods based on ratios of observed to expected counts and by a new statistical test, the linear risk score test, based on ranks and designed to be sensitive to excess incidence in close proximity to a putative source of risk. Setting-Electoral wards within 25 km of 23 nuclear installations and six control sites that had been investigated for suitability for generating stations but never used. Subjects-Children below age 15 in England and Wales, 1966-87. Main outcome measure-Registration of any leukaemia or non-Hodgkin's lymphoma. Results-In none of the 25 km circles around the installations was the incidence ratio significantly greater than 1.0. The only significant results for the linear risk score test were for Sellafield (P=0.00002) and Burghfield (P=0.031). The circles for Aldermaston and Burghfield overlap; the incidence ratio was 1.10 in each. One of the control sites gave a significant linear risk score test result (P=0.020). All the tests carried but were one sided with P values estimated by simulation. Conclusion-There is no evidence of a general increase of childhood leukaemia or non-Hodgkin's lymphoma around nuclear installations. Apart from Sellafield, the evidence for distance related risk is very weak.	UNIV OXFORD,CHILDHOOD CANC RES GRP,OXFORD OX2 6HJ,ENGLAND	University of Oxford	BITHELL, JF (corresponding author), UNIV OXFORD,DEPT STAT,OXFORD OX1 3TG,ENGLAND.							ALEXANDER FE, 1989, BRIT MED J, V299, P565; BARCLAY R, 1987, COMMUNITY MED, V9, P279; BARON JA, 1984, BRIT J CANCER, V50, P815, DOI 10.1038/bjc.1984.261; BITHELL JF, 1989, J EPIDEMIOL COMMUN H, V43, P79, DOI 10.1136/jech.43.1.79; BLACK D, 1984, INVESTIGATION POSSIB; COOKMOZAFFARI P, 1989, LANCET, V2, P1145; COOKMOZAFFARI P, 1987, STUDIES MED POPULATI, V51; COOKMOZAFFARI PJ, 1989, BRIT J CANCER, V59, P476, DOI 10.1038/bjc.1989.99; DOBSON AJ, 1990, INTRO STATISTICAL MO; DRAPER GJ, 1993, BRIT MED J, V306, P89, DOI 10.1136/bmj.306.6870.89; EWINGS PD, 1989, BRIT MED J, V299, P289, DOI 10.1136/bmj.299.6694.289; EWINGS PD, 1988, LEUKAEMIA INCIDENCE; FORMAN D, 1987, NATURE, V329, P499, DOI 10.1038/329499a0; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; KINLEN L, 1988, LANCET, V2, P1323; KINLEN LJ, 1993, BRIT MED J, V306, P743, DOI 10.1136/bmj.306.6880.743; KINLEN LJ, 1993, BRIT MED J, V306, P1718, DOI 10.1136/bmj.306.6894.1718; ROMAN E, 1987, BRIT MED J, V294, P597, DOI 10.1136/bmj.294.6572.597; ROMAN E, 1993, BMJ-BRIT MED J, V306, P615, DOI 10.1136/bmj.306.6878.615; STONE RA, 1988, STAT MED, V7, P649, DOI 10.1002/sim.4780070604; TAYLOR RH, 1989, BRIT MED J, V299, P565, DOI 10.1136/bmj.299.6698.565-a; Townsend PP., 1988, HLTH DEPRIVATION INE; URQUHART JD, 1991, BRIT MED J, V302, P687, DOI 10.1136/bmj.302.6778.687; 1989, 3RD REPORT INCIDENCE; 1988, 2ND REPORT INVESTIGA; [No title captured]	26	77	77	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 20	1994	309	6953					501	505		10.1136/bmj.309.6953.501	http://dx.doi.org/10.1136/bmj.309.6953.501			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD308	8086902	Green Published			2022-12-24	WOS:A1994PD30800014
J	ZHOU, GW; GUO, JC; HUANG, W; FLETTERICK, RJ; SCANLAN, TS				ZHOU, GW; GUO, JC; HUANG, W; FLETTERICK, RJ; SCANLAN, TS			CRYSTAL-STRUCTURE OF A CATALYTIC ANTIBODY WITH A SERINE-PROTEASE ACTIVE-SITE	SCIENCE			English	Article							3-DIMENSIONAL STRUCTURE; TRYPSIN; SPECIFICITY; TRIAD; FAB; HISTIDINE-159; SPECTROSCOPY; BINDING; PAPAIN	The three-dimensional structure of an unusually active hydrolytic antibody with a phosphonate transition state analog (hapten) bound to the active site has been solved to 2.5 Angstrom resolution. The antibody (17E8) catalyzes the hydrolysis of norleucine and methionine phenyl esters and is selective for amino acid esters that have the natural alpha-carbon L configuration. A plot of the pH-dependence of the antibody-catalyzed reaction is bell-shaped with an activity maximum at pH 9.5; experiments on mechanism lend support to the formation of a covalent acyl-antibody intermediate. The structural and kinetic data are complementary and support a hydrolytic mechanism for the antibody that is remarkably similar to that of the serine proteases. The antibody active site contains a Ser-His dyad structure proximal to the phosphorous atom of the bound hapten that resembles two of the three components of the Ser-His-Asp catalytic triad of serine proteases. The antibody active site also contains a Lys residue to stabilize oxyanion formation, and a hydrophobic binding pocket for specific substrate recognition of norleucine and methionine side chains. The structure identifies active site residues that mediate catalysis and suggests specific mutations that may improve the catalytic efficiency of the antibody. This high resolution structure of a catalytic antibody-hapten complex shows that antibodies can converge on active site structures that have arisen through natural enzyme evolution.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039304] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39304] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHMSEN L, 1991, BIOCHEMISTRY-US, V30, P4151, DOI 10.1021/bi00231a007; BLACKBURN S, 1976, ENZYME STRUCTURE FUN; BONE R, 1989, NATURE, V339, P191, DOI 10.1038/339191a0; BRUNGER AT, 1991, J MOL BIOL, V221, P239, DOI 10.1016/0022-2836(91)90817-P; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; COREY DR, 1992, J AM CHEM SOC, V114, P1784, DOI 10.1021/ja00031a037; COREY DR, 1992, J AM CHEM SOC, V114, P4905, DOI 10.1021/ja00038a067; CRAIK CS, 1987, SCIENCE, V237, P909, DOI 10.1126/science.3303334; CRAIK CS, 1985, SCIENCE, V228, P291, DOI 10.1126/science.3838593; CRONIN CN, 1987, J AM CHEM SOC, V109, P2222, DOI 10.1021/ja00241a072; Fersht A., 1985, ENZYME STRUCTURE MEC; GOLINELLIPIMPANEAU B, 1994, STRUCTURE, V2, P175, DOI 10.1016/S0969-2126(00)00019-8; Guo Jincan, 1994, Journal of the American Chemical Society, V116, P6062, DOI 10.1021/ja00093a002; HARLOW E, 1988, ANTIBODIES LABORATOR; HAYNES MR, 1994, SCIENCE, V263, P646, DOI 10.1126/science.8303271; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; HUSAIN SS, 1968, BIOCHEM J, V108, P855, DOI 10.1042/bj1080855; JANARIK J, 1991, J APPL CRYSTALLOGR, V24, P409; JOHNSON FA, 1981, BIOCHEMISTRY-US, V20, P52, DOI 10.1021/bi00504a600; JOHNSON FA, 1981, BIOCHEMISTRY-US, V20, P44, DOI 10.1021/bi00504a008; JOHNSON FA, 1981, BIOCHEMISTRY-US, V20, P48; Kabat EA, 1991, SEQUENCES PROTEINS I; KOSSIAKOFF AA, 1987, BIOL MACROMOLECULES, V3; KRIEGER M, 1974, J MOL BIOL, V83, P209, DOI 10.1016/0022-2836(74)90388-X; LASCOMBE MB, 1989, P NATL ACAD SCI USA, V86, P607, DOI 10.1073/pnas.86.2.607; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LESLEY SA, 1993, P NATL ACAD SCI USA, V90, P1160, DOI 10.1073/pnas.90.4.1160; POLLACK SJ, 1987, COLD SPRING HARB SYM, V52, P97, DOI 10.1101/SQB.1987.052.01.014; POLLACK SJ, 1986, SCIENCE, V234, P1570, DOI 10.1126/science.3787262; ROBERTS VA, 1994, J MOL BIOL, V235, P1098, DOI 10.1006/jmbi.1994.1060; SCANLAN TS, UNPUB; SEGAL DM, 1974, P NATL ACAD SCI USA, V71, P4298, DOI 10.1073/pnas.71.11.4298; SLOANE DL, 1991, NATURE, V354, P149, DOI 10.1038/354149a0; SPRANG S, 1987, SCIENCE, V237, P905, DOI 10.1126/science.3112942; STROUD RM, 1971, COLD SPRING HARB SYM, V36, P125, DOI 10.1101/SQB.1972.036.01.018; STROUD RM, 1974, SCI AM, V231, P74, DOI 10.1038/scientificamerican0774-74; TANG Y, 1991, P NATL ACAD SCI USA, V88, P8784, DOI 10.1073/pnas.88.19.8784; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261	39	178	182	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 19	1994	265	5175					1059	1064		10.1126/science.8066444	http://dx.doi.org/10.1126/science.8066444			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC539	8066444				2022-12-24	WOS:A1994PC53900024
J	RODRIGUEZVICIANA, P; WARNE, PH; DHAND, R; VANHAESEBROECK, B; GOUT, I; FRY, MJ; WATERFIELD, MD; DOWNWARD, J				RODRIGUEZVICIANA, P; WARNE, PH; DHAND, R; VANHAESEBROECK, B; GOUT, I; FRY, MJ; WATERFIELD, MD; DOWNWARD, J			PHOSPHATIDYLINOSITOL-3-OH KINASE AS A DIRECT TARGET OF RAS	NATURE			English	Article							GTPASE-ACTIVATING PROTEIN; GROWTH-FACTOR RECEPTOR; DIFFERENT SIGNALING PATHWAYS; SH3 DOMAIN; 3-KINASE; BIND; ASSOCIATION; EXPRESSION; 3'-KINASE; COMPLEX	Ras (p21(ras)) interacts directly with the catalytic subunit of phosphatidylinositol-3-OH kinase in a GTP-dependent manner through the Ras effector site. In vivo, dominant negative Ras mutant N17 inhibits growth factor induced production of 3' phosphorylated phosphoinositides in PC12 cells, and transfection of Ras, but not Raf, into COS cells results in a large elevation in the level of these lipids. Therefore Ras can probably regulate phosphatidylinositol-3-OH kinase, providing a point of divergence in signalling pathways downstream of Ras.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND; UNIV LONDON UNIV COLL,DEPT BIOCHEM & MOLEC BIOL,LONDON WC1E 6BT,ENGLAND	Cancer Research UK; Ludwig Institute for Cancer Research; University of London; University College London			Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729; Fry, Michael/0000-0001-8518-1370				BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DOWNWARD J, 1991, Current Biology, V1, P353, DOI 10.1016/0960-9822(91)90190-8; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GOUT I, 1992, BIOCHEM J, V288, P395, DOI 10.1042/bj2880395; HARLOW E, 1988, ANTIBODIES LABORATOR; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PAGE MJ, 1989, J BIOL CHEM, V264, P19147; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; REIF K, 1993, J BIOL CHEM, V268, P10780; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SJOLANDER A, 1991, P NATL ACAD SCI USA, V88, P7908, DOI 10.1073/pnas.88.18.7908; SJOLANDER A, 1992, BIOCHEM BIOPH RES CO, V189, P1503, DOI 10.1016/0006-291X(92)90245-G; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TUVESON DA, 1993, SCIENCE, V260, P986, DOI 10.1126/science.7684160; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VATANI A, 1990, CELL, V61, P769; VOGEL LB, 1993, MOL CELL BIOL, V13, P7408, DOI 10.1128/MCB.13.12.7408; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAME PH, 1993, NATURE, V364, P352; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	36	1632	1664	1	44	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 18	1994	370	6490					527	532		10.1038/370527a0	http://dx.doi.org/10.1038/370527a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC537	8052307				2022-12-24	WOS:A1994PC53700046
J	KAPHINGST, K; KUNES, S				KAPHINGST, K; KUNES, S			PATTERN-FORMATION IN THE VISUAL CENTERS OF THE DROSOPHILA BRAIN - WINGLESS ACTS VIA DECAPENTAPLEGIC TO SPECIFY THE DORSOVENTRAL AXIS	CELL			English	Article							SEGMENT-POLARITY GENE; CELL-CELL COMMUNICATION; MOLECULAR-ORGANIZATION; INT-1 PROTOONCOGENE; NERVOUS-SYSTEM; HEDGEHOG GENE; BETA FAMILY; MELANOGASTER; EXPRESSION; PROTEIN	A stepwise morphogenetic program of cell division and cell fate determination generates the precise neuronal architecture of the visual centers of the Drosophila brain. Here, we show that the assembly of the target structure for ingrowing retinal axons involves cell-cell interactions mediated by the secreted product of the wingless (wg) gene. wg, expressed in two symmetrical domains of the developing brain, is required to induce and maintain the expression of the secreted decapentaplegic (dpp) gene product in adjacent domains. wg and dpp function are required for target field neurons to adapt their proper fates and to send axons into the developing target structure. These observations implicate a cascade of diffusible signaling molecules in patterning the visual centers of the Drosophila brain.			KAPHINGST, K (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA.				NIGMS NIH HHS [GMO-7598-16] Funding Source: Medline; PHS HHS [R01-10112-01] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLENDOERFER KL, 1994, ANNU REV NEUROSCI, V17, P185, DOI 10.1146/annurev.neuro.17.1.185; ARIAS AM, 1988, DEVELOPMENT, V103, P157; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BIER E, 1988, SCIENCE, V240, P913, DOI 10.1126/science.3129785; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BRAITENBERG V, 1967, EXP BRAIN RES, V3, P271; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CHULAGRAFF Q, 1993, SCIENCE, V261, P1594, DOI 10.1126/science.8372355; COHEN B, 1993, DEVELOPMENT, V117, P597; COHEN SM, 1989, NATURE, V338, P432, DOI 10.1038/338432a0; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; EBENS AJ, 1993, CELL, V74, P15, DOI 10.1016/0092-8674(93)90291-W; FISCHBACH KF, 1989, CELL TISSUE RES, V258, P441, DOI 10.1007/BF00218858; GELBART WM, 1989, DEVELOPMENT, V107, P65; GIERER A, 1987, DEVELOPMENT, V101, P479; Goodman Corey S., 1993, P1131; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HIDALGO A, 1990, DEVELOPMENT, V110, P291; HOFBAUER A, 1990, ROUX ARCH DEV BIOL, V198, P264, DOI 10.1007/BF00377393; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; KASSIS JA, 1992, P NATL ACAD SCI USA, V89, P1919, DOI 10.1073/pnas.89.5.1919; KUNES S, 1993, J NEUROSCI, V13, P752; Kunes Samuel, 1993, Current Opinion in Neurobiology, V3, P53, DOI 10.1016/0959-4388(93)90035-W; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; Martinez Arias Alfonso, 1993, P517; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; MCCONNELL SK, 1991, ANNU REV NEUROSCI, V14, P269, DOI 10.1146/annurev.ne.14.030191.001413; MCMAHON AP, 1992, TRENDS GENET, V8, P236, DOI 10.1016/0168-9525(92)90122-K; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Meinertzhagen Ian A., 1993, P1363; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOHLER J, 1988, GENETICS, V120, P1061; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; POSAKONY LG, 1990, MECH DEVELOP, V33, P69, DOI 10.1016/0925-4773(90)90136-A; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; Sanchez D., 1915, TRAB LAB INVEST BIOL, V13, P1, DOI DOI 10.5962/BHL.TITLE.37839; SELLECK SB, 1991, NEURON, V6, P83, DOI 10.1016/0896-6273(91)90124-I; Sharma R. P., 1973, DROS INF SER, V50, P134; SKAER H, 1992, DEVELOPMENT, V116, P745; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; STJOHNSTON D, 1992, CELL, V68, P201; STJOHNSTON RD, 1990, GENE DEV, V4, P1114, DOI 10.1101/gad.4.7.1114; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; TRUJILLOCENOZ O, 1973, J ULTRA MOL STRUCT R, V42, P554, DOI 10.1016/S0022-5320(73)80027-9; TRUMAN JW, 1988, DEV BIOL, V125, P145, DOI 10.1016/0012-1606(88)90067-X; UDIN SB, 1988, ANNU REV NEUROSCI, V11, P289, DOI 10.1146/annurev.ne.11.030188.001445; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; WHITE K, 1978, DEV BIOL, V65, P296, DOI 10.1016/0012-1606(78)90029-5	61	97	97	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 12	1994	78	3					437	448		10.1016/0092-8674(94)90422-7	http://dx.doi.org/10.1016/0092-8674(94)90422-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PC405	8062386				2022-12-24	WOS:A1994PC40500010
J	HAJNOCZKY, G; THOMAS, AP				HAJNOCZKY, G; THOMAS, AP			THE INOSITOL TRISPHOSPHATE CALCIUM-CHANNEL IS INACTIVATED BY INOSITOL TRISPHOSPHATE	NATURE			English	Article							PERMEABILIZED HEPATOCYTES; CA2+ MOBILIZATION; RELEASE; 1,4,5-TRISPHOSPHATE; STORES; CELLS	ACTIVATION Of intracellular Ca2+ channels by inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3) represents the initial Ca2+ mobilization step in response to many extracellular signals(1). Here we report that Ins(1,4,5)P-3-induced channel activation in permeabilized hepatocytes is followed by a time-dependent inactivation, which is a direct consequence of ligand binding. The inactivation by Ins(1,4,5)P-3 parallels the quantal character of channel opening, giving rise to a unique process of incremental inactivation whereby discrete channel populations are inhibited at each Ins(1,4,5)P-3 dose. Ins(1,4,5)P-3 can induce inactivation in the absence of stored Ca2+, but the inactivation rate is enhanced by increases of cytosolic Ca2+. The inhibitory effect of Ins(1,4,5)P-3 can be reversed by Ins(1,4,5)P-3 washout, or by chelation of cytosolic Ca2+. Thus, Ins(1,4,5)P-3 and Ca2+ act as coinhibitors of the Ins(1,4,5)P-3-sensitive Ca2+ channel. Inactivation is an inherent consequence of Ins(1,4,5)P-3-induced channel opening which can terminate increases of cytosolic Ca2+.	THOMAS JEFFERSON UNIV, DEPT PATHOL & CELL BIOL, PHILADELPHIA, PA 19107 USA	Jefferson University			Thomas, Andrew/C-6755-2013	Thomas, Andrew/0000-0002-9026-7467				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; CHAMPEIL P, 1989, J BIOL CHEM, V264, P17665; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; HAJNOCZKY G, 1993, BIOCHEM J, V293, P413, DOI 10.1042/bj2930413; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; KINDMAN LA, 1993, BIOCHEMISTRY-US, V32, P1270, DOI 10.1021/bi00056a011; MARSHALL ICB, 1993, J BIOL CHEM, V268, P13214; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MUALLEM S, 1989, J BIOL CHEM, V264, P205; OLDERSHAW KA, 1991, BIOCHEM J, V278, P705, DOI 10.1042/bj2780705; PARKER I, 1990, SCIENCE, V250, P977, DOI 10.1126/science.2237441; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601	16	156	157	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 11	1994	370	6489					474	477		10.1038/370474a0	http://dx.doi.org/10.1038/370474a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	8047168				2022-12-24	WOS:A1994PB40700060
J	DING, HF; RIMSKY, S; BATSON, SC; BUSTIN, M; HANSEN, U				DING, HF; RIMSKY, S; BATSON, SC; BUSTIN, M; HANSEN, U			STIMULATION OF RNA-POLYMERASE-II ELONGATION BY CHROMOSOMAL PROTEIN HMG-14	SCIENCE			English	Article							ASSEMBLED CHROMATIN TEMPLATES; MOBILITY GROUP PROTEIN-14; ACCURATE TRANSCRIPTION; NUCLEOSOMES; GENES; DNA; EXPRESSION; SEQUENCE; INVITRO; CELLS	The high-mobility group protein 14 (HMG-14) is a non-histone chromosomal protein that is preferentially associated with transcriptionally active chromatin. To assess the effect of HMG-14 on transcription by RNA polymerase II, in vivo-assembled chromatin with elevated amounts of HMG-14 was obtained. Here it is shown that HMG-14 enhanced transcription on chromatin templates but not on DNA templates. This protein stimulated the rate of elongation by RNA polymerase II but not the level of initiation of transcription. These findings suggest that the association of HMG-14 with nucleosomes is part of the cellular process involved in the generation of transcriptionally active chromatin.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV MOLEC GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115; NCI,MOLEC CARCINOGENESIS LAB,BETHESDA,MD 20892	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Bustin, Michael/G-6155-2015	Hansen, Ulla/0000-0001-9803-4185; Rimsky, Sylvie/0000-0003-2654-3014; Ding, Han-Fei/0000-0001-5702-3439; Bustin, Michael/0000-0002-5147-7242	NIGMS NIH HHS [GM-36667] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; ALBRIGHT SC, 1980, J BIOL CHEM, V255, P3673; AUSUBEL FM, 1989, CURRENT PROTOCOLSIN; BATSON SC, 1993, NUCLEIC ACIDS RES, V21, P3459; BATSON SC, 1992, MOL CELL BIOL, V12, P1639, DOI 10.1128/MCB.12.4.1639; BUSTIN M, 1991, NUCLEIC ACIDS RES, V19, P3115, DOI 10.1093/nar/19.11.3115; BUSTIN M, 1990, J BIOL CHEM, V265, P20077; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CRIPPA MP, 1993, EMBO J, V12, P3855, DOI 10.1002/j.1460-2075.1993.tb06064.x; Ding H, UNPUB; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; FIRE A, 1984, J BIOL CHEM, V259, P2509; GIRI C, 1987, J BIOL CHEM, V262, P9839; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; GRUNSTEIN M, 1990, TRENDS GENET, V6, P395, DOI 10.1016/0168-9525(90)90299-L; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; Johns EW, 1982, HMG CHROMOSOMAL PROT; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MARDIAN JKW, 1980, SCIENCE, V209, P1534, DOI 10.1126/science.7433974; NICOLAS RH, 1983, NUCLEIC ACIDS RES, V11, P753, DOI 10.1093/nar/11.3.753; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PASH JM, 1993, J BIOL CHEM, V268, P13632; ROSEN BS, 1989, SCIENCE, V244, P1483, DOI 10.1126/science.2734615; SAMUELS M, 1982, J BIOL CHEM, V257, P4419; SANDEEN G, 1980, NUCLEIC ACIDS RES, V8, P3757, DOI 10.1093/nar/8.17.3757; SEALE RL, 1983, BIOCHEMISTRY-US, V22, P5008, DOI 10.1021/bi00290a020; STEIN A, 1983, NUCLEIC ACIDS RES, V11, P6803, DOI 10.1093/nar/11.19.6803; SWERDLOW PS, 1983, NUCLEIC ACIDS RES, V11, P387, DOI 10.1093/nar/11.2.387; TOMASETTO C, 1993, J CELL BIOL, V122, P157, DOI 10.1083/jcb.122.1.157; UCKER DS, 1984, J BIOL CHEM, V259, P7416; WEISBROD S, 1979, P NATL ACAD SCI USA, V76, P630, DOI 10.1073/pnas.76.2.630	33	77	78	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 5	1994	265	5173					796	799		10.1126/science.8047885	http://dx.doi.org/10.1126/science.8047885			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	8047885				2022-12-24	WOS:A1994PA37200037
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA TO SPONSOR WORKSHOP ON HIV DETECTION DURING WINDOW PERIOD IN DONOR SCREENING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	1994	272	5					344	344						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY903	8028152				2022-12-24	WOS:A1994NY90300006
J	CACALANO, G; LEE, J; KIKLY, K; RYAN, AM; PITTSMEEK, S; HULTGREN, B; WOOD, WI; MOORE, MW				CACALANO, G; LEE, J; KIKLY, K; RYAN, AM; PITTSMEEK, S; HULTGREN, B; WOOD, WI; MOORE, MW			NEUTROPHIL AND B-CELL EXPANSION IN MICE THAT LACK THE MURINE IL-8 RECEPTOR HOMOLOG	SCIENCE			English	Article							HUMAN INTERLEUKIN-8 RECEPTOR; OXYGEN METABOLITES; CYTOKINE FAMILY; CLONING; LUNG; ACCUMULATION; ACTIVATION; INHIBITOR; BINDING; INJURY	Interleukin-8 (IL-8) is a preinflammatory cytokine that specifically attracts and activates human neutrophils. A murine gene with a high degree of homology to the two known human IL-8 receptors was cloned and then deleted from the mouse genome by homologous recombination in embryonic stem (ES) cells. These mice, although outwardly healthy, had lymphadenopathy, resulting from an increase in B cells, and splenomegaly, resulting from an increase in metamyelocytes, band, and mature neutrophils. Thus, this receptor may participate in the expansion and development of neutrophils and B cells. This receptor was the major mediator of neutrophil migration to sites of inflammation and may provide a potential therapeutic target in inflammatory disease.	GENENTECH INC,DEPT CELL GENET,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT PHARMACOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT ENDOCRINE RES,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech			Huang, H/E-9490-2010					BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CERRETTI DP, 1993, GENOMICS, V18, P410, DOI 10.1006/geno.1993.1486; CERRETTI DP, 1993, MOL IMMUNOL, V30, P359; COLDITZ I, 1989, AM J PATHOL, V134, P755; DAVEY FR, 1984, CLIN DIAGNOSIS MANAG, P857; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; HECHTMAN DH, 1991, J IMMUNOL, V147, P883; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; JOHNSON KJ, 1981, J IMMUNOL, V126, P2365; KIKLY K, UNPUB; KIMATA H, 1992, J EXP MED, V176, P1227, DOI 10.1084/jem.176.4.1227; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEE J, 1992, J BIOL CHEM, V267, P16283; LEONARD EJ, 1990, J IMMUNOL, V144, P1323; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MULLIGAN MS, 1993, J IMMUNOL, V150, P5585; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; RAMPART M, 1989, AM J PATHOL, V135, P21; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; SCHALL TJ, 1991, CYTOKINE, V3, P165, DOI 10.1016/1043-4666(91)90013-4; SUEMATSU S, 1989, P NATL ACAD SCI USA, V86, P7547, DOI 10.1073/pnas.86.19.7547; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; TEKAMPOLSON P, 1990, J EXP MED, V172, P911, DOI 10.1084/jem.172.3.911; TILL GO, 1982, J CLIN INVEST, V69, P1126, DOI 10.1172/JCI110548; WATANABE K, 1993, EUR J BIOCHEM, V214, P267, DOI 10.1111/j.1432-1033.1993.tb17920.x; WATANABE K, 1989, J BIOL CHEM, V264, P18907; WOOD WB, UNPUB	30	556	566	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 29	1994	265	5172					682	684		10.1126/science.8036519	http://dx.doi.org/10.1126/science.8036519			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	8036519				2022-12-24	WOS:A1994NZ53800040
J	ONO, K; TSUJIMOTO, G; SAKAMOTO, A; ETO, K; MASAKI, T; OZAKI, Y; SATAKE, M				ONO, K; TSUJIMOTO, G; SAKAMOTO, A; ETO, K; MASAKI, T; OZAKI, Y; SATAKE, M			ENDOTHELIN-A RECEPTOR MEDIATES CARDIAC INHIBITION BY REGULATING CALCIUM AND POTASSIUM CURRENTS	NATURE			English	Article							GENE-RELATED PEPTIDE; VASOCONSTRICTOR PEPTIDE; CELLS; CLONING; HEART; CDNA; EXPRESSION; SUBTYPES; MYOCYTES; BINDING	VOLTAGE-SENSITIVE ion channels play fundamental roles in the regulation of cardiac function by various neurotransmitters(1,2). Endothelins(3) have strong positive inotropic(4) and chronotropic(5) effects, for,which recent studies have implicated various intracellular mechanisms(6,7). However, very little is known about the underlying ion-channel regulation by the peptide. We report here that endothelin-1 consistently hyperpolarizes the membrane and shortens the duration of the action potential in mammalian atrial myocytes, leading to suppression of electrical excitability of the heart. Endothelin-1, but not endothelin(3), inhibited the L-type calcium current by decreasing cyclic AMP accumulation and activated the muscarinic potassium current by stimulating a pertussis toxin-sensitive GTP-binding protein. Consistent with these results, endothelin-1 strongly reduced the heart rate when it was increased by beta-adrenoceptor stimulation. These effects were blocked by an ET(A) (endothelin-1-selective) receptor-selective antagonist, BQ123 (refs 8-11). The ET(A) receptor-mediated regulation of cardiac ion channels gives new insight into our understanding of the physiological and pathophysiological roles of endothelins in the control of cardiac function.	NATL CHILDRENS MED RES CTR,DIV MOLEC & CELLULAR PHARMACOL,SETAGAYA KU,TOKYO 154,JAPAN; KYOTO UNIV,FAC MED,DEPT PHARMACOL,SAKYO KU,KYOTO 60601,JAPAN	National Center for Child Health & Development - Japan; Kyoto University	ONO, K (corresponding author), NATL INST HLTH SCI,DIV CHEM PHARMACOL & PHYTOCHEM,SETAGAYA KU,1-18-1 KAMI YOHGA,TOKYO 158,JAPAN.							ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARAMORI I, 1992, J BIOL CHEM, V267, P12468; FRANCOCERECEDA A, 1990, ACTA PHYSIOL SCAND, V138, P539, DOI 10.1111/j.1748-1716.1990.tb08882.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARTZELL HC, 1987, J PHYSIOL-LONDON, V389, P411, DOI 10.1113/jphysiol.1987.sp016663; HILALDANDAN R, 1992, J BIOL CHEM, V267, P10620; HURI S, 1992, ENDOCRINOLOGY, V130, P1885; IHARA M, 1992, LIFE SCI, V50, P247, DOI 10.1016/0024-3205(92)90331-I; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; ISHIKAWA T, 1988, PFLUG ARCH EUR J PHY, V413, P108, DOI 10.1007/BF00581239; ISHIKAWA T, 1991, CIRC RES, V69, P918, DOI 10.1161/01.RES.69.4.918; ISHIKAWA T, 1988, AM J PHYSIOL, V255, pH970, DOI 10.1152/ajpheart.1988.255.4.H970; KIM D, 1991, CIRC RES, V69, P250, DOI 10.1161/01.RES.69.1.250; MASAKI T, 1992, MED RES REV, V12, P391, DOI 10.1002/med.2610120405; ONO K, 1991, J PHYSIOL-LONDON, V436, P195, DOI 10.1113/jphysiol.1991.sp018546; ONO K, 1989, NATURE, V340, P721, DOI 10.1038/340721a0; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; REID JJ, 1991, EUR J PHARMACOL, V194, P173, DOI 10.1016/0014-2999(91)90102-V; REUTER H, 1979, ANNU REV PHYSIOL, V41, P413, DOI 10.1146/annurev.ph.41.030179.002213; SAKAMOTO A, 1991, BIOCHEM BIOPH RES CO, V178, P656, DOI 10.1016/0006-291X(91)90158-4; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; TANAKA T, 1994, MOL PHARMACOL, V45, P724; TOHSE N, 1990, BRIT J PHARMACOL, V99, P437, DOI 10.1111/j.1476-5381.1990.tb12944.x; VOGELSANG M, 1994, J CARDIOVASC PHARM, V23, P344, DOI 10.1097/00005344-199402000-00025; WENNMALM A, 1991, J PHYSIOL-LONDON, V435, P163, DOI 10.1113/jphysiol.1991.sp018503; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	27	144	144	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 28	1994	370	6487					301	304		10.1038/370301a0	http://dx.doi.org/10.1038/370301a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ229	8035879				2022-12-24	WOS:A1994NZ22900066
J	DIVNE, C; STAHLBERG, J; REINIKAINEN, T; RUOHONEN, L; PETTERSSON, G; KNOWLES, JKC; TEERI, TT; JONES, TA				DIVNE, C; STAHLBERG, J; REINIKAINEN, T; RUOHONEN, L; PETTERSSON, G; KNOWLES, JKC; TEERI, TT; JONES, TA			THE 3-DIMENSIONAL CRYSTAL-STRUCTURE OF THE CATALYTIC CORE OF CELLOBIOHYDROLASE-I FROM TRICHODERMA-REESEI	SCIENCE			English	Article							3-DIMENSIONAL STRUCTURE; ENDOGLUCANASE-I; ACTIVE-SITE; X-RAY; CELLULASE; SYNERGISM; QM-9414; DOMAIN; INTACT; OLIGOSACCHARIDES	Cellulose is the major polysaccharide of plants where it plays a predominantly structural role. A variety of highly specialized microorganisms have evolved to produce enzymes that either synergistically or in complexes can carry out the complete hydrolysis of cellulose. The structure of the major cellobiohydrolase, CBHI, of the potent cellulolytic fungus Trichoderma reesei has been determined and refined to 1.8 angstrom resolution. The molecule contains a 40 angstrom long active site tunnel that may account for many of the previously poorly understood macroscopic properties of the enzyme and its interaction with solid cellulose. The active site residues were identified by solving the structure of the enzyme complexed with an oligosaccharide, o-iodobenzyl-1-thio-beta-cellobioside. The three-dimensional structure is very similar to a family of bacterial beta-glucanases with the main-chain topology of the plant legume lectins.	UPPSALA UNIV, CTR BIOMED, DEPT MOLEC BIOL, S-75124 UPPSALA, SWEDEN; VTT BIOTECHNOL & FOOD RES, SF-02044 ESPOO, FINLAND; UNIV UPPSALA, CTR BIOMED, DEPT BIOCHEM, S-75123 UPPSALA, SWEDEN; GLAXO INST MOLEC BIOL SA, CH-1228 PLAN LES OUATES, SWITZERLAND	Uppsala University; VTT Technical Research Center Finland; Uppsala University; GlaxoSmithKline			Teeri, Tuula T/E-7509-2013; Divne, Christina/E-8646-2010; Stahlberg, Jerry/D-4163-2013	Divne, Christina/0000-0002-5805-2693; Stahlberg, Jerry/0000-0003-4059-8580				ABUJA PM, 1988, EUR BIOPHYS J BIOPHY, V15, P339, DOI 10.1007/BF00254721; ANDERSON WF, 1981, J MOL BIOL, V147, P523, DOI 10.1016/0022-2836(81)90398-3; BAILEY MJ, 1981, ENZYME MICROB TECH, V3, P153, DOI 10.1016/0141-0229(81)90076-4; BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHANZY H, 1983, FEBS LETT, V153, P113, DOI 10.1016/0014-5793(83)80129-X; CHANZY H, 1985, FEBS LETT, V184, P285, DOI 10.1016/0014-5793(85)80623-2; CLAEYSSENS M, 1989, BIOCHEM J, V261, P819, DOI 10.1042/bj2610819; CLAEYSSENS M, 1990, FEBS LETT, V263, P89, DOI 10.1016/0014-5793(90)80712-R; DAVIES GJ, 1993, NATURE, V365, P362, DOI 10.1038/365362a0; DIVNE C, 1993, J MOL BIOL, V234, P905, DOI 10.1006/jmbi.1993.1640; DURAND H, 1988, ENZYME MICROB TECH, V10, P341, DOI 10.1016/0141-0229(88)90012-9; EDELMAN GM, 1972, P NATL ACAD SCI USA, V69, P2580, DOI 10.1073/pnas.69.9.2580; FAGERSTAM LG, 1980, FEBS LETT, V119, P97, DOI 10.1016/0014-5793(80)81006-4; FLOCCO MM, 1994, J MOL BIOL, V235, P709, DOI 10.1006/jmbi.1994.1022; Gritzali M., 1979, HYDROLYSIS CELLULOSE, V181, P237, DOI DOI 10.1021/BA-1979-0181.CH012; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1985, BIO-TECHNOL, V3, P722, DOI 10.1038/nbt0885-722; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HOJ PB, 1992, J BIOL CHEM, V267, P25059; IRWIN DC, 1993, BIOTECHNOL BIOENG, V42, P1002, DOI 10.1002/bit.260420811; JKCWLES K, 1988, J CHEM SOC CHEM COMM, P1401; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; JUY M, 1992, NATURE, V357, P89, DOI 10.1038/357089a0; KEITEL T, 1993, P NATL ACAD SCI USA, V90, P5287, DOI 10.1073/pnas.90.11.5287; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KONSTANTINIDIS AK, 1993, BIOCHEM J, V291, P883, DOI 10.1042/bj2910883; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; MARLE I, 1993, J CHROMATOGR, V648, P333, DOI 10.1016/0021-9673(93)80415-5; NIDETZKY B, 1994, BIOCHEM J, V298, P705, DOI 10.1042/bj2980705; NIDETZKY B, 1994, ENZYME MICROB TECH, V16, P43, DOI 10.1016/0141-0229(94)90108-2; NIKU-PAAVOLA M-L, 1986, Biotechnology and Applied Biochemistry, V8, P449; NUMMI M, 1983, BIOCHEM J, V215, P677, DOI 10.1042/bj2150677; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PENTTILA M, 1986, GENE, V45, P253, DOI 10.1016/0378-1119(86)90023-5; ROUVINEN J, 1990, SCIENCE, V249, P380, DOI 10.1126/science.2377893; SPEZIO M, 1993, BIOCHEMISTRY-US, V32, P9906, DOI 10.1021/bi00089a006; STAHLBERG J, 1993, BIOCHIM BIOPHYS ACTA, V1157, P107, DOI 10.1016/0304-4165(93)90085-M; STAHLBERG J, 1993, CELLULASES OTHER HYD, P273; SUOMINEN PL, 1993, MOL GEN GENET, V241, P523, DOI 10.1007/BF00279894; TOMME P, 1988, EUR J BIOCHEM, V170, P575, DOI 10.1111/j.1432-1033.1988.tb13736.x; VRSANSKA M, 1992, CARBOHYD RES, V227, P19, DOI 10.1016/0008-6215(92)85058-8; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; WOOD TM, 1989, ENZYME SYSTEMS LIGNO, P19; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	47	536	550	1	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 22	1994	265	5171					524	528		10.1126/science.8036495	http://dx.doi.org/10.1126/science.8036495			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	8036495				2022-12-24	WOS:A1994NY21600030
J	HELDE, KA; WILSON, ET; CRETEKOS, CJ; GRUNWALD, DJ				HELDE, KA; WILSON, ET; CRETEKOS, CJ; GRUNWALD, DJ			CONTRIBUTION OF EARLY CELLS TO THE FATE MAP OF THE ZEBRAFISH GASTRULA	SCIENCE			English	Article							EMBRYO; LINEAGE; BLASTOMERES; MOVEMENTS	Previously, a tissue-specific fate map was compiled for the gastrula stage of the zebrafish embryo, indicating that development subsequent to this stage follows a reproducible pattern. Here it is shown that each early zebrafish blastomere normally contributes to a subset of the gastrula and thus gives rise to a limited array of tissues. However, the final contribution that any early blastomere makes to the fate map in the gastrula cannot be predicted because of variability in both the position of the future dorsoventral axis with respect to the early cleavage blastomeres and the scattering of daughter cells as the gastrula is formed. Therefore, early cell divisions of the zebrafish embryo cannot reproducibly segregate determinants of tissue fates.			HELDE, KA (corresponding author), UNIV UTAH,ECCLES INST HUMAN GENET,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112, USA.		Cretekos, Chris J/D-8350-2013					ABDELILAH S, IN PRESS NATURE; HO RK, 1993, SCIENCE, V261, P109, DOI 10.1126/science.8316841; KANE DA, 1992, NATURE, V360, P735, DOI 10.1038/360735a0; KANE DA, 1993, DEVELOPMENT, V119, P447; KIMMEL CB, 1990, DEVELOPMENT, V108, P581; KIMMEL CB, 1986, SCIENCE, V231, P365, DOI 10.1126/science.231.4736.365; KIMMEL CB, 1994, DEVELOPMENT, V120, P265; KIMMEL CB, 1987, DEV BIOL, V124, P269, DOI 10.1016/0012-1606(87)90478-7; KIMMEL CB, 1985, DEV BIOL, V108, P78, DOI 10.1016/0012-1606(85)90010-7; KIMMEL CB, 1985, DEV BIOL, V108, P94, DOI 10.1016/0012-1606(85)90012-0; NUSSLEINVOLHARD C, 1992, DEVELOPMENT, V116, P1021; Oppenheimer JM, 1936, J EXP ZOOL, V72, P409, DOI 10.1002/jez.1400720304; Oppenheimer JM, 1936, J EXP ZOOL, V73, P405, DOI 10.1002/jez.1400730304; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STACHEL SE, 1993, DEVELOPMENT, V117, P1261; STREHLOW D, 1993, NATURE, V361, P451, DOI 10.1038/361451a0; WARGA RM, 1990, DEVELOPMENT, V108, P569; WETERFIELD M, 1993, ZEBRAFISH BOOK; WILSON ET, 1993, TRENDS GENET, V9, P348, DOI 10.1016/0168-9525(93)90039-K	19	72	74	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 22	1994	265	5171					517	520		10.1126/science.8036493	http://dx.doi.org/10.1126/science.8036493			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	8036493				2022-12-24	WOS:A1994NY21600028
J	MOHLER, KM; SLEATH, PR; FITZNER, JN; CERRETTI, DP; ALDERSON, M; KERWAR, SS; TORRANCE, DS; OTTENEVANS, C; GREENSTREET, T; WEERAWARNA, K; KRONHEIM, SR; PETERSEN, M; GERHART, M; KOZLOSKY, CJ; MARCH, CJ; BLACK, RA				MOHLER, KM; SLEATH, PR; FITZNER, JN; CERRETTI, DP; ALDERSON, M; KERWAR, SS; TORRANCE, DS; OTTENEVANS, C; GREENSTREET, T; WEERAWARNA, K; KRONHEIM, SR; PETERSEN, M; GERHART, M; KOZLOSKY, CJ; MARCH, CJ; BLACK, RA			PROTECTION AGAINST A LETHAL DOSE OF ENDOTOXIN BY AN INHIBITOR OF TUMOR-NECROSIS-FACTOR PROCESSING	NATURE			English	Article							MOLECULAR-CLONING; EMERGING FAMILY; TNF; PURIFICATION; LIGAND; LIPOPOLYSACCHARIDE; INTERLEUKIN-1-BETA; CYTOKINES; PRECURSOR; HOMOLOGY	TUMOUR necrosis factor (tumour necrosis factor-alpha/cachectin) plays a critical role in certain physiological defensive responses but causes severe damage to the host organism when produced in excess(1). There are two forms of tumour necrosis factor, a type II membrane protein of relative molecular mass 26,000 (26K) and a soluble, 17K form generated from the cell-bound protein by proteolytic cleavage(2,3). The two forms of tumour necrosis factor and lymphotoxin-alpha (tumour necrosis factor-beta/lymphotoxin), a related protein, have similar but apparently not identical biological activities(4-6). A therapeutic agent which inhibited the release of tumour necrosis factor, but did not reduce the cell-associated activity or the level of lymphotoxin-alpha, might preserve the benefits of these cytokines while preventing tumour necrosis factor-induced damage. Here we describe a potent inhibitor of tumour necrosis factor processing and report that it protects mice from a lethal dose of endotoxin.	IMMUNEX RES & DEV CORP,SEATTLE,WA 98101; AMER CYANAMID CO,LEDERLE LABS,DIV MED RES,PEARL RIVER,NY 10965									AGGARWAL BB, 1985, J BIOL CHEM, V260, P2345; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BIRKLAND TP, 1992, J LEUKOCYTE BIOL, V51, P296, DOI 10.1002/jlb.51.3.296; BLACK RA, 1988, J BIOL CHEM, V263, P9437; FIELDS GB, 1987, J BIOL CHEM, V262, P6221; GOODWIN RG, 1993, EUR J IMMUNOL, V23, P2631, DOI 10.1002/eji.1830231037; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; JUE DM, 1990, BIOCHEMISTRY-US, V29, P8371, DOI 10.1021/bi00488a025; KARP SE, 1992, J IMMUNOL, V149, P2076; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; KRONHEIM SR, 1992, ARCH BIOCHEM BIOPHYS, V296, P698, DOI 10.1016/0003-9861(92)90629-B; LEHMANN V, 1987, J EXP MED, V165, P657, DOI 10.1084/jem.165.3.657; LESSLAUER W, 1991, EUR J IMMUNOL, V21, P2883, DOI 10.1002/eji.1830211134; LIBBY RT, 1987, DNA-J MOLEC CELL BIO, V6, P221, DOI 10.1089/dna.1987.6.221; MAEDA T, 1983, BIOCHIM BIOPHYS ACTA, V731, P115, DOI 10.1016/0005-2736(83)90404-2; MALISZEWSKI CR, 1988, MOL IMMUNOL, V25, P429, DOI 10.1016/0161-5890(88)90162-9; MOHLER KM, 1993, J IMMUNOL, V151, P1548; ROQUES BP, 1990, TRENDS PHARMACOL SCI, V11, P245; SHERRY B, 1988, J CELL BIOL, V107, P1269, DOI 10.1083/jcb.107.4.1269; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; VILCEK J, 1991, J BIOL CHEM, V266, P7313; WANG AM, 1985, SCIENCE, V228, P149, DOI 10.1126/science.3856324; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; 1992, 12TH P AM PEPT S CAM	24	566	598	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 21	1994	370	6486					218	220		10.1038/370218a0	http://dx.doi.org/10.1038/370218a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX971	8028669				2022-12-24	WOS:A1994NX97100053
J	HAIMOV, I; LAUDON, M; ZISAPEL, N; SOUROUJON, M; NOF, D; SHLITNER, A; HERER, P; TZISCHINSKY, O; LAVIE, P				HAIMOV, I; LAUDON, M; ZISAPEL, N; SOUROUJON, M; NOF, D; SHLITNER, A; HERER, P; TZISCHINSKY, O; LAVIE, P			SLEEP DISORDERS AND MELATONIN RHYTHMS IN ELDERLY PEOPLE	BRITISH MEDICAL JOURNAL			English	Article									TECHNION ISRAEL INST TECHNOL,BRUCE RAPPAPORT FAC MED,SLEEP LAB,IL-31096 HAIFA,ISRAEL; NEURIM PHARMACEUT LTD,TEL AVIV,ISRAEL; TEL AVIV UNIV,GEORGE S WISE FAC LIFE SCI,DEPT BIOCHEM,IL-69978 TEL AVIV,ISRAEL; MACCABI PHARMACEUT LTD,TEL AVIV,ISRAEL	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Tel Aviv University			Lavie, Peretz/AAC-2736-2020; Laudon, Moshe/GXH-1907-2022					Dement W, 1985, HDB BIOL AGING, P692; GWINNER E, 1978, J COMP PHYSIOL, V127, P209, DOI 10.1007/BF01350111; Sadeh A., 1989, J AMBUL MONITOR, V2, P209; SHARMA M, 1989, BIOL PSYCHIAT, V25, P305, DOI 10.1016/0006-3223(89)90178-9; WISBERG J, 1990, SLEEP RES, V19, P384	5	246	251	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 16	1994	309	6948					167	167		10.1136/bmj.309.6948.167	http://dx.doi.org/10.1136/bmj.309.6948.167			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY229	8044096	Green Published			2022-12-24	WOS:A1994NY22900022
J	HJALMARS, U; KULLDORFF, M; GUSTAFSSON, G; GARWICZ, S; ANDERSONGARE, B; BJORK, O; FORESTIER, E; BEHRENDTZ, M; LONNERHOLM, G; MELLANDER, L; WRANNE, L				HJALMARS, U; KULLDORFF, M; GUSTAFSSON, G; GARWICZ, S; ANDERSONGARE, B; BJORK, O; FORESTIER, E; BEHRENDTZ, M; LONNERHOLM, G; MELLANDER, L; WRANNE, L			RISK OF ACUTE CHILDHOOD LEUKEMIA IN SWEDEN AFTER THE CHERNOBYL REACTOR ACCIDENT	BRITISH MEDICAL JOURNAL			English	Article								Objective-To evaluate the risk of acute childhood leukaemia in areas of Sweden contaminated after the Chernobyl reactor accident in April 1986. Design-Population based study of childhood leukaemia diagnosed during 1980-92. Setting-Coordinates for places of residence of all 1.6 million children aged 0-15 years; aerial mapped areas of Sweden heavily contaminated after the Chernobyl accident. Subjects-888 children aged 0-15 years with acute leukaemia diagnosed in Sweden during 1980-92, identified with place of birth and residence at diagnosis. Main outcome measures-Risk of leukaemia in areas contaminated after the Chernobyl accident compared with the rest of Sweden and in the same areas before the accident. Results-During six and a half years of follow up after the accident the odds ratio for acute leukaemia was 0.9 (95% confidence interval 0.6 to 1.4) in highly contaminated areas (greater than or equal to 10 kBq/m(2)) compared with the same areas before the accident. For the subgroup acute lymphoblastic leukaemia in children aged under 5 years at diagnosis the odds ratio was 1.5 (0.8 to 2.6). For all cases diagnosed after May 1986 in highly contaminated areas compared with areas of low contamination the odds ratio was 0.9 (0.7 to 1.3). For acute lymphblastic leukaemia in children aged under 5 years at diagnosis the odds ratio was 1.2 (0.8 to 1.9) in highly contaminated areas compared with areas of low contamination. Dose-response analysis showed no correlation between the degree of contamination and the incidence of childhood leukaemia. Conclusion-There has been no significant increase in the incidence of acute childhood leukaemia in areas of Sweden contaminated after the Chernobyl reactor accident.	UPPSALA UNIV,DEPT STAT,UPPSALA,SWEDEN	Uppsala University	HJALMARS, U (corresponding author), CENT HOSP,DEPT PAEDIAT,S-83183 OSTERSUND,SWEDEN.		Kulldorff, Martin/H-4282-2011					BITHELL JF, 1988, STAT MED, V7, P857, DOI 10.1002/sim.4780070804; Edvarson K, 1991, CHERNOBYL FALLOUT SW, P527; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; JOSEPH L, 1981, STATISTICAL METHODS; KINLEN LJ, 1993, BRIT MED J, V306, P1153, DOI 10.1136/bmj.306.6886.1153; Knox E. G., 1987, J SOC RADIOL PROT, V7, P3; PARKIN DM, 1993, EUR J CANCER, V29A, P87, DOI 10.1016/0959-8049(93)90582-Z; PRISYAZHIUK A, 1991, LANCET, V338, P1334, DOI 10.1016/0140-6736(91)92632-C; 1991, INT PROGRAMME HLTH E; 1991, ANN ICRP, V21, P1; 1989, SUMMARY REPORT CONSU	11	48	48	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 16	1994	309	6948					154	157		10.1136/bmj.309.6948.154	http://dx.doi.org/10.1136/bmj.309.6948.154			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY229	8044093	Green Published			2022-12-24	WOS:A1994NY22900018
J	AGGLETON, P; OREILLY, K; SLUTKIN, G; DAVIES, P				AGGLETON, P; OREILLY, K; SLUTKIN, G; DAVIES, P			RISKING EVERYTHING - RISK BEHAVIOR, BEHAVIOR-CHANGE, AND AIDS	SCIENCE			English	Article							CONDOM PROMOTION; MODEL; HIV; TRANSMISSION; AFRICA; WOMEN; SEX	Inquiry into the determinants of risk-related sexual behavior is important for the development of interventions to reduce the incidence of new cases of human immunodeficiency virus infection. Recent social and behavioral research has revealed much about the individual and social factors influencing risk-taking. Findings from these studies have been important in the development of new educational and community-based interventions for communities at risk in the developed and developing worlds.	UNIV PORTSMOUTH, SCH HLTH STUDIES, PORTSMOUTH, HANTS, ENGLAND	University of Portsmouth	AGGLETON, P (corresponding author), WHO, GLOBAL PROGRAMME AIDS, CH-1211 GENEVA, SWITZERLAND.							ALLEN S, 1992, JAMA-J AM MED ASSOC, V268, P3338, DOI 10.1001/jama.268.23.3338; ALTMAN D, 1991, AIDS FACING 2ND DECA, P1; Altman D., 1986, AIDS NEW PURITANISM; ANDERSON R M, 1991; ANKRAH EM, 1991, SOC SCI MED, V32, P967, DOI 10.1016/0277-9536(91)90155-6; [Anonymous], 1988, NEW PUBLIC HLTH; Bandura A., 1977, SOCIAL LEARNING THEO; BASSETT MT, 1991, INT J HEALTH SERV, V21, P143, DOI 10.2190/N0NJ-FKXB-CT25-PA09; Becker MH, 1974, HLTH BELIEF MODEL PE; Biberfeld G, 1991, AIDS, V5 Suppl 2, pS129, DOI 10.1097/00002030-199101001-00018; CATANIA JA, 1990, HEALTH EDUC QUART, V17, P53, DOI 10.1177/109019819001700107; CATES W, 1992, NEW ENGL J MED, V327, P492, DOI 10.1056/NEJM199208133270711; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P880; CLEARY PD, 1987, TAKING CARE UNDERSTA, P119, DOI DOI 10.1017/CBO9780511527760.009; DAVIES P, 1991, SOC AS AIDS, P111; Davies P, 1993, SEX GAY MEN AIDS; DEZALDUONDO BO, 1991, J SEX RES, V28, P223, DOI 10.1080/00224499109551607; FEE N, 1993, YOUNG PEOPLE AIDS ST; Fetscherin M, 2008, J ELECTRON COMMER RE, V9, P231; Finger W R, 1991, Netw Res Triangle Park N C, V12, P16; FORD N, 1991, SOC SCI MED, V33, P405, DOI 10.1016/0277-9536(91)90321-3; FORD NJ, 1993, 9TH INT C AIDS BERL; GILADA IS, 1993, WOMEN HIV AIDS, P276; HAYS RB, 1993, 9TH INT C AIDS BERL; Herdt G.H., 2018, SAME SEX DIFFERENT C; HOLLAND J, 1992, SOC AS AIDS, P142; HUNT CW, 1989, J HEALTH SOC BEHAV, V30, P353, DOI 10.2307/2136985; JOB RFS, 1988, AM J PUBLIC HEALTH, V78, P163, DOI 10.2105/AJPH.78.2.163; KAPLAN BJ, 1993, AIDS EDUC PREV, V5, P294; KATLAMA C, 1993, AIDS, V7, pS185, DOI 10.1097/00002030-199301001-00024; Kippax S., 1993, SUSTAINING SAFE SEX; KREPCHO MA, 1993, J PSYCHOACTIVE DRUGS, V25, P135, DOI 10.1080/02791072.1993.10472243; LAMPTEY P, 1993, 9TH INT C AIDS BERL, P18; Mann J., 1992, AIDS WORLD GLOBAL RE; MANN J, 1992, AIDS WORLD GLOBAL RE, P228; MCKUSICK L, 1985, SEX TRANSM DIS, V12, P229, DOI 10.1097/00007435-198510000-00012; MOULI VC, 1992, ALL AIDS COPPERBELT; NGUGI EN, 1988, LANCET, V2, P887, DOI 10.1016/S0140-6736(88)92480-4; POLLAK M, 1992, ASSESSING AIDS PREVE, P137; PROCHASKA JO, 1983, J CONSULT CLIN PSYCH, V51, P390, DOI 10.1037//0022-006X.51.3.390; SATO PA, 1989, AIDS, V3, pS301, DOI 10.1097/00002030-198901001-00043; SILVERMAN M, 1992, AIDS PREVENTION ED W, P352; SMALLMANRAYNOR M, 1992, ATLAS AIDS, P210; STIMSON G, 1991, SOC AS AIDS, P225; STIMSON G V, 1991, International Review of Psychiatry, V3, P401, DOI 10.3109/09540269109072146; ULIN PR, 1992, SOC SCI MED, V34, P63, DOI 10.1016/0277-9536(92)90068-2; Weinstein N. D., 1987, TAKING CARE UNDERSTA; WILLIAMS G, 1993, WORK AIDS WORKPLACE; Yeboah-Afari A, 1988, AIDSWATCH, V4, P4; ZWI A, 1993, BRIT MED J, V303, P1527; 1993, HIV DEV AFRICA; 1993, BEHAVIORAL SOCIAL SC, P41; 1993, 1993 WORLD BANK WORL, P99; 1993, GLOBAL AIDS NEWS, V3, P1; 1993, EFFECTIVE APPROACHES; 1994, CURRENT GLOBAL SITUA	56	96	97	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 15	1994	265	5170					341	345		10.1126/science.8023156	http://dx.doi.org/10.1126/science.8023156			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023156				2022-12-24	WOS:A1994NW81600026
J	STEINBACHER, S; SECKLER, R; MILLER, S; STEIPE, B; HUBER, R; REINEMER, P				STEINBACHER, S; SECKLER, R; MILLER, S; STEIPE, B; HUBER, R; REINEMER, P			CRYSTAL-STRUCTURE OF P22 TAILSPIKE PROTEIN - INTERDIGITATED SUBUNITS IN A THERMOSTABLE TRIMER	SCIENCE			English	Article							TAIL SPIKE PROTEIN; SENSITIVE FOLDING MUTATIONS; MOLECULAR-PROPERTIES; GLOBAL SUPPRESSORS; MUTANT PROTEINS; PHAGE-P22; BACTERIOPHAGE-P22; ENDORHAMNOSIDASE; PATHWAY; INVITRO	The tailspike protein (TSP) of Salmonella typhimurium phage P22 is a part of the apparatus by which the phage attaches to the bacterial host and hydrolyzes the O antigen. It has served as a model system for genetic and biochemical analysis of protein folding. The x-ray structure of a shortened TSP (residues 109 to 666) was determined to a 2.0 angstrom resolution. Each subunit of the homotrimer contains a large parallel beta helix. The interdigitation of the polypeptide chains at the carboxyl termini is important to protrimer formation in the folding pathway and to thermostability of the mature protein.	UNIV REGENSBURG,D-93040 REGENSBURG,GERMANY	University of Regensburg	STEINBACHER, S (corresponding author), MAX PLANCK INST BIOCHEM,STRUKT FORSCH ABT,KLOPFERSPITZ 18A,D-82152 MARTINSRIED,GERMANY.		Steipe, Boris/ABE-3813-2020	Steipe, Boris/0000-0002-1134-6758				BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BERGET PB, 1980, J VIROL, V34, P234, DOI 10.1128/JVI.34.1.234-243.1980; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P2767; BRUNSCHIER R, 1993, J BIOL CHEM, V268, P20071; CHEN BL, 1991, BIOCHEMISTRY-US, V30, P6260, DOI 10.1021/bi00239a026; DANNER M, 1993, PROTEIN SCI, V2, P1869, DOI 10.1002/pro.5560021109; DANNER M, 1993, EUR J BIOCHEM, V215, P653, DOI 10.1111/j.1432-1033.1993.tb18076.x; DANNER M, UNPUB; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FANE B, 1991, J BIOL CHEM, V266, P11640; FUCHS A, 1991, BIOCHEMISTRY-US, V30, P6598, DOI 10.1021/bi00240a032; GOLDENBERG D, 1982, P NATL ACAD SCI-BIOL, V79, P3403, DOI 10.1073/pnas.79.11.3403; GOLDENBERG DP, 1981, J MOL BIOL, V145, P633, DOI 10.1016/0022-2836(81)90307-7; GOLDENBERG DP, 1983, P NATL ACAD SCI-BIOL, V80, P7060, DOI 10.1073/pnas.80.23.7060; GOLDENBERG DP, 1982, J BIOL CHEM, V257, P7864; HAASEPETTINGELL CA, 1988, J BIOL CHEM, V263, P4977; ISRAEL JV, 1967, P NATL ACAD SCI USA, V57, P284, DOI 10.1073/pnas.57.2.284; IWASHITA S, 1976, EUR J BIOCHEM, V65, P87, DOI 10.1111/j.1432-1033.1976.tb10392.x; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; LEE SC, 1991, J BIOL CHEM, V266, P23191; MAURIDES PA, 1990, GENETICS, V125, P673; MESSERSCHMIDT A, 1990, J APPL CRYSTALLOGR, V23, P436, DOI 10.1107/S0021889890005301; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MESSERSCHMIDT A, 1991, CRYSTALLOGRAPHIC COM, V5, P115; MITRAKI A, 1991, SCIENCE, V253, P54, DOI 10.1126/science.1648264; MITRAKI A, 1992, FEBS LETT, V307, P20, DOI 10.1016/0014-5793(92)80894-M; SAUER RT, 1982, BIOCHEMISTRY-US, V21, P5811, DOI 10.1021/bi00266a014; SCHWARZ JJ, 1989, J BIOL CHEM, V264, P20112; SMITH DH, 1981, J MOL BIOL, V145, P653, DOI 10.1016/0022-2836(81)90308-9; VILLAFANE R, 1988, J MOL BIOL, V204, P607, DOI 10.1016/0022-2836(88)90359-2; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994	34	274	278	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 15	1994	265	5170					383	386		10.1126/science.8023158	http://dx.doi.org/10.1126/science.8023158			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023158				2022-12-24	WOS:A1994NW81600037
J	FRYDMAN, J; NIMMESGERN, E; OHTSUKA, K; HARTL, FU				FRYDMAN, J; NIMMESGERN, E; OHTSUKA, K; HARTL, FU			FOLDING OF NASCENT POLYPEPTIDE-CHAINS IN A HIGH-MOLECULAR-MASS ASSEMBLY WITH MOLECULAR CHAPERONES	NATURE			English	Article							T-COMPLEX POLYPEPTIDE-1; ESCHERICHIA-COLI DNAJ; HEAT-SHOCK PROTEINS; STRESS PROTEINS; BINDING-SPECIFICITY; PEPTIDE-BINDING; CENTRAL CAVITY; GROEL; TRANSLOCATION; CELL	The folding of polypeptides emerging from ribosomes was analysed in a mammalian translation system using firefly luciferase as a model protein. The growing polypeptide interacts with a specific set of molecular chaperones, including Hsp70, the DnaJ homologue Hsp40 and the chaperonin TRiC. The ordered assembly of these components on the nascent chain forms a high molecular mass complex that allows the cotranslational formation of protein domains and the completion of folding once the chain is released from the ribosome.	MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIPHYS PROGRAM,NEW YORK,NY 10021; AICHI CANC CTR,EXPTL RADIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Aichi Cancer Center			Hartl, F. Ulrich/Y-8206-2019	, judith/0000-0003-2302-6943				BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CZERMELY P, 1991, J BIOL CHEM, V266, P4943; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; ELLIS RJ, 1994, CURR OPIN STRUC BIOL, V4, P117, DOI 10.1016/S0959-440X(94)90069-8; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; Harlow E., 1988, ANTIBODIES LABORATOR, P1; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HATTORI H, 1993, J CELL SCI, V104, P629; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HORWICH AL, 1993, PHILOS T R SOC B, V339, P313, DOI 10.1098/rstb.1993.0030; JAENICKE R, 1987, PROG BIOPHYS MOL BIO, V49, P117, DOI 10.1016/0079-6107(87)90011-3; JAGUS R, 1987, METHOD ENZYMOL, V152, P267; KELLER GA, 1987, P NATL ACAD SCI USA, V84, P3264, DOI 10.1073/pnas.84.10.3264; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LEWIS MJ, 1985, EMBO J, V4, P3137, DOI 10.1002/j.1460-2075.1985.tb04056.x; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; MARCO S, IN PRESS BIOPHYS J; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; NIMMESGERN E, 1993, FEBS LETT, V331, P25, DOI 10.1016/0014-5793(93)80290-B; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; PELHAM H, 1988, NATURE, V332, P776, DOI 10.1038/332776a0; ROMMELAERE H, 1993, P NATL ACAD SCI USA, V90, P11975, DOI 10.1073/pnas.90.24.11975; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; STEWART ML, 1971, P NATL ACAD SCI USA, V68, P97, DOI 10.1073/pnas.68.1.97; STUART RA, 1994, TRENDS BIOCHEM SCI, V19, P87, DOI 10.1016/0968-0004(94)90041-8; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0	50	569	582	1	33	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 14	1994	370	6485					111	117		10.1038/370111a0	http://dx.doi.org/10.1038/370111a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW804	8022479				2022-12-24	WOS:A1994NW80400047
J	BUCKMAN, R; LEWITH, G				BUCKMAN, R; LEWITH, G			WHAT DOES HOMEOPATHT DO AND HOW	BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER	Robert Buckman, a medical oncologist, and George Lewith, a homoeopathic physician, met in Southampton while filming ''Magic or Medicine?,'' a television series of four programmes about what can and might be learnt from the popularity of complementary medicine. In particular, the series showed how the effect of the patient's and the doctor's beliefs affected the relationship between them. The two doctors so enjoyed talking with each other that they carried on their debate in letters to each other over the next year. We think that their exchange merits a wider readership.	CTR STUDY COMPLEMENTARY MED,SOUTHAMPTON SO15 2DT,HANTS,ENGLAND		BUCKMAN, R (corresponding author), TORONTO SUNNYBROOK REG CANC CTR,2075 BAYVIEW AVE,TORONTO M4N 3M5,ON,CANADA.			Lewith, George/0000-0002-2364-3960				BONADONNA G, 1976, NEW ENGL J MED, V294, P405, DOI 10.1056/NEJM197602192940801; Brigo B, 1991, BERL J RES HOM, V1, P98; BUCKMAN R, 1993, MAGIC MED; FERLEY JP, 1989, BRIT J CLIN PHARMACO, V27, P329, DOI 10.1111/j.1365-2125.1989.tb05373.x; FISHER P, 1989, BRIT MED J, V299, P365, DOI 10.1136/bmj.299.6695.365; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; LEWITH G, 1987, COMPLEMENTAYR MED RE, V2, P11; PETO R, 1984, LANCET, V2, P1205; REILLY DT, 1986, LANCET, V2, P881; REILLY DT, 1993, COMPLEMENTARY THE S1, V1, P24; SPIEGEL D, 1989, LANCET, V2, P888	11	18	18	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					103	106		10.1136/bmj.309.6947.103	http://dx.doi.org/10.1136/bmj.309.6947.103			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038642	Green Published			2022-12-24	WOS:A1994NW71600027
J	NAB, HW; HOP, WCJ; CROMMELIN, MA; KLUCK, HM; VANDERHEIJDEN, LH; COEBERGH, JWW				NAB, HW; HOP, WCJ; CROMMELIN, MA; KLUCK, HM; VANDERHEIJDEN, LH; COEBERGH, JWW			CHANGES IN LONG-TERM PROGNOSIS FOR BREAST-CANCER IN A DUTCH CANCER REGISTRY	BRITISH MEDICAL JOURNAL			English	Article							SURVIVAL; TRENDS; WOMEN; CURABILITY	Objectives-To assess whether the long term survival of patients with breast cancer has changed with time. Design-Population based descriptive study. Setting-Eindhoven Cancer Registry in south east Netherlands. Subjects-2O52 patients with first primary breast cancer diagnosed between 1955 and 1974. Main outcome measures-Overall survival and relative survival. Results-Overall survival was 35% (727 patients) after 10 years, 21% (267) after 20 years, and 15% (25) after 30 years. The corresponding relative survival rates were 43%, 34%, and 34%, respectively. Survival improved from 1955 onwards for all ages and all tumour stages, Improvement was observed in both overall and relative survival. Prognosis was strongly related to the stage at diagnosis in the first 10 years of follow up but independent of stage after 10 years. Survival of patients still alive after 19 years became similar to that of the general female population, Conclusions-Both short and long term survival improved considerably in all age groups. This improvement was most marked for patients who were diagnosed with a localised tumour. Patients who survive for 19 years may be considered cured,	ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam	NAB, HW (corresponding author), COMPREHENS CANC CTR S,REG BREAST CANC STUDY GRP,POB 231,5600 AE EINDHOVEN,NETHERLANDS.			Coebergh, Jan Willem/0000-0002-2419-3930				ADAMI HO, 1986, JNCI-J NATL CANCER I, V76, P653, DOI 10.1093/jnci/76.4.653; BERKSON J, 1950, P STAFF M MAYO CLIN, V25, P270; BRINKLEY D, 1984, LANCET, V1, P1118; CASCINELLI N, 1991, CANCER-AM CANCER SOC, V68, P427, DOI 10.1002/1097-0142(19910715)68:2<427::AID-CNCR2820680236>3.0.CO;2-Y; CAYGILL CPJ, 1991, TUMORI, V77, P126, DOI 10.1177/030089169107700207; COX DR, 1972, J R STAT SOC B, V34, P187; DANFORTH DN, 1986, J CLIN ONCOL, V4, P655, DOI 10.1200/JCO.1986.4.5.655; DUNCAN W, 1976, BRIT MED J, V2, P781, DOI 10.1136/bmj.2.6039.781; FEINSTEIN AR, 1985, NEW ENGL J MED, V312, P1604, DOI 10.1056/NEJM198506203122504; HAKULINEN T, 1982, BIOMETRICS, V38, P933, DOI 10.2307/2529873; HAKULINEN T, 1981, ANN CLIN RES S31, V13, P48; HAKULINEN T, 1987, APPL STAT-J ROY ST C, V36, P309; HIBBERD AD, 1983, BRIT MED J, V286, P1777, DOI 10.1136/bmj.286.6380.1777; JOENSUU H, 1991, BRIT MED J, V303, P155, DOI 10.1136/bmj.303.6795.155; LANGLANDS AO, 1979, BRIT MED J, V2, P1247, DOI 10.1136/bmj.2.6200.1247; LAVECCHIA C, 1992, EUR J CANCER, V28A, P927, DOI 10.1016/0959-8049(92)90153-S; MILLER BA, 1993, CA-CANCER J CLIN, V43, P27, DOI 10.3322/canjclin.43.1.27; NAB HW, 1994, EUR J CANCER, V30A, P50, DOI 10.1016/S0959-8049(05)80018-8; NAB HW, 1993, EUR J CANCER, V29A, P1557, DOI 10.1016/0959-8049(93)90294-P; PARKIN DM, 1992, CANCER INVIDENCE 5 C, V6; RUTQVIST LE, 1985, CANCER-AM CANCER SOC, V55, P658, DOI 10.1002/1097-0142(19850201)55:3<658::AID-CNCR2820550331>3.0.CO;2-P; 1992, ATLAS CANCER MORTALI; NIH882789 NCI PUBL, P69	23	26	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					83	86		10.1136/bmj.309.6947.83	http://dx.doi.org/10.1136/bmj.309.6947.83			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038671	Green Published			2022-12-24	WOS:A1994NW71600014
J	CHUNG, JK; GRAMMER, TC; LEMON, KP; KAZLAUSKAS, A; BLENIS, J				CHUNG, JK; GRAMMER, TC; LEMON, KP; KAZLAUSKAS, A; BLENIS, J			PDGF-DEPENDENT AND INSULIN-DEPENDENT PP70(S6K) ACTIVATION MEDIATED BY PHOSPHATIDYLINOSITOL-3-OH KINASE	NATURE			English	Article							GROWTH-FACTOR RECEPTOR; S6 PROTEIN-KINASE; SIGNAL-TRANSDUCTION; PHOSPHORYLATION; 3-KINASE; INHIBITION; P70(S6K); 3,4,5-TRISPHOSPHATE; EXPRESSION; WORTMANNIN	PLATELET-DERIVED growth factor receptor (PDGF-R) phosphorylation at tyrosines 740/751 and insulin receptor phosphorylation of insulin receptor substrate-1 effects the recruitment and activation of phosphatidylinositol-3-OH kinase (PI(3)K)(1-5). Changes in PI(3)K activity correlate with cell growth but its downstream signal transducers are unknown(4,5). Activation of the 70/85K S6 kinases (pp70(S6k)) by serine phosphorylation(6,7) results in 40S ribosomal protein S6 phosphorylation and is important for G1 cell-cycle transition in a variety of cells(8-11). Although receptor tyrosine kinases activate the microtubule-associated protein kinase cascade through SH2-/SH3-adaptor proteins, Sos and c-Ras(12), it is unclear how tyrosine kinases are coupled to the pp70(S6k) phosphorylation cascade. Here we report that PI(3)K mediates PDGF or insulin receptor signalling to pp70(S6k). PI(3)K-mediated activation of pp70(S6k) is independent of conventional protein kinase C isoforms. Additionally, rapamycin blocks pp70(S6k) activation by all mitogens(8-10), without inhibiting PI(3)M, and acts downstream this signalling system.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO 80206	Harvard University; Harvard Medical School; National Jewish Health								ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CHEATHAM B, IN PRESS MOL CELL BI; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2354; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIBE S, 1990, P NATL ACAD SCI USA, V87, P424, DOI 10.1073/pnas.87.1.424; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PARKER PJ, 1992, CELL GROWTH DIFFER, V3, P747; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUSA M, 1992, J BIOL CHEM, V267, P6905; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; TSAI M, 1993, EUR J IMMUNOL, V23, P3286, DOI 10.1002/eji.1830231234; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YANO H, 1993, J BIOL CHEM, V268, P25846	30	687	695	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 7	1994	370	6484					71	75		10.1038/370071a0	http://dx.doi.org/10.1038/370071a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV711	8015612				2022-12-24	WOS:A1994NV71100062
J	LIU, FY; ALTMAN, S				LIU, FY; ALTMAN, S			DIFFERENTIAL EVOLUTION OF SUBSTRATES FOR AN RNA ENZYME IN THE PRESENCE AND ABSENCE OF ITS PROTEIN COFACTOR	CELL			English	Article							4.5 S-RNA; ESCHERICHIA-COLI; RIBONUCLEASE-P; INVITRO; PRECURSOR; SEQUENCE; MOIETY; MODEL; GENE; LIFE	Selection of substrates for an RNA enzyme, the catalytic subunit of RNAase P from E. coli, has been carried out by simulation of evolution in vitro in the presence and absence of the protein cofactor of the enzyme. In the presence of the protein, substrates resembling precursor tRNAs, which were readily cleaved by the catalytic RNA, were selected in addition to others, with different sequences and structures (one of which resembled the precursor to 4.5S RNA) that were not readily cleaved by the catalytic RNA alone. The ribonucleoprotein enzyme is more versatile than the RNA enzyme, and our results suggest that it and 4.5S RNA may have evolved after ancestral tRNAs.			LIU, FY (corresponding author), YALE UNIV,DEPT BIOL,POB 6666,NEW HAVEN,CT 06520, USA.				NIGMS NIH HHS [GM19422] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019422, R01GM019422] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMAN S, 1993, FASEB J, V7, P7, DOI 10.1096/fasebj.7.1.7916700; BOTHWELL ALM, 1976, J BIOL CHEM, V251, P7709; BROWN S, 1987, CELL, V49, P825, DOI 10.1016/0092-8674(87)90620-9; CECH TR, 1993, RNA WORLD, P239; DARR SC, 1992, TRENDS BIOCHEM SCI, V17, P178, DOI 10.1016/0968-0004(92)90262-8; DEBRUIJN MHL, 1983, EMBO J, V2, P1309, DOI 10.1002/j.1460-2075.1983.tb01586.x; FEDOR M, 1993, BIOCHEMISTRY-US, V31, P12042; Fersht A., 1985, ENZYME STRUCTURE MEC; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GREEN R, 1990, NATURE, V347, P406, DOI 10.1038/347406a0; GUERRIERTAKADA C, 1989, SCIENCE, V246, P1578, DOI 10.1126/science.2480641; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HSU LM, 1984, J MOL BIOL, V178, P509, DOI 10.1016/0022-2836(84)90236-5; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; KAHLE D, 1990, EMBO J, V9, P1929, DOI 10.1002/j.1460-2075.1990.tb08320.x; KOMINE Y, 1994, IN PRESS P NATL ACAD; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; MCCLAIN WH, 1987, SCIENCE, V238, P527, DOI 10.1126/science.2443980; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; Moore M., 1993, RNA WORLD, P303; NOLAN JM, 1993, SCIENCE, V261, P762, DOI 10.1126/science.7688143; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; OKIMOTO R, 1990, EMBO J, V9, P3405, DOI 10.1002/j.1460-2075.1990.tb07542.x; PECKMILLER KA, 1991, J MOL BIOL, V221, P1; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; Sprinzl M., 1989, Nucleic Acids Research, V17, P1; STEINBERG S, 1993, NUCLEIC ACIDS RES, V21, P3011, DOI 10.1093/nar/21.13.3011; TALBOT SJ, 1994, BIOCHEMISTRY-US, V33, P1399, DOI 10.1021/bi00172a016; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VIOQUE A, 1988, J MOL BIOL, V202, P835, DOI 10.1016/0022-2836(88)90562-1; YUAN Y, 1994, SCIENCE, V263, P1269, DOI 10.1126/science.8122108	33	72	75	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					1093	1100		10.1016/0092-8674(94)90448-0	http://dx.doi.org/10.1016/0092-8674(94)90448-0			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	8020097				2022-12-24	WOS:A1994NV42500017
J	HOLLAND, BK				HOLLAND, BK			PROSPECTING FOR DRUGS IN ANCIENT TEXTS	NATURE			English	Editorial Material							PENNYROYAL OIL; HEPATOTOXICITY; MENTHOFURAN; GLUTATHIONE; PULEGONE				HOLLAND, BK (corresponding author), UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT PREVENT MED & COMMUNITY HLTH,NEWARK,NJ 07103, USA.							ATHERTON DJ, 1991, LANCET, V338, P510, DOI 10.1016/0140-6736(91)90580-I; BURTON JL, 1990, LANCET, V336, P1565, DOI 10.1016/0140-6736(90)93326-K; FARNSWORTH NR, 1983, NATURAL PRODUCTS DRU; FELLOWS L, 1992, LANCET, V339, P1330, DOI 10.1016/0140-6736(92)91967-D; FROEHLICH O, 1990, Journal of Agricultural and Food Chemistry, V38, P2057, DOI 10.1021/jf00101a012; GORDON WP, 1987, DRUG METAB DISPOS, V15, P589; GORDON WP, 1982, TOXICOL APPL PHARM, V65, P413, DOI 10.1016/0041-008X(82)90387-8; MCMANUS OB, 1993, BIOCHEMISTRY-US, V32, P6128, DOI 10.1021/bi00075a002; REYNOLDS T, 1991, J NATL CANCER I, V83, P594, DOI 10.1093/jnci/83.9.594; RIDDLE JM, 1992, AM SCI, V80, P226; SULLIVAN JB, 1979, JAMA-J AM MED ASSOC, V242, P2873; THOMASSEN D, 1991, DRUG METAB DISPOS, V19, P997; THOMASSEN D, 1990, J PHARMACOL EXP THER, V253, P567; VILLASENOR IM, 1993, CARCINOGENESIS, V14, P123, DOI 10.1093/carcin/14.1.123	14	46	48	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 30	1994	369	6483					702	702		10.1038/369702a0	http://dx.doi.org/10.1038/369702a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU581	8008059				2022-12-24	WOS:A1994NU58100027
J	COUPLAND, RM				COUPLAND, RM			EPIDEMIOLOGIC APPROACH TO SURGICAL-MANAGEMENT OF THE CASUALTIES OF WAR	BRITISH MEDICAL JOURNAL			English	Article							INTERNATIONAL-COMMITTEE; RED-CROSS; FALKLANDS WAR; EXPERIENCE; TRIAGE; INJURIES	The nature of modern conflicts precludes adequate medical care for most people wounded in wars. The traditional military approach of echeloned care for those wounded on the battlefield has limited relevance. I present an alternative, epidemiological approach whereby some affective care may reach many more. For a surgical facility to have a positive impact by using surgical and anaesthetic competence there must be access to the wounded; security for staff and patients; and a functioning hospital infrastructure. These all depend on respect for the first Geneva convention. Early hospital admission for urgent surgery is not so important if there is adequate first aid beforehand. The hospitals of the International Committee of the Red Cross have provided surgical care for thousands of wounded people by fulfilling these conditions. People wounded in modern conflicts would fare better if these priorities were recognised and less emphasis was placed on the more spectacular aspects of surgical care that benefit only a few.			COUPLAND, RM (corresponding author), RED CROSS,INT COMM,DIV MED,AVE PAIX,CH-1202 GENEVA,SWITZERLAND.							BELLAMY RF, 1992, WORLD J SURG, V16, P888, DOI 10.1007/BF02066987; BELLAMY RF, 1984, MIL MED, V149, P55; BOWEN TE, 1988, EMERGENCY WAR SURGER; CLYNE A J, 1955, J R Army Med Corps, V101, P33; COUPLAND RM, 1988, INJURY, V19, P259, DOI 10.1016/0020-1383(88)90041-1; COUPLAND RM, 1991, BMJ-BRIT MED J, V303, P1509, DOI 10.1136/bmj.303.6816.1509; COUPLAND RM, 1993, JAMA-J AM MED ASSOC, V270, P624, DOI 10.1001/jama.270.5.624; COUPLAND RM, 1992, INJURY, V23, P507, DOI 10.1016/0020-1383(92)90146-J; Coupland RM, 1993, WAR WOUNDS LIMBS SUR; CUTTING PA, 1992, INJURY, V23, P405, DOI 10.1016/0020-1383(92)90018-N; DANON YL, 1984, ISRAEL J MED SCI, V20, P300; DEWIND CM, 1987, ANN ROY COLL SURG, V69, P193; ESHAYACHAUVIN B, 1992, BRIT J ANAESTH, V68, P221, DOI 10.1093/bja/68.2.221; FRASER I, 1984, BRIT MED J, V289, P1723, DOI 10.1136/bmj.289.6460.1723; GERTSCH, 1987, BRIT J SURG, V74, P831; HARDAWAY RM, 1978, J TRAUMA, V18, P635, DOI 10.1097/00005373-197809000-00004; JACKSON DS, 1983, ANN ROY COLL SURG, V65, P281; LLEWELLYN CH, 1992, WORLD J SURG, V16, P904, DOI 10.1007/BF02066990; MALPASS CP, 1976, BRIT J SURG, V63, P482, DOI 10.1002/bjs.1800630621; MELLOR SG, 1989, BRIT J SURG, V76, P1006, DOI 10.1002/bjs.1800761006; MELSOM MA, 1975, ANN R COLL SURG ENGL, V56, P287; MUCKART DJJ, 1990, BRIT J SURG, V77, P652, DOI 10.1002/bjs.1800770620; Perrin P, 1991, INT REV RED CROSS, V284, P494; RAUTIO J, 1988, J TRAUMA, V28, P523, DOI 10.1097/00005373-198804000-00019; Rogov M, 1982, ISRAEL J MED SCI, V20, P369; ROZIN R, 1988, INJURY, V19, P193, DOI 10.1016/0020-1383(88)90014-9; ROZIN RR, 1987, J TRAUMA, V27, P656; Ryan J M, 1990, J R Army Med Corps, V136, P27; RYAN JM, 1984, ANN ROY COLL SURG, V66, P195; SMITH AM, 1989, FEB US NAV I P, P40; SMITH MSO, 1981, J R ARMY MED CORPS, V127, P31; TROUWBORST A, 1987, INJURY, V18, P96, DOI 10.1016/0020-1383(87)90181-1; 1986, 1949 GEN CONV AUG 12	33	49	50	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 25	1994	308	6945					1693	1697		10.1136/bmj.308.6945.1693	http://dx.doi.org/10.1136/bmj.308.6945.1693			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU483	8025468	Green Published			2022-12-24	WOS:A1994NU48300033
J	RANIERI, E; LEWIS, BD; GERACE, RL; RYALL, RG; MORRIS, CP; NELSON, PV; CAREY, WF; ROBERTSON, EF				RANIERI, E; LEWIS, BD; GERACE, RL; RYALL, RG; MORRIS, CP; NELSON, PV; CAREY, WF; ROBERTSON, EF			NEONATAL SCREENING FOR CYSTIC-FIBROSIS USING IMMUNOREACTIVE TRYPSINOGEN AND DIRECT GENE ANALYSIS - 4 YEARS EXPERIENCE	BRITISH MEDICAL JOURNAL			English	Article							MUTATION; DELTA-F508; POPULATION; GENOTYPE	Objective-To assess the performance and impact of a two tier neonatal screening programme for cystic fibrosis based on an initial estimation of immunoreactive trypsinogen followed by direct gene analysis. Design-Four year prospective study of two tier screening strategy. First tier: immunoreactive trypsinogen measured in dried blood spot samples from neonates aged 3-5 days. Second tier: direct gene analysis of cystic fibrosis mutations (Delta F-508, Delta I-506, G(551)D, G(542)X, and R(553)X) in samples with immunoreactive trypsinogen concentrations in highest 1% and in all neonates with meconium ileus or family history of cystic fibrosis. Setting-South Australian Neonatal Screening Programme, Adelaide. Subjects-All 88752 neonates born in South Australia between December 1989 and December 1993. Interventions-Neonates with two identifiable mutations were referred directly for clinical assessment and confirmatory sweat test; infants with only one identifiable mutation were recalled for sweat test at age 3-4 weeks. Parents of neonates identified as carriers of cystic fibrosis mutation were counselled and offered genetic testing. Main outcome measures-Identification of all children with cystic fibrosis in the screened population. Results-Of 1004 (1.13%) neonates with immunoreactive trypsinogen greater than or equal to 99th centile, 912 (90.8%) had no identifiable mutation. 23 neonates were homozygotes or compound heterozygotes; 69 carried one identifiable mutation, of whom six had positive sweat tests. Median age at clinical assessment for the 29 neonates with cystic fibrosis was 3 weeks; six had meconium ileus and two had affected siblings. 63 neonates were identified as carriers of a cystic fibrosis mutation. Extra laboratory costs for measuring immunoreactive trypsinogen and direct gene analysis were $A1.50 per neonate screened. Conclusion-This strategy results in early and accurate diagnosis of cystic fibrosis and performs better than screening strategies based on immunoreactive trypsinogen measurement alone.	WOMENS & CHILDRENS HOSP,DEPT CHEM PATHOL,STATE NEONATAL SCREENING SERV,ADELAIDE,SA 5006,AUSTRALIA; WOMENS & CHILDRENS HOSP,DEPT CHEM PATHOL,SPECIAL DIAGNOST LAB,ADELAIDE,SA 5006,AUSTRALIA	Womens & Childrens Hospital Australia; Womens & Childrens Hospital Australia	RANIERI, E (corresponding author), WOMENS & CHILDRENS HOSP,DEPT CHEM PATHOL,STATE SCREENING LAB,ADELAIDE,SA 5006,AUSTRALIA.			Morris, Phillip/0000-0001-8976-619X				[Anonymous], 1983, PEDIATRICS; BOLAND C, 1990, ARCH DIS CHILD, V65, P1240, DOI 10.1136/adc.65.11.1240; CHATFIELD S, 1991, ARCH DIS CHILD-FETAL, V66, P29, DOI 10.1136/adc.66.1_Spec_No.29; CULARD JF, 1994, HUM GENET, V93, P167; Dankert-Roelse J E, 1990, Acta Univ Carol Med (Praha), V36, P99; DANKERTROELSE JE, 1989, J PEDIATR-US, V114, P362, DOI 10.1016/S0022-3476(89)80552-9; Farrell P M, 1992, Adv Pediatr, V39, P35; GIBSON LE, 1959, PEDIATRICS, V23, P545; GREEN MR, 1993, ARCH DIS CHILD, V68, P464, DOI 10.1136/adc.68.4.464; GREGG RG, 1993, AM J HUM GENET, V52, P616; HAMMOND K, 1987, ADV NEONATAL SCREENI, P337; HAMMOND KB, 1991, NEW ENGL J MED, V325, P769, DOI 10.1056/NEJM199109123251104; HEELEY AF, 1992, ANN CLIN BIOCHEM, V29, P361, DOI 10.1177/000456329202900401; HENRY RL, 1990, J PAEDIATR CHILD H, V26, P150, DOI 10.1111/j.1440-1754.1990.tb02413.x; KEREM B, 1989, SCIENCE, V284, P1073; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; KIESEWETTER S, 1993, NAT GENET, V5, P274, DOI 10.1038/ng1193-274; KRAMER R, 1977, HELV PAEDIATR ACTA, V32, P107; LAROUCHE D, 1991, LANCET, V339, P55; Mischler E, 1989, Wis Med J, V88, P14; NELSON PV, 1990, MED J AUSTRALIA, V152, P328, DOI 10.5694/j.1326-5377.1990.tb120962.x; RANIERI E, 1991, BRIT MED J, V302, P1237, DOI 10.1136/bmj.302.6787.1237; ROCK MJ, 1990, PEDIATRICS, V85, P1001; ROCK MJ, 1989, PEDIATR PULM, V6, P42, DOI 10.1002/ppul.1950060111; ROSENSTEIN BJ, 1982, JOHNS HOPKINS MED J, V150, P113; RYALL RG, 1993, CLIN CHEM, V39, P224; RYLEY HC, 1992, BRIT MED BULL, V48, P805, DOI 10.1093/oxfordjournals.bmb.a072579; SPENCE WC, 1993, BIOCHEM MED METAB B, V49, P200, DOI 10.1006/bmmb.1993.1022; TLUCZEK A, 1992, J DEV BEHAV PEDIATR, V13, P181; WESLEY AW, 1989, AUST PAEDIATR J, V25, P151; WILCKEN B, 1993, SCREENING, V2, P43	32	52	53	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 4	1994	308	6942					1469	1472		10.1136/bmj.308.6942.1469	http://dx.doi.org/10.1136/bmj.308.6942.1469			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ229	8019280	Green Published			2022-12-24	WOS:A1994NQ22900016
J	SUPER, M; SCHWARZ, MJ; MALONE, G; ROBERTS, T; HAWORTH, A; DERMODY, G				SUPER, M; SCHWARZ, MJ; MALONE, G; ROBERTS, T; HAWORTH, A; DERMODY, G			ACTIVE CASCADE TESTING FOR CARRIERS OF CYSTIC-FIBROSIS GENE	BRITISH MEDICAL JOURNAL			English	Article							PRIMARY-CARE; CFTR GENE; DNA; PRACTITIONERS; MUTATIONS	Objective-To examine the acceptability, practicability, efficiency, and application of active screening for carriers of the cystic fibrosis gene in the extended families of those in whom the disease is present (cascade screening). Design-Paediatricians and physicians provide details of their affected patients, pedigrees are drawn up, and relatives offered tests after initial contact by the affected nuclear families. Affected patients are genotyped in a laboratory with a special interest in the genetics of cystic fibrosis. Setting-North Western health region. Subjects-Relatives and partners of 607 people with cystic fibrosis.	UNIV MANCHESTER,MANCHESTER M27 1HA,LANCS,ENGLAND	University of Manchester	SUPER, M (corresponding author), ROYAL MANCHESTER CHILDRENS HOSP,REG GENET SERV,MANCHESTER M27 1HA,ENGLAND.							BEKKER H, 1993, BRIT MED J, V306, P1584, DOI 10.1136/bmj.306.6892.1584; BURN J, 1993, BRIT MED J, V306, P1558, DOI 10.1136/bmj.306.6892.1558; CASKEY CT, 1990, AM J HUM GENET, V46, P393; DANKS DM, 1965, ANN HUM GENET, V28, P323, DOI 10.1111/j.1469-1809.1965.tb00489.x; FERRIE RM, 1992, AM J HUM GENET, V51, P251; HANDYSIDE AH, NEW ENGL J MED, V905, P92; HARRIS H, 1993, BRIT MED J, V306, P1580, DOI 10.1136/bmj.306.6892.1580; HUBBARD RC, 1992, NEW ENGL J MED, V326, P812, DOI 10.1056/NEJM199203193261207; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; LENCH N, 1988, LANCET, V1, P1356; MENNIE ME, 1992, LANCET, V340, P214, DOI 10.1016/0140-6736(92)90476-J; MODELL M, 1993, BRIT MED J, V307, P849, DOI 10.1136/bmj.307.6908.849; MORRAL N, 1992, HUM GENET, V88, P356; SCHWARZ MJ, 1990, HUM GENET, V85, P428, DOI 10.1007/BF02428298; SHOSHANI T, 1992, AM J HUM GENET, V50, P222; SUPER M, 1987, LANCET, V2, P782; SUPER M, 1992, EUR J PEDIATR, V151, P108, DOI 10.1007/BF01958953; SUPER M, 1992, LANCET, V340, P490, DOI 10.1016/0140-6736(92)91816-Q; SUPER M, 1992, J ROY SOC MED, V85, P6; WALD NJ, 1993, LANCET, V342, P1307, DOI 10.1016/0140-6736(93)92403-G; WATSON EK, 1991, BRIT MED J, V303, P504, DOI 10.1136/bmj.303.6801.504; WILFOND BS, 1990, JAMA-J AM MED ASSOC, V263, P2777, DOI 10.1001/jama.263.20.2777; 1992, LANCET, V340, P209; 1992, CYSTIC FIBROSIS DNA; 1990, CYSTIC FIBROSIS ADUL	25	63	63	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 4	1994	308	6942					1462	1467		10.1136/bmj.308.6942.1462	http://dx.doi.org/10.1136/bmj.308.6942.1462			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ229	8019278	Green Published			2022-12-24	WOS:A1994NQ22900013
J	PEAR, SM; WILLIAMSON, TH; BETTIN, KM; GERDING, DN; GALGIANI, JN				PEAR, SM; WILLIAMSON, TH; BETTIN, KM; GERDING, DN; GALGIANI, JN			DECREASE IN NOSOCOMIAL CLOSTRIDIUM-DIFFICILE-ASSOCIATED DIARRHEA BY RESTRICTING CLINDAMYCIN USE	ANNALS OF INTERNAL MEDICINE			English	Article						CROSS INFECTION; CLINDAMYCIN; DIARRHEA; CLOSTRIDIUM-DIFFICILE; CLOSTRIDIUM INFECTIONS	TOXIN-ASSOCIATED DIARRHEA; RISK-FACTORS; CROSS-INFECTION; COLITIS; OUTBREAK; ACQUISITION; SUSCEPTIBILITY; TRANSMISSION; DISEASE	Objective: To report the investigation and effective control of a nosocomial epidemic of Clostridium difficile-associated diarrhea. Design: Concurrent surveillance for identification of new nosocomial cases, retrospective case-control analysis, and hospital formulary control of antibiotic use. Setting: University-affiliated Veterans Affairs Medical Center located in southwestern United States. Patients: Hospitalized patients who developed diarrhea submitted stool specimens for cytotoxin assay. Patients who were positive for cytotoxin were compared with control patients without infection. Measurements: Isolates of C. difficile were typed by restriction endonuclease analysis. Antimicrobial agent use from hospital pharmacy records and selected patient data from chart review were correlated with frequency of specific laboratory abnormalities. Results: For 13 months, the monthly incidence of C. difficile infection averaged more than five times that for the previous 21 months. Stool specimens from 34 patients (59%) contained a single strain (restriction enzyme analysis type J7). Clindamycin was statistically associated with the epidemic as shown by the following: clindamycin use at our center compared with national normal values, clindamycin use for years before compared with during the epidemic, monthly use of clindamycin compared with monthly frequency of infection, frequency of infection in patients receiving clindamycin compared with that in patients receiving other antimicrobial agents, and amount of clindamycin used by infected patients compared with that used by control patients. Restricting clindamycin use led to a prompt decrease in infection rate and the type J7 organisms. Conclusion: A nosocomial epidemic of C. difficile diarrhea was controlled by analysis of antibiotic use patterns and by subsequent restriction of clindamycin.	VET AFFAIRS MED CTR, MED SERV 111, 6TH & AJO, TUCSON, AZ 85723 USA; VET AFFAIRS MED CTR, MINNEAPOLIS, MN 55417 USA; VET AFFAIRS LAKESIDE MED CTR, CHICAGO, IL 60611 USA; UNIV ARIZONA, TUCSON, AZ 85721 USA; NORTHWESTERN UNIV, CHICAGO, IL 60611 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Southern Arizona Veterans Affairs Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Arizona; Northwestern University			Galgiani, John/GLT-7012-2022; williamson, tom/AAP-3801-2020	williamson, tom/0000-0002-1879-449X				BARTLETT J, 1988, CLOSTRIDIUM DIFFICIL; BARTLETT JG, 1990, REV INFECT DIS, V12, pS243, DOI 10.1093/clinids/12.Supplement_2.S243; BARTLETT JG, 1981, JOHNS HOPKINS MED J, V149, P6; BROWN E, 1990, INFECT CONT HOSP EP, V11, P283; CLABOTS CR, 1988, J INFECT DIS, V158, P731, DOI 10.1093/infdis/158.4.731; CLABOTS CR, 1993, J CLIN MICROBIOL, V31, P1870, DOI 10.1128/JCM.31.7.1870-1875.1993; CLABOTS CR, 1987, DIAGN MICR INFEC DIS, V6, P49, DOI 10.1016/0732-8893(87)90113-1; CLABOTS CR, 1992, J INFECT DIS, V166, P561, DOI 10.1093/infdis/166.3.561; COHEN LE, 1973, JAMA-J AM MED ASSOC, V223, P1379, DOI 10.1001/jama.223.12.1379; CUMMING AD, 1986, BRIT MED J, V292, P238, DOI 10.1136/bmj.292.6515.238; DELMEE M, 1986, J INFECTION, V13, P5, DOI 10.1016/S0163-4453(86)92095-5; GEORGE WL, 1979, J CLIN MICROBIOL, V9, P214; GEORGE WL, 1978, CURR MICROBIOL, V1, P55, DOI 10.1007/BF02601709; GERDING DN, 1989, ANN INTERN MED, V110, P255, DOI 10.7326/0003-4819-110-4-255; GERDING DN, 1986, ARCH INTERN MED, V146, P95, DOI 10.1001/archinte.146.1.95; HEARD SR, 1986, J INFECT DIS, V153, P159, DOI 10.1093/infdis/153.1.159; JOHNSON S, 1990, LANCET, V336, P97, DOI 10.1016/0140-6736(90)91605-A; KOFSKY P, 1991, DIS COLON RECTUM, V34, P244, DOI 10.1007/BF02090164; MCFARLAND LV, 1989, NEW ENGL J MED, V320, P204, DOI 10.1056/NEJM198901263200402; PETERSON LR, 1988, DIAGN MICR INFEC DIS, V10, P85, DOI 10.1016/0732-8893(88)90045-4; POXTON IR, 1984, J MED MICROBIOL, V17, P317, DOI 10.1099/00222615-17-3-317; SCHIFMAN RB, 1991, PROBES ANTIMICROBIAL, pA90; STRUELENS MJ, 1991, AM J MED, V91, pS138, DOI 10.1016/0002-9343(91)90359-6; TEDESCO FJ, 1974, ANN INTERN MED, V81, P429, DOI 10.7326/0003-4819-81-4-429; THIBAULT A, 1991, INFECT CONT HOSP EP, V12, P345, DOI 10.2307/30145209; ZIMMERMAN RK, 1991, INFECT CONT HOSP EP, V12, P96; 1990, SAS STAT USERS GUIDE, V2, P495	27	176	178	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1994	120	4					272	277		10.7326/0003-4819-120-4-199402150-00003	http://dx.doi.org/10.7326/0003-4819-120-4-199402150-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW103	8080497				2022-12-24	WOS:A1994MW10300003
J	IRIE, K; GOTOH, Y; YASHAR, BM; ERREDE, B; NISHIDA, E; MATSUMOTO, K				IRIE, K; GOTOH, Y; YASHAR, BM; ERREDE, B; NISHIDA, E; MATSUMOTO, K			STIMULATORY EFFECTS OF YEAST AND MAMMALIAN 14-3-3-PROTEINS ON THE RAF PROTEIN-KINASE	SCIENCE			English	Article							ACTIVATION; IDENTIFICATION; INHIBITORS; DEFINITION; SEQUENCE; PATHWAY; C-RAF-1; CLONING; REGION; CELLS	Intracellular signaling from receptor tyrosine kinases in mammalian cells results in activation of a signal cascade that includes the guanine nucleotide-binding protein Ras and the protein kinases Raf, MEK [mitogen-activated protein kinase (MAPK) or extracellular signal-regulated kinase (ERK) kinase], and MAPK. MAPK activation that is dependent on the coupling of Ras and Raf was reconstituted in yeast. Yeast genes were isolated that, when overexpressed, enhanced the function of Raf. One of them is identical to BMH1, which encodes a protein similar to members of the mammalian 14-3-3 family. Bacterially synthesized mammalian 14-3-3 protein stimulated the activity of Raf prepared from yeast cells expressing c-Raf-1. Thus, the 14-3-3 protein may participate in or be required for activation of Raf.	NAGOYA UNIV,FAC SCI,DEPT MOLEC BIOL,CHIKUSA KU,NAGOYA 46401,JAPAN; KYOTO UNIV,INST VIRUS RES,DEPT MOLEC BIOL & GENET,SAKYO KU,KYOTO 60601,JAPAN; UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	Nagoya University; Kyoto University; University of North Carolina; University of North Carolina Chapel Hill				Yashar, Beverly M./0000-0003-0807-3258				AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; GOTOH Y, 1994, ONCOGENE, V9, P1891; GUAN C, 1987, GENE, V67, P21; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; KISHORE GM, 1988, ANNU REV BIOCHEM, V57, P627, DOI 10.1146/annurev.bi.57.070188.003211; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TOKER A, 1992, EUR J BIOCHEM, V206, P453, DOI 10.1111/j.1432-1033.1992.tb16946.x; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VANHEUSDEN GPH, 1992, FEBS LETT, V302, P145, DOI 10.1016/0014-5793(92)80426-H; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; YASHAR B, UNPUB; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	30	288	294	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 16	1994	265	5179					1716	1719		10.1126/science.8085159	http://dx.doi.org/10.1126/science.8085159			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG284	8085159				2022-12-24	WOS:A1994PG28400033
J	SMOTHERS, JF; VONDOHLEN, CD; SMITH, LH; SPALL, RD				SMOTHERS, JF; VONDOHLEN, CD; SMITH, LH; SPALL, RD			MOLECULAR EVIDENCE THAT THE MYXOZOAN PROTISTS ARE METAZOANS	SCIENCE			English	Article							EARLY EVOLUTION; RNA; SEQUENCES; MYXOSPOREA; EUKARYOTES; ORIGIN; PHYLA; TREES	The evolutionary origins of the protistan phylum, Myxozoa, have long been questioned. Although these obligate parasites are like protozoans in many features, several aspects of their ontogeny and morphology have implied a closer relationship to metazoan lineages. Phylogenetic analyses of 18S ribosomal RNA sequences from myxozoans and other eukaryotes, with the use of parsimony, distance, and maximum-likelihood methods, support the hypothesis that myxozoans are closely related to the bilateral animals. These results suggest that the Myxozoa, long considered an assemblage of protozoans, should be considered a metazoan phylum.	IDAHO STATE UNIV,DEPT BIOL SCI,POCATELLO,ID 83209; UNIV ARIZONA,DEPT ECOL & EVOLUTIONARY BIOL,TUCSON,AZ 85721	Idaho; Idaho State University; University of Arizona				von Dohlen, Carol/0000-0002-3961-251X				BACKELJAU T, 1993, CLADISTICS, V9, P167, DOI 10.1111/j.1096-0031.1993.tb00216.x; Butschli O, 1881, ZOOL JB F, V1, P162; CAVALIERSMITH T, 1993, MICROBIOL REV, V57, P953, DOI 10.1128/MMBR.57.4.953-994.1993; CHRISTEN R, 1991, EMBO J, V10, P499, DOI 10.1002/j.1460-2075.1991.tb07975.x; CORLISS JO, 1987, INT REV CYTOL, V100, P319; CORLISS JO, 1984, BIOSYSTEMS, V17, P87, DOI 10.1016/0303-2647(84)90003-0; CORLISS JO, 1994, ACTA PROTOZOOL, V34, P1; DONOGHUE MJ, 1992, ANN MO BOT GARD, V79, P333, DOI 10.2307/2399772; ERNISS DJ, 1992, SYST BIOL, V41, P305; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; GAJADHAR AA, 1991, MOL BIOCHEM PARASIT, V45, P147, DOI 10.1016/0166-6851(91)90036-6; Ghiselin M.T., 1988, Oxford Surveys in Evolutionary Biology, V5, P66; GRASSE P-P, 1978, Annales des Sciences Naturelles Zoologie et Biologie Animale, V20, P193; HILLIS DM, 1991, Q REV BIOL, V66, P411, DOI 10.1086/417338; JOHNSON AM, 1989, PARASITOL TODAY, V5, P102, DOI 10.1016/0169-4758(89)90046-X; KENT ML, IN PRESS CAN J ZOOL; KISHINO H, 1989, J MOL EVOL, V29, P170, DOI 10.1007/BF02100115; KNOLL AH, 1992, SCIENCE, V256, P622, DOI 10.1126/science.1585174; KRISTENSEN RM, 1983, Z ZOOL SYST EVOL, V21, P163; LAKE JA, 1990, P NATL ACAD SCI USA, V87, P763, DOI 10.1073/pnas.87.2.763; Lee J. J., 1985, ILLUSTRATED GUIDE PR; Lom J., 1990, P36; LOM J, 1989, J FISH DIS, V12, P151, DOI 10.1111/j.1365-2761.1989.tb00287.x; Lom J., 1965, Protistologica, V1, P53; LOM J, 1984, FOLIA PARASIT, V31, P193; LOM J, 1964, 3 P EUR REG C EL MIC, P191; Margulis L., 1982, 5 KINGDOMS ILLUSTRAT; Margulis L, 1990, HDB PROTOCTISTA; Meglitsch P.A., 1991, INVERTEBRATE ZOOLOGY; Mitchell L.G., 1977, PARASITIC PROTOZOA, VIV, P115; MITCHELL LG, 1989, CAN J ZOOL, V67, P1915, DOI 10.1139/z89-274; MORRIS SC, 1993, NATURE, V361, P219, DOI 10.1038/361219a0; OLSEN GJ, 1987, COLD SPRING HARB SYM, V52, P825, DOI 10.1101/SQB.1987.052.01.090; Perkins F.O., 1991, P261; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SPALL RD, 1973, THESIS OKLAHOMA STAT; Stolc A, 1899, B INT ACAD SCI BOHEM, V22, P1; SWOFFORD DL, PAUP PHYLOGENETIC AN; SWOFFORD DL, 1990, MOL SYSTEMATICS, pCH11; VOSSBRINCK CR, 1987, NATURE, V326, P411, DOI 10.1038/326411a0; WAINRIGHT PO, 1993, SCIENCE, V260, P340, DOI 10.1126/science.8469985; Weill R, 1938, TRAVAUX STATION ZOOL, V13, P727; Willmer P, 1990, INVERTEBRATE RELATIO; WOLF K, 1984, SCIENCE, V225, P1449, DOI 10.1126/science.225.4669.1449	44	194	215	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 16	1994	265	5179					1719	1721		10.1126/science.8085160	http://dx.doi.org/10.1126/science.8085160			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG284	8085160				2022-12-24	WOS:A1994PG28400034
J	NELSON, CA; PETZOLD, SJ; UNANUE, ER				NELSON, CA; PETZOLD, SJ; UNANUE, ER			PEPTIDES DETERMINE THE LIFE-SPAN OF MHC CLASS-II MOLECULES IN THE ANTIGEN-PRESENTING CELL	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; T-CELL; IMMUNOGENIC PEPTIDES; SURFACE EXPRESSION; LIVING CELLS; B-CELLS; IA; IDENTIFICATION; BINDING; PROTEIN	ALTHOUGH many peptides are generated during the intracellular processing of protein antigens, only a few are selected for recognition by the immune system(1-5). The immunodominant epitope of hen egg white lysozyme (HEL) for H-2(k) mice is contained in a tryptic fragment of amino-acid residues 46-61 (refs 6, 7). The core of this T-cell epitope, from amino acids 52 to 61 (DYGILQINSR), contains those residues required for binding to the class II molecule I-A(k) (ref. 7). Most of the naturally processed fragments recovered from I-A(k)-bearing antigen-presenting cells (APCs) cultured with HEL contained this 52-61 core sequence, presented as a nested set of peptides with extensions at both the amino and carboxyl termini(8). We now compare the handling by APCs of peptides containing HEL 52-61 to establish whether there is an advantage for the APC in selecting extended peptides: different complexes between peptides and major histocompatibility complex (MHC) molecules varied greatly in the amount of time associated with the APC, and in their immunogenic strength. This difference in persistence is one of the factors contributing to the selection and immune recognition of peptide-MHC complexes by T cells.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL)	NELSON, CA (corresponding author), WASHINGTON UNIV,SCH MED,CTR IMMUNOL,ST LOUIS,MO 63110, USA.							ADORINI L, 1988, J EXP MED, V168, P2091, DOI 10.1084/jem.168.6.2091; ADORINI L, 1989, NATURE, V342, P800, DOI 10.1038/342800a0; ALLEN PM, 1984, P NATL ACAD SCI-BIOL, V81, P2489, DOI 10.1073/pnas.81.8.2489; ALLEN PM, 1987, NATURE, V327, P713, DOI 10.1038/327713a0; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; BUUS S, 1987, SCIENCE, V235, P1353, DOI 10.1126/science.2435001; DOMMAIR K, 1989, COLD SPRING HARB SYM, V54, P409; GERMAIN RN, 1993, NATURE, V363, P725, DOI 10.1038/363725a0; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GLIMCHER LH, 1983, J IMMUNOL, V130, P2287; HARDING CV, 1989, P NATL ACAD SCI USA, V86, P4230, DOI 10.1073/pnas.86.11.4230; HAUGHTON G, 1986, IMMUNOL REV, V93, P35, DOI 10.1111/j.1600-065X.1986.tb01501.x; KATZ ME, 1982, EUR J IMMUNOL, V12, P535, DOI 10.1002/eji.1830120702; LANZAVECCHIA A, 1992, NATURE, V357, P249, DOI 10.1038/357249a0; NELSON CA, 1993, P NATL ACAD SCI USA, V90, P1227, DOI 10.1073/pnas.90.4.1227; NELSON CA, 1992, P NATL ACAD SCI USA, V89, P7380, DOI 10.1073/pnas.89.16.7380; Oi V T, 1978, Curr Top Microbiol Immunol, V81, P115; PEDRAZZINI T, 1991, J IMMUNOL, V146, P3496; PIERRES M, 1981, IMMUNOGENETICS, V14, P481, DOI 10.1007/BF00350120; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; ROSENTHAL AS, 1977, NATURE, V267, P156, DOI 10.1038/267156a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; WADE WF, 1989, P NATL ACAD SCI USA, V86, P6297, DOI 10.1073/pnas.86.16.6297	24	170	173	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 15	1994	371	6494					250	252		10.1038/371250a0	http://dx.doi.org/10.1038/371250a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG290	8078585				2022-12-24	WOS:A1994PG29000053
J	ECONOMOU, A; WICKNER, W				ECONOMOU, A; WICKNER, W			SECA PROMOTES PREPROTEIN TRANSLOCATION BY UNDERGOING ATP-DRIVEN CYCLES OF MEMBRANE INSERTION AND DEINSERTION	CELL			English	Article							COLI PLASMA-MEMBRANE; PRECURSOR PROTEIN TRANSLOCATION; PROTON MOTIVE FORCE; ESCHERICHIA-COLI; COAT PROTEIN; CYTOPLASMIC MEMBRANE; ESSENTIAL COMPONENT; SECRETORY PROTEIN; INNER MEMBRANE; TRIGGER FACTOR	SecA, the peripheral subunit of E. coli preprotein translocase, alternates between a membrane inserted and a deinserted state as part of the catalytic cycle of preprotein translocation. When SecA is complexed with SecY/E and preprotein, ATP drives a profound conformational change, leading to membrane insertion of a 30 kDa domain of SecA. The inserted domain is protease-inaccessible from the cytosolic side of the membrane, but becomes accessible upon membrane disruption. Concomitant with 30 kDa domain insertion, similar to 20 aminoacyl residues of the preprotein are translocated. Additional ATP, which may be hydrolyzed at the second ATP site of SecA, releases the translocated preprotein and allows the 30 kDa domain to deinsert, whence it can exchange with cytosolic SecA. Thus, SecA is the mobile subunit of an integral membrane transporter, consuming ATP during both the insertion and deinsertion phases of its catalytic cycle while guiding preprotein segments across the membrane.			ECONOMOU, A (corresponding author), DARTMOUTH COLL SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA.		Economou, Anastassios/P-8292-2017	Economou, Anastassios/0000-0002-1770-507X				AKITA M, 1991, BIOCHEM BIOPH RES CO, V174, P211, DOI 10.1016/0006-291X(91)90507-4; ARKOWITZ RA, 1993, EMBO J, V12, P243, DOI 10.1002/j.1460-2075.1993.tb05650.x; BAICHWAL V, 1993, P NATL ACAD SCI USA, V90, P620, DOI 10.1073/pnas.90.2.620; BASSILANA M, 1993, BIOCHEMISTRY-US, V32, P2626, DOI 10.1021/bi00061a021; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CHANG CN, 1978, P NATL ACAD SCI USA, V75, P361, DOI 10.1073/pnas.75.1.361; CHEN L, 1986, J BACTERIOL, V167, P389, DOI 10.1128/jb.167.1.389-392.1986; CROOKE E, 1988, EMBO J, V7, P1831, DOI 10.1002/j.1460-2075.1988.tb03015.x; CUNNINGHAM K, 1989, EMBO J, V8, P955, DOI 10.1002/j.1460-2075.1989.tb03457.x; DANIELS CJ, 1981, P NATL ACAD SCI-BIOL, V78, P5396, DOI 10.1073/pnas.78.9.5396; DATE T, 1980, P NATL ACAD SCI-BIOL, V77, P827, DOI 10.1073/pnas.77.2.827; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; DOLAN KM, 1991, J BIOL CHEM, V266, P23329; DOUVILLE K, 1994, J BIOL CHEM, V269, P18705; DRIESSEN AJM, 1993, BIOCHEMISTRY-US, V32, P13190, DOI 10.1021/bi00211a030; ENEQUIST HG, 1981, EUR J BIOCHEM, V116, P227, DOI 10.1111/j.1432-1033.1981.tb05323.x; FANDL JP, 1988, P NATL ACAD SCI USA, V85, P8953, DOI 10.1073/pnas.85.23.8953; FIKES JD, 1989, J BACTERIOL, V171, P402, DOI 10.1128/jb.171.1.402-409.1989; GARDEL C, 1987, J BACTERIOL, V169, P1286, DOI 10.1128/jb.169.3.1286-1290.1987; GELLER BL, 1986, P NATL ACAD SCI USA, V83, P4219, DOI 10.1073/pnas.83.12.4219; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; HENDRICK JP, 1991, J BIOL CHEM, V266, P24596; ITO K, 1980, J BIOL CHEM, V255, P2123; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; KAWASAKI S, 1993, J BIOL CHEM, V268, P8193; KERPPOLA RE, 1991, J BIOL CHEM, V266, P9857; KIM YJ, 1994, CELL, V78, P845; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KUMAMOTO CA, 1989, P NATL ACAD SCI USA, V86, P5320, DOI 10.1073/pnas.86.14.5320; LECKER S, 1989, EMBO J, V8, P2703, DOI 10.1002/j.1460-2075.1989.tb08411.x; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MARKWELL MAK, 1978, BIOCHEMISTRY-US, V17, P4807, DOI 10.1021/bi00615a031; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; OLIVER DB, 1993, MOL MICROBIOL, V7, P159, DOI 10.1111/j.1365-2958.1993.tb01107.x; OLIVER DB, 1990, J BIOENERG BIOMEMBR, V22, P311, DOI 10.1007/BF00763170; ROLLO EE, 1988, J BACTERIOL, V170, P3281, DOI 10.1128/jb.170.7.3281-3282.1988; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHIEBEL E, 1992, J BIOL CHEM, V267, P7505; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHMIDT MG, 1988, J BACTERIOL, V170, P3404, DOI 10.1128/jb.170.8.3404-3414.1988; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; SHIOZUKA K, 1990, J BIOL CHEM, V265, P18843; TANI K, 1989, J BIOL CHEM, V264, P18582; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; WEAVER AJ, 1992, J STRUCT BIOL, V109, P87, DOI 10.1016/1047-8477(92)90040-H; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WOLFE PB, 1983, METHOD ENZYMOL, V97, P40; YAMADA H, 1989, J BIOL CHEM, V264, P18577	54	487	494	1	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 9	1994	78	5					835	843		10.1016/S0092-8674(94)90582-7	http://dx.doi.org/10.1016/S0092-8674(94)90582-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PG296	8087850				2022-12-24	WOS:A1994PG29600012
J	VONGERSDORFF, H; MATTHEWS, G				VONGERSDORFF, H; MATTHEWS, G			INHIBITION OF ENDOCYTOSIS BY ELEVATED INTERNAL CALCIUM IN A SYNAPTIC TERMINAL	NATURE			English	Article							FROG NEUROMUSCULAR-JUNCTION; VESICLE FUSION; TRANSMITTER RELEASE; CHROMAFFIN CELLS; EXOCYTOSIS; SECRETION; MEMBRANE; ENDINGS; NEURONS; RETINA	DURING synaptic transmission in the nervous system, synaptic vesicles fuse with the plasma membrane of presynaptic terminals, releasing neurotransmitter by exocytosis(1,2). The vesicle membrane is then retrieved by endocytosis and recycled into new transmitter-containing vesicles. Exocytosis in synaptic terminals is calcium-dependent(7-9), and we now report that endocytosis also is regulated by the intracellular calcium concentration ([Ca2+](i)). Capacitance measurements(10,11) in synaptic terminals of retinal bipolar neurons revealed that endocytosis was strongly inhibited by elevated [Ca2+](i) in the range achieved by Ca2+-current activation. The rate of membrane retrieval was steeply dependent on [Ca2+](i), with a Hill coefficient of 4 and half-inhibition at similar to 500 nM. At [Ca2+](i) greater than or equal to 900 nM, endocytosis was entirely absent. The action of internal calcium on endocytosis represents a novel negative-feedback mechanism controlling the rate of membrane recovery in synaptic terminals after neurotransmitter secretion. As membrane retrieval is the first step in vesicle recycling, this mechanism may contribute to activity-dependent synaptic depression.			VONGERSDORFF, H (corresponding author), SUNY STONY BROOK, DEPT NEUROBIOL & BEHAV, STONY BROOK, NY 11794 USA.							AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CECCARELLI B, 1980, J CELL BIOL, V87, P297, DOI 10.1083/jcb.87.1.297; CHOW RH, 1992, NATURE, V356, P60, DOI 10.1038/356060a0; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HEIDELBERGER R, 1992, J PHYSIOL-LONDON, V447, P235, DOI 10.1113/jphysiol.1992.sp019000; HEUSER JE, 1981, J CELL BIOL, V88, P564, DOI 10.1083/jcb.88.3.564; HURLBUT WP, 1994, J MEMBRANE BIOL, V138, P91, DOI 10.1007/BF00211072; KATZ B, 1965, PROC R SOC SER B-BIO, V161, P496, DOI 10.1098/rspb.1965.0017; LINDAU M, 1988, PFLUG ARCH EUR J PHY, V411, P137, DOI 10.1007/BF00582306; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MATTEOLI M, 1992, J CELL BIOL, V117, P849, DOI 10.1083/jcb.117.4.849; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; MILLER TM, 1984, J CELL BIOL, V98, P685, DOI 10.1083/jcb.98.2.685; MULKEY RM, 1991, NATURE, V350, P153, DOI 10.1038/350153a0; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; NORDMANN JJ, 1992, NEUROSCIENCE, V49, P201, DOI 10.1016/0306-4522(92)90088-J; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; PYSH JJ, 1974, J CELL BIOL, V60, P365, DOI 10.1083/jcb.60.2.365; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; ROSENBOOM H, 1994, P NATL ACAD SCI USA, V91, P5267, DOI 10.1073/pnas.91.12.5267; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; SCHAEFFER SF, 1978, J CELL BIOL, V79, P802, DOI 10.1083/jcb.79.3.802; SHARMA RK, 1988, MOL ASPECTS CELLULAR, V5, P265; SUZUKI S, 1990, VISUAL NEUROSCI, V5, P223, DOI 10.1017/S0952523800000298; THOMAS P, 1994, J CELL BIOL, V124, P667, DOI 10.1083/jcb.124.5.667; THOMAS P, 1990, NEURON, V5, P723, DOI 10.1016/0896-6273(90)90226-6; TORRITARELLI F, 1985, J CELL BIOL, V101, P1386, DOI 10.1083/jcb.101.4.1386; VONGERSDORFF H, 1994, NATURE, V367, P735, DOI 10.1038/367735a0	31	226	229	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 25	1994	370	6491					652	655		10.1038/370652a0	http://dx.doi.org/10.1038/370652a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD310	8065451				2022-12-24	WOS:A1994PD31000051
J	JITSUKAWA, M; DJERASSI, C				JITSUKAWA, M; DJERASSI, C			BIRTH-CONTROL IN JAPAN - REALITIES AND PROGNOSIS	SCIENCE			English	Editorial Material							MIFEPRISTONE RU-486		STANFORD UNIV,ASIA PACIFIC RES CTR,DEPT CHEM,STANFORD,CA 94305	Stanford University	JITSUKAWA, M (corresponding author), STANFORD UNIV,ASIA PACIFIC RES CTR,DEPT ANTHROPOL,STANFORD,CA 94305, USA.							BUMILLER E, 1990, WASHINGTON POST 1025, pD6; BUMILLER E, 1990, WASHINGTON POST 1025, pD1; Coleman Samuel, 1983, FAMILY PLANNING JAPA; DJERASSI C, 1990, SCIENCE, V248, P1061, DOI 10.1126/science.2343313; DJERASSI C, 1987, TECHNOL SOC, V9, P157, DOI 10.1016/0160-791X(87)90021-2; DJERASSI C, 1991, SCI PUBLIC AFF LONDO, V6, P5; DJERASSI C, 1993, PILL PYGMY CHIMPS DE, pCH9; GLASIER A, 1992, NEW ENGL J MED, V327, P1041, DOI 10.1056/NEJM199210083271501; HENSHAW SK, 1990, FAM PLANN PERSPECT, V22, P76, DOI 10.2307/2135512; IKEGAMI C, 1991, HUM SEX, V5, P28; JANSSON Y, 1991, HUM SEX TOKYO, V2, P10; Kobayashi T, 1989, Int J Fertil, V34 Suppl, P14; KOBAYASHI T, 1992, MED FAIRU, V7, P2; Kuwabara Y, 1989, Int J Fertil, V34 Suppl, P18; MATSUMOTO S, 1991, MED FAIRU, V6, P2; MATSUMOTO S, 1988, CURR THER RES, V44, P115; MINAGUCHI H, 1993, NIHON ISHIKAI ZASSHI, V110, P1273; MUNAKATA T, 1992, EIZU TO SEKKUSU REPO; MURAMATSU M, 1974, ABORTION RES INT EXP, P133; PEYRON R, 1993, NEW ENGL J MED, V328, P1509, DOI 10.1056/NEJM199305273282101; POTTS M, 1977, ABORTION, P136; Satoh K, 1989, Int J Fertil, V34 Suppl, P8; SWAHN ML, 1990, HUM REPROD, V5, P402, DOI 10.1093/oxfordjournals.humrep.a137111; THOMSEN RJ, 1982, ATLAS INTRAUTERINE C, P108; UNO S, 1992, WOMENS MESSAGES JAPA, V9, P26; Weisman Steven R, 1992, N Y Times Web, pA3; YOSHITAKE T, CITED INDIRECTLY; 1987, PIRU WATASHITACHI WA; 1988, POPUL REP SER A, V7, P20; QUIET LOVE RELATIONS; 1992, KIROKU NIPPON NO JIN; 1983, KANASHIMI SABAKEMASU, P266; VITAL STATISTICS EUG; 1992, MED FAIRU, V7, P13; 1987, WKLY EPIDEMIOL REC, V62, P244	35	16	16	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 19	1994	265	5175					1048	1051		10.1126/science.8066442	http://dx.doi.org/10.1126/science.8066442			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC539	8066442				2022-12-24	WOS:A1994PC53900021
J	DALY, DA				DALY, DA			SPEECH CLUTTERING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											DALY, DA (corresponding author), UNIV MICHIGAN,ANN ARBOR,MI 48109, USA.							DALY D, 1988, FREEDOM FLUENCY; Daly D. A., 1993, STUTTERING RELATED D; DALY DA, 1986, ATYPICAL STUTTERER P; DALY DA, 1992, CLUTTERING CLIN PERS; Weiss D., 1964, CLUTTERING	5	1	1	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	1994	272	7					565	565		10.1001/jama.272.7.565	http://dx.doi.org/10.1001/jama.272.7.565			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB229	8046816				2022-12-24	WOS:A1994PB22900040
J	GELMAN, B				GELMAN, B			THE LITTLE PICTURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	1994	272	6					417	417						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA278	8040961				2022-12-24	WOS:A1994PA27800001
J	RAWLES, J				RAWLES, J			ATTITUDES OF GENERAL-PRACTITIONERS TO PREHOSPITAL THROMBOLYSIS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION	Objective-To investigate reasons for general practitioners not giving thrombolytic treatment to eligible patients with acute myocardial infarction. Design-Postal questionnaires were sent to 424 general practitioners. Subjects-97 general practitioners who had taken part in the Grampian region early anistreplase trial, 185 whose practices in Scotland were at least 24 km from a district general hospital, and 142 who had attended postgraduate conferences at which thrombolysis had been discussed; 87, 158, and 125 respectively responded. Main outcome measures-Answers to questions about readiness to use thrombolytic treatment. Results-Response rate was 87% (370/424). Almost all respondents (350) were convinced of benefits of thrombolysis for acute myocardial infarction, and 277 were convinced that there were additional benefits from its administration in the community at first opportunity. Most doctors working 16 km or more from hospital thought that giving treatment at home would appreciably save time (200/274). Most doctors agreed that they could make time to give thrombolytic treatment (278), and would be willing to record an electrocardiogram (284), and would be able to interpret it (280). Sixty four respondents (17%) reported using thrombolytic treatment in previous year. Among non-users, 150 (49%) were unwilling to use thrombolytic treatment without further training. While many non-users (210 (69%)) were willing to use thrombolytic treatment without encouragement from Department of Health, 184 (60%) were unwilling to use it unless encouraged to do so by their local cardiologist. Conclusions-The need to become better informed about thrombolysis and lack of encouragement from local cardiologists were important factors preventing wider use of thrombolytic treatment in the community by general practitioners.			RAWLES, J (corresponding author), UNIV ABERDEEN, MED ASSESSMENT RES UNIT, ABERDEEN AB9 2ZD, SCOTLAND.							[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; BIRKHEAD JS, 1992, BMJ-BRIT MED J, V305, P445, DOI 10.1136/bmj.305.6851.445; CHAMBERLAIN DA, 1988, LANCET, V1, P545; COLLINS R, 1991, BRIT HEART J, V66, P250; GATENBY R, 1992, BMJ-BRIT MED J, V305, P548; GEMMILL JD, 1993, BRIT HEART J, V70, P503; GORDON I, 1989, J ROY COLL GEN PRACT, V39, P49; GRAY D, 1993, LANCET, V341, P654, DOI 10.1016/0140-6736(93)90420-L; KETLEY D, 1993, LANCET, V342, P891, DOI 10.1016/0140-6736(93)91945-I; LEIZOROVICZ A, 1993, NEW ENGL J MED, V329, P383; LIDDELL R, 1990, BRIT J GEN PRACT, V40, P318; MCCREA WA, 1993, BRIT HEART J, V70, P219; RAWLES J, 1994, J AM COLL CARDIOL, V23, P1, DOI 10.1016/0735-1097(94)90494-4; RULE S, 1993, POSTGRAD MED J, V69, P190, DOI 10.1136/pgmj.69.809.190; WESTON CFM, 1994, BMJ-BRIT MED J, V308, P767, DOI 10.1136/bmj.308.6931.767; WILCOX RG, 1988, LANCET, V2, P525; 1992, BRIT HEART J, V68, P621	18	18	18	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 6	1994	309	6951					379	382		10.1136/bmj.309.6951.379	http://dx.doi.org/10.1136/bmj.309.6951.379			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB316	8081141	Green Published			2022-12-24	WOS:A1994PB31600024
J	THORNTON, JG; LILFORD, RJ				THORNTON, JG; LILFORD, RJ			ACTIVE MANAGEMENT OF LABOR - CURRENT KNOWLEDGE AND RESEARCH ISSUES	BRITISH MEDICAL JOURNAL			English	Article							CESAREAN-SECTION; PERINATAL-MORTALITY; NULLIPAROUS WOMEN; AMNIOTOMY; DECREASE; DYSTOCIA; DELIVERY; TRIAL	Objectives-To review the evidence that the package of labour interventions collectively called ''active management''-namely, strict diagnostic criteria for labour, early amniotomy, early use of oxytocin, and continuous professional support-reduce rates of caesarean sections and operative vaginal delivery in first labours. Design-Review of observational data, supplemented by evidence from four separate overviews of relevant randomised trials previously published as part of the Cochrane Collaboration pregnancy and childbirth database. Results-Observational data do not permit a clear conclusion. There have been no randomised trials of the total package of active management or of the use of strict diagnostic criteria alone, but trials of early amniotomy, early oxytocin, and these interventions combined do not suggest that these interventions are effective in reducing rates of caesarean sections or operative vaginal deliveries. In contrast, the provision of continuous professional support in labour seems to reduce both types of operative delivery, although the effect on caesarean sections is confined to those settings where non-professional companions are not normally present in labour. Conclusions-Delivery units should endeavour to provide continuous professional support in labour, but routine use of amniotomy and early oxytocin is not recommended.			THORNTON, JG (corresponding author), UNIV LEEDS,INST EPIDEMIOL & HLTH SERV RES,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND.		Thornton, Jim/B-8336-2008	Thornton, Jim/0000-0001-9764-6876				AKOURY HA, 1988, AM J OBSTET GYNECOL, V158, P255, DOI 10.1016/0002-9378(88)90133-0; BARRETT JFR, 1992, BRIT J OBSTET GYNAEC, V99, P5, DOI 10.1111/j.1471-0528.1992.tb14382.x; BREART G, 1993, CARE CONCERN CURE PE, P39; Caldeyro-Barcia R, 1972, INT J GYNECOL OBSTET, V10, P169; CARTMILL RSV, 1992, LANCET, V339, P1520, DOI 10.1016/0140-6736(92)91275-D; COHEN GR, 1987, AM J OBSTET GYNECOL, V157, P1174, DOI 10.1016/S0002-9378(87)80288-0; FRASER WD, 1993, NEW ENGL J MED, V328, P1145, DOI 10.1056/NEJM199304223281602; FRASER WD, 1992, PREGNANCY CHILDBIRTH; Friedman EA, 1978, LABOR CLIN EVALUATIO, V2nd; HODNERT ED, 1993, PREGNANCY CHILDBIRTH; KIERSE MJN, 1989, EFFECTIVE CARE PREGN, P951; LEVENO KJ, 1985, AM J OBSTET GYNECOL, V153, P838, DOI 10.1016/0002-9378(85)90686-6; LOPEZZENO JA, 1992, NEW ENGL J MED, V326, P450, DOI 10.1056/NEJM199202133260705; ODRISCOLL K, 1983, OBSTET GYNECOL, V61, P1; ODRISCOLL K, 1984, OBSTET GYNECOL, V63, P485; ODRISCOLL K, 1969, BMJ-BRIT MED J, V2, P477, DOI 10.1136/bmj.2.5655.477; ODRISCOLL K, 1973, BMJ-BRIT MED J, V3, P135, DOI 10.1136/bmj.3.5872.135; ODRISCOLL K, 1980, ACTIVE MANAGEMENT LA; PHILPOTT RH, 1972, J OBSTET GYN BR COMM, V79, P592; ROCHENSCHAUB A, 1990, LANCET, V335, P977; Scott J. L., 1981, BRIT MED J, V282, P1064; STUDD J, 1973, BRIT MED J, V4, P451, DOI 10.1136/bmj.4.5890.451; TURNER MJ, 1986, J OBSTET GYNAECOL, V7, P79, DOI 10.3109/01443618609112275; TURNER MJ, 1988, OBSTET GYNECOL, V71, P150; VANALTEN D, 1989, BRIT J OBSTET GYNAEC, V96, P656; 1994, ONLINE J CURR CLIN T, V3, P122	26	72	75	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 6	1994	309	6951					366	369		10.1136/bmj.309.6951.366	http://dx.doi.org/10.1136/bmj.309.6951.366			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB316	8081133	Green Published			2022-12-24	WOS:A1994PB31600015
J	DELATTRE, O; ZUCMAN, J; MELOT, T; GARAU, XS; ZUCKER, JM; LENOIR, GM; AMBROS, PF; SHEER, D; TURCCAREL, C; TRICHE, TJ; AURIAS, A; THOMAS, G				DELATTRE, O; ZUCMAN, J; MELOT, T; GARAU, XS; ZUCKER, JM; LENOIR, GM; AMBROS, PF; SHEER, D; TURCCAREL, C; TRICHE, TJ; AURIAS, A; THOMAS, G			THE EWING FAMILY OF TUMORS - A SUBGROUP OF SMALL-ROUND-CELL TUMORS DEFINED BY SPECIFIC CHIMERIC TRANSCRIPTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRIMITIVE NEUROECTODERMAL TUMORS; PERIPHERAL NEUROEPITHELIOMA; ALVEOLAR RHABDOMYOSARCOMA; CHROMOSOME-TRANSLOCATION; CYTOGENETIC ANALYSIS; GENE FUSION; SARCOMA; BONE; HISTOGENESIS; EXPRESSION	Background. Precise diagnosis of small-round-cell tumors is often a challenge to the pathologist and the clinical oncologist. In Ewing's sarcomas and related peripheral primitive neuroectodermal tumors, a t(11;22) translocation or a (21,22) rearrangement is associated with hybrid transcripts of the EWS gene with the FLI1 or ERG gene. To investigate the diagnostic implication of this observation, we searched for these hybrid transcripts in tumors from patients with clinical and radiologic features of Ewing's sarcoma or peripheral primitive neuroectodermal tumors. Methods. Samples of RNA from 114 tumors were reverse transcribed and subjected to the polymerase chain reaction with primers designed to amplify the relevant chimeric transcripts. All amplified products were sequenced. Results. In-frame hybrid transcripts were observed in 89 cases. A hybrid transcript was found in 83 of 87 cases (95 percent) of Ewing's sarcoma or peripheral primitive neuroectodermal tumors. Samples of RNA from all of 12 tumors that had been proved to be other than Ewing's sarcoma or neuroectodermal tumors had no hybrid transcript. However, 6 of 15 undifferentiated tumors whose type was ambiguous (nonsecreting, poorly differentiated neuroblastoma or undifferentiated sarcoma) contained a hybrid transcript, suggesting that they might have to be reclassified. Conclusions. A subgroup of small-round-cell tumors identified as belonging to the Ewing family of tumors can be defined according to a specific molecular genetic lesion that is detectable by a rapid, reliable, and efficient method. This approach can be applied to small specimens obtained by fine-needle biopsies.	INST CURIE,GENET TUMEURS LAB,INSERM,CONTRAT JEUNE FORMAT 9201,F-75231 PARIS 05,FRANCE; INST CURIE,SERV ONCOL PEDIAT,PARIS,FRANCE; INST CURIE,SERV ANATOMOPATHOL,PARIS,FRANCE; CHILDRENS HOSP,DEPT PATHOL & LAB MED,LOS ANGELES,CA 90027; IMPERIAL CANC RES FUND,HUMAN CYTOGENET LAB,LONDON WC2A 3PX,ENGLAND; CNRS,URA 1462,CYTOGENET CANCEROL LAB,F-06034 NICE,FRANCE; ST ANNA CHILDRENS HOSP,CHILDRENS CANC RES INST,VIENNA,AUSTRIA; INT AGCY RES CANC,F-69372 LYON,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Children's Hospital Los Angeles; Cancer Research UK; Centre National de la Recherche Scientifique (CNRS); Saint Anna Children's Hospital; World Health Organization; International Agency for Research on Cancer (IARC)			Manara, Maria Cristina/K-3366-2018; Scotlandi, Katia/J-9009-2016; j, zucman-rossi/AAV-3594-2021; zucman-rossi, Jessica/B-5098-2009; Sheer, Denise/C-6705-2011; Ambros, Peter/AAA-1266-2021	Manara, Maria Cristina/0000-0001-5686-720X; Scotlandi, Katia/0000-0001-6114-9499; j, zucman-rossi/0000-0002-5687-0334; zucman-rossi, Jessica/0000-0002-5687-0334; Sheer, Denise/0000-0001-9067-1796; Ambros, Peter/0000-0002-5507-7211; delattre, olivier/0000-0002-8730-2276	Cancer Research UK [A3585] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		AMBROS IM, 1991, CANCER, V67, P1886, DOI 10.1002/1097-0142(19910401)67:7<1886::AID-CNCR2820670712>3.0.CO;2-U; ASKIN FB, 1979, CANCER, V43, P2438, DOI 10.1002/1097-0142(197906)43:6<2438::AID-CNCR2820430640>3.0.CO;2-9; AURIAS A, 1983, NEW ENGL J MED, V309, P496; BARR FG, 1991, GENE CHROMOSOME CANC, V3, P153, DOI 10.1002/gcc.2870030212; CAVAZZANA AO, 1987, AM J PATHOL, V127, P507; DEHNER LP, 1993, AM J SURG PATHOL, V17, P1, DOI 10.1097/00000478-199301000-00001; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Ewing, 1921, P NEW YORK PATHOL S, V21, P17; FELLINGER EJ, 1991, AM J PATHOL, V139, P317; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GAUWERKY CE, 1993, SEMIN CANCER BIOL, V4, P333; GORMAN PA, 1991, CANCER GENET CYTOGEN, V51, P13, DOI 10.1016/0165-4608(91)90003-D; HAMILTON G, 1988, CANCER RES, V48, P6127; Horowitz ME, 1993, PRINCIPLES PRACTICE, P795; KISSANE JM, 1983, HUM PATHOL, V14, P773, DOI 10.1016/S0046-8177(83)80300-1; KOVAR H, 1990, ONCOGENE, V5, P1067; LIPINSKI M, 1987, CANCER RES, V47, P183; NASCIMENTO AG, 1980, AM J SURG PATHOL, V4, P29, DOI 10.1097/00000478-198004010-00003; NOGUERA R, 1992, LAB INVEST, V66, P143; PAPPO AS, 1993, HUM PATHOL, V24, P880, DOI 10.1016/0046-8177(93)90138-7; Sambrook J., 1989, MOL CLONING LAB MANU; TRICHE TJ, 1993, PRINCIPLES PRACTICE, P115; TURCCAREL C, 1983, NEW ENGL J MED, V309, P497; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; WHANGPENG J, 1984, NEW ENGL J MED, V311, P584, DOI 10.1056/NEJM198408303110907; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x; ZUCMAN J, 1992, GENE CHROMOSOME CANC, V5, P271, DOI 10.1002/gcc.2870050402	29	810	843	0	24	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 4	1994	331	5					294	299		10.1056/NEJM199408043310503	http://dx.doi.org/10.1056/NEJM199408043310503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ227	8022439				2022-12-24	WOS:A1994NZ22700003
J	HENRY, JM; MACPHERSON, IA; DONALD, SC				HENRY, JM; MACPHERSON, IA; DONALD, SC			SURVEY OF PRIVATE NURSING-HOMES IN 7 ENGLISH COUNTIES	BRITISH MEDICAL JOURNAL			English	Article									UNIV ABERDEEN,DEPT PUBL HLTH,ABERDEEN AB9 2ZD,SCOTLAND	University of Aberdeen								HENRY JM, 1993, SURVEY NURSING HOMES	1	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 30	1994	309	6950					314	314						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA373	8086870				2022-12-24	WOS:A1994PA37300021
J	COLLINGE, J; WHITTINGTON, MA; SIDLE, KCL; SMITH, CJ; PALMER, MS; CLARKE, AR; JEFFERYS, JGR				COLLINGE, J; WHITTINGTON, MA; SIDLE, KCL; SMITH, CJ; PALMER, MS; CLARKE, AR; JEFFERYS, JGR			PRION PROTEIN IS NECESSARY FOR NORMAL SYNAPTIC FUNCTION	NATURE			English	Article							INTRAHIPPOCAMPAL TETANUS TOXIN; LONG-TERM POTENTIATION; RAT; HIPPOCAMPUS; INVITRO; DEPRESSION; INDUCTION; RECEPTOR; DISEASE	THE prion diseases are neurodegenerative conditions, transmissible by inoculation, and in some cases inherited as an autosomal dominant disorder. They include Creutzfeldt-Jakob disease in humans and scrapie and bovine spongiform encephalopathy in animals. The prion consists principally of a post-translationally modified form of a host-encoded glycoprotein (PrPc), designated PrPSc (ref. 1); the normal cellular function of PrPc is, however, unknown. Although PrP is highly conserved among mammals and widely expressed in early embryogenesis, mice homozygous for disrupted PrP genes appear developmentally and behaviourally normal(2). PrP is a protein anchored to the neuronal surface by glycosylphosphatidylinositol, suggesting a role in cell signalling or adhesion. Here we report that hippocampal slices from PrP null mice have weakened GABA(A) (gamma-aminobutyric acid type A) receptor-mediated fast inhibition and impaired long-term potentiation. This impaired synaptic inhibition may be involved in the epileptiform activity seen in Creutzfeldt-Jakob disease and we argue that loss of function of PrPc may contribute to the early synaptic loss(3) and neuronal degeneration seen in these diseases.	ST MARYS HOSP,SCH MED,DEPT PHYSIOL & BIOPHYS,LONDON W2 1PG,ENGLAND; ST MARYS HOSP,DEPT NEUROL,LONDON W2 1NY,ENGLAND; UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,BRISTOL BS8 1TD,ENGLAND	Imperial College London; Imperial College London; University of Bristol	COLLINGE, J (corresponding author), ST MARYS HOSP,SCH MED,DEPT BIOCHEM & MOLEC GENET,PRION DIS GRP,LONDON W2 1PG,ENGLAND.		Jefferys, John G R/AAF-1164-2021; Smith, Corinne J/A-3170-2009; Jefferys, John/E-6132-2012	Jefferys, John G R/0000-0003-0106-4412; Smith, Corinne J/0000-0003-3364-7946; Jefferys, John/0000-0003-0106-4412; Whittington, Miles Adrian/0000-0002-0247-1362	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALGER BE, 1982, J PHYSIOL-LONDON, V328, P125, DOI 10.1113/jphysiol.1982.sp014256; ALLAN RD, 1980, BRIT J PHARMACOL, V70, P609, DOI 10.1111/j.1476-5381.1980.tb09779.x; BENDHEIM PE, 1992, NEUROLOGY, V42, P149, DOI 10.1212/WNL.42.1.149; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRACE HM, 1985, J PHYSIOL-LONDON, V368, P343, DOI 10.1113/jphysiol.1985.sp015861; Brown D A, 1981, Adv Biochem Psychopharmacol, V29, P321; BUELERH, 1992, NATURE, V356, P577; CLINTON J, 1993, NEUROREPORT, V4, P65, DOI 10.1097/00001756-199301000-00017; COAN EJ, 1989, NEUROSCI LETT, V105, P205, DOI 10.1016/0304-3940(89)90038-4; COLLINGE J, 1990, LANCET, V336, P7, DOI 10.1016/0140-6736(90)91518-F; DAVIES CH, 1990, J PHYSIOL-LONDON, V424, P513, DOI 10.1113/jphysiol.1990.sp018080; DEARMOND SJ, 1987, NEUROLOGY, V37, P1271, DOI 10.1212/WNL.37.8.1271; EMPSON RM, 1993, J PHYSIOL-LONDON, V465, P595, DOI 10.1113/jphysiol.1993.sp019695; GROVERLM, 1993, J NEUROPHYSIOL, V69, P1541; HERRON CE, 1985, NEUROSCI LETT, V61, P255, DOI 10.1016/0304-3940(85)90473-2; HUANG YY, 1992, SCIENCE, V255, P730, DOI 10.1126/science.1346729; JEFFERYS JGR, 1994, NEUROBIOL DIS, V1, P3; PALMER MS, 1991, NATURE, V352, P340, DOI 10.1038/352340a0; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; SMITH TL, 1985, J PHARMACOL EXP THER, V232, P702; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P501, DOI 10.1152/jn.1989.61.3.501; WEISSMANN C, 1991, NATURE, V349, P569, DOI 10.1038/349569a0	23	664	676	0	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 28	1994	370	6487					295	297		10.1038/370295a0	http://dx.doi.org/10.1038/370295a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ229	8035877				2022-12-24	WOS:A1994NZ22900064
J	KHOURY, SJ; WEINER, HL				KHOURY, SJ; WEINER, HL			KAPPA-LIGHT-CHAINS IN SPINAL-FLUID FOR DIAGNOSING MULTIPLE-SCLEROSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							CEREBROSPINAL-FLUID; NEUROLOGICAL DISEASES				KHOURY, SJ (corresponding author), BRIGHAM & WOMENS HOSP,BOSTON,MA, USA.							BOLLENGIER F, 1978, J CLIN CHEM CLIN BIO, V16, P165; FAGNART OC, 1988, J NEUROIMMUNOL, V19, P119, DOI 10.1016/0165-5728(88)90041-0; GALLO P, 1989, J NEUROL SCI, V94, P241, DOI 10.1016/0022-510X(89)90234-7; LAURENZI MA, 1980, ANN NEUROL, V8, P241, DOI 10.1002/ana.410080304; LINK H, 1987, ITAL J NEUROL SCI S, V6, P57; RUDICK RA, 1986, ARCH NEUROL-CHICAGO, V43, P456, DOI 10.1001/archneur.1986.00520050036018; SINDIC CJM, 1991, J NEUROIMMUNOL, V33, P63, DOI 10.1016/0165-5728(91)90035-6; STANESCU GL, 1991, J CLIN LAB ANAL, V5, P206, DOI 10.1002/jcla.1860050310	8	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 20	1994	272	3					242	243		10.1001/jama.272.3.242	http://dx.doi.org/10.1001/jama.272.3.242			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW185	8022046				2022-12-24	WOS:A1994NW18500032
J	BOREN, T; FALK, P; ROTH, KA; LARSON, G; NORMARK, S				BOREN, T; FALK, P; ROTH, KA; LARSON, G; NORMARK, S			ATTACHMENT OF HELICOBACTER-PYLORI TO HUMAN GASTRIC EPITHELIUM MEDIATED BY BLOOD-GROUP ANTIGENS	SCIENCE			English	Article							GLYCOLIPID RECEPTORS; ULCER DISEASE; BACTERIA; GLYCOSPHINGOLIPIDS	Helicobacter pylori is associated with development of gastritis, gastric ulcers, and adenocarcinomas in humans. The Lewis(b) (Le(b)) blood group antigen mediates H. pylori attachment to human gastric mucosa. Soluble glycoproteins presenting the Le(b) antigen or antibodies to the Le(b) antigen inhibited bacterial binding. Gastric tissue lacking Le(b) expression did not bind H. pylori. Bacteria did not bind to Le(b) antigen substituted with a terminal GalNAcalpha1-3 residue (blood group A determinant), suggesting that the availability of H. pylori receptors might be reduced in individuals of blood group A and B phenotypes, as compared with blood group O individuals.	WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; GOTHENBURG UNIV, SAHLGRENS HOSP, DEPT CLIN CHEM, S-41345 GOTHENBURG, SWEDEN; WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PHARMACOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Sahlgrenska University Hospital; University of Gothenburg; Washington University (WUSTL); Washington University (WUSTL)	BOREN, T (corresponding author), WASHINGTON UNIV, SCH MED, DEPT MOLEC MICROBIOL, ST LOUIS, MO 63110 USA.		Larson, Göran/AAF-3404-2019	Roth, Kevin/0000-0002-0643-995X	FOGARTY INTERNATIONAL CENTER [F05TW004669] Funding Source: NIH RePORTER; FIC NIH HHS [TW04669-02] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		AKOPYANZ N, 1992, NUCLEIC ACIDS RES, V20, P5137, DOI 10.1093/nar/20.19.5137; BAENZIGER J, 1974, J BIOL CHEM, V249, P7260; BORIELLO S P, 1981, Journal of Antimicrobial Chemotherapy, V7, P53; CLARKE CA, 1955, BRIT MED J, V2, P643, DOI 10.1136/bmj.2.4940.643; CLAUSEN H, 1989, VOX SANG, V56, P1, DOI 10.1111/j.1423-0410.1989.tb03040.x; DEBRAY H, 1981, EUR J BIOCHEM, V117, P41; DESCAMPS J, 1968, CR ACAD SCI D NAT, V266, P1775; EVANS DG, 1993, J BACTERIOL, V175, P674, DOI 10.1128/JB.175.3.674-683.1993; FALK P, 1993, P NATL ACAD SCI USA, V90, P2035, DOI 10.1073/pnas.90.5.2035; FALK P, IN PRESS METHODS ENZ; FAUCHERE JL, 1990, MICROB PATHOGENESIS, V9, P427, DOI 10.1016/0882-4010(90)90061-T; FINNE J, 1989, J BIOL CHEM, V264, P5720; FORMAN D, 1993, LANCET, V341, P1359; GRAHAM DY, 1988, J INFECT DIS, V157, P777, DOI 10.1093/infdis/157.4.777; GRAHAM DY, 1991, J GASTROEN HEPATOL, V6, P105, DOI 10.1111/j.1440-1746.1991.tb01448.x; HANSSON GC, 1985, ANAL BIOCHEM, V146, P158, DOI 10.1016/0003-2697(85)90410-5; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; LARSON G, 1988, J BIOL CHEM, V263, P10790; MARCUS DM, 1989, HUMAN IMMUNOGENETICS, P685; MENTIS A, 1991, EPIDEMIOL INFECT, V106, P221, DOI 10.1017/S0950268800048366; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PEREZPEREZ GI, 1990, J INFECT DIS, V161, P1237, DOI 10.1093/infdis/161.6.1237; SAITOH T, 1991, FEBS LETT, V282, P385, DOI 10.1016/0014-5793(91)80519-9; SAKAMOTO J, 1989, CANCER RES, V49, P745; SHARON N, 1986, LECTINS, P494; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; WYATT JI, 1988, J PATHOL, V154, P113, DOI 10.1002/path.1711540203	27	937	980	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 17	1993	262	5141					1892	1895		10.1126/science.8018146	http://dx.doi.org/10.1126/science.8018146			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM511	8018146				2022-12-24	WOS:A1993MM51100042
J	FORRESTER, WC; VANGENDEREN, C; JENUWEIN, T; GROSSCHEDL, R				FORRESTER, WC; VANGENDEREN, C; JENUWEIN, T; GROSSCHEDL, R			DEPENDENCE OF ENHANCER-MEDIATED TRANSCRIPTION OF THE IMMUNOGLOBULIN-MU GENE ON NUCLEAR MATRIX ATTACHMENT REGIONS	SCIENCE			English	Article							HEAVY-CHAIN ENHANCER; CHROMOSOMAL LOOP ANCHORAGE; TRANSGENIC MICE; REGULATORY ELEMENTS; BINDING SITES; IGH ENHANCER; C-MYC; PRE-B; EXPRESSION; CHROMATIN	Transcription of the immunoglobulin mu heavy chain locus is regulated by an intronic enhancer that is flanked on both sides by nuclear matrix attachment regions (MARs). These MARs have now been shown to be essential for transcription of a rearranged mu gene in transgenic B lymphocytes, but they were not required in stably transfected tissue culture cells. Normal rates of transcriptional initiation at a variable region promoter and the formation of an extended deoxyribonuclease I (DNase I)-sensitive chromatin domain were dependent on MARs, although DNase I hypersensitivity at the enhancer was detected in the absence of MARs. Thus, transcriptional activation of the mu gene during normal lymphoid development requires a synergistic collaboration between the enhancer and flanking MARs.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco								ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ARONOW BJ, 1992, MOL CELL BIOL, V12, P4170, DOI 10.1128/MCB.12.9.4170; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; BERGMAN Y, 1984, P NATL ACAD SCI-BIOL, V81, P7041, DOI 10.1073/pnas.81.22.7041; BETZ AG, 1994, CELL, V77, P239, DOI 10.1016/0092-8674(94)90316-6; BLAZQUEZ VC, 1989, J BIOL CHEM, V264, P21183; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; CHEN JZ, 1993, EMBO J, V12, P4635, DOI 10.1002/j.1460-2075.1993.tb06152.x; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COGNE M, 1994, CELL, V77, P737, DOI 10.1016/0092-8674(94)90057-4; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; EPNER E, 1992, Current Biology, V2, P262, DOI 10.1016/0960-9822(92)90379-O; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; GROSSCHEDL R, 1984, CELL, V38, P647, DOI 10.1016/0092-8674(84)90259-9; IMLER JL, 1987, MOL CELL BIOL, V7, P2558, DOI 10.1128/MCB.7.7.2558; JAHNER D, 1982, NATURE, V298, P623, DOI 10.1038/298623a0; JENUWEIN T, 1993, GENE DEV, V7, P2016, DOI 10.1101/gad.7.10.2016; JENUWEIN T, 1991, GENE DEV, V5, P932, DOI 10.1101/gad.5.6.932; JENUWEIN T, UNPUB; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; KILEDJIAN M, 1988, MOL CELL BIOL, V8, P145, DOI 10.1128/MCB.8.1.145; KIM KJ, 1979, J IMMUNOL, V122, P549; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LENNON GG, 1985, NATURE, V318, P475, DOI 10.1038/318475a0; LIBERMANN TA, 1991, MOL ASPECTS CELL REG, V6, P385; LICHTENSTEIN M, 1994, CELL, V76, P913, DOI 10.1016/0092-8674(94)90365-4; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MCKNIGHT RA, 1992, P NATL ACAD SCI USA, V89, P6943, DOI 10.1073/pnas.89.15.6943; MOORE BB, 1993, NUCLEIC ACIDS RES, V21, P1481, DOI 10.1093/nar/21.6.1481; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; POMMIER Y, 1990, J VIROL, V64, P419, DOI 10.1128/JVI.64.1.419-423.1990; ROSENBERG N, 1976, J EXP MED, V143, P1453, DOI 10.1084/jem.143.6.1453; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SCHEUERMANN RH, 1989, GENE DEV, V3, P1255, DOI 10.1101/gad.3.8.1255; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; STEIF A, 1989, NATURE, V341, P343; STORB U, 1981, NATURE, V294, P90, DOI 10.1038/294090a0; TRAVIS A, 1991, MOL CELL BIOL, V11, P5756, DOI 10.1128/MCB.11.11.5756; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; XU M, 1989, J BIOL CHEM, V264, P21190; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x	48	210	218	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 26	1994	265	5176					1221	1225		10.1126/science.8066460	http://dx.doi.org/10.1126/science.8066460			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD422	8066460				2022-12-24	WOS:A1994PD42200034
J	BROOKOFF, D; COOK, CS; WILLIAMS, C; MANN, CS				BROOKOFF, D; COOK, CS; WILLIAMS, C; MANN, CS			TESTING RECKLESS DRIVERS FOR COCAINE AND MARIJUANA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DRUG-USE; ALCOHOL; ABSTINENCE; ABUSERS; TRAUMA	Background. Driving under the influence of intoxicating drugs other than alcohol may be an important cause of traffic injuries. We used a rapid urine test to identify reckless drivers who were under the influence of cocaine or marijuana. Methods. We conducted a consecutive-sample study in Memphis, Tennessee, in the summer of 1993. Subjects arrested for reckless driving who were not apparently impaired by alcohol (did not have an odor of alcohol, tested negative on breath analysis, or both) were tested for cocaine and marijuana at the scene of arrest. The results of the drug tests were compared with clinical evaluations of intoxication made at the scene by a police officer. Results. A total of 175 subjects were stopped for reckless driving, and 150 (86 percent) submitted urine samples for drug testing at the scene of arrest. Eighty-eight of the 150 (59 percent) tested positive: 20 (13 percent) for cocaine, 50 (33 percent) for marijuana, and 18 (12 percent) for both drugs. Ninety-four of the 150 tested drivers were clinically considered to be intoxicated, and 80 of them (85 percent) tested positive for cocaine or marijuana. The intoxicated drivers had a broad range of affects and appearances. Nearly half the drivers intoxicated with cocaine performed normally on standard sobriety tests. Conclusions. Over half of the reckless drivers who were not intoxicated with alcohol were found to be intoxicated with other drugs. Toxicologic testing at the scene is a practical means of identifying drivers under the influence of drugs and is a useful adjunct to standard behavioral sobriety testing.	UNIV TENNESSEE,METHODIST HOSP,DEPT EMERGENCY MED,MEMPHIS,TN; MEMPHIS POLICE DEPT,MEMPHIS,TN; MEMPHIS STATE UNIV,DEPT ANTHROPOL,MEMPHIS,TN	University of Tennessee System; University of Tennessee Health Science Center; University of Memphis								BROOKOFF D, 1993, AM J PUBLIC HEALTH, V83, P369, DOI 10.2105/AJPH.83.3.369; BURKE WM, 1990, J CLIN PSYCHIAT, V51, P145; BYCK R, 1977, COCAINE OTHER STIMUL, P629; CHAVKIN W, 1991, JAMA-J AM MED ASSOC, V266, P1556, DOI 10.1001/jama.266.11.1556; DACKIS CA, 1982, AM J PSYCHIAT, V139, P1196; EVANS DG, 1990, DRUG TESTING LAW TEC; FELL JC, 1993, MMWR-MORBID MORTAL W, V42, P605; GAWIN FH, 1986, ARCH GEN PSYCHIAT, V43, P107; GRANT BF, 1990, DRUG ALCOHOL DEPEN, V25, P97, DOI 10.1016/0376-8716(90)90147-7; KIRBY JM, 1992, SOUTHERN MED J, V85, P800, DOI 10.1097/00007611-199208000-00003; LOWENSTEIN DH, 1987, AM J MED, V83, P841, DOI 10.1016/0002-9343(87)90640-1; LUNDBERG GD, 1986, JAMA-J AM MED ASSOC, V255, P529, DOI 10.1001/jama.255.4.529; MARSDEN ME, 1988, PREV MED, V17, P366, DOI 10.1016/0091-7435(88)90011-4; MARZUK PM, 1990, JAMA-J AM MED ASSOC, V263, P250, DOI 10.1001/jama.263.2.250; MAULL KI, 1984, JAMA-J AM MED ASSOC, V252, P1880, DOI 10.1001/jama.252.14.1880; MOSKOWITZ H, 1976, ACCIDENT ANAL PREV, V8, P45, DOI 10.1016/0001-4575(76)90033-6; MOSKOWITZ H, 1993, 1993 P INT C ALC DRU, P612; PANNER MJ, 1986, HASTINGS CENT REP, V16, P7, DOI 10.2307/3562082; RAFAELSEN OJ, 1973, SCIENCE, V179, P920, DOI 10.1126/science.179.4076.920; REMALEY AT, 1988, CLIN CHEM, V34, P1933; RESNICK RB, 1977, SCIENCE, V195, P696, DOI 10.1126/science.841307; SAYLOR KE, 1992, JAMA-J AM MED ASSOC, V267, P652, DOI 10.1001/jama.267.5.652; SKOLNICK A, 1990, JAMA-J AM MED ASSOC, V263, P3122; WEISS RD, 1988, AM J MED, V85, P879; WIDMARK EMP, 1981, PRINCIPLES APPLICATI; 1985, DHHS ADM851386 DEP H; 1985, JAMA-J AM MED ASSOC, V254, P2618; 1991, DRUNK DRIVING FACTS; 1986, FIELD EVALUATION LOS; 1988, FED REGISTER, V53, P970; 1992, DRUGS CRIME JUSTICE; 1988, USE CONTROLLED SUBST; 1992, DRUG EVALUATION CLAS	33	83	84	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 25	1994	331	8					518	522		10.1056/NEJM199408253310807	http://dx.doi.org/10.1056/NEJM199408253310807			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PD072	8041419				2022-12-24	WOS:A1994PD07200007
J	MCGEEHAN, GM; BECHERER, JD; BAST, RC; BOYER, CM; CHAMPION, B; CONNOLLY, KM; CONWAY, JG; FURDON, P; KARP, S; KIDAO, S; MCELROY, AB; NICHOLS, J; PRYZWANSKY, KM; SCHOENEN, F; SEKUT, L; TRUESDALE, A; VERGHESE, M; WARNER, J; WAYS, JP				MCGEEHAN, GM; BECHERER, JD; BAST, RC; BOYER, CM; CHAMPION, B; CONNOLLY, KM; CONWAY, JG; FURDON, P; KARP, S; KIDAO, S; MCELROY, AB; NICHOLS, J; PRYZWANSKY, KM; SCHOENEN, F; SEKUT, L; TRUESDALE, A; VERGHESE, M; WARNER, J; WAYS, JP			REGULATION OF TUMOR-NECROSIS-FACTOR-ALPHA PROCESSING BY A METALLOPROTEINASE INHIBITOR	NATURE			English	Article							MURINE TUMOR; MONO MAC-6; ACTIVATION; EXPRESSION; SECRETION; CLONING	TUMOUR necrosis factor-alpha (TNF-alpha) is a potent pro-inflammatory agent produced primarily by activated monocytes and macrophages(1). TNF-alpha is synthesized as a precursor protein of M(r) 26,000 (26K) which is processed to a secreted 17K mature form by cleavage of an Ala-Val bond between residues 76-77. The enzyme(s) responsible for processing pro-TNF-alpha has yet to be identified. Here, we describe the capacity of a metalloproteinase inhibitor, GI 129471, to block TNF-alpha secretion both in vitro and in vivo. The inhibition is specific to TNF-alpha; the production of other secreted cytokines, such as the interleukins IL-1 beta, IL-2, or IL-6, is not inhibited. The mechanism of inhibition occurs at a post-translational step in TNF-alpha production. Our data suggest that TNF-alpha processing is mediated by a unique Zn2+ endopeptidase which is inhibited by GI 129471 and would represent a novel target for therapeutic intervention in TNF-alpha associated pathologies.	DUKE UNIV,MED CTR,DUKE COMPREHENS CANC CTR,DEPT MED,DURHAM,NC 27710; MCGILL UNIV,JEWISH GEN HOSP,DEPT ONCOL,MONTREAL H3T 1E2,PQ,CANADA; UNIV N CAROLINA,SCH MED,DEPT PATHOL,CHAPEL HILL,NC 27516	Duke University; McGill University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	MCGEEHAN, GM (corresponding author), GLAXO INC,RES INST,RES TRIANGLE PK,NC 27709, USA.		Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462; Schoenen, Frank/0000-0003-2711-1117				BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BLACK RA, 1992, CYTOKINE, V3, P480; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; CAMPION C, 1990, Patent No. 05719; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; ISAYA G, 1992, P NATL ACAD SCI USA, V89, P8317, DOI 10.1073/pnas.89.17.8317; JUE DM, 1990, BIOCHEMISTRY-US, V29, P8371, DOI 10.1021/bi00488a025; KARP SE, 1992, J IMMUNOL, V149, P2076; KAWABATA S, 1993, J BIOL CHEM, V268, P12498; KIM KU, 1993, IMMUNOLOGY, V80, P134; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P37, DOI 10.1038/newbio238037a0; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MULLER R, 1986, FEBS LETT, V197, P99, DOI 10.1016/0014-5793(86)80306-4; NIEHORSTER M, 1990, BIOCHEM PHARMACOL, V40, P1601, DOI 10.1016/0006-2952(90)90461-S; PENNICA D, 1985, P NATL ACAD SCI USA, V82, P6060, DOI 10.1073/pnas.82.18.6060; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; PIEROTTI A, 1990, BIOCHEMISTRY-US, V29, P10323, DOI 10.1021/bi00497a006; PRADINESFIGUERES A, 1992, J BIOL CHEM, V267, P23261; SCUDERI P, 1989, J IMMUNOL, V143, P168; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; VERGHESE MW, 1981, J IMMUNOL, V127, P288; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324	26	546	607	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 18	1994	370	6490					558	561		10.1038/370558a0	http://dx.doi.org/10.1038/370558a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC537	8052311				2022-12-24	WOS:A1994PC53700055
J	CHAISSON, RE				CHAISSON, RE			SMOKING CESSATION IN PATIENTS WITH HIV	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							CIGARETTE-SMOKING; HOMOSEXUAL MEN; INFECTION; PROGRESSION; SUBSETS; AIDS				CHAISSON, RE (corresponding author), JOHNS HOPKINS UNIV,BALTIMORE,MD, USA.							BENOWITZ NL, 1993, DRUGS, V45, P157, DOI 10.2165/00003495-199345020-00001; BUSHKIN SE, 1992, 8TH INT C AIDS 3 STD; CAIAFFA WT, 1993, 11TH INT C AIDS BERL; CRAIB KJP, 1992, CLIN INVEST MED, V15, P301; HIRSCHTICK R, 1993, AM REV RESPIR DIS, V147, pA1003; NIEMAN R, 1992, 8TH INT C AIDS 3 STD; NIEMAN RB, 1993, AIDS, V7, P705, DOI 10.1097/00002030-199305000-00015; PARK LP, 1992, J ACQ IMMUN DEF SYND, V5, P1124; ROYCE RA, 1990, AIDS, V4, P327, DOI 10.1097/00002030-199004000-00007; SELWYN PA, 1992, NEW ENGL J MED, V327, P1697, DOI 10.1056/NEJM199212103272401; TOLLERUD DJ, 1991, AM REV RESPIR DIS, V144, P612, DOI 10.1164/ajrccm/144.3_Pt_1.612	11	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	1994	272	7					564	564						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB229	8046815				2022-12-24	WOS:A1994PB22900038
J	NIGHTINGALE, SL				NIGHTINGALE, SL			COMBINATION TUBERCULOSIS DRUG APPROVED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	1994	272	5					344	344						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY903	8028152				2022-12-24	WOS:A1994NY90300004
J	LIN, S; GAIANO, N; CULP, P; BURNS, JC; FRIEDMANN, T; YEE, JK; HOPKINS, N				LIN, S; GAIANO, N; CULP, P; BURNS, JC; FRIEDMANN, T; YEE, JK; HOPKINS, N			INTEGRATION AND GERM-LINE TRANSMISSION OF A PSEUDOTYPED RETROVIRAL VECTOR IN ZEBRAFISH	SCIENCE			English	Article							LEUKEMIA-VIRUS; CELLS; GENE; MICE	The zebrafish is rapidly becoming a popular model system for the study of vertebrate development because it is ideal for both embryological studies and genetic analysis. To determine if a retroviral vector pseudotyped with the envelope glycoprotein of the vesicular stomatitis virus could infect zebrafish embryos, and in particular, the cells destined to become the germ line, a pseudotyped virus was injected into blastula-stage zebrafish embryos. Fifty-one embryos were allowed to develop and eight transmitted proviral DNA to their progeny. Founders were mosaic, but as expected, transgenic F-1's transmitted proviral DNA in a Mendelian fashion to the F-2 progeny. Transgenic F-1 fish inherited a single integrated provirus, and a single founder could transmit more than one viral integration to its progeny. These results demonstrate that this pantropic pseudotyped vector, originally developed for human gene therapy, will make the use of retroviral vectors in zebrafish possible.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; UNIV CALIF SAN DIEGO,SCH MED,DEPT PEDIAT,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,SCH MED,CTR MOLEC GENET,LA JOLLA,CA 92093	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); University of California System; University of California San Diego; University of California System; University of California San Diego			Burns, Jane C/J-6167-2015		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020034] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA014051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL001855] Funding Source: NIH RePORTER; NCI NIH HHS [CA14051] Funding Source: Medline; NHLBI NIH HHS [HL-01855] Funding Source: Medline; NICHD NIH HHS [HD-20034] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; CEPKO CL, 1993, METHOD ENZYMOL, V225, P933; CHEN J, 1994, METH MOL G, V4, P123; CULP P, UNPUB; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GAIANO N, UNPUB; GRIDLEY T, 1987, TRENDS GENET, V3, P162, DOI 10.1016/0168-9525(87)90218-6; GRUNWALD DJ, 1992, GENET RES, V59, P103, DOI 10.1017/S0016672300030317; HUSZAR D, 1991, DEVELOPMENT, V113, P653; JAENISCH R, 1976, P NATL ACAD SCI USA, V73, P1260, DOI 10.1073/pnas.73.4.1260; KIMMEL CB, 1989, TRENDS GENET, V5, P283, DOI 10.1016/0168-9525(89)90103-0; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; MULLINS MC, 1994, CURR BIOL, V4, P189, DOI 10.1016/S0960-9822(00)00048-8; NJOLSTAD PR, 1988, FEBS LETT, V230, P25, DOI 10.1016/0014-5793(88)80634-3; RIGGLEMAN R, UNPUB; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; SOLNICAKREZEL L, 1994, GENETICS, V136, P1401; SORIANO P, 1986, CELL, V46, P19, DOI 10.1016/0092-8674(86)90856-1; VARMUS HE, 1982, SCIENCE, V216, P812, DOI 10.1126/science.6177038; VONMELCHNER H, 1992, GENE DEV, V6, P919, DOI 10.1101/gad.6.6.919; XU L, 1989, VIROLOGY, V171, P331, DOI 10.1016/0042-6822(89)90600-4	21	221	239	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 29	1994	265	5172					666	669		10.1126/science.8036514	http://dx.doi.org/10.1126/science.8036514			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	8036514				2022-12-24	WOS:A1994NZ53800034
J	SHAHAR, E; FOLSOM, AR; MELNICK, SL; TOCKMAN, MS; COMSTOCK, GW; GENNARO, V; HIGGINS, MW; SORLIE, PD; KO, WJ; SZKLO, M				SHAHAR, E; FOLSOM, AR; MELNICK, SL; TOCKMAN, MS; COMSTOCK, GW; GENNARO, V; HIGGINS, MW; SORLIE, PD; KO, WJ; SZKLO, M			DIETARY N-3 POLYUNSATURATED FATTY-ACIDS AND SMOKING-RELATED CHRONIC OBSTRUCTIVE PULMONARY-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CIGARETTE-SMOKING; FISH-OIL; SUPPLEMENTATION; EMPHYSEMA; NEUTROPHIL; GENERATION; INVITRO; HEALTH	Background. Fish contain n-3 polyunsaturated fatty acids, principally eicosapentaenoic acid and docosahexaenoic acid, which are known to interfere with the body's inflammatory response and may be of benefit in chronic inflammatory conditions. Methods. We studied the relation between the dietary intake of n-3 fatty acids and chronic obstructive pulmonary disease (COPD) in 8960 current or former smokers participating in a population-based study of atherosclerosis. Intake of fatty acids was estimated with a dietary questionnaire. The presence of COPD was assessed by a questionnaire on respiratory symptoms and by spirometry. Three case definitions of COPD were used: symptoms of chronic bronchitis (667 subjects), physician-diagnosed emphysema reported by the subject (185 subjects), and spirometrically detected COPD (197 subjects). Results. After control for pack-years of smoking, age, sex, race, height, weight, energy intake, and educational level, the combined intake of eicosapentaenoic acid and docosahexaenoic acid was inversely related to the risk of COPD in a quantity-dependent fashion. The adjusted odds ratio for the highest quartile of intake as compared with the lowest quartile was 0.66 for chronic bronchitis (95 percent confidence interval, 0.52 to 0.85; P<0.001 for linear trend across the range of intake values), 0.31 for physician-diagnosed emphysema (95 percent confidence interval, 0.18 to 0.52; P for linear trend, 0.003), and 0.50 for spirometrically detected COPD (95 percent confidence interval, 0.32 to 0.79; P for linear trend, 0.007). Conclusions. A high dietary intake of n-3 fatty acids may protect cigarette smokers against COPD.	JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD USA; IST NAZL RIC CANC, ENVIRONM EPIDEMIOL SERV, I-16132 GENOA, ITALY; NHLBI, DIV EPIDEMIOL & CLIN APPLICAT, BETHESDA, MD 20892 USA; UNIV N CAROLINA, CTR COLLABORAT STUDIES COORDINATING, CHAPEL HILL, NC USA	Johns Hopkins University; University of Genoa; IRCCS AOU San Martino IST; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of North Carolina; University of North Carolina Chapel Hill	SHAHAR, E (corresponding author), UNIV MINNESOTA, SCH PUBL HLTH, DIV EPIDEMIOL, 1300 S 2ND ST, SUITE 300, MINNEAPOLIS, MN 55454 USA.			Szklo, Moyses/0000-0001-9433-6266	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055016, N01HC055015, N01HC055022] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-55022, N01-HC-55015, N01-HC-55016] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1979, AM REV RESPIR DIS, V119, P831; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; AOKI M, 1989, CHEST, V96, pS343, DOI 10.1378/chest.96.3_Supplement.343S; COMSTOCK GW, 1973, ARCH ENVIRON HEALTH, V27, P143, DOI 10.1080/00039896.1973.10666343; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; ENDRES S, 1989, NEW ENGL J MED, V320, P265, DOI 10.1056/NEJM198902023200501; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; FISHER M, 1991, WORLD REV NUTR DIET, V66, P245; HEPBURN FN, 1986, J AM DIET ASSOC, V86, P788; HOIDAL JR, 1981, AM REV RESPIR DIS, V123, P85; HOOGSTEDEN HC, 1991, MEDIATORS PULMONARY, P185; JANOFF A, 1983, J APPL PHYSIOL, V55, P285, DOI 10.1152/jappl.1983.55.2.285; KREMER JM, 1987, ANN INTERN MED, V106, P497, DOI 10.7326/0003-4819-106-4-497; LEE TH, 1985, NEW ENGL J MED, V312, P1217, DOI 10.1056/NEJM198505093121903; LONDON SJ, 1991, AM J CLIN NUTR, V54, P340, DOI 10.1093/ajcn/54.2.340; MACNEE W, 1989, NEW ENGL J MED, V321, P924, DOI 10.1056/NEJM198910053211402; MCGOWAN SE, 1989, NEW ENGL J MED, V321, P968, DOI 10.1056/NEJM198910053211410; NIEWOEHNER DE, 1988, J LAB CLIN MED, V111, P15; SCHWARTZ J, 1990, AM J EPIDEMIOL, V132, P67, DOI 10.1093/oxfordjournals.aje.a115644; SILVERMAN DI, 1990, AM J CARDIOL, V66, P860, DOI 10.1016/0002-9149(90)90367-A; SIMOPOULOS AP, 1991, AM J CLIN NUTR, V54, P438, DOI 10.1093/ajcn/54.3.438; SPERLING RI, 1987, J IMMUNOL, V139, P4186; STENSON WF, 1992, ANN INTERN MED, V116, P609, DOI 10.7326/0003-4819-116-8-609; TOCKMAN MS, 1985, CHRONIC OBSTRUCTIVE, P43; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184; ZAKRZEWSKI JT, 1987, PROSTAGLANDINS, V33, P663, DOI 10.1016/0090-6980(87)90033-5; 1990, SAS STAT USERS GUIDE; 1976, COMPOSITION FOODS RA; 1981, FOOD CONSUMPTION STA	30	143	151	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 28	1994	331	4					228	233		10.1056/NEJM199407283310403	http://dx.doi.org/10.1056/NEJM199407283310403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY335	8015569				2022-12-24	WOS:A1994NY33500003
J	JOHNSTON, JA; KAWAMURA, M; KIRKEN, RA; CHEN, YQ; BLAKE, TB; SHIBUYA, K; ORTALDO, JR; MCVICAR, DW; O'SHEA, JJ				JOHNSTON, JA; KAWAMURA, M; KIRKEN, RA; CHEN, YQ; BLAKE, TB; SHIBUYA, K; ORTALDO, JR; MCVICAR, DW; O'SHEA, JJ			PHOSPHORYLATION AND ACTIVATION OF THE JAK-3 JANUS KINASE IN RESPONSE TO INTERLEUKIN-2	NATURE			English	Article							PROTEIN-TYROSINE KINASE; GAMMA SIGNAL-TRANSDUCTION; RECEPTOR-BETA; INTERFERON-ALPHA/BETA; IL-2; SUBUNIT; CHAIN; PATHWAY	LUTERLEUKIN-2 is an autocrine growth factor for T cells(1,2) which also activates other cells including B cells(3) and natural killer cells(4). The subunits of the interleukin-2 receptor (IL-2R) lack intrinsic enzymatic activity, but protein tyrosine phosphorylation is a critical event following ligand binding and src family kinases, such as Lck, are known to be activated by IL-2 (refs 5-9). However, IL-2 signalling can occur in the absence of receptor interaction with Lck, suggesting that other protein tyrosine kinases might be important(10). Here we report that a new member of the Janus family of kinases (Jak-3) is coupled to the IL-2R in human peripheral blood T cells and natural killer cells.	NCI, FREDERICK CANC RES & DEV CTR, BIOL RESPONSE MODIFIERS PROGRAM, MOLEC IMMUNOREGULAT LAB, FREDERICK, MD 21702 USA; NCI, FREDERICK CANC RES & DEV CTR, PRI DYNCORP, BIOL CARCINOGENESIS & DEV PROGRAM, FREDERICK, MD 21702 USA; NCI, FREDERICK CANC RES & DEV CTR, ADV BIOSCI LABS INC, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	JOHNSTON, JA (corresponding author), NCI, FREDERICK CANC RES & DEV CTR, EXPTL IMMUNOL LAB, LEUKOCYTE CELL BIOL SECT, FREDERICK, MD 21702 USA.		McVicar, Daniel/G-1970-2015	McVicar, Daniel/0000-0002-1112-5111				ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; FARRAR WL, 1989, J BIOL CHEM, V264, P12562; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HENRY CS, 1981, NATURE, V291, P335; KAWAMURA M, IN PRESS P NATN ACAD; KIRKEN RA, 1993, J BIOL CHEM, V268, P22765; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LEONARD WJ, 1983, P NATL ACAD SCI-BIOL, V80, P6957, DOI 10.1073/pnas.80.22.6957; MERIDA I, 1990, J BIOL CHEM, V265, P5690; MILLS GB, 1990, J BIOL CHEM, V265, P3561; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; TANIGUCHI T, 1988, A REV IMMUN, V4, P69; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WALDMANN TA, 1984, J EXP MED, V160, P1450, DOI 10.1084/jem.160.5.1450; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	28	546	569	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 14	1994	370	6485					151	153		10.1038/370151a0	http://dx.doi.org/10.1038/370151a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW804	8022485	Green Submitted			2022-12-24	WOS:A1994NW80400060
J	COLLEDGE, WH; CARLTON, MBL; UDY, GB; EVANS, MJ				COLLEDGE, WH; CARLTON, MBL; UDY, GB; EVANS, MJ			DISRUPTION OF C-MOS CAUSES PARTHENOGENETIC DEVELOPMENT OF UNFERTILIZED MOUSE EGGS	NATURE			English	Article							PROTO-ONCOGENE PRODUCT; PROTOONCOGENE PRODUCT; MEIOTIC MATURATION; XENOPUS EGGS; KINASE; GENE; FERTILIZATION; EXPRESSION; ACTIVATION; OOCYTES	THE c-mos proto-oncogene encodes a 37-39K cytoplasmic serine/threonine kinase(1) implicated in the meiotic maturation events during murine spermatogenesis(2) and oogenesis(3-6). In Xenopus, ectopic expression of pp39(mos) can promote both the meiotic maturation of oocytes(7-9) and also arrest the cleavage of blastomeres(10) To elucidate the role of pp39(mos) we have generated homozygous mutant mice by gene targeting in embryonic stem cells(11). These mice are viable and mutant males are fertile, demonstrating that pp39(mos) is not essential for spermatogenesis. In contrast, mutant females, have a reduced fertility because of the failure of mature eggs to arrest during meiosis. c-mos(-1-) oocytes undergo germinal vesicle breakdown and extrusion of both polar bodies followed in some cases by progression into cleavage. Mutant females also develop ovarian cysts. These results demonstrate that a major role for pp39(mos) is to prevent the spontaneous parthenogenetic activation of unfertilized eggs.	UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 1QR,CAMBS,ENGLAND; RUAKURA AGR CTR,HAMILTON,NEW ZEALAND	University of Cambridge; AgResearch - New Zealand	COLLEDGE, WH (corresponding author), UNIV CAMBRIDGE,WELLCOME CRC INST CANC & DEV BIOL,TENNIS COURT RD,CAMBRIDGE CB2 1QR,CAMBS,ENGLAND.		Colledge, William/X-4976-2019	Colledge, William/0000-0002-9603-4429	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; Bradley A, 1991, Curr Opin Biotechnol, V2, P823, DOI 10.1016/S0958-1669(05)80114-4; EPPIG JJ, 1993, METHOD ENZYMOL, V225, P77; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hogan B., 1986, MANIPULATING MOUSE E; KAUFMAN MH, 1986, GAMETE RES, V14, P255, DOI 10.1002/mrd.1120140309; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MUTTER GL, 1988, EMBO J, V7, P683, DOI 10.1002/j.1460-2075.1988.tb02863.x; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PROPST F, 1988, ONCOGENE, V2, P227; RATCLIFF R, 1993, NAT GENET, V4, P35, DOI 10.1038/ng0593-35; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; Talerman A, 1992, Curr Top Pathol, V85, P165; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WATANABE N, 1991, NATURE, V352, P247, DOI 10.1038/352247a0; WEBER M, 1991, DEV BIOL, V148, P393, DOI 10.1016/0012-1606(91)90347-6; WOOD TG, 1984, P NATL ACAD SCI-BIOL, V81, P7817, DOI 10.1073/pnas.81.24.7817; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZHAO X, 1990, ONCOGENE, V5, P1727	23	403	418	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 7	1994	370	6484					65	68		10.1038/370065a0	http://dx.doi.org/10.1038/370065a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV711	8015609				2022-12-24	WOS:A1994NV71100060
J	PHILLIPS, GD; HARRISON, NK; CUMMIN, ARC; WARD, J; SHENOY, VS; NEWEY, V; RITCHIE, D; WILLIAMS, IP; MILLARD, FJC				PHILLIPS, GD; HARRISON, NK; CUMMIN, ARC; WARD, J; SHENOY, VS; NEWEY, V; RITCHIE, D; WILLIAMS, IP; MILLARD, FJC			NEW METHOD FOR MEASURING COMPLIANCE WITH LONG-TERM OXYGEN TREATMENT	BRITISH MEDICAL JOURNAL			English	Article									UNIV LONDON ST GEORGES HOSP,DEPT MED PHYS,LONDON SW17 0QT,ENGLAND; ST ALBANS HOSP,DEPT CHEST MED,ST ALBANS AL3 5PN,HERTS,ENGLAND	St Georges University London	PHILLIPS, GD (corresponding author), UNIV LONDON ST GEORGES HOSP,CHEST CLIN,LONDON SW17 0QT,ENGLAND.							[Anonymous], 1981, LANCET, V1, P681; Nocturnal Oxygen Therapy Trial Group, 1980, ANN INTERN MED, V93, P391; Williams B, 1991, Health Trends, V23, P166; 1986, DHSS FPN398 DEP HLTH	4	6	6	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 11	1994	308	6943					1544	1545		10.1136/bmj.308.6943.1544	http://dx.doi.org/10.1136/bmj.308.6943.1544			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR110	8019312	Green Published			2022-12-24	WOS:A1994NR11000025
J	MAKELA, TP; TASSAN, JP; NIGG, EA; FRUTIGER, S; HUGHES, GJ; WEINBERG, RA				MAKELA, TP; TASSAN, JP; NIGG, EA; FRUTIGER, S; HUGHES, GJ; WEINBERG, RA			A CYCLIN ASSOCIATED WITH THE CDK-ACTIVATING KINASE MO15	NATURE			English	Article							PROTEIN-KINASE; CATALYTIC SUBUNIT; CELL-CYCLE; PHOSPHORYLATION; P34CDC2; CDC2; P40(MO15); P34(CDC2); INVITRO; YEAST	THE eukaryotic cell cycle is regulated by the sequential activation of cyclin-dependent kinases (CDKs)(1). CDK activation is dependent on cyclin binding(2-4) and phosphorylation of a conserved threonine (T161 in Cdc2)(5-9) mediated by the CDK-activating kinase CAK(9). A CDK-related kinase, MO15 (ref. 10), has been identified as the catalytic submit of CAK (refs 11-13). Here we use a yeast two-hybrid screen to show that a new human cyclin (cyclin H) is a MO15-associated protein. Cyclin H is a major MO15 partner in vivo and enhances the kinase activity of MO15 towards Cdk2/cyclin A. These findings demonstrate that a cyclin/kinase complex can function as a regulator of other cyclin/kinase complexes, and suggest that cyclin/kinase cascades may exist.	WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; SWISS INST EXPTL CANC RES,CH-1066 EPALINGES,SWITZERLAND; UNIV GENEVA,CTR MED UNIV,DEPT BIOCHIM MED,CH-1211 GENEVA 4,SWITZERLAND	Massachusetts Institute of Technology (MIT); Whitehead Institute; Swiss Institute Experimental Cancer Research; University of Geneva			makela, tomi/B-3734-2009	makela, tomi/0000-0002-4869-8044; nigg, erich/0000-0003-4835-5719				CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARLOW E, 1988, ANTIBODIES LABORATOR; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; LEVEDAKOU EN, 1994, ONCOGENE, V9, P1977; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MOLZ L, 1993, EMBO J, V12, P1723, DOI 10.1002/j.1460-2075.1993.tb05817.x; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; ORTIZ ML, 1992, FEBS LETT, V296, P300, DOI 10.1016/0014-5793(92)80309-5; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHUTTLEWORTH J, 1990, EMBO J, V9, P3233, DOI 10.1002/j.1460-2075.1990.tb07522.x; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; TASSAN JP, IN PRESS J CELL BIOL; VALAY JG, 1993, J MOL BIOL, V234, P307, DOI 10.1006/jmbi.1993.1587	26	242	246	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 15	1994	371	6494					254	257		10.1038/371254a0	http://dx.doi.org/10.1038/371254a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG290	8078587				2022-12-24	WOS:A1994PG29000055
J	IZAURRALDE, E; LEWIS, J; MCGUIGAN, C; JANKOWSKA, M; DARZYNKIEWICZ, E; MATTAJ, IW				IZAURRALDE, E; LEWIS, J; MCGUIGAN, C; JANKOWSKA, M; DARZYNKIEWICZ, E; MATTAJ, IW			A NUCLEAR CAP-BINDING PROTEIN COMPLEX INVOLVED IN PRE-MESSENGER-RNA SPLICING	CELL			English	Article							EUKARYOTIC MESSENGER-RNA; INITIATION FACTOR-4E; POLYMERASE-II; HELA-CELLS; EXPORT; ANALOGS; IDENTIFICATION; PURIFICATION; TRANSLATION; INVITRO	A cap-binding protein complex (CBC) present in the nuclei of HeLa cells has been characterized. Purified CBC consists of two previously identified proteins, CBP80 and CBP20. These proteins are shown to cofractionate to apparent homogeneity and to be coimmunoprecipitable with anti-CBP80 antibodies, Analysis of the inhibition of pre-mRNA splicing in vitro and in vivo by chemically modified analogs of the cap structure, and of the binding of these analogs to CBC in vitro, suggests a role for the complex in splicing. Extracts immunodepleted of CBC do not efficiently splice an adenoviral pre-mRNA owing to blockage of an early step in splicing complex formation. CBC may therefore play a role in pre-mRNA recognition.	UNIV WARSAW,DEPT CHEM,PL-02093 WARSAW,POLAND; UNIV WARSAW,DEPT BIOPHYS,PL-02089 WARSAW,POLAND	University of Warsaw; University of Warsaw	IZAURRALDE, E (corresponding author), EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,D-69117 HEIDELBERG,GERMANY.		Izaurralde, Elisa/G-3239-2012	Mattaj, Iain/0000-0002-5537-8284; Izaurralde, Elisa/0000-0001-7365-2649				ABOVICH N, 1994, IN PRESS GENES DEV, V8; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; CARBERRY SE, 1990, BIOCHEMISTRY-US, V29, P3337, DOI 10.1021/bi00465a027; DARGEMONT C, 1992, J CELL BIOL, V118, P1, DOI 10.1083/jcb.118.1.1; DARZYNKIEWICZ E, 1988, NUCLEIC ACIDS RES, V16, P8953, DOI 10.1093/nar/16.18.8953; DARZYNKIEWICZ E, 1985, BIOCHEMISTRY-US, V24, P1701, DOI 10.1021/bi00328a020; DARZYNKIEWICZ E, 1989, BIOCHEMISTRY-US, V28, P4771, DOI 10.1021/bi00437a038; DARZYNKIEWICZ E, 1990, NUCLEOS NUCLEOT, V9, P599, DOI 10.1080/07328319008045191; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; ECKNER R, 1991, EMBO J, V10, P3513, DOI 10.1002/j.1460-2075.1991.tb04915.x; EDERY I, 1985, P NATL ACAD SCI USA, V82, P7590, DOI 10.1073/pnas.82.22.7590; EPERON IC, 1993, EMBO J, V12, P3607, DOI 10.1002/j.1460-2075.1993.tb06034.x; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FILIPOWICZ W, 1978, FEBS LETT, V96, P1, DOI 10.1016/0014-5793(78)81049-7; Frohman MA, 1990, PCR PROTOCOLS GUIDE; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; FURUICHI Y, 1977, NATURE, V266, P235, DOI 10.1038/266235a0; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HAMM J, 1989, CELL, V59, P159, DOI 10.1016/0092-8674(89)90878-7; HARLOW E, 1988, ANTIBODIES LABORATOR; HODGES PE, 1994, CURR BIOL, V4, P264, DOI 10.1016/S0960-9822(00)00061-0; INOUE K, 1989, GENE DEV, V3, P1472, DOI 10.1101/gad.3.9.1472; IZAURRALDE E, 1992, J CELL BIOL, V118, P1287, DOI 10.1083/jcb.118.6.1287; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMOND AI, 1987, GENE DEV, V1, P532, DOI 10.1101/gad.1.6.532; LANG V, 1994, J BIOL CHEM, V269, P6117; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; MICHAUD S, 1993, GENE DEV, V7, P1008, DOI 10.1101/gad.7.6.1008; MURTHY KGK, 1991, NUCLEIC ACIDS RES, V19, P2685, DOI 10.1093/nar/19.10.2685; OHNO M, 1987, P NATL ACAD SCI USA, V84, P5187, DOI 10.1073/pnas.84.15.5187; OHNO M, 1990, NUCLEIC ACIDS RES, V18, P6989, DOI 10.1093/nar/18.23.6989; PATZELT E, 1987, NUCLEIC ACIDS RES, V15, P1387, DOI 10.1093/nar/15.4.1387; PATZELT E, 1983, NUCLEIC ACIDS RES, V11, P5821, DOI 10.1093/nar/11.17.5821; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; ROZEN F, 1987, NUCLEIC ACIDS RES, V15, P6489, DOI 10.1093/nar/15.16.6489; SALDITTGEORGIEFF M, 1980, CELL, V19, P69, DOI 10.1016/0092-8674(80)90389-X; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SHATKIN AJ, 1985, CELL, V40, P223, DOI 10.1016/0092-8674(85)90132-1; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SHIMOTOHNO K, 1977, P NATL ACAD SCI USA, V74, P2734, DOI 10.1073/pnas.74.7.2734; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONENBERG N, 1981, NUCLEIC ACIDS RES, V9, P1643, DOI 10.1093/nar/9.7.1643; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P174; TANI T, 1989, NATURE, V337, P87, DOI 10.1038/337087a0; TERNS MP, 1993, GENE DEV, V7, P1898, DOI 10.1101/gad.7.10.1898; UEMURA H, 1992, J BACTERIOL, V174, P5526, DOI 10.1128/JB.174.17.5526-5532.1992; WEBB NR, 1984, BIOCHEMISTRY-US, V23, P177, DOI 10.1021/bi00297a001; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243	65	427	437	1	28	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 26	1994	78	4					657	668		10.1016/0092-8674(94)90530-4	http://dx.doi.org/10.1016/0092-8674(94)90530-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	8069914				2022-12-24	WOS:A1994PD69300014
J	COUCKE, P; VANCAMP, G; DJOYODIHARJO, B; SMITH, SD; FRANTS, RR; PADBERG, GW; DARBY, JK; HUIZING, EH; CREMERS, CWRJ; KIMBERLING, WJ; OOSTRA, BA; VANDEHEYNING, PH; WILLEMS, PJ				COUCKE, P; VANCAMP, G; DJOYODIHARJO, B; SMITH, SD; FRANTS, RR; PADBERG, GW; DARBY, JK; HUIZING, EH; CREMERS, CWRJ; KIMBERLING, WJ; OOSTRA, BA; VANDEHEYNING, PH; WILLEMS, PJ			LINKAGE OF AUTOSOMAL-DOMINANT HEARING-LOSS TO THE SHORT ARM OF CHROMOSOME-1 IN 2 FAMILIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SYNDROME TYPE-I; WAARDENBURG SYNDROME; MOLECULAR-CLONING; COLLAGEN GENE; HUMAN GENOME; DEAFNESS; IMPAIRMENT; LOCALIZATION; ALPHA-1(XVI); MUTATIONS	Background. At least half of the cases of profound deafness of early onset are caused by genetic factors, but few of the genetic defects have been identified. This is particularly true of the most common hereditary forms of deafness, which occur in the absence of any associated syndrome. Methods. We studied a large Indonesian family in which hearing loss was inherited in an autosomal dominant pattern. The hearing loss first affects the high frequencies during the teens or 20s and becomes profound within 10 years. To locate the responsible gene, we performed genetic-linkage analysis, using microsatellite markers distributed over the entire genome. We then performed linkage analyses in an American family and a Dutch family with similar patterns of hereditary hearing loss. Results. In the extended Indonesian family, a gene linked to deafness mapped to chromosome Ip, with a multipoint rod score of more than 7. In the American family, deafness was linked to the same locus on chromosome 1p, with a multipoint rod score of more than 5. In the Dutch family, however, this locus was ruled out. The flanking markers D1S255 and D1S211 defined a region of 6 cM on chromosome 1p that is likely to contain the gene associated with deafness in the first two families. Conclusions. In some families with early-onset autosomal dominant hearing loss, the responsible gene is on chromosome 1p.	UNIV ANTWERP, DEPT MED GENET, B-2610 ANTWERP, BELGIUM; UNIV ANTWERP, DEPT OTORHINOLARYNGOL, B-2020 ANTWERP, BELGIUM; PADJADJARAN STATE UNIV, SCH MED, DEPT EAR NOSE & THROAT, BANDUNG, INDONESIA; BOYS TOWN NATL RES HOSP, CTR HEREDITARY COMMUN DISORDERS, BOYS TOWN, NE USA; LEIDEN UNIV, CTR GENET MED, DEPT HUMAN GENET, LEIDEN, NETHERLANDS; ACAD HOSP NIJMEGEN, DEPT NEUROL, NIJMEGEN, NETHERLANDS; ACAD HOSP NIJMEGEN, DEPT EAR NOSE & THROAT, NIJMEGEN, NETHERLANDS; ACAD HOSP UTRECHT, DEPT EAR NOSE & THROAT, UTRECHT, NETHERLANDS; ERASMUS UNIV ROTTERDAM, DEPT CLIN GENET, 3000 DR ROTTERDAM, NETHERLANDS	University of Antwerp; University of Antwerp; Universitas Padjadjaran; Boys Town National Research Hospital; Leiden University; Leiden University - Excl LUMC; Radboud University Nijmegen; Radboud University Nijmegen; Utrecht University; Utrecht University Medical Center; Erasmus University Rotterdam			Van Camp, Guy/F-3386-2013; Cremers, C.W.R.J./L-4254-2015; Padberg, G.W.A.M./H-8079-2014	Van Camp, Guy/0000-0001-5105-9000; 	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [P60DC000982] Funding Source: NIH RePORTER; NIDCD NIH HHS [P60-DC-00982] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BACH I, 1992, AM J HUM GENET, V51, P38; BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; CUTICCHIA AJ, 1993, NUCLEIC ACIDS RES, V21, P3003, DOI 10.1093/nar/21.13.3003; FREIMER NB, 1993, AM J HUM GENET, V52, P1102; GUILFORD P, 1994, NAT GENET, V6, P24, DOI 10.1038/ng0194-24; HAGEMAN MJ, 1977, AM J HUM GENET, V29, P468; HUGHES AE, 1993, GENOMICS, V15, P433, DOI 10.1006/geno.1993.1083; Huizing E H, 1966, Acta Otolaryngol, V61, P161, DOI 10.3109/00016486609127053; Huizing E H, 1966, Acta Otolaryngol, V61, P35, DOI 10.3109/00016486609127040; HUIZING EH, 1983, ACTA OTO-LARYNGOL, V95, P620, DOI 10.3109/00016488309139453; HULL R, 1978, HDB CLIN AUDIOLOGY, P426; KAPLAN J, 1992, GENOMICS, V14, P979, DOI 10.1016/S0888-7543(05)80120-X; KIMBERLING WJ, 1992, GENOMICS, V14, P988, DOI 10.1016/S0888-7543(05)80121-1; KIMBERLING WJ, 1990, GENOMICS, V7, P245, DOI 10.1016/0888-7543(90)90546-7; KNOWLES JA, 1992, AM J HUM GENET, V51, P905; LATHROP GM, 1984, AM J HUM GENET, V36, P460; LEON PE, 1981, AM J HUM GENET, V33, P209; LEON PE, 1992, P NATL ACAD SCI USA, V89, P5181, DOI 10.1073/pnas.89.11.5181; LEWIS RA, 1990, GENOMICS, V7, P250, DOI 10.1016/0888-7543(90)90547-8; MARAZITA ML, 1993, AM J MED GENET, V46, P486, DOI 10.1002/ajmg.1320460504; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MORTON NE, 1991, ANN NY ACAD SCI, V630, P16, DOI 10.1111/j.1749-6632.1991.tb19572.x; MURAGAKI Y, 1991, J BIOL CHEM, V266, P7721; OTT J, 1992, AM J HUM GENET, V51, P283; PAN TC, 1992, P NATL ACAD SCI USA, V89, P6565, DOI 10.1073/pnas.89.14.6565; PERALA M, 1993, FEBS LETT, V319, P177, DOI 10.1016/0014-5793(93)80062-Y; PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289; REARDON W, 1992, J MED GENET, V29, P521, DOI 10.1136/jmg.29.8.521; ROBINSON D, 1992, HUM GENET, V90, P316; SMITH RJH, 1992, GENOMICS, V14, P995, DOI 10.1016/S0888-7543(05)80122-3; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; VANDENWIJNGAART WSIM, 1985, AUDIOLOGY, V24, P336; VANDENWIJNGAART WSIM, 1985, AUDIOLOGY, V24, P233; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; YAMAGUCHI N, 1992, J BIOCHEM-TOKYO, V112, P856, DOI 10.1093/oxfordjournals.jbchem.a123989	35	106	108	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 18	1994	331	7					425	431		10.1056/NEJM199408183310702	http://dx.doi.org/10.1056/NEJM199408183310702			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB501	8035838	Bronze, Green Published			2022-12-24	WOS:A1994PB50100002
J	MUHLRAD, D; PARKER, R				MUHLRAD, D; PARKER, R			PREMATURE TRANSLATIONAL TERMINATION TRIGGERS MESSENGER-RNA DECAPPING	NATURE			English	Article							MESSENGER-RNA DECAY; NONSENSE MUTATIONS; ENDONUCLEOLYTIC CLEAVAGE; SACCHAROMYCES-CEREVISIAE; RICH SEQUENCES; DEGRADATION; POLY(A); YEAST; DEADENYLATION; STEP	THE degradation of messenger RNA in eukaryotic cells is initiated by endonucleolytic cleavage(1,2) or by shortening of the poly(A) tail(3-6), which for some mRNAs activates a deadenylation-dependent decapping reaction(7). One type of rapid mRNA degradation in eukaryotes is caused by premature termination of translation(8,9). This turnover process prevents the translation of aberrant mRNAs(10,11), may affect the abundance and splicing pattern of nuclear transcripts(12,13), and may be involved in the aetiology of human genetic disease(14). Here we show that premature translational termination in yeast triggers decapping, independent of deadenylation, thereby exposing the transcript to 5'-to-3' degradation. Inactivation of the 5'-to-3' exonuclease reveals an additional 3'-to-5' pathway of mRNA turnover. These observations provide in vivo evidence for two new mechanisms of mRNA decay.			MUHLRAD, D (corresponding author), UNIV ARIZONA,DEPT MOLEC & CELLULAR BIOL,LIFE SCI S,TUCSON,AZ 85721, USA.							BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; BROWN BD, 1993, GENE DEV, V7, P1620, DOI 10.1101/gad.7.8.1620; CAPONIGRO G, 1993, MOL CELL BIOL, V13, P5141, DOI 10.1128/MCB.13.9.5141; CHENG J, 1993, MOL CELL BIOL, V13, P1892, DOI 10.1128/MCB.13.3.1892; CHRISTENSEN AK, 1987, AM J ANAT, V178, P1, DOI 10.1002/aja.1001780102; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; HE F, 1993, P NATL ACAD SCI USA, V90, P7034, DOI 10.1073/pnas.90.15.7034; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; LOSSON R, 1979, P NATL ACAD SCI USA, V76, P5134, DOI 10.1073/pnas.76.10.5134; MAQUAT LE, 1981, CELL, V27, P543, DOI 10.1016/0092-8674(81)90396-2; MUHLRAD D, 1992, GENE DEV, V6, P2100, DOI 10.1101/gad.6.11.2100; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MUNROE D, 1990, GENE, V91, P151, DOI 10.1016/0378-1119(90)90082-3; NAEGER LK, 1992, GENE DEV, V6, P1107, DOI 10.1101/gad.6.6.1107; PELTZ SW, 1993, GENE DEV, V7, P1737, DOI 10.1101/gad.7.9.1737; PULAK R, 1993, GENE DEV, V7, P1885, DOI 10.1101/gad.7.10.1885; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; STEVENS A, 1987, ARCH BIOCHEM BIOPHYS, V252, P339, DOI 10.1016/0003-9861(87)90040-3; STOECKLE MY, 1992, NUCLEIC ACIDS RES, V20, P1123, DOI 10.1093/nar/20.5.1123; VREKEN P, 1992, MOL CELL BIOL, V12, P2986, DOI 10.1128/MCB.12.7.2986; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; YANG H, 1992, MOL CELL BIOL, V12, P1553, DOI 10.1128/MCB.12.4.1553	23	330	334	1	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 18	1994	370	6490					578	581		10.1038/370578a0	http://dx.doi.org/10.1038/370578a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC537	8052314				2022-12-24	WOS:A1994PC53700061
J	PENTON, A; CHEN, YJ; STAEHLINGHAMPTON, K; WRANA, JL; ATTISANO, L; SZIDONYA, J; CASSILL, JA; MASSAGUE, J; HOFFMANN, FM				PENTON, A; CHEN, YJ; STAEHLINGHAMPTON, K; WRANA, JL; ATTISANO, L; SZIDONYA, J; CASSILL, JA; MASSAGUE, J; HOFFMANN, FM			IDENTIFICATION OF 2 BONE MORPHOGENETIC PROTEIN TYPE-I RECEPTORS IN DROSOPHILA AND EVIDENCE THAT BRK25D IS A DECAPENTAPLEGIC RECEPTOR	CELL			English	Article							GROWTH-FACTOR-BETA; BIOCHEMICAL-CHARACTERIZATION; CYTOGENETIC ANALYSIS; GENE; MELANOGASTER; PATTERN; EMBRYO; MEMBER; FAMILY; SUPERFAMILY	Drosophila sequences at chromosomal positions 25D (Brk25D) and 43E (Brk43E) are similar to the TGF beta type I receptor serine/threonine kinases and are expressed broadly during embryogenesis. Brk25D binds dpp protein and bone morphogenetic protein 2 with high affinity. Mutations affecting Brk25D map to the gene thick veins and block the expression of two decapentaplegic-responsive (dpp-responsive) genes, dpp and labial, in the embryonic midgut. Defects in Brk25D receptor function combined with reduced expression of dpp ligand produce mutant phenotypes in the embryo and adult. Brk43E is the product of the gene saxophone, which also interacts with dpp. We conclude that dpp signaling in vivo is mediated by at least two receptors, Brk25D and Brk43E.	UNIV WISCONSIN, SCH MED, GENET LAB, MADISON, WI 53706 USA; MEM SLOAN KETTERING CANC CTR, HOWARD HUGHES MED INST, CELL BIOL & GENET PROGRAM, NEW YORK, NY 10021 USA; UNIV HORT & FOOD IND, DEPT GENET & PLANT BREEDING, H-1518 BUDAPEST, HUNGARY; UNIV TEXAS, DIV LIFE SCI, SAN ANTONIO, TX 78249 USA	University of Wisconsin System; University of Wisconsin Madison; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Corvinus University Budapest; University of Texas System	PENTON, A (corresponding author), UNIV WISCONSIN, SCH MED, MCARDLE LAB CANC RES, MADISON, WI 53706 USA.		Wrana, Jeffrey/F-8857-2013; Cassill, Aaron/F-5467-2010	Massague, Joan/0000-0001-9324-8408; Hoffmann, F. Michael/0000-0002-2770-9656	NCI NIH HHS [CA09135, CA07175] Funding Source: Medline; NCRR NIH HHS [RR06610] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009135, P30CA007175] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR006610] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ASHBURNER M, 1989, DROSOPHILA LABORATOR; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BIENZ M, 1994, TRENDS GENET, V10, P22, DOI 10.1016/0168-9525(94)90015-9; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; BRYANT PJ, 1988, DEV BIOL, V128, P386, DOI 10.1016/0012-1606(88)90300-4; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; CHILDS SR, 1993, P NATL ACAD SCI USA, V90, P9475, DOI 10.1073/pnas.90.20.9475; DOCTOR JS, 1992, DEV BIOL, V151, P491, DOI 10.1016/0012-1606(92)90188-M; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FROLIK CA, 1984, J BIOL CHEM, V259, P995; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEITZLER P, 1993, GENETICS, V135, P105; HURSH DA, 1993, DEVELOPMENT, V117, P1211; IRISH VF, 1987, GENE DEV, V1, P868, DOI 10.1101/gad.1.8.868; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; KOENIG BB, 1994, IN PRESS MOL CELL BI; Lawrence P.A., 1986, P229; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MASUCCI JD, 1993, DEV BIOL, V159, P276, DOI 10.1006/dbio.1993.1240; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PANGANIBAN GEF, 1990, MOL CELL BIOL, V10, P2669, DOI 10.1128/MCB.10.6.2669; ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90063-A; Sambrook J., 1989, MOL CLONING LAB MANU; SAMPATH TK, 1993, P NATL ACAD SCI USA, V90, P6004, DOI 10.1073/pnas.90.13.6004; SEGAL D, 1985, GENETICS, V109, P119; STAEHLINGHAMPTO.K, 1994, IN PRESS DEV BIOL; STAEHLINGHAMPTO.K, 1994, IN PRESS CELL GROWTH; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; SZIDONYA J, 1988, GENET RES, V51, P197, DOI 10.1017/S0016672300024290; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; TERRACOL R, 1994, IN PRESS GENETICS; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WHARTON KA, 1991, P NATL ACAD SCI USA, V88, P9214, DOI 10.1073/pnas.88.20.9214; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837	47	235	245	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 29	1994	78	2					239	250		10.1016/0092-8674(94)90294-1	http://dx.doi.org/10.1016/0092-8674(94)90294-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	8044838				2022-12-24	WOS:A1994NZ24200008
J	VALIMAKI, MJ; KARKKAINEN, M; LAMBERG-ALLARDT, C; LAITINEN, K; ALHAVA, E; HEIKKINEN, J; IMPIVAARA, O; MAKELA, P; PALMGREN, J; SEPPANEN, R; VUORI, I; AKERBLOM, HK; UHARI, M; VIIKARI, J; DAHL, M; PESONEN, E; PIETIKAINEN, M; SALO, M; AROMAA, A; KANNAS, L; KELTIKANGASJARVINEN, L; KUUSELA, V; PYORALA, K; RONNEMAA, T; RASANEN, L; SAMA, S; SEPPANEN, A; TELAMA, R				VALIMAKI, MJ; KARKKAINEN, M; LAMBERG-ALLARDT, C; LAITINEN, K; ALHAVA, E; HEIKKINEN, J; IMPIVAARA, O; MAKELA, P; PALMGREN, J; SEPPANEN, R; VUORI, I; AKERBLOM, HK; UHARI, M; VIIKARI, J; DAHL, M; PESONEN, E; PIETIKAINEN, M; SALO, M; AROMAA, A; KANNAS, L; KELTIKANGASJARVINEN, L; KUUSELA, V; PYORALA, K; RONNEMAA, T; RASANEN, L; SAMA, S; SEPPANEN, A; TELAMA, R			EXERCISE, SMOKING, AND CALCIUM INTAKE DURING ADOLESCENCE AND EARLY ADULTHOOD AS DETERMINANTS OF PEAK BONE MASS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MINERAL DENSITY; WOMEN; CHILDREN; DENSITOMETRY; BALANCE; FEMALES	Objective-To evaluate the contribution to peak bone mass of exercise, smoking, and calcium intake in adolescents and young adults. Design-Prospective cohort study with end point measurement (bane mineral density) after 11 years' follow up for lifestyle. Setting-Five university hospital clinics. Subjects-264 (153 females, 111 males) subjects aged 9 to 18 years at the beginning of the follow up and 20 to 29 years at the time of measurement of bone mineral density. Main outcome measure-Bone mineral density of lumbar spine and femoral neck by dual energy x ray absorptiometry; measures of physical activity and smoking and estimates of calcium intake repeated three times during follow up. Results-In the groups with the lowest and highest levels of exercise the femoral bone mineral densities (adjusted for age and weight) were 0.918 and 0.988 g/cm(2) for women (P = 0.015, analysis of covariance) and 0.943 and 1.042 g/cm(2) for men (P = 0.005), respectively; at the lumbar spine the respective values were 1.045 and 1.131 (P = 0.005) for men. In men the femoral bone mineral densities (adjusted for age, weight, and exercise) were 1.022 and 0.923 g/cm(2) for the groups with the lowest and highest values of smoking index (P = 0.054, analysis of covariance). In women the adjusted femoral. bone mineral density increased by 4.7% together with increasing calcium intake (P = 0.089, analysis of covariance). In multiple regression analysis on bone mineral density of the femoral neck, weight, exercise, age, and smoking were independent predictors for men; with weight, exercise, and age for women. These predictors together explained 38% of the variance in bone mineral density in women and 46% in men. At the lumbar spine, weight, smoking, and exercise were predictors for men; and only weight for women. Conclusions-Regular exercise and not smoking is important in achieving maximal peak bone mass in adolescents and young adults.	MINERVA FDN, INST MED RES, HELSINKI, FINLAND; UNIV HELSINKI, ALCOHOL DIS RES UNIT, HELSINKI, FINLAND; UNIV KUOPIO, CENT HOSP, DEPT SURG, KUOPIO, FINLAND; DEACONESS INST OULU, OSTEOPOROSIS CLIN, OULU, FINLAND; SOCIAL INSURANCE INST, RES & DEV UNIT, TURKU, FINLAND; UNIV HELSINKI, DEPT OBSTET & GYNAECOL, HELSINKI, FINLAND; NATL PUBL HLTH INST, HELSINKI, FINLAND; UKK INST HLTH PROMOT RES, TAMPERE, FINLAND; UNIV HELSINKI, CHILDRENS HOSP, DEPT PAEDIAT 2, HELSINKI, FINLAND; UNIV OULU, DEPT PAEDIAT, OULU, FINLAND; UNIV TURKU, DEPT MED, TURKU, FINLAND; UNIV TURKU, DEPT PAEDIAT, TURKU, FINLAND; UNIV HELSINKI, DEPT PAEDIAT 1, HELSINKI, FINLAND; UNIV KUOPIO, DEPT PAEDIAT, SF-70211 KUOPIO, FINLAND; TAMPERE UNIV, DEPT PAEDIAT, SF-33101 TAMPERE, FINLAND; SOCIAL INSURANCE INST, HELSINKI, FINLAND; UNIV HELSINKI, DEPT PSYCHOL, SF-00100 HELSINKI, FINLAND; STAT CENT BUR, HELSINKI, FINLAND; UNIV KUOPIO, DEPT MED, SF-70210 KUOPIO, FINLAND; UNIV HELSINKI, DEPT APPL CHEM & MICROBIOL, DIV NUTR, HELSINKI, FINLAND; UNIV HELSINKI, DEPT PUBL HLTH, HELSINKI, FINLAND; SOCIAL INSURANCE INST, REHABIL RES CTR, SF-20720 TURKU, FINLAND; UNIV JYVASKYLA, DEPT EDUC PHYS, SF-40100 JYVASKYLA, FINLAND	University of Helsinki; Kuopio University Hospital; University of Eastern Finland; University of Helsinki; Finland National Institute for Health & Welfare; UKK Institute; University of Helsinki; University of Oulu; University of Turku; University of Turku; University of Helsinki; University of Eastern Finland; Tampere University; University of Helsinki; University of Eastern Finland; University of Helsinki; University of Helsinki; University of Jyvaskyla	VALIMAKI, MJ (corresponding author), UNIV HELSINKI, CENT HOSP, DEPT MED 3, SF-00290 HELSINKI, FINLAND.			Palmgren, Juni/0000-0002-9031-8615; Lamberg-Allardt, Christel/0000-0001-7326-1904				ANGUS RM, 1988, BONE MINER, V4, P265; AVIOLI LV, 1991, CALCIFIED TISSUE INT, V48, P221, DOI 10.1007/BF02556371; BONJOUR JP, 1991, J CLIN ENDOCR METAB, V73, P555, DOI 10.1210/jcem-73-3-555; BYCKLING T, 1985, ACTA PAEDIATR SCAND, P195; CAULEY JA, 1988, JAMA-J AM MED ASSOC, V260, P3150, DOI 10.1001/jama.260.21.3150; GILSANZ V, 1988, CALCIFIED TISSUE INT, V43, P260, DOI 10.1007/BF02555144; HEANEY RP, 1990, J NUTR, V120, P869, DOI 10.1093/jn/120.8.869; Hui S L, 1990, Osteoporos Int, V1, P30, DOI 10.1007/BF01880413; JOHNSTON CC, 1992, NEW ENGL J MED, V327, P82, DOI 10.1056/NEJM199207093270204; KROGER H, 1992, BONE MINER, V17, P75, DOI 10.1016/0169-6009(92)90712-M; MATKOVIC V, 1990, AM J CLIN NUTR, V52, P878, DOI 10.1093/ajcn/52.5.878; MATKOVIC V, 1992, AM J CLIN NUTR, V55, P992, DOI 10.1093/ajcn/55.5.992; PARFITT AM, 1988, OSTEOPOROSIS ETIOLOG; PICARD D, 1988, BONE MINER, V4, P299; RASANEN L, 1991, ANN MED, V23, P73, DOI 10.3109/07853899109147934; RECKER RR, 1992, JAMA-J AM MED ASSOC, V268, P2403, DOI 10.1001/jama.268.17.2403; SANDLER RB, 1985, AM J CLIN NUTR, V42, P270, DOI 10.1093/ajcn/42.2.270; SLEMENDA CW, 1991, J BONE MINER RES, V6, P1227; SLEMENDA CW, 1991, J BONE MINER RES, V6, P561; SOWERS MF, 1985, PREV MED, V14, P585, DOI 10.1016/0091-7435(85)90079-9; TELAMA R, 1985, ACTA PAEDIATR SCAND, P169; VAINIO P, 1992, NUCL MED COMMUN, V13, P252, DOI 10.1097/00006231-199204000-00156; 1989, RECOMMENDED DIETARY	23	229	234	3	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 23	1994	309	6949					230	235		10.1136/bmj.309.6949.230	http://dx.doi.org/10.1136/bmj.309.6949.230			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ180	8069139	Green Published			2022-12-24	WOS:A1994NZ18000015
J	EDDY, DM				EDDY, DM			A CONVERSATION WITH MY MOTHER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		EDDY DM, 1992, JAMA-J AM MED ASSOC, V267, P1669, DOI 10.1001/jama.267.12.1669; EDDY DM, 1992, JAMA-J AM MED ASSOC, V267, P1674; HUMPHRY D, 1991, FINAL EXIT	3	49	51	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 20	1994	272	3					179	181		10.1001/jama.272.3.179	http://dx.doi.org/10.1001/jama.272.3.179			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW185	8022025				2022-12-24	WOS:A1994NW18500001
J	AUVINEN, A; HAKAMA, M; ARVELA, H; HAKULINEN, T; RAHOLA, T; SUOMELA, M; SODERMAN, B; RYTOMAA, T				AUVINEN, A; HAKAMA, M; ARVELA, H; HAKULINEN, T; RAHOLA, T; SUOMELA, M; SODERMAN, B; RYTOMAA, T			FALLOUT FROM CHERNOBYL AND INCIDENCE OF CHILDHOOD LEUKEMIA IN FINLAND, 1976-92	BRITISH MEDICAL JOURNAL			English	Article							CANCER	Objective-To assess effects of fallout from Chernobyl on incidence of childhood leukaemia in Finland. Design-Nationwide cohort study. External exposure measured for 455 Finnish municipalities with instruments driven 19000 km throughout the country. Values specific to municipalities corrected for shielding due to houses and fallout from A bomb testing. Internal exposure estimated from whole body measurements on a random sample of 81 children. Mean effective dose for two years after incident calculated from these measurements. Data on childhood leukaemia obtained from Finnish cancer registry and verified through hospitals treating childhood cancers. Setting-Finland, one of the countries most heavily contaminated by the Chernobyl accident; the population was divided into fifths by exposure. Subjects-Children aged 0-14 years in 1976-92. Main outcome measures-Standardised incidence ratio of childhood leukaemia and relative excess risk of childhood leukaemia per mSv. From incidence data of Finnish cancer registry for 1976-85, expected numbers specific to sex and age group (0-4, 5-9, and 10-14 years) were calculated for each municipality for three periods (1976-85, 1986-8, and 1989-92) and pooled as exposure fifths. Dose response was estimated as regression slope of standardised incidence ratios on mean doses for fifths for each period. Results-Population weighted mean effective doses for first two years after the accident were 410 mu Sv for the whole country and 970 mu Sv for the population fifth with the highest dose. In all Finland the incidence of childhood leukaemia did not increase 1976-92. The relative excess risk 1989-92 was not significantly different from zero (7% per mSv; 95% confidence interval -27% to 41%). Conclusions-An important increase in childhood leukaemia can be excluded. Any effect is smaller than eight extra cases per million children per year in Finland. The results are consistent with the magnitude of effect expected.	FINNISH CTR RADIAT & NUCL SAFETY,SF-00101 HELSINKI,FINLAND; UNIV TAMPERE,DEPT PUBL HLTH,SF-33101 TAMPERE,FINLAND; KAROLINSKA INST,CANC EPIDEMIOL UNIT,S-10401 STOCKHOLM,SWEDEN	Radiation & Nuclear Safety Authority (STUK); Tampere University; Karolinska Institutet	AUVINEN, A (corresponding author), FINNISH CANC REGISTRY,LIISANKATU 21B,SF-00170 HELSINKI,FINLAND.		Auvinen, Anssi/AAD-9311-2020; Auvinen, Anssi/AAL-2111-2020	Auvinen, Anssi/0000-0003-1125-4818				[Anonymous], 1988, SOURCES EFFECTS RISK; ARVELA H, 1990, RADIAT PROT DOSIM, V32, P177, DOI 10.1093/oxfordjournals.rpd.a080734; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; Finck R., 1991, CHERNOBYL FALLOUT SW, P489; IVANOV EP, 1993, NATURE, V365, P702, DOI 10.1038/365702a0; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; MJONES L, 1986, SSI8622 SWED RAD PRO; PARKIN M, 1992, EUR J CANCER A, V29, P87; RAHOLA T, 1991, STUKA91 FINN CTR RAD; RAHOLA T, 1990, STUKA81 FINN CTR RAD; SAXEN E, 1978, FINNISH CANCER REGIS; SHIMIZU Y, 1990, RADIAT RES, V121, P120, DOI 10.2307/3577495; 1991, BUILDINGS DWELLINGS; 1990, EUR12551 COMM EUR CO; 1992, CANCER SOC FINLAND P, V51	15	51	51	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 16	1994	309	6948					151	154		10.1136/bmj.309.6948.151	http://dx.doi.org/10.1136/bmj.309.6948.151			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY229	8044092	Green Published			2022-12-24	WOS:A1994NY22900017
J	CHO, YJ; GORINA, S; JEFFREY, PD; PAVLETICH, NP				CHO, YJ; GORINA, S; JEFFREY, PD; PAVLETICH, NP			CRYSTAL-STRUCTURE OF A P53 TUMOR-SUPPRESSOR DNA COMPLEX - UNDERSTANDING TUMORIGENIC MUTATIONS	SCIENCE			English	Article							WILD-TYPE P53; CELL-CYCLE CHECKPOINT; MUTANT P53; GENE AMPLIFICATION; BINDING DOMAIN; PROTEIN; CONFORMATION; RESOLUTION; CANCER; RECOGNITION	Mutations in the p53 tumor suppressor are the most frequently observed genetic alterations in human cancer. The majority of the mutations occur in the core domain which contains the sequence-specific DNA binding activity of the p53 protein (residues 102-292), and they result in loss of DNA binding. The crystal structure of a complex containing the core domain of human p53 and a DNA binding site has been determined at 2.2 angstroms resolution and refined to a crystallographic R factor of 20.5 percent. The core domain structure consists of a beta sandwich that serves as a scaffold for two large loops and a loop-sheet-helix motif. The two loops, which are held together in part by a tetrahedrally coordinated zinc atom, and the loop-sheet-helix motif form the DNA binding surface of p53. Residues from the loop-sheet-helix motif interact in the major groove of the DNA, while an arginine from one of the two large loops interacts in the minor groove. The loops and the loop-sheet-helix motif consist of the conserved regions of the core domain and contain the majority of the p53 mutations identified in tumors. The structure supports the hypothesis that DNA binding is critical for the biological activity of p53, and provides a framework for understanding how mutations inactivate it.			CHO, YJ (corresponding author), MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,1275 YORK AVE,NEW YORK,NY 10021, USA.			Jeffrey, Philip/0000-0002-4351-5341	NCI NIH HHS [NCI CA08748-29] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BARTEK J, 1990, ONCOGENE, V5, P893; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1990, XPLOR V2 1 MANUAL; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAINAUT P, 1993, CANCER RES, V53, P1739; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARPER JW, 1993, CELL, V75, P805; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN M, IN PRESS NUCLEIC ACI; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MONDRAGON A, 1991, J MOL BIOL, V219, P321, DOI 10.1016/0022-2836(91)90568-Q; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1992, NATURE, V358, P83; ROULD MR, 1989, PROGRAM DSCALEAD; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SAENGER W, 1984, PRINCIPLES NUCLEIC A; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; 1979, COLLABORATIVE COMPUT	64	2119	2169	3	196	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 15	1994	265	5170					346	355		10.1126/science.8023157	http://dx.doi.org/10.1126/science.8023157			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023157				2022-12-24	WOS:A1994NW81600027
J	WEINER, BM; KLECKNER, N				WEINER, BM; KLECKNER, N			CHROMOSOME PAIRING VIA MULTIPLE INTERSTITIAL INTERACTIONS BEFORE AND DURING MEIOSIS IN YEAST	CELL			English	Article								Fluorescence in situ hybridization analysis reveals that homologous chromosomes are paired in yeast cells about to enter meiosis. Fairing involves multiple interstitial interactions, one per similar to 65 kb. These observations exclude several classes of models for somatic/premeiotic pairing. The number of t = 0 pairing interactions is about the same as the number of subsequent meiotic recombination events. As cells enter meiosis, pairing disappears concomitant with DNA replication and then reappears, independent of synaptonemal complex. Mutant phenotypes suggest that formation of an individual meiotic pairing connection does not require a meiosis-specific double-stranded break (DSB). Mutants defective in recombination before or after DSBs exhibit pairing defects. These and other observations can be united by a model in which premeiotic pairing and early meiotic pairing occur by closely related paranemic DNA-DNA interactions between intact duplexes, with early meiotic interactions subsequently converted directly to plectonemic recombination intermediates via DSBs.			WEINER, BM (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, 7 DIVIN AVE, CAMBRIDGE, MA 02138 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014729] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM14729, GM44794] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; ALBINI SM, 1987, CHROMOSOMA, V95, P324, DOI 10.1007/BF00293179; ASSAAD FF, 1993, PLANT MOL BIOL, V22, P1067, DOI 10.1007/BF00028978; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; CAMERINIOTERO RD, 1993, CELL, V73, P217, DOI 10.1016/0092-8674(93)90224-E; CAMPBELL AM, 1993, GENE, V135, P147, DOI 10.1016/0378-1119(93)90059-C; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARPENTER ATC, 1987, BIOESSAYS, V6, P232, DOI 10.1002/bies.950060510; Carpenter ATC, 1988, GENETIC RECOMBINATIO, P529, DOI [10.1038/ng1287, DOI 10.1038/NG1287]; CHANDLEY AC, 1986, HUM GENET, V72, P50, DOI 10.1007/BF00278817; CHAUHAN KPS, 1968, CHROMOSOMA, V25, P297, DOI 10.1007/BF01183122; COMINGS DE, 1970, NATURE, V227, P451, DOI 10.1038/227451a0; COMINGS DE, 1971, NATURE, V233, P48, DOI 10.1038/233048a0; DRESSER ME, 1988, J CELL BIOL, V106, P567, DOI 10.1083/jcb.106.3.567; EGUCHI Y, 1991, ANNU REV BIOCHEM, V60, P631, DOI 10.1146/annurev.bi.60.070191.003215; ENGEBRECHT J, 1991, CELL, V66, P1257, DOI 10.1016/0092-8674(91)90047-3; ENGEBRECHT J, 1990, MOL CELL BIOL, V10, P2379, DOI 10.1128/MCB.10.5.2379; FOGEL S, 1983, YEAST GENETICS FUNDA, P65; FRIEDBERG EC, 1991, MOL CELLULAR BIOL YE, V1, P147; HOLLINGSWORTH NM, 1989, GENETICS, V121, P445; Jorgensen R., 1992, Agbiotech News and Information, V4, p265N; KLECKNER N, 1991, COLD SH Q B, V56, P729; KLECKNER N, 1993, COLD SPRING HARB SYM, V58, P553, DOI 10.1101/SQB.1993.058.01.062; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; KLEIN S, 1994, MYCOTA, V2; KOWALCZYKOWSKI SC, 1994, IN PRESS ANN REV BIO; LAWRENCE JB, 1988, CELL, V52, P51; LICHTER P, 1988, P NATL ACAD SCI USA, V85, P9664, DOI 10.1073/pnas.85.24.9664; LOIDL J, 1991, CHROMOSOMA, V100, P221, DOI 10.1007/BF00344155; LOIDL J, 1990, GENOME, V33, P759, DOI 10.1139/g90-115; MAGUIRE MP, 1983, J HERED, V74, P93, DOI 10.1093/oxfordjournals.jhered.a109748; McCLINTOCK BARBARA, 1933, ZEITSCHR WISS BIOL ABT B ZEITSCHR ZELLFORSCH U MIKROSK ANAT, V19, P191, DOI 10.1007/BF02462870; MCDERMOTT A, 1971, CAN J GENET CYTOL, V13, P536, DOI 10.1139/g71-079; MCGAVIN S, 1989, J THEOR BIOL, V136, P135, DOI 10.1016/S0022-5193(89)80221-8; Metz CW, 1916, J EXP ZOOL, V21, P213, DOI 10.1002/jez.1400210204; MITCHELL AP, 1994, MICROBIOL REV, V58, P56, DOI 10.1128/MMBR.58.1.56-70.1994; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MOENS PB, 1969, CHROMOSOMA, V28, P1, DOI 10.1007/BF00325986; MOENS PB, 1988, BIOESSAYS, V9, P151, DOI 10.1002/bies.950090503; Moses M. J., 1968, Annual Review of Genetics, V2, P363, DOI 10.1146/annurev.ge.02.120168.002051; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; OLSON MV, 1991, MOL CELLULAR BIOL YE, V1, P1; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; Rhoades MM, 1961, CELL, VIII, P1; RILEY R, 1977, PHILOS T R SOC B, V277, P191, DOI 10.1098/rstb.1977.0011; ROEDER GS, 1990, TRENDS GENET, V6, P385, DOI 10.1016/0168-9525(90)90297-J; ROSSIGNOL JL, 1994, EXPERIENTIA, V50, P307, DOI 10.1007/BF01924014; SCHERTHAN H, 1992, CHROMOSOMA, V101, P590, DOI 10.1007/BF00360535; SCHWACHA A, 1994, CELL, V76, P51, DOI 10.1016/0092-8674(94)90172-4; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SMITHIES O, 1986, PHILOS T ROY SOC B, V312, P291, DOI 10.1098/rstb.1986.0008; STACK SM, 1969, NATURE, V222, P1275, DOI 10.1038/2221275a0; STERN H, 1987, P303; STORY RM, 1993, SCIENCE, V259, P1892, DOI 10.1126/science.8456313; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; WANDALL A, 1985, CHROMOSOMA, V92, P254, DOI 10.1007/BF00329808; WILLIAMSON DH, 1983, EXP CELL RES, V145, P209, DOI 10.1016/S0014-4827(83)80022-6; WILSON JH, 1979, P NATL ACAD SCI USA, V76, P3641, DOI 10.1073/pnas.76.8.3641; WU TC, 1994, SCIENCE, V263, P515, DOI 10.1126/science.8290959; ZENVIRTH D, 1992, EMBO J, V11, P3441, DOI 10.1002/j.1460-2075.1992.tb05423.x; ZICKLER D, 1977, CHROMOSOMA, V61, P289, DOI 10.1007/BF00288615	66	328	332	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 1	1994	77	7					977	991		10.1016/0092-8674(94)90438-3	http://dx.doi.org/10.1016/0092-8674(94)90438-3			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	8020104				2022-12-24	WOS:A1994NV42500007
J	EVANS, DB; JAMISON, DT				EVANS, DB; JAMISON, DT			ECONOMICS AND THE ARGUMENT FOR PARASITIC DISEASE-CONTROL	SCIENCE			English	Editorial Material							CHILDREN; AFRICA; MALARIA; COST		UNIV CALIF LOS ANGELES,CTR PACIFIC RIM STUDIES,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles	EVANS, DB (corresponding author), UN DEV PROGRAM,WORLD BANK,WHO,SPECIAL PROGRAMME RES & TRAINING TROP DIS,CH-1211 GENEVA 27,SWITZERLAND.							[Anonymous], [No title captured]; BRIEGER WR, 1990, J TROP MED HYG, V93, P106; CALLENDER JEM, 1992, LANCET, V339, P181, DOI 10.1016/0140-6736(92)90246-Y; COOPER BS, 1976, SOC SECUR BULL, V39, P21; GUYATT HL, 1992, PARASITOL TODAY, V8, P397, DOI 10.1016/0169-4758(92)90187-7; JAMISON D, 1992, ENCY ED RES, P399; JAMISON DT, 1993, DIS CONTROL PRIORITI, P3; KORTE R, 1992, SOC SCI MED, V34, P1, DOI 10.1016/0277-9536(92)90060-4; MAX E, 1989, INT J LEPROSY, V57, P476; Mooney G, 1992, EC MED HLTH CARE, V2nd; Murray C. J. L., 1993, DIS CONTROL PRIORITI, P233; OVER M, 1992, HLTH ADULTS DEV WORL, P161; PICARD J, 1993, T ROY SOC TROP MED H, V87, P53, DOI 10.1016/0035-9203(93)90176-Q; Prescott N., 1989, Demography and vector-borne diseases., P155; Psacharopoulos G., 1993, POLICY RES WORKING P, V1067; SHEPARD DS, 1991, TROP MED PARASITOL, V42, P199; STEPHENSON LS, 1989, AM J TROP MED HYG, V41, P445, DOI 10.4269/ajtmh.1989.41.445; 1993, 1993 WORLD BANK WORL	18	5	6	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1866	1867		10.1126/science.8009213	http://dx.doi.org/10.1126/science.8009213			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NT847	8009213				2022-12-24	WOS:A1994NT84700026
J	MULLER, U; STEINHOFF, U; REIS, LFL; HEMMI, S; PAVLOVIC, J; ZINKERNAGEL, RM; AGUET, M				MULLER, U; STEINHOFF, U; REIS, LFL; HEMMI, S; PAVLOVIC, J; ZINKERNAGEL, RM; AGUET, M			FUNCTIONAL-ROLE OF TYPE-I AND TYPE-II INTERFERONS IN ANTIVIRAL DEFENSE	SCIENCE			English	Article							VESICULAR STOMATITIS; ALPHA-INTERFERON; INFLUENZA-VIRUS; MOUSE CELLS; MICE; EXPRESSION; RECEPTOR; GENES; PROTEIN; BETA	Mice lacking the known subunit of the type I interferon (IFN) receptor were completely unresponsive to type I IFNs, suggesting that this receptor chain is essential for type I IFN-mediated signal transduction. These mice showed no overt anomalies but were unable to cope with viral infections, despite otherwise normal immune responses. Comparison of mice lacking either type I or type II IFN receptors showed that, at least in response to some viruses, both IFN systems are essential for antiviral defense and are functionally nonredundant.	UNIV ZURICH,INST MOLEC BIOL 1,CH-8093 ZURICH,SWITZERLAND; UNIV ZURICH,INST EXPTL IMMUNOL,CH-8057 ZURICH,SWITZERLAND; UNIV ZURICH,INST MED VIROL,CH-8028 ZURICH,SWITZERLAND	University of Zurich; University of Zurich; University of Zurich			Pavlovic, Jovan/G-9669-2015; Li, Chia Cheng/D-9906-2015; Yang, Chen/G-1379-2010; Reis, Luiz F. L./C-4556-2013	Pavlovic, Jovan/0000-0003-4428-2487; Steinhoff, Ulrich/0000-0003-2141-7756; Reis, Luiz/0000-0002-4040-2456				BATTEGAY M, 1991, J VIROL METHODS, V33, P191, DOI 10.1016/0166-0934(91)90018-U; BINDER D, 1991, J IMMUNOL, V146, P4301; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; DEMAEYER E, 1908, INTERFERONS OTHER RE; FAUCONNIER B, 1969, NATURE, V222, P185, DOI 10.1038/222185a0; FLENNIKEN AM, 1988, J VIROL, V62, P3077, DOI 10.1128/JVI.62.9.3077-3083.1988; FLORES I, 1991, J BIOL CHEM, V266, P19875; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FOWLER AK, 1980, NATURE, V286, P266, DOI 10.1038/286266a0; GRAY PW, 1982, NATURE, V298, P859, DOI 10.1038/298859a0; GRESSER I, 1976, J EXP MED, V144, P1305, DOI 10.1084/jem.144.5.1305; GRESSER I, 1976, J EXP MED, V144, P1316, DOI 10.1084/jem.144.5.1316; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MERLIN G, 1985, J GEN VIROL, V66, P1149, DOI 10.1099/0022-1317-66-5-1149; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MOORE RN, 1984, SCIENCE, V223, P178, DOI 10.1126/science.6606850; MULLER U, UNPUB; PAVLOVIC J, 1990, J VIROL, V64, P3370, DOI 10.1128/JVI.64.7.3370-3375.1990; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; QUESADA JR, 1984, NEW ENGL J MED, V310, P15, DOI 10.1056/NEJM198401053100104; ROBERTS RM, 1991, PHARMACOL THERAPEUT, V51, P329, DOI 10.1016/0163-7258(91)90064-S; ROOST HP, 1990, EUR J IMMUNOL, V20, P2547, DOI 10.1002/eji.1830201204; RUTHERFORD MN, 1991, NUCLEIC ACIDS RES, V19, P1917, DOI 10.1093/nar/19.8.1917; Staeheli P, 1990, Adv Virus Res, V38, P147, DOI 10.1016/S0065-3527(08)60862-3; STAEHELI P, 1986, CELL, V44, P147, DOI 10.1016/0092-8674(86)90493-9; STEWART TA, 1993, SCIENCE, V260, P1942, DOI 10.1126/science.8100367; TALPAZ M, 1986, NEW ENGL J MED, V314, P1065, DOI 10.1056/NEJM198604243141701; UZE G, 1992, P NATL ACAD SCI USA, V89, P4774, DOI 10.1073/pnas.89.10.4774; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; WEBER H, 1987, EMBO J, V6, P591, DOI 10.1002/j.1460-2075.1987.tb04795.x; WEISS EH, 1984, NATURE, V310, P650, DOI 10.1038/310650a0; WEISSMANN C, 1986, PROG NUCLEIC ACID RE, V33, P251, DOI 10.1016/S0079-6603(08)60026-4; ZINKERNAGEL RM, 1993, IMMUNOL REV, V131, P199	35	1964	2023	172	449	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1918	1921		10.1126/science.8009221	http://dx.doi.org/10.1126/science.8009221			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	8009221				2022-12-24	WOS:A1994NT84700041
J	VANDERWAL, G; DILLMANN, RJM				VANDERWAL, G; DILLMANN, RJM			EUTHANASIA IN THE NETHERLANDS	BRITISH MEDICAL JOURNAL			English	Article							ASSISTED SUICIDE; FAMILY DOCTORS; LIFE	The practice of euthanasia in the Netherlands is often used as an argument in debates outside the Netherlands-hence a clear description of the Dutch situation is important. This article summarises recent data and discusses conceptual issues and relevant characteristics of the system of health care. Special emphasis is put on regulation, including relevant data on notification and prosecution. Besides the practice of euthanasia the Dutch are confronted with the gaps in reporting of cases to the public prosecutor and the existence of cases of ending a life without an explicit request. Nevertheless, the ''Dutch experiment'' need not inevitably lead down the slippery slope because of the visibility and openness of this part of medical practice. This will lead to increased awareness, more safeguards, and improvement of medical decisions concerning the end of life.	ROYAL DUTCH MED ASSOC,3502 LB UTRECHT,NETHERLANDS; HLTH PROV N HOLLAND,2001 DC HAARLEM,NETHERLANDS									ANNAS GJ, 1993, NEW ENGL J MED, V328, P1573, DOI 10.1056/NEJM199305273282121; BATTIN MP, 1990, PERSPECT BIOL MED, V34, P73; Bostrom B A, 1989, Issues Law Med, V4, P467; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; DEWACHTER MAM, 1989, JAMA-J AM MED ASSOC, V262, P3316, DOI 10.1001/jama.262.23.3316; DILLMANN RJM, 1994, EUROPEAN J HLTH LAW, V1, P81; FEBER HRG, 1989, NEDERLANDS JURISTEN, V64, P1441; Fenigsen R, 1989, Hastings Cent Rep, V19, P22, DOI 10.2307/3561967; Gomez Carlos F., 1991, REGULATING DEATH EUT; GUNNING KF, 1991, LANCET, V338, P1010, DOI 10.1016/0140-6736(91)91867-T; KUHSE H, 1988, MED J AUSTRALIA, V148, P623, DOI 10.5694/j.1326-5377.1988.tb116334.x; PIJNENBORG L, 1993, LANCET, V341, P1196, DOI 10.1016/0140-6736(93)91014-D; POLLARD BJ, 1991, MED J AUSTRALIA, V154, P613, DOI 10.5694/j.1326-5377.1991.tb121223.x; RIGTER H, 1988, BMJ-BRIT MED J, V297, P1593, DOI 10.1136/bmj.297.6663.1593; RIGTER H, 1989, HASTINGS CENT REP, V19, P31, DOI 10.2307/3561968; van Delden J J, 1992, Ned Tijdschr Geneeskd, V136, P644; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VANDELDEN JJM, 1993, BIOETHICS, V7, P323, DOI 10.1111/j.1467-8519.1993.tb00222.x; VANDELDEN JJM, 1993, HASTINGS CENT REP, V23, P24, DOI 10.2307/3562919; VANDERMAAS PJ, 1992, HLTH POLICY S1 S2, V22; VANDERWAL G, 1993, BIOETHICS, V7, P330, DOI 10.1111/j.1467-8519.1993.tb00223.x; VANDERWAL G, 1992, FAM PRACT, V9, P130, DOI 10.1093/fampra/9.2.130; VANDERWAL G, 1992, FAM PRACT, V9, P135, DOI 10.1093/fampra/9.2.135; VANDERWAL G, 1992, EUTHANASIA ASSISTED; VANDERWAL G, IN PRESS J AM GERIAT; VANDERWAL G, 1993, NEDERLANDS JURISTEN, V68, P444; ZYLICZ Z, 1991, LANCET, V338, P1150, DOI 10.1016/0140-6736(91)92010-Y; 1987, BIOETHICS, V1, P163; 1991, MED BESLISSINGEN RON	29	65	65	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 21	1994	308	6940					1346	1349		10.1136/bmj.308.6940.1346	http://dx.doi.org/10.1136/bmj.308.6940.1346			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NM989	8019226	Green Published			2022-12-24	WOS:A1994NM98900028
J	UITERWAAL, CSPM; GROBBEE, DE; WITTEMAN, JCM; VANSTIPHOUT, WAHJ; KRAUSS, XH; HAVEKES, LM; DEBRUIJN, AM; VANTOL, A; HOFMAN, A				UITERWAAL, CSPM; GROBBEE, DE; WITTEMAN, JCM; VANSTIPHOUT, WAHJ; KRAUSS, XH; HAVEKES, LM; DEBRUIJN, AM; VANTOL, A; HOFMAN, A			POSTPRANDIAL TRIGLYCERIDE RESPONSE IN YOUNG-ADULT MEN AND FAMILIAL RISK FOR CORONARY ATHEROSCLEROSIS	ANNALS OF INTERNAL MEDICINE			English	Article						CORONARY ARTERIOSCLEROSIS; TRIGLYCERIDES; CORONARY DISEASE; LIPOPROTEINS; HEREDITARY DISEASES	DENSITY LIPOPROTEIN CHOLESTEROL; ARTERY DISEASE; CHYLOMICRON REMNANTS; RICH LIPOPROTEINS; PLASMA-CLEARANCE; RETINYL ESTERS; METABOLISM; PRECIPITATION; LIPEMIA; VITAMIN	Objective: To determine whether an increased familial risk for coronary artery disease in young adult men is related to changes in postprandial lipoprotein metabolism. Design: Cross-sectional study. Setting: Coronary angiography departments of four central general hospitals in the Netherlands. Patients: 80 sons (mean age, 24.8 years) of men with severe coronary artery disease and 55 sons (mean age, 23.2 years) of controls. Measurements: Postprandial levels of serum triglycerides, retinyl palmitate, and total cholesterol were measured during a 12-hour period after a standardized oral lipid load. Results: Both groups showed a marked increase in levels of serum triglyceride and retinyl palmitate after lipid loading, reaching a maximum 4 to 6 hours postprandially. No changes in postprandial total cholesterol levels were observed in either group. Sons of men with coronary artery disease had prolonged postprandial hypertriglyceridemia when compared with sons of controls. Significant differences in postprandial triglyceride levels were found at 8 hours (difference, 0.35 mmol/L; 95% CI, 0.07 to 0.62 mmol/L), at 10 hours (difference, 0.21 mmol/L; CI, 0.06 to 0.36 mmol/L), and at 12 hours after lipid loading (difference, 0.13 mmol/L; CI, 0.01 to 0.26 mmol/L). Levels of postprandial retinyl palmitate were also slightly, but not statistically, different (mainly after 6 hours). Conclusions: Healthy young adult sons, whose fathers have established coronary artery disease, have prolonged postprandial hypertriglyceridemia. Changes in postprandial lipoprotein metabolism appear to be associated with familial risk for coronary atherosclerosis.	ZUIDERZIEKENHUIS ROTTERDAM, DEPT CARDIOL, 3075 EA ROTTERDAM, NETHERLANDS; TNO, INST AGEING & VASC RES, GAUBIUS LAB, 2300 AK LEIDEN, NETHERLANDS; ERASMUS UNIV ROTTERDAM, SCH MED, DEPT BIOCHEM, 3000 DR ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam; Erasmus MC; Netherlands Organization Applied Science Research; Erasmus University Rotterdam	UITERWAAL, CSPM (corresponding author), ERASMUS UNIV ROTTERDAM, SCH MED, DEPT EPIDEMIOL & BIOSTAT, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.		Grobbee, Diederick/C-7651-2014	Grobbee, Diederick/0000-0003-4472-4468				BERR F, 1984, J LIPID RES, V25, P805; BERR F, 1986, J LIPID RES, V27, P645; BOERWINKLE E, 1994, AM J HUM GENET, V54, P341; BRECKENRIDGE WC, 1978, NEW ENGL J MED, V298, P1265, DOI 10.1056/NEJM197806082982301; BURSTEIN M, 1970, J LIPID RES, V11, P583; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; CHEUNG MC, 1977, J CLIN INVEST, V60, P43, DOI 10.1172/JCI108767; COHN JS, 1988, J LIPID RES, V29, P469; COHN JS, 1989, METABOLISM, V38, P484, DOI 10.1016/0026-0495(89)90203-5; DAVIS CE, 1980, CIRCULATION, V62, P24; DECKELBAUM RJ, 1984, ARTERIOSCLEROSIS, V4, P225, DOI 10.1161/01.ATV.4.3.225; GIANTURCO SH, 1988, J CLIN INVEST, V82, P1633, DOI 10.1172/JCI113775; GIDEZ LI, 1982, J LIPID RES, V23, P1206; GOLDSTEIN JL, 1980, J BIOL CHEM, V255, P1839; GOODMAN DWS, 1966, J CLIN INVEST, V45, P1615, DOI 10.1172/JCI105468; GROOT PHE, 1991, ARTERIOSCLER THROMB, V11, P653, DOI 10.1161/01.ATV.11.3.653; GROVE TH, 1979, CLIN CHEM, V25, P560; HAVEKES LM, 1987, J LIPID RES, V28, P455; HAZZARD WR, 1976, METABOLISM, V25, P777, DOI 10.1016/0026-0495(76)90149-9; KRASINSKI SD, 1990, J CLIN INVEST, V85, P883, DOI 10.1172/JCI114515; KRASINSKI SD, 1990, METABOLISM, V39, P357, DOI 10.1016/0026-0495(90)90249-C; MCGILL HC, 1990, JAMA-J AM MED ASSOC, V264, P3018; MORRISON JA, 1982, METABOLISM, V31, P158, DOI 10.1016/0026-0495(82)90129-9; NEWMAN WP, 1986, NEW ENGL J MED, V314, P138, DOI 10.1056/NEJM198601163140302; PARTHASARATHY S, 1989, ARTERIOSCLEROSIS, V9, P398, DOI 10.1161/01.ATV.9.3.398; PATSCH JR, 1987, J CLIN INVEST, V80, P341, DOI 10.1172/JCI113078; PATSCH JR, 1992, ARTERIOSCLER THROMB, V12, P1336, DOI 10.1161/01.ATV.12.11.1336; PEARSON TA, 1979, AM J EPIDEMIOL, V109, P285, DOI 10.1093/oxfordjournals.aje.a112682; REDGRAVE T G, 1970, Journal of Clinical Investigation, V49, P465, DOI 10.1172/JCI106255; RYU JE, 1992, STROKE, V23, P823, DOI 10.1161/01.STR.23.6.823; SCHLIERF G, 1987, METABOLISM, V36, P726, DOI 10.1016/0026-0495(87)90107-7; SHERRILL BC, 1980, J BIOL CHEM, V255, P1804; SIMONS LA, 1987, ATHEROSCLEROSIS, V65, P181, DOI 10.1016/0021-9150(87)90020-7; SIMPSON HS, 1990, ATHEROSCLEROSIS, V85, P193, DOI 10.1016/0021-9150(90)90111-U; SLYPER AH, 1992, LANCET, V340, P289, DOI 10.1016/0140-6736(92)92368-P; STALENHOEF AFH, 1984, P NATL ACAD SCI-BIOL, V81, P1839, DOI 10.1073/pnas.81.6.1839; VANGENT CM, 1977, CLIN CHIM ACTA, V75, P243, DOI 10.1016/0009-8981(77)90195-4; WEINBERG R, 1982, AM J EPIDEMIOL, V116, P385, DOI 10.1093/oxfordjournals.aje.a113422; WEINTRAUB MS, 1987, J CLIN INVEST, V79, P1110, DOI 10.1172/JCI112926; WEINTRAUB MS, 1988, J CLIN INVEST, V82, P1884, DOI 10.1172/JCI113806; WILSON DE, 1983, METABOLISM, V32, P514, DOI 10.1016/0026-0495(83)90016-1; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473; 1989, VOORLICHTINGSBUREAU	43	111	113	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1994	121	8					576	+		10.7326/0003-4819-121-8-199410150-00004	http://dx.doi.org/10.7326/0003-4819-121-8-199410150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL486	8085689				2022-12-24	WOS:A1994PL48600004
J	HAYLES, J; FISHER, D; WOOLLARD, A; NURSE, P				HAYLES, J; FISHER, D; WOOLLARD, A; NURSE, P			TEMPORAL-ORDER OF S-PHASE AND MITOSIS IN FISSION YEAST IS DETERMINED BY THE STATE OF THE P34(CDC2) MITOTIC B-CYCLIN COMPLEX	CELL			English	Article							CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; PROTEIN-KINASE; BUDDING YEAST; GENE-PRODUCT; G2; FIBROBLASTS; INVOLVEMENT	We show here that the state of the p34(cdc2)-p56(cdc13) mitotic B cyclin complex determines whether a fission yeast cell undergoes S phase or mitosis. Mutants defective for p56(cdc13) reset to G1 and rereplicate their DNA, while cells completely lacking the p34(cdc2)-p56(cdc13) complex undergo multiple rounds of S phase. In contrast, formation of the p34(cdc2)-p56(cdc13) complex in G1 promotes cells inappropriately into mitosis. We propose that the temporal order of S phase and mitosis is maintained by the presence or absence of the p34(cdc2)-p56(cdc13) complex.			HAYLES, J (corresponding author), IMPERIAL CANC RES FUND, CELL CYCLE LAB, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.		Fisher, Daniel/D-6915-2018	Fisher, Daniel/0000-0002-0822-3482	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABE K, 1991, EXP CELL RES, V192, P122, DOI 10.1016/0014-4827(91)90166-R; AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; AVES SJ, 1985, EMBO J, V4, P457, DOI 10.1002/j.1460-2075.1985.tb03651.x; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; ENOCH T, 1991, CELL, V65, P921, DOI 10.1016/0092-8674(91)90542-7; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; FORSBURG SL, 1991, NATURE, V351, P245, DOI 10.1038/351245a0; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; FORSBURG SL, 1994, J CELL SCI, V107, P601; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; Goff LJ., 1990, BIOL RED ALGAE, P43; HAGAN I, 1988, J CELL SCI, V91, P587; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; JOHN B, 1990, MELOSIS; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; Leupold U., 1970, METHODS CELL PHYSL, V4, P169; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; Nagl W., 1985, CELL DIVISION CYCLE, P217; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; NURSE P, 1977, EXP CELL RES, V107, P365, DOI 10.1016/0014-4827(77)90358-5; OKEEFE SJ, 1991, P NATL ACAD SCI USA, V88, P7869, DOI 10.1073/pnas.88.17.7869; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAZER S, 1990, J CELL SCI, V97, P509; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SMITH AV, 1991, DEVELOPMENT, V112, P997; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X	41	336	343	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 9	1994	78	5					813	822		10.1016/S0092-8674(94)90542-8	http://dx.doi.org/10.1016/S0092-8674(94)90542-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PG296	8087848				2022-12-24	WOS:A1994PG29600010
J	SCHWARTZ, TB				SCHWARTZ, TB			ASK, AND IT SHALL BE GIVEN YOU	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1994	121	5					376	376		10.7326/0003-4819-121-5-199409010-00011	http://dx.doi.org/10.7326/0003-4819-121-5-199409010-00011			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD701	8042828				2022-12-24	WOS:A1994PD70100011
J	ROBERDS, SL; LETURCQ, F; ALLAMAND, V; PICCOLO, F; JEANPIERRE, M; ANDERSON, RD; LIM, LE; LEE, JC; TOME, FMS; ROMERO, NB; FARDEAU, M; BECKMANN, JS; KAPLAN, JC; CAMPBELL, KP				ROBERDS, SL; LETURCQ, F; ALLAMAND, V; PICCOLO, F; JEANPIERRE, M; ANDERSON, RD; LIM, LE; LEE, JC; TOME, FMS; ROMERO, NB; FARDEAU, M; BECKMANN, JS; KAPLAN, JC; CAMPBELL, KP			MISSENSE MUTATIONS IN THE ADHALIN GENE LINKED TO AUTOSOMAL RECESSIVE MUSCULAR-DYSTROPHY	CELL			English	Article							GLYCOPROTEIN COMPLEX; SKELETAL-MUSCLE; CARDIOMYOPATHIC HAMSTER; LINKAGE ANALYSIS; CYSTIC-FIBROSIS; DEFICIENCY; SARCOLEMMA; PROTEINS; HETEROGENEITY; ASSOCIATION	Adhalin, the 50 kDa dystrophin-associated glycoprotein, is deficient in skeletal muscle of patients having severe childhood autosomal recessive muscular dystrophy (SCARMD). In several North African families, SCARMD has been linked to chromosome 13q, but SCARMD has been excluded from linkage to this locus in other families. We have now cloned human adhalin cDNA and mapped the adhalin gene to chromosome 17q12-q21.33, excluding it from involvement in 13q-linked SCARMD. However, one allelic variant of a polymorphic microsatellite located within intron 6 of the adhalin gene cosegregated perfectly with the disease phenotype in a large family. Furthermore, missense mutations were identified within the adhalin gene that might cause SCARMD in this family. Thus, the adhalin gene is involved in at least one form of autosomal recessive muscular dystrophy.	UNIV IOWA, COLL MED, DEPT PHYSIOL & BIOPHYS, IOWA CITY, IA 52242 USA; UNIV PARIS 05, CHU COCHIN PORT ROYAL, INSERM, U129, F-75014 PARIS, FRANCE; UNIV PARIS 05, CHU COCHIN PORT ROYAL, BIOCHIM GENET LAB, F-75014 PARIS, FRANCE; CTR ETUD POLYMORPHISME HUMAIN, F-75010 PARIS, FRANCE; GENETHON, F-91000 EVRY, FRANCE; INSERM, U153, F-75005 PARIS, FRANCE; CNRS, F-75005 PARIS, FRANCE; HOP ROBERT DEBRE, PATHOL MUSCULAIRE LAB, F-75020 PARIS, FRANCE	University of Iowa; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite	ROBERDS, SL (corresponding author), UNIV IOWA, COLL MED, HOWARD HUGHES MED INST, IOWA CITY, IA 52242 USA.		Beckmann, Jacques S/A-9772-2008; Allamand, Valérie/AAH-6272-2021; Allamand, Valerie/M-4333-2017; Roberds, Steven L/AAP-4985-2020	Beckmann, Jacques S/0000-0002-9741-1900; Allamand, Valérie/0000-0001-8997-9742; Roberds, Steven L/0000-0003-0676-272X; Campbell, Kevin/0000-0003-2066-5889				ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; AZIBI K, 1993, HUM MOL GENET, V2, P1423; BASHIR R, 1994, HUM MOL GENET, V3, P455, DOI 10.1093/hmg/3.3.455; BECKMANN JS, 1991, CR ACAD SCI III-VIE, V312, P141; BENJELLOUNDELLAGI S, 1990, NEUROLOGY, V40, P1903; BENOTHMANE K, 1992, NAT GENET, V2, P315, DOI 10.1038/ng1292-315; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; ELKERCH F, 1994, J MED GENET, V31, P342, DOI 10.1136/jmg.31.4.342; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FARAG TI, 1990, AM J MED GENET, V37, P290, DOI 10.1002/ajmg.1320370229; FARDEAU M, 1993, CR ACAD SCI III-VIE, V316, P799; FOUGEROUSSE F, 1994, HUM MOL GENET, V3, P285, DOI 10.1093/hmg/3.2.285; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; HAMIDA MB, 1983, MUSCLE NERVE, V6, P469, DOI 10.1002/mus.880060702; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; HIGUCHI I, IN PRESS J CLIN INVE; IBRAGHIMOVBESKROVNAYA O, 1993, HUM MOL GENET, V2, P1651, DOI 10.1093/hmg/2.10.1651; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; IWATA Y, 1993, FEBS LETT, V329, P227, DOI 10.1016/0014-5793(93)80227-L; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LAZARO C, 1993, HUM MOL GENET, V2, P725, DOI 10.1093/hmg/2.6.725; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MATSUMURA K, 1992, NATURE, V359, P320, DOI 10.1038/359320a0; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; McKusick V.A., 1992, MENDELIAN INHERITANC; MIZUNO Y, 1994, MUSCLE NERVE, V17, P206, DOI 10.1002/mus.880170212; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; OHLENDIECK K, 1993, NEUROLOGY, V43, P795, DOI 10.1212/WNL.43.4.795; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; PASSOSBUENO MR, 1993, J MED GENET, V30, P385, DOI 10.1136/jmg.30.5.385; PASSOSBUENO MR, 1993, HUM MOL GENET, V2, P1945, DOI 10.1093/hmg/2.11.1945; ROBERDS SL, 1993, J BIOL CHEM, V268, P11496; ROBERDS SL, 1991, P NATL ACAD SCI USA, V88, P1798, DOI 10.1073/pnas.88.5.1798; ROBERDS SL, 1993, J BIOL CHEM, V268, P23739; ROMERO NB, 1994, CR ACAD SCI III-VIE, V317, P70; SALIH MAM, 1983, DEV MED CHILD NEUROL, V25, P43; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; YAMANOUCHI Y, 1994, NEUROMUSCULAR DISORD, V4, P49, DOI 10.1016/0960-8966(94)90047-7; YANG B, 1994, J BIOL CHEM, V269, P6040; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	47	430	446	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 26	1994	78	4					625	633		10.1016/0092-8674(94)90527-4	http://dx.doi.org/10.1016/0092-8674(94)90527-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	8069911				2022-12-24	WOS:A1994PD69300011
J	SPEVAK, MR; KLEINMAN, PK; BELANGER, PL; PRIMACK, C; RICHMOND, JM				SPEVAK, MR; KLEINMAN, PK; BELANGER, PL; PRIMACK, C; RICHMOND, JM			CARDIOPULMONARY-RESUSCITATION AND RIB FRACTURES IN INFANTS - A POSTMORTEM RADIOLOGIC-PATHOLOGICAL STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							COMPLICATIONS; CPR	Objective.-To determine the incidence of rib fractures visible at autopsy or with postmortem radiographs after cardiopulmonary resuscitation (CPR) in infants younger than 1 year. Design.-Retrospective review. Setting.-Medical examiner's office in a county consisting of a medium-sized city, towns, and rural areas. Patients.-Ninety-one infants (56 males, 35 females; mean age, 2.4 months; age range, 26 hours to 8.5 months) without evidence of child abuse who had undergone CPR before death. Methods.-Medical records, skeletal surveys, and autopsy results were reviewed. Results.-No patient had rib fractures. Conclusions.-Cardiopulmonary resuscitation is unlikely to cause rib fractures in infants.	UNIV MASSACHUSETTS,MED CTR,CHIEF MED EXAMINERS OFF,WORCESTER,MA	University of Massachusetts System; University of Massachusetts Worcester	SPEVAK, MR (corresponding author), UNIV MASSACHUSETTS,MED CTR,IMAGING CTR CHILD ABUSE & NEGLECT,DEPT RADIOL,WORCESTER,MA 01655, USA.							BEDELL SE, 1986, ARCH INTERN MED, V146, P1725, DOI 10.1001/archinte.146.9.1725; CAMERON JM, 1975, ATLAS BATTERED CHILD; FELDMAN KW, 1984, PEDIATRICS, V73, P339; KLEINMAN P K, 1989, Investigative Radiology, V24, pS132, DOI 10.1097/00004424-198912000-00235; KLEINMAN PK, 1987, DIAGNOSTIC IMAGING C, P67; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; NAGEL EL, 1981, CRIT CARE MED, V9, P424, DOI 10.1097/00003246-198105000-00037; Patterson R H, 1974, Med Ann Dist Columbia, V43, P389; RIKER WL, 1969, PEDIATR CLIN N AM, V16, P661; THALER MM, 1962, NEW ENGL J MED, V267, P500, DOI 10.1056/NEJM196209062671009; THOMAS PS, 1987, ANN RADIOL, V20, P115	11	75	76	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 24	1994	272	8					617	618		10.1001/jama.272.8.617	http://dx.doi.org/10.1001/jama.272.8.617			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC398	8057518				2022-12-24	WOS:A1994PC39800032
J	GIOVANNUCCI, E; RIMM, EB; STAMPFER, MJ; COLDITZ, GA; ASCHERIO, A; WILLETT, WC				GIOVANNUCCI, E; RIMM, EB; STAMPFER, MJ; COLDITZ, GA; ASCHERIO, A; WILLETT, WC			ASPIRIN USE AND THE RISK FOR COLORECTAL-CANCER AND ADENOMA IN MALE HEALTH-PROFESSIONALS	ANNALS OF INTERNAL MEDICINE			English	Article						ASPIRIN; COLORECTAL NEOPLASMS; ADENOMA; RISK; HEALTH PERSONNEL	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RHEUMATOID-ARTHRITIS; COLON CANCER; LARGE-BOWEL; INDOMETHACIN TREATMENT; ALCOHOL-CONSUMPTION; INTESTINAL TUMORS; REDUCED RISK; POLYPOSIS; SULINDAC	Objective: To determine whether regular use of aspirin decreases the risk for colorectal cancer. Design: Prospective cohort study. Setting: Male health professionals throughout the United States. Patients: 47 900 male respondents to a mailed questionnaire in 1986, who were 40 to 75 years of age. Measurements: Questionnaires in 1986, 1988, and 1990 about use of aspirin and other variables including occurrence of cancer. Results: 251 new patients were diagnosed with colorectal cancer during the study period. Regular users of aspirin (greater than or equal to 2 times per week) in 1986 had a lower risk for total colorectal cancer (relative risk [RR] = 0.68; 95% CI, 0.52 to 0.92) and advanced (metastatic and fatal) colorectal cancer (RR = 0.51; CI, 0.32 to 0.84) after controlling for age; history of polyp; previous endoscopy; parental history of colorectal cancer; smoking; body mass; physical activity; and intakes of red meat, vitamin E, and alcohol. The incremental association was greater among men who reported regular use of aspirin consistently on subsequent questionnaires. The total number of colorectal adenomas discovered among aspirin users was lower with or without overt or occult fecal blood. Thus, earlier diagnosis and treatment of adenomas did not account for the inverse association between aspirin and cancer. Conclusions: These results support laboratory, clinical, and other epidemiologic evidence that regular use of aspirin is associated with a decreased risk for colorectal cancer.	BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	GIOVANNUCCI, E (corresponding author), HARVARD UNIV, SCH MED, DEPT MED, CHANNING LAB, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [P01CA055075] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARON JA, 1991, NEW ENGL J MED, V325, P1644, DOI 10.1056/NEJM199112053252309; GANN PH, 1993, JNCI-J NATL CANCER I, V85, P1220, DOI 10.1093/jnci/85.15.1220; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GIOVANNUCCI E, 1994, J NATL CANCER I, V86, P183, DOI 10.1093/jnci/86.3.183; GONZAGA RAF, 1985, LANCET, V1, P751; GREENBERG ER, 1993, JNCI-J NATL CANCER I, V85, P912, DOI 10.1093/jnci/85.11.912; GRIDLEY G, 1993, JNCI-J NATL CANCER I, V85, P307, DOI 10.1093/jnci/85.4.307; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; ISOMAKI HA, 1978, J CHRON DIS, V31, P691, DOI 10.1016/0021-9681(78)90071-1; Kune GA, 2007, INT J EPIDEMIOL, V36, P951, DOI 10.1093/ije/dym193; LAAKSO M, 1986, J RHEUMATOL, V13, P522; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; LOGAN RFA, 1993, BRIT MED J, V307, P285, DOI 10.1136/bmj.307.6899.285; MARNETT LJ, 1992, CANCER RES, V52, P5575; NARISAWA T, 1981, CANCER RES, V41, P1954; PAGANINIHILL A, 1989, BRIT MED J, V299, P1247, DOI 10.1136/bmj.299.6710.1247; PELEG II, 1994, ARCH INTERN MED, V154, P394, DOI 10.1001/archinte.154.4.394; POLLARD M, 1980, CANCER TREAT REP, V64, P1323; POLLARD M, 1981, SCIENCE, V214, P558, DOI 10.1126/science.7291992; RIGAU J, 1991, ANN INTERN MED, V115, P952, DOI 10.7326/0003-4819-115-12-952; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; RIMM EB, 1990, AM J EPIDEMIOL, V131, P1068, DOI 10.1093/oxfordjournals.aje.a115598; ROSENBERG L, 1991, J NATL CANCER I, V83, P355, DOI 10.1093/jnci/83.5.355; Rothman K, 1986, MODERN EPIDEMIOLOGY; SCHREINEMACHERS DM, 1994, EPIDEMIOLOGY, V5, P138, DOI 10.1097/00001648-199403000-00003; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; SUH O, 1993, CANCER-AM CANCER SOC, V72, P1171, DOI 10.1002/1097-0142(19930815)72:4<1171::AID-CNCR2820720407>3.0.CO;2-D; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; THUN MJ, 1993, CANCER RES, V53, P1322; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X; WADDELL WR, 1983, J SURG ONCOL, V24, P83, DOI 10.1002/jso.2930240119; 1989, CANCER STATISTICS RE	34	681	711	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1994	121	4					241	246		10.7326/0003-4819-121-4-199408150-00001	http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB102	8037405				2022-12-24	WOS:A1994PB10200001
J	ZOHARY, E; SHADLEN, MN; NEWSOME, WT				ZOHARY, E; SHADLEN, MN; NEWSOME, WT			CORRELATED NEURONAL DISCHARGE RATE AND ITS IMPLICATIONS FOR PSYCHOPHYSICAL PERFORMANCE	NATURE			English	Article							VISUAL AREA MT; CORTICAL-NEURONS; SINGLE NEURONS; MONKEY; DISCRIMINATION; MICROSTIMULATION; ORIENTATION; FREQUENCY; STIMULI; MOTION	SINGLE neurone can signal subtle changes in the sensory environment with surprising fidelity, often matching the perceptual sensitivity of trained psychophysical observers This similarity poses an intriguing puzzle: why is psychophysical sensitivity not greater than that of single neurons? Pooling responses across neurons should average out noise in the activity of single cells, leading to substantially improved psychophysical performance. If, however, noise is correlated among these neurons, the beneficial effects of pooling would be diminished(10-12). To assess correlation within a pool, the responses of pairs of neurons were recorded simultaneously during repeated stimulus presentations. We report here that the observed covariation in spike count was relatively weak, the correlation coefficient averaging 0.12. A theoretical analysis revealed, however, that weak correlation can limit substantially the signalling capacity of the pool. In addition, theory suggests a relationship between neuronal responses and psychophysical decisions which may prove useful for identifying cell populations underlying specific perceptual capacities.	STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305	Stanford University			Shadlen, Michael Neil/AAL-1870-2020; Newsome, William T./W-7171-2019	Shadlen, Michael/0000-0002-2002-2210				Anderson T. W., 1958, INTRO MULTIVARIATE S; BRADLEY A, 1987, J NEUROPHYSIOL, V57, P755, DOI 10.1152/jn.1987.57.3.755; BRITTEN KH, 1992, J NEUROSCI, V12, P4745; CELEBRINI S, IN PRESS J NEUROSCI; DUBNER R, 1989, J NEUROPHYSIOL, V62, P450, DOI 10.1152/jn.1989.62.2.450; GAWNE TJ, 1993, J NEUROSCI, V13, P2758; Hawken M.J., 1990, P103; JOHNSON KO, 1980, J NEUROPHYSIOL, V43, P1793, DOI 10.1152/jn.1980.43.6.1793; JOHNSON KO, 1979, J NEUROPHYSIOL, V42, P1332, DOI 10.1152/jn.1979.42.5.1332; JOHNSON KO, 1973, J NEUROPHYSIOL, V36, P347, DOI 10.1152/jn.1973.36.2.347; MOUNTCASTLE VB, 1972, J NEUROPHYSIOL, V35, P122, DOI 10.1152/jn.1972.35.1.122; MOUNTCASTLE VB, 1969, J NEUROPHYSIOL, V32, P452, DOI 10.1152/jn.1969.32.3.452; MURASUGI CM, 1993, J NEUROSCI, V13, P1719; NEWSOME WT, 1988, J NEUROSCI, V8, P2201; NEWSOME WT, 1989, NEURAL MECHANISMS VI, P171; RECANZONE GH, 1992, J NEUROPHYSIOL, V67, P1071, DOI 10.1152/jn.1992.67.5.1071; SALZMAN CD, 1992, J NEUROSCI, V12, P2331; TOLHURST DJ, 1983, VISION RES, V23, P775, DOI 10.1016/0042-6989(83)90200-6; VANKAN P, 1985, EXPL BRAIN RES, P559; VOGELS R, 1990, J NEUROSCI, V10, P3543; WORGOTTER F, 1986, J NEUROSCI METH, V17, P141, DOI 10.1016/0165-0270(86)90067-1; ZEKI SM, 1974, J PHYSIOL-LONDON, V236, P549, DOI 10.1113/jphysiol.1974.sp010452	22	857	858	1	34	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 14	1994	370	6485					140	143		10.1038/370140a0	http://dx.doi.org/10.1038/370140a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW804	8022482				2022-12-24	WOS:A1994NW80400057
J	DOWNER, SM; CODY, MM; MCCLUSKEY, P; WILSON, PD; ARNOTT, SJ; LISTER, TA; SLEVIN, ML				DOWNER, SM; CODY, MM; MCCLUSKEY, P; WILSON, PD; ARNOTT, SJ; LISTER, TA; SLEVIN, ML			PURSUIT AND PRACTICE OF COMPLEMENTARY THERAPIES BY CANCER-PATIENTS RECEIVING CONVENTIONAL TREATMENT	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To determine what proportion of oncology patients receiving conventional medical treatment also use complementary treatments; to assess which complementary treatments are the most popular and to assess patients' motivation for using them; to evaluate associated advantages and risks. Design-Postal screening questionnaire followed by semistructured interview. Setting-Two hospitals in inner London. Subjects-600 unselected oncology patients aged 18 or over who had known their diagnosis of cancer for at least three months. Main outcome measures-Prevalence and demography of use of complementary therapies; patients' motivation and expectations of complementary therapies; areas of satisfaction and dissatisfaction associated with conventional and complementary therapies. Results-415 (69%) patients returned the questionnaire. 16% had used complementary therapies. The most popular were healing, relaxation, visualisation, diets, homoeopathy, vitamins, herbalism, and the Bristol approach. Patients using complementary therapies tended to be younger, of higher social class, and female. Three quarters used two or more therapies. Therapies were mostly used for anticipated antitumour effect. Ill effects of diets and herb treatments were described. Satisfaction with both conventional and complementary therapies was high, although diets often caused difficulties. Patients using complementary therapies were less satisfied with conventional treatments, largely because of side effects and lack of hope of cure. Benefits of complementary therapies were mainly psychological. Conclusions-A sizeable percentage of patients receiving conventional treatments for cancer also use complementary therapies. Patient satisfaction with complementary therapies, other than dietary therapies, was high even without the hoped for anticancer effect. Patients reported psychological benefits such as hope and optimism.	UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT MED ONCOL,LONDON EC1A 7BE,ENGLAND; UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT RADIOTHERAPY,LONDON EC1A 7BE,ENGLAND	University of London; Queen Mary University London; University of London; Queen Mary University London			McCluskey, Peter J/H-7607-2013	McCluskey, Peter J/0000-0002-8177-1637				ALDRIDGE D, 1989, BRIT MED J, V299, P1211; BAGENAL FS, 1990, LANCET, V336, P1185; CASSILETH BR, 1984, ANN INTERN MED, V101, P105, DOI 10.7326/0003-4819-101-1-105; Dickson A C, 1985, Oncol Nurs Forum, V12, P49; FULDER S, 1982, STATUS COMPLEMENTARY; LERNER IJ, 1984, CANCER, V53, P815, DOI 10.1002/1097-0142(19840201)53:3+<815::AID-CNCR2820531334>3.0.CO;2-U; SIKORA K, 1970, CANCER CARE, V7, P9; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; THOMAS KJ, 1991, BRIT MED J, V302, P207, DOI 10.1136/bmj.302.6770.207; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; 1986, ALTERNATIVE THERAPY	11	245	246	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					86	89		10.1136/bmj.309.6947.86	http://dx.doi.org/10.1136/bmj.309.6947.86			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038672	Green Published			2022-12-24	WOS:A1994NW71600015
J	LAND, MF; LEE, DN				LAND, MF; LEE, DN			WHERE WE LOOK WHEN WE STEER	NATURE			English	Article							COORDINATION	STEERING a car requires visual information from the changing pattern of the road ahead. There are many theories about what features a driver might use(1-3), and recent attempts to engineer self-steering vehicles have sharpened interest in the mechanisms involved(4,5). However, there is little direct information linking steering performance to the driver's direction of gaze(3). We have made simultaneous recordings of steering-wheel angle and drivers' gaze direction during a series of drives along a tortuous road. We found that drivers rely particularly on the 'tangent point' an the inside of each curve, seeking this point 1-2 s before each bend and returning to it throughout the bend. The direction of this point relative to the car's heading predicts the curvature of the road ahead, and we examine the way this information is used.	UNIV EDINBURGH, DEPT PSYCHOL, PERCEPT ACT LABS, EDINBURGH EH8 9JZ, SCOTLAND	University of Edinburgh	LAND, MF (corresponding author), UNIV SUSSEX, SCH BIOL SCI, SUSSEX CTR NEUROSCI, BRIGHTON BN1 9QG, ENGLAND.							BALLARD DH, 1992, PHILOS T R SOC B, V337, P331, DOI 10.1098/rstb.1992.0111; Carpenter RHS, 1988, MOVEMENTS EYES; Dickmanns E. D., 1993, [1993] Proceedings Fourth International Conference on Computer Vision, P608, DOI 10.1109/ICCV.1993.378155; LAND MF, 1992, NATURE, V359, P318, DOI 10.1038/359318a0; LAND MF, 1993, P IEEE SYST MAN CYB, V3, P490; LANDWEHR K, 1991, VISION VEHICLES, V3, P187; LEE DN, 1977, SCAND J PSYCHOL, V18, P224, DOI 10.1111/j.1467-9450.1977.tb00281.x; OKUNO A, 1992, VISION BASED VEHICLE, P222; Raviv D., 1991, Proceedings of the IEEE Workshop on Visual Motion (Cat. No.91TH0390-5), P217, DOI 10.1109/WVM.1991.212804; RIEMERSMA JBJ, 1991, VISION VEHICLES, V3, P163; SERAFIN C, 1993, UMTRI9329163 U MICH; WARREN WH, 1991, J EXP PSYCHOL HUMAN, V17, P28, DOI 10.1037/0096-1523.17.1.28	12	654	672	2	77	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 30	1994	369	6483					742	744		10.1038/369742a0	http://dx.doi.org/10.1038/369742a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU581	8008066				2022-12-24	WOS:A1994NU58100059
J	YU, P; KOSCOVILBOIS, M; RICHARDS, M; KOHLER, G; LAMERS, MC				YU, P; KOSCOVILBOIS, M; RICHARDS, M; KOHLER, G; LAMERS, MC			NEGATIVE FEEDBACK-REGULATION OF IGE SYNTHESIS BY MURINE CD23	NATURE			English	Article							LOW-AFFINITY RECEPTOR; FC-EPSILON-RII; B-CELLS; T-CELLS; FC-EPSILON-RII/CD23; LYMPHOCYTES; INHIBITION; ACTIVATION; RESPONSES; CLONES	IMMUNOGLOBULIN E is found in nanogram amounts in normal human and mouse serum. It is increased during parasitic infestations(1) and mediates allergy. CD23, the low-affinity receptor for IgE (Fc epsilon RII), has been proposed as an important regulator of IgE synthesis(2-4). The type-II transmembrane lectin(4) CD23 is expressed in the mouse on B cells and follicular dendritic cells. In humans there are two forms of CD23 which differ in their intracellular amino-terminal 6/7 amino acids(4); expression of the A-form corresponds to that of murine CD23, whereas the B-form is also found on T and other haematopoietic cells(4). CD23 has been implicated in cellular adhesion(5), antigen presentation(6), as a growth and differentiation factor for human B, T and plasma cells, and as a signal transduction molecule(7) (reviewed in refs 3, 8). Here we disrupt the gene coding for murine CD23 (ref. 9) to clarify the role of CD23 in vivo and find that B- and T-cell development is normal in these CD23-deficient mice. Immune responses to the helminth Nippostrongylus brasiliensis are unaffected, In contrast, immunization with thymus-dependent antigens leads to increased and sustained specific IgE antibody titres compared with controls. Formation of germinal centres is normal. These results suggest that murine CD23 acts as a negative feedback component of IgE regulation.	MAX PLANCK INST IMMUNBIOL,D-79108 FREIBURG,GERMANY; BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND; MED BIOL INST,LA JOLLA,CA 92037	Max Planck Society				Yu, Philipp/0000-0003-2629-6690				ADAMCZEWSKI M, 1991, EUR J IMMUNOL, V21, P617, DOI 10.1002/eji.1830210313; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; AYANE MP, 1990, NUCLEIC ACIDS RES, V17, P6722; BERTHO JM, 1991, EUR J IMMUNOL, V21, P1073, DOI 10.1002/eji.1830210433; CAMPBELL KA, 1992, EUR J IMMUNOL, V22, P2107, DOI 10.1002/eji.1830220822; CONRAD DH, 1990, ANNU REV IMMUNOL, V8, P623, DOI 10.1146/annurev.immunol.8.1.623; FLORESROMO L, 1993, SCIENCE, V261, P1038, DOI 10.1126/science.8351517; GORDON J, 1991, MONOGR ALLERGY CD23, V29; HAGAN P, 1991, NATURE, V349, P243, DOI 10.1038/349243a0; HEYMAN B, 1993, EUR J IMMUNOL, V23, P1739, DOI 10.1002/eji.1830230754; KEEGAN AD, 1989, J IMMUNOL, V142, P3868; KEHRY MR, 1989, P NATL ACAD SCI USA, V86, P7556, DOI 10.1073/pnas.86.19.7556; KOLB JP, 1993, J IMMUNOL, V150, P4798; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; LEBRUN P, 1987, J IMMUNOL, V139, P1459; LEDERMANN B, 1991, EXP CELL RES, V197, P254, DOI 10.1016/0014-4827(91)90430-3; LIU YJ, 1992, IMMUNOL TODAY, V13, P17, DOI 10.1016/0167-5699(92)90199-H; LUO H, 1991, J IMMUNOL, V146, P2125; MAEDA K, 1992, J IMMUNOL, V148, P2340; NITSCHKE L, 1993, BIOTECHNIQUES, V14, P914; RAO M, 1987, J IMMUNOL, V138, P1845; RICHARDS ML, 1991, J IMMUNOL, V147, P1067; SAXON A, 1991, J IMMUNOL, V147, P4000; SHERR E, 1989, J IMMUNOL, V142, P481; SINCLAIR NRS, 1983, IMMUNOL TODAY, V4, P35, DOI 10.1016/0167-5699(83)90107-X; STREET NE, 1990, J IMMUNOL, V144, P1629; SUUTTON BJ, 1993, NATURE, V366, P421; SWENDEMAN S, 1987, EMBO J, V6, P1637, DOI 10.1002/j.1460-2075.1987.tb02412.x; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5	29	196	200	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 30	1994	369	6483					753	756		10.1038/369753a0	http://dx.doi.org/10.1038/369753a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU581	8008068				2022-12-24	WOS:A1994NU58100063
J	CUMMINGS, P; STANFORD, JL; DALING, JR; WEISS, NS; MCKNIGHT, B				CUMMINGS, P; STANFORD, JL; DALING, JR; WEISS, NS; MCKNIGHT, B			RISK OF BREAST-CANCER IN RELATION TO THE INTERVAL SINCE LAST FULL-TERM PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article							INCREASE; AGE	Objective-To examine whether the risk of breast cancer is increased by a recent term pregnancy. Design-Population based case-control study. Setting-Eight areas in the United States. Subjects-Cases were 2279 multiparous women residents of the eight areas aged 25-49 who were diagnosed as having breast cancer during 1980-2. Controls were 2357 multiparous women selected from the same areas by random digit dialling. Main outcome measure-Relative risk of developing breast cancer according to the time interval since last full term pregnancy. Results-The distribution of intervals since the last term pregnancy was similar in cases and controls. Adjusted for age, parity, and age at first term pregnancy, the odds ratios observed for categories of years since the last full term pregnancy were: 0-2 years, odds ratio 1.16 (95% confidence interval 0.84 to 1.59); 3-6 years, odds ratio 1.21 (0.95 to 1.54); 7-9 years, odds ratio 1.04 (0.84 to 1.38); greater than or equal to 10 years, odds ratio 1.00 (reference). Conclusions-Among multiparous women aged 25-49 years there was no association between the risk of breast cancer and the time interval since the last full term pregnancy.	UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,SEATTLE,WA 98112	University of Washington; University of Washington Seattle					NCI NIH HHS [R35CA39779, R01CA01364, T32CA09168] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009168, R35CA039779] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMI HO, 1990, BRIT J CANCER, V62, P122, DOI 10.1038/bjc.1990.242; Breslow N, 1980, STATISTICAL METHODS, V32; BRUZZI P, 1988, BRIT MED J, V297, P1096, DOI 10.1136/bmj.297.6656.1096; JANERICH DT, 1982, AM J EPIDEMIOL, V116, P737, DOI 10.1093/oxfordjournals.aje.a113462; Kelsey JL, 1983, BREAST GYNECOLOGIC C; LAYDE PM, 1989, J CLIN EPIDEMIOL, V42, P963, DOI 10.1016/0895-4356(89)90161-3; LOGAN WPD, 1953, LANCET, V2, P1199; MACMAHON B, 1973, JNCI-J NATL CANCER I, V50, P21, DOI 10.1093/jnci/50.1.21; VATTEN LJ, 1992, EUR J CANCER, V28A, P1148, DOI 10.1016/0959-8049(92)90476-I; WILLIAMS EMI, 1990, BRIT MED J, V300, P578, DOI 10.1136/bmj.300.6724.578; WINGO PA, 1988, AM J EPIDEMIOL, V128, P206, DOI 10.1093/oxfordjournals.aje.a114942; WINGO PA, 1991, OBSTET GYNECOL, V78, P161; 1983, JAMA-J AM MED ASSOC, V249, P1591; 1986, NEW ENGL J MED, V315, P401	14	24	24	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 25	1994	308	6945					1672	1674		10.1136/bmj.308.6945.1672	http://dx.doi.org/10.1136/bmj.308.6945.1672			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU483	8025460	Green Published			2022-12-24	WOS:A1994NU48300019
J	KREZEL, AM; WAGNER, G; SEYMOURULMER, J; LAZARUS, RA				KREZEL, AM; WAGNER, G; SEYMOURULMER, J; LAZARUS, RA			STRUCTURE OF THE RGD PROTEIN DECORSIN - CONSERVED MOTIF AND DISTINCT FUNCTION IN LEECH PROTEINS THAT AFFECT BLOOD-CLOTTING	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; GLYCOPROTEIN-IIB-IIIA; PLATELET-AGGREGATION INHIBITORS; AMINO-ACID-SEQUENCE; RECOMBINANT HIRUDIN; DISTANCE GEOMETRY; 3-DIMENSIONAL STRUCTURES; ALPHA-THROMBIN; CELL-ADHESION; FACTOR-XA	The structure of the leech protein decorsin, a potent 39-residue antagonist of glycoprotein IIb-IIIa and inhibitor of platelet aggregation, was determined by nuclear magnetic resonance. In contrast to other disintegrins, the Arg-Gly-Asp (RGD)-containing region of decorsin is well defined. The three-dimensional structure of decorsin is similar to that of hirudin, an anticoagulant leech protein that potently inhibits thrombin. Amino acid sequence comparisons suggest that ornatin, another glycoprotein IIb-IIIa antagonist, and antistasin, a potent Factor Xa inhibitor and anticoagulant found in leeches, share the same structural motif. Although decorsin, hirudin, and antistasin all affect the blood clotting process and appear similar in structure, their mechanisms of action and epitopes important for binding to their respective targets are distinct.	HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; GENENTECH INC, DEPT PROT ENGN, San Francisco, CA 94080 USA	Harvard University; Harvard Medical School; Roche Holding; Genentech								ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; BANG NU, 1992, TRENDS CARDIOVAS MED, V2, P183, DOI 10.1016/1050-1738(92)90047-V; CHOU PY, 1977, J MOL BIOL, V115, P135, DOI 10.1016/0022-2836(77)90094-8; CLORE GM, 1987, EMBO J, V6, P529, DOI 10.1002/j.1460-2075.1987.tb04785.x; COLMAN RW, 1994, HEMOSTASIS THROMBOSI, P3; DENNIS MS, 1993, PROTEINS, V15, P312, DOI 10.1002/prot.340150308; DENNIS MS, 1990, P NATL ACAD SCI USA, V87, P2471, DOI 10.1073/pnas.87.7.2471; DICKINSON CD, 1994, J MOL BIOL, V236, P1079, DOI 10.1016/0022-2836(94)90013-2; DODT J, 1984, FEBS LETT, V165, P180, DOI 10.1016/0014-5793(84)80165-9; DUNWIDDIE C, 1989, J BIOL CHEM, V264, P16694; Fenton J W 2nd, 1981, Ann N Y Acad Sci, V370, P468, DOI 10.1111/j.1749-6632.1981.tb29757.x; FENTON JW, 1986, ANN NY ACAD SCI, V485, P5, DOI 10.1111/j.1749-6632.1986.tb34563.x; FOLKERS PJM, 1989, BIOCHEMISTRY-US, V28, P2601, DOI 10.1021/bi00432a038; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; HARUYAMA H, 1989, BIOCHEMISTRY-US, V28, P4301, DOI 10.1021/bi00436a027; HOLM L, 1992, PROTEIN SCI, V1, P1691, DOI 10.1002/pro.5560011217; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KNAPP A, 1992, J BIOL CHEM, V267, P24230; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREZEL AM, UNPUB; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; Lazarus Robert A., 1993, Current Opinion in Biotechnology, V4, P438, DOI 10.1016/0958-1669(93)90009-L; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MARKWARDT F, 1994, THROMB RES, V74, P1, DOI 10.1016/0049-3848(94)90032-9; Markwardt F., 1970, METHOD ENZYMOL, V19, P924, DOI [10.1016/0076-6879(70)19082-3, DOI 10.1016/0076-6879(70)19082-3]; MAZUR P, 1991, EUR J BIOCHEM, V202, P1073, DOI 10.1111/j.1432-1033.1991.tb16472.x; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; NUTT E, 1988, J BIOL CHEM, V263, P10162; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P7369, DOI 10.1021/bi00244a003; SAWYER RT, 1991, BIO-TECHNOL, V9, P513, DOI 10.1038/nbt0691-513; SEEMULLER U, 1986, PROTEINASE INHIBITOR, P337; SENN H, 1993, J MOL BIOL, V232, P907, DOI 10.1006/jmbi.1993.1439; SEYMOUR JL, 1990, J BIOL CHEM, V265, P10143; SEYMOURULMER J, UNPUB; SOLLNER C, 1994, EUR J BIOCHEM, V219, P937, DOI 10.1111/j.1432-1033.1994.tb18575.x; STEINER V, 1992, BIOCHEMISTRY-US, V31, P2294, DOI 10.1021/bi00123a012; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; SZYPERSKI T, 1992, J MOL BIOL, V228, P1206, DOI 10.1016/0022-2836(92)90326-F; SZYPERSKI T, 1992, J MOL BIOL, V228, P1193, DOI 10.1016/0022-2836(92)90325-E; TUSZYNSKI GP, 1987, J BIOL CHEM, V262, P9718; VITALI J, 1992, J BIOL CHEM, V267, P17670; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9	48	131	138	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 24	1994	264	5167					1944	1947		10.1126/science.8009227	http://dx.doi.org/10.1126/science.8009227			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	8009227				2022-12-24	WOS:A1994NT84700049
J	IIRI, T; HERZMARK, P; NAKAMOTO, JM; VANDOP, C; BOURNE, HR				IIRI, T; HERZMARK, P; NAKAMOTO, JM; VANDOP, C; BOURNE, HR			RAPID GDP RELEASE FROM G(S-ALPHA) IN PATIENTS WITH GAIN AND LOSS OF ENDOCRINE FUNCTION	NATURE			English	Article							CRYSTAL-STRUCTURE; ALPHA-SUBUNIT; GTP-BINDING; G-PROTEIN; SIGNAL TRANSDUCTION; PRECOCIOUS PUBERTY; PERTUSSIS TOXIN; RAS PROTEINS; RESOLUTION; HYDROLYSIS	LUTEINIZING hormone stimulates testicular Leydig cells to produce testosterone by binding to a receptor that activates the G protein G(s) and adenylyl cyclase. Testotoxicosis is a form of precocious puberty in which the Leydig cells secrete testosterone in the absence of luteinizing hormone, often due to constitutive activation of the luteinizing hormone receptor and (indirectly) G(s) (refs 1-4). Here we study two unrelated boys suffering from a paradoxical combination of testotoxicosis and pseudohypoparathyroidism type Ia (PHP-Ia)(5), a condition marked by resistance to hormones acting through cyclic AMP (parathyroid hormone and thyroid-stimulating hormone) as well as a 50% decrease in erythrocyte G(s) activity (the remaining 50% is due to the normal G(s) allele)(5,6). In both patients, a mutation in the gene encoding the G(s) alpha-subunit replaced alanine at position 366 with serine(5). We show that this alpha(s)-A366S mutation constitutively activates adenylyl cyclase in vitro, causing hormone-independent cAMP accumulation when expressed in cultured cells, and accounting for the testotoxicosis phenotype (as cAMP stimulates testosterone secretion). Although alpha(s)-A366S is quite stable at testis temperature, it is rapidly degraded at 37 degrees C, explaining the PHP-Ia phenotype caused by loss of G(s) activity. In vitro experiments indicate that accelerated release of GDP causes both the constitutive activity and the thermolability of alpha(s)-A366S.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF LOS ANGELES, DEPT PEDIAT, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles								BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; EGLI CA, 1985, J PEDIATR-US, V106, P33, DOI 10.1016/S0022-3476(85)80460-1; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; IIRI T, 1992, J BIOL CHEM, V267, P1020; KATADA T, 1986, J BIOL CHEM, V261, P8182; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NAKOMOTO JM, 1993, CLIN RES, V41, pA40; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; REITER EO, 1984, NEW ENGL J MED, V311, P515, DOI 10.1056/NEJM198408233110807; ROSS EM, 1977, J BIOL CHEM, V252, P6966; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; THOMAS TC, 1993, P NATL ACAD SCI USA, V90, P10295, DOI 10.1073/pnas.90.21.10295; VANDOP C, 1989, SEMIN NEPHROL, V9, P168; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; ZORGNIOTTI AW, 1991, ADV EXP MED BIOL, V286, P1	28	195	200	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 8	1994	371	6493					164	168		10.1038/371164a0	http://dx.doi.org/10.1038/371164a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF191	8072545				2022-12-24	WOS:A1994PF19100066
J	ROSENTHAL, N				ROSENTHAL, N			MOLECULAR MEDICINE - STALKING THE GENE - DNA LIBRARIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article														Rosenthal, Nadia/0000-0002-7599-7365				ROSENTHAL N, 1994, NEW ENGL J MED, V331, P315, DOI 10.1056/NEJM199408043310508; WATSON J, 1992, RECOMBINANT DNA SHOR	2	6	6	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 1	1994	331	9					599	600		10.1056/NEJM199409013310908	http://dx.doi.org/10.1056/NEJM199409013310908			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD699	8047086				2022-12-24	WOS:A1994PD69900008
J	HALL, CB; LONG, CE; SCHNABEL, KC; CASERTA, MT; MCINTYRE, KM; COSTANZO, MA; KNOTT, A; DEWHURST, S; INSEL, RA; EPSTEIN, LG				HALL, CB; LONG, CE; SCHNABEL, KC; CASERTA, MT; MCINTYRE, KM; COSTANZO, MA; KNOTT, A; DEWHURST, S; INSEL, RA; EPSTEIN, LG			HUMAN HERPESVIRUS-6 INFECTION IN CHILDREN - A PROSPECTIVE-STUDY OF COMPLICATIONS AND REACTIVATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; SUBITUM ROSEOLA INFANTUM; CENTRAL-NERVOUS-SYSTEM; EXANTHEM-SUBITUM; IDENTIFICATION; ANTIBODY; MENINGOENCEPHALITIS; TRANSMISSION; PREVALENCE; POLYMERASE	Background. Infect with human herpesvirus-6 (HHV-6) is nearly universal in infancy or early childhood. However, the-course of this infection, its complications, and its potential for persistence or reactivation remain unclear. Methods. We studied infants and children under the age of three years who presented to our emergency department with acute illnesses. Infants and young children without acute illness were studied as controls. HHV-6 infection was identified by blood-mononuclear-cell culture, serologic testing, and the polymerase chain reaction (PCR). Results. No primary HHV-6 infection was found among 582 infants and young children with acute nonfebrile illnesses or among 352 controls without acute illness. Of 1653 infants and young children with acute febrile illnesses, 160 (9.7 percent) had primary HHV-6 infection, as documented by viremia and seroconversion. They ranged in age from 2 weeks to 25 months; 23 percent were under the age of 6 months. HHV-6 infections accounted for 20 percent of 365 visits to the emergency department for febrile illnesses among children 6 to 12 months old. Of the 160 infants and young children with acute HHV-6 infections, 21 (13 percent) were hospitalized, and 21 had seizures. Often the seizures appeared late and were prolonged or recurrent. HHV-6 infections accounted for one third of all febrile seizures in children up to the age of two years. In follow-up studies over a period of one to two years, the HHV-6 genome persisted in blood mononuclear cells after primary infection in 37 of 56 children (66 percent). Reactivation, sometimes with febrile illnesses, was suggested by subsequent increases in antibody titers in 16 percent (30 of 187) and by PCR in 6 percent (17 of 278). No recurrent viremia was detected. Of 41 healthy newborns studied, 12 (29 percent) had the HHV-6 genome in their blood mononuclear cells; nevertheless, 6 of these newborns subsequently had primary HHV-6 infections. Conclusions. In infants and young children HHV-6 infection is a major cause of visits to the emergency department, febrile seizures, and hospitalizations. Perinatal transmission may occur, with possible asymptomatic, transient, or persistent neonatal infection.	UNIV ROCHESTER,SCH MED & DENT,DEPT MED,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT MICROBIOL & IMMUNOL,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT NEUROL,ROCHESTER,NY 14642	University of Rochester; University of Rochester; University of Rochester	HALL, CB (corresponding author), UNIV ROCHESTER,SCH MED & DENT,DEPT PEDIAT,ROCHESTER,NY 14642, USA.			Epstein, Leon/0000-0003-4264-3867; Dewhurst, Stephen/0000-0001-7729-7920	NCRR NIH HHS [5-MO1-RR-000-44] Funding Source: Medline; NIAID NIH HHS [R01 AI33020-02] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033020] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ablashi D V, 1991, In Vivo, V5, P193; ASANO Y, 1992, ARCH DIS CHILD, V67, P1484, DOI 10.1136/adc.67.12.1484; ASANO Y, 1990, LANCET, V335, P862, DOI 10.1016/0140-6736(90)90983-C; ASANO Y, 1991, J PEDIATR-US, V118, P891, DOI 10.1016/S0022-3476(05)82200-0; ASANO Y, 1991, NEW ENGL J MED, V324, P634; AUBIN JT, 1992, LANCET, V340, P482, DOI 10.1016/0140-6736(92)91801-E; BERENBERG W, 1949, NEW ENGL J MED, V241, P253, DOI 10.1056/NEJM194908182410701; Breese Jr. BB., 1941, NEW YORK J MED, V41, P1854; BURNSTINE RC, 1959, AMA J DIS CHILD, V98, P144, DOI 10.1001/archpedi.1959.02070020146002; CASERTA MT, 1993, ANNU REV MED, V44, P377, DOI 10.1146/annurev.med.44.1.377; CASERTA MT, 1993, CLIN INFECT DIS, V17, P557; CHANDRAN B, 1992, J MED VIROL, V37, P247, DOI 10.1002/jmv.1890370403; CHERRY JD, 1992, TXB PEDIATRIC INFECT, V2, P1789; CHOU SW, 1993, J LAB CLIN MED, V121, P388; CLEMENS HH, 1945, J PEDIATR-US, V26, P66, DOI 10.1016/S0022-3476(45)80135-X; CONE RW, 1993, NEW ENGL J MED, V329, P156, DOI 10.1056/NEJM199307153290302; Dean A. G., 1990, EPI INFO VERSION 5 W; DEWHURST S, 1993, J CLIN MICROBIOL, V31, P416, DOI 10.1128/JCM.31.2.416-418.1993; DEWHURST S, 1992, VIROLOGY, V190, P490, DOI 10.1016/0042-6822(92)91240-U; DROBYSKI WR, 1993, J INFECT DIS, V167, P735, DOI 10.1093/infdis/167.3.735; DUNNE WM, 1992, LANCET, V340, P121; DUNNE WM, 1993, J INFECT DIS, V168, P250, DOI 10.1093/infdis/168.1.250; EFSTATHIOU S, 1992, J GEN VIROL, V73, P1661, DOI 10.1099/0022-1317-73-7-1661; ENDERS G, 1990, INFECTION, V18, P12, DOI 10.1007/BF01644173; HALL CB, 1991, PEDIATR RES, V29, pA173; Huang L M, 1991, J Formos Med Assoc, V90, P579; HUANG LM, 1992, J INFECT DIS, V165, P1163, DOI 10.1093/infdis/165.6.1163; ISHIGURO N, 1990, ACTA PAEDIATR SCAND, V79, P987, DOI 10.1111/j.1651-2227.1990.tb11369.x; KAWAGUCHI S, 1992, PEDIATRICS, V90, P628; KEMPE CH, 1950, J PEDIATR-US, V37, P561, DOI 10.1016/S0022-3476(50)80266-4; KONDO K, 1993, J INFECT DIS, V167, P1197, DOI 10.1093/infdis/167.5.1197; KUSUHARA K, 1992, LANCET, V340, P482, DOI 10.1016/0140-6736(92)91800-N; LINNAVUORI K, 1992, PEDIATRICS, V89, P103; MOLLER K L, 1956, Acta Paediatr, V45, P534, DOI 10.1111/j.1651-2227.1956.tb06912.x; OKADA K, 1993, PEDIATR INFECT DIS J, V12, P204, DOI 10.1097/00006454-199303000-00006; PELLETT PE, 1990, ADV EXP MED BIOL, V278, P9; PELLETT PE, 1993, VIROLOGY, V195, P521, DOI 10.1006/viro.1993.1403; PELLETT PE, 1992, ADV VIRUS RES, V41, P1, DOI 10.1016/S0065-3527(08)60034-2; PORTOLANI M, 1993, J MED VIROL, V39, P146, DOI 10.1002/jmv.1890390211; POSSON DD, 1949, J PEDIATR-US, V35, P235, DOI 10.1016/S0022-3476(49)80239-3; PREZIOSO PJ, 1992, J PEDIATR-US, V120, P921, DOI 10.1016/S0022-3476(05)81962-6; PRUKSANANONDA P, 1992, NEW ENGL J MED, V326, P1445, DOI 10.1056/NEJM199205283262201; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; SUGA S, 1992, MICROBIOL IMMUNOL, V36, P495, DOI 10.1111/j.1348-0421.1992.tb02047.x; SUGA S, 1992, J MED VIROL, V38, P278, DOI 10.1002/jmv.1890380409; SUGA S, 1993, ANN NEUROL, V33, P597, DOI 10.1002/ana.410330607; TAKIKAWA T, 1992, LANCET, V340, P1288, DOI 10.1016/0140-6736(92)92989-S; YAMANISHI K, 1992, MICROBIOL IMMUNOL, V36, P551, DOI 10.1111/j.1348-0421.1992.tb02055.x; YAMANISHI K, 1988, LANCET, V1, P1065; YANAGI K, 1990, J INFECT DIS, V161, P153, DOI 10.1093/infdis/161.1.153-a; YOSHIKAWA T, 1991, BLOOD, V78, P1381; YOSHIKAWA T, 1990, PEDIATR INFECT DIS J, V9, P589, DOI 10.1097/00006454-199008000-00013; YOSHIKAWA T, 1992, PEDIATRICS, V89, P888	54	428	449	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 18	1994	331	7					432	438		10.1056/NEJM199408183310703	http://dx.doi.org/10.1056/NEJM199408183310703			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB501	8035839				2022-12-24	WOS:A1994PB50100003
J	WOLFENDEN, R; RADZICKA, A				WOLFENDEN, R; RADZICKA, A			ON THE PROBABILITY OF FINDING A WATER MOLECULE IN A NONPOLAR CAVITY	SCIENCE			English	Article							MUTATIONS	Measurements of solubility and vapor pressure indicate that the cost of making a cavity in a nonpolar solvent that is large enough to accommodate a single water molecule is just balanced by the attraction between the water molecule and the walls of the cavity. As a result of this unexpected coincidence, the equilibrium constant for entry of an isolated water molecule from the vapor phase into cyclohexane is almost exactly unity at room temperature. Molecules smaller than water prefer the vapor phase, whereas molecules larger than water prefer cyclohexane. In equilibrium with liquid water, the tendency of single water molecules to enter small nonpolar cavities, such as may be present in mutant proteins, is expected to be vanishingly small.			WOLFENDEN, R (corresponding author), UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018325, R37GM018325] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-18325] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUCKLE AM, 1993, J MOL BIOL, V234, P847, DOI 10.1006/jmbi.1993.1630; CHRISTIAN SD, 1970, Q REV CHEM SOC, V24, P20, DOI 10.1039/qr9702400020; DORSEY NE, 1950, PROPERTIES ORDINARY; DOYLE D, UNPUB; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1577, DOI 10.1021/bi00405a027; FINKELSTEIN A, 1987, WATER TRANSPORT LIPI, P94; Harkins WD, 1921, J AM CHEM SOC, V43, P35, DOI 10.1021/ja01434a006; PASCUALAHUIR JL, 1990, J COMPUT CHEM, V11, P1047, DOI 10.1002/jcc.540110907; RADZICKA A, 1988, BIOCHEMISTRY-US, V27, P1664, DOI 10.1021/bi00405a042; ROSE GD, 1993, ANNU REV BIOPH BIOM, V22, P381, DOI 10.1146/annurev.bb.22.060193.002121; UNGEMACH SR, 1974, J AM CHEM SOC, V96, P7898, DOI 10.1021/ja00833a010; VARADARAJAN R, 1992, BIOCHEMISTRY-US, V31, P12315, DOI 10.1021/bi00164a005; WADE RC, 1991, BIOPOLYMERS, V31, P919, DOI 10.1002/bip.360310802; WASHBURN EW, 1928, INT CRIT TABLES, V3, P210; WILHELM E, 1973, CHEM REV, V73, P1, DOI 10.1021/cr60281a001; WOLFENDEN R, 1983, SCIENCE, V222, P1087, DOI 10.1126/science.6359416; WOLFENDEN R, 1991, ACCOUNTS CHEM RES, V24, P209, DOI 10.1021/ar00007a004	18	91	91	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 12	1994	265	5174					936	937		10.1126/science.8052849	http://dx.doi.org/10.1126/science.8052849			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052849				2022-12-24	WOS:A1994PB49900036
J	BOSS, LP; TOOLE, MJ; YIP, R				BOSS, LP; TOOLE, MJ; YIP, R			ASSESSMENTS OF MORTALITY, MORBIDITY, AND NUTRITIONAL-STATUS IN SOMALIA DURING THE 1991-1992 FAMINE - RECOMMENDATIONS FOR STANDARDIZATION OF METHODS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REFUGEES; DISEASE; MALNUTRITION; RATES; SUDAN	Objectives.-To evaluate the various survey methods used in Somalia between 1991 and early 1993 while assessing documentation of mortality and malnutrition rates and common causes of morbidity and mortality. Data Sources.-Twenty-three population surveys were identified from the Center for Public Health Surveillance for Somalia, the United Nations Children's Fund, and other humanitarian organizations. Study Selection.-Only surveys with defined populations and apparently systematic methodology that focused on mortality, morbidity, and/or nutritional status were included. Results.-Extensive methodological differences were found among the 23 surveys. Target populations and sampling strategies varied widely. Twelve studies were considered not reproducible. Of the 16 studies assessing mortality, only eight assessed cause of death. Use of units of measurement and inclusion of denominators in rate calculations were inconsistent. None of the studies provided confidence intervals around the point estimates of the rates. Of the 11 studies providing information on morbidity, none provided case definitions. And in the 16 studies reporting nutritional status, a variety of measurement methods and definitions of malnutrition were used. Three studies presented information based on mid-upper-arm circumference measurements, and 10 presented weight-for-height data below 70% and 80% of the reference median; only four studies presented z scores.			BOSS, LP (corresponding author), CTR DIS CONTROL & PREVENT, MS F-57, 1600 CLIFTON RD NE, ATLANTA, GA 30333 USA.							ALLEN P, 1991, INTERAGENCY MOH NUTR; [Anonymous], 1986, B WORLD HEALTH ORGAN, V64, P929; BERN C, 1992, B WORLD HEALTH ORGAN, V70, P705; BOSS LP, 1987, INT J EPIDEMIOL, V16, P556, DOI 10.1093/ije/16.4.556; BROWN V, 1993, HODDUR SOMALIE IMPAC; DEWAAL A, 1989, POP STUD-J DEMOG, V43, P5, DOI 10.1080/0032472031000143826; GLASS RI, 1980, LANCET, V1, P868; HENDERSON RH, 1982, B WORLD HEALTH ORGAN, V60, P253; MANONCOURT S, 1992, LANCET, V340, P176, DOI 10.1016/0140-6736(92)93252-I; MEIJMAN B, 1993, MED NEWS         AUG, V2, P5; MERCER A, 1993, HLTH SURVEILLANCE RE; MOORE PS, 1993, LANCET, V341, P935, DOI 10.1016/0140-6736(93)91223-9; OREILLY F, 1992, NUTRITIONAL SURVEY B; RUTHERFORD GW, 1985, J TROP PEDIATRICS, V31, P143, DOI 10.1093/tropej/31.3.143; SANDLER RH, 1991, JAMA-J AM MED ASSOC, V266, P638, DOI 10.1001/jama.266.5.638; SEAMAN J, 1978, INT J EPIDEMIOL, V7, P31, DOI 10.1093/ije/7.1.31; SHEARS P, 1987, INT MIGR REV, V21, P783, DOI 10.2307/2546622; TOOLE M J, 1989, Bulletin of the World Health Organization, V67, P381; WOODRUFF BA, 1990, DISASTERS, V14, P151, DOI 10.1111/j.1467-7717.1990.tb01056.x; YIP R, 1993, JAMA-J AM MED ASSOC, V270, P587, DOI 10.1001/jama.270.5.587; 1993, UNPUB NUTRITION MORT; 1992, MMWR-MORBID MORTAL W, V41, P913; 1992, REPORT CONSULTATION; 1989, MMWR-MORBID MORTAL W, V38, P461; 1989, MMWR-MORBID MORTAL W, V38, P455; 1993, SURVEY RESULTS BELET; 1991, MMWR-MORBID MORTAL W, V40, P443; IN PRESS REPORT SUBC; 1991, MMWR-MORBID MORTAL W, V40, P13; 1992, UNPUB HLTH MORTALITY; 1988, MASURING CHANGE NUTR; 1992, CTR PUBLIC HLTH SURV, V2, P1; 1988, MMWR-MORBID MORTAL W, V37, P641; 1993, UNPUB RESULTS MORBID; 1990, MMWR-MORBID MORTAL W, V39, P707; 1992, MMWR MORB MORT SRR13, V41, P1; 1992, REPORT UNICEF RMO NU; 1990, MMWR-MORBID MORTAL W, V39, P715; 1992, HLTH MORTALITY ASSES; 1993, MMWR-MORBID MORTAL W, V42, P304; UNPUB RESULTS MORBID; 1993, NUTRITION HLTH ASSES; 1993, RESULTS MORBIDITY MO	43	41	41	1	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	1994	272	5					371	376						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY903	8028168				2022-12-24	WOS:A1994NY90300029
J	DEHAENELAMBERTZ, G; DEHAENE, S				DEHAENELAMBERTZ, G; DEHAENE, S			SPEED AND CEREBRAL CORRELATES OF SYLLABLE DISCRIMINATION IN INFANTS	NATURE			English	Article							1ST YEAR; PERCEPTION; ATTENTION; BRAIN; LIFE	THE remarkable linguistic abilities of human neonates are well documented(1-5). Young infants can discriminate phonemes even if they are not used in their native language(2-4), an ability which regresses during the first year of life(4,5). This ability to discriminate is often studied by repeating a stimulus for several minutes until some behavioural response of the infant habituates, and later examining whether the response recovers when the stimulus is changed(6). This method, however, does not reveal how fast infants can detect phonetic changes, nor what brain mechanisms are involved. We describe here high-density recordings of event-related potentials in three-month-old infants listening to syllables whose first consonants differed in place of articulation Two processing stages, corresponding to an increasingly refined analysis of the auditory input, were identified and localised to the temporal lobes. A late frontal response to novelty was also observed. The infant brain recognizes a phonetic change in less than 400 ms.	CNRS,SCI COGNIT & PSYCHOLINGUIST LAB,INSERM,F-75270 PARIS 06,FRANCE; EHESS,F-75270 PARIS 06,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	DEHAENELAMBERTZ, G (corresponding author), UNIV OREGON,INST COGNIT & DECIS SCI,EUGENE,OR 97405, USA.		Dehaene, Ghislaine/O-3633-2017	Dehaene, Ghislaine/0000-0003-2221-9081				BERTONCINI J, 1989, BRAIN LANG, V37, P591, DOI 10.1016/0093-934X(89)90113-2; BEST CT, 1988, J EXP PSYCHOL HUMAN, V14, P345, DOI 10.1037/0096-1523.14.3.345; BEST CT, 1982, PERCEPT PSYCHOPHYS, V31, P75, DOI 10.3758/BF03206203; CHI JG, 1977, ANN NEUROL, V1, P86, DOI 10.1002/ana.410010109; Courchesne E, 1983, TUTORIALS EVENT RELA, P329; EIMAS PD, 1971, SCIENCE, V171, P303, DOI 10.1126/science.171.3968.303; EMIAS PD, 1987, CATEGORICAL PERCEPTI, P161; JUSCZYK PW, 1985, MEASUREMENT AUDITION, P195; KUHL PK, 1992, SCIENCE, V255, P606, DOI 10.1126/science.1736364; LeMay M., 1984, CEREBRAL DOMINANCE B, P26; MILLS DL, 1993, J COGNITIVE NEUROSCI, V5, P317, DOI 10.1162/jocn.1993.5.3.317; MOLFESE DL, 1991, CEREBRAL LATERALITY, P71; NAATANEN R, 1990, BEHAV BRAIN SCI, V13, P201, DOI 10.1017/S0140525X00078407; Naatanen R, 1983, ADV PSYCHOL, P119, DOI DOI 10.1016/S0166-4115(08)62036-1; NELSON CA, 1992, DEV NEUROPSYCHOL, V8, P119, DOI 10.1080/87565649209540521; NOVAK GP, 1989, ELECTROEN CLIN NEURO, V73, P295, DOI 10.1016/0013-4694(89)90108-9; PERRIN F, 1989, ELECTROEN CLIN NEURO, V72, P184, DOI 10.1016/0013-4694(89)90180-6; Rothbart M. K., 1990, ADV PSYCHOL, V69, P47; SCHERG M, 1990, BESA BRAIN ELECTRICA; TUCKER DM, 1993, ELECTROEN CLIN NEURO, V87, P154, DOI 10.1016/0013-4694(93)90121-B; VARGHAKHADEM F, 1979, BRAIN LANG, V8, P19; WERKER JF, 1984, INFANT BEHAV DEV, V7, P49, DOI 10.1016/S0163-6383(84)80022-3; WITELSON SF, 1973, BRAIN, V96, P641, DOI 10.1093/brain/96.3.641; WOODS DL, 1986, ELECTROEN CLIN NEURO, V65, P447, DOI 10.1016/0168-5597(86)90024-9; [No title captured]	25	235	236	0	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 28	1994	370	6487					292	295		10.1038/370292a0	http://dx.doi.org/10.1038/370292a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NZ229	8035876				2022-12-24	WOS:A1994NZ22900063
J	LAUGHLAN, G; MURCHIE, AIH; NORMAN, DG; MOORE, MH; MOODY, PCE; LILLEY, DMJ; LUISI, B				LAUGHLAN, G; MURCHIE, AIH; NORMAN, DG; MOORE, MH; MOODY, PCE; LILLEY, DMJ; LUISI, B			THE HIGH-RESOLUTION CRYSTAL-STRUCTURE OF A PARALLEL-STRANDED GUANINE TETRAPLEX	SCIENCE			English	Article							TELOMERIC DNA; COMPLEX; OLIGONUCLEOTIDE; SEQUENCE; RNA	Repeat tracts of guanine bases found in DNA and RNA can form tetraplex structures in the presence of a variety of monovalent cations. Evidence suggests that guanine tetraplexes assume important functions within chromosomal telomeres, immunoglobulin switch regions, and the human immunodeficiency virus genome. The structure of a parallel-stranded tetraplex formed by the hexanucleotide d(TG(4)T) and stabilized by sodium cations was determined by x-ray crystallography to 1.2 angstroms resolution. Sharply resolved sodium cations were found between and within planes of hydrogen-bonded guanine quartets, and an ordered groove hydration was observed. Distinct intra- and intermolecular stacking arrangements were adopted by the guanine quartets. Thymine bases were exclusively involved in making extensive lattice contacts.	UNIV DUNDEE, DEPT BIOCHEM, CANC RES CAMPAIGN, NUCL ACID RES GRP, DUNDEE DD1 4HN, SCOTLAND; UNIV YORK, DEPT CHEM, YORK YO1 5DD, N YORKSHIRE, ENGLAND	University of Dundee; University of York - UK	LAUGHLAN, G (corresponding author), UNIV GLASGOW, MRC, VIROL UNIT, CHURCH ST, GLASGOW G11 5JR, SCOTLAND.		Moody, Peter/A-6832-2008	Moody, Peter/0000-0003-1762-9238				ABOULELA F, 1992, NATURE, V360, P280, DOI 10.1038/360280a0; ABOULELA F, IN PRESS J MOL BIOL; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BRUNGER AT, 1993, X PLOR SYSTEM XRAY C; CHEONG CJ, 1992, BIOCHEMISTRY-US, V31, P8406, DOI 10.1021/bi00151a003; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013; HARDIN CC, 1991, BIOCHEMISTRY-US, V30, P4460, DOI 10.1021/bi00232a013; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0; KARLE IL, 1974, BIOCHEMISTRY-US, V13, P2155, DOI 10.1021/bi00707a025; KIM J, 1991, NATURE, V351, P331, DOI 10.1038/351331a0; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; NAVAZA J, 1990, ACTA CRYSTALLOGR A, V46, P619, DOI 10.1107/S0108767390000290; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PIELES U, 1993, NUCLEIC ACIDS RES, V21, P3191, DOI 10.1093/nar/21.14.3191; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SHELDRICK GM, SHELX 93; SMITH FW, 1993, BIOCHEMISTRY-US, V32, P8682, DOI 10.1021/bi00084a040; SUNDQUIST WI, 1993, P NATL ACAD SCI USA, V90, P3393, DOI 10.1073/pnas.90.8.3393; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; WANG Y, 1993, J MOL BIOL, V234, P1171, DOI 10.1006/jmbi.1993.1668; WANG Y, 1992, BIOCHEMISTRY-US, V31, P8112, DOI 10.1021/bi00150a002; WANG Y, 1991, NUCLEIC ACIDS RES, V19, P4619, DOI 10.1093/nar/19.17.4619; WANG Y, 1993, STRUCTURE, V1, P263, DOI 10.1016/0969-2126(93)90015-9; WANG Y, 1991, J MOL BIOL, V222, P819, DOI 10.1016/0022-2836(91)90513-6; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7	29	495	504	0	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 22	1994	265	5171					520	524		10.1126/science.8036494	http://dx.doi.org/10.1126/science.8036494			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	8036494	Green Submitted			2022-12-24	WOS:A1994NY21600029
J	ZIMMERMAN, GC; GRABSKI, WJ				ZIMMERMAN, GC; GRABSKI, WJ			MALIGNANT-MELANOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											ZIMMERMAN, GC (corresponding author), BROOKE ARMY MED CTR,FT SAM HOUSTON,TX 78234, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 21	1994	331	3					168	168						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW797	8008030				2022-12-24	WOS:A1994NW79700005
J	FOSTER, PL; TRIMARCHI, JM				FOSTER, PL; TRIMARCHI, JM			ADAPTIVE REVERSION OF A FRAMESHIFT MUTATION IN ESCHERICHIA-COLI BY SIMPLE BASE DELETIONS IN HOMOPOLYMERIC RUNS	SCIENCE			English	Article							SALMONELLA-TYPHIMURIUM; SEQUENCE-ANALYSIS; MISMATCH REPAIR; DNA; HOMOLOG; CANCER; OCCUR	Spontaneous mutations are thought to occur primarily in growing cells. However, spontaneous mutations also arise in nutritionally deprived cells, and in some cases this process appears to be adaptive. Here it is reported that when a Lac(-) strain of Escherichia coli is under selection for lactose use, the spectrum of Lac(+) mutations that arises is different, and simpler, than that arising without selection. Mutations appearing during selection were mainly one-base deletions in runs of iterated bases. Similar mutations occurring in repetitive DNA elements are associated with a variety of human hereditary diseases and are increased in cells that cannot correct heteroduplex DNA.	BOSTON UNIV,SCH MED,BOSTON,MA 02118	Boston University	FOSTER, PL (corresponding author), BOSTON UNIV,SCH PUBL HLTH,DEPT ENVIRONM HLTH,BOSTON,MA 02118, USA.			Foster, Patricia/0000-0002-7236-4378; Trimarchi, Jeffrey/0000-0001-7923-1538	NIGMS NIH HHS [R01 GM054084-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054084] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON P, 1981, P NATL ACAD SCI-BIOL, V78, P3113, DOI 10.1073/pnas.78.5.3113; ASAI T, 1994, J BACTERIOL, V176, P1807, DOI 10.1128/jb.176.7.1807-1812.1994; BOE L, 1990, MOL MICROBIOL, V4, P597, DOI 10.1111/j.1365-2958.1990.tb00628.x; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; CAIRNS J, 1991, GENETICS, V128, P695; CALOS MP, 1981, J MOL BIOL, V153, P39, DOI 10.1016/0022-2836(81)90525-8; CUPPLES CG, 1990, GENETICS, V125, P275; DRAKE JW, 1991, ANNU REV GENET, V25, P125, DOI 10.1146/annurev.ge.25.120191.001013; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FOSTER PL, 1992, GENETICS, V131, P783; FOSTER PL, 1993, ANNU REV MICROBIOL, V47, P467; HALL BG, 1991, GENETICA, V84, P73, DOI 10.1007/BF00116545; HALL BG, 1990, GENETICS, V126, P5; HARRIS RS, 1994, SCIENCE, V264, P258, DOI 10.1126/science.8146657; HASTINGS PJ, 1992, ENCY IMMUNOLOGY, P602; HIGGINS NP, 1992, TRENDS BIOCHEM SCI, V17, P207, DOI 10.1016/0968-0004(92)90376-K; KUNKEL TA, 1988, BIOCHIM BIOPHYS ACTA, V951, P1, DOI 10.1016/0167-4781(88)90020-6; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Miller J.H., 1972, EXPT MOL GENETICS; MULLERHI.B, 1974, NATURE, V249, P561, DOI 10.1038/249561a0; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PRIVAL MJ, 1992, GENETICS, V132, P303; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; ROSENBERG SM, 1994, SCIENCE, V265, P405, DOI 10.1126/science.8023163; Roth Jurgen, COMMUNICATION; RYAN FJ, 1961, Z VEREBUNGSL, V92, P38, DOI 10.1007/BF01854099; SCHAAPER RM, 1987, P NATL ACAD SCI USA, V84, P6220, DOI 10.1073/pnas.84.17.6220; STAHL FW, 1992, GENETICS, V132, P865; STAHL FW, 1988, NATURE, V335, P112, DOI 10.1038/335112a0; STEELE DF, 1992, GENETICS, V132, P9; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014	35	169	174	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 15	1994	265	5170					407	409		10.1126/science.8023164	http://dx.doi.org/10.1126/science.8023164			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023164	Green Accepted			2022-12-24	WOS:A1994NW81600044
J	GODAL, T				GODAL, T			FIGHTING THE PARASITES OF POVERTY - PUBLIC RESEARCH, PRIVATE INDUSTRY, AND TROPICAL DISEASES	SCIENCE			English	Editorial Material											GODAL, T (corresponding author), UNDP,WORLD BANK,WHO,SPECIAL PROGRAMME RES & TRAINING TROP DIS,CH-1211 GENEVA,SWITZERLAND.							ABIOSE A, 1993, LANCET, V341, P130, DOI 10.1016/0140-6736(93)90002-X; HENDERSON RH, 1994, 4TH ANN PUBL HLTH FO; 1994, WKLY EPIDEMIOL REC, V69, P145; 1993, 1993 WORLD BANK WORL, P329; 1990, HLTH RES ESSENTIAL L, P136	5	9	9	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1864	1866		10.1126/science.8009212	http://dx.doi.org/10.1126/science.8009212			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NT847	8009212				2022-12-24	WOS:A1994NT84700025
J	SOUTTER, WP; FLETCHER, A				SOUTTER, WP; FLETCHER, A			INVASIVE CANCER OF THE CERVIX IN WOMEN WITH MILD DYSKARYOSIS FOLLOWED UP CYTOLOGICALLY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SMEAR; COLPOSCOPY; MANAGEMENT; ATYPIA	Mildly dyskaryotic smears are common, and women with such results are often followed up with further cervical smear tests. An important consideration in evaluating this practice would be the annual incidence of invasive cervical cancer. A reanalysis of five previous studies of the cytological follow up of women with mildly abnormal smear test results was undertaken to calculate this incidence. The annual incidence of invasive cancer in these women ranged from 0 to 420 per 100 000 women years. The large studies providing the most precise estimates had annual rates of 143 to 420 per 100 000 women years. This is 16 to 47 times greater than in-women aged 15-34 years in England and Wales. The average rate was 208 per 100 000 women years. Women with mild dyskaryosis are at high risk of developing invasive cervical cancer despite cytological follow up. A full appraisal of the costs and benefits of colposcopy in this situation is urgently required.	LONDON SCH HYG & TROP MED, DEPT EPIDEMIOL & POPULAT STUDIES, LONDON WC1E 7HT, ENGLAND	University of London; London School of Hygiene & Tropical Medicine	SOUTTER, WP (corresponding author), ROYAL POSTGRAD MED SCH, INST OBSTET & GYNAECOL, LONDON W12 0NN, ENGLAND.							ANDERSON DJ, 1992, BMJ-BRIT MED J, V305, P84, DOI 10.1136/bmj.305.6845.84; ANDERSON GH, 1988, BMJ-BRIT MED J, V296, P975, DOI 10.1136/bmj.296.6627.975; BOLGER BS, 1988, BRIT J OBSTET GYNAEC, V95, P1117, DOI 10.1111/j.1471-0528.1988.tb06788.x; COOPER P, 1992, CYTOPATHOLOGY, V3, P331; CUZICK J, 1994, BRIT J CANCER, V69, P167, DOI 10.1038/bjc.1994.28; FLETCHER A, 1990, BRIT MED J, V301, P641, DOI 10.1136/bmj.301.6753.641; HIRSCHOWITZ L, 1992, BRIT MED J, V304, P1209, DOI 10.1136/bmj.304.6836.1209; JOHNSON N, 1993, LANCET, V342, P91, DOI 10.1016/0140-6736(93)91290-3; JONES MH, 1992, LANCET, V339, P1440, DOI 10.1016/0140-6736(92)92031-A; KESIC VI, 1993, INT J GYNECOL CANCER, V3, P395, DOI 10.1046/j.1525-1438.1993.03060395.x; KIRBY AJ, 1992, LANCET, V339, P828, DOI 10.1016/0140-6736(92)90278-B; PEARSON SE, 1989, BRIT J OBSTET GYNAEC, V96, P486, DOI 10.1111/j.1471-0528.1989.tb02429.x; ROBERTSON JH, 1988, BRIT MED J, V297, P18, DOI 10.1136/bmj.297.6640.18; SIGURDSSON K, 1989, INT J CANCER, V43, P1, DOI 10.1002/ijc.2910430102; SOUTTER WP, 1986, BRIT J OBSTET GYNAEC, V93, P70, DOI 10.1111/j.1471-0528.1986.tb07816.x; SOUTTER WP, 1992, REPORT WORKSHOP MILD; WALKER EM, 1986, LANCET, V2, P672; WILKINSON C, 1990, BRIT MED J, V300, P440, DOI 10.1136/bmj.300.6722.440; 1990, SERIES MB1, V18; 1987, INTERCOLLEGIATE WORK	20	59	60	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 28	1994	308	6941					1421	1423		10.1136/bmj.308.6941.1421	http://dx.doi.org/10.1136/bmj.308.6941.1421			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP420	8019256	Green Published			2022-12-24	WOS:A1994NP42000022
J	BINCHY, JM; MOLYNEUX, EM; MANNING, J				BINCHY, JM; MOLYNEUX, EM; MANNING, J			ACCIDENTAL INGESTION OF METHADONE BY CHILDREN IN MERSEYSIDE	BRITISH MEDICAL JOURNAL			English	Article									ROYAL LIVERPOOL CHILDRENS HOSP,LIVERPOOL L12 2AP,ENGLAND; WIRRAL HOSP,ARROWE PK L49 5PE,MERSEYSIDE,ENGLAND	Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital								ARONOW R, 1973, CLIN TOXICOL, V6, P175, DOI 10.3109/15563657308990515; ARONOW R, 1972, J AMER MED ASSOC, V219, P321, DOI 10.1001/jama.219.3.321; BALTMAN S, 1971, PEDIATRICS, V48, P173; DIMAIO D J, 1973, Journal of Forensic Sciences, V18, P130; SMIALEK JE, 1977, JAMA-J AM MED ASSOC, V238, P2516, DOI 10.1001/jama.238.23.2516	5	61	62	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 21	1994	308	6940					1335	1336		10.1136/bmj.308.6940.1335	http://dx.doi.org/10.1136/bmj.308.6940.1335			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM989	8019221	Green Published			2022-12-24	WOS:A1994NM98900022
J	SHADICK, NA; PHILLIPS, CB; LOGIGIAN, EL; STEERE, AC; KAPLAN, RF; BERARDI, VP; DURAY, PH; LARSON, MG; WRIGHT, EA; GINSBURG, KS; KATZ, JN; LIANG, MH				SHADICK, NA; PHILLIPS, CB; LOGIGIAN, EL; STEERE, AC; KAPLAN, RF; BERARDI, VP; DURAY, PH; LARSON, MG; WRIGHT, EA; GINSBURG, KS; KATZ, JN; LIANG, MH			THE LONG-TERM CLINICAL OUTCOMES OF LYME-DISEASE - A POPULATION-BASED RETROSPECTIVE COHORT STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						LYME DISEASE; OUTCOME ASSESSMENT (HEALTH CARE); ARTHRITIS; VERBAL LEARNING; BORRELIA BURGDORFERI	NERVOUS-SYSTEM MANIFESTATIONS; BORRELIA-BURGDORFERI; FIBROMYALGIA; ARTHRITIS; SERODIAGNOSIS; DIAGNOSIS	Objective: To ascertain the prevalence of and risk factors for long-term sequelae from acute Lyme disease. Design: Population-based, retrospective cohort study. Setting: A coastal region endemic for Lyme disease. Participants: Patients with a history of Lyme disease who were previously treated with antibiotics were compared with randomly selected controls. Measurements: A standardized physical examination, health status measure (Short Form 36), psychometric test battery, and serologic analysis. Results: Compared with the control group (n = 43), the Lyme group (n = 38; mean duration from disease onset to study evaluation, 6.2 years) had more arthralgias (61% compared with 16%; P < 0.0001); distal paresthesias (16% compared with 2%; P = 0.03); concentration difficulties (16% compared with 2%; P= 0.03); and fatigue (26% compared with 9%; P = 0.04), and they had poorer global health status scores (P = 0.04). The Lyme group also had more abnormal joints (P = 0.02) and more verbal memory deficits (P = 0.01) than did the control group. Overall, 13 patients (34%; 95% CI, 19% to 49%) had long-term sequelae from Lyme disease (arthritis or recurrent arthralgias [n = 6], neurocognitive impairment [n = 4], and neuropathy or myelopathy [n = 3]). Compared with controls, patients who had long-term sequelae had higher IgG antibody titers to the spirochete (P = 0.03) and received treatment later (34.5 months compared with 2.7 months; P < 0.0001). Conclusions: Persons with a history pf Lyme disease have more musculoskeletal impairment and a higher prevalence of verbal memory impairment when compared with those without a history of Lyme disease. Our findings suggest that disseminated Lyme disease may be associated with long-term morbidity.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED, ROBERT B BRIGHAM MULTIPURPOSE ARTHRIT CTR, DEPT MED, BOSTON, MA 02115 USA; TUFTS UNIV, NEW ENGLAND MED CTR, SCH MED, DIV RHEUMATOL IMMUNOL, BOSTON, MA 02111 USA; TUFTS UNIV, NEW ENGLAND MED CTR, SCH MED, DEPT NEUROL, BOSTON, MA 02111 USA; IMUGENE INC, DIV RES, NORWOOD, MA 02062 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED, ROBERT B BRIGHAM MULTIPURPOSE ARTHRIT CTR, DEPT PATHOL, BOSTON, MA 02115 USA; FRAMINGHAM HEART DIS EPIDEMIOL STUDY, FRAMINGHAM, MA 01701 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Framingham Heart Study	SHADICK, NA (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, ROBERT B BRIGHAM MULTIPURPOSE ARTHRIT CTR, BOSTON, MA 02115 USA.			Larson, Martin/0000-0002-9631-1254; Steere, Allen/0000-0002-5268-9853	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007530, P60AR036308, R01AR020358] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR20358, AR07530, AR36308] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABERER E, 1991, J CLIN MICROBIOL, V29, P764, DOI 10.1128/JCM.29.4.764-772.1991; Army Individual Test Battery, 1944, MANUAL DIRECTIONS SC; BERARDI VP, 1988, J INFECT DIS, V158, P754, DOI 10.1093/infdis/158.4.754; Breslow N.E., 1980, STAT METHODS CANC RE, P192; BURGDORFER W, 1984, YALE J BIOL MED, V57, P515; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; DINERMAN H, 1992, ANN INTERN MED, V117, P281, DOI 10.7326/0003-4819-117-4-281; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; Duray P, 1985, LAB MED, V16, P685, DOI DOI 10.1093/LABMED/16.11.685; GRODZICKI RL, 1988, J INFECT DIS, V157, P790, DOI 10.1093/infdis/157.4.790; HAHN RD, 1959, ARCH NEURO PSYCHIATR, V81, P557, DOI 10.1001/archneurpsyc.1959.02340170023003; HALPERIN JJ, 1988, ANN NY ACAD SCI, V539, P24, DOI 10.1111/j.1749-6632.1988.tb31835.x; HALPERIN JJ, 1989, NEUROLOGY, V39, P753, DOI 10.1212/WNL.39.6.753; HSU VM, 1993, ARTHRITIS RHEUM, V36, P1493, DOI 10.1002/art.1780361103; KAPLAN RF, 1992, NEUROLOGY, V42, P1263, DOI 10.1212/WNL.42.7.1263; KRUPP LB, 1991, ARCH NEUROL-CHICAGO, V48, P1125, DOI 10.1001/archneur.1991.00530230033017; LASTAVICA CC, 1989, NEW ENGL J MED, V320, P133, DOI 10.1056/NEJM198901193200301; LOGIGIAN EL, 1990, NEW ENGL J MED, V323, P1438, DOI 10.1056/NEJM199011223232102; LOGIGIAN EL, 1992, NEUROLOGY, V42, P303, DOI 10.1212/WNL.42.2.303; Ober B. A, 1988, CALIFORNIA VERBAL LE; PACHNER AR, 1989, ARCH NEUROL-CHICAGO, V46, P790, DOI 10.1001/archneur.1989.00520430086023; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; SCHMUTZHARD E, 1992, 5TH INT C LYM BORR, P45; Shipley, 1946, I LIVING SCALE; SIGAL LH, 1990, AM J MED, V88, P577, DOI 10.1016/0002-9343(90)90520-N; STEERE AC, 1990, NEW ENGL J MED, V323, P219, DOI 10.1056/NEJM199007263230402; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; SZER IS, 1991, NEW ENGL J MED, V325, P159, DOI 10.1056/NEJM199107183250304; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WEBER K, 1988, PEDIATR INFECT DIS J, V7, P286, DOI 10.1097/00006454-198804000-00010; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; ZAR JH, 1984, BIOSTAT ANAL, P397; 1990, CONNECTICUT EPIDEMIO, V10, P9; 1948, EXAMINERS MANUAL PUR; 1985, DICT RHEUMATIC DISEA, V1, P78; 1993, MMWR-MORBID MORTAL W, V42, P2; 1990, SAS STAT USERS GUIDE, P175	40	189	193	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1994	121	8					560	+		10.7326/0003-4819-121-8-199410150-00002	http://dx.doi.org/10.7326/0003-4819-121-8-199410150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL486	8085687				2022-12-24	WOS:A1994PL48600002
J	STOCKDALE, FE				STOCKDALE, FE			MAMMOGRAPHY, NEEDLE-BIOPSY, AND TUMOR SPREAD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							BREAST				STOCKDALE, FE (corresponding author), STANFORD UNIV,SCH MED,STANFORD,CA 94305, USA.							FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; HARTER LP, 1992, RADIOLOGY, V185, P713, DOI 10.1148/radiology.185.3.1343569	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 21	1994	272	11					895	896						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG182	8078171				2022-12-24	WOS:A1994PG18200033
J	HANNON, GJ; BEACH, D				HANNON, GJ; BEACH, D			P15(INK4B) IS A POTENTIAL EFFECTOR OF TGF-BETA-INDUCED CELL-CYCLE ARREST	NATURE			English	Article							TRANSFORMING GROWTH-FACTOR; HOMOZYGOUS DELETIONS; INHIBITION; KINASES; LINE; MELANOMA	TRANSFORMING growth factor-beta (TGF-beta) inhibits cell proliferation by inducing a G1-phase cell cycle arrest(1). Normal progression through G1 is promoted by the activity of the cyclin-dependent protein kinases CDK4 and CDK6 (ref. 2), which are inhibited by the protein p16(INK4). We have isolated a new member of the p16(INK4) family, p15(INK4B). p15 expression is induced similar to 30-fold in human keratinocytes by treatment with TGF-beta, suggesting that p15 may act as an effector of TGF-beta-mediated cell cycle arrest. The gene encoding p15 is located on chromosome 9 adjacent to the p16 gene at a frequent site of chromosomal abnormality in human tumours (9p21).	COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute			Hannon, Gregory/AAB-3568-2019					BATES S, 1994, ONCOGENE, V9, P71; BELLO MJ, 1994, GENE CHROMOSOME CANC, V9, P33; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CHENG JQ, 1993, CANCER RES, V53, P4761; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; MANNING AM, 1991, ONCOGENE, V6, P1471; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MERLO A, 1994, CANCER RES, V54, P640; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MOSES HL, 1985, CANCER CELL, V3, P65; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; PETTY EM, 1993, AM J HUM GENET, V53, P96; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RODECK U, 1994, CANCER RES, V54, P575; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	28	1913	1989	1	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 15	1994	371	6494					257	261		10.1038/371257a0	http://dx.doi.org/10.1038/371257a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG290	8078588				2022-12-24	WOS:A1994PG29000056
J	DOBROWSKY, RT; WERNER, MH; CASTELLINO, AM; CHAO, MV; HANNUN, YA				DOBROWSKY, RT; WERNER, MH; CASTELLINO, AM; CHAO, MV; HANNUN, YA			ACTIVATION OF THE SPHINGOMYELIN CYCLE THROUGH THE LOW-AFFINITY NEUROTROPHIN RECEPTOR	SCIENCE			English	Article							NERVE GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; NGF RECEPTOR; CELL-DIFFERENTIATION; TRK PROTOONCOGENE; PROTEIN-KINASE; CERAMIDE; BINDING; EXPRESSION; RESPONSIVENESS	The role of the low-affinity neurotrophin receptor (p75(NTR)) in signal transduction is undefined. Nerve growth factor can activate the sphingomyelin cycle, generating the putative-lipid second messenger ceramide. In T9 glioma cells, addition of a cell-permeable ceramide analog mimicked the effects of nerve growth factor on cell growth inhibition and process formation. This signaling pathway appears to be mediated by p75(NTR) in T9 cells and NIH 3T3 cells overexpressing p75(NTR). Expression of an epidermal growth factor receptor-p75(NTR) chimera in T9 cells imparted to epidermal growth factor the ability to activate the sphingomyelin cycle. These data demonstrate that p75(NTR) is capable of signaling independently of the trk neurotrophin receptor (p140(trk)) and that ceramide may be a mediator in neurotrophin biology.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; CORNELL UNIV,COLL MED,DEPT CELL BIOL & ANAT,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DIV HEMATOL ONCOL,NEW YORK,NY 10021	Duke University; Duke University; Cornell University; Cornell University				Chao, Moses/0000-0002-6969-3744	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, R37GM043825] Funding Source: NIH RePORTER; NIA NIH HHS [AG05531] Funding Source: Medline; NIGMS NIH HHS [GM43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTON ES, 1994, P NATL ACAD SCI USA, V91, P2795, DOI 10.1073/pnas.91.7.2795; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BARRETT GL, 1994, P NATL ACAD SCI USA, V91, P6501, DOI 10.1073/pnas.91.14.6501; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; BIRREN SJ, 1992, SCIENCE, V257, P395, DOI 10.1126/science.1321502; Chan-Palay V., 1990, DEMENT GERIATR COGN, V1, P138, DOI [DOI 10.1159/0001, 10.1159/000107133, DOI 10.1159/000107133]; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DOBROWSKY RT, UNPUB; FEINSTEIN DL, 1990, FEBS LETT, V272, P7, DOI 10.1016/0014-5793(90)80437-N; GROB PM, 1985, J BIOL CHEM, V260, P8044; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; HERMANN JL, 1993, MOL BIOL CELL, V4, P1205; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAHLE P, 1992, J BIOL CHEM, V267, P13917; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KIM MY, 1991, J BIOL CHEM, V266, P484; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; MAHADEO D, 1994, J BIOL CHEM, V269, P6884; MARUSHIGE Y, 1987, CANCER RES, V47, P4109; MATHIAS S, 1991, P NATL ACAD SCI USA, V88, P10009, DOI 10.1073/pnas.88.22.10009; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MEAKIN SO, 1991, NEURON, V6, P153, DOI 10.1016/0896-6273(91)90130-R; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OHMICHI M, 1991, CELL REGUL, V2, P691, DOI 10.1091/mbc.2.9.691; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OLIVERA A, 1992, J BIOL CHEM, V267, P26121; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; REPRESA J, 1991, P NATL ACAD SCI USA, V88, P8016, DOI 10.1073/pnas.88.18.8016; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TANIUCHI M, 1988, J NEUROSCI, V8, P664; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; VOLONTE C, 1993, J BIOL CHEM, V268, P21410; VONBARTHELD CS, 1994, NEURON, V12, P639, DOI 10.1016/0896-6273(94)90219-4; YAN H, 1991, SCIENCE, V252, P561, DOI 10.1126/science.1850551	45	534	542	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 9	1994	265	5178					1596	1599		10.1126/science.8079174	http://dx.doi.org/10.1126/science.8079174			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF336	8079174				2022-12-24	WOS:A1994PF33600041
J	DAVIES, JL; KAWAGUCHI, Y; BENNETT, ST; COPEMAN, JB; CORDELL, HJ; PRITCHARD, LE; REED, PW; GOUGH, SCL; JENKINS, SC; PALMER, SM; BALFOUR, KM; ROWE, BR; FARRALL, M; BARNETT, AH; BAIN, SC; TODD, JA				DAVIES, JL; KAWAGUCHI, Y; BENNETT, ST; COPEMAN, JB; CORDELL, HJ; PRITCHARD, LE; REED, PW; GOUGH, SCL; JENKINS, SC; PALMER, SM; BALFOUR, KM; ROWE, BR; FARRALL, M; BARNETT, AH; BAIN, SC; TODD, JA			A GENOME-WIDE SEARCH FOR HUMAN TYPE-1 DIABETES SUSCEPTIBILITY GENES	NATURE			English	Article							MELLITUS IDDM; INSULIN GENE; LINKAGE ANALYSIS; QUANTITATIVE TRAITS; MENDELIAN FACTORS; HLA; POLYMORPHISM; REGION; LOCUS; MICE	We have searched the human genome for genes that predispose to type 1 (insulin-dependent) diabetes mellitus using semi-automated fluorescence-based technology and linkage analysis. In addition to IDDM1 (in the major histocompatibility complex on chromosome 6p21) and IDDM2 (in the insulin gene region on chromosome 11p15), eighteen different chromosome regions showed some positive evidence of linkage to disease. Linkages to chromosomes iio (IDDM4) and 6q (IDDM5) were confirmed by replication, and chromosome is may encode a fifth disease locus. There are probably no genes with large effects aside from IDDM1. Therefore polygenic inheritance Is indicated, with a major locus at the major histocompatibility complex.	UNIV OXFORD,WELLCOME TRUST CTR HUMAN GENET,OXFORD OX3 7BN,ENGLAND; UNIV BIRMINGHAM,BIRMINGHAM HEARTLANDS HOSP,DEPT MED DIABET ENDOCRINOL,BIRMINGHAM B9 5SS,W MIDLANDS,ENGLAND; HAMMERSMITH HOSP,MRC,CLIN RES CTR,LONDON W12 0NN,ENGLAND	University of Oxford; Wellcome Centre for Human Genetics; Heart of England NHS Foundation Trust; University of Birmingham; Imperial College London; Medical Research Council Clinical Trials Unit	DAVIES, JL (corresponding author), UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT SURG,OXFORD OX3 9DU,ENGLAND.		Peng, Bo/A-6920-2009; Todd, John A/A-3542-2010	Peng, Bo/0000-0001-8225-2284; Todd, John A/0000-0003-2740-8148; Cordell, Heather/0000-0002-1879-5572	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAIN SC, 1990, AUTOIMMUNITY, V7, P83, DOI 10.3109/08916939008993380; BAIN SC, 1992, NAT GENET, V2, P212, DOI 10.1038/ng1192-212; BARBOSA J, 1982, J CLIN ENDOCR METAB, V55, P193, DOI 10.1210/jcem-55-1-193; BELL GI, 1984, DIABETES, V33, P176, DOI 10.2337/diabetes.33.2.176; BRETT PM, 1991, NUCLEIC ACIDS RES, V19, P6978, DOI 10.1093/nar/19.24.6978-a; BUETOW KH, 1994, NAT GENET, V6, P391, DOI 10.1038/ng0494-391; CAILLATZUCMAN S, 1992, J CLIN INVEST, V90, P2242, DOI 10.1172/JCI116110; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; CORNALL RJ, 1991, NATURE, V353, P262, DOI 10.1038/353262a0; DUNSWORTH TS, 1982, DIABETES, V31, P991, DOI 10.2337/diabetes.31.11.991; EFF C, 1978, DIABETOLOGIA, V15, P169, DOI 10.1007/BF00421234; ELSTON RC, 1994, GENETIC APPROACHES M, P3; FOULIS AK, 1986, DIABETOLOGIA, V29, P267, DOI 10.1007/BF00452061; GHOSH S, 1993, NAT GENET, V4, P404, DOI 10.1038/ng0893-404; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; H/CEPH Collaborative Mapping Group, 1992, SCIENCE, V258, P67; HEARNE CM, 1992, TRENDS GENET, V8, P288, DOI 10.1016/0168-9525(92)90256-4; HODGE SE, 1981, LANCET, V2, P893; HODGE SE, 1983, AM J HUM GENET, V35, P1139; HOLMANS P, 1993, AM J HUM GENET, V52, P362; HYER RN, 1991, AM J HUM GENET, V48, P243; JULIER C, 1991, NATURE, V354, P155, DOI 10.1038/354155a0; JUNIEN C, 1991, CYTOGENET CELL GENET, V58, P459, DOI 10.1159/000133171; KARJALAINEN J, 1989, NEW ENGL J MED, V320, P881, DOI 10.1056/NEJM198904063201401; LANDER ES, 1989, GENETICS, V121, P185; LEBEAU MM, 1991, CYTOGENET CELL GENET, V58, P739, DOI 10.1159/000133178; LERNMARK A, 1990, AM J HUM GENET, V47, P1028; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MORTON NE, 1983, AM J HUM GENET, V35, P201; OWERBACH D, 1990, DIABETES, V39, P1504, DOI 10.2337/diabetes.39.12.1504; PATERSON AH, 1988, NATURE, V335, P721, DOI 10.1038/335721a0; PENROSE LS, 1953, ANN EUGENIC, V18, P120; POCIOT F, IN PRESS AUTOIMMUNIT; REED PW, 1994, NAT GENET, V7, P390, DOI 10.1038/ng0794-390; RISCH N, 1990, GENET EPIDEMIOL, V7, P3, DOI 10.1002/gepi.1370070103; RISCH N, 1990, AM J HUM GENET, V46, P242; RISCH N, 1993, AM J HUM GENET, V53, P702; RISCH N, 1987, AM J HUM GENET, V40, P1; RISCH N, 1991, AM J HUM GENET, V48, P1058; RISE ML, 1991, SCIENCE, V253, P669, DOI 10.1126/science.1871601; SCHWENGEL DA, 1994, GENOMICS, V22, P46, DOI 10.1006/geno.1994.1344; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; SUAREZ BK, 1994, GENETIC APPROACHES M, P23; THOMSON G, 1989, GENET EPIDEMIOL, V6, P155, DOI 10.1002/gepi.1370060129; TODD JA, 1994, DIABETIC MED, V11, P6, DOI 10.1111/j.1464-5491.1994.tb00222.x; TODD JA, 1991, NATURE, V351, P542, DOI 10.1038/351542a0; TODD JA, 1992, DIABETES, V41, P1029, DOI 10.2337/diabetes.41.9.1029; VANDEWALLE CL, 1993, DIABETOLOGIA, V36, P1155, DOI 10.1007/BF00401060; WEBER JL, 1989, AM J HUM GENET, V44, P388; ZIEGLE JS, 1992, GENOMICS, V14, P1026, DOI 10.1016/S0888-7543(05)80126-0	50	1212	1250	0	61	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 8	1994	371	6493					130	136		10.1038/371130a0	http://dx.doi.org/10.1038/371130a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF191	8072542				2022-12-24	WOS:A1994PF19100055
J	ANDINO, R; SILVERA, D; SUGGETT, SD; ACHACOSO, PL; MILLER, CJ; BALTIMORE, D; FEINBERG, MB				ANDINO, R; SILVERA, D; SUGGETT, SD; ACHACOSO, PL; MILLER, CJ; BALTIMORE, D; FEINBERG, MB			ENGINEERING POLIOVIRUS AS A VACCINE VECTOR FOR THE EXPRESSION OF DIVERSE ANTIGENS	SCIENCE			English	Article							PROTEIN-SYNTHESIS; 5' END; CHIMERAS; RNA; SEQUENCES; VIRUS	As a step toward developing poliovirus as a vaccine vector, poliovirus recombinants were constructed by fusing exogenous peptides (up to 400 amino acids) and an artificial cleavage site for viral protease 3C(pro) to the amino terminus of the viral polyprotein. Viral replication proceeded normally. An extended polyprotein was produced in infected cells and proteolytically processed into the complete array of viral proteins plus the foreign peptide, which was excluded from mature virions. The recombinants retained exogenous sequences through successive rounds of replication in culture and in vivo. Infection of animals with recombinants elicited a humoral immune response to the foreign peptides.	GLADSTONE INST VIROL & IMMUNOL,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94141; ROCKEFELLER UNIV,NEW YORK,NY 10021; UNIV CALIF DAVIS,SCH VET MED,DEPT VET PATHOL,DAVIS,CA 95616; UNIV CALIF DAVIS,SCH VET MED,CALIF REG PRIMATE RES CTR,DAVIS,CA 95616; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; Rockefeller University; University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California San Francisco	ANDINO, R (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,POB 419100,SAN FRANCISCO,CA 94141, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022346, R01AI035545, R37AI022346] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00169] Funding Source: Medline; NIAID NIH HHS [AI35545, AI22346] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; ANDINO R, UNPUB; ANSARDI DC, 1992, J VIROL, V66, P4556, DOI 10.1128/JVI.66.7.4556-4563.1992; AUSUBEL FM, 1992, CURRENT PROTOCOLS MO, V2; BERNSTEIN HD, 1985, MOL CELL BIOL, V5, P2913, DOI 10.1128/MCB.5.11.2913; BURKE KL, 1988, NATURE, V332, P81, DOI 10.1038/332081a0; CRABBE MJC, 1990, FEBS LETT, V271, P194, DOI 10.1016/0014-5793(90)80404-7; DEDIEU JF, 1992, J VIROL, V66, P3161, DOI 10.1128/JVI.66.5.3161-3167.1992; EVANS DJ, 1989, NATURE, V339, P385, DOI 10.1038/339385a0; FEINBERG MB, 1986, CELL, V46, P807, DOI 10.1016/0092-8674(86)90062-0; HEMINGTON DA, 1988, J EXP MED, V168, P1487; KOIKE S, 1991, P NATL ACAD SCI USA, V88, P951, DOI 10.1073/pnas.88.3.951; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; MELNICK JL, 1988, VACCINES, P115; NAMOTO A, 1982, P NATL ACAD SCI USA, V79, P5793; NIXON DF, 1991, AIDS, V5, P1049; PALMENBERG AC, 1990, ANNU REV MICROBIOL, V44, P603, DOI 10.1146/annurev.mi.44.100190.003131; PEARSON GDN, 1982, P NATL ACAD SCI-BIOL, V79, P2976, DOI 10.1073/pnas.79.9.2976; RACANIELLO VR, 1981, SCIENCE, V214, P916, DOI 10.1126/science.6272391; REN R, 1990, CELL, V63, P353, DOI 10.1016/0092-8674(90)90168-E; TOYODA H, 1984, J MOL BIOL, V174, P561, DOI 10.1016/0022-2836(84)90084-6; TRONO D, 1988, J VIROL, V62, P2291, DOI 10.1128/JVI.62.7.2291-2299.1988; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.biochem.56.1.365; YIM T, UNPUB	24	123	134	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 2	1994	265	5177					1448	1451		10.1126/science.8073288	http://dx.doi.org/10.1126/science.8073288			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	8073288				2022-12-24	WOS:A1994PE73300049
J	WALCO, GA; CASSIDY, RC; SCHECHTER, NL				WALCO, GA; CASSIDY, RC; SCHECHTER, NL			PAIN, HURT, AND HARM - THE ETHICS OF PAIN CONTROL IN INFANTS AND CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SICKLE-CELL DISEASE; POSTOPERATIVE ANALGESIA; MORPHINE INFUSION; PEDIATRIC PAIN; ADOLESCENTS; MANAGEMENT; UNDERTREATMENT; PHYSICIANS; EFFICACY; PATIENT		UNIV MED & DENT NEW JERSEY,NEWARK,NJ 07103; LONG ISL JEWISH MED CTR,SCHNEIDER CHILDRENS HOSP,NEW HYDE PK,NY 11042; UNIV CONNECTICUT,CTR HLTH,FARMINGTON,CT 06032	Rutgers State University New Brunswick; Rutgers State University Medical Center; Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; University of Connecticut								ANAND K J S, 1987, Anesthesiology (Hagerstown), V67, pA502, DOI 10.1097/00000542-198709001-00502; ANAND KJS, 1987, LANCET, V1, P62; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; ANAND R, 1987, LANCET, V2, P234; ANGELL M, 1982, NEW ENGL J MED, V306, P98, DOI 10.1056/NEJM198201143060210; ARUNASALAM K, 1983, ANAESTHESIA, V38, P529; BEASLEY SW, 1987, AUST NZ J SURG, V57, P233, DOI 10.1111/j.1445-2197.1987.tb01346.x; BERDE C, 1990, PEDIATRICS, V86, pS818; BERDE CB, 1991, J PEDIATR-US, V118, P460, DOI 10.1016/S0022-3476(05)82169-9; CHAPMAN CR, 1989, CANCER, V63, P1636; DILWORTH NM, 1987, J PEDIATR SURG, V22, P264, DOI 10.1016/S0022-3468(87)80343-3; Eland JM, 1977, PAIN SOURCE BOOK NUR, P453; Ferrell B R, 1991, J Clin Ethics, V2, P108; Fitzgerald M., 1993, PAIN INFANTS CHILDRE, P11; GRUNAU RVE, 1987, PAIN, V28, P395, DOI 10.1016/0304-3959(87)90073-X; HAMMOND D, 1979, PERSPECT BIOL MED, V23, P152; HAYNES RB, 1984, JAMA-J AM MED ASSOC, V251, P61, DOI 10.1001/jama.251.1.61; ILOWITE NT, 1992, ANN RHEUM DIS, V51, P313; KOREN G, 1985, J PEDIATR-US, V107, P963, DOI 10.1016/S0022-3476(85)80205-5; LEVINE JD, 1982, PAIN, V14, P85, DOI 10.1016/0304-3959(82)90090-2; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; MARKS RM, 1973, ANN INTERN MED, V78, P173, DOI 10.7326/0003-4819-78-2-173; MARSHALL RE, 1980, INFANT BEHAV DEV, V3, P1, DOI 10.1016/S0163-6383(80)80003-8; MCCAFFERY M, 1993, PAIN INFANTS CHILDRE, P295; MCGRATH PA, 1987, PAIN, V31, P147, DOI 10.1016/0304-3959(87)90033-9; MCGRATH PJ, 1989, PEDIATR CLIN N AM, V36, P823; MECHANIC D, 1980, J HEALTH SOC BEHAV, V21, P146, DOI 10.2307/2136734; MIASKOWSKI C, 1993, 7TH WORLD C PAIN PAR, P2; MILLER RR, 1978, J CLIN PHARMACOL, V18, P180, DOI 10.1002/j.1552-4604.1978.tb01591.x; Morrison R A, 1991, Pediatr Nurs, V17, P503; Nolan K., 1993, PAIN INFANTS CHILDRE, P123; PEGELOW CH, 1992, CLIN PEDIATR, V31, P211, DOI 10.1177/000992289203100404; PETRIE A, 1967, INDIVIDUALITY PAIN S; SANDLER AN, 1992, ANESTHESIOL CLIN N A, V10, P271; Schechter N, 1993, PAIN INFANTS CHILDRE; SCHECHTER NL, 1986, PEDIATRICS, V77, P11; SCHECHTER NL, 1986, J DEV BEHAV PEDIATR, V7, P350; SCHECHTER NL, 1989, PEDIATR CLIN N AM, V36, P781; SHANNON M, 1989, PEDIATR CLIN N AM, V36, P855; VAMI JW, 1989, PEDIATRICIAN, V16, P56; WALCO GA, 1990, J PEDIATR PSYCHOL, V15, P643, DOI 10.1093/jpepsy/15.5.643; WILLIAMSON PS, 1983, PEDIATRICS, V71, P36; YASTER M, 1988, J PEDIATR-US, V113, P421, DOI 10.1016/S0022-3476(88)80622-X; YASTER M, 1993, PAIN INFANTS CHILDRE, P145; ZELTZER LK, 1990, PEDIATRICS, V86, pS826; 1990, CANCER PAIN RELIEF P; 1992, AHCPR920032 AG HLTH; 1992, PRINCIPLES ANALGESIC; 1993, ACCREDITATION MANUAL	49	136	137	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 25	1994	331	8					541	544		10.1056/NEJM199408253310812	http://dx.doi.org/10.1056/NEJM199408253310812			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PD072	8041423				2022-12-24	WOS:A1994PD07200012
J	REID, IR; CHIN, K; EVANS, MC; JONES, JG				REID, IR; CHIN, K; EVANS, MC; JONES, JG			RELATION BETWEEN INCREASE IN LENGTH OF HIP AXIS IN OLDER WOMEN BETWEEN 1950S AND 1990S AND INCREASE IN AGE-SPECIFIC RATES OF HIP FRACTURE	BRITISH MEDICAL JOURNAL			English	Article							PROXIMAL FEMUR	Objective-To determine whether length of hip axis in elderly women has increased over the past 40 years and, if so, whether the increase may have contributed to the increase in the age adjusted rate of hip fractures during those years. Design-Retrospective assessment of anteroposterior x ray films of the pelvis. Setting-Radiology department of a rheumatology hospital, New Zealand. Patients-Two cohorts of women aged >60 (mean 70) who were x rayed on the same apparatus in either the 1950s or the 1990s. Main outcome-length of hip axis (distance from the medial aspect of the pelvis to the lateral aspect of the femur along the axis of the femoral neck), length of femoral neck (length of hip axis excluding the femoral head and more medial structures), and width of femoral neck (see figure). Results-Both the mean length of the hip axis and the mean length of the femoral neck were significantly greater in the women whose x ray films were taken in the 1990s than in those in the 1950s (124.0 mm (SE 1) v 130.5 (1), P=0.0002; 79.4 (1) v 84.9 (1), P<0.0001, respectively). The width of the femoral neck did not change, and the lengths expressed as ratios to width were greater in the more recent x ray films, indicating that these findings are not due to an unrecognised change in radiographic technique. Conclusions-An increase in the length of the hip axis in elderly women in New Zealand during the past 40 years has occurred which is large enough to account for the increase in the age adjusted rate of hip fractures during those years.	QUEEN ELIZABETH HOSP,ROTORUA,NEW ZEALAND		REID, IR (corresponding author), UNIV AUCKLAND,DEPT MED,PRIVATE BAG 92019,AUCKLAND,NEW ZEALAND.							BOYCE WJ, 1985, LANCET, V1, P150; FALCH JA, 1993, BONE, V14, P643, DOI 10.1016/8756-3282(93)90086-P; FAULKNER KG, 1993, J BONE MINER RES, V8, P1211, DOI 10.1002/jbmr.5650081008; JOHNELL O, 1984, ACTA ORTHOP SCAND, V55, P290, DOI 10.3109/17453678408992358; LAU EMC, 1993 OST P 4TH INT S, P58; LEWIS AF, 1981, BMJ-BRIT MED J, V283, P1217, DOI 10.1136/bmj.283.6301.1217; Rockwood P R, 1990, J Orthop Trauma, V4, P388, DOI 10.1097/00005131-199012000-00004; SPECTOR TD, 1990, BRIT MED J, V300, P1173, DOI 10.1136/bmj.300.6733.1173; WALLACE WA, 1983, LANCET, V1, P1413; ZETTERBERG C, 1982, ACTA ORTHOP SCAND, V53, P419, DOI 10.3109/17453678208992236	10	65	66	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 20	1994	309	6953					508	509		10.1136/bmj.309.6953.508	http://dx.doi.org/10.1136/bmj.309.6953.508			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD308	8086904	Green Published			2022-12-24	WOS:A1994PD30800017
J	STUCKEY, JA; SCHUBERT, HL; FAUMAN, EB; ZHANG, ZY; DIXON, JE; SAPER, MA				STUCKEY, JA; SCHUBERT, HL; FAUMAN, EB; ZHANG, ZY; DIXON, JE; SAPER, MA			CRYSTAL-STRUCTURE OF YERSINIA PROTEIN-TYROSINE-PHOSPHATASE AT 2.5-ANGSTROM AND THE COMPLEX WITH TUNGSTATE	NATURE			English	Article							VIRULENCE DETERMINANT; PURIFICATION; INTERMEDIATE; CATALYSIS; CYSTEINE; CHARGES; LAR	PROTEIN tyrosine phosphatases (PTPases) and kinases coregulate the critical levels of phosphorylation necessary for intracellular signalling, cell growth and differentiation(1,2). Yersinia, the causative bacteria of the bubonic plague and other enteric diseases, secrete an active PTPase(3), Yop51, that enters and suppresses host immune cells(4,5). Though the catalytic domain is only similar to 20% identical to human PTP1B(6), the Yersinia PTPase contains all of the invariant residues present in eukaryotic PTPases(7), including the nucleophilic Cys 403 which forms a phosphocysteine intermediate during catalysis(3,8-10). We present here structures of the unliganded (2.5 Angstrom resolution) and tungstate-bound (2.6 Angstrom) crystal forms which reveal that Cys 403 is positioned at the centre of a distinctive phosphate-binding loop. This loop is at the hub of several hydrogen-bond arrays that not only stabilize a bound oxyanion, but may activate Cys 403 as a reactive thiolate. Binding of tungstate triggers a conformational change that traps the oxyanion and swings Asp 356, an important catalytic residue(7), by similar to 6 Angstrom into the active site. The same anion-binding loop in PTPases is also found in the enzyme rhodanese(11).	UNIV MICHIGAN,DIV BIOPHYS RES,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109; UNIV MICHIGAN,WALTHER CANC INST,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Walther Cancer Institute			Fauman, Eric/AAC-8275-2020	Fauman, Eric/0000-0002-9739-0249				AQVIST J, 1991, P NATL ACAD SCI USA, V88, P2026, DOI 10.1073/pnas.88.5.2026; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; BOLIN I, 1988, MOL MICROBIOL, V2, P237, DOI 10.1111/j.1365-2958.1988.tb00025.x; BRUNGER TA, 1993, XPLOR VERSION 3 1 MA; CHO HJ, 1992, J AM CHEM SOC, V114, P7296, DOI 10.1021/ja00044a052; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GREGORET LM, 1991, PROTEINS, V9, P99, DOI 10.1002/prot.340090204; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEWIS SD, 1981, BIOCHEMISTRY-US, V20, P48, DOI 10.1021/bi00504a009; ORENGO CA, 1993, STRUCTURE, V1, P105, DOI 10.1016/0969-2126(93)90026-D; PATHAK D, 1990, J MOL BIOL, V214, P497, DOI 10.1016/0022-2836(90)90196-S; PLOEGMAN JH, 1979, J MOL BIOL, V127, P149, DOI 10.1016/0022-2836(79)90236-5; PLOEGMAN JH, 1978, NATURE, V273, P124, DOI 10.1038/273124a0; QUIOCHO FA, 1987, NATURE, V329, P561, DOI 10.1038/329561a0; STEIGEMANN W, 1974, THESIS TU MUNICH; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; TONKS NK, 1988, J BIOL CHEM, V263, P6722; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WIERENGA RK, 1986, T AM CRYSTALLOGR ASS, V22, P49; ZHANG ZY, 1992, J BIOL CHEM, V267, P23759; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; ZHANG ZY, 1994, ADV ENZYMOL RAMB, V68, P1; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624	31	376	383	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 18	1994	370	6490					571	575		10.1038/370571a0	http://dx.doi.org/10.1038/370571a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC537	8052312	Green Submitted			2022-12-24	WOS:A1994PC53700059
J	KLEIN, PS; MELTON, DA				KLEIN, PS; MELTON, DA			INDUCTION OF MESODERM IN XENOPUS-LAEVIS EMBRYOS BY TRANSLATION INITIATION-FACTOR 4E	SCIENCE			English	Article							EUKARYOTIC PROTEIN-SYNTHESIS; 3' UNTRANSLATED REGION; 5' NONCODING REGION; MESSENGER-RNA; SECONDARY STRUCTURE; ACTIVIN RECEPTOR; C-ELEGANS; MALIGNANT TRANSFORMATION; MIDBLASTULA TRANSITION; POLY(A) ADDITION	The microinjection of messenger RNA encoding the eukaryotic translation initiation factor 4E (elF-4E) into early embryos of Xenopus laevis leads to the induction of mesoderm in ectodermal explants. This induction occurs without a stimulation of overall protein synthesis and is blocked by the co-expression of a dominant negative mutant of the proto-oncogene ras or a truncated activin type II receptor. Although other translation factors have been studied in vertebrate and invertebrate embryos, none have been shown to play a direct role in development. The results here suggest a mechanism for relaying and amplifying signals for mesoderm induction.	HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA	Harvard University			Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				AHRINGER J, 1991, NATURE, V349, P346, DOI 10.1038/349346a0; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AUDET RG, 1987, DEV BIOL, V121, P58, DOI 10.1016/0012-1606(87)90138-2; BANVILLE D, 1985, NUCLEIC ACIDS RES, V13, P5407, DOI 10.1093/nar/13.15.5407; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; BU X, 1993, J BIOL CHEM, V268, P4975; COOKE J, 1987, DEVELOPMENT, V101, P893; DALE L, 1992, DEVELOPMENT, V115, P573; Davidson E. H., 1986, GENE ACTIVITY EARLY; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DWORKIN MB, 1985, P NATL ACAD SCI USA, V82, P7636, DOI 10.1073/pnas.82.22.7636; EPPIG JJ, 1976, IN VITRO CELL DEV B, V12, P418; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FLYNN JM, 1980, DEV BIOL, V75, P222, DOI 10.1016/0012-1606(80)90157-8; FOX CA, 1989, GENE DEV, V3, P2151, DOI 10.1101/gad.3.12b.2151; FREDERICKSON RM, 1992, MOL CELL BIOL, V12, P1239, DOI 10.1128/MCB.12.3.1239; FU LN, 1991, SCIENCE, V251, P807, DOI 10.1126/science.1990443; GOODWIN EB, 1993, CELL, V75, P329, DOI 10.1016/0092-8674(93)80074-O; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HEMMATIBRIVANLO.A, UNPUB; HEMMATIBRIVANLOU A, 1992, DEV DYNAM, V194, P1, DOI 10.1002/aja.1001940102; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; JARAMILLO M, 1991, J BIOL CHEM, V266, P10446; JONES EA, 1987, DEVELOPMENT, V101, P557; KAUFMAN RJ, 1993, J BIOL CHEM, V268, P11902; KLEIN PS, 1994, ENDOCR REV, V15, P326, DOI 10.1210/er.15.3.326; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; KURIHARA K, 1981, DEV GROWTH DIFFER, V23, P361; LAWSON TG, 1988, J BIOL CHEM, V263, P7266; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LEE G, 1984, CELL, V36, P729, DOI 10.1016/0092-8674(84)90353-2; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; LOPO AC, 1988, BIOCHEMISTRY-US, V27, P351, DOI 10.1021/bi00401a053; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MCGREW LL, 1989, GENE DEV, V3, P803, DOI 10.1101/gad.3.6.803; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; NAKAMURA O, 1970, P JPN ACAD, V46, P694, DOI 10.2183/pjab1945.46.694; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; RINKERSCHAEFFER CW, 1992, J BIOL CHEM, V267, P10659; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SAMBROOK J, 1990, MOL CLONING LABORATO; SLACK JMW, 1993, MECH DEVELOP, V41, P91, DOI 10.1016/0925-4773(93)90040-5; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P320, DOI 10.1016/0968-0004(90)90022-4; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; XU Z, 1990, CELL REGUL, V1, P1057, DOI 10.1091/mbc.1.13.1057	62	61	62	1	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 5	1994	265	5173					803	806		10.1126/science.8047887	http://dx.doi.org/10.1126/science.8047887			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	8047887				2022-12-24	WOS:A1994PA37200039
J	FRISCH, M; OLSEN, JH; BAUTZ, A; MELBYE, M				FRISCH, M; OLSEN, JH; BAUTZ, A; MELBYE, M			BENIGN ANAL LESIONS AND THE RISK OF ANAL CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CROHNS-DISEASE; CARCINOMA	Background. Benign anal lesions are often considered to cause a predisposition to anal cancer. To reexamine this association, we linked national data on hospital discharge and cancer in Denmark. Methods. After making certain exclusions, we used the Danish Central Hospital Discharge Register to identify 68,549 patients hospitalized with benign anal lesions between 1977 and 1989. Through computerized linkage to the Danish Cancer Registry, all incident cases of epidermoid anal cancer and colorectal cancer among these patients were identified. Follow-up for the occurrence of cancer started the month after the date of the first hospital discharge and continued until the patient died (10.6 percent of the sample), emigrated (0.7 percent), or was lost to follow-up (0.04 percent) or until December 31, 1989 (88.6 percent), whichever came first. Results. The median follow-up period was 6.2 years. There were 23 epidermoid anal cancers and 416 colorectal cancers. The overall relative risk of anal cancer (observed vs. expected cases) was 4.4 (95 percent confidence interval, 2.8 to 6.6). The relative risk was 12.0 (95 percent confidence interval, 5.2 to 23.6) within the first year after hospitalization for benign lesions, 4.6 (95 percent confidence interval, 2.3 to 8.3) from one to four years after hospitalization, and 1.8 (95 percent confidence interval, 0.5 to 4.7) five or more years after hospitalization. The risk of colorectal cancer was significantly increased only during the first year after hospitalization (relative risk, 2.6; 95 percent confidence interval, 2.1 to 3.1). Conclusions. There is a strong temporal association between the diagnosis of benign anal lesions and the diagnosis of anal cancer. Although we could not exclude the possibility of a moderate increase in the long-term risk of anal cancer, our data do not support the view that benign anal lesions cause anal cancer.	DANISH CANC SOC, RES CTR, DIV CANC EPIDEMIOL, COPENHAGEN, DENMARK	Danish Cancer Society	FRISCH, M (corresponding author), STATENS SERUM INST, DANISH EPIDEMIOL SCI CTR, EPIDEMIOL RES UNIT, 5 ARTILLERIVEJ, DK-2300 COPENHAGEN S, DENMARK.		Frisch, Morten/E-9206-2016	Frisch, Morten/0000-0002-3864-8860; Olsen, Jorgen Helge/0000-0001-9633-5662; melbye, mads/0000-0001-8264-6785				BACON HE, 1964, CANCER COLON RECTUM, P332; BRESLOW NE, 1987, IARC SCI PUBL, V82, P65; BROFELDT SA, 1927, ACTA SOC MED FENN DU, V8, P3; BUCKWALTER JA, 1957, ARCH SURG-CHICAGO, V75, P352; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P134, DOI 10.1093/ije/15.1.134; DALING JR, 1987, NEW ENGL J MED, V317, P973, DOI 10.1056/NEJM198710153171601; EWING J, 1940, NEOPLASTIC DISEASES, P726; FRISCH M, 1993, BMJ-BRIT MED J, V306, P419, DOI 10.1136/bmj.306.6875.419; GOULSTON KJ, 1986, LANCET, V2, P261; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; HOLLY EA, 1989, JNCI-J NATL CANCER I, V81, P1726, DOI 10.1093/jnci/81.22.1726; HUGHES LE, 1992, DIS COLON RECTUM, V35, P928, DOI 10.1007/BF02253493; Keyes EL, 1937, ANN SURG, V106, P1046, DOI 10.1097/00000658-193712000-00008; KLINE RJ, 1964, ARCH SURG-CHICAGO, V89, P989; Kune GA, 2007, INT J EPIDEMIOL, V36, P951, DOI 10.1093/ije/dym193; Leichman L P, 1990, Curr Probl Cancer, V14, P117; MELBYE M, 1994, LANCET, V343, P636, DOI 10.1016/S0140-6736(94)92636-0; PRESTON DM, 1983, BRIT J SURG, V70, P346, DOI 10.1002/bjs.1800700612; Rosser C., 1931, AM J SURG, V11, P328; Rothman KJ, 1982, CANCER EPIDEMIOLOGY, P15; SLATER G, 1984, ANN SURG, V199, P348, DOI 10.1097/00000658-198403000-00016; Storm H H, 1991, IARC Sci Publ, P220; 1986, VEJLEDNING UDTRAEK	23	42	47	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 4	1994	331	5					300	302		10.1056/NEJM199408043310504	http://dx.doi.org/10.1056/NEJM199408043310504			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ227	8022440	Bronze			2022-12-24	WOS:A1994NZ22700004
J	STOVER, E; KELLER, AS; COBEY, J; SOPHEAP, S				STOVER, E; KELLER, AS; COBEY, J; SOPHEAP, S			THE MEDICAL AND SOCIAL-CONSEQUENCES OF LAND MINES IN CAMBODIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERNATIONAL-COMMITTEE; RED-CROSS; EXPERIENCE; DEPRESSION		NYU,SCH MED,DEPT MED,NEW YORK,NY; AMER RED CROSS,WASHINGTON,DC 20006; AMER REFUGEE COMM,PHNOM PENH,CAMBODIA	New York University; American Red Cross	STOVER, E (corresponding author), PHYSICIANS HUMAN RIGHTS,100 BOYLSTON ST,SUITE 702,BOSTON,MA 02116, USA.							AKESODE FA, 1981, TROP GEOGR MED, V33, P71; ANDERSON K, 1993, HUMAN RIGHTS WATCH P; Becker Elizabeth, 1986, WAR WAS OVER CAMBODI; COUPLAND RM, 1991, BMJ-BRIT MED J, V303, P1509, DOI 10.1136/bmj.303.6816.1509; ESHAYACHAUVIN B, 1992, BRIT J ANAESTH, V68, P221, DOI 10.1093/bja/68.2.221; FAZOL R, 1989, J CARDIOVASC SURG, V30, P39; FINE J, 1992, HIDDEN ENEMIES LAND; GARACHON A, 1993, 1993 S ANT MIN MONTR, P93; GEIGER HJ, 1993, JAMA-J AM MED ASSOC, V270, P616; HIRSCHHORN N, 1991, CLIN NEEDS ASSESSMEN, P37; JOHNSON DE, 1981, J TRAUMA, V21, P486; JOHNSON SR, 1981, J BACTERIOL, V146, P632, DOI 10.1128/JB.146.2.632-638.1981; KASHANI JH, 1983, J CLIN PSYCHIAT, V44, P256; KING F, 1992, THESIS LONDON SCH TR; MARTIN ES, 1985, EXPLOSIVE REMNANTS W; MCCOLLOUGH NC, 1992, ORTHOP CLIN N AM, V3, P136; MCGRATH R, 1991, REPORT AFGHANISTAN M; MCGRATH R, 1992, HIDDEN DEATH LAND MI; MCGRATH R, 1993, LAND MINES ANGOLA; MOLLICA RF, 1990, AM J PSYCHIAT, V147, P83; MOLLICA RF, 1993, JAMA-J AM MED ASSOC, V270, P581, DOI 10.1001/jama.270.5.581; Mollica RF, 1988, CLIN GUIDELINES CROS, P262; MYERS H, 1993, CAMBODIA CANT WAIT, P12; MYSLIWIEK E, 1988, PUNISHING POOR INT I, P42; PIERCE RO, 1993, ORTHOPEDICS, V16, P793; RAUTIO J, 1988, J TRAUMA, V28, P523, DOI 10.1097/00005373-198804000-00019; RONE J, 1986, LAND MINES EL SALVAD; Ryan J M, 1988, J R Army Med Corps, V134, P119; RYBARCZYK BD, 1992, ARCH PHYS MED REHAB, V73, P1169; SHUKLA GD, 1982, BRIT J PSYCHIAT, V141, P50, DOI 10.1192/bjp.141.1.50; STOVER E, 1991, LAND MINES CAMBODIA, P59; THOMPSON DM, 1988, INT REHABIL MED, V5, P165; VARNI JW, 1991, ARCH PHYS MED REHAB, V72, P1053; 1990, CAMBODIA SITUATION C; 1980, UNDOCACONF9515 UN NA; 1993, HIDDEN KILLERS GLOBA; 1992, PERVERSE USE TECHNOL; 1994, LANDMINES UPDATE, P7; 1993, NY TIMES        1227, pA16; 1994, DEMINING SITUATION R; 1981, A36613 UN NAT PUBL; 1994, SECURITY REPORT	42	34	34	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	1994	272	5					331	336		10.1001/jama.272.5.331	http://dx.doi.org/10.1001/jama.272.5.331			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY903	8028149				2022-12-24	WOS:A1994NY90300001
J	WILSON, MA; MCNAUGHTON, BL				WILSON, MA; MCNAUGHTON, BL			REACTIVATION OF HIPPOCAMPAL ENSEMBLE MEMORIES DURING SLEEP	SCIENCE			English	Article							SYNAPTIC ENHANCEMENT; INFORMATION-STORAGE; ASSOCIATIVE MEMORY; UNIT ACTIVITY; PLASTICITY; POTENTIATION; DYNAMICS; RATES	Simultaneous recordings were made from large ensembles of hippocampal ''place cells'' in three rats during spatial behavioral tasks and in slow-wave sleep preceding and following these behaviors. Cells that fired together when the animal occupied particular locations in the environment exhibited an increased tendency to fire together during subsequent sleep, in comparison to sleep episodes preceding the behavioral tasks. Cells that were inactive during behavior, or that were active but had non-overlapping spatial firing, did not show this increase. This effect, which declined gradually during each post-behavior sleep session, may result from synaptic modification during waking experience. Information acquired during active behavior is thus re-expressed in hippocampal circuits during sleep, as postulated by some theories of memory consolidation.	UNIV ARIZONA, DEPT PSYCHOL, TUCSON, AZ 85724 USA; UNIV ARIZONA, DIV NEURAL SYST MEMORY & AGING, TUCSON, AZ 85724 USA	University of Arizona; University of Arizona					NIMH NIH HHS [MH46823] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH046823, R37MH046823] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AHISSAR E, 1992, SCIENCE, V257, P1412, DOI 10.1126/science.1529342; AMIT DJ, 1989, P NATL ACAD SCI USA, V86, P7871, DOI 10.1073/pnas.86.20.7871; BARNES CA, 1985, BEHAV NEUROSCI, V99, P1040, DOI 10.1037/0735-7044.99.6.1040; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P357, DOI 10.1113/jphysiol.1973.sp010274; BUZSAKI G, 1986, BRAIN RES, V398, P242, DOI 10.1016/0006-8993(86)91483-6; BUZSAKI G, 1989, NEUROSCIENCE, V31, P551, DOI 10.1016/0306-4522(89)90423-5; CHROBAK JJ, IN PRESS J NEUROSCI; GERSTEIN GL, 1969, SCIENCE, V164, P828, DOI 10.1126/science.164.3881.828; GIBSON WG, 1992, NEURAL NETWORKS, V5, P645, DOI 10.1016/S0893-6080(05)80042-5; HEBB DO, 1949, ORG BEHAVIOR; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; Landfield P. W., 1987, LONG TERM POTENTIATI; LEONARD BJ, 1987, BRAIN RES, V425, P174; MARR D, 1971, PHILOS T ROY SOC B, V262, P23, DOI 10.1098/rstb.1971.0078; McClelland J. L., 1992, Society for Neuroscience Abstracts, V18, P1216; MCGAUGH JL, 1972, MEMORY CONSOLIDATION; MCNAUGHTON BL, 1978, BRAIN RES, V157, P277, DOI 10.1016/0006-8993(78)90030-6; MCNAUGHTON BL, 1987, TRENDS NEUROSCI, V10, P408, DOI 10.1016/0166-2236(87)90011-7; MCNAUGHTON BL, 1990, NEUROSCIENCE CONNECT; MCNAUGHTON BL, 1983, NEUROBIOLOGY HIPPOCA, P609; MORRIS RGM, 1990, PHILOS T ROY SOC B, V329, P187, DOI 10.1098/rstb.1990.0164; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV, P150; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; PAVLIDES C, 1989, J NEUROSCI, V9, P2907; PERKEL DH, 1967, BIOPHYS J, V7, P419, DOI 10.1016/S0006-3495(67)86597-4; RANCK JB, 1973, EXP NEUROL, V41, P462, DOI 10.1016/0014-4886(73)90290-2; Squire L. R., 1984, MEMORY CONSOLIDATION, P185; TEYLER TJ, 1987, ANNU REV NEUROSCI, V10, P131, DOI 10.1146/annurev.ne.10.030187.001023; TREVES A, 1991, NETWORK-COMP NEURAL, V2, P371, DOI 10.1088/0954-898X/2/4/004; VANDERWOLF CH, 1969, ELECTROEN CLIN NEURO, V26, P407, DOI 10.1016/0013-4694(69)90092-3; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520; WOODY CD, 1972, J NEUROPHYSIOL, V35, P230, DOI 10.1152/jn.1972.35.2.230	32	1883	1912	5	171	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 29	1994	265	5172					676	679		10.1126/science.8036517	http://dx.doi.org/10.1126/science.8036517			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	8036517				2022-12-24	WOS:A1994NZ53800038
J	KABA, H; HAYASHI, Y; HIGUCHI, T; NAKANISHI, S				KABA, H; HAYASHI, Y; HIGUCHI, T; NAKANISHI, S			INDUCTION OF AN OLFACTORY MEMORY BY THE ACTIVATION OF A METABOTROPIC GLUTAMATE-RECEPTOR	SCIENCE			English	Article							PREGNANCY BLOCK; BRAIN-FUNCTION; MESSENGER-RNA; RAT-BRAIN; BULB; MODULATION; INHIBITION; SYSTEM	Female mice form an olfactory memory of male pheromones at mating; exposure to the pheromones of a strange male after that mating will block pregnancy. The formation of this memory is mediated by the accessory olfactory system, in which an increase in norepinephrine after mating reduces inhibitory transmission of gamma-aminobutyric acid from the granule cells to the mitral cells. This study shows that the activation of mGluR2, a metabotropic glutamate receptor that suppresses the gamma-aminobutyric acid inhibition of the mitral cells, permits the formation of a specific olfactory memory without the occurrence of mating by infusion of mGluR2 agonists into the female's accessory olfactory bulb. This memory faithfully reflects the memory formed at mating.	KOCHI MED SCH,DEPT PHYSIOL,NANKO KU,KOCHI 783,JAPAN; KYOTO UNIV,FAC MED,INST IMMUNOL,KYOTO 606,JAPAN	Kochi University; Kyoto University			Hayashi, Yasunori/C-2249-2008; Hayashi, Yasunori/AAF-1408-2019	Hayashi, Yasunori/0000-0002-7560-3004; Hayashi, Yasunori/0000-0002-7560-3004; Kaba, Hideto/0000-0002-5187-1995				BRENNAN P, 1990, SCIENCE, V250, P1223, DOI 10.1126/science.2147078; BRENNAN PA, 1992, NEUROSCIENCE, V49, P277, DOI 10.1016/0306-4522(92)90095-J; BRENNAN PA, 1989, NEUROSCIENCE, V33, P463, DOI 10.1016/0306-4522(89)90398-9; BRUCE HM, 1959, NATURE, V184, P105, DOI 10.1038/184105a0; HALASZ N, 1990, VERTEBRATE OLFACTORY; HAYASHI Y, 1994, J NEUROSCI, V14, P3370; HAYASHI Y, 1993, NATURE, V366, P687, DOI 10.1038/366687a0; JAHR CE, 1982, NATURE, V297, P227, DOI 10.1038/297227a0; KABA H, 1989, NEUROSCIENCE, V32, P657, DOI 10.1016/0306-4522(89)90287-X; KABA H, 1988, NEUROSCIENCE, V25, P1007, DOI 10.1016/0306-4522(88)90053-X; KABA H, 1988, NEUROSCIENCE, V24, P93, DOI 10.1016/0306-4522(88)90314-4; KEVERNE EB, 1983, TRENDS NEUROSCI, V6, P381, DOI 10.1016/0166-2236(83)90170-4; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OHISHI H, 1993, J COMP NEUROL, V335, P252, DOI 10.1002/cne.903350209; OHISHI H, 1993, NEUROSCIENCE, V53, P1009, DOI 10.1016/0306-4522(93)90485-X; ROSSER AE, 1985, NEUROSCIENCE, V15, P1141, DOI 10.1016/0306-4522(85)90258-1; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; TROMBLEY PQ, 1992, J NEUROSCI, V12, P3985	19	145	149	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 8	1994	265	5169					262	264		10.1126/science.8023145	http://dx.doi.org/10.1126/science.8023145			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV957	8023145				2022-12-24	WOS:A1994NV95700045
J	GU, H; MARTH, JD; ORBAN, PC; MOSSMANN, H; RAJEWSKY, K				GU, H; MARTH, JD; ORBAN, PC; MOSSMANN, H; RAJEWSKY, K			DELETION OF A DNA-POLYMERASE-BETA GENE SEGMENT IN T-CELLS USING CELL-TYPE-SPECIFIC GENE TARGETING	SCIENCE			English	Article							SITE-SPECIFIC RECOMBINATION; TRANSGENIC MICE; EXPRESSION; BACTERIOPHAGE-P1; PATHWAYS; REGIONS	Deletion of the promoter and the first exon of the DNA polymerase beta gene (pol beta) in the mouse germ line results in a lethal phenotype. With the use of the bacteriophage-derived, site-specific recombinase Cre in a transgenic approach, the same mutation can be selectively introduced into a particular cellular compartment-in this case, T cells. The impact of the mutation on those cells can then be analyzed because the mutant animals are viable.	UNIV BRITISH COLUMBIA, DEPT MED GENET, VANCOUVER V6T 1Z3, BC, CANADA; UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER V6T 1Z3, BC, CANADA; MAX PLANCK INST IMMUNOBIOL, D-79011 FREIBURG, GERMANY	University of British Columbia; University of British Columbia; Max Planck Society	GU, H (corresponding author), UNIV COLOGNE, INST GENET, D-50931 COLOGNE, GERMANY.			Rajewsky, Klaus/0000-0002-6633-6370				ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRENNER S, 1966, NATURE, V211, P242, DOI 10.1038/211242a0; CHAFFIN KE, 1990, EMBO J, V9, P3821, DOI 10.1002/j.1460-2075.1990.tb07600.x; FRY M, 1983, ENZYMES NUCLEIC ACID, P39; GARVIN AM, 1990, INT IMMUNOL, V2, P173, DOI 10.1093/intimm/2.2.173; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; Gu H.-Q., UNPUB; HIROSE F, 1989, EXP CELL RES, V181, P169, DOI 10.1016/0014-4827(89)90191-2; KOCKS C, 1989, ANNU REV IMMUNOL, V7, P537, DOI 10.1146/annurev.iy.07.040189.002541; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; ORBAN PC, 1992, P NATL ACAD SCI USA, V89, P6861, DOI 10.1073/pnas.89.15.6861; Sambrook J., 1989, MOL CLONING LAB MANU; SARTOR O, 1989, MOL CELL BIOL, V9, P2983, DOI 10.1128/MCB.9.7.2983; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; SAUER B, 1990, New Biologist, V2, P441; Sprent Jonathan, 1993, P75; STERNBERG N, 1981, J MOL BIOL, V150, P467, DOI 10.1016/0022-2836(81)90375-2; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; YAMAGUCHI M, 1987, MOL CELL BIOL, V7, P2012, DOI 10.1128/MCB.7.5.2012	21	1110	1265	0	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 1	1994	265	5168					103	106		10.1126/science.8016642	http://dx.doi.org/10.1126/science.8016642			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV301	8016642				2022-12-24	WOS:A1994NV30100036
J	PRUDENT, JR; UNO, T; SCHULTZ, PG				PRUDENT, JR; UNO, T; SCHULTZ, PG			EXPANDING THE SCOPE OF RNA CATALYSIS	SCIENCE			English	Article							LIGANDS; ENZYME; ANTIBODIES; EVOLUTION; LIBRARY; TETRAHYMENA; MOLECULES; SELECTION; RIBOZYME; INVITRO	The basic notions of transition state theory have been exploited in the past to generate highly selective catalysts from the vast library of antibody molecules in the immune system. These same ideas were used to isolate an RNA molecule, from a large library of RNAs, that catalyzes the isomerization of a bridged biphenyl. The RNA-catalyzed reaction displays Michaelis-Menten kinetics with a catalytic rate constant (k(cat)) of 2.8 x 10(-5) per minute and a Michaelis constant (K-m) of 542 mu M; the reaction is competitively inhibited by the planar transition state analog with an inhibition constant (K-i) value of similar to 7 mu M. This approach may provide a general strategy for expanding the scope of RNA catalysis beyond those reactions in which the substrates are nucleic acids or nucleic acid derivatives.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720; UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,BERKELEY,CA 94720	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley				Prudent, James/0000-0002-8948-1781	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008352] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM08352A] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; Criegee R, 1942, LIEBIGS ANN CHEM, V550, P99; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; GREEN R, 1992, SCIENCE, V258, P1910, DOI 10.1126/science.1470913; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HALDANE JBS, 1930, ENZYMES, P182; HALL DM, 1950, J CHEM SOC, P711, DOI 10.1039/jr9500000711; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; LEHMAN N, 1993, NATURE, V361, P182, DOI 10.1038/361182a0; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; MISLOW K, 1962, J AM CHEM SOC, V84, P1449, DOI 10.1021/ja00867a022; MISLOW K, 1964, J AM CHEM SOC, V86, P1710, DOI 10.1021/ja01063a014; NEEDELS MC, 1993, P NATL ACAD SCI USA, V90, P10700, DOI 10.1073/pnas.90.22.10700; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; Pauling L., 1946, CHEM ENG NEWS, V24, P1375, DOI [10.1021/cen-v024n010.p1375, DOI 10.1021/CEN-V024N010.P1375]; PICCIRILLI JA, 1992, SCIENCE, V256, P1420, DOI 10.1126/science.1604316; POLLACK SJ, 1986, SCIENCE, V234, P1570, DOI 10.1126/science.3787262; REBEK J, 1980, TETRAHEDRON LETT, V21, P2379, DOI 10.1016/S0040-4039(00)93154-X; SCHULTZ PG, 1989, ANGEW CHEM INT EDIT, V28, P1283, DOI 10.1002/anie.198912833; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SEGEL IH, 1975, ENZYME KINETICS, P46; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	32	136	150	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1924	1927						4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	8009223				2022-12-24	WOS:A1994NT84700043
J	MACGREGOR, JE; CAMPBELL, MK; MANN, EMF; SWANSON, KY				MACGREGOR, JE; CAMPBELL, MK; MANN, EMF; SWANSON, KY			SCREENING FOR CERVICAL INTRAEPITHELIAL NEOPLASIA IN NORTH-EAST SCOTLAND SHOWS FALL IN INCIDENCE AND MORTALITY FROM INVASIVE CANCER WITH CONCOMITANT RISE IN PREINVASIVE DISEASE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DYSKARYOSIS; CYTOLOGY; WOMEN; SMEAR; MILD; CARCINOMA; TRENDS	Objective-To assess the effect of screening for cervical intraepithelial neoplasia on the incidence of and mortality from invasive squamous cell carcinoma of cervix in north east Scotland and to discover why cases of invasive cancer still occur. Design-(a) Analysis of data on cases of cervical intraepithelial neoplasia obtained from the cytology data bank; (b) analysis of data on 612 women presenting with invasive squamous cancer during 1968-91, obtained from cancer registry and hospital records; (c) analysis of death rates obtained from the registrar general's (Scotland) annual reports, the Information Services Division of the Home and Health Department (Scotland), and local records for 1974-91; (d) case-control studies on 282 cases of invasive cancer and 108 deaths which occurred in 1982-91. Cases were matched with two controls both for age and for having a negative smear test result at the time of presentation of the case. Setting-North east Scotland (Grampian region, Orkney, and Shetland). Subjects-Women (n=306 608) who had had cervical smear tests between 1960 and 1991. Results-There had been a substantial increase in cases of cervical intraepithelial neoplasia grade III since 1982. The incidence of invasive cancer has fallen since the start of screening in 1960, the fall occurring mainly in the well screened age group 40-69 years. There was a rise in women aged under 40 and over 70. Women with invasive disease seen between 1982 and 1991 mostly presented at stage I. Of these, half were unscreened, one third were poorly screened, 11% were found in retrospect to have had abnormal cells, 3% had recurrence of disease after treatment for cervical intraepithelial neoplasia grade III, and 3% were lost to follow up. Death rates had fallen, most noticeably in women aged 45-64, who had had the opportunity to be screened and rescreened. There was a disturbing rise in deaths among women under 45. Most deaths (65%) occurred in unscreened women. Case-control studies showed that the longer the time and absence of a smear test before presentation the higher was the risk of invasive cancer and of death. Conclusions-Screening has been effective in reducing the incidence of and mortality from cervical cancer in north east Scotland. Most cases and deaths occurred in unscreened women or in those who had had few smears at long intervals, An increase in cases of cervical intraepithelial neoplasia grade III in women screened for the first time occurred during 1982-91.	UNIV ABERDEEN, HARRIS BIRTHRIGHT RES CTR, DEPT PATHOL, ABERDEEN AB9 2ZD, SCOTLAND; GRAMPIAN AREA HLTH BOARD, ABERDEEN, SCOTLAND; ABERDEEN ROYAL HOSP, NHS TRUST, ABERDEEN, SCOTLAND; UNIV ABERDEEN, HARRIS BIRTHRIGHT RES CTR, DEPT GYNAECOL, ABERDEEN, SCOTLAND	University of Aberdeen; University of Aberdeen			Campbell, Marion/ABB-7063-2020					ANDERSON DJ, 1992, BMJ-BRIT MED J, V305, P84, DOI 10.1136/bmj.305.6845.84; ANDERSON GH, 1988, BMJ-BRIT MED J, V296, P975, DOI 10.1136/bmj.296.6627.975; BERKELEY AS, 1980, LANCET, V2, P375; BETHWAITE P, 1992, BRIT J OBSTET GYNAEC, V99, P745, DOI 10.1111/j.1471-0528.1992.tb13877.x; COOK GA, 1984, BRIT J CANCER, V50, P367, DOI 10.1038/bjc.1984.185; COOPER P, 1992, CYTOPATHOLOGY, V3, P331; COPPLESON LW, 1974, AM J OBSTET GYNECOL, V119, P953, DOI 10.1016/0002-9378(74)90013-1; COTTON RE, 1986, BRIT MED J, V292, P799, DOI 10.1136/bmj.292.6523.799-a; CURLING M, 1992, ADV GYNAECOLOGICAL P, P62; CUZICK J, 1992, LANCET, V339, P959, DOI 10.1016/0140-6736(92)91532-D; GRAY M, 1992, GUIDELINES CLIN PRAC; HUSAIN OAN, 1974, J CLIN PATHOL, V27, P935, DOI 10.1136/jcp.27.12.935; ISMAIL SM, 1989, BRIT MED J, V298, P707, DOI 10.1136/bmj.298.6675.707; JHA PKS, 1993, LANCET, V341, P1116, DOI 10.1016/0140-6736(93)93128-N; KIRBY AJ, 1992, LANCET, V339, P828, DOI 10.1016/0140-6736(92)90278-B; LAARA E, 1987, LANCET, V1, P1247; LAWSON JG, 1956, J OBSTET GYNAECOL, V63, P819; MACGREGOR JE, 1993, BRIT J OBSTET GYNAEC, V100, P801, DOI 10.1111/j.1471-0528.1993.tb14301.x; MACGREGOR JE, 1991, BRIT J OBSTET GYNAEC, V98, P6, DOI 10.1111/j.1471-0528.1991.tb10302.x; MACGREGOR JE, 1961, BRIT MED J, V1, P1631; ROBERTSON AJ, 1989, J CLIN PATHOL, V42, P231, DOI 10.1136/jcp.42.3.231; SILCOCKS PBS, 1988, BRIT J OBSTET GYNAEC, V95, P1111, DOI 10.1111/j.1471-0528.1988.tb06787.x; SMITH A, 1988, BRIT MED J, V296, P1670, DOI 10.1136/bmj.296.6637.1670; THOMPSON B, 1993, HLTH ED J, V52, P62; THOMPSON B, 1989, HAVING 1ST BABY EXPE; VANOORTMARSSEN GJ, 1992, BRIT MED J, V305, P449, DOI 10.1136/bmj.305.6851.449; VANWIJNGAARDEN WJ, 1993, BRIT MED J, V306, P967, DOI 10.1136/bmj.306.6883.967; 1992, REGISTRAR GENERAL AN; 1990, GRAMPIAN HLTH BOARD, P14; 1990, FACTS CANCER; 1990, GRAMPIAN HLTH PROFIL	31	97	106	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 28	1994	308	6941					1407	1411		10.1136/bmj.308.6941.1407	http://dx.doi.org/10.1136/bmj.308.6941.1407			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP420	8019250	Green Published			2022-12-24	WOS:A1994NP42000015
J	MAYET, J; SHAHI, M; FOALE, RA; POULTER, NR; SEVER, PS; THOM, SAM				MAYET, J; SHAHI, M; FOALE, RA; POULTER, NR; SEVER, PS; THOM, SAM			RACIAL-DIFFERENCES IN CARDIAC STRUCTURE AND FUNCTION IN ESSENTIAL-HYPERTENSION	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LEFT-VENTRICULAR HYPERTROPHY; DIASTOLIC FUNCTION; BLOOD-PRESSURE; ECHOCARDIOGRAPHIC INDEXES; WHITE HYPERTENSIVES; HEART; BLACK; DOPPLER; VARIABLES; DISEASE	Objective-To assess racial differences in cardiac structure and function in patients presenting with previously untreated hypertension. Design-Untreated black patients with hypertension were compared with untreated white patients matched for age and sex. Both groups had similar body mass indices, blood pressures, and reported duration of hypertension. Setting-Cardiovascular risk factor clinic for outpatients. Subjects-36 men and 22 women with untreated essential hypertension. Main outcome measures-Variables of heart structure and function on cross sectional and Doppler echocardiography. Results-The black patients had a significantly greater interventricular septal thickness (mean 1.23 (95% confidence interval 1.14 to 1.33) v 1.09 (1.02 to 1.16) cm; P = 0 02) and posterior wall thickness (mean 1.14 (1.07 to 1.22) v 0.96 (0.88 to 1.03) cm; P - 0.001) than the white patients, although left ventricular internal diameter was not significantly different (mean 4.90 (4.68 to 5.12) v 4.82 (4.64 to 5.01) cm; P = 0.59). This resulted in a significantly greater left ventricular mass index (mean 151 (137 to 164) v 120 (107 to 133) g/m(2); P = 0.001) and relative wall thickness (mean 0.47 (0.43 to 0.51) v 0.40 (0.37 to 0.42) cm; P = 004) in the black patients. Comparison of Doppler measures of left ventricular diastolic function showed a significantly longer isovolumic relaxation time in black patients (mean 107 (98 to 116) v 92 (83 to 101) ms; P = 0 02) compared with white patients, although peak early to atrial filling ratios were similar in both groups (mean 1.14 (0.95 to 1.32) v 1.04 (0.94 to 1.15); P = 0.37). Conclusion-Among previously untreated hypertensive patients, black subjects compared with white subjects have significantly higher left ventricular mass index and relative wall thickness, as well as more impairment of left ventricular function during diastole.	ST MARYS HOSP, SCH MED, DEPT CARDIOL, LONDON W2 1NY, ENGLAND; UCL, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6EA, ENGLAND; ST MARYS HOSP, IMPERIAL COLL SCI TECHNOL & MED, SCH MED, PEART ROSE CLIN, LONDON W2 1NY, ENGLAND	Imperial College London; University of London; University College London; UCL Medical School; Imperial College London								[Anonymous], 1992, LANCET, V339, P28; BRUNNER HR, 1973, AM J MED, V55, P295, DOI 10.1016/0002-9343(73)90131-9; COLAN SD, 1985, J AM COLL CARDIOL, V6, P545, DOI 10.1016/S0735-1097(85)80111-X; COMSTOCK GW, 1957, AM J HYG, V65, P271, DOI 10.1093/oxfordjournals.aje.a119870; DEVEREUX RB, 1982, HYPERTENSION, V4, P524, DOI 10.1161/01.HYP.4.4.524; DOUGHERTY AH, 1984, AM J CARDIOL, V54, P778, DOI 10.1016/S0002-9149(84)80207-6; DUNN FG, 1983, J AM COLL CARDIOL, V1, P1348, DOI 10.1016/S0735-1097(83)80150-8; HAMMOND IW, 1984, J NATL MED ASSOC, V76, P247; HARSHFIELD GA, 1989, HYPERTENSION, V14, P598, DOI 10.1161/01.HYP.14.6.598; HARSHFIELD GA, 1990, J HUM HYPERTENS, V4, P43; HINDERLITER AL, 1992, AM J CARDIOL, V69, P1196, DOI 10.1016/0002-9149(92)90935-R; HYPERTENSION DETECTION FOLLOW-UP, 1977, AM J EPIDEMIOL, V106, P351; INOUYE I, 1984, AM J CARDIOL, V53, P120, DOI 10.1016/0002-9149(84)90695-7; LEE DK, 1992, JAMA-J AM MED ASSOC, V267, P3294, DOI 10.1001/jama.267.24.3294; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LEWIS JF, 1992, BRIT HEART J, V68, P296; MCDONOUGH JR, 1964, ANN INTERN MED, V61, P208, DOI 10.7326/0003-4819-61-2-208; MEADE TW, 1978, BRIT HEART J, V40, P789, DOI 10.1136/hrt.40.7.789; MENSAH G A, 1991, Journal of the American College of Cardiology, V17, p71A; MESSERLI FH, 1979, AM J MED, V67, P27, DOI 10.1016/0002-9343(79)90065-2; MURPHY MB, 1988, CIRCULATION, V48, pA2268; NEATON JD, 1984, AM HEART J, V108, P759, DOI 10.1016/0002-8703(84)90669-0; NISHIMURA RA, 1989, MAYO CLIN PROC, V64, P181, DOI 10.1016/S0025-6196(12)65673-0; OOI WL, 1989, HYPERTENSION, V14, P227, DOI 10.1161/01.HYP.14.3.227; PASIERSKI T, 1991, AM HEART J, V122, P1101, DOI 10.1016/0002-8703(91)90478-Z; PHILLIPS RA, 1989, J AM COLL CARDIOL, V14, P979, DOI 10.1016/0735-1097(89)90476-2; ROWLANDS DB, 1982, HYPERTENSION, V4, P817, DOI 10.1161/01.HYP.4.6.817; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; Savage D D, 1979, J Natl Med Assoc, V71, P709; SHAHI M, 1990, LANCET, V336, P458, DOI 10.1016/0140-6736(90)92010-F; SHAHI M, 1989, CLIN SCI, V76, pP22; SHAPIRO LM, 1984, BRIT HEART J, V51, P637; SMITH SA, 1989, BRIT HEART J, V61, P344; SPIRITO P, 1988, BRIT HEART J, V59, P672; STAMLER J, 1975, J CHRON DIS, V28, P527, DOI 10.1016/0021-9681(75)90060-0	35	67	68	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 16	1994	308	6935					1011	1014		10.1136/bmj.308.6935.1011	http://dx.doi.org/10.1136/bmj.308.6935.1011			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH089	8068083	Green Published			2022-12-24	WOS:A1994NH08900019
J	QIAN, YL; STURCHIO, NC; CHIARELLO, RP; LYMAN, PF; LEE, TL; BEDZYK, MJ				QIAN, YL; STURCHIO, NC; CHIARELLO, RP; LYMAN, PF; LEE, TL; BEDZYK, MJ			LATTICE LOCATION OF TRACE-ELEMENTS WITHIN MINERALS AND AT THEIR SURFACES WITH X-RAY STANDING WAVES	SCIENCE			English	Article							CALCITE; INTERFACE; SORPTION	The x-ray standing waves generated by dynamical Bragg diffraction were used to directly measure lattice locations of trace elements within and at the surface of a mineral single crystal. These high-precision measurements were made on natural Iceland spar calcite cleaved along the (<10(1)over bar 4>) plane and reacted with a dilute aqueous lead solution. Within the bulk crystal, naturally occurring trace manganese was found within (<10(1)over bar 4>) planes, consistent with its substitution for calcium. At the crystal surface, sorbed lead was found to be highly ordered and mostly within (<10(1)over bar 4>) planes. This demonstrates a powerful application of synchrotron radiation in the earth and environmental sciences.	ARGONNE NATL LAB,DIV MAT SCI,ARGONNE,IL 60439; NORTHWESTERN UNIV,DEPT MAT SCI & ENGN,EVANSTON,IL 60208; NORTHWESTERN UNIV,MAT RES CTR,EVANSTON,IL 60208	United States Department of Energy (DOE); Argonne National Laboratory; Northwestern University; Northwestern University			Bedzyk, Michael J/K-6903-2013; Bedzyk, Michael J/B-7503-2009	Sturchio, Neil/0000-0002-7581-9585	PHS HHS [IR01KD45295-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BATTERMAN BW, 1969, PHYS REV LETT, V22, P703, DOI 10.1103/PhysRevLett.22.703; BATTERMAN BW, 1964, REV MOD PHYS, V36, P681, DOI 10.1103/RevModPhys.36.681; BATTERMAN BW, 1964, PHYS REV A, V133, P759; BEDZYK M, 1985, SURF SCI, V152, P10, DOI 10.1016/0039-6028(85)90119-0; BEDZYK MJ, 1990, SCIENCE, V248, P52, DOI 10.1126/science.2321026; CHIARELLO RP, 1993, GEOCHIM COSMOCHIM AC, V57, P4103, DOI 10.1016/0016-7037(93)90356-2; COWAN PL, 1980, PHYS REV LETT, V44, P1680, DOI 10.1103/PhysRevLett.44.1680; CROMER DT, 1983, J APPL CRYSTALLOGR, V16, P437, DOI 10.1107/S0021889883010791; DAVIS JA, 1987, GEOCHIM COSMOCHIM AC, V51, P1477, DOI 10.1016/0016-7037(87)90330-9; GOLOVCHENKO JA, 1982, PHYS REV LETT, V49, P560, DOI 10.1103/PhysRevLett.49.560; GRATZ AJ, 1993, GEOCHIM COSMOCHIM AC, V57, P491, DOI 10.1016/0016-7037(93)90449-7; HAYES KF, 1987, SCIENCE, V238, P783, DOI 10.1126/science.238.4828.783; KRAUSE MO, 1979, J PHYS CHEM REF DATA, V8, P307, DOI 10.1063/1.555594; OHNESORGE F, 1993, SCIENCE, V260, P1451, DOI 10.1126/science.260.5113.1451; PINGITORE NE, 1986, GEOCHIM COSMOCHIM AC, V50, P2195, DOI 10.1016/0016-7037(86)90074-8; Reeder RJ, 1983, REV MINER GEOCHEM, V11, P1, DOI DOI 10.1515/9781501508134; ZACHARA JM, 1991, GEOCHIM COSMOCHIM AC, V55, P1549, DOI 10.1016/0016-7037(91)90127-Q; ZEGENHAGEN J, 1993, SURF SCI REP, V18, P199, DOI 10.1016/0167-5729(93)90025-K; [No title captured]	19	38	39	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 9	1994	265	5178					1555	1557		10.1126/science.8079168	http://dx.doi.org/10.1126/science.8079168			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF336	8079168				2022-12-24	WOS:A1994PF33600026
J	STUKENBERG, PT; TURNER, J; ODONNELL, M				STUKENBERG, PT; TURNER, J; ODONNELL, M			AN EXPLANATION FOR LAGGING-STRAND REPLICATION - POLYMERASE HOPPING AMONG DNA SLIDING CLAMPS	CELL			English	Article							III ACCESSORY PROTEINS; ESCHERICHIA-COLI; HOLOENZYME; COMPLEX; TEMPLATE; SUBUNIT; INVITRO; ORIGIN; SIZE	The replicase of E. coli, DNA polymerase III holoenzyme, is tightly fastened to DNA by its ring-shaped beta sliding clamp. However, despite being clamped to DNA, the polymerase must rapidly cycle on and off DNA to synthesize thousands of Okazaki fragments on the lagging strand. This study shows that DNA polymerase III holoenzyme cycles from one DNA to another by a novel mechanism of partial disassembly of its multisubunit structure and then reassembly. Upon completing a template, the polymerase disengages from its beta clamp, hops off DNA, and reassociates with another beta clamp at a new primed site. The original beta clamp is left on DNA and may be harnessed by other machineries to coordinate their action with chromosome replication.	CORNELL UNIV, COLL MED, HEARST RES FDN, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA	Cornell University; Cornell University; Howard Hughes Medical Institute	STUKENBERG, PT (corresponding author), CORNELL UNIV, COLL MED, DEPT MICROBIOL, NEW YORK, NY 10021 USA.			Stukenberg, Todd/0000-0002-6788-2111	NIGMS NIH HHS [GM38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839, R37GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BONNER CA, 1992, J BIOL CHEM, V267, P11431; BURGERS PMJ, 1983, J BIOL CHEM, V258, P7669; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1474; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FAY PJ, 1981, J BIOL CHEM, V256, P976; FLORESROZAS H, 1994, IN PRESS P NATL ACAD; GOGOL EP, 1992, J MOL BIOL, V224, P395, DOI 10.1016/0022-2836(92)91003-8; GREENSTEIN D, 1987, J MOL BIOL, V197, P157, DOI 10.1016/0022-2836(87)90115-X; HERENDEEN DR, 1992, SCIENCE, V256, P1298, DOI 10.1126/science.1598572; HUBSCHER U, 1992, TRENDS BIOCHEM SCI, V17, P55, DOI 10.1016/0968-0004(92)90499-Y; HUGHES AJ, 1991, J BIOL CHEM, V266, P4568; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; KELMAN Z, 1994, IN PRESS METH ENZYMO; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1992, DNA REPLICATION, P165; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; MAKI H, 1988, J BIOL CHEM, V263, P6570; MAKI S, 1988, J BIOL CHEM, V263, P6555; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MEYER TF, 1979, J BIOL CHEM, V254, P2642; MUNN MM, 1991, J BIOL CHEM, V266, P20034; Nossal N.G., 1983, BACTERIOPHAGE T4, P71; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ODONNELL M, 1992, MOL BIOL CELL, V3, P953, DOI 10.1091/mbc.3.9.953; ODONNELL ME, 1985, J BIOL CHEM, V260, P2875; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; ONRUST R, 1993, THESIS CORNELL U MED; OREILLY DR, 1989, NATURE, V337, P606, DOI 10.1038/337606a0; RICHEY B, 1987, J BIOL CHEM, V262, P7157; SINHA NK, 1980, J BIOL CHEM, V263, P6561; STUDWELL PS, 1990, UCLA SYM BI, V127, P153; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIAO H, 1993, J BIOL CHEM, V268, P11773; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	39	149	150	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 9	1994	78	5					877	887		10.1016/S0092-8674(94)90662-9	http://dx.doi.org/10.1016/S0092-8674(94)90662-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PG296	8087854				2022-12-24	WOS:A1994PG29600016
J	GEARING, AJH; BECKETT, P; CHRISTODOULOU, M; CHURCHILL, M; CLEMENTS, J; DAVIDSON, AH; DRUMMOND, AH; GALLOWAY, WA; GILBERT, R; GORDON, JL; LEBER, TM; MANGAN, M; MILLER, K; NAYEE, P; OWEN, K; PATEL, S; THOMAS, W; WELLS, G; WOOD, LM; WOOLLEY, K				GEARING, AJH; BECKETT, P; CHRISTODOULOU, M; CHURCHILL, M; CLEMENTS, J; DAVIDSON, AH; DRUMMOND, AH; GALLOWAY, WA; GILBERT, R; GORDON, JL; LEBER, TM; MANGAN, M; MILLER, K; NAYEE, P; OWEN, K; PATEL, S; THOMAS, W; WELLS, G; WOOD, LM; WOOLLEY, K			PROCESSING OF TUMOR-NECROSIS-FACTOR-ALPHA PRECURSOR BY METALLOPROTEINASES	NATURE			English	Article							COLLAGEN-INDUCED ARTHRITIS; TISSUE INHIBITOR; RABBIT BONE; CELLS; SECRETION; TIMP-2	TUMOUR necrosis factor-alpha (TNF-alpha) is a potent pro-inflammatory and immunomodulatory cytokine implicated in inflammatory conditions such as rheumatoid arthritis, Crohn's disease, multiple sclerosis and the cachexia associated with cancer or human immunodeficiency virus infection(1). TNF-alpha is initially expressed as a 233-amino-acid membrane-anchored precursor which is proteolytically processed to yield the mature, 157-amino-acid cytokine(2). The processing enzyme(s) which cleave TNF-alpha are unknown. Here we show that the release of mature TNF-alpha from leukocytes cultured in vitro is specifically prevented by synthetic hydroxamic acid-based metalloproteinase inhibitors, which also prevent the release of TNF-alpha into the circulation of endotoxin challenged rats. A recombinant, truncated TNF-alpha precursor is cleaved to biologically active, mature TNF-alpha by several matrix metalloproteinase enzymes. These results indicate that processing of the TNF-alpha precursor is dependent on at least one matrix metalloproteinase-like enzyme, inhibition of which represents a novel therapeutic mechanism for interfering with TNF-alpha production.	BRITISH BIOTECHNOL LTD, OXFORD OX4 5LY, ENGLAND									CARMICHAEL DF, 1989, AGENTS ACTIONS, V27, P378, DOI 10.1007/BF01972827; CAWSTON TE, 1981, BIOCHEM J, V195, P159, DOI 10.1042/bj1950159; CAWSTON TE, 1979, ANAL BIOCHEM, V99, P340, DOI 10.1016/S0003-2697(79)80017-2; DEZUBE BJ, 1993, CANCER IMMUNOL IMMUN, V36, P57, DOI 10.1007/BF01789132; DIMARTINO MJ, 1991, J CELL BIOCH SE, V19, P179; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362; ENDRES S, 1991, IMMUNOLOGY, V72, P56; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; FULCHER IS, 1982, BIOCHEM J, V203, P519, DOI 10.1042/bj2030519; GEE NS, 1987, BIOCHEM J, V246, P97, DOI 10.1042/bj2460097; IKEGAWA R, 1990, BIOCHEM BIOPH RES CO, V171, P669, DOI 10.1016/0006-291X(90)91198-2; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; MATTHEWS N, 1987, LYMPHOKINES INTERFER, P221; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; PRADINESFIGUERES A, 1992, J BIOL CHEM, V267, P23261; SELLERS A, 1978, BIOCHEM J, V171, P493, DOI 10.1042/bj1710493; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WILLIAMS RO, 1992, P NATL ACAD SCI USA, V89, P9784, DOI 10.1073/pnas.89.20.9784; WILSON BMG, 1991, J IMMUNOL METHODS, V139, P233, DOI 10.1016/0022-1759(91)90193-J	21	1100	1152	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 18	1994	370	6490					555	557		10.1038/370555a0	http://dx.doi.org/10.1038/370555a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC537	8052310				2022-12-24	WOS:A1994PC53700054
J	SU, XD; TADDEI, N; STEFANI, M; RAMPONI, G; NORDLUND, P				SU, XD; TADDEI, N; STEFANI, M; RAMPONI, G; NORDLUND, P			THE CRYSTAL-STRUCTURE OF A LOW-MOLECULAR-WEIGHT PHOSPHOTYROSINE PROTEIN PHOSPHATASE	NATURE			English	Article							CYTOSOLIC ACID-PHOSPHATASE; BOVINE HEART; CATALYTIC MECHANISM; GROWTH; REFINEMENT	PROTEIN tyrosine phosphorylation and dephosphorylation are central reactions for control of cellular division, differentiation and development(1). Here we describe the crystal structure of a low-molecular-weight phosphotyrosine protein phosphatase (PTPase)(2), a cytosolic phosphatase present in many mammalian cells. The enzyme catalyses the dephosphorylation of phosphotyrosine-containing substrates(3-6), and overexpression of the protein in normal and transformed cells inhibits cell. proliferation(7,8). The structure of the low-molecular-weight PTPase reveals an alpha/beta protein containing a phosphate-binding loop motif at the amino end of helix alpha 1. This motif includes the essential active-site residues Cys 12 and Arg 18 and bears striking similarities to the active-site motif recently described in the structure of human PTP1B(9). The structure ofthe low-molecular-weight PTPase supports a reaction mechanism involving the conserved Cys 12 as an attacking nucleophile in an in-line associative mechanism. The structure also suggests a catalytic role for Asp 129 in the reaction cycle.	UNIV FLORENCE,DEPT BIOCHEM SCI,FLORENCE,ITALY	University of Florence	SU, XD (corresponding author), UNIV STOCKHOLM,DEPT MOLEC BIOL,STOCKHOLM,SWEDEN.			Taddei, Niccolo/0000-0003-2513-1018; STEFANI, MASSIMO/0000-0002-4490-1922				BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BERTI A, IN PRESS FEBS LETT; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAMICI G, 1989, J BIOL CHEM, V264, P2560; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHERNOFF J, 1985, ARCH BIOCHEM BIOPHYS, V240, P135, DOI 10.1016/0003-9861(85)90016-5; CIRRI P, 1993, EUR J BIOCHEM, V214, P647, DOI 10.1111/j.1432-1033.1993.tb17965.x; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HIRAGA A, 1991, ADV PROTEIN PHOSPHAT, V6, P251; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1989, CRYSTALLOGRAPHIC COM; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; LESLIE AGW, 1987, ACTA CRYSTALLOGR A, V43, P134, DOI 10.1107/S0108767387099720; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; RAMPONI G, 1992, INT J CANCER, V51, P652, DOI 10.1002/ijc.2910510424; RAMPONI G, 1989, FEBS LETT, V250, P469, DOI 10.1016/0014-5793(89)80778-1; RUGGIERO M, 1993, FEBS LETT, V326, P294, DOI 10.1016/0014-5793(93)81811-D; STEFANI M, 1993, FEBS LETT, V326, P131, DOI 10.1016/0014-5793(93)81776-V; SU XD, 1994, FEBS LETT, V343, P107, DOI 10.1016/0014-5793(94)80299-8; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WO YYP, 1992, BIOCHEMISTRY-US, V31, P1712, DOI 10.1021/bi00121a019; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158; ZHANG ZY, 1991, BIOCHEMISTRY-US, V30, P8954, DOI 10.1021/bi00101a006	23	202	206	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 18	1994	370	6490					575	578		10.1038/370575a0	http://dx.doi.org/10.1038/370575a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC537	8052313				2022-12-24	WOS:A1994PC53700060
J	SEKUL, EA; CUPLER, EJ; DALAKAS, MC				SEKUL, EA; CUPLER, EJ; DALAKAS, MC			ASEPTIC-MENINGITIS ASSOCIATED WITH HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN THERAPY - FREQUENCY AND RISK-FACTORS	ANNALS OF INTERNAL MEDICINE			English	Article						MENINGITIS, ASEPTIC; IMMUNOGLOBULINS; DOSE-RESPONSE RELATIONSHIP DRUG; INJECTIONS, INTRAVENOUS; MIGRAINE	IMMUNE GLOBULIN; CONTROLLED TRIAL; NEUROPATHY; INFUSIONS	Objective: Intravenous immunoglobulin is widely used to treat various autoimmune disorders. After observing instances of aseptic meningitis in treated patients, we studied the frequency and associated risk factors for aseptic meningitis in patients treated with high-dose intravenous immunoglobulin. Design: Retrospective analysis of a prospective cohort study. Setting: Tertiary research referral center. Patients: 54 consecutive patients with various immune-related neuromuscular diseases participating in ongoing therapeutic trials of high-dose (2 g/kg) intravenous immunoglobulin. Measurements: Analysis of patient records for evidence of aseptic meningitis, associated risk factors, penetration of serum IgG into the cerebrospinal fluid, and clearance of cerebrospinal fluid IgG. Results: Of 54 patients, 6 (11%; 95% CI, 4% to 23%) developed aseptic meningitis within 24 hours after completion of the infusions. Symptoms, lasting 3 to 5 days, included severe headache, meningismus, photophobia, and fever. Cerebrospinal fluid showed pleocytosis in 4 patients (leukocyte count as high as 1169 x 10(6)/L in one patient), eosinophilia in 3 patients, and IgG elevation in all patients (as great as 7 times the upper limit of normal in one patient). Repeat cerebrospinal fluid and serum studies after 24 hours showed a 46% cerebrospinal fluid IgG clearance compared with an 11% clearance of serum IgG in one patient. Cerebrospinal fluid cultures were negative. Aseptic meningitis developed in 4 of 8 patients (50%; CI, 16% to 84%) with a history of migraine but in only 2 of 46 (4%; CI, 0.5% to 15%) patients without such a history (P = 0.003). Aseptic meningitis recurred in patients who had migraine despite the use of different commercial intravenous immunoglobulin preparations and slower rates of infusion. Conclusion: Aseptic meningitis develops in patients receiving high-dose intravenous immunoglobulin therapy. patients with a history of migraine are more likely to develop aseptic meningitis while receiving intravenous immunoglobulin therapy, regardless of the type of commercial preparation or the infusion rate. Possible inciting factors include the IgG itself, various stabilizing products within each of the preparations, cytokine release triggered by the therapy, or cerebrovascular sensitivity in migraineurs.	NINCDS, NEUROMUSCULAR DIS SECT, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)				Cupler, Edward/0000-0003-0958-8931				ACHIRON A, 1992, ARCH NEUROL-CHICAGO, V49, P1233, DOI 10.1001/archneur.1992.00530360031013; ADAIR JC, 1991, NEUROLOGY, V41, P249, DOI 10.1212/WNL.41.2_Part_1.249; ARUSRA E, 1989, CLIN IMMUNOL IMMUNOP, V53, pS170; BALLOW M, 1991, CANCER, V68, P1430, DOI 10.1002/1097-0142(19910915)68:6+<1430::AID-CNCR2820681405>3.0.CO;2-4; BUCKLEY RH, 1980, IMMUNOGLOBULINS CHAR, P3; CASTEELSVANDAELE M, 1990, NEW ENGL J MED, V323, P614; CHAUDHRY V, 1993, ANN NEUROL, V33, P237, DOI 10.1002/ana.410330303; CHEZ M, 1989, NEUROLOGY, V39, P1578, DOI 10.1212/WNL.39.12.1578; CONSTANTINESCU CS, 1993, NEW ENGL J MED, V329, P583, DOI 10.1056/NEJM199308193290820; COOK D, 1990, NEUROLOGY, V40, P212, DOI 10.1212/WNL.40.2.212; CUTLER RWP, 1970, J NEUROL SCI, V10, P259, DOI 10.1016/0022-510X(70)90154-1; DALAKAS MC, 1984, ANN NEUROL, V15, P590, DOI 10.1002/ana.410150612; DALAKAS MC, 1994, NEUROLOGY, V44, P223, DOI 10.1212/WNL.44.2.223; DALAKAS MC, 1994, SEMIN NEUROL, V14, P97, DOI 10.1055/s-2008-1041065; DALAKAS MC, 1993, NEW ENGL J MED, V329, P1993, DOI 10.1056/NEJM199312303292704; DALAKAS MC, 1994, IN PRESS ARCH NEUROL; DWYER JM, 1992, NEW ENGL J MED, V326, P107; Fishman RA, 1992, CEREBROSPINAL FLUID, P198; GELFAND EW, 1984, CLIN IMMUNOL IMMUNOP, V53, P51; GORDON MF, 1990, NEUROLOGY, V40, P163, DOI 10.1212/WNL.40.1.163; KATO E, 1988, JAMA-J AM MED ASSOC, V259, P3269, DOI 10.1001/jama.1988.03720220017011; KREMER I, 1983, NEW ENGL J MED, V308, P1481; Martelletti P, 1991, Acta Neurol (Napoli), V13, P448; Covelli V, 1992, Acta Neurol (Napoli), V14, P313; NEWBURGER JW, 1991, NEW ENGL J MED, V324, P1633, DOI 10.1056/NEJM199106063242305; NEWLAND A C, 1991, P15; Raskin N, 1988, HEADACHE; ROBERTON DM, 1988, AUST PAEDIATR J, V24, P174; SCHWARTZ SA, 1990, J CLIN IMMUNOL, V10, P81, DOI 10.1007/BF00918189; SERGENT JS, 1978, JAMA-J AM MED ASSOC, V240, P529; SOUEIDAN SA, 1993, NEUROLOGY, V43, P876, DOI 10.1212/WNL.43.5.876; TAN E, 1993, ARCH NEUROL-CHICAGO, V50, P137, DOI 10.1001/archneur.1993.00540020015010; VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705; VERARAMIREZ M, 1992, NEUROLOGY, V42, P1636, DOI 10.1212/WNL.42.8.1636-a	34	286	293	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1994	121	4					259	262		10.7326/0003-4819-121-4-199408150-00004	http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB102	8037406				2022-12-24	WOS:A1994PB10200004
J	KLIKS, SC; WARA, DW; LANDERS, DV; LEVY, JA				KLIKS, SC; WARA, DW; LANDERS, DV; LEVY, JA			FEATURES OF HIV-1 THAT COULD INFLUENCE MATERNAL-CHILD TRANSMISSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS-ASSOCIATED RETROVIRUS; V3 LOOP PEPTIDES; VERTICAL TRANSMISSION; INFECTED INDIVIDUALS; TYPE-1 VARIANTS; UNITED-STATES; GP120; MOTHERS; ANTIBODIES	Objective.-To evaluate the biological and serological properties of the human immunodeficiency virus type 1 (HIV-1) for factors potentially involved in the mother-to-child transmission of HIV-1. Design.-Isolates of HIV-1 were recovered from the blood of 12 of 44 nontransmitting mothers and six of eight transmitting mothers and their corresponding infants. These 24 HIV-1 isolates were compared for their biological and immunologic properties to discern any parameters that correlate with vertical transmission of HIV-1. Main Outcome Measures.-Replication capabilities of the above-mentioned HIV-1 isolates in human peripheral blood mononuclear cells (PBMCs), human macrophages, and various T-cell lines and the susceptibilities of the viruses to neutralization or enhancement by anti-HIV-1 antibodies in autologous serum samples from mothers and infants. Setting.-San Francisco Bay Area, California. Participants.-A cohort of 52 HIV-1-infected women and their infants in a prospective study on perinatal HIV transmission by the Bay Area Perinatal AIDS Center. Results.-The viral isolates from the transmitting mothers and their infants differed from the isolates from the nontransmitting mothers in their efficient replication in human PBMCs and in their ability to infect one or more human T-lymphocytic cell lines. All the HIV-1 isolates were able to infect human macrophages with only low-level replication and were unable to form syncytia in the MTP-lymphocytic cells. No correlation between transmission and reactivity of maternal serum samples to the peptide corresponding to the principal neutralization domain of the third hypervariable region of the viral envelope was observed. However, the majority (9/12) of maternal isolates from the nontransmitters were neutralized by their autologous serum samples compared with only two among six in the transmitter group (P<.07). Moreover, five infant isolates were resistant to neutralization by their respective mothers' serum samples, and one was sensitive to infection enhancement by the mother's serum. Another infant isolate was enhanced by his autologous serum. Conclusions.-Viral factors that appeared to correlate with mother-to-child transmission of HIV-1 observed in a small cohort included rapid or high-titered replication in human PBMCs, T-cell line tropism, and resistance to neutralization or a sensitivity to enhancement of infection by the maternal Serum.	UNIV CALIF SAN FRANCISCO,SCH MED,DIV PEDIAT IMMUNOL,SAN FRANCISCO,CA; SAN FRANCISCO GEN HOSP,DEPT OBSTET & GYNECOL,SAN FRANCISCO,CA 94110	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center	KLIKS, SC (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,CANC RES INST,SAN FRANCISCO,CA 94143, USA.				NIAID NIH HHS [R01 AI32446-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032446] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASJO B, 1986, LANCET, V2, P660; BROLIDEN PA, 1989, AIDS, V3, P577, DOI 10.1097/00002030-198909000-00004; CASTRO BA, 1988, J CLIN MICROBIOL, V26, P2371, DOI 10.1128/JCM.26.11.2371-2376.1988; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CHENGMAYER C, 1988, P NATL ACAD SCI USA, V85, P2815, DOI 10.1073/pnas.85.8.2815; CHENGMAYER C, 1989, P NATL ACAD SCI USA, V86, P8575, DOI 10.1073/pnas.86.21.8575; CHIN J, 1990, LANCET, V336, P221, DOI 10.1016/0140-6736(90)91743-T; CHU SY, 1991, PEDIATRICS, V87, P806; COURGNAUD V, 1991, AIDS RES HUM RETROV, V7, P337, DOI 10.1089/aid.1991.7.337; DEVASH Y, 1990, P NATL ACAD SCI USA, V87, P3445, DOI 10.1073/pnas.87.9.3445; EVANS LA, 1987, J IMMUNOL, V138, P3415; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; GOEDERT JJ, 1989, LANCET, V2, P1351; GORNY MK, 1992, J VIROL, V66, P7538, DOI 10.1128/JVI.66.12.7538-7542.1992; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; HALSEY NA, 1992, J ACQ IMMUN DEF SYND, V5, P153; HOFFMAN AD, 1985, VIROLOGY, V147, P326, DOI 10.1016/0042-6822(85)90135-7; HOMSY J, 1988, LANCET, V1, P1285; HOMSY J, 1990, J VIROL, V64, P1437, DOI 10.1128/JVI.64.4.1437-1440.1990; KESSON AM, 1993, J INFECT DIS, V168, P571, DOI 10.1093/infdis/168.3.571; KLIKS SC, 1993, P NATL ACAD SCI USA, V90, P11518, DOI 10.1073/pnas.90.24.11518; KOOT M, 1992, AIDS, V6, P49, DOI 10.1097/00002030-199201000-00006; LALLEMANT M, 1994, LANCET, V343, P1001, DOI 10.1016/S0140-6736(94)90126-0; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; LEVY JA, 1984, SCIENCE, V225, P840, DOI 10.1126/science.6206563; LEWIS SH, 1990, LANCET, V335, P565, DOI 10.1016/0140-6736(90)90349-A; LYMAN WD, 1990, AIDS, V4, P917, DOI 10.1097/00002030-199009000-00014; MARKHAM RB, 1994, LANCET, V343, P390, DOI 10.1016/S0140-6736(94)91225-4; MCDOUGAL JS, 1985, J IMMUNOL METHODS, V76, P171, DOI 10.1016/0022-1759(85)90489-2; MOK JYQ, 1989, ARCH DIS CHILD, V64, P1140, DOI 10.1136/adc.64.8.1140; MOORE JP, 1993, AIDS RES HUM RETROV, V9, P209, DOI 10.1089/aid.1993.9.209; PAN LZ, 1987, J INFECT DIS, V155, P626, DOI 10.1093/infdis/155.4.626; PAREKH BS, 1991, AIDS, V5, P1179, DOI 10.1097/00002030-199110000-00004; ROSSI P, 1989, P NATL ACAD SCI USA, V86, P8055, DOI 10.1073/pnas.86.20.8055; ROSSI P, 1992, J ACQ IMMUN DEF SYND, V5, P1169; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SAKAMOTO D, 1993, J CELL BIOCH E S, V17, P85; SCARLATTI G, 1993, P NATL ACAD SCI USA, V90, P1721, DOI 10.1073/pnas.90.5.1721; SCARLATTI G, 1993, VIROLOGY, V197, P624, DOI 10.1006/viro.1993.1637; SHIODA T, 1991, NATURE, V349, P167, DOI 10.1038/349167a0; STIEHM ER, 1991, J PEDIATR-US, V118, P410, DOI 10.1016/S0022-3476(05)82157-2; TATENO M, 1988, VIROLOGY, V167, P209; TERSMETTE M, 1989, LANCET, V1, P983; TUOFU Z, 1993, SCIENCE, V261, P1179; UGEN KE, 1992, J CLIN INVEST, V89, P1923, DOI 10.1172/JCI115798; VALENTIN A, 1990, VIROLOGY, V177, P790, DOI 10.1016/0042-6822(90)90551-2; WILLIAMSHERMAN D, 1993, 9TH P INT C AIDS BER, V1, P313; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; ZIEGLER JB, 1985, LANCET, V1, P896; 1991, LANCET, V337, P253; 1992, LANCET, V339, P1007; 1987, MMWR-MORBID MORTAL W, V36, P35; 1987, MMWR-MORBID MORTAL W, V36, P225	53	101	101	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	1994	272	6					467	474		10.1001/jama.272.6.467	http://dx.doi.org/10.1001/jama.272.6.467			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA278	8040983				2022-12-24	WOS:A1994PA27800029
J	SCHRADER, M; MULLER, KM; NAYERI, S; KAHLEN, JP; CARLBERG, C				SCHRADER, M; MULLER, KM; NAYERI, S; KAHLEN, JP; CARLBERG, C			VITAMIN-D-3 THYROID-HORMONE RECEPTOR HETERODIMER POLARITY DIRECTS LIGAND SENSITIVITY OF TRANSACTIVATION	NATURE			English	Article							RETINOIC ACID RECEPTORS; SIGNALING PATHWAYS; RESPONSE ELEMENTS; GENE-EXPRESSION; DIRECT REPEATS; X-RECEPTOR; RXR; BINDING; RAR; IDENTIFICATION	The nuclear receptors for 1,25-dihydroxyvitamin D-3 (VD) and 3,5,3'-triiodothyronine (T-3), that is, VDRs and T(3)Rs respectively, control aspects of homeostasis, cell growth and differentiation(1-4). They activate transcription from response elements consisting of direct repeats, palindromes and inverted palindromes(5-8) of a variety of hexameric core-binding motifs. VDRs bind preferentially to direct repeats spaced by three nucleotides, whereas T(3)Rs bind to direct repeats spaced by four nucleotides(9). VDRs and T(3)Rs can function as homodimers(5,6,10) but heterodimerization with retinoid X(11-14) Or retinoic acid receptors(15,16) increases their affinity for DNA in vitro and resulting transcriptional activity in vivo. We recently observed the formation of VDR-T(3)R heterodimers(17). Here we show that the polarity of the binding of such heterodimers to the VD response element of the rat 9K (relative molecular mass 9,000) calbindin's gene promoter was 5'-T(3)R-VDR-3', whereas on the mouse 28K calbindin VD response element(19) this polarity was reversed to 5'-VDR-T(3)R-3'. We also show that the ligand for the downstream receptor controls the transcriptional activity of the heterodimeric complex. Thus, polarity seems to be an important regulatory property of heterodimeric nuclear receptor complexes.			SCHRADER, M (corresponding author), UNIV GENEVA,HOP CANTONAL,DERMATOL CLIN,CH-1211 GENEVA 14,SWITZERLAND.		Carlberg, Carsten/C-9075-2011	Carlberg, Carsten/0000-0003-2633-0684				CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CARLBERG C, 1993, BIOCHEM BIOPH RES CO, V195, P1345, DOI 10.1006/bbrc.1993.2191; DARWISH HM, 1992, P NATL ACAD SCI USA, V89, P603, DOI 10.1073/pnas.89.2.603; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GILL RK, 1993, P NATL ACAD SCI USA, V90, P2984, DOI 10.1073/pnas.90.7.2984; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; NORMAN AW, 1992, J STEROID BIOCHEM, V41, P231, DOI 10.1016/0960-0760(92)90349-N; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PIKE JWA, 1991, REV NUTR, V11, P189; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; PREDKI PF, 1994, MOL ENDOCRINOL, V8, P31, DOI 10.1210/me.8.1.31; SCHRADER M, 1994, DNA CELL BIOL, V13, P333, DOI 10.1089/dna.1994.13.333; SCHRADER M, 1993, J BIOL CHEM, V268, P17830; SCHRADER M, 1994, J BIOL CHEM, V269, P5501; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; SCHRADER M, 1994, J MOL ENDOCRINOL, V12, P327, DOI 10.1677/jme.0.0120327; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VARGHESE S, 1988, J BIOL CHEM, V263, P9776; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	30	125	126	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 4	1994	370	6488					382	386		10.1038/370382a0	http://dx.doi.org/10.1038/370382a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA304	8047145				2022-12-24	WOS:A1994PA30400059
J	MOLLER, H; KNUDSEN, LB; LYNGE, E				MOLLER, H; KNUDSEN, LB; LYNGE, E			RISK OF TESTICULAR CANCER AFTER VASECTOMY - COHORT STUDY OF OVER 73000 MEN	BRITISH MEDICAL JOURNAL			English	Article							UNITED-STATES MEN; PROSTATE-CANCER; RETROSPECTIVE COHORT; RECORD LINKAGE; TESTIS CANCER; HOSPITALIZATION; ILLNESS; DISEASE; HEALTH	Objective-To confirm or refute reports that vasectomy may increase the risk of cancers of the testis and prostate. Design-Computerised record linkage study of cohort of men with vasectomy and comparison of cancer rates with those in the whole Danish population; manual check of all records of patients with testicular and prostate cancer diagnosed within the first year of follow up. Setting-Denmark 1977-89. Subjects-Cohort of 73 917 men identified in hospital discharge and pathology registers as having had a vasectomy for any reason during 1977-89. Main outcome measures-Observed incidences of testicular, prostate, and other cancers up to the end of 1989. Results-The overall pattern of cancer incidence in the study cohort was similar to that expected nationally. No increased incidence in testicular cancer was observed (70 cases; standardised morbidity ratio 1.01 (95% confidence interval 0.79 to 1.28)). The incidence during the first year of follow up was also close to that expected (nine cases; standardised morbidity ratio 0.80 (0.36 to 1.51)). The incidence of prostate cancer was not increased (165 cases; standardised morbidity ratio 0.98 (0.84 to 1.14)). Conclusions-The incidence of testicular cancer in men with vasectomy is no higher than in other men. Vasectomy does not cause testicular cancer and does not accelerate the growth or diagnosis of pre-existing testicular neoplasms. Data concerning a causal relation between vasectomy and prostate cancer were inconclusive.	DANISH CANC SOC,DK-2100 COPENHAGEN,DENMARK; DANMARKS STAT,DK-2100 COPENHAGEN,DENMARK	Danish Cancer Society				Moller, Henrik/0000-0001-8200-5929; Lynge, Elsebeth/0000-0003-4785-5236				Blom K, 1984, Ugeskr Laeger, V146, P616; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; CALE ARJ, 1990, BRIT MED J, V300, P370, DOI 10.1136/bmj.300.6721.370; FORD K, 1978, FAM PLANN PERSPECT, V10, P264, DOI 10.2307/2134378; GIOVANNUCCI E, 1993, JAMA-J AM MED ASSOC, V269, P873, DOI 10.1001/jama.269.7.873; GIOVANNUCCI E, 1993, JAMA-J AM MED ASSOC, V269, P878, DOI 10.1001/jama.269.7.878; GIOVANNUCCI E, 1992, NEW ENGL J MED, V326, P1392, DOI 10.1056/NEJM199205213262104; GIWERCMAN A, 1987, J UROLOGY, V138, P1214, DOI 10.1016/S0022-5347(17)43553-1; GOLDACRE M, 1979, VASECTOMY IMMUNOLOGI, P567; GOLDACRE MJ, 1978, AM J EPIDEMIOL, V108, P176, DOI 10.1093/oxfordjournals.aje.a112609; HAYES RB, 1993, AM J EPIDEMIOL, V137, P263, DOI 10.1093/oxfordjournals.aje.a116673; HONDA GD, 1988, BRIT J CANCER, V57, P326, DOI 10.1038/bjc.1988.74; JORGENSEN N, 1993, EUR J CANCER, V29A, P1062, DOI 10.1016/S0959-8049(05)80225-4; LYNGE E, 1990, Scandinavian Journal of Work Environment and Health, V16, P1; LYNGE E, 1933, EUR J CANCER, V29, P1064; MASSEY FJ, 1984, JAMA-J AM MED ASSOC, V252, P1023, DOI 10.1001/jama.252.8.1023; METTLIN C, 1990, AM J EPIDEMIOL, V132, P1056, DOI 10.1093/oxfordjournals.aje.a115747; MOLLER H, 1991, ACTA NEUROL SCAND, V84, P214, DOI 10.1111/j.1600-0404.1991.tb04941.x; MOSS AR, 1986, AM J EPIDEMIOL, V124, P39, DOI 10.1093/oxfordjournals.aje.a114369; NIENHUIS H, 1992, BRIT MED J, V304, P743, DOI 10.1136/bmj.304.6829.743; PETITTI DB, 1983, J UROLOGY, V129, P760, DOI 10.1016/S0022-5347(17)52345-9; PETITTI DB, 1982, AM J PUBLIC HEALTH, V72, P476, DOI 10.2105/AJPH.72.5.476; ROSENBERG L, 1990, AM J EPIDEMIOL, V132, P1051, DOI 10.1093/oxfordjournals.aje.a115746; ROSS RK, 1983, PROSTATE, V4, P333, DOI 10.1002/pros.2990040403; Schuman L M, 1993, J Clin Epidemiol, V46, P697; SIDNEY S, 1991, CANCER CAUSE CONTROL, V2, P113, DOI 10.1007/BF00053130; SIDNEY S, 1993, JAMA-J AM MED ASSOC, V270, P705, DOI 10.1001/jama.1993.03510060051018; SPITZ MR, 1991, AM J EPIDEMIOL, V134, P108, DOI 10.1093/oxfordjournals.aje.a115986; STRADER CH, 1988, AM J EPIDEMIOL, V128, P56, DOI 10.1093/oxfordjournals.aje.a114958; SWERDLOW AJ, 1989, INT J CANCER, V43, P549, DOI 10.1002/ijc.2910430403; SWERDLOW AJ, 1987, BRIT J CANCER, V55, P97, DOI 10.1038/bjc.1987.20; SZAREWSKI A, 1991, BRIT MED J, V302, P1224, DOI 10.1136/bmj.302.6787.1224; THORNHILL JA, 1988, EUR UROL, V14, P429; WALKER AM, 1981, JAMA-J AM MED ASSOC, V245, P2315, DOI 10.1001/jama.245.22.2315; WRIGHT N, 1977, Fertility and Contraception, V1, P41; 1988, IARC MONOGR EVAL CAR, V44	36	52	52	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 30	1994	309	6950					295	299		10.1136/bmj.309.6950.295	http://dx.doi.org/10.1136/bmj.309.6950.295			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA373	8086866	Green Published			2022-12-24	WOS:A1994PA37300016
J	BRUMMEL, TJ; TWOMBLY, V; MARQUES, G; WRANA, JL; NEWFELD, SJ; ATTISANO, L; MASSAGUE, J; OCONNOR, MB; GELBART, WM				BRUMMEL, TJ; TWOMBLY, V; MARQUES, G; WRANA, JL; NEWFELD, SJ; ATTISANO, L; MASSAGUE, J; OCONNOR, MB; GELBART, WM			CHARACTERIZATION AND RELATIONSHIP OF DPP RECEPTORS ENCODED BY THE SAXOPHONE AND THICK VEINS GENES IN DROSOPHILA	CELL			English	Article							GROWTH-FACTOR-BETA; PROTEIN-KINASE; CRYSTAL-STRUCTURE; TRANSFORMING GROWTH-FACTOR-BETA-2; CONSERVED FEATURES; GERM LAYERS; EXPRESSION; FAMILY; PATTERN; MELANOGASTER	The dpp/BMP family of TGF beta-related factors controls numerous events in pattern formation and morphogenesis. How these polypeptide signals are received and transduced by target cells is largely unknown. We combine molecular and genetic approaches to establish that the Drosophila saxophone (sax) gene encodes a dpp receptor. We compare the structural properties and expression patterns of sax with a second dpp receptor encoded by the thick veins (tkv) gene. While the sax gene is expressed ubiquitously, tkv is expressed in a highly localized and dynamic pattern during development. Some, but not all, of the tkv expression pattern parallels that of dpp. Ubiquitous expression of a tkv transgene rescues both tkv and sax loss-of function mutations. Thus, there is at least partial functional overlap of the sax and tkv receptors in vivo. We consider these observations in terms of possible ligand-receptor interactions during Drosophila development.	UNIV CALIF IRVINE, CTR DEV BIOL, IRVINE, CA 92717 USA; HARVARD UNIV, BIOL LABS, CAMBRIDGE, MA 02138 USA; MEM SLOAN KETTERING CANC CTR, CELL BIOL & GENET PROGRAM, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA	University of California System; University of California Irvine; Harvard University; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	BRUMMEL, TJ (corresponding author), UNIV CALIF IRVINE, DEPT MOLEC BIOL & BIOCHEM, IRVINE, CA 92717 USA.		O'Connor, Michael B/C-9977-2014; Wrana, Jeffrey/F-8857-2013	O'Connor, Michael B/0000-0002-3067-5506; Massague, Joan/0000-0001-9324-8408				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; Ausubel F.M., 1987, CURRENT PROTOCOLS MO; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHILDS SR, 1993, P NATL ACAD SCI USA, V90, P9475, DOI 10.1073/pnas.90.20.9475; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; DOCTOR JS, 1992, DEV BIOL, V151, P491, DOI 10.1016/0012-1606(92)90188-M; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FROLIK CA, 1984, J BIOL CHEM, V259, P995; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HURSH DA, 1993, DEVELOPMENT, V117, P1211; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOENIG BB, 1994, IN PRESS MOL CELL BI; Maniatis T., 1982, MOL CLONING; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PADGETT RW, 1993, P NATL ACAD SCI USA, V90, P2905, DOI 10.1073/pnas.90.7.2905; PANGANIBAN GEF, 1990, DEVELOPMENT, V110, P1041; Pardue ML, 1986, DROSOPHILA PRACTICAL, P111; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; PIROTTA V, 1988, VECTORS SURVEY MOL C, P437; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SAMPATH TK, 1990, J BIOL CHEM, V265, P13198; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLUNEGGER MP, 1993, J MOL BIOL, V231, P445, DOI 10.1006/jmbi.1993.1293; SCHUPBACH T, 1989, GENETICS, V121, P101; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TERRACOL R, 1994, IN PRESS GENETICS; VALE W, 1990, PEPTIDE GROWTH FACTO, P211; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WHARTON KA, 1991, P NATL ACAD SCI USA, V88, P9214, DOI 10.1073/pnas.88.20.9214; Wieschaus E., 1986, P199; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837	48	268	276	0	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 29	1994	78	2					251	261		10.1016/0092-8674(94)90295-X	http://dx.doi.org/10.1016/0092-8674(94)90295-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	8044839				2022-12-24	WOS:A1994NZ24200009
J	LINGAM, S; JOESTER, J				LINGAM, S; JOESTER, J			LESSON OF THE WEEK - SPONTANEOUS FRACTURES IN CHILDREN AND ADOLESCENTS WITH CEREBRAL-PALSY	BRITISH MEDICAL JOURNAL			English	Article									MELDRETH MANOR SCH,MELDRETH SG8 6LG,HERTS,ENGLAND		LINGAM, S (corresponding author), ST ANNS HOSP,WARD M2,ST ANNS RD,LONDON N15 3TH,ENGLAND.							RUBIN CT, 1984, J BONE JOINT SURG AM, V66A, P397, DOI 10.2106/00004623-198466030-00012	1	29	30	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 23	1994	309	6949					265	265		10.1136/bmj.309.6949.265	http://dx.doi.org/10.1136/bmj.309.6949.265			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ180	8069146	Green Published			2022-12-24	WOS:A1994NZ18000028
J	SCHWARTZ, AB				SCHWARTZ, AB			DIRECT CORTICAL REPRESENTATION OF DRAWING	SCIENCE			English	Article							UNIT-ACTIVITY; MOVEMENTS; KINEMATICS; GEOMETRY; LEECH	How the intention to act results in movement is a fundamental question of brain organization. Recent work has shown that this operation involves the cooperative interaction of large neuronal populations. A population vector method, by transforming neuronal activity to the spatial domain, was used to visualize the motor cortical representation of the hand's trajectory made by rhesus monkeys as they drew spirals. Hand path was accurately reflected by a series of population vectors calculated throughout the task. A psychophysical rule relating speed to curvature, the ''power law,'' was found in this cortical representation. The relative timing between each population vector and the corresponding portion of the movement was variable. The population vectors only preceded the movement in a predictive manner in portions of the spiral where the radius of curvature was greater than 6 centimeters. These results show that the movement trajectory is an important determinant of motor cortical activity and that this aspect of motor cortical activity may contribute only to discrete portions of the drawing movement.			SCHWARTZ, AB (corresponding author), BARROW NEUROL INST,DIV NEUROBIOL,350 W THOMAS RD,PHOENIX,AZ 85013, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026375] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-26375] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAEV KV, 1991, NEUROSCIENCE, V43, P237, DOI 10.1016/0306-4522(91)90431-M; EDELMAN GM, 1978, MINDFUL BRAIN; GEORGOPOULOS AP, 1989, SCIENCE, V243, P234, DOI 10.1126/science.2911737; GEORGOPOULOS AP, 1982, J NEUROSCI, V2, P1527; JUNG MW, 1993, HIPPOCAMPUS, V3, P165, DOI 10.1002/hipo.450030209; KALASKA JF, 1992, SCIENCE, V255, P1517, DOI 10.1126/science.1549781; LACQUANITI F, 1983, ACTA PSYCHOL, V54, P115, DOI 10.1016/0001-6918(83)90027-6; LOCKERY SR, 1990, J NEUROSCI, V10, P1811; LUNDBERG A, 1971, EXP BRAIN RES, V12, P317; MASSEY JT, 1992, EXP BRAIN RES, V88, P685; SCHWARTZ AB, 1993, J NEUROPHYSIOL, V70, P28, DOI 10.1152/jn.1993.70.1.28; SCHWARTZ AB, 1992, J NEUROPHYSIOL, V68, P528, DOI 10.1152/jn.1992.68.2.528; VIVIANI P, 1991, J EXP PSYCHOL HUMAN, V17, P198, DOI 10.1037/0096-1523.17.1.198; WANN J, 1988, J EXP PSYCHOL HUMAN, V14, P622, DOI 10.1037/0096-1523.14.4.622; WITTENBERG G, 1992, J NEUROPHYSIOL, V68, P1693, DOI 10.1152/jn.1992.68.5.1693; [No title captured]	16	242	243	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 22	1994	265	5171					540	542		10.1126/science.8036499	http://dx.doi.org/10.1126/science.8036499			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NY216	8036499				2022-12-24	WOS:A1994NY21600036
J	RIDDIHOUGH, G				RIDDIHOUGH, G			NO LIMITS ON RESTRICTION	NATURE			English	Note							CRYSTAL-STRUCTURE; ENDONUCLEASE											ATHANASIADIS A, 1994, NAT STRUCT BIOL, V1, P469, DOI 10.1038/nsb0794-469; CHENG X, IN PRESS EMBO J; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; NEWMAN M, 1994, STRUCTURE, V2, P439, DOI 10.1016/S0969-2126(00)00045-9; NEWMAN M, 1994, NATURE, V368, P660, DOI 10.1038/368660a0; RIDDIHOUGH G, 1994, NATURE, V368, P82, DOI 10.1038/368082a0; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x	7	3	3	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 7	1994	370	6484					78	78		10.1038/370078a0	http://dx.doi.org/10.1038/370078a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV711	8015614	Bronze			2022-12-24	WOS:A1994NV71100064
J	BROMWICH, P; COHEN, J; STEWART, I; WALKER, A				BROMWICH, P; COHEN, J; STEWART, I; WALKER, A			DECLINE IN SPERM COUNTS - AN ARTIFACT OF CHANGED REFERENCE RANGE OF NORMAL	BRITISH MEDICAL JOURNAL			English	Article								Objective-To investigate a reported fall in sperm counts during 1940-90 in relation to the reduced lower reference value of ''normal'' during the same period by assuming the null hypothesis that no change had occurred in the probability distribution of the sperm concentration. Design-Analysis by using various mathematical models of the probability distribution of sperm concentration together with experimental data which supported a model employing a logarithmic distribution.	UNIV WARWICK,CTR ECOSYST ANAL & MANAGEMENT,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND; MIDLAND FERTIL SERV,ALDRIDGE WS9 8LT,STAFFS,ENGLAND; UNIV WARWICK,INST MATH,NONLINEAR SYST LAB,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND	University of Warwick; University of Warwick								CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; Cohen J., 1971, Adv comp Physiol Biochem, V4, P267; Feller W., 1957, INTRO PROBABILITY TH; MOORE DS, 1993, INTRO PRACTICE STATI; 1993, HORIZON         1031	5	119	121	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 2	1994	309	6946					19	22		10.1136/bmj.309.6946.19	http://dx.doi.org/10.1136/bmj.309.6946.19			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV891	8044061	Green Published			2022-12-24	WOS:A1994NV89100016
J	KIMURA, T; NAKAYAMA, K; PENNINGER, J; KITAGAWA, M; HARADA, H; MATSUYAMA, T; TANAKA, N; KAMIJO, R; VILCEK, J; MAK, TW; TANIGUCHI, T				KIMURA, T; NAKAYAMA, K; PENNINGER, J; KITAGAWA, M; HARADA, H; MATSUYAMA, T; TANAKA, N; KAMIJO, R; VILCEK, J; MAK, TW; TANIGUCHI, T			INVOLVEMENT OF THE IRF-1 TRANSCRIPTION FACTOR IN ANTIVIRAL RESPONSES TO INTERFERONS	SCIENCE			English	Article							REGULATORY FACTOR-I; GAMMA SIGNAL-TRANSDUCTION; CONSTITUTIVE EXPRESSION; INDUCIBLE GENES; BINDING PROTEIN; NITRIC-OXIDE; CELL-LINE; INHIBITION; ACTIVATION; ALPHA	The mechanisms underlying interferon (IFN)-induced antiviral states are not well understood. Interferon regulatory factor-1 (IRF-1) is an IFN-inducible transcriptional activator, whereas IRF-2 suppresses IRF-1 action. The inhibition of encephalomyocarditis virus (EMCV) replication by IFN-alpha and especially by IFN-gamma was impaired in cells from mice with a null mutation in the IRF-1 gene (IRF-1(-/-) mice). The IRF-1(-/-) mice were less resistant than normal mice to EMCV infection, as revealed by accelerated mortality and a larger virus titer in target organs. The absence of IRF-1 did not clearly affect replication of two other types of viruses. Thus, IRF-1 is necessary for the antiviral action of IFNs against some viruses, but IFNs activate multiple activation pathways through diverse target genes to induce the antiviral state.	UNIV TORONTO,ONTARIO CANC INST,AMGEN INST,DEPT IMMUNOL & MED BIOPHYS,TORONTO M4X 1K9,ON,CANADA; NYU,MED CTR,DEPT MICROBIOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	University of Toronto; University Toronto Affiliates; University Health Network Toronto; New York University; New York University	KIMURA, T (corresponding author), OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN.		Kitagawa, Motoo/W-8468-2019; Nakayama, Katsutoshi/AAT-4536-2021; Penninger, Josef M/I-6860-2013; Harada, Hisashi/H-2815-2019	Kitagawa, Motoo/0000-0003-1036-840X; Nakayama, Katsutoshi/0000-0002-0141-7081; Penninger, Josef M/0000-0002-8194-3777; Harada, Hisashi/0000-0001-5993-1289; Kimura, Tohru/0000-0001-9227-0996; Tanaka, Nobuyuki/0000-0002-6373-2220	NCI NIH HHS [R35CA49731] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA049731] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; Anderson Sylvia L., 1992, Journal of Interferon Research, V12, pS86; BAIER LJ, 1993, NUCLEIC ACIDS RES, V21, P4830, DOI 10.1093/nar/21.20.4830; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; CHENG YSE, 1991, MOL CELL BIOL, V11, P4717, DOI 10.1128/MCB.11.9.4717; CONSTANTOULAKIS P, 1993, SCIENCE, V259, P1314, DOI 10.1126/science.7680491; CROEN KD, 1993, J CLIN INVEST, V91, P2446, DOI 10.1172/JCI116479; Demaeyer E., 1988, INTERFERONS OTHER RE; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; FISCHER DG, 1993, SCIENCE, V262, P250, DOI 10.1126/science.8211145; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; GLASGOW L A, 1970, Journal of General Physiology, V56, P212, DOI 10.1085/jgp.56.1.212; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HESSEL BA, 1993, EMBO J, V12, P3297; IMAM AMA, 1990, NUCLEIC ACIDS RES, V18, P6573, DOI 10.1093/nar/18.22.6573; JOHN J, 1991, MOL CELL BIOL, V11, P4189, DOI 10.1128/MCB.11.8.4189; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; KERR IM, 1992, J INTERFERON RES, V12, P237, DOI 10.1089/jir.1992.12.237; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; MURPHY BR, 1968, J EXP MED, V127, P1035, DOI 10.1084/jem.127.5.1035; NAKAYAMA K, UNPUB; PARRINGTON J, 1993, EUR J BIOCHEM, V214, P617, DOI 10.1111/j.1432-1033.1993.tb17961.x; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PENNINGER J, UNPUB; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PINE R, 1992, J VIROL, V66, P4470, DOI 10.1128/JVI.66.7.4470-4478.1992; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; RUFFNER H, 1993, P NATL ACAD SCI USA, V90, P11503, DOI 10.1073/pnas.90.24.11503; RYSIECKI G, 1989, J INTERFERON RES, V9, P649, DOI 10.1089/jir.1989.9.649; SEN GC, 1992, J BIOL CHEM, V267, P5017; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; STARK GR, 1992, J INTERFERON RES, V12, P147, DOI 10.1089/jir.1992.12.147; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA N, IN PRESS CELL; Vilcek J., 1990, HDB EXPT PHARM, V95, P3; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; WYNN TA, 1991, J IMMUNOL, V147, P4384; YAMAMOTO HM, UNPUB; YULEE LY, 1990, MOL CELL BIOL, V10, P3087, DOI 10.1128/MCB.10.6.3087	52	269	275	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1921	1924		10.1126/science.8009222	http://dx.doi.org/10.1126/science.8009222			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	8009222				2022-12-24	WOS:A1994NT84700042
J	NANCARROW, JK; KREMER, E; HOLMAN, K; EYRE, H; DOGGETT, NA; LEPASLIER, D; CALLEN, DF; SUTHERLAND, GR; RICHARDS, RI				NANCARROW, JK; KREMER, E; HOLMAN, K; EYRE, H; DOGGETT, NA; LEPASLIER, D; CALLEN, DF; SUTHERLAND, GR; RICHARDS, RI			IMPLICATIONS OF FRA16A STRUCTURE FOR THE MECHANISM OF CHROMOSOMAL FRAGILE SITE GENESIS	SCIENCE			English	Article							X-SYNDROME; HUNTINGTONS-DISEASE; MYOTONIC-DYSTROPHY; MENTAL-RETARDATION; MOLECULAR ANALYSIS; UNSTABLE ELEMENT; REPEAT SEQUENCE; FMR1 GENE; DNA; INSTABILITY	Fragile sites are chemically induced nonstaining gaps in chromosomes. Different fragile sites vary in frequency in the population and in the chemistry of their induction. DNA sequences encompassing and including the rare, autosomal, folate-sensitive fragile site, FRA16A, were isolated by positional cloning. The molecular basis of FRA16A was found to be expansion of a normally polymorphic p(CCG), repeat. This repeat was adjacent to a CpG island that was methylated in fragile site-expressing individuals. The FRA16A locus in individuals who do not express the fragile site is not a site of DNA methylation (imprinting), which suggests that the methylation associated with fragile sites may be a consequence and not a cause of their genesis.	WOMENS & CHILDRENS HOSP,CTR GENET MED,DEPT CYTOGENET & MOLEC GENET,ADELAIDE,SA 5006,AUSTRALIA; LOS ALAMOS NATL LAB,CTR HUMAN GENOME STUDIES,LOS ALAMOS,NM 87545; LOS ALAMOS NATL LAB,DIV LIFE SCI,LOS ALAMOS,NM 87545; CTR ETUD POLYMORPHISME HUMAIN,F-750101 PARIS,FRANCE	Womens & Childrens Hospital Australia; United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory			Sutherland, Grant Robert/D-2606-2012; Kremer, Eric J/D-3734-2013; Callen, David F/G-1975-2012; Richards, Robert/ABE-6423-2020; Kremer, EJ/P-9838-2019	Kremer, EJ/0000-0001-6114-7530; Le Paslier, Denis/0000-0003-4335-9956; Callen, David/0000-0002-6189-9991; Richards, Robert Ian/0000-0002-5978-6453				ASHIZAWA T, 1994, AM J HUM GENET, V54, P414; BRUNNER HG, 1993, AM J HUM GENET, V53, P1016; CALLEN DF, 1992, GENOMICS, V13, P1178, DOI 10.1016/0888-7543(92)90035-Q; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GOLDBERG YP, 1993, NAT GENET, V5, P174, DOI 10.1038/ng1093-174; HANSEN RS, 1992, HUM MOL GENET, V1, P571, DOI 10.1093/hmg/1.8.571; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; HARLEY HG, 1993, AM J HUM GENET, V52, P1164; JANSEN G, 1993, HUM MOL GENET, V2, P1221, DOI 10.1093/hmg/2.8.1221; KNIGHT SJL, 1993, CELL, V74, P27; KOZMAN H, 1992, GENET LIFE SCI ADV, V11, P229; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LAIRD C, 1987, TRENDS GENET, V3, P274, DOI 10.1016/0168-9525(87)90268-X; LAIRD CD, 1987, GENETICS, V117, P587; LAVEDAN C, 1993, AM J HUM GENET, V52, P875; NANCARROW J, UNPUB; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; RENNIE J, 1993, SCI AM           MAR, P88; RICHARDS RI, 1993, HUM MOL GENET, V2, P1429, DOI 10.1093/hmg/2.9.1429; RICHARDS RI, 1991, J MED GENET, V28, P856, DOI 10.1136/jmg.28.12.856; ROUSSEAU F, 1991, NEW ENGL J MED, V325, P1673, DOI 10.1056/NEJM199112123252401; SHERMAN SL, 1986, HUM GENET, V72, P123; SNELL RG, 1993, NAT GENET, V4, P393, DOI 10.1038/ng0893-393; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; SUTHERLAND GR, 1993, J MED GENET, V30, P978, DOI 10.1136/jmg.30.12.978; TELENIUS H, 1993, HUM MOL GENET, V2, P1535, DOI 10.1093/hmg/2.10.1535; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; YU S, 1992, AM J HUM GENET, V50, P968; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	30	139	141	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1938	1941		10.1126/science.8009225	http://dx.doi.org/10.1126/science.8009225			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	8009225				2022-12-24	WOS:A1994NT84700047
J	BLOCH, AB; CAUTHEN, GM; ONORATO, IM; DANSBURY, KG; KELLY, GD; DRIVER, CR; SNIDER, DE				BLOCH, AB; CAUTHEN, GM; ONORATO, IM; DANSBURY, KG; KELLY, GD; DRIVER, CR; SNIDER, DE			NATIONWIDE SURVEY OF DRUG-RESISTANT TUBERCULOSIS IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MYCOBACTERIUM-TUBERCULOSIS; TRANSMISSION; OUTBREAK	Objective.-To determine antituberculosis drug resistance patterns, geographic distribution, demographic characteristics, and risk factors of reported tuberculosis (TB) patients in the United States. Design.-Survey of reported TB cases in the United States. For culture-positive cases reported to the Centers for Disease Control and Prevention, we asked health departments to provide drug susceptibility test results from initial Mycobacterium tuberculosis isolates. Study Population.-Culture-positive TB cases in the United States reported during the first quarter of 1991. Main Outcome Measures.-Individual TB case reports submitted to the Centers for Disease Control and Prevention and drug susceptibility test results. Result.-Resistance to one or more antituberculosis drugs was found in 14.2% of cases. Resistance to isoniazid and/or rifampin was found in 9.5% of cases whose isolates were tested against one or both drugs; such cases were found in 107 counties in 33 states. Resistance to both isoniazid and rifampin (multidrug-resistant [MDR] TB) was found in 3.5% of cases whose isolates were tested against both drugs; such cases were found in 35 counties in 13 states. New York City accounted for 61.4% of the nation's MDR TB cases. The 3-month population-based incidence rate of MDR TB in New York City was 52.4 times (95% confidence interval [CI], 35.5 to 78.3) that of the rest of the nation (9.559 vs 0.182 cases per million population). Compared with the rate in non-Hispanic whites in the rest of the nation (0.032 cases per million), the relative risk of MDR TB in New York City non-Hispanic whites was 39.0 (95% CI, 8.1 to 164.5), 299.3 (95% CI, 112.5 to 927.1) in Hispanics, 420.9 (95% CI, 121.0 to 1515.8) in Asian/Pacific islanders, and 701.0 (95% CI, 296.4 to 2018.1) in non-Hispanic blacks. Conclusions.-With nearly 10% of TB patients resistant to isoniazid and/or rifampin, greater use of four-drug regimens and directly observed therapy is indicated. Aggressive intervention to prevent the further spread of MDR TB is needed to find every TB patient and to provide optimal patient, management to ensure completion of chemotherapy.			BLOCH, AB (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR PREVENT SERV,DIV TB ELIMINAT,INFORMAT SERV OFF,ATLANTA,GA 30333, USA.							[Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; BARNES PF, 1987, AM REV RESPIR DIS, V136, P325, DOI 10.1164/ajrccm/136.2.325; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; CORONADO VG, 1993, J INFECT DIS, V168, P1052, DOI 10.1093/infdis/168.4.1052; CORONADO VG, 1992, NOV WORLD C TUB BETH; DAVIDSON PT, 1987, AM REV RESPIR DIS, V136, P255, DOI 10.1164/ajrccm/136.2.255; Dean A. G., 1990, EPI INFO VERSION 5 W; DOOLEY SW, 1992, ANN INTERN MED, V117, P257, DOI 10.7326/0003-4819-117-3-257; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; IKEDA R, 1992, 32ND INT C ANT AG CH; ISEMAN MD, 1989, CLIN CHEST MED, V10, P341; ISEMAN MD, 1993, NEW ENGL J MED, V328, P576, DOI 10.1056/NEJM199302253280811; ISEMAN MD, 1993, NEW ENGL J MED, V329, P784, DOI 10.1056/NEJM199309093291108; JEREB J, 1992, NOV WORLD C TUB BETH; Jereb J A, 1991, MMWR CDC Surveill Summ, V40, P23; KENT JH, 1993, MED CLIN N AM, V77, P1391, DOI 10.1016/S0025-7125(16)30200-0; KOPANOFF DE, 1978, AM REV RESPIR DIS, V118, P835; KOPANOFF DE, 1988, AM J PUBLIC HEALTH, V78, P30, DOI 10.2105/AJPH.78.1.30; MAHMOUDI A, 1993, JAMA-J AM MED ASSOC, V270, P65, DOI 10.1001/jama.270.1.65; MITCHISON DA, 1985, TUBERCLE, V66, P219, DOI 10.1016/0041-3879(85)90040-6; NARDELL EA, 1993, AM REV RESPIR DIS, V148, P2, DOI 10.1164/ajrccm/148.1.2; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; Prevention and control of influenza, 1990, MMWR MORB MORTAL WKL, V39, P1; REICHMAN LB, 1991, AM REV RESPIR DIS, V144, P741, DOI 10.1164/ajrccm/144.4.741; RIEDER HL, 1989, JAMA-J AM MED ASSOC, V262, P385, DOI 10.1001/jama.262.3.385; SNIDER DE, 1991, AM REV RESPIR DIS, V144, P732, DOI 10.1164/ajrccm/144.3_Pt_1.732; TENOVER FC, 1993, J CLIN MICROBIOL, V31, P767, DOI 10.1128/JCM.31.4.767-770.1993; Tuberculosis morbidity-United States, 1992, MMWR MORB MORTAL WKL, V42, P703; USSERY XT, 1992, 32ND INT C ANT AG CH; VALWAY SE, 1990, IN PRESS J INFECT DI; VALWAY SE, 1991, IN PRESS AM J EPIDEM; 1991, MMWR MORB MORTAL WKL, V40, P585; 1983, MMWR MORB MORTAL WKL, V32, P521; 1992, AM REV RESPIR DIS, V146, P1623; 1992, MMWR MORB MORTAL WKL, V41, P59; 1986, AM REV RESPIR DIS, V134, P855; 1992, MMWR MORB MORTAL WKL, V41, P507; 1993, OTAH574 US C OFF TEC; 1993, MMWR MORB MORTAL WKL, V42, P696; 1992, MMWR MORB MORTAL WKL, V41, P49; 1989, MMWR MORB MORTAL SS3, V38, P1; 1980, MMWR MORB MORTAL WKL, V29, P345; 1993, MMWR MORB MORTAL WKL, V42, P1	47	297	306	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 2	1994	271	9					665	671		10.1001/jama.271.9.665	http://dx.doi.org/10.1001/jama.271.9.665			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX570	8080502				2022-12-24	WOS:A1994MX57000026
J	GRINSPOON, L; BAKALAR, JB				GRINSPOON, L; BAKALAR, JB			THE WAR ON DRUGS - A PEACE PROPOSAL	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PROHIBITION				GRINSPOON, L (corresponding author), HARVARD UNIV,SCH MED,BOSTON,MA 02115, USA.							Austin J, 1989, NCCD PRISON POPULATI; DENNIS RJ, 1990, DRUG PROHIBITION CON; DINARDO J, 1991, ARE MARIHUANA ALCOHO; Erickson P. G., 1989, SOCIAL PHARM, V3, P249; GILL AM, 1992, IND LABOR RELAT REV, V45, P419, DOI 10.2307/2524269; GRINSPOON L, 1990, N C J INT LAW COMMER, V15, P505; Grinspoon L., 1993, MARIHUANA FORBIDDEN; HORGAN J, 1990, NEW REPUBLIC    0402, P22; Jolliffe N, 1936, SCIENCE, V83, P306, DOI 10.1126/science.83.2152.306-a; Kolb L, 1924, PUBLIC HEALTH REP, V39, P1179, DOI 10.2307/4577168; LEVINE HG, 1991, MILBANK Q, V69, P461, DOI 10.2307/3350105; MAYES LC, 1992, JAMA-J AM MED ASSOC, V267, P406, DOI 10.1001/jama.267.3.406; Moore M.H., 1981, ALCOHOL PUBLIC POLIC; MOORE MH, 1977, BUY BUST EFFECTIVE R; NADELMANN EA, 1992, DAEDALUS, V121, P85; NADELMANN EA, 1988, FOREIGN POLICY, V70, P83; OMALLEY PM, 1985, NIDA RES MONOGRAPH, V61; POPE HG, 1990, AM J PSYCHIAT, V147, P998; SHEDLER J, 1990, AM PSYCHOL, V45, P612, DOI 10.1037/0003-066X.45.5.612; SINGLE E W, 1989, Journal of Public Health Policy, V10, P456, DOI 10.2307/3342518; SKOLNICK AA, 1992, JAMA-J AM MED ASSOC, V268, P3177, DOI 10.1001/jama.268.22.3177; TERRIS M, 1967, AM J PUBLIC HEALTH N, V57, P2076, DOI 10.2105/AJPH.57.12.2076; TREBACH AS, 1987, GREAT DRUG WAR; Weil Andrew, 1980, MARRIAGE SUN MOON QU; WILSON JQ, 1990, DRUGS CRIME; WISOTSKY S, 1992, POLICY ANAL, V180; 1989, NATIONAL DRUG CONTRO; 1985, NATIONAL HOUSEHOLD S; 1991, CRIME US; 1992, NATIONAL DRUG CONTRO	30	19	19	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 3	1994	330	5					357	360		10.1056/NEJM199402033300513	http://dx.doi.org/10.1056/NEJM199402033300513			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MU489	8043062				2022-12-24	WOS:A1994MU48900013
J	GURNEY, AL; CARVERMOORE, K; DESAUVAGE, FJ; MOORE, MW				GURNEY, AL; CARVERMOORE, K; DESAUVAGE, FJ; MOORE, MW			THROMBOCYTOPENIA IN C-MPL-DEFICIENT MICE	SCIENCE			English	Article								Thrombopoietin (TPO) is a cytokine that is involved in the regulation of platelet production. The receptor for TPO is c-Mpl. To further investigate the role and specificity of this receptor in regulating megakaryocytopoiesis, c-mpl-deficient mice were generated by gene targeting. The c-mpl(-/-) mice had an 85 percent decrease in their number of platelets and megakaryocytes but had normal amounts of other hematopoietic cell types. These mice also had increased concentrations of circulating TPO. These results show that c-mpl specifically regulates megakaryocytopoiesis and thrombopoiesis through activation by its ligand TPO.	GENENTECH INC,DEPT CELL GENET,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech			de Sauvage, Frederic/ABE-8400-2020	de Sauvage, Frederic/0000-0002-5275-2584				Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CARVERMOORE K, UNPUB; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GURNEY AL, UNPUB; HOFFMAN R, 1981, NEW ENGL J MED, V305, P533, DOI 10.1056/NEJM198109033051001; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; METHIA N, 1993, BLOOD, V82, P1395; MIGNOTTE V, 1994, GENOMICS, V20, P5, DOI 10.1006/geno.1994.1120; NAKEFF A, 1975, ACTA HAEMATOL-BASEL, V54, P340, DOI 10.1159/000208096; ODELL TT, 1961, P SOC EXP BIOL MED, V108, P428; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WENDLING F, 1994, NATURE, V369, P571, DOI 10.1038/369571a0	16	542	554	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 2	1994	265	5177					1445	1447		10.1126/science.8073287	http://dx.doi.org/10.1126/science.8073287			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	8073287				2022-12-24	WOS:A1994PE73300048
J	PROLLA, TA; PANG, QS; ALANI, E; KOLODNER, RD; LISKAY, RM				PROLLA, TA; PANG, QS; ALANI, E; KOLODNER, RD; LISKAY, RM			MLH1, PMS1, AND MSH2 INTERACTIONS DURING THE INITIATION OF DNA MISMATCH REPAIR IN YEAST	SCIENCE			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; GENETIC INSTABILITY; PROTEIN; MUTATIONS; MUTL; ASSOCIATION; HOMOLOG	The discovery that mutations in DNA mismatch repair genes can cause hereditary nonpolyposis colorectal cancer has stimulated interest in understanding the mechanism of DNA mismatch repair in eukaryotes. In the yeast Saccharomyces cerevisiae, DNA mismatch repair requires the MSH2, MLH1, and PMS1 proteins. Experiments revealed that the yeast MLH1 and PMS1 proteins physically associate, possibly forming a heterodimer, and that MLH1 and PMS1 act in concert to bind a MSH2-heteroduplex complex containing a G-T mismatch. Thus, MSH2, MLH1, and PMS1 are likely to form a ternary complex during the initiation of eukaryotic DNA mismatch repair.	OREGON HLTH SCI UNIV,DEPT MOLEC & MED GENET,PORTLAND,OR 97201; YALE UNIV,SCH MED,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELL & MOLEC BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Oregon Health & Science University; Yale University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School					NHGRI NIH HHS [HG00305/GM50006] Funding Source: Medline; NIGMS NIH HHS [GM 45413, GM 322741] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045413] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AAITONEN LA, 1993, SCIENCE, V260, P812; ALANI E, 1994, GENETICS, V137, P19; BENDE SM, 1991, NUCLEIC ACIDS RES, V19, P1549, DOI 10.1093/nar/19.7.1549; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; HAN HJ, 1993, CANCER RES, V53, P5087; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JIRICNY J, 1988, NUCLEIC ACIDS RES, V16, P7843, DOI 10.1093/nar/16.16.7843; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LOATHE RA, 1993, CANCER RES, V53, P5849; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MERLO A, 1994, CANCER RES, V54, P2098; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; NICOLAIDES NC, IN PRESS NATURE; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; REENAN RAG, 1992, GENETICS, V132, P975; RISINGER JI, 1993, CANCER RES, V53, P5100; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; SAUER RT, 1983, J MOL BIOL, V168, P699, DOI 10.1016/S0022-2836(83)80070-9; SHENA M, 1991, METHOD ENZYMOL, V194, P389; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VONHIPPEL PH, 1994, SCIENCE, V263, P769, DOI 10.1126/science.8303292; WATSON P, 1993, CANCER, V71, P677, DOI 10.1002/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO;2-#; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152	35	282	306	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 19	1994	265	5175					1091	1093		10.1126/science.8066446	http://dx.doi.org/10.1126/science.8066446			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC539	8066446				2022-12-24	WOS:A1994PC53900035
J	PARTON, RF; VANKELECOM, IFJ; CASSELMAN, MJA; BEZOUKHANOVA, CP; UYTTERHOEVEN, JB; JACOBS, PA				PARTON, RF; VANKELECOM, IFJ; CASSELMAN, MJA; BEZOUKHANOVA, CP; UYTTERHOEVEN, JB; JACOBS, PA			AN EFFICIENT MIMIC OF CYTOCHROME-P-450 FROM A ZEOLITE ENCAGED IRON COMPLEX IN A POLYMER MEMBRANE	NATURE			English	Article							ALIPHATIC HYDROXYLATION; PORPHYRIN COMPLEXES; HYDROGEN-PEROXIDE; ALKANE OXIDATION; CATALYSTS; MANGANESE; MECHANISM; PYRIDINE	MANY attempts have been made to mimic the catalytic oxidative properties of the enzyme cytochrome P-450. For homogeneous systems' the mechanisms of oxidation can be readily determined but proper mimicry of the protein environment is difficult to achieve. Heterogeneous mimics have been designed that use organometallic complexes encapsulated in the supercages of zeolites(2,3), which enables control of selectivity and inhibition of auto-oxidation. But these systems do not show any mechanistic analogy with the enzymatic process, and the oxidation rates tend to be low. Here we report a composite catalytic system that achieves realistic mimicry of cytochrome P-450 as well as catalytic turnover rates that make the system industrially viable. Our catalyst incorporates iron phthalocyanine complexes encapsulated in crystals of zeolite Y, which are in turn embedded ina polydimethylsiloxane membrane. The polymer acts as a mimic of the phospholipid membrane in which cytochrome P-450 resides(4), acting as an interface between two immiscible phases and avoiding the need for solvents or phase-transfer agents. This system oxidizes alkanes at room temperature at rates comparable to those of the enzyme(5). The observation of a large kinetic isotope effect and the preferential oxidation of tertiary C-H bonds suggest close mechanistic similarities to the enzymatic process.			PARTON, RF (corresponding author), KATHOLIEKE UNIV LEUVEN, CENTRUM OPPERVLAKTECHEM KATALYSE, DEPT INTERFACE CHEM, B-3001 HEVERLEE, BELGIUM.		Vankelecom, Ivo/AAL-5006-2020; Nanozymes, Nanozymes/D-8197-2019					ARMOR JN, 1989, APPL CATAL, V102, P1; ASADA T, 1991, MEMBRANE SCI TECHNOL, V1, P439; BARTON DHR, 1991, TETRAHEDRON LETT, V32, P3811; BELL RP, 1974, CHEM SOC REV, V3, P513, DOI 10.1039/cs9740300513; BOWERS C, 1990, J CATAL, V122, P271, DOI 10.1016/0021-9517(90)90281-N; CAMBLOR MA, 1993, J ZEOLITES, V13, P82; CHE CM, 1993, J CHEM SOC DA, P1259; CORMA A, 1994, J CHEM SOC CHEM COMM, P147, DOI 10.1039/c39940000147; DEVOS DE, 1994, MACROMOL SYMP, V80, P157, DOI 10.1002/masy.19940800112; GROVES JT, 1990, J AM CHEM SOC, V112, P7796, DOI 10.1021/ja00177a050; GROVES JT, 1983, J AM CHEM SOC, V105, P6243, DOI 10.1021/ja00358a009; GROVES JT, 1985, J CHEM EDUC, V62, P928, DOI 10.1021/ed062p928; HUYBRECHTS DRC, 1990, NATURE, V345, P240, DOI 10.1038/345240a0; ICHIKAWA M, 1991, STUD SURF SCI CATAL, V60, P335; Ingelman-Sundberg M, 1986, CYTOCHROME P450 STRU, P119; KHENKIN AM, 1989, NEW J CHEM, V13, P659; KNOPSGERRITS PP, 1994, NATURE, V369, P543, DOI 10.1038/369543a0; KWART H, 1982, ACCOUNTS CHEM RES, V15, P401, DOI 10.1021/ar00084a004; LEISING RA, 1993, J AM CHEM SOC, V115, P9524, DOI 10.1021/ja00074a017; Mansuy D., 1989, ACTIVATION FUNCTIONA, P195; MENAGE S, 1993, INORG CHEM, V32, P4766, DOI 10.1021/ic00074a019; MEUNIER B, 1992, CHEM REV, V92, P1411, DOI 10.1021/cr00014a008; NAKAMURA M, 1990, B CHEM SOC JPN, V63, P3334, DOI 10.1246/bcsj.63.3334; NAM W, 1989, NEW J CHEM, V13, P677; PARTON R, 1992, NATO ADV SCI I C-MAT, V352, P555; PARTON RF, 1991, STUD SURF SCI CATAL, V59, P395; PENNERHAHN JE, 1983, J BIOL CHEM, V258, P2761; SOROKIN A, 1993, J AM CHEM SOC, V115, P7293, DOI 10.1021/ja00069a031; SOROKIN AB, 1990, J CHEM SOC CHEM COMM, P45, DOI 10.1039/c39900000045; TANEV PT, 1994, NATURE, V368, P321, DOI 10.1038/368321a0; Tolman C. A., 1989, ACTIVATION FUNCTIONA, P303; Ullrich V, 1979, Top Curr Chem, V83, P67	32	255	258	2	81	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 18	1994	370	6490					541	544		10.1038/370541a0	http://dx.doi.org/10.1038/370541a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	PC537	8052309				2022-12-24	WOS:A1994PC53700049
J	YU, RT; MCKEOWN, M; EVANS, RM; UMESONO, K				YU, RT; MCKEOWN, M; EVANS, RM; UMESONO, K			RELATIONSHIP BETWEEN DROSOPHILA GAP GENE TAILLESS AND A VERTEBRATE NUCLEAR RECEPTOR TLX	NATURE			English	Article							9-CIS RETINOIC ACID; EMBRYONIC TERMINI; DNA-BINDING; SUPERFAMILY; EXPRESSION; CLONING; REGION; BRAIN; SITES; CELL	We report here the identification of a unique vertebrate nuclear receptor, Tlx, which is expressed exclusively in the neuroepithelium of the embryonic brain. Sequence comparison reveals striking similarity to the product of the Drosophila terminal/gap gene tailless (tll)(1), which is expressed in the embryonic brain and is required for brain development in flies. In vitro DNA-binding assays demonstrated that Tlx and Tll proteins share a target gene specificity that, is unique among the nuclear receptor superfamily. Ectopic expression of Tlx in fly embryos caused a repression of segmentation comparable to that elicited by Tll. The similarities in structure, expression pattern, target gene specificity and phenotypes in transgenic flies suggest conservation of genetic programs upstream and downstream of this Tlx/Tll class of nuclear receptors during embryogenesis.	SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,GENE EXPRESS LAB,LA JOLLA,CA 92037; SALK INST BIOL STUDIES,MOLEC BIOL & VIROL LAB,LA JOLLA,CA 92037; UNIV CALIF SAN DIEGO,GRAD PROGRAM MOLEC PATHOL,LA JOLLA,CA 92037	Howard Hughes Medical Institute; Salk Institute; Salk Institute; University of California System; University of California San Diego			Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				BLUMBERG B, 1992, P NATL ACAD SCI USA, V89, P2321, DOI 10.1073/pnas.89.6.2321; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FIGDOR MC, 1993, NATURE, V363, P630, DOI 10.1038/363630a0; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HOCH M, 1992, SCIENCE, V256, P94, DOI 10.1126/science.1348871; KAKIZUKA A, 1993, ESSENTIAL DEV BIOL P, P223; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MCKEOWN M, 1988, CELL, V53, P887, DOI 10.1016/S0092-8674(88)90369-8; MIYAJIMA N, 1988, NUCLEIC ACIDS RES, V16, P11057, DOI 10.1093/nar/16.23.11057; ORO AE, 1992, DEVELOPMENT, V115, P449; PANKRATZ MJ, 1992, SCIENCE, V255, P986, DOI 10.1126/science.1546296; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; POTTER E, 1992, P NATL ACAD SCI USA, V89, P4192, DOI 10.1073/pnas.89.9.4192; RITCHIE HH, 1990, NUCLEIC ACIDS RES, V18, P6857, DOI 10.1093/nar/18.23.6857; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; STEINGRIMSSON E, 1991, SCIENCE, V254, P418, DOI 10.1126/science.1925599; STRECKER TR, 1988, DEVELOPMENT, V102, P721; TAUZ D, 1989, CHROMOSOMA, V98, P81; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418	28	161	173	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 4	1994	370	6488					375	379		10.1038/370375a0	http://dx.doi.org/10.1038/370375a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA304	8047143				2022-12-24	WOS:A1994PA30400057
J	VIOLI, F; FERRO, D; BASILI, S; DANGELO, A; MAZZOLA, G; QUINTARELLI, C; CORDOVA, C				VIOLI, F; FERRO, D; BASILI, S; DANGELO, A; MAZZOLA, G; QUINTARELLI, C; CORDOVA, C			RELATION BETWEEN LUPUS ANTICOAGULANT AND SPLANCHNIC VENOUS THROMBOSIS IN CIRRHOSIS OF THE LIVER	BRITISH MEDICAL JOURNAL			English	Article							ANTIPHOSPHOLIPID ANTIBODIES		UNIV ROMA LA SAPIENZA,IST TERAPIA MED,ROME,ITALY; IRCCS,HOSP SAN RAFFAELE,SERV COAGULAZ,MILAN,ITALY	Sapienza University Rome; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	VIOLI, F (corresponding author), POLICLIN UMBERTO 1,IST CLIN MED 1,I-00185 ROME,ITALY.		Violi, Francesco/K-1509-2016; ferro, domenico/AAT-5861-2020; Basili, Stefania/K-4024-2016; D'Angelo, Armando/K-2583-2018	Violi, Francesco/0000-0002-6610-7068; Basili, Stefania/0000-0002-6987-1926; D'Angelo, Armando/0000-0002-9857-4509				ALSEED A, 1991, THROMB HAEMOSTASIS, V65, P2028; ASHERSON RA, 1991, CLIN EXP RHEUMATOL, V9, P341; DANGELO SV, 1992, THROMB HAEMOSTASIS, V67, P631; OKA K, 1979, THROMB HAEMOSTASIS, V42, P564; VIOLI F, 1990, THROMB HAEMOSTASIS, V63, P183	5	49	51	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 23	1994	309	6949					239	240		10.1136/bmj.309.6949.239	http://dx.doi.org/10.1136/bmj.309.6949.239			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ180	8069141	Green Published			2022-12-24	WOS:A1994NZ18000017
J	DORER, DR; HENIKOFF, S				DORER, DR; HENIKOFF, S			EXPANSIONS OF TRANSGENE REPEATS CAUSE HETEROCHROMATIN FORMATION AND GENE SILENCING IN DROSOPHILA	CELL			English	Article							POSITION EFFECT VARIEGATION; P-ELEMENT TRANSPOSITION; WHITE GENE; MELANOGASTER; EXPRESSION; CHROMOSOME; TRANSVECTION; CHROMATIN; TRANSCRIPTION; INSERTIONS	Closely linked repeats of a Drosophila P transposon carrying a white transgene were found to cause white variegation. Arrays of three or more transgenes produced phenotypes similar to classical heterochromatin-induced position-effect variegation (PEV), and these phenotypes were modified by known modifiers of PEV. This effect on the repeated transgenes was much stronger for a site near centric heterochromatin than it was for a medial site, and it strengthened with increasing copy number. Differences between variegated phenotypes could be accounted for if different topological structures were generated by pairing between closely linked repeat sequences. We propose that pairing of repeats underlies heterochromatin formation and is responsible for diverse gene silencing phenomena in animals and plants.			DORER, DR (corresponding author), FRED HUTCHINSON CANC RES CTR,HOWARD HUGHES MED INST,DIV BASIC SCI,SEATTLE,WA 98104, USA.			Henikoff, Steven/0000-0002-7621-8685				ASSAAD FF, 1993, PLANT MOL BIOL, V22, P1067, DOI 10.1007/BF00028978; BATES G, 1994, BIOESSAYS, V16, P277, DOI 10.1002/bies.950160411; BENDER W, 1983, J MOL BIOL, V168, P17, DOI 10.1016/S0022-2836(83)80320-9; Bernard J., 1988, EUKARYOTE GENOME DEV, DOI [10.1007/978-94-011-5991-3, DOI 10.1007/978-94-011-5991-3]; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BONIFER C, 1991, J CELL BIOCHEM, V47, P99, DOI 10.1002/jcb.240470203; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; COOLEY L, 1990, P NATL ACAD SCI USA, V87, P3170, DOI 10.1073/pnas.87.8.3170; DANIELS SB, 1993, GENETICS, V133, P623; DAVIS BP, 1988, GENE DEV, V2, P13, DOI 10.1101/gad.2.1.13; EISSENBERG JC, 1991, TRENDS GENET, V7, P335, DOI 10.1016/0168-9525(91)90424-O; EISSENBERG JC, 1989, BIOESSAYS, V11, P14, DOI 10.1002/bies.950110105; Ephrussi B, 1944, P NATL ACAD SCI USA, V30, P183, DOI 10.1073/pnas.30.8.183; FAUVARQUE MO, 1993, GENE DEV, V7, P1508, DOI 10.1101/gad.7.8.1508; Gans M., 1953, B BIOL FRANCE BELG S, V38, P1; GRIGLIATTI T, 1991, FUNCTIONAL ORG NUCLE, P587; GUBB D, 1990, GENETICS, V126, P167; HAWLEY RS, 1988, GENETICS, V119, P85; HAWLEY RS, 1993, DEV GENET, V13, P440; HENIKOFF S, 1993, CHROMOSOME, P183; HIRAOKA Y, 1993, J CELL BIOL, V120, P591, DOI 10.1083/jcb.120.3.591; KASSIS JA, 1991, GENETICS, V128, P751; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; KKOPCZYNSKI CC, 1992, J CELL BIOL, V119, P503; LAIRD CD, 1987, GENETICS, V117, P587; LEVIS R, 1982, P NATL ACAD SCI-BIOL, V79, P564, DOI 10.1073/pnas.79.2.564; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MANUELIDIS L, 1990, SCIENCE, V250, P1533, DOI 10.1126/science.2274784; Matzke M., 1994, Homologous recombination and gene silencing in plants., P271; Metz CW, 1916, J EXP ZOOL, V21, P213, DOI 10.1002/jez.1400210204; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; POWERS JA, 1993, J CELL BIOL, V120, P291, DOI 10.1083/jcb.120.2.291; Rabl C, 1885, MORPHOL JB, V10, P214; REUTER G, 1992, BIOESSAYS, V14, P605, DOI 10.1002/bies.950140907; ROBERTSON HM, 1988, GENETICS, V118, P461; SIMON JA, 1985, CELL, V40, P805, DOI 10.1016/0092-8674(85)90340-X; SMABROOK J, 1989, MOL CLONING LABORATO; SPOFFORD JB, 1976, GENETICS BIOL DROS C, V1, P955; STELLER H, 1985, EMBO J, V4, P167, DOI 10.1002/j.1460-2075.1985.tb02332.x; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; STUART GW, 1990, DEVELOPMENT, V109, P577; TALBERT PB, 1994, GENETICS, V136, P559; TARTOF KD, 1984, CELL, V37, P869, DOI 10.1016/0092-8674(84)90422-7; TARTOF KD, 1991, CELL, V65, P201, DOI 10.1016/0092-8674(91)90153-P; TOWER J, 1993, GENETICS, V133, P347; WAKIMOTO BT, 1990, GENETICS, V125, P141; WILSON C, 1989, GENE DEV, V3, P1301, DOI 10.1101/gad.3.9.1301; WINES DR, 1992, GENETICS, V131, P683; ZACHAR Z, 1985, COLD SPRING HARB SYM, V50, P337, DOI 10.1101/SQB.1985.050.01.043; ZHANG P, 1993, GENETICS, V133, P361	52	452	473	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					993	1002		10.1016/0092-8674(94)90439-1	http://dx.doi.org/10.1016/0092-8674(94)90439-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	8020105				2022-12-24	WOS:A1994NV42500008
J	THOMAS, BJ; GUNNING, DA; CHO, J; ZIPURSKY, SL				THOMAS, BJ; GUNNING, DA; CHO, J; ZIPURSKY, SL			CELL-CYCLE PROGRESSION IN THE DEVELOPING DROSOPHILA EYE - ROUGHEX ENCODES A NOVEL PROTEIN REQUIRED FOR THE ESTABLISHMENT OF G1	CELL			English	Article							POLARITY GENE HEDGEHOG; MAMMALIAN FIBROBLASTS; SEVENLESS PROTEIN; G2-M TRANSITION; TYROSINE-KINASE; TGF-BETA; HOMOLOG; RETINA; DIFFERENTIATION; PROLIFERATION	The onset of pattern formation in the developing Drosophila eye is marked by the simultaneous synchronization of all cells in the G1 phase of the cell cycle. These cells will then either commit to another round of cell division or differentiate into neurons. Although cell cycle synchronization occurs in rougher (rux) mutants, cells circumvent G1 and all cells enter S phase, including cells that would normally differentiate. This leads to defects in early steps of pattern formation and cell fate determination. rux is suppressed by mutations in genes that promote cell cycle progression (i.e., cyclin A and string) and enhanced by mutations in genes that promote differentiation (i.e., Ras1 and Star). rux encodes a novel protein of 335 amino acids. We propose that rux functions as a negative regulator of G1 progression in the developing eye.	UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	THOMAS, BJ (corresponding author), UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90024, USA.							ALPHEY L, 1992, CELL, V69, P977, DOI 10.1016/0092-8674(92)90616-K; ASHBURNER M, DROSOPHILA LABORATOR; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; Cagan Ross Leigh, 1992, P189; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHEYETTE BNR, 1994, NEURON, V12, P1; EBENS AJ, 1993, CELL, V74, P15, DOI 10.1016/0092-8674(93)90291-W; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GONCZY P, 1994, CELL, V77, P1015, DOI 10.1016/0092-8674(94)90441-3; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; HUNTER T, 1993, CELL, V75, P1; KAFATOS FC, 1991, TRENDS GENET, V7, P155, DOI 10.1016/0168-9525(91)90104-X; KNOBLICH JA, 1993, EMBO J, V12, P65, DOI 10.1002/j.1460-2075.1993.tb05632.x; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOLODKIN A, 1993, IN PRESS DEVELOPMENT; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEHNER CF, 1989, CELL, V56, P957, DOI 10.1016/0092-8674(89)90629-6; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; Murray A, 1993, CELL CYCLE INTRO; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SPRAGUE GF, 1992, MOL CELLULAR BIOL YE; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TRUMAN JW, 1988, DEV BIOL, V125, P145, DOI 10.1016/0012-1606(88)90067-X; WEN ME, 1993, CELL, V74, P1009; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	42	166	170	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					1003	1014		10.1016/0092-8674(94)90440-5	http://dx.doi.org/10.1016/0092-8674(94)90440-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	8020091				2022-12-24	WOS:A1994NV42500009
J	BROWN, EJ; ALBERS, MW; SHIN, TB; ICHIKAWA, K; KEITH, CT; LANE, WS; SCHREIBER, SL				BROWN, EJ; ALBERS, MW; SHIN, TB; ICHIKAWA, K; KEITH, CT; LANE, WS; SCHREIBER, SL			A MAMMALIAN PROTEIN TARGETED BY G1-ARRESTING RAPAMYCIN-RECEPTOR COMPLEX	NATURE			English	Article							P70 S6 KINASE; IMMUNOSUPPRESSANT RAPAMYCIN; INDUCED INHIBITION; LYMPHOCYTES-T; YEAST; IMMUNOPHILIN; ACTIVATION; ARREST; FK506; PROLIFERATION	THE structurally related natural products rapamycin and FK506 bind to the same intracellular receptor, FKBP12, yet the resulting complexes interfere with distinct signalling pathways(1,2). FKBP12- rapamycin inhibits progression through the G1 phase of the cell cycle in osteosarcoma(3), liver(4,5) and T cells(6,7) as well as in yeasts, and interferes with mitogenic signalling pathways that are involved in G1 progressiong(9,10), namely with activation of the protein p70(S6k) (refs 5, 11-13) and cyclin-dependent kinases(3,14-16). Here we isolate a mammalian FKBP-rapamycin-associated protein (FRAP) whose binding to structural variants of rapamycin complexed to FKBP12 correlates with the ability of these ligands to inhibit cell-cycle progression. Peptide sequences from purified bovine FRAP were used to isolate a human cDNA clone that is highly related to the DRR1/TOR1 and DRR2/TOR2 gene products from Saccharomyces cerevisiae(8,17,18). Although it has not been previously demonstrated that either of the DRR/TOR gene products can bind the FKBP-rapamycin complex directly(17,19), these yeast genes have been genetically linked to a rapamycin-sensitive pathway and are thought to encode lipid kinases(17-20).	HARVARD UNIV,HOWARD HUGHES MED INST,DEPT CHEM,CAMBRIDGE,MA 02138; HARVARD UNIV,HARVARD MICROCHEM FACIL,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute; Harvard University								ALBERS MW, 1993, J BIOL CHEM, V268, P22825; ALBERS MW, 1993, ANN NY ACAD SCI, V696, P54; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUMONT FJ, 1990, J IMMUNOL, V144, P251; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; FOOR F, 1992, NATURE, V360, P682; FRANCAVILLA A, 1992, HEPATOLOGY, V15, P871, DOI 10.1002/hep.1840150520; GALAT A, 1992, BIOCHEMISTRY-US, V31, P2427, DOI 10.1021/bi00123a031; HAYWARD CM, 1993, J AM CHEM SOC, V115, P9345, DOI 10.1021/ja00073a083; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; HULTSCH T, 1992, MOL BIOL CELL, V3, P981, DOI 10.1091/mbc.3.9.981; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; MORICE WG, 1993, J BIOL CHEM, V268, P22737; MORICE WG, 1993, J BIOL CHEM, V268, P3734; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Sambrook J., 1989, MOL CLONING LAB MANU; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9	27	1583	1691	7	137	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 30	1994	369	6483					756	758		10.1038/369756a0	http://dx.doi.org/10.1038/369756a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU581	8008069				2022-12-24	WOS:A1994NU58100064
J	JACOBSON, RH; ZHANG, XJ; DUBOSE, RF; MATTHEWS, BW				JACOBSON, RH; ZHANG, XJ; DUBOSE, RF; MATTHEWS, BW			3-DIMENSIONAL STRUCTURE OF BETA-GALACTOSIDASE FROM ESCHERICHIA-COLI	NATURE			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; ALPHA-COMPLEMENTATION; WEISSENBERG CAMERA; DIFFRACTION DATA; LACZ GENE; CRYSTALLOGRAPHY; REFINEMENT; EXPRESSION; PROGRAM	THE beta-galactosidase from Escherichia coli was instrumental in the development of the operon model(1), and today is one of the most commonly used enzymes in molecular biology. Here we report the structure of this protein and show that it is a tetramer with 222- point symmetry. The 1,023-amino-acid polypeptide chain(2,3) folds into five sequential domains, with an extended segment at the amino terminus. The participation of this amino-terminal segment in a subunit interface, coupled with the observation that each active site is made up of elements from two different subunits, provides a structural rationale for the phenomenon of alpha-complementation. The structure represents the longest polypeptide chain for which an atomic structure has been determined. Our results show that it is possible successfully to study non-viral protein crystals with unit cell dimensions in excess of 500 Angstrom and with relative molecular masses in the region of 2,000K per asymmetric unit. Non-crystallographic symmetry averaging proved to be a very powerful tool in the structure determination, as has been shown in other contexts(31,32).	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,HOWARD HUGHES MED INST,EUGENE,OR 97403; UNIV OREGON,DEPT PHYS,EUGENE,OR 97403	University of Oregon; Howard Hughes Medical Institute; University of Oregon; University of Oregon								ADAMS RM, 1994, J BIOL CHEM, V269, P5666; BRANDEN CI, 1980, Q REV BIOPHYS, V13, P317, DOI 10.1017/S0033583500001712; BUVINGER WE, 1985, J BACTERIOL, V163, P850, DOI 10.1128/JB.163.3.850-857.1985; CELADA F, 1974, BIOCHEMISTRY-US, V13, P5543, DOI 10.1021/bi00724a014; CUPPLES CG, 1990, J BIOL CHEM, V265, P5512; FOWLER AV, 1978, J BIOL CHEM, V253, P5521; GAYKEMA WPJ, 1984, NATURE, V309, P23, DOI 10.1038/309023a0; GEBLER JC, 1992, J BIOL CHEM, V267, P11126; HANCOCK KR, 1991, J BACTERIOL, V173, P3084, DOI 10.1128/JB.173.10.3084-3095.1991; HEINZ DW, 1994, PROTEIN ENG, V7, P301, DOI 10.1093/protein/7.3.301; HENDERSON DR, 1986, CLIN CHEM, V32, P1637; HIGASHI T, 1989, J APPL CRYSTALLOGR, V22, P9, DOI 10.1107/S0021889888009562; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; JACOBSON RH, 1992, J MOL BIOL, V223, P1177, DOI 10.1016/0022-2836(92)90269-P; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KALNINS A, 1983, EMBO J, V2, P593, DOI 10.1002/j.1460-2075.1983.tb01468.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANGLEY KE, 1975, P NATL ACAD SCI USA, V72, P1254, DOI 10.1073/pnas.72.4.1254; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P37, DOI 10.1038/newbio238037a0; RAYMENT I, 1983, ACTA CRYSTALLOGR A, V39, P102, DOI 10.1107/S0108767383000197; RING M, 1990, ARCH BIOCHEM BIOPHYS, V283, P342, DOI 10.1016/0003-9861(90)90652-F; ROSSMANN MG, 1985, NATURE, V317, P153; SAKABE N, 1991, NUCL INSTRUM METH A, V303, P448, DOI 10.1016/0168-9002(91)90282-U; SCHMIDT BF, 1989, J BACTERIOL, V171, P625, DOI 10.1128/jb.171.2.625-635.1989; SCHROEDER CJ, 1991, J GEN MICROBIOL, V137, P369, DOI 10.1099/00221287-137-2-369; STOKES HW, 1985, MOL BIOL EVOL, V2, P469; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; ULLMANN A, 1967, J MOL BIOL, V24, P339, DOI 10.1016/0022-2836(67)90341-5; Weinstock G M, 1983, Gene Amplif Anal, V3, P27; ZABIN I, 1982, MOL CELL BIOCHEM, V49, P87	32	538	550	2	86	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 30	1994	369	6483					761	766		10.1038/369761a0	http://dx.doi.org/10.1038/369761a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU581	8008071				2022-12-24	WOS:A1994NU58100066
J	HYNDMAN, SJ; WILLIAMS, DRR; MERRILL, SL; LIPSCOMBE, JM; PALMER, CR				HYNDMAN, SJ; WILLIAMS, DRR; MERRILL, SL; LIPSCOMBE, JM; PALMER, CR			RATES OF ADMISSION TO HOSPITAL FOR ASTHMA	BRITISH MEDICAL JOURNAL			English	Article							ACUTE CHILDHOOD ASTHMA; TRENDS; CHILDREN; INCREASE; HEALTH; CARE	Objective-To describe trends in hospital admission rates for asthma in England and Wales (1976-85), the East Anglian region (from 1976 to 1991-2), and Wales (1980-90). Design-Descriptive study. Setting-Hospitals in England and Wales; hospitals in the East Anglian Regional Health Authority; hospitals in Wales. Main outcome measures-Hospital admissions for asthma as principal diagnosis in England and Wales (Hospital In-patient Enquiry, 1976-85), for the East Anglian region (Hospital In-patient Enquiry, 1976-7; Hospital Activity Analysis, 1978-86; Regional Information System, 1987-8 to 1991-2), and for Wales (Hospital Activity Analysis, l980-90). Results-Rates for England and Wales as a whole showed a steady upward trend throughout the period examined. Rates in East Anglia, though they were similar to the national trends in the early years, showed a peak in 1985 (for males and females) with some indication of a decline in rates thereafter. Rates for Wales showed an upward trend until 1988 (for both males and females) after which they showed a decline. Conclusions-Interpretation of the East Anglian trends is made more difficult by the change in England in 1987 of the system for the collection of hospital admission data. The fact that the rates for the East Anglian region seem to decline before this change and other considerations suggest that the observed trends, although partly reflecting the disruption of the coding during the changeover in systems, may not be entirely artefactual. The possible roles of diagnostic transfer and changes in the delivery of care, asthma treatment, admission and readmission policies, and the severity and prevalence of asthma in changing admission rates are considered. The changing bends in admission rates for East Anglia and Wales reflect recently published trends for mortality from asthma in England.			HYNDMAN, SJ (corresponding author), UNIV CAMBRIDGE,INST PUBL HLTH,DEPT COMMUNITY MED,HLTH SERV RES GRP,UNIV FORVIE SITE,CAMBRIDGE CB2 2SR,CAMBS,ENGLAND.							ANDERSON HR, 1990, THORAX, V45, P431, DOI 10.1136/thx.45.6.431; ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; ANDERSON HR, 1978, ARCH DIS CHILD, V53, P295, DOI 10.1136/adc.53.4.295; ANDERSON HR, 1980, BRIT MED J, V281, P1191, DOI 10.1136/bmj.281.6249.1191; [Anonymous], 1990, BMJ, V301, P797; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; CARMAN PG, 1990, MED J AUSTRALIA, V152, P23, DOI 10.5694/j.1326-5377.1990.tb124423.x; CHARLTON I, 1991, BRIT J GEN PRACT, V41, P227; CLARK TJH, 1990, OCCURRENCE COST ASTH; GARDNER MJ, 1989, STATISTICS CONFIDENC; HALFON N, 1986, AM J PUBLIC HEALTH, V76, P1308, DOI 10.2105/AJPH.76.11.1308; KHOT A, 1984, BRIT MED J, V289, P235, DOI 10.1136/bmj.289.6439.235; MITCHELL EA, 1985, ARCH DIS CHILD, V60, P376, DOI 10.1136/adc.60.4.376; MITCHELL EA, 1989, EUR RESPIR J, V2, P470; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STORR J, 1988, ARCH DIS CHILD, V63, P774, DOI 10.1136/adc.63.7.774; STRACHAN DP, 1992, BRIT MED J, V304, P819, DOI 10.1136/bmj.304.6830.819; TAYLOR DR, 1993, THORAX, V48, P134, DOI 10.1136/thx.48.2.134; 1993, HOSPITAL EPISODE STA, V1; 1980, HOSPITAL INPATIENT E; 1990, BRIT MED J, V301, P651	22	87	87	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 18	1994	308	6944					1596	1600		10.1136/bmj.308.6944.1596	http://dx.doi.org/10.1136/bmj.308.6944.1596			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NT528	8025425	Green Published			2022-12-24	WOS:A1994NT52800016
J	SAWYER, SM; BOWES, G; PHELAN, PD				SAWYER, SM; BOWES, G; PHELAN, PD			VULVO-VAGINAL CANDIDIASIS IN YOUNG-WOMEN WITH CYSTIC-FIBROSIS	BRITISH MEDICAL JOURNAL			English	Article									UNIV MELBOURNE,ROYAL CHILDRENS HOSP,DEPT THORAC MED,PARKVILLE,VIC 3052,AUSTRALIA; UNIV MELBOURNE,ROYAL CHILDRENS HOSP,DEPT PAEDIAT,PARKVILLE,VIC 3052,AUSTRALIA	Royal Children's Hospital Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; University of Melbourne								BLUM RW, 1991, PEDIATRICIAN, V18, P1010; ELBORN JS, 1991, THORAX, V46, P881, DOI 10.1136/thx.46.12.881; O'Neill S, 1989, Aust Fam Physician, V18, P99; SPARKS JM, 1991, J REPROD MED, V36, P745	4	30	30	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 18	1994	308	6944					1609	1609		10.1136/bmj.308.6944.1609	http://dx.doi.org/10.1136/bmj.308.6944.1609			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NT528	8025429	Green Published			2022-12-24	WOS:A1994NT52800020
J	HOU, JZ; SCHINDLER, U; HENZEL, WJ; HO, TC; BRASSEUR, M; MCKNIGHT, SL				HOU, JZ; SCHINDLER, U; HENZEL, WJ; HO, TC; BRASSEUR, M; MCKNIGHT, SL			AN INTERLEUKIN-4-INDUCED TRANSCRIPTION FACTOR - IL-4 STAT	SCIENCE			English	Article							RECEPTOR GAMMA-CHAIN; B-CELLS; TYROSINE PHOSPHORYLATION; FUNCTIONAL COMPONENT; LYMPHOCYTES-B; FC-EPSILON; EXPRESSION; PROTEINS; SEQUENCE; LINE	Interleukin-4 (IL-4) is an immunomodulatory cytokine secreted by activated T lymphocytes, basophils, and mast cells. It plays an important role in modulating the balance of T helper (Th) cell subsets, favoring expansion of the Th2 lineage relative to Th1. Imbalance of these T lymphocyte subsets has been implicated in immunological diseases including allergy, inflammation, and autoimmune disease. IL-4 may mediate its biological effects, at least in part, by activating a tyrosine-phosphorylated DNA binding protein. This protein has now been purified and its encoding gene cloned. Examination of the primary amino acid sequence of this protein indicates that it is a member of the signal transducers and activators of transcription (Stat) family of DNA binding proteins, hereby designated IL-4 Stat. Study of the inhibitory activities of phosphotyrosine-containing peptides derived from the intracellular domain of the IL-4 receptor provided evidence for direct coupling of receptor and transcription factor during the IL-4 Stat activation cycle. Such observations indicate that IL-4 Stat has the same functional domain for both receptor coupling and dimerization.	TULARIK INC, San Francisco, CA 94080 USA; GENENTECH INC, San Francisco, CA 94080 USA	Roche Holding; Genentech				Henzel, William/0000-0003-2940-3797				AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BOOTHBY M, 1988, SCIENCE, V242, P1559, DOI 10.1126/science.3144043; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; CONRAD DH, 1987, J IMMUNOL, V139, P2290; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEFRANCE T, 1987, J EXP MED, V165, P1459, DOI 10.1084/jem.165.6.1459; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HENZEL WJ, 1987, J CHROMATOGR, V404, P41, DOI 10.1016/S0021-9673(01)86835-7; HENZEL WJ, 1990, ANAL BIOCHEM, V187, P228, DOI 10.1016/0003-2697(90)90448-I; HUDAK SA, 1987, P NATL ACAD SCI USA, V84, P4606, DOI 10.1073/pnas.84.13.4606; IZUHARA K, 1993, J BIOL CHEM, V268, P13097; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; KRUTZSCH HC, 1993, ANAL BIOCHEM, V209, P109, DOI 10.1006/abio.1993.1089; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Matthews B., COMMUNICATION; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MOSSING MC, 1990, SCIENCE, V250, P1712, DOI 10.1126/science.2148648; NOELLE R, 1984, P NATL ACAD SCI-BIOL, V81, P6149, DOI 10.1073/pnas.81.19.6149; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; OHARA J, 1987, NATURE, V325, P537, DOI 10.1038/325537a0; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; POLLA BS, 1986, P NATL ACAD SCI USA, V83, P4878, DOI 10.1073/pnas.83.13.4878; ROEHM NW, 1984, J EXP MED, V160, P679, DOI 10.1084/jem.160.3.679; ROTHMAN P, 1988, J EXP MED, V168, P2385, DOI 10.1084/jem.168.6.2385; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; Sambrook J., 1989, MOL CLONING LAB MANU; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHREIBER R, COMMUNICATION; SELDIN DC, 1994, P NATL ACAD SCI USA, V91, P2140, DOI 10.1073/pnas.91.6.2140; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WONG SC, 1993, TECHNIQUES PROTEIN C, V4, P371; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; YUAN X, 1992, P NATL ACAD SCI USA, V89, P7840; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	43	761	786	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 16	1994	265	5179					1701	1706		10.1126/science.8085155	http://dx.doi.org/10.1126/science.8085155			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG284	8085155				2022-12-24	WOS:A1994PG28400029
J	GARROW, JS				GARROW, JS			CONTROVERSIES IN MANAGEMENT - SHOULD OBESITY BE TREATED - TREATMENT IS NECESSARY	BRITISH MEDICAL JOURNAL			English	Article											GARROW, JS (corresponding author), UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,RANK DEPT HUMAN NUTR,LONDON EC1M 6BQ,ENGLAND.							BORTZ WM, 1969, AM J MED, V47, P325, DOI 10.1016/0002-9343(69)90159-4; Bush A., 1988, Journal of Human Nutrition and Dietetics, V1, P429, DOI 10.1111/j.1365-277X.1988.tb00216.x; GARNER DM, 1991, CLIN PSYCHOL REV, V11, P729, DOI 10.1016/0272-7358(91)90128-H; Garrow J.S., 1988, OBESITY RELATED DISE; GARROW JS, 1989, LANCET, V1, P1429; GARROW JS, 1993, HUMAN NUTR DIETETICS, P465; White A, 1993, HLTH SURVEY ENGLAND	7	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 10	1994	309	6955					654	655		10.1136/bmj.309.6955.654	http://dx.doi.org/10.1136/bmj.309.6955.654			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG020	8086991	Green Published			2022-12-24	WOS:A1994PG02000033
J	WOOLEY, SC; GARNER, DM				WOOLEY, SC; GARNER, DM			CONTROVERSIES IN MANAGEMENT - SHOULD OBESITY BE TREATED - DIETARY TREATMENTS FOR OBESITY ARE INEFFECTIVE	BMJ-BRITISH MEDICAL JOURNAL			English	Article									BECK INST COGNIT THERAPY & RES, BALA CYNWOOD, PA 19001 USA		WOOLEY, SC (corresponding author), UNIV CINCINNATI, COLL MED, CINCINNATI, OH 45267 USA.							ANDRES R, 1993, ANN INTERN MED, V119, P737, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00022; BROWNELL KD, 1991, BEHAV THER, V22, P153, DOI 10.1016/S0005-7894(05)80174-1; Ernsberger Paul, 1987, J OBESITY WEIGHT REG, V6, P58; GARNER DM, 1991, CLIN PSYCHOL REV, V6, P58; GORTMAKER SL, 1993, NEW ENGL J MED, V329, P1008, DOI 10.1056/NEJM199309303291406; Keesey R.E., 1993, OBESITY THEORY THERA, P77; Meyer JM, 1993, OBESITY THEORY THERA, P137; RAVITCH MM, 1979, ANN SURG, V190, P382, DOI 10.1097/00000658-197909000-00014; Ravussin E, 1993, OBESITY THEORY THERA, P97; Rothblum E. D, 1994, FEMINIST PERSPECTIVE, P53; STUNKARD AJ, 1993, NEW ENGL J MED, V329, P1036, DOI 10.1056/NEJM199309303291411; Wadden T., 1993, OBESITY THEORY THERA, V2, P163; Wadden T, 1993, OBESITY THEORY THERA, P197; 1992, NATIONAL I HLTH TECH	14	35	36	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 10	1994	309	6955					655	656						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG020	8086992				2022-12-24	WOS:A1994PG02000034
J	HANNAFORD, PC; KAY, CR; FERRY, S				HANNAFORD, PC; KAY, CR; FERRY, S			AGISM AS EXPLANATION FOR SEXISM IN PROVISION OF THROMBOLYSIS	BRITISH MEDICAL JOURNAL			English	Article							CORONARY; DISEASE; WOMEN				HANNAFORD, PC (corresponding author), ROYAL COLL GEN PRACTITIONERS,MANCHESTER RES UNIT,MANCHESTER M22 4DB,LANCS,ENGLAND.		Hannaford, Philip C/B-7867-2012					AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; DUDLEY NJ, 1992, AGE AGEING, V21, P95, DOI 10.1093/ageing/21.2.95; Fibrinolytic 'Therapy Trialists' (FTT) Collaborative Group, 1994, LANCET, V343, P311; PETTICREW M, 1993, BMJ-BRIT MED J, V306, P1164, DOI 10.1136/bmj.306.6886.1164; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402	5	24	24	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 3	1994	309	6954					573	573		10.1136/bmj.309.6954.573	http://dx.doi.org/10.1136/bmj.309.6954.573			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF330	8086943	Green Published			2022-12-24	WOS:A1994PF33000017
J	GELLERT, GA				GELLERT, GA			PREPARING FOR EMERGING INFECTIONS	NATURE			English	Editorial Material											GELLERT, GA (corresponding author), PROJECT HOPE,CTR HLTH SCI EDUC,MILLWOOD,VA 22646, USA.							DUCHIN JS, 1994, NEW ENGL J MED, V330, P949, DOI 10.1056/NEJM199404073301401; HUGHES JM, 1993, SCIENCE, V262, P850, DOI 10.1126/science.8235607; KILBOURNE ED, 1990, JAMA-J AM MED ASSOC, V264, P68, DOI 10.1001/jama.264.1.68; Lederberg J., 1992, EMERGING INFECTIONS; 1993, MMWR-MORBID MORTAL W, V4, P441; 1994, MMWR-MORBID MORTAL W, V43, P45	6	9	9	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 11	1994	370	6489					409	410		10.1038/370409a0	http://dx.doi.org/10.1038/370409a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	8047155	Green Published, Bronze			2022-12-24	WOS:A1994PB40700022
J	GROMPE, M; STLOUIS, M; DEMERS, SI; ALDHALIMY, M; LECLERC, B; TANGUAY, RM				GROMPE, M; STLOUIS, M; DEMERS, SI; ALDHALIMY, M; LECLERC, B; TANGUAY, RM			SINGLE MUTATION OF THE FUMARYLACETOACETATE HYDROLASE GENE IN FRENCH-CANADIANS WITH HEREDITARY TYROSINEMIA TYPE-I	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DNA; QUEBEC; IDENTIFICATION; DEFICIENT	Background. Hereditary tyrosinemia type I is an autosomal recessive inborn error of metabolism caused by a deficiency of the enzyme fumarylacetoacetate hydrolase. The disorder clusters in the Saguenay-Lac-St.-Jean area of Quebec. In this region, 1 of 1846 newborns is affected and 1 of every 22 persons is thought to be a carrier. Recently, we identified a splice mutation and two nonsense mutations in the fumarylacetoacetate hydrolase gene in two patients from Quebec with tyrosinemia type I. Methods. We used allele-specific-oligonucleotide hybridization to examine the frequency of these three candidate mutations in patients with tyrosinemia type I and in the population of Quebec. Results. The splice mutation was found in 100 percent of patients from the Saguenay-Lac-St.-Jean area and in 28 percent of patients from other regions of the world. Of 25 patients from the Saguenay-Lac-St.-Jean region, 20 (80 percent) were homozygous for this mutation, a guanine-to-adenine change in the splice-donor sequence in intron 12 of the gene, indicating that it causes most cases of tyrosinemia type I in the region. The frequency of carrier status, based on screening of blood spots from newborns, was about 1 per 25 in the Saguenay-Lac-St.-Jean population and about 1 per 66 overall in Quebec. Conclusions. This study identified the most prevalent mutation causing hereditary tyrosinemia in French Canada; it also showed the feasibility of DNA-based testing for carriers in the population at risk.	OREGON HLTH SCI UNIV,DEPT PEDIAT,PORTLAND,OR 97201; CHU LAVAL,CTR RECH,GENET CELLULAIRE & MOLEC LAB,ST FOY,PQ,CANADA	Oregon Health & Science University; Laval University	GROMPE, M (corresponding author), OREGON HLTH SCI UNIV,DEPT MOLEC & MED GENET,MAIL CODE L103,3181 SW SAM JACKSON PK RD,PORTLAND,OR 97201, USA.			Grompe, Markus/0000-0002-6616-4345	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD028585] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-28585-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AGSTERIBBE E, 1990, NUCLEIC ACIDS RES, V18, P1887, DOI 10.1093/nar/18.7.1887; DEBRAEKELEER M, 1990, AM J HUM GENET, V47, P302; DEMERS SI, 1994, AM J HUM GENET, V55, P327; GROMPE M, 1993, HUM MUTAT, V2, P85, DOI 10.1002/humu.1380020205; HARTL DL, 1988, PRIMER POPULATION GE, P7; HECHTMAN P, 1990, AM J HUM GENET, V47, P815; HOBBS HH, 1987, NEW ENGL J MED, V317, P734, DOI 10.1056/NEJM198709173171204; John S. W. M., 1992, Human Mutation, V1, P72, DOI 10.1002/humu.1380010112; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; Kvittingen E.A., 1986, SCAND J CLIN LAB I S, V184, P27; KVITTINGEN EA, 1983, PEDIATR RES, V17, P541, DOI 10.1203/00006450-198307000-00005; LABELLE Y, 1993, HUM MOL GENET, V2, P941, DOI 10.1093/hmg/2.7.941; LABERGE C, 1990, AM J HUM GENET, V47, P329; LABERGE C, 1969, AM J HUM GENET, V21, P36; LINDBLAD B, 1977, P NATL ACAD SCI USA, V74, P4641, DOI 10.1073/pnas.74.10.4641; LINDSTEDT S, 1992, LANCET, V340, P813, DOI 10.1016/0140-6736(92)92685-9; MITCHELL G, 1990, NEW ENGL J MED, V322, P432, DOI 10.1056/NEJM199002153220704; MITCHELL GA, IN PRESS METABOLIC B, V1; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; PARADISK, 1990, AM J HUM GENET, V47, P328; PHANEUF D, 1992, J CLIN INVEST, V90, P1185, DOI 10.1172/JCI115979; PHANEUF D, 1991, AM J HUM GENET, V48, P525; ROZEN R, 1992, AM J MED GENET, V42, P360, DOI 10.1002/ajmg.1320420322; SALT A, 1992, ACTA PAEDIATR, V81, P449, DOI 10.1111/j.1651-2227.1992.tb12270.x; Sambrook J., 1989, MOL CLONING LAB MANU; STLOUIS M, 1994, HUM MOL GENET, V3, P69, DOI 10.1093/hmg/3.1.69; TANGUAY RM, 1990, AM J HUM GENET, V47, P308; TANGUAY RM, 1984, ADV GENE TECHNOLOGY, P250; WALSH PS, 1991, BIOTECHNIQUES, V10, P506, DOI 10.2144/000114018; WU DY, 1989, DNA-J MOLEC CELL BIO, V8, P135, DOI 10.1089/dna.1.1989.8.135; [No title captured]	31	94	97	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 11	1994	331	6					353	357		10.1056/NEJM199408113310603	http://dx.doi.org/10.1056/NEJM199408113310603			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA374	8028615				2022-12-24	WOS:A1994PA37400003
J	NELSON, S; TOTH, L; SHETH, B; SUR, M				NELSON, S; TOTH, L; SHETH, B; SUR, M			ORIENTATION SELECTIVITY OF CORTICAL-NEURONS DURING INTRACELLULAR BLOCKADE OF INHIBITION	SCIENCE			English	Article							CAT VISUAL-CORTEX; RAT HIPPOCAMPAL SLICES; SYNAPTIC POTENTIALS; STRIATE CORTEX; SIMPLE CELLS; MECHANISMS; RESPONSES; EXCITATION; RECORDINGS; RECEPTOR	Neurons in the primary visual cortex of the cat are selectively activated by stimuli with particular orientations. This selectivity can be disrupted by the application of antagonists of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) to a local region of the cortex. In order to determine whether inhibitory inputs are necessary for a single cortical neuron to show orientation selectivity, GABA receptors were blocked intracellularly during whole cell recording. Although the membrane potential, spontaneous activity, subfield antagonism, and directional selectivity of neurons were altered after they were perfused internally with the blocking solution, 18 out of 18 neurons remained selective for stimulus orientation. These results indicate that excitatory inputs are sufficient to generate orientation selectivity.			NELSON, S (corresponding author), MIT, DEPT BRAIN & COGNIT SCI, CAMBRIDGE, MA 02139 USA.			Nelson, Sacha/0000-0002-0108-8599	NATIONAL EYE INSTITUTE [U01EY006363, U10EY006363] Funding Source: NIH RePORTER; NEI NIH HHS [EY07023, EY06363] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AKAIKE N, 1985, EXPERIENTIA, V41, P70; AKAIKE N, 1989, J NEUROPHYSIOL, V62, P1388, DOI 10.1152/jn.1989.62.6.1388; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BONDS AB, 1989, VISUAL NEUROSCI, V2, P41, DOI 10.1017/S0952523800004314; BORGGRAHAM LJ, 1992, THESIS MIT; CHAPMAN B, 1991, J NEUROSCI, V11, P1347; CREUTZFELDT OD, 1974, EXP BRAIN RES, V21, P251; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P735, DOI 10.1113/jphysiol.1991.sp018733; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P659, DOI 10.1113/jphysiol.1991.sp018730; FERSTER D, 1986, J NEUROSCI, V6, P1284; FERSTER D, 1988, J NEUROSCI, V8, P1172; FERSTER D, 1992, J NEUROSCI, V12, P1262; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; JAGADEESH B, 1993, SCIENCE, V262, P1901, DOI 10.1126/science.8266083; KOKUBUN S, 1991, PFLUG ARCH EUR J PHY, V418, P204, DOI 10.1007/BF00370515; MATTHEWS G, 1989, J PHYSIOL-LONDON, V418, P131, DOI 10.1113/jphysiol.1989.sp017831; METHERATE R, 1993, J NEUROSCI, V13, P5312, DOI 10.1523/JNEUROSCI.13-12-05312.1993; NELSON SB, 1991, J NEUROSCI, V11, P369; OTIS TS, 1993, J PHYSIOL-LONDON, V463, P391, DOI 10.1113/jphysiol.1993.sp019600; SHIRASAKI T, 1992, J PHYSIOL-LONDON, V449, P551, DOI 10.1113/jphysiol.1992.sp019101; SILLITO AM, 1975, J PHYSIOL-LONDON, V250, P305, DOI 10.1113/jphysiol.1975.sp011056; SILLITO AM, 1979, J PHYSIOL-LONDON, V289, P33, DOI 10.1113/jphysiol.1979.sp012723; SILLITO AM, 1977, J PHYSIOL-LONDON, V271, P699, DOI 10.1113/jphysiol.1977.sp012021; SILLITO AM, 1980, BRAIN RES, V194, P517, DOI 10.1016/0006-8993(80)91234-2; Somers D., 1993, Society for Neuroscience Abstracts, V19, P628; STELZER A, 1988, SCIENCE, V241, P339, DOI 10.1126/science.2455347; STERN P, 1992, J PHYSIOL-LONDON, V449, P247, DOI 10.1113/jphysiol.1992.sp019085; VOLGUSHEV M, 1993, VISUAL NEUROSCI, V10, P1151, DOI 10.1017/S0952523800010257; WHITE EL, 1989, CORTICAL CIRCUITS, P69; XING P, 1991, NEUROREPORT, V2, P485; YAKUSHIJI T, 1987, NEUROSCIENCE, V22, P1123, DOI 10.1016/0306-4522(87)92987-3	32	207	210	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 5	1994	265	5173					774	777		10.1126/science.8047882	http://dx.doi.org/10.1126/science.8047882			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	8047882				2022-12-24	WOS:A1994PA37200031
J	FABRE, E; BOELENS, WC; WIMMER, C; MATTAJ, IW; HURT, EC				FABRE, E; BOELENS, WC; WIMMER, C; MATTAJ, IW; HURT, EC			NUP145P IS REQUIRED FOR NUCLEAR EXPORT OF MESSENGER-RNA AND BINDS HOMOPOLYMERIC RNA IN-VITRO VIA A NOVEL CONSERVED MOTIF	CELL			English	Article							XENOPUS-LAEVIS OOCYTES; PORE MEMBRANE DOMAIN; COLD-SHOCK PROTEIN; PRE-MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; RIBONUCLEOPROTEIN-PARTICLES; NUCLEOCYTOPLASMIC TRANSPORT; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE	An essential yeast protein, Nup145p, is identified via its genetic interaction with the nucleoporin Nsp1p. Nup145p contains GLFG repeats and localizes to nuclear pores. Depletion of Nup145p in vivo leads rapidly to nuclear retention of polyadenylated RNAs and more slowly to cytoplasmic accumulation of a nuclear reporter protein. A stretch of 140 amino acids within Nup145p is conserved in two other yeast nucleoporins, Nup116p and Nup100p, and in an uncharacterized C. elegans protein. Genetic experiments in yeast reveal that the three copies of the motif carry out an essential, redundant function. Fragments of Nup145p and Nup116p including this motif bind specifically to homopolymeric RNAs in vitro. Nup145p, Nup116p, and Nup100p thus represent a novel class of nucleoporins involved in nucleocytoplasmic transport.			FABRE, E (corresponding author), EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,D-69117 HEIDELBERG,GERMANY.		Boelens, Wilbert/D-8877-2012; Ed Hurt, Dr./AAE-8874-2019	Ed Hurt, Dr./0000-0002-4535-8255; FABRE, Emmanuelle/0000-0002-0009-4604; Mattaj, Iain/0000-0002-5537-8284				AKEY CW, 1993, J CELL BIOL, V122, P1, DOI 10.1083/jcb.122.1.1; AKEY CW, 1989, J CELL BIOL, V109, P955, DOI 10.1083/jcb.109.3.955; AMBERG DC, 1992, GENE DEV, V6, P1173, DOI 10.1101/gad.6.7.1173; ANDREAZZOLI M, 1993, NUCLEIC ACIDS RES, V21, P4218, DOI 10.1093/nar/21.18.4218; ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BATAILLE N, 1990, J CELL BIOL, V111, P1571, DOI 10.1083/jcb.111.4.1571; BERBEN G, 1991, YEAST, V7, P475, DOI 10.1002/yea.320070506; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; Bossie MA, 1992, CURR OPIN GENET DEV, V2, P768, DOI 10.1016/S0959-437X(05)80137-6; CARMOFONSECA M, 1991, EUR J CELL BIOL, V55, P17; CORDES V, 1991, EUR J CELL BIOL, V55, P31; DABAUVALLE MC, 1988, CHROMOSOMA, V97, P193, DOI 10.1007/BF00292960; DARGEMONT C, 1992, J CELL BIOL, V118, P1, DOI 10.1083/jcb.118.1.1; DAVIS LI, 1990, CELL, V61, P965, DOI 10.1016/0092-8674(90)90062-J; DREYFUSS G, 1986, ANNU REV CELL BIOL, V2, P459, DOI 10.1146/annurev.cellbio.2.1.459; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; DWORETZKY SI, 1988, J CELL BIOL, V106, P575, DOI 10.1083/jcb.106.3.575; ECKNER R, 1991, EMBO J, V10, P3513, DOI 10.1002/j.1460-2075.1991.tb04915.x; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; FEATHERSTONE C, 1988, J CELL BIOL, V107, P1289, DOI 10.1083/jcb.107.4.1289; FINLAY DR, 1991, J CELL BIOL, V114, P169, DOI 10.1083/jcb.114.1.169; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; GOLDFARB DS, 1992, CELL, V70, P185, DOI 10.1016/0092-8674(92)90094-S; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; GRANDI P, 1993, EMBO J, V12, P3061, DOI 10.1002/j.1460-2075.1993.tb05975.x; GREBER UF, 1990, EMBO J, V9, P1495, DOI 10.1002/j.1460-2075.1990.tb08267.x; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; HALLBERG E, 1993, J CELL BIOL, V122, P513, DOI 10.1083/jcb.122.3.513; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; HINSHAW JE, 1992, CELL, V69, P1133, DOI 10.1016/0092-8674(92)90635-P; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HURT EC, 1993, FEBS LETT, V325, P76, DOI 10.1016/0014-5793(93)81417-X; HURT EC, 1988, EUR J CELL BIOL, V46, P554; ITOH H, 1983, J BACTERIOL, V153, P163; Izaurralde E, 1992, Semin Cell Biol, V3, P279, DOI 10.1016/1043-4682(92)90029-U; IZAURRALDE E, 1992, J CELL BIOL, V118, P1287, DOI 10.1083/jcb.118.6.1287; JARMOLOWSKI A, 1994, J CELL BIOL, V124, P627, DOI 10.1083/jcb.124.5.627; JARNIK M, 1991, J STRUCT BIOL, V107, P291, DOI 10.1016/1047-8477(91)90054-Z; KADOWAKI T, 1992, P NATL ACAD SCI USA, V89, P2312, DOI 10.1073/pnas.89.6.2312; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KIM YJ, 1993, MOL CELL BIOL, V13, P174, DOI 10.1128/MCB.13.1.174; KOLLURI R, 1992, NUCLEIC ACIDS RES, V20, P111, DOI 10.1093/nar/20.1.111; KOSTER M, 1991, EMBO J, V10, P3087, DOI 10.1002/j.1460-2075.1991.tb07861.x; LANDSMAN D, 1992, NUCLEIC ACIDS RES, V20, P2861, DOI 10.1093/nar/20.11.2861; LEGRAIN P, 1989, CELL, V57, P573, DOI 10.1016/0092-8674(89)90127-X; LOEB JDJ, 1993, MOL BIOL CELL, V4, P209, DOI 10.1091/mbc.4.2.209; Maquat LE, 1991, CURR OPIN CELL BIOL, V3, P1004, DOI 10.1016/0955-0674(91)90121-E; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MATTAJ IW, 1989, CELL, V57, P1, DOI 10.1016/0092-8674(89)90164-5; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; MICHAUD N, 1992, J CELL BIOL, V116, P851, DOI 10.1083/jcb.116.4.851; MURRAY MT, 1991, J CELL BIOL, V112, P1, DOI 10.1083/jcb.112.1.1; MUTVEI A, 1992, EUR J CELL BIOL, V59, P280; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NEHRBASS U, 1993, EUR J CELL BIOL, V62, P1; NEHRBASS U, 1990, CELL, V61, P979, DOI 10.1016/0092-8674(90)90063-K; NIGG EA, 1991, CELL, V66, P15, DOI 10.1016/0092-8674(91)90135-L; PANTE N, 1993, J CELL BIOL, V122, P977, DOI 10.1083/jcb.122.5.977; PINOLROMA S, 1993, MOL CELL BIOL, V13, P5762, DOI 10.1128/MCB.13.9.5762; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; ROBZYK K, 1992, NUCLEIC ACIDS RES, V20, P3790, DOI 10.1093/nar/20.14.3790; ROUT MP, 1993, J CELL BIOL, V123, P771, DOI 10.1083/jcb.123.4.771; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5466; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; SCHNUCHEL A, 1993, NATURE, V364, P169, DOI 10.1038/364169a0; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STARR CM, 1990, J CELL BIOL, V110, P1861, DOI 10.1083/jcb.110.6.1861; STOTZ A, 1990, GENE, V95, P91, DOI 10.1016/0378-1119(90)90418-Q; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TERNS MP, 1993, GENE DEV, V7, P1898, DOI 10.1101/gad.7.10.1898; TOBIAN JA, 1985, CELL, V43, P415, DOI 10.1016/0092-8674(85)90171-0; WENTE SR, 1993, J CELL BIOL, V123, P275, DOI 10.1083/jcb.123.2.275; WENTE SR, 1992, J CELL BIOL, V119, P705, DOI 10.1083/jcb.119.4.705; WIMMER C, 1992, EMBO J, V11, P5051, DOI 10.1002/j.1460-2075.1992.tb05612.x; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOZNIAK RW, 1992, J CELL BIOL, V119, P1441, DOI 10.1083/jcb.119.6.1441; ZASLOFF M, 1983, P NATL ACAD SCI-BIOL, V80, P6436, DOI 10.1073/pnas.80.21.6436	87	123	129	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 29	1994	78	2					275	289		10.1016/0092-8674(94)90297-6	http://dx.doi.org/10.1016/0092-8674(94)90297-6			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	8044840				2022-12-24	WOS:A1994NZ24200011
J	WALKER, NPC; TALANIAN, RV; BRADY, KD; DANG, LC; BUMP, NJ; FERENZ, CR; FRANKLIN, S; GHAYUR, T; HACKETT, MC; HAMMILL, LD; HERZOG, L; HUGUNIN, M; HOUY, W; MANKOVICH, JA; MCGUINESS, L; ORLEWICZ, E; PASKIND, M; PRATT, CA; REIS, P; SUMMANI, A; TERRANOVA, M; WELCH, JP; XIONG, L; MOLLER, A; TRACEY, DE; KAMEN, R; WONG, WW				WALKER, NPC; TALANIAN, RV; BRADY, KD; DANG, LC; BUMP, NJ; FERENZ, CR; FRANKLIN, S; GHAYUR, T; HACKETT, MC; HAMMILL, LD; HERZOG, L; HUGUNIN, M; HOUY, W; MANKOVICH, JA; MCGUINESS, L; ORLEWICZ, E; PASKIND, M; PRATT, CA; REIS, P; SUMMANI, A; TERRANOVA, M; WELCH, JP; XIONG, L; MOLLER, A; TRACEY, DE; KAMEN, R; WONG, WW			CRYSTAL-STRUCTURE OF THE CYSTEINE PROTEASE INTERLEUKIN-1-BETA-CONVERTING ENZYME - A (P20/P10)(2) HOMODIMER	CELL			English	Article							IL-1-BETA CONVERTING ENZYME; DEATH GENE CED-3; CELL-DEATH; 3-DIMENSIONAL STRUCTURE; TRIACYLGLYCEROL LIPASE; INTERLEUKIN 1-BETA; MOLECULAR-CLONING; TRIAD FORMS; RESOLUTION; FIBROBLASTS	Interleukin-1 beta-converting enzyme (ICE) proteolytically cleaves pro-IL-1 beta to its mature, active form. The crystal structure at 2.5 Angstrom resolution of a recombinant human ICE-tetrapeptide chloromethylketone complex reveals that the holoenzyme is a homodimer of catalytic domains, each of which contains a p20 and a p10 subunit. The spatial separation of the C-terminus of p20 and the N-terminus of pin in each domain suggests two alternative pathways of assembly and activation in vivo. ICE is homologous to the C. elegans cell death gene product, CED-3, and these may represent a novel class of cytoplasmic cysteine proteases that are important in programmed cell death (apoptosis). Conservation among members of the ICE/CED-3 family of the amino acids that form the active site region of ICE supports the hypothesis that they share functional similarities.	BASF BIORES CORP, WORCESTER, MA 01605 USA	BASF	WALKER, NPC (corresponding author), BASF AG, MAIN LAB, D-67056 LUDWIGSHAFEN, GERMANY.		Somani, ally-khan/AAA-9656-2020	Somani, Ally-Khan/0000-0003-2166-4896				BAKER EN, 1980, J MOL BIOL, V141, P441, DOI 10.1016/0022-2836(80)90255-7; BARR PJ, 1994, BIO-TECHNOL, V12, P487, DOI 10.1038/nbt0594-487; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLACK RA, 1988, J BIOL CHEM, V263, P9437; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P11; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURNETT RM, 1974, J BIOL CHEM, V249, P4383; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHAPMAN KT, 1992, BIOORG MED CHEM LETT, V2, P613, DOI 10.1016/S0960-894X(01)81209-9; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; Drenth J, 1971, Adv Protein Chem, V25, P79, DOI 10.1016/S0065-3233(08)60279-X; DRENTH J, 1972, EUR J BIOCHEM, V26, P177, DOI 10.1111/j.1432-1033.1972.tb01754.x; EKLUND H, 1976, J MOL BIOL, V102, P27, DOI 10.1016/0022-2836(76)90072-3; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GROCHULSKI P, 1993, J BIOL CHEM, V268, P12843; HEINEMANN U, 1982, J MOL BIOL, V161, P591, DOI 10.1016/0022-2836(82)90410-7; HENDRICKSON WA, 1981, NATURE, V290, P107, DOI 10.1038/290107a0; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; HOWARD AD, 1991, J IMMUNOL, V147, P2964; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HUDIG D, 1993, CURR OPIN IMMUNOL, V5, P90, DOI 10.1016/0952-7915(93)90086-8; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; LEVITT M, 1976, NATURE, V261, P552, DOI 10.1038/261552a0; McPherson A Jr, 1976, Methods Biochem Anal, V23, P249, DOI 10.1002/9780470110430.ch4; MILLER DK, 1993, J BIOL CHEM, V268, P18062; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOLINEAUX SM, 1993, P NATL ACAD SCI USA, V90, P1809, DOI 10.1073/pnas.90.5.1809; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; NETT MA, 1992, J IMMUNOL, V149, P3254; NOBLE MEM, 1993, FEBS LETT, V331, P123, DOI 10.1016/0014-5793(93)80310-Q; PERREGAUX D, 1992, J IMMUNOL, V149, P1294; POWERS JC, 1977, CHEM BIOCH AMINO ACI, V4, P65; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROSENBERG M, 1983, METHOD ENZYMOL, V101, P123; SCHRAG JD, 1991, NATURE, V351, P761, DOI 10.1038/351761a0; SHAW E, 1990, ADV ENZYMOL RAMB, V63, P271; SIELECKI AR, 1989, SCIENCE, V243, P1346, DOI 10.1126/science.2493678; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; STERNBERG MJE, 1977, J MOL BIOL, V110, P269, DOI 10.1016/S0022-2836(77)80072-7; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; WRIGHT CS, 1969, NATURE, V221, P235, DOI 10.1038/221235a0; YOUNG PR, 1988, J CELL BIOL, V107, P447, DOI 10.1083/jcb.107.2.447; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZIMMERMAN M, 1976, ANAL BIOCHEM, V70, P258, DOI 10.1016/S0003-2697(76)80066-8	60	518	556	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 29	1994	78	2					343	352		10.1016/0092-8674(94)90303-4	http://dx.doi.org/10.1016/0092-8674(94)90303-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	8044845				2022-12-24	WOS:A1994NZ24200017
J	AICKIN, R; HILL, D; KEMP, A				AICKIN, R; HILL, D; KEMP, A			MEASLES IMMUNIZATION IN CHILDREN WITH ALLERGY TO EGG	BRITISH MEDICAL JOURNAL			English	Article							RUBELLA VACCINE; MUMPS; IMMUNIZATION; HYPERSENSITIVITY; PROTEIN; IGE	Objective-To examine the occurrence of adverse reactions to measles vaccine given as a single dose to children with egg allergy, and to determine if the administration of single dose to children with a positive result in an intradermal skin prick test with the vaccine is associated with adverse reactions, Design-Review of results of immunisation and prospective study of 96 consecutively presenting children given intradermal skin testing with the vaccine. Setting-Children's allergy centre. Subjects-410 children sensitive to egg referred to the allergy unit for advice about measles immunisation. Main outcome measures-Nature and severity of reactions associated with the administration of measles vaccine. Results-All children had a positive result in a skin prick test with egg white, and five had a positive result in a skin prick test with vaccine. Of 96 consecutive children, 46 had a positive result in an intradermal test with vaccine. After immunisation with a full dose (0.5 ml) of vaccine adverse reactions were associated with a mild reaction in four children, none of whom required treatment. Only one of the 46 children with a positive result in an intradermal vaccine skin test had a reaction associated with vaccine administration. None of the children with a positive result in a skin prick test with measles vaccine reacted to the vaccine. The rate of minor reactions to the vaccine not requiring treatment was 0.98% (95% confidence interval 0.27% to 2.48%) and serious reactions requiring treatment was 0% (0% to 0.9%). Conclusion-Chiidren with IgE mediated allergic reactions to egg protein should be investigated and managed by practitioners with special knowledge in this subject. Measles immunisation should be performed in a setting where any adverse reactions can be dealt with appropriately. Skin tests and measles vaccine and desensitisation are not necessary.	ROYAL CHILDRENS HOSP,DEPT ALLERGY,MELBOURNE,VIC,AUSTRALIA	Royal Children's Hospital Melbourne								BECK SA, 1991, PEDIATRICS, V88, P913; BRUNO G, 1990, LANCET, V335, P739, DOI 10.1016/0140-6736(90)90863-Z; FASANO MB, 1992, J PEDIATR-US, V120, P878, DOI 10.1016/S0022-3476(05)81953-5; HERMAN JJ, 1983, J PEDIATR-US, V102, P196, DOI 10.1016/S0022-3476(83)80519-8; HILL DJ, 1988, CLIN ALLERGY, V18, P481, DOI 10.1111/j.1365-2222.1988.tb02898.x; JUNTUNENBACKMAN K, 1987, AM J DIS CHILD, V141, P1103, DOI 10.1001/archpedi.1987.04460100081032; KAMIN PB, 1963, JAMA-J AM MED ASSOC, V185, P647, DOI 10.1001/jama.1963.03060080043012; KELSO JM, 1993, J ALLERGY CLIN IMMUN, V91, P867, DOI 10.1016/0091-6749(93)90344-F; KEMP A, 1990, AM J DIS CHILD, V144, P33, DOI 10.1001/archpedi.1990.02150250039027; LAVI S, 1990, JAMA-J AM MED ASSOC, V263, P269, DOI 10.1001/jama.263.2.269; MCEWEN J, 1983, MED J AUSTRALIA, V2, P503, DOI 10.5694/j.1326-5377.1983.tb122619.x; PUVYADA L, 1993, PEDIATRICS, V91, P835; STIEHM ER, 1990, AM J DIS CHILD, V144, P32, DOI 10.1001/archpedi.1990.02150250034026; VANASPEREN PP, 1984, J ALLERGY CLIN IMMUN, V73, P381, DOI 10.1016/0091-6749(84)90412-3; VANASPEREN PP, 1981, MED J AUSTRALIA, V2, P330; 1989, PRODUCT INFORMATION; 1991, REPORT COMMITTEE INF	17	52	53	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 23	1994	309	6949					223	225		10.1136/bmj.309.6949.223	http://dx.doi.org/10.1136/bmj.309.6949.223			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ180	8069138	Green Published			2022-12-24	WOS:A1994NZ18000013
J	PALLAS, DC; FU, H; HAEHNEL, LC; WELLER, W; COLLIER, RJ; ROBERTS, TM				PALLAS, DC; FU, H; HAEHNEL, LC; WELLER, W; COLLIER, RJ; ROBERTS, TM			ASSOCIATION OF POLYOMAVIRUS MIDDLE TUMOR-ANTIGEN WITH 14-3-3-PROTEINS	SCIENCE			English	Article							SMALL T-ANTIGEN; CELLULAR PROTEINS; TRANSFORMATION; PHOSPHATASE-2A; COMPLEXES; FAMILY; CELLS	To carry out its transformation function, the middle tumor antigen (MT) of murine polyomavirus associates with a number of cellular proteins involved in regulation of cell proliferation, including pp60(c-Src), phosphatidylinositol 3-kinase, protein phosphatase 2A, Src homologous and collagen protein and growth factor receptor-binding protein 2. Here, two additional MT-associated proteins were identified as members of the 14-3-3 family of proteins. Yeast homologs of 14-3-3 proteins have recently been shown to play a role in the timing of mitosis. Thus, regulation of 14-3-3 protein function by MT may contribute to the development of neoplasia.	HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,SHIPLEY INST MED,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	PALLAS, DC (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOLEC BIOL,BOSTON,MA 02115, USA.			Collier, R John/0000-0002-2427-4239	NATIONAL CANCER INSTITUTE [R01CA030002, R29CA045285, P01CA050661, R01CA057327, R37CA030002] Funding Source: NIH RePORTER; NCI NIH HHS [CA50661, CA30002, CA45285, R01 CA057327] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; FU H, UNPUB; KAPLAN D R, 1988, Biochimica et Biophysica Acta, V948, P345; MORGAN WC, 1988, J VIROL, V62, P3407, DOI 10.1128/JVI.62.9.3407-3414.1988; PALLAS D, UNPUB; PALLAS DC, 1989, J VIROL, V63, P4533, DOI 10.1128/JVI.63.11.4533-4539.1989; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; PALLAS DC, 1986, J VIROL, V60, P1075, DOI 10.1128/JVI.60.3.1075-1084.1986; PALLAS DC, 1988, J VIROL, V62, P3934, DOI 10.1128/JVI.62.11.3934-3940.1988; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0	16	164	167	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 22	1994	265	5171					535	537		10.1126/science.8036498	http://dx.doi.org/10.1126/science.8036498			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	8036498				2022-12-24	WOS:A1994NY21600034
J	PEPPER, A; DELANEY, T; WASHBURN, T; POOLE, D; CHORY, J				PEPPER, A; DELANEY, T; WASHBURN, T; POOLE, D; CHORY, J			DET1, A NEGATIVE REGULATOR OF LIGHT-MEDIATED DEVELOPMENT AND GENE-EXPRESSION IN ARABIDOPSIS, ENCODES A NOVEL NUCLEAR-LOCALIZED PROTEIN	CELL			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; CHLOROPLAST DEVELOPMENT; SACCHAROMYCES-CEREVISIAE; PLANT; SEQUENCE; YEAST; TRANSFORMATION; PATHWAYS; MUTANTS; DNA	The mechanisms by which plants integrate light signals to modify endogenous developmental programs are largely unknown. One candidate for a signal transduction component that may integrate light with developmental pathways is the Arabidopsis DET1 gene product. Here we report the positional cloning of the DET1 locus and show that DET1 is a unique nuclear-localized protein. An analysis of a number of det1 mutants indicates that mutants with partial DET1 activity develop as light-grown plants in the dark. det1 null mutants share this phenotype, but also display severe defects in temporal and spatial regulation of gene expression. These results suggest that DET1 acts in the nucleus to control the cell type-specific expression of light-regulated promoters.			PEPPER, A (corresponding author), SALK INST, PLANT BIOL LAB, SAN DIEGO, CA 92186 USA.		Delaney, Terrence P/A-2947-2008					ABEL S, 1994, P NATL ACAD SCI USA, V91, P326, DOI 10.1073/pnas.91.1.326; AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; BROWN JWS, 1986, NUCLEIC ACIDS RES, V14, P9549, DOI 10.1093/nar/14.24.9549; CARRINGTON JC, 1991, PLANT CELL, V3, P953, DOI 10.1105/tpc.3.9.953; CASTLE LA, 1994, PLANT CELL, V6, P25, DOI 10.1105/tpc.6.1.25; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CHORY J, 1993, TRENDS GENET, V9, P167, DOI 10.1016/0168-9525(93)90163-C; CHORY J, 1991, NEW BIOL, V3, P538; CHORY J, 1990, P NATL ACAD SCI USA, V87, P8776, DOI 10.1073/pnas.87.22.8776; CHORY J, 1989, CELL, V58, P991, DOI 10.1016/0092-8674(89)90950-1; CHORY J, 1994, PLANT PHYSIOL, V104, P339, DOI 10.1104/pp.104.2.339; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Dellaporta SL., 1983, PLANT MOL BIOL REP, V1, P19, DOI [10.1007/BF02712670, DOI 10.1007/BF02712670]; DENG XW, 1994, CELL, V76, P423, DOI 10.1016/0092-8674(94)90107-4; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; LIN S, 1993, PLANT CELL, V5, P109, DOI 10.1105/tpc.5.1.109; Meer I. M. van der, 1993, Control of plant gene expression., P125; MISERA S, 1994, IN PRESS MOL GEN GEN; MULLET JE, 1988, ANNU REV PLANT PHYS, V39, P475, DOI 10.1146/annurev.arplant.39.1.475; NEUHAUS G, 1993, CELL, V73, P937, DOI 10.1016/0092-8674(93)90272-R; OLSZEWSKI NE, 1988, NUCLEIC ACIDS RES, V16, P10765, DOI 10.1093/nar/16.22.10765; RAIKHEL N, 1992, PLANT PHYSIOL, V100, P1627, DOI 10.1104/pp.100.4.1627; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Rose MD., 1990, METHODS YEAST GENETI; SCHULTZ J, 1990, MOL CELL BIOL, V10, P4744, DOI 10.1128/MCB.10.9.4744; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; VIERSTRA RD, 1993, PLANT PHYSIOL, V103, P679, DOI 10.1104/pp.103.3.679; WANG HM, 1993, MOL CELL BIOL, V13, P1805, DOI 10.1128/MCB.13.3.1805; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; WARPEHA KMF, 1991, P NATL ACAD SCI USA, V88, P8925, DOI 10.1073/pnas.88.20.8925; YOUNG JC, 1992, PLANTA, V188, P106, DOI 10.1007/BF00198946	36	242	250	2	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 15	1994	78	1					109	116		10.1016/0092-8674(94)90577-0	http://dx.doi.org/10.1016/0092-8674(94)90577-0			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033202				2022-12-24	WOS:A1994NX32800013
J	ODOWD, TC; BOURNE, N				ODOWD, TC; BOURNE, N			INVENTING A NEW DIAGNOSTIC-TEST FOR VAGINAL INFECTION	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BACTERIAL VAGINOSIS; CHLAMYDIA-TRACHOMATIS; WOMEN; FLUID	Bacterial vaginosis, which is underdiagnosed in clinical practice, has a characteristic fishy smell because of production of diamines. This smell is the basis of a visual rapid diagnostic test that is technically simple to perform. The test has been patented in Europe and America, and a licence agreement has been negotiated. This paper describes the process from idea to invention to patenting and licensing. The combined costs of research and patenting were met by a multinational company in return for rights to exploit the patented invention. The process has taken nine years and has needed clinical, scientific, legal, and commercial input to get the test to the marketplace.	UNIV WALES COLL CARDIFF, CARDIFF CF1 3XA, S GLAM, WALES	Cardiff University	ODOWD, TC (corresponding author), TRINITY COLL DUBLIN, DEPT COMMUNITY HLTH & GEN PRACTICE, DUBLIN 2, IRELAND.							[Anonymous], 1977, PATENTS ACT; CHEN KCS, 1982, J INFECT DIS, V145, P337, DOI 10.1093/infdis/145.3.337; DAVIS RH, 1991, Patent No. 2215044; GARDNER HL, 1955, AM J OBSTET GYNECOL, V69, P962, DOI 10.1016/0002-9378(55)90095-8; GRAVETT M G, 1986, Journal of the American Medical Association, V256, P1899, DOI 10.1001/jama.256.14.1899; GRAVETT MG, 1986, OBSTET GYNECOL, V67, P229, DOI 10.1097/00006250-198602000-00013; KROHN MA, 1989, J CLIN MICROBIOL, V27, P1266, DOI 10.1128/JCM.27.6.1266-1271.1989; LARSSON PG, 1992, AM J OBSTET GYNECOL, V166, P100, DOI 10.1016/0002-9378(92)91838-2; MARTIUS J, 1988, OBSTET GYNECOL, V71, P89; MEAD G, 1992, FINANCIAL TIMES 0409, P11; ODOWD TC, 1988, BRIT MED J, V292, P1640; PEARSON H, 1990, COMMERCIAL EXPLOITAT, P1; THOMASON JL, 1988, OBSTET GYNECOL, V71, P67; WATTS DH, 1990, OBSTET GYNECOL, V75, P52; 1992, PREPARE UK PATENT AP; 1992, INTELLECTUAL PROPERT, P1	16	6	7	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 2	1994	309	6946					40	42		10.1136/bmj.309.6946.40	http://dx.doi.org/10.1136/bmj.309.6946.40			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV891	8044068	Green Published			2022-12-24	WOS:A1994NV89100026
J	HENKEL, T; LING, PD; HAYWARD, SD; PETERSON, MG				HENKEL, T; LING, PD; HAYWARD, SD; PETERSON, MG			MEDIATION OF EPSTEIN-BARR-VIRUS EBNA2 TRANSACTIVATION BY RECOMBINATION SIGNAL-BINDING PROTEIN J(K)	SCIENCE			English	Article							RNA POLYMERASE-II; NUCLEAR ANTIGEN-2; DROSOPHILA HOMOLOG; J-KAPPA; PROMOTER; SEQUENCE; ELEMENT; GENE; DNA; PURIFICATION	The Epstein-Barr virus (EBV) transactivator protein, termed Epstein-Barr virus nuclear antigen 2 (EBNA2), plays a critical role in the regulation of latent viral transcription and in the immortalization of EBV-infected B cells. Unlike most transcription factors, EBNA2 does not bind directly to its cis-responsive DNA element but requires a cellular factor, termed C-promoter binding factor 1 (CBF1). Here, CBF1 was purified and was found to directly interact with EBNA2. CBF1 is identical to a protein thought to be involved in immunoglobulin gene rearrangement, RBPJ(k)appa. Contrary to previous reports, CBF1-RBPJ(k)appa did not bind to the recombination signal sequences but instead bound to sites in the EBV C-promoter and in the CD23 promoter.	TULARIK INC,S SAN FRANCISCO,CA 94080; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University					NATIONAL CANCER INSTITUTE [R37CA042245, R01CA042245] Funding Source: NIH RePORTER; NCI NIH HHS [CA42245] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMAKAWA R, 1993, GENOMICS, V17, P306, DOI 10.1006/geno.1993.1326; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; CORDIER M, 1990, J VIROL, V64, P1002, DOI 10.1128/JVI.64.3.1002-1013.1990; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAHRAEUS R, 1990, P NATL ACAD SCI USA, V87, P7390, DOI 10.1073/pnas.87.19.7390; FURUKAWA T, 1992, CELL, V69, P1191, DOI 10.1016/0092-8674(92)90640-X; HAMAGUCHI Y, 1992, J BIOCHEM-TOKYO, V112, P314, DOI 10.1093/oxfordjournals.jbchem.a123898; HAMAGUCHI Y, 1989, NUCLEIC ACIDS RES, V17, P9015, DOI 10.1093/nar/17.22.9015; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; HENKEL T, UNPUB; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JIN XW, 1992, J VIROL, V66, P2846, DOI 10.1128/JVI.66.5.2846-2852.1992; KIEFF E, 1990, VIROLOGY, P1889; LIEBERMAN PM, 1989, J VIROL, V63, P3040, DOI 10.1128/JVI.63.7.3040-3050.1989; LING PD, 1993, J VIROL, V67, P2990, DOI 10.1128/JVI.67.6.2990-3003.1993; LING PD, 1993, P NATL ACAD SCI USA, V90, P9237, DOI 10.1073/pnas.90.20.9237; MATSUNAMI N, 1989, NATURE, V342, P934, DOI 10.1038/342934a0; MILLER G, 1990, VIROLOGY, P1921; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWEISGUTH F, 1992, CELL, V69, P1199, DOI 10.1016/0092-8674(92)90641-O; SUNG NS, 1991, J VIROL, V65, P2161; TUN T, 1994, NUCLEIC ACIDS RES, V22, P965, DOI 10.1093/nar/22.6.965; WANG F, 1991, J VIROL, V65, P4101, DOI 10.1128/JVI.65.8.4101-4106.1991; ZIMBERSTROBL U, 1993, EMBO J, V12, P167, DOI 10.1002/j.1460-2075.1993.tb05642.x	24	382	394	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 1	1994	265	5168					92	95		10.1126/science.8016657	http://dx.doi.org/10.1126/science.8016657			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV301	8016657				2022-12-24	WOS:A1994NV30100032
J	MCCLELLAN, M; MCNEIL, BJ; NEWHOUSE, JP				MCCLELLAN, M; MCNEIL, BJ; NEWHOUSE, JP			DOES MORE INTENSIVE TREATMENT OF ACUTE MYOCARDIAL-INFARCTION IN THE ELDERLY REDUCE MORTALITY - ANALYSIS USING INSTRUMENTAL VARIABLES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; BYPASS GRAFT-SURGERY; IMMEDIATE ANGIOPLASTY; HEALTH-CARE; MANAGEMENT; OUTCOMES; TRIALS; RATES; QUALITY; VOLUME	Objective.-To determine the effect of more intensive treatments on mortality in elderly patients with acute myocardial infarction (AMI). Design.-Analysis of incremental treatment effects using differential distances as instrumental variables to account for unobserved case-mix variation (selection bias) in observational Medicare claims data (1987 through 1991). Main Outcome Measures.-Survival to 4 years after AMI. Results.-Patients who receive different treatments differ in observable and unobservable health characteristics, biasing estimates of treatment effects based on standard methods of adjusting for observable differences. Patients' differential distances to alternative types of hospitals are strong independent predictors of how intensively an AMI patient will be treated and appear uncorrelated with health status. Thus, differential distances approximately randomize patients to different likelihoods of receiving intensive treatments. Comparisons of patient groups that differ only in differential distances show that the impact on mortality at 1 to 4 years after AMI of the incremental (''marginal'') use of invasive procedures in Medicare patients was at most 5 percentage points; this gain was achieved during the first day of hospitalization and therefore appears attributable to treatments other than the procedures. Admission to a hospital treating a high volume of AMI patients was associated with an effect on mortality at 4 years of less than 1 percentage point, again arising on day 1. Patients living in rural areas experienced acute mortality that was an additional 0.6 percentage-point higher, after controlling for less access to intensive treatments. Conclusions.-For elderly patients with AMI, the aspects of treatment most affecting long-term survival relate to care within the first 24 hours of admission. The survival benefits from greater use of catheterization and revascularization procedures appear minimal in marginal patients.	HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT RADIOL,BOSTON,MA 02115; HARVARD UNIV,JOHN F KENNEDY SCH GOVT,CAMBRIDGE,MA 02138	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University	MCCLELLAN, M (corresponding author), NATL BUR ECON RES,1050 MASSACHUSETTS AVE,CAMBRIDGE,MA 02138, USA.		Newhouse, Joseph/AGJ-5632-2022		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R03HS007638, R01HS006341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000186] Funding Source: NIH RePORTER; AHRQ HHS [R03-HS07638-01, R0I-HS06341] Funding Source: Medline; NIA NIH HHS [T32-AG00186-03] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON C, 1994, SCIENCE, V263, P1080, DOI 10.1126/science.8108722; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BLUMBERG MS, 1987, HEALTH SERV RES, V21, P715; BLUSTEIN J, 1993, JAMA-J AM MED ASSOC, V270, P344, DOI 10.1001/jama.270.3.344; CHAMBERLAIN G, 1987, J ECONOMETRICS, V34, P305, DOI 10.1016/0304-4076(87)90015-7; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; FORD E, 1989, AM J PUBLIC HEALTH, V79, P437, DOI 10.2105/AJPH.79.4.437; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; GRADY ML, 1992, AHCPR920056 AG HLTH; GREENFIELD S, 1988, JAMA-J AM MED ASSOC, V260, P2253, DOI 10.1001/jama.260.15.2253; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; HUGHES RG, 1988, MED CARE, V26, P1057, DOI 10.1097/00005650-198811000-00004; IMBENS A, 1994, ECONOMETRICA, V62, P467; MCCLELLAN MB, 1994, MARGINAL BENEFITS ME; MCCLELLAN MB, 1994, EFFECTS HOSPITAL TEC; NEWEY WK, 1985, ECONOMETRICA, V53, P1047, DOI 10.2307/1911011; PARK RE, 1990, JAMA-J AM MED ASSOC, V264, P484; RJ Bowden, 1984, INSTRUMENTAL VARIABL; ROPER WL, 1988, NEW ENGL J MED, V319, P1197, DOI 10.1056/NEJM198811033191805; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; SHAPIRO DW, 1993, ANNU REV PUBL HEALTH, V14, P219, DOI 10.1146/annurev.pu.14.050193.001251; SHOWSTACK JA, 1987, JAMA-J AM MED ASSOC, V257, P785, DOI 10.1001/jama.257.6.785; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; Wagner D P, 1986, Health Aff (Millwood), V5, P148, DOI 10.1377/hlthaff.5.2.148; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; YUSUF S, 1990, CIRCULATION, V82, P117; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002; 1992, C PROFILING WASHINGT	34	627	630	4	43	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 21	1994	272	11					859	866		10.1001/jama.272.11.859	http://dx.doi.org/10.1001/jama.272.11.859			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PG182	8078163				2022-12-24	WOS:A1994PG18200024
J	RAGSDALE, DS; MCPHEE, JC; SCHEUER, T; CATTERALL, WA				RAGSDALE, DS; MCPHEE, JC; SCHEUER, T; CATTERALL, WA			MOLECULAR DETERMINANTS OF STATE-DEPENDENT BLOCK OF NA+ CHANNELS BY LOCAL-ANESTHETICS	SCIENCE			English	Article							SQUID GIANT-AXONS; SOMATIC-CELL LINE; SODIUM-CHANNELS; RAT-BRAIN; MYELINATED NERVE; POTASSIUM CHANNELS; SLOW INACTIVATION; GATING PROPERTIES; IONIC CURRENTS; ALPHA-SUBUNIT	Sodium ion (Na+) channels, which initiate the action potential in electrically excitable cells, are the molecular targets of local anesthetic drugs. Site-directed mutations in transmembrane segment S6 of domain IV of the Na+ channel alpha subunit from rat brain selectively modified drug binding to resting or to open and inactivated channels when expressed in Xenopus oocytes. Mutation F1764A, near the middle of this segment, decreased the affinity of open and inactivated channels to 1 percent of the wild-type value, resulting in almost complete abolition of both the use-dependence and voltage-dependence of drug block, whereas mutation N1769A increased the affinity of the resting channel 15-fold. Mutation I1760A created an access pathway for drug molecules to reach the receptor site from the extracellular side. The results define the location of the local anesthetic receptor site in the pore of the Na+ channel and identify molecular determinants of the state-dependent binding of local anesthetics.			RAGSDALE, DS (corresponding author), UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195, USA.				NHLBI NIH HHS [P01-HL44948] Funding Source: Medline; NINDS NIH HHS [R01-NS15751] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015751] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADELMAN WJ, 1969, J GEN PHYSIOL, V54, P589, DOI 10.1085/jgp.54.5.589; AULD VJ, 1990, P NATL ACAD SCI USA, V87, P323, DOI 10.1073/pnas.87.1.323; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; BACKX PH, 1992, SCIENCE, V257, P248, DOI 10.1126/science.1321496; BEAN BP, 1983, J GEN PHYSIOL, V81, P613, DOI 10.1085/jgp.81.5.613; BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; BOKESCH PM, 1986, J PHARMACOL EXP THER, V237, P773; BRISMAR T, 1977, J PHYSIOL-LONDON, V270, P283, DOI 10.1113/jphysiol.1977.sp011952; BUTTERWORTH JF, 1990, ANESTHESIOLOGY, V72, P711, DOI 10.1097/00000542-199004000-00022; CAHALAN MD, 1979, BIOPHYS J, V27, P39, DOI 10.1016/S0006-3495(79)85201-7; CAHALAN MD, 1978, BIOPHYS J, V23, P285, DOI 10.1016/S0006-3495(78)85449-6; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CATTERALL WA, 1992, TRENDS PHARMACOL SCI, V13, P256, DOI 10.1016/0165-6147(92)90079-L; CATTERALL WA, 1987, TRENDS PHARMACOL SCI, V8, P57, DOI 10.1016/0165-6147(87)90011-3; CHANDLER WK, 1970, J PHYSIOL-LONDON, V211, P707, DOI 10.1113/jphysiol.1970.sp009300; CHOI KL, 1993, NEURON, V10, P533, DOI 10.1016/0896-6273(93)90340-W; COURTNEY KR, 1975, J PHARMACOL EXP THER, V195, P225; COURTNEY KR, 1988, J MOL CELL CARDIOL, V20, P465; FOX JM, 1976, BIOCHIM BIOPHYS ACTA, V426, P232, DOI 10.1016/0005-2736(76)90334-5; FRAZIER DT, 1970, J PHARMACOL EXP THER, V171, P45; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HILLE B, 1977, J GEN PHYSIOL, V69, P497, DOI 10.1085/jgp.69.4.497; HONDEGHEM LM, 1977, BIOCHIM BIOPHYS ACTA, V472, P373, DOI 10.1016/0304-4157(77)90003-X; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; KAYANO T, 1988, FEBS LETT, V228, P187, DOI 10.1016/0014-5793(88)80614-8; KIRSCH GE, 1993, NEURON, V11, P503, DOI 10.1016/0896-6273(93)90154-J; MCPHEE JC, IN PRESS P NATL ACAD; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; PATTON DE, 1992, P NATL ACAD SCI USA, V89, P10905, DOI 10.1073/pnas.89.22.10905; QUANDT FN, 1987, J PHYSIOL-LONDON, V392, P563, DOI 10.1113/jphysiol.1987.sp016797; RAGSDALE DS, 1991, MOL PHARMACOL, V40, P756; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RUDY B, 1978, J PHYSIOL-LONDON, V283, P1; SCHEUER T, 1990, SCIENCE, V247, P854, DOI 10.1126/science.2154850; SHELDON RS, 1991, MOL PHARMACOL, V39, P609; STARMER CF, 1990, AM J PHYSIOL, V259, pH626, DOI 10.1152/ajpheart.1990.259.2.H626; STARMER CF, 1986, BIOPHYS J, V49, P913, DOI 10.1016/S0006-3495(86)83719-5; STARMER CF, 1986, AM J PHYSIOL, V251, pH848, DOI 10.1152/ajpheart.1986.251.4.H848; STRICHARTZ GR, 1973, J GEN PHYSIOL, V62, P37, DOI 10.1085/jgp.62.1.37; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P9203; WEST JW, 1992, NEURON, V8, P59, DOI 10.1016/0896-6273(92)90108-P; YEH JZ, 1985, BIOPHYS J, V47, P685, DOI 10.1016/S0006-3495(85)83965-5; ZAMPONI GW, 1993, BIOPHYS J, V65, P2335, DOI 10.1016/S0006-3495(93)81292-X	47	680	688	2	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 16	1994	265	5179					1724	1728		10.1126/science.8085162	http://dx.doi.org/10.1126/science.8085162			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG284	8085162				2022-12-24	WOS:A1994PG28400036
J	GURWITZ, JH; AVORN, J; BOHN, RL; GLYNN, RJ; MONANE, M; MOGUN, H				GURWITZ, JH; AVORN, J; BOHN, RL; GLYNN, RJ; MONANE, M; MOGUN, H			INITIATION OF ANTIHYPERTENSIVE TREATMENT DURING NONSTEROIDAL ANTIINFLAMMATORY DRUG-THERAPY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTIINFLAMMATORY DRUGS; BLOOD-PRESSURE; ELDERLY PERSONS; ESSENTIAL-HYPERTENSION; PEPTIC-ULCER; RISK; KNEE; OSTEOARTHRITIS; PROSTAGLANDINS; METAANALYSIS	Objective.-To determine whether there is an increased risk for the initiation of antihypertensive therapy in older persons prescribed nonaspirin, nonsteroidal antiinflammatory drugs (NSAIDs). Design.-Case-control study. Setting.-New Jersey Medicaid program. Patients.-Medicaid enrollees aged 65 years and older. The 9411 case patients were newly started on an antihypertensive medication between November 1981 and February 1990. A similar number of controls were randomly selected among other enrollees. Main Outcome Measures.-We used logistic regression to determine the odds ratio for the initiation of antihypertensive therapy in patients using NSAIDs relative to nonusers, after adjusting for age, sex, race, nursing home residence, number of prescriptions filled, intensity of physician utilization, and days hospitalized. Results.-The adjusted odds ratio for the initiation of antihypertensive therapy for recent NSAID users compared with nonusers was 1.66 (95% confidence interval, 1.54 to 1.80). The odds ratio increased with increasing daily NSAID dose: the adjusted odds ratio for users of low average daily doses relative to nonusers was 1.55 (95% Cl, 1.38 to 1.74), that for medium-dose users was 1.64 (95% Cl, 1.44 to 1.87), and that for high-dose users was 1.82 (95% Cl, 1.62 to 2.05). Conclusions.-Use of NSAIDs may increase the risk for initiation of antihypertensive therapy in older persons. Given the high prevalence of NSAID use by elderly persons, this association may have important public health implications for the management of hypertension in the older population.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV PREVENT MED,BOSTON,MA 02115; BROCKTON W ROXBURY VET AFFAIRS MED CTR,BROCKTON,MA	Harvard University; Brigham & Women's Hospital; Harvard University	GURWITZ, JH (corresponding author), BRIGHAM & WOMENS HOSP,DIV GERONTOL,PROGRAM ANAL CLIN STRATEGIES,221 LONGWOOD AVE,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE ON AGING [K08AG000642, K08AG000510, P30AG008812, P60AG008812] Funding Source: NIH RePORTER; NIA NIH HHS [KO8 AG000642, AG-08812, KO8 AG00510] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Applegate W B, 1992, Clin Geriatr Med, V8, P103; BEERS MH, 1990, J AM GERIATR SOC, V38, P1183, DOI 10.1111/j.1532-5415.1990.tb01496.x; BRADLEY JD, 1991, NEW ENGL J MED, V325, P87, DOI 10.1056/NEJM199107113250203; CHRISCHILLES EA, 1993, J GERONTOL, V48, pM91, DOI 10.1093/geronj/48.3.M91; CLIVE DM, 1984, NEW ENGL J MED, V310, P563, DOI 10.1056/NEJM198403013100905; COHEN RA, 1993, VITAL HLTH STAT 3, V29; Cox DR., 1970, ANAL BINARY DATA; FELSON DT, 1988, ANN INTERN MED, V109, P18, DOI 10.7326/0003-4819-109-1-18; FELSON DT, 1992, ANN INTERN MED, V116, P535, DOI 10.7326/0003-4819-116-7-535; GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003-4819-115-10-787; GRIFFIN MR, 1988, ANN INTERN MED, V109, P359, DOI 10.7326/0003-4819-109-5-359; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; GURWITZ JH, 1990, JAMA-J AM MED ASSOC, V264, P471, DOI 10.1001/jama.264.4.471; JOHNSON AG, 1993, BRIT J CLIN PHARMACO, V35, P455, DOI 10.1111/j.1365-2125.1993.tb04169.x; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P160; KOVAR PA, 1992, ANN INTERN MED, V116, P529, DOI 10.7326/0003-4819-116-7-529; MACKENZIE T, 1984, NEPHRON, V38, P178, DOI 10.1159/000183304; MECONI M, 1987, J AM GERIATR SOC, V35, P239; MURRAY MD, 1990, ANN INTERN MED, V112, P559, DOI 10.7326/0003-4819-112-8-559; POPE JE, 1993, ARCH INTERN MED, V153, P477, DOI 10.1001/archinte.153.4.477; PSATY BM, 1993, JAMA-J AM MED ASSOC, V270, P1837, DOI 10.1001/jama.270.15.1837; RADACK K, 1987, J GEN INTERN MED, V2, P108, DOI 10.1007/BF02596307; RAY WA, 1993, NEW ENGL J MED, V329, P2029, DOI 10.1056/NEJM199312303292710; Rothman KJ, 1986, MODERN EPIDEMIOLOGY, P84; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; SOUMERAI SB, 1987, NEW ENGL J MED, V317, P550, DOI 10.1056/NEJM198708273170906; STAMLER J, 1991, HYPERTENSION, V18, P95, DOI 10.1161/01.HYP.18.3_Suppl.I95; STOFF JS, 1986, AM J MED, V80, P56, DOI 10.1016/0002-9343(86)90932-0; TAN SY, 1978, PROSTAG OTH LIPID M, V15, P139, DOI 10.1016/S0090-6980(78)80012-4; TRIMARCO B, 1985, AM J CARDIOL, V55, P116, DOI 10.1016/0002-9149(85)90311-X; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x; 1985, SAS USERS GUIDE STAT; 1994, PHYSICIANS DESK REFE; 1992, STAT B METROPOLITAN, V73, P24; 1985, PHYSICIANS DESK REFE; 1985, 3204 US DEP HLTH HUM; 1991, JAMA-J AM MED ASSOC, V265, P3255; 1981, MED LETT DRUGS THER, V23, P1; 1982, MED LETT DRUGS THER, V24, P63	39	158	161	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 14	1994	272	10					781	786		10.1001/jama.272.10.781	http://dx.doi.org/10.1001/jama.272.10.781			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF188	8078142				2022-12-24	WOS:A1994PF18800026
J	DEYOE, EA; FELLEMAN, DJ; VANESSEN, DC; MCCLENDON, E				DEYOE, EA; FELLEMAN, DJ; VANESSEN, DC; MCCLENDON, E			MULTIPLE PROCESSING STREAMS IN OCCIPITOTEMPORAL VISUAL-CORTEX	NATURE			English	Article							MACAQUE MONKEY; AREA V2; ASSOCIATION CORTEX; STRIATE CORTEX; CONNECTIONS; SEGREGATION; ORGANIZATION; COLOR; ANATOMY; FORM	THE earliest stages of cortical visual processing in areas V1 and V2 of the macaque monkey contain internal subdivisions ('blobs' and 'interblobs' in layer 4B in V1; thin, thick and interstripes in V2) that are selectively interconnected and contain neurons with distinctive visual response properties(1-10). Here ae use anatomical pathway tracing to demonstrate that higher visual areas, V4 and the ventral posterior inferotemporal cortex, each contain anatomical subdivisions that have distinct input and output projections. These findings, in conjunction with others(11-15), suggest that modularity and multistream processing within individual cortical areas are widespread features of neocortical organization.	UNIV TEXAS,SCH MED,DEPT NEUROBIOL & ANAT,HOUSTON,TX 77030; CALTECH,DIV BIOL 21676,PASADENA,CA 91125	University of Texas System; California Institute of Technology	DEYOE, EA (corresponding author), MED COLL WISCONSIN,DEPT CELLULAR BIOL & ANAT,8701 WATERTOWN PLANK RD,MILWAUKEE,WI 53226, USA.							BORN RT, 1992, NATURE, V357, P497, DOI 10.1038/357497a0; Desimone R., 1989, HDB NEUROPSYCHOLOGY, P267; DEYOE E A, 1988, Investigative Ophthalmology and Visual Science, V29, P115; DEYOE EA, 1985, NATURE, V317, P58, DOI 10.1038/317058a0; DEYOE EA, 1988, TRENDS NEUROSCI, V11, P219, DOI 10.1016/0166-2236(88)90130-0; DEYOE EA, 1990, VISUAL NEUROSCI, V5, P67, DOI 10.1017/S0952523800000080; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FERRERA VP, 1992, NATURE, V358, P756, DOI 10.1038/358756a0; GOLDMANRAKIC PS, 1982, SCIENCE, V216, P755, DOI 10.1126/science.6177037; GROSSBERG S, 1987, PERCEPT PSYCHOPHYS, V41, P87, DOI 10.3758/BF03204874; HUBEL DH, 1987, J NEUROSCI, V7, P3378; KRUBITZER LA, 1989, BRAIN RES, V478, P161, DOI 10.1016/0006-8993(89)91490-X; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; LIVINGSTONE MS, 1984, J NEUROSCI, V4, P2830; LIVINGSTONE MS, 1984, J NEUROSCI, V4, P309; LUND JS, 1988, ANNU REV NEUROSCI, V11, P253, DOI 10.1146/annurev.ne.11.030188.001345; MALPELI JG, 1981, J NEUROPHYSIOL, V46, P1102, DOI 10.1152/jn.1981.46.5.1102; Maunsell J H, 1992, Curr Opin Neurobiol, V2, P506, DOI 10.1016/0959-4388(92)90188-Q; MAUNSELL JHR, 1987, A REV NEUROSCI, V10, P353; SHIPP S, 1989, EUR J NEUROSCI, V1, P333, DOI 10.1111/j.1460-9568.1989.tb00799.x; SHIPP S, 1985, NATURE, V315, P322, DOI 10.1038/315322a0; TANAKA M, 1990, ANAT EMBRYOL, V181, P19; TOOTELL RBH, 1989, J NEUROSCI, V9, P2620; TSO DY, 1988, J NEUROSCI, V8, P1712; UNGERLEIDER LG, 1986, J COMP NEUROL, V248, P190, DOI 10.1002/cne.902480204; VANESSEN DC, 1982, J NEUROSCI, V2, P265; VANESSEN DC, 1980, J COMP NEUROL, V191, P255, DOI 10.1002/cne.901910208; VANESSEN DC, 1990, COLD SPRING HARB SYM, V55, P679; VANESSEN DC, 1994, COGNITIVE NEUROSCIEN, P383; ZEKI S, 1989, EUR J NEUROSCI, V1, P494, DOI 10.1111/j.1460-9568.1989.tb00356.x	30	138	138	2	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 8	1994	371	6493					151	154		10.1038/371151a0	http://dx.doi.org/10.1038/371151a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF191	8072543				2022-12-24	WOS:A1994PF19100062
J	BREWER, RD; MORRIS, PD; COLE, TB; WATKINS, S; PATETTA, MJ; POPKIN, C				BREWER, RD; MORRIS, PD; COLE, TB; WATKINS, S; PATETTA, MJ; POPKIN, C			THE RISK OF DYING IN ALCOHOL-RELATED AUTOMOBILE CRASHES AMONG HABITUAL DRUNK DRIVERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREVENTION; DRINKING	Background. Reports suggest that people who drive while intoxicated by alcohol may do so repeatedly. We hypothesized that persons arrested for driving while impaired might be at increased risk for death in an alcohol-related motor vehicle crash. To evaluate this possibility, we studied the deaths of drivers in alcohol-related motor vehicle accidents in North Carolina over a 10-year period. Methods. We compared drivers who died in motor vehicle crashes from 1980 through 1989 and who had blood alcohol concentrations of at least 20 mg per deciliter (4.3 mmol per liter), referred to as the case drivers, with those who died in crashes but had blood alcohol concentrations below 20 mg per deciliter, referred to as the control drivers. We identified case drivers and control drivers through the state Medical Examiner System. We then searched North Carolina driver-history. files for the five years before each death to identify arrests for driving while impaired. Results. We linked a total of 1646 case drivers and 1474 control drivers to their driver-history files. Case drivers were more likely than control drivers to have been arrested for driving while impaired (26 percent vs. 3 percent). After we controlled for potential confounding variables, case drivers 21 to 34 years of age were 4.3 times more likely (95 percent confidence interval, 2.7 to 6.8) than control drivers to have been arrested for driving while impaired; case drivers 35 years of age or older were 11.7 times more likely (95 percent confidence interval, 6.8 to 20.1). The strength of the association appeared to increase with the number of prior arrests. Case drivers were also more likely than the general population of currently licensed drivers to have been arrested. Conclusions. Arrests for driving while impaired substantially increase the risk of eventual death in an alcohol-related crash. Aggressive intervention in the cases of people arrested for driving while impaired may decrease the likelihood of a future fatal alcohol-related crash.	CTR DIS CONTROL & PREVENT, DIV FIELD EPIDEMIOL, EPIDEMIOL PROGRAM OFF, EPIDEM INTELLIGENCE SERV, ATLANTA, GA USA; N CAROLINA DEPT ENVIRONM HLTH & NAT RESOURCES, INJURY CONTROL SECT, RALEIGH, NC USA; N CAROLINA DEPT ENVIRONM HLTH & NAT RESOURCES, DIV STAT & INFORMAT SERV, RALEIGH, NC USA; UNIV N CAROLINA, HIGHWAY SAFETY RES CTR, CHAPEL HILL, NC USA	Centers for Disease Control & Prevention - USA; University of North Carolina; University of North Carolina Chapel Hill	BREWER, RD (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR INJURY PREVENT & CONTROL, DIV UNINTENT INJURY PREVENT, ATLANTA, GA 30341 USA.				PHS HHS [H28/CCH401640011] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDREASSON S, 1991, BRIT J ADDICT, V86, P877; ARSTEINKERSLAKE GW, 1985, TYPOLOGICAL ANAL CAL; CLARK CD, 1972, HIT LAB REP, V2, P1; Clark WB, 1991, ALCOHOL AM DRINKING; COLQUITT M, 1987, NEW ENGL J MED, V317, P1262, DOI 10.1056/NEJM198711123172005; DEAN AD, 1991, EPI INFO VERION 5 0; FELL JC, 1989, HEALTH EDUC QUART, V16, P335, DOI 10.1177/109019818901600303; FILKINS LD, 1970, ALCOHOL ABUSE TRAFFI; FINE EW, 1976, ANN NY ACAD SCI, V273, P637, DOI 10.1111/j.1749-6632.1976.tb52938.x; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; MAULL KI, 1984, JAMA-J AM MED ASSOC, V252, P1880, DOI 10.1001/jama.252.14.1880; MAULL KI, 1982, SOUTHERN MED J, V75, P794, DOI 10.1097/00007611-198207000-00005; MOSKOWITZ JM, 1989, J STUD ALCOHOL, V50, P54, DOI 10.15288/jsa.1989.50.54; Richman A, 1985, J Stud Alcohol Suppl, V10, P21; SELZER ML, 1969, BEHAV SCI, V14, P1, DOI 10.1002/bs.3830140102; SHORE ER, 1988, EVAL PROGRAM PLANN, V11, P245, DOI 10.1016/0149-7189(88)90020-1; SLEET DA, 1989, HEALTH EDUC QUART, V16, P329, DOI 10.1177/109019818901600302; SMITH PF, 1989, HEALTH EDUC QUART, V16, P345, DOI 10.1177/109019818901600304; SODERSTROM CA, 1992, JAMA-J AM MED ASSOC, V267, P2756, DOI 10.1001/jama.267.20.2756; STERLINGSMITH RS, 1974, PSYCHOSOCIAL ANAL OP; Vaillant G.E., 1995, WISDOM EGO; 1992, NHTSA23 TECHN TRANSF; 1992, DHHS PHS921232 PUBL; 1989, SAS RELEASE 6 03; 1993, MMWR-MORBID MORTAL W, V42, P905; 1992, STATISTICAL ABSTRACT	26	90	93	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 25	1994	331	8					513	517		10.1056/NEJM199408253310806	http://dx.doi.org/10.1056/NEJM199408253310806			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD072	8041418				2022-12-24	WOS:A1994PD07200006
J	NGUYEN, PV; ABEL, T; KANDEL, ER				NGUYEN, PV; ABEL, T; KANDEL, ER			REQUIREMENT OF A CRITICAL PERIOD OF TRANSCRIPTION FOR INDUCTION OF A LATE-PHASE OF LTP	SCIENCE			English	Article							LONG-TERM POTENTIATION; RABBIT FOLLOWING STIMULATION; NMDA RECEPTOR ACTIVATION; DEPENDENT PROTEIN-KINASE; IMMEDIATE EARLY GENES; SYNAPTIC TRANSMISSION; LASTING POTENTIATION; PERFORANT PATH; MESSENGER-RNA; DENTATE GYRUS	Repeated high-frequency trains of stimuli induce long-term potentiation (LTP) in the CA1 region that persists for up to 8 hours in hippocampal slices and for days in intact animals. This long time course has made LTP an attractive model for certain forms of long-term memory in the mammalian brain. A hallmark of long-term memory in the intact animal is a requirement for transcription, and thus whether the late phase of LTP (L-LTP) requires transcription was investigated here. With the use of different inhibitors, it was found in rat hippocampal slices that the induction of L-LTP [produced either by tetanic stimulation or by application of the cyclic adenosine monophosphate (cAMP) analog Sp-cAMPS (Sp-cyclic adenosine 3',5'-monophosphorothioate)] was selectively prevented when transcription was blocked immediately after tetanization or during application of cAMP. As with behavioral memory, this requirement for transcription had a critical time window, Thus, the late phase of LTP in the CA1 region requires transcription during a critical period, perhaps because cAMP-inducible genes must be expressed during this period.	COLUMBIA UNIV, COLL PHYS & SURG, CTR NEUROBIOL & BEHAV, NEW YORK, NY 10032 USA	Columbia University	NGUYEN, PV (corresponding author), COLUMBIA UNIV, COLL PHYS & SURG, HOWARD HUGHES MED INST, 722 W 168 ST, NEW YORK, NY 10032 USA.		Abel, Ted/AAX-2825-2021	Abel, Ted/0000-0003-2423-4592; Nguyen, Peter/0000-0002-1419-5975	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM032099] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32099] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM WC, 1991, MOL NEUROBIOL, V5, P297, DOI 10.1007/BF02935553; AGRANOFF B, 1970, CHEM MOOD MOTIVATION; ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; ANDERSEN P, 1977, NATURE, V266, P736, DOI 10.1038/266736a0; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P357, DOI 10.1113/jphysiol.1973.sp010274; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; CASTELLUCCI VF, 1988, NEURON, V1, P321, DOI 10.1016/0896-6273(88)90080-3; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; CHETKOVICH DM, 1993, J NEUROCHEM, V61, P1933, DOI 10.1111/j.1471-4159.1993.tb09836.x; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DOUGLAS RM, 1975, BRAIN RES, V86, P205, DOI 10.1016/0006-8993(75)90697-6; DRAGUNOW M, 1989, NEUROSCI LETT, V101, P274, DOI 10.1016/0304-3940(89)90545-4; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; Frey Uwe, 1993, Society for Neuroscience Abstracts, V19, P912; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; Huang Y Y, 1994, Learn Mem, V1, P74; HURWITZ J, 1962, P NATL ACAD SCI USA, V48, P1222, DOI 10.1073/pnas.48.7.1222; JEFFERY KJ, 1990, MOL BRAIN RES, V8, P267, DOI 10.1016/0169-328X(90)90039-G; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; LYNCH GS, 1977, NATURE, V266, P737, DOI 10.1038/266737a0; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MATTHIES H, 1989, PROG NEUROBIOL, V32, P277, DOI 10.1016/0301-0082(89)90024-5; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; OTANI S, 1989, NEUROSCIENCE, V28, P519, DOI 10.1016/0306-4522(89)90001-8; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; RAJU U, 1991, SCIENCE, V253, P673, DOI 10.1126/science.1871602; REICH E, 1961, SCIENCE, V134, P556, DOI 10.1126/science.134.3478.556; REICH E, 1962, P NATL ACAD SCI USA, V48, P1238, DOI 10.1073/pnas.48.7.1238; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; Sobell H M, 1973, Prog Nucleic Acid Res Mol Biol, V13, P153, DOI 10.1016/S0079-6603(08)60103-8; STEWARD O, 1992, TRENDS NEUROSCI, V15, P180, DOI 10.1016/0166-2236(92)90170-D; TAMM I, 1978, ADV VIRUS RES, V22, P188; TEYLER TJ, 1984, BRAIN RES REV, V7, P15, DOI 10.1016/0165-0173(84)90027-4; WORLEY PF, 1993, J NEUROSCI, V13, P4776	45	689	704	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 19	1994	265	5175					1104	1107		10.1126/science.8066450	http://dx.doi.org/10.1126/science.8066450			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC539	8066450				2022-12-24	WOS:A1994PC53900040
J	CHAMBERLAND, ME; PETERSEN, LR; MUNN, VP; WHITE, CR; JOHNSON, ES; BUSCH, MP; GRINDON, AJ; KAMEL, H; NESS, PM; SHAFER, AW; ZEGER, G				CHAMBERLAND, ME; PETERSEN, LR; MUNN, VP; WHITE, CR; JOHNSON, ES; BUSCH, MP; GRINDON, AJ; KAMEL, H; NESS, PM; SHAFER, AW; ZEGER, G			HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION AMONG HEALTH-CARE WORKERS WHO DONATE BLOOD	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS; HEALTH PERSONNEL; BLOOD DONORS; BLOOD BANKS; OCCUPATIONAL EXPOSURE	HIV-INFECTION; MEMBERS	Objective: To estimate the prevalence of human immunodeficiency virus (HIV) infection among health care workers who donate blood. Design: Point prevalence survey of blood donors. Setting: 20 U.S. blood centers that participate in an ongoing interview study of HIV-seropositive blood donors. Measurements: Prevalence rates for HIV in persons who reported being health care workers were measured directly for 6 of the 20 blood centers. For the other 14 centers, we derived the numerator from the interview study in the same manner used for the 6 centers; we estimated the denominator using blood collection logs at those centers and extrapolations from the survey completed at the 6 blood centers. Results: Between March 1990 and August 1991, 8519 health care workers donated blood at 6 hospitals and other medical facilities. Three persons were HIV seropositive: Two reported being health care workers and having nonoccupational risk factors for HIV infection; the occupation and other possible risk factors of the third seropositive donor could not be determined. Therefore, the highest overall prevalence of HIV infection among health care worker donors at these 6 centers was 0.04% (3 of 8519; upper limit of 95% CI, 0.1%). We estimated that during the same period, approximately 36 329 health care workers were tested for HIV at all 20 centers. Twenty-seven persons infected with HIV who donated at hospitals were identified; 7 did not return for interviews, so their health care occupations could not be verified. Thus, the highest estimated overall prevalence of HIV infection among health care worker donors at the 20 centers was 0.07% (27 of 36 329; upper limit of CI, 0.1%). Of the 20 known health care worker donors, 11 reported nonoccupational risks for HIV infection; 3 of the remaining 9 health care workers described occupational blood exposures that could have resulted in transmission of HIV. Conclusions: Blood donors can serve as a sentinel cohort when evaluating the risk for occupationally acquired HIV infection. These findings suggest that among the many health care worker donors in this study, HIV infection attributable to occupational exposure was uncommon.	IRWIN MEM BLOOD CTR, SAN FRANCISCO, CA USA; AMER RED CROSS, ATLANTA, GA USA; AMER RED CROSS, PHILADELPHIA, PA USA; AMER RED CROSS, BALTIMORE, MD USA; AMER RED CROSS, DETROIT, MI USA; UNIV CALIF LOS ANGELES HOSP, LOS ANGELES, CA USA	American Red Cross; American Red Cross; American Red Cross; American Red Cross; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	CHAMBERLAND, ME (corresponding author), CTR DIS CONTROL, HOSP INFECT PROGRAM, 1600 CLIFTON RD, MAILSTOP A-07, ATLANTA, GA 30333 USA.							CHAMBERLAND ME, 1991, JAMA-J AM MED ASSOC, V266, P3459, DOI 10.1001/jama.266.24.3459; CIESIELSKI CA, 1990, NEW ENGL J MED, V322, P1156; COWAN DN, 1991, JAMA-J AM MED ASSOC, V265, P2826, DOI 10.1001/jama.265.21.2826; GRUNINGER SE, 1992, J AM DENT ASSOC, V123, P57, DOI 10.14219/jada.archive.1992.0075; KELLEY PW, 1990, AM J PUBLIC HEALTH, V80, P405, DOI 10.2105/AJPH.80.4.405; KLEIN RS, 1988, NEW ENGL J MED, V318, P86, DOI 10.1056/NEJM198801143180205; PETERSEN LR, 1990, PUBLIC HEALTH REP, V105, P153; PETERSEN LR, 1991, TRANSFUSION, V31, P698, DOI 10.1046/j.1537-2995.1991.31892023493.x; TOKARS JI, 1992, JAMA-J AM MED ASSOC, V268, P489, DOI 10.1001/jama.268.4.489; 1987, MMWR-MORBID M     S2, V36, pS1; 1993, PHS HIVNCID1193036 D; 1992, HIV AIDS SURVEILLANC	12	14	14	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1994	121	4					269	273		10.7326/0003-4819-121-4-199408150-00006	http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB102	8037407				2022-12-24	WOS:A1994PB10200006
J	MANSOUR, SJ; MATTEN, WT; HERMANN, AS; CANDIA, JM; RONG, S; FUKASAWA, K; VANDEWOUDE, GF; AHN, NG				MANSOUR, SJ; MATTEN, WT; HERMANN, AS; CANDIA, JM; RONG, S; FUKASAWA, K; VANDEWOUDE, GF; AHN, NG			TRANSFORMATION OF MAMMALIAN-CELLS BY CONSTITUTIVELY ACTIVE MAP KINASE KINASE	SCIENCE			English	Article							PROTEIN S6 KINASE; GROWTH-FACTOR; SIGNAL-TRANSDUCTION; XENOPUS-OOCYTES; PHOSPHORYLATION; MOS; ACTIVATION; CASCADE; INVITRO; RAS	Mitogen-activated protein (MAP) kinase kinase (MAPKK) activates MAP kinase in a signal transduction pathway that mediates cellular responses to growth and differentiation factors. Oncogenes such as ras, src, raf, and mos have been proposed to transform cells by prolonging the activated state of MAPKK and of components downstream in the signaling pathway. To test this hypothesis, constitutively active MAPKK mutants were designed that had basal activities up to 400 times greater than that of the unphosphorylated wild-type kinase. Expression of these mutants in mammalian cells activated AP-1-regulated transcription. The cells formed transformed foci, grew efficiently in soft agar, and were highly tumorigenic in nude mice. These findings indicate that constitutive activation of MAPKK is sufficient to promote cell transformation.	UNIV COLORADO,HOWARD HUGHES MED INST,DEPT CHEM & BIOCHEM,BOULDER,CO 80309; UNIV COLORADO,DEPT MOLEC CELLULAR & DEV BIOL,BOULDER,CO 80309; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NCI NIH HHS [N01-CO-74101] Funding Source: Medline; NIGMS NIH HHS [GM48521] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048521] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN NG, 1991, J BIOL CHEM, V266, P4220; AHN NG, 1990, J BIOL CHEM, V265, P11487; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BLAIR DG, 1980, P NATL ACAD SCI-BIOL, V77, P3504, DOI 10.1073/pnas.77.6.3504; BLAIR DG, 1986, CELL, V46, P785, DOI 10.1016/0092-8674(86)90354-5; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; FUKASAWA K, IN PRESS CELL GROWTH; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GREGORY JS, 1989, J BIOL CHEM, V264, P18397; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MANSOUR SJ, IN PRESS J BIOCH; MARIAS R, 1993, CELL, V73, P381; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIDA E, 1992, INT REV CYTOL, V138, P211, DOI 10.1016/S0074-7696(08)61589-2; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RESING KA, UNPUB; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; SETH A, 1992, J BIOL CHEM, V267, P24796; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VERLHAC MH, 1994, DEVELOPMENT, V120, P1017; VERON M, 1993, P NATL ACAD SCI USA, V90, P10618, DOI 10.1073/pnas.90.22.10618; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YEW N, 1993, CURR OPIN GENET DEV, V3, P19, DOI 10.1016/S0959-437X(05)80336-3; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	51	1298	1333	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 12	1994	265	5174					966	970		10.1126/science.8052857	http://dx.doi.org/10.1126/science.8052857			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052857				2022-12-24	WOS:A1994PB49900047
J	GALCHEVAGARGOVA, Z; DERIJARD, B; WU, IH; DAVIS, RJ				GALCHEVAGARGOVA, Z; DERIJARD, B; WU, IH; DAVIS, RJ			AN OSMOSENSING SIGNAL-TRANSDUCTION PATHWAY IN MAMMALIAN-CELLS	SCIENCE			English	Article							C-JUN ACTIVITY; ACTIVATION DOMAIN; PHOSPHORYLATION; OSMOREGULATION; KINASE; SERINE-63; YEAST	The osmotic balance between the cytoplasmic and extracellular compartments of cells is critical for the control of cell volume. A mammalian protein kinase, Jnk, which is a distant relative of the mitogen-activated protein kinase group, was activated by phosphorylation on threonine and tyrosine in osmotically shocked cells. The activation of Jnk may be relevant to the biological response to osmotic shock because the expression of human Jnk in the yeast Saccharomyces cerevisiae rescued a defect in growth on hyper-osmolar media. These data indicate that related protein kinases may mediate osmosensing signal transduction in yeast and mammalian cells.	UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,PROGRAM MOLEC MED,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester								ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOGUSLAWSKI G, 1987, P NATL ACAD SCI USA, V84, P5848, DOI 10.1073/pnas.84.16.5848; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; DALLASTA V, 1994, J BIOL CHEM, V269, P10485; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FINKENZELLER G, 1994, FEBS LETT, V340, P163, DOI 10.1016/0014-5793(94)80129-0; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GRINSTEIN S, 1990, ANNU REV PHYSIOL, V52, P399; HAMAMURA M, 1992, BRAIN RES, V572, P42, DOI 10.1016/0006-8993(92)90448-I; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JILL LE, 1987, AM J PHYSIOL, V252, pF1; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; OKADA Y, 1989, NEWS PHYSIOL SCI, V4, P238; PAREDES A, 1992, AM J PHYSIOL, V263, pC1282, DOI 10.1152/ajpcell.1992.263.6.C1282; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; TILLY BC, 1993, J BIOL CHEM, V268, P19919; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C	22	538	556	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 5	1994	265	5173					806	808		10.1126/science.8047888	http://dx.doi.org/10.1126/science.8047888			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	8047888				2022-12-24	WOS:A1994PA37200040
J	HATTORI, M; ADACHI, H; TSUJIMOTO, M; ARAI, H; INOUE, K				HATTORI, M; ADACHI, H; TSUJIMOTO, M; ARAI, H; INOUE, K			MILLER-DIEKER LISSENCEPHALY GENE ENCODES A SUBUNIT OF BRAIN PLATELET-ACTIVATING-FACTOR	NATURE			English	Article							FACTOR ACETYLHYDROLASE; FACTOR PAF; CHROMOSOME-17P13; PURIFICATION; RECEPTOR; REPEATS; CLONES; PCR	PLATELET-ACTIVATING factor (PAF) is involved in a variety of biological and pathological processes(1) and PAF acetylhydrolase, which inactivates PAF by removing the acetyl group at the sn-2 position, is widely distributed in plasma and tissue cytosols(2,3). One isoform of PAP acetylhydrolase present in bovine brain cortex is a heterotrimer comprising subunits with relative molecular masses of 45K, 30K and 29K (ref. 4). We have now isolated the complementary DNA for the 45K subunit. Sequence analysis revealed a striking identity (99%) of the subunit with a protein encoded by the causative gene (LIS-1) for MiUer-Dieker lissencephaly(5), a human brain malformation manifested by a smooth cerebral surface and abnormal neuronal migration. This indicates that the LIS-1 gene product is a human homologue of the 45K subunit of intracellular PAF acetylhydrolase. Our results raise the possibility that PAF and PAF acetylhydrolase are important in the formation of the brain cortex during differentiation and development.	SUNTORY INST BIOMED RES,MISHIMA 618,OSAKA,JAPAN	Suntory Holdings Ltd	HATTORI, M (corresponding author), UNIV TOKYO,FAC PHARMACEUT SCI,DEPT HLTH CHEM,BUNKYO KU,TOKYO 113,JAPAN.		Hattori, Mitsuharu/F-3859-2010	Hattori, Mitsuharu/0000-0002-0503-4969				BITO H, 1992, NEURON, V9, P285, DOI 10.1016/0896-6273(92)90167-C; CATALAN RE, 1992, BIOCHEM BIOPH RES CO, V183, P300, DOI 10.1016/0006-291X(92)91643-5; DOBYNS WB, 1993, JAMA-J AM MED ASSOC, V270, P2838, DOI 10.1001/jama.270.23.2838; DYNLACHT BD, 1993, NATURE, V363, P176, DOI 10.1038/363176a0; FARR RS, 1980, CLIN IMMUNOL IMMUNOP, V15, P318, DOI 10.1016/0090-1229(80)90044-6; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; ISOLA NR, 1991, BIOTECHNIQUES, V11, P580; KATO K, 1994, NATURE, V367, P175, DOI 10.1038/367175a0; KORNECKI E, 1988, SCIENCE, V240, P1792, DOI 10.1126/science.3381103; KWIATKOWSKI TJ, 1990, NUCLEIC ACIDS RES, V18, P7191, DOI 10.1093/nar/18.23.7191; LEDBETTER SA, 1992, AM J HUM GENET, V50, P182; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SOGOS V, 1990, J NEUROSCI RES, V27, P706, DOI 10.1002/jnr.490270431; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4223; VANDERNVOORN L, 1992, FEBS LETT, V507, P131	18	434	443	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 21	1994	370	6486					216	218		10.1038/370216a0	http://dx.doi.org/10.1038/370216a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX971	8028668				2022-12-24	WOS:A1994NX97100052
J	OSWALD, H; PHELAN, PD; LANIGAN, A; HIBBERT, M; BOWES, G; OLINSKY, A				OSWALD, H; PHELAN, PD; LANIGAN, A; HIBBERT, M; BOWES, G; OLINSKY, A			OUTCOME OF CHILDHOOD ASTHMA IN MID-ADULT LIFE	BRITISH MEDICAL JOURNAL			English	Article									UNIV MELBOURNE,ROYAL CHILDRENS HOSP,DEPT PAEDIAT,PARKVILLE,VIC 3052,AUSTRALIA; ROYAL CHILDRENS HOSP,DEPT THORAC MED,MELBOURNE,VIC,AUSTRALIA; ROYAL CHILDRENS HOSP,CTR ADOLESCENT HLTH,MELBOURNE,VIC,AUSTRALIA; UNIV MELBOURNE,DEPT PAEDIAT,MELBOURNE,VIC,AUSTRALIA	Royal Children's Hospital Melbourne; University of Melbourne; Royal Children's Hospital Melbourne; Royal Children's Hospital Melbourne; University of Melbourne								KELLY WJW, 1987, BRIT MED J, V294, P1059, DOI 10.1136/bmj.294.6579.1059; MARTIN AJ, 1980, BRIT MED J, V280, P1397, DOI 10.1136/bmj.280.6229.1397; MCNICOL KN, 1973, BRIT MED J, V4, P7, DOI 10.1136/bmj.4.5883.7; WILLIAMS H, 1969, BRIT MED J, V4, P321, DOI 10.1136/bmj.4.5679.321	4	100	102	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					95	96		10.1136/bmj.309.6947.95	http://dx.doi.org/10.1136/bmj.309.6947.95			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038676	Green Published			2022-12-24	WOS:A1994NW71600019
J	HIRSCHMANN, R; SMITH, AB; TAYLOR, CM; BENKOVIC, PA; TAYLOR, SD; YAGER, KM; SPRENGELER, PA; BENKOVIC, SJ				HIRSCHMANN, R; SMITH, AB; TAYLOR, CM; BENKOVIC, PA; TAYLOR, SD; YAGER, KM; SPRENGELER, PA; BENKOVIC, SJ			PEPTIDE-SYNTHESIS CATALYZED BY AN ANTIBODY CONTAINING A BINDING-SITE FOR VARIABLE AMINO-ACIDS	SCIENCE			English	Article							REACTIVITY	Monoclonal antibodies, induced with a phosphonate diester hapten, catalyzed the coupling of p-nitrophenyl esters of N-acetyl valine, leucine, and phenylalanine with tryptophan amide to form the corresponding dipeptides. All possible stereoisomeric combinations of the ester and amide substrates were coupled at comparable rates. The antibodies did not catalyze the hydrolysis of the dipeptide product nor hydrolysis or racemization of the activated esters. The yields of the dipeptides ranged from 44 to 94 percent. The antibodies were capable of multiple turnovers at rates that exceeded the rate of spontaneous ester hydrolysis. This achievement suggests routes toward creating a small number of antibody catalysts for polypeptide syntheses.	UNIV PENN,MONELL CHEM SENSES CTR,DEPT CHEM,RES STRUCT MATTER LAB,PHILADELPHIA,PA 19104; PENN STATE UNIV,DEPT CHEM,UNIV PK,PA 16802	Monell Chemical Senses Center; University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University	HIRSCHMANN, R (corresponding author), UNIV PENN,DEPT CHEM,PHILADELPHIA,PA 19104, USA.		Taylor, Carol/B-4841-2012	Taylor, Carol/0000-0002-6262-0796	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045611] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-45611] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAHMSER L, 1991, BIOCHEMISTRY-US, V30, P4151; AREVALO JH, 1993, NATURE, V365, P859, DOI 10.1038/365859a0; BENKOVIC SJ, 1992, ANNU REV BIOCHEM, V61, P29; BENOITON NL, 1983, PEPTIDES, V5, pCH4; COCHRAN AG, 1991, J AM CHEM SOC, V113, P6670, DOI 10.1021/ja00017a046; FERSHT AR, 1970, J AM CHEM SOC, V92, P5442, DOI 10.1021/ja00721a024; GREEN BS, 1991, CATALYTIC ANTIBODIES, V159, P139; GUTTE B, 1969, J AM CHEM SOC, V91, P501, DOI 10.1021/ja01030a050; HEARD AL, 1963, J CHEM SOC, V1963, P5807; HIRSCHMANN R, 1969, J AM CHEM SOC, V91, P509; HIRSCHMANN R, UNPUB; HOEGER C, 1989, J CHROMATOGR, V404, P307; JACOBSEN JR, 1992, SCIENCE, V256, P365, DOI 10.1126/science.256.5055.365; Jakubke HD., 1987, PEPTIDES ANAL SYNTHE, V9, P103; KAISER ET, 1989, SCIENCE, V243, P187, DOI 10.1126/science.2492114; KIRBY DA, 1993, J CHROMATOGR, V648, P257, DOI 10.1016/0021-9673(93)83309-G; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MOULT J, 1976, J MOL BIOL, V74, P137; NAPPER AD, 1987, SCIENCE, V237, P1041, DOI 10.1126/science.3616626; RIVIER JE, 1978, J LIQ CHROMATOGR, V1, P343, DOI 10.1080/01483917808060004; SCHULTZ PG, 1989, ANGEW CHEM INT EDIT, V28, P1283, DOI 10.1002/anie.198912833; SCHWYZER R, 1966, HELV CHIM ACTA, V49, P134, DOI 10.1002/hlca.660490120; SIEPKE G, 1986, ANGEW CHEM INT EDIT, V25, P535; STANFIELD RL, 1993, STRUCTURE, V1, P83, DOI 10.1016/0969-2126(93)90024-B; STEWART JD, 1993, CHEM SOC REV, V22, P213, DOI 10.1039/cs9932200213	27	395	405	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 8	1994	265	5169					234	237		10.1126/science.8023141	http://dx.doi.org/10.1126/science.8023141			4	Multidisciplinary Sciences	Current Chemical Reactions (CCR-EXPANDED); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV957	8023141				2022-12-24	WOS:A1994NV95700037
J	SATO, H; TAKINO, T; OKADA, Y; CAO, J; SHINAGAWA, A; YAMAMOTO, E; SEIKI, M				SATO, H; TAKINO, T; OKADA, Y; CAO, J; SHINAGAWA, A; YAMAMOTO, E; SEIKI, M			A MATRIX METALLOPROTEINASE EXPRESSED ON THE SURFACE OF INVASIVE TUMOR-CELLS	NATURE			English	Article							IV COLLAGENASE; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR; ACTIVATION; FIBROBLASTS; GELATINASE; ASSOCIATION; METASTASIS; CARCINOMA; PRECURSOR	GELATINASE A (type-IV collagenase; M(r) 72,000) is produced by tumour stroma cells and is believed to be crucial for their invasion and metastasis, acting by degrading extracellular matrix macromolecules such as type IV collagen(1-3). An inactive precursor of gelatinase A (pro-gelatinase A) is secreted and activated in invasive tumour tissue(4-7) as a result of proteolysis which is mediated by a fraction of tumour cell membrane that is sensitive to metalloproteinase inhibitors(4,5). Here we report the cloning of the complementary DNA encoding a new matrix metalloproteinase with a potential transmembrane domain. Expression of the gene product on the cell surface induces specific activation of pro-gelatinase A in vitro and enhances cellular invasion of the reconstituted basement membrane. Tumour cells of invasive lung carcinomas, which contain activated forms of gelatinase A, were found to express the transcript and the gene product. The new metalloproteinase may thus trigger invasion by tumour cells by activating pro-gelatinase A on the tumour cell surface.	KANAZAWA UNIV,CANC RES INST,DEPT MOLEC VIROL & ONCOL,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,SCH MED,DEPT ORAL SURG,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,SCH MED,DEPT PATHOL,KANAZAWA,ISHIKAWA 920,JAPAN; FUJI CHEM IND CO LTD,RES INST,DEPT BIOCHEM,TAKAOKA,TOYAMA 933,JAPAN	Kanazawa University; Kanazawa University; Kanazawa University			SATO, Hiroshi/D-8454-2015; TAKINO, Takahisa/D-8460-2015; Seiki, Motoharu/K-9443-2015; Okada, Yasunori/B-5550-2014	Okada, Yasunori/0000-0001-9208-4755				ALBINI A, 1987, CANCER RES, V47, P3239; AZZAM HS, 1992, CANCER RES, V52, P4540; AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BROWN PD, 1990, CANCER RES, V50, P6184; BROWN PD, 1993, J NATL CANCER I, V85, P574, DOI 10.1093/jnci/85.7.574; BROWN PD, 1993, CLIN EXP METASTAS, V11, P183, DOI 10.1007/BF00114976; BROWN PD, 1993, KIDNEY INT, V43, P163, DOI 10.1038/ki.1993.27; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; JIANG WP, 1992, FEBS LETT, V312, P110, DOI 10.1016/0014-5793(92)80916-5; Kleiner DE, 1993, CURR OPIN CELL BIOL, V5, P891, DOI 10.1016/0955-0674(93)90040-W; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Matrisian L M, 1990, Semin Cancer Biol, V1, P107; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; POULSOM R, 1992, AM J PATHOL, V141, P389; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TEMPLETON NS, 1990, CANCER RES, V50, P5431; TRYGGVASON K, 1993, BREAST CANCER RES TR, V24, P209, DOI 10.1007/BF01833261; TSUCHIYA Y, 1993, CANCER RES, V53, P1397; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	30	2349	2440	5	107	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 7	1994	370	6484					61	65		10.1038/370061a0	http://dx.doi.org/10.1038/370061a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV711	8015608				2022-12-24	WOS:A1994NV71100059
J	VARTIAINEN, E; PUSKA, P; PEKKANEN, J; TUOMILEHTO, J; JOUSILAHTI, P				VARTIAINEN, E; PUSKA, P; PEKKANEN, J; TUOMILEHTO, J; JOUSILAHTI, P			CHANGES IN RISK-FACTORS EXPLAIN CHANGES IN MORTALITY FROM ISCHEMIC-HEART-DISEASE IN FINLAND	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NORTH-KARELIA; DECLINE	Objective-To estimate the extent to which changes in the main coronary risk factors (serum cholesterol concentration, blood pressure, and smoking) explain the decline in mortality from ischaemic heart disease and to evaluate the relative importance of change in each of these risk factors. Design-Predicted changes in ischaemic heart disease mortality were calculated by a logistic regression model using the risk factor levels assessed by cross sectional population surveys, in 1972, 1977, 1982, 1987, and 1992. These predicted changes were compared with observed changes in mortality statistics. Setting-North Karelia and Kuopio provinces, Finland. Subjects-14257 men and 14786 women aged 30-59 randomly selected from the national population register. Main outcome measures-Levels of the risk factors and predicted and observed changes in mortality from ischaemic heart disease. Results-The observed changes in the risk factors in the population from 1972 to 1992 predicted a decline in mortality from ischaemic heart disease of 44% (95% confidence interval 37% to 50%) in men and 49% (37% to 59%) in women. The observed decline was 55% (51% to 58%) and 68% (61 to 74) respectively. Conclusion-An assessment of the data on the risk factors for ischaemic heart disease and mortality suggests that most of the decline in mortality from ischaemic heart disease can be explained by changes in the three main coronary risk factors.			VARTIAINEN, E (corresponding author), NATL PUBL HLTH INST, DEPT EPIDEMIOL & HLTH PROMOT, MANNERHEIMINTIE 166, SF-00300 HELSINKI, FINLAND.							ALROOMI KA, 1989, AM J EPIDEMIOL, V129, P503, DOI 10.1093/oxfordjournals.aje.a115161; DWYER T, 1980, INT J EPIDEMIOL, V9, P65, DOI 10.1093/ije/9.1.65; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; JACKSON R, 1987, INT J EPIDEMIOL, V16, P377, DOI 10.1093/ije/16.3.377; NICOLOSI A, 1988, INT J EPIDEMIOL, V17, P766, DOI 10.1093/ije/17.4.766; Ovcarov V K, 1978, World Health Stat Q, V31, P208; PIETINEN P, 1990, LIPIDS HLTH; PUSKA P, 1985, ANNU REV PUBL HEALTH, V6, P147, DOI 10.1146/annurev.pu.06.050185.001051; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; SALONEN JT, 1979, BRIT MED J, V2, P1178, DOI 10.1136/bmj.2.6199.1178; SIGFUSSON N, 1991, BRIT MED J, V302, P1371, DOI 10.1136/bmj.302.6789.1371; SYTKOWSKI PA, 1990, NEW ENGL J MED, V322, P1635, DOI 10.1056/NEJM199006073222304; TAO SC, 1989, INT J EPIDEMIOL, V18, pS159; TUOMILEHTO J, 1986, BRIT MED J, V293, P1068, DOI 10.1136/bmj.293.6554.1068; Uemura K, 1985, World Health Stat Q, V38, P142; UESHIMA H, 1987, AM J EPIDEMIOL, V125, P62, DOI 10.1093/oxfordjournals.aje.a114512; VARTIAINEN E, 1991, INT J EPIDEMIOL, V20, P651, DOI 10.1093/ije/20.3.651; *WHO MONICA PROJ P, 1988, J CLIN EPIDEMIOL, V41, P105, DOI [DOI 10.1016/0895-4356(88)90084-4, 10.1016/0895-4356(88)90084-4]; 1992, MINISTRY AGR FORESTR, V11; 1987, AM J EPIDEMIOL, V1, P95	20	344	351	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 2	1994	309	6946					23	27		10.1136/bmj.309.6946.23	http://dx.doi.org/10.1136/bmj.309.6946.23			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV891	8044063	Green Published			2022-12-24	WOS:A1994NV89100019
J	WARD, BJ; TATE, PA				WARD, BJ; TATE, PA			ATTITUDES AMONG NHS DOCTORS TO REQUESTS FOR EUTHANASIA	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To explore NHS doctors' attitudes to competent patients' requests for euthanasia and to estimate the proportion of doctors who have taken active steps to hasten a patient's death. Design-Anonymous postal questionnaire, with no possibility of follow up. The survey was conducted from December 1992 to March 1993. Subjects-All (221) general practitioners and 203 hospital consultants in one area of England. Results-273 doctors responded to a question on whether a patient had ever asked them to hasten death. Of these, 163 had been asked to; 124 of these had been asked to take active steps to hasten death; 38 of 119 (32%) of these had complied with such a request (95% confidence interval 23% to 40%). This proportion represented 12% of all those who returned a completed questionnaire and 9% of all those who had been sent a questionnaire (95% confidence interval 6.3% to 11.7%). A larger proportion of the respondents (142/307 (46%)), however, would consider taking active steps to bring about the death of a patient if it was legal to do so. Conclusions-Many doctors face difficult decisions about euthanasia. For the benefit of both patients and doctors euthanasia should be discussed more openly.	UNIV CAMBRIDGE,DEPT ANAT,CAMBRIDGE CB2 3DY,ENGLAND	University of Cambridge								KUHSE H, 1988, MED J AUSTRALIA, V148, P623, DOI 10.5694/j.1326-5377.1988.tb116334.x; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; VANDERWAL G, 1992, FAM PRACT, V9, P130, DOI 10.1093/fampra/9.2.130; 1988, BRIT MED J, V296, P1376; 1987, ATTITUDES EUTHANASIA	5	112	113	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 21	1994	308	6940					1332	1334		10.1136/bmj.308.6940.1332	http://dx.doi.org/10.1136/bmj.308.6940.1332			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM989	8019219	Green Published			2022-12-24	WOS:A1994NM98900020
J	NICHOL, KL; MARGOLIS, KL; WUORENMA, J; VONSTERNBERG, T				NICHOL, KL; MARGOLIS, KL; WUORENMA, J; VONSTERNBERG, T			THE EFFICACY AND COST-EFFECTIVENESS OF VACCINATION AGAINST INFLUENZA AMONG ELDERLY PERSONS LIVING IN THE COMMUNITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE RESPIRATORY-DISEASE; UNITED-STATES; NURSING-HOME; A H3N2; EPIDEMICS; MORTALITY; PNEUMONIA; IMPACT; IMMUNIZATION; ASSOCIATION	Background. Despite recommendations for annual vaccination against influenza, more than half of elderly Americans do not receive this vaccine. In a serial cohort study, we assessed the efficacy and cost effectiveness of influenza vaccine administered to older persons living in the community. Methods. Using administrative data bases, we studied men and women over 64 years of age who were enrolled in a large health maintenance organization in the Minneapolis-St. Paul area. We examined the rate of vaccination and the occurrence of influenza and its complications in each of three seasons: 1990-1991, 1991-1992, and 1992-1993. Outcomes were adjusted for age, sex, diagnoses indicating a high risk, use of medications, and previous use of health care services. Results. Each cohort included more than 25,000 persons 65 years of age or older. Immunization rates ranged from 45 percent to 58 percent. Although the vaccine recipients had more coexisting illnesses at base line than those who did not receive the vaccine, during each influenza season vaccination was associated with a reduction in the rate of hospitalization for pneumonia and influenza (by 48 to 57 percent, P less than or equal to 0.002) and for all acute and chronic respiratory conditions (by 27 to 39 percent, P less than or equal to 0.01). Vaccination was also associated with a 37 percent reduction (P = 0.04) in the rate of hospitalization for congestive heart failure during the 1991-1992 season, when influenza A was epidemic. The costs of hospitalization for all types of illness studied were lower in the vaccinated group during 1991-1992 (range of reduction, 47 to 66 percent; P<0.005) and for acute and chronic respiratory conditions and congestive heart failure in 1990-1991 (reductions of 37 percent and 43 percent, respectively; P less than or equal to 0.05). Direct savings per year averaged $117 per person vaccinated (range, $21 to $235), with cumulative savings of nearly $5 million. Vaccination was also associated with reductions of 39 to 54 percent in mortality from all causes during the three influenza seasons (P<0.001). Conclusions. For elderly citizens living in the community, vaccination against influenza is associated with reductions in the rate of hospitalization and in deaths from influenza and its complications, as compared with the rates in unvaccinated elderly persons, and vaccination produces direct dollar savings.	HENNEPIN CTY MED CTR, MINNEAPOLIS, MN USA; GRP HLTH INC, MINNEAPOLIS, MN USA	Hennepin County Medical Center	NICHOL, KL (corresponding author), VET AFFAIRS MED CTR, GEN INTERNAL MED SECT, 1 VET DR, MINNEAPOLIS, MN 55417 USA.			Margolis, Karen/0000-0003-1862-7402				[Anonymous], 1994, MMWR Recomm Rep, V43, P1; ARDEN NH, 1988, ARCH INTERN MED, V148, P865, DOI 10.1001/archinte.148.4.865; BARKER W, 1993, OPTIONS CONTROL INFL, V2, P143; BARKER WH, 1982, ARCH INTERN MED, V142, P85, DOI 10.1001/archinte.142.1.85; BLACKWELDER WC, 1982, AM REV RESPIR DIS, V125, P511, DOI 10.1164/arrd.1982.125.5.511; EDMONDSON WP, 1971, AM J EPIDEMIOL, V93, P480, DOI 10.1093/oxfordjournals.aje.a121282; Fedson D S, 1992, Clin Geriatr Med, V8, P183; FEDSON DS, 1993, JAMA-J AM MED ASSOC, V270, P1956, DOI 10.1001/jama.270.16.1956; FEDSON DS, 1992, ANN INTERN MED, V116, P550, DOI 10.7326/0003-4819-116-7-550; FOSTER DA, 1992, AM J EPIDEMIOL, V136, P296, DOI 10.1093/oxfordjournals.aje.a116495; GLEZEN WP, 1987, AM REV RESPIR DIS, V136, P550, DOI 10.1164/ajrccm/136.3.550; GLEZEN WP, 1982, EPIDEMIOL REV, V4, P25, DOI 10.1093/oxfordjournals.epirev.a036250; GROSS PA, 1988, ARCH INTERN MED, V148, P562, DOI 10.1001/archinte.148.3.562; HELLIWELL BE, 1988, CAN J PUBLIC HEALTH, V79, P175; IEZZONI LI, 1994, RISK ADJUSTMENT MEAS, P1; LUI KJ, 1987, AM J PUBLIC HEALTH, V77, P712, DOI 10.2105/AJPH.77.6.712; MARGOLIS KL, 1992, J AM GERIATR SOC, V40, P1021, DOI 10.1111/j.1532-5415.1992.tb04480.x; MAUCHER JM, 1990, AGE, V13, P81, DOI 10.1007/BF02432385; MCBEAN AM, 1993, ARCH INTERN MED, V153, P2105, DOI 10.1001/archinte.153.18.2105; MULLOOLY J, 1993, EXCERPTA MED, V2, P53; PATRIARCA PA, 1985, JAMA-J AM MED ASSOC, V253, P1136, DOI 10.1001/jama.253.8.1136; PAUL WS, 1988, J INFECT DIS, V157, P633, DOI 10.1093/infdis/157.4.633; PERROTTA DM, 1985, AM J EPIDEMIOL, V122, P468, DOI 10.1093/oxfordjournals.aje.a114128; RIDDIOUGH MA, 1983, JAMA-J AM MED ASSOC, V249, P3189; RUSSELL LB, 1992, HEALTH AFFAIR, V11, P162, DOI 10.1377/hlthaff.11.2.162; SAAH AJ, 1986, ARCH INTERN MED, V146, P2353, DOI 10.1001/archinte.146.12.2353; SACKETT DL, 1985, CLIN EPIDEMIOLOGY BA, P285; SCHOENBA.SC, 1969, B WORLD HEALTH ORGAN, V41, P531; STRASSBURG MA, 1986, VACCINE, V4, P38, DOI 10.1016/S0264-410X(86)80002-0; STRIKAS R, 1993, EXCERPTA MED, P153; STUART WH, 1969, J AMER MED ASSOC, V209, P232, DOI 10.1001/jama.209.2.232; WILLIAMS WW, 1988, ANN INTERN MED, V108, P616, DOI 10.7326/0003-4819-108-4-616; WILLIAMS WW, 1988, ANN INTERN MED, V109, P348, DOI 10.7326/0003-4819-109-4-348_2; 1989, GUIDE CLIN PREVENTIV, P363; 1990, MMWR-MORBID MORTAL W, V39, P165; 1990, DIS CONTROL NEWSL, V19, P33; 1979, CAN MED ASS J, V121, P1193; 1993, MMWR-MORBID MORTAL W, V42, P385; 1990, MMWR-MORBID MORTAL W, V39, P204; 1993, MMWR-MORBID MORTAL W, V42, P601; 1994, GUIDE ADULT IMMUNIZA, P21; 1993, MMWR-MORBID MORTAL W, V42, P768; 1993, DIS CONTROL NEWSL, V21, P37; 1981, COST EFFECTIVENESS I; 1992, DIS CONTROL NEWSL, V20, P33; 1990, MMWR-MORBID MORTAL W, V39, P159	46	769	792	1	54	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 22	1994	331	12					778	784		10.1056/NEJM199409223311206	http://dx.doi.org/10.1056/NEJM199409223311206			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG301	8065407				2022-12-24	WOS:A1994PG30100006
J	DOYLE, MP				DOYLE, MP			COOKING WITH SALMONELLA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											DOYLE, MP (corresponding author), UNIV GEORGIA,CTR FOOD SAFETY & QUAL ENHANCEMENT,GRIFFIN,GA, USA.							COTTERILL JO, 1973, POULTRY SCI, V52, P568; HUMPHREY TJ, 1990, EPIDEMIOL INFECT, V104, P237, DOI 10.1017/S0950268800059409; RODIGUE DC, 1990, EPIDEMIOL INFECT, V105, P21; STLOUIS ME, 1988, JAMA-J AM MED ASSOC, V259, P2103, DOI 10.1001/jama.259.14.2103	4	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 21	1994	272	11					895	895						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG182	8078170				2022-12-24	WOS:A1994PG18200032
J	FREED, E; SYMONS, M; MACDONALD, SG; MCCORMICK, F; RUGGIERI, R				FREED, E; SYMONS, M; MACDONALD, SG; MCCORMICK, F; RUGGIERI, R			BINDING OF 14-3-3-PROTEINS TO THE PROTEIN-KINASE RAF AND EFFECTS ON ITS ACTIVATION	SCIENCE			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE; GROWTH-FACTOR; GENE-PRODUCT; IN-VITRO; IDENTIFICATION; P21(RAS); FAMILY; CELLS; TRANSFORMATION	To identify proteins that may participate in the activation of the protein kinase Raf, proteins that interact with Raf were selected in a two-hybrid screen. Two members of the 14-3-3 protein family were isolated that interacted with both the amino terminal regulatory regions of Raf and the kinase domain of Raf, but did not compete with the guanine nucleotide-binding protein Ras for binding to Raf. 14-3-3 proteins associated with Raf in mammalian cells and accompanied Raf to the membrane in the presence of activated Ras. in yeast cells expressing Raf and MEK, mammalian 14-3-3 beta or 14-3-3 zeta activated Raf to a similar extent as did expression of Ras. Therefore, 14-3-3 proteins may participate in or be required for the regulation of Raf function. These findings suggest a role for 14-3-3 proteins in Raf-mediated signal transduction.			FREED, E (corresponding author), ONYX PHARMACEUT,RICHMOND,CA 94806, USA.							AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; BRASELMANN S, UNPUB; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; ERREDE B, 1989, GENE DEV, V3, P1349, DOI 10.1101/gad.3.9.1349; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FREED EO, UNPUB; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; ICHIMURA T, 1991, J NEUROCHEM, V56, P1449, DOI 10.1111/j.1471-4159.1991.tb11446.x; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; KIZAKAKONDOH S, 1992, MOL CELL BIOL, V12, P5078, DOI 10.1128/MCB.12.11.5078; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEFFERS H, 1993, J MOL BIOL, V231, P982, DOI 10.1006/jmbi.1993.1346; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MACDONALD SG, UNPUB; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1991, J BIOL CHEM, V266, P14866; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUGGIERI R, 1992, MOL CELL BIOL, V12, P758, DOI 10.1128/MCB.12.2.758; Ruggieri R., UNPUB; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SYMONS MCR, UNPUB; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRAVERSE S, 1993, ONCOGENE, V8, P3175; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VANAELST L, COMMUNICATION; VANHEUSDEN GPH, 1992, FEBS LETT, V302, P145, DOI 10.1016/0014-5793(92)80426-H; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YASHAR B, UNPUB; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZUPAN LA, 1992, J BIOL CHEM, V267, P8707	54	384	398	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 16	1994	265	5179					1713	1716		10.1126/science.8085158	http://dx.doi.org/10.1126/science.8085158			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG284	8085158				2022-12-24	WOS:A1994PG28400032
J	TREIER, M; STASZEWSKI, LM; BOHMANN, D				TREIER, M; STASZEWSKI, LM; BOHMANN, D			UBIQUITIN-DEPENDENT C-JUN DEGRADATION IN-VIVO IS MEDIATED BY THE DELTA-DOMAIN	CELL			English	Article							METAL CHELATE ADSORBENT; CELL-SPECIFIC INHIBITOR; SHORT-LIVED PROTEIN; TRANSCRIPTIONAL ACTIVATION; FOS PROTEIN; V-JUN; ONCOGENE; AP-1; TRANSFORMATION; SEQUENCES	The role of the ubiquitin-dependent proteolysis system in c-Jun breakdown was investigated. Using in vitro experiments and a novel in vivo assay that utilizes molecularly-tagged ubiquitin and c-Jun proteins, it was shown that c-Jun, but not its transforming counterpart, retroviral v-Jun, can be efficiently multiubiquitinated. Consistently, v-Jun has a longer half-life than c-Jun. Mutagenesis experiments indicate that the reason for the escape of v-Jun from multiubiquitination and its resulting stabilization is the deletion of the delta domain, a stretch of 27 amino acids that is present in c-Jun but not in v-Jun. c-Jun sequences containing the delta domain, when transferred to the bacterial beta-galactosidase protein, function as a cis-acting ubiquitination and degradation signal. The correlation between transforming ability and the escape from ubiquitin-dependent degradation described here suggests a novel route to oncogenesis.			TREIER, M (corresponding author), EUROPEAN MOLEC BIOL LAB,DIFFERENTIAT PROGRAMME,D-69012 HEIDELBERG,GERMANY.		Treier, Mathias/AAD-6388-2021					ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; BAICHWAL VR, 1992, GENE DEV, V6, P1493, DOI 10.1101/gad.6.8.1493; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; COHN SL, 1990, ONCOGENE, V5, P1821; Curran T, 1988, ONCOGENE HDB, P307; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; Hochstrasser Mark, 1992, Current Opinion in Cell Biology, V4, P1024, DOI 10.1016/0955-0674(92)90135-Y; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; JENTSCH S, 1992, ANNU REV GENET, V26, P177; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KELLERMAN KA, 1990, GENE DEV, V4, P1936, DOI 10.1101/gad.4.11.1936; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LEVINGER L, 1982, CELL, V28, P375, DOI 10.1016/0092-8674(82)90355-5; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MORGAN IM, 1993, ONCOGENE, V8, P1135; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; TEBB G, 1993, GENE DEV, V7, P517, DOI 10.1101/gad.7.3.517; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5	45	847	871	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 9	1994	78	5					787	798		10.1016/S0092-8674(94)90502-9	http://dx.doi.org/10.1016/S0092-8674(94)90502-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PG296	8087846				2022-12-24	WOS:A1994PG29600008
J	LEHMING, N; THANOS, D; BRICKMAN, JM; MA, J; MANIATIS, T; PTASHNE, M				LEHMING, N; THANOS, D; BRICKMAN, JM; MA, J; MANIATIS, T; PTASHNE, M			AN HMG-LIKE PROTEIN THAT CAN SWITCH A TRANSCRIPTIONAL ACTIVATOR TO A REPRESSOR	NATURE			English	Article							BETA-INTERFERON GENE; DORSOVENTRAL PATTERN; DORSAL MORPHOGEN; DROSOPHILA; ENHANCER; SILENCER; CONVERSION; PROMOTERS; ELEMENTS; CACTUS	ONE protein can activate some genes and repress others in the same cell(1). The Drosophila protein Dorsal(2) (which, like the human protein NF-kappa B-3, is a member of the Rel family of transcriptional activators) activates the twist gene and represses the zen gene in the ventral region of early embryos(4,5). Here we describe a Drosophila HMG1 protein, called DSP1 (dorsal switch protein), that converts Dorsal and NF-kappa B from transcriptional activators to repressors. This effect requires a sequence termed a negative regulatory element (NRE), found adjacent to Dorsal-binding sites in the zen promoter and adjacent to the NF-kappa B-binding site in the human interferon-beta (IFN-beta) enhancer(6-8). Previous studies have shown that another type of HMG protein, HMG I(Y), can stimulate NF-kappa B activity(9). Thus, the HMG-like proteins DSP1 and HMG I(Y) can determine whether a specific regulator functions as an activator or a repressor of transcription.			LEHMING, N (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,7 DIVIN AVE,CAMBRIDGE,MA 02138, USA.		Thanos, Dimitris/AAE-5720-2019; Ma, Jun/GLT-4809-2022	Ma, Jun/0000-0002-1609-3294; Brickman, Joshua/0000-0003-1580-7491				BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; DOYLE HJ, 1989, GENE DEV, V3, P1518, DOI 10.1101/gad.3.10.1518; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GOODBOURN S, 1986, CELL, V45, P601, DOI 10.1016/0092-8674(86)90292-8; GOODBOURN S, 1988, P NATL ACAD SCI USA, V85, P1447, DOI 10.1073/pnas.85.5.1447; GRILLI M, 1993, INT REV CYTOL, V143, P1; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; IP YT, 1991, CELL, V64, P439; JIANG J, 1993, EMBO J, V12, P3201, DOI 10.1002/j.1460-2075.1993.tb05989.x; Johnson A. A, 1992, TRANSCRIPTIONAL REGU, P975; KAMENS J, 1991, NEW BIOL, V3, P1005; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KING CY, 1993, P NATL ACAD SCI USA, V90, P1190; KIROV N, 1993, EMBO J, V12, P3193, DOI 10.1002/j.1460-2075.1993.tb05988.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; NOURBAKHSH M, 1993, EMBO J, V12, P451, DOI 10.1002/j.1460-2075.1993.tb05677.x; PTASHNE M, 1992, GENETIC SWITCH GENE; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUSHLOW CA, 1989, CELL, V59, P1165, DOI 10.1016/0092-8674(89)90772-1; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; THANOS D, 1993, COLD SPRING HARB SYM, V58, P73, DOI 10.1101/SQB.1993.058.01.011; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P	31	206	212	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 8	1994	371	6493					175	179		10.1038/371175a0	http://dx.doi.org/10.1038/371175a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF191	8072548				2022-12-24	WOS:A1994PF19100069
J	LILFORD, R; JONES, AM; BISHOP, DT; THORNTON, J; MUELLER, R				LILFORD, R; JONES, AM; BISHOP, DT; THORNTON, J; MUELLER, R			CASE-CONTROL STUDY OF WHETHER SUBFERTILITY IN MEN IS FAMILIAL	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MALE-INFERTILITY; DISORDERS	Objective-To test the hypothesis that subfertility in men is familial and to examine the distribution of subfertility within families for consistency with a genetic cause. Design-Case-control study and segregation analysis. Setting-Two teaching hospitals in Leeds. Subjects-Cases (probands) were men with an abnormal sperm count who attended a subfertility clinic and whose partners had no major factor contravening fertility. Controls were fathers of two or more childen recruited through vasectomy clinics or a maternity department. Main outcome measures-The incidence of involuntary childlessness among brothers with partners and among sisters and second and third degree male relatives. When possible clinical and laboratory details were obtained from involuntarily childless brothers. Results-Seventeen of the 148 (11.5%) brothers of probands but none of the 169 brothers of controls had sought medical advice for childlessness (P < 0.0005). Four probands had more than one involuntarily childless brother. There were six further brothers whose childlessness was thought to be involuntary bringing the total prevalence of subfertility among brothers of probands to 16%. Segregation analysis was consistent with an autosomal recessive mode of inheritance accounting for 60% of subfertility in men. Seventeen of the 346 (4.9%) uncles of probands and 10 of 420 (2.8%) uncles of controls were reported to be involuntarily childless (P = 0.09), but there was no difference in childlessness among sisters. In three families sperm counts from ''affected'' brothers confirmed the diagnosis and showed considerable similarities within but not between families. Conclusion-Subfertility in men has a familial component, and the observations are consistent with an autosomal recessive mode of inheritance in over half the cases. Several different genes are probably involved.			LILFORD, R (corresponding author), UNIV LEEDS, DEPT CLIN MED, INST EPIDEMIOL & HLTH SERV RES, LEEDS LS2 9LN, W YORKSHIRE, ENGLAND.		Thornton, Jim/B-8336-2008	Thornton, Jim/0000-0001-9764-6876; Bishop, Tim/0000-0002-8752-8785	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AFZELIUS BA, 1975, J CELL BIOL, V66, P225, DOI 10.1083/jcb.66.2.225; [Anonymous], [No title captured]; Cavalli-Sforza L.L., 1971, GENETICS HUMAN POPUL; CHUBB C, 1989, J ANDROL, V10, P77; CZYGLIK F, 1986, FERTIL STERIL, V45, P255; DEBRAEKELEER M, 1991, HUM REPROD, V6, P245, DOI 10.1093/oxfordjournals.humrep.a137315; EIBEN B, 1987, ANDROLOGIA, V19, P684; JOHNSON G, 1987, BRIT MED J, V294, P804, DOI 10.1136/bmj.294.6575.804; MATSUDA T, 1991, INT J FERTIL, V36, P178; Maule J. P, 1962, SEMEN ANIMALS ARTIFI; MILLER D, 1994, HUM REPROD, V9, P864, DOI 10.1093/oxfordjournals.humrep.a138607; NAVARRETE C, 1986, ANN GENET-PARIS, V29, P98; PEARSON PL, 1970, CYTOGENETICS, V9, P460, DOI 10.1159/000130115; PINSKY L, 1987, ADV HUM GENET, V16, P299; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; TEMPLETON A, 1990, BRIT MED J, V301, P148, DOI 10.1136/bmj.301.6744.148; VOGT P, 1992, HUM GENET, V89, P491; Watson PF., 1990, MARSHALLS PHYSL REPR; 1987, LABORATORY MANUAL EX	19	136	139	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 3	1994	309	6954					570	573		10.1136/bmj.309.6954.570	http://dx.doi.org/10.1136/bmj.309.6954.570			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF330	8086942	Green Published			2022-12-24	WOS:A1994PF33000016
J	BULLOUGH, PA; HUGHSON, FM; SKEHEL, JJ; WILEY, DC				BULLOUGH, PA; HUGHSON, FM; SKEHEL, JJ; WILEY, DC			STRUCTURE OF INFLUENZA HEMAGGLUTININ AT THE PH OF MEMBRANE-FUSION	NATURE			English	Article							VIRUS HEMAGGLUTININ; CONFORMATIONAL CHANGE; PROTEIN MODELS; ACTIVATION; ACID; GLYCOPROTEIN; ANTIBODIES; HEMOLYSIS; MECHANISM; RESOLUTION	Low pH induces a conformational change in the influenza virus haemagglutinin, which then mediates fusion of the viral and host cell membranes. The three-dimensional structure of a fragment of the haemagglutinin in this conformation reveals a major refolding of the secondary and tertiary structure of the molecule. The apolar fusion peptide moves at least 100 Angstrom to one tip of the molecule. At the other end a helical segment unfolds, a subdomain relocates reversing the chain direction, and part of the structure becomes disordered.	HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138; HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138; NATL INST MED RES,LONDON NW7 1AA,ENGLAND	Harvard University; Harvard University; Howard Hughes Medical Institute; MRC National Institute for Medical Research				Bullough, Per/0000-0001-8147-1127				BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BRAND CM, 1972, NATURE-NEW BIOL, V238, P145, DOI 10.1038/newbio238145a0; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BULLOUGH PA, 1994, J MOL BIOL, V236, P1262, DOI 10.1016/0022-2836(94)90027-2; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DANIELS RS, 1985, CELL, V40, P431, DOI 10.1016/0092-8674(85)90157-6; DANIELS RS, 1987, EMBO J, V6, P1459, DOI 10.1002/j.1460-2075.1987.tb02387.x; DANIELS RS, 1985, ORIGIN PANDEMIC INFL, P8; DANIELS RS, 1985, ORIGIN PANDEMIC INFL, P1; DOMS RW, 1985, J BIOL CHEM, V260, P2973; ELLENS H, 1990, BIOCHEMISTRY-US, V29, P9697, DOI 10.1021/bi00493a027; GETHING MJ, 1986, J CELL BIOL, V102, P11, DOI 10.1083/jcb.102.1.11; GODLEY L, 1992, CELL, V68, P635, DOI 10.1016/0092-8674(92)90140-8; GOLDSMITH EJ, 1994, STRUCTURE, V2, P241, DOI 10.1016/S0969-2126(00)00025-3; GRAVES PN, 1983, VIROLOGY, V126, P106, DOI 10.1016/0042-6822(83)90465-8; HUANG RTC, 1981, VIROLOGY, V110, P243, DOI 10.1016/0042-6822(81)90030-1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; KRAULIS P, 1991, J APPL CRYSTALLOGR, V24, P924; Leslie A.G.W., 1992, CCP4 ESF EACMB NEWSL; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MAEDA T, 1980, FEBS LETT, V122, P283, DOI 10.1016/0014-5793(80)80457-1; MCLACHLAN AD, 1983, J MOL BIOL, V164, P605, DOI 10.1016/0022-2836(83)90053-0; METCALF P, 1987, NATURE, V325, P84, DOI 10.1038/325084a0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RUIGROK RWH, 1988, J GEN VIROL, V69, P2785, DOI 10.1099/0022-1317-69-11-2785; RUIGROK RWH, 1986, EMBO J, V5, P41, DOI 10.1002/j.1460-2075.1986.tb04175.x; RUIGROK RWH, 1986, VIROLOGY, V155, P484, DOI 10.1016/0042-6822(86)90210-2; SAUTER NK, 1992, BIOCHEMISTRY-US, V31, P9609, DOI 10.1021/bi00155a013; SKEHEL JJ, 1975, P NATL ACAD SCI USA, V72, P93, DOI 10.1073/pnas.72.1.93; SKEHEL JJ, 1982, P NATL ACAD SCI-BIOL, V79, P968, DOI 10.1073/pnas.79.4.968; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SPRUCE AE, 1989, NATURE, V342, P555, DOI 10.1038/342555a0; STEGMANN T, 1993, VIRAL FUSION MECHANI, P89; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; WARD CW, 1980, AUST J BIOL SCI, V33, P441; WEBSTER RG, 1983, VIROLOGY, V126, P587, DOI 10.1016/S0042-6822(83)80015-4; WEIS WI, 1990, J MOL BIOL, V212, P737, DOI 10.1016/0022-2836(90)90234-D; WHARTON SA, 1988, J BIOL CHEM, V263, P4474; WHITE J, 1981, J CELL BIOL, V89, P674, DOI 10.1083/jcb.89.3.674; WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.biochem.56.1.365; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; YEWDELL JW, 1983, J VIROL, V48, P239, DOI 10.1128/JVI.48.1.239-248.1983; 1979, SERC4 DAR LAB COLL C	50	1358	1423	2	181	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 1	1994	371	6492					37	43		10.1038/371037a0	http://dx.doi.org/10.1038/371037a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE381	8072525				2022-12-24	WOS:A1994PE38100042
J	TEDDER, DG; ASHLEY, R; TYLER, KL; LEVIN, MJ				TEDDER, DG; ASHLEY, R; TYLER, KL; LEVIN, MJ			HERPES-SIMPLEX VIRUS-INFECTION AS A CAUSE OF BENIGN RECURRENT LYMPHOCYTIC MENINGITIS	ANNALS OF INTERNAL MEDICINE			English	Article						HERPES SIMPLEX; MENINGITIS, VIRAL; CEREBROSPINAL FLUID; HERPES GENITALIS; CENTRAL NERVOUS SYSTEM	POLYMERASE CHAIN-REACTION; CEREBROSPINAL-FLUID; MOLLARETS MENINGITIS; GENITAL HERPES; ENCEPHALITIS; TYPE-2; DIAGNOSIS; DNA; HERPESVIRUSES; PATIENT	Objective: To identify the role of herpes simplex virus (HSV) in causing benign recurrent lymphocytic meningitis. Design: Prospective cohort study. Setting: Tertiary referral center. Patients: 20 consecutive patients with a provisional diagnosis of benign recurrent lymphocytic meningitis had cerebrospinal fluid specimens submitted between 1990 and 1993 to the diagnostic virology laboratory. Thirteen patients met our criteria for benign recurrent lymphocytic meningitis. Measurements: Herpes simplex virus DNA was detected in cerebrospinal fluid specimens using the polymerase chain reaction, followed by hybridization with a HSV-specific DNA probe. Herpes simplex virus type 1 and type 2 DNA products were distinguished by digestion with restriction enzymes and analysis by gel electrophoresis. Anti-HSV antibodies in cerebrospinal fluid were detected by immunoblot. Results: The patients had 3 to 9 attacks (mean, 4.6 attacks) of benign recurrent lymphocytic meningitis during periods ranging from 2 to 21 years (mean, 8.4 years). Three of 13 patients had known recurrent genital herpes. Cerebrospinal fluid analysis showed 48 to 1600 cells/mu L, glucose levels of more than 2.22 mmol/L (40 mg/dL), and protein levels of 41 to 240 mg/dL (0.41 to 2.4 g/L). Herpes simplex virus DNA and anti-HSV antibodies were detected in cerebrospinal fluid samples in 11 of 13 patients (84.6%; 95% CI, 55% to 98%). Ten of these 11 patients had HSV type 2 DNA and HSV type 2 antibodies. One patient had HSV type 1 DNA and HSV type 1 antibodies in the cerebrospinal fluid. The remaining two patients had only anti-HSV type 2 antibodies. Conclusions: Herpes simplex virus, predominantly HSV type 2, was the major agent causing benign recurrent lymphocytic meningitis that met our specified diagnostic criteria.	UNIV COLORADO, HLTH SCI CTR, DEPT PEDIAT INFECT DIS, DENVER, CO 80262 USA; CHILDRENS HOSP, DENVER, CO 80218 USA; VET AFFAIRS MED CTR, NEUROL SERV 127, DENVER, CO 80220 USA; UNIV WASHINGTON, CHILDRENS HOSP & MED CTR, DEPT LAB MED, VIROL LAB, SEATTLE, WA 98105 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Children's Hospital Colorado; US Department of Veterans Affairs; Veterans Health Administration (VHA); Seattle Children's Hospital; University of Washington; University of Washington Seattle			Tyler, Kenneth L./J-2420-2019	Tyler, Kenneth L./0000-0003-3294-5888	NIAID NIH HHS [AI-20381] Funding Source: Medline; NINDS NIH HHS [NINCDS P1NS32228A] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020381] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U01NS032228, R01NS032228] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARCHARD JM, 1992, NEW ENGL J MED, V326, P893; ASHLEY R, 1992, ADV HOST DEFENSE MEC, V8, P201; ASHLEY RL, 1989, CLIN LAB MED, V9, P405, DOI 10.1016/S0272-2712(18)30611-5; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; AURELIUS E, 1993, J MED VIROL, V39, P179, DOI 10.1002/jmv.1890390302; AURELIUS E, 1991, LANCET, V337, P189, DOI 10.1016/0140-6736(91)92155-U; BARINGER JR, 1974, NEW ENGL J MED, V291, P828, DOI 10.1056/NEJM197410172911606; BERGER JR, 1991, LANCET, V337, P1360, DOI 10.1016/0140-6736(91)93051-A; BERGSTROM T, 1990, J INFECT DIS, V162, P322, DOI 10.1093/infdis/162.2.322; BERGSTROM T, 1990, SCAND J INFECT DIS, V22, P239, DOI 10.3109/00365549009037909; BRUYN GW, 1962, NEUROLOGY, V12, P745, DOI 10.1212/WNL.12.11.745; COHEN BA, 1992, ANN NEUROL, V32, P295; DAVISON AJ, 1983, J GEN VIROL, V64, P1927, DOI 10.1099/0022-1317-64-9-1927; FREDERIKS JAM, 1978, HDB CLIN NEUROLOGY, V34, P545; GRAMAN PS, 1987, ARCH NEUROL-CHICAGO, V44, P1204, DOI 10.1001/archneur.1987.00520230084023; HERMANS PE, 1972, AM J MED, V52, P128, DOI 10.1016/0002-9343(72)90014-9; KAHLON J, 1987, J INFECT DIS, V155, P38, DOI 10.1093/infdis/155.1.38; KIMURA H, 1991, J INFECT DIS, V164, P289, DOI 10.1093/infdis/164.2.289; KLAPPER PE, 1990, J MED VIROL, V32, P261, DOI 10.1002/jmv.1890320413; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; Mollaret MP, 1944, REV NEUROL-FRANCE, V76, P57; MOLLARET P, 1977, REV NEUROL, V133, P225; MOLLARET P, 1952, Bull Mem Soc Med Hop Paris, V68, P946; MOLLARET P, 1945, ANN I PASTEUR PARIS, V71, P1; PAL GS, 1987, BRIT MED J, V295, P367, DOI 10.1136/bmj.295.6594.367; PICARD FJ, 1993, NEUROLOGY, V43, P1722, DOI 10.1212/WNL.43.9.1722; PLUMMER G, 1973, J INFECT DIS, V128, P345, DOI 10.1093/infdis/128.3.345; PRICE RW, 1986, CRC CR REV CL NEUROB, V2, P61; PUCHHAMMERSTOCKL E, 1990, J MED VIROL, V32, P77, DOI 10.1002/jmv.1890320202; ROWLEY AH, 1990, LANCET, V335, P440, DOI 10.1016/0140-6736(90)90667-T; SKOLDENBERG B, 1975, SCAND J INFECT DIS, V7, P227, DOI 10.3109/inf.1975.7.issue-4.01; STALDER H, 1973, NEW ENGL J MED, V289, P1296, DOI 10.1056/NEJM197312132892409; STEEL JG, 1982, ANN NEUROL, V11, P17, DOI 10.1002/ana.410110104; STEVENS JG, 1989, MICROBIOL REV, V53, P318, DOI 10.1128/MMBR.53.3.318-332.1989; STRAUS SE, 1990, PRINCIPLES PRACTICE, P1139; TYLER KL, 1983, ARCH NEUROL-CHICAGO, V40, P42, DOI 10.1001/archneur.1983.04050010062017; VONHOFF DD, 1975, WESTERN J MED, V123, P490; WARREN KG, 1977, LANCET, V2, P637; WHITLEY RJ, 1990, NEW ENGL J MED, V323, P242, DOI 10.1056/NEJM199007263230406; WHITLEY RJ, 1991, INFECTIONS CENTRAL N, P41; YAMAMOTO LJ, 1991, NEW ENGL J MED, V325, P1082, DOI 10.1056/NEJM199110103251507	41	131	134	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1994	121	5					334	338		10.7326/0003-4819-121-5-199409010-00004	http://dx.doi.org/10.7326/0003-4819-121-5-199409010-00004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD701	8042822				2022-12-24	WOS:A1994PD70100004
J	ROTHE, M; WONG, SC; HENZEL, WJ; GOEDDEL, DV				ROTHE, M; WONG, SC; HENZEL, WJ; GOEDDEL, DV			A NOVEL FAMILY OF PUTATIVE SIGNAL TRANSDUCERS ASSOCIATED WITH THE CYTOPLASMIC DOMAIN OF THE 75 KDA TUMOR-NECROSIS-FACTOR RECEPTOR	CELL			English	Article							NF-KAPPA-B; TNF RECEPTOR; MOLECULAR-CLONING; ZINC-FINGER; PROTEIN; ACTIVATION; EXPRESSION; GENE; STIMULATION; MEDIATOR	Mutational analysis identified a C-terminal region of 78 amine acids within the cytoplasmic domain of the human 75 kDa tumor necrosis factor receptor (TNF-R2) that is required for signal transduction. This region was subsequently shown to mediate the interaction of cytoplasmic factors with TNF-R2. Two of these factors were isolated and molecularly cloned using biochemical purification and the yeast two-hybrid system. TNF receptor-associated factor 1 (TRAF1) and TRAF2 are the first two members of a novel protein family containing a never C-terminal homology region, the TRAP domain. In addition, TRAF2 contains an N-terminal RING finger motif. TRAF1 and TRAF2 can form homo- and heterotypic dimers. Our analysis indicates that TRAF1 and TRAF2 are associated with the cytoplasmic domain of TNF-R2 in a heterodimeric complex in which TRAF2 contacts the receptor directly. TRAF1 interacts with TNF-RP indirectly through heterodimer formation with TRAF2.	GENENTECH INC, DEPT PROT CHEM, San Francisco, CA 94080 USA	Roche Holding; Genentech	ROTHE, M (corresponding author), GENENTECH INC, DEPT MOLEC BIOL, 460 POINT SAN BRUNO BLVD, San Francisco, CA 94080 USA.			Henzel, William/0000-0003-2940-3797				ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BAZAN JF, 1993, CURR BIOL, V3, P603, DOI 10.1016/0960-9822(93)90009-D; BERG JM, 1990, J BIOL CHEM, V265, P6513; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; GEHR G, 1992, J IMMUNOL, V149, P911; GOEDDEL DV, 1986, COLD SPRING HARB SYM, V51, P597, DOI 10.1101/SQB.1986.051.01.072; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; GRELL M, 1993, LYMPHOKINE CYTOK RES, V12, P143; HELLER RA, 1992, CELL, V70, P47; ITOH N, 1993, J BIOL CHEM, V268, P10932; JACOBSEN FW, 1994, IN PRESS P NATL ACAD; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KRUPPA G, 1992, J IMMUNOL, V148, P3152; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MUNKER R, 1986, NATURE, V323, P79, DOI 10.1038/323079a0; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; PENNICA D, 1992, J BIOL CHEM, V267, P21172; PFIZENMAIER K, 1992, TUMOR NECROSIS FACTO, P439; ROTHE J, 1992, IMMUNOL RES, V11, P81, DOI 10.1007/BF02918612; Sambrook J., 1989, MOL CLONING LAB MANU; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; VANDENABEELE P, 1992, J EXP MED, V176, P1015, DOI 10.1084/jem.176.4.1015; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	45	915	987	2	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 26	1994	78	4					681	692		10.1016/0092-8674(94)90532-0	http://dx.doi.org/10.1016/0092-8674(94)90532-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	8069916				2022-12-24	WOS:A1994PD69300016
J	SUNG, P				SUNG, P			CATALYSIS OF ATP-DEPENDENT HOMOLOGOUS DNA PAIRING AND STRAND EXCHANGE BY YEAST RAD51 PROTEIN	SCIENCE			English	Article							ESCHERICHIA-COLI RECA; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; GENE; RECOMBINATION; HELICASE; ENCODES; CLONING; REPAIR; MOUSE	The RAD51 gene of Saccharomyces cerevisiae is required for genetic recombination and DNA double-strand break repair. Here it is demonstrated that RAD51 protein pairs circular viral single-stranded DNA from phi X 174 or M13 with its respective homologous linear double-stranded form. The product of synapsis between these DNA partners is further processed by RAD51 to yield nicked circular duplex DNA, which indicates that RAD51 can catalyze strand exchange. The pairing and strand exchange reaction requires adenosine triphosphate, a result consistent with the presence of a DNA-dependent adenosine triphosphatase activity in RAD51 protein. Thus, RAD51 is a eukaryotic recombination protein that can catalyze the strand exchange reaction.			SUNG, P (corresponding author), UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555, USA.							ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; BEZZUBOVA O, 1993, NUCLEIC ACIDS RES, V21, P1577, DOI 10.1093/nar/21.7.1577; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; KANS JA, 1991, GENE, V105, P139, DOI 10.1016/0378-1119(91)90527-I; KLECKNER N, 1991, COLD SH Q B, V56, P729; MORITA T, 1993, P NATL ACAD SCI USA, V90, P6577, DOI 10.1073/pnas.90.14.6577; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; RADDING CM, 1991, J BIOL CHEM, V266, P5355; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; STORY RM, 1993, SCIENCE, V259, P1892, DOI 10.1126/science.8456313; SUNG P, 1987, P NATL ACAD SCI USA, V84, P6045, DOI 10.1073/pnas.84.17.6045; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; SUNG PH, UNPUB; YOSHIMURA Y, 1993, NUCLEIC ACIDS RES, V21, P1665, DOI 10.1093/nar/21.7.1665	20	733	757	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 26	1994	265	5176					1241	1243		10.1126/science.8066464	http://dx.doi.org/10.1126/science.8066464			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD422	8066464				2022-12-24	WOS:A1994PD42200040
J	KWON, H; IMBALZANO, AN; KHAVARI, PA; KINGSTON, RE; GREEN, MR				KWON, H; IMBALZANO, AN; KHAVARI, PA; KINGSTON, RE; GREEN, MR			NUCLEOSOME DISRUPTION AND ENHANCEMENT OF ACTIVATOR BINDING BY A HUMAN SW1/SNF COMPLEX	NATURE			English	Article							TRANSCRIPTIONAL ACTIVATION; YEAST; GAL4; DNA; SNF2/SWI2; PROTEINS; INVITRO; FAMILY; CHROMATIN; DOMAINS	CHROMATIN structure can affect the transcriptional activity of eukaryotic structural genes by blocking access of sequence-specific activator proteins (activators) to their promoter-binding sites(1). For example, the DNA-binding domain of the yeast GAL4 protein interacts very poorly with nucleosome cores compared with naked DNA(2) (and see below), and binding of other activators is even more strongly inhibited(2,3). The way in which activators bind to nucleosomal DNA is therefore a critical aspect of transcriptional activation. Genetic studies have suggested that the multi-component SWI/SNF complex of Saccharomyces cerevisiae facilitates transcription by altering the structure of the chromatin(4,5). Here we identify and partially purify a human homologue of the yeast SWI/SNF complex (hSWI/SNF complex). We show that a partially purified hSWI/SNF complex mediates the ATP-dependent disruption of a nucleosome, thereby enabling the activators, GAL4-VP16 and GAL4-AH, to bind within a nucleosome core. We conclude that the hSWI/SNF complex acts directly to reorganize chromatin structure so as to facilitate binding of transcription factors.	UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,PROGRAM MOLEC MED,WORCESTER,MA 01605; MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; STANFORD UNIV,CTR MOILEC & GENET MED,HOWARD HUGHES MED INST,STANFORD,CA 94305	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Stanford University								CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; HENIKOFF S, 1993, TRENDS BIOCHEM SCI, V18, P291, DOI 10.1016/0968-0004(93)90037-N; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LAURENT BC, 1992, MOL CELL BIOL, V12, P1893, DOI 10.1128/MCB.12.4.1893; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LIN YS, 1988, CELL, V54, P659, DOI 10.1016/S0092-8674(88)80010-2; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; PECK LJ, 1983, P NATL ACAD SCI-BIOL, V80, P6206, DOI 10.1073/pnas.80.20.6206; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; TAYLOR ICA, 1991, GENE DEV, V5, P1285, DOI 10.1101/gad.5.7.1285; WORKMAN JL, 1991, METHOD CELL BIOL, V35, P419; WORKMAN JL, 1991, CELL, V64, P533, DOI 10.1016/0092-8674(91)90237-S; WORKMAN JL, 1992, SCIENCE, V258, P1780, DOI 10.1126/science.1465613; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	24	647	655	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 11	1994	370	6489					477	481		10.1038/370477a0	http://dx.doi.org/10.1038/370477a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	8047169				2022-12-24	WOS:A1994PB40700061
J	DIFFLEY, JFX; COCKER, JH; DOWELL, SJ; ROWLEY, A				DIFFLEY, JFX; COCKER, JH; DOWELL, SJ; ROWLEY, A			2 STEPS IN THE ASSEMBLY OF COMPLEXES AT YEAST REPLICATION ORIGINS IN-VIVO	CELL			English	Article							CEREVISIAE CELL-CYCLE; DNA-BINDING FACTORS; SACCHAROMYCES-CEREVISIAE; RECOGNITION COMPLEX; TRANSCRIPTIONAL REPRESSION; SUBCELLULAR-LOCALIZATION; CHROMATIN ORGANIZATION; MULTIPROTEIN COMPLEX; CHROMOSOMAL ORIGIN; LICENSING FACTOR	The integration of chromosomal DNA replication into the eukaryotic cell cycle might involve temporal regulation of interactions between cellular factors and replication origins. We show here that yeast replication origins exist in two chromatin states during the cell cycle. In the postreplicative state, genomic footprints closely resemble those produced in vitro by the purified ORC and ABF1 proteins, indicating that the binding of these proteins to replication origins is not sufficient to drive the initiation of DNA replication. The prereplicative state is characterized by an additional region of protection overlapping the ORC footprint. This prereplicative complex appears near the end of mitosis and persists through G1. After entry into S phase, origins return to the postreplicative state. Similarities in temporal regulation of the prereplicative state and the Xenopus licensing factor suggest that mechanisms limiting DNA replication to once per cell cycle may be conserved among eukaryotes.			DIFFLEY, JFX (corresponding author), IMPERIAL CANC RES FUND, CLARE HALL LABS, S MIMMS EN6 3LD, HERTS, ENGLAND.			Diffley, John/0000-0001-5184-7680; Dowell, Simon/0000-0001-6499-7573				ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BLOW JJ, 1993, J CELL BIOL, V122, P993, DOI 10.1083/jcb.122.5.993; Blumenthal AB, 1974, COLD SPRING HARB SYM, V38, P205, DOI 10.1101/sqb.1974.038.01.024; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1991, BIOESSAYS, V13, P317, DOI 10.1002/bies.950130702; BROACH JR, 1982, COLD SPRING HARB SYM, V47, P1165, DOI 10.1101/SQB.1983.047.01.132; BROACH JR, 1991, MOL BIOL YEAST SACCH, P297; BROWN JA, 1991, MOL CELL BIOL, V11, P5301, DOI 10.1128/MCB.11.10.5301; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; CALLAN HG, 1973, COLD SPRING HARB SYM, V38, P195; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; CELNIKER SE, 1984, MOL CELL BIOL, V4, P2455, DOI 10.1128/MCB.4.11.2455; CHEN YR, 1992, P NATL ACAD SCI USA, V89, P10459, DOI 10.1073/pnas.89.21.10459; COVERLEY D, 1993, J CELL BIOL, V122, P985, DOI 10.1083/jcb.122.5.985; DELLASETA F, 1990, J BIOL CHEM, V265, P15168; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1989, SCIENCE, V246, P1034, DOI 10.1126/science.2511628; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; DIFFLEY JFX, 1992, MOL BIOL SACCHAROMYC, P25; DORSMAN JC, 1990, NUCLEIC ACIDS RES, V18, P2769, DOI 10.1093/nar/18.9.2769; DUBEY DD, 1991, MOL CELL BIOL, V11, P5346, DOI 10.1128/MCB.11.10.5346; ESTES HG, 1992, P NATL ACAD SCI USA, V89, P11156, DOI 10.1073/pnas.89.23.11156; FAGRELIUS TJ, 1984, J MOL BIOL, V173, P1, DOI 10.1016/0022-2836(84)90400-5; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; FANGMAN WL, 1992, CELL, V71, P363, DOI 10.1016/0092-8674(92)90505-7; FERGUSON BM, 1992, CELL, V68, P333, DOI 10.1016/0092-8674(92)90474-Q; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; HAND R, 1978, CELL, V15, P317, DOI 10.1016/0092-8674(78)90001-6; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; HUIBREGTSE JM, 1991, METHOD ENZYMOL, V194, P550; JACOBS CW, 1988, J CELL BIOL, V107, P1409, DOI 10.1083/jcb.107.4.1409; JOHNSTON LH, 1990, MOL CELL BIOL, V10, P1358, DOI 10.1128/MCB.10.4.1358; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; KIMMERLY W, 1988, EMBO J, V7, P2241, DOI 10.1002/j.1460-2075.1988.tb03064.x; KOSHLAND D, 1985, CELL, V40, P393, DOI 10.1016/0092-8674(85)90153-9; LIVINGSTON DM, 1977, J MOL BIOL, V116, P249, DOI 10.1016/0022-2836(77)90215-7; LOHR D, 1988, BIOCHEMISTRY-US, V27, P3961, DOI 10.1021/bi00411a011; LONG CM, 1985, MOL CELL BIOL, V5, P3124, DOI 10.1128/MCB.5.11.3124; MAHONEY DJ, 1991, GENE DEV, V5, P605, DOI 10.1101/gad.5.4.605; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; RHODE PR, 1992, MOL CELL BIOL, V12, P1064, DOI 10.1128/MCB.12.3.1064; RIVIER DH, 1992, SCIENCE, V256, P659, DOI 10.1126/science.1585179; RIVIN CJ, 1980, J CELL BIOL, V85, P96, DOI 10.1083/jcb.85.1.96; SRIENC F, 1985, MOL CELL BIOL, V5, P1676, DOI 10.1128/MCB.5.7.1676; SWEDER KS, 1988, J BIOL CHEM, V263, P17270; THOMA F, 1984, J MOL BIOL, V177, P715, DOI 10.1016/0022-2836(84)90046-9; TOYN JH, 1994, EMBO J, V13, P1103, DOI 10.1002/j.1460-2075.1994.tb06359.x; UMEK RM, 1989, BIOCHIM BIOPHYS ACTA, V1007, P1, DOI 10.1016/0167-4781(89)90123-1; VEIT BE, 1985, MOL CELL BIOL, V5, P2190, DOI 10.1128/MCB.5.9.2190; WALKER SS, 1990, P NATL ACAD SCI USA, V87, P4665, DOI 10.1073/pnas.87.12.4665; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149; ZAKIAN VA, 1979, CELL, V17, P923, DOI 10.1016/0092-8674(79)90332-5; [No title captured]	62	479	487	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 29	1994	78	2					303	316		10.1016/0092-8674(94)90299-2	http://dx.doi.org/10.1016/0092-8674(94)90299-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	8044842				2022-12-24	WOS:A1994NZ24200013
J	WERTZ, DC; FANOS, JH; REILLY, PR				WERTZ, DC; FANOS, JH; REILLY, PR			GENETIC TESTING FOR CHILDREN AND ADOLESCENTS - WHO DECIDES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUNTINGTON DISEASE; ILLNESS; CONSENT; PARTICIPATION; PHYSICIANS; DECISIONS; ATTITUDES; CANCER; ISSUES; ADULTS	In the future there is likely to be a large array of DNA-based tests to diagnose single-gene disorders and to identify predispositions to genetically influenced disorders. This article focuses on ethical, legal, and psychological implications of testing healthy children and adolescents for such disorders. Testing may offer medical or psychological benefits but may harm parent-child bonds or the child's self-concept. Clinicians may encounter situations where they must weigh the child's or adolescent's wishes against wishes of parents. We examine the legal history and current status of miners as health care consumers; psychosocial research on their maturity to make choices; impact of testing on intrafamilial relationships; views of national commissions on appropriate ages of assent and full informed consent; ethical and legal requirements for competence in children and adolescents; and disclosure of genetic information. We propose guidelines for predictive genetic testing and counseling of children and discuss risks and benefits of testing.	CALIF PACIFIC MED CTR, SAN FRANCISCO, CA USA	California Pacific Medical Center	WERTZ, DC (corresponding author), EUNICE KENNEDY SHRIVER CTR MENTAL RETARDAT INC, DIV SOCIAL SCI ETH & LAW, 200 TRAPELO RD, WALTHAM, MA 02254 USA.				NHGRI NIH HHS [R01-HG00639-02, R01-HG00540-02] Funding Source: Medline; NICHD NIH HHS [N01-HD-1-3136] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD013136] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000540, R01HG000639] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		AMBUEL B, 1992, LAW HUMAN BEHAV, V16, P129, DOI 10.1007/BF01044794; ANDREWS LB, 1987, MED GENETICS LEGAL F, P115; Aries 27Philippe, 1965, CENTURIES CHILDHOOD; BAUER IL, 1952, J PEDIATR-US, V40, P796, DOI 10.1016/S0022-3476(52)80083-6; BEAUCHAMP TL, 1984, MED ETHICS MORAL RES; BEAUCHAMP TL, 1979, PRINCIPLES BIOMEDICA, P50; BENNETT R, 1976, VA LAW REV, V62, P285, DOI 10.2307/1072299; BIBACE R, 1980, PEDIATRICS, V66, P912; BIESECKER BB, 1993, JAMA-J AM MED ASSOC, V269, P1970, DOI 10.1001/jama.269.15.1970; BLOCH M, 1989, AM J MED GENET, V32, P217, DOI 10.1002/ajmg.1320320215; BLOCH M, 1990, AM J HUM GENET, V46, P1; BRETT AS, 1986, NEW ENGL J MED, V315, P1347, DOI 10.1056/NEJM198611203152109; Brock DW, 1989, CHILDREN HLTH CARE M, P181; Broyde Channah Sageev, 1987, Natl Jew Law Rev, V2, P123; BUCHANAN AE, 1989, DECIDING OTHERS ETHI, P215; CAPRON AM, 1982, WHO SPEAKS CHILD PRO, P57; CHAPMAN MA, 1990, AM J HUM GENET, V47, P1; Childress J., 1982, WHO SHOULD DECIDE PA; Clow C L, 1977, Prog Clin Biol Res, V18, P381; CLOW CL, 1977, PEDIATRICS, V59, P86; CRAUFURD D, 1990, LANCET, V335, P1406, DOI 10.1016/0140-6736(90)91289-M; Dunn J., 1985, SISTERS BROTHERS; EISER C, 1983, CHILD CARE HLTH DEV, V9, P233, DOI 10.1111/j.1365-2214.1983.tb00320.x; ENGELHARDT HT, 1982, CONT ISSUES BIOETHIC, P132; Ewald Linda Sorenson, 1982, St Louis Univ Law J, V25, P689; FANOS JH, 1992, PEDIATR PULM, P228; FANOS JH, 1987, DEV CONSEQUENCES ADU; FANOS JH, 1993, AM J HUM GENET S, V53; Feigenbaum Matthew S, 1992, De Paul Law Rev, V41, P841; FLETCHER JC, 1989, PRINCIPLES PRACTICE, P309; FOX S, 1989, AM J MED GENET, V32, P211, DOI 10.1002/ajmg.1320320214; Freedman Stephen D, 1980, Cap Univ Law Rev, V10, P309; FRIEDENBERG EA, 1965, COMING AGE AM GROWTH; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; GABOW PA, 1989, AM J KIDNEY DIS, V13, P85; GANS JE, 1993, POLICY COMPENDIUM CO; GAYLIN W, 1982, HASTINGS CENT REP, V12, P33, DOI 10.2307/3561805; Gilligan Carol., 1982, DIFFERENT VOICE; Green A. H., 1985, POST TRAUMATIC STRES, P133; GREEN M, 1964, PEDIATRICS, V34, P58; GRISSO T, 1981, JUVENILES WAIVER RIG; GRISSO T, 1983, PROFESSIONAL PSYCHOL, V9, P412; HARPER PS, 1990, LANCET, V335, P1205, DOI 10.1016/0140-6736(90)92713-R; HOLDER A, 1989, CHILDREN HLTH CARE M, P161; Holder A R, 1988, Law Med Health Care, V16, P219; HOLDER AR, 1977, LEGAL ISSUES PEDIATR; Katz J., 1984, SILENT WORLD DOCTOR; Katz J., 1972, EXPT HUMAN BEINGS; KESSLER S, 1988, AM J MED GENET, V31, P617, DOI 10.1002/ajmg.1320310316; Kett Joseph F., 1977, RITES PASSAGE ADOLES; KISTER MC, 1980, CHILD DEV, V51, P839, DOI 10.1111/j.1467-8624.1980.tb02621.x; Kohlberg L., 1976, MORAL DEV BEHAV THEO, P31; KOOCHER G P, 1986, Cancer, V58, P468, DOI 10.1002/1097-0142(19860715)58:2+<468::AID-CNCR2820581310>3.0.CO;2-Q; KORSCH BM, 1961, J MED ASS GA, V50, P519; LEIKIN SL, 1982, MAKING HLTH CARE DEC, V3, P175; Lewis C. E., 1983, CHILDRENS COMPETENCE, P75; LEWIS CC, 1980, AM J ORTHOPSYCHIAT, V50, P446, DOI 10.1111/j.1939-0025.1980.tb03304.x; LEWIS CE, 1978, AM J PUBLIC HEALTH, V68, P1079, DOI 10.2105/AJPH.68.11.1079; LOCICERO A, 1976, CHILDRENS RIGHTS MEN, P13; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Macklin R, 1982, WHO SPEAKS CHILD PRO, P265; MADDUX JE, 1986, AM PSYCHOL, V41, P25, DOI 10.1037/0003-066X.41.1.25; MEAD M, 1971, COMING AGE SAMOA; MELTON GB, 1983, CHILDRENS COMPETENCE, P1; MELTON GB, 1982, RIGHTS CHILDREN LEGA, P161; MILLSTEIN SG, 1981, PEDIATRICS, V68, P834; MORRIS M, 1988, LANCET, V2, P1069, DOI 10.1016/S0140-6736(88)90078-5; Nicholson RH, 1986, MED RES CHILDREN ETH; Nickerson B., 1991, J ADOLESCENT RES, V6, P70, DOI DOI 10.1177/074355489161006; PAGE A, 1992, AM J HUM GENET S, V51; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PERRIN EC, 1981, PEDIATRICS, V67, P841; PETERSEN GM, 1993, HUM GENET, V91, P307; Piaget J., 1965, MORAL JUDGEMENT CHIL; Piaget J., 1969, PSYCHOL CHILD; Platt Anthony M., 2009, CHILD SAVERS INVENTI; REILLY P, 1991, SURGICAL SOLUTION; Ruddick W., 1989, CHILDREN HLTH CARE M, P221; SCHERER DG, 1988, LAW HUMAN BEHAV, V12, P123, DOI 10.1007/BF01073121; SHARPE NF, 1993, AM J MED GENET, V46, P250, DOI 10.1002/ajmg.1320460232; SHERIDAN MS, 1975, SOC WORK, V20, P40; Sherwin S., 1992, NO LONGER PATIENT FE; SPONETTA JJ, 1981, LIVING CHILDHOOD CAN, P5; SUSMAN EJ, 1992, J PEDIATR-US, V121, P547, DOI 10.1016/S0022-3476(05)81142-4; SUSMAN EJ, 1987, J DEV BEHAV PEDIATR, V8, P266; THOMASMA DC, 1983, ANN INTERN MED, V98, P243, DOI 10.7326/0003-4819-98-2-243; Wadlington Walter, 1973, Osgoode Hall Law J, V11, P115; WADLINGTON WJ, 1983, CHILDRENS COMPETENCE, P57; WAISBREN SE, 1991, AM J PUBLIC HEALTH, V81, P299, DOI 10.2105/AJPH.81.3.299; Weithorn L. A., 1983, CHILDRENS COMPETENCE, P235; WEITHORN LA, 1982, CHILD DEV, V53, P1589, DOI 10.1111/j.1467-8624.1982.tb03482.x; WENT L, 1990, J MED GENET, V27, P34, DOI 10.1136/jmg.27.1.34; Wertz Dorothy C, 1993, J Womens Health, V2, P173, DOI 10.1089/jwh.1993.2.173; Wexler N S, 1985, Prog Med Genet, V6, P277; WIGGINS S, 1992, NEW ENGL J MED, V327, P1401, DOI 10.1056/NEJM199211123272001; Zelizer V., 1985, PRICING PRICELESS CH; 1993, ASSESSING GENETIC RI; 1977, DHEW OS770004 PUBL, V1, P1213; 1993, GPO0887809 NAT COMM; FED REGISTER, V48, P9818; 1982, MAKING HLTH CARE DEC, V1, P60; 1993, GENETIC TESTING CHIL; 1987, GUIDELINES RES INVOL	103	216	216	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 21	1994	272	11					875	881		10.1001/jama.272.11.875	http://dx.doi.org/10.1001/jama.272.11.875			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG182	8078166				2022-12-24	WOS:A1994PG18200027
J	GILLINGSMITH, C; TOOZSHOBSON, P; POTTS, DJ; TOUQUET, R; BEARD, RW				GILLINGSMITH, C; TOOZSHOBSON, P; POTTS, DJ; TOUQUET, R; BEARD, RW			MANAGEMENT OF BLEEDING IN EARLY-PREGNANCY IN ACCIDENT AND EMERGENCY DEPARTMENTS	BRITISH MEDICAL JOURNAL			English	Article									ST MARKS HOSP,DEPT ACCID & EMERGENCY,LONDON W2 1NY,ENGLAND	Imperial College London				Toozs-Hobson, Philip/0000-0002-1859-9934				CHAMBERLAIN G, 1991, BRIT MED J, V302, P1141, DOI 10.1136/bmj.302.6785.1141; GILLINGSMITH C, 1988, ARCH EMERG MED, V5, P133; HUGGON AM, 1993, ARCH EMERG MED, V10, P306; TOUQUET R, 1994, MED NEGLIGENCE; 1991, PRESCRIBERS J, V31, P137	5	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 3	1994	309	6954					574	575						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF330	8086945				2022-12-24	WOS:A1994PF33000019
J	STENDAHL, O; KRAUSE, KH; KRISCHER, J; JERSTROM, P; THELER, JM; CLARK, RA; CARPENTIER, JL; LEW, DP				STENDAHL, O; KRAUSE, KH; KRISCHER, J; JERSTROM, P; THELER, JM; CLARK, RA; CARPENTIER, JL; LEW, DP			REDISTRIBUTION OF INTRACELLULAR CA2+ STORES DURING PHAGOCYTOSIS IN HUMAN NEUTROPHILS	SCIENCE			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; FREE CALCIUM; FUNCTIONAL EXPRESSION; ENDOPLASMIC-RETICULUM; HL-60 CELLS; CA-2+ PUMP; PROTEIN; CALRETICULIN; ACTIVATION; GRADIENTS	Subcellular gradients of cytosolic free Ca2+ concentration, [Ca2+](i), are thought to be critical for the localization of functional responses within a cell. A potential but previously unexplored mechanism for the generation of gradients of [Ca2+](i) is the accumulation of Ca2+ stores at the site of Ca2+ action. The distribution of the Ca2+ store markers Ca2+-dependent adenosine triphosphatase and calreticulin was investigated in resting and phagocytosing human neutrophils. Both proteins showed an evenly distributed fine granular pattern in nonphagocytosing cells, but became markedly concentrated in the filamentous actin-rich cytoplasmic area around the ingested particle during phagocytosis. This redistribution began at early stages of phagocytosis and did not depend on an increase in [Ca2+](i). Thus, accumulation of Ca2+ stores in a restricted area of the cell may contribute to the generation of localized increases in [Ca2+](i).	HOP CANTONAL UNIV GENEVA, DIV INFECT DIS, CH-1211 GENEVA 14, SWITZERLAND; CTR MED UNIV GENEVA, DEPT MORPHOL, CH-1211 GENEVA 4, SWITZERLAND; VET ADM MED CTR, DEPT MED, IOWA CITY, IA 52242 USA; UNIV IOWA, IOWA CITY, IA 52242 USA	University of Geneva; University of Geneva; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Iowa	STENDAHL, O (corresponding author), LINKOPING UNIV, DEPT MED MICROBIOL, S-58185 LINKOPING, SWEDEN.		Krischer, Jeffrey P/I-5004-2012; Clark, Robert/Q-6764-2019; Krause, Karl-Heinz/E-8030-2011	Clark, Robert/0000-0002-4892-3619; Krause, Karl-Heinz/0000-0002-9033-6768				ALI SM, 1989, NATURE, V340, P313, DOI 10.1038/340313a0; ARBER S, 1992, J CELL BIOL, V116, P113, DOI 10.1083/jcb.116.1.113; BENGTSSON T, 1993, EUR J CELL BIOL, V62, P49; BENGTSSON T, 1988, J BIOL CHEM, V263, P17385; BOURGUIGNON LYW, 1993, J BIOL CHEM, V268, P7290; BRUNDAGE RA, 1991, SCIENCE, V254, P703, DOI 10.1126/science.1948048; BURK SE, 1989, J BIOL CHEM, V264, P18561; CLARK RD, UNPUB; DIVIRGILIO F, 1984, NATURE, V310, P691, DOI 10.1038/310691a0; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GILL DL, 1989, NATURE, V342, P16, DOI 10.1038/342016a0; GROVER AK, 1992, CELL CALCIUM, V13, P9, DOI 10.1016/0143-4160(92)90025-N; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; JACONI MEE, 1990, J CELL BIOL, V110, P1555, DOI 10.1083/jcb.110.5.1555; JOSEPH SK, 1993, J BIOL CHEM, V268, P6477; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KHAN AA, 1992, P NATL ACAD SCI USA, V89, P2849, DOI 10.1073/pnas.89.7.2849; KRAUSE KH, 1990, BIOCHEM J, V270, P545, DOI 10.1042/bj2700545; KRAUSE KH, 1991, FEBS LETT, V285, P225, DOI 10.1016/0014-5793(91)80806-E; KRAUSE KH, UNPUB; LEW DP, 1985, NATURE, V315, P509, DOI 10.1038/315509a0; LEW PD, 1986, J CELL BIOL, V102, P2197, DOI 10.1083/jcb.102.6.2197; LYTTON J, 1988, J BIOL CHEM, V263, P15024; MARKS PW, 1990, CELL CALCIUM, V11, P18, DOI 10.1016/0143-4160(90)90069-7; MATTSON MP, 1990, DEV BRAIN RES, V52, P201, DOI 10.1016/0165-3806(90)90236-R; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MURATA T, 1987, INFECT IMMUN, V55, P1784, DOI 10.1128/IAI.55.8.1784-1791.1987; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; PENG YW, 1991, NEURON, V6, P525, DOI 10.1016/0896-6273(91)90055-5; POENIE M, 1987, EMBO J, V6, P2223, DOI 10.1002/j.1460-2075.1987.tb02494.x; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; ROSSIER MF, 1991, TRENDS NEUROSCI, V14, P310, DOI 10.1016/0166-2236(91)90143-I; SAWYER W, 1992, J LEUKOCYTE BIOL, V51, P437; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; THELER JM, 1991, J RECEPTOR RES, V11, P627, DOI 10.3109/10799899109066431; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; VALERIUS NH, 1981, CELL, V24, P195, DOI 10.1016/0092-8674(81)90515-8; VANDELDEN C, 1992, BIOCHEM J, V281, P651, DOI 10.1042/bj2810651; WILLIAMS DA, 1985, NATURE, V318, P558, DOI 10.1038/318558a0; YELAMARTY RV, 1990, J CLIN INVEST, V85, P1799, DOI 10.1172/JCI114638	42	131	131	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 2	1994	265	5177					1439	1441		10.1126/science.8073285	http://dx.doi.org/10.1126/science.8073285			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	8073285				2022-12-24	WOS:A1994PE73300046
J	KEENE, WE; MCANULTY, JM; HOESLY, FC; WILLIAMS, LP; HEDBERG, K; OXMAN, GL; BARRETT, TJ; PFALLER, MA; FLEMING, DW				KEENE, WE; MCANULTY, JM; HOESLY, FC; WILLIAMS, LP; HEDBERG, K; OXMAN, GL; BARRETT, TJ; PFALLER, MA; FLEMING, DW			A SWIMMING-ASSOCIATED OUTBREAK OF HEMORRHAGIC COLITIS CAUSED BY ESCHERICHIA-COLI O157-H7 AND SHIGELLA-SONNEI	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEMOLYTIC-UREMIC SYNDROME; WATERBORNE OUTBREAK; GEL-ELECTROPHORESIS; NURSING-HOME; TOXIN-II; O157-H7; INFECTIONS; DIARRHEA; TRANSMISSION; CONSUMPTION	Background. In the summer of 1991, simultaneous outbreaks of bloody diarrhea and hemolytic-uremic syndrome caused by Escherichia coli O157:H7 and of bloody diarrhea caused by Shigella sonnei were traced to a lakeside park near Portland, Oregon. Methods. We identified cases primarily from routine surveillance reports. In case-control studies, the activities of persons with park-associated E. coli O157:H7 or S. sonnei infections were compared independently with those of three sets of controls. We also evaluated environmental conditions at the park and subtyped the bacterial isolates. Results. We identified 21 persons with park-associated E. coli O157:H7 infections (all of them children; median age, six years) and 38 persons with S. sonnei infections (most of them children). These 59 people had visited the park over a 24-day period. Their illnesses were not associated with food or beverage consumption. All the case patients reported swimming, however, and in case-control studies swimming was strongly associated with both types of infection (P = 0.015 or less). The case patients were more likely than the controls to report having swallowed lake water, and they had spent more time in the lake. Numbers of enterococci indicative of substantial fecal contamination (geometric mean, > 50 per deciliter) were detected in the swimming area during some but not all of the outbreak period. Park-associated E. coli O157:H7 isolates were identical by pulsed-field gel electrophoresis and were distinguishable from other isolates in the Portland area. Conclusions. Lake water that was fecally contaminated by bathers was the most likely vehicle for the transmission of both the E. coli O157:H7 and the S. sonnei infections. The unusually prolonged outbreak suggests both the survival of these enteric organisms in lake water and a low infectious dose.	CTR DIS CONTROL & PREVENT, EPIDEM INTELLIGENCE SERV, ATLANTA, GA 30341 USA; CTR DIS CONTROL & PREVENT, ENTER DIS BRANCH, ATLANTA, GA 30341 USA; MULTNOMAH CTY HLTH DEPT, PORTLAND, OR USA; OREGON HLTH SCI UNIV, DEPT PATHOL, PORTLAND, OR 97201 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Oregon Health & Science University	KEENE, WE (corresponding author), OREGON HLTH DIV, CTR DIS PREVENT & EPIDEMIOL, 800 NE OREGON ST, SUITE 772, PORTLAND, OR 97232 USA.							[Anonymous], 1992, STANDARD METHODS EXA; Balows A, 1991, MANUAL CLIN MICROBIO; BARON RC, 1982, AM J EPIDEMIOL, V115, P163, DOI 10.1093/oxfordjournals.aje.a113287; BARRETT TJ, 1991, CURR MICROBIOL, V23, P189, DOI 10.1007/BF02092278; BELONGIA EA, 1991, J INFECT DIS, V164, P338, DOI 10.1093/infdis/164.2.338; BELONGIA EA, 1993, JAMA-J AM MED ASSOC, V269, P883, DOI 10.1001/jama.269.7.883; BESSER RE, 1993, JAMA-J AM MED ASSOC, V269, P2217, DOI 10.1001/jama.269.17.2217; BLOSTEIN J, 1991, PUBLIC HEALTH REP, V106, P317; BOHM H, 1992, J CLIN MICROBIOL, V30, P2169; BRENNIMAN GR, 1981, AM J PUBLIC HEALTH, V71, P283, DOI 10.2105/AJPH.71.3.283; CARTER AO, 1987, NEW ENGL J MED, V317, P1496, DOI 10.1056/NEJM198712103172403; DEV VJ, 1991, LANCET, V337, P1412, DOI 10.1016/0140-6736(91)93092-N; DUFOUR AP, 1984, EPA600184004 REP; Duncan L., 1987, Canada Diseases Weekly Report, V13, P5; DUPONT HL, 1989, J INFECT DIS, V159, P1126, DOI 10.1093/infdis/159.6.1126; FLEISHER JM, 1993, INT J EPIDEMIOL, V22, P698, DOI 10.1093/ije/22.4.698; GOERING RV, 1990, J CLIN MICROBIOL, V28, P426, DOI 10.1128/JCM.28.3.426-429.1990; GOERING RV, 1990, J CLIN MICROBIOL, V28, P1088; GRIFFIN PM, 1991, EPIDEMIOL REV, V13, P60, DOI 10.1093/oxfordjournals.epirev.a036079; HARTSTEIN AI, 1990, INFECT CONT HOSP EP, V11, P531; KEENE WE, 1993, 33 INT C ANT AG CHEM, P354; MAKINTUBEE S, 1987, AM J PUBLIC HEALTH, V77, P166, DOI 10.2105/AJPH.77.2.166; MCGOWAN KL, 1989, LANCET, V1, P967; Mitscherlich E., 1984, MICROBIAL SURVIVAL E; MORGAN D, 1993, EPIDEMIOL INFECT, V111, P181, DOI 10.1017/S0950268800056880; NEWLAND JW, 1988, J CLIN MICROBIOL, V26, P1292, DOI 10.1128/JCM.26.7.1292-1297.1988; OSTROFF SM, 1990, AM J EPIDEMIOL, V132, P239, DOI 10.1093/oxfordjournals.aje.a115653; PAVIA AT, 1990, J PEDIATR-US, V116, P544, DOI 10.1016/S0022-3476(05)81600-2; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; ROSENBERG ML, 1976, JAMA-J AM MED ASSOC, V236, P1849, DOI 10.1001/jama.236.16.1849; RYAN CA, 1986, J INFECT DIS, V154, P631, DOI 10.1093/infdis/154.4.631; SORVILLO FJ, 1988, AM J TROP MED HYG, V38, P613, DOI 10.4269/ajtmh.1988.38.613; SPIKA JS, 1986, J PEDIATR-US, V109, P287, DOI 10.1016/S0022-3476(86)80386-9; SWERDLOW DL, 1992, ANN INTERN MED, V117, P812, DOI 10.7326/0003-4819-117-10-812; WELLS JG, 1991, J CLIN MICROBIOL, V29, P985, DOI 10.1128/JCM.29.5.985-989.1991; Zar JH., 1999, BIOSTAT ANAL; 1981, EPI80922 CTR DIS CON; 1982, MMWR-MORBID MORTAL W, V30, P633; 1986, EPA440584002 REP; 1986, CAN MED ASSOC J, V134, P50; 1982, MMWR-MORBID MORTAL W, V30, P623; 1993, MMWR-MORBID MORTAL W, V42, P85; 1969, MMWR-MORBID MORTAL W, V18, P403	43	240	243	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 1	1994	331	9					579	584		10.1056/NEJM199409013310904	http://dx.doi.org/10.1056/NEJM199409013310904			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD699	8047082				2022-12-24	WOS:A1994PD69900004
J	FRY, DW; KRAKER, AJ; MCMICHAEL, A; AMBROSO, LA; NELSON, JM; LEOPOLD, WR; CONNERS, RW; BRIDGES, AJ				FRY, DW; KRAKER, AJ; MCMICHAEL, A; AMBROSO, LA; NELSON, JM; LEOPOLD, WR; CONNERS, RW; BRIDGES, AJ			A SPECIFIC INHIBITOR OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR TYROSINE KINASE	SCIENCE			English	Article							MONOCLONAL-ANTIBODIES; TRANSGENIC MICE; BREAST-CANCER; TGF-ALPHA; OVEREXPRESSION; ACTIVATION; ONCOGENE	A small molecule called PD 153035 inhibited the epidermal growth factor (EGF) receptor tyrosine kinase with a 5-pM inhibition constant. The inhibitor was specific for the EGF receptor tyrosine kinase and inhibited other purified tyrosine kinases only at micromolar or higher concentrations. PD 153035 rapidly suppressed autophosphorylation of the EGF receptor at low nanomolar concentrations in fibroblasts or in human epidermoid carcinoma cells and selectively blocked EGF-mediated cellular processes including mitogenesis, early gene expression, and oncogenic transformation. PD 153035 demonstrates an increase in potency over that of other tyrosine kinase inhibitors of four to five orders of magnitude for inhibition of isolated EGF receptor tyrosine kinase and three to four orders of magnitude for inhibition of cellular phosphorylation.			FRY, DW (corresponding author), WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,2800 PLYMOUTH RD,ANN ARBOR,MI 48105, USA.							AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BRUNTON VG, 1993, CANCER CHEMOTH PHARM, V32, P1, DOI 10.1007/BF00685870; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; FRY D, UNPUB; GILL GN, 1987, MOL CELL ENDOCRINOL, V51, P169, DOI 10.1016/0303-7207(87)90027-X; GILL GN, 1987, METHOD ENZYMOL, V146, P82; GRIMAUX M, 1989, BREAST CANCER RES TR, V14, P77, DOI 10.1007/BF01805978; GRUAN E, 1989, INT J CELL CLONING, V7, P242; HENDLER FJ, 1989, CANCER CEL, V7, P347; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; MACIAS A, 1987, ANTICANCER RES, V7, P459; MASUI H, 1984, CANCER RES, V44, P1002; MASUI H, 1986, CANCER RES, V46, P5592; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; MUKAIDA H, 1991, CANCER, V68, P142, DOI 10.1002/1097-0142(19910701)68:1<142::AID-CNCR2820680126>3.0.CO;2-X; NAKAMURA M, 1990, CANCER, V65, P1980; NEAL DE, 1985, LANCET, V1, P366; NICHOLSON S, 1991, BRIT J CANCER, V63, P146, DOI 10.1038/bjc.1991.30; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; RODECK U, 1987, CANCER RES, V47, P3692; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; STERN DF, 1987, SCIENCE, V235, P321, DOI 10.1126/science.3492043; TRAXLER PM, 1991, J MED CHEM, V34, P2328, DOI 10.1021/jm00112a003; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513	29	781	848	0	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 19	1994	265	5175					1093	1095		10.1126/science.8066447	http://dx.doi.org/10.1126/science.8066447			3	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC539	8066447				2022-12-24	WOS:A1994PC53900036
J	SYLVESTRE, DL; RAVETCH, JV				SYLVESTRE, DL; RAVETCH, JV			FC-RECEPTORS INITIATE THE ARTHUS REACTION - REDEFINING THE INFLAMMATORY CASCADE	SCIENCE			English	Article							MAST-CELLS; RESPONSES	Antibody-antigen complexes initiate the inflammatory response and are central to the pathogenesis of tissue injury. The classical model for this immunopathological cascade, the Arthus reaction, was reinvestigated with a murine strain deficient in Fe receptor expression. Despite normal inflammatory responses to other stimuli, the inflammatory response to immune complexes was markedly attenuated. These results suggest that immune complex-triggered inflammation is initiated by cell bound Fe receptors and is then amplified by cellular mediators and activated complement. These results redefine the inflammatory cascade and may offer other approaches for the study and treatment of immunological injury.			SYLVESTRE, DL (corresponding author), SLOAN KETTERING INST,DEWITT WALLACE RES LAB,1275 YORK AVE,NEW YORK,NY 10021, USA.		Ravetch, Jeffrey/Z-1596-2019	Ravetch, Jeffrey/0000-0003-2024-9041	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001067, R37AI034662, R01AI034662] Funding Source: NIH RePORTER; NIAID NIH HHS [AI01067, AI34662] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arthus M, 1903, CR SOC BIOL, V55, P817; BENACERRAF B, 1950, J IMMUNOL, V64, P1; BENACERRAF BARUJ, 1959, AMER JOUR PATHOL, V35, P75; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Cannon PR, 1941, J IMMUNOL, V40, P127; COCHRANE CG, 1970, J IMMUNOL, V105, P55; COCHRANE CG, 1958, J EXP MED, V108, P591, DOI 10.1084/jem.108.5.591; COCHRANE CG, 1959, J EXP MED, V110, P481, DOI 10.1084/jem.110.3.481; COCHRANE CG, 1974, INFLAMMATORY PROCESS, V3, pCH3; Culbertson JT, 1935, J IMMUNOL, V29, P29; DEWAAL RMW, 1988, J IMMUNOL METHODS, V108, P213, DOI 10.1016/0022-1759(88)90422-X; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; FEARON DT, 1983, ANNU REV IMMUNOL, V1, P243, DOI 10.1146/annurev.iy.01.040183.001331; FISCHEL EE, 1947, J IMMUNOL, V55, P337; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; HMPHREY JH, 1955, BR J EXP PATHOL, V36, P283; HUMPHREY JH, 1955, BRIT J EXP PATHOL, V36, P268; ISSEKUTZ AC, 1988, METHOD ENZYMOL, V162, P301; OVARY Z, 1982, INT ARCH ALLER A IMM, V69, P385, DOI 10.1159/000233205; PERLMUTTER DH, 1986, ANNU REV IMMUNOL, V4, P231, DOI 10.1146/annurev.iy.04.040186.001311; POBER JS, 1993, J IMMUNOL, V150, P5114; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, IN PRESS CELL; SCHULMAN ES, 1993, CRIT REV IMMUNOL, V13, P35; STETSON CA, 1951, J EXP MED, V94, P349; SYLVESTRE DL, UNPUB; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; WARD PA, 1964, FED PROC, V23, P509; ZHANG Y, 1992, SCIENCE, V258, P1957, DOI 10.1126/science.1470922; ZHANG Y, 1991, J CLIN INVEST, V88, P841, DOI 10.1172/JCI115385	30	265	306	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 19	1994	265	5175					1095	1098		10.1126/science.8066448	http://dx.doi.org/10.1126/science.8066448			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC539	8066448				2022-12-24	WOS:A1994PC53900037
J	HARDY, LM; HAYNES, BF; VOLBERDING, PA				HARDY, LM; HAYNES, BF; VOLBERDING, PA			GENE-THERAPY FOR HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									DUKE UNIV,SCH MED,ROUNDTABLE DEV DRUGS & VACCINES AGAINST AIDS,DURHAM,NC 27706; SAN FRANCISCO GEN HOSP,AIDS PROGRAM & CLIN ONCOL,SAN FRANCISCO,CA 94110	Duke University; San Francisco General Hospital Medical Center									0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	1994	272	6					423	423						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA278	8040965				2022-12-24	WOS:A1994PA27800005
J	MAHAJANMIKLOS, S; COOLEY, L				MAHAJANMIKLOS, S; COOLEY, L			THE VILLIN-LIKE PROTEIN ENCODED BY THE DROSOPHILA QUAIL GENE IS REQUIRED FOR ACTIN BUNDLE ASSEMBLY DURING OOGENESIS	CELL			English	Article							BRUSH-BORDER CYTOSKELETON; SEVERING PROTEINS; BICAUDAL-D; GELSOLIN; MELANOGASTER; SEQUENCE; DOMAINS; ORGANIZATION; MORPHOLOGY; RESIDUES	Mutations in the Drosophila quail gene result in female sterility due to the disruption of cytoplasmic transport from the nurse cells into the oocyte late in oogenesis. Nurse cells from quail mutant egg chambers fail to assemble cytoplasmic actin filament bundles correctly. We have cloned the quail gene and found that it encodes a protein with homology to the vertebrate actin-regulating protein villin. Unlike vertebrate villin, which is restricted to specialized absorptive epithelial cells, the villin-like protein encoded by quail is germline specific in adult flies. Antibodies directed against the quail protein show a striking colocalization with filamentous actin in the nurse cells and the oocyte. Our results demonstrate that the villin-like product of quail is required for the formation of cytoplasmic actin filament bundles in nurse cells, possibly by regulating both the polymerization and organization of actin filaments as demonstrated for vertebrate villin in vitro.			MAHAJANMIKLOS, S (corresponding author), YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510, USA.				NIGMS NIH HHS [GM43301] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043301] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMPE C, 1987, EMBO J, V6, P4149, DOI 10.1002/j.1460-2075.1987.tb02761.x; ANDRE E, 1988, J BIOL CHEM, V263, P722; ARPIN M, 1988, J CELL BIOL, V107, P1759, DOI 10.1083/jcb.107.5.1759; BAZARI WL, 1988, P NATL ACAD SCI USA, V85, P4986, DOI 10.1073/pnas.85.14.4986; BONFANTI P, 1992, EUR J CELL BIOL, V57, P298; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BRYAN J, 1993, P NATL ACAD SCI USA, V90, P9115, DOI 10.1073/pnas.90.19.9115; CAMPBELL HD, 1993, P NATL ACAD SCI USA, V90, P11386, DOI 10.1073/pnas.90.23.11386; CANT K, 1994, J CELL BIOL, V125, P369, DOI 10.1083/jcb.125.2.369; COOLEY L, 1992, CELL, V69, P173, DOI 10.1016/0092-8674(92)90128-Y; DEARRUDA MV, 1992, J BIOL CHEM, V267, P13079; DIMITRIADIS VK, 1984, CAN J ZOOL, V62, P659, DOI 10.1139/z84-097; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRANCK Z, 1990, J CELL BIOL, V111, P2475, DOI 10.1083/jcb.111.6.2475; FRIEDERICH E, 1992, CELL, V70, P81, DOI 10.1016/0092-8674(92)90535-K; FRIEDERICH E, 1989, CELL, V59, P461, DOI 10.1016/0092-8674(89)90030-5; FRIEDERICH E, 1990, BIOESSAYS, V12, P403, DOI 10.1002/bies.950120902; GUTZEIT HO, 1986, J CELL SCI, V80, P159; HARLOW E, 1988, ANTIBODIES LABORATOR; HEINTZELMAN MB, 1992, CURR TOP DEV BIOL, V26, P93, DOI 10.1016/S0070-2153(08)60442-1; HEINTZELMAN MB, 1993, J MOL BIOL, V230, P709, DOI 10.1006/jmbi.1993.1191; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HOFMANN A, 1993, FEBS LETT, V328, P71, DOI 10.1016/0014-5793(93)80968-Z; King R. C., 1970, OVARIAN DEV DROSOPHI; KNOWLES BA, 1994, TRENDS GENET, V10, P235, DOI 10.1016/0168-9525(94)90170-8; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; Louvard D, 1989, CURR OPIN CELL BIOL, V1, P51, DOI 10.1016/S0955-0674(89)80036-5; MAUNOURY R, 1988, EMBO J, V7, P3321, DOI 10.1002/j.1460-2075.1988.tb03203.x; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MOOSEKER MS, 1985, ANNU REV CELL BIOL, V1, P209, DOI 10.1146/annurev.cellbio.1.1.209; PATERSON J, 1991, GENETICS, V129, P1073; PRENDERGAST GC, 1991, EMBO J, V10, P757, DOI 10.1002/j.1460-2075.1991.tb08007.x; RANA AP, 1993, P NATL ACAD SCI USA, V90, P6651, DOI 10.1073/pnas.90.14.6651; ROBINE S, 1985, P NATL ACAD SCI USA, V82, P8488, DOI 10.1073/pnas.82.24.8488; ROBINSON DN, 1994, DEVELOPMENT, V120, P2015; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 1989, MOL CLONING LAB MANU; SCHUPBACH T, 1991, GENETICS, V129, P1119; SCOTT MP, 1983, CELL, V35, P763, DOI 10.1016/0092-8674(83)90109-5; Spradling Allan C., 1993, P1; STELLA MC, 1994, J CELL BIOL, V125, P607, DOI 10.1083/jcb.125.3.607; STEWARD R, 1986, GENETICS, V113, P665; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; THEURKAUF WE, 1993, DEVELOPMENT, V118, P1169, DOI 10.1016/0168-9525(93)90134-4; TOWER J, 1993, GENETICS, V133, P3347; VERHEYEN EM, 1994, DEVELOPMENT, V120, P717; WARN RM, 1985, EXP CELL RES, V157, P355, DOI 10.1016/0014-4827(85)90120-X; WAY M, 1988, J MOL BIOL, V203, P1127, DOI 10.1016/0022-2836(88)90132-5; Weeds A, 1993, CURR OPIN CELL BIOL, V5, P63, DOI 10.1016/S0955-0674(05)80009-2; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WRIGHT TRF, 1976, GENETICS, V84, P267; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9	54	120	121	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 29	1994	78	2					291	301		10.1016/0092-8674(94)90298-4	http://dx.doi.org/10.1016/0092-8674(94)90298-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	8044841				2022-12-24	WOS:A1994NZ24200012
J	CALLAHAN, TL; HALL, JE; ETTNER, SL; CHRISTIANSEN, CL; GREENE, MF; CROWLEY, WF				CALLAHAN, TL; HALL, JE; ETTNER, SL; CHRISTIANSEN, CL; GREENE, MF; CROWLEY, WF			THE ECONOMIC-IMPACT OF MULTIPLE-GESTATION PREGNANCIES AND THE CONTRIBUTION OF ASSISTED-REPRODUCTION TECHNIQUES TO THEIR INCIDENCE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INVITRO FERTILIZATION; INTRAFALLOPIAN TRANSFER; INFANT-MORTALITY; UNITED-STATES; BIRTH-WEIGHT; MANAGEMENT; PREVENTION; OVULATION; TRIPLETS; TWINS	Background. Although the medical complications associated with multiple-gestation pregnancies have been well documented, little is known about the effects of such pregnancies on the use of health care resources and the associated costs. This is an important issue because of the increasing use of assisted-reproduction techniques, which commonly result in multiple-gestation pregnancies. Methods. We determined hospital charges and the use of assisted-reproduction techniques (such as induction of ovulation, in vitro fertilization, and gamete intrafallopian transfer) for 13,206 pregnant women (11,986 with singleton pregnancies, 1135 with twin pregnancies, and 85 with more than two fetuses) who were admitted for delivery to Brigham and Women's Hospital, Boston, in 1986 through 1991 and their 14,033 neonates (11,671 singletons, 2144 twins, and 218 resulting from higher-order multiple gestations). Results. After we controlled for variables known to affect hospital charges, the predicted total charges to the family in 1991 for a singleton delivery were $9,845, as compared with $37,947 for twins ($18,974 per baby) and $109,765 for triplets ($36,588 per baby). Assisted-reproduction techniques were used in 2 percent of singleton, 35 percent of twin, and 77 percent of higher-order multiple-gestation pregnancies; such procedures were approximately equally divided between induction of ovulation alone and in vitro fertilization or gamete intrafallopian transfer. Conclusions. Multiple-gestation pregnancies, a high proportion of which result from the use of assisted-reproduction techniques, dramatically increase hospital charges. If all the multiple gestations resulting from assisted-reproduction techniques had been singleton pregnancies, the predicted savings to the health care delivery system in the study hospital alone would have been over $3 million per year. Although assisted reproduction provides tremendous benefits to families with infertility, the increased medical risks entailed by multiple-gestation pregnancies and the associated costs cannot be ignored. We suggest that more attention be paid to approaches to infertility that reduce the likelihood of multiple gestation.	MASSACHUSETTS GEN HOSP,NATL CTR INFERTIL RES,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT MED,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT OBSTET GYNECOL,BOSTON,MA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital			Hall, Janet E/F-3516-2019	Hall, Janet E/0000-0003-4644-3061; Christiansen, Cindy/0000-0001-9951-480X	NCRR NIH HHS [MO1-RR-01066] Funding Source: Medline; NICHD NIH HHS [U54-HD-29164] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD029164] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BERKI SE, 1987, PEDIATRICS, V79, P874; BERKOWITZ RL, 1993, AM J OBSTET GYNECOL, V169, P17, DOI 10.1016/0002-9378(93)90124-2; BOLLEN N, 1991, FERTIL STERIL, V55, P314; BOTTING BJ, 1987, ARCH DIS CHILD, V62, P941, DOI 10.1136/adc.62.9.941; CORSON SL, 1989, FERTIL STERIL, V51, P644; DEMUYLDER X, 1982, ACTA GENET MED GEMEL, V31, P149, DOI 10.1017/S0001566000008230; DUAN N, 1983, J AM STAT ASSOC, V78, P605, DOI 10.2307/2288126; ELSTER AD, 1991, OBSTET GYNECOL, V77, P387; Ewald U, 1991, Int J Technol Assess Health Care, V7 Suppl 1, P155; FAUSER BCJM, 1993, BAILLIERE CLIN OB GY, V7, P309, DOI 10.1016/S0950-3552(05)80133-6; Gennaro S, 1992, Image J Nurs Sch, V24, P191; GILSTRAP LC, 1988, CLIN PERINATOL, V15, P71, DOI 10.1016/S0095-5108(18)30725-5; GRUTZNERKONNECKE H, 1990, ACTA GENET MED GEMEL, V39, P491, DOI 10.1017/S000156600000372X; GUTTMACHER AF, 1953, OBSTET GYNECOL, V2, P22; HARRIS J, 1979, BELL J ECON, V1, P224; HECHT BR, 1993, ASSIST REPROD REV, V3, P75; HOWIE PW, 1988, BMJ-BRIT MED J, V297, P433, DOI 10.1136/bmj.297.6646.433; JACKSONBEECK M, 1983, JAMA-J AM MED ASSOC, V250, P2826, DOI 10.1001/jama.250.20.2826; KETTERLINUS RD, 1990, J ADOLESCENT HEALTH, V11, P423, DOI 10.1016/0197-0070(90)90090-O; KIELY JL, 1992, AM J DIS CHILD, V146, P862, DOI 10.1001/archpedi.1992.02160190094029; LEROY F, 1990, ACTA GENET MED GEMEL, V39, P371, DOI 10.1017/S0001566000005298; LEVENE MI, 1992, BRIT J OBSTET GYNAEC, V99, P607, DOI 10.1111/j.1471-0528.1992.tb13831.x; LIPITZ S, 1989, AM J OBSTET GYNECOL, V161, P1279, DOI 10.1016/0002-9378(89)90683-2; LIPITZ S, 1990, OBSTET GYNECOL, V76, P215; LUKE B, 1992, J REPROD MED, V37, P661; MACLENNAN AH, 1990, LANCET, V335, P267, DOI 10.1016/0140-6736(90)90079-K; MALMSTROM PM, 1990, ACTA GENET MED GEMEL, V39, P507, DOI 10.1017/S0001566000003755; MARTIN KA, 1993, J CLIN ENDOCR METAB, V77, P125, DOI 10.1210/jc.77.1.125; MCCARTHY BJ, 1981, AM J OBSTET GYNECOL, V141, P252; NEWMAN RB, 1989, AM J OBSTET GYNECOL, V161, P547, DOI 10.1016/0002-9378(89)90354-2; NIJS M, 1993, FERTIL STERIL, V59, P1245; POLSON DW, 1987, CLIN ENDOCRINOL, V26, P205, DOI 10.1111/j.1365-2265.1987.tb00778.x; REIN MS, 1990, INT J FERTIL, V35, P154; RESNICK MB, 1986, PEDIATRICS, V78, P820; SCHENKER JG, 1981, FERTIL STERIL, V35, P105; WAPNER RJ, 1990, LANCET, V335, P90, DOI 10.1016/0140-6736(90)90550-O; WEEKES ARL, 1977, BRIT J OBSTET GYNAEC, V84, P161, DOI 10.1111/j.1471-0528.1977.tb12549.x; 1990, BRIT MED J, V300, P1229; 1993, FERTIL STERIL, V59, P956; 1988, INFERTILITY MED SOCI	40	328	332	0	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 28	1994	331	4					244	249		10.1056/NEJM199407283310407	http://dx.doi.org/10.1056/NEJM199407283310407			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NY335	8015572	Bronze			2022-12-24	WOS:A1994NY33500007
J	BRODY, DJ; PIRKLE, JL; KRAMER, RA; FLEGAL, KM; MATTE, TD; GUNTER, EW; PASCHAL, DC				BRODY, DJ; PIRKLE, JL; KRAMER, RA; FLEGAL, KM; MATTE, TD; GUNTER, EW; PASCHAL, DC			BLOOD LEAD LEVELS IN THE US POPULATION - PHASE-1 OF THE 3RD NATIONAL-HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES-III, 1988 TO 1991)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; EXPOSURE; CHILDREN; IMPAIRMENT; TOXICOLOGY	Objective.-To determine mean blood lead levels and their sociodemographic correlates in the US population. Design.-Nationally representative cross-sectional health examination survey that included measurements of venous blood lead. Participants.-A total of 13 201 persons aged 1 year and older examined during phase 1 of the third National Health and Nutrition Examination Survey (1988 to 1991). Results.-The overall mean blood lead level for the US population was 0.14 mu mol/L (2.8 mu g/dL). Blood lead levels were consistently higher for younger children than for older children, for older adults than for younger adults, for males than for females, for blacks than for whites, and for central-city residents than for non-central-city residents. Other correlates of higher blood lead levels included low income, low educational attainment, and residence in the Northeast region of the United States, National estimates for children 1 to 5 years of age indicate that 8.9%, or approximately 1.7 million children, have blood lead levels 0.48 mu mol/L (10 mu g/dL) or greater. These levels are high enough to be of health concern under 1991 Centers for Disease Control and Prevention guidelines. Conclusions.-The low overall mean blood lead levels demonstrate a major public health success in primary prevention efforts. However, exposure to lead at levels that may adversely affect the health of children remains a problem especially for those who are minority, urban, and from low-income families. Strategies to identify the most vulnerable risk groups are necessary to further reduce lead exposure in the United States.	CTR DIS CONTROL & PREVENT,NATL CTR ENVIRONM HLTH,DIV ENVIRONM HLTH LAB SCI,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,NATL CTR ENVIRONM HLTH,LEAD POISONING PREVENT BRANCH,ATLANTA,GA 30341	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	BRODY, DJ (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,DIV HLTH EXAMINAT STAT,6525 BELCREST RD,ROOM 900,HYATTSVILLE,MD 20782, USA.		Flegal, Katherine M/A-4608-2013	Flegal, Katherine/0000-0002-0838-469X				[Anonymous], 1988, NATURE EXTENT LEAD P; [Anonymous], 1991, PREVENTING LEAD POIS; BELLINGER DC, 1992, PEDIATRICS, V90, P855; BINDER S, 1991, STRATEGIC PLAN ELIMI; BINNS HJ, 1994, PEDIATRICS, V93, P164; CARTERPOKRAS O, 1990, PUBLIC HEALTH REP, V105, P388; DAVIS JM, 1987, NATURE, V329, P298; DIETRICH KN, 1993, PEDIATRICS, V91, P301; DIETRICH KN, 1993, NEUROTOXICOL TERATOL, V15, P37, DOI 10.1016/0892-0362(93)90043-N; EZZATI TM, 1992, VITAL HLTH STAT 2, V113; FLEGAL KM, 1991, DIABETES CARE, V14, P628, DOI 10.2337/diacare.14.7.628; GELLERT GA, 1993, JAMA-J AM MED ASSOC, V270, P69, DOI 10.1001/jama.270.1.69; GUNTER EW, 1986, HHANES1982 1984 CTR; HUNTER JM, 1977, SOC SCI MED, V11, P691, DOI 10.1016/0037-7856(77)90155-X; Johnson B L, 1993, Ann Epidemiol, V3, P175; LANDRIGAN PJ, 1990, ENVIRON HEALTH PERSP, V89, P61, DOI 10.2307/3430898; MAHAFFEY KR, 1982, NEW ENGL J MED, V307, P573, DOI 10.1056/NEJM198209023071001; MARINO PE, 1990, AM J PUBLIC HEALTH, V80, P1183, DOI 10.2105/AJPH.80.10.1183; MILLER DT, 1987, ANALYST, V112, P1701, DOI 10.1039/an9871201701; MUSHAK P, 1989, ENVIRON RES, V50, P11, DOI 10.1016/S0013-9351(89)80046-5; NEEDLEMAN HL, 1981, ANNU REV PUBL HEALTH, V2, P277, DOI 10.1146/annurev.pu.02.050181.001425; PIRKLE JL, 1994, JAMA-J AM MED ASSOC, V272, P284, DOI 10.1001/jama.272.4.284; PIRKLE JL, 1985, AM J EPIDEMIOL, V121, P246, DOI 10.1093/oxfordjournals.aje.a113995; RIFAI N, 1993, THER DRUG MONIT, V15, P71, DOI 10.1097/00007691-199304000-00001; SCHAFFER SJ, 1994, PEDIATRICS, V93, P159; SCHWARTZ J, 1991, ARCH ENVIRON HEALTH, V46, P300, DOI 10.1080/00039896.1991.9934391; SCHWARTZ J, 1986, PEDIATRICS, V77, P281; SCHWARTZ J, 1987, ARCH ENVIRON HEALTH, V42, P153, DOI 10.1080/00039896.1987.9935814; Sempos CT., 1991, MONITORING DIETARY I, P99; SHAH BV, 1991, SUDAAN USERS MANUAL; SILBERGELD EK, 1991, ENVIRON HEALTH PERSP, V91, P63, DOI 10.2307/3430984; SILBERGELD EK, 1990, ENVIRON HEALTH PERSP, V89, P49, DOI 10.2307/3430896; SILBERGELD EK, 1992, FASEB J, V6, P3201, DOI 10.1096/fasebj.6.13.1397842; STAESSEN JA, 1992, NEW ENGL J MED, V327, P151, DOI 10.1056/NEJM199207163270303; TEJEDA DM, 1994, PEDIATRICS, V93, P192; WEITZMAN M, 1993, JAMA-J AM MED ASSOC, V269, P1647, DOI 10.1001/jama.269.13.1647; 1988, CURRENT POPULATI P60, V163; 1993, MMWR-MORBID MORTAL W, V42, P522; 1987, ANN HIST REV FNS PRO; 1990, SAS LANGUAGE REFEREN; 1992, MMWR-MORBID MORTAL W, V41, P715; 1989, CURRENT POPULATI P60, V171; 1991, CURRENT POPULATI P60, V175	43	463	474	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 27	1994	272	4					277	283		10.1001/jama.272.4.277	http://dx.doi.org/10.1001/jama.272.4.277			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NX806	8028140				2022-12-24	WOS:A1994NX80600029
J	MILLER, M; HUTCHINS, GM				MILLER, M; HUTCHINS, GM			HEMOCHROMATOSIS, MULTIORGAN HEMOSIDEROSIS, AND CORONARY-ARTERY DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							LOW-DENSITY-LIPOPROTEIN; ISCHEMIC-HEART-DISEASE; IRON; RISK; AUTOPSY	Objective.-To examine the prevalence of coronary artery disease (CAD) in autopsies of patients with iron-overload syndromes. Design.-Retrospective autopsy study of CAD in cases of hemochromatosis and multiorgan hemosiderosis. Setting.-Registry of nearly 48 000 autopsies performed at The Johns Hopkins Hospital between 1889 and 1992. Subjects.-One hundred twenty-three subjects were studied. In a 2:1 control-case ratio, 82 controls matched by age, race, and sex were compared with 41 cases with iron overload. Main Outcome Measure.-Severity of CAD. Results.-Pathological description of the coronary arteries were recorded as advanced or severe in 12% of iron-overload cases (n=41) (mean age, 57.6+/-13.2 years) compared with 38% of controls (n=82) (mean age, 57.0+/-13.8 years) (P=.01). The prevalence of three-vessel disease assessed by postmortem coronary arteriography was 11.1% in iron-overload cases (n=18) (mean age, 61.7+/-12.2 years) compared with 33.3% in controls (n=36) (mean age, 61.1+/-12.5 years) (P=.04). The odds ratio of CAD with iron overload was 0.18 (95% confidence interval, 0.04 to 0.73). Conclusions.-Iron overload resulting from hemochromatosis or multiorgan hemosiderosis is not associated with an increased prevalence of CAD.	UNIV MARYLAND,MED SYST,DIV CARDIOL,BALTIMORE,MD 21201; JOHNS HOPKINS MED INST,DEPT PATHOL,DIV AUTOPSY PATHOL,BALTIMORE,MD 21205	University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins Medicine			Miller, Michael/AGX-6773-2022	Miller, Michael/0000-0002-1679-2095	NHLBI NIH HHS [KO7-HL-02263-03] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K07HL002263] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASCHERIO A, 1994, CIRCULATION, V89, P969, DOI 10.1161/01.CIR.89.3.969; CUTLER DJ, 1980, AM J MED, V69, P923, DOI 10.1016/S0002-9343(80)80020-9; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; GOLDSTEIN JL, 1982, MED CLIN N AM, V66, P335, DOI 10.1016/S0025-7125(16)31424-9; Hennekens CH., 1987, EPIDEMIOLOGY MED CHA, P54; HUTCHINS GM, 1973, JOHNS HOPKINS MED J, V133, P96; KUZUYA M, 1990, BIOCHEM INT, V22, P567; MACDONALD RA, 1960, ARCH INTERN MED, V105, P686, DOI 10.1001/archinte.1960.00270170024004; MCCORD JM, 1991, CIRCULATION, V83, P1112, DOI 10.1161/01.CIR.83.3.1112; MCINTOSH HD, 1991, ERA CARDIOVASCULAR M, P316; MOORE GW, 1984, AM J PATHOL, V115, P36; SALONEN JT, 1992, CIRCULATION, V86, P803, DOI 10.1161/01.CIR.86.3.803; SEMPOS CT, 1994, NEW ENGL J MED, V330, P1119, DOI 10.1056/NEJM199404213301604; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; SULLIVAN JL, 1989, AM HEART J, V117, P1177, DOI 10.1016/0002-8703(89)90887-9; SULLIVAN JL, 1981, LANCET, V1, P1293; VONRECKLINGHAUS.F, 1889, HEIDELBERG J, V52, P324	17	70	72	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 20	1994	272	3					231	233		10.1001/jama.272.3.231	http://dx.doi.org/10.1001/jama.272.3.231			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW185	8022042				2022-12-24	WOS:A1994NW18500025
J	PISACANE, A; IMPAGLIAZZO, N; RUSSO, M; VALIANI, R; MANDARINI, A; FLORIO, C; VIVO, P				PISACANE, A; IMPAGLIAZZO, N; RUSSO, M; VALIANI, R; MANDARINI, A; FLORIO, C; VIVO, P			BREAST-FEEDING AND MULTIPLE-SCLEROSIS	BRITISH MEDICAL JOURNAL			English	Article									OSPED ANTONIO CARDARELLI,DIV NEUROL,NAPLES,ITALY; ASSOC ITALIANA SCLEROSI MULTIPLA,NAPLES,ITALY	Antonio Cardarelli Hospital	PISACANE, A (corresponding author), UNIV NAPLES FEDERICO II,DIPARTIMENTO PEDIAT,VIA PANSINI 5,I-80131 NAPLES,ITALY.							AGRANOFF BW, 1974, LANCET, V2, P1061; FARQUHARSON J, 1992, LANCET, V340, P810, DOI 10.1016/0140-6736(92)92684-8; HANSON LA, 1985, PEDIATRICS, V75, P172; MARTYN CN, 1991, CIBA F SYMP, V156, P93; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302	5	47	49	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 28	1994	308	6941					1411	1412		10.1136/bmj.308.6941.1411	http://dx.doi.org/10.1136/bmj.308.6941.1411			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP420	8019251	Green Published			2022-12-24	WOS:A1994NP42000016
J	FRIES, JF; SINGH, G; MORFELD, D; HUBERT, HB; LANE, NE; BROWN, BW				FRIES, JF; SINGH, G; MORFELD, D; HUBERT, HB; LANE, NE; BROWN, BW			RUNNING AND THE DEVELOPMENT OF DISABILITY WITH AGE	ANNALS OF INTERNAL MEDICINE			English	Article						RUNNING; AGING; EXERCISE; DISABLED; PHYSICAL FITNESS	WEIGHT-BEARING EXERCISE; PHYSICAL-ACTIVITY; OSTEO-ARTHRITIS; BONE-DENSITY; HEALTH OUTCOMES; OSTEOARTHRITIS; KNEE; ASSOCIATION; DIMENSIONS; MORTALITY	Objective: To determine, by longitudinal study, whether regular vigorous running activity is associated with accelerated, unchanged, or postponed development of disability with increasing age. Study Design: 8-year prospective, longitudinal study with yearly assessments. Participants: 451 members of a runners' club and 330 community controls who were initially 50 to 72 years old (also characterized as ''ever-runners'' [n = 534] and ''never-runners'' [n = 247], respectively). Measurements: The dependent variable was disability as assessed by the Health Assessment Questionnaire and separately validated in these participant cohorts. Covariates included age, sex, body mass index, comorbid conditions, education level, smoking history, alcohol intake, mean blood pressure, initial disability level, family history of arthritis, and radiologic evidence of osteoarthritis of the knee in a subsample. Results: Initially, the runners were leaner, reported joint symptoms less frequently, took fewer medications, had fewer medical problems, and had fewer instances of and less severity of disability, suggesting either that the average previous 12 years of running had improved health or that self-selection bias was present. After 8 years of longitudinal study, the differences in initial disability levels (0.026 compared with 0.079; P < 0.001) had steadily increased to 0.071 for runners compared with 0.242 for controls (P < 0.001). The difference was consistent for men and women. The rate of development of disability was several times lower in the runners' club members than in community controls; this difference persisted after adjusting for age, sex, body mass, baseline disability, smoking history, history of arthritis, or other comorbid conditions (slopes of progression of disability for the years 1984 to 1992, after adjusting for covariates: men in the runners' club, 0.004 [SE, 0.002]; community controls, 0.012 [SE, 0.002]; women in the runners' club, 0.009 [SE, 0.005]; community controls, 0.027 [SE, 0.004]; P < 0.002 for both sets of comparisons). In addition to differences in disability, there were significant differences in mortality between the runners' club members (1.49%) and community controls (7.09%) (P < 0.001). These differences remained significant after adjusting for age, sex, body mass, comorbid conditions, education level, smoking history, alcohol intake, and mean blood pressure (P < 0.002, conditional risk ratio for community controls compared with the runners, 4.27; 95% CI, 1.78 to 10.26). Conclusions: Older persons who engage in vigorous running and other aerobic activities have lower mortality and slower development of disability than do members of the general population. This association is probably related to increased aerobic activity, strength, fitness, and increased organ reserve rather than to an effect of postponed osteoarthritis development.	STANFORD UNIV, SCH MED, DEPT HLTH RES & POLICY, STANFORD, CA 94305 USA	Stanford University			Fries, James F/F-6271-2011		NIAMS NIH HHS [AR20610-16] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020610] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BROWN JH, 1984, AM J PUBLIC HEALTH, V74, P159, DOI 10.2105/AJPH.74.2.159; BRUCE RA, 1984, MED SCI SPORT EXER, V16, P8; CURFMAN GD, 1993, NEW ENGL J MED, V328, P574, DOI 10.1056/NEJM199302253280810; Dill D B, 1967, J Sports Med Phys Fitness, V7, P4; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; FRIES JF, 1982, J RHEUMATOL, V9, P789; GLYN JH, 1966, BMJ-BRIT MED J, V2, P739, DOI 10.1136/bmj.2.5516.739; HANNAN MT, 1993, J RHEUMATOL, V20, P704; HAWLEY DJ, 1991, J RHEUMATOL, V18, P1552; LANE NE, 1986, JAMA-J AM MED ASSOC, V255, P1147; LANE NE, 1987, AM J MED, V82, P772, DOI 10.1016/0002-9343(87)90014-3; LANE NE, 1989, J RHEUMATOL, V16, P637; LANE NE, 1990, AM J MED, V88, P452, DOI 10.1016/0002-9343(90)90422-A; LANE NE, 1993, J RHEUMATOL, V20, P461; LARSON EB, 1986, ANN INTERN MED, V105, P783, DOI 10.7326/0003-4819-105-5-783; LUBECK DP, 1985, MED CARE, V23, P266, DOI 10.1097/00005650-198503000-00008; MCALINDON TE, 1993, ANN RHEUM DIS, V52, P258, DOI 10.1136/ard.52.4.258; MICHEL BA, 1989, ARCH INTERN MED, V149, P2325, DOI 10.1001/archinte.149.10.2325; MICHEL BA, 1992, INT ORTHOP, V16, P87; MICHEL BA, 1991, ANN MED, V23, P397, DOI 10.3109/07853899109148081; MICHEL BA, 1992, CLIN RHEUMATOL, V11, P235, DOI 10.1007/BF02207964; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PANUSH RS, 1986, JAMA-J AM MED ASSOC, V255, P1152, DOI 10.1001/jama.255.9.1152; POCOCK NA, 1986, J CLIN INVEST, V78, P618, DOI 10.1172/JCI112618; RADIN EL, 1972, LANCET, V1, P519; Ramey D R, 1992, Arthritis Care Res, V5, P119, DOI 10.1002/art.1790050303; REIMANN I, 1973, ACTA ORTHOP SCAND, V44, P496, DOI 10.3109/17453677308989085; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SANDVIK L, 1993, NEW ENGL J MED, V328, P533, DOI 10.1056/NEJM199302253280803; STEWART AL, 1993, GERONTOLOGIST, V33, P782, DOI 10.1093/geront/33.6.782	30	107	108	1	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1994	121	7					502	509		10.7326/0003-4819-121-7-199410010-00005	http://dx.doi.org/10.7326/0003-4819-121-7-199410010-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ102	8067647				2022-12-24	WOS:A1994PJ10200005
J	KUUSISTO, J; KOIVISTO, K; KERVINEN, K; MYKKANEN, L; HELKALA, EL; VANHANEN, M; HANNINEN, T; PYORALA, K; KESANIEMI, YA; RIEKKINEN, P; LAAKSO, M				KUUSISTO, J; KOIVISTO, K; KERVINEN, K; MYKKANEN, L; HELKALA, EL; VANHANEN, M; HANNINEN, T; PYORALA, K; KESANIEMI, YA; RIEKKINEN, P; LAAKSO, M			ASSOCIATION OF APOLIPOPROTEIN-E PHENOTYPES WITH LATE-ONSET ALZHEIMERS-DISEASE - POPULATION-BASED STUDY	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; E POLYMORPHISM; DEMENTIA; LINKAGE; ALLELE; EPSILON-4; MEMORY	Objective-To determine the association between the e4 allele of apolipoprotein E and Alzheimer's disease in a randomly selected population sample. Design-Cross sectional population based study. Subjects-980 people aged 69 to 78 (349 men, 631 women). Setting-Population of Kuopio, eastern Finland. Main outcome measures-Presence of e4 allele and diagnosis of Alzheimer's disease by detailed neurological and neurophysiological evaluation. Results-46 (4.7%) subjects were classified as having probable or possible Alzheimer's disease. The frequency of the apolipoprotein E e4 allele was 0.359 in patients with Alzheimer's disease and 0.165 in subjects without dementia (P<0.0001). The prevalence of Alzheimer's disease was 2.9% in subjects with no e4 alleles, 7.6% in subjects with one e4 allele, and 21.4% in subjects with two e4 alleles of apolipoprotein E. Conclusions-Allele e4 of apolipoprotein is associated with Alzheimer's disease in a dose-response fashion in a randomly selected elderly population.	KUOPIO UNIV HOSP,DEPT MED,KUOPIO,FINLAND; KUOPIO UNIV HOSP,DEPT NEUROL,KUOPIO,FINLAND; OULU UNIV HOSP,DEPT INTERNAL MED,OULU,FINLAND; UNIV OULU,BIOCTR,OULU,FINLAND	Kuopio University Hospital; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; University of Oulu; University of Oulu								BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; BUTTERS N, 1987, J CLIN EXP NEUROPSYC, V9, P479, DOI 10.1080/01688638708410764; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; EHNHOLM C, 1986, J LIPID RES, V27, P227; Elston RC, 1987, ESSENTIALS BIOSTATIS; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746; GERDES LU, 1992, GENET EPIDEMIOL, V9, P155, DOI 10.1002/gepi.1370090302; GROBER E, 1988, NEUROLOGY, V38, P90; HACHINSKI VC, 1974, LANCET, V2, P207; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; KAY DWK, 1991, REV CLIN GERONTOLOGY, V1, P55; KERVINEN K, 1994, ATHEROSCLEROSIS, V105, P89, DOI 10.1016/0021-9150(94)90011-6; Koivisto K, 1992, J Geriatr Psychiatry Neurol, V5, P162; LAAKSO M, 1991, BMJ-BRIT MED J, V303, P1159, DOI 10.1136/bmj.303.6811.1159; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MENZEL HJ, 1986, ELECTROPHORESIS, V7, P492, DOI 10.1002/elps.1150071103; MYKKANEN L, 1990, DIABETES CARE, V13, P1099, DOI 10.2337/diacare.13.11.1099; PAYNE MN, 1992, LANCET, V340, P1350, DOI 10.1016/0140-6736(92)92532-K; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; SAUNDERS AM, 1993, LANCET, V342, P710, DOI 10.1016/0140-6736(93)91709-U; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SCHELLENBERG GD, 1991, AM J HUM GENET, V48, P563; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P8098; SULKAVA R, 1985, NEUROLOGY, V35, P1025, DOI 10.1212/WNL.35.7.1025; UKKOLA O, 1993, ATHEROSCLEROSIS, V101, P9, DOI 10.1016/0021-9150(93)90096-D; VANBOCKXMEER FM, 1992, LANCET, V340, P879, DOI 10.1016/0140-6736(92)93288-X; WARRINGTON EK, 1966, BRAIN, V89, P53, DOI 10.1093/brain/89.1.53; 1987, DIAGNOSTIC STATISTIC	35	182	184	1	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 10	1994	309	6955					636	638		10.1136/bmj.309.6955.636	http://dx.doi.org/10.1136/bmj.309.6955.636			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG020	8086986	Green Published			2022-12-24	WOS:A1994PG02000019
J	SURRIDGE, C				SURRIDGE, C			SHORTING OUT THE CELLULAR BATTERY	NATURE			English	Article							COLICIN-A	A low-resolution structure of the bacterial toxin collicin Ia provides a model for its lethal membrane association and an explanation for the anomalous behaviour of its C-terminal peptide fragment.						Surridge, Christopher/0000-0003-4264-5176				GHOSH P, 1994, NAT STRUCT BIOL, V1, P597, DOI 10.1038/nsb0994-597; PARKER MW, 1992, J MOL BIOL, V224, P639, DOI 10.1016/0022-2836(92)90550-4; SANSOM MSP, 1994, NAT STRUCT BIOL, V1, P563, DOI 10.1038/nsb0994-563; STEIN PE, 1994, NAT STRUCT BIOL, V1, P591, DOI 10.1038/nsb0994-591; WORMALD MR, 1990, EUR J BIOCHEM, V191, P155, DOI 10.1111/j.1432-1033.1990.tb19105.x	5	1	1	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 1	1994	371	6492					84	84		10.1038/371084a0	http://dx.doi.org/10.1038/371084a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE381	8072534	Bronze			2022-12-24	WOS:A1994PE38100058
J	VONKORFF, M; BARLOW, W; CHERKIN, D; DEYO, RA				VONKORFF, M; BARLOW, W; CHERKIN, D; DEYO, RA			EFFECTS OF PRACTICE STYLE IN MANAGING BACK PAIN	ANNALS OF INTERNAL MEDICINE			English	Article						PHYSICIANS PRACTICE PATTERNS; BACK PAIN; SELF CARE; COST-BENEFIT ANALYSIS; BED REST	PHYSICIAN EDUCATION INTERVENTION; IMPROVE PRIMARY CARE; DISABILITY; IMPACT	Objective: To assess the effects of a practice style of back pain management consistent with self-care (infrequent prescribing of pain medications and bed rest) on long-term functional outcomes, costs of care, and patient satisfaction. Design: A quasi-experimental observational study in which primary care physicians (n = 44) were categorized according to one of three practice style groups defined by a low, moderate, or high frequency of prescribing pain medications and bed rest for many patients (average, 24 patients per physician). Setting: Primary care practices of a large, staff model health maintenance organization, Group Health Cooperative of Puget Sound. Patients: Consecutive patients with back or neck pain of participating primary care physicians. Patients were interviewed 1 month (n = 1071) and 1 year and 2 years (n = 911) after their index visits. Results: Patients in the three practice style groups rated similarly the quality of medical care received for back pain. Patients treated by physicians who infrequently prescribed pain medications and bed rest were more satisfied with education about back pain. On a scale of 0 to 10, the mean rating of agreement with the statement, ''After your visit with the doctor, you fully understood how to take care of your back problem,'' was 5.6 +/- 3.6 among patients of physicians who frequently prescribed medication and rest and was 6.6 +/- 3.5) among those who infrequently prescribed medication and bed rest. At 1 month, 30% of patients of physicians who infrequently prescribed medications and bed rest were graded as having moderate to severe activity limitation because of back pain, whereas 37% of patients in the moderate group had this grading, and 46% of patients of physicians who frequently prescribed were graded as having moderate to severe activity limitation. Differences in activity limitation by practice style group were no longer evident at 1 or 2 years of follow-up. The total 1-year costs of back care were higher among patients seen by physicians who frequently prescribed bed rest and pain medications (cost, $768 +/- $1592) than among those seen by physicians who infrequently prescribed (cost, $428 +/- $665), due largely to differences in inpatient and specialty care costs. The adjusted difference in costs, after controlling for case-mix variables, was $277 (95% Cl, $85.50 to $471.32). Conclusions: A practice style consistent with back pain self-care yielded similar long-term pain and functional outcomes at lower cost and was associated with higher satisfaction with patient education compared with a practice style characterized by more frequent prescribing of pain medications and bed rest.			VONKORFF, M (corresponding author), GRP HLTH COOPERAT PUGET SOUND, CTR HLTH STUDIES, 1730 MINOR AVE, SUITE 1600, SEATTLE, WA 98101 USA.			VonKorff, Michael/0000-0001-5386-8477	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006168, P01HS006344] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE008773] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS06168, P01 HS06344] Funding Source: Medline; NIDCR NIH HHS [P01 DE08773] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		CHERKIN D, 1991, SPINE, V16, P1168, DOI 10.1097/00007632-199110000-00007; CHERKIN D, 1991, SPINE, V16, P1173, DOI 10.1097/00007632-199110000-00008; CYPRESS BK, 1983, AM J PUBLIC HEALTH, V73, P389, DOI 10.2105/AJPH.73.4.389; DEYO RA, 1986, NEW ENGL J MED, V315, P1064, DOI 10.1056/NEJM198610233151705; DEYO RA, 1983, JAMA-J AM MED ASSOC, V250, P1057; DONNER A, 1981, AM J EPIDEMIOL, V114, P906, DOI 10.1093/oxfordjournals.aje.a113261; FORDYCE WE, 1986, J BEHAV MED, V9, P127, DOI 10.1007/BF00848473; FORDYCE WE, 1976, BEHAVIORAL METHODS C; FRYMOYER JW, 1991, ORTHOP CLIN N AM, V22, P263; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; LINTON SJ, 1993, PAIN, V54, P353, DOI 10.1016/0304-3959(93)90037-P; Osterweis M., 1987, PAIN DISABILITY CLIN; PHILIPS HC, 1991, BEHAV RES THER, V29, P435, DOI 10.1016/0005-7967(91)90127-O; PHILIPS HC, 1991, BEHAV RES THER, V29, P443, DOI 10.1016/0005-7967(91)90128-P; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; ROTER DL, 1989, ANNU REV PUBL HEALTH, V10, P163, DOI 10.1146/annurev.pu.10.050189.001115; VONKORFF M, 1993, SPINE, V18, P855, DOI 10.1097/00007632-199306000-00008; VONKORFF M, 1992, PAIN, V50, P133, DOI 10.1016/0304-3959(92)90154-4; VONKORFF M, IN PRESS 7TH P WORLD, V2; Waddell G, 1991, Neurosurg Clin N Am, V2, P719; WHITNEY CW, 1992, PAIN, V50, P281, DOI 10.1016/0304-3959(92)90032-7; 1989, SAS USERS GUIDE STAT; 1987, SPINE S1, V12, pS1	23	98	98	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1994	121	3					187	195		10.7326/0003-4819-121-3-199408010-00005	http://dx.doi.org/10.7326/0003-4819-121-3-199408010-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY338	8017745				2022-12-24	WOS:A1994NY33800005
J	LIU, DJ; DAY, LA				LIU, DJ; DAY, LA			PF1 VIRUS STRUCTURE - HELICAL COAT PROTEIN AND DNA WITH PARAXIAL PHOSPHATES	SCIENCE			English	Article							LASER RAMAN-SPECTROSCOPY; FILAMENTOUS BACTERIOPHAGE-PFL; BACTERIAL VIRUS-PF1; NEUTRON-DIFFRACTION; LINEAR DICHROISM; ELECTRON-DENSITY; XF; FD; RESOLUTION; IKE	The helical path of the DNA in filamentous bacteriophage Pf1 was deduced from different kinds of existing structural information, including results from x-ray fiber diffraction. The DNA has the same pitch, 16 angstroms, as the surrounding helix of protein subunits; the rise and rotation per nucleotide are 6.1 angstroms and 132 degrees, respectively; and the phosphates are 2.5 angstroms from the axis. The DNA in Pf1 is, therefore, the most extended and twisted DNA structure known. On the basis of the DNA structure and extensive additional information about the protein, a model of the virion is proposed. In the model, the DNA bases reach out, into the protein, and the lysine and arginine side chains reach in, between the DNA bases, to stabilize the paraxial phosphate charges; the conformation of the protein subunit is combination of alpha and 3(10) helices.			LIU, DJ (corresponding author), PUBL HLTH RES INST CITY NEW YORK INC,455 1ST AVE,NEW YORK,NY 10016, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042286] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42286] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BRYAN RK, 1983, P NATL ACAD SCI-BIOL, V80, P4728, DOI 10.1073/pnas.80.15.4728; CASADEVALL A, 1983, BIOCHEMISTRY-US, V22, P4831, DOI 10.1021/bi00289a033; CASADEVALL A, 1988, BIOCHEMISTRY-US, V27, P3599, DOI 10.1021/bi00410a010; CLACK BA, 1992, BIOPOLYMERS, V32, P795, DOI 10.1002/bip.360320708; CROSS TA, 1983, BIOCHEMISTRY-US, V22, P721, DOI 10.1021/bi00273a002; DAY LA, 1979, NUCLEIC ACIDS RES, V7, P1393, DOI 10.1093/nar/7.6.1393; DAY LA, 1988, ANNU REV BIOPHYS BIO, V17, P509; FRITZSCHE H, 1986, STUD BIOPHYS, V116, P175; GREULICH KO, 1984, BIOCHIM BIOPHYS ACTA, V782, P446, DOI 10.1016/0167-4781(84)90053-8; HILL DF, 1991, J MOL BIOL, V218, P349, DOI 10.1016/0022-2836(91)90717-K; KLUG A, 1958, ACTA CRYSTALLOGR, V11, P199, DOI 10.1107/S0365110X58000517; KOSTRIKIS LG, 1994, BIOCHEMISTRY-US, V33, P1694, DOI 10.1021/bi00173a011; MAKOWSKI L, 1981, J MOL BIOL, V145, P611; MARVIN DA, 1992, PHASE TRANSIT, V39, P45, DOI 10.1080/01411599208203472; MARVIN DA, 1987, J MOL BIOL, V193, P315, DOI 10.1016/0022-2836(87)90222-1; MARZEC CJ, 1988, BIOPHYS J, V53, P425, DOI 10.1016/S0006-3495(88)83119-9; MARZEC CJ, 1993, J BIOMOL STRUCT DYN, V10, P1091, DOI 10.1080/07391102.1993.10508697; MARZEC CJ, UNPUB; NAKASHIMA Y, 1980, J MOL BIOL, V138, P493, DOI 10.1016/S0022-2836(80)80014-3; NAMBUDRIPAD R, 1991, J MOL BIOL, V220, P359, DOI 10.1016/0022-2836(91)90019-3; NAMBUDRIPAD R, 1991, SCIENCE, V252, P1305, DOI 10.1126/science.1925543; NAVE C, 1981, J MOL BIOL, V149, P675, DOI 10.1016/0022-2836(81)90353-3; PAULING L, 1951, P NATL ACAD SCI USA, V37, P205, DOI 10.1073/pnas.37.4.205; REISBERG SA, 1989, THESIS NEW YORK U; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; SHON KJ, 1991, SCIENCE, V252, P1303, DOI 10.1126/science.1925542; STARK W, 1988, J MOL BIOL, V199, P171, DOI 10.1016/0022-2836(88)90387-7; TAKEYA K, 1966, VIROLOGY, V28, P163, DOI 10.1016/0042-6822(66)90317-5; THOMAS GJ, 1983, J MOL BIOL, V165, P321, DOI 10.1016/S0022-2836(83)80260-5; THOMAS GJ, 1988, BIOCHEMISTRY-US, V27, P4350, DOI 10.1021/bi00412a023; THOMAS GJ, 1985, SPECTROCHIM ACTA A, V41, P217, DOI 10.1016/0584-8539(85)80100-8; TORBET J, 1981, BIOPOLYMERS, V20, P2657, DOI 10.1002/bip.1981.360201212; WISEMAN RL, 1977, J MOL BIOL, V116, P607, DOI 10.1016/0022-2836(77)90088-2	34	84	86	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 29	1994	265	5172					671	674		10.1126/science.8036516	http://dx.doi.org/10.1126/science.8036516			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	8036516				2022-12-24	WOS:A1994NZ53800036
J	RING, BZ; ROBERTS, JW				RING, BZ; ROBERTS, JW			FUNCTION OF A NONTRANSCRIBED DNA STRAND SITE IN TRANSCRIPTION ELONGATION	CELL			English	Article							COLI RNA-POLYMERASE; PHAGE-LAMBDA; PAUSE SITE; Q-PROTEIN; TERMINATION; RHO; REGION; ANTITERMINATION; SEQUENCE; PROMOTER	A prolonged pause in transcription elongation at positions +16 and +17 of the phage lambda late gene operon has an important role in the modification of RNA polymerase by the lambda gene Q transcription antiterminator. Mutations included in the transcription bubble of the paused transcription complex, particularly at +2 and +6, abolish pausing and the ability of Q protein to modify RNA polymerase. By transcribing heteroduplex templates made in vitro, we show that the sites identified by these mutations act through the nontranscribed strand of DNA. This result suggests unexpected regulatory functions of the nontranscribed DNA strand in transcription.			RING, BZ (corresponding author), CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,BIOTECHNOL BLDG,ITHACA,NY 14853, USA.				NIGMS NIH HHS [GM21941] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021941, R01GM021941] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAMBERLIN M, 1994, IN PRESS HARVEY LECT; CHAN CL, 1993, J MOL BIOL, V233, P25, DOI 10.1006/jmbi.1993.1482; CHENG SWC, 1991, SCIENCE, V254, P1205, DOI 10.1126/science.1835546; Dahlberg JE, 1973, VIRUS RES, P533; FARNHAM PJ, 1981, NUCLEIC ACIDS RES, V9, P563, DOI 10.1093/nar/9.3.563; FISHER RF, 1983, J BIOL CHEM, V258, P8146; GILBERT W, 1974, COLD SPRING HARB SYM, V38, P845; GOLIGER JA, 1989, J MOL BIOL, V210, P461, DOI 10.1016/0022-2836(89)90123-X; GRAYHACK EJ, 1985, CELL, V42, P259, DOI 10.1016/S0092-8674(85)80121-5; GUO HC, 1990, THESIS CORNELL U ITH; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; KAINZ M, 1992, SCIENCE, V255, P838, DOI 10.1126/science.1536008; LANDICK R, 1987, ESCHERICHIA COLI SAL, P1276; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; METZGER W, 1989, EMBO J, V8, P2745, DOI 10.1002/j.1460-2075.1989.tb08416.x; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; ROBERTS J, 1992, TRANSCRIPTIONAL REGU, P389; ROSENBERG M, 1978, NATURE, V272, P414, DOI 10.1038/272414a0; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; Sambrook J., 1989, MOL CLONING LAB MANU; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241; YANG X, 1988, THESIS CORNELL U ITH; YANG XJ, 1987, GENE DEV, V1, P217, DOI 10.1101/gad.1.3.217; YANG XJ, 1989, P NATL ACAD SCI USA, V86, P5301, DOI 10.1073/pnas.86.14.5301; YARNELL WS, 1992, CELL, V69, P1181, DOI 10.1016/0092-8674(92)90639-T	25	58	58	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 29	1994	78	2					317	324		10.1016/0092-8674(94)90300-X	http://dx.doi.org/10.1016/0092-8674(94)90300-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	8044843				2022-12-24	WOS:A1994NZ24200014
J	LEE, HC; AARHUS, R; GRAEFF, R; GURNACK, ME; WALSETH, TF				LEE, HC; AARHUS, R; GRAEFF, R; GURNACK, ME; WALSETH, TF			CYCLIC ADP RIBOSE ACTIVATION OF THE RYANODINE RECEPTOR IS MEDIATED BY CALMODULIN	NATURE			English	Article							SEA-URCHIN EGG; CALCIUM RELEASE; CA2+ RELEASE; MICROSOMES; MODULATION; CHANNEL; BINDING	CYCLIC ADP-ribose (cADPR) is a newly identified nucleotide(1,2) which can release calcium from a variety of cells(3-6), suggesting it is a messenger for mobilizing internal Ca2+ stores. Its cyclic structure has now been confirmed by X-ray crystallography(7). Available results are consistent with it being a modulator of Ca2+-induced Ca2+ releases(8-10). Here we report that sea urchin egg microsomes purified by Percoll gradients lose sensitivity to cADPR, but the response can be restored by a soluble protein in the supernatant. Purification and characterization of the protein indicate that it is calmodulin. It appears to be sensitizing the Ca2+ release mechanism because caffeine and strontium, agonists of Ca2+-induced Ca2+ release, can also mimic calmodulin in conferring cADPR-sensitivity. Although evidence indicates that cADPR may be an activator of the ryanodine receptor(8-10), present results point to the importance of accessory proteins such as calmodulin in modulating its activity.	UNIV MINNESOTA,DEPT PHARMACOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities	LEE, HC (corresponding author), UNIV MINNESOTA,DEPT PHYSIOL,MINNEAPOLIS,MN 55455, USA.		Walseth, Timothy F/F-9518-2010; Lee, Hon Cheung/C-4329-2009; Graeff, Richard Milton/B-3425-2011	Walseth, Timothy F/0000-0003-2558-7859; 				CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; ENAN E, 1992, BIOCHEM PHARMACOL, V43, P1777, DOI 10.1016/0006-2952(92)90710-Z; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; HASHIMOTO Y, 1987, J BIOL CHEM, V262, P8051; KOSHIYAMA H, 1991, J BIOL CHEM, V266, P16985; LEE HC, 1994, NAT STRUCT BIOL, V1, P143, DOI 10.1038/nsb0394-143; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, J BIOL CHEM, V268, P293; LEE HC, 1991, J BIOL CHEM, V266, P2276; MCPHERSON SM, 1992, J CELL BIOL, V116, P1111, DOI 10.1083/jcb.116.5.1111; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; PAYNE ME, 1989, J BIOL CHEM, V262, P8051; SHEN SS, 1989, BIOCHEM BIOPH RES CO, V161, P1100, DOI 10.1016/0006-291X(89)91356-9; SMITH JS, 1989, CIRC RES, V64, P352, DOI 10.1161/01.RES.64.2.352; TAKASAWA S, SCIENCE, V370, P93; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; WALSETH TF, 1993, J BIOL CHEM, V268, P26686; WHITE A, 1993, FEBS LETT, V318, P21	19	209	213	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 28	1994	370	6487					307	309		10.1038/370307a0	http://dx.doi.org/10.1038/370307a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ229	8035880				2022-12-24	WOS:A1994NZ22900068
J	AMON, A; IRNIGER, S; NASMYTH, K				AMON, A; IRNIGER, S; NASMYTH, K			CLOSING THE CELL-CYCLE CIRCLE IN YEAST - G2 CYCLIN PROTEOLYSIS INITIATED AT MITOSIS PERSISTS UNTIL THE ACTIVATION OF G1 CYCLINS IN THE NEXT CYCLE	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; POSITIVE FEEDBACK; S-PHASE; PROTEIN; KINASE; CDC28; CLN1; PHOSPHORYLATION; DEGRADATION	It is thought that DNA replication and mitosis in yeast are triggered by oscillations in the level of G1-specific (CLN1 and CLN2) and G2-specific (CLB1-CLB4) cyclins, which determine the substrate specificity of the CDC28 protein kinase. It is not understood how the time and order of appearance of different cyclin types are determined. We show here that CLB2 proteolysis, which is important for transition from mitosis to G1, is not confined to a narrow window at the end of mitosis as previously thought but continues until reactivation of CDC28 by CLN cyclins toward the end of the subsequent G1 period. Thus, cell cycle-regulated proteolysis prevents accumulation of G2-specific CLB cyclins during G1 and thereby ensures that the CLN-associated forms of the CDC28 kinase are activated without interference from CLB cylins. Accumulation of CLN cyclins leads to inactivation of CLB cyclin proteolysis, which is a precondition for subsequent activation of G2-specific B-type cyclins.	RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)				Amon, Angelika/0000-0001-9837-0314; Nasmyth, Kim/0000-0001-7030-4403				AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; CHEREST H, 1985, GENE, V34, P269; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; CVRCKOVA F, 1993, EMBO J, V12, P5277, DOI 10.1002/j.1460-2075.1993.tb06223.x; DIRICK L, 1991, NATURE, V351, P754, DOI 10.1038/351754a0; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; FITCH I, 1992, MOL BIOL CELL, V3, P805, DOI 10.1091/mbc.3.7.805; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GRANDIN N, 1993, MOL CELL BIOL, V13, P2113, DOI 10.1128/MCB.13.4.2113; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; LEW DJ, 1993, J CELL BIOL, V120, P1305, DOI 10.1083/jcb.120.6.1305; Maniatis T., 1982, MOL CLONING; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MORTIMER RK, 1969, YEASTS, V1, P385; MOUNTAIN HA, 1991, YEAST, V7, P873, DOI 10.1002/yea.320070814; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NASMYTH K, 1993, CURR OPIN GENET DEV, V3, P286, DOI 10.1016/0959-437X(93)90036-O; NASMYTH K, 1991, COLD SPRING HARB SYM, V56, P9; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROSE MD, 1990, LABORATORY COURSE MA; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SIMCHEN G, 1972, EXP CELL RES, V75, P207, DOI 10.1016/0014-4827(72)90538-1; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x	31	409	412	1	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 1	1994	77	7					1037	1050		10.1016/0092-8674(94)90443-X	http://dx.doi.org/10.1016/0092-8674(94)90443-X			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NV425	8020094				2022-12-24	WOS:A1994NV42500012
J	GOLINO, P; PISCIONE, F; BENEDICT, CR; ANDERSON, HV; CAPPELLIBIGAZZI, M; INDOLFI, C; CONDORELLI, M; CHIARIELLO, M; WILLERSON, JT				GOLINO, P; PISCIONE, F; BENEDICT, CR; ANDERSON, HV; CAPPELLIBIGAZZI, M; INDOLFI, C; CONDORELLI, M; CHIARIELLO, M; WILLERSON, JT			LOCAL EFFECT OF SEROTONIN RELEASED DURING CORONARY ANGIOPLASTY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CYCLIC FLOW VARIATIONS; VASOCONSTRICTOR ACTIVITY; ARTERIES; INVIVO; MEDIATORS; VASOSPASM; INJURY; DOGS; THROMBOXANE-A2; NITROGLYCERIN	Background. Serotonin is released after the aggregation of platelets, a phenomenon that may occur after coronary angioplasty. We sought to determine whether serotonin is released into the coronary circulation during coronary angioplasty and to assess whether serotonin can affect coronary-artery tone during angioplasty. Methods. Blood samples were drawn from the ascending aorta and the coronary sinus of eight patients scheduled to undergo angioplasty of the left anterior descending or circumflex coronary artery. Samples were obtained before angioplasty and after each balloon dilation. The dimensions of arterial segments distal to the site of dilation were measured angiographically before angioplasty and 5 and 15 minutes after the last dilation in these eight patients and in seven similar patients; the latter group was treated with ketanserin, a serotonin(2)-receptor antagonist, before angioplasty. Results. Before the eight patients underwent angioplasty, their mean (+/-SE) plasma serotonin level in the aorta was 2.5+/-0.7 ng per milliliter and that in the coronary sinus was 2.3+/-0.6 ng per milliliter (P = 0.34). The seretonin level in plasma from the coronary sinus rose significantly, to 31.5+/-13.5, 17.6+/-5.3, and 29.1+/-8.1 ng per milliliter after the first, second, and third dilations, respectively (P = 0.014 for the comparison with preoperative levels). In contrast, the serotonin level in plasma from the ascending aorta did not change. The cross-sectional area of the coronary artery was significantly reduced 5 and 15 minutes after the last dilation (from a preoperative value of 3.7+/-0.5 mm(2) to 2.7+/-0.4 mm(2) 15 minutes after the last dilation; P = 0.011). This vasoconstriction was significantly blunted in the seven patients who received ketanserin (from 3.7+/-0.5 mm(2) before angioplasty to 3.9+/-0.4 mm(2) after 15 minutes) (P = 0.017 for comparison with the eight patients who did not receive ketanserin). Conclusions. Serotonin is released into the coronary circulation during angioplasty, and this vasoactive substance may contribute to the occurrence of vasoconstriction distal to the dilated site. The vasoconstriction is attenuated by ketanserin, a serotonin(2)-receptor antagonist.	UNIV NAPLES,SCH MED 2,DEPT INTERNAL MED,NAPLES,ITALY; UNIV TEXAS,HLTH SCI CTR,DEPT INTERNAL MED,HOUSTON,TX; UNIV TEXAS,HLTH SCI CTR,DIV CARDIOL,HOUSTON,TX	University of Naples Federico II; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston	GOLINO, P (corresponding author), UNIV NAPLES,SCH MED 2,DIV CARDIOL,VIA SERGIO PANSINI 5,I-80131 NAPLES,ITALY.			GOLINO, Paolo/0000-0002-3590-6983; INDOLFI, Ciro/0000-0003-1241-6487	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K04HL001669] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-1669] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS GA, 1984, THROMB HAEMOSTASIS, V52, P45; ASHTON JH, 1986, CIRCULATION, V73, P572, DOI 10.1161/01.CIR.73.3.572; ASHTON JH, 1987, CIRCULATION, V76, P952, DOI 10.1161/01.CIR.76.4.952; BRUM JM, 1984, CIRCULATION, V70, P1066, DOI 10.1161/01.CIR.70.6.1066; COHEN RA, 1987, CIRC RES, V61, P829, DOI 10.1161/01.RES.61.6.829; CRAGG A, 1983, AM J CARDIOL, V51, P1441, DOI 10.1016/0002-9149(83)90326-0; DORROS G, 1983, CIRCULATION, V67, P723, DOI 10.1161/01.CIR.67.4.723; ELLIS SG, 1988, CIRCULATION, V77, P372, DOI 10.1161/01.CIR.77.2.372; FISCHELL TA, 1988, CIRCULATION, V78, P1323, DOI 10.1161/01.CIR.78.6.1323; FISCHELL TA, 1990, J CLIN INVEST, V86, P575, DOI 10.1172/JCI114747; GOLINO P, 1990, J AM COLL CARDIOL, V15, P718, DOI 10.1016/0735-1097(90)90652-6; GOLINO P, 1989, CIRCULATION, V79, P154, DOI 10.1161/01.CIR.79.1.154; GOLINO P, 1991, NEW ENGL J MED, V324, P641, DOI 10.1056/NEJM199103073241001; HOLLMAN J, 1983, J AM COLL CARDIOL, V2, P1039, DOI 10.1016/S0735-1097(83)80327-1; HOLLMAN J, 1983, CIRCULATION, V68, P725, DOI 10.1161/01.CIR.68.4.725; HUSSAIN MN, 1987, BIOCHEM MED METAB B, V37, P314, DOI 10.1016/0885-4505(87)90042-9; LAM JYT, 1987, CIRCULATION, V75, P243, DOI 10.1161/01.CIR.75.1.243; LAM JYT, 1988, CIRCULATION, V78, P712, DOI 10.1161/01.CIR.78.3.712; LAMPING KG, 1985, CIRC RES, V57, P46, DOI 10.1161/01.RES.57.1.46; MABIN TA, 1985, J AM COLL CARDIOL, V5, P198, DOI 10.1016/S0735-1097(85)80037-1; MCFADDEN EP, 1991, NEW ENGL J MED, V324, P648, DOI 10.1056/NEJM199103073241002; RUBANYI GM, 1987, J AM COLL CARDIOL, V9, P1243, DOI 10.1016/S0735-1097(87)80462-X; SHIMOKAWA H, 1987, CIRC RES, V61, P256, DOI 10.1161/01.RES.61.2.256; SIGAL SL, 1991, ARTERIOSCLER THROMB, V11, P770, DOI 10.1161/01.ATV.11.3.770; SIMPFENDORFER C, 1987, AM J CARDIOL, V59, P267, DOI 10.1016/0002-9149(87)90797-1; SNEDECOR GW, 1980, STATISTICAL METHODS, P291; SPEARS JR, 1983, CIRCULATION, V68, P453, DOI 10.1161/01.CIR.68.2.453; Tousoulis Dimitris, 1993, Journal of the American College of Cardiology, V21, p341A; TSCHOPP TB, 1977, THROMB RES, V11, P619, DOI 10.1016/0049-3848(77)90020-2; VANDENBERG EK, 1989, CIRCULATION, V79, P116, DOI 10.1161/01.CIR.79.1.116; WALLER BF, 1984, AM J CARDIOL, V53, pC42, DOI 10.1016/0002-9149(84)90744-6; WILLERSON JT, 1989, CIRCULATION, V80, P198, DOI 10.1161/01.CIR.80.1.198	32	138	149	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 24	1994	330	8					523	528		10.1056/NEJM199402243300802	http://dx.doi.org/10.1056/NEJM199402243300802			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX436	8043066	Bronze			2022-12-24	WOS:A1994MX43600002
J	GRUNSTEIN, RR; HO, KKY; SULLIVAN, CE				GRUNSTEIN, RR; HO, KKY; SULLIVAN, CE			EFFECT OF OCTREOTIDE, A SOMATOSTATIN ANALOG, ON SLEEP-APNEA IN PATIENTS WITH ACROMEGALY	ANNALS OF INTERNAL MEDICINE			English	Article						ACROMEGALY; SLEEP APNEA SYNDROMES; OCTREOTIDE; SOMATOTROPIN; INSULIN-LIKE GROWTH FACTOR	VENTILATORY RESPONSE; SMS-201-995; REVERSAL; HUMANS	Objective: To determine the effects of octreotide, a somatostatin analog, on the severity of sleep apnea and on growth hormone levels in patients with acromegaly. Design: Open-label, prospective study. Setting: Tertiary referral hospital. Patients: 19 patients with active acromegaly. Intervention: Octreotide in a 6-month, stepwise incremental dosage. Measurements: Sleep studies and indices of hormonal activity (levels of insulin-like growth factor 1 [IGF-1] and growth hormone). Results: A 50% decrease occurred in the respiratory disturbance index (baseline compared with 6 months, 39 events/h compared with 19 events/h; P = 0.0002), and a 40% decrease occurred in total apnea time (27.6% of total sleep time compared with 15.1%; P = 0.001). Indices of oxygen desaturation, sleep quality, and subjective sleepiness improved after 6 months of octreotide. A parallel decrease was noted in mean levels of growth hormone (40.0 mu g/L compared with 9.1 mu g/L; P = 0.003) and IGF-1 (107 nmol/L compared with 47 nmol/L; P = 0.0001). However, no correlation was noted between the decrease in the total amount of sleep time spent in apnea and the decrease in growth hormone levels (rho = -0.35; P > 0.2). The residual respiratory disturbance index after 6 months of treatment was similar in patients who improved, regardless of whether or not biochemical remission (IGF-I < 35 nmol/L) occurred. Conclusions: Improvement in indices of sleep apnea severity occurs in association with octreotide treatment in patients with sleep apnea and acromegaly. However, sleep apnea may either persist despite normalization of growth hormone levels or may improve markedly even if there is only partial biochemical remission.	ST VINCENTS HOSP, GARVAN INST MED RES, SYDNEY, NSW 2010, AUSTRALIA; UNIV SYDNEY, DEPT MED, SYDNEY, NSW 2006, AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of Sydney			Ho, Ken/AAA-7428-2019; Ho, Ken KY/E-5832-2011	Ho, Ken/0000-0002-2508-9588; 				ASTROM C, 1991, NEUROENDOCRINOLOGY, V53, P328, DOI 10.1159/000125737; BAUER W, 1982, LIFE SCI, V31, P1133, DOI 10.1016/0024-3205(82)90087-X; CADIEUX RJ, 1982, J CLIN ENDOCR METAB, V55, P18, DOI 10.1210/jcem-55-1-18; CHANSON P, 1986, LANCET, V1, P1270; CHAPMAN KR, 1988, J APPL PHYSIOL, V64, P1000, DOI 10.1152/jappl.1988.64.3.1000; CHAPPEL W, 1896, J LARYNGOL OTOL, V10, P142; CHEN ZB, 1990, J APPL PHYSIOL, V69, P2233, DOI 10.1152/jappl.1990.69.6.2233; CHERNIACK NS, 1984, J CLIN INVEST, V73, P1501, DOI 10.1172/JCI111355; DANGUIR J, 1989, NEUROSCI LETT, V98, P154, DOI 10.1016/0304-3940(89)90502-8; ESNAULT S, 1989, Neurophysiologie Clinique, V19, P367, DOI 10.1016/S0987-7053(89)80089-9; FILUK RB, 1988, J APPL PHYSIOL, V65, P1050, DOI 10.1152/jappl.1988.65.3.1050; GLEESON K, 1989, J APPL PHYSIOL, V67, P1630, DOI 10.1152/jappl.1989.67.4.1630; GRUNSTEIN RR, 1991, ANN INTERN MED, V115, P527, DOI 10.7326/0003-4819-115-7-527; HART TB, 1985, ARCH INTERN MED, V145, P865, DOI 10.1001/archinte.145.5.865; HO KY, 1990, ANN INTERN MED, V112, P173, DOI 10.7326/0003-4819-112-3-173; HODDES E, 1973, PSYCHOPHYSIOLOGY, V10, P431, DOI 10.1111/j.1469-8986.1973.tb00801.x; ISSA FG, 1986, CHEST, V90, P165, DOI 10.1378/chest.90.2.165; ISSA FG, 1986, ELECTROEN CLIN NEURO, V63, P10, DOI 10.1016/0013-4694(86)90056-8; KALIA M, 1984, BRAIN RES, V296, P339, DOI 10.1016/0006-8993(84)90070-2; LAMBERTS SWJ, 1992, ENDOCRIN METAB CLIN, V21, P737, DOI 10.1016/S0889-8529(18)30211-1; LAROCHE C, 1976, ANN MED INTERNE, V127, P381; LONGOBARDO GS, 1989, ANN BIOMED ENG, V17, P377, DOI 10.1007/BF02368057; MAIN G, 1988, POSTGRAD MED J, V64, P945, DOI 10.1136/pgmj.64.758.945; MAXWELL DL, 1986, J APPL PHYSIOL, V60, P997, DOI 10.1152/jappl.1986.60.3.997; MELMED S, 1990, NEW ENGL J MED, V322, P966, DOI 10.1056/NEJM199004053221405; MEYER TJ, 1993, CHEST, V103, P756, DOI 10.1378/chest.103.3.756; MEZON BJ, 1980, AM J MED, V69, P615, DOI 10.1016/0002-9343(80)90477-5; PEKKARINEN T, 1987, CLIN ENDOCRINOL, V27, P649, DOI 10.1111/j.1365-2265.1987.tb02947.x; PERKS WH, 1980, BRIT MED J, V280, P894, DOI 10.1136/bmj.280.6218.894; ROSENSTOCK J, 1982, J ROY SOC MED, V75, P209; ROXBURGH F, 1896, BRIT MED J, V2, P63; SULLIVAN CE, 1984, SLEEP BREATHING; SULLIVAN CE, 1989, PRINCIPLES PRACTICE; SVANBORG E, 1993, CHEST, V104, P340, DOI 10.1378/chest.104.2.340; YAMAMOTO Y, 1988, ACTA PHYSIOL SCAND, V134, P529, DOI 10.1111/j.1365-201X.1988.tb10631.x; Younes M., 1989, CURR PULMONOL, V10, P265; ZIEMER DC, 1988, AM J MED SCI, V295, P49, DOI 10.1097/00000441-198801000-00010	37	107	109	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1994	121	7					478	483		10.7326/0003-4819-121-7-199410010-00002	http://dx.doi.org/10.7326/0003-4819-121-7-199410010-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ102	8067645				2022-12-24	WOS:A1994PJ10200002
J	CACERES, JF; STAMM, S; HELFMAN, DM; KRAINER, AR				CACERES, JF; STAMM, S; HELFMAN, DM; KRAINER, AR			REGULATION OF ALTERNATIVE SPLICING IN-VIVO BY OVEREXPRESSION OF ANTAGONISTIC SPLICING FACTORS	SCIENCE			English	Article							PRE-MESSENGER-RNA; PREMESSENGER RNA; NONMUSCLE CELLS; SITE SELECTION; SR PROTEINS; GENE; INVITRO; EXPRESSION; EXON; CIS	The opposing effects of SF2/ASF and heterogeneous nuclear ribonucleoprotein (hnRNP) A1 influence alternative splicing in vitro. SF2/ASF or hnRNP A1 complementary DNAs were transiently overexpressed in HeLa cells, and the effect on alternative splicing of several cotransfected reporter genes was measured. Increased expression of SF2/ASF activated proximal 5' splice sites, promoted inclusion of a neuron-specific exon, and prevented abnormal exon skipping. Increased expression of hnRNP A1 activated distal 5' splice sites. Therefore, variations in the intracellular levels of antagonistic splicing factors influence different modes of alternative splicing in vivo and may be a natural mechanism for tissue-specific or developmental regulation of gene expression.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory			Helfman, David M./C-2058-2011; Caceres, Javier F/D-5260-2013	Caceres, Javier F/0000-0001-8025-6169; Krainer, Adrian/0000-0001-9024-9501				AYANE M, 1991, NUCLEIC ACIDS RES, V19, P1273, DOI 10.1093/nar/19.6.1273; BERK AJ, 1978, CELL, V14, P695, DOI 10.1016/0092-8674(78)90252-0; CACERES JF, UNPUB; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GE H, 1991, CELL, V66, P372; GILMAN M, 1988, CURRENT PROTOCOLS MO, V1; GUO W, 1993, NUCLEIC ACIDS RES, V21, P4762, DOI 10.1093/nar/21.20.4762; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; HANAMURA A, UUNPUB; HELFMAN DM, 1988, GENE DEV, V2, P1627, DOI 10.1101/gad.2.12a.1627; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; KIM YJ, 1992, GENE DEV, V6, P2569, DOI 10.1101/gad.6.12b.2569; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; MAYEDA A, 1993, MOL CELL BIOL, V13, P2993, DOI 10.1128/MCB.13.5.2993; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; PERRICAUDET M, 1979, NATURE, V281, P694, DOI 10.1038/281694a0; SPAETE RR, 1985, J VIROL, V56, P135, DOI 10.1128/JVI.56.1.135-143.1985; STAMM S, 1992, NUCLEIC ACIDS RES, V20, P5097, DOI 10.1093/nar/20.19.5097; STEPHENS C, 1987, EMBO J, V6, P2027, DOI 10.1002/j.1460-2075.1987.tb02467.x; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; SVENSSON C, 1983, J MOL BIOL, V165, P475, DOI 10.1016/S0022-2836(83)80214-9; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; TREISMAN R, 1983, P NATL ACAD SCI-BIOL, V80, P7428, DOI 10.1073/pnas.80.24.7428; VELLARD M, 1992, P NATL ACAD SCI USA, V89, P2511, DOI 10.1073/pnas.89.7.2511; YANG XM, 1994, P NATL ACAD SCI USA, V91, P6924, DOI 10.1073/pnas.91.15.6924; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	36	556	561	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 16	1994	265	5179					1706	1709		10.1126/science.8085156	http://dx.doi.org/10.1126/science.8085156			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG284	8085156				2022-12-24	WOS:A1994PG28400030
J	HATA, Y; STRYKER, MP				HATA, Y; STRYKER, MP			CONTROL OF THALAMOCORTICAL AFFERENT REARRANGEMENT BY POSTSYNAPTIC ACTIVITY IN DEVELOPING VISUAL-CORTEX	SCIENCE			English	Article							OCULAR DOMINANCE COLUMNS; PLASTICITY; BLOCKADE; SITES	The formation of specific connections in the developing central nervous system is thought to result from mechanisms that increase the strengths of synapses at which pre- and postsynaptic activity are correlated and decrease it otherwise. In the visual cortex, initially widespread inputs normally sort out into eye-specific patches during early life. If only one eye can see during this period, its patches are much larger than normal, and patches from the occluded eye become much smaller. Anatomical experiments here show that closed-eye inputs expand within a region of cortex that is silenced, establishing that inhibition of common target cells gives less active inputs a competitive advantage.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,CTR INTEGRAT NEUROSCI,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco				Stryker, Michael/0000-0003-1546-5831	NEI NIH HHS [EY02874, R01 EY002874] Funding Source: Medline; NATIONAL EYE INSTITUTE [R37EY002874, R01EY002874] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANTONINI A, 1993, J NEUROSCI, V13, P3549; BOWERY NG, 1982, TRENDS PHARMACOL SCI, V3, P400, DOI 10.1016/0165-6147(82)91205-6; HILL DR, 1981, NATURE, V290, P149, DOI 10.1038/290149a0; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; LEVAY S, 1978, J COMP NEUROL, V179, P223, DOI 10.1002/cne.901790113; LEVAY S, 1980, J COMP NEUROL, V191, P1, DOI 10.1002/cne.901910102; NEEDLER MC, 1984, BRAIN RES, V308, P347, DOI 10.1016/0006-8993(84)91076-X; OLAVARRIA J, 1985, J NEUROSCI METH, V15, P191, DOI 10.1016/0165-0270(85)90098-6; REITER HO, 1986, EXP BRAIN RES, V65, P182; REITER HO, 1988, P NATL ACAD SCI USA, V85, P3623, DOI 10.1073/pnas.85.10.3623; SCHLAGGAR BL, 1993, NATURE, V364, P623, DOI 10.1038/364623a0; SHATZ CJ, 1978, J PHYSIOL-LONDON, V281, P267, DOI 10.1113/jphysiol.1978.sp012421; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P1003, DOI 10.1152/jn.1963.26.6.1003	13	108	109	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 16	1994	265	5179					1732	1735		10.1126/science.8085163	http://dx.doi.org/10.1126/science.8085163			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG284	8085163				2022-12-24	WOS:A1994PG28400038
J	SIK, A; YLINEN, A; PENTTONEN, M; BUZSAKI, G				SIK, A; YLINEN, A; PENTTONEN, M; BUZSAKI, G			INHIBITORY CA1-CA3-HILAR REGION FEEDBACK IN THE HIPPOCAMPUS	SCIENCE			English	Article							LONG-TERM POTENTIATION; NITRIC-OXIDE SYNTHASE; RAT HIPPOCAMPUS; DENTATE GYRUS; CA1 REGION; PYRAMIDAL NEURONS; CELLS; ORGANIZATION; INTERNEURONS; MESSENGER	The organization of the hippocampus is generally thought of as a series of cell groups that form a unidirectionally excited chain, regulated by localized inhibitory circuits. With the use of in vivo intracellular labeling, histochemical, and extracellular tracing methods, a longitudinally widespread, inhibitory feedback in rat brain from the CA1 area to the CA3 and hilar regions was observed. This long-range, cross-regional inhibition may allow precise synchronization of population activity by timing the occurrence of action potentials in the principal cells and may contribute to the coordinated induction of synaptic plasticity in distributed networks.	RUTGERS STATE UNIV,CTR MOLEC & BEHAV NEUROSCI,NEWARK,NJ 07102	Rutgers State University Newark; Rutgers State University New Brunswick			Penttonen, Markku/B-8348-2013	Penttonen, Markku/0000-0002-1033-7286; Buzsaki, Gyorgy/0000-0002-3100-4800				AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; ANDERSEN P, 1971, EXP BRAIN RES, V13, P222; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BUCKMASTER PS, 1992, HIPPOCAMPUS, V2, P349, DOI 10.1002/hipo.450020403; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; BULLOCK TH, 1990, NEUROSCIENCE, V38, P609, DOI 10.1016/0306-4522(90)90055-9; BUZSAKI G, 1987, BRAIN RES, V400, P334, DOI 10.1016/0006-8993(87)90632-9; BUZSAKI G, 1989, NEUROSCIENCE, V31, P551, DOI 10.1016/0306-4522(89)90423-5; Buzsaki G, 1991, Hippocampus, V1, P163, DOI 10.1002/hipo.450010205; BUZSAKI G, 1992, SCIENCE, V256, P1025, DOI 10.1126/science.1589772; DASILVA FHL, 1990, PHYSIOL REV, V70, P453, DOI 10.1152/physrev.1990.70.2.453; Douglas RJ, 1990, NEURAL COMPUT, V2, P283, DOI 10.1162/neco.1990.2.3.283; ENGEL J, 1990, NEUROLOGY, V40, P1670, DOI 10.1212/WNL.40.11.1670; GULYAS AI, 1993, EUR J NEUROSCI, V5, P1729, DOI 10.1111/j.1460-9568.1993.tb00240.x; GULYAS AI, 1993, NATURE, V366, P683, DOI 10.1038/366683a0; HALASY K, 1993, EUR J NEUROSCI, V5, P411, DOI 10.1111/j.1460-9568.1993.tb00508.x; HAN ZS, 1993, EUR J NEUROSCI, V5, P395, DOI 10.1111/j.1460-9568.1993.tb00507.x; HOLSHEIMER J, 1989, EXP BRAIN RES, V77, P69, DOI 10.1007/BF00250568; HORIKAWA K, 1988, J NEUROSCI METH, V25, P1, DOI 10.1016/0165-0270(88)90114-8; HYMAN BT, 1986, ANN NEUROL, V20, P472, DOI 10.1002/ana.410200406; KAWAGUCHI Y, 1987, BRAIN RES, V416, P369, DOI 10.1016/0006-8993(87)90921-8; KUNKEL DD, 1988, SYNAPSE, V2, P382, DOI 10.1002/syn.890020405; LACAILLE JC, 1987, J NEUROSCI, V7, P1979; LI XG, 1994, J COMP NEUROL, V339, P181, DOI 10.1002/cne.903390204; LI XG, 1992, EXP BRAIN RES, V90, P519; LYTTON WW, 1991, J NEUROPHYSIOL, V66, P1059, DOI 10.1152/jn.1991.66.3.1059; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; PULSINELLI WA, 1979, STROKE, V10, P267, DOI 10.1161/01.STR.10.3.267; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; SIK A, 1993, EUR J NEUROSCI, V5, P1719, DOI 10.1111/j.1460-9568.1993.tb00239.x; SLOVITER RS, 1987, J COMP NEUROL, V256, P42, DOI 10.1002/cne.902560105; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; TAMAMAKI N, 1990, J COMP NEUROL, V291, P509, DOI 10.1002/cne.902910403; TAMAMAKI N, 1991, J COMP NEUROL, V303, P435, DOI 10.1002/cne.903030309; TAMAMAKI N, 1988, BRAIN RES, V452, P255, DOI 10.1016/0006-8993(88)90030-3; VALTSCHANOFF JG, 1993, J COMP NEUROL, V331, P111, DOI 10.1002/cne.903310107; VINCENT SR, 1992, NEUROSCIENCE, V46, P755, DOI 10.1016/0306-4522(92)90184-4; YLINEN A, IN PRESS J NEUROSCI; YOUNG HM, 1992, HISTOCHEMISTRY, V97, P375, DOI 10.1007/BF00270041; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	42	165	166	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 16	1994	265	5179					1722	1724		10.1126/science.8085161	http://dx.doi.org/10.1126/science.8085161			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG284	8085161				2022-12-24	WOS:A1994PG28400035
J	PALOMBELLA, VJ; RANDO, OJ; GOLDBERG, AL; MANIATIS, T				PALOMBELLA, VJ; RANDO, OJ; GOLDBERG, AL; MANIATIS, T			THE UBIQUITIN-PROTEASOME PATHWAY IS REQUIRED FOR PROCESSING THE NF-KAPPA-B1 PRECURSOR PROTEIN AND THE ACTIVATION OF NF-KAPPA-B	CELL			English	Article							DNA-BINDING SUBUNIT; TRANSCRIPTION FACTOR; P50 PRECURSOR; ANTIGEN PRESENTATION; 65-KD SUBUNIT; REL ONCOGENE; COMPLEX; GENE; P105; INHIBITOR	We demonstrate an essential role for the proteasome complex in two proteolytic processes required for activation of the transcription factor NF-kappa B. The p105 precursor of the p50 subunit of NF-kappa B is processed in vitro by an ATP-dependent process that requires proteasomes and ubiquitin conjugation. The C-terminal region of p105 is rapidly degraded, leaving the N-terminal p50 domain. p105 processing can be blocked in intact cells with inhibitors of the proteasome or in yeast with proteasome mutants. These inhibitors also block the activation of NF-kappa B and the rapid degradation of I kappa B alpha induced by tumor necrosis factor alpha. Thus, the ubiquitin-proteasome pathway functions not only in the complete degradation of polypeptides, but also in the regulated processing of precursors into active proteins.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School	PALOMBELLA, VJ (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138, USA.			Rando, Oliver/0000-0003-1516-9397	NIAID NIH HHS [AI20642] Funding Source: Medline; NIGMS NIH HHS [GM46147] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020642, R37AI020642] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046147] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BEERS EP, 1993, J BIOL CHEM, V268, P21645; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; COLLINS T, 1993, LAB INVEST, V68, P499; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GRILLI M, 1993, INT REV CYTOL, V143, P1; HARLOW E, 1988, ANTIBODIES LABORATOR; HEGDE AN, 1993, P NATL ACAD SCI USA, V90, P7436, DOI 10.1073/pnas.90.16.7436; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOUGH R, 1987, J BIOL CHEM, V262, P8303; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MA DM, 1993, GENE DEV, V7, P2246, DOI 10.1101/gad.7.11.2246; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2597, DOI 10.1073/pnas.86.8.2597; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NEUMANN M, 1992, ONCOGENE, V7, P2095; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RIVIERE Y, 1991, NATURE, V350, P625, DOI 10.1038/350625a0; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHEFFNER M, 1992, EMBO J, V11, P2425, DOI 10.1002/j.1460-2075.1992.tb05307.x; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TANAKA K, 1992, NEW BIOL, V4, P173; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VISNITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WHALEN AM, 1993, J CELL BIOL, V123, P523, DOI 10.1083/jcb.123.3.523; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235	71	1917	2025	0	74	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 9	1994	78	5					773	785		10.1016/S0092-8674(94)90482-0	http://dx.doi.org/10.1016/S0092-8674(94)90482-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PG296	8087845				2022-12-24	WOS:A1994PG29600007
J	NIGHTINGALE, SL				NIGHTINGALE, SL			BROCHURES ON SEAFOOD SAFETY FOR PEOPLE WITH CERTAIN DISEASES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 24	1994	272	8					582	582		10.1001/jama.272.8.582	http://dx.doi.org/10.1001/jama.272.8.582			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC398	8057499				2022-12-24	WOS:A1994PC39800004
J	BARTZOKAS, CA; JOHNSON, R; JANE, M; MARTIN, MV; PEARCE, PK; SAW, Y				BARTZOKAS, CA; JOHNSON, R; JANE, M; MARTIN, MV; PEARCE, PK; SAW, Y			RELATION BETWEEN MOUTH AND HEMATOGENOUS INFECTION IN TOTAL JOINT REPLACEMENTS	BRITISH MEDICAL JOURNAL			English	Article							TOTAL HIP-REPLACEMENT; PROPHYLACTIC ANTIBIOTICS; HEMATOGENOUS INFECTION; ARTHROPLASTY	Objective-To investigate the source of infections associated with orthopaedic prostheses. Design-Analysis of four infections of prosthetic joints with case records; minimum inhibitory and minimum bactericidal concentrations and sodium dodecylsulphate polyacrylamide gel electrophoresis of the cell wall polypeptides of the Streptococcus sanguis isolates from the mouth and infected prostheses; examination of the patients' mouths for periodontal disease and caries. Subjects-Four adults (three men) aged 58-83. Results-For each patient the strain of S sanguis isolated from the mouth was indistinguishable from that isolated from the prosthesis. Ah patients had severe periodontal disease and caries. Conclusions-The mouth was probably the source of bacterial infection in the prosthetic joints of these patients; the route of infection was possibly haematogenous. Incipient oral infection should be treated before joint replacement, and oral health should be maintained indefinitely.	WIRRAL HOSP NHS TRUST,WIRRAL L49 5PE,MERSEYSIDE,ENGLAND; LIVERPOOL DENT HOSP,LIVERPOOL L3 5PS,MERSEYSIDE,ENGLAND	University of Liverpool								AHLBERG A, 1978, CLIN ORTHOP RELAT R, V137, P69; ARTZ TD, 1975, J BONE JOINT SURG AM, V57, P1024; BEIGHTON D, 1991, J MED MICROBIOL, V35, P367, DOI 10.1099/00222615-35-6-367; Brand R A, 1975, J Iowa Med Soc, V65, P388; CARLSSON AS, 1977, ACTA ORTHOP SCAND, V48, P405, DOI 10.3109/17453677708992017; CREUSS RL, 1975, CLIN ORTHOPAEDICS, V106, P99; DOWNES EM, 1977, J BONE JOINT SURG BR, V59, P42, DOI 10.1302/0301-620X.59B1.845227; Jacobson J J, 1988, J Dent Educ, V52, P599; KLENERMAN L, 1984, J BONE JOINT SURG BR, V66, P645, DOI 10.1302/0301-620X.66B5.6389556; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATTIMER GL, 1979, JAMA-J AM MED ASSOC, V242, P2213, DOI 10.1001/jama.242.20.2213; LINDQVIST C, 1985, ACTA ORTHOP SCAND, V56, P506, DOI 10.3109/17453678508993046; MULLIGAN R, 1980, J AM DENT ASSOC, V101, P44, DOI 10.14219/jada.archive.1980.0334; REEVES DS, 1978, LABORATORY METHODS A; RUBIN R, 1976, ORAL SURG ORAL MED O, V41, P18, DOI 10.1016/0030-4220(76)90247-4; RUSSELL RRB, 1976, MICROBIOS LETT, V2, P55; SCHURMAN DJ, 1976, WESTERN J MED, V125, P226; STINCHFIELD FE, 1980, J BONE JOINT SURG AM, V62, P1345, DOI 10.2106/00004623-198062080-00015; WILSON PD, 1975, SURG CLIN N AM, V55, P1431	19	73	74	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 20	1994	309	6953					506	508		10.1136/bmj.309.6953.506	http://dx.doi.org/10.1136/bmj.309.6953.506			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD308	8086903	Green Published			2022-12-24	WOS:A1994PD30800016
J	WARK, NC				WARK, NC			30 YEARS LATER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	1994	272	7					497	498						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB229	8046787				2022-12-24	WOS:A1994PB22900001
J	AUSTOKER, J				AUSTOKER, J			CANCER PREVENTION IN PRIMARY-CARE - SCREENING FOR COLORECTAL-CANCER	BRITISH MEDICAL JOURNAL			English	Article							FECAL OCCULT BLOOD; SIGMOIDOSCOPY; MORTALITY; HEMOCCULT; TESTS	In the United Kingdom there are almost 31000 new cases of colorectal cancer each year and nearly 20000 deaths. It is the second most common cause of all deaths from cancer in the United Kingdom. The efficacy of screening with faecal occult blood tests to detect and treat tumours at an early stage, and thereby to reduce mortality, is currently being assessed in several randomised controlled trials. In general, faecal occult blood tests have a low sensitivity and only moderate levels of uptake among the population invited for screening. Until the studies in Denmark, Sweden, and Nottingham report their findings, there is no case for providing such screening routinely to an asymptomatic population. Detecting and removing premalignant adenomas by flexible sigmoidoscopy could be more effective than detecting early localised, asymptomatic cancers in reducing deaths from colorectal cancer. It is estimated that screening people at about the age of 60 by a single flexible sigmoidoscopy examination with appropriate colonoscopic surveillance could prevent 5500 cases of colorectal cancer and 3500 deaths in the United Kingdom each year. A randomised controlled trial to confirm these observations should be seen as a priority.			AUSTOKER, J (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,CANC RES CAMPAIGN,PRIMARY CARE EDUC RES GRP,OXFORD OX2 6PE,ENGLAND.							AHLQUIST DA, 1993, JAMA-J AM MED ASSOC, V269, P1262, DOI 10.1001/jama.269.10.1262; ATKIN WS, 1992, NEW ENGL J MED, V326, P658, DOI 10.1056/NEJM199203053261002; ATKIN WS, 1993, LANCET, V341, P736, DOI 10.1016/0140-6736(93)90499-7; AUSTOKER J, 1994, BRIT MED J, V308, P1610, DOI 10.1136/bmj.308.6944.1610; BLALOCK SJ, 1987, PREV MED, V16, P9, DOI 10.1016/0091-7435(87)90002-8; BOX V, 1984, PUBLIC HEALTH, V98, P16, DOI 10.1016/S0033-3506(84)80055-4; CHAMBERLAIN J, 1990, BRIT J CANCER, V62, P1, DOI 10.1038/bjc.1990.216; CUZICK J, 1993, COMMUNICATION; EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373; Farrands P A, 1984, Community Med, V6, P12; Hardcastle J, 1991, Eur J Cancer Prev, V1 Suppl 2, P21, DOI 10.1097/00008469-199110002-00004; HARDCASTLE JD, 1989, LANCET, V1, P1160; HOBBS FDR, 1992, BRIT MED J, V304, P483, DOI 10.1136/bmj.304.6825.483; HUNTER W, 1991, FAM PRACT, V8, P367, DOI 10.1093/fampra/8.4.367; KINSELLA AR, 1993, COLORECTAL CANCER SC; KRONBORG O, 1989, SCAND J GASTROENTERO, V24, P599, DOI 10.3109/00365528909093096; LEVIN B, 1992, NEW ENGL J MED, V326, P700, DOI 10.1056/NEJM199203053261009; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; MANT D, 1992, BRIT J GEN PRACT, V42, P18; MANT D, 1990, BRIT J GEN PRACT, V40, P423; NEUGUT AI, 1988, GASTROENTEROLOGY, V95, P492, DOI 10.1016/0016-5085(88)90511-2; NEWCOMB PA, 1992, JNCI-J NATL CANCER I, V84, P1572, DOI 10.1093/jnci/84.20.1572; PONDER B, 1994, GENETIC TESTING CANC; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SELBY JV, 1993, LANCET, V341, P728, DOI 10.1016/0140-6736(93)90493-Z; Silman A, 1984, Community Med, V6, P8; THOMAS W, 1991, CANCER SCREENING, P106; Verne J, 1993, Eur J Cancer Prev, V2, P301, DOI 10.1097/00008469-199307000-00003; WINAWER SJ, 1991, JNCI-J NATL CANCER I, V83, P243, DOI 10.1093/jnci/83.4.243; WINAWER SJ, 1993, NEW ENGL J MED, V328, P1416, DOI 10.1056/NEJM199305133281909; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; 1993, CANCER LARGE BOWEL	32	42	42	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 6	1994	309	6951					382	386		10.1136/bmj.309.6951.382	http://dx.doi.org/10.1136/bmj.309.6951.382			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB316	8081142	Green Published			2022-12-24	WOS:A1994PB31600025
J	NUDLER, E; GOLDFARB, A; KASHLEV, M				NUDLER, E; GOLDFARB, A; KASHLEV, M			DISCONTINUOUS MECHANISM OF TRANSCRIPTION ELONGATION	SCIENCE			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; TERNARY COMPLEXES; CLEAVAGE; DNA	During transcription elongation, three flexibly connected parts of RNA polymerase of Escherichia coli advance along the template so that the front-end domain is followed by the catalytic site which in turn is followed by the RNA product binding site. The advancing enzyme was found to maintain the same conformation throughout extended segments of the transcribed region. However, when the polymerase traveled across certain DNA sites that seemed to briefly anchor the front-end domain, cyclic shifting of the three parts, accompanied by buildup and relief of internal strain, was observed. Thus, elongation proceeded in alternating laps of monotonous and inchworm-like movement with the flexible RNA polymerase configuration being subject to direct sequence control.	PUBL HLTH RES INST CITY NEW YORK INC,NEW YORK,NY 10016					Nudler, Evgeny/0000-0002-8811-3071	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049242] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49242] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN CR, 1994, P NATL ACAD SCI USA, V91, P3784, DOI 10.1073/pnas.91.9.3784; ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; CHAMBERLIN MJ, 1994, HARVEY LECTURES 88, P1; GU WG, 1993, J BIOL CHEM, V268, P25604; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; LUSE DS, COMMUNICATION; MUSTAEV A, 1993, J BIOL CHEM, V268, P19185; NUDLER E, UNPUB; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; SHI YB, 1988, J MOL BIOL, V199, P277, DOI 10.1016/0022-2836(88)90314-2; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; YAGER TD, 1987, CELLULAR MOL BIOL, P1241	14	141	141	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 5	1994	265	5173					793	796		10.1126/science.8047884	http://dx.doi.org/10.1126/science.8047884			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	8047884				2022-12-24	WOS:A1994PA37200036
J	NAGATAKI, S; SHIBATA, Y; INOUE, S; YOKOYAMA, N; IZUMI, M; SHIMAOKA, K				NAGATAKI, S; SHIBATA, Y; INOUE, S; YOKOYAMA, N; IZUMI, M; SHIMAOKA, K			THYROID-DISEASES AMONG ATOMIC-BOMB SURVIVORS IN NAGASAKI	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NECK IRRADIATION; HODGKINS-DISEASE; RADIATION; CARCINOMA; HEAD; CHILDHOOD; CANCER; THYROGLOBULIN; EXPOSURE; INFANCY	Objective.-To elucidate the current thyroid disease status for the Nagasaki Adult Health Study cohort of the Radiation Effects Research Foundation. Design.-Survey study. Setting.- Nagasaki, Japan. Participants.-Cohort members of the Nagasaki Adult Health Study who received biennial health examinations from October 1984 to April 1987 (n=2856). A total of 2587 subjects remained after exclusion of persons exposed in Hiroshima or in utero and those who were not in Nagasaki at the time of the bombing. Thyroid radiation dose by the dosimetry system established in 1986 was available for 1978 of the 2587 subjects. Main Outcome Measures.-Thyroid diseases were diagnosed using uniform procedures including ultrasonic scanning. The relationship of the prevalence of each thyroid disease with thyroid radiation dose, sex, and age was analyzed using logistic models. Results.-A significant dose-response relationship was observed for solid nodules, which include cancer, adenoma, adenomatous goiter, and nodules without histological diagnosis, and for antibody-positive spontaneous hypothyroidism (autoimmune hypothyroidism) but not for other diseases. The prevalence of solid nodules showed a monotonic dose-response relationship, yet that of autoimmune hypothyroidism displayed a concave dose-response relationship reaching a maximum (+/-SE) level of 0.7 +/- 0.2 Sv. Conclusions.-The present study confirmed the results of previous studies by showing a significant increase in solid nodules with dose to the thyroid and demonstrated for the first time a significant increase in autoimmune disease among atomic bomb survivors. A concave dose-response relationship indicates the necessity for further studies on the effects of relatively low doses of radiation on thyroid disease.	RADIAT EFFECTS RES FDN, NAGASAKI, JAPAN	Radiation Effects Research Foundation - Japan	NAGATAKI, S (corresponding author), NAGASAKI UNIV, SCH MED, DEPT INTERNAL MED 1, SAKAMOTO 1-7-1, NAGASAKI 852, JAPAN.			nagataki, shigenobu/0000-0002-9974-3554				AKIBA S, 1991, 591 RAD EFF RES F RE; DEGROOT L, 1973, JAMA-J AM MED ASSOC, V225, P487, DOI 10.1001/jama.225.5.487; DIXON WJ, 1983, BMDP STATISTICAL SOF; DUFFY BJ, 1950, CANCER, V3, P1018, DOI 10.1002/1097-0142(1950)3:6<1018::AID-CNCR2820030611>3.0.CO;2-H; FAVUS MJ, 1976, NEW ENGL J MED, V294, P1019, DOI 10.1056/NEJM197605062941901; HEGEDUS L, 1983, J CLIN ENDOCR METAB, V56, P260, DOI 10.1210/jcem-56-2-260; HEMPELMANN LH, 1975, J NATL CANCER I, V55, P519, DOI 10.1093/jnci/55.3.519; JOENSUU H, 1986, ACTA RADIOL ONCOL, V25, P167, DOI 10.3109/02841868609136397; JOHNSON KG, 1965, 1065 AT BOMB CAS COM; KAPLAN MM, 1988, J CLIN ENDOCR METAB, V66, P376, DOI 10.1210/jcem-66-2-376; KOTANI T, 1982, CLIN IMMUNOL IMMUNOP, V24, P111, DOI 10.1016/0090-1229(82)90094-0; LESSARD E, 1985, BNL51882 REP; MODAN B, 1974, LANCET, V1, P277; MORIMOTO I, 1987, J NUCL MED, V28, P1115; NAGATAKI S, 1989, LANCET, V2, P385; NAGATAKI S, 1993, 80 YEARS HASHIMOTO D; NELDER JA, 1983, GENERALIZED LINEAR M; NELSON DF, 1978, CANCER-AM CANCER SOC, V42, P2553, DOI 10.1002/1097-0142(197812)42:6<2553::AID-CNCR2820420608>3.0.CO;2-H; OKAJIMA S, 1990, HEALTH PHYS, V58, P591, DOI 10.1097/00004032-199005000-00004; PARKER LN, 1974, ANN INTERN MED, V80, P600, DOI 10.7326/0003-4819-80-5-600; PARKER LN, 1973, J CLIN ENDOCR METAB, V37, P797, DOI 10.1210/jcem-37-5-797; PINCUS RA, 1967, ANN INTERN MED, V66, P1154, DOI 10.7326/0003-4819-66-6-1154; PRAGER D, 1972, CANCER, V29, P458, DOI 10.1002/1097-0142(197202)29:2<458::AID-CNCR2820290232>3.0.CO;2-N; Rasmussen S N, 1974, J Clin Ultrasound, V2, P143, DOI 10.1002/jcu.1870020211; REFETOFF S, 1975, NEW ENGL J MED, V292, P171, DOI 10.1056/NEJM197501232920402; Roesch WC, 1987, US JAPAN JOINT REASS, V1; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SCHNEIDER AB, 1977, ANN INTERN MED, V86, P29, DOI 10.7326/0003-4819-86-1-29; SHAFER RB, 1975, ARCH INTERN MED, V135, P843, DOI 10.1001/archinte.135.6.843; SLATSTEI.E, 1971, J CLIN ENDOCR METAB, V32, P833, DOI 10.1210/jcem-32-6-833; SOCOLOW EL, 1963, NEW ENGL J MED, V268, P406, DOI 10.1056/NEJM196302212680803; TAMURA K, 1981, CANCER-AM CANCER SOC, V47, P2704, DOI 10.1002/1097-0142(19810601)47:11<2704::AID-CNCR2820471129>3.0.CO;2-G; WOOD JW, 1969, AM J EPIDEMIOL, V89, P4, DOI 10.1093/oxfordjournals.aje.a120914; YOKOYAMA N, 1986, J NUCL MED, V27, P1475	34	109	112	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	1994	272	5					364	370		10.1001/jama.272.5.364	http://dx.doi.org/10.1001/jama.272.5.364			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY903	8028167				2022-12-24	WOS:A1994NY90300028
J	KRAMER, J; RAJCZY, K; HEGYI, L; FULOP, T; MOHACSI, A; MEZEI, Z; KELTAI, M; BLASKO, G; FERENCZY, E; ANHTUAN, N; FUST, G				KRAMER, J; RAJCZY, K; HEGYI, L; FULOP, T; MOHACSI, A; MEZEI, Z; KELTAI, M; BLASKO, G; FERENCZY, E; ANHTUAN, N; FUST, G			C4B(ASTERISK)Q0 ALLOTYPE AS RISK FACTOR FOR MYOCARDIAL-INFARCTION	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-COMPLEMENT; 4TH COMPONENT		SEMMELWEIS UNIV MED,SCH MED,INST GERONTOL,BUDAPEST,HUNGARY; SZENT IMRE HOSP,BUDAPEST,HUNGARY; DEBRECEN UNIV MED,SCH MED,DEPT MED 1,H-4012 DEBRECEN,HUNGARY; SZENT ISTVAN HOSP,BUDAPEST,HUNGARY; HUNGARIAN INST CARDIOL,BUDAPEST,HUNGARY	Semmelweis University; University of Debrecen	KRAMER, J (corresponding author), NATL INST HAEMATOL BLOOD TRANSFUS & IMMUNOL,DEPT IMMUNOPATHOL,POB 44,H-1502 BUDAPEST,HUNGARY.							AWDEH ZL, 1980, P NATL ACAD SCI-BIOL, V77, P3576, DOI 10.1073/pnas.77.6.3576; GELTMAN EM, 1979, CIRCULATION, V60, P805, DOI 10.1161/01.CIR.60.4.805; GERSH BJ, 1987, CARDIOLOGY FUNDAMENT, P1116; KRAMER J, 1991, HUM GENET, V86, P595; SIM E, 1986, BIOCHEM J, V239, P763, DOI 10.1042/bj2390763	5	33	33	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 30	1994	309	6950					313	314		10.1136/bmj.309.6950.313	http://dx.doi.org/10.1136/bmj.309.6950.313			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA373	8086869	Green Published			2022-12-24	WOS:A1994PA37300020
J	CARRIER, DR; HEGLUND, NC; EARLS, KD				CARRIER, DR; HEGLUND, NC; EARLS, KD			VARIABLE GEARING DURING LOCOMOTION IN THE HUMAN MUSCULOSKELETAL SYSTEM	SCIENCE			English	Article							MUSCLE; FOOT	Human feet and toes provide a mechanism for changing the gear ratio of the ankle extensor muscles during a running step. A variable gear ratio could enhance muscle performance during constant-speed running by applying a more effective prestretch during landing, while maintaining the muscles near the high-efficiency or high-power portion of the force-velocity curve during takeoff. Furthermore, during acceleration, variable gearing may allow muscle contractile properties to remain optimized despite rapid changes in running speed. Forceplate and kinematic analyses of running steps show low gear ratios at touchdown that increase throughout the contact phase.	PHAROS SYST INC, S CHELMSFORD, MA 01824 USA		CARRIER, DR (corresponding author), BROWN UNIV, DEPT ECOL & EVOLUTIONARY BIOL, PROVIDENCE, RI 02912 USA.							ALEXANDER RMN, 1977, J ZOOL, V183, P125, DOI 10.1111/j.1469-7998.1977.tb04177.x; [Anonymous], 1982, ANAL VERTEBRATE STRU; BIEWENER AA, 1989, SCIENCE, V245, P45, DOI 10.1126/science.2740914; BIEWENER AA, 1993, J BIOMECH, V26, P294; CARRIER DR, 1983, J ZOOL, V201, P27; CARRIER DR, 1980, AM ZOOL, V20, P895; CAVAGNA GA, 1986, AM J PHYSIOL, V251, pC571, DOI 10.1152/ajpcell.1986.251.4.C571; COATES MI, 1990, NATURE, V347, P66, DOI 10.1038/347066a0; GANS C, 1991, J BIOMECH, V24, P53, DOI 10.1016/0021-9290(91)90377-Y; HAYASHI T, 1987, BIOMECHANICS A, V7, P203; HENNIG EM, 1982, J BIOMED ENG, V4, P213, DOI 10.1016/0141-5425(82)90005-X; HILDEBRAND M, 1982, ANAL VERTEBRATE STRU, P417; Hill A. V., 1950, Science Progress London, V38, P209; LORD M, 1986, J BIOMED ENG, V8, P283, DOI 10.1016/0141-5425(86)90060-9; NALBACH G, 1989, J COMP PHYSIOL A, V165, P321, DOI 10.1007/BF00619351; ROME LC, 1988, NATURE, V335, P824, DOI 10.1038/335824a0; Schaeffer Bobb, 1947, AMER MUS NOVITATES, V1356, P1; WISSER A, 1988, ZOOMORPHOLOGY, V107, P359, DOI 10.1007/BF00312219	18	129	131	3	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 29	1994	265	5172					651	653		10.1126/science.8036513	http://dx.doi.org/10.1126/science.8036513			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	8036513				2022-12-24	WOS:A1994NZ53800030
J	KUCZMARSKI, RJ; FLEGAL, KM; CAMPBELL, SM; JOHNSON, CL				KUCZMARSKI, RJ; FLEGAL, KM; CAMPBELL, SM; JOHNSON, CL			INCREASING PREVALENCE OF OVERWEIGHT AMONG US ADULTS - THE NATIONAL-HEALTH AND NUTRITION EXAMINATION SURVEYS, 1960 TO 1991	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BODY-MASS INDEX; UNITED-STATES ADULTS; WEIGHT-LOSS; ANTHROPOMETRIC MEASUREMENTS; SOCIOECONOMIC-FACTORS; SKINFOLD THICKNESS; SECULAR TRENDS; RISK-FACTORS; OBESITY; WOMEN	Objective.-To examine trends in overweight prevalence and body mass index of the US adult population. Design.-Nationally representative cross-sectional surveys with an in-person interview and a medical examination, including measurement of height and weight. Setting/Participants.-Between 6000 and 13000 adults aged 20 through 74 years examined in each of four separate national surveys during 1960 to 1962 (the first National Health Examination Survey [NHES I]), 1971 to 1974 (the first National Health and Nutrition Examination Survey [NHANES I]), 1976 to 1980 (NHANES II), and 1988 to 1991 (NHANES III phase 1). Results.-In the period 1988 to 1991, 33.4% of US adults 20 years of age or older were estimated to be overweight. Comparisons of the 1988 to 1991 overweight prevalence estimates with data from earlier surveys indicate dramatic increases in all race/sex groups. Overweight prevalence increased 8% between the 1976 to 1980 and 1988 to 1991 surveys. During this period, for adult men and women aged 20 through 74 years, mean body mass index increased from 25.3 to 26.3; mean body weight increased 3.6 kg. Conclusions.-These nationally representative data document a substantial increase in overweight among US adults and support the findings of other investigations that show notable increases in overweight during the past decade. These observations suggest that the Healthy People 2000 objective of reducing the prevalence of overweight US adults to no more than 20% may not be met by the year 2000. Understanding the reasons underlying the increase in the prevalence of overweight in the United States and elucidating the potential consequences in terms of morbidity and mortality present a challenge to our understanding of the, etiology, treatment, and prevention of overweight.	CTR DIS CONTROL & PREVENT, NATL CTR HLTH STAT, DIV HLTH EXAMINAT STAT, HYATTSVILLE, MD 20782 USA	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)			Flegal, Katherine M/A-4608-2013	Flegal, Katherine/0000-0002-0838-469X				ANDRES R, 1985, ANN INTERN MED, V103, P1030, DOI 10.7326/0003-4819-103-6-1030; [Anonymous], 1985, ANN INTERN MED, V103, P1073, DOI 10.7326/0003-4819-103-6-1073; BEGLEY CE, 1991, J AM DIET ASSOC, V91, P1255; BLAIR SN, 1993, ANN INTERN MED, V119, P702, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00015; BRAY GA, 1992, AM J CLIN NUTR, V55, P488, DOI 10.1093/ajcn/55.2.488s; CHUMLEA WC, 1990, AM J CLIN NUTR, V51, pS902, DOI 10.1093/ajcn/51.5.902; CHUNG CS, 1992, AM J PUBLIC HEALTH, V82, P1544, DOI 10.2105/AJPH.82.11.1544; Colditz G A, 1992, Am J Clin Nutr, V55, p503S, DOI 10.1093/ajcn/55.2.503s; Emery E M, 1993, Am J Health Promot, V7, P342; EZZATI RM, 1992, VITAL HLTH STAT 113, V2; FLEGAL KM, 1988, AM J CLIN NUTR, V48, P544, DOI 10.1093/ajcn/48.3.544; FLEGAL KM, 1988, AM J CLIN NUTR, V48, P535, DOI 10.1093/ajcn/48.3.535; FLETCHER SW, 1993, ANN INTERN MED, V119, P764, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00026; FULWOOD R, 1981, VITAL HLTH STAT 224, V11; GOODRICK GK, 1991, J AM DIET ASSOC, V91, P1243; HIGGINS M, 1993, ANN INTERN MED, V119, P758, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00025; HIMES JH, 1994, AM J CLIN NUTR, V59, P307, DOI 10.1093/ajcn/59.2.307; HORM J, 1993, ANN INTERN MED, V119, P672, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00009; JARRETT RJ, 1986, BRIT MED J, V293, P493, DOI 10.1136/bmj.293.6545.493; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; KUCZMARSKI R J, 1992, American Journal of Clinical Nutrition, V55, p495S, DOI 10.1093/ajcn/55.2.495s; KUCZMARSKI RJ, 1990, ANTHROPOMETRIC ASSES; KUMANYIKA S, 1993, J AM DIET ASSOC, V93, P416, DOI 10.1016/0002-8223(93)92287-8; KUMANYIKA SK, 1991, ETHNIC DIS, V2, P166; KUSKOWSKAWOLK A, 1989, INT J OBESITY, V13, P441; LEVY AS, 1993, ANN INTERN MED, V119, P661, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00007; LEVY BT, 1988, J FAM PRACTICE, V27, P285; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; Lohman TG, 1988, ANTHROPOMETRIC STAND; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MARKS GC, 1989, AM J EPIDEMIOL, V130, P578, DOI 10.1093/oxfordjournals.aje.a115372; MAURER KR, 1985, VITAL HLTH STAT 19, V1; MCARTOR RE, 1992, INT J OBESITY, V16, P335; MCDOWELL A, 1981, VITAL HLTH STAT 15, V1; MCGINNIS JM, 1992, MED SCI SPORT EXER, V24, pS196; NAJJAR MF, 1989, VITAL HLTH STAT 239, V11; NAJJAR MF, 1987, VITAL HLTH STAT 238, V11; PAMUK ER, 1993, ANN INTERN MED, V119, P744, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00023; PETITTI DB, 1988, AM J PREV MED, V4, P327, DOI 10.1016/S0749-3797(18)31141-3; PIANI A, 1993, VITAL HLTH STAT 185, V10; PISUNYER FX, 1991, AM J CLIN NUTR, V53, pS1595; PISUNYER FX, 1992, ANN INTERN MED, V55, pS503; RISSANEN A, 1989, J CLIN EPIDEMIOL, V42, P781, DOI 10.1016/0895-4356(89)90076-0; ROWLAND ML, 1990, AM J CLIN NUTR, V52, P1125, DOI 10.1093/ajcn/52.6.1125; SCHOENBORN CA, 1987, EVAL HEALTH PROF, V10, P438, DOI 10.1177/016327878701000405; SCHOENBORN CA, 1988, VITAL HLTH STAT 163, V10; SEIDELL JC, 1992, INT J OBESITY, V16, pS31; SERDULA MK, 1993, ANN INTERN MED, V119, P667, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00008; SHAH BV, 1991, SUDAAN USERS MANUAL; SHAH M, 1991, INT J OBESITY, V15, P499; SPRAFKA JM, 1990, AM J EPIDEMIOL, V132, P489, DOI 10.1093/oxfordjournals.aje.a115685; STOUDT HW, 1965, VITAL HLTH STAT 8, V11; WADDEN TA, 1993, ANN INTERN MED, V119, P688, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00012; WEIGLE DS, 1990, WESTERN J MED, V153, P421; White A, 1993, HLTH SURVEY ENGLAND; WIENPAHL J, 1990, J CLIN EPIDEMIOL, V43, P949, DOI 10.1016/0895-4356(90)90078-4; 1973, VITAL HLTH STAT 10, V1; 1993, MMWR-MORBID MORTAL W, V42, P576; 1993, NIH931088 NAT HEART; 1990, SAS STAT USERS GUIDE; 1965, VITAL HLTH STAT 4, V1; 1981, PC801B1 US DEP COMM, V1, pCHB; [No title captured]; 1990, PHS9050212 US DEP HL	64	2145	2181	2	52	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 20	1994	272	3					205	211		10.1001/jama.272.3.205	http://dx.doi.org/10.1001/jama.272.3.205			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW185	8022039				2022-12-24	WOS:A1994NW18500021
J	REUVENY, E; SLESINGER, PA; INGLESE, J; MORALES, JM; INIGUEZLLUHI, JA; LEFKOWITZ, RJ; BOURNE, HR; JAN, YN; JAN, LY				REUVENY, E; SLESINGER, PA; INGLESE, J; MORALES, JM; INIGUEZLLUHI, JA; LEFKOWITZ, RJ; BOURNE, HR; JAN, YN; JAN, LY			ACTIVATION OF THE CLONED MUSCARINIC POTASSIUM CHANNEL BY G-PROTEIN BETA-GAMMA-SUBUNITS	NATURE			English	Article							COUPLED RECEPTOR KINASES; K+-CHANNEL; ION CHANNELS; MECHANISM; EXPRESSION; ALPHA; CLONING; CYCLASE; HEART	ACETYLCHOLINE released during parasympathetic stimulation of the vagal nerve slows the heart rate through the activation of muscarinic receptors and subsequent opening of an inwardly rectifying potassium channel(1) The activation of these muscarinic potassium channels is mediated by a pertussis toxin-sensitive heterotrimeric GTP-binding protein (G protein)(2,3). It has not been resolved whether exogenously applied G(alpha)(4,5) or G(beta gamma)(6,7), Or both, activate the channel. Using a heterologous expression system, we have tested the ability of different G protein subunits to activate the cloned muscarinic potassium channel, GIRK1(8,9). We report here that coexpression of GIRK1 with G(beta gamma) but not G(alpha beta gamma) in Xenopus oocytes results in channel activity that persists in the absence of cytoplasmic GTP. This activity is reduced by fusion proteins of the beta-adrenergic receptor kinase and of recombinant G(alpha i)-GDP, both of which are known to interact with G(beta gamma)(10,11). Moreover, application of recombinant G(beta gamma), but not G(alpha i)-GTP-gamma S, activates GIRK1 channels. Thus G(beta gamma) appears to be sufficient for the activation of GIRK1 muscarinic potassium channels.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Duke University; Howard Hughes Medical Institute; Duke University; Duke University; University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	REUVENY, E (corresponding author), UNIV CALIF SAN FRANCISCO,HORMONE RES INST,SAN FRANCISCO,CA 94143, USA.		Lefkowitz, Robert/AAW-2649-2021	Jan, Yuh Nung/0000-0003-1367-6299; Iniguez-Lluhi, Jorge/0000-0001-7010-089X; Jan, Lily/0000-0003-3938-8498				BIRNBAUMER L, 1987, NATURE, V327, P21, DOI 10.1038/327021a0; BREITWIESER GE, 1988, J GEN PHYSIOL, V91, P469, DOI 10.1085/jgp.91.4.469; BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; INGLESE J, 1994, P NATL ACAD SCI USA, V91, P3637, DOI 10.1073/pnas.91.9.3637; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; INGLESE J, 1993, J BIOL CHEM, V268, P23735; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; ITO H, 1991, J GEN PHYSIOL, V98, P517, DOI 10.1085/jgp.98.3.517; ITO H, 1992, J GEN PHYSIOL, V99, P961, DOI 10.1085/jgp.99.6.961; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KURACHI Y, 1989, PFLUG ARCH EUR J PHY, V413, P325, DOI 10.1007/BF00583550; KUROSE H, 1986, J BIOL CHEM, V261, P6423; LEE E, 1994, METHOD ENZYMOL, V237, P146; LINDER ME, 1990, J BIOL CHEM, V265, P8243; LOGOTHETIS DE, 1988, P NATL ACAD SCI USA, V85, P5814, DOI 10.1073/pnas.85.16.5814; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; OKABE K, 1991, J GEN PHYSIOL, V97, P1279, DOI 10.1085/jgp.97.6.1279; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SULLIVAN KA, 1986, P NATL ACAD SCI USA, V83, P6687, DOI 10.1073/pnas.83.18.6687; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; TRAUTWEIN W, 1958, PFLUG ARCH GES PHYS, V266, P324, DOI 10.1007/BF00416781; YATANI A, 1990, AM J PHYSIOL, V258, pH1507, DOI 10.1152/ajpheart.1990.258.5.H1507; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; YATANI A, 1987, SCIENCE, V235, P207, DOI 10.1126/science.2432660	30	432	443	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 14	1994	370	6485					143	146		10.1038/370143a0	http://dx.doi.org/10.1038/370143a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW804	8022483				2022-12-24	WOS:A1994NW80400058
J	JENKINS, MA; HOPPER, JL; BOWES, G; CARLIN, JB; FLANDER, LB; GILES, GG				JENKINS, MA; HOPPER, JL; BOWES, G; CARLIN, JB; FLANDER, LB; GILES, GG			FACTORS IN CHILDHOOD AS PREDICTORS OF ASTHMA IN ADULT LIFE	BRITISH MEDICAL JOURNAL			English	Article							NATURAL-HISTORY; DISEASE; AGE; FOLLOW; BIRTH	Objective-To determine which factors measured in childhood predict asthma in adult life. Design-Prospective study over 25 years of a birth cohort initially studied at the age of 7. Setting-Tasmania, Australia. Subjects-1494 men and women surveyed in 1991-3 when aged 29 to 32 (75% of a random stratified sample from the 1968 Tasmanian asthma survey of children born in 1961 and at school in Tasmania). Main outcome measures-Self reported asthma or wheezy breathing in the previous 12 months (current asthma). Result-Of the subjects with asthma or wheezy breathing by the age of 7, as reported by their parents 25.6% (190/741) reported current asthma as an adult compared with 10.8% (81/753) of subjects without parent reported childhood asthma (P<0.001). Factors measured at the age of 7 that independently predicted current asthma as an adult were being female (odds ratio 1.57; 95% confidence interval 1.19 to 2.08); having a history of eczema (1.45; 1.04 to 2.03); having a low mild forced expiratory flow rate (interquartile odds ratio 1.40; 1.15 to 1.71); having a mother or father with a history of asthma (1.74 (1.23 to 2.47) and 1.68 (1.18 to 2.38) respectively); and having childhood asthma (1.59; 1.10 to 2.29) and, if so, having the first attack after the age of 2 (1.66; 1.17 to 2.36) or having had more than 10 attacks (1.70; 1.17 to 2.48). Conclusion-Children with asthma reported by their parents in 1968 were more likely than not to be free of symptoms as adults. The subjects who had more severe asthma (especially if it developed after the age of 2 and was associated with reduced expiratory flow), were female, or had parents who had asthma were at an increased risk of having asthma as an adult. These findings have implications for the treatment and prognosis of childhood asthma, targeting preventive and educational strategies, and understanding the onset of asthma in adult life.	UNIV MELBOURNE,DEPT PUBL HLTH & COMMUNITY MED,CARLTON,VIC 3053,AUSTRALIA; ROYAL CHILDRENS HOSP,CLIN EPIDEMIOL & BIOSTAT UNIT,PARKVILLE,VIC 3052,AUSTRALIA; UNIV MELBOURNE,CTR ADOLESCENT HLTH,PARKVILLE,VIC 3052,AUSTRALIA; ANTICANC COUNCIL VICTORIA,CTR CANC EPIDEMIOL,CARLTON,VIC 3053,AUSTRALIA	University of Melbourne; Royal Children's Hospital Melbourne; University of Melbourne			Carlin, John B/B-3492-2012; Carlin, John/AAG-4332-2020; Jenkins, Mark/P-7803-2015	Carlin, John B/0000-0002-2694-9463; Carlin, John/0000-0002-2694-9463; Jenkins, Mark/0000-0002-8964-6160; Flander, Louisa/0000-0003-0824-9364; Giles, Graham/0000-0003-4946-9099				ANDERSON HR, 1992, THORAX, V47, P537, DOI 10.1136/thx.47.7.537; ANDERSON HR, 1986, J EPIDEMIOL COMMUN H, V40, P121, DOI 10.1136/jech.40.2.121; BAKER RJ, 1978, GLIM SYSTEM; BLAIR H, 1977, ARCH DIS CHILD, V52, P613, DOI 10.1136/adc.52.8.613; BRONNIMANN S, 1986, CHEST, V90, P480, DOI 10.1378/chest.90.4.480; BURR ML, 1993, MONOGR ALLERGY, V31, P80; DAY NE, 1976, TISSUE ANTIGENS, V8, P109; FLANDER LB, 1983, 111TH P ANN M AM PUB, P181; GIBSON T, 1969, J BIOMECH, V2, P201, DOI 10.1016/0021-9290(69)90032-3; GILES GG, 1984, AUST NZ J MED, V14, P631, DOI 10.1111/j.1445-5994.1984.tb05015.x; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HOPPER JL, 1992, AM J EPIDEMIOL, V136, P1138, DOI 10.1093/oxfordjournals.aje.a116580; HOSMER DW, 1980, APPLIED LOGISTIC REG; Jenkins M A, 1993, Paediatr Perinat Epidemiol, V7, P67, DOI 10.1111/j.1365-3016.1993.tb00602.x; KELLY WJW, 1987, BRIT MED J, V294, P1059, DOI 10.1136/bmj.294.6579.1059; KENDALL MG, 1973, ADV THEORY STAT, V2, P231; PETO J, 1980, BANBURY REPORT, V4, P203; PHELAN PD, 1982, RESPIRATORY ILLNESS; Rubio RL, 1988, ALLERGOL IMMUNOPATH, V16, P263; SHERMAN CB, 1990, AM J EPIDEMIOL, V132, P83, DOI 10.1093/oxfordjournals.aje.a115646; SKOBELOFF EM, 1992, JAMA-J AM MED ASSOC, V268, P3437, DOI 10.1001/jama.268.24.3437; STECENKO AA, 1991, AM REV RESPIR DIS, V144, P1008, DOI 10.1164/ajrccm/144.5.1008; STICK SM, 1991, AM REV RESPIR DIS, V144, P1012, DOI 10.1164/ajrccm/144.5.1012	23	189	196	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					90	93		10.1136/bmj.309.6947.90	http://dx.doi.org/10.1136/bmj.309.6947.90			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038673	Green Published			2022-12-24	WOS:A1994NW71600016
J	DOLPH, PJ; MANSONHING, H; YARFITZ, S; COLLEY, NJ; DEER, JR; SPENCER, M; HURLEY, JB; ZUKER, CS				DOLPH, PJ; MANSONHING, H; YARFITZ, S; COLLEY, NJ; DEER, JR; SPENCER, M; HURLEY, JB; ZUKER, CS			AN EYE-SPECIFIC G-BETA SUBUNIT ESSENTIAL FOR TERMINATION OF THE PHOTOTRANSDUCTION CASCADE	NATURE			English	Article							PROTEIN-KINASE-C; GAMMA-SUBUNITS; PHOSPHOLIPASE-C; PHOTORECEPTOR DEACTIVATION; DROSOPHILA PHOTORECEPTORS; ADENYLYL CYCLASE; ALPHA-SUBUNITS; RECEPTORS; TRANSDUCTION; ASSOCIATION	HETEROTRIMERIC G proteins couple various receptors to intracellular effector molecules. Although the role of the G alpha subunit in effector activation, guanine nucleotide exchange and GTP hydrolysis has been well studied(1-4), the cellular functions of the G beta subunits are less well understood(5,6). G beta gamma dimers bind G alpha subunits and anchor them to the membrane for presentation to the receptor(7,9). Tn specific systems, the G beta subunits have also been implicated in direct coupling to ion channels and to effector molecules(10-19). We have isolated Drosophila melanogaster mutants defective in an eye-specific G-protein beta-subunit (G beta e), and show here that the beta-subunit is essential for G-protein-receptor coupling in vivo. Remarkably, G beta mutants are also severely defective in the deactivation of the light response, demonstrating an essential role for the G beta subunit in terminating the active state of this signalling cascade.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of Washington; University of Washington Seattle					NEI NIH HHS [R01 EY008768] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008768] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BLANK JL, 1992, J BIOL CHEM, V267, P23069; BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4363, DOI 10.1073/pnas.87.11.4363; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOYER JL, 1992, J BIOL CHEM, V267, P25451; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FUNG BKK, 1983, J BIOL CHEM, V258, P495; HARDIE RC, 1991, P ROY SOC B-BIOL SCI, V245, P203, DOI 10.1098/rspb.1991.0110; Iniguez-Lluhi Jorge, 1993, Trends in Cell Biology, V3, P230, DOI 10.1016/0962-8924(93)90122-H; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KURJAN J, 1992, ANNU REV BIOCHEM, V61, P1097; LEE YJ, 1990, NEURON, V5, P889, DOI 10.1016/0896-6273(90)90349-K; LILLY P, 1993, GENE DEV, V7, P986, DOI 10.1101/gad.7.6.986; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MINKE B, 1986, MOL MECHANISM PHOTOR, P241; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RANGANATHAN R, 1991, NATURE, V354, P230, DOI 10.1038/354230a0; RANGANATHAN R, 1991, TRENDS NEUROSCI, V14, P486, DOI 10.1016/0166-2236(91)90060-8; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; YARFITZ S, 1991, NEURON, V7, P429, DOI 10.1016/0896-6273(91)90295-B; YARFITZ S, 1988, P NATL ACAD SCI USA, V85, P7134, DOI 10.1073/pnas.85.19.7134; Zuker Charles S., 1992, Current Opinion in Neurobiology, V2, P622, DOI 10.1016/0959-4388(92)90029-K	33	52	53	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 7	1994	370	6484					59	61		10.1038/370059a0	http://dx.doi.org/10.1038/370059a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV711	8015606				2022-12-24	WOS:A1994NV71100058
J	LINDENSTROM, E; BOYSEN, G; NYBOE, J				LINDENSTROM, E; BOYSEN, G; NYBOE, J			INFLUENCE OF TOTAL CHOLESTEROL, HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL, AND TRIGLYCERIDES ON RISK OF CEREBROVASCULAR-DISEASE - THE COPENHAGEN CITY HEART-STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SERUM-CHOLESTEROL; CARDIOVASCULAR-DISEASE; FOLLOW-UP; CEREBRAL INFARCTION; STROKE INCIDENCE; CORONARY; MEN; FRAMINGHAM; DENMARK; JAPAN	Objective-To estimate the influence of plasma total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease. Design-The Copenhagen city heart study is a prospective observational survey with two cardiovascular examinations at five year intervals. Non-fasting plasma lipids were measured in participants once at each examination, along with other variables. The Cox regression model was used to establish the effect of the factors recorded on cerebrovascular events of mostly, but not exclusively, ischaemic origin. Subjects-19 698 women and men at least 20 years old, randomly selected after age stratification from an area of central Copenhagen. Main outcome measures-Initial cases of stroke and transient ischaemic attack recorded from hospital records and death certificates from 1976 through 1988. Results-660 non-haemorrhagic and 33 haemorrhagic events were recorded. Total cholesterol was positively associated with risk of non-haemorrhagic events, but only for levels > 8 mmol/l, corresponding to the upper 5% of the distribution in the study population. For lower plasma cholesterol values the relative risk remained nearly constant. Plasma triglyceride concentration was significantly, positively associated with risk of non-haemorrhagic events. The relative risk corresponding to an increase of 1 mmol/l was 1.12 (95% confidence interval 1.07 to 1.16). There was a negative, log linear association between high density lipoprotein cholesterol and risk of non-haemorrhagic events (0.53 (0.34 to 0.83)). There was no indication that the effects of plasma lipids were different in women and men. Conclusions-The pattern of the association between plasma cholesterol and risk of ischaemic cerebrovascular disease was not log linear, and the increased risk was confined to the upper 5% of the cholesterol distribution. Further studies should concentrate on the association between plasma cholesterol and verified haemorrhagic stroke.	RIGSHOSP, COPENHAGEN CITY HEART STUDY, DK-2200 COPENHAGEN N, DENMARK	Rigshospitalet	LINDENSTROM, E (corresponding author), HVIDOVRE UNIV HOSP, DEPT NEUROL, 433, KETTEGARDS ALLE 30, DK-2650 HVIDOVRE, DENMARK.							Appleyard M., 1989, SCAND J SOC MED, V41, P1; ARONOW WS, 1988, ANGIOLOGY, V39, P563, DOI 10.1177/000331978803900701; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; BIHARIVARGA M, 1981, ATHEROSCLEROSIS, V40, P337, DOI 10.1016/0021-9150(81)90144-1; BOYSEN G, 1988, STROKE, V19, P1345, DOI 10.1161/01.STR.19.11.1345; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P73; CHEN ZM, 1989, NEW ENGL J MED, V321, P1339; COX DR, 1972, J R STAT SOC B, V34, P187; DAVIS CE, 1990, JAMA-J AM MED ASSOC, V264, P3044, DOI 10.1001/jama.264.23.3044; DYER AR, 1981, J CHRON DIS, V34, P249, DOI 10.1016/0021-9681(81)90030-8; Gatchev O, 1993, Ann Epidemiol, V3, P403, DOI 10.1016/1047-2797(93)90068-F; GERTLER MM, 1968, GERIATRICS, V23, P135; GORDON T, 1981, ARCH INTERN MED, V141, P1128, DOI 10.1001/archinte.141.9.1128; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; JAKOBSON T, 1967, ACTA MED SCAND, V182, P233; JENSEN G, 1983, ACTA MED SCAND S682, V214, P18; KAGAN A, 1974, J CHRON DIS, V27, P345, DOI 10.1016/0021-9681(74)90014-9; KANNEL WB, 1976, CEREBRAL ARTERIAL DI, P1; LINDENSTROM E, 1993, NEUROEPIDEMIOLOGY, V12, P37, DOI 10.1159/000110297; LINDENSTROM E, 1993, NEUROEPIDEMIOLOGY, V12, P43, DOI 10.1159/000110298; LINDENSTROM E, 1992, STROKE, V23, P28, DOI 10.1161/01.STR.23.1.28; MEYER JS, 1959, ARCH NEUROL-CHICAGO, V1, P303, DOI 10.1001/archneur.1959.03840030061006; MUI K, 1989, Osaka City Medical Journal, V35, P145; MURAI A, 1981, STROKE, V12, P167, DOI 10.1161/01.STR.12.2.167; NUBIOLA AR, 1981, ARCH NEUROL-CHICAGO, V38, P468, DOI 10.1001/archneur.1981.00510070102026; PATERSON J C, 1960, Can Med Assoc J, V82, P6; PRENTICE RL, 1982, BIOMETRIKA, V69, P331, DOI 10.1093/biomet/69.2.331; QUIZIBLASH N, 1991, BRIT MED J, V303, P605; QUIZIBLASH N, 1992, CEREBROVASC DIS, V2, P127; REED DM, 1990, AM J EPIDEMIOL, V131, P579, DOI 10.1093/oxfordjournals.aje.a115542; ROBINSON RW, 1963, ANN INTERN MED, V59, P180, DOI 10.7326/0003-4819-59-2-180; ROSSNER S, 1978, LANCET, V1, P577; RYU JE, 1992, STROKE, V23, P823, DOI 10.1161/01.STR.23.6.823; SHIMAMOTO T, 1989, CIRCULATION, V79, P503, DOI 10.1161/01.CIR.79.3.503; SIDHARAM R, 1992, NEUROEPIDEMIOLOGY, V11, P24; SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; STEMMERMANN GN, 1991, ARCH INTERN MED, V151, P969, DOI 10.1001/archinte.151.5.969; STOKES J, 1987, CIRCULATION, V75, P65; STRACHAN D, 1991, J CLIN EPIDEMIOL, V44, P1187, DOI 10.1016/0895-4356(91)90151-X; TAGGART H, 1979, EUR J CLIN INVEST, V9, P219, DOI 10.1111/j.1365-2362.1979.tb00926.x; UESHIMA H, 1980, PREV MED, V9, P722, DOI 10.1016/0091-7435(80)90017-1; WELIN L, 1987, NEW ENGL J MED, V317, P521, DOI 10.1056/NEJM198708273170901; WESTLUND K, 1972, SCAND J CLIN LAB INV, V30, P1; WILHELMSEN L, 1990, CLIN EXP HYPERTENS A, V12, P845, DOI 10.3109/10641969009073504; Wolf P A, 1978, Adv Neurol, V19, P107; WOLF PA, 1986, SEMIN NEUROL, V6, P243, DOI 10.1055/s-2008-1041467; WOO J, 1990, STROKE, V21, P1407, DOI 10.1161/01.STR.21.10.1407; WOO J, 1991, STROKE, V22, P203, DOI 10.1161/01.STR.22.2.203; YANO K, 1989, STROKE, V20, P1460, DOI 10.1161/01.STR.20.11.1460; YATSU FM, 1989, ANN NEUROL, V26, P3, DOI 10.1002/ana.410260102	51	275	290	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 2	1994	309	6946					11	15		10.1136/bmj.309.6946.11	http://dx.doi.org/10.1136/bmj.309.6946.11			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV891	8044059	Green Published			2022-12-24	WOS:A1994NV89100013
J	KURAHASHI, T; LOWE, G; GOLD, GH				KURAHASHI, T; LOWE, G; GOLD, GH			SUPPRESSION OF ODORANT RESPONSES BY ODORANTS IN OLFACTORY RECEPTOR-CELLS	SCIENCE			English	Article							NUCLEOTIDE-GATED CONDUCTANCE; SENSITIVE ADENYLATE-CYCLASE; ADAPTIVE PROPERTIES; TRANSDUCTION; CHANNELS; NEURONS; SALAMANDER; MEMBRANE; CILIA; ACTIVATION	Odorants activate an inward current in vertebrate olfactory receptor cells. Here it is shown, in receptor cells from the newt, that odorants can also suppress this current, by a mechanism that is distinct from inhibition and adaptation. Suppression provides a simple explanation for two seemingly unrelated phenomena: the anomalously long latency of olfactory transduction and the existence of an ''off response'' at the end of a prolonged stimulus. Suppression may influence the perception of odorants by masking odorant responses and by sharpening the odorant specificities of single cells.	MONELL CHEM SENSES CTR,PHILADELPHIA,PA 19104	Monell Chemical Senses Center								ANHOLT RRH, 1987, BIOCHEMISTRY-US, V26, P788, DOI 10.1021/bi00377a020; ARZT AH, 1986, J COMP PHYSIOL A, V158, P479, DOI 10.1007/BF00603794; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CAIN WS, 1975, CHEM SENS FLAV, V1, P339, DOI 10.1093/chemse/1.3.339; DIONNE VE, 1992, J GEN PHYSIOL, V99, P415, DOI 10.1085/jgp.99.3.415; FIRESTEIN S, 1989, SCIENCE, V244, P79, DOI 10.1126/science.2704991; FIRESTEIN S, 1993, J PHYSIOL-LONDON, V468, P1; FIRESTEIN S, 1991, J NEUROSCI, V11, P3565; FIRESTEIN S, 1990, J PHYSIOL-LONDON, V430, P135, DOI 10.1113/jphysiol.1990.sp018286; FRINGS S, 1992, J GEN PHYSIOL, V100, P45, DOI 10.1085/jgp.100.1.45; GESTELAND RC, 1965, J PHYSIOL-LONDON, V181, P525, DOI 10.1113/jphysiol.1965.sp007781; GETCHELL TV, 1978, J PHYSIOL-LONDON, V282, P541, DOI 10.1113/jphysiol.1978.sp012480; GETCHELL TV, 1978, J PHYSIOL-LONDON, V282, P521, DOI 10.1113/jphysiol.1978.sp012479; HUQUE T, 1986, BIOCHEM BIOPH RES CO, V137, P36, DOI 10.1016/0006-291X(86)91172-1; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KLEENE SJ, 1991, J MEMBRANE BIOL, V120, P75, DOI 10.1007/BF01868593; KLEENE SJ, 1993, NEURON, V11, P123, DOI 10.1016/0896-6273(93)90276-W; KLEENE SJ, 1991, J NEUROSCI, V11, P3624; KOLESNIKOV SS, 1990, FEBS LETT, V266, P96, DOI 10.1016/0014-5793(90)81515-P; KRAMER RH, 1992, NEURON, V9, P897, DOI 10.1016/0896-6273(92)90242-6; KURAHASHI T, 1991, NEUROREPORT, V2, P5, DOI 10.1097/00001756-199101000-00001; KURAHASHI T, 1990, J PHYSIOL-LONDON, V430, P355, DOI 10.1113/jphysiol.1990.sp018295; KURAHASHI T, 1990, BRAIN RES, V515, P261, DOI 10.1016/0006-8993(90)90605-B; KURAHASHI T, 1989, J PHYSIOL-LONDON, V419, P177, DOI 10.1113/jphysiol.1989.sp017868; KURAHASHI T, 1993, NATURE, V363, P71, DOI 10.1038/363071a0; KURAHASHI T, 1989, ZOOL SCI, V6, P19; LAMB TD, 1992, TRENDS NEUROSCI, V15, P291, DOI 10.1016/0166-2236(92)90079-N; LOWE G, 1991, J PHYSIOL-LONDON, V442, P147, DOI 10.1113/jphysiol.1991.sp018787; LOWE G, 1993, NATURE, V366, P283, DOI 10.1038/366283a0; LOWE G, 1993, J PHYSIOL-LONDON, V462, P175, DOI 10.1113/jphysiol.1993.sp019550; MENINI A, 1993, J PHYSIOL-LONDON, V468, P1; MICHEL WC, 1991, J NEUROPHYSIOL, V65, P446, DOI 10.1152/jn.1991.65.3.446; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; PACE U, 1985, NATURE, V316, P255, DOI 10.1038/316255a0; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; RESTREPO D, 1990, SCIENCE, V249, P1166, DOI 10.1126/science.2168580; SHIBUYA TATSUAKI, 1960, JAPANESE JOUR PHYSIOL, V10, P317; SHIRLEY SG, 1986, BIOCHEM J, V240, P605, DOI 10.1042/bj2400605; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; SUZUKI N, 1989, CHEM SENSES, V1, P469; TAKAGI SADAYUKI F., 1960, JAPANESE JOUR PHYSIOL, V10, P385; TAKAGI SF, 1959, NATURE, V184, P60, DOI 10.1038/184060a0; ZUFALL F, 1991, P ROY SOC B-BIOL SCI, V246, P225, DOI 10.1098/rspb.1991.0148	46	88	88	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 1	1994	265	5168					118	120		10.1126/science.8016645	http://dx.doi.org/10.1126/science.8016645			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV301	8016645				2022-12-24	WOS:A1994NV30100040
J	KARHUNEN, PJ; ERKINJUNTTI, T; LAIPPALA, P				KARHUNEN, PJ; ERKINJUNTTI, T; LAIPPALA, P			MODERATE ALCOHOL-CONSUMPTION AND LOSS OF CEREBELLAR PURKINJE-CELLS	BRITISH MEDICAL JOURNAL			English	Article							BRAIN ATROPHY; DRINKING; VALIDITY; AUTOPSY; DEGENERATION; NEURONS; LESIONS; DAMAGE; DEATH	Objective-To examine the dose-response effect of alcohol consumption on the number of cerebellar Purkinje cells. Design-A prospective necropsy study combined with detailed reports on use of alcohol from a relative or friend. The number of Purkinje cells was counted in the anterior midsagittal section of the cerebellar vermis, the area of which was measured by computer assisted morphometry. Setting-Department of forensic medicine, University of Helsinki. Subjects-66 men, aged 35 to 69 years, subjected to medicolegal necropsy because of sudden or violent death. The average all year daily alcohol consumption over the year was 0 to 10 g in 17 men, 11 to 80 g in 24 men, and more than 80 g in 25 men. Main outcome measures-Number of Purkinje cells, alcohol consumption. Results-The numbers and density of Purkinje cells in the cross section of vermis showed a consistent but weak decrease with increasing daily alcohol intake but not with age. A wide variation in the cell counts was observed, especially in men drinking more than 80 g, suggesting differences in the susceptibility to effects of alcohol. Compared with men drinking 40 g or less, a long term moderate consumption of an average of 41 to 80 g daily was associated with a significant average loss of 242 (95% confidence interval 45 to 439) Purkinje cells (15.2%) from a mean of 1583 to 1341 cells. In those drinking 81 to 180 g the average loss was 535 (259 to 811) cells (33.4%) to a mean of 1048 cells. The density of cells in the cross section of vermis also fell significantly by 0.9 cell/mm (0.1 to 1.7) when the daily consumption exceeded 40 g and by 1.4 cell/mm (0.3 to 2.5) when the intake was 81 to 180 g. Only three cases (4.5%); in the series showed macroscopical cerebellar atrophy. Conclusion-Long term intake of moderate doses of alcohol daily for 20-30 years may damage the cerebellum before the onset of macroscopical atrophy. Despite distinct individual differences an all year average daily alcohol intake of 41-80 g results in a risk of significant loss of Purkinje cells.	UNIV HELSINKI,DEPT FORENS MED,SF-00300 HELSINKI,FINLAND; UNIV HELSINKI,DEPT NEUROL,MED RES UNIT,HELSINKI,FINLAND	University of Helsinki; University of Helsinki	KARHUNEN, PJ (corresponding author), UNIV TAMPERE,DEPT PUBL HLTH,BIOMETRY UNIT,PL 607,SF-33101 TAMPERE,FINLAND.							ACKER W, 1982, J NEUROL NEUROSUR PS, V45, P984, DOI 10.1136/jnnp.45.11.984; ALTERMAN AI, 1989, ALCOHOL CLIN EXP RES, V13, P799, DOI 10.1111/j.1530-0277.1989.tb00425.x; ALTURA BM, 1983, SCIENCE, V220, P331, DOI 10.1126/science.6836278; CALA LA, 1978, AUST NZ J MED, V8, P147, DOI 10.1111/j.1445-5994.1978.tb04502.x; ESTRIN WJ, 1987, ALCOHOL CLIN EXP RES, V11, P372, DOI 10.1111/j.1530-0277.1987.tb01327.x; FULLER RK, 1988, ALCOHOL CLIN EXP RES, V12, P201, DOI 10.1111/j.1530-0277.1988.tb00180.x; GURLING HMD, 1991, BRIT J ADDICT, V86, P151; HARPER C, 1987, BRIT MED J, V294, P534, DOI 10.1136/bmj.294.6571.534; HARPER C, 1988, J NEUROL NEUROSUR PS, V51, P909, DOI 10.1136/jnnp.51.7.909; HILLBOM M, 1986, J NEUROL SCI, V73, P45, DOI 10.1016/0022-510X(86)90062-6; KARHUNEN PJ, 1990, ALCOHOL ALCOHOLISM, V25, P25; KERR JT, 1989, ALCOHOL CLIN EXP RES, V13, P730, DOI 10.1111/j.1530-0277.1989.tb00412.x; MIDANIK LT, 1989, BRIT J ADDICT, V84, P1419; MUURONEN A, 1989, ALCOHOL CLIN EXP RES, V13, P137, DOI 10.1111/j.1530-0277.1989.tb00298.x; PHILLIPS SC, 1987, BRAIN, V110, P301, DOI 10.1093/brain/110.2.301; SAVOLAINEN VT, 1992, ALCOHOL CLIN EXP RES, V16, P661, DOI 10.1111/j.1530-0277.1992.tb00655.x; SAVOLAINEN VT, 1993, ALCOHOL CLIN EXP RES, V17, P1112, DOI 10.1111/j.1530-0277.1993.tb05673.x; SKULLERUD K, 1991, INT J LEGAL MED, V104, P209, DOI 10.1007/BF01369809; SORENSEN TIA, 1989, LIVER, V9, P189; SUN GY, 1985, ALCOHOLISM CLIN EXP, V9, P95; TAVARES MA, 1987, ALCOHOL CLIN EXP RES, V11, P315, DOI 10.1111/j.1530-0277.1987.tb01315.x; THOMSON AD, 1988, HUM TOXICOL, V7, P455, DOI 10.1177/096032718800700513; TORVIK A, 1986, J NEUROL SCI, V75, P43, DOI 10.1016/0022-510X(86)90049-3; TORVIK A, 1982, J NEUROL SCI, V56, P233, DOI 10.1016/0022-510X(82)90145-9; VICTOR M, 1959, ARCH NEUROL-CHICAGO, V1, P579, DOI 10.1001/archneur.1959.03840060001001; VICTOR M, 1978, ADV NEUROLOGY; WATSON CG, 1984, J STUD ALCOHOL, V45, P344, DOI 10.15288/jsa.1984.45.344; 1987, MED CONSEQUENCES ALC, P125	28	76	76	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 25	1994	308	6945					1663	1667		10.1136/bmj.308.6945.1663	http://dx.doi.org/10.1136/bmj.308.6945.1663			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NU483	8025457	Green Published			2022-12-24	WOS:A1994NU48300016
J	PEAT, JK; VANDENBERG, RH; GREEN, WF; MELLIS, CM; LEEDER, SR; WOOLCOCK, AJ				PEAT, JK; VANDENBERG, RH; GREEN, WF; MELLIS, CM; LEEDER, SR; WOOLCOCK, AJ			CHANGING PREVALENCE OF ASTHMA IN AUSTRALIAN CHILDREN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HOUSE-DUST MITE; RESPIRATORY SYMPTOMS; BRONCHIAL HYPERRESPONSIVENESS; SCHOOLCHILDREN; CHILDHOOD; POPULATION; ALLERGENS; ATOPY; EXPOSURE	Objective-To investigate whether prevalence of asthma in children increased in 10 years. Design-Serial cross sectional studies of two populations of children by means of standard protocol. Setting-Two towns in New South Wales: Belmont (coastal and humid) and Wagga Wagga (inland and dry). Subjects-Children aged 8-10 years: 718 in Belmont and 769 in Wagga Wagga in 1982; 873 in Belmont and 795 in Wagga Wagga in 1992. Main outcome measures-History of respiratory illness recorded by parents in self administered questionnaire; airway hyperresponsiveness by histamine inhalation test; atopy by skin prick tests; counts of house dust mites in domestic dust. Results-Prevalence of wheeze in previous 12 months increased in Belmont, from 10.4% (75/718) in 1982 to 27.6% (240/873) in 1992 (P<0.001), and in Wagga Wagga, from 15.5% (119/769) to 23.1% (183/795) (P<0.001). The prevalence of airway hyperresponsiveness increased twofold in Belmont to 19.8% (173/873) (P<0.001) and 1.4-fold in Wagga Wagga to 18.1% (P<0.05). The prevalence of airway hyperresponsiveness increased mainly in atopic children only, but the prevalence of atopy was unchanged (about 28.5% in Belmont and about 32.5% in Wagga Wagga). Numbers of house dust mites increased 5.5-fold in Belmont and 4.5-fold in Wagga Wagga. Conclusions-We suggest that exposure to higher allergen levels has increased airway abnormalities in atopic children or that mechanisms that protected airways of earlier generations of children have been altered by new environmental factors.	UNIV SYDNEY, DEPT MED, SYDNEY, NSW 2006, AUSTRALIA; ROYAL PRINCE ALFRED HOSP, INST RESP MED, ALLEN & HANBURYS EPIDEMIOL UNIT, SYDNEY, NSW 2050, AUSTRALIA; WESTMEAD HOSP, DEPT COMMUNITY MED, WESTMEAD, NSW 2145, AUSTRALIA	University of Sydney; University of Sydney; University of Sydney								BAUMAN A, 1992, MED J AUSTRALIA, V156, P827, DOI 10.5694/j.1326-5377.1992.tb136992.x; BAUMAN A, 1992, AUST NZ J MED, V22, P36, DOI 10.1111/j.1445-5994.1992.tb01706.x; BRITTON WJ, 1986, INT J EPIDEMIOL, V15, P202, DOI 10.1093/ije/15.2.202; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; FEATHER IH, 1993, THORAX, V48, P5, DOI 10.1136/thx.48.1.5; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; GERGEN PJ, 1988, PEDIATRICS, V81, P1; GREEN WF, 1978, CLIN ALLERGY, V8, P135, DOI 10.1111/j.1365-2222.1978.tb00458.x; HABY MM, 1994, EUR RESPIR J, V7, P43, DOI 10.1183/09031936.94.07010043; HILL R, 1989, BRIT MED J, V299, P898, DOI 10.1136/bmj.299.6704.898; HOLT PG, 1990, PEDIATR ALLERGY IMMU, V1, P3; HURRY VM, 1988, AUST NZ J MED, V18, P745, DOI 10.1111/j.1445-5994.1988.tb00173.x; LEE DA, 1983, BRIT MED J, V286, P1256, DOI 10.1136/bmj.286.6373.1256; MITCHELL EA, 1985, ARCH DIS CHILD, V60, P376, DOI 10.1136/adc.60.4.376; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; PEAT JK, 1992, BMJ-BRIT MED J, V305, P1326, DOI 10.1136/bmj.305.6865.1326; PEAT JK, 1994, AUST NZ J MED, V24, P270, DOI 10.1111/j.1445-5994.1994.tb02171.x; PEAT JK, 1991, AM REV RESPIR DIS, V144, P663, DOI 10.1164/ajrccm/144.3_Pt_1.663; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; PEAT JK, 1990, J ALLERGY CLIN IMMUN, V85, P65, DOI 10.1016/0091-6749(90)90223-Q; PEAT JK, 1992, SEARCH, V23, P252; PEAT JK, 1994, IN PRESS EUR RESPIR; PECKHAM C, 1978, J EPIDEMIOL COMMUN H, V32, P79, DOI 10.1136/jech.32.2.79; Pepys J., 1975, BR J HOSP MED, V14, P412; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; ROBERTSON CF, 1991, BMJ-BRIT MED J, V302, P1116, DOI 10.1136/bmj.302.6785.1116; SALOME CM, 1987, CLIN ALLERGY, V17, P271, DOI 10.1111/j.1365-2222.1987.tb02015.x; SHAW RA, 1990, ARCH DIS CHILD, V65, P1319, DOI 10.1136/adc.65.12.1319; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; TOELLE BG, 1992, AM REV RESPIR DIS, V146, P633, DOI 10.1164/ajrccm/146.3.633; VARJONEN E, 1992, ALLERGY, V47, P243, DOI 10.1111/j.1398-9995.1992.tb00657.x; WOOLCOCK AJ, 1991, EUR RESPIR REV, V1, P243; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; 1985, SAS USERS GUIDE STAT	37	424	427	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 18	1994	308	6944					1591	1596		10.1136/bmj.308.6944.1591	http://dx.doi.org/10.1136/bmj.308.6944.1591			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NT528	8025424	Green Published			2022-12-24	WOS:A1994NT52800015
J	DERKSEN, J; NAGESSER, SK; MEINDERS, AE; HAAK, HR; VANDEVELDE, CJH				DERKSEN, J; NAGESSER, SK; MEINDERS, AE; HAAK, HR; VANDEVELDE, CJH			IDENTIFICATION OF VIRILIZING ADRENAL-TUMORS IN HIRSUTE WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADRENOCORTICAL TUMORS; ADENOMA; TESTOSTERONE; VIRILIZATION; ADULT	Background. Hirsutism in women is usually caused by benign adrenal or ovarian disorders, but it can also be caused by adrenal carcinoma. The most effective way to identify such carcinomas is not known. Methods. We measured serum and urinary steroids before and after the administration of 3 mg of dexamethasone per day for five days in 14 hirsute women with histologically proved adrenal tumors (12 adrenal carcinomas and 2 adrenal adenomas) and in 73 women with hirsutism of non-neoplastic origin. Results. All the women with adrenal tumors had elevated basal serum concentrations of testosterone or dehydroepiandrosterone sulfate, as compared with 36 of the 73 women with non-neoplastic hirsutism (sensitivity, 100 percent; 95 percent confidence interval, 77 to 100; specificity, 50 percent; 95 percent confidence interval, 38 to 62). After the administration of dexamethasone, serum dehydroepiandrosterone sulfate concentrations and urinary 17-ketosteroid excretion decreased to values similar to those in normal women in all the women with non-neoplastic hirsutism, but in none of the 12 with adrenal tumors who were tested. All the women who did not have adrenal tumors had serum cortisol concentrations below 3.3 mu g per deciliter (90 nmol per liter) after dexamethasone administration, whereas in all 12 patients tested who had tumors the values were higher. The suppression of serum dehydroepiandrosterone sulfate and cortisol and urinary 17-ketosteroid excretion excluded the likelihood of adrenal tumors with a sensitivity of 100 percent (95 percent confidence interval, 74 to 100) and a specificity of 100 percent (95 percent confidence interval, 89 to 100). Conclusions. Among women with hirsutism, an adrenal tumor is unlikely it the patient has normal basal serum concentrations of testosterone and dehydroepiandrosterone sulfate. In women in whom these concentrations are elevated, a tumor is unlikely if the serum concentration of dehydroepiandrosterone sulfate and urinary 17-ketosteroid excretion are in the normal basal range and the serum cortisol concentration is less than 3.3 mu g per deciliter after the administration of dexamethasone.	LEIDEN UNIV HOSP, DEPT ENDOCRINOL & METAB, LEIDEN, NETHERLANDS; LEIDEN UNIV HOSP, DEPT SURG, LEIDEN, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)	DERKSEN, J (corresponding author), UNIV LEIDEN HOSP, DEPT GEN INTERNAL MED, BLDG 1, CL-R41, POB 9600, 2300 RC LEIDEN, NETHERLANDS.							ADAMS J, 1986, BRIT MED J, V293, P355, DOI 10.1136/bmj.293.6543.355; ANDERSON DC, 1978, CLIN ENDOCRINOL, V9, P1, DOI 10.1111/j.1365-2265.1978.tb03567.x; BERTAGNA C, 1981, AM J MED, V71, P855, DOI 10.1016/0002-9343(81)90384-3; CHECK JH, 1978, OBSTET GYNECOL, V51, pS46; CLOUSTON WM, 1989, CLIN ENDOCRINOL, V31, P467, DOI 10.1111/j.1365-2265.1989.tb01270.x; DELGAUDIO A, 1993, CANCER, V72, P1997; FERRIMAN D, 1961, J CLIN ENDOCR METAB, V21, P1440, DOI 10.1210/jcem-21-11-1440; GABRILOVE JL, 1981, ENDOCR REV, V2, P462, DOI 10.1210/edrv-2-4-462; GARDNER MJ, 1990, STATISTICS CONFIDENC, P28; GREENBLATT RB, 1963, HIRSUTE FEMALE, P109; KAMILARIS TC, 1987, JAMA-J AM MED ASSOC, V258, P2558, DOI 10.1001/jama.258.18.2558; KENDALL JW, 1968, NEW ENGL J MED, V279, P532, DOI 10.1056/NEJM196809052791007; KIRK JMW, 1990, J CLIN ENDOCR METAB, V70, P1280, DOI 10.1210/jcem-70-5-1280; MAHESH VB, 1968, AM J OBSTET GYNECOL, V100, P1043, DOI 10.1016/S0002-9378(15)33402-5; MAROULIS GB, 1981, FERTIL STERIL, V36, P273; OLEARY TJ, 1986, J PEDIATR-US, V109, P840, DOI 10.1016/S0022-3476(86)80707-7; SAMAAN NA, 1975, OBSTET GYNECOL, V46, P104, DOI 10.1097/00006250-197507000-00022; TAYLOR L, 1986, FERTIL STERIL, V46, P1005; TURPIN G, 1986, REV MED INTERNE, V7, P371, DOI 10.1016/S0248-8663(86)80126-6; VANDEKAMP JJP, 1984, EUR J PEDIATR, V142, P140, DOI 10.1007/BF00445598; VANSETERS AP, 1991, ACTA ENDOCRINOL-COP, V124, P526, DOI 10.1530/acta.0.1240526; VANSETERS AP, 1981, CLIN ENDOCRINOL, V14, P325; VILLEE DB, 1967, J CLIN ENDOCR METAB, V27, P1112, DOI 10.1210/jcem-27-8-1112; VONSLOOTEN H, 1985, CANCER, V55, P766; YUEN BH, 1983, AM J OBSTET GYNECOL, V145, P164, DOI 10.1016/0002-9378(83)90484-2	25	107	114	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 13	1994	331	15					968	973		10.1056/NEJM199410133311502	http://dx.doi.org/10.1056/NEJM199410133311502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK504	8084355				2022-12-24	WOS:A1994PK50400002
J	CHAUDHARY, AK; NOKUBO, M; REDDY, GR; YEOLA, SN; MORROW, JD; BLAIR, IA; MARNETT, LJ				CHAUDHARY, AK; NOKUBO, M; REDDY, GR; YEOLA, SN; MORROW, JD; BLAIR, IA; MARNETT, LJ			DETECTION OF ENDOGENOUS MALONDIALDEHYDE-DEOXYGUANOSINE ADDUCTS IN HUMAN LIVER	SCIENCE			English	Article							LIPID-PEROXIDATION; DNA-ADDUCTS; CANCER; MALONALDEHYDE; DERIVATIVES; NUCLEOSIDES; HOMOLOG; ACID	Endogenous DNA adducts may contribute to the etiology of human genetic disease and cancer. One potential source of endogenous DNA adducts is lipid peroxidation, which generates mutagenic carbonyl compounds such as malondialdehyde. A sensitive mass spectrometric method permitted detection and quantitation of the major malondialdehyde-DNA adduct, a pyrimidopurinone derived from deoxyguanosine. DNA from disease-free human liver was found to contain 5400 adducts per cell, a frequency comparable to that of adducts formed by exogenous carcinogens.	VANDERBILT UNIV,SCH MED,AB HANCOCK JR MEM LAB CANC RES,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PHARMACOL,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; Vanderbilt University			Blair, Ian A/B-3320-2010		NCI NIH HHS [CA47479] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline; NIGMS NIH HHS [GM42056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM042056, R01GM042056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; BASU AK, 1983, CARCINOGENESIS, V4, P331, DOI 10.1093/carcin/4.3.331; BENAMIRA M, IN PRESS CARCINOGENE; BERNHEIM F, 1948, J BIOL CHEM, V174, P257; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; Chaudhary A, UNPUB; DIX TA, 1983, SCIENCE, V221, P77, DOI 10.1126/science.6304879; DIX TA, 1993, CHEM RES TOXICOL, V6, P2, DOI 10.1021/tx00031a001; Esterbauer H., 1982, FREE RADICAL LIPID P, P101; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FLOYD RA, IN PRESS 1ST P OXYG; HANAWALT PC, 1986, TRENDS GENET, V2, P124, DOI 10.1016/0168-9525(86)90201-5; JANERO DR, 1990, FREE RADICAL BIO MED, V9, P515, DOI 10.1016/0891-5849(90)90131-2; Kagan V. E, 1988, LIPID PEROXIDATION B; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MARNETT LJ, 1986, J AM CHEM SOC, V108, P1348, DOI 10.1021/ja00266a065; MARNETT LJ, 1993, CHEM RES TOXICOL, V6, P771, DOI 10.1021/tx00036a005; MILLER EC, 1966, PHARMACOL REV, V18, P805; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MUKAI FH, 1976, SCIENCE, V191, P868, DOI 10.1126/science.766187; NOKUBO M, UNPUB; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARK EM, 1992, P NATL ACAD SCI USA, V89, P3375, DOI 10.1073/pnas.89.8.3375; PHILLIPS DH, 1990, INT J CANCER, V46, P569, DOI 10.1002/ijc.2910460403; RANDERATH K, 1993, MUTAT RES, V295, P11, DOI 10.1016/0921-8734(93)90007-P; SETO H, 1983, B CHEM SOC JPN, V56, P1799, DOI 10.1246/bcsj.56.1799; Singer B., 1983, MOL BIOL MUTAGENS CA; Spalding J. W., 1988, NATL TOXICOL PROGRAM, V331, P5; WAGNER JR, 1992, P NATL ACAD SCI USA, V89, P3380, DOI 10.1073/pnas.89.8.3380; 1984, CHEM CARCINOGENS	31	408	414	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 9	1994	265	5178					1580	1582		10.1126/science.8079172	http://dx.doi.org/10.1126/science.8079172			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF336	8079172				2022-12-24	WOS:A1994PF33600035
J	XU, B; SELSING, E				XU, B; SELSING, E			ANALYSIS OF SEQUENCE TRANSFERS RESEMBLING GENE CONVERSION IN A MOUSE ANTIBODY TRANSGENE	SCIENCE			English	Article							HEAVY-CHAIN TRANSGENE; RECOMBINATION; MUTATION; SEGMENT	The role of gene conversion in murine immunoglobulin gene diversification is unclear. An antibody gene construct designed to provide the homologous donor and acceptor sequences required for conversion mechanisms was produced and used to generate transgenic mice. When these transgenic mice were immunized, DNA sequence transfers between tandem transgene VDJ regions were detectable and resembled gene conversion events. There is a strong link between these conversion-like sequence transfers and transgene somatic hypermutation, suggesting that both processes might occur at the same stage of B cell differentiation.			XU, B (corresponding author), TUFTS UNIV,SCH MED,SACKLER SCH GRAD BIOMED SCI,DEPT PATHOL,136 HARRISON AVE,BOSTON,MA 02111, USA.							CHIEN NC, 1988, J EXP MED, V167, P954, DOI 10.1084/jem.167.3.954; CREWS S, 1981, CELL, V25, P59, DOI 10.1016/0092-8674(81)90231-2; DURDIK J, 1989, P NATL ACAD SCI USA, V86, P2346, DOI 10.1073/pnas.86.7.2346; GERSTEIN RM, 1990, CELL, V63, P537, DOI 10.1016/0092-8674(90)90450-S; KNIGHT KL, 1990, CELL, V60, P963, DOI 10.1016/0092-8674(90)90344-E; KRAWINKEL U, 1986, NUCLEIC ACIDS RES, V14, P3871, DOI 10.1093/nar/14.9.3871; KRAWINKEL U, 1983, P NATL ACAD SCI-BIOL, V80, P4997, DOI 10.1073/pnas.80.16.4997; REYNAUD CA, 1987, CELL, V48, P379, DOI 10.1016/0092-8674(87)90189-9; ROTHSTEIN TL, 1983, MOL IMMUNOL, V20, P161, DOI 10.1016/0161-5890(83)90127-X; SOHN J, 1993, J EXP MED, V177, P493, DOI 10.1084/jem.177.2.493; THOMPSON CB, 1987, CELL, V48, P369, DOI 10.1016/0092-8674(87)90188-7; WYSOCKI LJ, 1990, J EXP MED, V172, P315, DOI 10.1084/jem.172.1.315	12	43	44	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 9	1994	265	5178					1590	1593		10.1126/science.8079173	http://dx.doi.org/10.1126/science.8079173			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF336	8079173				2022-12-24	WOS:A1994PF33600039
J	SOUTTER, WP				SOUTTER, WP			IMMEDIATE REFERRAL TO COLPOSCOPY IS SAFER	BRITISH MEDICAL JOURNAL			English	Article							CERVICAL SMEAR				SOUTTER, WP (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,LONDON W12 0HS,ENGLAND.							BOLGER BS, 1988, BRIT J OBSTET GYNAEC, V95, P1117, DOI 10.1111/j.1471-0528.1988.tb06788.x; FLANNELLY G, 1994, BRIT MED J, V308, P1399, DOI 10.1136/bmj.308.6941.1399; FLETCHER A, 1990, BRIT MED J, V301, P641, DOI 10.1136/bmj.301.6753.641; JARMULOWICZ MR, 1989, BRIT J OBSTET GYNAEC, V96, P1061, DOI 10.1111/j.1471-0528.1989.tb03381.x; JOHNSON N, 1993, LANCET, V342, P91, DOI 10.1016/0140-6736(93)91290-3; MITCHELL H, 1990, BRIT MED J, V300, P1622, DOI 10.1136/bmj.300.6740.1622; ROBERTSON JH, 1988, BRIT MED J, V297, P18, DOI 10.1136/bmj.297.6640.18; SOUTTER WP, 1986, BRIT J OBSTET GYNAEC, V93, P70, DOI 10.1111/j.1471-0528.1986.tb07816.x; SOUTTER WP, 1994, BMJ-BRIT MED J, V308, P1421, DOI 10.1136/bmj.308.6941.1421; SOUTTER WP, 1992, REPORT WORKSHOP MILD; WILKINSON C, 1990, BRIT MED J, V300, P440, DOI 10.1136/bmj.300.6722.440; 1987, REPORT INTERCOLLEGIA; 1986, BRIT MED J, V293, P659	13	15	15	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 3	1994	309	6954					591	592		10.1136/bmj.309.6954.591	http://dx.doi.org/10.1136/bmj.309.6954.591			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF330	8086951	Green Published			2022-12-24	WOS:A1994PF33000028
J	PUROHIT, P; STERN, S				PUROHIT, P; STERN, S			INTERACTIONS OF A SMALL RNA WITH ANTIBIOTIC AND RNA LIGANDS OF THE 30S SUBUNIT	NATURE			English	Article							16S RIBOSOMAL-RNA; I INTRON RNA; CHEMICAL PROBES; P-SITE; BINDING; NUCLEOTIDES; INHIBITION	IT is now generally accepted that 16S and 23S ribosomal RNA play important roles in the decoding and peptidyl transferase activities of ribosomes(1,2). Despite their complex structures and numerous associated proteins it is possible that small domains of these rRNAs can fold and function autonomously, particularly those that appear devoid of protein interactions(3). One candidate for such a domain is the decoding region, located near the 3' end of 16S rRNA (Fig. 1a, b). Consistent with this hypothesis, aminoglycoside antibiotics that interact with the decoding region in 30S subunits interact with other RNAs in the absence of proteins(4-7). In addition, certain activities of self-splicing introns, at least superficially, resemble translational decoding(8,9). We report here that an oligoribonucleotide analogue of the decoding region interacts with both antibiotic and RNA ligands of the 30S subunit in a manner that correlates with normal subunit function. The activities of the decoding region analogue suggest that the intimidating structural complexity of the ribosome can be, to some degree, circumvented.			PUROHIT, P (corresponding author), UNIV MASSACHUSETTS, SCH MED, PROGRAM MOLEC MED, 373 PLANTAT ST, WORCESTER, MA 01605 USA.							DAVIS PW, 1993, NUCLEIC ACIDS RES, V21, P537, DOI 10.1093/nar/21.3.537; GUTELL RR, 1985, PROG NUCLEIC ACID RE, V32, P155, DOI 10.1016/S0079-6603(08)60348-7; GUTELL RR, 1993, TRANSLATIONAL APPARATUS, P477; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; MOAZED D, 1987, BIOCHIMIE, V69, P879, DOI 10.1016/0300-9084(87)90215-X; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; Noller H.F., 1993, RNA WORLD, P137; NOLLER HF, 1984, ANNU REV BIOCHEM, V53, P119, DOI 10.1146/annurev.bi.53.070184.001003; NOLLER HF, 1990, RIBOSOME, P73; NOLTER HF, 1991, NATURE, V353, P302; PEATTIE DA, 1980, P NATL ACAD SCI-BIOL, V77, P4679, DOI 10.1073/pnas.77.8.4679; PRINCE JB, 1982, P NATL ACAD SCI-BIOL, V79, P5450, DOI 10.1073/pnas.79.18.5450; ROSE SJ, 1983, J MOL BIOL, V167, P103, DOI 10.1016/S0022-2836(83)80036-9; SCHROEDER R, 1993, SCIENCE, V260, P1443, DOI 10.1126/science.8502988; STERN S, 1988, METHOD ENZYMOL, V164, P481; STERN S, 1989, SCIENCE, V244, P783, DOI 10.1126/science.2658053; TUERK C, 1988, P NATL ACAD SCI USA, V85, P1364, DOI 10.1073/pnas.85.5.1364; VONAHSEN U, 1992, J MOL BIOL, V226, P935, DOI 10.1016/0022-2836(92)91043-O; VONAHSEN U, 1993, SCIENCE, V260, P1500, DOI 10.1126/science.8502993; VONAHSEN U, 1991, NATURE, V353, P368, DOI 10.1038/353368a0; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467; WOODCOCK J, 1991, EMBO J, V10, P3099, DOI 10.1002/j.1460-2075.1991.tb07863.x; ZAPP ML, 1993, CELL, V74, P969, DOI 10.1016/0092-8674(93)90720-B	26	260	278	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 25	1994	370	6491					659	662		10.1038/370659a0	http://dx.doi.org/10.1038/370659a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD310	8065453				2022-12-24	WOS:A1994PD31000053
J	ETTER, A; BERNARD, V; KENZELMANN, M; TOBLER, H; MULLER, F				ETTER, A; BERNARD, V; KENZELMANN, M; TOBLER, H; MULLER, F			RIBOSOMAL HETEROGENEITY FROM CHROMATIN DIMINUTION IN ASCARIS-LUMBRICOIDES	SCIENCE			English	Article							PROTEIN GENES; NUCLEOTIDE-SEQUENCE; BINDING-PROTEIN; TURNER SYNDROME; RNA; S19; ORGANIZATION; EXPRESSION; GENOME; YEAST	The genome of Ascaris lumbricoides encodes both germline- and soma-specific proteins homologous to the eukaryotic small ribosomal protein (Rp) S19. The two Ascaris homologs differ by 24 amino acid substitutions and are both components of the small ribosomal subunits. In oocytes, the germline RpS19 homolog (RpS19G) predominates. During chromatin diminution, however, the gene is eliminated from all presomatic cells, and RpS19G is replaced by the product of the somatic gene (RpS19S). Chromatin diminution in A. lumbricoides causes a change in the protein composition of ribosomes during development and represents an alternative means of gene regulation.	UNIV FRIBOURG,INST ZOOL,CH-1700 FRIBOURG,SWITZERLAND	University of Fribourg								AEBY P, 1986, EMBO J, V5, P3353, DOI 10.1002/j.1460-2075.1986.tb04650.x; BAUMGARTNER S, 1993, NUCLEIC ACIDS RES, V21, P3897, DOI 10.1093/nar/21.16.3897; BRADSHAW RE, 1991, GENE, V108, P157, DOI 10.1016/0378-1119(91)90502-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DONOVAN DM, 1990, MOL CELL BIOL, V10, P6097, DOI 10.1128/MCB.10.11.6097; ETTER A, 1991, P NATL ACAD SCI USA, V88, P1593, DOI 10.1073/pnas.88.5.1593; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; GODAY C, 1993, PARASITOL TODAY, V9, P319, DOI 10.1016/0169-4758(93)90229-9; GORENSTEIN C, 1976, P NATL ACAD SCI USA, V73, P1547, DOI 10.1073/pnas.73.5.1547; GUNDERSON JH, 1987, SCIENCE, V238, P933, DOI 10.1126/science.3672135; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HARLOW E, 1988, ANTIBODIES LABORATOR; KIMURA J, 1987, FEBS LETT, V224, P65, DOI 10.1016/0014-5793(87)80423-4; KONDOH N, 1992, CANCER RES, V52, P791; LUTSCH G, 1990, EUR J CELL BIOL, V51, P140; MOLENAAR CMT, 1984, NUCLEIC ACIDS RES, V12, P7345, DOI 10.1093/nar/12.19.7345; MORITZ KB, 1976, NATURE, V259, P55, DOI 10.1038/259055a0; MULLER F, 1982, NUCLEIC ACIDS RES, V10, P7493, DOI 10.1093/nar/10.23.7493; MULLER F, 1991, CELL, V67, P815, DOI 10.1016/0092-8674(91)90076-B; NILSEN TW, 1993, ANNU REV MICROBIOL, V47, P413, DOI 10.1146/annurev.mi.47.100193.002213; Poinar GO., 1983, NATURAL HIST NEMATOD; RAMAGOPAL S, 1993, TRANSLATIONAL APPARATUS, P713; Sambrook J., 1989, MOL CLONING LAB MANU; Spedding G, 1990, RIBOSOMES PROTEIN SY, P9; SPICHER A, 1994, DEV BIOL, V164, P72, DOI 10.1006/dbio.1994.1181; STORTKUHL KF, 1994, CELL TISSUE RES, V275, P27, DOI 10.1007/BF00305373; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUZUKI K, 1990, BIOCHIMIE, V72, P299, DOI 10.1016/0300-9084(90)90088-X; TOBLER H, 1992, TRENDS GENET, V8, P427, DOI 10.1016/0168-9525(92)90326-Y; TOBLER H, 1986, RESULTS PROBLEMS CEL, V13; WARNER JR, 1977, J MOL BIOL, V115, P315, DOI 10.1016/0022-2836(77)90157-7; WATANABE M, 1993, NAT GENET, V4, P268, DOI 10.1038/ng0793-268; WOLFFE AP, 1988, SCIENCE, V241, P1626, DOI 10.1126/science.3420414	33	45	47	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 12	1994	265	5174					954	956		10.1126/science.8052853	http://dx.doi.org/10.1126/science.8052853			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052853				2022-12-24	WOS:A1994PB49900043
J	OROURKE, B; RAMZA, BM; MARBAN, E				OROURKE, B; RAMZA, BM; MARBAN, E			OSCILLATIONS OF MEMBRANE CURRENT AND EXCITABILITY DRIVEN BY METABOLIC OSCILLATIONS IN HEART-CELLS	SCIENCE			English	Article							PURINE NUCLEOTIDE CYCLE; SENSITIVE K+ CHANNELS; CALCIUM CHANNELS; GLYCOLYTIC OSCILLATIONS; POTENTIAL OSCILLATIONS; INTRACELLULAR CALCIUM; MUSCLE EXTRACTS; ATP; MYOCYTES; MODULATION	Periodic changes in membrane ionic current linked to intrinsic oscillations of energy metabolism were identified in guinea pig cardiomyocytes. Metabolic stress initiated cyclical activation of adenosine triphosphate-sensitive potassium current and concomitant suppression of depolarization-evoked intracellular calcium transients. The oscillations in membrane current and excitation-contraction coupling were linked to oscillations in the oxidation state of pyridine nucleotides but were not driven by pacemaker currents or alterations in the concentration of cytosolic calcium. Interventions that altered the rate of glucose metabolism modulated the oscillations, suggesting that the rhythms originated at the level of glycolysis. The energy-driven oscillations in potassium currents produced cyclical changes in the cardiac action potential and thus may contribute to the genesis of arrhythmias during metabolic compromise.	JOHNS HOPKINS UNIV, DEPT MED, DIV CARDIOL, BALTIMORE, MD 21205 USA	Johns Hopkins University			Marban, Eduardo/GWC-8514-2022	O'Rourke, Brian/0000-0002-5548-4853	NHLBI NIH HHS [R01 HL 36957] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036957] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRES V, 1990, J BIOL CHEM, V265, P21441; AON MA, 1991, J CELL SCI, V99, P325; BACKX PH, 1991, AM J HYPERTENS, V4, pS416, DOI 10.1093/ajh/4.7.416S; BELLES B, 1988, PFLUG ARCH EUR J PHY, V411, P353, DOI 10.1007/BF00587713; BOITEUX A, 1975, P NATL ACAD SCI USA, V72, P3829, DOI 10.1073/pnas.72.10.3829; CHANCE B, 1965, J BIOL CHEM, V240, P3170; CHANCE B, 1964, BIOCHEMISTRY-US, V52, P337; CHEN V, 1985, BIOCHIM BIOPHYS ACTA, V846, P398, DOI 10.1016/0167-4889(85)90012-6; COLLATZ KG, 1990, COMP BIOCHEM PHYS B, V96, P771, DOI 10.1016/0305-0491(90)90229-M; CONNOR JA, 1979, J EXP BIOL, V81, P153; CORKEY BE, 1988, J BIOL CHEM, V263, P4254; ENG J, 1989, BIOPHYS J, V55, P621, DOI 10.1016/S0006-3495(89)82859-0; FRENKEL R, 1966, ARCH BIOCHEM BIOPHYS, V115, P112, DOI 10.1016/S0003-9861(66)81046-9; FRENKEL R, 1968, ARCH BIOCHEM BIOPHYS, V125, P157, DOI 10.1016/0003-9861(68)90650-4; GHOSH A, 1964, BIOCHEM BIOPH RES CO, V16, P174, DOI 10.1016/0006-291X(64)90357-2; GOLDBETER A, 1980, MATH MODELS MOL CELL, P260; GOLDMAN YE, 1982, NATURE, V300, P701, DOI 10.1038/300701a0; GOOCH VD, 1974, BIOCHIM BIOPHYS ACTA, V346, P245, DOI 10.1016/0304-4173(74)90002-0; GWILT M, 1993, EUR J PHARMACOL, V236, P107, DOI 10.1016/0014-2999(93)90232-7; HESS B, 1983, H-S Z PHYSIOL CHEM, V364, P1; Hess B, 1979, Ann N Y Acad Sci, V316, P203, DOI 10.1111/j.1749-6632.1979.tb29470.x; KEUNG EC, 1991, J CLIN INVEST, V88, P1772, DOI 10.1172/JCI115497; KORT AA, 1985, J PHYSIOL-LONDON, V367, P291, DOI 10.1113/jphysiol.1985.sp015825; LEDERER WJ, 1989, J PHYSIOL-LONDON, V419, P193, DOI 10.1113/jphysiol.1989.sp017869; MARKUS M, 1984, FEBS LETT, V172, P235, DOI 10.1016/0014-5793(84)81132-1; MEECH RW, 1979, J EXP BIOL, V81, P93; MEISSNER G, 1987, J BIOL CHEM, V262, P3065; MITRA R, 1985, AM J PHYSIOL, V249, P1056, DOI 10.1152/ajpheart.1985.249.5.H1056; OROURKE B, 1992, SCIENCE, V257, P245, DOI 10.1126/science.1321495; RAPP PE, 1977, J THEOR BIOL, V66, P497, DOI 10.1016/0022-5193(77)90299-5; Stryer L, 1981, BIOCHEMISTRY; TORNHEIM K, 1974, J BIOL CHEM, V249, P3241; TORNHEIM K, 1979, J THEOR BIOL, V79, P491, DOI 10.1016/0022-5193(79)90240-6; TSIEN RW, 1979, J EXP BIOL, V81, P205; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSUCHIYA K, 1992, P NATL ACAD SCI USA, V89, P6418, DOI 10.1073/pnas.89.14.6418; WEISS JN, 1992, J PHYSIOL-LONDON, V447, P649, DOI 10.1113/jphysiol.1992.sp019022; Wit A. L., 1993, VENTRICULAR ARRHYTHM	38	212	222	2	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 12	1994	265	5174					962	966		10.1126/science.8052856	http://dx.doi.org/10.1126/science.8052856			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052856				2022-12-24	WOS:A1994PB49900046
J	KAO, CM; KATZ, L; KHOSLA, C				KAO, CM; KATZ, L; KHOSLA, C			ENGINEERED BIOSYNTHESIS OF A COMPLETE MACROLACTONE IN A HETEROLOGOUS HOST	SCIENCE			English	Article							METHYLMALONYL-COA EPIMERASE; COENZYME-A MUTASE; POLYKETIDE SYNTHASE; SACCHAROPOLYSPORA-ERYTHRAEA; ESCHERICHIA-COLI; STREPTOMYCES-ERYTHREUS; MACROLIDE ANTIBIOTICS; PROPIONIBACTERIUM-SHERMANII; PHYSICOCHEMICAL PROPERTIES; NUCLEOTIDE-SEQUENCE	Macrocyclic polyketides have been subjects of great interest in synthetic and biosynthetic chemistry because of their structural complexity and medicinal activities. With expression of the entire 6-deoxyerythronolide B synthase (DEBS) (10,283 amino acids) in a heterologous host, substantial quantities of 6-deoxyerythronolide B (6dEB), the aglycone of the macrolide antibiotic erythromycin, and 8,8a-deoxyoleandolide, a 14-membered lactone ring identical to 6dEB except for a methyl group side chain in place of an ethyl unit, were synthesized in Streptomyces coelicolor. The biosynthetic strategy utilizes a genetic approach that facilitates rapid structural manipulation of DEBS or other modular polyketide synthases (PKSs), including those found in actinomycetes with poorly developed genetic methods. From a technological viewpoint, this approach should allow the rational design of biosynthetic products and may eventually lead to the generation of diverse polyketide libraries by means of combinatorial cloning of naturally occurring and mutant PKS modules.	STANFORD UNIV,DEPT CHEM ENGN,STANFORD,CA 94305; ABBOTT LABS,ANTIINFECT DISCOVERY RES,ABBOTT PK,IL 60064	Stanford University; Abbott Laboratories				Khosla, Chaitan/0000-0001-6529-495X				ALBERSSCHONBERG G, 1981, J AM CHEM SOC, V103, P4216, DOI 10.1021/ja00404a040; BIBB MJ, 1989, EMBO J, V8, P2727, DOI 10.1002/j.1460-2075.1989.tb08414.x; BIBB MJ, 1994, GENE, V142, P31, DOI 10.1016/0378-1119(94)90351-4; BIRCH A, 1993, J BACTERIOL, V175, P3511, DOI 10.1128/jb.175.11.3511-3519.1993; BRENDELBERGER G, 1988, ANGEW CHEM INT EDIT, V27, P1089, DOI 10.1002/anie.198810891; CAFFREY P, 1992, FEBS LETT, V304, P225, DOI 10.1016/0014-5793(92)80624-P; CANE DE, 1983, J AM CHEM SOC, V105, P4110, DOI 10.1021/ja00350a070; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; DONADIO S, 1993, P NATL ACAD SCI USA, V90, P7119, DOI 10.1073/pnas.90.15.7119; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; DONADIO S, 1992, GENE, V115, P97, DOI 10.1016/0378-1119(92)90546-2; DORMAN DE, 1976, HELV CHIM ACTA, V59, P2625, DOI 10.1002/hlca.19760590802; FERNANDEZMORENO MA, 1992, J BIOL CHEM, V267, P19278; FU H, IN PRESS BIOCHEMISTR; FU H, 1993, IN PRESS J AM CHEM S, V115, P11671; FULLER JQ, 1983, BIOCHEM J, V213, P643, DOI 10.1042/bj2130643; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; Hopwood D. A., 1985, GENETIC MANIPULATION; HSIEH YJ, 1994, J BACTERIOL, V176, P714, DOI 10.1128/jb.176.3.714-724.1994; HUNAITI AA, 1984, ANTIMICROB AGENTS CH, V25, P173, DOI 10.1128/AAC.25.2.173; HUNAITI AR, 1982, ARCH BIOCHEM BIOPHYS, V216, P362, DOI 10.1016/0003-9861(82)90222-3; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; KATZ L, UNPUB; KIBWAGE IO, 1987, J ANTIBIOT, V40, P1; LEADLAY PF, 1981, BIOCHEM J, V197, P413, DOI 10.1042/bj1970413; MACNEIL DJ, 1992, GENE, V115, P119, DOI 10.1016/0378-1119(92)90549-5; MACNEIL DJ, 1988, J BACTERIOL, V170, P5607, DOI 10.1128/jb.170.12.5607-5612.1988; Maniatis T., 1982, MOL CLONING; MARDSEN AFA, 1994, SCIENCE, V263, P378; MARTIN JR, 1974, J ANTIBIOT, V27, P570, DOI 10.7164/antibiotics.27.570; MCDANIEL R, 1993, J AM CHEM SOC, V115, P11671, DOI 10.1021/ja00078a002; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; MCDANIEL RG, UNPUB; NOURSE JG, 1975, J AM CHEM SOC, V97, P4584, DOI 10.1021/ja00849a021; OCONNOR M, 1989, SCIENCE, V244, P1307, DOI 10.1126/science.2660262; OHagan D., 1991, POLYKETIDE METABOLIT; OMURA S, 1983, J ANTIBIOT, V36, P614, DOI 10.7164/antibiotics.36.614; ONO M, 1983, J ANTIBIOT, V36, P509, DOI 10.7164/antibiotics.36.509; PIEPER R, UNPUB; POSPISIL S, 1983, J ANTIBIOT, V36, P617, DOI 10.7164/antibiotics.36.617; REYNOLDS KA, 1988, J CHEM SOC PERK T 1, P3195, DOI 10.1039/p19880003195; ROBERTS GA, 1993, EUR J BIOCHEM, V214, P305, DOI 10.1111/j.1432-1033.1993.tb17925.x; SHERMAN DH, 1989, EMBO J, V8, P2717, DOI 10.1002/j.1460-2075.1989.tb08413.x; SHERMAN MM, 1986, J ANTIBIOT, V39, P1135, DOI 10.7164/antibiotics.39.1135; TAKIGUCHI Y, 1983, J ANTIBIOT, V36, P502, DOI 10.7164/antibiotics.36.502; TUAN JS, 1990, GENE, V90, P21, DOI 10.1016/0378-1119(90)90435-T; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WEBER JM, 1991, SCIENCE, V252, P114, DOI 10.1126/science.2011746; YU TW, 1994, J BACTERIOL, V176, P2627, DOI 10.1128/JB.176.9.2627-2634.1994	49	212	252	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 22	1994	265	5171					509	512		10.1126/science.8036492	http://dx.doi.org/10.1126/science.8036492			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	8036492				2022-12-24	WOS:A1994NY21600025
J	CAELLES, C; HELMBERG, A; KARIN, M				CAELLES, C; HELMBERG, A; KARIN, M			P53-DEPENDENT APOPTOSIS IN THE ABSENCE OF TRANSCRIPTIONAL ACTIVATION OF P53-TARGET GENES	NATURE			English	Article							REPLICATION FACTOR-A; DNA-REPLICATION; THYMOCYTE APOPTOSIS; CELL-DEATH; WILD-TYPE; P53; PROTEIN; MUTANT; TRANSFORMATION; LOCALIZATION	THE tumour suppressor p53 is required to induce programmed cell death (apoptosis) by DNA-damaging agents(1,2). As p53 is a transcriptional activator(3) that mediates gene induction after DNA damage(4), it has been proposed to be a genetic switch that activates apoptosis-mediator genes(5). Here we evaluate the role of p53 in DNA-damage-induced apoptosis by establishing derivatives of GHFT1 cells, that are somatotropic progenitors immortalized by expression of SV40 T-antigen(6), which express a temperature-sensitive p53 mutant(7). In these cells induction of apoptosis by DNA damage depends strictly on p53 function. A shift to the permissive temperature triggers apoptosis following DNA damage, but this is independent of new RNA or protein synthesis. The extent of apoptotic DNA cleavage is directly proportional to the period during which p53 is functional. These results do not support the proposal that p53 is an activator of apoptosis-mediator genes but rather indicate that p53 either represses genes necessary for cell survival(8) or is a component of the enzymatic machinery for apoptotic cleavage or repair of DNA(5).	UNIV CALIF SAN DIEGO,SCH MED,CTR MOLEC GENET,DEPT PHARMACOL,PROGRAM BIOMED SCI,LA JOLLA,CA 92093	University of California System; University of California San Diego								BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HARPER JW, 1993, CELL, V75, P805; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HIBI M, 1993, GENE DEV, V7, P2134; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LEVINE AJ, 1993, BIOL CHEM H-S, V374, P227; LEW D, 1993, GENE DEV, V7, P683, DOI 10.1101/gad.7.4.683; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAGIMOV N, 1993, ONCOGENE, V8, P1183; TILLY JL, 1993, J CELL PHYSIOL, V154, P519, DOI 10.1002/jcp.1041540310; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; Wyllie A H, 1992, Semin Immunol, V4, P389; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	33	852	868	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 21	1994	370	6486					220	223		10.1038/370220a0	http://dx.doi.org/10.1038/370220a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX971	8028670				2022-12-24	WOS:A1994NX97100054
J	KONDRASHOV, AS				KONDRASHOV, AS			THE ASEXUAL PLOIDY CYCLE AND THE ORIGIN OF SEX	NATURE			English	Article							CELL-FUSION; EVOLUTION; MEIOSIS; AMEBA; DNA; REPRODUCTION; GYMNAMOEBIA; SELECTION; MUTATIONS; ADVANTAGE	SEX involves syngamy (gamete fusion), which doubles the amount of DNA in a cell, and meiosis(1), which halves it. The result is a 'ploidy cycle' of alternating diploid and haploid phases. Asexual reproduction does not require changes of ploidy, and yet asexual forms may have ploidy cycles. Here I show that such cycles lessen the mutation load, compared with permanent diploidy or polyploidy, and are thus likely to evolve in cases where it is always advantageous to have more than one copy of the genome per cell. The asexual ploidy cycle could have facilitated the origin of sex, by providing a means of orderly genetic reduction available immediately after the origin of syngamy.			KONDRASHOV, AS (corresponding author), CORNELL UNIV,ECOL & SYSTEMAT SECT,ITHACA,NY 14853, USA.							AFONKIN SJ, 1986, ARCH PROTISTENKD, V131, P101, DOI 10.1016/S0003-9365(86)80067-7; [Anonymous], 1988, SEX DEATH PROTOZOA H; Bernstein C., 1991, AGING SEX DNA REPAIR; BRUGEROLLE G, 1993, J EUKARYOT MICROBIOL, V40, P616, DOI 10.1111/j.1550-7408.1993.tb06118.x; BYERS TJ, 1986, INT REV CYTOL, V99, P311; CHARLESWORTH B, 1990, GENET RES, V55, P199, DOI 10.1017/S0016672300025532; CLEVELAND LR, 1947, SCIENCE, V105, P287, DOI 10.1126/science.105.2724.287; CROW J. F., 1970, Biomathematics. Volume 1. Mathematical topics in population genetics., P128; DICKSON DPE, 1984, HEREDITY, V53, P717, DOI 10.1038/hdy.1984.129; DRAKE JW, 1991, P NATL ACAD SCI USA, V88, P7160, DOI 10.1073/pnas.88.16.7160; FAN JB, 1991, NUCLEIC ACIDS RES, V19, P1905, DOI 10.1093/nar/19.8.1905; HAIG D, 1993, J THEOR BIOL, V163, P15, DOI 10.1006/jtbi.1993.1104; HASIMOTO T, 1994, MOL BIOL EVOL, V11, P65; HURST LD, 1993, NATURE, V365, P206, DOI 10.1038/365206a0; HURST LD, 1991, J THEOR BIOL, V150, P561, DOI 10.1016/S0022-5193(05)80447-3; KIMURA M, 1966, GENETICS, V54, P1337; KIRKPATRICK M, 1989, NATURE, V339, P300, DOI 10.1038/339300a0; KNOLL AH, 1992, SCIENCE, V256, P622, DOI 10.1126/science.1585174; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; KONDRASHOV AS, 1994, GENETICS, V137, P311; KONDRASHOV AS, 1982, GENET RES, V40, P325, DOI 10.1017/S0016672300019194; KONDRASHOV AS, 1993, J HERED, V84, P372, DOI 10.1093/oxfordjournals.jhered.a111358; LEWIS WM, 1985, AM NAT, V125, P692, DOI 10.1086/284372; MAGUIRE MP, 1992, J THEOR BIOL, V154, P43, DOI 10.1016/S0022-5193(05)80187-0; Margulis L, 1990, HDB PROTOCTISTA; Margulis L, 1986, ORIGINS SEX; MULLER DG, 1967, PLANTA, V75, P39, DOI 10.1007/BF00380838; Raikov I.B., 1989, Progress in Protistology, V3, P21; SERAVIN LN, 1983, TSITOLOGIYA+, V25, P194; SERAVIN LN, 1984, TSITOLOGIYA+, V26, P123; SERAVIN LN, 1985, ZOOL ZH, V64, P1090; WILLUMSEN NBS, 1987, ARCH PROTISTENKD, V134, P303, DOI 10.1016/S0003-9365(87)80002-7; [No title captured]; [No title captured]	34	72	80	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 21	1994	370	6486					213	216		10.1038/370213a0	http://dx.doi.org/10.1038/370213a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX971	8028667				2022-12-24	WOS:A1994NX97100051
J	ROBERTSON, CM; HAWKINS, MM; KINGSTON, JE				ROBERTSON, CM; HAWKINS, MM; KINGSTON, JE			LATE DEATHS AND SURVIVAL AFTER CHILDHOOD-CANCER - IMPLICATIONS FOR CURE	BRITISH MEDICAL JOURNAL			English	Article							PRIMARY TUMORS	Objectives-To investigate causes of death and survival in subjects who had survived at least five years after diagnosis of childhood cancer; to compare observed mortality with that expected in the general population; and to compare results with a corresponding cohort diagnosed earlier. Design-Retrospective cohort study. Setting-Population based National Register of Childhood Tumours. Subjects-9080 five year survivors of childhood cancer diagnosed in Britain during 1971-85, of whom 793 had died. Comparison with corresponding cohort diagnosed during 1940-70. Main outcome measures-Cause of death established from all available sources of information (including hospital and general practitioner records and postmortem reports) and underlying cause of death coded on death certificate. Results-Of the 781 deaths for which sufficient information was available, death was attributed to recurrent tumour in 578 (74%) cases, treatment related effect in 121 (15%), second primary tumour 52 (7%), and other causes in 30 (4%). Comparison of observed mortality with that expected in the general population indicated a fourfold excess of deaths from non-neoplasic causes. The risk of dying of recurrent tumour in the next 10 years after surviving five years from diagnosis during 1940-70 and 1971-85 fell from 12% to 8%. The risk of dying from a treatment related effect increased slightly from 1% to 2%. Conclusion-Improvements in five year survival after childhood cancer have been accompanied by a reduction in risk of dying from recurrent tumour during the subsequent 10 years and by a slight increase in risk of dying from treatment related effects. The results provide information relevant to decisions concerning balance between effective treatments and their potentially harmful effects.	UNIV OXFORD,CHILDHOOD CANC RES GRP,OXFORD OX2 6HJ,ENGLAND; ST BARTHOLOMEWS HOSP,LONDON EC1,ENGLAND	University of Oxford								ALASIRI RH, 1992, MED PEDIATR ONCOL, V20, P315, DOI 10.1002/mpo.2950200409; BIRCH JM, 1987, INT J CANCER, V40, P620, DOI 10.1002/ijc.2910400508; Breslow N. E., 1987, STATISTICAL METHODS, VII; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P134, DOI 10.1093/ije/15.1.134; HAWKINS MM, 1989, ARCH DIS CHILD, V64, P798, DOI 10.1136/adc.64.6.798; HAWKINS MM, 1990, ARCH DIS CHILD, V65, P1356, DOI 10.1136/adc.65.12.1356; HAWKINS MM, 1987, BRIT J CANCER, V56, P339, DOI 10.1038/bjc.1987.200; KINGSTON JE, 1987, BRIT J CANCER, V56, P331, DOI 10.1038/bjc.1987.199; LIPSHULTZ SE, 1991, NEW ENGL J MED, V324, P808, DOI 10.1056/NEJM199103213241205; NICHOLSON HS, 1994, CANCER, V73, P3094; ODRISCOLL BR, 1990, NEW ENGL J MED, V323, P378, DOI 10.1056/NEJM199008093230604; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; ROBERTSON CM, 1992, ARCH DIS CHILD, V67, P1378, DOI 10.1136/adc.67.11.1378; STEINHERZ LJ, 1991, JAMA-J AM MED ASSOC, V266, P1672, DOI 10.1001/jama.266.12.1672; STILLER CA, 1990, BRIT J CANCER, V62, P806, DOI 10.1038/bjc.1990.383; [No title captured]; 1965, MANUAL INT STATISTIC	17	95	97	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 16	1994	309	6948					162	166		10.1136/bmj.309.6948.162	http://dx.doi.org/10.1136/bmj.309.6948.162			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY229	8044095	Green Published			2022-12-24	WOS:A1994NY22900021
J	WARREN, AJ; COLLEDGE, WH; CARLTON, MBL; EVANS, MJ; SMITH, AJH; RABBITTS, TH				WARREN, AJ; COLLEDGE, WH; CARLTON, MBL; EVANS, MJ; SMITH, AJH; RABBITTS, TH			THE ONCOGENIC CYSTEINE-RICH LIM DOMAIN PROTEIN RBTN2 IS ESSENTIAL FOR ERYTHROID DEVELOPMENT	CELL			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; TRANSCRIPTION FACTOR GATA-1; EMBRYONIC STEM-CELLS; MOUSE EMBRYO; ERYTHROPOIETIN RECEPTOR; MESSENGER-RNAS; SCL GENE; C-MYC; DIFFERENTIATION; EXPRESSION	The LIM domain protein rbtn2 is associated with T cell acute leukemias. We demonstrate that rbtn2 is a nuclear protein expressed in the erythroid lineage in vivo, and using homologous recombination, we show that it is essential for erythroid development in mice. The homozygous rbtn2 null mutation leads to failure of yolk sac erythropoiesis and embryonic lethality around E10.5. Moreover, in vitro differentiation of yolk sac tissue from homozygous mutant mice and sequentially targeted double-mutant ES cells demonstrates a block to erythroid development. This shows a pivotal role for a LIM domain protein in lineage specification during mammalian development and suggests that RBTN2 and GATA-1 are critical at similar stages of erythroid differentiation.	UNIV CAMBRIDGE,WELLCOME CANC RES CAMPAIGN INST,CAMBRIDGE CB2 1QR,ENGLAND; UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE CB2 1QR,ENGLAND	University of Cambridge; University of Cambridge	WARREN, AJ (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.		Colledge, William/X-4976-2019; Rabbitts, Terence/D-6262-2016	Colledge, William/0000-0002-9603-4429; Rabbitts, Terence/0000-0002-4982-2609	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; ARCHER VEV, 1994, P NATL ACAD SCI USA, V91, P316, DOI 10.1073/pnas.91.1.316; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BOEHM T, 1990, EMBO J, V9, P857, DOI 10.1002/j.1460-2075.1990.tb08183.x; BOEHM T, 1990, ONCOGENE, V5, P1103; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOEHM T, 1988, ONCOGENE, V3, P691; BOEHM T, 1991, ONCOGENE, V6, P695; BOEHM T, 1988, EMBO J, V7, P2011, DOI 10.1002/j.1460-2075.1988.tb03040.x; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; CHENG JT, 1993, ONCOGENE, V8, P667; CHIBA T, 1993, P NATL ACAD SCI USA, V90, P11593, DOI 10.1073/pnas.90.24.11593; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUI DHK, 1975, BRIT J HAEMATOL, V29, P553, DOI 10.1111/j.1365-2141.1975.tb02742.x; CHUI DHK, 1974, DEV BIOL, V40, P256, DOI 10.1016/0012-1606(74)90128-6; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CRAWFORD AW, 1992, J CELL BIOL, V116, P1381, DOI 10.1083/jcb.116.6.1381; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FISCH P, 1993, ONCOGENE, V8, P3271; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; GREEN AR, 1992, ONCOGENE, V7, P653; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; GREEN SM, 1989, ONCOGENE, V4, P737; HEBERLEIN C, 1992, MOL CELL BIOL, V12, P1815, DOI 10.1128/MCB.12.4.1815; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KASTER KR, 1983, NUCLEIC ACIDS RES, V11, P6895, DOI 10.1093/nar/11.19.6895; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; KOSA JL, 1994, BIOCHEMISTRY-US, V33, P468, DOI 10.1021/bi00168a011; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEFRANC MP, 1986, CELL, V45, P237, DOI 10.1016/0092-8674(86)90388-0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; MOUTHON MA, 1993, BLOOD, V81, P647; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RAIMONDI SC, 1993, BLOOD, V81, P2237; RIBEIRO RC, 1991, BLOOD, V78, P466; Robertson E. J., 1987, TERATOCARCINOMAS EMB; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; RUSSELL ES, 1968, GENETICS, V58, P259; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SANCHEZGARCIA I, 1993, SEMIN CANCER BIOL, V4, P349; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; SOFRONIEW MV, 1983, HDB CHEM NEUROANATOM, V1, P210; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WHITE JG, 1987, J CELL BIOL, V105, P41, DOI 10.1083/jcb.105.1.41; WILES MV, 1991, DEVELOPMENT, V111, P259; WULF GM, 1993, EMBO J, V12, P5065, DOI 10.1002/j.1460-2075.1993.tb06200.x; YENOFSKY RL, 1990, P NATL ACAD SCI USA, V87, P3435, DOI 10.1073/pnas.87.9.3435; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	65	534	551	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 15	1994	78	1					45	57		10.1016/0092-8674(94)90571-1	http://dx.doi.org/10.1016/0092-8674(94)90571-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033210				2022-12-24	WOS:A1994NX32800007
J	HASHIMOTO, N; WATANABE, N; FURUTA, Y; TAMEMOTO, H; SAGATA, N; YOKOYAMA, M; OKAZAKI, K; NAGAYOSHI, M; TAKEDA, N; IKAWA, Y; AIZAWA, S				HASHIMOTO, N; WATANABE, N; FURUTA, Y; TAMEMOTO, H; SAGATA, N; YOKOYAMA, M; OKAZAKI, K; NAGAYOSHI, M; TAKEDA, N; IKAWA, Y; AIZAWA, S			PARTHENOGENETIC ACTIVATION OF OOCYTES IN C-MOS-DEFICIENT MICE	NATURE			English	Article							PROTO-ONCOGENE PRODUCT; MEIOTIC MATURATION; XENOPUS OOCYTES; MOUSE-TISSUES; MEIOSIS-II; EGGS; PROTOONCOGENE; TRANSCRIPTS; EXPRESSION; FEATURES	IN Xenopus the c-mos proto-oncogene product (Mos) is essential for the initiation of oocyte maturation(1), for the progression from meiosis I to meiosis II2,3 and for the second meiotic metaphase arrest, acting as an essential component of the cytostatic factor CSF4,5. Its function in mouse oocytes is unclear(6-9), however, as is the biological significance of c-mos mRNA expression in testes(1,10) and several somatic tissues(1,10,11). We have generated c-mos-deficient mice by gene targeting in embryonic stem cells. These mice grew at the same rate as their wild-type counterparts and reproduction was normal in the males, but the fertility of the females was very low. The c-mos-deficient female mice developed ovarian teratomas at a high frequency. Oocytes from these females matured to the second meiotic metaphase both in vivo and in vitro, but were activated without fertilization. The results indicate that in mice Mos plays a role in the second meiotic metaphase arrest, but does not seem to be essential for the initiation of oocyte maturation, spermatogenesis or somatic cell cycle.	MITSUBISHI KASEI INST LIFE SCI,11 MINAMIOOYA,MACHIDA,TOKYO 194,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,TSUKUBA,IBARAKI 305,JAPAN; KURUME UNIV,INST LIFE SCI,DIV MOLEC GENET,KURUME,FUKUOKA 830,JAPAN; TOKYO MED & DENT UNIV,SCH MED,DEPT BIOCHEM,TOKYO 113,JAPAN	RIKEN; Kurume University; Tokyo Medical & Dental University (TMDU)			Okazaki, Kenji/H-4393-2012; Watanabe, Nobumoto/N-6959-2015	Watanabe, Nobumoto/0000-0002-2130-1334				DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; EPPIG JJ, 1977, NATURE, V269, P517, DOI 10.1038/269517a0; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HASHIMOTO N, 1988, DEV BIOL, V126, P242, DOI 10.1016/0012-1606(88)90135-2; HASHIMOTO N, 1990, DEV GROWTH DIFFER, V32, P197; HERZOG NK, 1989, ONCOGENE, V4, P1307; HOGAN B, 1986, MANIPULATING MOUSE E, V106; INOUE M, 1975, BIOL REPROD, V13, P546, DOI 10.1095/biolreprod13.5.546; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; WOLF DP, 1978, DEV BIOL, V64, P1, DOI 10.1016/0012-1606(78)90056-8; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458; Yoda Y., 1971, JAPANESE J ANIM REPR, V16, P147, DOI [DOI 10.1262/JRD1955.16.147, 10.1262/jrd1955.16.147]; ZHAO X, 1990, ONCOGENE, V5, P1727; ZHAO X, 1991, ONCOGENE, V6, P43	24	394	412	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 7	1994	370	6484					68	71		10.1038/370068a0	http://dx.doi.org/10.1038/370068a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV711	8015610				2022-12-24	WOS:A1994NV71100061
J	ZHANG, J; DAWSON, VL; DAWSON, TM; SNYDER, SH				ZHANG, J; DAWSON, VL; DAWSON, TM; SNYDER, SH			NITRIC-OXIDE ACTIVATION OF POLY(ADP-RIBOSE) SYNTHETASE IN NEUROTOXICITY	SCIENCE			English	Article							GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; ADP-RIBOSYLATION; RIBONUCLEOTIDE REDUCTASE; GLUTAMATE NEUROTOXICITY; DNA DAMAGE; CELLS; INHIBITION; POLYMERASE; CALCIUM; NICOTINAMIDE	Poly(adenosine 5'-diphosphoribose) synthetase (PARS) is a nuclear enzyme which, when activated by DNA strand breaks, adds up to 100 adenosine 5'-diphosphoribose (ADP-ribose) units to nuclear proteins such as histones and PARS itself. This activation can lead to cell death through depletion of beta-nicotinamide adenine dinucleotide (the source of ADP-ribose) and adenosine triphosphate. Nitric oxide (NO) stimulated ADP-ribosylation of PARS in rat brain. Benzamide and other derivatives, which inhibit PARS, blocked N-methyl-D-aspartate- and NO-mediated neurotoxicity with relative potencies paralleling their ability to inhibit PARS. Thus, NO appeared to elicit neurotoxicity by activating PARS.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; NIDA,ADDICT RES CTR,MOLEC NEUROPSYCHIAT SECT,BALTIMORE,MD 21224; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Dawson, Valina/Y-9757-2019	Dawson, Valina/0000-0002-2915-3970	NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-271-90-7408, DA-00266, DA-00074] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BANASIK M, 1992, J BIOL CHEM, V267, P1569; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1990, J NEUROSCI, V10, P2493; CLEAVER JE, 1991, MUTAT RES, V257, P1, DOI 10.1016/0165-1110(91)90016-O; DAWSON TM, IN PRESS J NEUROSCI; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; DIMMELER S, 1992, J BIOL CHEM, V267, P16771; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; GAAL JC, 1987, TRENDS BIOCHEM SCI, V12, P129, DOI 10.1016/0968-0004(87)90061-2; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; KALLMANN B, 1992, LIFE SCI, V51, P671, DOI 10.1016/0024-3205(92)90240-P; KOTS AY, 1992, FEBS LETT, V300, P9, DOI 10.1016/0014-5793(92)80153-8; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; LEPOIVRE M, 1990, J BIOL CHEM, V265, P14143; LOWRY OH, 1964, J BIOL CHEM, V239, P18; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; MCNERNEY R, 1989, BIOCHIM BIOPHYS ACTA, V1009, P185, DOI 10.1016/0167-4781(89)90099-7; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; Molina Y Vedia Luis, 1992, Journal of Biological Chemistry, V267, P24929; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; RALEY KM, 1990, NEUROSCI LETT, V110, P118, DOI 10.1016/0304-3940(90)90798-E; RANDALL RD, 1992, J NEUROSCI, V12, P1882; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; UEMATSU D, 1989, BRAIN RES, V482, P129, DOI 10.1016/0006-8993(89)90549-0; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; ZHANG J, 1992, P NATL ACAD SCI USA, V89, P9382, DOI 10.1073/pnas.89.20.9382	34	1035	1084	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 4	1994	263	5147					687	689		10.1126/science.8080500	http://dx.doi.org/10.1126/science.8080500			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU964	8080500				2022-12-24	WOS:A1994MU96400051
J	KOGAN, MD; PAPPAS, G; YU, SM; KOTELCHUCK, M				KOGAN, MD; PAPPAS, G; YU, SM; KOTELCHUCK, M			OVER-THE-COUNTER MEDICATION USE AMONG US PRESCHOOL-AGE CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SELF-MEDICATION; COMMON COLD	Objective.-To estimate the prevalence of recent over-the-counter (OTC) medication use in a national sample of preschool-age children. Design.-Follow-up survey of a nationally representative sample of 3-year-old children in the US population by telephone or personal interview. Participants.-A total of 8145 children whose mothers were interviewed for the 1991 Longitudinal Follow-up to the National Maternal and Infant Health Survey. Main Outcome Measures.-Report of any OTC medications given in the past 30 days and the type of medications that the child received. Results.-During the past 30 days, 53.7% of all 3-year-old children in the United States were given some OTC medications. Among OTC medication users, the most common medications reported were Tylenol (66.7%) and cough or cold medicine (66.7%). Most respondents reported that recent child illness episodes (70%) were treated with OTC medications. After adjustment for recent child illness, women who were white (odds ratio [OR], 1.32; 95% confidence interval [Cl], 1.13 to 1.55), were more educated (OR, 1.58; 95% CI, 1.24 to 2.00), and had higher incomes (OR, 1.75; 95% Cl, 1.33 to 2.30) were more likely to have given their child OTC medications. Women without health insurance were also more likely to have given OTC medications (OR, 1.27; 95% Cl, 1.04 to 1.55). Provider visits, but not telephone calls, were associated with a reduction in OTC medication usage. Conclusions.-Over-the-counter medications are an important component of health care for treating illness in US preschool-age children. The high prevalence of use has occurred despite the dearth of scientific proof for the effectiveness of certain classes of OTC medications and the risks associated with improper use.	US HLTH RESOURCES & SERV ADM, BUR MATERNAL & CHILD HLTH, ROCKVILLE, MD USA; UNIV N CAROLINA, DEPT MATERNAL & CHILD HLTH, CHAPEL HILL, NC USA	United States Health Resources & Service Administration (HRSA); University of North Carolina; University of North Carolina Chapel Hill	KOGAN, MD (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR HLTH STAT, 6525 BELCREST RD, ROOM 840, HYATTSVILLE, MD 20782 USA.							BLAKE KD, 1993, LANCET, V341, P640, DOI 10.1016/0140-6736(93)90410-I; BONADIO WA, 1993, CLIN PEDIATR, V32, P343, DOI 10.1177/000992289303200604; BUSH PJ, 1976, MED CARE, V14, P1014; CHRISCHILLES EA, 1992, J GERONTOL, V47, pM137, DOI 10.1093/geronj/47.5.M137; CONN VS, 1991, J ADV NURS, V16, P1190, DOI 10.1111/j.1365-2648.1991.tb01528.x; CRAIG RS, 1992, J DRUG EDUC, V22, P303, DOI 10.2190/2NHN-NUY7-Q88U-CDJH; DRWALKLEIN LA, 1992, CLIN PHARMACY, V11, P1005; DUKES GE, 1990, AM J MED, V88, pS24, DOI 10.1016/0002-9343(90)90272-F; Dunnell Karen, 1972, MED TAKERS PRESCRIBE; FRIEDMAN A D, 1990, Pediatric Emergency Care, V6, P6, DOI 10.1097/00006565-199003000-00003; GINSBURG CM, 1973, AM J DIS CHILD, V125, P241, DOI 10.1001/archpedi.1973.04160020065012; HAGGERTY RJ, 1972, PEDIATR CLIN N AM, V19, P101; HUTTON N, 1991, J PEDIATR-US, V118, P125, DOI 10.1016/S0022-3476(05)81865-7; JEFFERYS M, 1960, Br J Prev Soc Med, V14, P64; JOHNSON RE, 1983, MED CARE, V21, P225, DOI 10.1097/00005650-198302000-00009; KNAPP DA, 1972, AM J HOSP PHARM, V29, P1004, DOI 10.1093/ajhp/29.12.1004; KOVAR MG, 1985, PUBLIC HEALTH REP, V100, P470; LITOVITZ T, 1992, PEDIATRICS, V89, P999; Lowenstein S R, 1987, Adv Intern Med, V32, P207; Maheady D C, 1989, J Pediatr Health Care, V3, P246; MAIMAN LA, 1986, SOC SCI MED, V22, P41, DOI 10.1016/0277-9536(86)90307-2; MAIMAN LA, 1982, PUBLIC HEALTH REP, V97, P140; PICKERING LK, 1991, J PEDIATR-US, V118, pS118, DOI 10.1016/S0022-3476(05)81439-8; Rosenthal I., 1988, DRUG TOPICS, V132, P62; RUMACK BH, 1974, PEDIATRICS, V53, P495; SAKCHAINANONT B, 1990, Journal of the Medical Association of Thailand, V73, P96; SANDERSON M, 1991, BIRTH-ISS PERINAT C, V18, P26, DOI 10.1111/j.1523-536X.1991.tb00050.x; SCHACHTEL BP, 1993, CLIN PHARMACOL THER, V53, P593, DOI 10.1038/clpt.1993.75; SMITH MBH, 1993, JAMA-J AM MED ASSOC, V269, P2258, DOI 10.1001/jama.269.17.2258; 1993, LONGITUDINAL FOLLOW; 1993, SURVEY DATA ANAL VER; 1993, PHYSICIANS DESK REFE	32	164	170	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 5	1994	272	13					1025	1030		10.1001/jama.272.13.1025	http://dx.doi.org/10.1001/jama.272.13.1025			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH775	8089884				2022-12-24	WOS:A1994PH77500027
J	RODGERS, KR; SPIRO, TG				RODGERS, KR; SPIRO, TG			NANOSECOND DYNAMICS OF THE R-]T TRANSITION IN HEMOGLOBIN - ULTRAVIOLET RAMAN STUDIES	SCIENCE			English	Article							SPIN COBALT PORPHYRINS; MOLECULAR STEREOCHEMISTRY; COOPERATIVITY; BINDING; OXYGEN; IRON; SPECTROSCOPY; RESOLUTION; PHOTOLYSIS; MODEL	Pulse-probe transient Raman spectroscopy, with probe excitation at 230 nanometers, reveals changes in signals arising from tyrosine and tryptophan residues of the hemoglobin molecule as it moves from the relaxed (R) to the tense (T) state after photodeligation. Signals associated with intersubunit contacts in the T state develop in about 10 microseconds but are preceded by quite different signals, which reach maximum amplitude in about 50 nanoseconds. These signals involve the interior tryptophan residues that bridge the A and E helices by means of H bonds between the indole rings and serine or threonine side chains. Alterations of the H bond strengths, as a result of interhelix motions, can account for the signals. A model is proposed here in which loss of the ligand from the heme binding pocket is concerted with inward motion of the adjacent E helix; this motion, along with a complementary motion of the proximal F helix, transmits the energy associated with heme deligation to the subunit interfaces, leading to the T state rearrangement.	PRINCETON UNIV,DEPT CHEM,PRINCETON,NJ 08544; N DAKOTA STATE UNIV,DEPT CHEM,FARGO,ND 58105	Princeton University; North Dakota State University Fargo					NIGMS NIH HHS [GM 25158] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025158] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1993, TRENDS BIOCHEM SCI, V18, P385, DOI 10.1016/0968-0004(93)90095-5; ACKERS GK, 1992, SCIENCE, V255, P54, DOI 10.1126/science.1553532; ANFINRUD PA, 1989, P NATL ACAD SCI USA, V86, P8387, DOI 10.1073/pnas.86.21.8387; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; DASGUPTA S, 1986, BIOCHEMISTRY-US, V25, P5941, DOI 10.1021/bi00368a016; DWYER PN, 1974, J AM CHEM SOC, V96, P4815, DOI 10.1021/ja00822a018; FERMI G, 1977, J MOL BIOL, V114, P421, DOI 10.1016/0022-2836(77)90259-5; FERMI G, 1984, J MOL BIOL, V175, P159, DOI 10.1016/0022-2836(84)90472-8; FRIEDMAN JM, 1983, J BIOL CHEM, V258, P564; FRIEDMAN JM, 1982, ANNU REV PHYS CHEM, V33, P471, DOI 10.1146/annurev.pc.33.100182.002351; GELLIN BR, 1983, J MOL BIOL, V171, P489; HARADA I, 1988, ADV INFRARED RAMAN S, V13, pCH3; HOFRICHTER J, 1983, P NATL ACAD SCI-BIOL, V80, P2235, DOI 10.1073/pnas.80.8.2235; HOPFIELD JJ, 1971, J MOL BIOL, V61, P425, DOI 10.1016/0022-2836(71)90391-3; IKEDASAITO M, 1977, J BIOL CHEM, V252, P8639; LADNER RC, 1977, J MOL BIOL, V114, P385, DOI 10.1016/0022-2836(77)90256-X; LITTLE RG, 1974, J AM CHEM SOC, V96, P4452, DOI 10.1021/ja00821a018; LUISI B, 1989, J MOL BIOL, V206, P723, DOI 10.1016/0022-2836(89)90579-2; MARTIN JL, 1983, P NATL ACAD SCI-BIOL, V80, P173, DOI 10.1073/pnas.80.1.173; MIURA T, 1989, J RAMAN SPECTROSC, V20, P667, DOI 10.1002/jrs.1250201007; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; PERUTZ MF, 1990, ANNU REV PHYSIOL, V52, P1; PERUTZ MF, 1979, ANNU REV BIOCHEM, V48, P327, DOI 10.1146/annurev.bi.48.070179.001551; RAVA RP, 1985, J PHYS CHEM-US, V89, P1856, DOI 10.1021/j100256a007; RODGERS KR, 1992, J AM CHEM SOC, V114, P3697, DOI 10.1021/ja00036a019; SAWICKI CA, 1979, J BIOL CHEM, V254, P4058; SAWICKI CA, 1976, J BIOL CHEM, V251, P1533; SCHEIDT WR, 1974, J AM CHEM SOC, V96, P90, DOI 10.1021/ja00808a014; SCOTT TW, 1983, FEBS LETT, V158, P68, DOI 10.1016/0014-5793(83)80678-4; TURNER GJ, 1992, PROTEINS, V14, P333, DOI 10.1002/prot.340140303	30	85	85	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 16	1994	265	5179					1697	1699		10.1126/science.8085153	http://dx.doi.org/10.1126/science.8085153			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG284	8085153				2022-12-24	WOS:A1994PG28400027
J	MCCOMBS, RJ; MARCADIS, DE; ELLIS, J; WEINBERG, RB				MCCOMBS, RJ; MARCADIS, DE; ELLIS, J; WEINBERG, RB			ATTENUATED HYPERCHOLESTEROLEMIC RESPONSE TO A HIGH-CHOLESTEROL DIET IN SUBJECTS HETEROZYGOUS FOR THE APOLIPOPROTEIN A-IV-2 ALLELE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIGH-DENSITY-LIPOPROTEINS; A-IV POLYMORPHISM; ESTER TRANSFER PROTEIN; SERUM-CHOLESTEROL; PLASMA-LIPOPROTEINS; E PHENOTYPE; C-III; GENE; ABSORPTION; FREQUENCY	Background. Previous studies have suggested that the variant apolipoprotein (ape) allele apo A-IV-2 may influence the response of the plasma cholesterol concentration to dietary cholesterol. Methods. We measured plasma lipids and lipoproteins in 11 subjects who were heterozygous for the apo A-IV-2 allele (ape A-IV-1/2 heterozygotes) and a control group of 12 subjects who were homozygous for the common apo A-IV allele (ape A-IV-III homozygotes) in an outpatient dietary-modification study. (Approximately one in seven persons in the United States is a heterozygote.) The subjects consumed a low-cholesterol diet (about 200 mg [0.5 mmol] of cholesterol per day) during a two-week run-in period; daily cholesterol intake was then increased to approximately 1100 mg (2.8 mmol) by the addition of four egg yolks per day. Results. The fat intake and the ratio of polyunsaturated to saturated fat were similar in the two groups throughout the study. After three weeks of egg intake, the mean plasma total cholesterol increased by 22 mg per deciliter (0.57 mmol per liter) in the ape A-IV-1/1 group, but by only 6 mg per deciliter (0.15 mmol per liter) in the apo A-IV-1/2 group (P = 0.05). The mean plasma low-density lipoprotein cholesterol increased by 19 mg per deciliter (0.49 mmol per liter) in the apo A-IV-1/1 group, but by only 1 mg per deciliter (0.03 mmol per liter) in the ape A-IV-1/2 group (P = 0.03). There were no changes in the plasma triglyceride or high-density lipoprotein cholesterol concentrations in either group. Conclusions. The apo A-IV-2 allele attenuates the hypercholesterolemic response to the short-term ingestion of a very-high-cholesterol diet and may partially account for the heterogeneous response to dietary cholesterol. However, cholesterol intake in this study was more than twice that of the general population; whether the apo A-IV-2 allele alters responsiveness at lower levels of cholesterol intake remains to be determined.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT INTERNAL MED,GASTROENTEROL SECT,WINSTON SALEM,NC 27257	Wake Forest University; Wake Forest Baptist Medical Center					NCRR NIH HHS [M01-RR07122] Funding Source: Medline; NHLBI NIH HHS [R01 HL030897-23, HL30897, R01 HL030897] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR007122] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL030897, R01HL030897] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		APFELBAUM TF, 1987, AM J PHYSIOL, V252, pG662, DOI 10.1152/ajpgi.1987.252.5.G662; APPLEBAUMBOWDEN D, 1984, AM J CLIN NUTR, V39, P360, DOI 10.1093/ajcn/39.3.360; Barter Philip, 1993, Current Opinion in Lipidology, V4, P210, DOI 10.1097/00041433-199306000-00006; BEYNEN AC, 1987, ADV LIPID RES, V22, P115; BISGAIER CL, 1985, J LIPID RES, V26, P11; BOERWINKLE E, 1991, AM J HUM GENET, V49, P1145; BRESLOW JL, 1989, J CLIN INVEST, V84, P373, DOI 10.1172/JCI114176; DEKNIJFF P, 1988, J LIPID RES, V29, P1621; DORY L, 1985, J LIPID RES, V26, P519; DREON DM, 1992, MONOGR HUM GENET, V14, P325; EICHNER JE, 1989, GENET EPIDEMIOL, V6, P493, DOI 10.1002/gepi.1370060404; ELSHOURBAGY NA, 1986, J BIOL CHEM, V261, P1998; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GLATZ JFC, 1993, ANN NY ACAD SCI, V676, P163; GOFF DC, 1993, AM J EPIDEMIOL, V137, P171, DOI 10.1093/oxfordjournals.aje.a116657; GOLDBERG IJ, 1990, J BIOL CHEM, V265, P4266; GREEN PHR, 1980, J CLIN INVEST, V65, P911, DOI 10.1172/JCI109745; GYLLING H, 1992, J LIPID RES, V33, P1361; HANIS CL, 1991, HUM GENET, V86, P323; HIXSON JE, 1993, J BIOL CHEM, V268, P15667; KAPRIO J, 1991, ARTERIOSCLER THROMB, V11, P1330, DOI 10.1161/01.ATV.11.5.1330; KATAN MB, 1987, AM J EPIDEMIOL, V125, P387, DOI 10.1093/oxfordjournals.aje.a114545; KEM F, 1991, NEW ENGL J MED, V324, P896; KESANIEMI YA, 1987, J CLIN INVEST, V80, P578, DOI 10.1172/JCI113107; KEYS A, 1965, METABOLIS, V14, P759, DOI 10.1016/0026-0495(65)90002-8; LEHTIMAKI T, 1992, ANN MED, V24, P61, DOI 10.3109/07853899209164146; LOHSE P, 1990, J BIOL CHEM, V265, P10061; MAHLEY RW, 1984, J LIPID RES, V25, P1277; MARTIN LJ, 1993, J LIPID RES, V34, P437; MATA P, 1992, CIRCULATION, V86, P405; MCNAMARA DJ, 1987, J CLIN INVEST, V79, P1729, DOI 10.1172/JCI113013; MENZEL HJ, 1990, HUM GENET, V84, P344; MENZEL HJ, 1988, HUM GENET, V79, P368; MIETTINEN TA, 1989, AM J CLIN NUTR, V49, P629, DOI 10.1093/ajcn/49.4.629; MISTRY P, 1981, J CLIN INVEST, V67, P493, DOI 10.1172/JCI110058; NESTEL PJ, 1976, METABOLISM, V25, P1591, DOI 10.1016/0026-0495(76)90112-8; ORDOVAS JM, 1989, J BIOL CHEM, V264, P16339; RYE KA, 1992, J LIPID RES, V33, P215; SCHONFELD G, 1982, J CLIN INVEST, V69, P1072, DOI 10.1172/JCI110542; STEINMETZ A, 1990, J BIOL CHEM, V265, P7859; STEINMETZ A, 1985, J BIOL CHEM, V260, P2258; WEINBERG RB, 1990, J BIOL CHEM, V265, P18372; WEINBERG RB, 1983, J LIPID RES, V24, P52; WEINBERG RB, 1985, J LIPID RES, V26, P26	44	96	96	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 15	1994	331	11					706	710		10.1056/NEJM199409153311104	http://dx.doi.org/10.1056/NEJM199409153311104			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF332	8058077				2022-12-24	WOS:A1994PF33200004
J	BLOWER, SM; MCLEAN, AR				BLOWER, SM; MCLEAN, AR			PROPHYLACTIC VACCINES, RISK BEHAVIOR-CHANGE, AND THE PROBABILITY OF ERADICATING HIV IN SAN-FRANCISCO	SCIENCE			English	Article							EFFICACY	Theory is linked with data to assess the probability of eradicating human immunodeficiency virus (HIV) in San Francisco through the use of prophylactic vaccines. The necessary vaccine efficacy levels and population coverage levels for eradication are quantified. The likely impact of risk behavior changes on vaccination campaigns is assessed. The results show it is unlikely that vaccines will be able to eradicate HIV in San Francisco unless they are combined with considerable reductions in risk behaviors. Furthermore, if risk behavior increases as the result of a vaccination campaign, then vaccination could result in a perverse outcome by increasing the severity of the epidemic.	UNIV OXFORD, DEPT ZOOL, OXFORD OX1 3PS, ENGLAND	University of Oxford	BLOWER, SM (corresponding author), UNIV CALIF BERKELEY, SCH PUBL HLTH, DEPT EPIDEMIOL, BERKELEY, CA 94720 USA.				NIAID NIH HHS [AI33831] Funding Source: Medline; NIDA NIH HHS [1R29DA08153] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R29DA008153] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ANDERSON R M, 1991; HALLORAN ME, 1992, AM J EPIDEMIOL, V136, P328, DOI 10.1093/oxfordjournals.aje.a116498; LONGINI IM, 1993, STAT MED, V12, P249, DOI 10.1002/sim.4780120309; MACDONALD G, 1952, Trop Dis Bull, V49, P813; MCLEAN AR, 1993, P ROY SOC B-BIOL SCI, V253, P9, DOI 10.1098/rspb.1993.0075; OSMOND DH, IN PRESS AM J PUBLIC; SMITH PG, 1984, INT J EPIDEMIOL, V13, P87, DOI 10.1093/ije/13.1.87	7	189	190	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 2	1994	265	5177					1451	1454		10.1126/science.8073289	http://dx.doi.org/10.1126/science.8073289			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	8073289				2022-12-24	WOS:A1994PE73300050
J	LANGECARTER, CA; JOHNSON, GL				LANGECARTER, CA; JOHNSON, GL			RAS-DEPENDENT GROWTH-FACTOR REGULATION OF MEK KINASE IN PC12 CELLS	SCIENCE			English	Article							ACTIVATED PROTEIN-KINASE; MAP KINASE; SIGNAL-TRANSDUCTION; THREONINE KINASE; INHIBITION; TYROSINE; INSULIN; ERKS; CAMP	Mitogen-activated protein kinases (MAPKs) are rapidly activated in response to stimulation of diverse receptor types. MAPKs are positively regulated by phosphorylation on threonine and tyrosine by MAP kinase or extracellular signal-regulated kinase (ERK) kinases (MEKs). MEK kinase (MEKK) is part of a family of serine-threonine protein kinases that phosphorylate and activate MEKs independently of Raf. MEKK was rapidly and persistently activated in response to stimulation of resting PC12 cells with epidermal growth factor (EGF). Nerve growth factor (NGF) and 12-O-tetradecanoylphorbol-13-acetate (TPA) also activated MEKK, although to a lesser degree than did EGF. Activation of MEKK and B-Raf in response to EGF was inhibited by expression of dominant negative N(17)Ras. Expression of oncogenic Ras resulted in activation of MEKK. Stimulation of synthesis of cyclic adenosine 3',5'-monophosphate abolished activation of MEKK and B-Raf by EGF, NGF, and TPA. Thus, Ras simultaneously controls the activation of members of the Raf and MEKK families of protein kinases.	UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80206	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	LANGECARTER, CA (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,1400 JACKSON ST,DENVER,CO 80206, USA.			Lange, Carol/0000-0003-2751-3976	NCI NIH HHS [CA58157] Funding Source: Medline; NIDDK NIH HHS [DK37871] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030324, R37GM030324] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blank J. H., UNPUB; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; GARDNER AM, 1994, MOL BIOL CELL, V5, P193, DOI 10.1091/mbc.5.2.193; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HAYSTEAD CMM, 1994, J BIOL CHEM, V269, P12804; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER C, UNPUB; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; NEIMAN AM, 1993, TRENDS GENET, V9, P390, DOI 10.1016/0168-9525(93)90139-9; PORRAS A, 1994, J BIOL CHEM, V269, P12741; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; SEGER R, 1992, J BIOL CHEM, V267, P25628; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; VAILLANCOURT RR, 1992, MOL CELL BIOL, V12, P3733; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WOOD KW, 1992, CELL, V68, P1031; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	33	325	330	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 2	1994	265	5177					1458	1461		10.1126/science.8073291	http://dx.doi.org/10.1126/science.8073291			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	8073291				2022-12-24	WOS:A1994PE73300052
J	MADURA, K; VARSHAVSKY, A				MADURA, K; VARSHAVSKY, A			DEGRADATION OF G-ALPHA BY THE N-END RULE PATHWAY	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; PHEROMONE RESPONSE; G-PROTEINS; YEAST; UBIQUITIN; SUBUNIT; SIGNAL; MYRISTOYLATION; RECOGNITION; CONJUGATION	The N-end rule relates the in vivo half-life of a protein to the identity of its amino-terminal residue. Overexpression of targeting components of the N-end rule pathway in Saccharomyces cerevisiae inhibited the growth of haploid but not diploid cells. This ploidy-dependent toxicity was shown to result from enhanced degradation of Gpa1, the alpha subunit (G alpha) of a heterotrimeric guanine nucleotide-binding protein (G protein) that regulates cell differentiation in response to mating pheromones. Sst2, a protein whose absence renders cells hypersensitive to pheromone, was essential for degradation of G alpha but not other N-end rule substrates, suggesting the involvement of an indirect, or trans-, targeting mechanism. G alpha degradation by the N-end rule pathway adds another regulatory dimension to the multitude of signaling functions mediated by G proteins.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology								Ausubel FM, 1992, CURRENT PROTOCOLS MO; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER RT, 1991, P NATL ACAD SCI USA, V88, P1090, DOI 10.1073/pnas.88.4.1090; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; CROSS F, 1988, ANNU REV CELL BIOL, V4, P429, DOI 10.1146/annurev.cb.04.110188.002241; DEGROOT RJ, 1991, P NATL ACAD SCI USA, V88, P8967, DOI 10.1073/pnas.88.20.8967; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; DOHLMAN HG, 1993, P NATL ACAD SCI USA, V90, P9688, DOI 10.1073/pnas.90.20.9688; DOHMEN J, UNPUB; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FIELDS S, 1990, TRENDS BIOCHEM SCI, V15, P270, DOI 10.1016/0968-0004(90)90052-D; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HERSKOWITZ I, 1992, MOL CELLULAR BIOL YE, V2, P583; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; Hochstrasser Mark, 1992, Current Opinion in Cell Biology, V4, P1024, DOI 10.1016/0955-0674(92)90135-Y; HONERMARCK H, 1992, BIOCHEM BIOPH RES CO, V189, P280; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; KURJAN J, 1993, ANNU REV GENET, V27, P147; LEBERER E, 1993, MOL GEN GENET, V241, P241, DOI 10.1007/BF00284675; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; MADURA K, 1993, J BIOL CHEM, V268, P12046; MADURA K, UNPUB; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cellbio.7.1.699; NASMYTH KA, 1980, P NATL ACAD SCI-BIOL, V77, P2119, DOI 10.1073/pnas.77.4.2119; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; Reed SI, 1991, CURR OPIN GENET DEV, V1, P391, DOI 10.1016/S0959-437X(05)80305-3; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SPRAGUE GF, 1992, MOL CELLULAR BIOL YE, V2, P657; STONE DE, 1991, GENE DEV, V5, P1969, DOI 10.1101/gad.5.11.1969; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; UTHRIE C, 1991, GUIDE YEAST GENETICS; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3	45	134	134	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 2	1994	265	5177					1454	1458		10.1126/science.8073290	http://dx.doi.org/10.1126/science.8073290			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	8073290				2022-12-24	WOS:A1994PE73300051
J	MATTHEWS, S; BARLOW, P; BOYD, J; BARTON, G; RUSSELL, R; MILLS, H; CUNNINGHAM, M; MEYERS, N; BURNS, N; CLARK, N; KINGSMAN, S; KINGSMAN, A; CAMPBELL, I				MATTHEWS, S; BARLOW, P; BOYD, J; BARTON, G; RUSSELL, R; MILLS, H; CUNNINGHAM, M; MEYERS, N; BURNS, N; CLARK, N; KINGSMAN, S; KINGSMAN, A; CAMPBELL, I			STRUCTURAL SIMILARITY BETWEEN THE P17 MATRIX PROTEIN OF HIV-1 AND INTERFERON-GAMMA	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; 3-DIMENSIONAL STRUCTURE; TERMINAL REGION; ASSIGNMENT; C-13; INTERLEUKIN-1-BETA; SPECTROSCOPY; RESONANCE; BACKBONE; SPECTRA	THE human immunodeficiency virus (HIV) matrix protein, p17, Forms the outer shell of the core of the virus, lining the inner surface of the viral membrane(1-4). The protein has several key functions. It orchestrates viral assembly via targeting signals that direct the gag precursor polyprotein, p55, to the host cell membrane(1,5-7) and it interacts with the transmembrane protein, gp41, to retain the env-encoded proteins in the virus(8). In addition, p17 contains a nuclear localization signal that directs the preintegration complex to the nucleus of infected cells(9). This permits the virus to infect productively non-dividing cells, a distinguishing feature of HIV and other lentiviruses. We have determined the solution structure of p17 by nuclear magnetic resonance (NMR) with a root-mean square deviation for the backbone of the well-defined regions of 0.9 Angstrom. It consists of four helices connected by short loops and an irregular, mixed beta-sheet which provides a positively charged surface for interaction with the inner layer of the membrane. The helical topology is unusual; the Brookhaven protein database contains only one similar structure, that of the immune modulator interferon-gamma.	UNIV OXFORD, DEPT BIOCHEM, OXFORD OX1 3QU, ENGLAND; UNIV OXFORD, OXFORD CTR MOLEC SCI, OXFORD OX1 3QU, ENGLAND; UNIV OXFORD, MOLEC BIOPHYS LAB, OXFORD OX1 3QU, ENGLAND; BRITISH BIOTECHNOL LTD, OXFORD OX4 5LY, ENGLAND	University of Oxford; University of Oxford; University of Oxford			Barlow, Paul N/G-2853-2011; Barton, Geoffrey/N-1037-2019; Russell, Rob/AAH-9145-2019; Barton, Geoffrey J/C-6267-2011; Russell, Robert/GWU-6389-2022	Barton, Geoffrey/0000-0002-9014-5355; Russell, Rob/0000-0002-1905-4717; Russell, Robert/0000-0002-7213-1398; Matthews, Steve/0000-0003-0676-0927				ARNOLD E, 1991, ADV VIRUS RES, V39, P1; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; Brunger A. T., 1993, XPLOR MANUAL VER 3 1; BRYANT M, 1990, P NATL ACAD SCI USA, V87, P523, DOI 10.1073/pnas.87.2.523; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; DRISCOLL PC, 1990, BIOCHEMISTRY-US, V29, P3542, DOI 10.1021/bi00466a018; EALICK SE, 1991, SCIENCE, V252, P698, DOI 10.1126/science.1902591; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; GEIDERBLOM HR, 1989, ARCH VIROL, V106, P1; GONZALEZ SA, 1993, VIROLOGY, V194, P548, DOI 10.1006/viro.1993.1293; GRZESIEK S, 1992, BIOCHEMISTRY-US, V31, P8180, DOI 10.1021/bi00150a009; JOHNSON RP, 1991, J IMMUNOL, V147, P1512; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LUNDELL D, 1991, PROTEIN ENG, V4, P335, DOI 10.1093/protein/4.3.335; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MATTHEWS SJ, 1993, BIOCHEMISTRY-US, V32, P657, DOI 10.1021/bi00053a034; NERMUT MV, 1994, VIROLOGY, V198, P288, DOI 10.1006/viro.1994.1032; NIIGES M, 1988, PROTEIN ENG, V2, P27; RUSSELL RB, 1992, PROTEINS, V14, P309, DOI 10.1002/prot.340140216; SAMUDZI CT, 1991, J BIOL CHEM, V266, P21791; SPEARMAN P, 1994, J VIROL, V68, P3232, DOI 10.1128/JVI.68.5.3232-3242.1994; STUART D, 1993, CURR OPIN STRUC BIOL, V3, P167, DOI 10.1016/S0959-440X(05)80148-4; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; YU XF, 1992, J VIROL, V66, P4966, DOI 10.1128/JVI.66.8.4966-4971.1992; YUAN X, 1993, J VIROL, V67, P6387, DOI 10.1128/JVI.67.11.6387-6394.1993; ZHOU WJ, 1994, J VIROL, V68, P2556, DOI 10.1128/JVI.68.4.2556-2569.1994	28	125	128	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 25	1994	370	6491					666	668		10.1038/370666a0	http://dx.doi.org/10.1038/370666a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD310	8065455				2022-12-24	WOS:A1994PD31000055
J	SCHIFF, SJ; JERGER, K; DUONG, DH; CHANG, T; SPANO, ML; DITTO, WL				SCHIFF, SJ; JERGER, K; DUONG, DH; CHANG, T; SPANO, ML; DITTO, WL			CONTROLLING CHAOS IN THE BRAIN	NATURE			English	Article							RAT HIPPOCAMPAL SLICE; INTERICTAL SPIKING; POTASSIUM; SEIZURES; SYSTEM	In a spontaneously bursting neuronal network in vitro, chaos can be demonstrated by the presence of unstable fixed-point behaviour. Chaos control techniques can increase the periodicity of such neuronal population bursting behaviour. Periodic pacing is also effective in entraining such systems, although in a qualitatively different fashion. Using a strategy of anticontrol such systems can be made less periodic. These techniques may be applicable to in vivo epileptic foci.	GEORGE WASHINGTON UNIV, SCH MED, WASHINGTON, DC 20010 USA; USN, CTR SURFACE WARFARE, WHITE OAK LAB, SILVER SPRING, MD 20903 USA; GEORGIA INST TECHNOL, SCH PHYS, ATLANTA, GA 30332 USA	George Washington University; United States Department of Defense; United States Navy; University System of Georgia; Georgia Institute of Technology	SCHIFF, SJ (corresponding author), CHILDRENS NATL MED CTR, DEPT NEUROSURG, WASHINGTON, DC 20010 USA.		Ditto, William/AAK-9827-2020; Spano, Mark L/B-6883-2011	Ditto, William/0000-0002-7416-8012; Chang, Taeun/0000-0002-1797-8449				AUERBACH D, 1992, PHYS REV LETT, V69, P3479, DOI 10.1103/PhysRevLett.69.3479; CHANG T, 1994, BIOPHYS J, V67, P671, DOI 10.1016/S0006-3495(94)80526-0; DITTO WL, 1990, PHYS REV LETT, V65, P3211, DOI 10.1103/PhysRevLett.65.3211; DURAND D, 1986, BRAIN RES, V382, P139, DOI 10.1016/0006-8993(86)90121-6; GARFINKEL A, 1992, SCIENCE, V257, P1230, DOI 10.1126/science.1519060; GOTMAN J, 1991, CAN J NEUROL SCI, V18, P573, DOI 10.1017/S031716710003273X; HUNT ER, 1991, PHYS REV LETT, V67, P1953, DOI 10.1103/PhysRevLett.67.1953; JEFFERYS JGR, 1981, J PHYSIOL-LONDON, V319, P143, DOI 10.1113/jphysiol.1981.sp013897; KATZ A, 1991, ELECTROEN CLIN NEURO, V79, P153, DOI 10.1016/0013-4694(91)90054-8; KAYYALI H, 1991, EXP NEUROL, V113, P249, DOI 10.1016/0014-4886(91)90181-B; KORN SJ, 1987, J NEUROPHYSIOL, V57, P325, DOI 10.1152/jn.1987.57.1.325; OTT E, 1990, PHYS REV LETT, V64, P1196, DOI 10.1103/PhysRevLett.64.1196; Ott E., 1993, CHAOS DYNAMICAL SYST; Pedley TA, 1990, CURRENT PRACTICE CLI, P107; PETROV V, 1993, NATURE, V361, P240, DOI 10.1038/361240a0; ROLLINS RW, 1993, PHYS REV E, V47, pR780, DOI 10.1103/PhysRevE.47.R780; ROY R, 1992, PHYS REV LETT, V68, P1259, DOI 10.1103/PhysRevLett.68.1259; RUTECKI PA, 1985, J NEUROPHYSIOL, V54, P1363, DOI 10.1152/jn.1985.54.5.1363; SCHIFF SJ, 1994, BIOPHYS J, V67, P684, DOI 10.1016/S0006-3495(94)80527-2; SHINBROT T, 1993, NATURE, V363, P411, DOI 10.1038/363411a0; Traub R.D., 1991, NEURONAL NETWORKS HI; TRAUB RD, 1990, J NEUROPHYSIOL, V64, P1009, DOI 10.1152/jn.1990.64.3.1009; TRAYNELIS SF, 1988, J NEUROPHYSIOL, V59, P259, DOI 10.1152/jn.1988.59.1.259	23	718	751	3	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 25	1994	370	6491					615	620		10.1038/370615a0	http://dx.doi.org/10.1038/370615a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD310	8065447				2022-12-24	WOS:A1994PD31000040
J	PAHOR, M; GURALNIK, JM; SALIVE, ME; CHRISCHILLES, EA; BROWN, SL; WALLACE, RB				PAHOR, M; GURALNIK, JM; SALIVE, ME; CHRISCHILLES, EA; BROWN, SL; WALLACE, RB			PHYSICAL-ACTIVITY AND RISK OF SEVERE GASTROINTESTINAL HEMORRHAGE IN OLDER PERSONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTI-INFLAMMATORY DRUGS; CORONARY HEART-DISEASE; COMMUNITY-BASED SAMPLE; BLEEDING PEPTIC-ULCER; DIVERTICULAR-DISEASE; EXERCISE; MEN; MORTALITY; ADULTS; FICSIT	Objective.-To assess whether regular physical activity is associated with a decreased risk of severe gastrointestinal hemorrhage (GIH) in older persons. Design.-Cohort study with 3 years of follow-up. Setting.-Three communities of the Established Populations for Epidemiologic Studies of the Elderly. Participants.-A total of 8205 persons aged 68 years or older, yielding 22 277 person-years of follow-up. Measurements.-The occurrence of severe GIH was defined as either a hospital discharge diagnosis of gastrointestinal bleeding associated with blood transfusion or death during the hospital stay or a nonhospital death with mention of GIH on the death certificate. Physical activity was measured by self-reported frequency of walking, gardening, or doing vigorous physical activity. Those participants doing the activity three times per week or more were compared with the remaining participants. Adjusted relative risks (RRs) of GIH were controlled for age, gender, body mass index, blood pressure, chronic conditions, number of hospital admissions in the past year, and number and types of drugs taken. Results.-Severe GIH occurred in 241 participants (rate, 10.8 per 1000 person-years). After adjusting for potential confounding variables, the RRs and 95% confidence intervals (Cls) for severe GIH associated with walking, gardening, and vigorous physical activity were 0.6 (0.4 to 0.8), 0.8 (0.5 to 1.1), and 0.7 (0.4 to 1.2), respectively. The RR associated with a summary variable for the three activities was 0.7 (95% Cl, 0.5 to 0.9). These results were consistent after stratifying on health status and disability or by excluding those who were not mobile, ie, not able to walk half a mile or climb a flight of stairs. Conclusions.-Regular physical activity is associated with a decreased risk for severe GIH in older persons.	NIA,EPIDEMIOL DEMOG & BIOMETRY PROGRAM,BETHESDA,MD; UNIV IOWA,DEPT PREVENT MED & ENVIRONM HLTH,IOWA CITY,IA 52242	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Iowa	PAHOR, M (corresponding author), UNIV CATTOLICA SACRO CUORE,DEPT GERONTOL,LGO F VITO 1,I-00168 ROME,ITALY.							ADES PA, 1993, CIRCULATION, V88, P572, DOI 10.1161/01.CIR.88.2.572; AHREN C, 1973, ACTA PHYSIOL SCAND, V88, P541, DOI 10.1111/j.1748-1716.1973.tb05483.x; ALMY TP, 1980, NEW ENGL J MED, V302, P324, DOI 10.1056/NEJM198002073020605; [Anonymous], 1988, INT CLASSIFICATION D; BIATARONE MA, 1993, J AM GERIATR SOC, V41, P333; BLAIR SN, 1993, CIRCULATION, V88, P1402, DOI 10.1161/01.CIR.88.3.1402; BLAIR SN, 1992, ANNU REV PUBL HEALTH, V13, P99, DOI 10.1146/annurev.pu.13.050192.000531; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; BORDLEY DR, 1985, JAMA-J AM MED ASSOC, V253, P3282, DOI 10.1001/jama.253.22.3282; BORTZ WM, 1982, JAMA-J AM MED ASSOC, V248, P1203, DOI 10.1001/jama.248.10.1203; BORTZ WM, 1989, J AM GERIATR SOC, V37, P1092, DOI 10.1111/j.1532-5415.1989.tb06926.x; BRANICKI FJ, 1992, J GASTROEN HEPATOL, V7, P184, DOI 10.1111/j.1440-1746.1992.tb00959.x; BRESALIER RS, 1991, J CLIN GASTROENTEROL, V13, pS35; BROUNS F, 1993, SPORTS MED, V15, P242, DOI 10.2165/00007256-199315040-00003; Buchner D M, 1992, Clin Geriatr Med, V8, P1; BUCHNER DM, 1993, J AM GERIATR SOC, V41, P297, DOI 10.1111/j.1532-5415.1993.tb06708.x; BUCHNER DM, 1992, ANNU REV PUBL HEALTH, V13, P469, DOI 10.1146/annurev.publhealth.13.1.469; BUCHNER DM, 1993, J AM GERIATR SOC, V41, P321, DOI 10.1111/j.1532-5415.1993.tb06711.x; CAMPBELL AJ, 1993, J EPIDEMIOL COMMUN H, V47, P23, DOI 10.1136/jech.47.1.23; CARSON JL, 1991, AM J MED, V91, P223, DOI 10.1016/0002-9343(91)90119-I; CARSON JL, 1987, ARCH INTERN MED, V147, P1054, DOI 10.1001/archinte.147.6.1054; CARSON JL, 1987, ARCH INTERN MED, V147, P85, DOI 10.1001/archinte.147.1.85; CHESKIN LJ, 1990, GASTROENTEROL CLIN N, V19, P391; COOK DJ, 1994, NEW ENGL J MED, V330, P377, DOI 10.1056/NEJM199402103300601; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; DONAHUE RP, 1988, AM J PUBLIC HEALTH, V78, P683, DOI 10.2105/AJPH.78.6.683; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; GILBERT DA, 1990, GASTROINTEST ENDOSC, V36, pS8; GUESS HA, 1988, J CLIN EPIDEMIOL, V41, P35, DOI 10.1016/0895-4356(88)90007-8; HOLVOET J, 1991, GUT, V32, P730, DOI 10.1136/gut.32.7.730; HOPKINS A, 1990, BMDP STATISTICAL SOF, P769; HUDDY SPJ, 1991, BRIT J SURG, V78, P293, DOI 10.1002/bjs.1800780309; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KAUFMAN DW, 1993, CLIN PHARMACOL THER, V53, P485, DOI 10.1038/clpt.1993.55; KOHL HW, 1988, SPORTS MED, V6, P222, DOI 10.2165/00007256-198806040-00004; LACROIX AZ, 1993, AM J EPIDEMIOL, V137, P858, DOI 10.1093/oxfordjournals.aje.a116747; MANSON JE, 1992, JAMA-J AM MED ASSOC, V268, P63, DOI 10.1001/jama.268.1.63; MCINTOSH JH, 1988, AM J EPIDEMIOL, V128, P761, DOI 10.1093/oxfordjournals.aje.a115029; PAHOR M, 1994, J AM GERIATR SOC, V42, P1; Reinus J F, 1991, Clin Geriatr Med, V7, P301; REINUS JF, 1990, GASTROENTEROL CLIN N, V19, P293; ROSOW I, 1966, J GERONTOL, V21, P556, DOI 10.1093/geronj/21.4.556; SAUVE JS, 1993, INT ANESTHESIOL CLIN, V31, P169, DOI 10.1097/00004311-199331020-00011; SCHOENBERG MH, 1984, ACTA CHIR SCAND, V150, P301; SHEPHARD RJ, 1993, SPORTS MED, V15, P258, DOI 10.2165/00007256-199315040-00004; SILEN W, 1987, CLIN INVEST MED, V10, P270; SIMONSICK EM, 1993, AM J PUBLIC HEALTH, V83, P1443, DOI 10.2105/AJPH.83.10.1443; SOMERVILLE K, 1986, LANCET, V1, P462; WOLF SL, 1993, J AM GERIATR SOC, V41, P329, DOI 10.1111/j.1532-5415.1993.tb06713.x; YOUNG DR, 1993, AM J EPIDEMIOL, V138, P205, DOI 10.1093/oxfordjournals.aje.a116849; 1977, JAMA-J AM MED ASSOC, V237, P2385; 1991, VITAL STATISTICS US; 1984, VITAL STATISTICS US; 1991, VITAL HLTH STATISTIC	54	34	35	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 24	1994	272	8					595	599		10.1001/jama.272.8.595	http://dx.doi.org/10.1001/jama.272.8.595			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PC398	8057514				2022-12-24	WOS:A1994PC39800028
J	KOPP, E; GHOSH, S				KOPP, E; GHOSH, S			INHIBITION OF NF-KAPPA-B BY SODIUM-SALICYLATE AND ASPIRIN	SCIENCE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS; TUMOR NECROSIS FACTOR; EXPRESSION; BINDING; CELLS; GENE; RESISTANCE; INDUCTION; DRUGS; HSP70	The transcription factor nuclear factor-kappa B (NF-kappa B) is critical for the inducible expression of multiple cellular and viral genes involved in inflammation and infection including interleukin-1 (IL-1), IL-6, and adhesion molecules. The anti-inflammatory drugs sodium salicylate and aspirin inhibited the activation of NF-kappa B, which further explains the mechanism of action of these drugs. This inhibition prevented the degradation of the NF-kappa B inhibitor, I kappa B, and therefore NF-kappa B was retained in the cytosol. Sodium salicylate and aspirin also inhibited NF-kappa B-dependent transcription from the Ig kappa enhancer and the human immunodeficiency virus (HIV) long terminal repeat (LTR) in transfected T cells.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,IMMUNOBIOL SECT,NEW HAVEN,CT 06536; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06536; YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06536	Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University; Yale University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033443] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 33443-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAMSON S, 1985, P NATL ACAD SCI USA, V82, P7227, DOI 10.1073/pnas.82.21.7227; ABRAMSON SB, 1989, ARTHRITIS RHEUM, V32, P1, DOI 10.1002/anr.1780320102; AUSUBEL FM, 1991, CURRENT PROTOCOLS MO, V14; BEGG AA, 1993, GENE DEV, V7, P2064; BROOKS PM, 1986, CLIN PHARM ANTIINFLA, P32; DEGITZ K, 1991, J BIOL CHEM, V266, P14024; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; FAMAEY JP, 1992, THERAPEUTIC APPLICAT; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; MACILWAIN C, 1993, NATURE, V364, P369; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; PALMOSKI MJ, 1984, ARTHRITIS RHEUM, V27, P398, DOI 10.1002/art.1780270406; PALMOSKI MJ, 1985, ARTHRITIS RHEUM, V28, P237, DOI 10.1002/art.1780280226; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; Rainsford K.D., 1984, ASPIRIN SALICYLATES; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; VANE JR, 1990, STROKE S, V4, P12; WEISSMANN G, 1991, SCI AM, V264, P84, DOI 10.1038/scientificamerican0191-84	27	1533	1604	0	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 12	1994	265	5174					956	959		10.1126/science.8052854	http://dx.doi.org/10.1126/science.8052854			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052854				2022-12-24	WOS:A1994PB49900044
J	ABDELILAH, S; SOLNICAKREZEL, L; STAINIER, DYR; DRIEVER, W				ABDELILAH, S; SOLNICAKREZEL, L; STAINIER, DYR; DRIEVER, W			IMPLICATIONS FOR DORSOVENTRAL AXIS DETERMINATION FROM THE ZEBRAFISH MUTATION JANUS	NATURE			English	Article							OCCURRING DIBLASTODERMIC EGGS; XENOPUS-LAEVIS; CELL LINEAGE; FATE MAP; CLEAVAGE; EMBRYOS; EXPRESSION; ORGANIZER; PATTERN; GENES	THE mechanisms underlying the formation of dorsoventral polarity in the zebrafish Danio rerio are unknown. Here we describe the zebrafish recessive maternal-effect mutation janus(m55). The mutant phenotype is a division of the blastoderm along the first cleavage plane into two detached half-sized blastoderms. Partial-axis bifurcation occurs in a subset of mutants. Analysis of goosecoid expression in the mutant embryos indicates that only one organizer region is present in each embryo. Furthermore, the position of this organizer region is random with respect to the first cleavage plant bisecting the two blastoderms. Finally, cell tracing in wild-type embryos demonstrates that there is no strict correlation of the dorsoventral axis with early cleavage planes in zebrafish. These findings support the notion that the establishment of the dorsoventral axis and the first cleavage planes are determined by separate mechanisms in the zebrafish embryo.	HARVARD UNIV,SCH MED,BOSTON,MA 02129	Harvard University; Harvard Medical School	ABDELILAH, S (corresponding author), MASSACHUSETTS GEN HOSP,CARDIOVASC RES CTR,13TH ST,BLDG 149,BOSTON,MA 02129, USA.			Stainier, Didier/0000-0002-0382-0026; Driever, Wolfgang/0000-0002-9551-9141				BLACK SD, 1988, DEV BIOL, V128, P65, DOI 10.1016/0012-1606(88)90267-9; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; CARROLL CR, 1973, DEV BIOL, V32, P155, DOI 10.1016/0012-1606(73)90227-3; CARTER CA, 1993, J MORPHOL, V215, P301, DOI 10.1002/jmor.1052150309; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; DANILCHIK MV, 1988, DEV BIOL, V128, P58, DOI 10.1016/0012-1606(88)90266-7; DROIN A, 1984, ROUX ARCH DEV BIOL, V193, P86, DOI 10.1007/BF00848635; GERHART J, 1981, NATURE, V292, P511, DOI 10.1038/292511a0; GERHART J, 1989, DEVELOPMENT, V107, P37; GEVERS P, 1992, ROUX ARCH DEV BIOL, V201, P275, DOI 10.1007/BF00592108; HELDE KA, 1994, SCIENCE, V265, P517, DOI 10.1126/science.8036493; IKENISHI K, 1988, DEV BIOL, V125, P458, DOI 10.1016/0012-1606(88)90227-8; KIMMEL CB, 1990, DEVELOPMENT, V108, P581; KIMMEL CB, 1987, DEV BIOL, V124, P269, DOI 10.1016/0012-1606(87)90478-7; KIMMEL CB, 1985, DEV BIOL, V108, P78, DOI 10.1016/0012-1606(85)90010-7; KUBOTA HY, 1991, DEV BIOL, V144, P145, DOI 10.1016/0012-1606(91)90486-M; LAALE HW, 1984, CAN J ZOOL, V62, P386, DOI 10.1139/z84-060; MALACINSKI GM, 1974, SCIENCE, V184, P1142, DOI 10.1126/science.184.4142.1142; Oppenheimer JM, 1936, J EXP ZOOL, V73, P405, DOI 10.1002/jez.1400730304; OXTOBY E, 1993, NUCLEIC ACIDS RES, V21, P1087, DOI 10.1093/nar/21.5.1087; SCHIRONE RC, 1968, J EXP ZOOL, V169, P43, DOI 10.1002/jez.1401690106; STACHEL SE, 1993, DEVELOPMENT, V117, P1261; STREHLOW D, 1993, NATURE, V361, P451, DOI 10.1038/361451a0; Westerfield M, 1993, ZEBRAFISH BOOK	24	43	46	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 11	1994	370	6489					468	471		10.1038/370468a0	http://dx.doi.org/10.1038/370468a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	8047167				2022-12-24	WOS:A1994PB40700058
J	ROUND, A; MARSHALL, AJ				ROUND, A; MARSHALL, AJ			SURVEY OF GENERAL-PRACTITIONERS PREHOSPITAL MANAGEMENT OF SUSPECTED ACUTE MYOCARDIAL-INFARCTION	BRITISH MEDICAL JOURNAL			English	Article									DERRIFORD HOSP,PLYMOUTH PL6 5QT,DEVON,ENGLAND	Derriford Hospital	ROUND, A (corresponding author), PLYMOUTH & TORBAY HLTH AUTHOR,PLYMOUTH PL6 5QZ,DEVON,ENGLAND.							BOUTEN MJM, 1991, EUR HEART J, V12, P39; Fibrinolytic 'Therapy Trialists' (FTT) Collaborative Group, 1994, LANCET, V343, P311; WAINE C, 1993, BRIT HEART J, V70, P218; 1992, BRIT MED J, V305, P588; 1989, BRIT MED J, V299, P555	5	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 6	1994	309	6951					375	376		10.1136/bmj.309.6951.375	http://dx.doi.org/10.1136/bmj.309.6951.375			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB316	8081137	Green Published			2022-12-24	WOS:A1994PB31600019
J	PIRKLE, JL; BRODY, DJ; GUNTER, EW; KRAMER, RA; PASCHAL, DC; FLEGAL, KM; MATTE, TD				PIRKLE, JL; BRODY, DJ; GUNTER, EW; KRAMER, RA; PASCHAL, DC; FLEGAL, KM; MATTE, TD			THE DECLINE IN BLOOD LEAD LEVELS IN THE UNITED-STATES - THE NATIONAL-HEALTH AND NUTRITION EXAMINATION SURVEYS (NHANES)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To describe trends in blood lead levels for the US population and selected population subgroups during the time period between 1976 and 1991. Design.-Two nationally representative cross-sectional surveys and one cross-sectional survey representing Mexican Americans in the southwestern United States. Setting/Participants.-Participants in two national surveys that included blood lead measurements: the second National Health and Nutrition Examination Survey, 1976 to 1980 (n=9832), and phase 1 of the third National Health and Nutrition Examination Survey, 1988 to 1991 (n=12119). Also, Mexican Americans participating in the Hispanic Health and Nutrition Examination Survey, 1982 to 1984 (n=5682). Results.-The mean blood lead level of persons aged 1 to 74 years dropped 78%, from 0.62 to 0.14 mu mol/L (12.8 to 2.8 mu g/dL). Mean blood lead levels of children aged 1 to 5 years declined 77% (0.66 to 0.15 mu mol/L [13.7 to 3.2 mu g/dL]) for non-Hispanic white children and 72% (0.97 to 0.27 mu mol/L [20.2 to 5.6 mu g/dL]) for non-Hispanic black children. The prevalence of blood lead levels 0.48 mu mol/L (10 mu g/dL) or greater for children aged 1 to 5 years declined from 85.0% to 5.5% for non-Hispanic white children and from 97.7% to 20.6% for non-Hispanic black children. Similar declines were found in population subgroups defined by age, sex, race/ethnicity, income level, and urban status. Mexican Americans also showed similar declines in blood lead levels of a slightly smaller magnitude over a shorter time. Conclusions.-The results demonstrate a substantial decline in blood lead levels of the entire US population and within selected subgroups of the population. The major cause of the observed decline in blood lead levels is most likely the removal of 99.8% of lead from gasoline and the removal of lead from soldered cans. Although these data indicate major progress in reducing lead exposure, they also show that the same sociodemographic factors continue to be associated with higher blood lead levels, including younger age, male sex, non-Hispanic black race/ethnicity, and low income level. Future efforts to remove other lead sources (eg, paint, dust, and soil) are needed but will be more difficult than removing lead from gasoline and soldered cans.	CTR DIS CONTROL & PREVENT,NATL CTR ENVIRONM HLTH,LEAD POISONING PREVENT BRANCH,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,DIV HLTH EXAMINAT STAT,HYATTSVILLE,MD 20782	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	PIRKLE, JL (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR ENVIRONM HLTH,DIV ENVIRONM HLTH LAB SCI,ATLANTA,GA 30333, USA.		Flegal, Katherine M/A-4608-2013	Flegal, Katherine/0000-0002-0838-469X				ADAMS M A, 1991, Chemical Speciation and Bioavailability, V3, P37; ANNEST JL, 1983, NEW ENGL J MED, V308, P1373, DOI 10.1056/NEJM198306093082301; ANNEST JL, 1984, VITAL HLTH STAT 11, V223; [Anonymous], 1988, NATURE EXTENT LEAD P; [Anonymous], 1991, PREVENTING LEAD POIS; BOLGER P M, 1991, Chemical Speciation and Bioavailability, V3, P31; BRODY DJ, 1994, JAMA-J AM MED ASSOC, V272, P277, DOI 10.1001/jama.272.4.277; CARTERPOKRAS O, 1990, PUBLIC HEALTH REP, V105, P388; EZZATI TM, 1992, VITAL HLTH STAT 2, V113; MAHAFFEY KR, 1982, NEW ENGL J MED, V307, P573, DOI 10.1056/NEJM198209023071001; MILLER DT, 1987, ANALYST, V112, P1701, DOI 10.1039/an9871201701; SHAH BV, 1991, SUDAAN USERS MANUAL; [No title captured]; 1990, SAS LANGUAGE VERSION; 1981, LABORATORY PROCEDURE; 1992, FOOD SOFT DRINK CAN; 1991, H15089 US DEP COMM C; 1986, EPA600883028AF REP; 1982, H15080 US DEP COMM C; 1985, VITAL HLTH STAT 1, V19; 1981, VITAL HLTH STAT 1, V15; 1991, Q SUMMARY LEAD PHASE	22	693	715	1	52	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 27	1994	272	4					284	291		10.1001/jama.272.4.284	http://dx.doi.org/10.1001/jama.272.4.284			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NX806	8028141				2022-12-24	WOS:A1994NX80600030
J	WILLMAN, CL; BUSQUE, L; GRIFFITH, BB; FAVARA, BE; MCCLAIN, KL; DUNCAN, MH; GILLILAND, DG				WILLMAN, CL; BUSQUE, L; GRIFFITH, BB; FAVARA, BE; MCCLAIN, KL; DUNCAN, MH; GILLILAND, DG			LANGERHANS-CELL HISTIOCYTOSIS (HISTIOCYTOSIS-X) - A CLONAL PROLIFERATIVE DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHROMOSOME INACTIVATION; METHYLATION PATTERNS; DENDRITIC CELLS; HUMAN-TUMORS; M27-BETA; ORIGIN; PROBE; POLYMORPHISMS; LESIONS	Background. The lesions of Langerhans'-cell histiocytosis (histiocytosis X), a proliferative histiocytic disorder of unknown cause, contain histiocytes similar in phenotype to dendritic Langerhans' cells. The disease ranges in severity from a fatal leukemia-like disorder to an isolated lytic lesion of bone. Intermediate forms of the disease are usually characterized by multiorgan involvement, diabetes insipidus, and a chronic course. Methods. To determine whether Langerhans' histiocytosis is a polyclonal reactive disease or a clonal disorder, we used X-linked polymorphic DNA probes (HUMARA, PGK, M27 beta[DXS255], and HPRT) to assess clonality in lesional tissues and control leukocytes from 10 female patients with various forms of the disease. Lymphoid clonality was also assessed by analysis of rearrangements at immunoglobulin and T-cell-receptor gene loci. Results. The HUMARA assay detected clonal cells in the lesions of 9 of the 10 patients: 3 patients had acute disseminated disease, 3 had unifocal disease, and 3 had intermediate forms. The percentage of clonal cells closely approximated the percentage of CD1a-positive histiocytes in each lesion. Clonality was also confirmed in two of nine cases with the PGK or M27 beta probe. Extreme constitutional lyonization precluded assessment of clonality in the 10th case. Lymphoid clonality was ruled out in all cases. Conclusions. The detection of clonal histiocytes in all forms of Langerhans'-cell histiocytosis indicates that this disease is probably a clonal neoplastic disorder with highly variable biologic behavior. Thus, genetic mutations that promote clonal expansion of Langerhans' cells or their precursors may now be identified.	UNIV NEW MEXICO,SCH MED,DEPT PATHOL,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,SCH MED,DEPT PEDIAT,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,SCH MED,CTR MOLEC & CELLULAR DIAGNOST,ALBUQUERQUE,NM 87131; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; ALL CHILDRENS HOSP,DEPT PATHOL & LAB MED,ST PETERSBURG,FL; TEXAS CHILDRENS HOSP,BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030	University of New Mexico; University of New Mexico; University of New Mexico; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Baylor College of Medicine	WILLMAN, CL (corresponding author), UNIV NEW MEXICO,SCH MED,CTR CANC,900 CAMINO SALUD NE,ALBUQUERQUE,NM 87131, USA.			McClain, Kenneth/0000-0003-0725-6263				ABRAHAMSON G, 1990, BRIT J HAEMATOL, V74, P371, DOI 10.1111/j.1365-2141.1990.tb02601.x; ALLEN RC, 1992, AM J HUM GENET, V51, P1229; [Anonymous], 1987, LANCET, V1, p[208, 209]; BOYD Y, 1990, GENOMICS, V7, P182, DOI 10.1016/0888-7543(90)90539-7; BROADBENT V, 1984, LANCET, V1, P253; BUSQUE L, 1994, NUCLEIC ACIDS RES, V22, P697, DOI 10.1093/nar/22.4.697; BUSQUE L, 1993, BLOOD, V82, P337; CACHIA PG, 1992, GENOMICS, V14, P70, DOI 10.1016/S0888-7543(05)80285-X; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; FAVARA BE, 1990, LEUKEMIA LYMPHOMA, V2, P141, DOI 10.3109/10428199009053518; FAVARA BE, 1991, SEMIN ONCOL, V18, P3; FEY MF, 1992, J CLIN INVEST, V89, P1438, DOI 10.1172/JCI115733; GALE RE, 1991, BRIT J HAEMATOL, V79, P193, DOI 10.1111/j.1365-2141.1991.tb04521.x; GILLILAND DG, 1991, P NATL ACAD SCI USA, V88, P6848, DOI 10.1073/pnas.88.15.6848; GREENBERGER JS, 1981, MEDICINE, V60, P311, DOI 10.1097/00005792-198109000-00001; HAGE C, 1993, HUM PATHOL, V24, P840, DOI 10.1016/0046-8177(93)90133-2; Hand. A., 1893, ARCH PEDIAT, V10, P673; HODGES E, 1991, BRIT J HAEMATOL, V77, P315, DOI 10.1111/j.1365-2141.1991.tb08577.x; KNUDSON AG, 1985, CANCER RES, V45, P1437; KOMP DM, 1987, NEW ENGL J MED, V316, P747, DOI 10.1056/NEJM198703193161211; KURAHASHI H, 1991, BLOOD, V77, P1161; LAHEY ME, 1962, J PEDIATR-US, V60, P664, DOI 10.1016/S0022-3476(62)80091-2; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LEAHY MA, 1993, J INVEST DERMATOL, V101, P642, DOI 10.1111/1523-1747.ep12371669; MCCLAIN K, IN PRESS AM J HEMATO; MIERAU GW, IN PRESS PEDIATR PAT; NEZELOF C, 1973, BIOMEDICINE, V18, P365; NEZELOF C, 1979, CANCER, V44, P1824, DOI 10.1002/1097-0142(197911)44:5<1824::AID-CNCR2820440542>3.0.CO;2-J; STARZL TE, 1984, LANCET, V1, P583; VANDERVALK P, 1984, VIRCHOWS ARCH B, V45, P169; VOGELSTEIN B, 1985, SCIENCE, V227, P642, DOI 10.1126/science.2982210; VOGELSTEIN B, 1987, CANCER RES, V47, P4806; WEISS LM, 1986, NEW ENGL J MED, V315, P475, DOI 10.1056/NEJM198608213150802; WEISS LM, 1985, NEW ENGL J MED, V313, P539, DOI 10.1056/NEJM198508293130903; WEISS LM, 1986, HUM PATHOL, V17, P179, DOI 10.1016/S0046-8177(86)80291-X; WILLMAN CL, 1990, CLIN LAB MED, V10, P119, DOI 10.1016/S0272-2712(18)30585-7	36	728	762	0	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 21	1994	331	3					154	160		10.1056/NEJM199407213310303	http://dx.doi.org/10.1056/NEJM199407213310303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW797	8008029				2022-12-24	WOS:A1994NW79700003
J	KLAES, A; MENNE, T; STOLLEWERK, A; SCHOLZ, H; KLAMBT, C				KLAES, A; MENNE, T; STOLLEWERK, A; SCHOLZ, H; KLAMBT, C			THE ETS TRANSCRIPTION FACTORS ENCODED BY THE DROSOPHILA GENE POINTED DIRECT GLIAL-CELL DIFFERENTIATION IN THE EMBRYONIC CNS	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; GROWTH CONE GUIDANCE; AXON PATHWAYS; NEURONAL DIFFERENTIATION; SPINAL-CORD; MELANOGASTER; MIGRATION; PATTERN; MIDLINE; PROTEIN	The Drosophila gene pointed (pnt) encodes two putative transcription factors (P1 and P2) of the Ets family, which in the embryonic CNS are found exclusively in glial cells. Loss of pnt function leads to poorly differentiated glial cells and a marked decrease in the expression of the neuronal antigen 22C10 in the MP2 neurons, which are known to interact intimately with the pnt(P1)-expressing longitudinal glial cells. Ectopic expression of pnt(P1) RNA forces additional CNS cells to enter the glial differentiation pathway. Interestingly, the additional glial-like cells are often flanked by cells that ectopically express the neuronal antigen 22C10. Therefore, both the pnt loss-of-function as well as the gain-of-function phenotype suggest that glial cells are able to induce 22C10 expression on neighboring neurons. This was further verified by cell transplantation experiments. Thus, pnt is not only required but also sufficient for several aspects of glial differentiation.			KLAES, A (corresponding author), UNIV COLOGNE,INST ENTWICKLUNGSBIOL,D-50923 COLOGNE,GERMANY.		Scholz, Henrike/ABE-1063-2020					BASTIANI MJ, 1986, J NEUROSCI, V6, P3542; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; BOSSING T, 1994, IN PRESS DEVELOPMENT; BOVOLENTA P, 1991, DEVELOPMENT, V113, P625; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAMPBELL RM, 1993, DEVELOPMENT, V119, P1217; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CANAL I, 1986, J NEUROGENET, V3, P293, DOI 10.3109/01677068609106856; CHOI KW, 1994, NEURON, V12, P423, DOI 10.1016/0896-6273(94)90282-8; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; EBENS AJ, 1993, CELL, V74, P15, DOI 10.1016/0092-8674(93)90291-W; FISHELL G, 1991, DEVELOPMENT, V113, P755; FREEMAN M, 1992, CELL, V69, P963, DOI 10.1016/0092-8674(92)90615-J; FUJITA CS, 1982, P NATL ACAD SCI USA, V79, P59; GARRIGA G, 1993, DEVELOPMENT, V117, P1071; GIANGRANDE A, 1994, DEVELOPMENT, V120, P523; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; IP TY, 1992, GENE DEV, V6, P1728; JACOBS JR, 1989, NEURON, V2, P1625; JACOBS JR, 1989, J NEUROSCI, V9, P2412; JACOBS JR, 1989, J NEUROSCI, V9, P2402; JACOBS JR, 1993, J NEUROBIOL, V24, P611, DOI 10.1002/neu.480240507; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; KLAMBT C, 1991, GLIA, V4, P205, DOI 10.1002/glia.440040212; KLAMBT C, 1992, GENE DEV, V6, P1668, DOI 10.1101/gad.6.9.1668; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KOLODKIN AL, 1994, IN PRESS DEVELOPMENT; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MAYER U, 1988, GENE DEV, V2, P1496, DOI 10.1101/gad.2.11.1496; MENNE TV, 1994, DEVELOPMENT, V120, P123; MLODZIK M, 1990, GENE DEV, V4, P1848, DOI 10.1101/gad.4.11.1848; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; RAZ E, 1992, DEVELOPMENT, V114, P113; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; RUTLEDGE BJ, 1992, GENE DEV, V6, P1503, DOI 10.1101/gad.6.8.1503; Sambrook J., 1989, MOL CLONING LAB MANU; SCHOLZ H, 1993, GENETICS, V135, P455; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; SILVER J, 1984, DEV BIOL, V106, P485, DOI 10.1016/0012-1606(84)90248-3; SILVER J, 1982, J COMP NEUROL, V210, P10, DOI 10.1002/cne.902100103; SINGER M, 1979, J COMP NEUROL, V185, P1, DOI 10.1002/cne.901850102; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TECHNAU GM, 1986, ROUX ARCH DEV BIOL, V195, P389, DOI 10.1007/BF00402872; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; THOMAS JB, 1988, CELL, V52, P133, DOI 10.1016/0092-8674(88)90537-5; TOMASELLI KJ, 1988, NEURON, V1, P33, DOI 10.1016/0896-6273(88)90207-3; TYTELL M, 1984, BRAIN RES, V324, P223, DOI 10.1016/0006-8993(84)90032-5; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WILSON MA, 1988, DEVELOPMENT, V102, P537; WINBERG ML, 1992, DEVELOPMENT, V115, P903	55	212	214	1	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 15	1994	78	1					149	160		10.1016/0092-8674(94)90581-9	http://dx.doi.org/10.1016/0092-8674(94)90581-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033206				2022-12-24	WOS:A1994NX32800017
J	LOVLEY, DR; WOODWARD, JC; CHAPELLE, FH				LOVLEY, DR; WOODWARD, JC; CHAPELLE, FH			STIMULATED ANOXIC BIODEGRADATION OF AROMATIC-HYDROCARBONS USING FE(III) LIGANDS	NATURE			English	Article							DENITRIFYING CONDITIONS; AQUIFER MICROORGANISMS; DISSIMILATORY FE(III); MICROBIAL-DEGRADATION; ORGANIC CONTAMINANTS; REDUCING CONDITIONS; HYDROGEN-PEROXIDE; IRON REDUCTION; SHALLOW SAND; GROUNDWATER	CONTAMINATION of ground waters with water-soluble aromatic hydrocarbons, common components of petroleum pollution, often produces anoxic conditions under which microbial degradation of the aromatics is slow(1-7). Oxygen is often added to contaminated ground water to stimulate biodegradation, but this can be technically difficult and expensive(1,5-8). Insoluble Fe(III) oxides, which are generally abundant in shallow aquifers, are alternative potential oxidants, but are difficult for microorganisms to access(9). Here we report that adding organic ligands that bind to Fe(III) dramatically increases its bioavailability, and that in tbe presence of these ligands, rates of degradation of aromatic hydrocarbons in anoxic aquifer sediments are comparable to those in oxic sediments. We find that even benzene, which is notoriously refractory in the absence of oxygen, can be rapidly degraded. Our results suggest that increasing the bioavailability of Fe(III) by adding suitable ligands provides a potential alternative to oxygen addition for the bioremediation of petroleum-contaminated aquifers.	US GEOL SURVEY, DIV WATER RESOURCES, COLUMBIA, SC 29210 USA	United States Department of the Interior; United States Geological Survey	LOVLEY, DR (corresponding author), US GEOL SURVEY, DIV WATER RESOURCES, 430 NATL CTR, RESTON, VA 22092 USA.							ACTON DW, 1992, J CONTAM HYDROL, V9, P325, DOI 10.1016/0169-7722(92)90002-V; ANID PJ, 1993, WATER RES, V27, P685, DOI 10.1016/0043-1354(93)90178-K; ARNOLD RG, 1988, BIOTECHNOL BIOENG, V32, P1081, DOI 10.1002/bit.260320902; BAEDECKER MJ, 1993, APPL GEOCHEM, V8, P569, DOI 10.1016/0883-2927(93)90014-8; BARBARO JR, 1992, J CONTAM HYDROL, V11, P245, DOI 10.1016/0169-7722(92)90019-B; BARKER JF, 1987, GROUND WATER MONIT R, V7, P64, DOI 10.1111/j.1745-6592.1987.tb01063.x; BELLER HR, 1992, APPL ENVIRON MICROB, V58, P786, DOI 10.1128/AEM.58.3.786-793.1992; EDWARDS EA, 1992, APPL ENVIRON MICROB, V58, P2663, DOI 10.1128/AEM.58.8.2663-2666.1992; FLYVBJERG J, 1993, J CONTAM HYDROL, V12, P133, DOI 10.1016/0169-7722(93)90018-N; GILLHAM RW, 1990, GROUND WATER, V28, P858, DOI 10.1111/j.1745-6584.1990.tb01720.x; GRBICGALIC D, 1987, APPL ENVIRON MICROB, V53, P254; HUTCHINS S R, 1991, Environmental Toxicology and Chemistry, V10, P1437, DOI 10.1897/1552-8618(1991)10[1437:OBBUDC]2.0.CO;2; HUTCHINS SR, 1991, ENVIRON SCI TECHNOL, V25, P68, DOI 10.1021/es00013a005; KUHN EP, 1988, APPL ENVIRON MICROB, V54, P490, DOI 10.1128/AEM.54.2.490-496.1988; LEE MD, 1988, CRIT REV ENV CONTR, V18, P29, DOI 10.1080/10643388809388342; LOVLEY DR, 1989, NATURE, V339, P297, DOI 10.1038/339297a0; LOVLEY DR, 1991, MICROBIOL REV, V55, P259, DOI 10.1128/MMBR.55.2.259-287.1991; LOVLEY DR, 1987, APPL ENVIRON MICROB, V53, P2636, DOI 10.1128/AEM.53.11.2636-2641.1987; LOVLEY DR, IN PRESS ENV SCI TEC; LYNGKILDE J, 1992, J CONTAM HYDROL, V10, P291, DOI 10.1016/0169-7722(92)90012-4; MAJOR DW, 1988, GROUND WATER, V26, P8, DOI 10.1111/j.1745-6584.1988.tb00362.x; MORGAN P, 1992, WATER RES, V26, P73, DOI 10.1016/0043-1354(92)90113-I; PARDIECK DL, 1992, J CONTAM HYDROL, V9, P221, DOI 10.1016/0169-7722(92)90006-Z; RODEN EE, 1993, APPL ENVIRON MICROB, V59, P734, DOI 10.1128/AEM.59.3.734-742.1993; SALANITRO JP, 1993, GROUND WATER MONIT R, V13, P150, DOI 10.1111/j.1745-6592.1993.tb00459.x; THOMAS JM, 1989, ENVIRON SCI TECHNOL, V23, P760, DOI 10.1021/es00065a004; VROBLESKY DA, 1994, WATER RESOUR RES, V30, P1561, DOI 10.1029/94WR00067; WILSON BH, 1986, ENVIRON SCI TECHNOL, V20, P997, DOI 10.1021/es00152a005	28	249	264	6	106	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 14	1994	370	6485					128	131		10.1038/370128a0	http://dx.doi.org/10.1038/370128a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW804	8022480				2022-12-24	WOS:A1994NW80400052
J	CRAIG, AD; BUSHNELL, MC				CRAIG, AD; BUSHNELL, MC			THE THERMAL GRILL ILLUSION - UNMASKING THE BURN OF COLD PAIN	SCIENCE			English	Article							DORSAL HORN; SKIN; CAT; PRIMATE; STIMULATION; RESPONSES; NEURONS; SENSITIVITY; MECHANISMS; AFFERENTS	In Thunberg's thermal grill illusion, first demonstrated in 1896, a sensation of strong, often painful heat is elicited by touching interlaced warm and cool bars to the skin. Neurophysiological recordings from two classes of ascending spinothalamic tract neurons that are sensitive to innocuous or noxious cold showed differential responses to the grill. On the basis of these results, a simple model of central disinhibition, or unmasking, predicted a quantitative correspondence between grill-evoked pain and cold-evoked pain, which was verified psychophysically. This integration of pain and temperature can explain the thermal grill illusion and the burning sensation of cold pain and may also provide a basis for the cold-evoked, burning pain of the classic thalamic pain syndrome.	BARROW NEUROL INST,DIV NEUROSURG,PHOENIX,AZ 85013; UNIV MONTREAL,FAC MED DENT,CTR RECH SCI NEUROL,MONTREAL H3C 3J7,PQ,CANADA; UNIV MONTREAL,FAC MED DENT,DEPT STOMATOL,MONTREAL H3C 3J7,PQ,CANADA	Barrow Neurological Institute; Universite de Montreal; Universite de Montreal	CRAIG, AD (corresponding author), BARROW NEUROL INST,DIV NEUROBIOL,350 W THOMAS RD,PHOENIX,AZ 85013, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025616] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007402] Funding Source: NIH RePORTER; NIDA NIH HHS [DA07402] Funding Source: Medline; NINDS NIH HHS [NS25616] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALRUTZ S, 1897, UPPSALA LAKFOREN FOR, V2, P445; BINI G, 1984, PAIN, V18, P239, DOI 10.1016/0304-3959(84)90819-4; BOIVIE J, 1989, PAIN, V37, P173, DOI 10.1016/0304-3959(89)90128-0; BORING EG, 1942, SENSATION PERCEPTION, P504; BROMAGE PR, 1980, PAIN, V9, P145, DOI 10.1016/0304-3959(80)90003-2; BUSHNELL MC, 1989, EXP BRAIN RES, V78, P415; BUSHNELL MC, 1993, SOC NEUR ABSTR, V19, P1573; CHRISTENSEN BN, 1970, J NEUROPHYSIOL, V33, P293, DOI 10.1152/jn.1970.33.2.293; Craig A. D., 1992, Society for Neuroscience Abstracts, V18, P385; CRAIG AD, 1991, J COMP NEUROL, V313, P377, DOI 10.1002/cne.903130212; CRAIG AD, 1985, J PHYSIOL-LONDON, V365, P197, DOI 10.1113/jphysiol.1985.sp015767; CRAIG AD, 1994, BRAIN RES, V636, P233, DOI 10.1016/0006-8993(94)91022-7; CRAIG AD, 1991, BRAIN RES, V558, P93, DOI 10.1016/0006-8993(91)90719-C; CRAIG AD, 1991, PAIN CENTRAL NERVOUS, P157; CRAIG AG, UNPUB; DARIANSMITH I, 1984, HDB PHYSL 1, V3, P879; DOSTROVSKY JO, 1978, J PHYSIOL-LONDON, V277, P29, DOI 10.1113/jphysiol.1978.sp012258; FERRINGTON DG, 1988, J NEUROPHYSIOL, V59, P886, DOI 10.1152/jn.1988.59.3.886; GELDARD FA, 1972, HUMAN SENSES, P359; GEORGOPOULOS AP, 1976, J NEUROPHYSIOL, V39, P71, DOI 10.1152/jn.1976.39.1.71; HARDY JD, 1951, SCIENCE, V114, P149, DOI 10.1126/science.114.2954.149; HELLON R, 1983, HDB PHYSL 2, P659; JEANMONOD D, 1994, NEUROREPORT, V4, P475; JONES SF, 1988, PAIN, V34, P117, DOI 10.1016/0304-3959(88)90156-X; KENSHALO DR, 1982, PAIN, V12, P141, DOI 10.1016/0304-3959(82)90190-7; KRESS M, 1992, J NEUROPHYSIOL, V68, P581, DOI 10.1152/jn.1992.68.2.581; KURU M, 1949, SENSORY PATHS SPINAL; LAMOTTE RH, 1982, BRAIN RES, V244, P279, DOI 10.1016/0006-8993(82)90086-5; LAMOTTE RH, 1978, J NEUROPHYSIOL, V41, P509, DOI 10.1152/jn.1978.41.2.509; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; NORRSELL U, 1989, EXP BRAIN RES, V78, P369; OSGOOD PF, 1990, BRAIN RES, V507, P11, DOI 10.1016/0006-8993(90)90514-C; Perl E. R., 1984, HDB PHYSL 2 1, VIII, P915; STRASSMAN AM, 1993, J NEUROPHYSIOL, V70, P1811, DOI 10.1152/jn.1993.70.5.1811; SUGIURA Y, 1986, SCIENCE, V234, P358, DOI 10.1126/science.3764416; TALBOT JD, 1991, SCIENCE, V251, P1355, DOI 10.1126/science.2003220; TAYLOR DJ, 1993, SOMATOSENS MOT RES, V10, P455, DOI 10.3109/08990229309028850; THURBERG T, 1896, UPPSALA LAKFOREN FOR, V2, P489; VOGT BA, 1987, J COMP NEUROL, V262, P271, DOI 10.1002/cne.902620208; WAHREN LK, 1989, PAIN, V38, P313, DOI 10.1016/0304-3959(89)90218-2; Willis William D., 1985, PAIN SYSTEM; YARNITSKY D, 1990, BRAIN, V113, P893, DOI 10.1093/brain/113.4.893	42	301	309	3	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 8	1994	265	5169					252	255		10.1126/science.8023144	http://dx.doi.org/10.1126/science.8023144			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV957	8023144				2022-12-24	WOS:A1994NV95700042
J	OBRIEN, T; HARDIN, S; GREENLEAF, A; LIS, JT				OBRIEN, T; HARDIN, S; GREENLEAF, A; LIS, JT			PHOSPHORYLATION OF RNA-POLYMERASE-II C-TERMINAL DOMAIN AND TRANSCRIPTIONAL ELONGATION	NATURE			English	Article							TATA-BINDING PROTEIN; DROSOPHILA-MELANOGASTER; LARGEST SUBUNIT; HEAT-SHOCK; NONPHOSPHORYLATED FORM; IN-VIVO; 5' END; GENES; INITIATION; COMPLEX	THE carboxy-terminal domain (CTD) of the large subunit of RNA polymerase II is essential in vivo(1-4), and is found in either an unphosphorylated (IIa) or hyperphosphorylated (IIo) form(5,6). The Drosophila uninduced hsp70 and hsp26 genes, and the constitutively expressed beta-1 tubulin and Gapdh-2 genes, contain an RNA polymerase II complex which pauses after synthesizing a short transcript(7-10). We report here that, using an in vivo ultraviolet crosslinking technique(11) and antibodies directed against the IIa and IIo forms of the CTD12, these paused polymerases have an unphosphorylated CTD. For genes containing a 5' paused polymerase, passage of the paused RNA polymerase into an elongationally competent mode in vivo coincides with phosphorylation of the CTD. Also, the level of phosphorylation of the CTD of elongating polymerases is shown not to be related to the level of transcription, but is promoter specific.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Cornell University; Duke University								ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; CADENA DL, 1987, J BIOL CHEM, V262, P12468; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; GILMOUR D, 1991, METHODS CELL BIOL FU, P369; HACKETT RW, 1983, NUCLEIC ACIDS RES, V11, P7011, DOI 10.1093/nar/11.20.7011; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; LAYBOURN PJ, 1989, J BIOL CHEM, V264, P6693; LIFTON RP, 1977, COLD SPRING HARB SYM, V42, P1047, DOI 10.1101/SQB.1978.042.01.105; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; OBRIEN T, 1993, MOL CELL BIOL, V13, P3456, DOI 10.1128/MCB.13.6.3456; OBRIEN T, 1991, MOL CELL BIOL, V11, P5285, DOI 10.1128/MCB.11.10.5285; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; RASMUSSEN EB, 1993, P NATL ACAD SCI USA, V90, P7923, DOI 10.1073/pnas.90.17.7923; ROUGVIE A, 1989, THESIS CORNELL U ITH; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WEEKS JR, 1982, J BIOL CHEM, V257, P5884; WEEKS JR, 1993, GENE DEV, V7, P2329, DOI 10.1101/gad.7.12a.2329; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698	24	299	300	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 7	1994	370	6484					75	77		10.1038/370075a0	http://dx.doi.org/10.1038/370075a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV711	8015613				2022-12-24	WOS:A1994NV71100063
J	LU, M; CAMPBELL, JL; BOYE, E; KLECKNER, N				LU, M; CAMPBELL, JL; BOYE, E; KLECKNER, N			SEQA - A NEGATIVE MODULATOR OF REPLICATION INITIATION IN ESCHERICHIA-COLI	CELL			English	Article							DNA-BINDING PROTEINS; ESCHERICHIA-COLI; CHROMOSOMAL REPLICATION; DAM METHYLTRANSFERASE; FLOW-CYTOMETRY; GATC SITES; ORIGIN; METHYLATION; GENE; MEMBRANE	In E. coli, replication initiates at a genetically unique origin, oriC. Rapidly growing cells contain multiple oriC copies. Initiation occurs synchronously, once and only once per cell cycle at all origins present. Secondary initiations are prevented by a sequestration process that acts uniquely on newly replicated origins, which are marked because they are hemimethylated at GATC sites. We report the identification of a gene required for sequestration and demonstrate that this gene, seqA, also serves as a negative modulator of the primary initiation process. All previously identified in vivo initiation factors play positive roles. Thus, precise control of replication initiation may involve a balance between positive and negative elements. We suggest that SeqA might be a cooperativity factor, acting to make the replication initiation process dependent upon cooperative interactions among components.	INST CANC RES,DEPT BIOPHYS,N-0310 OSLO,NORWAY		LU, M (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.				NIGMS NIH HHS [GM25326, GM15405] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025326, F32GM015405, R37GM025326] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADHYA S, 1971, J BACTERIOL, V108, P621, DOI 10.1128/JB.108.2.621-626.1971; ATLUNG T, 1993, J BACTERIOL, V175, P6573; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BAKER TA, 1992, ANNU REV GENET, V26, P447; BAKKER A, 1989, J BACTERIOL, V171, P5738, DOI 10.1128/jb.171.10.5738-5742.1989; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BOYE E, 1991, RES MICROBIOL, V142, P131, DOI 10.1016/0923-2508(91)90020-B; BOYE E, 1991, J BACTERIOL, V173, P4537, DOI 10.1128/JB.173.14.4537-4539.1991; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; BOYE E, 1988, BIOCHIM BIOPHYS ACTA, V951, P359, DOI 10.1016/0167-4781(88)90107-8; BOYE E, 1992, DNA REPLICATION CELL, V43, P15; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; CAMPBELL JL, 1991, THESIS HARVARD U CAM; CARL PL, 1970, MOL GEN GENET, V109, P107, DOI 10.1007/BF00269647; CHAKRABORTI A, 1992, J BACTERIOL, V174, P7202, DOI 10.1128/jb.174.22.7202-7206.1992; ELLEDGE SJ, 1989, GENE DEV, V3, P185, DOI 10.1101/gad.3.2.185; FINKEL SE, 1992, MOL MICROBIOL, V6, P3257, DOI 10.1111/j.1365-2958.1992.tb02193.x; GOODRICH JA, 1990, NUCLEIC ACIDS RES, V18, P4993, DOI 10.1093/nar/18.17.4993; HANSEN EB, 1984, MOL GEN GENET, V196, P387, DOI 10.1007/BF00436184; HANSEN FG, 1991, RES MICROBIOL, V142, P161, DOI 10.1016/0923-2508(91)90025-6; HENDRICKSON WG, 1982, CELL, V30, P915, DOI 10.1016/0092-8674(82)90296-3; HUGHES P, 1984, J MOL BIOL, V176, P155, DOI 10.1016/0022-2836(84)90386-3; HUPP TR, 1993, J BIOL CHEM, V268, P13128; HWANG DS, 1992, J BIOL CHEM, V267, P2209; JOHNSON RC, 1988, P NATL ACAD SCI USA, V85, P3484, DOI 10.1073/pnas.85.10.3484; KELTENBERGERGUJ.G, 1978, MOL GEN GENET, V162, P9; KOGOMA T, 1986, J BACTERIOL, V166, P361, DOI 10.1128/jb.166.2.361-363.1986; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; Kornberg A., 1991, DNA REPLICATION; KUSANO T, 1984, J BACTERIOL, V158, P313, DOI 10.1128/JB.158.1.313-316.1984; LANDOULSI A, 1990, CELL, V63, P1053, DOI 10.1016/0092-8674(90)90508-C; LOUARN J, 1984, MOL GEN GENET, V195, P170, DOI 10.1007/BF00332741; MAGEE TR, 1992, EMBO J, V11, P4219, DOI 10.1002/j.1460-2075.1992.tb05516.x; MAHAFFY JM, 1989, J THEOR BIOL, V140, P453, DOI 10.1016/S0022-5193(89)80109-2; MEIJER M, 1979, P NATL ACAD SCI USA, V76, P580, DOI 10.1073/pnas.76.2.580; MESSER W, 1985, EMBO J, V4, P1327, DOI 10.1002/j.1460-2075.1985.tb03780.x; Miller J.H., 1972, EXPT MOL GENETICS; MORRISON DA, 1977, J BACTERIOL, V132, P349, DOI 10.1128/JB.132.1.349-351.1977; OGDEN GB, 1988, CELL, V54, P127, DOI 10.1016/0092-8674(88)90186-9; Radman M., 1980, PROGR ENV MUTAGENESI, P121; REX JH, 1991, J BACTERIOL, V173, P5944, DOI 10.1128/jb.173.19.5944-5953.1991; RUDD KE, 1992, SHORT COURSE BACTERI; RUSSELL DW, 1987, CELL, V50, P1071, DOI 10.1016/0092-8674(87)90173-5; Sambrook J., 1989, MOL CLONING LAB MANU; SAMITT CE, 1989, EMBO J, V8, P989, DOI 10.1002/j.1460-2075.1989.tb03462.x; SCHAEFER C, 1991, MOL GEN GENET, V226, P34, DOI 10.1007/BF00273584; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SINGER M, 1989, MICROBIOL REV, V53, P1; SKARSTAD K, 1983, J BACTERIOL, V154, P656, DOI 10.1128/JB.154.2.656-662.1983; SKARSTAD K, 1988, J BACTERIOL, V170, P852, DOI 10.1128/jb.170.2.852-858.1988; SKARSTAD K, 1986, EMBO J, V5, P1711, DOI 10.1002/j.1460-2075.1986.tb04415.x; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; SKARSTAD K, 1990, EMBO J, V9, P2341, DOI 10.1002/j.1460-2075.1990.tb07406.x; SLATER S, 1993, J BACTERIOL, V175, P4260, DOI 10.1128/JB.175.13.4260-4262.1993; SLILATY SN, 1987, P NATL ACAD SCI USA, V84, P3987, DOI 10.1073/pnas.84.12.3987; SMITH DW, 1985, EMBO J, V4, P1319, DOI 10.1002/j.1460-2075.1985.tb03779.x; STORTS DR, 1988, J BACTERIOL, V170, P1541, DOI 10.1128/jb.170.4.1541-1547.1988; THEISEN PW, 1993, MOL MICROBIOL, V10, P575, DOI 10.1111/j.1365-2958.1993.tb00929.x; VINELLA D, 1992, J BACTERIOL, V174, P2388, DOI 10.1128/JB.174.7.2388-2390.1992; ZYSKIND JW, 1986, CELL, V46, P489, DOI 10.1016/0092-8674(86)90873-1	60	414	421	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 6	1994	77	3					413	426		10.1016/0092-8674(94)90156-2	http://dx.doi.org/10.1016/0092-8674(94)90156-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NK970	8011018				2022-12-24	WOS:A1994NK97000012
J	MARCUS, RH; SARELI, P; POCOCK, WA; BARLOW, JB				MARCUS, RH; SARELI, P; POCOCK, WA; BARLOW, JB			THE SPECTRUM OF SEVERE RHEUMATIC MITRAL-VALVE DISEASE IN A DEVELOPING-COUNTRY - CORRELATIONS AMONG CLINICAL PRESENTATION, SURGICAL PATHOLOGICAL FINDINGS, AND HEMODYNAMIC SEQUELAE	ANNALS OF INTERNAL MEDICINE			English	Article							NATURAL-HISTORY; UNITED-STATES; FEVER; REGURGITATION; PENICILLIN; CARDITIS; PROLAPSE	Objective: To describe the demographic, pathologic, and hemodynamic profiles of patients with severe rheumatic mitral valve disease in a developing country and to assess their relation to uncontrolled rheumatic disease activity. Design: Retrospective, cross-sectional, cohort study. Setting: Tertiary medical center in Soweto, South Africa. Patients: 714 of 737 consecutive black patients, 4 to 73 years old, with pure mitral regurgitation, pure mitral stenosis, or mixed mitral disease who had mitral valve surgery and in whom preoperative and surgical data were concordant. Measurements: Valve lesions were evaluated on the basis of clinical, echocardiographic, hemodynamic, and surgical pathologic data. Active rheumatic carditis was diagnosed according to clinical evidence for concurrent acute rheumatic fever (Jones criteria), macroscopic appearances at surgery, and histologic findings. Results: 219 patients had pure mitral regurgitation, 275 had pure mitral stenosis, and 220 had mixed lesions. Ongoing rheumatic activity was diagnosed in 106 patients with pure regurgitation (47%) and in only 5 patients with pure stenosis (2%). Pure regurgitation was the most common lesion in the first and second decades; the relative prevalence of pure stenosis increased with age. Purely regurgitant valves had pliable, unscarred leaflets (95%), dilated mitral annuli (95%), elongated chordae tendineae (92%), and anterior leaflet prolapse (81%). In contrast, purely stenotic valves had fused leaflet commissures (100%) and rigid leaflets (38%) but no evidence of prolapse. Conclusions: The spectrum of rheumatic mitral valve disease that is hemodynamically severe in developing countries differs from that currently reported in the United States. Severe, pure rheumatic mitral regurgitation is as prevalent as pure stenosis but has an entirely different time course, surgical anatomy, and relation to disease activity, suggesting a separate pathophysiologic mechanism.	UNIV WITWATERSRAND, SCH MED, DEPT MED, JOHANNESBURG 2193, SOUTH AFRICA	University of Witwatersrand								BAILEY C P, 1956, N Y State J Med, V56, P825; BARLOW JB, 1990, S AFR MED J, V78, P181; BARLOW JB, 1975, AM HEART J, V90, P636, DOI 10.1016/0002-8703(75)90229-X; BARLOW JB, 1987, PERSPECTIVES MITRAL, P227; BLAND EF, 1951, CIRCULATION, V4, P836, DOI 10.1161/01.CIR.4.6.836; BORMAN JB, 1961, AM HEART J, V61, P763, DOI 10.1016/0002-8703(61)90460-4; BRAUNWALD E, 1988, HEART DISEASE, P1039; BULKLEY BH, 1975, AM J MED, V59, P457, DOI 10.1016/0002-9343(75)90252-1; CARPENTIER A, 1980, J THORAC CARDIOV SUR, V79, P338; CHERIAN G, 1964, BRIT HEART J, V26, P157; CHESLER E, 1966, S AFR MED J, V40, P99; Clawson BJ, 1940, AM HEART J, V20, P454, DOI 10.1016/S0002-8703(40)90878-X; DUPLESSIS LA, 1969, J THORAC CARDIOV SUR, V58, P730, DOI 10.1016/S0022-5223(19)42553-1; EDWARDS WD, 1978, CIRCULATION, V57, P181, DOI 10.1161/01.CIR.57.1.181; GORDIS L, 1969, J AMER MED ASSOC, V210, P862, DOI 10.1001/jama.210.5.862; GOTSMAN MS, 1973, THORAX, V28, P453, DOI 10.1136/thx.28.4.453; GOTSMAN MS, 1975, AM HEART J, V90, P685, DOI 10.1016/0002-8703(75)90456-1; GROSSMAN W, 1986, CARDIAC CATHETERIZAT, P364; HALL RJ, 1989, DISEASES CARDIAC VAL, P143; JOHN S, 1983, CIRCULATION, V68, P891, DOI 10.1161/01.CIR.68.5.891; KAPLAN EL, 1988, INT J CARDIOL, V21, P3, DOI 10.1016/0167-5273(88)90003-4; Kinsley R H, 1981, Surg Annu, V13, P299; KLIBANOFF E, 1966, J AMER MED ASSOC, V195, P895, DOI 10.1001/jama.195.11.895; LEMBO NJ, 1988, CIRCULATION, V77, P830, DOI 10.1161/01.CIR.77.4.830; MARCUS R, 1989, CIRCULATION S2, V80, P507; MARCUS RH, 1989, AM J CARDIOL, V63, P577, DOI 10.1016/0002-9149(89)90902-8; MASSELL BF, 1988, NEW ENGL J MED, V318, P280, DOI 10.1056/NEJM198802043180504; OLSON LJ, 1987, MAYO CLIN PROC, V62, P22, DOI 10.1016/S0025-6196(12)61522-5; PADMAVATI S, 1978, B WORLD HEALTH ORGAN, V56, P543; SELZER A, 1972, CIRCULATION, V45, P878, DOI 10.1161/01.CIR.45.4.878; SELZER A, 1972, MEDICINE, V51, P337, DOI 10.1097/00005792-197209000-00001; STOLLERMAN GH, 1975, RHEUMATIC FEVER STRE, P127; TOMARU T, 1987, CIRCULATION, V76, P68, DOI 10.1161/01.CIR.76.1.68; TOMPKINS DG, 1972, CIRCULATION, V45, P543, DOI 10.1161/01.CIR.45.3.543; WALLER BF, 1982, AM HEART J, V104, P276, DOI 10.1016/0002-8703(82)90204-6; WHITE PD, 1951, HEART DISEASE, P670; WOOD PH, 1957, DISEASES HEART CIRCU, P517; ZABRISKIE JB, 1985, CIRCULATION, V71, P1077, DOI 10.1161/01.CIR.71.6.1077; 1965, CIRCULATION, V32, P64	39	132	134	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1994	120	3					177	183		10.7326/0003-4819-120-3-199402010-00001	http://dx.doi.org/10.7326/0003-4819-120-3-199402010-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU303	8043061				2022-12-24	WOS:A1994MU30300001
J	SIMPSONBROSE, M; TREISMAN, J; DESPLAN, C				SIMPSONBROSE, M; TREISMAN, J; DESPLAN, C			SYNERGY BETWEEN THE HUNCHBACK AND BICOID MORPHOGENS IS REQUIRED FOR ANTERIOR PATTERNING IN DROSOPHILA	CELL			English	Article							SEGMENTATION GENE HUNCHBACK; HEAD DEVELOPMENT; BODY PATTERN; GAP GENE; GRADIENT MORPHOGEN; EMPTY SPIRACLES; EMBRYO; PROTEIN; EXPRESSION; KRUPPEL	Anterior patterning of the Drosophila embryo is specified by the localized expression of the gap genes, which is controlled by the gradient of the maternal morphogen bicoid (bcd). Another maternal component, hunch back (hb), can substitute for bcd in the thorax and abdomen. Here we show that hb is required for bcd to execute all of its functions. Removal of both maternal and zygotic hb produces embryos with disrupted polarity that fail to express all known bcd target genes correctly. Proper expression of hb and the head gap genes requires synergistic activation by hb and bcd. We propose that it is the combined activity of bcd and hb, and not bcd alone, that forms the morphogenetic gradient that specifies polarity along the embryonic axis and patterns the embryo. bcd may be a newly acquired Drosophila gene, which is gradually replacing some of the functions performed by maternal hb in other species.			SIMPSONBROSE, M (corresponding author), ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA.			Desplan, Claude/0000-0002-6914-1413; Treisman, Jessica/0000-0002-7453-107X				COHEN SM, 1990, NATURE, V346, P482, DOI 10.1038/346482a0; DALTON D, 1989, GENE DEV, V3, P1940, DOI 10.1101/gad.3.12a.1940; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1990, DEVELOPMENT, V109, P811; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; ELDON ED, 1991, DEVELOPMENT, V111, P367; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FINKELSTEIN R, 1990, NATURE, V346, P485, DOI 10.1038/346485a0; GAVIS ER, 1992, CELL, V71, P301, DOI 10.1016/0092-8674(92)90358-J; HANES SD, 1994, MOL CELL BIOL, V14, P3364, DOI 10.1128/MCB.14.5.3364; HOCH M, 1991, EMBO J, V10, P2267, DOI 10.1002/j.1460-2075.1991.tb07763.x; HULSKAMP M, 1990, NATURE, V346, P577, DOI 10.1038/346577a0; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; JIANG J, 1993, EMBO J, V12, P3201, DOI 10.1002/j.1460-2075.1993.tb05989.x; KIROV N, 1993, EMBO J, V12, P3193, DOI 10.1002/j.1460-2075.1993.tb05988.x; KRAUT R, 1991, DEVELOPMENT, V111, P601; KRAUT R, 1991, DEVELOPMENT, V111, P611; KRESZBERG M, 1994, IN PRESS P NATL ACAD; LEHMANN R, 1987, DEV BIOL, V119, P402, DOI 10.1016/0012-1606(87)90045-5; LUKOWITZ W, 1994, MECH DEVELOP, V45, P105, DOI 10.1016/0925-4773(94)90024-8; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; OHARE K, 1983, CELL, V34, P25, DOI 10.1016/0092-8674(83)90133-2; RONCHI E, 1993, CELL, V74, P347, DOI 10.1016/0092-8674(93)90425-P; SCHRODER R, 1993, ROUX ARCH DEV BIOL, V203, P34, DOI 10.1007/BF00539888; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; SOMMER R, 1991, DEVELOPMENT, V113, P419; STANOJEVIC D, 1991, SCIENCE, V254, P1385, DOI 10.1126/science.1683715; STJOHNSTON D, 1992, CELL, V68, P201; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TAUTZ D, 1987, NATURE, V327, P383, DOI 10.1038/327383a0; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TREISMAN J, 1989, NATURE, V341, P335, DOI 10.1038/341335a0; WALLDORF U, 1992, EMBO J, V11, P2247, DOI 10.1002/j.1460-2075.1992.tb05284.x; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WIMMER EA, 1993, NATURE, V366, P690, DOI 10.1038/366690a0; ZUO P, 1991, GENE DEV, V5, P254, DOI 10.1101/gad.5.2.254	46	202	205	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 9	1994	78	5					855	865		10.1016/S0092-8674(94)90622-X	http://dx.doi.org/10.1016/S0092-8674(94)90622-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PG296	8087852				2022-12-24	WOS:A1994PG29600014
J	MAGIAKOU, MA; MASTORAKOS, G; OLDFIELD, EH; GOMEZ, MT; DOPPMAN, JL; CUTLER, GB; NIEMAN, LK; CHROUSOS, GP				MAGIAKOU, MA; MASTORAKOS, G; OLDFIELD, EH; GOMEZ, MT; DOPPMAN, JL; CUTLER, GB; NIEMAN, LK; CHROUSOS, GP			CUSHINGS-SYNDROME IN CHILDREN AND ADOLESCENTS - PRESENTATION, DIAGNOSIS, AND THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORTICOTROPIN-RELEASING HORMONE; DIFFERENTIAL-DIAGNOSIS; STIMULATION TEST; FREE CORTISOL; DISEASE; CHILDHOOD; MICROADENOMAS	Background and Methods. Cushing's syndrome is rare in children and adolescents. We analyzed the clinical presentation, diagnostic evaluation, and treatment of 59 patients with Cushing's syndrome between the ages of 4 and 20 years who were admitted to the National Institutes of Health during the period from 1982 to 1992. The cause of hypercortisolism was identified by low- and high-dose dexamethasone suppression tests, the ovine corticotropin-releasing hormone (CRH) stimulation test, imaging studies, and bilateral sampling of the inferior petrosal sinuses combined with administration of CRH. Results. Fifty patients had Cushing's disease, six had primary adrenal disease, and three had ectopic corticotropin secretion. The initial signs were excessive weight gain in 90 percent of the patients and growth retardation in 83 percent. Most patients (81 percent) had normal bone age at the time of diagnosis. Forty-seven percent had hypertension, whereas only 19 percent had mental or behavioral problems. The high-dose dexamethasone suppression test and the CRH stimulation test identified 68 and 80 percent, respectively, of the patients with Cushing's disease. Magnetic resonance imaging of the pituitary indicated the presence of tumor in 52 percent of the patients with pituitary adenomas. The maximal central-to-peripheral ratio of plasma corticotropin during sampling of the interior petrosal sinuses was greater than or equal to 2.5 in all the patients with Cushing's disease and <2.5 in those with ectopic corticotropin secretion. Remission of hypercortisolism was achieved in 48 of the 49 patients who underwent transsphenoidal surgery for Cushing's disease, in all 6 of the patients who underwent adrenalectomy for primary adrenal disease, and in the 2 patients in whom the ectopic source of corticotropin could be identified. Conclusions. Weight gain and growth retardation are common clinical characteristics of Cushing's syndrome in children and adolescents. Diagnostic evaluation of such patients with CRH stimulation alone and combined with inferior petrosal sinus sampling and imaging studies is accurate, and therapy is usually successful.	NINCDS,SURG NEUROL BRANCH,BETHESDA,MD 20892; NIH,DEPT DIAGNOST RADIOL,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA	MAGIAKOU, MA (corresponding author), NICHHD,DEV ENDOCRINOL BRANCH,BLDG 10,RM 10N262,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							CHROUSOS GP, 1984, NEW ENGL J MED, V310, P622, DOI 10.1056/NEJM198403083101004; DANON M, 1975, J PEDIATR-US, V87, P917, DOI 10.1016/S0022-3476(75)80905-X; DOPPMAN JL, 1984, RADIOLOGY, V150, P99, DOI 10.1148/radiology.150.1.6316418; DOPPMAN JL, 1988, J COMPUT ASSIST TOMO, V12, P728, DOI 10.1097/00004728-198809010-00002; FLACK MR, 1992, ANN INTERN MED, V116, P211, DOI 10.7326/0003-4819-116-3-211; FRANKS RC, 1973, J CLIN ENDOCR METAB, V36, P702, DOI 10.1210/jcem-36-4-702; FRIEDMAN RB, 1989, J NEUROSURG, V71, P520, DOI 10.3171/jns.1989.71.4.0520; GOMEZ MT, 1991, J PEDIATR-US, V118, P256, DOI 10.1016/S0022-3476(05)80496-2; JENNINGS AS, 1977, NEW ENGL J MED, V297, P957, DOI 10.1056/NEJM197711032971801; JOB JC, 1981, PEDIATRIC ENDOCRINOL, P275; JONES KL, 1990, PEDIATR CLIN N AM, V37, P1313; KAO M, 1975, CLIN CHEM, V21, P1644; KAPLAN SA, 1979, PEDIATR CLIN N AM, V26, P65; KORTHSCHUTZ S, 1984, ADRENAL DISEASES CHI, V13, P185; KRIEGER DT, 1982, CUSHINGS SYNDROME; LACROIX A, 1992, NEW ENGL J MED, V327, P974, DOI 10.1056/NEJM199210013271402; LIDDLE GW, 1960, J CLIN ENDOCR METAB, V20, P1539, DOI 10.1210/jcem-20-12-1539; MAMPALAM TJ, 1988, ANN INTERN MED, V109, P487, DOI 10.7326/0003-4819-109-6-487; MCARTHUR RG, 1972, MAYO CLIN PROC, V47, P318; MUGURUZA MTG, 1989, J PEDIATR-US, V115, P270, DOI 10.1016/S0022-3476(89)80081-2; MURPHY BEP, 1968, J CLIN ENDOCR METAB, V28, P343, DOI 10.1210/jcem-28-3-343; NEW MI, 1989, CLIN PEDIATRIC ENDOC, P181; NIEMAN LK, 1993, J CLIN ENDOCR METAB, V77, P1308, DOI 10.1210/jc.77.5.1308; NIEMAN LK, 1989, J CLIN ENDOCR METAB, V69, P165, DOI 10.1210/jcem-69-1-165; OLDFIELD EH, 1991, NEW ENGL J MED, V325, P897, DOI 10.1056/NEJM199109263251301; OLDFIELD EH, 1992, NEW ENGL J MED, V326, P1172; ORTH DN, 1978, METHOD HORM RADIOIMM, P245; SILBER RH, 1954, J BIOL CHEM, V210, P923; STREETEN DHP, 1975, PEDIATRICS, V56, P797; STRICKLAND AL, 1972, AM J DIS CHILD, V123, P207, DOI 10.1001/archpedi.1972.02110090077007; STYNE DM, 1984, NEW ENGL J MED, V310, P889, DOI 10.1056/NEJM198404053101405; THOMAS CG, 1984, ANN SURG, V199, P538, DOI 10.1097/00000658-198405000-00008; TYRRELL JB, 1978, NEW ENGL J MED, V298, P753, DOI 10.1056/NEJM197804062981401	33	292	300	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 8	1994	331	10					629	636		10.1056/NEJM199409083311002	http://dx.doi.org/10.1056/NEJM199409083311002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE382	8052272				2022-12-24	WOS:A1994PE38200002
J	KREJCHI, MT; ATKINS, EDT; WADDON, AJ; FOURNIER, MJ; MASON, TL; TIRRELL, DA				KREJCHI, MT; ATKINS, EDT; WADDON, AJ; FOURNIER, MJ; MASON, TL; TIRRELL, DA			CHEMICAL SEQUENCE CONTROL OF BETA-SHEET ASSEMBLY IN MACROMOLECULAR CRYSTALS OF PERIODIC POLYPEPTIDES	SCIENCE			English	Article							SOLID-STATE; CONFORMATION; CHAIN; MORPHOLOGY; EXPRESSION; GENES	A family of uniform periodic polypeptides has been prepared by bacterial expression of the corresponding artificial genes, with the objective of exploring the potential for control of supramolecular organization in genetically engineered protein-based polymeric materials. The repeating units of the polypeptides consist of oligomeric alanylglycine sequences interspersed with glutamic acid residues inserted at intervals of 8 to 14 amino acids. Crystallization of such materials from formic acid produces beta-sheet structures in the solid state, as shown by vibrational spectroscopy, nuclear magnetic resonance spectroscopy, and wide-angle x-ray diffraction. The diffraction results, together with observations from electron microscopy, are consistent with the formation of needle-shaped lamellar crystals whose thickness is controlled by the periodicity of the primary sequence. These results can be used to control solid-state structure in macromolecular materials.	UNIV MASSACHUSETTS,DEPT POLYMER SCI & ENGN,AMHERST,MA 01003; UNIV BRISTOL,HH WILLS PHYS LAB,BRISTOL BS8 1TL,AVON,ENGLAND; UNIV MASSACHUSETTS,DEPT BIOCHEM & MOLEC BIOL,AMHERST,MA 01003	University of Massachusetts System; University of Massachusetts Amherst; University of Bristol; University of Massachusetts System; University of Massachusetts Amherst								ATKINS EDT, 1992, MACROMOLECULES, V25, P917, DOI 10.1021/ma00028a063; ATKINS EDT, 1972, J POLYM SCI POL LETT, V10, P863, DOI 10.1002/pol.1972.130101108; BASSETT DC, 1981, MORPHOLOGY POLYM; BROWN L, 1956, T FARADAY SOC, V52, P537, DOI 10.1039/tf9565200537; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DREYFUS P, 1970, J POLYM SCI POL LETT, V8, P253, DOI 10.1002/pol.1970.110080407; DREYFUSS P, 1970, J MACROMOL SCI PHYS, VB  4, P811, DOI 10.1080/00222347008217125; FERRARI FA, 1836, Patent No. 927258; FISCHER EW, 1957, Z NATURFORSCH PT A, V12, P753, DOI 10.1515/zna-1957-0912; Fraser R.D.B., 1973, CONFORMATION FIBROUS; FRASER RDB, 1965, J MOL BIOL, V11, P706, DOI 10.1016/S0022-2836(65)80028-6; Fritsch E., 1989, MOL CLONING LABORATO, P3; FRUSHOUR BG, 1976, J MACROMOL SCI R M C, VC 15, P29; FRUSHOUR BG, 1975, BIOPOLYMERS, V14, P2115, DOI 10.1002/bip.1975.360141011; GEDDES AJ, 1968, J MOL BIOL, V32, P343, DOI 10.1016/0022-2836(68)90014-4; HIRICHSEN G, 1973, MAKROMOL CHEM, V166, P291; ISHIDA M, 1990, MACROMOLECULES, V23, P88, DOI 10.1021/ma00203a017; KAMTEKAR S, 1993, SCIENCE, V262, P1680, DOI 10.1126/science.8259512; KEITH HD, 1969, BIOPOLYMERS, V7, P775, DOI 10.1002/bip.1969.360070512; KELLER A, 1959, J POLYM SCI, V36, P361, DOI 10.1002/pol.1959.1203613032; KELLER A, 1957, PHILOS MAG, V2, P1171, DOI 10.1080/14786435708242746; KREJCHI MT, UNPUB; KRIMM S, 1986, ADV PROTEIN CHEM, V38, P181, DOI 10.1016/S0065-3233(08)60528-8; LUCAS F, 1960, J MOL BIOL, V2, P339, DOI 10.1016/S0022-2836(60)80045-9; MAGILL JH, 1981, POLYMER, V22, P43, DOI 10.1016/0032-3861(81)90075-6; MARSH RE, 1955, BIOCHIM BIOPHYS ACTA, V16, P1, DOI 10.1016/0006-3002(55)90178-5; MCBRIDE LJ, 1983, TETRAHEDRON LETT, V24, P345; MCGRATH KP, 1992, J AM CHEM SOC, V114, P727, DOI 10.1021/ja00028a048; MIYAZAWA T, 1961, J AM CHEM SOC, V83, P712, DOI 10.1021/ja01464a042; MOORE WH, 1976, BIOPOLYMERS, V15, P2483; NEMETHY G, 1972, MACROMOLECULES, V5, P755, DOI 10.1021/ma60030a017; PARKHE AD, 1993, MACROMOLECULES, V26, P6691, DOI 10.1021/ma00076a067; SAITO H, 1984, MACROMOLECULES, V17, P1405, DOI 10.1021/ma00137a018; SAKAOKU K, 1973, J POLYM SCI POL PHYS, V11, P31, DOI 10.1002/pol.1973.180110104; SMITH BJ, 1988, METHODS MOL BIOL NEW, P70; Staudinger H, 1920, BER DTSCH CHEM GES, V53, P1073, DOI 10.1002/cber.19200530627; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TILL PH, 1957, J POLYM SCI, V24, P301, DOI 10.1002/pol.1957.1202410616; Tirrell DA, 1991, CURR OPIN STRUC BIOL, V1, P638, DOI 10.1016/S0959-440X(05)80089-2; VONK CG, 1982, SMALL ANGLE XRAY SCA, P443; WARWICKER JO, 1960, J MOL BIOL, V2, P350, DOI 10.1016/S0022-2836(60)80046-0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	42	240	246	0	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 2	1994	265	5177					1427	1432		10.1126/science.8073284	http://dx.doi.org/10.1126/science.8073284			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	8073284				2022-12-24	WOS:A1994PE73300043
J	DOWELL, SJ; ROMANOWSKI, P; DIFFLEY, JFX				DOWELL, SJ; ROMANOWSKI, P; DIFFLEY, JFX			INTERACTION OF DBF4, THE CDC7 PROTEIN-KINASE REGULATORY SUBUNIT, WITH YEAST REPLICATION ORIGINS IN-VIVO	SCIENCE			English	Article							DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; RECOGNITION COMPLEX; S-PHASE; TRANSCRIPTION; GENE; SEQUENCE; SYSTEM; ACTIVATION; MUTATIONS	DNA replication in the budding yeast Saccharomyces cerevisiae initiates from origins of specific DNA sequences during S phase. A screen based on two- and one-hybrid approaches demonstrates that the product of the DBF4 gene interacts with yeast replication origins in vivo. The Dbf4 protein interacts with and positively regulates the activity of the Cdc7 protein kinase, which is required for entry into S phase in the yeast mitotic cell cycle. The analysis described here suggests a model in which one function of Dbf4 may be to recruit the Cdc7 protein kinase to initiation complexes.	IMPERIAL CANC RES FUND, CLARE HALL LABS, S MIMMS EN6 3LD, HERTS, ENGLAND; UNIV GDANSK SCH MED, DEPT BIOL & GENET, PL-80211 GDANSK, POLAND	Fahrenheit Universities; Medical University Gdansk				Dowell, Simon/0000-0001-6499-7573; Diffley, John/0000-0001-5184-7680				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AXELROD A, 1991, MOL CELL BIOL, V11, P1080, DOI 10.1128/MCB.11.2.1080; BELL SD, COMMUNICATION; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BROACH JR, 1982, COLD SPRING HARB SYM, V47, P1165, DOI 10.1101/SQB.1983.047.01.132; BUCHMAN AR, 1990, MOL CELL BIOL, V10, P887, DOI 10.1128/MCB.10.3.887; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; CELNIKER SE, 1984, MOL CELL BIOL, V4, P2455, DOI 10.1128/MCB.4.11.2455; CHAPMAN JW, 1989, EXP CELL RES, V180, P419, DOI 10.1016/0014-4827(89)90068-2; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DIFFLEY JFX, 1992, J BIOL CHEM, V267, P3368; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; DOWELL SJ, UNPUB; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; JACKSON AL, 1993, MOL CELL BIOL, V13, P2899, DOI 10.1128/MCB.13.5.2899; JAZWINSKI SM, 1988, P NATL ACAD SCI USA, V85, P2101, DOI 10.1073/pnas.85.7.2101; JOHNSTON LH, 1991, COLD SH Q B, V56, P169; JOHNSTON LH, 1982, MOL GEN GENET, V186, P439, DOI 10.1007/BF00729466; KITADA K, 1992, GENETICS, V131, P21; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; PALZKILL TG, 1988, CELL, V53, P441, DOI 10.1016/0092-8674(88)90164-X; ROWLEY A, 1994, BBA-GENE STRUCT EXPR, V1217, P239, DOI 10.1016/0167-4781(94)90283-6; SOLOMON NA, 1992, YEAST, V8, P273, DOI 10.1002/yea.320080405	33	176	182	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 26	1994	265	5176					1243	1246		10.1126/science.8066465	http://dx.doi.org/10.1126/science.8066465			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD422	8066465				2022-12-24	WOS:A1994PD42200041
J	MUHUA, L; KARPOVA, TS; COOPER, JA				MUHUA, L; KARPOVA, TS; COOPER, JA			A YEAST ACTIN-RELATED PROTEIN HOMOLOGOUS TO THAT IN VERTEBRATE DYNACTIN COMPLEX IS IMPORTANT FOR SPINDLE ORIENTATION AND NUCLEAR MIGRATION	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; CAPPING PROTEIN; CYTOPLASMIC DYNEIN; CAENORHABDITIS-ELEGANS; VESICLE MOTILITY; SHUTTLE VECTORS; NULL MUTATIONS; GENE; CYTOSKELETON; DISRUPTION	Spindle orientation controls nuclear migration and segregation during mitosis. In yeast, defects in dynein and astral microtubules lead to abnormal spindle orientation and nuclear migration. Dynactin complex is necessary for dynein-mediated vesicle motility in vitro. The major polypeptide of dynactin complex is an actin-related protein in the family Arp1. We have identified in S. cerevisiae a novel actin-related gene, ACTS, in the Arp1 family. An act5 null mutant has defects in spindle orientation and nuclear migration, as does overexpression of Act5p. The phenotype of a double mutant lacking dynein and Act5p is similar to that of single mutants. Therefore, dynactin complex is in the same pathway as dynein and may be necessary for the action of dynein in vivo.			MUHUA, L (corresponding author), WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA.		Cooper, John/E-9389-2012; Cooper, John/D-4448-2014	Cooper, John/0000-0002-0933-4571; Karpova, Tatiana/0000-0001-6025-2128	NIGMS NIH HHS [GM47337] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047337] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1993, MOL BIOL CELL, V4, P459, DOI 10.1091/mbc.4.5.459; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMATRUDA JF, 1992, J CELL BIOL, V117, P1067, DOI 10.1083/jcb.117.5.1067; AMATRUDA JF, 1990, NATURE, V344, P352, DOI 10.1038/344352a0; AMATRUDA JF, 1992, J CELL BIOL, V119, P1151, DOI 10.1083/jcb.119.5.1151; BALASUBRAMANIAN MK, 1992, NATURE, V360, P84, DOI 10.1038/360084a0; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CLARK SW, 1992, NATURE, V359, P246, DOI 10.1038/359246a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRUBIN DG, 1993, MOL BIOL CELL, V4, P1277, DOI 10.1091/mbc.4.12.1277; ESHEL D, 1993, P NATL ACAD SCI USA, V90, P11172, DOI 10.1073/pnas.90.23.11172; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FRYBERG C, 1994, J MOL BIOL, V241, P498; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; HARATA M, 1994, IN PRESS P NATL ACAD; HEIN J, 1990, METHOD ENZYMOL, V183, P626; Herman IM, 1993, CURR OPIN CELL BIOL, V5, P48, DOI 10.1016/S0955-0674(05)80007-9; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HYMAN AA, 1987, J CELL BIOL, V105, P2123, DOI 10.1083/jcb.105.5.2123; HYMAN AA, 1989, J CELL BIOL, V109, P1185, DOI 10.1083/jcb.109.3.1185; IIDA K, 1993, GENE, V124, P115; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KARLSSON R, 1991, MOL CELL BIOL, V11, P213, DOI 10.1128/MCB.11.1.213; KARPOVA TS, 1993, GENETICS, V135, P693; LEESMILLER JP, 1992, NATURE, V359, P244, DOI 10.1038/359244a0; LI YY, 1993, P NATL ACAD SCI USA, V90, P10096, DOI 10.1073/pnas.90.21.10096; LIU HP, 1992, GENETICS, V132, P665; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MCMILLAN JN, 1994, J CELL BIOL, V125, P143, DOI 10.1083/jcb.125.1.143; MELKI R, 1993, J CELL BIOL, V122, P1301, DOI 10.1083/jcb.122.6.1301; NEFSKY B, 1992, EUR J BIOCHEM, V206, P949, DOI 10.1111/j.1432-1033.1992.tb17005.x; PALMER RE, 1992, J CELL BIOL, V119, P583, DOI 10.1083/jcb.119.3.583; PASCHAL BM, 1993, J BIOL CHEM, V268, P15318; PIPERNO G, 1985, J CELL BIOL, V101, P2085, DOI 10.1083/jcb.101.6.2085; PLAMANN M, 1994, IN PRESS J CELL BIOL; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; READ EB, 1992, MOL BIOL CELL, V3, P429, DOI 10.1091/mbc.3.4.429; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFER DA, 1994, J CELL BIOL, V126, P403, DOI 10.1083/jcb.126.2.403; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; SCHWOB E, 1992, NATURE, V355, P179, DOI 10.1038/355179a0; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; SIKORSKI RS, 1989, GENETICS, V122, P19; WADDLE JA, 1993, MOL BIOL CELL, V4, P907, DOI 10.1091/mbc.4.9.907; WADDLE JA, 1994, IN PRESS DEVELOPMENT, V120; XIANG X, 1994, P NATL ACAD SCI USA, V91, P2100, DOI 10.1073/pnas.91.6.2100	51	199	200	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 26	1994	78	4					669	679		10.1016/0092-8674(94)90531-2	http://dx.doi.org/10.1016/0092-8674(94)90531-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	8069915				2022-12-24	WOS:A1994PD69300015
J	UHLIN, U; EKLUND, H				UHLIN, U; EKLUND, H			STRUCTURE OF RIBONUCLEOTIDE REDUCTASE PROTEIN R1	NATURE			English	Article							ESCHERICHIA-COLI; LACTOBACILLUS-LEICHMANNII; DIPHOSPHATE REDUCTASE; SUBUNIT INTERACTION; BARREL ENZYMES; INHIBITION; REFINEMENT; MUTANT; SITE; R2	Ribonucleotide reductase is the only enzyme that catalyses de novo formation of deoxyribonucleotides and is thus a key enzyme in DNA synthesis. The radical-based reaction involves five cysteines. Two redox-active cysteines are located at adjacent antiparallel strands in a new type of ten-stranded alpha/beta-barrel, and two others at the carboxyl end in a flexible arm. The fifth cysteine, in a loop in the centre of the barrel, is positioned to initiate the radical reaction.			UHLIN, U (corresponding author), SWEDISH UNIV AGR SCI, UPPSALA BIOMED CTR, DEPT MOLEC BIOL, BOX 590, S-75124 UPPSALA, SWEDEN.							ABERG A, 1989, J BIOL CHEM, V264, P12249; ABERG A, 1993, THESIS U STOCKHOLM; BJORKLUND S, 1990, BIOCHEMISTRY-US, V29, P5452; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BOOKER S, 1993, BIOCHEM SOC T, V21, P727, DOI 10.1042/bst0210727; BOOKER S, 1993, P NATL ACAD SCI USA, V90, P8352, DOI 10.1073/pnas.90.18.8352; Branden CI, 1991, CURR OPIN STRUC BIOL, V1, P978, DOI 10.1016/0959-440X(91)90094-A; BRICOGNE G, 1974, ACTA CRYSTALLOGR A, VA 30, P395, DOI 10.1107/S0567739474010722; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CLIMENT I, 1991, BIOCHEMISTRY-US, V30, P5164, DOI 10.1021/bi00235a008; CLIMENT I, 1992, BIOCHEMISTRY-US, V31, P4801, DOI 10.1021/bi00135a009; COHEN EA, 1986, NATURE, V321, P441, DOI 10.1038/321441a0; DUTIA BM, 1986, NATURE, V321, P439, DOI 10.1038/321439a0; ELLEDGE SJ, 1992, TRENDS BIOCHEM SCI, V17, P119, DOI 10.1016/0968-0004(92)90249-9; ERIKSSON S, 1986, J BIOL CHEM, V261, P1878; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; KARLSSON M, 1992, J BIOL CHEM, V267, P12622; KNIGHT S, 1989, THESIS SWEDISH U AGR; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LIN ANI, 1987, BIOCHEMISTRY-US, V26, P6905, DOI 10.1021/bi00396a006; LYCKSELL PO, 1994, BIOCHEMISTRY-US, V33, P2838, DOI 10.1021/bi00176a013; MAO SS, 1989, P NATL ACAD SCI USA, V86, P1485, DOI 10.1073/pnas.86.5.1485; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9752, DOI 10.1021/bi00155a031; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9744, DOI 10.1021/bi00155a030; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9733, DOI 10.1021/bi00155a029; MOSS N, 1993, J MED CHEM, V36, P3005, DOI 10.1021/jm00072a021; NORDLUND P, 1993, J MOL BIOL, V232, P123, DOI 10.1006/jmbi.1993.1374; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; Nyborg J., 1977, ROTATION METHOD CRYS, P139; OTWINOWSKI Z, 1991, DENZO MANUAL; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; PRONGAY AJ, 1990, J BIOL CHEM, V265, P18968; REICHARD P, 1983, SCIENCE, V221, P514, DOI 10.1126/science.6306767; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; SCHULZ GE, 1978, NATURE, V273, P120, DOI 10.1038/273120a0; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; THELANDER L, 1976, J BIOL CHEM, V251, P1398; TUGGLE CK, 1990, J BACTERIOL, V172, P1711, DOI 10.1128/jb.172.4.1711-1718.1990; UHLIN U, 1993, FEBS LETT, V336, P148, DOI 10.1016/0014-5793(93)81629-E; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WILMANNS M, 1991, BIOCHEMISTRY-US, V30, P9161, DOI 10.1021/bi00102a006; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	47	505	515	2	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 18	1994	370	6490					533	539		10.1038/370533a0	http://dx.doi.org/10.1038/370533a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC537	8052308				2022-12-24	WOS:A1994PC53700047
J	LIU, JP; SIM, ATR; ROBINSON, PJ				LIU, JP; SIM, ATR; ROBINSON, PJ			CALCINEURIN INHIBITION OF DYNAMIN-I GTPASE ACTIVITY COUPLED TO NERVE-TERMINAL DEPOLARIZATION	SCIENCE			English	Article							PROTEIN-PHOSPHORYLATION; MECHANOCHEMICAL ENZYME; BINDING PROTEINS; SYNAPTOSOMES; ENDOCYTOSIS; CALCIUM; DEPHOSPHORYLATION; MICROTUBULES; PHOSPHATASES; SHIBIRE	Dynamin I is a nerve terminal phosphoprotein with intrinsic guanosine triphosphatase (GTPase) activity that is required for endocytosis. Upon depolarization and synaptic vesicle recycling, dynamin I undergoes a rapid dephosphorylation. Dynamin I was found to be a specific high-affinity substrate for calcineurin in vitro. At low concentrations, calcineurin dephosphorylated dynamin I that had been phosphorylated by protein kinase C. The dephosphorylation inhibited dynamin I GTPase activity in vitro and after depolarization of nerve terminals. The effect in nerve terminals was prevented by the calcineurin inhibitor cyclosporin A. This suggests that in nerve terminals, calcineurin serves as a Ca2+-sensitive switch for depolarization-evoked synaptic vesicle recycling.	UNIV NEWCASTLE,NEUROSCI GRP,NEWCASTLE,NSW 2308,AUSTRALIA	University of Newcastle	LIU, JP (corresponding author), JOHN HUNTER HOSP,ENDOCRINE UNIT,LOCKED BAG 1,HUNTER REG MAIL CTR,NEWCASTLE,NSW 2310,AUSTRALIA.		Liu, Jun-Ping/AAA-5521-2020; Robinson, Phillip J/G-4008-2011	Liu, Jun-Ping/0000-0001-7442-2116; Robinson, Phillip J/0000-0002-7878-0313				CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; KING MM, 1984, J BIOL CHEM, V259, P8080; KRUEGER BK, 1977, J BIOL CHEM, V252, P2764; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU JP, IN PRESS J BIOL CHEM; LIU Y, 1989, J BIOL CHEM, V264, P12800; NAKATA T, 1993, J CELL SCI, V105, P1; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; PLEY U, 1993, CRIT REV BIOCHEM MOL, V28, P431, DOI 10.3109/10409239309078441; ROBINSON PJ, 1992, J BIOL CHEM, V267, P21637; ROBINSON PJ, 1983, J NEUROCHEM, V41, P909, DOI 10.1111/j.1471-4159.1983.tb09034.x; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; SCHMID SL, 1992, BIOESSAYS, V14, P589, DOI 10.1002/bies.950140903; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; SIM ATR, 1991, NEUROSCI LETT, V126, P203, DOI 10.1016/0304-3940(91)90554-7; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; TUMA PL, 1993, J BIOL CHEM, V268, P17240; TYAN TA, 1993, NEURON, V11, P713; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553	25	189	192	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 12	1994	265	5174					970	973		10.1126/science.8052858	http://dx.doi.org/10.1126/science.8052858			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052858				2022-12-24	WOS:A1994PB49900048
J	OHNO, T; GORDON, D; SAN, H; POMPILI, VJ; IMPERIALE, MJ; NABEL, GJ; NABEL, EG				OHNO, T; GORDON, D; SAN, H; POMPILI, VJ; IMPERIALE, MJ; NABEL, GJ; NABEL, EG			GENE-THERAPY FOR VASCULAR SMOOTH-MUSCLE CELL-PROLIFERATION AFTER ARTERIAL INJURY	SCIENCE			English	Article							HERPES-SIMPLEX VIRUS; TRANSLUMINAL CORONARY ANGIOPLASTY; ENDOTHELIAL-CELLS; BALLOON ANGIOPLASTY; INTIMAL HYPERPLASIA; EXPRESSION INVIVO; RETROVIRAL VECTOR; ADENOVIRAL VECTOR; CONTROLLED TRIAL; MODEL	Accumulation of vascular smooth muscle cells as a consequence of arterial injury is a major feature of vascular proliferative disorders. Molecular approaches to the inhibition of smooth muscle cell proliferation in these settings could potentially limit intimal expansion. This problem was approached by introducing adenoviral vectors encoding the herpesvirus thymidine kinase (tk) into porcine arteries that had been injured by a balloon on a catheter. These smooth muscle cells were shown to be infectable with adenoviral vectors, and introduction of the tk gene rendered them sensitive to the nucleoside analog ganciclovir. When this vector was introduced into porcine arteries immediately after a balloon injury, intimal hyperplasia decreased after a course of ganciclovir treatment. No major local or systemic toxicities were observed. These data suggest that transient expression of an enzyme that catalyzes the formation of a cytotoxic drug locally may limit smooth muscle cell proliferation in response to balloon injury.	UNIV MICHIGAN, MED CTR, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT PATHOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT MICROBIOL & IMMUNOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	OHNO, T (corresponding author), UNIV MICHIGAN, MED CTR, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL143507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI033355] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43507] Funding Source: Medline; NIAID NIH HHS [AI33355] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALCON R, 1992, CIRCULATION, V86, P100; BARR E, 1994, GENE THER, V1, P51; BAUMGARTNER HR, 1976, THROMB HAEMOSTASIS, V35, P124, DOI 10.1055/s-0038-1647919; BLOCK PC, 1981, NEW ENGL J MED, V305, P382, DOI 10.1056/NEJM198108133050706; BORRELLI E, 1988, P NATL ACAD SCI USA, V85, P7572, DOI 10.1073/pnas.85.20.7572; BREAKEFIELD XO, 1991, NEW BIOL, V3, P203; CHEN SH, 1994, P NATL ACAD SCI USA, V91, P3054, DOI 10.1073/pnas.91.8.3054; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; DAVIDSON BL, 1993, NAT GENET, V3, P219, DOI 10.1038/ng0393-219; DUNNETT CW, 1964, BIOMETRICS, V20, P482, DOI 10.2307/2528490; EZZEDDINE ZD, 1991, NEW BIOL, V3, P608; FAXON DP, 1992, CIRCULATION, V86, P53; FIELD AK, 1983, P NATL ACAD SCI-BIOL, V80, P4139, DOI 10.1073/pnas.80.13.4139; FRENCH J. E., 1965, ANN N Y ACAD SCI, V127, P780, DOI 10.1111/j.1749-6632.1965.tb49444.x; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GINSBURG D, 1992, BLOOD, V79, P2507; GONCHOROFF NJ, 1986, J IMMUNOL METHODS, V93, P97, DOI 10.1016/0022-1759(86)90438-2; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; GUZMAN PJ, 1993, CIRCULATION, V88, P2838, DOI 10.1161/01.CIR.88.6.2838; HEYMAN RA, 1989, P NATL ACAD SCI USA, V86, P2698, DOI 10.1073/pnas.86.8.2698; ISIK FF, 1992, AM J PATHOL, V141, P1139; KNUDTSON ML, 1990, J AM COLL CARDIOL, V15, P691, DOI 10.1016/0735-1097(90)90648-9; LANDAU C, 1994, NEW ENGL J MED, V330, P981, DOI 10.1056/NEJM199404073301407; LECLERC G, 1992, J CLIN INVEST, V90, P936, DOI 10.1172/JCI115970; LEE SW, 1993, CIRC RES, V73, P797, DOI 10.1161/01.RES.73.5.797; LEMARCHAND P, 1993, CIRC RES, V72, P1132, DOI 10.1161/01.RES.72.5.1132; LEMARCHAND P, 1992, P NATL ACAD SCI USA, V89, P6482, DOI 10.1073/pnas.89.14.6482; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MONCADA S, 1977, THROMB RES, V11, P323, DOI 10.1016/0049-3848(77)90185-2; MOOLTEN FL, 1990, HUM GENE THER, V1, P125, DOI 10.1089/hum.1990.1.2-125; MOOLTEN FL, 1990, J NATL CANCER I, V82, P297, DOI 10.1093/jnci/82.4.297; MORISHITA R, 1994, J CLIN INVEST, V93, P1458, DOI 10.1172/JCI117123; MORISHITA R, 1993, P NATL ACAD SCI USA, V90, P8474, DOI 10.1073/pnas.90.18.8474; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NABEL EG, 1993, P NATL ACAD SCI USA, V90, P10759, DOI 10.1073/pnas.90.22.10759; NABEL EG, 1993, J CLIN INVEST, V91, P1822, DOI 10.1172/JCI116394; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; NABEL EG, 1989, SCIENCE, V244, P1342, DOI 10.1126/science.2499928; NABEL EG, 1993, NATURE, V362, P844, DOI 10.1038/362844a0; NABEL EG, 1992, P NATL ACAD SCI USA, V89, P5157, DOI 10.1073/pnas.89.11.5157; OHNO T, UNPUB; OKEEFE JH, 1992, J AM COLL CARDIOL, V19, P1597, DOI 10.1016/0735-1097(92)90624-V; PEPINE CJ, 1990, CIRCULATION, V81, P1753, DOI 10.1161/01.CIR.81.6.1753; PLAUTZ G, 1991, NEW BIOL, V3, P709; POMPILI VJ, UNPUB; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; PRESCOTT MF, 1991, AM J PATHOL, V139, P139; REITMAN JS, 1982, ATHEROSCLEROSIS, V43, P119, DOI 10.1016/0021-9150(82)90104-6; REKHTER MD, 1993, AM J PATHOL, V143, P1634; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHWARTZ RS, 1990, CIRCULATION, V82, P2190, DOI 10.1161/01.CIR.82.6.2190; SCHWARTZ RS, 1994, ARTERIOSCLER THROMB, V14, P395, DOI 10.1161/01.ATV.14.3.395; SCHWARTZ RS, 1992, J AM COLL CARDIOL, V19, P267, DOI 10.1016/0735-1097(92)90476-4; SERRUYS PW, 1991, CIRCULATION, V84, P1568, DOI 10.1161/01.CIR.84.4.1568; SERRUYS PW, 1992, CIRCULATION, V86, P100; SHIMOKAWA H, 1989, CIRC RES, V64, P900, DOI 10.1161/01.RES.64.5.900; SIMON RH, 1993, HUM GENE THER, V4, P771, DOI 10.1089/hum.1993.4.6-771; SIMONS M, 1994, J CLIN INVEST, V93, P2351, DOI 10.1172/JCI117240; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SIMS FH, 1989, PATHOLOGY, V21, P115, DOI 10.3109/00313028909059547; SMITH KO, 1982, ANTIMICROB AGENTS CH, V22, P55, DOI 10.1128/AAC.22.1.55; STEELE PM, 1985, CIRC RES, V57, P105, DOI 10.1161/01.RES.57.1.105; WEINER BH, 1986, NEW ENGL J MED, V315, P841, DOI 10.1056/NEJM198610023151401; WEINER BH, 1985, CIRCULATION, V72, P1081, DOI 10.1161/01.CIR.72.5.1081; Winer BJ, 1971, STATISTICAL PRINCIPL, P261; WISSLER RW, 1968, ANN NY ACAD SCI, V149, P907	68	424	467	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 5	1994	265	5173					781	784		10.1126/science.8047883	http://dx.doi.org/10.1126/science.8047883			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	8047883				2022-12-24	WOS:A1994PA37200033
J	KARNI, A; TANNE, D; RUBENSTEIN, BS; ASKENASY, JJM; SAGI, D				KARNI, A; TANNE, D; RUBENSTEIN, BS; ASKENASY, JJM; SAGI, D			DEPENDENCE ON REM-SLEEP OF OVERNIGHT IMPROVEMENT OF A PERCEPTUAL SKILL	SCIENCE			English	Article							PARADOXICAL SLEEP; CORTEX; MEMORY; DISCRIMINATION; CONSOLIDATION; ACETYLCHOLINE; PLASTICITY	Several paradigms of perceptual learning suggest that practice can trigger long-term, experience-dependent changes in the adult visual system of humans. As shown here, performance of a basic visual discrimination task improved after a normal night's sleep. Selective disruption of rapid eye movement (REM) sleep resulted in no performance gain during a comparable sleep interval, although non-REM slow-wave sleep disruption did not affect improvement. On the other hand, deprivation of REM sleep had no detrimental effects on the performance of a similar, but previously learned, task. These results indicate that a process of human memory consolidation, active during sleep, is strongly dependent on REM sleep.	WEIZMANN INST SCI,DEPT NEUROBIOL,IL-76100 REHOVOT,ISRAEL; CHAIM SHEBA MED CTR,DEPT NEUROL,IL-52621 TEL HASHOMER,ISRAEL; CHAIM SHEBA MED CTR,OSCAR SAGER SLEEP RES LAB,IL-52621 TEL HASHOMER,ISRAEL	Weizmann Institute of Science; Chaim Sheba Medical Center; Chaim Sheba Medical Center			Tanne, David/F-2560-2010; Sagi, Dov/A-5454-2008	Tanne, David/0000-0002-6699-2220; Sagi, Dov/0000-0002-8446-9230				AGNEW HW, 1967, PERCEPT MOTOR SKILL, V24, P851, DOI 10.2466/pms.1967.24.3.851; AHISSAR M, 1993, P NATL ACAD SCI USA, V90, P5718, DOI 10.1073/pnas.90.12.5718; BALL K, 1987, VISION RES, V27, P935; BEAR MF, 1986, NATURE, V320, P172, DOI 10.1038/320172a0; CASTALDO V, 1974, PERCEPT MOTOR SKILL, V39, P1023, DOI 10.2466/pms.1974.39.3.1023; CHERNIK DA, 1972, PERCEPT MOTOR SKILL, V34, P283, DOI 10.2466/pms.1972.34.1.283; DUJARDIN K, 1990, PHYSIOL BEHAV, V47, P1271, DOI 10.1016/0031-9384(90)90382-E; EMPSON JAC, 1970, NATURE, V227, P287, DOI 10.1038/227287a0; FIORENTINI A, 1981, VISION RES, V21, P1149, DOI 10.1016/0042-6989(81)90017-1; FISHBEIN W, 1977, BEHAV BIOL, V19, P425, DOI 10.1016/S0091-6773(77)91903-4; FOWLER MJ, 1973, SCIENCE, V179, P302, DOI 10.1126/science.179.4070.302; Hobson J A, 1992, Curr Opin Neurobiol, V2, P759, DOI 10.1016/0959-4388(92)90130-D; HOBSON JA, 1990, J NEUROSCI, V10, P371; HORNE JA, 1984, BIOL PSYCHOL, V18, P165, DOI 10.1016/0301-0511(84)90001-2; JASPER HH, 1971, SCIENCE, V172, P601, DOI 10.1126/science.172.3983.601; JULIANO SL, 1991, P NATL ACAD SCI USA, V88, P780, DOI 10.1073/pnas.88.3.780; KARNI A, 1991, P NATL ACAD SCI USA, V88, P4966, DOI 10.1073/pnas.88.11.4966; KARNI A, 1993, NATURE, V365, P250, DOI 10.1038/365250a0; KARNI A, 1990, Investigative Ophthalmology and Visual Science, V31, P562; KARNI A, 1994, MATURATIONAL WINDOWS; KARNI A, 1992, THESIS WEIZMANN I SC; KOVACS I, COMMUNICATION; LLINAS RR, 1991, NEUROSCIENCE, V44, P521, DOI 10.1016/0306-4522(91)90075-Y; MISHKIN M, 1952, J EXP PSYCHOL, V43, P43, DOI 10.1037/h0061361; MISHKIN M, 1984, NEUROBIOLOGY LEARNIN, P64; MOSES JM, 1975, PSYCHOPHYSIOLOGY, V12, P141, DOI 10.1111/j.1469-8986.1975.tb01264.x; POGGIO T, 1992, SCIENCE, V256, P1018, DOI 10.1126/science.1589770; POLAT U, 1994, MATURATIONAL WINDOWS; Rechtschaffen A., 1968, MANUAL STANDARDIZED; SHIU LP, 1992, PERCEPT PSYCHOPHYS, V52, P282; SMITH C, 1982, PHYSIOL BEHAV, V29, P469, DOI 10.1016/0031-9384(82)90268-2; SMITH C, 1985, NEUROSCI BIOBEHAV R, V9, P157, DOI 10.1016/0149-7634(85)90042-9; SQUIRE LR, 1987, MEMORY BRAIN, P164; TILLEY AJ, 1978, BIOL PSYCHOL, V6, P293, DOI 10.1016/0301-0511(78)90031-5; Winson J, 1993, Curr Opin Neurobiol, V3, P243, DOI 10.1016/0959-4388(93)90217-M	35	683	703	1	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 29	1994	265	5172					679	682		10.1126/science.8036518	http://dx.doi.org/10.1126/science.8036518			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NZ538	8036518				2022-12-24	WOS:A1994NZ53800039
J	HERSCHBACH, BM; ARNAUD, MB; JOHNSON, AD				HERSCHBACH, BM; ARNAUD, MB; JOHNSON, AD			TRANSCRIPTIONAL REPRESSION DIRECTED BY THE YEAST ALPHA-2 PROTEIN IN-VITRO	NATURE			English	Article							MATING-TYPE LOCUS; SACCHAROMYCES-CEREVISIAE; POLYMERASE-II; ACTIVATION; DROSOPHILA; BINDS; NUCLEOSOMES; OPERATOR; COMPLEX; DOMAIN	THE alpha 2 protein, a homeodomain protein involved in specifying cell type in the budding yeast Saccharomyces cerevisiae, is a transcriptional repressor(1,2). alpha 2 binds cooperatively with Mcm1, a serum response factor-related protein, to the a-specific gene operator(3-6). The alpha 2-Mcm1 complex in turn recruits Ssn6 and Tup1 to the operator, and we believe that these latter two proteins are responsible for the transcriptional repression(7-9). Placement of the a-specific gene operator in any of a variety of positions upstream of a test promoter leads to repression of that promoter in vivo(9-11). In this respect, the a-specific gene operator resembles a negatively acting enhancer. Here we describe the in vitro reconstitution of this example of negative control from a distance. We observe repression in vitro in the absence of exogenously added activator protein and on templates that lack binding sites for known activator proteins, and we infer that alpha 2-directed repression acts on the general transcription machinery.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	HERSCHBACH, BM (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							AMMERER G, 1990, GENE DEV, V4, P299, DOI 10.1101/gad.4.2.299; EMAMI KH, 1992, EMBO J, V11, P5005, DOI 10.1002/j.1460-2075.1992.tb05607.x; GUARENTE L, 1984, CELL, V36, P503, DOI 10.1016/0092-8674(84)90243-5; HERSCHBACH BM, 1993, MOL CELL BIOL, V13, P4029, DOI 10.1128/MCB.13.7.4029; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; Johnson A. A, 1992, TRANSCRIPTIONAL REGU, P975; JOHNSON AD, 1985, CELL, V53, P927; JOHNSON FB, 1992, GENE DEV, V6, P2177, DOI 10.1101/gad.6.11.2177; Johnson SL, 1991, THESIS U WASHINGTON; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KELEHER CA, 1989, MOL CELL BIOL, V9, P5228, DOI 10.1128/MCB.9.11.5228; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; MUKAI Y, 1991, MOL CELL BIOL, V11, P3773, DOI 10.1128/MCB.11.7.3773; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; ROTH SY, 1992, GENE DEV, V6, P411, DOI 10.1101/gad.6.3.411; ROTH SY, 1990, MOL CELL BIOL, V10, P2247, DOI 10.1128/MCB.10.5.2247; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SCHULTZ J, 1987, MOL CELL BIOL, V7, P3637, DOI 10.1128/MCB.7.10.3637; SHIMIZU M, 1991, EMBO J, V10, P3033, DOI 10.1002/j.1460-2075.1991.tb07854.x; SILICIANO PG, 1984, CELL, V37, P969, DOI 10.1016/0092-8674(84)90431-8; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; SZE JY, 1992, SCIENCE, V258, P1143, DOI 10.1126/science.1439822; TATCHELL K, 1981, CELL, V27, P25, DOI 10.1016/0092-8674(81)90357-3; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307; WOONTNER M, 1990, J BIOL CHEM, V265, P8979; WOOTNER M, 1991, MOL CELL BIOL, V11, P4555	30	99	100	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 28	1994	370	6487					309	311		10.1038/370309a0	http://dx.doi.org/10.1038/370309a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ229	8035881				2022-12-24	WOS:A1994NZ22900069
J	LEE, PR				LEE, PR			IRRADIATION TO PREVENT FOODBORNE ILLNESS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US PHS,WASHINGTON,DC	United States Public Health Service									0	12	14	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 27	1994	272	4					261	261		10.1001/jama.272.4.261	http://dx.doi.org/10.1001/jama.272.4.261			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NX806	8028126				2022-12-24	WOS:A1994NX80600004
J	SPERLING, K; PELZ, J; WEGNER, RD; DORRIES, A; GRUTERS, A; MIKKELSEN, M				SPERLING, K; PELZ, J; WEGNER, RD; DORRIES, A; GRUTERS, A; MIKKELSEN, M			SIGNIFICANT INCREASE IN TRISOMY-21 IN BERLIN 9 MONTHS AFTER THE CHERNOBYL REACTOR ACCIDENT - TEMPORAL CORRELATION OR CAUSAL RELATION	BRITISH MEDICAL JOURNAL			English	Article							DOWNS-SYNDROME; RISK; ABNORMALITIES; RADIATION; EUROPE	Objective-To assess whether the increased prevalence of trisomy 21 in West Berlin in January 1987 might have been causally related to exposure to ionising radiation as a result of the Chernobyl reactor accident or was merely a chance event. Design-Analysis of monthly prevalence of trisomy 21 in West Berlin from January 1980 to December 1989. Setting-Confines of West Berlin. Results-Owing to the former ''island'' situation of West Berlin and its well organised health services, ascertainment of trisomy 21 was thought to be almost complete. A cluster of 12 cases occurred in January 1987 as compared with two or three expected. After exclusion of factors that might have explained the increase, including maternal age distribution, only exposure to radiation as a result of the Chernobyl reactor accident remained. In six of seven cases that could be studied cytogenetically the extra chromosome was of maternal origin, confirming that nondisjunction had occurred at about the time of conception. Conclusion-On the basis of two assumptions -(a) that maternal meiosis is an error prone process susceptible to exogenous factors at the time of conception; (b) that owing to the high prevalence of iodine deficiency in Berlin a large amount of iodine-131 would have been accumulated over a short period-it is concluded that the increased prevalence of trisomy 21 in West Berlin in January 1987 was causally related to a short period of exposure to ionising radiation as a result of the Chernobyl reactor accident.	INST GESCHICHTE MED,D-79104 FREIBURG,GERMANY; FREE UNIV BERLIN,KINDERKLIN,D-14059 BERLIN,GERMANY; JOHN F KENNEDY INST,DK-2600 GLOSTRUP,DENMARK	Free University of Berlin	SPERLING, K (corresponding author), FREE UNIV BERLIN,INST HUMAN GENET,D-14059 BERLIN,GERMANY.							ANSPAUGH LR, 1988, SCIENCE, V242, P1513, DOI 10.1126/science.3201240; ANTONARAKIS SE, 1993, TRENDS GENET, V9, P142, DOI 10.1016/0168-9525(93)90210-9; CZEIZEL A, 1989, HUM GENET, V82, P359; CZEIZEL A, 1988, ACTA MORPHOL HUNG, V36, P63; CZEIZEL AE, 1993, LANCET, V341, P539, DOI 10.1016/0140-6736(93)90293-P; DELANGE F, 1989, B WORLD HEALTH ORGAN, V67, P317; DELANGE F, 1986, BIOL NEONATE, V49, P322, DOI 10.1159/000242547; DEWALS P, 1988, INT J EPIDEMIOL, V17, P230, DOI 10.1093/ije/17.1.230; Diggle P, 1990, TIME SERIES BIOSTATI; DULK H, 1991, EUROCAT REGISTRY DES; FIALKOW PJ, 1970, ANN NY ACAD SCI, V171, P500, DOI 10.1111/j.1749-6632.1970.tb39359.x; GERMAN J, 1968, NATURE, V217, P516, DOI 10.1038/217516a0; HANSMANN I, 1990, TRENDS CHROMOSOME RE, P165; HARJULEHTOMERVAALA T, 1992, MUTAT RES, V275, P81, DOI 10.1016/0921-8734(92)90011-D; HELLER CG, 1963, SCIENCE, V140, P184, DOI 10.1126/science.140.3563.184; HOOK EB, 1989, AM J HUM GENET, V45, P855; JANERICH DT, 1977, LANCET, V1, P515; JORGBLOET PH, 1982, HUM GENET, V62, P134; KALLEN B, 1989, HEREDITAS, V110, P55, DOI 10.1111/j.1601-5223.1989.tb00417.x; KLINE J, 1985, ANEUPLOIDY ETIOLOGY, P149; KOCHUPILLAI N, 1976, NATURE, V262, P60, DOI 10.1038/262060a0; LIENERT GA, 1978, VERTEILUNGSFREIE MET, V2; LINDSTEN J, 1981, TRISOMY, V21, P1195; RAMSAY CN, 1991, BIOMED PHARMACOTHER, V45, P267, DOI 10.1016/0753-3322(91)90028-R; SPERLING K, 1991, BIOMED PHARMACOTHER, V45, P255, DOI 10.1016/0753-3322(91)90026-P; SPERLING K, 1984, MUTATIONS MAN, P128; SPERLING K, 1987, ANN U SARAVIENSIS S, V7, P307; SPERLING K, 1987, ANN U SARAV MED S, V7, P305; STEINMETZ KH, 1987, RADIOAKTIVITATSMESSU, P439; THIEME C, 1989, KINDERARZT, V20, P857; TORFS CP, 1990, AM J HUM GENET, V47, P727; VOGEL F, 1992, HUM GENET, V89, P127; WINTER M, 1986, RADIOAKTIVITAZ BRD S; WITOWSKI R, 1987, Z KLINISCHE MED, V24, P2203; 1985, LANCET, V1, P1289; 1980, SCIENCE, V209, P877	36	74	77	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 16	1994	309	6948					158	162		10.1136/bmj.309.6948.158	http://dx.doi.org/10.1136/bmj.309.6948.158			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY229	8044094	Green Published			2022-12-24	WOS:A1994NY22900020
J	CLORE, GM; OMICHINSKI, JG; SAKAGUCHI, K; ZAMBRANO, N; SAKAMOTO, H; APPELLA, E; GRONENBORN, AM				CLORE, GM; OMICHINSKI, JG; SAKAGUCHI, K; ZAMBRANO, N; SAKAMOTO, H; APPELLA, E; GRONENBORN, AM			HIGH-RESOLUTION STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTIDIMENSIONAL NMR	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; ISOTOPICALLY ENRICHED PROTEINS; RESTRAINED MOLECULAR-DYNAMICS; MULTIPLE QUANTUM COHERENCE; DNA-BINDING; DISTANCE GEOMETRY; 3-DIMENSIONAL STRUCTURE; J COUPLINGS; PEPTIDE COMPLEX; LARGER PROTEINS	The three-dimensional structure of the oligomerization domain (residues 319 to 360) of the tumor suppressor p53 has been solved by multidimensional heteronuclear magnetic resonance (NMR) spectroscopy. The domain forms a 20-kilodalton symmetric tetramer with a topology made up from a dimer of dimers. The two primary dimers each comprise two antiparallel helices linked by an antiparallel beta sheet. One beta strand and one helix are contributed from each monomer. The interface between the two dimers forming the tetramer is mediated solely by helix-helix contacts. The overall result is a symmetric, four-helix bundle with adjacent helices oriented antiparallel to each other and with the two antiparallel beta sheets located on opposing faces of the molecule. The tetramer is stabilized not only by hydrophobic interactions within the protein core but also by a number of electrostatic interactions. The implications of the structure of the tetramer for the biological function of p53 are discussed.	NIDDKD,CHEM PHYS LAB,BETHESDA,MD 20892; NCI,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Clore, G Marius/L-2546-2018; Sakamoto, Hiroshi/A-3181-2011; Zambrano, Nicola/B-9352-2014; Clore, G. Marius/A-3511-2008	Clore, G Marius/0000-0003-3809-1027; Zambrano, Nicola/0000-0001-9395-3481; Clore, G. Marius/0000-0003-3809-1027; Sakaguchi, Kazuyasu/0000-0002-8434-4171; Gronenborn, Angela M/0000-0001-9072-3525				ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; BAX A, 1992, J AM CHEM SOC, V114, P6923, DOI 10.1021/ja00043a052; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CHOTHIA C, 1981, J MOL BIOL, V145, P215, DOI 10.1016/0022-2836(81)90341-7; CLICHE L, 1990, P NATL ACAD SCI USA, V87, P3240; CLORE G M, 1991, Journal of Biomolecular NMR, V1, P13, DOI 10.1007/BF01874566; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P5671, DOI 10.1021/bi00476a004; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P12, DOI 10.1021/bi00215a002; CLORE GM, 1986, EMBO J, V5, P2729, DOI 10.1002/j.1460-2075.1986.tb04557.x; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLORE GM, 1991, PROG NUCL MAG RES SP, V23, P43, DOI 10.1016/0079-6565(91)80002-J; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; DAMICO D, 1992, ONCOGENE, V7, P339; DECASTRO E, 1992, VISP 1 0 USERS GUIDE; DELANO W, 1993, AVS XPLOR USERS MANU; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GARRETT DS, 1994, J MAGN RESON SER B, V104, P99, DOI 10.1006/jmrb.1994.1061; GRZESIEK S, 1992, J MAGN RESON, V96, P215, DOI 10.1016/0022-2364(92)90307-S; GRZESIEK S, 1993, J BIOMOL NMR, V3, P487; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLLSTEIN M, 1993, SCIENCE, V262, P1980; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IKURA M, 1990, J AM CHEM SOC, V112, P9020, DOI 10.1021/ja00180a080; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; IKURA M, 1993, SCIENCE, V261, P438; KAY LE, 1990, SCIENCE, V249, P411, DOI 10.1126/science.2377896; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIU FS, 1994, OBSTET GYNECOL, V83, P118; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MIYAMOTO H, 1993, ONCOL RES, V5, P245; MUELLER L, 1987, J MAGN RESON, V72, P191, DOI 10.1016/0022-2364(87)90188-0; NILGES M, 1993, PROTEINS, V17, P297, DOI 10.1002/prot.340170307; NILGES M, 1990, BIOPOLYMERS, V29, P813, DOI 10.1002/bip.360290415; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; NISHIDA N, 1993, CANCER RES, V53, P368; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; POWERS R, 1993, BIOCHEMISTRY-US, V32, P6744, DOI 10.1021/bi00077a030; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; SAKAMOTO H, IN PRESS P NATL ACAD; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; VUISTER GW, 1993, J AM CHEM SOC, V115, P5334, DOI 10.1021/ja00065a071; VUISTER GW, 1993, J MAGN RESON SER B, V101, P210, DOI 10.1006/jmrb.1993.1035; VUISTER GW, 1994, METHOD ENZYMOL, V239, P79; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WILLIAMSON MP, 1985, J MOL BIOL, V182, P295, DOI 10.1016/0022-2836(85)90347-X; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	69	299	306	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 15	1994	265	5170					386	391		10.1126/science.8023159	http://dx.doi.org/10.1126/science.8023159			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023159				2022-12-24	WOS:A1994NW81600038
J	POLYAK, K; LEE, MH; ERDJUMENTBROMAGE, H; KOFF, A; ROBERTS, JM; TEMPST, P; MASSAGUE, J				POLYAK, K; LEE, MH; ERDJUMENTBROMAGE, H; KOFF, A; ROBERTS, JM; TEMPST, P; MASSAGUE, J			CLONING OF P27(KIP1), A CYCLIN-DEPENDENT KINASE INHIBITOR AND A POTENTIAL MEDIATOR OF EXTRACELLULAR ANTIMITOGENIC SIGNALS	CELL			English	Article							FC-GAMMA-RIII; CELL-CYCLE; GROWTH-FACTOR; TGF-BETA; GENE-EXPRESSION; CDK2 ACTIVITY; G1 CYCLIN; FIBROBLASTS; PROTEIN; PHASE	We cloned p27(Kip1), a cyclin-dependent kinase inhibitor implicated in G1 phase arrest by TGF beta and cell-cell contact. p27(Kip1) associates with cyclin E-Cdk2 complexes in vivo and in vitro, prevents their activation, and inhibits previously activated complexes, and p27(Kip1) overexpression obstructs cell entry into S phase. p27(Kip1) potently inhibits Rb phosphorylation by cyclin E-Cdk2, cyclin A-Cdk2, and cyclin D2-Cdk4. p27(Kip1) is highly conserved and broadly expressed in human tissues, and its mRNA levels are similar in proliferating and quiescent cells. p27(Kip1) has a region of sequence similarity to p21(Cip1/WAF1), the Cdk inhibitor whose transcription is stimulated by p53. A p27(Kip1) peptide corresponding to this region retains Cdk inhibitory activity. We suggest that cell contact, TGF beta, and p53 all restrain cell proliferation through related Cdk inhibitors.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021; FRED HUTCHINSON CANC RES CTR,DEPT BASIC SCI,SEATTLE,WA 98104	Memorial Sloan Kettering Cancer Center; Fred Hutchinson Cancer Center	POLYAK, K (corresponding author), HOWARD HUGHES MED INST,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021, USA.			Lee, Mong-Hong/0000-0001-8675-8215; Erdjument-Bromage, Hediye/0000-0003-0224-3594; Massague, Joan/0000-0001-9324-8408				ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; COCKS BG, 1992, J BIOL CHEM, V267, P12307; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELICONE C, 1994, IN PRESS J CHROMATOG; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; JIANG W, 1993, ONCOGENE, V8, P3447; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PINES J, 1994, TRENDS BIOCHEM SCI, V19, P143, DOI 10.1016/0968-0004(94)90272-0; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; WIRTHMUELLER U, 1992, J EXP MED, V175, P1381, DOI 10.1084/jem.175.5.1381; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	40	2068	2207	3	57	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 15	1994	78	1					59	66		10.1016/0092-8674(94)90572-X	http://dx.doi.org/10.1016/0092-8674(94)90572-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033212				2022-12-24	WOS:A1994NX32800008
J	TZAMARIAS, D; STRUHL, K				TZAMARIAS, D; STRUHL, K			FUNCTIONAL DISSECTION OF THE YEAST CYC8-TUP1 TRANSCRIPTIONAL CO-REPRESSOR COMPLEX	NATURE			English	Article							DNA-BINDING SPECIFICITY; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID RECEPTOR; GLUCOSE REPRESSION; ACTIVATION DOMAIN; ESCHERICHIA-COLI; SHUTTLE VECTORS; PROTEIN; GENES; PURIFICATION	DNA-BINDING repressor proteins mediate regulation of yeast genes by cell type (Mcm1/alpha 2 and a1/alpha 2), glucose (Mig1) and oxygen (Rox1) (refs 1-4 respectively). An unusual feature of all these regulatory pathways is that transcriptional repression requires two physically associated proteins(5) that do not bind DNA Cyc8(Ssn6) and Tup1. The Cyc8-Tup1 complex has been proposed to be a corepressor that is recruited to target promoters by pathway-specific DNA-binding proteins(6), but the specific functions of the individual proteins are unknown. Here we show that when it is bound upstream of a functional promoter through the LexA DNA-binding domain, Tup1 represses transcription in the absence of Cyc8. Deletion analysis indicates that Tup1 contains at least two non-overlapping transcriptional repression regions with minimal primary sequence similarity, and a separable Cyc8-interaction domain. These Tup1 domains, which do not include the beta-transducin motifs(7), are necessary and partially sufficient for Tup1 function. We suggest that Tup1 performs the repression function of the Cyc8-Tup1 co-repressor complex, and that Cyc8 serves as a link with the pathway-specific DNA-binding proteins.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School								CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; GOUTTE C, 1988, CELL, V52, P875, DOI 10.1016/0092-8674(88)90429-1; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; JAYNES JB, 1991, EMBO J, V10, P1427, DOI 10.1002/j.1460-2075.1991.tb07663.x; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KIM J, 1993, P NATL ACAD SCI USA, V90, P4513, DOI 10.1073/pnas.90.10.4513; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; NEHLIN JO, 1991, EMBO J, V10, P3373, DOI 10.1002/j.1460-2075.1991.tb04901.x; NELSON M, 1989, MOL CELL BIOL, V9, P384, DOI 10.1128/MCB.9.2.384; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; SCHULTZ J, 1990, MOL CELL BIOL, V10, P4744, DOI 10.1128/MCB.10.9.4744; SCHULTZ J, 1987, MOL CELL BIOL, V7, P3637, DOI 10.1128/MCB.7.10.3637; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TZAMARIAS D, 1992, P NATL ACAD SCI USA, V89, P2007, DOI 10.1073/pnas.89.6.2007; WILLIAMS FE, 1990, MOL CELL BIOL, V10, P6500, DOI 10.1128/MCB.10.12.6500; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307; ZITOMER RS, 1992, MICROBIOL REV, V56, P1	30	286	292	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 30	1994	369	6483					758	761		10.1038/369758a0	http://dx.doi.org/10.1038/369758a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU581	8008070				2022-12-24	WOS:A1994NU58100065
J	RHOADS, JE				RHOADS, JE			MEMOIR OF A SURGICAL NUTRITIONIST	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											RHOADS, JE (corresponding author), UNIV PENN, SCH MED, DEPT SURG, 3400 SPRUCE ST, PHILADELPHIA, PA 19104 USA.							WILLIFORD WO, 1991, NEW ENGL J MED, V325, P525; WILMORE DW, 1968, J AMER MED ASSOC, V203, P860, DOI 10.1001/jama.203.10.860	2	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 28	1994	272	12					963	966						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG737	8084065				2022-12-24	WOS:A1994PG73700025
J	HOHLFELD, P; DAFFOS, F; COSTA, JM; THULLIEZ, P; FORESTIER, F; VIDAUD, M				HOHLFELD, P; DAFFOS, F; COSTA, JM; THULLIEZ, P; FORESTIER, F; VIDAUD, M			PRENATAL-DIAGNOSIS OF CONGENITAL TOXOPLASMOSIS WITH A POLYMERASE-CHAIN-REACTION TEST ON AMNIOTIC-FLUID	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FETAL TOXOPLASMOSIS; TISSUE-CULTURE; FOLLOW-UP; GONDII; PREGNANCY; AMPLIFICATION; AMNIOCENTESIS; SAMPLES; PCR; INFECTIONS	Background. Congenital infection with Toxoplasma gondii can produce serious sequelae. However, there is little consensus about screening during pregnancy, and the tests used to establish a prenatal diagnosis of toxoplasmosis are complex and slow. We evaluated a simpler approach that is based on a polymerase-chain-reaction (PCR) test. Methods. Prenatal diagnostic tests, including ultrasonography, amniocentesis, and fetal-blood sampling, were performed in 2632 women with T. gondii infection acquired during pregnancy. In 339 consecutive women, a competitive PCR test for T, gondii was performed on amniotic fluid, and its results were compared with those of conventional diagnostic tests. The PCR test targets the B1 gene of T. gondii, uses an internal control, and can be completed in a day. Positive tests were confirmed by serologic testing of newborns or by autopsy in terminated pregnancies. Results. Overall, the risk of fetal infection was 7.4 percent, but it increased sharply with gestational age. Congenital infection was demonstrated in 34 of 339 fetuses by conventional methods, and the PCR test was positive in ail 34. In three other fetuses, only the PCR test gave positive results, and follow-up testing confirmed the presence of congenital toxoplasmosis. The PCR test gave one false negative result but no false positive results. The PCR test performed better than conventional parasitologic methods (sensitivity, 97.4 percent vs. 89.5 percent; negative predictive value, 99.7 percent vs. 98.7 percent). Conclusions. For the prenatal diagnosis of congenital T. gondii infection, an approach based on a PCR test performed on amniotic fluid is rapid, safe, and accurate.	INST PUERICULTURE, SERV MED & BIOL FOETALES, F-75014 PARIS, FRANCE; INST PUERICULTURE, TOXOPLASMOSE LAB, F-75014 PARIS, FRANCE				Vidaud, Michel/O-7346-2017					Aspock H., 1986, Mitteilungen der Osterreichischen Gesellschaft fur Tropenmedizin und Parasitologie, V8, P105; BRETAGNE S, 1993, J INFECT DIS, V168, P1585, DOI 10.1093/infdis/168.6.1585; CAZENAVE J, 1992, PRENATAL DIAG, V12, P119, DOI 10.1002/pd.1970120207; COUVREUR J, 1991, ARCH FR PEDIATR, V48, P397; DAFFOS F, 1985, AM J OBSTET GYNECOL, V153, P655, DOI 10.1016/S0002-9378(85)80254-4; DAFFOS F, 1988, NEW ENGL J MED, V318, P271, DOI 10.1056/NEJM198802043180502; DALTON ME, 1993, NEW ENGL J MED, V328, P114; DEROUIN F, 1988, EUR J CLIN MICROBIOL, V7, P423, DOI 10.1007/BF01962355; DEROUIN F, 1987, J CLIN MICROBIOL, V25, P1597, DOI 10.1128/JCM.25.9.1597-1600.1987; DESMONTS G, 1985, LANCET, V1, P500; DESMONTS G, 1990, LANCET, V336, P1017, DOI 10.1016/0140-6736(90)92485-Z; DESMONTS G, 1990, PRESSE MED, V19, P1445; DUPOUYCAMET J, 1992, ANN BIOL CLIN-PARIS, V50, P315; ENDERS G, 1988, INFEKTIONEN IMPFUNGE, P143; Flamm H, 1981, Padiatr Grenzgeb, V20, P27; FORESTIER F, 1988, AM J OBSTET GYNECOL, V158, P1184, DOI 10.1016/0002-9378(88)90251-7; FOULON W, 1988, OBSTET GYNECOL, V72, P363; FRIESE K, 1991, GEBURTSH FRAUENHEILK, V51, P890, DOI 10.1055/s-2008-1026231; GARCIA AGP, 1968, ARCH DIS CHILD, V43, P705, DOI 10.1136/adc.43.232.705; GHIDINI A, 1993, AM J OBSTET GYNECOL, V168, P1339, DOI 10.1016/S0002-9378(11)90761-3; GROVER CM, 1990, J CLIN MICROBIOL, V28, P2297, DOI 10.1128/JCM.28.10.2297-2301.1990; GUAY JM, 1993, J CLIN MICROBIOL, V31, P203, DOI 10.1128/JCM.31.2.203-207.1993; HALL SM, 1992, BMJ-BRIT MED J, V305, P291, DOI 10.1136/bmj.305.6848.291; HALLIDAY JL, 1992, LANCET, V340, P1236; HALLIDAY JL, 1992, LANCET, V340, P886, DOI 10.1016/0140-6736(92)93293-V; HOHLFELD P, 1989, J PEDIATR-US, V115, P765, DOI 10.1016/S0022-3476(89)80660-2; HOHLFELD P, 1991, ULTRASOUND OBST GYN, V1, P241, DOI 10.1046/j.1469-0705.1991.01040241.x; JEANNEL D, 1990, LANCET, V336, P359, DOI 10.1016/0140-6736(90)91890-M; JOYNSON DHM, 1988, LANCET, V2, P795; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LONGO MC, 1990, GENE, V93, P125, DOI 10.1016/0378-1119(90)90145-H; MCCABE R, 1988, NEW ENGL J MED, V318, P313, DOI 10.1056/NEJM198802043180509; MITCHELL CD, 1990, PEDIATR INFECT DIS J, V9, P512, DOI 10.1097/00006454-199007000-00012; PROMPELER HJ, 1989, GEBURTSH FRAUENHEILK, V49, P642, DOI 10.1055/s-2008-1026670; Remington JS., 1990, INFECT DIS FETUS NEW, V3, P89; SAVVA D, 1990, J MED MICROBIOL, V32, P25, DOI 10.1099/00222615-32-1-25; SIBLEY LD, 1992, NATURE, V359, P82, DOI 10.1038/359082a0; SIEBERT PD, 1993, BIOTECHNIQUES, V14, P244; SMIDTJENSEN S, 1992, LANCET, V340, P1237, DOI 10.1016/0140-6736(92)92946-D; TABOR A, 1986, LANCET, V1, P1287; THALHAMMER O, 1979, WIEN KLIN WOCHENSCHR, V91, P20; THULLIEZ P, 1992, SCAND J INFECT DIS, P18; VANDEVEN E, 1991, J CLIN MICROBIOL, V29, P2120, DOI 10.1128/JCM.29.10.2120-2124.1991	43	289	308	1	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 15	1994	331	11					695	699		10.1056/NEJM199409153311102	http://dx.doi.org/10.1056/NEJM199409153311102			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF332	8058075				2022-12-24	WOS:A1994PF33200002
J	BAIER, H; BONHOEFFER, F				BAIER, H; BONHOEFFER, F			ATTRACTIVE AXON GUIDANCE MOLECULES	SCIENCE			English	Editorial Material							CENTRAL-NERVOUS-SYSTEM; NEURITE GROWTH; TARGETS; PROTEIN				BAIER, H (corresponding author), MAX PLANCK INST ENTWICKLUNGSBIOL,POB 2109,D-72011 TUBINGEN,GERMANY.							BAIER H, 1992, SCIENCE, V255, P472, DOI 10.1126/science.1734526; BONHOEFFER F, 1984, TRENDS NEUROSCI, V7, P378, DOI 10.1016/S0166-2236(84)80060-0; CAJAL SRY, 1892, CELLULE, V9, P119; GUNDERSEN RW, 1979, SCIENCE, V206, P1079, DOI 10.1126/science.493992; HEDGECOCK EM, 1990, NEURON, V2, P61; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; LEMMON V, 1992, J NEUROSCI, V12, P818; LUMSDEN AGS, 1983, NATURE, V306, P786, DOI 10.1038/306786a0; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MITCHELL KA, UNPUB; PINI A, 1993, SCIENCE, V261, P95, DOI 10.1126/science.8316861; PLACZEK M, 1990, DEVELOPMENT, V110, P19; SCHWAB ME, 1990, TRENDS NEUROSCI, V13, P452, DOI 10.1016/0166-2236(90)90098-U; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; STAHL B, 1990, NEURON, V5, P735, DOI 10.1016/0896-6273(90)90227-7; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0	17	43	44	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 9	1994	265	5178					1541	1542		10.1126/science.8079167	http://dx.doi.org/10.1126/science.8079167			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF336	8079167				2022-12-24	WOS:A1994PF33600022
J	RESTREPO, BI; BARBOUR, AG				RESTREPO, BI; BARBOUR, AG			ANTIGEN DIVERSITY IN THE BACTERIUM B-HERMSII THROUGH SOMATIC MUTATIONS IN REARRANGED VMP GENES	CELL			English	Article							RELAPSING FEVER BORRELIA; LINEAR PLASMIDS; POINT MUTATIONS; DNA; CHICKEN; BURGDORFERI; EXPRESSION; AGENT; RECOMBINATION; TRYPANOSOME	B. hermsii counters host immunity with multiphasic antigenic variation. Th is is conferred by interplasmidic and intraplasmidic rearrangements of vmp genes. In several independent events, activation of a silent vmp gene through intraplasmidic deletions but not interplasmidic recombinations was followed by the appearance at its 5' end of multiple mutations that were not present in the silent gene. The prevalence of mutant alleles in postswitch populations increased during infections. Differences between the silent and expressed genes were at the same nucleotides at which vmp pseudogenes differed, suggesting these were templates for postswitch gene conversions. The mechanism of this bacterium to generate diversity, namely, intramolecular deletions followed by mutations in the rearranged gene, mirrors the strategy used by vertebrate hosts to eliminate it.	UNIV TEXAS, HLTH SCI CTR, DEPT MED, SAN ANTONIO, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	RESTREPO, BI (corresponding author), UNIV TEXAS, HLTH SCI CTR, DEPT MICROBIOL, SAN ANTONIO, TX 78284 USA.		Barbour, Alan/B-3160-2009	Barbour, Alan/0000-0002-0719-5248; Restrepo, Blanca I/0000-0002-3743-9098	NIAID NIH HHS [AI24424] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024424, R37AI024424] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; BALTZ T, 1991, EMBO J, V10, P1653, DOI 10.1002/j.1460-2075.1991.tb07688.x; Barbour A G, 1993, Trends Microbiol, V1, P236, DOI 10.1016/0966-842X(93)90139-I; BARBOUR AG, 1982, J EXP MED, V156, P1312, DOI 10.1084/jem.156.5.1312; BARBOUR AG, 1984, YALE J BIOL MED, V57, P521; BARBOUR AG, 1991, MOL MICROBIOL, V5, P489, DOI 10.1111/j.1365-2958.1991.tb02132.x; BARBOUR AG, 1991, INFECT IMMUN, V59, P390, DOI 10.1128/IAI.59.1.390-397.1991; BARBOUR AG, 1988, J CLIN MICROBIOL, V26, P475, DOI 10.1128/JCM.26.3.475-478.1988; BARBOUR AG, 1987, SCIENCE, V237, P409, DOI 10.1126/science.3603026; BARBOUR AG, 1985, GENOME REARRANGEMENT, P123; BORST P, 1987, SCIENCE, V235, P658, DOI 10.1126/science.3544215; BRAATEN BA, 1994, CELL, V76, P577, DOI 10.1016/0092-8674(94)90120-1; BURMAN N, 1990, MOL MICROBIOL, V4, P1715, DOI 10.1111/j.1365-2958.1990.tb00549.x; CADAVID D, 1994, J EXP MED, V179, P631, DOI 10.1084/jem.179.2.631; CADAVID D, 1993, J INFECT DIS, V168, P143, DOI 10.1093/infdis/168.1.143; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; HUGHES CAN, 1990, J BACTERIOL, V172, P6602, DOI 10.1128/jb.172.11.6602-6604.1990; KITTEN T, 1990, P NATL ACAD SCI USA, V87, P6077, DOI 10.1073/pnas.87.16.6077; KITTEN T, 1992, GENETICS, V132, P311; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; LU Y, 1993, CELL, V72, P397, DOI 10.1016/0092-8674(93)90116-8; MAIZELS N, 1989, TRENDS GENET, V5, P4, DOI 10.1016/0168-9525(89)90004-8; MCCORMACK WT, 1990, GENE DEV, V4, P548, DOI 10.1101/gad.4.4.548; MEIER JT, 1985, CELL, V41, P403, DOI 10.1016/S0092-8674(85)80013-1; MOLTER G, 1987, IMMUNOL REV, V96, P1; PARVARI R, 1987, EMBO J, V6, P97, DOI 10.1002/j.1460-2075.1987.tb04724.x; PIASTERK RH, 1985, NATURE, V318, P257; RADDING CM, 1982, COLD SPRING HARB SYM, V47, P821, DOI 10.1101/SQB.1983.047.01.094; RESTREPO BI, 1992, MOL MICROBIOL, V6, P3299, DOI 10.1111/j.1365-2958.1992.tb02198.x; RESTREPO BI, 1994, MOL MICROBIOL, V13, P287, DOI 10.1111/j.1365-2958.1994.tb00423.x; REYNAUD CA, 1989, CELL, V59, P171, DOI 10.1016/0092-8674(89)90879-9; REYNAUD CA, 1985, CELL, V40, P283, DOI 10.1016/0092-8674(85)90142-4; REYNAUD CA, 1987, CELL, V48, P379, DOI 10.1016/0092-8674(87)90189-9; ROBERTS D, 1985, CELL, V43, P117, DOI 10.1016/0092-8674(85)90017-0; SADZIENE A, 1992, J EXP MED, V176, P799, DOI 10.1084/jem.176.3.799; Sambrook J., 1989, MOL CLONING LAB MANU; SEIFERT HS, 1988, MICROBIOL REV, V52, P327, DOI 10.1128/MMBR.52.3.327-336.1988; STOENNER HG, 1982, J EXP MED, V156, P1297, DOI 10.1084/jem.156.5.1297; STRAUSS EC, 1986, ANAL BIOCHEM, V154, P353, DOI 10.1016/0003-2697(86)90536-1; Swanson J., 1989, MOBILE DNA, P743; VANDERPLOEG LHT, 1992, TRENDS GENET, V8, P452, DOI 10.1016/0168-9525(92)90179-8; WEBSTER RG, 1982, NATURE, V296, P115, DOI 10.1038/296115a0	42	66	76	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 9	1994	78	5					867	876		10.1016/S0092-8674(94)90642-4	http://dx.doi.org/10.1016/S0092-8674(94)90642-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PG296	8087853				2022-12-24	WOS:A1994PG29600015
J	DENG, TL; KARIN, M				DENG, TL; KARIN, M			C-FOS TRANSCRIPTIONAL ACTIVITY STIMULATED BY H-RAS-ACTIVATED PROTEIN-KINASE DISTINCT FROM JNK AND ERK	NATURE			English	Article							CELL-PROLIFERATION; TYROSINE KINASES; JUN ACTIVITY; MAP KINASES; PHOSPHORYLATION; DOMAIN; RECEPTOR; COMPLEX; EXPRESSION; ONCOGENES	RAS proteins exert their mitogenic and oncogenic effects through activation of downstream protein kinases(1). An important question is how Ras-generated signals reach the nucleus to activate downstream target genes. AP-1, a heterodimeric complex of Jun and Fos proteins, which activates mitogen-inducible genes(2), is a major nuclear target of Ras(3). Ras can stimulate AP-1 activity by inducing c-fos transcription(2,3), a process which is probably mediated by the ERK1 and -2 mitogen-activated protein (MAP) kinases(4), which phosphorylate the transcription factor Elk-1/TCF5,6. Besides inducing transcription from fos and jun genes, mitogens and Ras proteins enhance AP-1 activity through phosphorylation of c-Jun(7,8). Phosphorylation of the c-Jun activation domain leads to c-jun induction through an autoregulatory loop(2). Ras- and ultraviolet-responsive protein kinases that phosphorylate c-Jun on serine residues at positions 63 and 73 and stimulate its transcriptional activity have been identified(9). These proline-directed kinases, termed JNKs, are novel MAP kinases(10). It is not clear, however, whether c-Jun is the only recipient and JNK the only transducer of the Ras signal to AP-1 proteins, A short sequence surrounding the major JNK phosphorylation site of c-Jun is conserved in c-Fos and is part of its activation domain(11), suggesting that c-Fos may be similarly regulated. Here we show that Ras does indeed augment the transcriptional activity of c-Fos through phosphorylation at Thr 232, the homologue of Ser 73 of c-Jun. However, this is mediated by a novel Ras- and mitogen-responsive proline-directed protein kinase that is different from JNKs and ERKs. Therefore, at least three types of proline-directed kinases(4) transmit Ras- and mitogen-generated signals to the transcriptional machinery.	UNIV CALIF SAN DIEGO, SCH MED, CTR MOLEC GENET, DEPT PHARMACOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego								ALVAREZ E, 1991, J BIOL CHEM, V266, P15297; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLENIS J, 1991, CANCER CELL-MON REV, V3, P445; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DETOGNI P, 1988, MOL CELL BIOL, V8, P2251, DOI 10.1128/MCB.8.5.2251; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P312; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; Landon, 1977, Methods Enzymol, V47, P145; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; WEST BL, 1987, MOL CELL BIOL, V7, P1193, DOI 10.1128/MCB.7.3.1193; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030	41	322	328	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 8	1994	371	6493					171	175		10.1038/371171a0	http://dx.doi.org/10.1038/371171a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF191	8072547				2022-12-24	WOS:A1994PF19100068
J	HARBURY, PB; KIM, PS; ALBER, T				HARBURY, PB; KIM, PS; ALBER, T			CRYSTAL-STRUCTURE OF AN ISOLEUCINE-ZIPPER TRIMER	NATURE			English	Article							ALPHA-FIBROUS PROTEINS; HELICAL COILED COILS; GCN4 LEUCINE-ZIPPER; AMINO-ACID SEQUENCE; HEMAGGLUTININ; REFINEMENT; GLYCOPROTEIN; SPECIFICITY; NUCLEOTIDE; RESOLUTION	SUBUNIT oligomerization in many proteins is mediated by short coiled-coil motifs(1,2). These motifs share a characteristic seven-amino-acid repeat containing hydrophobic residues at the first (a) and fourth (d) positions. Despite this common pattern, different sequences form two-, three- and four-stranded helical ropes. We have investigated the basis for oligomer choice by characterizing variants(3) of the GCN4 lencine-zipper dimerization domain that adopt trimeric or tetrameric structures in response to mutations at the a and d positions. We now report the high-resolution X-ray crystal structure of an isoleucine-containing mutant that folds into a parallel three-stranded, alpha-helical coiled coil. In contrast to the dimer and tetramer structures(3,4), the interior packing of the trimer can accommodate beta-branched residues in the most preferred rotamer at both hydrophobic positions. Compatibility of the shape of the core amino acids with the distinct packing spaces in the two-, three- and four-stranded conformations appears to determine the oligomerization state of the GCN4 leucine-zipper variants.	MIT,HOWARD HUGHES MED INST,WHITEHEAD INST,DEPT BIOL,CAMBRIDGE,MA 02142; UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; University of California System; University of California Berkeley	HARBURY, PB (corresponding author), HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115, USA.							BECK K, 1993, J MOL BIOL, V231, P311, DOI 10.1006/jmbi.1993.1284; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHOTHIA C, 1981, J MOL BIOL, V145, P215, DOI 10.1016/0022-2836(81)90341-7; COELINGH KLV, 1988, VIROLOGY, V162, P137, DOI 10.1016/0042-6822(88)90402-3; COHEN C, 1994, SCIENCE, V263, P488, DOI 10.1126/science.8290957; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CONWAY JF, 1990, INT J BIOL MACROMOL, V12, P328, DOI 10.1016/0141-8130(90)90023-4; CONWAY JF, 1991, INT J BIOL MACROMOL, V13, P14, DOI 10.1016/0141-8130(91)90004-E; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P685, DOI 10.1107/S0365110X53001952; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DUNCAN R, 1990, VIROLOGY, V174, P399, DOI 10.1016/0042-6822(90)90093-7; ELANGO N, 1986, J VIROL, V57, P481, DOI 10.1128/JVI.57.2.481-489.1986; GARBER AT, 1989, EMBO J, V8, P1727, DOI 10.1002/j.1460-2075.1989.tb03565.x; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HARBURY PH, 1994, THESIS HARVARD U; HU JC, 1992, PROGR NUCLEIC ACIDS, P82; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; SEO J, 1993, PROTEINS, V15, P223, DOI 10.1002/prot.340150302; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; STRONG JE, 1991, VIROLOGY, V184, P23, DOI 10.1016/0042-6822(91)90818-V; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	31	421	462	3	45	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 1	1994	371	6492					80	83		10.1038/371080a0	http://dx.doi.org/10.1038/371080a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE381	8072533				2022-12-24	WOS:A1994PE38100056
J	SYMONDS, H; KRALL, L; REMINGTON, L; SAENZROBLES, M; LOWE, S; JACKS, T; VANDYKE, T				SYMONDS, H; KRALL, L; REMINGTON, L; SAENZROBLES, M; LOWE, S; JACKS, T; VANDYKE, T			P53-DEPENDENT APOPTOSIS SUPPRESSES TUMOR-GROWTH AND PROGRESSION IN-VIVO	CELL			English	Article							WILD-TYPE P53; VIRUS-40 T-ANTIGEN; TRANSGENIC MICE; GENE AMPLIFICATION; CHOROID-PLEXUS; TUMORIGENESIS; MUTANT; CELLS; EXPRESSION; MUTATIONS	To determine the contribution of p53 loss to tumor progression, we have induced abnormal proliferation in the brain choroid plexus epithelium of transgenic mice using a SV40 T antigen fragment that perturbs pRB family function but does not affect p53 function. Tumors induced by this mutant develop slowly compared with those induced by wild-type T antigen. Suppressed tumor growth is directly attributable to p53 function, since rapid tumor development occurs when the T antigen fragment is expressed in p53-null mice. In p53-heterozygous mice, stochastic loss of the wildtype p53 allele results in the focal emergence of aggressive tumor nodules characteristic of tumor progression. In each case, aggressive tumor development in the absence of p53 function corresponds to a decrease in the level of apoptosis. These results provide in vivo evidence that p53-dependent apoptosis, occurring in response to oncogenic events, is a critical regulator of tumorigenesis.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139; UNIV PITTSBURGH,SCH MED,DEPT PEDIAT,PITTSBURGH,PA 15213	Massachusetts Institute of Technology (MIT); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	SYMONDS, H (corresponding author), UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599, USA.				NATIONAL CANCER INSTITUTE [R01CA046283] Funding Source: NIH RePORTER; NCI NIH HHS [CA46283] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTEK J, 1991, ONCOGENE, V6, P1699; CHEN JD, 1992, ONCOGENE, V7, P1167; CHEN JD, 1989, J VIROL, V63, P2204, DOI 10.1128/JVI.63.5.2204-2214.1989; CHEN JD, 1991, MOL CELL BIOL, V11, P5968, DOI 10.1128/MCB.11.12.5968; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ICHIKAWA A, 1992, BLOOD, V79, P2701; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MYMRYK JS, 1994, ONCOGENE, V9, P1187; PIPAS JM, 1983, MOL CELL BIOL, V3, P203, DOI 10.1128/MCB.3.2.203; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SCHULTZE B, 1981, CELL TISSUE KINET, V14, P309, DOI 10.1111/j.1365-2184.1981.tb00535.x; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SYMONDS HS, 1993, MOL CELL BIOL, V13, P3255, DOI 10.1128/MCB.13.6.3255; VANDYKE TA, 1987, J VIROL, V61, P2029, DOI 10.1128/JVI.61.6.2029-2032.1987; VANDYKE TA, 1994, SEMIN CANCER BIOL, V5; WHITE E, 1993, P SOC EXP BIOL MED, V204, P30; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	32	879	891	0	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 26	1994	78	4					703	711		10.1016/0092-8674(94)90534-7	http://dx.doi.org/10.1016/0092-8674(94)90534-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	8069917				2022-12-24	WOS:A1994PD69300018
J	CHANG, PC; COHEN, SN				CHANG, PC; COHEN, SN			BIDIRECTIONAL REPLICATION FROM AN INTERNAL ORIGIN IN A LINEAR STREPTOMYCES PLASMID	SCIENCE			English	Article							DNA FRAGMENTS	Commonly, linear replicons that have protein covalently attached to 5' DNA termini replicate by protein-primed, strand-displacing, continuous synthesis of full-length strands. The synthesis of DNA in pSLA2, a 17-kilobase linear plasmid of Streptomyces rochei containing 5' terminal protein, occurs bidirectionally from an internally located replication origin. The replication intermediates are linear duplex molecules that have recessed (similar to 280 nucleotides) 5' ends rather than full-length single strands. The 3' over-hangs may serve as templates for the non-displacing synthesis of the lagging strand terminus primed by the covalently attached 5' DNA binding protein.	STANFORD UNIV,SCH MED,DEPT GENET,STANFORD,CA 94305	Stanford University								BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; HARDING NE, 1980, VIROLOGY, V104, P323, DOI 10.1016/0042-6822(80)90337-2; HINNEBUSCH J, 1993, MOL MICROBIOL, V10, P917, DOI 10.1111/j.1365-2958.1993.tb00963.x; HIROCHIKA H, 1982, PLASMID, V7, P59, DOI 10.1016/0147-619X(82)90027-0; HIROCHIKA H, 1984, EMBO J, V3, P761, DOI 10.1002/j.1460-2075.1984.tb01881.x; Hopwood D. A., 1985, GENETIC MANIPULATION; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; KINASHI H, 1987, NATURE, V328, P454, DOI 10.1038/328454a0; LECHNER RL, 1977, CELL, V12, P1007, DOI 10.1016/0092-8674(77)90165-9; LIN YS, 1993, MOL MICROBIOL, V10, P923, DOI 10.1111/j.1365-2958.1993.tb00964.x; MEINHARDT F, 1990, CURR GENET, V17, P89, DOI 10.1007/BF00312851; SAKAGUCHI K, 1990, MICROBIOL REV, V54, P66, DOI 10.1128/MMBR.54.1.66-74.1990; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; Sambrook J., 1989, MOL CLONING LAB MANU; SHIFFMAN D, 1992, P NATL ACAD SCI USA, V89, P6129, DOI 10.1073/pnas.89.13.6129; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUGIMOTO K, 1968, P NATL ACAD SCI USA, V60, P1356, DOI 10.1073/pnas.60.4.1356; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WU XN, 1993, J BACTERIOL, V175, P37, DOI 10.1128/JB.175.1.37-52.1993	21	87	95	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 12	1994	265	5174					952	954		10.1126/science.8052852	http://dx.doi.org/10.1126/science.8052852			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052852				2022-12-24	WOS:A1994PB49900042
J	GRAINGER, DJ; KEMP, PR; LIU, AC; LAWN, RM; METCALFE, JC				GRAINGER, DJ; KEMP, PR; LIU, AC; LAWN, RM; METCALFE, JC			ACTIVATION OF TRANSFORMING GROWTH-FACTOR-BETA IS INHIBITED IN TRANSGENIC APOLIPOPROTEIN(A) MICE	NATURE			English	Article							SMOOTH-MUSCLE CELLS; EXPRESSING HUMAN APOLIPOPROTEIN(A); LIPOPROTEIN(A); PROLIFERATION; OSTEOPONTIN; CULTURE; INVITRO	A HIGH concentration of serum lipoprotein(a) is a risk factor for atherosclerosis(1-3). Lipoprotein(a) consists of low-density lipoprotein with the additional protein component, apolipoprotein(a), a homologue of plasminogen(4). Lipoprotein(a) and apolipoprotein(a) enhance proliferation of human vascular smooth muscle cells (hVSMCs) in culture by inhibiting activation of plasminogen to plasmin, thus blocking the proteolytic activation of transforming growth factor-beta (TGF-beta)(5), an autocrine inhibitor of hVSMC proliferation(5,6). The hypothesis that this pathway is a key step in atherogenesis(5) is tested on transgenic mice expressing the human apolipoprotein(a) gene. We show here that the activation of TGF-beta is inhibited in the aortic wall and serum of mice expressing apolipoprotein(a), as a consequence of apolipoprotein(a) inhibition of plasminogen activation. These effects are closely correlated with VSMC activation.	STANFORD UNIV,SCH MED,DIV CARDIOVASC MED,STANFORD,CA 94305	Stanford University	GRAINGER, DJ (corresponding author), UNIV CAMBRIDGE,DEPT BIOCHEM,TENNIS COURT RD,CAMBRIDGE CB2 1QW,ENGLAND.			Kemp, Paul/0000-0001-8975-7293	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CAMPBELL JH, 1985, ARTERIOSCLEROSIS, V5, P318, DOI 10.1161/01.ATV.5.4.318; CHIESA G, 1992, J BIOL CHEM, V267, P24369; CUSHING GL, 1989, ARTERIOSCLEROSIS, V9, P593, DOI 10.1161/01.ATV.9.5.593; GADEAU AP, 1993, ARTERIOSCLER THROMB, V13, P120, DOI 10.1161/01.ATV.13.1.120; GENEST JJ, 1992, CIRCULATION, V85, P2025, DOI 10.1161/01.CIR.85.6.2025; GIACHELLI C, 1991, BIOCHEM BIOPH RES CO, V177, P867, DOI 10.1016/0006-291X(91)91870-I; GIACHELLI CM, 1993, J CLIN INVEST, V92, P1686, DOI 10.1172/JCI116755; GRAINGER DJ, 1993, SCIENCE, V260, P1655, DOI 10.1126/science.8503012; KIRSCHENLOHR HL, 1993, AM J PHYSIOL, V265, pC571, DOI 10.1152/ajpcell.1993.265.2.C571; KOJIMA S, 1991, J CELL BIOL, V113, P1439, DOI 10.1083/jcb.113.6.1439; KREUZER J, 1994, CHEM PHYS LIPIDS, V67-8, P175, DOI 10.1016/0009-3084(94)90137-6; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILES LA, 1990, THROMB HAEMOSTASIS, V63, P331; OBRIEN ER, 1993, CIRC RES, V73, P223, DOI 10.1161/01.RES.73.2.223; RATH M, 1989, ARTERIOSCLEROSIS, V9, P579, DOI 10.1161/01.ATV.9.5.579; RINDERKNECHT H, 1960, EXPERIENTIA, V16, P430, DOI 10.1007/BF02178856; SCHREINER PJ, 1993, ARTERIOSCLER THROMB, V13, P826, DOI 10.1161/01.ATV.13.6.826; SHANAHAN CM, 1993, CIRC RES, V73, P193, DOI 10.1161/01.RES.73.1.193; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631	21	337	352	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 11	1994	370	6489					460	462		10.1038/370460a0	http://dx.doi.org/10.1038/370460a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	8047165				2022-12-24	WOS:A1994PB40700056
J	EADS, JC; SCAPIN, G; XU, YM; GRUBMEYER, C; SACCHETTINI, JC				EADS, JC; SCAPIN, G; XU, YM; GRUBMEYER, C; SACCHETTINI, JC			THE CRYSTAL-STRUCTURE OF HUMAN HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE WITH BOUND GMP	CELL			English	Article							LESCH-NYHAN; NUCLEOSIDE HYDROLASE; TRANSITION-STATE; DEFICIENCY; PATIENT; EXPRESSION; STABILITY; PURINE; GENE	The crystal structure of HGPRTase with bound GMP has been determined and refined to 2.5 Angstrom resolution, The enzyme has a core alpha/beta structure resembling the nucleotide-binding fold of dehydrogenases, and a second lobe composed of residues from the amino and carboxy termini. The GMP molecule binds in an anti conformation in a solvent-exposed cleft of the enzyme. Lys-165, which forms a hydrogen bond to O6 of GMP, appears to be critical for determining the specificity for guanine and hypoxanthine over adenine. The location of active site residues also provides evidence for a possible mechanism for general base-assisted HGPRTase catalysis. A rationalization of the effects on stability and activity of naturally occurring single amino acid mutations of HGPRTase is presented, including a discussion of several mutations at the active site that lead to Lesch-Nyhan syndrome.	TEMPLE UNIV, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA; FELS INST CANC RES, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	EADS, JC (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT BIOCHEM, 1300 MORRIS PK AVE, BRONX, NY 10461 USA.				NATIONAL CANCER INSTITUTE [P30CA012227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048623] Funding Source: NIH RePORTER; NCI NIH HHS [5-P30-CA12227] Funding Source: Medline; NIGMS NIH HHS [GM48623] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGOS P, 1983, J BIOL CHEM, V258, P6450; ARNOLD WJ, 1971, J BIOL CHEM, V246, P7398; BLABER M, 1994, J MOL BIOL, V235, P600, DOI 10.1006/jmbi.1994.1016; BOUWENSROMBOUTS AGM, 1993, HUM GENET, V91, P451, DOI 10.1007/BF00217770; BRENNAND J, 1983, J BIOL CHEM, V258, P9593; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1992, XPLOR VERSION 3 0 MA; DAVIDSON BL, 1988, GENE, V68, P85, DOI 10.1016/0378-1119(88)90601-4; DAVIDSON BL, 1989, J BIOL CHEM, V264, P520; DAVIDSON BL, 1988, GENE, V63, P331, DOI 10.1016/0378-1119(88)90536-7; DOVEY HF, 1984, MOL BIOCHEM PARASIT, V11, P157, DOI 10.1016/0166-6851(84)90062-8; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FUJIMORI S, 1991, ADV EXP MED BIOL, V309, P101; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GIACOMELLO A, 1978, J BIOL CHEM, V253, P6038; GOLDBERG AL, 1976, ANNU REV BIOCHEM, V45, P747, DOI 10.1146/annurev.bi.45.070176.003531; GORDON RB, 1991, ADV EXP MED BIOL, V309, P95; Gutteridge W, 1977, BIOCH PARASITIC PROT, P69, DOI 10.1007/978-1-349-15809-6_6; HORENSTEIN BA, 1991, BIOCHEMISTRY-US, V30, P10788, DOI 10.1021/bi00108a026; HORENSTEIN BA, 1993, BIOCHEMISTRY-US, V32, P7089, DOI 10.1021/bi00079a004; HOROVITZ A, 1992, J MOL BIOL, V227, P560, DOI 10.1016/0022-2836(92)90907-2; HOVEJENSEN B, 1986, J BIOL CHEM, V261, P6765; HOWARD AJ, 1986, GUIDE DATA REDUCTION; JOHNSON GG, 1979, SCIENCE, V203, P174, DOI 10.1126/science.569362; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRENITSKY TA, 1969, J BIOL CHEM, V244, P1263; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; MAIN P, 1993, SQUASH SUITE PROGRAM; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; MUSICK WDL, 1981, CRC CR REV BIOCH MOL, V11, P1, DOI 10.3109/10409238109108698; NICHOLLS A, 1993, GRASP; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SAENGER W, 1984, PRINCIPLES NUCLEIC A, P72; SCAPIN G, 1994, BIOCHEMISTRY-US, V33, P1287, DOI 10.1021/bi00172a001; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; STOUT JT, 1989, METABOLIC BASIS INHE, P1007; STRAUSS M, 1978, EUR J BIOCHEM, V90, P89, DOI 10.1111/j.1432-1033.1978.tb12578.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VELLIEUX FMD, 1993, DEMON PROGRAM SUITE; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; WILSON JM, 1983, NEW ENGL J MED, V309, P900; WILSON JM, 1982, J BIOL CHEM, V257, P978; WILSON JM, 1986, J CLIN INVEST, V77, P188, DOI 10.1172/JCI112275; YAMADA Y, 1991, ADV EXP MED BIOL, V309, P121	47	211	214	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 29	1994	78	2					325	334		10.1016/0092-8674(94)90301-8	http://dx.doi.org/10.1016/0092-8674(94)90301-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NZ242	8044844				2022-12-24	WOS:A1994NZ24200015
J	ARIAS, J; ALBERTS, AS; BRINDLE, P; CLARET, FX; SMEAL, T; KARIN, M; FERAMISCO, J; MONTMINY, M				ARIAS, J; ALBERTS, AS; BRINDLE, P; CLARET, FX; SMEAL, T; KARIN, M; FERAMISCO, J; MONTMINY, M			ACTIVATION OF CAMP AND MITOGEN RESPONSIVE GENES RELIES ON A COMMON NUCLEAR FACTOR	NATURE			English	Article							C-JUN; TRANSCRIPTIONAL ACTIVATION; PHOSPHORYLATION; CREB; FOS; PROMOTERS; COMPLEX; KINASE; DOMAIN; BINDS	A NUMBER of Signalling pathways stimulate transcription of target genes through nuclear factors whose activities are primarily regulated by phosphorylation. Cyclic AMP regulates the expression of numerous genes, for example, through the protein kinase-A (PKA)-mediated phosphorylation of transcription factor CREB at Ser133(1,2) Although phosphorylation may stimulate transcriptional activators by modulating their nuclear transport or DNA-binding affinity(3), CREB belongs to a class of proteins whose phosphorylation appears specifically to enhance their trans-activation potential(1,2,4). Recent work describing a phospho-CREB binding protein (CBP)(5) which interacts specifically with the CREB trans-activation domain prompted us to examine whether CBP is necessary for cAMP regulated transcription. We report here that microinjection of an anti-CBP antiserum into fibroblasts can inhibit transcription from a cAMP responsive promoter. Surprisingly, CBP also cooperates with upstream activators such as c-Jun, which are involved in mitogen responsive transcription(6). We propose that CBP is recruited to the promoter through interaction with certain phosphorylated factors, and that CBP may thus play a critical role in the transmission of inductive signals from cell surface receptor to the transcriptional apparatus.	UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, PROGRAM BIOMED SCI, LA JOLLA, CA 92093 USA; IMPERIAL CANC RES FUND, TRANSCRIPT LAB, LONDON WC2A 3PX, ENGLAND	University of California System; University of California San Diego; University of California System; University of California San Diego; Cancer Research UK	ARIAS, J (corresponding author), SALK INST BIOL STUDIES, CLAYTON FDN LABS PEPTIDE BIOL, 10010 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Claret, Francois X/R-2104-2016	Claret, Francois X/0000-0003-4629-6495; Brindle, Paul/0000-0001-7172-8478				ALBERTS AS, 1993, MOL CELL BIOL, V13, P2104, DOI 10.1128/MCB.13.4.2104; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MEINKOTH J, 1990, CIBA F SYMP, V150, P47; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	21	689	705	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 21	1994	370	6486					226	229		10.1038/370226a0	http://dx.doi.org/10.1038/370226a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX971	8028671				2022-12-24	WOS:A1994NX97100056
J	BOUVIER, M; WILEY, DC				BOUVIER, M; WILEY, DC			IMPORTANCE OF PEPTIDE AMINO AND CARBOXYL TERMINI TO THE STABILITY OF MHC CLASS-I MOLECULES	SCIENCE			English	Article							HISTOCOMPATIBILITY COMPLEX-MOLECULES; VIRUS MATRIX PROTEIN; VIRAL PEPTIDES; THERMAL-STABILITY; BINDING; HLA-A2; RECOGNITION; ANTIGENS; HLA-B27; IDENTIFICATION	An influenza virus matrix peptide in which either the charged amino or carboxyl terminus was substituted by methyl groups promoted folding of the class I human histocompatibility antigen (HLA-A2). A peptide modified at both termini did not promote stable folding. The thermal stability of HLA-A2 complexed with peptides that did not have either terminus was similar to 22 degrees C lower than that of the control peptide, whereas matrix peptide in which both anchor positions were substituted by alanines had its stability decreased by only 5.5 degrees C. Thus, the conserved major histocompatibility complex class I residues at both ends of the peptide binding site form energetically important sites for binding the termini of short peptides.	HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02138 USA	Harvard University; Harvard University; Howard Hughes Medical Institute								BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BEDNAREK MA, 1991, J IMMUNOL, V147, P4047; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CERUNDOLO V, 1991, EUR J IMMUNOL, V21, P2069, DOI 10.1002/eji.1830210915; CHEN Y, 1994, J IMMUNOL, V152, P2874; COLLINS EJ, UNPUB; ELLIOTT T, 1992, EUR J IMMUNOL, V22, P2085, DOI 10.1002/eji.1830220819; FAHNESTOCK ML, 1992, SCIENCE, V258, P1658, DOI 10.1126/science.1360705; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; Ghosh P., UNPUB; GUO H, UNPUB; GUO HC, 1993, P NATL ACAD SCI USA, V90, P8053, DOI 10.1073/pnas.90.17.8053; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HECHT MH, 1984, P NATL ACAD SCI-BIOL, V81, P5685, DOI 10.1073/pnas.81.18.5685; HECHT MH, 1983, P NATL ACAD SCI-BIOL, V80, P2676, DOI 10.1073/pnas.80.9.2676; Heinrikson R L, 1977, Methods Enzymol, V47, P175; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; LATRON F, 1992, SCIENCE, V257, P964, DOI 10.1126/science.1380181; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; MADDEN DR, 1992, CURR OPIN STRUC BIOL, V2, P300; MATSUMURA M, 1992, J BIOL CHEM, V267, P23589; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MORRISON J, 1992, EUR J IMMUNOL, V22, P903, DOI 10.1002/eji.1830220404; OLSEN AC, 1994, EUR J IMMUNOL, V24, P385, DOI 10.1002/eji.1830240218; OSAPAY G, 1991, TECHNIQUES PROTEIN C, V2, P221; PARKER KC, 1992, J IMMUNOL, V149, P3580; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3; SAITO Y, 1993, J BIOL CHEM, V268, P21309; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SAUMA SY, 1993, HUM IMMUNOL, V37, P252, DOI 10.1016/0198-8859(93)90508-X; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; STERN LJ, 1994, STRUCTURE, V2, P245, DOI 10.1016/S0969-2126(00)00026-5; UTZ U, 1992, J IMMUNOL, V149, P214; YOUNG ACM, 1994, CELL, V76, P39, DOI 10.1016/0092-8674(94)90171-6; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403	44	231	239	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 15	1994	265	5170					398	402		10.1126/science.8023162	http://dx.doi.org/10.1126/science.8023162			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023162				2022-12-24	WOS:A1994NW81600041
J	CHEN, Y; EBRIGHT, YW; EBRIGHT, RH				CHEN, Y; EBRIGHT, YW; EBRIGHT, RH			IDENTIFICATION OF THE TARGET OF A TRANSCRIPTION ACTIVATOR PROTEIN BY PROTEIN-PROTEIN PHOTO-CROSS-LINKING	SCIENCE			English	Article							COLI RNA-POLYMERASE; CAP-DNA COMPLEX; ESCHERICHIA-COLI; ALPHA-SUBUNIT; RECEPTOR PROTEIN; POSITIVE CONTROL; CAMP-CRP; PROMOTER; REGION; MUTATIONS	Here it is shown, with the use of protein-protein photocrosslinking, that the carboxyl-terminal region of the alpha subunit of RNA polymerase (RNAP) is in direct physical proximity to the activating region of the catabolite gene activator protein (CAP) in the ternary complex of the lac promoter, RNAP, and CAP, These results strongly support the proposal that transcription activation by CAP involves protein-protein contact between the carboxyl-terminal region of the alpha subunit and the activating region of CAP.	RUTGERS STATE UNIV, DEPT CHEM, NEW BRUNSWICK, NJ 08855 USA; RUTGERS STATE UNIV, WAKSMAN INST, NEW BRUNSWICK, NJ 08855 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick			Ebright, Richard/O-3321-2019	Ebright, Richard/0000-0001-8915-7140	NIGMS NIH HHS [GM41376] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041376] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL A, 1990, NUCLEIC ACIDS RES, V18, P7243, DOI 10.1093/nar/18.24.7243; EBRIGHT RH, 1993, MOL MICROBIOL, V8, P797, DOI 10.1111/j.1365-2958.1993.tb01626.x; ESCHENLAUER AC, 1991, J BACTERIOL, V173, P5024, DOI 10.1128/jb.173.16.5024-5029.1991; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HEYDUK T, 1993, NATURE, V364, P548, DOI 10.1038/364548a0; HU JC, 1985, MOL GEN GENET, V199, P7, DOI 10.1007/BF00327502; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KOLB A, 1993, NUCLEIC ACIDS RES, V21, P319, DOI 10.1093/nar/21.2.319; KUMAR A, 1994, J MOL BIOL, V235, P405, DOI 10.1006/jmbi.1994.1001; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LI M, 1994, SCIENCE, V263, P75, DOI 10.1126/science.8272867; Niu W., UNPUB; OVCHINNIKOV YA, 1977, FEBS LETT, V76, P108, DOI 10.1016/0014-5793(77)80131-2; RUSSO FD, 1992, J BIOL CHEM, V267, P14515; SARIS CJM, 1983, ANAL BIOCHEM, V132, P54, DOI 10.1016/0003-2697(83)90425-6; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; ZHANG XP, 1991, J BIOMOL STRUCT DYN, V9, P463, DOI 10.1080/07391102.1991.10507929; ZHANG XP, 1992, J BIOL CHEM, V267, P8136; ZHOU YH, 1993, P NATL ACAD SCI USA, V90, P6081, DOI 10.1073/pnas.90.13.6081; ZHOU YH, 1993, CELL, V73, P375, DOI 10.1016/0092-8674(93)90236-J; ZOU C, 1992, MOL MICROBIOL, V6, P2599, DOI 10.1111/j.1365-2958.1992.tb01437.x; [No title captured]	25	114	117	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 1	1994	265	5168					90	92		10.1126/science.8016656	http://dx.doi.org/10.1126/science.8016656			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV301	8016656				2022-12-24	WOS:A1994NV30100031
J	SIM, BKL; CHITNIS, CE; WASNIOWSKA, K; HADLEY, TJ; MILLER, LH				SIM, BKL; CHITNIS, CE; WASNIOWSKA, K; HADLEY, TJ; MILLER, LH			RECEPTOR AND LIGAND DOMAINS FOR INVASION OF ERYTHROCYTES BY PLASMODIUM-FALCIPARUM	SCIENCE			English	Article							BINDING ANTIGEN; GLYCOPHORIN-A; MALARIA PARASITES; AMINO-ACID; GLYCOPROTEIN; MEMBRANE; POLYMORPHISM; KNOWLESI; PROTEINS; SEQUENCE	A 175-kilodalton erythrocyte binding protein, EBA-175, of the parasite Plasmodium falciparum mediates the invasion of erythrocytes. The erythrocyte receptor for EBA-175 is dependent on sialic acid. The domain of EBA-175 that binds erythrocytes was identified as region II with the use of truncated portions of EBA-175 expressed on COS cells. Region II, which contains a cysteine-rich motif, and native EBA-175 bind specifically to glycophorin A, but not to glycophorin B, on the erythrocyte membrane. Erythrocyte recognition of EBA-175 requires both sialic acid and the peptide backbone of glycophorin A. The identification of both the receptor and ligand domains may suggest rational designs for receptor blockade and vaccines.	NIH,MALARIA RES LAB,BETHESDA,MD 20892; UNIV LOUISVILLE,DEPT MED,LOUISVILLE,KY 40292; POLISH ACAD SCI,INST IMMUNOL & EXPTL THERAPY,DEPT IMMUNOCHEM,PL-53114 WROCLAW,POLAND	National Institutes of Health (NIH) - USA; University of Louisville; Polish Academy of Sciences; Hirszfeld Institute of Immunology & Experimental Therapy of the Polish Academy of Sciences				Chitnis, Chetan/0000-0002-8773-9865; Wasniowska, Kazimiera/0000-0001-7629-2589				ADAMS JH, 1992, P NATL ACAD SCI USA, V89, P7085, DOI 10.1073/pnas.89.15.7085; ANSTEE DJ, 1981, SEMIN HEMATOL, V18, P13; BLUMENFELD OO, 1981, P NATL ACAD SCI-BIOL, V78, P747, DOI 10.1073/pnas.78.2.747; BLUMENFELD OO, 1978, P NATL ACAD SCI USA, V75, P2727, DOI 10.1073/pnas.75.6.2727; BREUER WV, 1983, BIOCHIM BIOPHYS ACTA, V755, P263, DOI 10.1016/0304-4165(83)90213-1; CAMUS D, 1985, SCIENCE, V230, P553, DOI 10.1126/science.3901257; CHITNIS CE, IN PRESS J EXP MED; COHEN GH, 1988, J VIROL, V62, P1932, DOI 10.1128/JVI.62.6.1932-1940.1988; DAHR W, 1980, H-S Z PHYSIOL CHEM, V361, P895, DOI 10.1515/bchm2.1980.361.1.895; FURTHMAYR H, 1978, NATURE, V271, P519, DOI 10.1038/271519a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HADLEY TJ, 1987, J CLIN INVEST, V80, P1190, DOI 10.1172/JCI113178; HAYNES JD, 1988, J EXP MED, V167, P1873, DOI 10.1084/jem.167.6.1873; KLOTZ FW, 1992, MOL BIOCHEM PARASIT, V51, P49, DOI 10.1016/0166-6851(92)90199-T; LISOWSKA E, 1987, MOL IMMUNOL, V24, P605, DOI 10.1016/0161-5890(87)90041-1; MILLER LH, 1977, J EXP MED, V146, P277, DOI 10.1084/jem.146.1.277; ORLANDI PA, 1992, J CELL BIOL, V116, P901, DOI 10.1083/jcb.116.4.901; PERKINS M, 1981, J CELL BIOL, V90, P563, DOI 10.1083/jcb.90.3.563; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SIM BKL, 1990, J CELL BIOL, V111, P1877, DOI 10.1083/jcb.111.5.1877; TOMITA M, 1978, BIOCHEMISTRY-US, V17, P4756, DOI 10.1021/bi00615a025; WARREN L, 1959, J BIOL CHEM, V234, P1971; Wasniowska K, 1985, GLYCOCONJUGATE J, V2, P163; 1989, SAS STAT USERS GUIDE, V2, P1135	24	451	476	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1941	1944		10.1126/science.8009226	http://dx.doi.org/10.1126/science.8009226			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	8009226				2022-12-24	WOS:A1994NT84700048
J	HOUGHTON, DJ; AITCHISON, FA; WILKINSON, L; WILSON, JA				HOUGHTON, DJ; AITCHISON, FA; WILKINSON, L; WILSON, JA			USE OF SINUS X-RAY-FILMS BY GENERAL-PRACTITIONERS	BRITISH MEDICAL JOURNAL			English	Article									ROYAL INFIRM,DEPT OTOLARYNGOL HEAD & NECK SURG,GLASGOW G31 2ER,SCOTLAND; ROYAL INFIRM,DEPT RADIOL,GLASGOW G31 2ER,SCOTLAND	Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh				wilson, janet/0000-0002-6416-5870				FASCENELLI FW, 1969, ARCH OTOLARYNGOL, V90, P98; HAVAS TE, 1988, ARCH OTOLARYNGOL, V114, P856; PFLEIDERER AG, 1986, CLIN OTOLARYNGOL, V11, P455, DOI 10.1111/j.1365-2273.1986.tb00151.x; WILSON PS, 1990, J LARYNGOL OTOL, V104, P694, DOI 10.1017/S0022215100113647; 1993, MAKING BEST USE DEPA	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 18	1994	308	6944					1608	1609		10.1136/bmj.308.6944.1608	http://dx.doi.org/10.1136/bmj.308.6944.1608			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NT528	8025428	Green Published			2022-12-24	WOS:A1994NT52800019
J	WOODALL, CJ; RIDING, MH; GRAHAM, DI; CLEMENTS, GB				WOODALL, CJ; RIDING, MH; GRAHAM, DI; CLEMENTS, GB			SEQUENCES SPECIFIC FOR ENTEROVIRUS DETECTED IN SPINAL-CORD FROM PATIENTS WITH MOTOR-NEURON DISEASE	BRITISH MEDICAL JOURNAL			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; SUPEROXIDE-DISMUTASE; TISSUE	Objective-To investigate the association enteroviruses with motor neurone disease, known as amyotrophic lateral sclerosis. Design-Analysis by enterovirus polymerase chain reaction of wax embedded material from spinal cords taken at necropsy from subjects with motor neurone disease and from age and sex matched controls. Setting-Specimens were collected in the west of Scotland and in London between 1982 and 1992. Results-Sequences specific for a non-poliovirus type enterovirus were detected in spinal cord tissue from subjects with motor neurone disease. Amplification of a 414 base RNA target sequence in the conserved enterovirus 5' untranslated region from wax embedded tissue sections was successful in tissue from eight of 11 cases of sporadic motor neurone disease, one of two cases of familial motor neurone disease, and the one case of poliomyelitis, but not in the six matched controls or one case of antecedent poliomyelitis. In addition, sequences were detected in spinal cords from one monkey infected with wild type poliovirus and one monkey infected with polio vaccine. Comparison of sequences from cases of motor neurone disease with sequences of corresponding regions of the 5' untranslated regions of known picornaviruses showed them to be tightly grouped within the enterovirus genus closely related to coxsackievirus type B but not to polioviruses. Sequences derived from different parts of the spinal cord of the same subjects were identical, but sequences differed between individual subjects. Conclusions-Conserved enteroviral sequences closely related to coxsackie B virus sequences were detectable in spinal cords from subjects with sporadic motor neurone disease and from one subject with possible familial motor neurone disease.	RUCHILL HOSP,REG VIRUS LAB,GLASGOW G20 9NB,SCOTLAND; UNIV EDINBURGH,ROYAL DICK SCH VET STUDIES,DEPT VET PATHOL,EDINBURGH EH9 1QH,MIDLOTHIAN,SCOTLAND; RUCHILL HOSP,SCOTTISH CTR INFECT & ENVIRONM HLTH,SCOTTISH SERUM BANK,GLASGOW G20 9NB,LANARK,SCOTLAND; SO GEN HOSP,INST NEUROL SCI,DEPT NEUROPATHOL,GLASGOW G51 4TF,SCOTLAND	University of Edinburgh; University of Glasgow								[Anonymous], 1990, LANCET, V336, P1033; BRAHIC M, 1985, ANN NEUROL, V18, P337, DOI 10.1002/ana.410180311; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; GOW JW, 1991, BRIT MED J, V302, P692, DOI 10.1136/bmj.302.6778.692; HEIMANPATTERSON TD, 1986, AMYOTROPHIC LATERAL, P85; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; MARTYN CN, 1988, LANCET, V1, P1319, DOI 10.1016/S0140-6736(88)92129-0; MINOR PD, 1990, TOPLEY WILSONS PRINC, V4, P324; NORBY E, 1990, VIROLOGY, P1028; OLDSTONE MBA, 1989, J INFECT DIS, V159, P384, DOI 10.1093/infdis/159.3.384; PALMENBERG AC, 1988, MOL ASPECTS PICORNAV, P211; POSKANZER DC, 1969, MOTOR NEURON DISEASE, P286; ROOS RP, 1980, ARCH NEUROL-CHICAGO, V37, P312, DOI 10.1001/archneur.1980.00500540090016; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; RUECKERT R R, 1990, P507; STANWAY G, 1990, J GEN VIROL, V71, P2483, DOI 10.1099/0022-1317-71-11-2483; VIOLA MV, 1980, ANN NEUROL, V5, P402; WEINER LP, 1980, NEUROLOGY, V30, P1319, DOI 10.1212/WNL.30.12.1319; WOODALL CJ, 1993, J CLIN PATHOL, V46, P276, DOI 10.1136/jcp.46.3.276; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153; ZILKHA K J, 1962, Proc R Soc Med, V55, P1028; 1991, PROGRAM MANUAL GCG P	23	73	75	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 11	1994	308	6943					1541	1543		10.1136/bmj.308.6943.1541	http://dx.doi.org/10.1136/bmj.308.6943.1541			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR110	8019310	Green Published			2022-12-24	WOS:A1994NR11000023
J	MOLBAK, K; GOTTSCHAU, A; AABY, P; HOJLYNG, N; INGHOLT, L; DASILVA, APJ				MOLBAK, K; GOTTSCHAU, A; AABY, P; HOJLYNG, N; INGHOLT, L; DASILVA, APJ			PROLONGED BREAST-FEEDING, DIARRHEAL DISEASE, AND SURVIVAL OF CHILDREN IN GUINEA-BISSAU	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PROTECTION; DIARRHEAL; COMMUNITY; STATE	Objective-To analyse the impact of breast feeding on diarrhoeal disease and survival in children above 1 year of age in Guinea-Bissau, west Africa. Design-A community study of an open cohort followed up weekly by interviews over 15 months. Data on feeding practices, anthropometry, and survival were recorded for three years. Setting-301 randomly selected houses in a semiurban area in the capital, Bissau. Subjects-849 children aged less than 3 years. Main outcome measures-Incidence and duration of diarrhoea, weight for age, and death of a child. Results-The incidence of diarrhoea was higher in weaned children than in partially breast fed children, both in 1 year olds (relative risk 1.41; 95% confidence interval 1.23 to 1.62) and in 2 year olds (1.67; 1.29 to 2.15). The mean duration of an episode of diarrhoea was 5.3 days in breast fed children compared with 6.3 days in weaned children (P= 0.001). Independent of the age of weaning, a similar increase was found in an analysis comparing, for each child, the rate and duration of diarrhoea one month before and one month after weaning. Children with low weight for age were breast fed longer than the better nourished children (P=0.02). Children aged 12-35 months who were not breast fed had a 3.5 times higher mortality (1.4 to 8.3) than breast fed children. Conclusions-The beneficial effects of breast feeding are not restricted to infancy. Though children who are partially breast fed after infancy may have a lower state of nutrition than the weaned ones, the benefit in terms of lower morbidity may be more important for child survival in places with a high morbidity from diarrhoea and with high mortality.	STATENS SERUM INST, DEPT STAT, DK-2300 COPENHAGEN, DENMARK; STATENS SERUM INST, DEPT INFECT IMMUNOL, PARASITOL LAB, DK-2300 COPENHAGEN, DENMARK; NATL PUBL HLTH LAB, BISSAU, GUINEA BISSAU	Statens Serum Institut; Statens Serum Institut	MOLBAK, K (corresponding author), STATENS SERUM INST, DANISH EPIDEMIOL SCI CTR, EPIDEMIOL RES UNIT, DK-2300 COPENHAGEN S, DENMARK.			Aaby, Peter/0000-0001-8331-1389; Molbak, Kare/0000-0002-3100-4990				BRAKOHIAPA LA, 1988, LANCET, V2, P416; BRIEND A, 1988, BRIT MED J, V296, P879, DOI 10.1136/bmj.296.6626.879; BROWN KH, 1989, PEDIATRICS, V83, P31; CLEMENS JD, 1986, AM J EPIDEMIOL, V123, P710, DOI 10.1093/oxfordjournals.aje.a114291; DETTWYLER KA, 1987, SOC SCI MED, V24, P633, DOI 10.1016/0277-9536(87)90306-6; Diarrhoea Kirkwood B., 1991, DIS MORTALITY SUBSAH, P134; FEACHEM RG, 1984, B WORLD HEALTH ORGAN, V62, P271; GOLDMAN AS, 1983, ACTA PAEDIATR SCAND, V72, P133, DOI 10.1111/j.1651-2227.1983.tb09679.x; HABICHT JP, 1986, AM J EPIDEMIOL, V123, P279, DOI 10.1093/oxfordjournals.aje.a114236; HUTTLY SRA, 1987, T ROY SOC TROP MED H, V81, P865, DOI 10.1016/0035-9203(87)90055-1; Jelliffe D. B., 1978, HUMAN MILK MODERN WO; KLEINBAUM DG, 1988, APPL REGRESSION ANAL, P497; Mata L J, 1976, Ciba Found Symp, P311; MICHAELSEN KF, 1988, LANCET, V2, P788; MOLBAK K, 1992, T ROY SOC TROP MED H, V86, P216, DOI 10.1016/0035-9203(92)90580-6; MOLBAK K, 1990, PEDIATR INFECT DIS J, V9, P566, DOI 10.1097/00006454-199008000-00008; TANGERMANN RH, 1988, LANCET, V2, P1016, DOI 10.1016/S0140-6736(88)90761-1; VICTORA CG, 1984, AM J CLIN NUTR, V39, P307, DOI 10.1093/ajcn/39.2.307; VICTORA CG, 1987, LANCET, V2, P319; Wyatt R G, 1972, Arch Latinoam Nutr, V22, P629	20	95	99	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 28	1994	308	6941					1403	1406		10.1136/bmj.308.6941.1403	http://dx.doi.org/10.1136/bmj.308.6941.1403			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP420	8019249	Green Published			2022-12-24	WOS:A1994NP42000014
J	LEY, C; LE, C; OLSHEN, EM; REINGOLD, AL				LEY, C; LE, C; OLSHEN, EM; REINGOLD, AL			THE USE OF SEROLOGIC TESTS FOR LYME-DISEASE IN A PREPAID HEALTH PLAN IN CALIFORNIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LINKED IMMUNOSORBENT-ASSAY; BORRELIA-BURGDORFERI; TICK BITES; ANTIBODY; LABORATORIES; POPULATION	Objective.-To determine the reason(s) why serologic tests for Lyme disease are performed, who initiates the test requests, and how the test results are used in a clinical setting. Design.-Retrospective cohort. Setting.-Prepaid health plan in northern California. Patients.-Consecutive sample of 117 patients for whom at least one serologic test for Lyme disease was performed during a 3-month period. Main Outcome Measures.-Reason for ordering and result of the serologic test, differential diagnoses, and treatment. Results.-One of 117 patients had antibodies to Borrelia burgdorferi. Fifty-six percent of test requests were initiated by the physician and 35% by the patient. Of 66 tests ordered by the physician, 20% were performed because of suspected early Lyme disease, 6% as follow-up of a tick bite, 2% to confirm a prior history of Lyme disease, 14% as a workup for arthritis, and 60% as one of a battery of laboratory tests for vague symptoms. Of 41 tests initiated by the patient, 51% were performed because of a history of a tick bite. The reasons for ordering 10 tests were undetermined. Conclusion.-Only 19% of all serologic tests for Lyme disease were performed because the physician suspected Lyme disease in the patient. Particularly in light of the low probability of contracting Lyme disease in California, it appears that this serologic test is being overused. Indiscriminate testing increases health care costs and does not appear to affect treatment decisions. Education is needed regarding the limitations of this serologic test.	KAISER PERMANENTE MED GRP,SANTA ROSA,CA	Kaiser Permanente; Permanente Medical Groups	LEY, C (corresponding author), UNIV CALIF BERKELEY,SCH PUBL HLTH,EPIDEMIOL PROGRAM,140 WARREN HALL,BERKELEY,CA 94720, USA.				PHS HHS [U50/CCU906612-02] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAKKEN LL, 1992, JAMA-J AM MED ASSOC, V268, P891, DOI 10.1001/jama.268.7.891; BERGER BW, 1992, J CLIN MICROBIOL, V30, P359, DOI 10.1128/JCM.30.2.359-361.1992; BURDGE DR, 1993, CLIN INFECT DIS, V16, P558, DOI 10.1093/clind/16.4.558; BURGDORFER W, 1985, AM J TROP MED HYG, V34, P925, DOI 10.4269/ajtmh.1985.34.925; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; FAHRER H, 1991, J INFECT DIS, V163, P305, DOI 10.1093/infdis/163.2.305; HANRAHAN JP, 1984, J INFECT DIS, V150, P489, DOI 10.1093/infdis/150.4.489; HEDBERG CW, 1987, J INFECT DIS, V155, P1325, DOI 10.1093/infdis/155.6.1325; LANE RS, 1990, J CLIN MICROBIOL, V28, P1774, DOI 10.1128/JCM.28.8.1774-1779.1990; MAGID D, 1992, NEW ENGL J MED, V327, P534, DOI 10.1056/NEJM199208203270806; MAGNARELLI LA, 1984, J CLIN MICROBIOL, V20, P181, DOI 10.1128/JCM.20.2.181-184.1984; PIESMAN J, 1991, J INFECT DIS, V163, P895, DOI 10.1093/infdis/163.4.895; PIESMAN J, 1993, J INFECT DIS, V167, P1082, DOI 10.1093/infdis/167.5.1082; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; RUSSELL H, 1984, J INFECT DIS, V149, P465, DOI 10.1093/infdis/149.3.465; SCHWARTZ BS, 1989, JAMA-J AM MED ASSOC, V262, P3431, DOI 10.1001/jama.262.24.3431; SHAPIRO ED, 1992, NEW ENGL J MED, V327, P1769, DOI 10.1056/NEJM199212173272501; SHRESTHA M, 1985, AM J MED, V78, P235, DOI 10.1016/0002-9343(85)90432-2; STEERE AC, 1993, JAMA-J AM MED ASSOC, V269, P1812, DOI 10.1001/jama.269.14.1812; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1986, J INFECT DIS, V154, P295, DOI 10.1093/infdis/154.2.295; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; 1991, WIS EPIDEMIOL B, V13; 1990, MMWR MORB MORTAL WKL, V39, P19; 1991, CALIFORNIA MORRB	27	31	31	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	1994	271	6					460	463		10.1001/jama.271.6.460	http://dx.doi.org/10.1001/jama.271.6.460			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU491	8080498				2022-12-24	WOS:A1994MU49100034
J	SCHICK, BP				SCHICK, BP			CLINICAL IMPLICATIONS OF BASIC RESEARCH - HOPE FOR TREATMENT OF THROMBOCYTOPENIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							MPL				SCHICK, BP (corresponding author), THOMAS JEFFERSON UNIV,PHILADELPHIA,PA 19107, USA.							DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; GEWIRTZ AM, 1994, HEMOSTASIS THROMBOSI, P353; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; METHIA N, 1993, BLOOD, V82, P1395; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WENDLING F, 1994, NATURE, V369, P571, DOI 10.1038/369571a0	8	12	13	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 29	1994	331	13					875	876		10.1056/NEJM199409293311312	http://dx.doi.org/10.1056/NEJM199409293311312			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH530	8078536				2022-12-24	WOS:A1994PH53000012
J	ZHOU, JS; HOFFMAN, BM				ZHOU, JS; HOFFMAN, BM			STERN-VOLMER IN REVERSE - 2/1 STOICHIOMETRY OF THE CYTOCHROME-C CYTOCHROME-C PEROXIDASE ELECTRON-TRANSFER COMPLEX	SCIENCE			English	Article							METALLOPROTEIN COMPLEX; IONIC-STRENGTH; BINDING; RECOGNITION; PLASTOCYANIN; EQUILIBRIUM; ASSOCIATION; MOLECULES; DIFFUSION	A reverse protocol for measurements of molecular binding and reactivity by excited-state quenching has been developed in which the quencher, held at a fixed concentration, is titrated by a photoexcitable probe molecule whose decay is monitored. The binding stoichiometries, affinities, and reactivities of the electron-transfer complexes between cytochrome c (Cc) and cytochrome c peroxidase (CcP) were determined over a wide range of ionic strengths (4.5 to 118 millimolar) by the study of photoinduced electron-transfer quenching of the triplet excited state of zinc-substituted Cc (ZnCc) by Fe(3+)CcP. The 2:1 stoichiometry seen for the binding of Cc to CcP at low ionic strength persists at the physiologically relevant ionic strengths and likely has functional significance. Analysis of the stoichiometric binding and rate constants confirms that one surface domain of CcP binds Cc with a high affinity but with poor electron-transfer quenching of triplet-state ZnCc, whereas a second binds weakly but with a high rate of electron-transfer quenching.	NORTHWESTERN UNIV, DEPT CHEM, EVANSTON, IL 60208 USA	Northwestern University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL013531, R37HL013531] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL13531] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERATAN DN, 1992, SCIENCE, V258, P1740, DOI 10.1126/science.1334572; CLARKE MJ, 1991, STRUCT BONDING BERLI, V75, P1; CONKLIN KT, 1986, INORG CHEM, V25, P4804, DOI 10.1021/ic00247a003; EISEN HN, 1971, METHODS IMMUNOLOGY I, V3, P395; ERMAN JE, 1980, J BIOL CHEM, V255, P6224; GUPTA RK, 1973, BIOCHIM BIOPHYS ACTA, V292, P502, DOI 10.1016/0005-2728(73)90056-X; HAZZARD JT, 1988, BIOCHEM BIOPH RES CO, V151, P429, DOI 10.1016/0006-291X(88)90611-0; KANG CH, 1977, J BIOL CHEM, V252, P919; Klotz I.M, 1986, INTRO BIOMOLECULAR E; KLOTZ IM, 1979, ARCH BIOCHEM BIOPHYS, V193, P314, DOI 10.1016/0003-9861(79)90036-5; KLOTZ IM, 1985, Q REV BIOPHYS, V18, P227, DOI 10.1017/S0033583500000354; LAURENCE DJR, 1952, BIOCHEM J, V51, P168, DOI 10.1042/bj0510168; LEONARD JJ, 1974, BIOCHEMISTRY-US, V13, P1465, DOI 10.1021/bi00704a023; MCLENDON G, 1993, J AM CHEM SOC, V115, P3665, DOI 10.1021/ja00062a035; MCLENDON G, 1991, STRUCT BOND, V75, P159; MOCHAN E, 1970, BIOCHIM BIOPHYS ACTA, V216, P80, DOI 10.1016/0005-2728(70)90161-1; MOCHAN E, 1971, BIOCHEM J, V121, P69, DOI 10.1042/bj1210069; MOORE GR, 1980, J INORG BIOCHEM, V12, P1, DOI 10.1016/S0162-0134(00)80039-2; NICHOLLS P, 1972, BIOCHIM BIOPHYS ACTA, V279, P306, DOI 10.1016/0304-4165(72)90147-X; NOCEK JM, 1991, J AM CHEM SOC, V113, P6822, DOI 10.1021/ja00018a017; NORTHRUP SH, 1988, SCIENCE, V241, P67, DOI 10.1126/science.2838904; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; SIGEL H, 1992, MET IONS BIOL SYST, V27, P1; STEMP EDA, 1993, BIOCHEMISTRY-US, V32, P10848, DOI 10.1021/bi00091a041; Stern O, 1919, PHYS Z, V20, P183; VANDERKOOI JM, 1976, EUR J BIOCHEM, V64, P381, DOI 10.1111/j.1432-1033.1976.tb10312.x; VELICK SF, 1961, LIGHT LIFE, P108; WALLIN SA, 1991, J AM CHEM SOC, V113, P1842, DOI 10.1021/ja00005a065; WEBER G, 1965, PROTEINS, V3, P445; YI Q, 1994, J AM CHEM SOC, V116, P1981, DOI 10.1021/ja00084a043; YONETANI T, 1966, J BIOL CHEM, V241, P700; ZHANG QP, 1990, J PHYS CHEM-US, V94, P8628, DOI 10.1021/j100387a003; ZHOU JS, 1993, J AM CHEM SOC, V115, P10796, DOI 10.1021/ja00076a042; ZHOU JS, 1992, J AM CHEM SOC, V114, P3562, DOI 10.1021/ja00035a065; ZHOU JS, 1993, J AM CHEM SOC, V115, P11008, DOI 10.1021/ja00076a076	35	91	91	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 16	1994	265	5179					1693	1696		10.1126/science.8085152	http://dx.doi.org/10.1126/science.8085152			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG284	8085152				2022-12-24	WOS:A1994PG28400026
J	SCOTT, EW; SIMON, MC; ANASTASI, J; SINGH, H				SCOTT, EW; SIMON, MC; ANASTASI, J; SINGH, H			REQUIREMENT OF TRANSCRIPTION FACTOR PU.1 IN THE DEVELOPMENT OF MULTIPLE HEMATOPOIETIC LINEAGES	SCIENCE			English	Article							MURINE FETAL LIVER; BONE-MARROW; REGULATES EXPRESSION; PUTATIVE ONCOGENE; LYMPHOCYTES-B; ETS ONCOGENE; CHAIN GENE; STEM-CELLS; PRO-B; STAGE	The transcription factor PU.1 is a hematopoietic-specific member of the ets family. Mice carrying a mutation in the PU.1 locus were generated by gene targeting. Homozygous mutant embryos died at a late gestational stage. Mutant embryos produced normal numbers of megakaryocytes and erythroid progenitors, but some showed an impairment of erythroblast maturation. An invariant consequence of the mutation was a multilineage defect in the generation of progenitors for B and T lymphocytes, monocytes, and granulocytes. Thus, the developmental programs of lymphoid and myeloid lineages require a common genetic function likely acting at the level of a multipotential progenitor.	UNIV CHICAGO, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MED, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PATHOL, CHICAGO, IL 60637 USA	University of Chicago; Howard Hughes Medical Institute; University of Chicago; University of Chicago; University of Chicago			Simon, Celeste/AAG-3941-2021		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008933] Funding Source: NIH RePORTER; NIAID NIH HHS [F32 AI08933] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel F, 1989, MOL REPROD DEV, V1, P146; BARON MH, 1986, CELL, V46, P591, DOI 10.1016/0092-8674(86)90885-8; Coligan J.E., 1993, CURRENT PROTOCOLS IM; COLLINS MD, 1989, AM J PHYSIOL, V257, pR542, DOI 10.1152/ajpregu.1989.257.3.R542; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; FELDHAUS AL, 1992, MOL CELL BIOL, V12, P1126, DOI 10.1128/MCB.12.3.1126; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HIRAYAMA F, 1992, P NATL ACAD SCI USA, V89, P5907, DOI 10.1073/pnas.89.13.5907; HROMAS R, 1993, BLOOD, V82, P2998; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LENNON GG, 1990, J IMMUNOL, V144, P1983; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MILLER CL, 1991, MOL CELL BIOL, V11, P4885, DOI 10.1128/MCB.11.10.4885; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PALACIOS R, 1992, MOL CELL BIOL, V12, P518, DOI 10.1128/MCB.12.2.518; PALACIOS R, 1993, BLOOD, V81, P1222; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; Robertson E. J., 1987, TERATOCARCINOMAS EMB; ROTHENBERG EV, 1992, ADV IMMUNOL, V51, P85, DOI 10.1016/S0065-2776(08)60487-3; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SCOTT EW, 1993, MOL CELL BIOL, V13, P543, DOI 10.1128/MCB.13.1.543; SCOTT EW, UNPUB; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; TRINCHIERI G, 1990, NEOPLASTIC HEMATOPAT; Williams WJ., 1990, HEMATOLOGY HEMATOLOGY, V4th; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	40	1260	1275	2	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 9	1994	265	5178					1573	1577		10.1126/science.8079170	http://dx.doi.org/10.1126/science.8079170			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF336	8079170				2022-12-24	WOS:A1994PF33600033
J	BUSH, AI; PETTINGELL, WH; MULTHAUP, G; PARADIS, MD; VONSATTEL, JP; GUSELLA, JF; BEYREUTHER, K; MASTERS, CL; TANZI, RE				BUSH, AI; PETTINGELL, WH; MULTHAUP, G; PARADIS, MD; VONSATTEL, JP; GUSELLA, JF; BEYREUTHER, K; MASTERS, CL; TANZI, RE			RAPID INDUCTION OF ALZHEIMER A-BETA AMYLOID FORMATION BY ZINC	SCIENCE			English	Article							PRECURSOR PROTEIN GENE; CEREBRAL-HEMORRHAGE; DOWNS-SYNDROME; DISEASE; MUTATION; PEPTIDE; BRAIN; AGGREGATION; DEMENTIA; HIPPOCAMPUS	A beta(1-40), a major component of Alzheimer's disease cerebral amyloid, is present in the cerebrospinal fluid and remains relatively soluble at high concentrations (less than or equal to 3.7 mM). Thus, physiological factors which induce A beta amyloid formation could provide clues to the pathogenesis of the disease. It has been shown that human A beta specifically and saturably binds zinc. Here, concentrations of zinc above 300 nM rapidly destabilized human A beta(1-40) solutions, inducing tinctorial amyloid formation. However, rat A beta(1-40) binds zinc less avidly and is immune to these effects, perhaps explaining the scarcity with which these animals form cerebral A beta amyloid. These data suggest a role for cerebral zinc metabolism in the neuropathogenesis of Alzheimer's disease.	MASSACHUSETTS GEN HOSP, GENET & AGING LAB, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT NEUROL, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT PSYCHIAT, BOSTON, MA 02114 USA; UNIV HEIDELBERG, ZENTRUM MOLEK BIOL HEIDELBERG, HEIDELBERG, GERMANY; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02114 USA; UNIV MELBOURNE, DEPT PATHOL, PARKVILLE, VIC 3052, AUSTRALIA; MENTAL HLTH RES INST VICTORIA, PARKVILLE, VIC, AUSTRALIA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Ruprecht Karls University Heidelberg; Harvard University; Harvard Medical School; University of Melbourne			Bush, Ashley/Y-2457-2019; Tanzi, Rudolph/AAE-9622-2019; Bush, Ashley I/A-1186-2007	Bush, Ashley/0000-0001-8259-9069; Tanzi, Rudolph/0000-0002-7032-1454; Bush, Ashley I/0000-0001-8259-9069; Paradis, Marc d./0000-0003-2387-3157	NIA NIH HHS [R01 AG11899-01] Funding Source: Medline; NINDS NIH HHS [R01 NS30428-03] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030428] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011899] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; BACKSTROM JR, 1992, J NEUROCHEM, V58, P983, DOI 10.1111/j.1471-4159.1992.tb09352.x; BURNET FM, 1981, LANCET, V1, P186; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; BUSH AI, 1994, J BIOL CHEM, V269, P12152; BUSH AI, 1992, THESIS U MELBOURNE; BUSH AW, UNPUB; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; CONSTANTINIDIS J, 1990, Encephale, V16, P231; CORRIGAN FM, 1993, BIOMETALS, V6, P149; DAVIES IJT, 1968, J CLIN PATHOL, V21, P359, DOI 10.1136/jcp.21.3.359; FRANCESCHI C, 1988, J MENT DEFIC RES, V32, P169; FREDERICKSON CJ, 1983, BRAIN RES, V273, P335, DOI 10.1016/0006-8993(83)90858-2; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HAASS C, COMMUNICATION; HENDRIKS L, 1992, NAT GENET, V1, P218, DOI 10.1038/ng0692-218; HERSHEY CO, 1983, NEUROLOGY, V33, P1350, DOI 10.1212/WNL.33.10.1350; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; HOWELL GA, 1984, NATURE, V308, P736, DOI 10.1038/308736a0; HYMAN BT, 1986, ANN NEUROL, V20, P472, DOI 10.1002/ana.410200406; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JOHNSTONE EM, 1991, MOL BRAIN RES, V10, P299, DOI 10.1016/0169-328X(91)90088-F; LEVY E, 1990, SCIENCE, V248, P1124, DOI 10.1126/science.2111584; MANTYH PW, 1993, J NEUROCHEM, V61, P1171, DOI 10.1111/j.1471-4159.1993.tb03639.x; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHIVERS BD, 1988, EMBO J, V7, P1365, DOI 10.1002/j.1460-2075.1988.tb02952.x; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; STEWART GR, 1984, BRAIN RES, V290, P43, DOI 10.1016/0006-8993(84)90734-0; TOMSKI SJ, 1992, ARCH BIOCHEM BIOPHYS, V294, P630, DOI 10.1016/0003-9861(92)90735-F; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2; VAUGHAN DW, 1981, J NEUROPATH EXP NEUR, V40, P472, DOI 10.1097/00005072-198107000-00009; WENSTRUP D, 1990, BRAIN RES, V533, P125, DOI 10.1016/0006-8993(90)91804-P	39	1375	1415	1	134	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 2	1994	265	5177					1464	1467		10.1126/science.8073293	http://dx.doi.org/10.1126/science.8073293			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	8073293				2022-12-24	WOS:A1994PE73300054
J	PANTALEO, G; DEMAREST, JF; SOUDEYNS, H; GRAZIOSI, C; DENIS, F; ADELSBERGER, JW; BORROW, P; SAAG, MS; SHAW, GM; SEKALY, RP; FAUCI, AS				PANTALEO, G; DEMAREST, JF; SOUDEYNS, H; GRAZIOSI, C; DENIS, F; ADELSBERGER, JW; BORROW, P; SAAG, MS; SHAW, GM; SEKALY, RP; FAUCI, AS			MAJOR EXPANSION OF CD8+ T-CELLS WITH A PREDOMINANT V-BETA USAGE DURING THE PRIMARY IMMUNE-RESPONSE TO HIV	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; VARIABLE REGION GENES; CD8+ LYMPHOCYTES-T; VACCINIA VIRUS; EXPRESSION VECTOR; INFECTION; CHAIN; RECOGNITION; SEQUENCES; DIVERSITY	A SIGNIFICANT proportion (up to 70%) of individuals experience an acute clinical syndrome of varying severity associated with primary infection with the human immunodeficiency virus (HIV)(1-4). We report here studies on six individuals who showed an acute HIV syndrome which generally resolved within four weeks, concomitant with a dramatic downregulation of viraemia(2-5). To characterize the T-cell-mediated primary immune response to HIV, we used combined semiquantitative polymerase chain reaction assay and cytofluorometry to analyse the T-cell antigen receptor repertoire in sequential peripheral blood mononuclear cells from the patients. We found major oligoclonal expansions in a restricted set of variable-domain beta-chain (V beta) families. Cells expressing the expanded V beta s predominantly expressed the CD8 T-cell differentiation antigen and mediated HIV-specific cytotoxicity. Major oligoclonal expansions of these CD8(+) T lymphocytes may represent an important component of the primary immune response to viral infections and may help to clarify both the immunopathogenic and the protective mechanisms of HIV infection.	INST RECH CLIN MONTREAL, IMMUNOL LAB, MONTREAL H2W 1R7, PQ, CANADA; PROGRAM RESOURCES INC DYNCORP, FREDERICK, MD 21702 USA; UNIV ALABAMA, DEPT MED, BIRMINGHAM, AL 35294 USA; Scripps Res Inst, DEPT NEUROPHARMACOL, DIV VIROL, LA JOLLA, CA 92037 USA; UNIV MONTREAL, DEPT MICROBIOL & IMMUNOL, MONTREAL H3C 3J7, PQ, CANADA; MCGILL UNIV, DEPT MICROBIOL & IMMUNOL, MONTREAL H3A 2B4, PQ, CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Alabama System; University of Alabama Birmingham; Scripps Research Institute; Universite de Montreal; McGill University	PANTALEO, G (corresponding author), NIAID, IMMUNOREGULAT LAB, BETHESDA, MD 20892 USA.		Pantaleo, Giuseppe/K-6163-2016; graziosi, cecilia/M-1882-2019	Borrow, Persephone/0000-0002-3877-9780				BORROW P, IN PRESS J VIROL; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; EARL PL, 1990, J VIROL, V64, P2448, DOI 10.1128/JVI.64.5.2448-2451.1990; FERRADINI L, 1991, EUR J IMMUNOL, V21, P935, DOI 10.1002/eji.1830210412; GRAZIOSI C, 1993, P NATL ACAD SCI USA, V90, P6405, DOI 10.1073/pnas.90.14.6405; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; KALAMS SA, 1994, J EXP MED, V179, P1261, DOI 10.1084/jem.179.4.1261; KARACOSTAS V, 1989, P NATL ACAD SCI USA, V86, P8964, DOI 10.1073/pnas.86.22.8964; KIMURA N, 1987, EUR J IMMUNOL, V17, P375, DOI 10.1002/eji.1830170312; LABRECQUE N, 1993, J EXP MED, V177, P1735, DOI 10.1084/jem.177.6.1735; MACDONALD HR, 1993, J EXP MED, V177, P1487, DOI 10.1084/jem.177.5.1487; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; PANTALEO G, 1990, P NATL ACAD SCI USA, V87, P4818, DOI 10.1073/pnas.87.12.4818; PANTALEO G, 1990, J IMMUNOL, V144, P1696; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; REBAI N, 1994, P NATL ACAD SCI USA, V91, P1529, DOI 10.1073/pnas.91.4.1529; SMITH TJ, 1993, BLOOD, V81, P1521; TILLINGHAST JP, 1986, SCIENCE, V233, P879, DOI 10.1126/science.3755549; TOYONAGA B, 1985, P NATL ACAD SCI USA, V82, P8624, DOI 10.1073/pnas.82.24.8624; WALKER BD, 1989, P NATL ACAD SCI USA, V86, P9514, DOI 10.1073/pnas.86.23.9514	26	566	584	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 11	1994	370	6489					463	467		10.1038/370463a0	http://dx.doi.org/10.1038/370463a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	8047166	Bronze			2022-12-24	WOS:A1994PB40700057
J	ZOLOPA, AR; HAHN, JA; GORTER, R; MIRANDA, J; WLODARCZYK, D; PETERSON, J; PILOTE, L; MOSS, AR				ZOLOPA, AR; HAHN, JA; GORTER, R; MIRANDA, J; WLODARCZYK, D; PETERSON, J; PILOTE, L; MOSS, AR			HIV AND TUBERCULOSIS INFECTION IN SAN-FRANCISCOS HOMELESS ADULTS - PREVALENCE AND RISK-FACTORS IN A REPRESENTATIVE SAMPLE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INTRAVENOUS-DRUG-USERS; NEW-YORK-CITY; UNITED-STATES; SHELTER; WOMEN; MEN; HEALTH; EPIDEMIC; OUTBREAK	Objective.-To determine the prevalence and risk factors for human immunodeficiency virus (HIV) and tuberculosis (TB) infection and investigate the relationship between these two infections in homeless adults. Design.-Cross-sectional study. Setting.-Inner-city shelters and free meal programs. Participants.-A representative sample of 1226 adults (greater than or equal to 18 years) were enrolled from community sites. Main Outcome Measures.-Serum HIV-1 antibody status and tuberculin skin test reactivity. Results.-Human immunodeficiency virus seroprevalence was 8.5% (95% confidence interval [Cl], 7.0% to 10.1%) and the prevalence of TB infection was 32% (95% Cl, 30% to 37%). Nineteen percent of the HIV-seropositive subjects had positive tuberculin skin tests. Independent risk factors for HIV infection included younger age, black race, male homosexual contact, injection drug use, use of injection drugs in shooting galleries, and selling sex. Tuberculosis infection was associated with the duration of homelessness and living in crowded shelters or single-room-occupancy hotels. Injection drug use, a risk factor for HIV, was also a risk factor for TB, with a particularly strong association in women. No evidence of an association between TB and HIV infection was found, even after accounting for anergy. Conclusions.-The homeless population in the United States should be considered a group at high risk for HIV infection and TB. Given the constellation of risk factors present, the high prevalence of infection, and lack of access to medical services, we anticipate that these communicable diseases in this population will represent a growing public health problem.	UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA 94143; SAN FRANCISCO GEN HOSP,DIV EPIDEMIOL & MED,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143; SAN FRANCISCO DEPT PUBL HLTH,SAN FRANCISCO,CA	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; San Francisco Department of Public Health			Hahn, Judith/J-5813-2014	Hahn, Judith/0000-0002-2697-8264; Pilote, Louise/0000-0002-6159-0628	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004363] Funding Source: NIH RePORTER; NIDA NIH HHS [R01-DA04363-07] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ALLEN DM, 1992, 8TH INT C AIDS AMST, V2, pC297; ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; BARRY MA, 1986, PUBLIC HEALTH REP, V101, P487; BREAKEY WR, 1989, JAMA-J AM MED ASSOC, V262, P1352, DOI 10.1001/jama.262.10.1352; BROWN SM, 1974, ARCH INTERN MED, V134, P1001, DOI 10.1001/archinte.134.6.1001; BRUNDNEY K, 1991, AM REV RESPIR DIS, V144, P745; BURNAM MA, 1988, EVALUATION REV, V12, P117, DOI 10.1177/0193841X8801200202; CELENTANO DD, 1991, AM J PUBLIC HEALTH, V81, P1291, DOI 10.2105/AJPH.81.10.1291; CHAISSON RE, 1989, JAMA-J AM MED ASSOC, V261, P561, DOI 10.1001/jama.261.4.561; CHIASSON MA, 1991, AIDS, V5, P1121, DOI 10.1097/00002030-199109000-00011; CHU SY, 1990, JAMA-J AM MED ASSOC, V264, P225, DOI 10.1001/jama.264.2.225; COATES T, 1990, AIDS 2 DECADE, P38; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; ELBASSEL N, 1991, PUBLIC HEALTH REP, V106, P586; ELLERBROCK TV, 1992, NEW ENGL J MED, V327, P1704, DOI 10.1056/NEJM199212103272402; ENGLE A, 1977, US DHEW HRA771649 PU; ERICKSON JR, 1992, 8TH INT C AIDS AMST, V2, pC297; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; GELBERG L, 1989, JAMA-J AM MED ASSOC, V262, P1973, DOI 10.1001/jama.262.14.1973; HOLMES KK, 1990, AM J PUBLIC HEALTH, V80, P858, DOI 10.2105/AJPH.80.7.858; KINSEY AC, 1948, SEXUAL BEHAVIOR HUMA, P638; Knopf SA, 1914, J AMER MED ASSOC, V63, P1720; MARKOWITZ N, 1993, ANN INTERN MED, V119, P185, DOI 10.7326/0003-4819-119-3-199308010-00002; MCADAM JM, 1990, CHEST, V97, P798, DOI 10.1378/chest.97.4.798; MCADAM JM, 1990, SAFETY NET HLTH SOCI, P234; MOSS AR, 1992, BRIT J ADDICT, V87, P467; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; NOLAN CM, 1991, AM REV RESPIR DIS, V143, P257, DOI 10.1164/ajrccm/143.2.257; PABLOSMENDEZ A, 1990, NEW YORK STATE J MED, V90, P351; REICHMAN LB, 1978, AM REV RESPIR DIS, V117, P705; REICHMAN LB, 1992, NEW ENGL J MED, V326, P703; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; SCHIEFFELBEIN CW, 1988, ARCH INTERN MED, V148, P1843, DOI 10.1001/archinte.148.8.1843; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SHLAY J, 1992, 8TH INT C AIDS AMST, V2, pC298; SLUTKIN G, 1986, AM REV RESPIR DIS, V134, P1048, DOI 10.1164/arrd.1986.134.5.1048; TERRIS M, 1948, AM J PUBLIC HEALTH, V88, P1061; TORRES RA, 1990, ARCH INTERN MED, V150, P2030, DOI 10.1001/archinte.150.10.2030; TUBARO E, 1983, J INFECT DIS, V148, P656, DOI 10.1093/infdis/148.4.656; WINKLEBY MA, 1992, AM J PUBLIC HEALTH, V82, P1394; 1979, TUBER LUNG DIS, V60, P191; 1991, MMWR-MORBID MORTAL W, V40, P859; 1991, MMWR-MORBID MORTAL W, V40, P869; 1985, MMWR-MORBID MORTAL W, V34, P429; 1993, HIV SEROPREVALENCE R, V4, P7; 1993, HIV SEROPREVALENCE R, V4, P6; 1991, MMWR-MORBID MORTAL W, V40, P865; 1989, MMWR-MORBID MORTAL W, V38, P236; 1992, MMWR-MORBID MORTAL W, V41, P1	49	200	203	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	1994	272	6					455	461		10.1001/jama.272.6.455	http://dx.doi.org/10.1001/jama.272.6.455			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PA278	8040981				2022-12-24	WOS:A1994PA27800027
J	ROSKIES, AL; OLEARY, DDM				ROSKIES, AL; OLEARY, DDM			CONTROL OF TOPOGRAPHIC RETINAL AXON BRANCHING BY INHIBITORY MEMBRANE-BOUND MOLECULES	SCIENCE			English	Article							RECEPTOR ANTAGONISTS DISRUPT; POSITION-SPECIFIC PROPERTIES; TECTAL CELL-MEMBRANES; RETINOTECTAL PROJECTION; VISUAL-SYSTEM; XENOPUS TADPOLES; NEURITE GROWTH; MAP FORMATION; INVITRO; GUIDANCE	Retinotopic map development in nonmammalian vertebrates appears to be controlled by molecules that guide or restrict retinal axons to correct locations in their targets. However, the retinotopic map in the superior colliculus (SC) of the rat is developed instead by a topographic bias in collateral branching and arborization. Temporal retinal axons extending across alternating membranes from the topographically correct rostral SC or the incorrect caudal SC of embryonic rats preferentially branch on rostral membranes. Branching preference is due to an inhibitory phosphatidylinositol-linked molecule in the caudal SC. Thus, position-encoding membrane-bound molecules may establish retinotopic maps in mammals by regulating axon branching, not by directing axon growth.	SALK INST BIOL STUDIES,MOLEC NEUROBIOL LAB,LA JOLLA,CA 92037	Salk Institute					NEI NIH HHS [NEI RO1 EY07025] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007025] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BAIER H, 1992, SCIENCE, V255, P472, DOI 10.1126/science.1734526; BANDTLOW C, 1990, J NEUROSCI, V10, P3837, DOI 10.1523/JNEUROSCI.10-12-03837.1990; BONHOEFFER F, 1984, TRENDS NEUROSCI, V7, P378, DOI 10.1016/S0166-2236(84)80060-0; BRONNERFRASER M, 1985, J CELL BIOL, V101, P610, DOI 10.1083/jcb.101.2.610; CLINE HT, 1989, NEURON, V3, P413, DOI 10.1016/0896-6273(89)90201-8; COLELLO RJ, IN PRESS J NEUROSCI; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; CORNEL E, 1992, NEURON, V9, P1001, DOI 10.1016/0896-6273(92)90061-H; COX EC, 1990, NEURON, V2, P31; DAVIES JA, 1990, NEURON, V4, P11, DOI 10.1016/0896-6273(90)90439-M; Fraser S E, 1992, Curr Opin Neurobiol, V2, P83, DOI 10.1016/0959-4388(92)90167-J; FUJISAWA H, 1984, DEV GROWTH DIFFER, V26, P545; FUJISAWA H, 1987, J COMP NEUROL, V260, P127, DOI 10.1002/cne.902600110; GIERER A, 1987, DEVELOPMENT, V101, P479; GODEMENT P, 1989, DEVELOPMENT, V106, P313; GODEMENT P, 1987, DEVELOPMENT, V101, P697; HARRIS WA, 1989, NATURE, V339, P218, DOI 10.1038/339218a0; HOLT CE, 1983, NATURE, V301, P150, DOI 10.1038/301150a0; HOLT CE, 1993, J NEUROBIOL, V24, P1400, DOI 10.1002/neu.480241011; HONIG MG, 1989, TRENDS NEUROSCI, V12, P333, DOI 10.1016/0166-2236(89)90040-4; JOHNSTON AR, 1991, DEVELOPMENT, V113, P409; KAPFHAMMER JP, 1987, J NEUROSCI, V7, P201; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MATSUI K A, 1989, Society for Neuroscience Abstracts, V15, P1212; Montague PR, 1991, CEREB CORTEX, V1, P199, DOI 10.1093/cercor/1.3.199; NAKAMURA H, 1989, J NEUROSCI, V9, P3776; OLEARY DDM, 1992, SEMIN NEUROSCI, V4, P365; OROURKE NA, 1990, NEURON, V5, P159, DOI 10.1016/0896-6273(90)90306-Z; OROURKE NA, 1986, DEV BIOL, V114, P265, DOI 10.1016/0012-1606(86)90191-0; Roskies A. L., 1992, Society for Neuroscience Abstracts, V18, P222; SAKAGUCHI DS, 1985, J NEUROSCI, V5, P3228; Sanes J R, 1993, Curr Opin Neurobiol, V3, P67, DOI 10.1016/0959-4388(93)90037-Y; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SHATZ CJ, 1993, CELL NEURON S, V72, P77; SIMON DK, 1992, J NEUROSCI, V12, P1212; SIMON DK, 1992, P NATL ACAD SCI USA, V89, P10593, DOI 10.1073/pnas.89.22.10593; SIMON DK, 1992, NEURON, V9, P1; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; STAHL B, 1990, NEURON, V5, P735, DOI 10.1016/0896-6273(90)90227-7; STUERMER CAO, 1988, J NEUROSCI, V8, P4513; THANOS S, 1987, J COMP NEUROL, V261, P155, DOI 10.1002/cne.902610114; THANOS S, 1984, J COMP NEUROL, V224, P407, DOI 10.1002/cne.902240308; TUTTLE R, 1991, J NEUROSCI METH, V39, P193, DOI 10.1016/0165-0270(91)90085-E; UDIN SB, 1988, ANNU REV NEUROSCI, V11, P289, DOI 10.1146/annurev.ne.11.030188.001445; VIELMETTER J, 1989, NEURON, V2, P1331, DOI 10.1016/0896-6273(89)90071-8; VONBOXBERG Y, 1993, NEURON, V10, P345; WALTER J, 1987, DEVELOPMENT, V101, P685; WALTER J, 1990, J PHYSIOL-PARIS, V84, P104; WALTER J, 1987, DEVELOPMENT, V101, P909	50	116	116	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 5	1994	265	5173					799	803		10.1126/science.8047886	http://dx.doi.org/10.1126/science.8047886			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	8047886				2022-12-24	WOS:A1994PA37200038
J	NEWTON, JA; SCHNEPF, GA; WALLACE, MR; LOBEL, HO; KENNEDY, CA; OLDFIELD, EC				NEWTON, JA; SCHNEPF, GA; WALLACE, MR; LOBEL, HO; KENNEDY, CA; OLDFIELD, EC			MALARIA IN US MARINES RETURNING FROM SOMALIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							PLASMODIUM-FALCIPARUM; PREVENTION; TRAVELERS; AFRICA	Objective.-To identify malaria in US Marines returning from Somalia and to determine their compliance with chemoprophylaxis. Design.-Case series. Setting.-The US Navy health care system. Patients.-Consecutive sample of 106 US Marines diagnosed with malaria after returning from Somalia in 1993. Main Outcome Measures.-Identification of the incidence and clinical features of imported malaria. Determination of compliance with chemoprophylaxis in this cohort. Results.-As of December 20, 1993, there were 112 cases of imported malaria in 106 US Marine Corps personnel returning from Somalia. Plasmodium vivax accounted for 97 (87%) of 112 malaria cases, and Plasmodium falciparum accounted for eight (7%) of 112 cases. Mixed infection with P vivax and P falciparum was noted in six (5%) of 112 cases, and a single case of Plasmodium malariae was identified. Patients with P falciparum malaria were diagnosed a mean of 20.9 days (range, 1 to 82 days) after returning to the United States compared with 91.8 days (range, 7 to 228 days) for P vivax infection (P<.0001). The self-reported chemoprophylaxis compliance rate was 56%; however, only 45 (50%) of 90 patients were given an optimal chemoprophylaxis regimen. Conclusions.-Noncompliance with personal protective measures and chemoprophylaxis contributed to the largest outbreak of imported malaria in US military personnel since the Vietnam conflict. Since military personnel frequently go on leave after deployment, health care providers throughout the United States must be aware of the presence of imported malaria from Somalia.	USN,MED CTR,DEPT CLIN INVEST,SAN DIEGO,CA 92134; USN,MED CTR,DEPT INTERNAL MED,DIV INFECT DIS,SAN DIEGO,CA; USN HOSP,DEPT INTERNAL MED,CAMP PENDLETON,CA; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV PARASIT DIS,ATLANTA,GA	United States Department of Defense; United States Navy; United States Department of Defense; United States Navy; United States Department of Defense; United States Navy; Centers for Disease Control & Prevention - USA								BARRETT O, 1969, AM J TROP MED HYG, V18, P495, DOI 10.4269/ajtmh.1969.18.495; KEAN BH, 1976, AM J MED, V61, P159, DOI 10.1016/0002-9343(76)90164-9; LACKRITZ EM, 1991, JAMA-J AM MED ASSOC, V265, P383, DOI 10.1001/jama.265.3.383; LOBEL HO, 1985, J INFECT DIS, V152, P613, DOI 10.1093/infdis/152.3.613; LYNK A, 1989, PEDIATR INFECT DIS J, V8, P745, DOI 10.1097/00006454-198911000-00003; OLDFIELD EC, 1993, CLIN INFECT DIS S3, V16, pS131; ROMBO L, 1987, TROP MED PARASITOL, V38, P49; WALLACE MR, 1993, CLIN INFECT DIS, V17, P510, DOI 10.1093/clinids/17.3.510; ZUCKER JR, 1993, INFECT DIS CLIN N AM, V7, P547; 1993, MMWR-MORBID MORTAL W, V42, P524; 1993, MMWR-MORBID MORTAL W, V42, P976; 1991, 1990 CTR DIS CONTR M	12	60	60	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	1994	272	5					397	399		10.1001/jama.272.5.397	http://dx.doi.org/10.1001/jama.272.5.397			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY903	8028173				2022-12-24	WOS:A1994NY90300034
J	NIGHTINGALE, SL				NIGHTINGALE, SL			POSSIBLE ELECTROMAGNETIC-INTERFERENCE PROBLEMS WITH WHEELCHAIRS AND OTHER MEDICAL DEVICES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	1994	272	5					344	344						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY903	8028152				2022-12-24	WOS:A1994NY90300005
J	HENNINGFIELD, JE; KOZLOWSKI, LT; BENOWITZ, NL				HENNINGFIELD, JE; KOZLOWSKI, LT; BENOWITZ, NL			A PROPOSAL TO DEVELOP MEANINGFUL LABELING FOR CIGARETTES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							LOW-YIELD CIGARETTES; CARBON-MONOXIDE; NICOTINE; SMOKING; TAR; BLOCKING; EXPOSURE; VENTS		PENN STATE UNIV,COLL HLTH & HUMAN DEV,PROGRAM BIOBEHAV HLTH,UNIV PK,PA 16802; UNIV CALIF SAN FRANCISCO,DIV CLIN PHARMACOL & EXPTL THERAPEUT,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	HENNINGFIELD, JE (corresponding author), NIDA,ADDICT RES CTR,CLIN PHARMACOL BRANCH,POB 5180,BALTIMORE,MD 21224, USA.							BENOWITZ NL, 1986, JAMA-J AM MED ASSOC, V256, P241; BENOWITZ NL, 1983, NEW ENGL J MED, V309, P139, DOI 10.1056/NEJM198307213090303; BENOWITZ NL, 1984, CLIN PHARMACOL THER, V35, P499, DOI 10.1038/clpt.1984.67; BENOWITZ NL, 1986, NEW ENGL J MED, V315, P1310, DOI 10.1056/NEJM198611203152102; BENOWITZ NL, IN PRESS N ENGL J ME; Browne C. L., 1990, DESIGN CIGARETTES; COHEN JB, 1992, J PUBLIC POLICY MARK, V11, P82, DOI 10.1177/074391569201100109; HENNINGFIELD JE, 1984, ADV BEHAV PHARMACOL, V4, P131; KOZLOWSKI LT, 1980, SCIENCE, V209, P1550, DOI 10.1126/science.7433979; KOZLOWSKI LT, 1988, AM J PUBLIC HEALTH, V78, P694, DOI 10.2105/AJPH.78.6.694; KOZLOWSKI LT, 1989, PHARMACOL BIOCHEM BE, V33, P815, DOI 10.1016/0091-3057(89)90476-0; KOZLOWSKI LT, 1981, JAMA-J AM MED ASSOC, V245, P158, DOI 10.1001/jama.245.2.158; KOZLOWSKI LT, 1983, NATIONAL I DRUG ABUS, V48; PILLSBURY HC, 1969, J ASSOC OFF ANA CHEM, V52, P458; SHAPIRO E, 1994, WALL STREET J   0421, pB7; YOUNG JC, 1981, J TOXICOL ENV HEALTH, V7, P801, DOI 10.1080/15287398109530021; 1991, TAR NICOTINE CARBON; 1993, FED REG 4       0106; 1988, DHHS CDC888406 PUBL; 1986, DHHS CDC878398 PUBL	20	36	36	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 27	1994	272	4					312	314		10.1001/jama.272.4.312	http://dx.doi.org/10.1001/jama.272.4.312			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NX806	8028146				2022-12-24	WOS:A1994NX80600035
J	DUGUID, JKM; BROMILOW, I				DUGUID, JKM; BROMILOW, I			VALUE OF KLEIHAUER TESTING AFTER ADMINISTRATION OF ANTI-D-IMMUNOGLOBULIN	BRITISH MEDICAL JOURNAL			English	Article											DUGUID, JKM (corresponding author), NATL BLOOD TRANSFUS SERV MERSEY & N WALES,LIVERPOOL L7 8TW,MERSEYSIDE,ENGLAND.							LEE D, 1993, BRIT MED J, V307, P1145, DOI 10.1136/bmj.307.6912.1145-d; POLESKY HF, 1981, AM J CLIN PATHOL, V76, P525; 1991, PRESCRIBERS J, V31, P137; 1992, NOTE GUIDANCE CORE S	4	22	22	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 23	1994	309	6949					240	240		10.1136/bmj.309.6949.240	http://dx.doi.org/10.1136/bmj.309.6949.240			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ180	8069142	Green Published			2022-12-24	WOS:A1994NZ18000018
J	SIMON, R; CARPENTER, R; DOYLE, S; COEN, E				SIMON, R; CARPENTER, R; DOYLE, S; COEN, E			FIMBRIATA CONTROLS FLOWER DEVELOPMENT BY MEDIATING BETWEEN MERISTEM AND ORGAN IDENTITY GENES	CELL			English	Article							FLORAL HOMEOTIC GENES; ANTIRRHINUM-MAJUS; ARABIDOPSIS; TRANSCRIPTION; TRANSPOSON; EXPRESSION; DEFICIENS	Two major classes of genes directing flower development have so far been described: early activated genes regulating meristem identity and later acting genes controlling organ identity. Here, we show that the fimbriata (fim) gene acts between these two classes in a sequence of gene activation. The fim gene, originally described in 1930, was cloned by transposon tagging from Antirrhinum majus and encodes a product with no detectable homology to other proteins. Mutations in fim result in partial homeotic transformations of floral organs and in reduced determinacy of the meristem. Expression and function of fim depends on the activity of meristem identity genes, and fim in turn controls the spatial and temporal expression of organ identity genes. The pattern of fim expression defines a new domain of the floral meristem that changes with time in a complementary manner to those of the meristem identity gene floricaula and the organ identity gene plena.			SIMON, R (corresponding author), JOHN INNES CTR PLANT SCI RES,COLNEY LANE,NORWICH NR4 7UH,NORFOLK,ENGLAND.		Simon, Rudiger/T-6755-2018	Simon, Rudiger/0000-0002-1317-7716				BAUR ERWIN, 1930, ZEITSCHR BOT, V23, P676; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1992, DEVELOPMENT, V114, P599; BRADLEY D, 1993, CELL, V72, P85, DOI 10.1016/0092-8674(93)90052-R; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COEN ES, 1993, PLANT CELL, V5, P1175, DOI 10.1105/tpc.5.10.1175; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; HARTE C, 1951, Z INDUKT ABSTAMM VER, V83, P392; HUIJSER P, 1992, EMBO J, V11, P1239, DOI 10.1002/j.1460-2075.1992.tb05168.x; LYDALL D, 1991, GENE DEV, V5, P2405, DOI 10.1101/gad.5.12b.2405; SCHULTZ EA, 1991, PLANT CELL, V3, P1221, DOI 10.1105/tpc.3.11.1221; SCHWARZSOMMER Z, 1992, EMBO J, V11, P251, DOI 10.1002/j.1460-2075.1992.tb05048.x; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x	16	103	106	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 15	1994	78	1					99	107		10.1016/0092-8674(94)90576-2	http://dx.doi.org/10.1016/0092-8674(94)90576-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033217				2022-12-24	WOS:A1994NX32800012
J	MOHR, G; CAPRARA, MG; GUO, QB; LAMBOWITZ, AM				MOHR, G; CAPRARA, MG; GUO, QB; LAMBOWITZ, AM			A TYROSYL-TRANSFER-RNA SYNTHETASE CAN FUNCTION SIMILARLY TO AN RNA STRUCTURE IN THE TETRAHYMENA RIBOZYME	NATURE			English	Article							GROUP-I INTRON; SECONDARY STRUCTURE; TERTIARY STRUCTURE; SEQUENCE; CORE; DOMAIN; SITES	GROUP I introns are highly structured RNAs which catalyse their own splicing by guanosine-initiated transesterification reactions(1,2). Their catalytic core is generally stabilized by RNA-RNA interactions within the core and with peripheral RNA structures(3,4). Additionally, some group I introns require proteins for efficient splicing in vivo(5). The Neurospora CYT-18 protein, the mitochondrial tyrosyl-transfer RNA synthetase (mt TyrRS), promotes splicing of the Neurospora mitochondrial large ribosomal RNA (LSU) and other group I introns by stabilizing the catalytically active structure of the intron core(6-8). We report here that CYT-18 functions similarly to a peripheral RNA structure, P5abc, that stabilizes the catalytic core of the Tetrahymena LSU intron. The CYT-18 protein and P5abc RNA bind to overlapping sites in the intron core, inducing similar conformational changes correlated with splicing activity. Our results show that a protein can play the role of an RNA structure in a catalytic RNA, a substitution postulated for the evolution of nuclear pre-messenger RNA introns from self-splicing introns(9,10).	OHIO STATE UNIV, DEPT MOLEC GENET, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DEPT BIOCHEM, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, DEPT MED BIOCHEM, COLUMBUS, OH 43210 USA; OHIO STATE UNIV, CTR BIOTECHNOL, COLUMBUS, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University				Mohr, Georg/0000-0002-6411-0685				AKINS RA, 1987, CELL, V50, P331, DOI 10.1016/0092-8674(87)90488-0; BANERJEE AR, 1993, BIOCHEMISTRY-US, V32, P153, DOI 10.1021/bi00052a021; BEEN MD, 1985, NUCLEIC ACIDS RES, V13, P8389, DOI 10.1093/nar/13.23.8389; BURKE JM, 1987, NUCLEIC ACIDS RES, V15, P7217, DOI 10.1093/nar/15.18.7217; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CHEMIACK AD, 1990, CELL, V62, P745; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; FLOR PJ, 1989, EMBO J, V8, P3391, DOI 10.1002/j.1460-2075.1989.tb08503.x; GUO QB, 1992, GENE DEV, V6, P1357, DOI 10.1101/gad.6.8.1357; INOUE T, 1985, P NATL ACAD SCI USA, V82, P648, DOI 10.1073/pnas.82.3.648; JAEGER JA, 1990, BIOCHEMISTRY-US, V29, P10147, DOI 10.1021/bi00496a002; JAEGER L, 1991, J MOL BIOL, V221, P1153, DOI 10.1016/0022-2836(91)90925-V; JOYCE GF, 1989, NUCLEIC ACIDS RES, V17, P7879, DOI 10.1093/nar/17.19.7879; KITTLE JD, 1991, GENE DEV, V5, P1009, DOI 10.1101/gad.5.6.1009; LAMBOWITZ AM, 1990, TRENDS BIOCHEM SCI, V15, P440, DOI 10.1016/0968-0004(90)90283-H; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOHR G, 1992, CELL, V69, P483, DOI 10.1016/0092-8674(92)90449-M; MURPHY FL, 1993, BIOCHEMISTRY-US, V32, P5291, DOI 10.1021/bi00071a003; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; SALDANHA R, 1993, FASEB J, V7, P15, DOI 10.1096/fasebj.7.1.8422962; SALVO JLG, 1990, J MOL BIOL, V211, P537, DOI 10.1016/0022-2836(90)90264-M; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; STREICHER B, 1993, NUCLEIC ACIDS RES, V21, P311; VANDERHORST G, 1991, P NATL ACAD SCI USA, V88, P184, DOI 10.1073/pnas.88.1.184; WILLIAMSON CL, 1987, J BIOL CHEM, V262, P14672; YOUNG B, 1991, CELL, V67, P1007, DOI 10.1016/0092-8674(91)90373-7; ZAUG AJ, 1986, NATURE, V324, P429, DOI 10.1038/324429a0	28	105	114	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 14	1994	370	6485					147	150		10.1038/370147a0	http://dx.doi.org/10.1038/370147a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW804	8022484				2022-12-24	WOS:A1994NW80400059
J	WITTHUHN, BA; SILVENNOINEN, O; MIURA, O; LAI, KS; CWIK, C; LIU, ET; IHLE, JN				WITTHUHN, BA; SILVENNOINEN, O; MIURA, O; LAI, KS; CWIK, C; LIU, ET; IHLE, JN			INVOLVEMENT OF THE JAK-3 JANUS KINASE IN SIGNALING BY INTERLEUKIN-2 AND INTERLEUKIN-4 IN LYMPHOID AND MYELOID CELLS	NATURE			English	Article							PROTEIN-TYROSINE KINASE; RECEPTOR GAMMA-CHAIN; ERYTHROPOIETIN RECEPTOR; INTERFERON-ALPHA/BETA; TRANSDUCTION; PHOSPHORYLATION; PATHWAY; FAMILY; IL-2	MANY cytokines function through interaction with receptors of the cytokine receptor superfamily. Although lacking catalytic domains, cytokine receptors couple ligand binding to induction of protein tyrosine phosphorylation. Recent studie(1-10) have shown that one or more of the Janus kinase family members (Jaks) associate with cytokine receptors and are tyrosine phosphorylated and activated following ligand binding. Here we describe a new Jak family kinase, Jak-3, and demonstrate that Jak-3, and to a lesser extent Jak-1, are tyrosine phosphorylated and Jak-3 is activated in the responses to interleukin-2 and interleukin-4 in T cells and myeloid cells. Jak-3 activation requires the serine-rich, membrane-proximal domain of the interleukin-3 receptor beta-chain, but does not require the acidic domain that is required for association and activation of Src family kinases.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; UNIV N CAROLINA, SCH MED, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, DEPT BIOL, CHAPEL HILL, NC 27599 USA	St Jude Children's Research Hospital; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill			witthuhn, bruce/GSE-3193-2022; Liu, Edison/C-4141-2008	Miura, Osamu/0000-0002-0981-3054				AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ARTGETSINGER LS, 1993, CELL, V74, P237; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; CANCE WG, 1993, INT J CANCER, V54, P571, DOI 10.1002/ijc.2910540409; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; HARPUR AG, 1992, ONCOGENE, V7, P1347; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KIRKEN RA, 1993, J BIOL CHEM, V268, P22765; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SANCHEZ MP, 1994, P NATL ACAD SCI USA, V91, P1819, DOI 10.1073/pnas.91.5.1819; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	30	584	598	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 14	1994	370	6485					153	157		10.1038/370153a0	http://dx.doi.org/10.1038/370153a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW804	8022486				2022-12-24	WOS:A1994NW80400061
J	BARRETT, JFR; WHITTAKER, PG; WILLIAMS, JG; LIND, T				BARRETT, JFR; WHITTAKER, PG; WILLIAMS, JG; LIND, T			ABSORPTION OF NONHEME IRON FROM FOOD DURING NORMAL-PREGNANCY	BRITISH MEDICAL JOURNAL			English	Article							FOLATE SUPPLEMENTS; DIETARY IRON; ZINC	Objective-To determine whether the increased iron demands of pregnancy could be met by increased absorption from dietary sources. Design and setting-longitudinal prospective study in the research unit of a maternity hospital. Subjects-12 normal pregnant women. Interventions-At 12, 24, and 36 weeks' gestation (within one week) and 16-24 weeks after delivery women ate a breakfast of meat, bread, and orange juice (3.2 mg iron), extrinsically labelled with the stable isotope iron-54 (2.8 mg); the stable isotope iron-57 (200 mu g) was given intravenously. Main outcome measures-Serum samples were taken for 10 hours after administration of the isotopes; ratios of the isotopes were measured by inductively coupled plasma mass spectrometry, and the absorption of oral iron was calculated. Results-The geometric mean (95% confidence interval) absorption of iron at 12, 24, and 36 weeks' gestation was 7% (5% to 11%), 36% (28% to 47%), and 66% (57% to 76%) respectively. At 16-24 weeks after delivery the absorption was 11% (6% to 21%). The mean increase in absorption at 36 weeks (compared with that at 12 weeks) was 9.1 times (6.0 to 13.7). One pregnant woman developed iron deficiency anaemia but was otherwise indistinguishable from the others. Conclusions-An increase in the absorption of iron from food is a physiological consequence of normal pregnancy, not the result of developing anaemia during pregnancy, and such an increase is large enough to meet the increased requirements of pregnancy provided that the dietary intake is adequate.	UNIV NEWCASTLE UPON TYNE,ROYAL VICTORIA INFIRM,DEPT OBSTET & GYNAECOL,NEWCASTLE TYNE NE1 4LP,ENGLAND; UNIV LONDON IMPERIAL COLL SCI & TECHNOL,NERC,ICP MS FACIL,ASCOT SL5 7TE,BERKS,ENGLAND	Newcastle University - UK; Imperial College London; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC)								BARRETT JFR, IN PRESS CLIN SCI; BJORNRASMUSSEN E, 1976, AM J CLIN NUTR, V26, P1311; BLACK AE, 1986, BRIT J NUTR, V56, P59, DOI 10.1079/BJN19860085; BONNAR J, 1969, LANCET, V1, P457; Bothwell T.H., 1979, IRON METABOLISM MAN; COOK JD, 1991, AM J CLIN NUTR, V54, P717, DOI 10.1093/ajcn/54.4.717; CROFTON RW, 1989, AM J CLIN NUTR, V50, P141, DOI 10.1093/ajcn/50.1.141; DARKE SJ, 1980, BRIT J NUTR, V44, P243, DOI 10.1079/BJN19800037; Gibaldi M., 1982, PHARMACOKINETICS, P145; HAHN PF, 1951, AM J OBSTET GYNECOL, V61, P477, DOI 10.1016/0002-9378(51)91394-4; HAMBIDGE KM, 1987, OBSTET GYNECOL, V70, P593; HEINRICH HC, 1970, IRON DEFICIENCY, P213; HEMMINKI E, 1978, BRIT J OBSTET GYNAEC, V85, P404, DOI 10.1111/j.1471-0528.1978.tb14905.x; HIBBARD BM, 1988, BRIT MED J, V297, P1324, DOI 10.1136/bmj.297.6659.1324; HORN E, 1988, BRIT MED J, V297, P1325, DOI 10.1136/bmj.297.6659.1325; HYTTEN F, 1985, CLIN HAEMATOL, V14, P601; LIND T, 1983, NUTRITION PREGNANCY, P181; MONSEN ER, 1978, AM J CLIN NUTR, V31, P134, DOI 10.1093/ajcn/31.1.134; Paul A.A., 1978, MCCANCE WIDDOWSONS C; PRITCHARD JA, 1970, IRON DEFICIENCY, P173; Ramdath D D, 1989, Nutr Res Rev, V2, P29, DOI 10.1079/NRR19890006; REYNOLDS LG, 1985, S AFR MED J, V67, P680; ROSSANDER L, 1979, AM J CLIN NUTR, V32, P2484, DOI 10.1093/ajcn/32.12.2484; SCHOFIELD C, 1989, BRIT J NUTR, V62, P363, DOI 10.1079/BJN19890037; SOUTHON S, 1989, BRIT J NUTR, V62, P707, DOI 10.1079/BJN19890071; Svanberg B, 1975, Acta Obstet Gynecol Scand Suppl, V48, P43; TAYLOR DJ, 1982, BRIT J OBSTET GYNAEC, V89, P1011, DOI 10.1111/j.1471-0528.1982.tb04656.x; WHITTAKER PG, 1991, BRIT J NUTR, V65, P457, DOI 10.1079/BJN19910104; 1979, 15 DEP HLTH SOC SEC; 1981, GEIGY SCI TABLES; 1991, PURE APPL CHEM, V63, P991; 1972, WHO TECH REP SER, V503, P29; 1993, JAMA-J AM MED ASSOC, V270, P2846; 1990, NUTRITION PREGNANCY, P272	34	115	116	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					79	82		10.1136/bmj.309.6947.79	http://dx.doi.org/10.1136/bmj.309.6947.79			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038670	Green Published			2022-12-24	WOS:A1994NW71600013
J	BLATTER, EE; ROSS, W; TANG, H; GOURSE, RL; EBRIGHT, RH				BLATTER, EE; ROSS, W; TANG, H; GOURSE, RL; EBRIGHT, RH			DOMAIN ORGANIZATION OF RNA-POLYMERASE ALPHA-SUBUNIT - C-TERMINAL-85 AMINO-ACIDS CONSTITUTE A DOMAIN CAPABLE OF DIMERIZATION AND DNA-BINDING	CELL			English	Article							ESCHERICHIA-COLI; TRANSCRIPTION ACTIVATION; CAMP-CRP; PROMOTERS; PROTEINS; PURIFICATION; REGION	Using limited proteolysis, we show that the Escherichia coli RNA polymerase alpha subunit consists of an N-terminal domain comprised of amino acids 8-241, a C-terminal domain comprised of amino acids 249-329, and an unstructured and/or flexible interdomain linker. We have carried out a detailed structural and functional analysis of an 85 amino acid proteolytic fragment corresponding to the C-terminal domain (alpha CTD-2). Our results establish that alpha CTD-2 has a defined secondary structure (similar to 40% alpha helix, similar to 0% beta sheet). Our results further establish that alpha CTD-2 is a dimer and that alpha CTD-2 exhibits sequence-specific DNA binding activity. Our results suggest a model for the mechanism of involvement of alpha in transcription activation by promoter upstream elements and upstream-binding activator proteins.	RUTGERS STATE UNIV, WAKSMAN INST, NEW BRUNSWICK, NJ 08855 USA; UNIV WISCONSIN, DEPT BACTERIOL, MADISON, WI 53706 USA	Rutgers State University New Brunswick; University of Wisconsin System; University of Wisconsin Madison	BLATTER, EE (corresponding author), RUTGERS STATE UNIV, DEPT CHEM, NEW BRUNSWICK, NJ 08855 USA.		Ebright, Richard/O-3321-2019	Ebright, Richard/0000-0001-8915-7140	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037048, R01GM041376, R01GM037048, R01GM051527] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51527, GM37048, GM41376] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSTEN BM, 1976, BIOCHEM BIOPH RES CO, V72, P411, DOI 10.1016/S0006-291X(76)80058-7; BORUKHOV S, 1993, PROTEIN EXPRES PURIF, V4, P503, DOI 10.1006/prep.1993.1066; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; Burgess RR, 1976, RNA POLYMERASE, P69; BURGNER R L, 1991, P3; Chamberlin M., 1976, RNA POLYMERASE BOOK, P17; CHEN Y, 1994, SCIENCE, V265, P90, DOI 10.1126/science.8016656; DEUSCHLE U, 1986, EMBO J, V5, P2987, DOI 10.1002/j.1460-2075.1986.tb04596.x; EBRIGHT RH, 1993, MOL MICROBIOL, V8, P797, DOI 10.1111/j.1365-2958.1993.tb01626.x; HARLOW E, 1988, ANTIBODIES LABORATOR; HAYWARD RS, 1991, J MOL BIOL, V221, P23, DOI 10.1016/0022-2836(91)80197-3; Hermanson G.T., 1992, IMMOBILIZED AFFINITY; IGARASHI K, 1991, J MOL BIOL, V218, P1, DOI 10.1016/0022-2836(91)90865-4; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; Ishihama A, 1981, Adv Biophys, V14, P1; ISHIHAMA A, 1992, MOL MICROBIOL, V6, P3283, DOI 10.1111/j.1365-2958.1992.tb02196.x; JANIN J, 1985, METHOD ENZYMOL, V115, P420; JOVIN TM, 1977, NATURE, V269, P668, DOI 10.1038/269668a0; KOLB A, 1993, NUCLEIC ACIDS RES, V21, P319, DOI 10.1093/nar/21.2.319; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; NEWLANDS JT, 1992, NUCLEIC ACIDS RES, V20, P719, DOI 10.1093/nar/20.4.719; NEWLANDS JT, 1991, J MOL BIOL, V220, P569, DOI 10.1016/0022-2836(91)90101-B; OGATA RT, 1978, P NATL ACAD SCI USA, V75, P5851, DOI 10.1073/pnas.75.12.5851; PABO CO, 1979, P NATL ACAD SCI USA, V76, P1608, DOI 10.1073/pnas.76.4.1608; PERCZEL A, 1991, PROTEIN ENG, V4, P669, DOI 10.1093/protein/4.6.669; PORTER RR, 1973, SCIENCE, V180, P713, DOI 10.1126/science.180.4087.713; RAO L, 1994, J MOL BIOL, V235, P1421, DOI 10.1006/jmbi.1994.1098; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; RUSSO FD, 1992, J BIOL CHEM, V267, P14515; RYU S, 1994, IN PRESS P NATL ACAD; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schulz G. E., 1979, PRINCIPLES PROTEIN S; SELUTCHENKO OA, 1985, BIOORG KHIM+, V11, P480; SHEER D, 1990, ANAL BIOCHEM, V187, P76, DOI 10.1016/0003-2697(90)90419-A; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VONHIPPEL PH, 1992, TRANSCRIPTIONAL REGU, P179; WILSON JE, 1991, METHOD BIOCHEM ANAL, V35, P207; ZHOU Y, 1994, IN PRESS J MOL BIOL; ZHOU Y, 1994, IN PRESS EMBO J; ZILLIG W, 1976, RNA POLYMERASE, P101; ZOU C, 1992, MOL MICROBIOL, V6, P2599, DOI 10.1111/j.1365-2958.1992.tb01437.x	44	203	204	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 9	1994	78	5					889	896		10.1016/S0092-8674(94)90682-3	http://dx.doi.org/10.1016/S0092-8674(94)90682-3			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PG296	8087855				2022-12-24	WOS:A1994PG29600017
J	ZHANG, JZ; DAVLETOV, BA; SUDHOF, TC; ANDERSON, RGW				ZHANG, JZ; DAVLETOV, BA; SUDHOF, TC; ANDERSON, RGW			SYNAPTOTAGMIN-I IS A HIGH-AFFINITY RECEPTOR FOR CLATHRIN-AP-2 - IMPLICATIONS FOR MEMBRANE RECYCLING	CELL			English	Article							COATED VESICLES; NEUROTRANSMITTER RELEASE; INVITRO BINDING; GOLGI MEMBRANES; PROTEIN; EXOCYTOSIS; DOMAIN; FUSION; PITS; DROSOPHILA	In nerve terminals, Ca2+-stimulated synaptic vesicle exocytosis is rapidly followed by endocytosis. Synaptic vesicle endocytosis requires clathrin-coated pits similar to receptor-mediated endocytosis in fibroblasts. Binding of clathrin AP-2 (adaptor complex) to an unidentified high affinity membrane receptor appears to be necessary for coated pit assembly in fibroblasts. We now show that synaptic vesicles have a high affinity AP-2 site (K-D, similar to 1 x 10(-10) M) similar to the one observed in fibroblasts. Using a combination of competition and direct binding assays, we demonstrate that synaptotagmin I, an intrinsic membrane protein of synaptic vesicles, has all of the properties of the AP-2 receptor and that AP-2 binds to the second C-2 domain in the molecule. Thus, synaptotagmin I may be a multifunctional protein with a function in endocytosis in addition to the previously proposed role in exocytosis.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	ZHANG, JZ (corresponding author), UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235, USA.		Davletov, Bazbek/ABA-8569-2021	Davletov, Bazbek/0000-0003-4658-3275	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson R G, 1993, Trends Cell Biol, V3, P177, DOI 10.1016/0962-8924(93)90205-F; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; FISHER GW, 1983, DEV BIOL, V99, P456, DOI 10.1016/0012-1606(83)90295-6; GARCIA CK, 1994, CELL, V76, P865, DOI 10.1016/0092-8674(94)90361-1; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HATA Y, 1993, NEURON, V10, P307, DOI 10.1016/0896-6273(93)90320-Q; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; JOHNSTON PA, 1989, J BIOL CHEM, V264, P1268; KOHTZ DS, 1988, J BIOL CHEM, V263, P7418; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; MAHAFFEY DT, 1989, J CELL BIOL, V108, P1615, DOI 10.1083/jcb.108.5.1615; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; NANDI PK, 1982, P NATL ACAD SCI-BIOL, V79, P5881, DOI 10.1073/pnas.79.19.5881; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; PATHAK RK, 1990, J CELL BIOL, V111, P347, DOI 10.1083/jcb.111.2.347; PEARSE BMF, 1985, EMBO J, V4, P2457, DOI 10.1002/j.1460-2075.1985.tb03956.x; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PEELER JS, 1993, J CELL BIOL, V120, P47, DOI 10.1083/jcb.120.1.47; PERIN MS, 1994, J BIOL CHEM, V269, P8576; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; PFEFFER SR, 1983, J CELL BIOL, V97, P40, DOI 10.1083/jcb.97.1.40; POODRY CA, 1973, DEV BIOL, V32, P373, DOI 10.1016/0012-1606(73)90248-0; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SEAMAN MNJ, 1993, J CELL BIOL, V123, P1093, DOI 10.1083/jcb.123.5.1093; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SOSA MA, 1993, J BIOL CHEM, V268, P12537; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1993, CELL, V75, P1; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107	47	436	443	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 9	1994	78	5					751	760		10.1016/S0092-8674(94)90442-1	http://dx.doi.org/10.1016/S0092-8674(94)90442-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PG296	8087843				2022-12-24	WOS:A1994PG29600005
J	WEINSTEIN, DC; ALTABA, ARI; CHEN, WS; HOODLESS, P; PREZIOSO, VR; JESSELL, TM; DARNELL, JE				WEINSTEIN, DC; ALTABA, ARI; CHEN, WS; HOODLESS, P; PREZIOSO, VR; JESSELL, TM; DARNELL, JE			THE WINGED-HELIX TRANSCRIPTION FACTOR HNF-3-BETA IS REQUIRED FOR NOTOCHORD DEVELOPMENT IN THE MOUSE EMBRYO	CELL			English	Article							CELL-SPECIFIC EXPRESSION; HOMEOBOX GENE XHOX3; FLOOR PLATE; FORK-HEAD; XENOPUS-LAEVIS; MESODERM FORMATION; NEURAL EXPRESSION; PATTERN-FORMATION; NERVOUS-SYSTEM; MUTANT EMBRYOS	HNF-3 beta, a transcription factor of the winged-helix family, is expressed in embryonic and adult endoderm and also in midline cells of the node, notochord, and floor plate in mouse embryos. To define the function of HNF-3 beta a targeted mutation in the HNF 3P locus was generated by homologous recombination in embryonic stem cells. Mice lacking HNF-3 beta die by embryonic day (6) 10-11. Mutant embryos examined from E6.5 to E9.5 do not form a distinct node and lack a notochord. In addition, mutant embryos show marked defects in the organization of somites and neural tube that may result from the absence of the notochord. The neural tube of mutant embryos exhibits overt anteroposterior polarity but lacks a floor plate and motor neurons. Endodermal cells are present but fail to form a gut tube in mutant embryos. These studies indicate that HNF-3 beta has an essential role in the development of axial mesoderm in mouse embryos.	COLUMBIA UNIV,CTR NEUROBIOL & BEHAV,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	WEINSTEIN, DC (corresponding author), ROCKEFELLER UNIV,MOLEC CELL BIOL LAB,NEW YORK,NY 10021, USA.			Ruiz i Altaba, Ariel/0000-0003-2292-3933; Weinstein, Daniel/0000-0001-7832-9285; Hoodless, Pamela/0000-0003-1371-0725	NATIONAL CANCER INSTITUTE [R01CA016006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS030532] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16006] Funding Source: Medline; NIGMS NIH HHS [GM 07982-09] Funding Source: Medline; NINDS NIH HHS [NS 30532] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTABA AR, 1989, CELL, V57, P317, DOI 10.1016/0092-8674(89)90969-0; ALTABA AR, 1993, J NEUROBIOL, V24, P1276, DOI 10.1002/neu.480241004; ALTABA ARI, 1992, DEVELOPMENT, V116, P81; ALTABA ARI, 1993, P NATL ACAD SCI USA, V90, P8268, DOI 10.1073/pnas.90.17.8268; ALTABA ARI, 1993, MECH DEVELOP, V44, P91, DOI 10.1016/0925-4773(93)90060-B; ALTABA ARI, 1990, DEVELOPMENT, V108, P595; ALTABA ARI, 1992, DEVELOPMENT, V115, P67; ANG SL, 1993, DEVELOPMENT, V118, P139; ANG SL, 1993, DEVELOPMENT, V119, P1301; BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; BEDDINGTON RSP, 1994, DEVELOPMENT, V120, P613; BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; BOLCE ME, 1993, DEV BIOL, V160, P413, DOI 10.1006/dbio.1993.1317; BOVOLENTA P, 1991, DEVELOPMENT, V113, P625; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRANDSABERI B, 1993, ANAT EMBRYOL, V188, P239; Chesley P, 1935, J EXP ZOOL, V70, P429, DOI 10.1002/jez.1400700306; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CILIBERTO G, 1985, CELL, V41, P531, DOI 10.1016/S0092-8674(85)80026-X; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; COSTA RH, 1986, MOL CELL BIOL, V6, P4697, DOI 10.1128/MCB.6.12.4697; COURTOIS G, 1987, SCIENCE, V238, P688, DOI 10.1126/science.3499668; CUNLIFFE V, 1992, NATURE, V358, P427, DOI 10.1038/358427a0; DIETRICH S, 1993, MECH DEVELOP, V44, P189, DOI 10.1016/0925-4773(93)90067-8; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; DIXON JE, 1989, DEVELOPMENT, V106, P749; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; DONIACH T, 1992, SCIENCE, V257, P542, DOI 10.1126/science.1636091; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; FUJII T, 1994, DEV DYNAM, V199, P73, DOI 10.1002/aja.1001990108; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; Gruneberg, 1963, PATHOLOGY DEVELPMENT; HALPERN ME, 1993, CELL, V75, P99, DOI 10.1016/0092-8674(93)90682-G; HARLAND RM, 1991, METHOD CELL BIOL, V36, P675; HERRMANN BG, 1991, DEVELOPMENT, V113, P913; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; JESSELL TM, 1992, HARVEY LECT, V86, P67; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KISPERT A, 1994, DEV BIOL, V161, P179, DOI 10.1006/dbio.1994.1019; KNOCHEL S, 1992, MECH DEVELOP, V38, P157, DOI 10.1016/0925-4773(92)90007-7; KORZH V, 1993, DEVELOPMENT, V118, P417; KOSEKI H, 1993, DEVELOPMENT, V119, P649; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LAWSON KA, 1991, DEVELOPMENT, V113, P891; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; OTT MO, 1984, EMBO J, V3, P2505, DOI 10.1002/j.1460-2075.1984.tb02164.x; PANI L, 1992, MOL CELL BIOL, V12, P552, DOI 10.1128/MCB.12.2.552; PAPALOPULU N, 1993, DEVELOPMENT, V117, P961; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; POURQUIE O, 1993, P NATL ACAD SCI USA, V90, P5242, DOI 10.1073/pnas.90.11.5242; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; Ruiz i Altaba A., 1993, CURR OPIN GENE DEV, V3, P633; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SASAKI H, 1993, DEVELOPMENT, V118, P47; SCHULTEMERKER S, 1992, DEVELOPMENT, V116, P1021; SCHULTEMERKER S, 1994, DEVELOPMENT, V120, P1009; SELLECK MAJ, 1991, DEVELOPMENT, V112, P615; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; Spemann H., 1938, EMBRYONIC DEV INDUCT; STRAHLE U, 1993, GENE DEV, V7, P1436, DOI 10.1101/gad.7.7b.1436; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; THEILER K, 1959, AM J ANAT, V104, P319, DOI 10.1002/aja.1001040302; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VONDASSOW G, 1993, GENE DEV, V7, P355, DOI 10.1101/gad.7.3.355; WALKER MD, 1983, NATURE, V306, P557, DOI 10.1038/306557a0; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; YOUN BW, 1981, DEV BIOL, V83, P339, DOI 10.1016/0012-1606(81)90479-6	82	687	705	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 26	1994	78	4					575	588		10.1016/0092-8674(94)90523-1	http://dx.doi.org/10.1016/0092-8674(94)90523-1			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	8069910				2022-12-24	WOS:A1994PD69300007
J	REDGMENT, CJ; ALSHAWAF, T; GRUDZINSKAS, JG; CRAFT, IL				REDGMENT, CJ; ALSHAWAF, T; GRUDZINSKAS, JG; CRAFT, IL			GAMETE INTRAFALLOPIAN TRANSFER IN OLDER WOMEN - EFFECT OF LIMITING NUMBER OF GAMETES TRANSFERRED	BRITISH MEDICAL JOURNAL			English	Article									LONDON GYNAECOL & FERTIL CTR,LONDON W1N 1AF,ENGLAND; ROYAL LONDON HOSP,ACAD DEPT OBSTET & GYNAECOL,LONDON E1 1BB,ENGLAND	Barts Health NHS Trust; Royal London Hospital								CRAFT I, 1988, LANCET, V1, P1094; CRAFT I, 1993, LANCET, V341, P697, DOI 10.1016/0140-6736(93)90467-U; NELSON JR, 1993, FERTIL STERIL, V60, P116; SAUER MV, 1992, LANCET, V286, P1275; 1993, ANN REPORT, P19	5	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 20	1994	309	6953					510	511		10.1136/bmj.309.6953.510	http://dx.doi.org/10.1136/bmj.309.6953.510			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PD308	8086905	Green Published			2022-12-24	WOS:A1994PD30800019
J	HAFNER, MS; SUDMAN, PD; VILLABLANCA, FX; SPRADLING, TA; DEMASTES, JW; NADLER, SA				HAFNER, MS; SUDMAN, PD; VILLABLANCA, FX; SPRADLING, TA; DEMASTES, JW; NADLER, SA			DISPARATE RATES OF MOLECULAR EVOLUTION IN COSPECIATING HOSTS AND PARASITES	SCIENCE			English	Article							POCKET GOPHERS RODENTIA; GENETIC DIFFERENTIATION; PHYLOGENETIC TREES; BASE SUBSTITUTIONS; MITOCHONDRIAL-DNA; TRICHODECTIDAE; MALLOPHAGA; GEOMYIDAE; GENOME; GEOMYDOECUS	DNA sequences for the gene encoding mitochondrial cytochrome oxidase I in a group of rodents (pocket gophers) and their ectoparasites (chewing lice) provide evidence for cospeciation and reveal different rates of molecular evolution in the hosts and their parasites. The overall rate of nucleotide substitution (both silent and replacement changes) is approximately three times higher in lice, and the rate of synonymous substitution (based on analysis of fourfold degenerate sites) is approximately an order of magnitude greater in lice. The difference in synonymous substitution rate between lice and gophers correlates with a difference of similar magnitude in generation times.	LOUISIANA STATE UNIV, DEPT ZOOL & PHYSIOL, BATON ROUGE, LA 70803 USA; NO ILLINOIS UNIV, DEPT BIOL SCI, DE KALB, IL 60115 USA	Louisiana State University System; Louisiana State University; Northern Illinois University	HAFNER, MS (corresponding author), LOUISIANA STATE UNIV, MUSEUM NAT SCI, BATON ROUGE, LA 70803 USA.		Hypsa, Vaclav/G-9847-2014					ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BROWN GG, 1982, P NATL ACAD SCI-BIOL, V79, P3246, DOI 10.1073/pnas.79.10.3246; CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033; DEMASTES JW, 1993, J MAMMAL, V74, P521, DOI 10.2307/1382271; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; FUKAMIKOBAYASHI K, 1991, J MOL EVOL, V32, P79, DOI 10.1007/BF02099932; HAFNER MS, 1991, J MAMMAL, V72, P1, DOI 10.2307/1381975; HAFNER MS, 1982, Z ZOOL SYST EVOL, V20, P118; HAFNER MS, 1988, NATURE, V332, P258, DOI 10.1038/332258a0; HAFNER MS, 1990, SYST ZOOL, V39, P192, DOI 10.2307/2992181; HELLENTHAL RA, 1984, J KANSAS ENTOMOL SOC, V57, P231; HILLIS DM, 1992, J HERED, V83, P189, DOI 10.1093/oxfordjournals.jhered.a111190; HILLIS DM, 1993, METHOD ENZYMOL, V224, P456, DOI 10.1016/0076-6879(93)24035-S; HONEYCUTT RL, 1982, J MAMMAL, V63, P208, DOI 10.2307/1380629; HUELSENBECK JP, 1993, SYST BIOL, V42, P247, DOI 10.2307/2992463; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; Kimura M, 1985, NEUTRAL THEORY MOL E; KISHINO H, 1989, J MOL EVOL, V29, P170, DOI 10.1007/BF02100115; KONDO R, 1993, J MOL EVOL, V36, P517, DOI 10.1007/BF00556356; Liu H, 1992, MOL PHYLOGENET EVOL, V1, P41, DOI 10.1016/1055-7903(92)90034-E; MANTEL N, 1967, CANCER RES, V27, P209; Marshall AG., 1981, ECOLOGY ECTOPARASITI; MARTIN AP, 1993, P NATL ACAD SCI USA, V90, P4087, DOI 10.1073/pnas.90.9.4087; MARTIN AP, 1992, NATURE, V357, P153, DOI 10.1038/357153a0; NADLER SA, 1989, ANN ENTOMOL SOC AM, V82, P109, DOI 10.1093/aesa/82.1.109; NADLER SA, 1990, EVOLUTION, V44, P942, DOI 10.1111/j.1558-5646.1990.tb03816.x; NADLER SA, 1993, INT J PARASITOL, V23, P191, DOI 10.1016/0020-7519(93)90141-K; Nelson G, 1981, SYSTEMATICS BIOGEORA; PAGE RDM, 1994, SYST BIOL, V43, P58, DOI 10.2307/2413581; PAGE RDM, 1993, INT J PARASITOL, V23, P499, DOI 10.1016/0020-7519(93)90039-2; PAGE RDM, 1990, SYST ZOOL, V39, P205, DOI 10.2307/2992182; PRICE RD, 1971, J MED ENTOMOL, V8, P228, DOI 10.1093/jmedent/8.3.228; Russell, 1968, U KANS PUBL MUS NAT, V16, P473; RUST RW, 1974, OECOLOGIA, V15, P287, DOI 10.1007/BF00345184; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sokal Robert R., 1969, BIOMETRY; Sudman PD, 1992, MOL PHYLOGENET EVOL, V1, P17, DOI 10.1016/1055-7903(92)90031-B; Swofford David L., 1990, P411; WOLFE KH, 1989, NATURE, V337, P283, DOI 10.1038/337283a0; WU CI, 1985, P NATL ACAD SCI USA, V82, P1741, DOI 10.1073/pnas.82.6.1741; [No title captured]	41	381	391	0	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 19	1994	265	5175					1087	1090		10.1126/science.8066445	http://dx.doi.org/10.1126/science.8066445			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC539	8066445	Green Submitted			2022-12-24	WOS:A1994PC53900034
J	XU, D; EMOTO, N; GIAID, A; SLAUGHTER, C; KAW, S; DEWIT, D; YANAGISAWA, M				XU, D; EMOTO, N; GIAID, A; SLAUGHTER, C; KAW, S; DEWIT, D; YANAGISAWA, M			ECE-1 - A MEMBRANE-BOUND METALLOPROTEASE THAT CATALYZES THE PROTEOLYTIC ACTIVATION OF BIG ENDOTHELIN-1	CELL			English	Article							RECEPTOR ANTAGONIST; CONVERTING ENZYME; NEUTRAL ENDOPEPTIDASE; MOLECULAR-CLONING; MESSENGER-RNA; EXPRESSION; CELLS; SEQUENCE; SUBTYPE; PROTEIN	Endothelin-1 (ET-1), a 21-residue vasoactive peptide, is produced in vascular endothelial cells from the 38-residue inactive intermediate big endothelin-1 via a specific cleavage at Trp-21-Val-22. The protease that catalyzes the conversion, endothelin-converting enzyme (ECE), constitutes a potential regulatory site for the production of the active peptide. We report the identification of ECE-1, a novel membrane-bound neutral metalloprotease that is expressed abundantly in endothelial cells in vivo and is structurally related to neutral endopeptidase 24.11 and Kell blood group protein. When transfected into cultured cells that normally secrete only big ET-1, the ECE-1 cDNA conferred the ability to secrete mature ET-1. In transfected cells, ECE-1 processes endogenously synthesized big ET-1 as well as exogenously supplied big ET-1, which interacts with ECE-1 on the cell surface. ECE-1 may provide a target for pharmacological intervention to alter ET-1 production.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235; MONTREAL GEN HOSP,DEPT PATHOL,MONTREAL H3G 1A4,PQ,CANADA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; McGill University	XU, D (corresponding author), UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235, USA.			Emoto, Noriaki/0000-0001-6673-2616				AHN K, 1992, P NATL ACAD SCI USA, V89, P8606, DOI 10.1073/pnas.89.18.8606; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BENIGNI A, 1993, KIDNEY INT, V44, P440, DOI 10.1038/ki.1993.263; BLOOM ITM, 1993, SURGERY, V114, P480; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLOZEL M, 1993, NATURE, V365, P759, DOI 10.1038/365759a0; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; GELLAI M, 1994, J CLIN INVEST, V93, P900, DOI 10.1172/JCI117046; GIAID A, 1993, NEW ENGL J MED, V328, P1732, DOI 10.1056/NEJM199306173282402; GIAID A, 1991, HISTOCHEMISTRY, V95, P303; GROVER GJ, 1993, CARDIOVASC RES, V27, P1613, DOI 10.1093/cvr/27.9.1613; IMAI T, 1992, BIOCHEM BIOPH RES CO, V182, P1115, DOI 10.1016/0006-291X(92)91847-J; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; INOUE A, 1989, J BIOL CHEM, V264, P14954; ITO H, 1993, J CLIN INVEST, V92, P398, DOI 10.1172/JCI116579; ITOH S, 1993, BIOCHEM BIOPH RES CO, V195, P969, DOI 10.1006/bbrc.1993.2139; KIVLIGHN SD, 1993, KIDNEY INT, V45, P131; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; LEE ME, 1991, J BIOL CHEM, V266, P16188; LEE S, 1991, P NATL ACAD SCI USA, V88, P6353, DOI 10.1073/pnas.88.14.6353; MALFROY B, 1988, FEBS LETT, V229, P206, DOI 10.1016/0014-5793(88)80828-7; MCMAHON EG, 1991, P NATL ACAD SCI USA, V88, P703, DOI 10.1073/pnas.88.3.703; NAKAJIMA K, 1989, J CARDIOVASC PHARM, V13, pS8, DOI 10.1097/00005344-198900135-00004; NISHIKIBE M, 1993, LIFE SCI, V52, P717, DOI 10.1016/0024-3205(93)90233-S; NISHIKORI K, 1991, NEUROCHEM INT, V18, P535, DOI 10.1016/0197-0186(91)90152-4; OHLSTEIN EH, 1994, IN PRESS P NATL ACAD; OHNAKA K, 1993, J BIOL CHEM, V268, P26759; OKADA K, 1993, EUR J BIOCHEM, V218, P493, DOI 10.1111/j.1432-1033.1993.tb18401.x; OPGENORTH TJ, 1992, FASEB J, V6, P2653, DOI 10.1096/fasebj.6.9.1612289; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; ROQUES BP, 1993, PHARMACOL REV, V45, P87; ROSOLOWSKY LJ, 1994, AM J PHYSIOL-ENDOC M, V266, P107; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; SAWAMURA T, 1991, BIOCHEM BIOPH RES CO, V174, P779, DOI 10.1016/0006-291X(91)91485-U; SEIDAH NG, 1993, ANN NY ACAD SCI, V680, P135, DOI 10.1111/j.1749-6632.1993.tb19680.x; SOGABE K, 1993, J PHARMACOL EXP THER, V264, P1040; STEIN PD, 1994, J MED CHEM, V37, P329, DOI 10.1021/jm00029a001; SUZUKI N, 1990, J IMMUNOL METHODS, V127, P165, DOI 10.1016/0022-1759(90)90065-4; TAKAHASHI M, 1993, J BIOL CHEM, V268, P21395; TSURUMI Y, 1994, J ANTIBIOT, V47, P667; TURNER AJ, 1993, BIOCHEM SOC T, V21, P697, DOI 10.1042/bst0210697; UJIIE K, 1992, J CLIN INVEST, V90, P1043, DOI 10.1172/JCI115918; Vane J R, 1992, J Physiol Pharmacol, V43, P195; VIJAYARAGHAVAN J, 1990, J BIOL CHEM, V265, P14150; WAXMAN L, 1993, ARCH BIOCHEM BIOPHYS, V308, P240; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YANAGISAWA M, 1994, CIRCULATION, V89, P1320, DOI 10.1161/01.CIR.89.3.1320	48	807	821	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 12	1994	78	3					473	485		10.1016/0092-8674(94)90425-1	http://dx.doi.org/10.1016/0092-8674(94)90425-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PC405	8062389				2022-12-24	WOS:A1994PC40500013
J	DEVINCENZI, I				DEVINCENZI, I			LONGITUDINAL-STUDY OF HUMAN-IMMUNODEFICIENCY-VIRUS TRANSMISSION BY HETEROSEXUAL PARTNERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEXUAL TRANSMISSION; HIV; DISEASE; WOMEN; MEN	Background. Worldwide, the predominant mode of human immunodeficiency virus (HIV) transmission is heterosexual intercourse, but the risk of heterosexual transmission and the effectiveness of measures to prevent it are not well defined. Methods. We conducted a prospective study of HIV-negative subjects whose only risk of HIV infection was a stable heterosexual relationship with an HIV-infected partner. Every six months the subjects were interviewed, tested for HIV, and counseled about safe sexual practices. Results. A total of 304 HIV-negative subjects (196 women and 108 men) were followed for an average of 20 months. During the study, 130 couples (42.8 percent) ended their sexual relationships, most often because of the HIV-infected partner's illness or death. Of the 256 couples who continued to have sexual relations for more than three months after enrollment in the study, only 124 (48.4 percent) used condoms consistently for vaginal and anal intercourse. Among these couples, none of the seronegative partners became infected with HIV, despite a total of about 15,000 episodes of intercourse. Among the 121 couples who used condoms inconsistently, the rate of seroconversion was 4.8 per 100 person-years (95 percent confidence interval, 2.5 to 8.4). Eleven couples refused to answer questions about condom use. The risk of transmission increased with advanced stages of HIV infection in the index partners (P<0.02) and with genital infection in the HIV-negative partners (P<0.04). Withdrawal to avoid ejaculation in the vagina had a protective effect in uninfected women (P<0.02). Conclusions. Consistent use of condoms for heterosexual intercourse is highly effective in preventing the transmission of HIV. Among couples not using condoms regularly, the risk of HIV transmission varies widely.			DEVINCENZI, I (corresponding author), HOP NATL ST MAURICE,EUROPEAN CTR EPIDEMIOL MONITORING AIDS,14 RUE VAL DOSNE,F-94410 ST MAURICE,FRANCE.							ANDERSON DJ, 1992, JAMA-J AM MED ASSOC, V267, P2769, DOI 10.1001/jama.267.20.2769; CHANCHEE C, 1991, GENITOURIN MED, V67, P173; DIXON WJ, 1990, BMDP STATISTICAL SOF, V2, P739; HAVERKOS HW, 1992, JAMA-J AM MED ASSOC, V268, P1855, DOI 10.1001/jama.1992.03490140063023; KAMENGA M, 1991, AIDS, V5, P61, DOI 10.1097/00002030-199101000-00009; KAPLAN EH, 1990, J ACQ IMMUN DEF SYND, V3, P55; KEET IPM, 1992, AIDS, V6, P223, DOI 10.1097/00002030-199202000-00014; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; PADIAN NS, 1993, J ACQ IMMUN DEF SYND, V6, P1043; PUDNEY J, 1992, LANCET, V340, P1470, DOI 10.1016/0140-6736(92)92659-4; ROSENBERG MJ, 1992, AM J PUBLIC HEALTH, V82, P1473, DOI 10.2105/AJPH.82.11.1473; SARACCO A, 1993, J ACQ IMMUN DEF SYND, V6, P497; SIDDIQUI NS, 1992, AIDS, V6, P1529, DOI 10.1097/00002030-199212000-00017; SIDDIQUI NS, 1993, AIDS, V7, P444; VOELLER B, 1990, AIDS SEX INTEGRATED, P276; WELLER SC, 1993, SOC SCI MED, V36, P1635, DOI 10.1016/0277-9536(93)90352-5; WILEY JA, 1989, STAT MED, V8, P93, DOI 10.1002/sim.4780080110; 1986, MMWR-MORBID MORTAL W, V35, P334; 1992, BRIT MED J, V304, P809	19	505	512	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 11	1994	331	6					341	346		10.1056/NEJM199408113310601	http://dx.doi.org/10.1056/NEJM199408113310601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PA374	8028613				2022-12-24	WOS:A1994PA37400001
J	WIEDMANN, B; SAKAI, H; DAVIS, TA; WIEDMANN, M				WIEDMANN, B; SAKAI, H; DAVIS, TA; WIEDMANN, M			A PROTEIN COMPLEX REQUIRED FOR SIGNAL-SEQUENCE-SPECIFIC SORTING AND TRANSLOCATION	NATURE			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; LARGE RIBOSOMAL-SUBUNIT; RECOGNITION PARTICLE; NASCENT PREPROLACTIN; ESCHERICHIA-COLI; CROSS-LINKING; POLYPEPTIDE-CHAINS; RECEPTOR; TRANSCRIPTION; CELL	We have purified a nascent-polypeptide-associated complex (NAC) which prevents short ribosome-associated nascent polypeptides from inappropriate interactions with proteins in the cytosol. NAC binds nascent-polypeptide domains emerging from ribosomes unless a signal peptide is fully exposed. Depletion of cytosolic proteins (including NAC) from ribosomes carrying nascent polypeptides allows the signal recognition particle (SRP) to crosslink to polypeptides irrespective of whether or not they contain signal peptides. In the absence of cytosol, proteins lacking signal peptides can be mistranslocated into the endoplasmic reticulum in vitro, albeit with low efficiency. Readdition of NAC restores the specificity of SRP and fidelity of translocation.	MEM SLOAN KETTERING CANC CTR, CELLULAR BIOCHEM & BIOPHYS PROGRAM, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center								BERNABEU C, 1982, P NATL ACAD SCI-BIOL, V79, P3111, DOI 10.1073/pnas.79.10.3111; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1970, J CELL BIOL, V45, P130, DOI 10.1083/jcb.45.1.130; BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BRUNNER J, 1993, ANNU REV BIOCHEM, V62, P483, DOI 10.1146/annurev.bi.62.070193.002411; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILMORE R, 1982, J CELL BIOL, V95, P463, DOI 10.1083/jcb.95.2.463; GILMORE R, 1991, METHOD CELL BIOL, V34, P223; GORLICH D, 1991, METHOD CELL BIOL, V34, P241; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HIGH S, 1991, J CELL BIOL, V113, P25, DOI 10.1083/jcb.113.1.25; KANNO M, 1992, GENE, V117, P219, DOI 10.1016/0378-1119(92)90732-5; KRIEG UC, 1986, P NATL ACAD SCI USA, V83, P8604, DOI 10.1073/pnas.83.22.8604; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; RAPIEJKO PJ, 1992, J CELL BIOL, V117, P493, DOI 10.1083/jcb.117.3.493; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1984, CELL, V38, P5, DOI 10.1016/0092-8674(84)90520-8; WALTER P, 1983, METHOD ENZYMOL, V96, P682; WALTER P, 1983, J CELL BIOL, V97, P1693, DOI 10.1083/jcb.97.6.1693; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WIEDMANN M, 1987, J CELL BIOL, V104, P201, DOI 10.1083/jcb.104.2.201; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0; YONATH A, 1987, SCIENCE, V236, P813, DOI 10.1126/science.3576200	30	331	349	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 11	1994	370	6489					434	440		10.1038/370434a0	http://dx.doi.org/10.1038/370434a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	8047162				2022-12-24	WOS:A1994PB40700048
J	BURDEN, AD; VESTEY, JP; SIREL, JM; AITCHISON, TC; HUNTER, JAA; MACKIE, RM				BURDEN, AD; VESTEY, JP; SIREL, JM; AITCHISON, TC; HUNTER, JAA; MACKIE, RM			MULTIPLE PRIMARY MELANOMA - RISK-FACTORS AND PROGNOSTIC IMPLICATIONS	BRITISH MEDICAL JOURNAL			English	Article							CUTANEOUS MALIGNANT-MELANOMA		UNIV EDINBURGH,ROYAL INFIRM,DEPT DERMATOL,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND; UNIV GLASGOW,DEPT STAT,GLASGOW G12 8QW,SCOTLAND	Royal Infirmary of Edinburgh; University of Edinburgh; University of Glasgow	BURDEN, AD (corresponding author), UNIV GLASGOW,WESTERN INFIRM,DEPT DERMATOL,GLASGOW G11 6NT,SCOTLAND.							GUPTA BK, 1991, CANCER-AM CANCER SOC, V67, P1984, DOI 10.1002/1097-0142(19910401)67:7<1984::AID-CNCR2820670727>3.0.CO;2-H; KANG S, 1992, CANCER, V70, P1911, DOI 10.1002/1097-0142(19921001)70:7<1911::AID-CNCR2820700718>3.0.CO;2-Q; MACKIE R, 1992, LANCET, V339, P971, DOI 10.1016/0140-6736(92)91539-K; Scheibner A, 1982, Australas J Dermatol, V23, P1, DOI 10.1111/j.1440-0960.1982.tb00230.x; SLINGLUFF CL, 1993, SURGERY, V113, P330	5	39	39	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 6	1994	309	6951					375	375						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB316	8081136				2022-12-24	WOS:A1994PB31600018
J	ROBERTSON, JR; RONALD, PJM; RAAB, GM; ROSS, AJ; PARPIA, T				ROBERTSON, JR; RONALD, PJM; RAAB, GM; ROSS, AJ; PARPIA, T			DEATHS, HIV-INFECTION, ABSTINENCE, AND OTHER OUTCOMES IN A COHORT OF INJECTING DRUG-USERS FOLLOWED UP FOR 10 YEARS	BRITISH MEDICAL JOURNAL			English	Article							RISK-TAKING BEHAVIOR; HEROIN-ADDICTION; RECOVERY	Objective-To trace, follow up, and interview a group of patients known to be injecting drug users in order to establish current drug taking and other features related to drug use over 10 gears. Design-Descriptive follow up study of a cohort of injecting drug users established between 1982 and 1985. Setting-General practice based patient population study initially, with later tracing of subjects throughout the United Kingdom through NHS Central Registries and current general practitioners. Subjects-203 injecting drug users recruited up to December 1985. Main outcome measures-Survival, cause of death, abstinence, or continued drug use; HIV status; and demographic variables. Results-Of the 203 injecting drug users recruited into the study, over half were known to be HIV positive and 42 died of various causes (increasingly AIDS). From the start of follow up in 1990, 163 (91%) of the 180 survivors were traced, of whom 116 (71%) were interviewed. Dramatic changes had occurred in drug taking, with a move away from injecting towards oral drug use. A few patients, however, continued to inject. 90 (78%) of those interviewed had been in prison, of whom 37 (41%) had injected drugs while in prison. Conclusions-The pattern of deaths had changed from being largely due to overdose in the early 1980s to predominantly AIDS related in later years, The reduction in deaths due to overdose may have been connected with but was not always causally related to a new approach by legal, social, and medical services. Drug use continues in a modified form in a large proportion of patients followed up. As a group, drug users require long term support for a multiplicity of problems.	CTR HIV RES,MRC BIOSTAT INITIAT AIDS & HIV RES SCOTLAND,EDINBURGH EH9 3JN,MIDLOTHIAN,SCOTLAND		ROBERTSON, JR (corresponding author), MUIRHOUSE MED GRP,EDINBURGH DRUG ADDICT STUDY,EDINBURGH EH4 4PL,MIDLOTHIAN,SCOTLAND.							[Anonymous], 1988, AIDS DRUG MISUSE 1; BATH GE, 1993, LANCET, V342, P1368, DOI 10.1016/0140-6736(93)92279-3; BEWLEY TH, 1968, BRIT MED J, V1, P725, DOI 10.1136/bmj.1.5594.725; BUCKNALL ABV, 1986, J ROY COLL GEN PRACT, V36, P120; CHAPPLE PAL, 1972, BRIT J ADDICT, V67, P33; CHERUBIN CE, 1993, ANN INTERN MED, V119, P1017, DOI 10.7326/0003-4819-119-10-199311150-00009; GREENWOOD J, 1990, BRIT MED J, V300, P587, DOI 10.1136/bmj.300.6724.587; NEWMAN RG, 1988, NEW ENGL J MED, V318, P386; ROBERTSON JR, 1988, BRIT J ADDICT, V83, P387; ROBINS LN, 1993, ADDICTION, V88, P1041, DOI 10.1111/j.1360-0443.1993.tb02123.x; RONALD PJM, 1993, BRIT MED J, V307, P1184, DOI 10.1136/bmj.307.6913.1184; RONALD PJM, 1992, BRIT J ADDICT, V87, P115; SELWYN PA, 1993, ANN INTERN MED, V119, P1044, DOI 10.7326/0003-4819-119-10-199311150-00013; SKIDMORE CA, 1989, BRIT J ADDICT, V84, P695; SKIDMORE CA, 1990, BRIT MED J, V300, P219, DOI 10.1136/bmj.300.6719.219; STIMSON GV, 1978, BRIT MED J, V1, P1190, DOI 10.1136/bmj.1.6121.1190; VALLAINT GE, 1973, ARCH GEN PSYCHIAT, V29, P237; WALDORF D, 1979, J DRUG ISSUES, V9, P281, DOI 10.1177/002204267900900212; 1989, AIDS DRUGS MISUSE 2; 1985, MISUSE DRUGS SPECIAL; 1988, LANCET, V2, P1039; 1984, GUIDELINES GOOD CLIN; 1993, AIDS DRUGS MISUSE UP; 1992, GUIDELINES GOOD CLIN	24	46	46	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 6	1994	309	6951					369	372		10.1136/bmj.309.6951.369	http://dx.doi.org/10.1136/bmj.309.6951.369			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PB316	8081134	Green Published			2022-12-24	WOS:A1994PB31600016
J	ROSENTHAL, N				ROSENTHAL, N			TOOLS OF THE TRADE - RECOMBINANT-DNA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article														Rosenthal, Nadia/0000-0002-7599-7365				LEWIN B, 1993, GENES, V5; WATSON J, 1992, RECOMBINANT DNA SHOR	2	27	27	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 4	1994	331	5					315	317		10.1056/NEJM199408043310508	http://dx.doi.org/10.1056/NEJM199408043310508			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NZ227	8022444				2022-12-24	WOS:A1994NZ22700008
J	NEUMANN, PJ; GHARIB, SD; WEINSTEIN, MC				NEUMANN, PJ; GHARIB, SD; WEINSTEIN, MC			THE COST OF A SUCCESSFUL DELIVERY WITH IN-VITRO FERTILIZATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEONATAL INTENSIVE-CARE; LOW-BIRTH-WEIGHT; INVITRO FERTILIZATION; ASSISTED CONCEPTION; MULTIPLE BIRTHS; OVARIAN-CANCER; TRIPLET; PREGNANCIES; INFERTILITY; RISKS	Background. The use of in vitro fertilization has engendered considerable debate about who should have the procedure, whether health insurance should cover the cost, and if so, to what extent. We investigated the cost of a successful delivery with in vitro fertilization. Methods. We calculated the cost per successful delivery with in vitro fertilization (defined as at least one live birth) for a general population of couples undergoing in vitro fertilization and for two subgroups: couples with a diagnosis of tubal disease (who have a better chance of success), and couples in which the woman is over the age of 40 years and the man has a low sperm count (who have a lower chance of success). Information on charges per cycle of in vitro fertilization was obtained from six facilities across the country; delivery rates with this procedure were estimated from the literature. Results. On average, the cost incurred per successful delivery with in vitro fertilization increases from $66,667 for the first cycle of in vitro fertilization to $114,286 by the sixth cycle. The cost increases because with each cycle in which fertilization fails, the probability that a subsequent effort will be successful declines. Sensitivity analyses indicated that the cost per delivery ranges from $44,000 to $211,940. For couples with a better chance of successful in vitro fertilization (i.e., those with a diagnosis of tubal disease), it costs $50,000 per delivery for the first cycle and $72,727 for the sixth. For couples in which the woman is older and there is a diagnosis of male-factor infertility, the cost rises from $160,000 for the first cycle to $800,000 for the sixth. Conclusions. The debate about insurance coverage for in vitro fertilization must take into account ethical judgments and social values. But analyses of costs and cost effectiveness help elucidate the economic implications of using in vitro fertilization and thus inform the policy discussion.	BRIGHAM & WOMENS HOSP, DIV GEN MED & PRIMARY CARE, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	NEUMANN, PJ (corresponding author), PROJECT HOPE CTR HLTH AFFAIRS, SUITE 600, 7500 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA.							BLACKMAN JA, 1991, PEDIATR CLIN N AM, V38, P1497; BONNICKSEN AL, 1989, IN VITRO FERTILIZATI; BOTTING BJ, 1987, ARCH DIS CHILD, V62, P941, DOI 10.1136/adc.62.9.941; BOYLE MH, 1983, NEW ENGL J MED, V308, P1330, DOI 10.1056/NEJM198306023082206; BRANDES JM, 1992, PEDIATRICS, V90, P424; BROMWICH P, 1989, LANCET, V2, P1327; DALTON M, 1989, LANCET, V2, P1327; DEMOUZON J, 1993, FERTIL STERIL, V59, P587; EDWARDS RG, 1989, LANCET, V2, P1328; Ewald U, 1991, Int J Technol Assess Health Care, V7 Suppl 1, P155; GUZICK DS, 1986, FERTIL STERIL, V46, P663; HARTZ SC, 1992, FERTIL STERIL, V57, P15; HERSHLAG A, 1991, FERTIL STERIL, V56, P913; HOWE RS, 1988, FERTIL STERIL, V49, P726; HULL MGR, 1992, BRIT MED J, V304, P1465, DOI 10.1136/bmj.304.6840.1465; JOHANNES CB, 1993, FERTIL STERIL, V59, P250, DOI 10.1016/S0015-0282(16)55656-8; KELLY TE, 1986, CLIN GENETICS GENETI, P218; KINGSLAND CR, 1990, EUR J OBSTET GYN R B, V34, P197, DOI 10.1016/0028-2243(90)90071-8; LEVENE MI, 1992, BRIT J OBSTET GYNAEC, V99, P607, DOI 10.1111/j.1471-0528.1992.tb13831.x; LEVRAN D, 1990, NEW ENGL J MED, V323, P1153, DOI 10.1056/NEJM199010253231701; NEUMANN PJ, 1994, MED CARE, V32, P686, DOI 10.1097/00005650-199407000-00003; PADILLA SL, 1989, FERTIL STERIL, V52, P270; PAGE H, 1989, J ROY SOC MED, V82, P99, DOI 10.1177/014107688908200216; Petrikovsky B M, 1989, Obstet Gynecol Surv, V44, P578, DOI 10.1097/00006254-198908000-00002; SASSOON DA, 1990, OBSTET GYNECOL, V75, P817; SCHENKER JG, 1994, FERTIL STERIL, V61, P411; SEOUD MAF, 1992, FERTIL STERIL, V57, P825; SMITH BH, 1991, BRIT MED J, V302, P127, DOI 10.1136/bmj.302.6769.127; SPIRTAS R, 1993, FERTIL STERIL, V59, P291; TAN SL, 1992, LANCET, V339, P1390, DOI 10.1016/0140-6736(92)91205-M; TRAVERS B, 1992, BRIT MED J, V305, P50, DOI 10.1136/bmj.305.6844.50-c; WAGNER MG, 1989, LANCET, V2, P1027; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1175, DOI 10.1093/oxfordjournals.aje.a116426; 1993, INFERTILITY NATIONAL; 1990, ANN CLIN SPECIFIC RE; 1991, STATE LAWS INFERTILI; 1989, CLIN GYNECOLOGIC END, P611; 1987, 38 OFF TECHN ASS HLT	39	184	184	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 28	1994	331	4					239	243		10.1056/NEJM199407283310406	http://dx.doi.org/10.1056/NEJM199407283310406			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY335	8015571				2022-12-24	WOS:A1994NY33500006
J	ROSENBERG, SM; LONGERICH, S; GEE, P; HARRIS, RS				ROSENBERG, SM; LONGERICH, S; GEE, P; HARRIS, RS			ADAPTIVE MUTATION BY DELETIONS IN SMALL MONONUCLEOTIDE REPEATS	SCIENCE			English	Article							ESCHERICHIA-COLI; FRAMESHIFT MUTATION; MISMATCH REPAIR; TUMOR-CELLS; RECOMBINATION; RECD; GENE; MUTANTS; ORIGIN; CANCER	Adaptive reversion of a +1 frameshift mutation in Escherichia coli, which requires homologous recombination functions, is shown here to occur by -1 deletions in regions of small mononucleotide repeats. This pattern makes improbable recombinational mechanisms for adaptive mutation in which blocks of sequences are transferred into the mutating gene, and it supports mechanisms that use DNA polymerase errors. The pattern appears similar to that of mutations found in yeast cells and in hereditary colon cancer cells that are deficient in mismatch repair. These results suggest a recombinational mechanism for adaptive mutation that functions through polymerase errors that persist as a result of a deficiency in post-synthesis mismatch repair.	UNIV ALBERTA, DEPT GENET, EDMONTON T6G 2E9, AB, CANADA; UNIV CALIF BERKELEY, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA	University of Alberta; University of California System; University of California Berkeley	ROSENBERG, SM (corresponding author), UNIV ALBERTA, FAC MED, DEPT BIOCHEM, EDMONTON T6G 2H7, AB, CANADA.			Rosenberg, Susan M./0000-0003-1444-473X				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; AMUNDSEN SK, 1986, P NATL ACAD SCI USA, V83, P5558, DOI 10.1073/pnas.83.15.5558; BIEK DP, 1986, J BACTERIOL, V167, P594, DOI 10.1128/jb.167.2.594-603.1986; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; CAIRNS J, 1991, GENETICS, V128, P695; DEMEREC M, 1962, P NATL ACAD SCI USA, V48, P1696, DOI 10.1073/pnas.48.10.1696; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FLEACH FS, 1993, CELL, V75, P1215; FOSTER PL, 1992, GENETICS, V131, P783; FOSTER PL, 1993, ANNU REV MICROBIOL, V47, P467; GRAFEN A, 1988, NATURE, V336, P525, DOI 10.1038/336525b0; HALL BG, 1990, GENETICS, V125, P5; HARRIS RS, 1994, SCIENCE, V264, P258, DOI 10.1126/science.8146657; HASTINGS PJ, 1992, ENCY IMMUNOLOGY, P602; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JAYARAMAN R, 1992, J GENET, V71, P23, DOI 10.1007/BF02927873; Luria SE, 1943, GENETICS, V28, P491; MAGNI GE, 1962, GENETICS, V47, P1097; MAIZELS N, 1991, CELL, V48, P359; MCGILL C, 1993, CURR GENET, V23, P430; Miller J.H., 1992, SHORT COURSE BACTERI, P150; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PASZEWSKI A, 1964, NATURE, V204, P809, DOI 10.1038/204809a0; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; ROSENBERG SM, 1991, BIOCHIMIE, V73, P385, DOI 10.1016/0300-9084(91)90105-A; ROTH J, 1992, GENETICS, V132, P865; ROTHENFLUH H, 1993, TODAYS LIFE SCI, V5, P8; STAHL FW, 1989, NATURE, V355, P112; Steele E.J., 1979, SOMATIC SELECTION AD; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; STRAUSS BS, 1992, CANCER RES, V52, P249; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; THALER DS, 1994, TRENDS ECOL EVOL, V9, P108, DOI 10.1016/0169-5347(94)90208-9; THALER DS, 1989, GENOME, V31, P53, DOI 10.1139/g89-013; THALER DS, 1990, BACTERIAL CHROMOSOME, P445	35	193	199	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 15	1994	265	5170					405	407		10.1126/science.8023163	http://dx.doi.org/10.1126/science.8023163			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023163				2022-12-24	WOS:A1994NW81600043
J	BRETELER, MMB; CLAUS, JJ; GROBBEE, DE; HOFMAN, A				BRETELER, MMB; CLAUS, JJ; GROBBEE, DE; HOFMAN, A			CARDIOVASCULAR-DISEASE AND DISTRIBUTION OF COGNITIVE FUNCTION IN ELDERLY PEOPLE - THE ROTTERDAM STUDY	BRITISH MEDICAL JOURNAL			English	Article							MINI-MENTAL-STATE; ARTERIAL-DISEASE; SENILE DEMENTIA; POPULATION	Objective-To investigate the distribution of cognitive function in elderly people and to assess the impact of clinical manifestations of atherosclerotic disease on this distribution. Design-Single centre population based cross sectional door to door study. Setting--Ommoord, a suburb of Rotterdam, the Netherlands. Subjects-4971 subjects aged 55 to 94 years. Main outcome measure-Cognitive function as measured by the mini mental state examination. Results-The overall participation rate in the study was 80%. Cognitive test data were available for 90% of the participants. Increasing age and lower educational level were associated with poorer cognitive function. Previous vascular events, presence of plaques in the carotid arteries, and presence of peripheral arterial atherosclerotic disease were associated with worse cognitive performance independent of the effects of age and education. On average the differences were moderate; however, they reflected the net result of a shift of the total population distribution of cognitive function towards lower values. Thereby, they resulted in a considerable increase in the proportion of subjects with scores indicative of dementia. Conclusions-These findings are compatible with the view that atherosclerotic disease accounts for considerable cognitive impairment in the general population.	ERASMUS UNIV ROTTERDAM,SCH MED,DEPT NEUROL,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam	BRETELER, MMB (corresponding author), ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,3000 DR ROTTERDAM,NETHERLANDS.		Grobbee, Diederick/C-7651-2014; Breteler, Monique M.B./J-5058-2014	Grobbee, Diederick/0000-0003-4472-4468; Breteler, Monique M.B./0000-0002-0626-9305				BRAYNE C, 1988, LANCET, V1, P1265; BRAYNE C, 1990, AGE AGEING, V19, P91, DOI 10.1093/ageing/19.2.91; BRETELER MMB, 1992, NEUROEPIDEMIOLOGY, V11, P23, DOI 10.1159/000110957; DEWEY ME, 1990, CASE FINDING DEMENTI; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FOWKES FGR, 1991, INT J EPIDEMIOL, V20, P384, DOI 10.1093/ije/20.2.384; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; HACHINSKI V, 1992, LANCET, V340, P645; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; RAPP PR, 1992, TRENDS NEUROSCI, V15, P340, DOI 10.1016/0166-2236(92)90051-9; ROMAN GC, 1987, JAMA-J AM MED ASSOC, V258, P1782, DOI 10.1001/jama.258.13.1782; Rose G., 1992, STRATEGY PREVENTIVE; Rothman K, 1986, MODERN EPIDEMIOLOGY; ROWE JW, 1987, SCIENCE, V237, P143, DOI 10.1126/science.3299702; SCHERR PA, 1988, AM J EPIDEMIOL, V128, P1084; SCHROLL M, 1981, J CHRON DIS, V34, P261, DOI 10.1016/0021-9681(81)90031-X; STEWART RB, 1991, GERONTOLOGY, V37, P2272; TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x; VOGT MT, 1992, J CLIN EPIDEMIOL, V45, P529, DOI 10.1016/0895-4356(92)90102-S; 1987, SOI1978 NETH CENTR B	20	419	427	0	22	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 18	1994	308	6944					1604	1608		10.1136/bmj.308.6944.1604	http://dx.doi.org/10.1136/bmj.308.6944.1604			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NT528	8025427	Green Published			2022-12-24	WOS:A1994NT52800018
J	PEEL, NFA; BARRINGTON, NA; SMITH, TWD; EASTELL, R				PEEL, NFA; BARRINGTON, NA; SMITH, TWD; EASTELL, R			DISTAL FOREARM FRACTURE AS RISK FACTOR FOR VERTEBRAL OSTEOPOROSIS	BRITISH MEDICAL JOURNAL			English	Article									UNIV SHEFFIELD,DEPT HUMAN METAB & CLIN BIOCHEM,SHEFFIELD,ENGLAND; NO GEN HOSP,DEPT DIAGNOST IMAGING,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND; NO GEN HOSP,DEPT ORTHOPAED,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND	University of Sheffield; Northern General Hospital; Northern General Hospital			Eastell, Richard/G-5851-2011	Eastell, Richard/0000-0002-0323-3366				KLEINBAUM DJ, 1978, APPLIED REGRESSION A; OWEN RA, 1982, CLIN ORTHOPAEDICS, V171, P37; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; ROSS PD, 1991, ANN INTERN MED, V114, P919, DOI 10.7326/0003-4819-114-11-919	4	32	32	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 11	1994	308	6943					1543	1544		10.1136/bmj.308.6943.1543	http://dx.doi.org/10.1136/bmj.308.6943.1543			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR110	8019311	Green Published			2022-12-24	WOS:A1994NR11000024
J	TSAI, FY; KELLER, G; KUO, FC; WEISS, M; CHEN, JZ; ROSENBLATT, M; ALT, FW; ORKIN, SH				TSAI, FY; KELLER, G; KUO, FC; WEISS, M; CHEN, JZ; ROSENBLATT, M; ALT, FW; ORKIN, SH			AN EARLY HEMATOPOIETIC DEFECT IN MICE LACKING THE TRANSCRIPTION FACTOR GATA-2	NATURE			English	Article							EMBRYONIC STEM-CELLS; ERYTHROID-DIFFERENTIATION; TARGETED MUTATION; DEVELOPING MOUSE; DNA-BINDING; YOLK-SAC; ES CELLS; EXPRESSION; GENE; HEMATOPOIESIS	Blood cell development relies on the expansion and maintenance of haematopoietic stem and progenitor cells in the embryo. By gene targeting in mouse embryonic stem cells, we demonstrate that the transcription factor GATA-2 plays a critical role in haematopoiesis, particularly of an adult type. We propose that GATA-2 regulates genes controlling growth factor responsiveness or the proliferative capacity of early haematopoietic cells.	CHILDRENS HOSP,DIV HEMATOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PEDIAT,BOSTON,MA 02115; CHILDRENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,CTR BLOOD RES,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO 80206	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; National Jewish Health			Weiss, Mitchell J/W-9814-2018	Weiss, Mitchell J/0000-0003-2460-3036; Keller, Gordon/0000-0001-9309-9297				BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; CHEN JZ, 1993, CURR BIOL, V3, P405, DOI 10.1016/0960-9822(93)90347-Q; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DORFMAN DM, 1992, J BIOL CHEM, V267, P1279; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FLEISCHMAN RA, 1993, TRENDS GENET, V9, P285, DOI 10.1016/0168-9525(93)90015-A; GEISSLER EN, 1981, GENETICS, V97, P337; GODIN IE, 1993, NATURE, V364, P67, DOI 10.1038/364067a0; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KELLER G, 1993, MOL CELL BIOL, V13, P472; KELLEY C, IN PRESS DEV BIOL; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEONARD M, 1993, BLOOD, V82, P1071; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MOUTHON MA, 1993, BLOOD, V81, P647; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; ORKIN SH, 1992, BLOOD, V80, P575; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Robertson E. J., 1987, TERATOCARCINOMAS EMB; RUSSELL ES, 1968, GENETICS, V58, P259; RUSSELL ES, 1979, ADV GENET, V20, P358; Sambrook J., 1989, MOL CLONING LAB MANU; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VISVADER J, 1993, BLOOD, V82, P1493; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WHITNEY JB, 1978, BIOCHEM GENET, V16, P667, DOI 10.1007/BF00484723; WILES MV, 1991, DEVELOPMENT, V111, P259; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650	39	1157	1184	4	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 15	1994	371	6494					221	226		10.1038/371221a0	http://dx.doi.org/10.1038/371221a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG290	8078582				2022-12-24	WOS:A1994PG29000043
J	ANG, SL; ROSSANT, J				ANG, SL; ROSSANT, J			HNF-3-BETA IS ESSENTIAL FOR NODE AND NOTOCHORD FORMATION IN MOUSE DEVELOPMENT	CELL			English	Article							DEVELOPING NERVOUS-SYSTEM; EMBRYONIC STEM-CELLS; GERM LAYER FORMATION; GENE FORK-HEAD; FLOOR PLATE; CHICK-EMBRYO; NEURAL INDUCTION; XENOPUS-LAEVIS; FROG EMBRYOS; PATTERN-FORMATION	HNF-3 beta, a member of the HNF-3/fork head family of transcription factors, is expressed in the node, notochord, floor plate, and gut in mouse embryos. A null mutation of this gene leads to embryonic lethality. The primary defect of HNF-3 beta(-/-) embryos is an absence of organized node and notochord formation, which leads to secondary defects in dorsal-ventral patterning of the neural tube. In contrast, patterning along the anterior-posterior axis was surprisingly little affected. Although HNF-3 beta is required for node and notochord formation, some organizer activity persists in the absence of these structures. HNF-3 beta is not required for the development of definitive endoderm cells, but foregut morphogenesis is severely affected in HNF-3 beta(-/-)embryos.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO M5G 1X5,ON,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ON,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto								ALTABA AR, 1993, J NEUROBIOL, V24, P1276, DOI 10.1002/neu.480241004; ALTABA ARI, 1992, DEVELOPMENT, V116, P81; ALTABA ARI, 1993, P NATL ACAD SCI USA, V90, P8268, DOI 10.1073/pnas.90.17.8268; ALTABA ARI, 1993, MECH DEVELOP, V44, P91, DOI 10.1016/0925-4773(93)90060-B; ANG SL, 1993, DEVELOPMENT, V118, P139; ANG SL, 1993, DEVELOPMENT, V119, P1301; BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; BEDDINGTON RSP, 1993, CURR OPIN GENET DEV, V3, P655, DOI 10.1016/0959-437X(93)90103-V; BEDDINGTON RSP, 1994, DEVELOPMENT, V120, P613; BEDDINGTON RSP, 1989, DEVELOPMENT, V116, P357; BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CONLON RA, 1993, METHOD ENZYMOL, V225, P373; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DIAS MS, 1990, ANAT REC, V229, P437; DIETRICH S, 1993, MECH DEVELOP, V44, P189, DOI 10.1016/0925-4773(93)90067-8; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; DONIACH T, 1993, J NEUROBIOL, V24, P1256, DOI 10.1002/neu.480241003; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; GOSSLER A, 1989, SCIENCE, V244, P463, DOI 10.1126/science.2497519; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; GUILLEMOT F, 1993, MECH DEVELOP, V42, P171, DOI 10.1016/0925-4773(93)90006-J; HEMMATIBRIVANLOU A, 1990, SCIENCE, V250, P800, DOI 10.1126/science.1978411; HERRMANN BG, 1991, DEVELOPMENT, V113, P913; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; JONES EA, 1989, DEVELOPMENT, V107, P785; KNOCHEL S, 1992, MECH DEVELOP, V38, P157, DOI 10.1016/0925-4773(92)90007-7; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LAI E, 1990, GENE DEV, V4, P1426; LAWSON KA, 1987, DEVELOPMENT, V101, P627; LAWSON KA, 1991, DEVELOPMENT, V113, P891; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MOENS CB, 1992, GENE DEV, V6, P691, DOI 10.1101/gad.6.5.691; MONAGHAN AP, 1993, DEVELOPMENT, V119, P567; MOTRO B, 1991, DEVELOPMENT, V113, P1207; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NIEHRS C, 1993, CELL, V72, P491, DOI 10.1016/0092-8674(93)90069-3; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; POURQUIE O, 1993, P NATL ACAD SCI USA, V90, P5242, DOI 10.1073/pnas.90.11.5242; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; Ruiz i Altaba A., 1993, CURR OPIN GENE DEV, V3, P633; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SASAKI H, 1993, DEVELOPMENT, V118, P47; SCHOENWOLF GC, 1992, DEV DYNAM, V193, P235, DOI 10.1002/aja.1001930304; SCHULTEMERKER S, 1994, DEVELOPMENT, V120, P843; SELLECK MAJ, 1991, DEVELOPMENT, V112, P615; SELLECK MAJ, 1992, DEVELOPMENT, V114, P403; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; SIVE HL, 1993, GENE DEV, V7, P1, DOI 10.1101/gad.7.1.1; SLACK JMW, 1992, DEVELOPMENT, V114, P285; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STOREY KG, 1992, DEVELOPMENT, V114, P729; STRAHLE U, 1993, GENE DEV, V7, P1436, DOI 10.1101/gad.7.7b.1436; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANSTRAATEN HWM, 1989, DEVELOPMENT, V107, P793; Waddington CH, 1933, J EXP BIOL, V10, P38; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; WILKINSON DG, 1989, NATURE, V341, P405, DOI 10.1038/341405a0; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I; WURST W, 1993, GENE TARGETING PRACT, P31; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	68	857	877	2	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 26	1994	78	4					561	574		10.1016/0092-8674(94)90522-3	http://dx.doi.org/10.1016/0092-8674(94)90522-3			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	8069909				2022-12-24	WOS:A1994PD69300006
J	DERRY, JMJ; OCHS, HD; FRANCKE, U				DERRY, JMJ; OCHS, HD; FRANCKE, U			ISOLATION OF A NOVEL GENE MUTATED IN WISKOTT-ALDRICH SYNDROME	CELL			English	Article							HUMAN X-CHROMOSOME; LYMPHOCYTE SURFACE SIALOGLYCOPROTEIN; TRANSCRIPTION FACTOR; FUNCTIONAL DISSECTION; CELL LINEAGES; EXPRESSION; REGION; IDENTIFICATION; SEQUENCES; PROTEIN	Wiskott-Aldrich syndrome (WAS) is an X-linked recessive immunodeficiency characterized by eczema, thrombocytopenia, and recurrent infections. Linkage studies have placed the gene at Xp11.22-p11.23. We have isolated from this interval a novel gene, WASP, which is expressed in lymphocytes, spleen, and thymus. The gene is not expressed in two unrelated WAS patients, one of whom has a single base deletion that produces a frame shift and premature termination of translation. Two additional patients have been identified with point mutations that change the same arginine residue to either a histidine or a leucine. WASP encodes a 501 amino acid proline-rich protein that is likely to be a key regulator of lymphocyte and platelet function.	STANFORD UNIV, MED CTR, DEPT GENET, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, DEPT PEDIAT, STANFORD, CA 94305 USA; UNIV WASHINGTON, SCH MED, DEPT PEDIAT, SEATTLE, WA 98195 USA	Stanford University; Stanford University; University of Washington; University of Washington Seattle	DERRY, JMJ (corresponding author), STANFORD UNIV, MED CTR, BECKMAN CTR MOLEC & GENET MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA.							Ammann AJ, 1989, IMMUNOLOGIC DISORDER, P257; BASILE GD, 1989, LANCET, V2, P1319; BROCHSTEIN JA, 1991, J PEDIATR-US, V119, P907, DOI 10.1016/S0022-3476(05)83041-0; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; Creighton T. E., 1984, PROTEINS, P242; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DONNER M, 1988, BLOOD, V72, P1849; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FEARON ER, 1988, BLOOD, V72, P1735; GEALY WJ, 1980, LANCET, V1, P63; GERAGHTY MT, 1993, GENOMICS, V16, P440, DOI 10.1006/geno.1993.1208; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; Goodship J., 1991, J PEDIATR, V119, P907; GREEN ED, 1990, SCIENCE, V250, P94, DOI 10.1126/science.2218515; GREER WL, 1989, GENOMICS, V4, P60, DOI 10.1016/0888-7543(89)90315-7; GREER WL, 1989, BIOCHEM CELL BIOL, V67, P503, DOI 10.1139/o89-081; GREER WL, 1990, GENOMICS, V6, P568, DOI 10.1016/0888-7543(90)90489-H; GREER WL, 1992, HUM GENET, V88, P453, DOI 10.1007/BF00215681; HIGGINS EA, 1991, J BIOL CHEM, V266, P6280; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; IMAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P4503, DOI 10.1093/nar/19.16.4503; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KWAN S-P, 1988, Genomics, V3, P39, DOI 10.1016/0888-7543(88)90156-5; KWAN SP, 1991, GENOMICS, V10, P29, DOI 10.1016/0888-7543(91)90480-3; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAFRENIERE RG, 1991, GENOMICS, V11, P352, DOI 10.1016/0888-7543(91)90143-3; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MAJERUS PW, 1987, MOL BASIS BLOOD DISE, P689; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MOLINA IJ, 1993, J IMMUNOL, V151, P4383; MOLINA IJ, 1992, J EXP MED, V176, P867, DOI 10.1084/jem.176.3.867; MORGAN JG, 1992, NUCLEIC ACIDS RES, V20, P5173, DOI 10.1093/nar/20.19.5173; Nizetle D., 1991, BLOOD, V77, P2677; NOTARANGELO LD, 1991, HUM GENET, V88, P237; OCHS HD, 1980, BLOOD, V55, P243; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; OPPENHEIM JJ, 1970, J IMMUNOL, V104, P835; PEACOCKE M, 1987, P NATL ACAD SCI USA, V84, P3430, DOI 10.1073/pnas.84.10.3430; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; PILLER F, 1991, J EXP MED, V173, P1501, DOI 10.1084/jem.173.6.1501; RAMBALDI I, 1994, NUCLEIC ACIDS RES, V22, P376, DOI 10.1093/nar/22.3.376; REMOLDODONNELL E, 1984, J EXP MED, V159, P1705, DOI 10.1084/jem.159.6.1705; REMOLDODONNELL E, 1987, BLOOD, V70, P104; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHLESSINGER D, 1993, CYTOGENET CELL GENET, V64, P147, DOI 10.1159/000133572; SHELLEY CS, 1989, P NATL ACAD SCI USA, V86, P2819, DOI 10.1073/pnas.86.8.2819; SIMON HU, 1992, J CLIN INVEST, V90, P1396, DOI 10.1172/JCI116006; SIMPSON SB, 1994, MOL CELL BIOL, V14, P1835, DOI 10.1128/MCB.14.3.1835; STANDEN GR, 1986, Q J MED, V59, P401; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	56	738	772	0	30	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 26	1994	78	4					635	644		10.1016/0092-8674(94)90528-2	http://dx.doi.org/10.1016/0092-8674(94)90528-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	8069912				2022-12-24	WOS:A1994PD69300012
J	MOSCICKI, RA; SANMARTIN, JE; QUINTERO, CH; RAUCH, SD; NADOL, JB; BLOCH, KJ				MOSCICKI, RA; SANMARTIN, JE; QUINTERO, CH; RAUCH, SD; NADOL, JB; BLOCH, KJ			SERUM ANTIBODY TO INNER-EAR PROTEINS IN PATIENTS WITH PROGRESSIVE HEARING-LOSS - CORRELATION WITH DISEASE-ACTIVITY AND RESPONSE TO CORTICOSTEROID TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AUTOANTIBODIES; TESTS	Objective.-To test whether detection of serum antibody to a 68-kd inner ear protein distinguishes among different causes of sensorineural hearing loss, and identifies patients with active disease and those likely to respond to corticosteroid therapy. Design.-Serum samples were tested by Western blot using bovine inner ear extract as antigen, and results were correlated with patient information obtained by chart review. Setting.-Referral center. Subjects of Study.-Serum samples were obtained from patients with idiopathic, progressive, bilateral sensorineural hearing loss (IPBSNHL) (n=72) otosclerosis (n=11), Cogan's syndrome (n=8), patients with positive tests for antinuclear antibodies (n=10), and normal controls (n=53). Main Outcome Measure.-Detection of serum antibody to a 68-kd inner eat protein. Results.-Serum from 42 of 72 patients with IPBSNHL reacted with a 68-kd protein constituent of inner ear extract. This reactivity was not detected in serum from 11 of 11 patients with otosclerosis, or in eight of eight with Cogan's syndrome. It was found in serum from one of 10 patients with a positive test for antinuclear antibody and in one of 53 normal controls. Antibody to the 68-kd protein was detected in serum from 89% of patients with actively progressing IPBSNHL and none of the 25 patients with inactive disease (P<.001). Patients who were antibody-positive responded to steroid treatment more frequently than did those who were antibody-negative (P<.001). Conclusions.-These results indicate that the presence of circulating antibody to a 68-kd constituent of bovine inner ear extract serves as a marker for IPBSNHL and that its presence correlates with disease activity and responsiveness to corticosteroid treatment.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA; HARVARD UNIV,SCH MED,DEPT OTOL & LARYNGOL,BOSTON,MA 02115; MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA; MASSACHUSETTS GEN HOSP,ALLERGY UNIT,GEN MED SERV,BOSTON,MA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts Eye & Ear Infirmary; Harvard University; Massachusetts General Hospital	MOSCICKI, RA (corresponding author), MASSACHUSETTS GEN HOSP,CLIN IMMUNOL UNIT,32 FRUIT ST,BULLFINCH 422,BOSTON,MA 02114, USA.				NIDCD NIH HHS [DC00824] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC000824] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ARNOLD W, 1987, ACTA OTO-LARYNGOL, V103, P373; ARNOLD W, 1985, ACTA OTO-LARYNGOL, V99, P437, DOI 10.3109/00016488509108935; BARNETTE WN, 1981, ANAL BIOCHEM, V112, P195; HARRIS JP, 1990, LARYNGOSCOPE, V100, P516; HUGHES GB, 1986, LARYNGOSCOPE, V96, P502, DOI 10.1288/00005537-198605000-00006; HUGHES GB, 1984, LARYNGOSCOPE, V94, P758; HUGHES GB, 1991, ADV OTO-RHINO-LARYNG, V46, P82; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCABE BF, 1984, AM J OTOL, V5, P447; MCCABE BF, 1979, ANN OTO RHINOL LARYN, V88, P585, DOI 10.1177/000348947908800501; NADOL JB, 1993, NEW ENGL J MED, V329, P1092, DOI 10.1056/NEJM199310073291507; RAFFIN MJM, 1980, J SPEECH HEAR RES, V23, P5, DOI 10.1044/jshr.2301.05; RAUCH SD, 1992, ANN OTO RHINOL LARYN, V101, P688; WADDELL WJ, 1956, J LAB CLIN MED, V48, P311; WILSON WR, 1980, ARCH OTOLARYNGOL, V106, P772; YAMANOBE S, 1993, LARYNGOSCOPE, V103, P319, DOI 10.1288/00005537-199303000-00013; YAMANOBE S, 1993, ANN OTO RHINOL LARYN, V102, P22, DOI 10.1177/000348949310200105; Zar JH., 1999, BIOSTAT ANAL	18	158	163	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 24	1994	272	8					611	616		10.1001/jama.272.8.611	http://dx.doi.org/10.1001/jama.272.8.611			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PC398	8057517				2022-12-24	WOS:A1994PC39800031
J	DECOCK, KM; EKPINI, E; GNAORE, E; KADIO, A; GAYLE, HD				DECOCK, KM; EKPINI, E; GNAORE, E; KADIO, A; GAYLE, HD			THE PUBLIC-HEALTH IMPLICATIONS OF AIDS RESEARCH IN AFRICA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SUB-SAHARAN AFRICA; SEXUALLY-TRANSMITTED DISEASES; HIV-INFECTION; COTE-DIVOIRE; RISK-FACTORS; CROSS-REACTIVITY; CASE-DEFINITION; IVORY-COAST; TRANSMISSION	The human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) epidemic has led to greatly increased international collaboration for medical research, mainly epidemiologic in nature, in Africa. Greater understanding of HIV/AIDS has resulted, and considerable training and technology transfer have occurred. However, analytic and descriptive research in countries heavily affected by AIDS has been slow to turn to assessment of interventions, and practical benefits to those countries' public health and policies have lagged behind scientific knowledge. This article considers the public health implications of selected HIV/AIDS research in sub-Saharan Africa and discusses opportunities for interventions and more applied research. Topics covered include HIV testing and its role, surveillance, control of sexually transmitted diseases, the vulnerability of youth and women, tuberculosis, HIV/AIDS care, and the inadequacy of resources currently committed to HIV/AIDS prevention and control in resource-poor countries. Research on HIV/AIDS in Africa has yielded crucial information but now should prioritize interventions and their evaluation. Specific goals that might limit the effects of the HIV/AIDS epidemic in resource-poor countries are achievable given vision, commitment, and resources.	PROJET RETRO CI,ABIDJAN,COTE IVOIRE; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA 30341; NATL AIDS CONTROL PROGRAMME,ABIDJAN,COTE IVOIRE; CHU TREICHVILLE,INFECT DIS SERV,ABIDJAN,COTE IVOIRE	Centers for Disease Control & Prevention - USA								ACKAH A, 1993, 9TH INT C AIDS BERL; ADJORLOLOJOHNSON G, 1994, JAMA-J AM MED ASSOC, V272, P462, DOI 10.1001/jama.272.6.462; AIDS S, 1991, PLUM, V5, pS65; AISU T, 1993, 9TH INT C AIDS BERL; ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; ALLEN S, 1992, JAMA-J AM MED ASSOC, V268, P3338, DOI 10.1001/jama.268.23.3338; ANCELLEPARK R, 1993, LANCET, V341, P441, DOI 10.1016/0140-6736(93)93040-8; ANDREASSON PA, 1993, AIDS, V7, P989, DOI 10.1097/00002030-199307000-00013; [Anonymous], 1993, Wkly Epidemiol Rec, V68, P361; BARRY M, 1988, NEW ENGL J MED, V319, P1083, DOI 10.1056/NEJM198810203191609; BATTER V, 1993, 9TH INT C AIDS BERL; BERKLEY SF, 1989, J INFECT DIS, V160, P22, DOI 10.1093/infdis/160.1.22; BRATTEGAARD K, 1993, AIDS, V7, P883, DOI 10.1097/00002030-199306000-00019; BUEHLER JW, 1993, AIDS, V7, pS73, DOI 10.1097/00002030-199301001-00010; CAMERON D W, 1990, AIDS (London), V4, pS99; CAMERON DW, 1989, LANCET, V2, P403; CHIN J, 1990, AIDS (London), V4, pS277, DOI 10.1097/00002030-199001001-00045; CHIN J, 1990, B WORLD HEALTH ORGAN, V68, P529; CHIN J, 1990, LANCET, V336, P221, DOI 10.1016/0140-6736(90)91743-T; DECOCK KM, 1991, AIDS, V5, P859, DOI 10.1097/00002030-199107000-00010; DECOCK KM, 1990, AIDS, V4, P875, DOI 10.1097/00002030-199009000-00007; DECOCK KM, 1990, SCIENCE, V249, P793, DOI 10.1126/science.2167515; DECOCK KM, 1991, AIDS, V5, pS21; DECOCK KM, 1993, JAMA-J AM MED ASSOC, V270, P2083, DOI 10.1001/jama.270.17.2083; DECOCK KM, 1993, LANCET, V342, P437, DOI 10.1016/0140-6736(93)92853-L; DECOCK KM, 1989, AIDS, V3, pS89, DOI 10.1097/00002030-198901001-00013; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; DECOCK KM, 1989, LANCET, V2, P408; DECOCK KM, 1993, AM J PUBLIC HEALTH, V83, P1385, DOI 10.2105/AJPH.83.10.1385; DECOCK KM, 1991, BMJ-BRIT MED J, V303, P1185, DOI 10.1136/bmj.303.6811.1185; DELEYS R, 1990, J VIROL, V64, P1207, DOI 10.1128/JVI.64.3.1207-1216.1990; DIALLO MO, 1992, AIDS, V6, P581, DOI 10.1097/00002030-199206000-00010; ECKHOLM E, 1991, NY TIMES        1029, pB6; EVANS LA, 1988, LANCET, V2, P1389; GARNETT GP, 1993, T ROY SOC TROP MED H, V87, P19, DOI 10.1016/0035-9203(93)90522-R; GAYLE HD, 1992, J ACQ IMMUN DEF SYND, V5, P513; GELBER RD, 1994, EXECUTIVE SUMMARY AC; GEORGE JR, 1992, LANCET, V340, P337, DOI 10.1016/0140-6736(92)91406-X; GHIJS P, 1993, 9TH INT C AIDS BERL; GRANT J, 1994, STATE WORLDS CHILDRE, P69; GURTLER LG, 1994, J VIROL, V68, P1581; HEYMANN DL, 1990, AIDS, V4, P469, DOI 10.1097/00002030-199005000-00017; LACKRITZ EM, 1992, LANCET, V340, P524, DOI 10.1016/0140-6736(92)91719-O; LACKRITZ EM, 1993, 9 INT C AIDS BERL; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; LAGA M, 1991, AIDS, V5, pS55; LAGA M, IN PRESS AIDS; LEPAGE P, 1993, AM J EPIDEMIOL, V137, P589, DOI 10.1093/oxfordjournals.aje.a116716; LOUSSERTAJAKA I, 1994, LANCET, V343, P1393, DOI 10.1016/S0140-6736(94)92524-0; LUCAS SB, 1994, BRIT MED J, V308, P1531, DOI 10.1136/bmj.308.6943.1531; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; MANN J, 1992, AIDS WORLD, P421; MBOUP S, 1991, AIDS, V5, pS93; MERTENS TE, 1990, AIDS, V4, P57, DOI 10.1097/00002030-199001000-00008; MUKADI Y, 1993, LANCET, V342, P143, DOI 10.1016/0140-6736(93)91346-N; MULDER DW, 1994, LANCET, V343, P1021, DOI 10.1016/S0140-6736(94)90133-3; MULDER DW, 1994, AIDS, V8, P87, DOI 10.1097/00002030-199401000-00013; MUREKEZI C, 1993, 9TH INT C AIDS BERL; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; MWINGA AG, 1993, TUBERCULOSIS BACK FU, P166; NELSON AM, 1991, AIDS, V5, P583, DOI 10.1097/00002030-199105000-00018; NTITA I, 1991, AIDS, V5, P437, DOI 10.1097/00002030-199104000-00013; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; PIOT P, 1990, J ACQ IMMUN DEF SYND, V3, P403; PIOT P, 1987, J INFECT DIS, V155, P1108, DOI 10.1093/infdis/155.6.1108; PIOT P, 1991, AIDS, V5, pS1; PIOT P, 1990, HDB AIDS PREVENTION, P1; PLUMMER FA, 1991, AIDS, V5, pS169; RAYFIELD M, 1988, J INFECT DIS, V158, P1170, DOI 10.1093/infdis/158.6.1170; RICHARDS S, IN PRESS TUBER LUNG; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SAVARIT D, 1992, BRIT MED J, V305, P498, DOI 10.1136/bmj.305.6852.498; SCHULZER M, 1992, TUBERCLE LUNG DIS, V73, P52, DOI 10.1016/0962-8479(92)90080-4; SCHUTZ R, 1993, BRIT MED J, V307, P1517, DOI 10.1136/bmj.307.6918.1517; SERWADDA D, 1985, LANCET, V2, P849, DOI 10.1016/S0140-6736(85)90122-9; SHAPIRO HT, 1990, SCIENCE, V250, P609, DOI 10.1126/science.250.4981.609; SPIELBERG F, 1989, LANCET, V1, P580; STLOUIS ME, 1993, JAMA-J AM MED ASSOC, V269, P2853, DOI 10.1001/jama.269.22.2853; TAMASHIRO H, 1993, LANCET, V342, P87, DOI 10.1016/0140-6736(93)91289-X; TEDDER RS, 1988, LANCET, V2, P927; TEMMERMAN M, 1992, AIDS, V6, P1181, DOI 10.1097/00002030-199210000-00019; TRAOREETTIEGNE V, 1993, 9 INT C AIDS BERL; VANDEPERRE P, 1991, NEW ENGL J MED, V325, P593, DOI 10.1056/NEJM199108293250901; 1993, 1993 WORLD BANK WORL, P103; 1993, HIV AIDS SURVEILLANC; 1986, WKLY EPIDEMIOL REC, V61, P72; 1993, INVESTING HLTH WORLD, P37; 1993, INVESTING HLTH WORLD, P99; 1994, WKLY EPIDEMIOL REC, V69, P5; 1992, MMWR-MORBID MORTAL W, V41, P1	90	29	29	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	1994	272	6					481	486		10.1001/jama.272.6.481	http://dx.doi.org/10.1001/jama.272.6.481			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA278	8040984				2022-12-24	WOS:A1994PA27800031
J	ICKOVICS, JR; MORRIL, AC; BEREN, SE; WALSH, U; RODIN, J				ICKOVICS, JR; MORRIL, AC; BEREN, SE; WALSH, U; RODIN, J			LIMITED EFFECTS OF HIV COUNSELING AND TESTING FOR WOMEN - A PROSPECTIVE-STUDY OF BEHAVIORAL AND PSYCHOLOGICAL CONSEQUENCES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objectives.-To assess the consequences of human immunodeficiency virus (HIV) counseling and testing for seronegative women in terms of sexual behavior and psychological outcomes. Design.-The design is prospective and longitudinal, using repeated measures. Participants were interviewed at recruitment, 2 weeks later (when tested women received results), and 3 months later. Setting.-Four community health clinics in southern Connecticut; all provide HIV counseling and testing and other specialized and primary health care services. Study Participants.-A sequential sample of women were recruited for two study groups: those seeking HIV counseling and testing (n=152), and a comparison group never tested for HIV (n=78), matched by clinic, race, and age. Main Outcome Measures.-A composite measure of sexual risk was developed, based on sexual activity, condom use, and partner risk factors. Psychometrically valid and reliable measures of general psychological functioning and acquired immunodeficiency syndrome (AIDS)-specific psychological indicators were also used. Results.-Average level of sexual risk was lower for tested than nontested women at all three interviews. For both groups, there was no significant change in sexual risk from baseline to 3-month follow-up. At the individual level, there was no difference in the number of women who decreased or increased sexual risk. For tested women, intrusive thoughts about AIDS and estimated chance of getting AIDS decreased after counseling and testing. Conclusions.-Behavioral and psychological consequences of HIV counseling and testing for women at risk for HIV were limited. These results have implications for further prevention interventions.	YALE UNIV, DEPT PSYCHOL, NEW HAVEN, CT 06520 USA	Yale University	ICKOVICS, JR (corresponding author), YALE UNIV, SCH MED, DEPT INTERNAL MED, POB 208025, SHM IE-61 RWJ CLIN SCHOLARS, NEW HAVEN, CT 06520 USA.							ADIB SM, 1991, AIDS, V5, P757, DOI 10.1097/00002030-199106000-00018; ANTONI MH, 1990, PSYCHOSOM MED, V52, P496, DOI 10.1097/00006842-199009000-00002; BECK AT, 1974, J CONSULT CLIN PSYCH, V42, P861, DOI 10.1037/h0037562; CATANIA JA, 1992, SCIENCE, V258, P1101, DOI 10.1126/science.1439818; COATES TJ, 1988, AM PSYCHOL, V43, P859, DOI 10.1037/0003-066X.43.11.859; COATES TJ, 1987, JAMA-J AM MED ASSOC, V258, P1889, DOI 10.1001/jama.1987.03400140051006; Cohen J., 1988, STATISTICAL POWER AN, DOI DOI 10.1234/12345678; Crandall R., 1973, MEASURES SOCIAL PSYC, P45; Derogatis L R, 1974, Mod Probl Pharmacopsychiatry, V7, P79; DOLL LS, 1990, HEALTH PSYCHOL, V9, P253, DOI 10.1037/0278-6133.9.3.253; FOX R, 1987, AIDS, V1, P241; HIGGINS DL, 1991, JAMA-J AM MED ASSOC, V266, P2419, DOI 10.1001/jama.266.17.2419; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; ICKOVICS JR, 1992, HEALTH PSYCHOL, V11, P1, DOI 10.1037/0278-6133.11.1.1; JACOBSEN PB, 1990, J CONSULT CLIN PSYCH, V58, P31, DOI 10.1037/0022-006X.58.1.31; JOSEPH JG, 1987, J APPL SOC PSYCHOL, V17, P231, DOI 10.1111/j.1559-1816.1987.tb00312.x; KELLY JA, 1990, J CONSULT CLIN PSYCH, V58, P117, DOI 10.1037/0022-006X.58.1.117; MCCLELLAND GH, 1993, PSYCHOL BULL, V114, P376, DOI 10.1037/0033-2909.114.2.376; MCCUSKER J, 1988, AM J PUBLIC HEALTH, V78, P462, DOI 10.2105/AJPH.78.4.462; Ostrow D G, 1989, AIDS Educ Prev, V1, P1; PERRY SW, 1990, AIDS, V4, P145, DOI 10.1097/00002030-199002000-00008; RODIN J, 1989, ANNU REV PSYCHOL, V40, P533, DOI 10.1146/annurev.ps.40.020189.002533; Rosenberg M., 1965, MEASUREMENT SELF EST, DOI [10.1515/9781400876136, DOI 10.1515/9781400876136]; SCHEIER MF, 1985, HEALTH PSYCHOL, V4, P219, DOI 10.1037/0278-6133.4.3.219; SELWYN PA, 1989, JAMA-J AM MED ASSOC, V261, P3567, DOI 10.1001/jama.261.24.3567; Siegel S., 1956, NONPARAMETRIC STAT B; WALLSTON KA, 1978, HEALTH EDUC QUART, V6, P160, DOI 10.1177/109019817800600107; WENGER NS, 1991, AM J PUBLIC HEALTH, V81, P1580, DOI 10.2105/AJPH.81.12.1580; WENGER NS, 1992, ANN INTERN MED, V117, P905, DOI 10.7326/0003-4819-117-11-905; WIKTOR SZ, 1990, J ACQ IMMUN DEF SYND, V3, P62; WINOKUR A, 1984, BRIT J PSYCHIAT, V144, P395, DOI 10.1192/bjp.144.4.395; 1992, MMWR-MORBID MORTAL W, V41, P613; 1993, HIV AIDS SURVEILLANC; 1988, 1988 PRES COMM HUM I	35	64	64	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	1994	272	6					443	448		10.1001/jama.272.6.443	http://dx.doi.org/10.1001/jama.272.6.443			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PA278	8040979				2022-12-24	WOS:A1994PA27800025
J	OETTGEN, HC; MARTIN, TR; WYNSHAWBORIS, A; DENG, CX; DRAZEN, JM; LEDER, P				OETTGEN, HC; MARTIN, TR; WYNSHAWBORIS, A; DENG, CX; DRAZEN, JM; LEDER, P			ACTIVE ANAPHYLAXIS IN IGE-DEFICIENT MICE	NATURE			English	Article							PERTUSSIGEN PERTUSSIS TOXIN; IMMUNOGLOBULIN HEAVY-CHAIN; MAST-CELLS; CUTANEOUS ANAPHYLAXIS; HISTAMINE-RELEASE; MOUSE; LYMPHOCYTES; LETHALITY; MUTATION; ANTIGEN	The IgE-triggered release of mast cell mediators in response to antigen is thought to be the primary event in immediate hypersensitivity reactions such as systemic anaphylaxis(1). Although mast cells and basophils can be activated in vitro by non-IgE stimuli(2-5), it is not known whether these triggers lead to physiological changes in vivo. To investigate this possibility, we generated mice with a homozygous null mutation of the CE gene. Such mice make no IgE, but produce other immunoglobulin isotypes normally. We report that despite the IgE deficiency, sensitized mutant mice become anaphylactic on antigen challenge and display tachycardia and pulmonary function changes similar to those seen in wildtype animals. These responses are accompanied by vascular leak, sharply elevated plasma histamine and rapid death. IgE-independent anaphylaxis does not depend on complement activation, but, as indicated in studies using genetically immunodeficient RAG-2(-) and SCID mice, does require a functional immune system. Such results clearly demonstrate that non-IgE pathways for hypersensitivity reactions exist in mice.	CHILDRENS HOSP,DEPT PEDIAT,INA SUE PERLMUTTER LAB,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital	OETTGEN, HC (corresponding author), HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,200 LONGWOOD AVE,BOSTON,MA 02115, USA.		deng, chuxia/N-6713-2016; Drazen, Jeffrey M/E-5841-2012	Drazen, Jeffrey/0000-0003-2715-9890				ARIMURA A, 1990, IMMUNOL INVEST, V19, P227, DOI 10.3109/08820139009041837; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; CLAUSEN C R, 1970, Journal of Immunology, V104, P312; DAERON M, 1982, CELL IMMUNOL, V70, P27, DOI 10.1016/0008-8749(82)90130-7; DOMBROWICZ D, 1993, CELL, V75, P979; FOX PC, 1982, J IMMUNOL, V129, P314; HOOK WA, 1975, J IMMUNOL, V114, P1185; INAGAKI N, 1992, JPN J PHARMACOL, V59, P201, DOI 10.1254/jjp.59.201; KATZ HR, 1992, J IMMUNOL, V148, P868; KLERX JPAM, 1983, J IMMUNOL METHODS, V63, P215, DOI 10.1016/0022-1759(83)90425-8; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MARTIN TR, 1993, J IMMUNOL, V151, P367; MARTIN TR, 1989, J CLIN INVEST, V83, P1375, DOI 10.1172/JCI114025; MU HH, 1993, INFECT IMMUN, V61, P2834, DOI 10.1128/IAI.61.7.2834-2840.1993; MUNOZ JJ, 1990, CELL IMMUNOL, V127, P327, DOI 10.1016/0008-8749(90)90136-F; MUNOZ JJ, 1987, INFECT IMMUN, V55, P1004, DOI 10.1128/IAI.55.4.1004-1008.1987; NUSSENZWEIG RS, 1964, J EXP MED, V120, P315, DOI 10.1084/jem.120.2.315; ROTHMAN P, 1988, J EXP MED, V168, P2385, DOI 10.1084/jem.168.6.2385; Rothman P, 1989, Semin Immunol, V1, P65; SALOGA J, 1993, J CLIN INVEST, V91, P133, DOI 10.1172/JCI116162; SHIMIZU A, 1982, CELL, V28, P499, DOI 10.1016/0092-8674(82)90204-5; SHIMIZU A, 1981, NATURE, V289, P149, DOI 10.1038/289149a0; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; SILVERS WS, 1992, ANN ALLERGY, V68, P58; STEVENS RL, 1989, IMMUNOL TODAY, V10, P381, DOI 10.1016/0167-5699(89)90272-7; SUN SJ, 1992, J LAB CLIN MED, V120, P589; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANDENBERG CW, 1991, J IMMUNOL METHODS, V136, P287, DOI 10.1016/0022-1759(91)90015-8; VAZ E M, 1970, International Archives of Allergy and Applied Immunology, V39, P459	30	337	348	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 4	1994	370	6488					367	370		10.1038/370367a0	http://dx.doi.org/10.1038/370367a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA304	8047141				2022-12-24	WOS:A1994PA30400054
J	STEMMER, WPC				STEMMER, WPC			RAPID EVOLUTION OF A PROTEIN IN-VITRO BY DNA SHUFFLING	NATURE			English	Article							SEARCHING SEQUENCE SPACE; SPECTRUM BETA-LACTAMASES; MOLECULAR EVOLUTION; ENSEMBLE MUTAGENESIS	DNA shuffling is a method for in vitro homologous recombination of pools of selected mutant genes by random fragmentation and polymerase chain reaction (PCR) reassembly(1). Computer simulations called genetic algorithms(2-4) have demonstrated the importance of iterative homologous recombination for sequence evolution. Oligonucleotide cassette mutagenesis(5-11) and error-prone PCR are not combinatorial and thus are limited in searching sequence space(1,14). We have tested mutagenic DNA shuffling for molecular evolution(14-18) in a beta-lactamase model system(9,19). Three cycles of shuffling and two cycles of backcrossing with wild-type DNA, to eliminate non-essential mutations, were each followed by selection on increasing concentrations of the antibiotic cefotaxime. We report here that selected mutants had a minimum inhibitory concentration of 640 mu g ml(-1), a 32,000-fold increase and 64-fold greater than any published TEM-1 derived enzyme. Cassette mutagenesis and error-prone PCR resulted in only a 16-fold increase(9).			STEMMER, WPC (corresponding author), AFFYMAX RES INST,4001 MIRANDA AVE,PALO ALTO,CA 94304, USA.		Wood, David W/B-2992-2012					AMBLER RP, 1991, BIOCHEM J, V276, P269, DOI 10.1042/bj2760269; ARKIN AP, 1992, P NATL ACAD SCI USA, V89, P7811, DOI 10.1073/pnas.89.16.7811; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; COLLATZ E, 1990, MOL MICROBIOL, V4, P1615, DOI 10.1111/j.1365-2958.1990.tb00537.x; DELAGRAVE S, 1993, BIO-TECHNOL, V11, P1548, DOI 10.1038/nbt1293-1548; HERMES JD, 1990, P NATL ACAD SCI USA, V87, P696, DOI 10.1073/pnas.87.2.696; HOLLAND JH, 1992, SCI AM, V267, P66, DOI 10.1038/scientificamerican0792-66; HOLLAND JH, 1992, ADAPTATION NATURAL A; HUSE WD, 1989, SCIENCE, V246, P1275, DOI 10.1126/science.2531466; JACOBY GA, 1991, ANTIMICROB AGENTS CH, V35, P1697, DOI 10.1128/AAC.35.9.1697; JOYCE GF, 1992, SCI AM, V267, P90, DOI 10.1038/scientificamerican1292-90; Kauffman S. A., 1993, ORIGINS ORDER; KAUFFMAN SA, 1992, J THEOR BIOL, V157, P1, DOI 10.1016/S0022-5193(05)80753-2; Leung DW, 1989, TECHNIQUE, V1, P11; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; OLIPHANT AR, 1986, GENE, V44, P177, DOI 10.1016/0378-1119(86)90180-0; PALZKILL T, 1992, J BACTERIOL, V174, P5237, DOI 10.1128/JB.174.16.5237-5243.1992; PHILIPPON A, 1989, ANTIMICROB AGENTS CH, V33, P1131, DOI 10.1128/AAC.33.8.1131; STEMMER WPC, IN PRESS P NATN ACAD; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WATSON N, 1988, GENE, V70, P399, DOI 10.1016/0378-1119(88)90212-0; [No title captured]	22	1456	2414	18	358	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 4	1994	370	6488					389	391		10.1038/370389a0	http://dx.doi.org/10.1038/370389a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA304	8047147				2022-12-24	WOS:A1994PA30400061
J	DIEKMANN, D; ABO, A; JOHNSTON, C; SEGAL, AW; HALL, A				DIEKMANN, D; ABO, A; JOHNSTON, C; SEGAL, AW; HALL, A			INTERACTION OF RAC WITH P67(PHOX) AND REGULATION OF PHAGOCYTIC NADPH OXIDASE ACTIVITY	SCIENCE			English	Article							GTP-BINDING-PROTEIN; CELL-FREE SYSTEM; RESPIRATORY BURST; ADP-RIBOSYLATION; GENE-PRODUCT; ACTIVATION; COMPONENTS; RHO; CYTOCHROME-B558; TRANSLOCATION	Rho and Rac, two members of the Ras superfamily of guanosine triphosphate (GIP)-binding proteins, regulate a variety of signal transduction pathways in eukaryotic cells. Upon stimulation of phagocytic cells, Rac enhances the activity of the enzyme nicotinamide adenine dinucleotide phosphate (reduced) (NADPH) oxidase, resulting in the production of superoxide radicals. Activation of the NADPH oxidase requires the assembly of a multimolecular complex at the plasma membrane consisting of two integral membrane proteins, gp91(phox) and p2l(phox), and two cytosolic proteins, p67(phox) and p47(phox). Rac1 interacted directly with p67(phox) in GTP-dependent manner. Modified forms of Rac with mutations in the effector site did not stimulate oxidase activity or bind to p67(phox). Thus, p67(phox) appears to be the Rac effector protein in the NADPH oxidase complex.	UCL, CANC RES CAMPAIGN,ONCOGENE & SIGNAL TRANSDUCT GRP, MRC,MOLEC & CELL BIOL LAB, LONDON WC1E 6BT, ENGLAND; UCL, DEPT BIOCHEM, LONDON WC1E 6BT, ENGLAND; UCL, DEPT MED, LONDON WC1E 6JJ, ENGLAND	University of London; University College London; University of London; University College London; University of London; University College London				Tapon, Dagmar/0000-0003-3837-4764; Segal, Anthony/0000-0001-7602-9043	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BROMBERG Y, 1994, J BIOL CHEM, V269, P7055; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HALL A, 1986, J BIOL CHEM, V261, P963; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; JOUAN A, 1993, BIOCHEM BIOPH RES CO, V197, P1296, DOI 10.1006/bbrc.1993.2618; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MIZUNO T, 1992, J BIOL CHEM, V267, P10215; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; MORII N, 1992, J BIOL CHEM, V267, P20921; PARK JW, 1992, J BIOL CHEM, V267, P19901; PARK JW, 1992, J BIOL CHEM, V267, P17327; QUINN MT, 1993, J BIOL CHEM, V268, P20983; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROTROSEN D, 1993, J BIOL CHEM, V268, P14256; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; SELF AJ, 1993, ONCOGENE, V8, P655; SELF AJ, UNPUB; THELEN M, 1993, PHYSIOL REV, V73, P797, DOI 10.1152/physrev.1993.73.4.797; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	32	352	361	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 22	1994	265	5171					531	533		10.1126/science.8036496	http://dx.doi.org/10.1126/science.8036496			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	8036496				2022-12-24	WOS:A1994NY21600032
J	CHOI, KW; BENZER, S				CHOI, KW; BENZER, S			ROTATION OF PHOTORECEPTOR CLUSTERS IN THE DEVELOPING DROSOPHILA EYE REQUIRES THE NEMO GENE	CELL			English	Article							PROTEIN-KINASE; IMAGINAL DISKS; NEURAL DEVELOPMENT; PATTERN-FORMATION; SCATTER FACTOR; CELL-DIVISION; RECEPTOR; TYROSINE; RETINA; PHOSPHORYLATION	The Drosophila eye consists of a reiterative hexagonal array of photoreceptor cell clusters, the ommatidia. During normal morphogenesis, the clusters in the dorsal or ventral halves of the disc rotate 90 degrees in opposite directions, forming mirror images across a dorsoventral equator. In the mutant nemo (nmo), there is an initial turning of approximately 45 degrees, but further rotation is blocked. Genetic mosaic analysis indicates that the nmo gene acts upon each cluster as a whole; normal nmo function in one or more photoreceptor cells appears to be sufficient to induce full rotation. The nmo gene sequence encodes a serine/threonine protein kinase homolog, suggesting that the kinase is required to initiate the second step of rotation. In another mutant, roulette, excessive rotation through varying angles occurs in many ommatidia. This defect is suppressed by nmo, indicating that nmo acts upstream in a rotation-regulating pathway.			CHOI, KW (corresponding author), CALTECH,DIV BIOL,PASADENA,CA 91125, USA.		Choi, Kwang-Wook/C-1707-2011	Choi, Kwang-Wook/0000-0002-8997-3065	NEI NIH HHS [EY0 9278] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009278] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABBOTT MK, 1991, GENETICS, V129, P783; ADLER PN, 1987, DEV GENET, V8, P99, DOI 10.1002/dvg.1020080206; BAIROCH A, 1988, NATURE, V331, P22, DOI 10.1038/331022a0; BAKER NE, 1992, DEV BIOL, V150, P381, DOI 10.1016/0012-1606(92)90250-K; BAKER NE, 1992, J NEUROGENET, V8, P85, DOI 10.3109/01677069209084154; BANERJEE U, 1990, NEURON, V4, P177, DOI 10.1016/0896-6273(90)90093-U; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BIGGS WH, 1992, P NATL ACAD SCI USA, V89, P6295, DOI 10.1073/pnas.89.14.6295; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CAGAN RL, 1989, DEV BIOL, V136, P346, DOI 10.1016/0012-1606(89)90261-3; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; DEUCHAR EM, 1971, J EMBRYOL EXP MORPH, V25, P189; Dietrich W, 1909, Z WISS ZOOL ABT A, V92, P465; DUERR B, 1993, PLANT CELL, V5, P87, DOI 10.1105/tpc.5.1.87; ENGELS WR, 1986, FOCUS, V8, P6; FLEISCHMAN RA, 1993, TRENDS GENET, V9, P285, DOI 10.1016/0168-9525(93)90015-A; FRISTROM D, 1976, DEV BIOL, V54, P163, DOI 10.1016/0012-1606(76)90296-7; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; Gleichauf R, 1936, Z WISS ZOOL ABT A, V148, P1; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GUBB D, 1982, J EMBRYOL EXP MORPH, V68, P37; GUMBINER BM, 1992, CELL, V69, P385, DOI 10.1016/0092-8674(92)90440-N; HAMILTON L, 1969, J EMBRYOL EXP MORPH, V22, P253; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HART AC, 1990, GENE DEV, V4, P1835, DOI 10.1101/gad.4.11.1835; HIME G, 1992, DEVELOPMENT, V114, P165; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; ITOH N, 1986, P NATL ACAD SCI USA, V83, P4081, DOI 10.1073/pnas.83.11.4081; KLAMBT C, 1992, GENE DEV, V6, P1668, DOI 10.1101/gad.6.9.1668; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; MELAMED J, 1975, J ULTRA MOL STRUCT R, V51, P79, DOI 10.1016/S0022-5320(75)80010-4; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; OWAKI H, 1993, EMBO J, V12, P4367, DOI 10.1002/j.1460-2075.1993.tb06121.x; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Pirrotta V., 1986, DROSOPHILA PRACTICAL, P83; READY DF, 1989, TRENDS NEUROSCI, V12, P102, DOI 10.1016/0166-2236(89)90166-5; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; REINKE R, 1988, CELL, V52, P291, DOI 10.1016/0092-8674(88)90518-1; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; RUTISHAUSER U, 1988, PHYSIOL REV, V68, P819, DOI 10.1152/physrev.1988.68.3.819; Sambrook J., 1989, MOL CLONING LAB MANU; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THEISEN H, 1994, DEVELOPMENT, V120, P347; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1985, J EMBRYOL EXP MORPH, V89, P313; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WHITE K, 1978, DEV BIOL, V65, P298; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZIPURSKY SL, 1984, CELL, V36, P15, DOI 10.1016/0092-8674(84)90069-2	53	157	159	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 15	1994	78	1					125	136		10.1016/0092-8674(94)90579-7	http://dx.doi.org/10.1016/0092-8674(94)90579-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033204				2022-12-24	WOS:A1994NX32800015
J	DOYAL, L; WILSHER, D				DOYAL, L; WILSHER, D			WITHHOLDING AND WITHDRAWING LIFE-SUSTAINING TREATMENT FROM ELDERLY PEOPLE - TOWARDS FORMAL GUIDELINES	BRITISH MEDICAL JOURNAL			English	Article							ETHICS	Clinicians often decide either to withhold or to withdraw lifesaving treatment in elderly patients. Considerable disagreement exists about the circumstances in which such actions can be defended. Debates about the scarcity of resources in the NHS add urgency to the need to resolve this disagreement. Competent elderly patients have a legal and moral right to decide whether to receive life sustaining treatment. Such treatment should not be withheld or withdrawn on the basis of a patient's age alone. Principles for making decisions about Life sustaining treatment in incompetent elderly patients can be defended and should exist as written guidelines.	UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEP HUMAN SCI & MED ETH,LONDON E1 2AD,ENGLAND	University of London; Queen Mary University London	DOYAL, L (corresponding author), LONDON MED COLL,DEPT HUMAN SCI & MED ETH,LONDON E1 2AD,ENGLAND.							[Anonymous], 1993, LANCET, V342, P1; ASPLUND K, 1989, STROKE, V20, P1107, DOI 10.1161/01.STR.20.8.1107; Buchanan AE, 1989, DECIDING OTHERS ETHI; DOYAL L, 1993, BRIT MED J, V306, P1593, DOI 10.1136/bmj.306.6892.1593; DOYAL L, 1990, J LAW SOC, V17, P1, DOI 10.2307/1409951; DOYAL L, 1994, ARCH DIS CHILD, V70, P66; Doyal L., 1991, THEORY HUMAN NEED, DOI DOI 10.1007/978-1-349-21500-3; Dworkin R., 1993, LIFES DOMINION; EVANS JG, 1989, AGE AGEING, V18, P217, DOI 10.1093/ageing/18.4.217; FRASER M, 1987, DEMENTIA ITS NATURE; Harris J., 1985, VALUE LIFE; Parfit Derek., 1984, REASONS PERSONS; RACHELS J., 1986, END LIFE EUTHANASIA; VOLICER L, 1986, JAMA-J AM MED ASSOC, V256, P2210, DOI 10.1001/jama.256.16.2210; Wicclair M., 1993, ETHICS ELDERLY; WILLIAMS F, 1993, BRIT J HOSP MED, V50, P50; 1994, ENSURING EQUITY QUAL; 1994, REPORT; 1988, LIVING WILL CONSENT; 1994, BUTTERWORTHS MEDICOL, V15, P77	20	36	36	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 25	1994	308	6945					1689	1692		10.1136/bmj.308.6945.1689	http://dx.doi.org/10.1136/bmj.308.6945.1689			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU483	8025466	Green Published			2022-12-24	WOS:A1994NU48300031
J	ANDERSON, HR; BUTLAND, BK; STRACHAN, DP				ANDERSON, HR; BUTLAND, BK; STRACHAN, DP			TRENDS IN PREVALENCE AND SEVERITY OF CHILDHOOD ASTHMA	BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY SYMPTOMS; CHILDREN; HEALTH	Objective-To test the null hypothesis that there has been no change in the prevalence or severity of childhood asthma over recent years. Design-Repeated population prevalence survey with questionnaires completed by parents followed by home interviews with parents. Setting-London borough of Croydon, 1978 and 1991. Subjects-All children in one year of state and private primary schools aged 71/2 to 81/2 years at screening survey. Main outcome measures-Trends in symptoms, acute severe attacks, and chronic disability. Results-For 1978 and 1991 respectively, the response rates were 4147/4763 and 3070/3786, and home interviews were obtained from 273/288 and 319/395 parents of currently wheezy children. Between 1978 and 1991 there were significant relative increases in prevalence ratios in the 12 month prevalence of attacks of wheezing or asthma (1.16; 95% confidence interval 1.02 to 1.31), the one month prevalence of wheezing episodes (1.78; 1.15 to 2.74), and the one month prevalence of night waking (1.81; 1.01 to 3.23) but not in frequent (greater than or equal to 5) attacks over the past year (1.05; 0.79 to 1.40). There were substantial and significant decreases in the 12 month prevalence of absence from school of more than 10 days due to wheezing (0.52; 0.30 to 0.90), any days in bed (0.67; 0.93 to 1.01), and restriction of activities at home (0.51; 0.31 to 0.83) and an equivalent but not significant fall in speech limiting attacks (0.51; 0.24 to 1.11). Conclusion-The small increase in the prevalence of wheezy children and relatively greater increase in persistent wheezing suggests a change in the environmental determinants of asthma. In contrast and paradoxically the frequency of wheezing attacks remains unchanged and there are indications that severe attacks and chronic disability have fallen by about half; this may be due to an improvement in treatment received by wheezy children.			ANDERSON, HR (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.		Anderson, Hugh R/A-7417-2016	Butland, Barbara/0000-0001-9952-3108				ANDERSON HR, 1983, J EPIDEMIOL COMMUN H, V37, P180, DOI 10.1136/jech.37.3.180; ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; ANDERSON HR, 1983, ARCH DIS CHILD, V58, P777, DOI 10.1136/adc.58.10.777; ANDERSON HR, 1986, J EPIDEMIOL COMMUN H, V40, P121, DOI 10.1136/jech.40.2.121; ANDERSON HR, 1993, PAEDIATRIC RESPIRATO, V1, P6; ANDERSON HR, 1993, THORAX, V48, P451; AYRES JG, 1993, BRIT J GEN PRACT, V43, P361; BURNEY PGJ, 1990, BRIT MED J, V300, P1306, DOI 10.1136/bmj.300.6735.1306; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; FLANDERS WD, 1987, J CHRON DIS, V40, P697, DOI 10.1016/0021-9681(87)90106-8; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; STRACHAN DP, 1992, BRIT MED J, V304, P873; TAYLOR B, 1984, LANCET, V2, P1255, DOI 10.1016/S0140-6736(84)92805-8; WHINCUP PH, 1993, ARCH DIS CHILD, V68, P729, DOI 10.1136/adc.68.6.729; 1989, SAS STAT USERS GUIDE, V2, P846	16	196	199	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 18	1994	308	6944					1600	1604		10.1136/bmj.308.6944.1600	http://dx.doi.org/10.1136/bmj.308.6944.1600			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NT528	8025426	Green Published			2022-12-24	WOS:A1994NT52800017
J	CONE, RW; HOBSON, AC; BROWN, Z; ASHLEY, R; BERRY, S; WINTER, C; COREY, L				CONE, RW; HOBSON, AC; BROWN, Z; ASHLEY, R; BERRY, S; WINTER, C; COREY, L			FREQUENT DETECTION OF GENITAL HERPES-SIMPLEX VIRUS-DNA BY POLYMERASE CHAIN-REACTION AMONG PREGNANT-WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFECTION; DELIVERY; LESIONS; TYPE-1; ENCEPHALITIS; SEQUENCE; CULTURES	Objective.-To investigate the prevalence and level of genital herpes simplex virus (HSV) among women at delivery. Design, Patients, and Setting.-A prospective analysis of HSV by culture and by polymerase chain reaction (PCR) of genital specimens and by HSV serologic studies in 100 asymptomatic women in labor; prospective analysis of HSV by PCR among 50 seronegative nonpregnant women at a student health center; and retrospective analysis of genital specimens for HSV by PCR from 17 HSV culture-positive women with uninfected neonates and from two HSV culture-negative women with HSV-infected neonates. All pregnant women were at a university hospital. Main Outcome Measures.-Presence of HSV by culture and levels of HSV by quantitative, type-specific PCR in cervical and vulvar specimens; HSV serologic testing by Western blot. Results.-All of the 100 asymptomatic women in labor who were studied prospectively were HSV culture negative. In nine HSV was recovered by PCR. Herpes simplex virus was recovered by PCR in one of the 50 seronegative nonpregnant women; she soon became seropositive. All 17 culture-positive women had HSV recovered by PCR. High levels of HSV DNA were obtained by PCR from the two culture-negative women with infected neonates. Among those from whom HSV was recovered by PCR, HSV DNA levels were 250 times higher from culture-positive samples than from culture-negative samples (11 571 genome equivalents vs 46 genome equivalents; P<.001). Conclusions.-The frequency of infant exposure to HSV DNA-containing secretions from HSV-seropositive mothers is about eight times higher than previously reported using HSV culture methods. High maternal levels of HSV DNA may be associated with an increased frequency of transmission of HSV to the infant.	UNIV WASHINGTON,DEPT LAB MED,DIV VIROL,SEATTLE,WA 98144; UNIV WASHINGTON,DEPT OBSTET & GYNECOL,SEATTLE,WA; UNIV WASHINGTON,DEPT INFECT DIS,SEATTLE,WA; UNIV WASHINGTON,DEPT MED,SEATTLE,WA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NIAID NIH HHS [AI 30731] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030731] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; BZIK DJ, 1986, VIROLOGY, V155, P322, DOI 10.1016/0042-6822(86)90196-0; CONE RW, 1991, J INFECT DIS, V164, P757, DOI 10.1093/infdis/164.4.757; CONE RW, 1992, J CLIN MICROBIOL, V30, P3185, DOI 10.1128/JCM.30.12.3185-3189.1992; CONE RW, 1993, J CLIN MICROBIOL, V31, P1774, DOI 10.1128/JCM.31.7.1774-1776.1993; COREY L, 1988, LANCET, V1, P1; HARDY DA, 1990, J INFECT DIS, V162, P1031, DOI 10.1093/infdis/162.5.1031; KOUTSKY LA, 1992, NEW ENGL J MED, V326, P1533, DOI 10.1056/NEJM199206043262305; LANGENBERG A, 1988, J CLIN MICROBIOL, V26, P1772, DOI 10.1128/JCM.26.9.1772-1774.1988; LASKY LA, 1984, DNA-J MOLEC CELL BIO, V3, P23, DOI 10.1089/dna.1.1984.3.23; MALM G, 1991, ACTA PAEDIATR SCAND, V80, P226, DOI 10.1111/j.1651-2227.1991.tb11838.x; NAHMIAS AJ, 1971, AM J OBSTET GYNECOL, V110, P825, DOI 10.1016/0002-9378(71)90580-1; NAHMIAS AJ, 1982, J INFECT DIS, V145, P829, DOI 10.1093/infdis/145.6.829; PROBER CG, 1992, CLIN INFECT DIS, V15, P1031, DOI 10.1093/clind/15.6.1031; PROBER CG, 1988, NEW ENGL J MED, V318, P887, DOI 10.1056/NEJM198804073181404; RANDOLPH AG, 1993, JAMA-J AM MED ASSOC, V270, P77, DOI 10.1001/jama.270.1.77; STAGNO S, 1985, NEW ENGL J MED, V313, P1327, DOI 10.1056/NEJM198511213132105; WHITLEY RJ, 1992, NEW ENGL J MED, V327, P782; WHITLEY RJ, 1988, J INFECT DIS, V158, P109, DOI 10.1093/infdis/158.1.109	20	97	99	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 14	1994	272	10					792	796		10.1001/jama.272.10.792	http://dx.doi.org/10.1001/jama.272.10.792			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF188	8078144				2022-12-24	WOS:A1994PF18800028
J	LAIDLAW, DAH; BLOOM, PA; HUGHES, AO; SPARROW, JM; MARMION, VJ				LAIDLAW, DAH; BLOOM, PA; HUGHES, AO; SPARROW, JM; MARMION, VJ			THE SIGHT TEST FEE - EFFECT ON OPHTHALMOLOGY REFERRALS AND RATE OF GLAUCOMA DETECTION	BRITISH MEDICAL JOURNAL			English	Article							DISEASE	Objective-To assess changes, if any, in the numbers of referrals and outcome of glaucoma referrals to the hospital eye service since the introduction of the sight test fee on 1 April 1989. Design-Review of referral records and clinical notes. Setting-Referrals to the Bristol Eye Hospital. Subjects-51 919 patients referred to the Bristol Eye Hospital between 1984 and 1992. 9438 case notes of patients referred between 1987 and 1991 were examined in detail. Main outcome measures-Numbers of referrals; rate of adult true positive glaucoma referrals. Results-Referrals to the Bristol Eye Hospital were between 13.7% and 19.0% fewer than expected after the introduction of the sight test fee. True positive glaucoma referrals were reduced by the same proportion. Conclusions-The numbers of patients being identified as requiring treatment or follow up for potentially blinding glaucoma have declined by nearly one fifth since the introduction of the sight test fee. An increased prevalence of preventable blindness may result.	UNIV BRISTOL,DEPT EPIDEMIOL & PUBL HLTH MED,BRISTOL BS8 2PR,ENGLAND; UNIV BRISTOL,DEPT OPHTHALMOL,BRISTOL BS1 2LX,ENGLAND	University of Bristol; University of Bristol	LAIDLAW, DAH (corresponding author), BRISTOL EYE HOSP,BRISTOL BS1 2LX,ENGLAND.							Brittain G P, 1988, Health Trends, V20, P43; GHAFOUR IM, 1983, BRIT J OPHTHALMOL, V67, P209, DOI 10.1136/bjo.67.4.209; GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P196; GREY RHB, 1989, BRIT J OPHTHALMOL, V73, P88, DOI 10.1136/bjo.73.2.88; HALL C, 1989, INDEPENDENT     1230, P3; HARRISON RJ, 1988, BRIT MED J, V297, P1162, DOI 10.1136/bmj.297.6657.1162; HITCHINGS RA, 1993, BR J OPHTHALMOL, V77, P236; Hoskins HD, 1989, BECKER SHAFFERS DIAG; JAY JL, 1993, BRIT J OPHTHALMOL, V77, P176, DOI 10.1136/bjo.77.3.176; ROSENTHAL AR, 1990, BRIT MED J, V300, P695, DOI 10.1136/bmj.300.6726.695; SORSBY A, 1966, 114 PUBL HLTH MED SU; TUCK MW, 1991, BRIT MED J, V302, P998, DOI 10.1136/bmj.302.6783.998; 1991, INFORMATION ORG INDI; 1989, OFFICE POPULATION VS, V16; 1992, OPTICS GLANCE	15	27	27	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 10	1994	309	6955					634	636		10.1136/bmj.309.6955.634	http://dx.doi.org/10.1136/bmj.309.6955.634			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG020	8086985	Green Published			2022-12-24	WOS:A1994PG02000018
J	BLOOM, BR				BLOOM, BR			THE UNITED-STATES NEEDS A NATIONAL VACCINE AUTHORITY	SCIENCE			English	Editorial Material											BLOOM, BR (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,BRONX,NY 10461, USA.							[Anonymous], 1993, WORLD DEV REPORT INV; RABINOVICH NR, 1994, SCIENCE, V265, P1401, DOI 10.1126/science.7521064; 1994, DEV NATIONAL CHILDHO; 1993, CHILDRENS VACCINE IN; 1994, COMMERCIAL PERSPECTI; 1993, ASSESSMENT FEASIBILI; 1992, MMWR-MORBID MORTAL W, V41, P104; 1992, ACCESS CHILDHOOD IMM; 1986, VACCINE SUPPLY INNOV; 1990, HLTH RES ESSENTIAL L; 1994, ADULT IMMUNIZATION; 1994, EMERGING INFECTIONS; 1994, STATE LOCAL IMPEDIME; 1994, DISEASE PREVENTION V; 1993, JAMA-J AM MED ASSOC, V269, P1817; 1990, STATE WORLDS CHILDRE; 1993, STATE WORLDS CHILDRE; 1991, JAMA-J AM MED ASSOC, V226, P1547	18	13	15	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 2	1994	265	5177					1378	1380		10.1126/science.8073275	http://dx.doi.org/10.1126/science.8073275			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	8073275				2022-12-24	WOS:A1994PE73300027
J	CALKINS, DJ; SCHEIN, SJ; TSUKAMOTO, Y; STERLING, P				CALKINS, DJ; SCHEIN, SJ; TSUKAMOTO, Y; STERLING, P			M-CONE AND L-CONE IN MACAQUE FOVEA CONNECT TO MIDGET GANGLION-CELLS BY DIFFERENT NUMBERS OF EXCITATORY SYNAPSES	NATURE			English	Article							BIPOLAR CELLS; ELECTRON-MICROSCOPY; MONKEY RETINA; CAT RETINA	VISUAL acuity depends on the fine-grained neural image set by the foveal cone mosaic(1-3). To preserve this spatial detail, cones transmit through non-divergent pathways: cone-->midget bipolar cell-->midget ganglion cell. Adequate gain must be established along each pathway; crosstalk and sources of variation between pathways must be minimized. These requirements raise fundamental questions regarding the synaptic connections: (1) how many synapses from bipolar to ganglion cell transmit a cone signal and with what degree of crosstalk between adjacent pathways; (2) how accurately these connections are reproduced across the mosaic; and (3) whether the midget circuits for middle (M) and long (L) wavelength sensitive cones are the same. We report here that the midget ganglion cell collects without crosstalk either 28 +/- 14 or 47 +/- 3 midget bipolar synapses. Two cone types are defined by this difference; being about equal in number and distributing randomly in small clusters of like type, they are probably M and L.	UNIV CALIF LOS ANGELES,DEPT PSYCHOL,LOS ANGELES,CA 90024; HYOGO MED UNIV,DEPT ANAT,NISHINOMIYA,HYOGO 663,JAPAN	University of California System; University of California Los Angeles; Hyogo College of Medicine; University of Hyogo	CALKINS, DJ (corresponding author), UNIV PENN,DEPT NEUROSCI,PHILADELPHIA,PA 19104, USA.			Calkins, David/0000-0002-8475-9959				ANHELT P, 1990, J COMP NEUROL, V293, P39; BOYCOTT BB, 1969, PHILOS T ROY SOC B, V255, P109, DOI 10.1098/rstb.1969.0004; COHEN E, 1992, EUR J NEUROSCI, V4, P506, DOI 10.1111/j.1460-9568.1992.tb00901.x; DACEY DM, 1994, NATURE, V367, P731, DOI 10.1038/367731a0; DACEY DM, 1992, P NATL ACAD SCI USA, V89, P9666, DOI 10.1073/pnas.89.20.9666; DEVALOIS RL, 1974, VISION RES, V14, P75, DOI 10.1016/0042-6989(74)90118-7; DOWLING JE, 1966, PROC R SOC SER B-BIO, V166, P80, DOI 10.1098/rspb.1966.0086; GIACOMELLI F, 1971, J HISTOCHEM CYTOCHEM, V19, P426, DOI 10.1177/19.7.426; KLUG K, 1992, SOC NEUR ABSTR; KLUG K, 1993, ARVO ABSTR; KOLB H, 1970, PHILOS T R SOC B, V258, P261, DOI 10.1098/rstb.1970.0036; KOLB H, 1991, J COMP NEUROL, V303, P617, DOI 10.1002/cne.903030408; KOUYAMA N, 1992, J NEUROSCI, V12, P1233; MARIANI AP, 1984, NATURE, V308, P184, DOI 10.1038/308184a0; MCGUIRE BA, 1984, J NEUROSCI, V4, P2920; MENDENHALL W, 1990, MATH STATISTICS APPL, P708; MERIGAN WH, 1990, VISION RES, V30, P985, DOI 10.1016/0042-6989(90)90107-V; MOLLON JD, 1992, NATURE, V360, P677, DOI 10.1038/360677a0; NELSON R, 1978, J NEUROPHYSIOL, V41, P472, DOI 10.1152/jn.1978.41.2.472; Polyak S. L., 1941, RETINA-J RET VIT DIS; SMITH RG, 1987, J NEUROSCI METH, V21, P55, DOI 10.1016/0165-0270(87)90102-6; TSUKAMOTO Y, 1992, VISION RES, V32, P1809, DOI 10.1016/0042-6989(92)90042-H; WASSLE H, 1989, EUR J NEUROSCI, V1, P421, DOI 10.1111/j.1460-9568.1989.tb00350.x; WILLIAMS DR, 1986, TRENDS NEUROSCI, V9, P193, DOI 10.1016/0166-2236(86)90058-5	24	153	153	1	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 1	1994	371	6492					70	72		10.1038/371070a0	http://dx.doi.org/10.1038/371070a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE381	8072528				2022-12-24	WOS:A1994PE38100053
J	MATSUSHIMA, GK; TANIIKE, M; GLIMCHER, LH; GRUSBY, MJ; FRELINGER, JA; SUZUKI, K; TING, JPY				MATSUSHIMA, GK; TANIIKE, M; GLIMCHER, LH; GRUSBY, MJ; FRELINGER, JA; SUZUKI, K; TING, JPY			ABSENCE OF MHC CLASS-II MOLECULES REDUCES CNS DEMYELINATION, MICROGLIAL/MACROPHAGE INFILTRATION, AND TWITCHING IN MURINE GLOBOID-CELL LEUKODYSTROPHY	CELL			English	Article							COMPLEX CLASS-II; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS; T-CELLS; HLA-DR; SIGNAL TRANSDUCTION; LYMPHOCYTES-B; IA ANTIGENS; HUMAN-BRAIN	Globoid cell leukodystrophy (GLD) is a severe genetic demyelinating disorder with an increased number of la (immune response antigen) positive brain microglial macrophages. To assess the role of aberrant la expression in the central nervous system (CNS), twitcher mice, which represent the murine model for GLD, were mated with la(-) transgenic mice. Compared with the la(+) controls, la(-) twitcher mice showed a profound reduction in the severity of demyelinating lesions correlated with significantly fewer microglia/macrophages. Most importantly, la(-) twitcher mice showed significantly reduced twitching compared with la(+) twitcher mice. In contrast with experimental allergic encephalomyelitis (EAE), there was no significant amount of inflammatory T cell infiltrates, implying that T eels may not play a predominant role in this disease. These findings may have broad therapeutic implications for Alzheimer's disease, Parkinson's disease, and Huntington's disease, which display enhanced la expression in the CNS without obvious T cell infiltrates.	UNIV N CAROLINA, DEPT MICROBIOL & IMMUNOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT PATHOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, BRAIN & DEV RES CTR, CHAPEL HILL, NC 27599 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT CANC BIOL, BOSTON, MA 02115 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	MATSUSHIMA, GK (corresponding author), UNIV N CAROLINA, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA.		Frelinger, Jeffrey A/F-2448-2014	Frelinger, Jeffrey A/0000-0002-2503-6267	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020288, R37AI021569, R37AI020288, R01AI021569] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024453] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 20288, AI 21569] Funding Source: Medline; NINDS NIH HHS [NS 24453] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDRE P, 1994, J EXP MED, V179, P763, DOI 10.1084/jem.179.2.763; BALUYUT AR, 1993, CELL IMMUNOL, V147, P353, DOI 10.1006/cimm.1993.1075; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BISHOP GA, 1989, P NATL ACAD SCI USA, V86, P5933, DOI 10.1073/pnas.86.15.5933; BISHOP GA, 1986, P NATL ACAD SCI USA, V83, P7410, DOI 10.1073/pnas.83.19.7410; BROWN T, 1993, CURRENT PROTOCOLS MO; CAMBIER JC, 1989, J EXP MED, V170, P877, DOI 10.1084/jem.170.3.877; CAMBIER JC, 1987, NATURE, V327, P629, DOI 10.1038/327629a0; CHAO CC, 1993, J IMMUNOL, V151, P1473; CHATILA T, 1993, IMMUNOL REV, V131, P43, DOI 10.1111/j.1600-065X.1993.tb01529.x; COHEN IH, 1990, GENETIC MAPS LOCUS M; COLTON CA, 1992, J NEUROIMMUNOL, V40, P89, DOI 10.1016/0165-5728(92)90216-8; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; DUCHEN LW, 1980, BRAIN, V103, P695, DOI 10.1093/brain/103.3.695; EHRICH EW, 1993, J EXP MED, V178, P713, DOI 10.1084/jem.178.2.713; FRELINGER JA, 1975, SCIENCE, V188, P268, DOI 10.1126/science.1118728; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.iy.11.040193.002155; GRIFFIN JW, 1992, J NEUROIMMUNOL, V40, P153, DOI 10.1016/0165-5728(92)90129-9; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; HARTON JA, 1993, J IMMUNOL, V151, P5282; HAUSER SL, 1983, J NEUROIMMUNOL, V5, P197, DOI 10.1016/0165-5728(83)90010-3; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; HIGASHI Y, 1992, J NEUROPATH EXP NEUR, V51, P47, DOI 10.1097/00005072-199201000-00007; HOOGERBRUGGE PM, 1988, SCIENCE, V239, P1035, DOI 10.1126/science.3278379; JUHLER M, 1984, BRAIN RES, V302, P347, DOI 10.1016/0006-8993(84)90249-X; KIEFER R, 1991, J NEUROIMMUNOL, V34, P99, DOI 10.1016/0165-5728(91)90119-R; KOBAYASHI T, 1982, BIOCHEM MED METAB B, V27, P8, DOI 10.1016/0006-2944(82)90003-5; KONDO A, 1987, BRAIN RES, V425, P186, DOI 10.1016/0006-8993(87)90499-9; LANE PJL, 1990, J IMMUNOL, V144, P3684; LANG AE, 1991, NEUROLOGY CLIN PRACT, P320; LI H, 1993, NEUROPATH APPL NEURO, V19, P214, DOI 10.1111/j.1365-2990.1993.tb00431.x; LOUGHLIN AJ, 1993, IMMUNOLOGY, V79, P125; MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101; MATHIS DJ, 1983, P NATL ACAD SCI-BIOL, V80, P273, DOI 10.1073/pnas.80.1.273; MATSUSHIMA GK, 1992, MOL CELL BIOL, V12, P5610, DOI 10.1128/MCB.12.12.5610; MATTIACE LA, 1990, AM J PATHOL, V136, P1101; MCGEER PL, 1988, ACTA NEUROPATHOL, V76, P550, DOI 10.1007/BF00689592; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; MERRILL JE, 1993, J IMMUNOL, V151, P2132; MOONEY NA, 1990, J IMMUNOL, V145, P2070; MOORE KW, 1993, ANNU REV IMMUNOL, V11, P165, DOI 10.1146/annurev.immunol.11.1.165; NABAVI N, 1992, NATURE, V360, P266, DOI 10.1038/360266a0; NABAVI N, 1989, J IMMUNOL, V142, P1444; ODUM N, 1991, EUR J IMMUNOL, V21, P123, DOI 10.1002/eji.1830210119; OHNO M, 1993, BRAIN RES, V625, P186, DOI 10.1016/0006-8993(93)91058-Z; OHNO M, 1993, BRAIN RES, V602, P268, DOI 10.1016/0006-8993(93)90692-G; OHNO M, 1992, DEV BRAIN RES, V67, P37, DOI 10.1016/0165-3806(92)90023-P; PANITCH HS, 1987, NEUROLOGY, V37, P1097, DOI 10.1212/WNL.37.7.1097; PERLMUTTER LS, 1992, J NEUROSCI RES, V33, P549, DOI 10.1002/jnr.490330407; POSER CM, 1980, ARCH NEUROL-CHICAGO, V37, P471, DOI 10.1001/archneur.1980.00500570019001; SEARS ES, 1978, ARCH NEUROL-CHICAGO, V35, P426, DOI 10.1001/archneur.1978.00500310028006; SEDGWICK JD, 1993, J EXP MED, V177, P1145, DOI 10.1084/jem.177.4.1145; SHEEHAN DC, 1980, THEORY PRACTICE HIST, P263; SPERTINI F, 1992, J IMMUNOL, V149, P65; STEINMAN L, 1991, ADV IMMUNOL, V49, P357; Steinman L, 1988, Adv Neurol, V47, P255; STERNBER.LA, 1970, J HISTOCHEM CYTOCHEM, V18, P315, DOI 10.1177/18.5.315; STOLL G, 1989, J NEUROSCI, V9, P2327; STYREN SD, 1990, EXP NEUROL, V110, P93, DOI 10.1016/0014-4886(90)90054-V; SUZUKI K, 1983, AM J PATHOL, V111, P394; SUZUKI K, 1989, METABOLIC BASIS INHE, P1699; SUZUKI K, IN PRESS MICR RES TE; SUZUMURA A, 1993, J IMMUNOL, V151, P2150; TAKAHASHI H, 1984, ACTA NEUROPATHOL, V62, P298, DOI 10.1007/BF00687612; THACH WT, 1992, ANNU REV NEUROSCI, V15, P403, DOI 10.1146/annurev.neuro.15.1.403; TING JPY, 1983, IMMUNOGENETICS, V17, P295, DOI 10.1007/BF00364413; TING JPY, 1981, P NATL ACAD SCI-BIOL, V78, P3170, DOI 10.1073/pnas.78.5.3170; TOIMOTO H, 1993, AM J PATHOL, V143, P579; TRAUGOTT U, 1983, SCIENCE, V219, P308, DOI 10.1126/science.6217550; TREDE NS, 1991, J IMMUNOL, V146, P2310; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051	73	100	104	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 26	1994	78	4					645	656		10.1016/0092-8674(94)90529-0	http://dx.doi.org/10.1016/0092-8674(94)90529-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	8069913				2022-12-24	WOS:A1994PD69300013
J	CANTWELL, MF; SNIDER, DE; CAUTHEN, GM; ONORATO, IM				CANTWELL, MF; SNIDER, DE; CAUTHEN, GM; ONORATO, IM			EPIDEMIOLOGY OF TUBERCULOSIS IN THE UNITED-STATES, 1985 THROUGH 1992	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; RACIAL-DIFFERENCES; SUSCEPTIBILITY; DISEASE; RISK	Objective.-To examine the distribution and sources of increased tuberculosis (TB) morbidity in the United States from 1985 through 1992. Design.-Review of TB surveillance data. Participants.-All incident TB cases in the United States reported to the Centers for Disease Control and Prevention from 1980 through 1992. Main Outcome Measures.-Changes in reported number of TB cases from 1985 through 1992 were analyzed by sex, race/ethnicity, age, country of birth (1986 through 1992), site of disease, geographic location; and socioeconomic status (through 1991). From 1985 through 1992, reported number of cases was compared with expected number of cases, extrapolated from 1980 through 1984 trends, to estimate excess cases by sex, race/ethnicity, and age. Results.-Increases in number of cases from 1985 through 1992 were concentrated among racial/ethnic minorities, persons 25 to 44 years of age, males, and the foreign-born. Excess cases occurred in both sexes, all racial/ethnic groups, and all age groups. Foreign-born cases accounted for 60% of the total increase in the number of US cases from 1986 through 1992 and had the greatest impact among Asians, Hispanics, females, and persons other than those 25 to 44 years of age. Human immunodeficiency virus infection had the greatest impact on TB morbidity among whites, blacks, males, and persons 25 to 44 years of age. From 1985 through 1992, the number of cases among children 4 years old or younger increased 36%, suggesting that transmission of TB increased during this period. Conclusions.-Multiple factors contributed to the recent increases in the number of TB cases. The effectiveness of TB screening in immigrants needs further evaluation. Intensified efforts to determine the human immunodeficiency virus status of persons with TB are needed. Screening of subpopulations at increased risk for tuberculous infection or TB should be expanded.	CTR DIS CONTROL & PREVENT,NATL CTR PREVENT SERV,OFF DIRECTOR,ATLANTA,GA 30341	Centers for Disease Control & Prevention - USA	CANTWELL, MF (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR PREVENT SERV,DIV TB ELIMINAT,1600 CLIFTON RD,E-10,ATLANTA,GA 30333, USA.							BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BLUM RN, 1993, CHEST, V103, P1670, DOI 10.1378/chest.103.6.1670; CAUTHEN GM, 1991, 7TH INT C AIDS FLOR; DRIVER CR, 1992, MAY AM LUNG ASS AM T; GLASSER D, 1978, MARYLAND PHARMAC JUL, P10; KUSHIGEMACHI M, 1984, J CHRON DIS, V37, P853, DOI 10.1016/0021-9681(84)90018-3; MANOFF SB, 1988, 4TH INT C AIDS STOCK; NOLAN CM, 1988, AM REV RESPIR DIS, V137, P805, DOI 10.1164/ajrccm/137.4.805; ONORATO I, 1993, 33RD INT C ANT AG NE; PITCHENIK AE, 1988, CLIN CHEST MED, V9, P425; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; RIEDER HL, 1986, CHEST, V90, P469, DOI 10.1378/chest.90.4.469; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702; THEUER CP, 1990, J INFECT DIS, V162, P8, DOI 10.1093/infdis/162.1.8; 1990, MMWR-MORBID MORTAL W, V39, P1; 1993, HIV AIDS SURVEILLANC, P1; 1992, CURRENT POPULATI P25; 1993, STATISTICAL YB IMMIG; [No title captured]; 1993, MMWR MORBID MORTAL W, V42, P696; 1991, TECHNICAL INSTRUCTIO; 1982, CENSUS POPULATION HO; 1992, AIDS PUBLIC INFORMAT; 1992, MMWR-MORBID MORTAL W, V41, P1	25	336	345	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	1994	272	7					535	539		10.1001/jama.272.7.535	http://dx.doi.org/10.1001/jama.272.7.535			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB229	8046808				2022-12-24	WOS:A1994PB22900031
J	CORR, M; SLANETZ, AE; BOYD, LF; JELONEK, MT; KHILKO, S; ALRAMADI, BK; KIM, YS; MAHER, SE; BOTHWELL, ALM; MARGULIES, DH				CORR, M; SLANETZ, AE; BOYD, LF; JELONEK, MT; KHILKO, S; ALRAMADI, BK; KIM, YS; MAHER, SE; BOTHWELL, ALM; MARGULIES, DH			T-CELL RECEPTOR-MHC CLASS-I PEPTIDE INTERACTIONS - AFFINITY, KINETICS, AND SPECIFICITY	SCIENCE			English	Article							SURFACE-PLASMON RESONANCE; MONOCLONAL-ANTIBODY; LYMPHOCYTES-T; BINDING; COMPLEX; ANTIGEN; MOLECULE; RECOGNITION; PROTEINS; ANTISERA	The critical discriminatory event in the activation of T lymphocytes bearing alpha beta T cell receptors (TCRs) is their interaction with a molecular complex consisting of a peptide bound to a major histocompatibility complex (MHC)-encoded class I or class II molecule on the surface of an antigen-presenting cell. The kinetics of binding were measured of a purified TCR to molecular complexes of a purified soluble analog of the murine MHC class I molecule H-2L(d) (sH-2L(d)) and a synthetic octamer peptide p2CL in a direct, real-time assay based on surface plasmon resonance. The kinetic dissociation rate of the MHC-peptide complex from the TCR was rapid (2.6 x 10(-2) second(-1), corresponding to a half-time for dissociation of approximately 27 seconds), and the kinetic association rate was 2.1 x 10(5) M(-1) second(-1). The equilibrium constant for dissociation was approximately 10(-7) M. These values indicate that TCRs must interact with a multivalent array of MHC-peptide complexes to trigger T cell signaling.	NIAID,MOLEC BIOL SECT,IMMUNOL LAB,BETHESDA,MD 20892; YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,DEPT BIOL,NEW HAVEN,CT 06520	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Yale University; Yale University				Margulies, David/0000-0001-8530-7375				Berzofsky Jay A., 1993, P421; BOYD LA, UNPUB; BOYD LF, 1992, P NATL ACAD SCI USA, V89, P2242, DOI 10.1073/pnas.89.6.2242; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CORR M, 1992, J EXP MED, V176, P1681, DOI 10.1084/jem.176.6.1681; CORR M, 1993, J EXP MED, V178, P1877, DOI 10.1084/jem.178.6.1877; CORR M, UNPUB; DALPORTO J, 1993, P NATL ACAD SCI USA, V90, P6671, DOI 10.1073/pnas.90.14.6671; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; HONG SC, 1992, CELL, V69, P999, DOI 10.1016/0092-8674(92)90618-M; JELONEK MT, UNPUB; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; KHILKO S, UNPUB; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P7922, DOI 10.1073/pnas.81.24.7922; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P573, DOI 10.1073/pnas.81.2.573; KUBO RT, 1989, J IMMUNOL, V142, P2736; Margulies David H., 1993, Journal of Molecular Recognition, V6, P59, DOI 10.1002/jmr.300060204; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; SCHNECK J, 1989, CELL, V56, P47, DOI 10.1016/0092-8674(89)90982-3; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; SLANETZ AE, 1991, EUR J IMMUNOL, V21, P179, DOI 10.1002/eji.1830210127; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAERZ UD, 1985, J IMMUNOL, V134, P3994; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0	30	308	321	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 12	1994	265	5174					946	949		10.1126/science.8052850	http://dx.doi.org/10.1126/science.8052850			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB499	8052850				2022-12-24	WOS:A1994PB49900040
J	ROTHMAN, KJ; MICHELS, KB				ROTHMAN, KJ; MICHELS, KB			THE CONTINUING UNETHICAL USE OF PLACEBO CONTROLS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RHEUMATOID-ARTHRITIS; DOUBLE-BLIND; HEART-FAILURE; MAJOR DEPRESSION; CONTROLLED TRIAL; INDUCED NAUSEA; EFFICACY; CHEMOTHERAPY; METOCLOPRAMIDE; ONDANSETRON		HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	ROTHMAN, KJ (corresponding author), BOSTON UNIV, SCH PUBL HLTH, BOSTON, MA 02118 USA.			Rothman, Kenneth/0000-0003-2398-1705				AMSTERDAM JD, 1989, PHARMACOPSYCHIATRY, V22, P137, DOI 10.1055/s-2007-1014596; ANNAS GJ, 1992, NAZI DOCTORS NUREMBE, P331; Annas GJ, 1992, NAZI DOCTORS NUREMBE, P339; BECK TM, 1993, ANN INTERN MED, V118, P407, DOI 10.7326/0003-4819-118-6-199303150-00002; BOWDEN CL, 1994, JAMA-J AM MED ASSOC, V271, P918, DOI 10.1001/jama.271.12.918; BRAUNWALD E, 1991, NEW ENGL J MED, V325, P351, DOI 10.1056/NEJM199108013250508; CARR AA, 1991, J CLIN PHARMACOL, V31, P144, DOI 10.1002/j.1552-4604.1991.tb03698.x; CASSILETH BR, 1980, NEW ENGL J MED, V302, P896, DOI 10.1056/NEJM198004173021605; CITRON ML, 1993, ANN INTERN MED, V118, P470, DOI 10.7326/0003-4819-118-6-199303150-00013; COWLEY AJ, 1993, INT J CARDIOL, V38, P167, DOI 10.1016/0167-5273(93)90176-H; COX R, 1982, CANCER CHEMOTH PHARM, V8, P133, DOI 10.1007/BF00292884; CUBEDDU LX, 1990, NEW ENGL J MED, V322, P810, DOI 10.1056/NEJM199003223221204; CUNNINGHAM D, 1987, BRIT MED J, V295, P250, DOI 10.1136/bmj.295.6592.250; EDGE SB, 1987, AM J CLIN ONCOL-CANC, V10, P257, DOI 10.1097/00000421-198706000-00020; FABRE LF, 1990, J CLIN PSYCHIAT, V51, P55; FABRE LF, 1991, 5TH WORLD C BIOL PSY; FELSON DT, 1990, ARTHRITIS RHEUM, V33, P1449, DOI 10.1002/art.1780331001; GANDARA DR, 1992, SEMIN ONCOL, V19, P67; GARDNER MJ, 1986, BMJ-BRIT MED J, V292, P746, DOI 10.1136/bmj.292.6522.746; GRALLA RJ, 1987, MED CLIN N AM, V71, P289, DOI 10.1016/S0025-7125(16)30871-9; GREENE BM, 1985, NEW ENGL J MED, V313, P133, DOI 10.1056/NEJM198507183130301; Grodin MA., 1992, NAZI DOCTORS NUREMBE, P121; HILL AB, 1963, BMJ-BRIT MED J, P1043, DOI 10.1136/bmj.1.5337.1043; JOHNSEN V, 1989, SCAND J RHEUMATOL, V18, P251, DOI 10.3109/03009748909095027; KELBAEK H, 1993, EUR HEART J, V14, P692, DOI 10.1093/eurheartj/14.5.692; KIEV A, 1992, J CLIN PSYCHIAT, V53, P27; PACKER M, 1993, J AM COLL CARDIOL, V22, P65, DOI 10.1016/0735-1097(93)90816-J; RICKELS K, 1992, J CLIN PSYCHIAT, V53, P30; ROTHMAN KJ, 1986, ANN INTERN MED, V105, P445, DOI 10.7326/0003-4819-105-3-445; SALSBURG DS, 1985, AM STAT, V39, P220, DOI 10.2307/2683942; SAVITZ DA, 1993, REPROD TOXICOL, V7, P95, DOI 10.1016/0890-6238(93)90242-Y; SILVERSTONE T, 1993, INT CLIN PSYCHOPHARM, V7, P133, DOI 10.1097/00004850-199300730-00002; SMITH WT, 1992, J CLIN PSYCHIAT, V53, P36; SPRIET A, 1994, CHOICE COMPARATOR PL; SVETKEY LP, 1988, CURR THER RES CLIN E, V43, P969; Temple R, 1982, DRUG INF J, V10-17, DOI DOI 10.1177/009286158201600102; TORVIK D, 1986, BRIT J CLIN PHARMACO, V21, pS69, DOI 10.1111/j.1365-2125.1986.tb02856.x; TRENTHAM DE, 1993, SCIENCE, V261, P1727, DOI 10.1126/science.8378772; TUGWELL P, 1990, LANCET, V335, P1051, DOI 10.1016/0140-6736(90)92630-Z; WALKER AM, 1986, AM J PUBLIC HEALTH, V76, P556, DOI 10.2105/AJPH.76.5.556; WILLIAMS HJ, 1988, ARTHRITIS RHEUM, V31, P702, DOI 10.1002/art.1780310602; 1988, GUIDELINES CLIN EVAL; 1987, FOOD DRUGS, V21	43	492	499	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 11	1994	331	6					394	398		10.1056/NEJM199408113310611	http://dx.doi.org/10.1056/NEJM199408113310611			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA374	8028622				2022-12-24	WOS:A1994PA37400011
J	MARFIN, AA; MOORE, J; COLLINS, C; BIELLIK, R; KATTEL, U; TOOLE, MJ; MOORE, PS				MARFIN, AA; MOORE, J; COLLINS, C; BIELLIK, R; KATTEL, U; TOOLE, MJ; MOORE, PS			INFECTIOUS-DISEASE SURVEILLANCE DURING EMERGENCY RELIEF TO BHUTANESE REFUGEES IN NEPAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MENINGOCOCCAL MENINGITIS; DEVELOPING-COUNTRIES; MORTALITY TRENDS; VERBAL AUTOPSY; PUBLIC-HEALTH; POPULATIONS; THAILAND; SOMALIA; VALIDATION; INTERVIEWS	Objective.-To implement simplified infectious disease surveillance and epidemic disease control during the relocation of Bhutanese refugees to Nepal. Design.-Longitudinal observation study of mortality and morbidity. Setting.-Refugee health units in six refugee camps housing 73 500 Bhutanese refugees in the eastern tropical lowland between Nepal and India. Interventions.-Infectious disease surveillance and community-based programs to promote vitamin A supplementation, measles vaccination, oral rehydration therapy, and early use of antibiotics to treat acute respiratory infection. Main Outcome Measures.-Crude mortality rate, mortality rate for children younger than 5 years, and cause-specific mortality. Results.-Crude mortality rates up to 1.15 deaths per 10 000 persons per day were reported during the first 6 months of surveillance The leading causes of death were measles, diarrhea, and acute respiratory infections. Surveillance data were used to institute changes in public health management including measles vaccination, vitamin A supplementation, and control programs for diarrhea and acute respiratory infections and to ensure rapid responses to cholera, Shigella dysentery, and meningoencephalitis. Within 4 months of establishing disease control interventions, crude mortality rates were reduced by 75% and were below emergency levels. Conclusions.-Simple, sustainable disease surveillance in refugee populations is essential during emergency relief efforts. Data can be used to direct community-based public health interventions to control common infectious diseases and reduce high mortality rates among refugees while placing a minimal burden on health workers.	CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV VECTOR BORNE INFECT DIS, FT COLLINS, CO USA; SAVE CHILDREN FUND UNITED KINGDOM, LONDON, ENGLAND; WHO, Kathmandu, NEPAL; CTR DIS CONTROL & PREVENT, INT HLTH PROGRAM OFF, ATLANTA, GA USA	Centers for Disease Control & Prevention - USA; Save the Children; World Health Organization; Centers for Disease Control & Prevention - USA			Moore, Patrick/GVR-8294-2022; Moore, Patrick S./F-3960-2011	Moore, Patrick S./0000-0002-8132-858X				BANG AT, 1992, B WORLD HEALTH ORGAN, V70, P499; COCHI SL, 1987, INT J EPIDEMIOL, V16, P91, DOI 10.1093/ije/16.1.91; DESENCLOS JC, 1990, INT J EPIDEMIOL, V19, P367, DOI 10.1093/ije/19.2.367; ELIAS CJ, 1990, AM J PUBLIC HEALTH, V80, P824, DOI 10.2105/AJPH.80.7.824; GLASS RI, 1980, LANCET, V1, P868; HAKEWILL PA, 1991, TROP DOCT, V21, P24, DOI 10.1177/00494755910210S106; KALTER HD, 1991, INT J EPIDEMIOL, V20, P193, DOI 10.1093/ije/20.1.193; KALTER HD, 1990, INT J EPIDEMIOL, V19, P380, DOI 10.1093/ije/19.2.380; KLAUCKE DN, 1988, MMWR S5, V37, P1; MANONCOURT S, 1992, LANCET, V340, P176, DOI 10.1016/0140-6736(92)93252-I; MOORE PS, 1990, B WORLD HEALTH ORGAN, V68, P587; MOORE PS, 1993, LANCET, V341, P935, DOI 10.1016/0140-6736(93)91223-9; OGAWA S, 1992, Southeast Asian Journal of Tropical Medicine and Public Health, V23, P37; PACQUEMARGOLIS S, 1990, SOC SCI MED, V31, P585, DOI 10.1016/0277-9536(90)90094-9; TOOLE M J, 1989, Bulletin of the World Health Organization, V67, P381; TOOLE MJ, 1988, J TROP PEDIATRICS, V34, P218, DOI 10.1093/tropej/34.5.218; TOOLE MJ, 1988, B WORLD HEALTH ORGAN, V66, P237; TOOLE MJ, 1992, LANCET, V339, P1214, DOI 10.1016/0140-6736(92)91143-V; TOOLE MJ, 1990, JAMA-J AM MED ASSOC, V263, P3296, DOI 10.1001/jama.263.24.3296; TOOLE MJ, 1993, JAMA-J AM MED ASSOC, V270, P600, DOI 10.1001/jama.270.5.600; TOOLE MJ, 1992, MMWR-MORBID MORTAL W, V41, P1; 1978, LAY REPORTING HLTH I	22	31	31	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	1994	272	5					377	381		10.1001/jama.272.5.377	http://dx.doi.org/10.1001/jama.272.5.377			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY903	8028169				2022-12-24	WOS:A1994NY90300030
J	AOSAKI, T; GRAYBIEL, AM; KIMURA, M				AOSAKI, T; GRAYBIEL, AM; KIMURA, M			EFFECT OF THE NIGROSTRIATAL DOPAMINE SYSTEM ON ACQUIRED NEURAL RESPONSES IN THE STRIATUM OF BEHAVING MONKEYS	SCIENCE			English	Article							TERM SYNAPTIC DEPRESSION; PARKINSONS-DISEASE; PREFRONTAL CORTEX; RAT NEOSTRIATUM; NEURONS; PHYSIOLOGY; DEPLETION; LESIONS; ANATOMY; MATRIX	Dysfunction of the nigrostriatal dopamine system results in marked disorders of movement such as occur in Parkinson's disease. Functions of this dopamine-containing projection system were examined in monkeys trained in a classical conditioning task, and the effects of striatal dopamine depletion were tested. Unilateral dopamine loss substantially reduced the acquired sensory responsiveness of striatal neurons monitored electrophysiologically. This effect was ipsilateral and selective, and could be reversed by apomorphine. These results suggest that the primate nigrostriatal system modulates expression of neuronal response plasticity in the striatum during sensorimotor learning.	OSAKA UNIV,FAC HLTH & SPORT SCI,TOYONAKA,OSAKA 560,JAPAN; MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139	Osaka University; Massachusetts Institute of Technology (MIT)				Graybiel, Ann/0000-0002-4326-7720	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025529] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS25529] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AOSAKI T, UNPUB; AOSAKI T, IN PRESS; APICELLA P, 1991, EXP BRAIN RES, V84, P672; ARTIEDA J, 1992, BRAIN, V115, P199, DOI 10.1093/brain/115.1.199; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; BLOOM FE, 1979, NEUROSCIENCES 4TH ST, P51; BROCHTIE JM, 1991, MOV DISORD, V6, P133; CALABRESI P, 1992, NEUROSCI LETT, V142, P95, DOI 10.1016/0304-3940(92)90628-K; CALABRESI P, 1992, J NEUROSCI, V12, P4224; CARLI M, 1985, NATURE, V313, P679, DOI 10.1038/313679a0; COOLS AR, 1984, J NEUROL NEUROSUR PS, V47, P443, DOI 10.1136/jnnp.47.5.443; FLOWERS KA, 1976, BRAIN, V99, P269, DOI 10.1093/brain/99.2.269; GRACE AA, 1991, NEUROSCIENCE, V41, P1, DOI 10.1016/0306-4522(91)90196-U; GRAYBIEL AM, 1987, P NATL ACAD SCI USA, V84, P303, DOI 10.1073/pnas.84.1.303; Hornykiewicz O., 1966, BIOCH PHARM BASAL GA, P171; KAWAGUCHI Y, 1992, J NEUROPHYSIOL, V67, P1669, DOI 10.1152/jn.1992.67.6.1669; KIMURA M, 1990, EXP BRAIN RES, V82, P672; KIMURA M, 1984, P NATL ACAD SCI-BIOL, V81, P4998, DOI 10.1073/pnas.81.15.4998; KOOB GF, 1989, NEUROSCI BIOBEHAV R, V13, P135, DOI 10.1016/S0149-7634(89)80022-3; LJUNGBERG T, 1992, J NEUROPHYSIOL, V67, P145, DOI 10.1152/jn.1992.67.1.145; LJUNGBERG T, 1993, J NEUROSCI, V13, P900; MCDONALD RJ, 1993, BEHAV NEUROSCI, V107, P3, DOI 10.1037/0735-7044.107.1.3; Mishkin M., 1984, NEUROBIOL LEARN MEM, P65, DOI DOI 10.1523/JNEUROSCI.0840-16.2016; MOORE RY, 1979, ANNU REV NEUROSCI, V2, P113, DOI 10.1146/annurev.ne.02.030179.000553; MOORE RY, 1978, ANNU REV NEUROSCI, V1, P129, DOI 10.1146/annurev.ne.01.030178.001021; NAKAMURA T, 1988, BRAIN RES, V474, P327; SAINTCYR JA, 1988, BRAIN, V111, P941, DOI 10.1093/brain/111.4.941; SAWAGUCHI T, 1990, J NEUROPHYSIOL, V63, P1385, DOI 10.1152/jn.1990.63.6.1385; SAWAGUCHI T, 1990, J NEUROPHYSIOL, V63, P1401, DOI 10.1152/jn.1990.63.6.1401; SCHULTZ W, 1982, PROG NEUROBIOL, V18, P121, DOI 10.1016/0301-0082(82)90015-6; TETRUD JW, 1989, SCIENCE, V245, P519, DOI 10.1126/science.2502843; VONVOIGTLANDER PF, 1973, NEUROPHARMACOLOGY, V12, P451, DOI 10.1016/0028-3908(73)90061-0; WILSON CJ, 1990, J NEUROSCI, V10, P508	33	305	308	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 15	1994	265	5170					412	415		10.1126/science.8023166	http://dx.doi.org/10.1126/science.8023166			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023166				2022-12-24	WOS:A1994NW81600046
J	LATTERICH, M; SCHEKMAN, R				LATTERICH, M; SCHEKMAN, R			THE KARYOGAMY GENE KAR2 AND NOVEL PROTEINS ARE REQUIRED FOR ER-MEMBRANE FUSION	CELL			English	Article							TRANSPORT VESICLE FORMATION; ENDOPLASMIC-RETICULUM; NUCLEAR-FUSION; SECRETORY PATHWAY; TRANSMEMBRANE PROTEIN; GOLGI-APPARATUS; YEAST; TRANSLOCATION; RECONSTITUTION; BINDING	We have developed assays using cells and isolated membranes to identify factors mediating fusion of the ER-nuclear membrane network in yeast. When cells containing distinctly tagged ER-nuclear envelops membranes are observed during mating, the markers of both parental membranes become colocalized in a process sharing a genetic requirement with karyogamy. Using isolated membranes, we find that fusion between ER compartments requires ATP, but not cytosol, Sec17p (alpha-SNAP), or Sec18p (NSF), the latter two being required at the fusion step in vesicular transport. Proteins tightly associated with the ER membrane are essential for fusion, as is Kar2p (BiP), an ER lumenal hsp70 homolog. BiP may activate an ER-localized fusogen, allowing nuclear fusion and karyogamy in yeast.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley	LATTERICH, M (corresponding author), UNIV CALIF BERKELEY, HOWARD HUGHES MED INST, BERKELEY, CA 94720 USA.							ABEIJON C, 1992, TRENDS BIOCHEM SCI, V17, P32, DOI 10.1016/0968-0004(92)90424-8; ARIS JP, 1991, METHOD ENZYMOL, V194, P735; BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BARLOWE C, 1993, J BIOL CHEM, V268, P873; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BERLIN V, 1991, METHOD ENZYMOL, V194, P774; BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; BRODSKY JL, 1993, J CELL BIOL, V120, P95, DOI 10.1083/jcb.120.1.95; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BYERS B, 1982, MOL BIOL YEAST SACCH, P59; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; ESMON B, 1984, J BIOL CHEM, V259, P322; FELDHEIM D, 1992, MOL CELL BIOL, V12, P3288, DOI 10.1128/MCB.12.7.3288; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; GRIFF IC, 1992, J BIOL CHEM, V267, P12106; HICKE L, 1992, MOL BIOL CELL, V3, P667, DOI 10.1091/mbc.3.6.667; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KAISER CA, 1990, MOL CELL BIOL, V10, P3163, DOI 10.1128/MCB.10.6.3163; KURIHARA LJ, 1994, IN PRESS J CELL BIOL; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MELUH PB, 1990, CELL, V60, P1029, DOI 10.1016/0092-8674(90)90351-E; MORI K, 1993, CELL, V74, P743; NEWPORT J, 1992, J CELL BIOL, V116, P295, DOI 10.1083/jcb.116.2.295; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; REXACH M, 1994, IN PRESS J CELL BIOL; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROBERTS CJ, 1989, J CELL BIOL, V108, P1363, DOI 10.1083/jcb.108.4.1363; ROSE MD, 1991, ANNU REV MICROBIOL, V45, P539; ROSE MD, 1987, CELL, V48, P1047, DOI 10.1016/0092-8674(87)90712-4; ROSE MD, 1986, MOL CELL BIOL, V6, P3490, DOI 10.1128/MCB.6.10.3490; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROSE MD, 1990, METHDOS YEAST GENETI; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; Sambrook J., 1989, MOL CLONING LAB MANU; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SZTUL E, 1993, J BIOL CHEM, V268, P1876; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WATKINS JD, 1993, J BIOL CHEM, V268, P5182; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; WILSON KL, 1988, J CELL BIOL, V107, P57, DOI 10.1083/jcb.107.1.57; WUESTEHUBE LJ, 1992, METHOD ENZYMOL, V219, P124	59	99	99	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 15	1994	78	1					87	98		10.1016/0092-8674(94)90575-4	http://dx.doi.org/10.1016/0092-8674(94)90575-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033215				2022-12-24	WOS:A1994NX32800011
J	SPEIR, E; MODALI, R; HUANG, ES; LEON, MB; SHAWL, F; FINKEL, T; EPSTEIN, SE				SPEIR, E; MODALI, R; HUANG, ES; LEON, MB; SHAWL, F; FINKEL, T; EPSTEIN, SE			POTENTIAL ROLE OF HUMAN CYTOMEGALOVIRUS AND P53 INTERACTION IN CORONARY RESTENOSIS	SCIENCE			English	Article							CELLULAR TUMOR-ANTIGEN; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS; NUCLEAR ANTIGEN; PROTEIN; VIRUS; EXPRESSION; CARCINOMA; PROLIFERATION; ANTIBODY	A subset of patients who have undergone coronary angioplasty develop restenosis, a vessel renarrowing characterized by excessive proliferation of smooth muscle cells (SMCs). Of 60 human restenosis lesions examined, 23 (38 percent) were found to have accumulated high amounts of the tumor suppressor protein p53, and this correlated with the presence of human cytomegalovirus (HCMV) in the lesions. SMCs grown from the lesions expressed HCMV protein IE84 and high amounts of p53. HCMV infection of cultured SMCs enhanced p53 accumulation, which correlated temporally with IE84 expression. IE84 also bound to p53 and abolished its ability to transcriptionally activate a reporter gene. Thus, HCMV, and IE84-mediated inhibition of p53 function, may contribute to the development of restenosis.	BIOSERVE BIOTECHNOL LTD,LAUREL,MD 20707; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; WASHINGTON HOSP CTR,WASHINGTON CARDIOL CTR,DIV CARDIOL,WASHINGTON,DC 20010; WASHINGTON ADVENTIST HOSP,DEPT CARDIOL,TAKOMA PK,MD 20912	University of North Carolina; University of North Carolina Chapel Hill; MedStar Washington Hospital Center	SPEIR, E (corresponding author), NIH,CARDIOL BRANCH,BLDG 10,BETHESDA,MD 20892, USA.							ALBRECHT T, 1993, FRONTIERS VIROLOGY, V2, pCH19; BENDITT EP, 1973, P NATL ACAD SCI USA, V70, P1753, DOI 10.1073/pnas.70.6.1753; BENNETT WP, 1991, ONCOGENE, V6, P101; FABRICANT CG, 1978, J EXP MED, V148, P335, DOI 10.1084/jem.148.1.335; FINKEL T, 1993, J BIOL CHEM, V268, P5; GUMERLOCK PH, 1991, CANCER RES, V51, P1632; GUREVICH I, 1992, HEART LUNG, V21, P85; HAGEMEIER C, 1992, J VIROL, V66, P4452, DOI 10.1128/JVI.66.7.4452-4456.1992; HUANG ES, 1993, FRONTIERS VIROLOGY, V2, P247; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEMSTROM KB, 1993, J CLIN INVEST, V92, P549, DOI 10.1172/JCI116622; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MELNICK JL, 1993, FRONTIERS VIROLOGY, V2, pCH4; MIDGLEY CA, 1992, J CELL SCI, V101, P183; NELSON JA, 1984, J VIROL, V49, P109, DOI 10.1128/JVI.49.1.109-115.1984; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SPEIR E, 1992, CIRCULATION, V86, P538, DOI 10.1161/01.CIR.86.2.538; SPEIR E, 1992, CIRC RES, V71, P251, DOI 10.1161/01.RES.71.2.251; SPEIR E, UNPUB; STENBERG RM, 1989, J VIROL, V63, P2699, DOI 10.1128/JVI.63.6.2699-2708.1989; SZEKELY L, 1993, P NATL ACAD SCI USA, V90, P5455, DOI 10.1073/pnas.90.12.5455; TSUKADA T, 1987, AM J PATHOL, V126, P51; TUMILOWICZ JJ, 1985, J VIROL, V56, P839, DOI 10.1128/JVI.56.3.839-845.1985; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHANG Q, 1994, MOL CELL BIOL, V14, P1929, DOI 10.1128/MCB.14.3.1929	32	672	713	2	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 15	1994	265	5170					391	394		10.1126/science.8023160	http://dx.doi.org/10.1126/science.8023160			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW816	8023160				2022-12-24	WOS:A1994NW81600039
J	MAGGI, E; MAZZETTI, M; RAVINA, A; ANNUNZIATO, F; DECARLI, M; PICCINNI, MP; MANETTI, R; CARBONARI, M; PESCE, AM; DELPRETE, G; ROMAGNANI, S				MAGGI, E; MAZZETTI, M; RAVINA, A; ANNUNZIATO, F; DECARLI, M; PICCINNI, MP; MANETTI, R; CARBONARI, M; PESCE, AM; DELPRETE, G; ROMAGNANI, S			ABILITY OF HIV TO PROMOTE A T(H)1 TO T(H)0 SHIFT AND TO REPLICATE PREFERENTIALLY IN T(H)2 AND T(H)0 CELLS	SCIENCE			English	Article							ACQUIRED IMMUNODEFICIENCY SYNDROME; CD4+ T-CELLS; LYMPHOKINE ACTIVITIES; CYTOKINE PRODUCTION; SELECTIVE DEFECT; LYMPHOCYTES-T; HELPER; ACTIVATION; INFECTION; PROFILES	Both interferon gamma (IFN-gamma) produced by T helper 1 (T(H)1) lymphocytes and interleukin-4 (IL-4) produced by T(H)2 lymphocytes were reduced in either bulk circulating mononuclear cells or mitogen-induced CD4(+) T cell clones from the peripheral blood of individuals infected with human immunodeficiency virus (HIV). There was a preferential reduction in clones producing IL-4 and IL-5 in the advanced phases of infection. However, enhanced proportions of CD4(+) T cell clones producing both T(H)1-type and T(H)2-type cytokines (T(H)0 clones) were generated from either skin-infiltrating T cells that had been activated in vivo or peripheral blood T cells stimulated by antigen in vitro when cells were isolated from HIV-infected individuals. All T(H)2 and most T(H)0 clones supported viral replication, although viral replication was not detected in any of the T(H)1 clones infected in vitro with HIV. These results suggest that HIV (i) does not induce a definite T(H)1 to T(H)2 switch, but can favor a shift to the T(H)0 phenotype in response to recall antigens, and (ii) preferentially replicates in CD4(+) T cells producing T(H)2-type cytokines (T(H)2 and T(H)0).	UNIV FLORENCE,DIV CLIN IMMUNOL & ALLERGY,FLORENCE,ITALY; UNIV ROMA LA SAPIENZA,DIV CLIN IMMUNOL & ALLERGY,ROME,ITALY	University of Florence; Sapienza University Rome			Maggi, Enrico/AAA-8045-2019; Annunziato, Francesco/C-1155-2013	Maggi, Enrico/0000-0002-1824-3583; Annunziato, Francesco/0000-0001-8798-7589				AMELSEN JC, 1991, IMMUNOL TODAY, V12, P102; BOWEN DL, 1985, ANN INTERN MED, V103, P704, DOI 10.7326/0003-4819-103-5-704; BRINCHMANN JE, 1990, J IMMUNOL, V144, P2961; CARBONARI M, 1993, TRENDS GENET, V9, P42; CHEHIMI J, IN PRESS J EXP MED; CLERICI M, 1994, J CLIN INVEST, V93, P768, DOI 10.1172/JCI117031; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; CLERICI M, 1993, J CLIN INVEST, V91, P759, DOI 10.1172/JCI116294; DELPRETE GF, 1993, EUR J IMMUNOL, V23, P1445, DOI 10.1002/eji.1830230707; DELPRETE GF, 1991, J CLIN INVEST, V88, P346, DOI 10.1172/JCI115300; FAHEY JL, 1984, AM J MED, V76, P95, DOI 10.1016/0002-9343(84)90756-3; GENDELMAN HE, 1990, J EXP MED, V172, P1433, DOI 10.1084/jem.172.5.1433; GRAZLOSI C, COMMUNICATION; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; MACCHIA D, 1993, NATURE, V363, P464, DOI 10.1038/363464a0; MACCHIA D, 1991, J IMMUNOL, V146, P3414; MACKEWICZ C, 1992, AIDS RES HUM RETROV, V8, P1039, DOI 10.1089/aid.1992.8.1039; MAGGI E, 1987, EUR J IMMUNOL, V17, P1685, DOI 10.1002/eji.1830171202; MAGGI E, 1988, EUR J IMMUNOL, V18, P1045, DOI 10.1002/eji.1830180712; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MANETTI R, IN PRESS REV IMMUNOL; MARGOLICK JB, 1985, J CLIN INVEST, V76, P709, DOI 10.1172/JCI112025; MORETTA A, 1983, J EXP MED, V158, P571, DOI 10.1084/jem.158.2.571; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; PALIARD X, 1990, J IMMUNOL, V144, P849; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; POLI G, 1992, AIDS RES HUM RETROV, V8, P191, DOI 10.1089/aid.1992.8.191; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; ROMAGNANI S, 1989, CLIN IMMUNOL IMMUNOP, V50, P13; ROMAGNANI S, IN PRESS IMMUNOL REV; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; STREET NE, 1990, J IMMUNOL, V144, P1629; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188	36	473	489	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 8	1994	265	5169					244	248		10.1126/science.8023142	http://dx.doi.org/10.1126/science.8023142			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV957	8023142				2022-12-24	WOS:A1994NV95700040
J	LETTERIO, JJ; GEISER, AG; KULKARNI, AB; ROCHE, NS; SPORN, MB; ROBERTS, AB				LETTERIO, JJ; GEISER, AG; KULKARNI, AB; ROCHE, NS; SPORN, MB; ROBERTS, AB			MATERNAL RESCUE OF TRANSFORMING GROWTH-FACTOR-BETA-1 NULL MICE	SCIENCE			English	Article							FACTOR-BETA; EXPRESSION; MOUSE; RATS; LYMPHOCYTES; ANTIBODIES; DISEASE; ANTIGEN	Maternal sources of transforming growth factor-beta 1 (TGF-beta 1) are shown here to contribute to the normal appearance and perinatal survival of TGF-beta 1 null newborn mice. Labeled TGF-beta 1 crossed the placenta and was recovered intact from various tissues after oral administration to mouse pups. TGF beta-1 protein was also detected in cells recovered from breast milk. In immunohistochemical analyses, TGF-beta 1 null embryos and null newborn pups born to TGF-beta 1 heterozygotes stained positive for TGF-beta 1, whereas those born to a null female were negative and had severe cardiac abnormalities. These results suggest an important role for maternal sources of TGF-beta 1 during development and, more generally, provide evidence for maternal rescue of targeted gene disruption in the fetus.	NINCDS,DEV & METAB NEUROL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	LETTERIO, JJ (corresponding author), NCI,CHEMOPREVENT LAB,BETHESDA,MD 20892, USA.							ABRAHAMSON DR, 1981, J CELL BIOL, V91, P270, DOI 10.1083/jcb.91.1.270; ADENIYIJONES SCA, 1987, J IMMUNOL, V138, P1408; BOTTAZZO GF, 1985, NEW ENGL J MED, V313, P353, DOI 10.1056/NEJM198508083130604; Brambell FWR., 1970, N HOLL RES MONOGR FR, V18; CELADA A, 1993, J EXP MED, V177, P691, DOI 10.1084/jem.177.3.691; COX DA, 1991, EUR J BIOCHEM, V197, P353, DOI 10.1111/j.1432-1033.1991.tb15918.x; DANIELPOUR D, 1993, J IMMUNOL METHODS, V158, P17, DOI 10.1016/0022-1759(93)90254-5; Danielpour D, 1989, GROWTH FACTORS, V2, P61, DOI 10.3109/08977198909069082; DRESSER DW, 1990, J REPROD IMMUNOL, V18, P293, DOI 10.1016/0165-0378(90)90050-G; ERICKSON HP, 1993, J CELL BIOL, V120, P1079, DOI 10.1083/jcb.120.5.1079; FLANDERS KC, 1989, J CELL BIOL, V108, P653, DOI 10.1083/jcb.108.2.653; GEISER AG, 1993, P NATL ACAD SCI USA, V90, P9944, DOI 10.1073/pnas.90.21.9944; HANAFUSA T, 1983, LANCET, V2, P1111; HEINE UI, 1987, J CELL BIOL, V105, P2861, DOI 10.1083/jcb.105.6.2861; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LETTERIO JJ, UNPUB; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MILLAN FA, 1991, DEVELOPMENT, V111, P131; POPLIKER M, 1987, DEV BIOL, V119, P38, DOI 10.1016/0012-1606(87)90204-1; ROBERTS A, 1990, PEPTIDE GROWTH FACTO, V1, pCH8; SEELIG LL, 1981, TRANSPLANTATION, V32, P308, DOI 10.1097/00007890-198110000-00010; SEELIG LL, 1987, J REPROD IMMUNOL, V10, P285, DOI 10.1016/0165-0378(87)90031-3; SHIMAMURA M, 1994, BLOOD, V83, P926, DOI 10.1182/blood.V83.4.926.bloodjournal834926; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; STACH RM, 1993, J EXP MED, V17, P841; TOKUYAMA H, 1989, CELL BIOL INT REP, V13, P251, DOI 10.1016/0309-1651(89)90147-1; WAKEFIELD LM, 1990, J CLIN INVEST, V86, P1976, DOI 10.1172/JCI114932; 1992, MOL REPROD DEV, V32	29	441	460	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1936	1938		10.1126/science.8009224	http://dx.doi.org/10.1126/science.8009224			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	8009224				2022-12-24	WOS:A1994NT84700046
J	KUPERSMITH, MJ; ROSENBERG, C; KLEINBERG, D				KUPERSMITH, MJ; ROSENBERG, C; KLEINBERG, D			VISUAL-LOSS IN PREGNANT-WOMEN WITH PITUITARY-ADENOMAS	ANNALS OF INTERNAL MEDICINE			English	Article						PREGNANCY; PROLACTINOMA; PITUITARY NEOPLASMS; VISION DISORDERS; VISUAL FIELDS	TUMORS; BROMOCRIPTINE; PROLACTIN; HYPERPROLACTINEMIA	Objective: To investigate the potential risk for developing visual loss during single or multiple pregnancies in women with pituitary adenomas. Design: Cohort study. Setting: Referral center of a neuro-ophthalmology service. Patients: 65 consecutive women with pituitary adenomas who had not been previously treated with surgery or radiation were monitored during 111 pregnancies. Sixty had increased levels of serum prolactin or growth hormone and 5 did not. Main Outcome Measures: Visual field or acuity loss was compared with the baseline size of the adenoma measured on the coronal view of the computed tomographic or magnetic resonance image. Results: Computed tomography or magnetic resonance imaging showed a definitive tumor (>0.3 cm, vertical height) in 57 patients, 8 of whom had macroadenomas (greater than or equal to 1.1 cm). Visual field loss occurred in 6 of 8 primiparous patients, all with adenomas greater than 1.1 cm (range, 1.2 to 2.5 cm). None of the 57 patients (95% CI, 0% to 6.3%) with a microadenoma or presumed microadenoma of 1 cm or smaller developed visual loss-after as many as four full-term pregnancies. Conclusions: The risk for developing visual loss during single or multiple pregnancies in patients with microadenomas was small. Six of eight pregnant women with macroadenomas, however, developed visual field loss during pregnancy.	NYU, MED CTR, DEPT NEUROL, NEW YORK, NY 10016 USA; NYU, MED CTR, DEPT MED, NEW YORK, NY 10016 USA; DEPT VET AFFAIRS MED CTR, NEW YORK, NY USA	New York University; New York University	KUPERSMITH, MJ (corresponding author), NYU, MED CTR, DEPT OPHTHALMOL, 530 1ST AVE 3B, NEW YORK, NY 10016 USA.							BERGH T, 1982, CLIN ENDOCRINOL, V17, P625, DOI 10.1111/j.1365-2265.1982.tb01636.x; BERGH T, 1978, BRIT MED J, V1, P875, DOI 10.1136/bmj.1.6117.875; BERGH T, 1981, ACTA ENDOCRINOL-COP, V98, P333, DOI 10.1530/acta.0.0980333; BRESLOW NE, 1980, IARC SCI PUBL, V32, P191; CANALES ES, 1981, FERTIL STERIL, V36, P524; CORENBLUM B, 1979, FERTIL STERIL, V32, P183; GEMZELL C, 1979, FERTIL STERIL, V31, P363; GOODMAN L A, 1984, Obstetrics and Gynecology, V64, p2S; KRUPP P, 1987, KLIN WOCHENSCHR, V65, P823, DOI 10.1007/BF01727477; LAMBERTS SWJ, 1979, FERTIL STERIL, V31, P614; MAGYAR DM, 1978, AM J OBSTET GYNECOL, V132, P739, DOI 10.1016/S0002-9378(78)80008-8; MELMED S, 1986, ANN INTERN MED, V105, P238, DOI 10.7326/0003-4819-105-2-238; MOLITCH ME, 1985, NEW ENGL J MED, V312, P1364, DOI 10.1056/NEJM198505233122106; MORNEX R, 1978, J CLIN ENDOCR METAB, V47, P290, DOI 10.1210/jcem-47-2-290; PEILLON F, 1988, ADV PITUITARY ADENOM, P67; RJOSK HK, 1982, ACTA ENDOCRINOL-COP, V100, P337, DOI 10.1530/acta.0.1000337; RUIZVELASCO V, 1984, FERTIL STERIL, V41, P793; SAMAAN NA, 1984, AM J OBSTET GYNECOL, V148, P466, DOI 10.1016/0002-9378(84)90728-2; SHELINE GE, 1984, PROGR ENDOCRINE RES, V1, P93; SHEWCHUK AB, 1980, AM J OBSTET GYNECOL, V136, P659, DOI 10.1016/0002-9378(80)91020-0; THORNER MO, 1979, BRIT MED J, V2, P771, DOI 10.1136/bmj.2.6193.771; THORNER MO, 1981, J CLIN ENDOCR METAB, V53, P480, DOI 10.1210/jcem-53-3-480; VANCE ML, 1987, ENDOCRIN METAB CLIN, V16, P731, DOI 10.1016/S0889-8529(18)30471-7; VANROON E, 1981, FERTIL STERIL, V36, P173; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401; Zar J., 1984, BIOSTAT ANAL, P261; ZARATE A, 1979, ACTA ENDOCRINOL-COP, V92, P407, DOI 10.1530/acta.0.0920407; 1990, SAS STAT USERS GUIDE, V2, P891	28	86	89	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1994	121	7					473	477		10.7326/0003-4819-121-7-199410010-00001	http://dx.doi.org/10.7326/0003-4819-121-7-199410010-00001			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ102	8067644				2022-12-24	WOS:A1994PJ10200001
J	LENFANT, C				LENFANT, C			LIFE-STYLE CHANGES, LOW-DOSE DIURETICS SHOULD BE FIRST CHOICE FOR TREATING HYPERTENSION IN THE ELDERLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											LENFANT, C (corresponding author), NHLBI, BLDG 31, ROOM 2B19, BETHESDA, MD 20892 USA.							[Anonymous], 1991, JAMA, V265, P3255; BLACK HR, 1994, HYPERTENSION, V23, P275; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154	3	7	7	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 21	1994	272	11					842	842		10.1001/jama.272.11.842	http://dx.doi.org/10.1001/jama.272.11.842			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG182	8078153				2022-12-24	WOS:A1994PG18200005
J	CHARLESWORTH, B; SNIEGOWSKI, P; STEPHAN, W				CHARLESWORTH, B; SNIEGOWSKI, P; STEPHAN, W			THE EVOLUTIONARY DYNAMICS OF REPETITIVE DNA IN EUKARYOTES	NATURE			English	Review							ELEMENT COPY NUMBER; GROUP-II INTRON; DROSOPHILA-MELANOGASTER; TRANSPOSABLE ELEMENTS; POPULATION-GENETICS; SATELLITE DNA; Y-CHROMOSOME; CENTROMERIC HETEROCHROMATIN; HIGH-FREQUENCY; TANDEM ARRAYS	Repetitive DNA sequences form a large portion of the genomes of eukaryotes. The 'selfish DNA' hypothesis proposes that they are maintained by their ability to replicate within the genome. The behaviour of repetitive sequences can result in mutations that cause genetic diseases, and confer significant fitness losses on the organism. Features of the organization of repetitive sequences in eukaryotic genomes, and their distribution in natural populations, reflect the evolutionary forces acting on selfish DNA.	MICHIGAN STATE UNIV, CTR MICROBIAL ECOL, E LANSING, MI 48824 USA; UNIV MARYLAND, DEPT ZOOL, COLLEGE PK, MD 20742 USA	Michigan State University; University System of Maryland; University of Maryland College Park	CHARLESWORTH, B (corresponding author), UNIV CHICAGO, DEPT ECOL & EVOLUT, 1101 E 57TH ST, CHICAGO, IL 60637 USA.		Stephan, Wolfgang/GOV-6503-2022					Armour JAL, 1992, CURR OPIN GENET DEV, V2, P850, DOI 10.1016/S0959-437X(05)80106-6; BACHMANN L, 1993, MOL BIOL EVOL, V10, P647; BATZER MA, 1991, GENOMICS, V9, P481, DOI 10.1016/0888-7543(91)90414-A; BELLIS M, 1987, MOL BIOL EVOL, V4, P351; BENNETT MD, 1972, PROC R SOC SER B-BIO, V181, P109, DOI 10.1098/rspb.1972.0042; Berg D. E., 1989, MOBILE DNA; Bernard J., 1988, EUKARYOTE GENOME DEV, DOI [10.1007/978-94-011-5991-3, DOI 10.1007/978-94-011-5991-3]; BIEMONT C, 1992, GENETICA, V86, P67, DOI 10.1007/BF00133712; Bingham PM, 1989, MOBILE DNA, P485; BLESSMANN H, 1992, EMBO J, V11, P4459; BRENNER S, 1993, NATURE, V366, P265, DOI 10.1038/366265a0; BRITTEN RJ, 1994, P NATL ACAD SCI USA, V91, P5992, DOI 10.1073/pnas.91.13.5992; BRITTEN RJ, 1969, SCIENCE, V165, P349, DOI 10.1126/science.165.3891.349; BROOKFIELD JFY, 1991, GENETICS, V128, P471; BRUFORD MW, 1993, CURR OPIN GENET DEV, V3, P939, DOI 10.1016/0959-437X(93)90017-J; BRUTLAG DL, 1980, ANNU REV GENET, V14, P121, DOI 10.1146/annurev.ge.14.120180.001005; CABOT EL, 1993, GENETICS, V135, P477; CAMERON JR, 1979, CELL, V16, P739, DOI 10.1016/0092-8674(79)90090-4; Cavalier-Smith T., 1985, P105; Cavalier-Smith T, 1985, EVOLUTION GENOME SIZ; CHARLESWORTH B, 1991, SCIENCE, V251, P1030, DOI 10.1126/science.1998119; CHARLESWORTH B, 1992, GENET RES, V60, P103, DOI 10.1017/S0016672300030792; CHARLESWORTH B, 1992, GENET RES, V60, P115, DOI 10.1017/S0016672300030809; CHARLESWORTH B, 1989, ANNU REV GENET, V23, P251, DOI 10.1146/annurev.ge.23.120189.001343; CHARLESWORTH B, 1986, GENETICS, V112, P947, DOI 10.1093/genetics/112.4.947; Charlesworth B., 1985, POPULATION GENETICS, P213; Crow JF, 1983, GENET BIOL DROSOPHIL, P1; Deininger PL, 1989, MOBILE DNA, P619; DEKA R, 1991, GENOMICS, V11, P83, DOI 10.1016/0888-7543(91)90104-M; DIRIENZO A, 1994, P NATL ACAD SCI USA, V91, P3166, DOI 10.1073/pnas.91.8.3166; DOOLITTLE WF, 1980, NATURE, V284, P601, DOI 10.1038/284601a0; Dover G. A., 1982, GENOME EVOLUTION; DOWSETT AP, 1982, P NATL ACAD SCI-BIOL, V79, P4570, DOI 10.1073/pnas.79.15.4570; EANES WF, 1992, GENET RES, V59, P1, DOI 10.1017/S0016672300030111; EDWARDS A, 1992, GENOMICS, V12, P241, DOI 10.1016/0888-7543(92)90371-X; EICHER EM, 1989, GENETICS, V122, P181; Eickbush Thomas H., 1994, P121; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GANGULY R, 1992, P NATL ACAD SCI USA, V89, P1340, DOI 10.1073/pnas.89.4.1340; GLOOR NB, 1991, SCIENCE, P1110; GRAY IC, 1991, P ROY SOC B-BIOL SCI, V243, P241, DOI 10.1098/rspb.1991.0038; HARDING RM, 1993, GENETICS, V135, P911; HAWLEY RS, 1993, TRENDS GENET, V9, P310; HEY J, 1989, MOL BIOL EVOL, V6, P66; HOCHSTENBACH R, IN PRESS J MOL EVOL; HOLMES SE, 1994, NAT GENET, V7, P143, DOI 10.1038/ng0694-143; HUNT JA, 1984, P NATL ACAD SCI-BIOL, V81, P7146, DOI 10.1073/pnas.81.22.7146; JABS EW, 1989, P NATL ACAD SCI USA, V86, P202, DOI 10.1073/pnas.86.1.202; JEFFREYS AJ, 1994, NAT GENET, V6, P136, DOI 10.1038/ng0294-136; KIDWELL MG, 1992, GENETICA, V86, P275, DOI 10.1007/BF00133726; KIM A, 1994, P NATL ACAD SCI USA, V91, P1285, DOI 10.1073/pnas.91.4.1285; KRUGER J, 1975, J MOL EVOL, V4, P201, DOI 10.1007/BF01732983; KUHL DPA, 1993, CURR OPIN GENET DEV, V3, P404, DOI 10.1016/0959-437X(93)90112-3; LAKICH D, 1993, NAT GENET, V5, P236, DOI 10.1038/ng1193-236; LANGLEY CH, 1988, GENET RES, V52, P223, DOI 10.1017/S0016672300027695; LEHRMAN MA, 1987, CELL, V48, P827, DOI 10.1016/0092-8674(87)90079-1; LEIGH EG, 1973, GENETICS, V73, P1; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; LEVIS RW, 1993, CELL, V75, P1083, DOI 10.1016/0092-8674(93)90318-K; LINDAHL T, 1994, CURR BIOL, V4, P249, DOI 10.1016/S0960-9822(00)00056-7; LOHE AR, 1993, GENETICS, V134, P1149; MACKAY TFC, 1992, GENETICS, V130, P315; MACKAY TFC, 1986, GENET RES, V48, P77, DOI 10.1017/S0016672300024794; MARTIN G, 1983, J MOL EVOL, V19, P203, DOI 10.1007/BF02099967; MCCLINTOCK B, 1984, SCIENCE, V226, P792, DOI 10.1126/science.15739260; MCDONALD JF, 1993, CURR OPIN GENET DEV, V3, P855, DOI 10.1016/0959-437X(93)90005-A; MONTGOMERY E, 1987, GENET RES, V49, P31, DOI 10.1017/S0016672300026707; MONTGOMERY EA, 1991, GENETICS, V129, P1085; MUELLER MW, 1993, NATURE, V366, P174, DOI 10.1038/366174a0; NEVERS P, 1977, NATURE, V268, P109, DOI 10.1038/268109a0; NUZHDIN SV, IN PRESS MOL BIOL EV; OKUMURA K, 1987, NUCLEIC ACIDS RES, V15, P7477, DOI 10.1093/nar/15.18.7477; ORGEL LE, 1980, NATURE, V284, P604, DOI 10.1038/284604a0; PAGEL M, 1992, P ROY SOC B-BIOL SCI, V249, P119, DOI 10.1098/rspb.1992.0093; REED KM, 1994, J MOL EVOL, V38, P352, DOI 10.1007/BF00163152; ROBERTSON HM, 1993, NATURE, V362, P241, DOI 10.1038/362241a0; SCHLOTTERER C, 1992, NUCLEIC ACIDS RES, V20, P211, DOI 10.1093/nar/20.2.211; SELLEM CH, 1993, NATURE, V366, P176, DOI 10.1038/366176a0; SHAPIRO JA, 1992, GENETICA, V86, P99, DOI 10.1007/BF00133714; SMITH GP, 1976, SCIENCE, V191, P528, DOI 10.1126/science.1251186; SNIEGOWSKI PD, 1994, GENETICS, V137, P815; STEINEMANN M, 1992, P NATL ACAD SCI USA, V89, P7591, DOI 10.1073/pnas.89.16.7591; STEPHAN W, 1989, MOL BIOL EVOL, V6, P198, DOI 10.1093/oxfordjournals.molbev.a040542; STEPHAN W, 1994, GENETICS, V136, P333, DOI 10.1093/genetics/136.1.333; STEPHAN W, 1986, GENET RES, V47, P167, DOI 10.1017/S0016672300023089; STEPHAN W, 1987, GENET RES, V50, P41, DOI 10.1017/S0016672300023326; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; SYVANEN M, 1984, ANNU REV GENET, V18, P271, DOI 10.1146/annurev.ge.18.120184.001415; TACHIDA H, 1993, GENETICS, V133, P1023; TYLERSMITH C, 1993, CURR OPIN GENET DEV, V3, P390, DOI 10.1016/0959-437X(93)90110-B; VALDES AM, 1993, GENETICS, V133, P737; VAURY C, 1989, CHROMOSOMA, V98, P215, DOI 10.1007/BF00329686; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; WALSH JB, 1987, GENETICS, V115, P553; WARBURTON PE, 1993, MOL CELL BIOL, V13, P6520, DOI 10.1128/MCB.13.10.6520; WEISSENBACH J, 1993, CURR OPIN GENET DEV, V3, P414, DOI 10.1016/0959-437X(93)90114-5; WEVRICK R, 1989, P NATL ACAD SCI USA, V86, P9394, DOI 10.1073/pnas.86.23.9394; WICHMAN HA, 1992, GENETICA, V86, P287, DOI 10.1007/BF00133727; WILKE CM, 1992, GENETICA, V86, P155, DOI 10.1007/BF00133718; WU CI, 1991, EVOLUTION AT THE MOLECULAR LEVEL, P177; ZHONG N, 1993, NAT GENET, V5, P248, DOI 10.1038/ng1193-248; [No title captured]	102	1258	1315	4	140	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 15	1994	371	6494					215	220		10.1038/371215a0	http://dx.doi.org/10.1038/371215a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG290	8078581				2022-12-24	WOS:A1994PG29000042
J	ROUSSEAU, F; BONAVENTURE, J; LEGEAIMALLET, L; PELET, A; ROZET, JM; MAROTEAUX, P; LEMERRER, M; MUNNICH, A				ROUSSEAU, F; BONAVENTURE, J; LEGEAIMALLET, L; PELET, A; ROZET, JM; MAROTEAUX, P; LEMERRER, M; MUNNICH, A			MUTATIONS IN THE GENE ENCODING FIBROBLAST GROWTH-FACTOR RECEPTOR-3 IN ACHONDROPLASIA	NATURE			English	Article							BIRTH PREVALENCE RATES; TERMINAL DIFFERENTIATION; SKELETAL DYSPLASIAS; SIGNAL TRANSDUCTION; FAMILY	ACHONDROPLASIA, the most common cause of chondrodysplasia in man (1 in 15,000 live births), is a condition of unknown origin characterized by short-limbed dwarfism and macrocephaly(1,2). More than 90% of cases are sporadic and there is an increased paternal age at the time of conception of affected individuals, suggesting that de novo mutations are of paternal origin. Affected individuals are fertile and achondroplasia is transmitted as a fully penetrant autosomal dominant trait, accounting for rare familial forms of the disease (10%)(3-6). In contrast, homozygous achondroplasia is usually lethal in the neonatal period and affects 25% of the offspring of matings between heterozygous achondroplasia parents. The gene responsible for achondroplasia has been mapped to chromosome 4p16.3 (refs 7, 8); the genetic interval encompassing the disease gene contains a member of the fibroblast-growth-factor receptor (FGFR(3)) family which is expressed in articular chondrocytes. Here we report the finding of recurrent missense mutations in a CpG doublet of the transmembrane domain of the FGFR(3) protein (glycine substituted with arginine at residue 380, G380R) in 17 sporadic cases and 6 unrelated familial forms of achondroplasia. We show that the mutant genotype segregates with the disease in these families. Thus it appears that recurrent mutations of a single amino acid in the transmembrane domain of the FGFR(3) protein account for all cases (23/23) of achondroplasia in our series.	HOP NECKER ENFANTS MALAD, INST NECKER, CNRS, ER 88, INSERM, U393, SERV GENET, F-75743 PARIS 15, FRANCE; HOP NECKER ENFANTS MALAD, INST NECKER,CNRS,ER 88,INSERM, U393,UNITE RECH HANDICAPS GENET ENFANT, F-75743 PARIS 15, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Legeai-Mallet, Laurence/E-6112-2016; ROZET, Jean-Michel/E-5737-2016	Legeai-Mallet, Laurence/0000-0003-4989-5856; ROZET, Jean-Michel/0000-0001-7951-7886; PELET, Anastella/0000-0002-8353-1725				EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; GARDNER RJM, 1977, CLIN GENET, V11, P31; IWAMOTO M, 1991, J BIOL CHEM, V266, P461; KATO Y, 1990, J BIOL CHEM, V265, P5903; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; LEMERRER M, 1994, NAT GENET, V6, P318; Maroteaux P, 1964, Clin Orthop Relat Res, V33, P91; MURDOCH JL, 1970, ANN HUM GENET, V33, P227, DOI 10.1111/j.1469-1809.1970.tb01648.x; OBERKLAID F, 1979, J MED GENET, V16, P140, DOI 10.1136/jmg.16.2.140; ORIOLI IM, 1986, J MED GENET, V23, P328, DOI 10.1136/jmg.23.4.328; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; STANESCU R, 1990, AM J MED GENET, V37, P412, DOI 10.1002/ajmg.1320370323; STOLL C, 1989, CLIN GENET, V35, P88; THOMPSON LM, 1991, GENOMICS, V11, P1133, DOI 10.1016/0888-7543(91)90041-C; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELINOV M, 1994, NAT GENET, V6, P314, DOI 10.1038/ng0394-314; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	18	678	714	5	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 15	1994	371	6494					252	254		10.1038/371252a0	http://dx.doi.org/10.1038/371252a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG290	8078586				2022-12-24	WOS:A1994PG29000054
J	KIM, YJ; RAJAPANDI, T; OLIVER, D				KIM, YJ; RAJAPANDI, T; OLIVER, D			SECA PROTEIN IS EXPOSED TO THE PERIPLASMIC SURFACE OF THE ESCHERICHIA-COLI INNER MEMBRANE IN ITS ACTIVE STATE	CELL			English	Article							ESCHERICHIA-COLI; TRANSLOCATION ATPASE; PLASMA-MEMBRANE; PRECURSOR PROTEINS; INVERTED VESICLES; EXPORT; GENE; PHOSPHOLIPIDS; PREPROTEIN; RECONSTITUTION	E. coli cells harboring pCG169 containing the secD secF locus possessed SecA protein almost entirely in an integral membrane form in which it displayed normal protein translocation activity. These results imply that integral membrane SecA is the catalytically active form of this enzyme and that products of the secD secF locus regulate SecA association with the inner membrane. Protease and biotinylation accessibility studies of right side-out and inside-out membrane vesicles derived from this strain revealed that SecA was exposed to the periplasmic surface of the inner membrane. These studies suggest a model of bacterial protein secretion, whereby insertion of SecA into the inner membrane and its association with SecY/E/G promotes assembly of active protein-conducting channels comprised in part of integral membrane SecA protein, and products of the secD secF locus regulate the channel assembly-disassembly reaction by modulating the SecA insertion-deinsertion step.			KIM, YJ (corresponding author), WESLEYAN UNIV, DEPT MOLEC BIOL & BIOCHEM, MIDDLETOWN, CT 06459 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042033] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 42033] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AKITA M, 1990, J BIOL CHEM, V265, P8164; ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; ARKOWITZ RA, 1994, EMBO J, V13, P954, DOI 10.1002/j.1460-2075.1994.tb06340.x; BAICHWAL V, 1993, P NATL ACAD SCI USA, V90, P620, DOI 10.1073/pnas.90.2.620; BIEKERBRADY K, 1992, EMBO J, V11, P3165, DOI 10.1002/j.1460-2075.1992.tb05393.x; BREMER E, 1990, GENE, V96, P59, DOI 10.1016/0378-1119(90)90341-N; BREUKINK E, 1992, BIOCHEMISTRY-US, V31, P1119, DOI 10.1021/bi00119a021; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; BRUNDAGE L, 1992, J BIOL CHEM, V267, P4166; CABELLI RJ, 1991, J BIOL CHEM, V266, P24420; CABELLI RJ, 1988, CELL, V55, P683, DOI 10.1016/0092-8674(88)90227-9; CUNNINGHAM K, 1989, P NATL ACAD SCI USA, V86, P8630, DOI 10.1073/pnas.86.22.8630; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; FANDL JP, 1988, P NATL ACAD SCI USA, V85, P8953, DOI 10.1073/pnas.85.23.8953; GARDEL C, 1987, J BACTERIOL, V169, P1286, DOI 10.1128/jb.169.3.1286-1290.1987; GARDEL C, 1990, EMBO J, V9, P3209, DOI 10.1002/j.1460-2075.1990.tb07519.x; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; Kaback H. R., 1971, METHOD ENZYMOL, V22, P99, DOI DOI 10.1016/0076-6879(71)22015-2; KAWASAKI S, 1993, J BIOL CHEM, V268, P8193; KIM YJ, 1994, FEBS LETT, V339, P175, DOI 10.1016/0014-5793(94)80410-9; KUMAMOTO CA, 1991, MOL MICROBIOL, V5, P19, DOI 10.1111/j.1365-2958.1991.tb01821.x; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; MATSUYAMA S, 1990, FEBS LETT, V269, P96, DOI 10.1016/0014-5793(90)81128-B; MCGOVERN K, 1991, EMBO J, V10, P2773, DOI 10.1002/j.1460-2075.1991.tb07826.x; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; OLIVER DB, 1993, MOL MICROBIOL, V7, P159, DOI 10.1111/j.1365-2958.1993.tb01107.x; OLIVER DB, 1990, J BIOENERG BIOMEMBR, V22, P311, DOI 10.1007/BF00763170; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; POGLIANO JA, 1994, EMBO J, V13, P554, DOI 10.1002/j.1460-2075.1994.tb06293.x; RAJAPANDI T, 1994, J BACTERIOL, V176, P4444, DOI 10.1128/jb.176.14.4444-4447.1994; SAGARA K, 1994, J BACTERIOL, V176, P4111, DOI 10.1128/JB.176.13.4111-4116.1994; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SCHMIDT MG, 1988, J BACTERIOL, V170, P3404, DOI 10.1128/jb.170.8.3404-3414.1988; SCHMIDT MG, 1989, J BACTERIOL, V171, P643, DOI 10.1128/jb.171.2.643-649.1989; SHIBA K, 1984, EMBO J, V3, P631, DOI 10.1002/j.1460-2075.1984.tb01859.x; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; TAURA T, 1992, MOL GEN GENET, V234, P429, DOI 10.1007/BF00538702; TAURA T, 1994, MOL GEN GENET, V243, P261, DOI 10.1007/BF00301061; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; VANDERPLAS J, 1983, J BACTERIOL, V153, P1027, DOI 10.1128/JB.153.2.1027-1037.1983; VANDERWOLK J, 1993, MOL MICROBIOL, V8, P31; VONBOXBERG Y, 1990, EUR J BIOCHEM, V190, P249; WATANABE M, 1990, P NATL ACAD SCI USA, V87, P1960, DOI 10.1073/pnas.87.5.1960; WATANABE M, 1993, P NATL ACAD SCI USA, V90, P9011, DOI 10.1073/pnas.90.19.9011; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533	51	162	163	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 9	1994	78	5					845	853						9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PG296	8087851				2022-12-24	WOS:A1994PG29600013
J	FISHER, RP; MORGAN, DO				FISHER, RP; MORGAN, DO			A NOVEL CYCLIN ASSOCIATES WITH MO15/CDK7 TO FORM THE CDK-ACTIVATING KINASE	CELL			English	Article							PROTEIN-KINASE; DEPENDENT KINASE-2; CATALYTIC SUBUNIT; CELL-CYCLE; PHOSPHORYLATION; YEAST; CDC2; IDENTIFICATION; PURIFICATION; P34(CDC2)	Phosphorylation by the CDK-activating kinase (CAK) is a required step in the activation of cyclin-dependent kinases. We have purified CAK from mammalian cells; the enzyme comprises two major polypeptides of 42 and 37 kDa. Protein sequencing indicates that the 42 kDa subunit is the mammalian homolog of MO15, a protein kinase known to be a component of CAK in amphibians and echinoderms. Cloning of a cDNA encoding the 37 kDa subunit identifies it as a novel cyclin (cyclin H). We have reconstituted CAK in vitro with the MO15 catalytic subunit and cyclin H, demonstrating that MO15 is a cyclin-dependent kinase (CDK7). Like other CDKs, MO15/CDK7 contains a conserved threonine required for full activity; mutation of this residue severely reduces CAK activity. The CAK holoenzyme activates complexes of CDK2 and CDC2 with various cyclins and also phosphorylates CDK2, but not CDC2, in the absence of cyclin. Thus, CAK is a CDK-cyclin complex implicated in the control of multiple cell cycle transitions.			FISHER, RP (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.			Morgan, David/0000-0001-8753-4416				CONNELLCROWLEY L, 1993, MOL BIOL CELL, V4, P79, DOI 10.1091/mbc.4.1.79; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEVEDAKOU EN, 1994, ONCOGENE, V9, P1977; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LORCA T, 1992, EMBO J, V11, P2381, DOI 10.1002/j.1460-2075.1992.tb05302.x; MATHUR R, 1984, BIOCHEM J, V222, P261, DOI 10.1042/bj2220261; MOLZ L, 1989, GENETICS, V122, P773; MOLZ L, 1993, EMBO J, V12, P1723, DOI 10.1002/j.1460-2075.1993.tb05817.x; MORGAN DO, 1994, CURR OPIN CELL BIOL, V6, P239, DOI 10.1016/0955-0674(94)90142-2; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NUGENT JHA, 1991, J CELL SCI, V99, P669; O'Reilly DR, 1993, BACULOVIRUS EXPRESSI; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RIJKEN DC, 1981, J BIOL CHEM, V256, P7035; ROSENBLATT J, 1993, J MOL BIOL, V230, P1317, DOI 10.1006/jmbi.1993.1248; SCHILD D, 1990, P NATL ACAD SCI USA, V87, P2916, DOI 10.1073/pnas.87.8.2916; SHUTTLEWORTH J, 1990, EMBO J, V9, P3233, DOI 10.1002/j.1460-2075.1990.tb07522.x; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; VALAY JG, 1993, J MOL BIOL, V234, P307, DOI 10.1006/jmbi.1993.1587	35	565	588	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 26	1994	78	4					713	724		10.1016/0092-8674(94)90535-5	http://dx.doi.org/10.1016/0092-8674(94)90535-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PD693	8069918				2022-12-24	WOS:A1994PD69300019
J	PETER, M; HERSKOWITZ, I				PETER, M; HERSKOWITZ, I			DIRECT INHIBITION OF THE YEAST CYCLIN-DEPENDENT KINASE CDC28-CLN BY FAR1	SCIENCE			English	Article							SIGNAL-TRANSDUCTION PATHWAY; CLN2 GENE-EXPRESSION; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; MATING PHEROMONE; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; POSITIVE FEEDBACK; G1 CYCLINS; ACTIVATION	Cell cycle arrest of Saccharomyces cerevisiae in G(1) by the antimitogen alpha-factor is mediated by activation of a signal transduction pathway that results in inhibition of the cyclin-dependent kinase Cdc28-Cln. The Farl protein is required for cell cycle arrest and associates with the Cdc28-Cln complex. The kinase activity of Cdc28-Cln was directly inhibited by Far1 both in vivo and in vitro, thus demonstrating that Far1 acts at the final step in the alpha-factor response pathway by inhibiting a G(1) cyclin-dependent kinase.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,GENET PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIGMS NIH HHS [GM31286] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031286] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHANG F, 1992, MOL BIOL CELL, V3, P445, DOI 10.1091/mbc.3.4.445; CHANG F, 1991, THESIS U CALIFORNIA; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; DESHALES R, COMMUNICATION; DIRICK L, 1991, NATURE, V351, P754, DOI 10.1038/351754a0; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; DONOVAN JD, 1994, GENE DEV, V8, P1640, DOI 10.1101/gad.8.14.1640; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; ERREDE B, 1989, GENE DEV, V3, P1349, DOI 10.1101/gad.3.9.1349; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FUTCHER BA, 1991, SEMIN CELL BIOL, V2, P205; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; HICKS JB, 1976, GENETICS, V83, P245; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LEVIN DE, 1993, CURR OPIN CELL BIOL, V5, P245; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cellbio.7.1.699; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; NASMYTH K, 1993, NATURE, V366, P634, DOI 10.1038/366634a0; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NEIMAN AM, 1993, TRENDS GENET, V9, P390, DOI 10.1016/0168-9525(93)90139-9; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PETER M, UNPUB; PINES J, 1993, CURR BIOL, V3, P544, DOI 10.1016/0960-9822(93)90053-Q; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1993, EMBO J, V12, P3111; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SIKORSKI RS, 1989, GENETICS, V122, P19; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SORGER P, COMMUNICATION; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; TYERS M, 1992, EMBO J, V11, P1772; VALDIVIESO MH, 1993, MOL CELL BIOL, V13, P1013, DOI 10.1128/MCB.13.2.1013; WHITEWAY M, 1990, MOL CELL BIOL, V10, P217, DOI 10.1128/MCB.10.1.217; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555	48	204	208	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 26	1994	265	5176					1228	1231		10.1126/science.8066461	http://dx.doi.org/10.1126/science.8066461			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD422	8066461				2022-12-24	WOS:A1994PD42200036
J	COBLEIGH, MA; BERRIS, RF; BUSH, T; DAVIDSON, NE; ROBERT, NJ; SPARANO, JA; TORMEY, DC; WOOD, WC				COBLEIGH, MA; BERRIS, RF; BUSH, T; DAVIDSON, NE; ROBERT, NJ; SPARANO, JA; TORMEY, DC; WOOD, WC			ESTROGEN REPLACEMENT THERAPY IN BREAST-CANCER SURVIVORS - A TIME FOR CHANGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							MAMMOGRAPHIC PARENCHYMAL PATTERNS; POSTMENOPAUSAL WOMEN; PREMENOPAUSAL WOMEN; EXOGENOUS ESTROGEN; CONTRACEPTIVE STEROIDS; ADJUVANT CHEMOTHERAPY; TAMOXIFEN THERAPY; HORMONE USE; RISK; CARCINOMA		HEMATOL ONCOL ASSOCIATES, DENVER, CO USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD USA; JOHNS HOPKINS UNIV, CTR ONCOL, BALTIMORE, MD 21205 USA; FAIRFAX ONCOL ASSOCIATES, ANNANDALE, VA USA; ALBERT EINSTEIN CANC CTR, BRONX, NY USA; EASTERN COOPERAT ONCOL GRP, OPERAT OFF, DENVER, CO USA; EMORY UNIV, SCH MED, ATLANTA, GA USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Yeshiva University; Emory University	COBLEIGH, MA (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT INTERNAL MED, DIV HEMATOL ONCOL, MED ONCOL SECT, CHICAGO, IL 60612 USA.							ADAMI HO, 1987, NEW ENGL J MED, V316, P752; ADAMI HO, 1986, NEW ENGL J MED, V315, P559, DOI 10.1056/NEJM198608283150906; [Anonymous], 1992, Lancet, V339, P1; ARMSTRONG BK, 1988, MED J AUSTRALIA, V148, P213, DOI 10.5694/j.1326-5377.1988.tb99424.x; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BERGKVIST L, 1989, AM J EPIDEMIOL, V130, P221, DOI 10.1093/oxfordjournals.aje.a115328; BERKOWITZ JE, 1990, RADIOLOGY, V174, P199, DOI 10.1148/radiology.174.1.2152982; BLAND KI, 1980, CANCER, V45, P3027, DOI 10.1002/1097-0142(19800615)45:12<3027::AID-CNCR2820451225>3.0.CO;2-2; BONADONNA G, 1979, ADJUVANT THERAPY CAN, V2, P227; BRINTON LA, 1986, BRIT J CANCER, V54, P825, DOI 10.1038/bjc.1986.246; BROWNSON RC, 1988, ARCH INTERN MED, V148, P140, DOI 10.1001/archinte.148.1.140; BURING JE, 1987, AM J EPIDEMIOL, V125, P939, DOI 10.1093/oxfordjournals.aje.a114632; BUSH TL, 1993, EPIDEMIOL REV, V15, P233, DOI 10.1093/oxfordjournals.epirev.a036110; COLDITZ GA, 1990, JAMA-J AM MED ASSOC, V264, P2648, DOI 10.1001/jama.264.20.2648; CREASMAN WT, 1991, OBSTET GYNECOL, V77, P308, DOI 10.1097/00006250-199102000-00031; CRIQUI MH, 1988, AM J EPIDEMIOL, V128, P606, DOI 10.1093/oxfordjournals.aje.a115008; DAVIDSON JA, 1992, MED J AUSTRALIA, V157, P429, DOI 10.5694/j.1326-5377.1992.tb137283.x; DEVOR M, 1992, AM J MED, V92, P275, DOI 10.1016/0002-9343(92)90077-O; DISAIA PJ, 1993, CANCER-AM CANCER SOC, V71, P1490, DOI 10.1002/cncr.2820710414; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; DUPONT WD, 1989, CANCER-AM CANCER SOC, V63, P948, DOI 10.1002/1097-0142(19890301)63:5<948::AID-CNCR2820630527>3.0.CO;2-U; EDEN JA, 1992, MED J AUSTRALIA, V157, P247, DOI 10.5694/j.1326-5377.1992.tb137129.x; EDEN JA, 1992, MED J AUSTRALIA, V157, P175, DOI 10.5694/j.1326-5377.1992.tb137081.x; EDEN JA, IN PRESS MED J AUST; EWERTZ M, 1988, INT J CANCER, V42, P832, DOI 10.1002/ijc.2910420606; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; FISHER B, 1989, NEW ENGL J MED, V320, P474; FORNANDER T, 1989, LANCET, V1, P117; GAMBRELL RD, 1984, AM J OBSTET GYNECOL, V150, P119; GAMBRELL RD, 1983, OBSTET GYNECOL, V62, P435; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRADY D, 1992, ANN INTERN MED, V117, P1038; Harvey E B, 1985, Natl Cancer Inst Monogr, V68, P99; HENDERSON BE, 1983, BRIT J CANCER, V47, P749, DOI 10.1038/bjc.1983.127; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HENDERSON IC, 1993, CANCER-AM CANCER SOC, V71, P2127, DOI 10.1002/1097-0142(19930315)71:6+<2127::AID-CNCR2820711602>3.0.CO;2-2; HENRICH JB, 1992, JAMA-J AM MED ASSOC, V268, P1900, DOI 10.1001/jama.268.14.1900; HEUSON JC, 1976, CANCER TREAT REP, V60, P1463; HIATT RA, 1984, CANCER, V54, P139, DOI 10.1002/1097-0142(19840701)54:1<139::AID-CNCR2820540128>3.0.CO;2-X; HOOGSTRATEN B, 1982, CANCER RES, V42, P4788; HOOGSTRATEN B, 1984, CANCER, V54, P2248, DOI 10.1002/1097-0142(19841115)54:10<2248::AID-CNCR2820541031>3.0.CO;2-D; HOOVER R, 1981, J NATL CANCER I, V67, P815; HORWITZ RI, 1984, AM J MED, V76, P192, DOI 10.1016/0002-9343(84)90773-3; HUG V, 1985, J CLIN ONCOL, V3, P1672, DOI 10.1200/JCO.1985.3.12.1672; HULKA BS, 1982, AM J OBSTET GYNECOL, V143, P638, DOI 10.1016/0002-9378(82)90108-9; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; HUTCHINSONWILLIAMS KA, 1991, YALE J BIOL MED, V64, P607; JORDAN VC, 1987, CANCER RES, V47, P624; KAUFMAN DW, 1984, JAMA-J AM MED ASSOC, V252, P63, DOI 10.1001/jama.252.1.63; KAUFMAN DW, 1991, AM J EPIDEMIOL, V134, P1375, DOI 10.1093/oxfordjournals.aje.a116041; KAUFMAN Z, 1991, CLIN RADIOL, V43, P389, DOI 10.1016/S0009-9260(05)80566-5; KELSEY JL, 1988, CANCER RES, V48, P5615; KELSEY JL, 1981, JNCI-J NATL CANCER I, V67, P327; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; KING RM, 1985, SURG GYNECOL OBSTET, V160, P228; LAM HYP, 1984, BIOCHEM BIOPH RES CO, V118, P27, DOI 10.1016/0006-291X(84)91062-3; LIPPMAN M, 1976, CANCER RES, V36, P4595; LOBO RA, 1990, OBSTET GYNECOL, V75, pS18; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; MANDEVILLE R, 1984, EUR J CANCER CLIN ON, V20, P983, DOI 10.1016/0277-5379(84)90174-3; MANNI A, 1980, CANCER TREAT REP, V64, P779; MANSOUR EG, 1989, NEW ENGL J MED, V320, P485, DOI 10.1056/NEJM198902233200803; MARCHANT DJ, 1993, CANCER, V71, P2169, DOI 10.1002/1097-0142(19930315)71:6+<2169::AID-CNCR2820711608>3.0.CO;2-B; MARGREITER R, 1984, BREAST CANCER RES TR, V4, P45, DOI 10.1007/BF01806987; MATTHEWS PN, 1981, BRIT MED J, V282, P774, DOI 10.1136/bmj.282.6266.774; MCDONALD CC, 1991, BRIT MED J, V303, P435, DOI 10.1136/bmj.303.6800.435; MEHTA RR, 1992, BREAST CANCER RES TR, V20, P125; MERRILL JM, 1992, JAMA-J AM MED ASSOC, V267, P568; MILLER BA, 1993, CA-CANCER J CLIN, V43, P27, DOI 10.3322/canjclin.43.1.27; MILLS PK, 1989, CANCER, V64, P591, DOI 10.1002/1097-0142(19890801)64:3<591::AID-CNCR2820640305>3.0.CO;2-U; NAYFIELD SG, 1991, J NATL CANCER I, V83, P1450, DOI 10.1093/jnci/83.20.1450; NOMURA AMY, 1986, INT J CANCER, V37, P49, DOI 10.1002/ijc.2910370109; OBRIAN CA, 1985, CANCER RES, V45, P2462; PALMER JR, 1991, AM J EPIDEMIOL, V134, P1386, DOI 10.1093/oxfordjournals.aje.a116042; PLANTING AST, 1985, CANCER TREAT REP, V69, P363; POWLES TJ, 1988, LANCET, V2, P344; POWLES TJ, 1990, LANCET, V336, P48, DOI 10.1016/0140-6736(90)91555-O; PRITCHARD KI, 1980, CANCER TREAT REP, V64, P787; RIBEIRO G, 1986, BRIT J SURG, V73, P607, DOI 10.1002/bjs.1800730805; ROHAN TE, 1988, MED J AUSTRALIA, V148, P217; ROSEN PP, 1993, J CLIN ONCOL, V11, P2090, DOI 10.1200/JCO.1993.11.11.2090; ROSS RK, 1980, JAMA-J AM MED ASSOC, V243, P1635, DOI 10.1001/jama.243.16.1635; SAWKA CA, 1986, CANCER RES, V46, P3152; SHERMAN B, 1983, CANCER, V51, P1527, DOI 10.1002/1097-0142(19830415)51:8<1527::AID-CNCR2820510828>3.0.CO;2-T; SHERMAN BM, 1979, J CLIN INVEST, V64, P398, DOI 10.1172/JCI109475; SMITH DC, 1975, NEW ENGL J MED, V293, P1164, DOI 10.1056/NEJM197512042932302; SPENCER JD, 1978, BRIT MED J, V1, P1024, DOI 10.1136/bmj.1.6119.1024; SPICER DV, 1991, J NATL CANCER I, V83, P63, DOI 10.1093/jnci/83.1.63; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; STOLL BA, 1988, LANCET, V1, P1278; STOLL BA, 1967, BRIT MED J, V1, P150, DOI 10.1136/bmj.1.5533.150; STOLL BA, 1989, EUR J CANCER CLIN ON, V25, P1909, DOI 10.1016/0277-5379(89)90372-6; STOMPER PC, 1990, RADIOLOGY, V174, P487, DOI 10.1148/radiology.174.2.2136958; SUNDERLAND MC, 1991, J CLIN ONCOL, V9, P1283, DOI 10.1200/JCO.1991.9.7.1283; THERIAULT RL, 1991, ANN ONCOL, V2, P709, DOI 10.1093/oxfordjournals.annonc.a057847; THOMAS DB, 1982, JNCI-J NATL CANCER I, V69, P1017; VIGNON F, 1987, BIOCHEM BIOPH RES CO, V146, P1502, DOI 10.1016/0006-291X(87)90819-9; WADA T, 1981, CANCER TREAT REP, V65, P728; WILE AG, 1993, AM J SURG, V165, P372, DOI 10.1016/S0002-9610(05)80848-7; WILE AG, 1991, P AN M AM SOC CLIN, V10, P58; WILKUND I, 1992, MATURITAS, V14, P211; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P209, DOI 10.1001/jama.257.2.209; YOSHIDA M, 1982, JPN J CLIN ONCOL, V12, P57; 1992, HORMONE REPLACEMENT, P166; 1989, N ENGL JMED, V320, P491	107	135	136	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	1994	272	7					540	545		10.1001/jama.272.7.540	http://dx.doi.org/10.1001/jama.272.7.540			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB229	8046809				2022-12-24	WOS:A1994PB22900032
J	HEBERLE, J; RIESLE, J; THIEDEMANN, G; OESTERHELT, D; DENCHER, NA				HEBERLE, J; RIESLE, J; THIEDEMANN, G; OESTERHELT, D; DENCHER, NA			PROTON MIGRATION ALONG THE MEMBRANE-SURFACE AND RETARDED SURFACE TO BULK TRANSFER	NATURE			English	Article							HALOBACTERIUM-HALOBIUM; PURPLE-MEMBRANE; BACTERIORHODOPSIN; WATER; TRANSLOCATION; PHOTOCYCLE	Since the proposal of the chemiosmotic theory(1) there has been a continuing debate about how protons that have been pumped across membranes reach another membrane protein that utilizes the established pH gradient. Evidence has been gathered in favour of a 'delocalized' theory, in which the pumped protons equilibrate with the aqueous bulk phase before being consumed, and a 'localized' one, in which protons move exclusively along the membrane surface(2,3). We report here that after proton release by an integral membrane protein, long-range proton transfer along the membrane surface is faster than proton exchange with the bulk water phase. The rate of lateral proton diffusion can be calculated by considering the buffer capacity of the membrane surface. Our results suggest that protons can efficiently diffuse along the membrane surface between a source and a sink (for example H+-ATP synthase) without dissipation losses into the aqueous bulk.	MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY; TH DARMSTADT, INST BIOCHEM, D-64287 DARMSTADT, GERMANY; HAHN MEITNER INST BERLIN GMBH, D-14109 BERLIN, GERMANY	Max Planck Society; Technical University of Darmstadt; Helmholtz Association; Helmholtz-Zentrum fuer Materialien und Energie GmbH (HZB)			Heberle, Joachim/D-8605-2016; Dencher, Norbert/G-6640-2014	Heberle, Joachim/0000-0001-6321-2615; 				ANTONENKO YN, 1993, BIOCHIM BIOPHYS ACTA, V1150, P45, DOI 10.1016/0005-2736(93)90119-K; BAUER PJ, 1976, BIOPHYS STRUCT MECH, V2, P79, DOI 10.1007/BF00535654; BURGHAUS PA, 1989, ARCH BIOCHEM BIOPHYS, V275, P395, DOI 10.1016/0003-9861(89)90387-1; FLITSCH SL, 1989, BIOCHEMISTRY-US, V28, P7800, DOI 10.1021/bi00445a041; GRZESIEK S, 1986, BIOPHYS J, V50, P265, DOI 10.1016/S0006-3495(86)83460-9; GRZESIEK S, 1986, FEBS LETT, V208, P337, DOI 10.1016/0014-5793(86)81045-6; GUTMAN M, 1990, BIOCHIM BIOPHYS ACTA, V1015, P391, DOI 10.1016/0005-2728(90)90073-D; HEBERLE J, 1993, EMBO J, V12, P3721, DOI 10.1002/j.1460-2075.1993.tb06049.x; HEBERLE J, 1990, FEBS LETT, V277, P277, DOI 10.1016/0014-5793(90)80864-F; HEBERLE J, 1992, P NATL ACAD SCI USA, V89, P5996, DOI 10.1073/pnas.89.13.5996; HEBERLE J, 1992, NATO ADV SCI I B-PHY, V291, P187; JUNGE W, 1987, BIOCHIM BIOPHYS ACTA, V890, P1, DOI 10.1016/0005-2728(87)90061-2; KASIANOWICZ J, 1987, J MEMBRANE BIOL, V99, P227; LEBERLE K, 1989, BIOPHYS J, V55, P637, DOI 10.1016/S0006-3495(89)82861-9; LECHNER RE, 1994, BIOPHYS CHEM, V49, P91, DOI 10.1016/0301-4622(93)E0086-K; MICHEL H, 1980, BIOCHEMISTRY-US, V19, P4607, DOI 10.1021/bi00561a011; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; OESTERHELT D, 1973, FEBS LETT, V36, P72, DOI 10.1016/0014-5793(73)80339-4; POLLE A, 1989, BIOPHYS J, V56, P27, DOI 10.1016/S0006-3495(89)82649-9; PRATS M, 1986, NATURE, V322, P756, DOI 10.1038/322756a0; SCHWEIGER U, 1994, BIOCHEMISTRY-US, V33, P535, DOI 10.1021/bi00168a019	21	278	282	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 4	1994	370	6488					379	382		10.1038/370379a0	http://dx.doi.org/10.1038/370379a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA304	8047144				2022-12-24	WOS:A1994PA30400058
J	WRANA, JL; ATTISANO, L; WIESER, R; VENTURA, F; MASSAGUE, J				WRANA, JL; ATTISANO, L; WIESER, R; VENTURA, F; MASSAGUE, J			MECHANISM OF ACTIVATION OF THE TGF-BETA RECEPTOR	NATURE			English	Article							TRANSFORMING GROWTH-FACTOR; TRANSMEMBRANE SERINE KINASE; EXPRESSION CLONING; ACTIVIN RECEPTOR; II RECEPTORS; SIGNAL TRANSDUCTION; CELL-PROLIFERATION; THREONINE KINASE; IDENTIFICATION; INHIBITION	Transforming growth factor-beta (TGF-beta) signals by contacting two distantly related transmembrane serine/threonine kinases called receptors I and II. The role of these molecules in signalling has now been determined. TGF-beta binds directly to receptor II, which is a constitutively active kinase. Bound TGF-beta is then recognized by receptor I which is recruited into the complex and becomes phosphorylated by receptor II. Phosphorylation allows receptor I to propagate the signal to downstream substrates. This provides a mechanism by which a cytokine can generate the first step of a signalling cascade.	MEM SLOAN KETTERING CANC CTR, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, CELL BIOL & GENET PROGRAM, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center			Ventura, Francesc/K-9700-2014; Ventura, Francesc/ABG-2285-2020; Wrana, Jeffrey/F-8857-2013	Ventura, Francesc/0000-0001-9673-9405; Ventura, Francesc/0000-0001-9673-9405; Wieser, Rotraud/0000-0003-4384-6658; Massague, Joan/0000-0001-9324-8408				ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BOYD FT, 1989, J BIOL CHEM, V264, P2272; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHEIFETZ S, 1990, J BIOL CHEM, V265, P20533; CHILDS SR, 1993, P NATL ACAD SCI USA, V90, P9475, DOI 10.1073/pnas.90.20.9475; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOENIG BB, IN PRESS MOL CELL BI; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MARSHALL CJ, 1994, NATURE, V367, P686, DOI 10.1038/367686a0; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MATHEWS LS, 1993, J BIOL CHEM, V268, P19013; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Pawson T, 1992, CURR OPIN GENET DEV, V2, P4, DOI 10.1016/S0959-437X(05)80314-4; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TSUCHIDA K, 1993, P NATL ACAD SCI USA, V90, P11242, DOI 10.1073/pnas.90.23.11242; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, MOL CELL BIOL, V14, P944, DOI 10.1128/MCB.14.2.944	43	2049	2145	2	92	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 4	1994	370	6488					341	347		10.1038/370341a0	http://dx.doi.org/10.1038/370341a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA304	8047140				2022-12-24	WOS:A1994PA30400046
J	JEN, J; KIM, HG; PIANTADOSI, S; LIU, ZF; LEVITT, RC; SISTONEN, P; KINZLER, KW; VOGELSTEIN, B; HAMILTON, SR				JEN, J; KIM, HG; PIANTADOSI, S; LIU, ZF; LEVITT, RC; SISTONEN, P; KINZLER, KW; VOGELSTEIN, B; HAMILTON, SR			ALLELIC LOSS OF CHROMOSOME 18Q AND PROGNOSIS IN COLORECTAL-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; SURGICAL ADJUVANT THERAPY; GENETIC ALTERATIONS; P53 GENE; MICROSATELLITE INSTABILITY; ADHESION MOLECULES; FLOW-CYTOMETRY; RECTAL-CANCER; CARCINOMA; DNA	Background. Colorectal cancer occurs in approximately 150,000 people each year in the United States. Prognostic assessment influences the treatment of patients with colorectal cancer, including decisions about adjuvant therapy. We evaluated chromosome 18q allelic loss, a genetic event associated with tumor progression, as a prognostic marker for this disease. Methods. We developed procedures to examine the status of chromosome 18q with microsatellite markers and DNA from formalin-fixed, paraffin-embedded tumors. Allelic loss of chromosome 18q was assessed in 145 consecutively resected stage II or III colorectal carcinomas.	JOHNS HOPKINS UNIV, SCH MED, DEPT ONCOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT ANESTHESIOL & CRIT CARE MED, BALTIMORE, MD 21205 USA; FINNISH RED CROSS & BLOOD TRANSFUS SERV, HELSINKI, FINLAND	Johns Hopkins University; Johns Hopkins University					NCI NIH HHS [CA-47527, CA-35494, CA-09243] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035494, T32CA009243, R37CA035494, R01CA047527] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; [Anonymous], 1985, NEW ENGL J MED, V312, P1465; BAAS IO, 1994, J PATHOL, V172, P5, DOI 10.1002/path.1711720104; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BECKMANN JS, 1992, GENOMICS, V12, P627, DOI 10.1016/0888-7543(92)90285-Z; BELL SM, 1993, GASTROENTEROLOGY, V104, P57, DOI 10.1016/0016-5085(93)90835-Z; COHN KH, 1991, LANCET, V338, P722, DOI 10.1016/0140-6736(91)91444-Y; COX DR, 1972, J R STAT SOC B, V34, P187; CRISSMAN JD, 1989, PATHOL ANNU, V24, P103; CRISSMAN JD, 1993, COLORECTAL CANCER, P57; DEANS GT, 1992, BRIT J SURG, V79, P608, DOI 10.1002/bjs.1800790706; DOUGLASS HO, 1986, NEW ENGL J MED, V315, P1294; ENSLEY JF, 1993, CYTOMETRY, V14, P550, DOI 10.1002/cyto.990140515; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINKELSTEIN SD, 1993, ARCH SURG-CHICAGO, V128, P526; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GRUIS NA, 1993, BRIT J CANCER, V68, P308, DOI 10.1038/bjc.1993.333; GUYER M, 1992, SCIENCE, V258, P67; HAHN M, 1993, CLIN CHEM, V39, P549; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P1444; HAMELIN R, 1994, GASTROENTEROLOGY, V106, P42, DOI 10.1016/S0016-5085(94)94217-X; HAMILTON SR, 1993, GASTROENTEROLOGY, V105, P3, DOI 10.1016/0016-5085(93)90003-U; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; Hedrick Lora, 1993, Trends in Cell Biology, V3, P36, DOI 10.1016/0962-8924(93)90148-T; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JASS JR, 1989, J CLIN PATHOL, V42, P254, DOI 10.1136/jcp.42.3.254; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KERN SE, 1989, JAMA-J AM MED ASSOC, V262, P1952; KIM HG, 1994, AM J PATHOL, V145, P148; KROOK JE, 1991, NEW ENGL J MED, V324, P709, DOI 10.1056/NEJM199103143241101; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LAURENTPUIG P, 1992, GASTROENTEROLOGY, V102, P1136; LAURIE JA, 1989, J CLIN ONCOL, V7, P1447, DOI 10.1200/JCO.1989.7.10.1447; LITT M, 1993, BIOTECHNIQUES, V15, P280; LOUIS DN, 1992, AM J PATHOL, V141, P777; MANTEL N, 1959, J NATL CANCER I, V22, P719; MELTZER SJ, 1991, P NATL ACAD SCI USA, V88, P4976, DOI 10.1073/pnas.88.11.4976; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; NIGAM AK, 1993, BRIT J CANCER, V68, P507, DOI 10.1038/bjc.1993.377; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OCONNELL MJ, 1992, CANCER-AM CANCER SOC, V70, P1732, DOI 10.1002/1097-0142(19920915)70:4+<1732::AID-CNCR2820701614>3.0.CO;2-#; OFFERHAUS GJA, 1992, GASTROENTEROLOGY, V102, P1612, DOI 10.1016/0016-5085(92)91721-F; PELTOMAKI P, 1993, CANCER RES, V53, P5853; REMVIKOS Y, 1992, BRIT J CANCER, V66, P758, DOI 10.1038/bjc.1992.352; RISINGER JI, 1992, HUM MOL GENET, V1, P657, DOI 10.1093/hmg/1.8.657-a; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHIBATA D, 1992, AM J PATHOL, V141, P539; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VASEN HFA, 1991, LANCET, V338, P877, DOI 10.1016/0140-6736(91)91520-5; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WIELENGA VJM, 1993, CANCER RES, V53, P4754; ZETTER BR, 1993, SEMIN CANCER BIOL, V4, P219; 1993, CANCER FACTS FIGURES	57	639	653	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 28	1994	331	4					213	221		10.1056/NEJM199407283310401	http://dx.doi.org/10.1056/NEJM199407283310401			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY335	8015568				2022-12-24	WOS:A1994NY33500001
J	MARKO, JF; SIGGIA, ED				MARKO, JF; SIGGIA, ED			FLUCTUATIONS AND SUPERCOILING OF DNA	SCIENCE			English	Article							HELICAL REPEAT; CIRCULAR DNAS; RING-CLOSURE; FLEXIBILITY; ELASTICITY; DIFFUSION; MOLECULES; DYNAMICS; TWIST	Frequently, DNA in vivo is organized into loops that are partially underwound and consequently form interwound helical supercoils. Methods from polymer statistical mechanics are used to show how the competition between entropy (thermal fluctuations) and elastic energy determines supercoil radius and pitch, in good agreement with recent experiments and simulations. Supercoil reorganization by means of slithering (reptation) of the DNA along the supercoil is argued to be a slow process. Extension of supercoiled DNA by an applied force shows a number of unexpected features, including coexistence of interwound and helical states.	CORNELL UNIV,ATOM & SOLID STATE PHYS LAB,ITHACA,NY 14853	Cornell University			Marko, John F./AAY-7111-2021	Marko, John F./0000-0003-4151-9530				BATES AD, 1993, DNA TOPOLOGY, pCH4; BEDNAR J, 1994, J MOL BIOL, V235, P825, DOI 10.1006/jmbi.1994.1042; BENHAM CJ, 1983, BIOPOLYMERS, V22, P2477, DOI 10.1002/bip.360221112; BENJAMIN HW, 1986, P RA WELCH F C CHEM, V29, P107; BERG OG, 1984, BIOPOLYMERS, V23, P1869, DOI 10.1002/bip.360231005; BOLES TC, 1990, J MOL BIOL, V213, P931, DOI 10.1016/S0022-2836(05)80272-4; COZZARELLI NR, 1990, DNA TOPOLOGY ITS BIO, pCH4; CROTHERS DM, 1992, METHOD ENZYMOL, V212, P3; DAOUD M, 1981, J PHYS-PARIS, V42, P1359, DOI 10.1051/jphys:0198100420100135900; DOI M, 1975, CHEM PHYS, V11, P115, DOI 10.1016/0301-0104(75)80044-9; FULLER FB, 1971, P NATL ACAD SCI USA, V68, P815, DOI 10.1073/pnas.68.4.815; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; HELFRICH W, 1978, Z NATURFORSCH A, V33, P305; LEBRET M, 1979, BIOPOLYMERS, V18, P1709, DOI 10.1002/bip.1979.360180710; LEBRET M, 1984, BIOPOLYMERS, V23, P1835, DOI 10.1002/bip.360231004; LEIBLER S, 1989, STATISTICAL MECHANIC, V5, P81; MARK JE, UNPUB; PARKER CN, 1991, CELL, V66, P781, DOI 10.1016/0092-8674(91)90121-E; RYBENKOV VV, 1993, P NATL ACAD SCI USA, V90, P5307, DOI 10.1073/pnas.90.11.5307; SCHLICK T, 1992, J MOL BIOL, V223, P1089, DOI 10.1016/0022-2836(92)90263-J; SHAW SY, 1993, SCIENCE, V260, P533, DOI 10.1126/science.8475384; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; TANAKA F, 1985, J CHEM PHYS, V83, P6017, DOI 10.1063/1.449637; TAYLOR WH, 1990, J MOL BIOL, V212, P363, DOI 10.1016/0022-2836(90)90131-5; VOLOGODSKII AV, 1992, J MOL BIOL, V227, P1224, DOI 10.1016/0022-2836(92)90533-P; WHITE JH, 1969, AM J MATH, V91, P693, DOI 10.2307/2373348; WOLFF AP, 1993, CHROMATIN	27	192	192	2	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 22	1994	265	5171					506	508		10.1126/science.8036491	http://dx.doi.org/10.1126/science.8036491			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	8036491				2022-12-24	WOS:A1994NY21600024
J	ALBERT, MS; CATES, GD; DRIEHUYS, B; HAPPER, W; SAAM, B; SPRINGER, CS; WISHNIA, A				ALBERT, MS; CATES, GD; DRIEHUYS, B; HAPPER, W; SAAM, B; SPRINGER, CS; WISHNIA, A			BIOLOGICAL MAGNETIC-RESONANCE-IMAGING USING LASER POLARIZED XE-129	NATURE			English	Article							NUCLEAR-SPIN RELAXATION; PROJECTION RECONSTRUCTION; XENON; GAS; EXCHANGE; NMR; SOLUBILITY; LIQUIDS; BRAIN	AS currently implemented, magnetic resonance imaging (MRI) relies on the protons of water molecules in tissue to provide the NMR signal. Protons are, however, notoriously difficult to image in some biological environments of interest, notably the lungs(1) and lipid bilayer membranes such as those in the brain(2). Here we show that Xe-129 gas can be used for high-resolution MRI when the nuclear-spin polarization of the atoms is increased by laser optical pumping and spin exchange(3-6). This process produces hyperpolarized Xe-129, in which the magnetization is enhanced by a factor of about 10(5). By introducing hyperpolarized Xe-129 into mouse lungs we have obtained images of the lung gas space with a speed and a resolution better than those available from proton MRI(1,7) or emission tomography(8,9). As xenon (a safe general anaesthetic) is rapidly-and safely transferred from the lungs to blood and thence to other tissues(8,9), where it is concentrated in lipid(10-15) and protein(13,15-18) components, images of the circulatory system, the brain and other vital organs can also be obtained. Because the magnetic behaviour of Xe-129 is very sensitive to its environment, and is different from that of (H2O)-H-1, MRI using hyperpolarized Xe-129 should involve distinct and sensitive mechanisms for tissue contrast.	PRINCETON UNIV,DEPT PHYS,PRINCETON,NJ 08544	Princeton University	ALBERT, MS (corresponding author), SUNY STONY BROOK,DEPT CHEM,STONY BROOK,NY 11794, USA.			Driehuys, Bastiaan/0000-0002-1236-4210; Springer, Charles/0000-0002-5966-2135				ALBERT MS, 1993, MAGNET RESON MED, V29, P700, DOI 10.1002/mrm.1910290520; ALBERT MS, 1992, 11TH P SMRM ANN M NE, P2104; ALBERT MS, 1992, 11TH P SMRM ANN M NE, P4710; BARANY M, 1987, MAGN RESON IMAGING, V5, P393, DOI 10.1016/0730-725X(87)90128-7; BERGIN CJ, 1991, RADIOLOGY, V179, P777, DOI 10.1148/radiology.179.3.2027991; BHASKAR ND, 1982, PHYS REV LETT, V49, P25, DOI 10.1103/PhysRevLett.49.25; BLUMGART HL, 1927, J CLIN INVEST, V4, P423; BLUMGART HL, 1927, J CLIN INVEST, V4, P339; CATES GD, 1992, PHYS REV A, V45, P4631, DOI 10.1103/PhysRevA.45.4631; CATES GD, 1990, PHYS REV LETT, V65, P2591, DOI 10.1103/PhysRevLett.65.2591; DIEHL P, 1990, J MAGN RESON, V88, P660, DOI 10.1016/0022-2364(90)90299-O; FULLERTON GD, 1988, BIOMEDICAL MAGNETIC, P147; GATZKE M, 1993, PHYS REV LETT, V70, P690, DOI 10.1103/PhysRevLett.70.690; GEWALT SL, 1993, MAGNET RESON MED, V29, P99, DOI 10.1002/mrm.1910290117; HAASE A, 1986, J MAGN RESON, V67, P258, DOI 10.1016/0022-2364(86)90433-6; HAPPER W, 1984, PHYS REV A, V29, P3092, DOI 10.1103/PhysRevA.29.3092; JAMESON CJ, 1988, J CHEM PHYS, V89, P4074, DOI 10.1063/1.454842; KNUDSEN GM, IN PRESS AM J PHYSL; MAYO JR, 1987, RADIOLOGY, V163, P507, DOI 10.1148/radiology.163.2.3562834; MILLER KW, 1981, P NATL ACAD SCI-BIOL, V78, P4946, DOI 10.1073/pnas.78.8.4946; NEWBURY NR, 1993, PHYS REV A, V48, P4411, DOI 10.1103/PhysRevA.48.4411; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; POLLACK GL, 1984, J CHEM PHYS, V81, P3239, DOI 10.1063/1.448032; RAFTERY D, 1991, PHYS REV LETT, V66, P584, DOI 10.1103/PhysRevLett.66.584; SCHOENBORN BP, 1969, J MOL BIOL, V45, P297, DOI 10.1016/0022-2836(69)90106-5; Susskind H, 1978, Prog Nucl Med, V5, P144; Susskind H, 1978, Prog Nucl Med, V5, P13; TILTON RF, 1982, BIOCHEMISTRY-US, V21, P6850, DOI 10.1021/bi00269a035; WILCOCK RJ, 1978, J CHEM THERMODYN, V10, P817, DOI 10.1016/0021-9614(78)90154-4; WILHELM E, 1977, CHEM REV, V77, P219, DOI 10.1021/cr60306a003; WISHNIA A, 1969, BIOCHEMISTRY-US, V8, P5064, DOI 10.1021/bi00840a058; WISHNIA A, 1969, BIOCHEMISTRY-US, V8, P5070, DOI 10.1021/bi00840a059	32	835	864	5	150	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 21	1994	370	6486					199	201		10.1038/370199a0	http://dx.doi.org/10.1038/370199a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX971	8028666				2022-12-24	WOS:A1994NX97100045
J	AUSTOKER, J				AUSTOKER, J			CANCER PREVENTION IN PRIMARY-CARE - SCREENING AND SELF-EXAMINATION FOR BREAST-CANCER	BRITISH MEDICAL JOURNAL			English	Article							WOMEN; MAMMOGRAPHY; ATTENDANCE; ATTITUDES	Breast cancer is the major form of cancer in women, with nearly 30 000 new cases and over 15 000 deaths in the United Kingdom each year. Breast screening by mammography has been shown in randomised trials to reduce mortality from breast cancer in women aged 50 and over. An NHS breast screening programme has been in operation in the United Kingdom since 1988. Its aim is to reduce mortality from breast cancer by 25% in the population of women invited to be screened. The uptake of mammography among the eligible population may be the single most important determinant if the programme is to be effective. Primary care teams have an important part to play in encouraging women to attend for screening and in providing information, advice, and reassurance at all stages of the screening process. To date, routine breast self examination has not been shown to be an effective method of screening for breast cancer and should not therefore be promoted as a primary screening procedure. There is, however, a case to be made for women to become more ''breast aware.''			AUSTOKER, J (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,CANC RES CAMPAIGN,PRIMARY CARE EDUC RES GRP,OXFORD OX2 6PE,ENGLAND.							AUSTOKER J, 1990, INVOLVING PRIMARY CA; AUSTOKER J, 1993, BREAST SCREENING ACC, P34; AUSTOKER J, 1992, BREAST CANCER SCREEN; Baines C. J., 1988, SCREENING BREAST CAN, P85; BAINES CJ, 1992, CANCER, V69, P1942, DOI 10.1002/1097-0142(19920401)69:7+<1942::AID-CNCR2820691712>3.0.CO;2-K; BAINES CJ, 1983, CAN MED ASSOC J, V128, P255; BERAL V, 1993, LANCET, V341, P1509, DOI 10.1016/0140-6736(93)90639-X; CHAMBERLAIN J, 1993, EUR J CANCER, V29A, P1804, DOI 10.1016/0959-8049(93)90524-J; CHAMBERLAIN J, BMJ, V353; CHAMPION V, 1992, CANCER, V69, P1985, DOI 10.1002/1097-0142(19920401)69:7+<1985::AID-CNCR2820691720>3.0.CO;2-C; CLOVER KA, 1991, MED J AUSTRALIA, V156, P91; COCKBURN J, 1989, MED J AUSTRALIA, V151, P391, DOI 10.5694/j.1326-5377.1989.tb101221.x; Coleman E A, 1991, J Cancer Educ, V6, P83; DAY NE, 1991, BRIT MED BULL, V47, P400, DOI 10.1093/oxfordjournals.bmb.a072479; FALLOWFIELD LJ, 1990, J ROY SOC MED, V83, P547, DOI 10.1177/014107689008300905; FOX SA, 1991, ARCH INTERN MED, V151, P50, DOI 10.1001/archinte.151.1.50; FRANK JW, 1985, LANCET, V2, P654; FRENCH K, 1982, BRIT MED J, V285, P617, DOI 10.1136/bmj.285.6342.617; HILL D, 1988, BRIT MED J, V297, P271, DOI 10.1136/bmj.297.6643.271; Kee F, 1992, Eur J Cancer Prev, V1, P231, DOI 10.1097/00008469-199204000-00004; KRUSE J, 1987, OBSTET GYNECOL, V70, P744; MACHARDY L, 1991, BREAST SCREENING PRI; MACLEAN U, 1984, J EPIDEMIOL COMMUN H, V38, P278, DOI 10.1136/jech.38.4.278; MANT D, 1991, BRIT MED BULL, V47, P455, DOI 10.1093/oxfordjournals.bmb.a072483; MANT D, 1992, BREAST, V1, P108; OMALLEY MS, 1987, JAMA-J AM MED ASSOC, V257, P2197; RIMER BK, 1989, RADIOLOGY, V172, P243, DOI 10.1148/radiology.172.1.2740510; SEMIGLAZOV VF, 1992, EUR J EPIDEMIOL, V8, P498, DOI 10.1007/BF00146366; WALD NJ, 1994, CONSENSUS C BREAST C; 1993, NHS BREAST SCREENING; 1991, FACTSHEET 7 BREAST C	31	51	51	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 16	1994	309	6948					168	174		10.1136/bmj.309.6948.168	http://dx.doi.org/10.1136/bmj.309.6948.168			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY229	8044097	Green Published			2022-12-24	WOS:A1994NY22900023
J	KREK, W; EWEN, ME; SHIRODKAR, S; ARANY, Z; KAELIN, WG; LIVINGSTON, DM				KREK, W; EWEN, ME; SHIRODKAR, S; ARANY, Z; KAELIN, WG; LIVINGSTON, DM			NEGATIVE REGULATION OF THE GROWTH-PROMOTING TRANSCRIPTION FACTOR E2F-1 BY A STABLY BOUND CYCLIN A-DEPENDENT PROTEIN-KINASE	CELL			English	Article							RETINOBLASTOMA GENE-PRODUCT; CELL-CYCLE; DIHYDROFOLATE-REDUCTASE; S-PHASE; VIRAL ONCOPROTEINS; COMPLEX-FORMATION; BINDING PROTEIN; IDENTIFICATION; CLONING; P107	Cyclin A-kinase, an enzyme required for coordinating S phase progression, forms stable in vivo complexes with E2F-1, a growth-promoting transcription factor, which binds to the retinoblastoma gene product and is involved in the timely activation of genes whose products contribute to G1 exit and S phase traversal. Complex formation results in a negative biochemical effect of cyclin A-kinase: the shut-off of E2F-1-dependent DNA binding function in S/G2. Thus, specific and timely cell cycle-dependent interactions of E2F-1 with proteins that inhibit its function (i.e., RB during G1 and cyclin A-kinase during S/G2) may contribute to the periodicity of expression of certain E2F-1-responsive genes at the G1/S transition.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	KREK, W (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,44 BINNEY ST,BOSTON,MA 02115, USA.							AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FARNHAM PJ, 1985, J BIOL CHEM, V260, P7675; FLEMINGTON EK, 1993, IN PRESS P NATL ACAD; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; MARIDOR G, 1993, J CELL SCI, V106, P535; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; NEVINS JR, 1992, SCIENCE, V258, P424; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	44	445	457	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 15	1994	78	1					161	172		10.1016/0092-8674(94)90582-7	http://dx.doi.org/10.1016/0092-8674(94)90582-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033208				2022-12-24	WOS:A1994NX32800018
J	SALMON, D; GEUSKENS, M; HANOCQ, F; HANOCQQUERTIER, J; NOLAN, D; RUBEN, L; PAYS, E				SALMON, D; GEUSKENS, M; HANOCQ, F; HANOCQQUERTIER, J; NOLAN, D; RUBEN, L; PAYS, E			A NOVEL HETERODIMERIC TRANSFERRIN RECEPTOR ENCODED BY A PAIR OF VSG EXPRESSION SITE-ASSOCIATED GENES IN TRYPANOSOMA-BRUCEI	CELL			English	Article							VARIANT SURFACE GLYCOPROTEIN; BLOOD-STREAM FORM; TRYPANOSOMA-BRUCEI; AFRICAN TRYPANOSOMES; MEDIATED ENDOCYTOSIS; FLAGELLAR POCKET; TRANSCRIPTION; MEMBRANE; IDENTIFICATION; LOCALIZATION	In T. brucei, a transferrin-binding protein has been found to share sequence homology with pESAG-7 and -6, the products of two related genes present in the VSG gene polycistronic transcription unit. When expressed in Xenopus oocytes, they appear as N-glycosylated proteins secreted in the medium (pESAG-7) and GPI anchored to the membrane (pESAG-6). These proteins are able to homo- or heterodimerize, probably through association in the same orientation. Only heterodimers can bind Tf, possibly two molecules per dimer. A comparison of Tf binding to pESAG-7/6-expressing oocytes and trypanosomes suggests that pESAG-7/6 is the Tf receptor of the parasite. In trypanosomes, the majority of pESAG-7/6 is released from the membrane and associates, together with Tf, with a glycosylated matrix present in the lumen of the flagellar pocket. Both pESAG-7/6 and Tf are internalized via coated pits and vesicles. These observations suggest a novel mode of Tf binding and uptake in trypanosomes.	SO METHODIST UNIV,DEPT BIOL SCI,DALLAS,TX 75275	Southern Methodist University	SALMON, D (corresponding author), UNIV BRUSSELS,DEPT MOLEC BIOL,B-1640 RHODE ST GENESE,BELGIUM.		Salmon, Didier/M-5670-2013	Nolan, Derek/0000-0002-3742-4304				ALEXANDRE S, 1988, MOL CELL BIOL, V8, P2367, DOI 10.1128/MCB.8.6.2367; AVRAMEAS S, 1971, IMMUNOCHEMISTRY, V8, P1175, DOI 10.1016/0019-2791(71)90395-8; BALBER AE, 1990, CRIT REV IMMUNOL, V10, P177; BALTZ T, 1985, EMBO J, V4, P1273, DOI 10.1002/j.1460-2075.1985.tb03772.x; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRINGAUD F, 1993, MOL CELL BIOL, V13, P1146, DOI 10.1128/MCB.13.2.1146; BULOW R, 1989, J CELL SCI, V93, P233; COPPENS I, 1988, P NATL ACAD SCI USA, V85, P6753, DOI 10.1073/pnas.85.18.6753; COPPENS I, 1987, J PROTOZOOL, V34, P465, DOI 10.1111/j.1550-7408.1987.tb03216.x; CULLY DF, 1985, CELL, V42, P173, DOI 10.1016/S0092-8674(85)80113-6; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; GEUSKENS M, 1982, ONCODEV BIOL MED, V3, P291; GRAB DJ, 1993, EUR J CELL BIOL, V62, P114; GRAB DJ, 1992, EUR J CELL BIOL, V59, P398; GURDON JB, 1976, J EMBRYOL EXP MORPH, V36, P523; HOBBS MR, 1990, MOL BIOCHEM PARASIT, V43, P1, DOI 10.1016/0166-6851(90)90125-6; JACKSON DG, 1993, J BIOL CHEM, V268, P8085; KARIN M, 1981, J BIOL CHEM, V256, P3245; KOOTER JM, 1987, CELL, V51, P261, DOI 10.1016/0092-8674(87)90153-X; MAY WS, 1985, J MEMBRANE BIOL, V88, P205, DOI 10.1007/BF01871086; PAINDAVOINE P, 1992, MOL CELL BIOL, V12, P1218, DOI 10.1128/MCB.12.3.1218; PAYS E, 1989, CELL, V57, P835, DOI 10.1016/0092-8674(89)90798-8; ROSS DT, 1991, EMBO J, V10, P2047, DOI 10.1002/j.1460-2075.1991.tb07735.x; SCALA C, 1992, J HISTOCHEM CYTOCHEM, V40, P1799, DOI 10.1177/40.11.1431065; SCHELL D, 1991, EMBO J, V10, P1061, DOI 10.1002/j.1460-2075.1991.tb08045.x; SCHELL D, 1991, PARASITOL RES, V77, P558, DOI 10.1007/BF00931012; SCHELL D, 1993, EMBO J, V12, P2990; SCHNEIDER C, 1982, J BIOL CHEM, V257, P8516; SHIH YJ, 1990, J BIOL CHEM, V265, P19077; STANLEY KK, 1984, EMBO J, V3, P1420; THIERY JP, 1967, J MICROSC-PARIS, V6, P987; THIERY JP, 1974, J MICROSC-PARIS, V21, P225; TROWBRIDGE IS, 1981, P NATL ACAD SCI-BIOL, V78, P3039, DOI 10.1073/pnas.78.5.3039; Vijayaraghavan P, 1992, Clin Physiol Biochem, V9, P138; WEBSTER P, 1993, PARASITOL TODAY, V9, P201, DOI 10.1016/0169-4758(93)90008-4; ZAMZE SE, 1988, EUR J BIOCHEM, V176, P527, DOI 10.1111/j.1432-1033.1988.tb14310.x; ZIEGELBAUER K, 1993, INFECT IMMUN, V61, P4540, DOI 10.1128/IAI.61.11.4540-4545.1993; ZIEGELBAUER K, 1992, J BIOL CHEM, V267, P10797	38	155	155	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 15	1994	78	1					75	86		10.1016/0092-8674(94)90574-6	http://dx.doi.org/10.1016/0092-8674(94)90574-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033214				2022-12-24	WOS:A1994NX32800010
J	AUSTOKER, J				AUSTOKER, J			CANCER PREVENTION - SETTING THE SCENE	BRITISH MEDICAL JOURNAL			English	Article							HEALTH	Each year in the United Kingdom there are over 300 000 new cases of cancer and nearly 165 000 deaths from cancer. It is widely believed that as many as four fifths of all cancers are preventable by means that are already available. The Health of the Nation and the Europe Against Cancer programme have set targets and strategies for reducing the risk of cancer. An approach based on the whole population will achieve the greatest reductions in morbidity and mortality. Complementary to this is the individual approach, which can be based in primary care and targeted at high risk subjects, Health promotion and screening in primary care are not in themselves self evidently valuable. Their effectiveness must be tested rigorously and scientifically. Furthermore, because of limited time and resources, health education in primary care should be focused on interventions that are likely to achieve the greatest benefit, such as helping people to stop smoking.			AUSTOKER, J (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,CANC RES CAMPAIGN,PRIMARY CARE EDUC RES GRP,OXFORD OX2 6PE,ENGLAND.							CALNAN M, 1989, SOCIAL DILEMMAS CANC, P91; CALNAN M, 1992, CORONARY HEART DISEA; COULTER A, 1993, PREVENTION GENERAL P, P19; DELAMOTHE T, 1991, BRIT MED J, V303, P1046, DOI 10.1136/bmj.303.6809.1046; DICLEMENTE CC, 1991, J CONSULT CLIN PSYCH, V59, P295, DOI 10.1037/0022-006X.59.2.295; DOLL R, 1993, REDUCING RISK CANCER, P14; Doll R, 1981, THE CAUSES OF CANCER; KELLY MP, 1992, BRIT J GEN PRACT, V42, P223; Love R R, 1988, J Cancer Educ, V3, P71; MANT D, 1994, BRIT J GEN PRACT, V44, P51; Prochaska J. O., 1986, TREATING ADDICTIVE B, P3, DOI DOI 10.1007/978-1-4613-2191-0_; ROLLNICK S, 1993, BRIT MED J, V307, P188, DOI 10.1136/bmj.307.6897.188; Rollnick S, 1992, J MENT HEALTH, V1, P25, DOI DOI 10.3109/09638239209034509; Rose G., 1992, STRATEGY PREVENTIVE; STOATE HG, 1989, J ROY COLL GEN PRACT, V39, P193; STOTT N, 1994, BRIT MED J, V308, P285, DOI 10.1136/bmj.308.6924.285; WILSON JMJ, 1968, WHO PUBLIC HLTH PAPE, P34; WRIGH L, 1992, HLTH LIFESTYLES OXFO; 1992, HLTH NATION STRATEGY; 1994, BRIT MED J, V308, P313; 1993, CANCER RES CAMPAIGN; 1994, BRIT MED J, V308, P308; 1993, EUROPEAN CODE CANCER; 1992, CRC11 CANC RES CAMP; 1994, SCI YB	25	12	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 28	1994	308	6941					1415	1420		10.1136/bmj.308.6941.1415	http://dx.doi.org/10.1136/bmj.308.6941.1415			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP420	8019255	Green Published			2022-12-24	WOS:A1994NP42000021
J	BROWN, SL; SALIVE, ME; HARRIS, TB; SIMONSICK, EM; GURALNIK, JM; KOHOUT, FJ				BROWN, SL; SALIVE, ME; HARRIS, TB; SIMONSICK, EM; GURALNIK, JM; KOHOUT, FJ			LOW-CHOLESTEROL CONCENTRATIONS AND SEVERE DEPRESSIVE SYMPTOMS IN ELDERLY PEOPLE	BRITISH MEDICAL JOURNAL			English	Article							LOW SERUM-CHOLESTEROL; PRIMARY PREVENTION; MORTALITY; MEN; PROGRESS	Objective-To investigate the reported association between low serum cholestrol concentration and severe depressive symptoms in an elderly population. Design-Cross sectional analysis of pooled data from three communities of the established populations for epidemiologic studies of the elderly. Participants who completed their interview, including the Centers for Epidemiologic Studies' depression scale and consented to measurement of their cholesterol concentration were included in the study. Subjects-3939 men and women aged greater than or equal to 71. Methods-chi(2) analysis, t tests, and multivariate regression analysis of the association between low cholesterol concentration and severe depressive symptoms. All analyses were stratified by sex, and multivariate analyses were adjusted for age, self reported health, physical function, number of drugs used, and weight loss. Main outcome measure-Score of depressive symptoms on the Centers for Epidemiologic Studies' depression scale. Results-Depressive symptoms, cholesterol concentration, weight, and use of drugs were all associated with age in men and women. The relative odds of severe depressive symptoms (score greater than or equal to 16) for those with low cholesterol concentrations (<4.14 mmol/l) were 1.9 (95% confidence interval, 1.1 to 3.3) for the older group of men and 1.8 (1.1 to 2.9) for the older group of women. This association was also observed when depressive symptoms were analysed as a continuous rather than a categorical variable. In multivariate models that adjusted for age, self reported health, physical function, number of drugs used, and weight loss, the association was substantially weakened. Conclusions-After several factors relating to health had been controlled for, no significant association between low cholesterol concentration and severe depressive symptoms was found.	UNIV IOWA,COLL DENT,IOWA CITY,IA 52242	University of Iowa	BROWN, SL (corresponding author), NIA,EPIDEMIOL DEMOG & BIOMETRY PROGRAM,7201 WINSCONSIN AVE,SUITE 3C309,BETHESDA,MD 20892, USA.		Simonsick, Eleanor/W-6864-2019					ASBERG M, 1976, ARCH GEN PSYCHIAT, V9, P51; BLAZER D, 1991, J GERONTOL, V46, pM210, DOI 10.1093/geronj/46.6.M210; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; CORNONIHUNTLEY J, 1986, US PHS NIH862443 PUB; ENGELBERG H, 1992, LANCET, V339, P727, DOI 10.1016/0140-6736(92)90609-7; HARRIS T, 1992, J CLIN EPIDEMIOL, V45, P595, DOI 10.1016/0895-4356(92)90131-6; Harris T, 1992, Ann Epidemiol, V2, P35, DOI 10.1016/1047-2797(92)90035-O; Hooker K., 1992, BEHAV HLTH AGING, V2, P81; KATZ S, 1970, GERONTOLOGIST, V10, P20, DOI 10.1093/geront/10.1_Part_1.20; Kohout F J, 1993, J Aging Health, V5, P179, DOI 10.1177/089826439300500202; LINDBERG G, 1992, BRIT MED J, V305, P277, DOI 10.1136/bmj.305.6848.277; MANSON JE, 1992, NEW ENGL J MED, V326, P1406, DOI 10.1056/NEJM199205213262107; MORGAN RE, 1993, LANCET, V341, P75, DOI 10.1016/0140-6736(93)92556-9; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NEATON JD, 1992, ARCH INTERN MED, V152, P1490, DOI 10.1001/archinte.152.7.1490; PALINKAS LA, 1993, LANCET, V341, P563, DOI 10.1016/0140-6736(93)90328-E; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROY A, 1988, ACTA PSYCHIAT SCAND, V78, P529, DOI 10.1111/j.1600-0447.1988.tb06380.x; SMITH GD, 1993, LANCET, V341, P434; TRAN ZV, 1985, JAMA-J AM MED ASSOC, V254, P919, DOI 10.1001/jama.254.7.919	20	103	103	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 21	1994	308	6940					1328	1332		10.1136/bmj.308.6940.1328	http://dx.doi.org/10.1136/bmj.308.6940.1328			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM989	8019218	Green Published			2022-12-24	WOS:A1994NM98900019
J	RYAN, KE; MACLENNAN, S; BARBARA, JAJ; HEWITT, PE				RYAN, KE; MACLENNAN, S; BARBARA, JAJ; HEWITT, PE			FOLLOW-UP OF BLOOD-DONORS POSITIVE FOR ANTIBODIES TO HEPATITIS-C VIRUS	BRITISH MEDICAL JOURNAL			English	Article									N LONDON BLOOD TRANSFUS CTR,LONDON NW9 5BG,ENGLAND									AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; MACLENNAN S, IN PRESS TRANSFUSION; 1993, DRUG THER B, V31, P61	4	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 12	1994	308	6930					696	697		10.1136/bmj.308.6930.696	http://dx.doi.org/10.1136/bmj.308.6930.696			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA869	8068079	Green Published			2022-12-24	WOS:A1994NA86900022
J	JAN, LY; JAN, YN				JAN, LY; JAN, YN			POTASSIUM CHANNELS AND THEIR EVOLVING GATES	NATURE			English	Article							K+-CHANNEL; CHLORIDE CHANNEL; INWARD RECTIFICATION; ESCHERICHIA-COLI; PORE; INACTIVATION; EXPRESSION; SUBUNIT; VOLTAGE; REGION	Potassium channels allow potassium ions to flow across the membrane and play a key role in maintaining membrane potential. Recent research has begun to reveal how these channels transport potassium in preference to other ions, how their activity is controlled, and how they ate related to other channels.			JAN, LY (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT BIOCHEM & PHYSIOL, SAN FRANCISCO, CA 94143 USA.			Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299				ALTENDORF K, 1992, ANN NY ACAD SCI, V671, P228, DOI 10.1111/j.1749-6632.1992.tb43799.x; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; BABILA T, 1994, NEURON, V12, P615, DOI 10.1016/0896-6273(94)90217-8; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BEZANILLA F, 1977, J GEN PHYSIOL, V70, P549, DOI 10.1085/jgp.70.5.549; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; GILLESPIE PG, 1993, NEURON, V11, P581, DOI 10.1016/0896-6273(93)90071-X; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; Hille B., 1992, IONIC CHANNELS EXCIT; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; ISHIHARA K, 1989, J PHYSIOL-LONDON, V419, P297, DOI 10.1113/jphysiol.1989.sp017874; KIRSCH GE, 1989, AM J PHYSIOL, V257, pH334, DOI 10.1152/ajpheart.1989.257.1.H334; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LOGOTHETIS DE, 1992, NEURON, V8, P531, DOI 10.1016/0896-6273(92)90281-H; LOPEZ GA, 1994, NATURE, V367, P179, DOI 10.1038/367179a0; LOPEZBARNEO J, 1993, RECEPTOR CHANNEL, V1, P61; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MILKMAN R, 1994, P NATL ACAD SCI USA, V91, P3510, DOI 10.1073/pnas.91.9.3510; NEYTON J, 1988, J GEN PHYSIOL, V92, P569, DOI 10.1085/jgp.92.5.569; NIKAIDO H, 1992, SCIENCE, V258, P936, DOI 10.1126/science.1279804; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PARCEJ DN, 1992, BIOCHEMISTRY-US, V31, P11084, DOI 10.1021/bi00160a018; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; SCHLOSSER A, 1991, J BACTERIOL, V173, P3170; SCHROEDER JI, 1994, ANNU REV BIOPH BIOM, V23, P441, DOI 10.1146/annurev.bb.23.060194.002301; SLESINGER PA, 1993, NEURON, V11, P739, DOI 10.1016/0896-6273(93)90083-4; SOLA, 1994, BIOPHYS J, V66, pA23; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; TAGLIALATELA M, 1994, SCIENCE, V264, P844, DOI 10.1126/science.8171340; TRUBE G, 1989, SECRETION ITS CONTRO; TYTGAT J, 1992, NATURE, V359, P420, DOI 10.1038/359420a0; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WANG WH, 1992, ANNU REV PHYSIOL, V54, P81; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	50	259	261	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 8	1994	371	6493					119	122		10.1038/371119a0	http://dx.doi.org/10.1038/371119a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF191	8072541				2022-12-24	WOS:A1994PF19100053
J	SHAFI, MI				SHAFI, MI			CONTROVERSIES IN MANAGEMENT - MANAGEMENT OF WOMEN WITH MILD DYSKARYOSIS - CYTOLOGICAL SURVEILLANCE AVOIDS OVERTREATMENT .1.	BRITISH MEDICAL JOURNAL			English	Article							CERVICAL-CANCER; CARCINOMA; SMEARS				SHAFI, MI (corresponding author), DUDLEY RD GEN HOSP,BIRMINGHAM B18 7QH,W MIDLANDS,ENGLAND.							BENEDET JL, 1985, OBSTET GYNECOL, V65, P557; COOPER P, 1992, CYTOPATHOLOGY, V3, P331; CUZICK J, 1992, LANCET, V339, P959, DOI 10.1016/0140-6736(92)91532-D; DUNCAN ID, 1992, NHS CERVICAL SCREENI; FLANNELLY G, 1994, BRIT MED J, V308, P1399, DOI 10.1136/bmj.308.6941.1399; JARMULOWICZ MR, 1989, BRIT J OBSTET GYNAEC, V96, P1061, DOI 10.1111/j.1471-0528.1989.tb03381.x; LUESLEY DM, 1990, BRIT MED J, V300, P1690, DOI 10.1136/bmj.300.6741.1690; MACGREGOR JE, 1994, BMJ-BRIT MED J, V308, P1407, DOI 10.1136/bmj.308.6941.1407; MCINDOE WA, 1984, OBSTET GYNECOL, V64, P451; ROBERTSON JH, 1988, BRIT MED J, V297, P18, DOI 10.1136/bmj.297.6640.18; SEDLACEK TV, 1992, COLPOSCOPIST, V14, P1; 1993, CERVICAL CANCER RES	12	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 3	1994	309	6954					590	591		10.1136/bmj.309.6954.590	http://dx.doi.org/10.1136/bmj.309.6954.590			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF330	8086950	Green Published			2022-12-24	WOS:A1994PF33000027
J	MORGENBESSER, SD; WILLIAMS, BO; JACKS, T; DEPINHO, RA				MORGENBESSER, SD; WILLIAMS, BO; JACKS, T; DEPINHO, RA			P53-DEPENDENT APOPTOSIS PRODUCED BY RB-DEFICIENCY IN THE DEVELOPING MOUSE LENS	NATURE			English	Article							HUMAN PAPILLOMAVIRUS TYPE-16; WILD-TYPE P53; TRANSGENIC MICE; CELL-DEATH; RAT LENS; GENE; EYE; TRANSFORMATION; KERATINOCYTES; EXPRESSION	THE retinoblastoma tumour-suppressor gene (RB) has been implicated in negative growth regulation, induction of differentiation, and inhibition of cellular transformation(1). Homozygous inactivation of the Rb gene in the mouse leads to mid-gestational lethality with defects in erythropoiesis and neurogenesis(2-4). Here we describe the effects of the Rb-deficient state on the development of the ocular lens. The regional compartmentalization of growth, differentiation and apoptosis in the developing lens provides an ideal system to examine more closely the relationships of these processes in vivo. We demonstrate that loss of Rb function is associated with unchecked proliferation, impaired expression of differentiation markers, and inappropriate apoptosis in lens fibre cells. In addition, we show that ectopic apoptosis in Rb-deficient lenses is dependent on p53, because embryos doubly null for Rb and p53 show a nearly complete suppression of this effect. This developmental system provides a framework for understanding the consequences of the frequent mutation of both RB and p53 in human cancer.	MIT,CTR CANC RES,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Yeshiva University; Albert Einstein College of Medicine			Williams, Bart/A-3539-2013	Williams, Bart/0000-0002-5261-5301; DePinho, Ronald/0000-0002-5625-577X				BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRIEP AE, 1993, J VIROL, V67, P1373, DOI 10.1128/JVI.67.3.1373-1384.1993; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; ISHAZAKI Y, 1993, J CELL BIOL, V121, P899; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MCAVOY JW, 1978, J EMBRYOL EXP MORPH, V44, P149; MUNGER K, 1989, J VIROL, V63, P4417; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PEI YF, 1970, ANAT REC, V168, P105, DOI 10.1002/ar.1091680109; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHIELS A, 1991, BIOCHIM BIOPHYS ACTA, V1097, P318, DOI 10.1016/0925-4439(91)90087-P; SILVER J, 1973, J MORPHOL, V140, P159, DOI 10.1002/jmor.1051400204; WATANABE S, 1989, J VIROL, V63, P965, DOI 10.1128/JVI.63.2.965-969.1989; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WILLIAMS BO, IN PRESS EMBO J; YANCEY SB, 1988, J CELL BIOL, V106, P705, DOI 10.1083/jcb.106.3.705; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	28	576	585	1	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 1	1994	371	6492					72	74		10.1038/371072a0	http://dx.doi.org/10.1038/371072a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE381	8072529				2022-12-24	WOS:A1994PE38100054
J	ROMEO, R; POL, S; BERTHELOT, P; BRECHOT, C				ROMEO, R; POL, S; BERTHELOT, P; BRECHOT, C			ERADICATION OF HEPATITIS-C VIRUS-RNA AFTER ALPHA-INTERFERON THERAPY	ANNALS OF INTERNAL MEDICINE			English	Note							LIVER-DISEASE; HCV; MULTICENTER; VIREMIA; SERUM		CHU NECKER, PARIS, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	ROMEO, R (corresponding author), UNIV MILAN, INST INTERNAL MED, VIA PACE 9, I-20122 MILAN, ITALY.			Romeo, Raffaella/0000-0002-7858-4670				ALBERTI A, 1992, LANCET, V340, P697, DOI 10.1016/0140-6736(92)92234-7; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; BRILLANTI S, 1993, LANCET, V341, P464, DOI 10.1016/0140-6736(93)90210-8; BROUWER JT, 1993, HEPATOLOGY, V18, pA110; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; GIL B, 1993, HEPATOLOGY, V18, P1050; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; NOUSBAUM JB, 1993, HEPATOLOGY, V18, pA88; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; ROMEO R, 1993, TRANSFUSION, V33, P629, DOI 10.1046/j.1537-2995.1993.33893342742.x; ZAAIJER HL, 1993, LANCET, V341, P722, DOI 10.1016/0140-6736(93)90488-3	11	67	67	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1994	121	4					276	277		10.7326/0003-4819-121-4-199408150-00008	http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00008			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB102	8037409				2022-12-24	WOS:A1994PB10200008
J	ROUSSELET, J; SALOME, L; AJDARI, A; PROST, J				ROUSSELET, J; SALOME, L; AJDARI, A; PROST, J			DIRECTIONAL MOTION OF BROWNIAN PARTICLES INDUCED BY A PERIODIC ASYMMETRIC POTENTIAL	NATURE			English	Article								STRUCTURES possessing spatial asymmetry should act as pumps in the presence of dissipation alone(1-4), without the need for macroscopic forces or temperature differences(5) to drive vectorial motion. It has been shown theoretically(2-4,6,7) that particles subjected to an asymmetric periodic potential can display net directional motion even if the space-averaged forte is zero. Here we demonstrate such behaviour experimentally. We have studied the behaviour of colloidal particles suspended in solution and exposed to a sawtooth dielectric potential which is turned on and off periodically. The particles exhibit net motion with a velocity that depends on their size, suggesting applications in separation processes for objects in the size range 0.1-5 mu m-a range that includes biological structures such as viruses, cells and chromosomes(8). We furthermore point out the analogy between our device and motor protein assemblies.	ECOLE SUPER PHYS & CHIM IND VILLE PARIS, PHYSICOCHIM THEOR GRP, CNRS, URA 1382, F-75231 PARIS 05, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)	ROUSSELET, J (corresponding author), CTR RECH PAUL PASCAL, AVE A SCHWEITZER, F-33600 PESSAC, FRANCE.			SALOME, Laurence/0000-0001-9667-4154				AJDARI A, 1992, CR ACAD SCI II, V315, P1635; AJDARI A, 1993, Patent No. 9311346; AJDARI A, 1992, THESIS U PARIS 6; ASTUMIAN RD, 1994, PHYS REV LETT, V72, P1766, DOI 10.1103/PhysRevLett.72.1766; CORDOVA NJ, 1991, NATO ADV SCI I B-PHY, V263, P207; Curie P., 1894, J PHYS THEOR APPL, V3, P393, DOI DOI 10.1051/JPHYSTAP:018940030039300; DOERING CR, 1994, PHYS REV LETT, V72, P2984, DOI 10.1103/PhysRevLett.72.2984; FELICI N, 1971, CR ACAD SCI B PHYS, V273, P1004; FEYNMAN RP, 1966, FEYNMAN LECT PHYS, V1, pCH46; MAGNASCO MO, 1993, PHYS REV LETT, V71, P1477, DOI 10.1103/PhysRevLett.71.1477; PESKIN CS, 1994, CELL MECHANICS CELLU; PROST J, 1994, PHYS REV LETT, V72, P2652, DOI 10.1103/PhysRevLett.72.2652	12	575	595	4	73	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 11	1994	370	6489					446	448		10.1038/370446a0	http://dx.doi.org/10.1038/370446a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PB407	8047163				2022-12-24	WOS:A1994PB40700051
J	KIM, DS; BONHOEFFER, T				KIM, DS; BONHOEFFER, T			REVERSE OCCLUSION LEADS TO A PRECISE RESTORATION OF ORIENTATION PREFERENCE MAPS IN VISUAL-CORTEX	NATURE			English	Article							MONOCULAR DEPRIVATION; STRIATE CORTEX; FUNCTIONAL ARCHITECTURE; INTRINSIC SIGNALS; KITTENS; CAT; ORGANIZATION; SELECTIVITY; DOMAINS; AREA-18	In the visual system of young kittens, the layout of the cortical maps for ocular dominance and orientation preference converges to an equilibrium state within the first few weeks of life and normally remains largely unchanged. If during the critical period, however, patterned visual experience is restricted to only one eye for a few days, cortical neurons lose their ability to respond to stimulation of the deprived eye. We used the 'reverse occlusion' protocol together with chronical optical imaging to investigate how the profound anatomical changes accompanying monocular deprivation(1) affect the spatial pattern of the cortical orientation preference map. We report here that after 1 week of monocular deprivation, cortical orientation maps for the deprived eye had vanished, But we also discovered that after subsequent reverse occlusion the restored orientation maps were very similar to the original maps. This demonstrates that in spite of functional disconnection of one eye after monocular deprivation, the layout of cortical orientation maps, when re-established for this eye, is not formed from scratch but is strongly influenced by previous experience.	MAX PLANCK INST PSYCHIAT,D-82152 MUNCHEN MARTINSRI,GERMANY; MAX PLANCK INST BRAIN RES,D-60528 FRANKFURT,GERMANY	Max Planck Society; Max Planck Society			Bonhoeffer, Tobias/B-9481-2009; Kim, Dae-Shik/C-2071-2011	Bonhoeffer, Tobias/0000-0001-7897-6634; 				ANTONINI A, 1993, SCIENCE, V260, P1819, DOI 10.1126/science.8511592; BLAKEMORE C, 1982, J PHYSIOL-LONDON, V327, P463, DOI 10.1113/jphysiol.1982.sp014243; BLAKEMORE C, 1974, J PHYSIOL-LONDON, V237, P195, DOI 10.1113/jphysiol.1974.sp010478; BLASDEL GG, 1992, J NEUROSCI, V12, P3139, DOI 10.1523/JNEUROSCI.12-08-03139.1992; BONHOEFFER T, 1993, J NEUROSCI, V13, P4157; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; CHAPMAN B, 1991, J NEUROSCI, V11, P1347; FITZPATRICK D, 1993, SOC NEUR ABSTR, V19; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; KOSSUT M, 1991, EXP BRAIN RES, V85, P519; MIOCHE L, 1989, J NEUROPHYSIOL, V62, P185, DOI 10.1152/jn.1989.62.1.185; MOVSHON JA, 1976, J PHYSIOL-LONDON, V261, P125, DOI 10.1113/jphysiol.1976.sp011551; SHATZ CJ, 1978, J PHYSIOL-LONDON, V281, P267, DOI 10.1113/jphysiol.1978.sp012421; SWINDALE NV, 1987, J NEUROSCI, V7, P1414; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630; VANSLUYTERS RC, 1978, J PHYSIOL-LONDON, V284, P1	19	75	75	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 4	1994	370	6488					370	372		10.1038/370370a0	http://dx.doi.org/10.1038/370370a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA304	8047142				2022-12-24	WOS:A1994PA30400055
J	LONGSTRETH, WT; NELSON, LM; KOEPSELL, TD; VANBELLE, G				LONGSTRETH, WT; NELSON, LM; KOEPSELL, TD; VANBELLE, G			SUBARACHNOID HEMORRHAGE AND HORMONAL FACTORS IN WOMEN - A POPULATION-BASED CASE-CONTROL STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						SUBARACHNOID HEMORRHAGE; HORMONE REPLACEMENT THERAPY, POSTMENOPAUSAL; MENSTRUATION; ESTROGENS	ORAL-CONTRACEPTIVES; CIGARETTE-SMOKING; REPLACEMENT THERAPY; RISK-FACTORS; CARDIOVASCULAR-DISEASE; POSTMENOPAUSAL WOMEN; PROXY RESPONDENTS; FOLLOW-UP; STROKE; HYPERTENSION	Objective: To determine the degree to which endogenous and exogenous hormonal factors influence the risk for subarachnoid hemorrhage in women. Design: A population-based case-control study. Setting: King County, Washington. Participants: 103 women with an incident, spontaneous subarachnoid hemorrhage and 2 age- and sex-matched controls per case-patient who were identified through random-digit dialing. Measurements: Information on exposures was collected during in-person interviews of case-patients, controls, and their surrogates. Results: Premenopausal women, especially those without a history of smoking or hypertension, were at a reduced risk for subarachnoid hemorrhage compared with age-matched postmenopausal women (odds ratio, 0.24; 95% CI, 0.09 to 0.68). The use of hormone replacement therapy was associated with a reduced risk (odds ratio, 0.47; CI, 0.26 to 0.86); the reduction was significantly greater in women who had smoked than in those that had never smoked. Of the 23 premenopausal case-patients, 74% were either menstruating when hemorrhaging occurred or had had their last menstrual period 21 or more days before hemorrhaging compared with the expected 43% (difference, 31%; CI, 4% to 58%). Conclusions: Premenopausal women are at reduced risk for subarachnoid hemorrhage, especially those without a history of smoking or hypertension. Hormone replacement therapy reduced the risk only in postmenopausal women who had ever smoked. Among women still menstruating, the risk for hemorrhage was greatest in the perimenstrual period.	UNIV WASHINGTON, SCH MED, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT ENVIRONM HLTH, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH PUBL HLTH & COMMUNITY MED, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Nelson, Lorene M/D-1305-2011		NINDS NIH HHS [R01 NS22690] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022690] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAM S, 1981, BRIT MED J, V282, P1277, DOI 10.1136/bmj.282.6272.1277; BARON JA, 1990, AM J OBSTET GYNECOL, V162, P502, DOI 10.1016/0002-9378(90)90420-C; BOLOGNIA JL, 1989, MATURITAS, V11, P295, DOI 10.1016/0378-5122(89)90026-1; BONITA R, 1986, STROKE, V17, P831, DOI 10.1161/01.STR.17.5.831; BOURNE T, 1990, LANCET, V335, P1470, DOI 10.1016/0140-6736(90)91505-5; BRASS LM, 1990, J CARDIOVASC TECHNOL, V9, P68; BRINCAT M, 1983, BRIT MED J, V287, P1337, DOI 10.1136/bmj.287.6402.1337; DAVIES OL, 1980, STATISTICAL METHODS, V1; FALKEBORN M, 1993, ARCH INTERN MED, V153, P1201, DOI 10.1001/archinte.153.10.1201; FISCH IR, 1977, JAMA-J AM MED ASSOC, V237, P2499, DOI 10.1001/jama.237.23.2499; Fleiss JL., 1981, STAT METHODS RATES P, V2, P22; GANGAR KF, 1991, LANCET, V338, P839; GILL JS, 1986, NEW ENGL J MED, V315, P1041, DOI 10.1056/NEJM198610233151701; GILL JS, 1987, CLIN SCI, V73, pP57; HANDA H, 1983, STROKE, V14, P857, DOI 10.1161/01.STR.14.6.857; HEYMAN A, 1976, NEUROLOGY, V26, P358; KNEKT P, 1991, J CLIN EPIDEMIOL, V44, P933, DOI 10.1016/0895-4356(91)90056-F; Lind T, 1979, Br J Obstet Gynaecol, V86 Suppl 3, P1, DOI 10.1111/j.1471-0528.1979.tb16232.x; LINDEGARD B, 1987, ACTA NEUROL SCAND, V76, P37, DOI 10.1111/j.1600-0404.1987.tb03541.x; LONGSTRETH WT, 1985, STROKE, V16, P377, DOI 10.1161/01.STR.16.3.377; LONGSTRETH WT, 1992, STROKE, V23, P1242, DOI 10.1161/01.STR.23.9.1242; LONGSTRETH WT, 1993, NEUROLOGY, V43, P712, DOI 10.1212/WNL.43.4.712; MARSHALL JC, 1989, ENDOCRINOLOGOY, P1940; MASHCHAK CA, 1985, J REPROD MED, V30, P805; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; NELSON LM, 1994, EPIDEMIOLOGY, V5, P204, DOI 10.1097/00001648-199403000-00011; NELSON LM, 1990, EPIDEMIOL REV, V12, P71, DOI 10.1093/oxfordjournals.epirev.a036063; PETITTI DB, 1979, JAMA-J AM MED ASSOC, V242, P1150, DOI 10.1001/jama.242.11.1150; POULTER NR, 1991, ADV CONTRACEPTION S3, V7, P65; PRENTICE RL, 1987, ADV CANCER RES, V49, P285, DOI 10.1016/S0065-230X(08)60801-5; PRENTICE RL, 1988, AM J EPIDEMIOL, V127, P213, DOI 10.1093/oxfordjournals.aje.a114797; ROBINSON RW, 1977, NEW ENGL J MED, V86, P597; ROBISON LL, 1984, AM J EPIDEMIOL, V120, P164, DOI 10.1093/oxfordjournals.aje.a113866; SARREL PM, 1990, MATURITAS, V12, P287, DOI 10.1016/0378-5122(90)90008-T; SHAMMA F, 1992, Neurology, V42, P272; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STOBER T, 1985, J NEUROL, V232, P67, DOI 10.1007/BF00313903; THOROGOOD M, 1990, BRIT J FAMILY PLANNI, V0016; THOROGOOD M, 1992, AM J EPIDEMIOL, V136, P35, DOI 10.1093/oxfordjournals.aje.a116418; TORNER JC, 1984, SEMIN NEUROL, V4, P354, DOI 10.1055/s-2008-1041565; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; WALKER AM, 1988, AM J EPIDEMIOL, V127, P905, DOI 10.1093/oxfordjournals.aje.a114893; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025; WREN BG, 1992, MED J AUSTRALIA, V157, P204, DOI 10.5694/j.1326-5377.1992.tb137091.x; 1982, JAMA-J AM MED ASSOC, V247, P633	45	142	144	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1994	121	3					168	173		10.7326/0003-4819-121-3-199408010-00002	http://dx.doi.org/10.7326/0003-4819-121-3-199408010-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY338	8017743				2022-12-24	WOS:A1994NY33800002
J	FORD, JC; ALKHODAIRY, F; FOTOU, E; SHELDRICK, KS; GRIFFITHS, DJF; CARR, AM				FORD, JC; ALKHODAIRY, F; FOTOU, E; SHELDRICK, KS; GRIFFITHS, DJF; CARR, AM			14-3-3-PROTEIN HOMOLOGS REQUIRED FOR THE DNA-DAMAGE CHECKPOINT IN FISSION YEAST	SCIENCE			English	Article							SCHIZOSACCHAROMYCES-POMBE; KINASE-C; GENE; CLONING; REPLICATION; THIAMINE; MITOSIS; REPAIR; FAMILY	During the cell cycle, DNA is replicated and segregated equally into two daughter cells. The DNA damage checkpoint ensures that DNA damage is repaired before mitosis is attempted. Genetic studies of the fission yeast Schizosaccharomyces pombe have identified two genes, rad24 and rad25, that are required for this checkpoint. These genes encode 14-3-3 protein homologs that together provide a function that is essential for cell proliferation. In addition, S. pombe rad24 null mutants, and to a lesser extent rad25 null mutants, enter mitosis prematurely, which indicates that 14-3-3 proteins have a role in determining the timing of mitosis.	UNIV SUSSEX,MRC,CELL MUTAT UNIT,BRIGHTON BN1 9RR,ENGLAND	University of Sussex				Carr, Antony Michael/0000-0002-2028-2389				AITKEN A, 1990, NATURE, V344, P594; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; BARBET N, 1992, GENE, V114, P59, DOI 10.1016/0378-1119(92)90707-V; BARBET NC, 1993, NATURE, V364, P824, DOI 10.1038/364824a0; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; CARR AM, 1993, NUCLEIC ACIDS RES, V21, P1345, DOI 10.1093/nar/21.6.1345; ENOCH T, 1991, CELL, V65, P921, DOI 10.1016/0092-8674(91)90542-7; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; ISOBE T, 1992, FEBS LETT, V308, P121, DOI 10.1016/0014-5793(92)81257-M; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MURRAY JM, 1992, NUCLEIC ACIDS RES, V20, P2673, DOI 10.1093/nar/20.11.2673; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; SHELDRICK KS, 1993, BIOESSAYS, V15, P775, DOI 10.1002/bies.950151202; SHELDRICK KS, UNPUB; TODA T, 1993, EMBO J, V12, P1987, DOI 10.1002/j.1460-2075.1993.tb05848.x; VANHEUSDEN GPH, 1992, FEBS LETT, V302, P145, DOI 10.1016/0014-5793(92)80426-H; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; ZUPAN LA, 1992, J BIOL CHEM, V267, P8707	23	319	325	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 22	1994	265	5171					533	535		10.1126/science.8036497	http://dx.doi.org/10.1126/science.8036497			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	8036497				2022-12-24	WOS:A1994NY21600033
J	PEREIRA, L; LEVRAN, O; RAMIREZ, F; LYNCH, JR; SYKES, B; PYERITZ, RE; DIETZ, HC				PEREIRA, L; LEVRAN, O; RAMIREZ, F; LYNCH, JR; SYKES, B; PYERITZ, RE; DIETZ, HC			A MOLECULAR APPROACH TO THE STRATIFICATION OF CARDIOVASCULAR RISK IN FAMILIES WITH MARFANS-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONNECTIVE-TISSUE; FIBRILLIN GENES; MISSENSE MUTATION; CALCIUM-BINDING; SYNDROME LOCUS; CHROMOSOME-15; DIAGNOSIS; LINKAGE; DISORDER; SEQUENCE	Background. The fibrillin gene encodes a protein in the extracellular matrix, and this protein is widely distributed in elastic tissues. The fibrillin gene is the site of mutations causing Marfan's syndrome. This disorder shows a high degree of clinical variability both between and within families. Each family appears to have a unique mutation in the fibrillin gene, which precludes the routine use of mutation screening for presymptomatic diagnosis of the disorder. The goal of this study was to develop a widely applicable method of molecular diagnosis. Methods. We used three newly characterized intragenic sites of normal DNA repeat-sequence variation (i.e., polymorphisms) as markers to follow the inheritance pattern of specific copies (alleles) of the fibrillin gene in multiple kindreds with various clinical features of Marfan's syndrome. Results. The polymorphic markers allowed identification of the particular copy of the fibrillin gene that cosegregated with Marfan's syndrome in 13 of the 14 families tested. In 11 families a definite presymptomatic diagnosis of Marfan's syndrome could be made in family members who had only equivocal manifestations of the disorder. In two other families, some family members demonstrated either classic Marfan's syndrome or a milder but closely related phenotype. The copy of the fibrillin gene that cosegregated with classic Marfan's syndrome was not inherited by family members with the latter, atypical, form of the disease. These milder phenotypes, previously diagnosed as Marfan's syndrome, were not associated with aortic involvement. Conclusions, These results document the usefulness of novel polymorphic DNA repeat sequences in the presymptomatic diagnosis of Marfan's syndrome. Our findings also demonstrate that the various clinical phenotypes seen in selected families may be due not to single fibrillin mutations, but rather to different genetic alterations. These findings underscore the need for a modification of the current diagnostic criteria for Marfan's syndrome in order to achieve accurate risk assessment.	CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029; UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,HEADINGTON,OXON,ENGLAND; ALLEGHENY SINGER RES INST,DEPT HUMAN GENET,PITTSBURGH,PA 15212; JOHNS HOPKINS UNIV,SCH MED,DIV PEDIAT CARDIOL,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH MED,CTR MED GENET,BALTIMORE,MD 21205	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Oxford; Johns Hopkins University; Johns Hopkins University			Pyeritz, Reed/A-1364-2010; Pereira, Lygia V/C-1049-2012	Pereira, Lygia V/0000-0002-0002-725X	NCRR NIH HHS [RR-007722] Funding Source: Medline; NHLBI NIH HHS [HL-02815, HL-35877] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035877] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEIGHTON P, 1988, AM J MED GENET, V29, P581, DOI 10.1002/ajmg.1320290316; BOILEAU C, 1993, AM J HUM GENET, V53, P46; CLARK BA, 1991, NUCLEIC ACIDS RES, V19, P4309, DOI 10.1093/nar/19.15.4309; Dietz Harry C., 1992, Human Mutation, V1, P366, DOI 10.1002/humu.1380010504; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; DIETZ HC, 1992, J CLIN INVEST, V89, P1674, DOI 10.1172/JCI115766; DIETZ HC, 1991, GENOMICS, V9, P355, DOI 10.1016/0888-7543(91)90264-F; DIETZ HC, 1993, GENOMICS, V17, P468, DOI 10.1006/geno.1993.1349; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; GLESBY MJ, 1989, JAMA-J AM MED ASSOC, V262, P523, DOI 10.1001/jama.262.4.523; GODFREY M, 1993, AM J HUM GENET, V53, P472; GOTT VL, 1991, ANN THORAC SURG, V52, P38, DOI 10.1016/0003-4975(91)91414-Q; HEWETT DR, 1993, HUM MOL GENET, V2, P475, DOI 10.1093/hmg/2.4.475; KAINULAINEN K, 1992, P NATL ACAD SCI USA, V89, P5917, DOI 10.1073/pnas.89.13.5917; KAINULAINEN K, 1990, NEW ENGL J MED, V323, P935, DOI 10.1056/NEJM199010043231402; KAINULAINEN K, 1991, AM J HUM GENET, V49, P662; KUNKEL LM, 1977, P NATL ACAD SCI USA, V74, P1245, DOI 10.1073/pnas.74.3.1245; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MURDOCH JL, 1972, NEW ENGL J MED, V286, P804, DOI 10.1056/NEJM197204132861502; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; PYERITZ RE, 1979, NEW ENGL J MED, V300, P772, DOI 10.1056/NEJM197904053001406; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SARFARAZI M, 1992, J MED GENET, V29, P75, DOI 10.1136/jmg.29.2.75; SHORES J, 1994, NEW ENGL J MED, V330, P1335, DOI 10.1056/NEJM199405123301902; TSIPOURAS P, 1991, P NATL ACAD SCI USA, V88, P4486, DOI 10.1073/pnas.88.10.4486; TSIPOURAS P, 1992, NEW ENGL J MED, V326, P905, DOI 10.1056/NEJM199204023261401; ZAGURSKY RJ, 1985, GENE ANAL TECH, V2, P89, DOI 10.1016/0735-0651(85)90011-1; [No title captured]	30	100	106	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 21	1994	331	3					148	153		10.1056/NEJM199407213310302	http://dx.doi.org/10.1056/NEJM199407213310302			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW797	8008028	Bronze			2022-12-24	WOS:A1994NW79700002
J	WEI, N; CHAMOVITZ, DA; DENG, XW				WEI, N; CHAMOVITZ, DA; DENG, XW			ARABIDOPSIS COP9 IS A COMPONENT OF A NOVEL SIGNALING COMPLEX MEDIATING LIGHT CONTROL OF DEVELOPMENT	CELL			English	Article							GENE-EXPRESSION; REGULATED DEVELOPMENT; HYPOCOTYL ELONGATION; PROTEIN; PHYTOCHROME; MUTANTS; ENCODES	Environmental light signals are sensed by multiple families of photoreceptors and transduced by largely unknown mechanisms to regulate plant development. In this report, genetic analysis suggested that light signals perceived by both phytochromes and a blue light receptor converge to repress the action of Arabidopsis COP9 in suppressing seedling photomorphogenesis. Molecular cloning of the gene revealed that COP9 encodes a novel protein of 197 amino acids whose expression is not regulated by light. COP9 functions as a large (>560 kDa) complex(es) that is probably subjected to light modulation. In addition, COP8 and COP11 are required for either the COP9 complex formation or its stability. Therefore COP9, together with COP8 and COP11, defines a novel signaling step in mediating light control of plant development.			WEI, N (corresponding author), YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520, USA.		Chamovitz, Daniel/S-5021-2019; Deng, Xing Wang/ABF-4107-2020	Chamovitz, Daniel/0000-0002-2815-2909; 				AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; ANG LH, 1994, PLANT CELL, V6, P613, DOI 10.1105/tpc.6.5.613; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; CASTLE LA, 1994, PLANT CELL, V6, P25, DOI 10.1105/tpc.6.1.25; CHORY J, 1993, TRENDS GENET, V9, P167, DOI 10.1016/0168-9525(93)90163-C; CHORY J, 1992, DEVELOPMENT, V115, P337; DENG XW, 1994, CELL, V76, P423, DOI 10.1016/0092-8674(94)90107-4; DENG XW, 1992, CELL, V71, P791, DOI 10.1016/0092-8674(92)90555-Q; FURUYA M, 1993, ANNU REV PLANT PHYS, V44, P617, DOI 10.1146/annurev.pp.44.060193.003153; GLASS DB, 1986, J BIOL CHEM, V261, P2987; KAUFMAN LS, 1993, PLANT PHYSIOL, V102, P333, DOI 10.1104/pp.102.2.333; Kendrick RE, 1993, PHOTOMORPHOGENESIS P; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KOORNNEEF M, 1980, Z PFLANZENPHYSIOL, V100, P147, DOI 10.1016/S0044-328X(80)80208-X; LISCUM E, 1991, PLANT CELL, V3, P685, DOI 10.1105/tpc.3.7.685; MCNELLIS TW, 1994, PLANT CELL, V6, P487, DOI 10.1105/tpc.6.4.487; MISERA S, 1994, IN PRESS MOL GEN GEN; QUAIL PH, 1991, ANNU REV GENET, V25, P389, DOI 10.1146/annurev.ge.25.120191.002133; ROGERS SG, 1987, METHOD ENZYMOL, V153, P253; ROMERO LC, 1993, P NATL ACAD SCI USA, V90, P1465, DOI 10.1073/pnas.90.4.1465; SPREITZER RJ, 1993, ANNU REV PLANT PHYS, V44, P411, DOI 10.1146/annurev.pp.44.060193.002211; VIERSTRA RD, 1993, PLANT PHYSIOL, V103, P679, DOI 10.1104/pp.103.3.679; WEI N, 1992, PLANT CELL, V4, P1507, DOI 10.1105/tpc.4.12.1507; WEI N, 1994, PLANT CELL, V6, P629, DOI 10.1105/tpc.6.5.629; WHITELAM GC, 1993, PLANT CELL, V5, P757, DOI 10.1105/tpc.5.7.757	25	286	304	0	41	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 15	1994	78	1					117	124		10.1016/0092-8674(94)90578-9	http://dx.doi.org/10.1016/0092-8674(94)90578-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	8033203				2022-12-24	WOS:A1994NX32800014
J	FISHER, P; WARD, A				FISHER, P; WARD, A			MEDICINE IN EUROPE .8. COMPLEMENTARY MEDICINE IN EUROPE	BRITISH MEDICAL JOURNAL			English	Article							ALTERNATIVE MEDICINE; PRACTITIONERS	Complementary or unconventional treatments are used by many doctors and other therapists throughout Europe, The major forms are acupuncture, homoeopathy, manual therapy or manipulation, and phytotherapy or herbal medicine. The relative popularity of therapies differs between countries, but public demand is strong and growing. Regulation of practitioners varies widely: in most countries only registered health professionals may practice, but in the United Kingdom practice is virtually unregulated. Germany and some Scandinavian countries have intermediate systems. Legal reforms are in progress in the Netherlands and the United Kingdom. European institutions are starting to influence the development of complementary medicine. Harmonisation of training and regulation of practitioners is the challenge for the future.			FISHER, P (corresponding author), ROYAL LONDON HOMOEOPATH HOSP,GREAT ORMOND ST,LONDON WC1N 3HR,ENGLAND.							ANDERSON E, 1988, J R COLL GEN PRACT, V38, P511; BOUCHAYER F, 1991, COMPLEMENTARY MED EU; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; FULDER S, 1981, STATUS COMPLEMENTARY; FULDER SJ, 1985, LANCET, V2, P542; HALPERN S, 1985, HLTH SOCIAL SER 0606, P702; HUGGON T, 1990, J ALTERNATIVE CO JAN; KNIPSCHILD P, 1990, SOC SCI MED, V31, P625, DOI 10.1016/0277-9536(90)90099-E; MATTHIESSEN P, 1992, MATERIALIEN GESUNDHE, V21; PIETRONI PC, 1992, BRIT MED J, V305, P564, DOI 10.1136/bmj.305.6853.564; RASMUSSEN N, 1991, COMPLEMENTARY MED EU; REILLY DT, 1983, BRIT MED J, V287, P337, DOI 10.1136/bmj.287.6388.337; SERMEUS G, 1991, COMPLEMENTARY MED EU; SWAYNE JMD, 1989, J ROY COLL GEN PRACT, V39, P503; VANDIJK P, 1993, GENEWIJZEN NEDERLAND; VASKILAMPI T, 1991, COMPLEMENTARY MED EU; VISSER J, 1991, COMPLEMENTARY MED EU; WHARTON R, 1986, BRIT MED J, V292, P1498, DOI 10.1136/bmj.292.6534.1498; 1989, TIMES           1113; 1992, OFFICIAL J EURO 1013; 1992, DOCTOR          0716, P17; 1992, EEC MARKET HOMOEOPAT; 1989, REPORT ALTERNATIVE M; 1993, COMPLEMENTARY MED NE; 1993, HOMEOPATHIE 1993; 1993, COMPLEMENTARY THERAP; 1992, REGULATON PRACTITION	27	496	512	2	44	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 9	1994	309	6947					107	111		10.1136/bmj.309.6947.107	http://dx.doi.org/10.1136/bmj.309.6947.107			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW716	8038643	Green Published			2022-12-24	WOS:A1994NW71600028
J	CZEIZEL, AE; KODAJ, I; LENZ, W				CZEIZEL, AE; KODAJ, I; LENZ, W			SMOKING DURING PREGNANCY AND CONGENITAL LIMB DEFICIENCY	BRITISH MEDICAL JOURNAL			English	Article							MATCHED CASE-CONTROL; MULTIVARIATE-ANALYSIS; REDUCTION DEFECTS; HUNGARY; FAMILY	Objective-To examine genetic and environmental factors in the origin of isolated congenital limb deficiencies. Design-Case-control study with questionnaire at a family interview of cases of isolated congenital Limb deficiencies (six types), negative controls (matched for age, sex, and place of residence), and positive controls (cases of sentinel anomalies). Setting-The database of the Hungarian Congenital Abnormality Registry, 1975-84, complemented by three other sources of ascertainment (1 575 904 births). Subjects-537 case-control pairs; 392 positive controls. Main outcome measures-smoking during pregnancy, congenital limb deficiencies. Results-The adjusted rate of smoking during pregnancy was significantly higher in the mothers of cases of terminal transverse defect (relative odds 1.48; 95% confidence interval 0.98 to 2.23; P=0.017). This finding supports the hypothesis of vascular disruption as a cause of congenital limb deficiency. Conclusions-Maternal smoking during pregnancy raises the relative odds for terminal transverse limb deficiencies.	NATL INST HYG,DEPT HUMAN GENET & TERATOL,WHO,COLLABORATING CTR COMMUNITY CONTROL HEREDITARY DI,BUDAPEST,HUNGARY; STATE HOSP,DEPT OBSTET & GYNAECOL,BUDAPEST,HUNGARY; UNIV MUNSTER,INST HUMAN GENET,W-4400 MUNSTER,GERMANY	World Health Organization; University of Munster								ARO T, 1984, INT J EPIDEMIOL, V13, P459, DOI 10.1093/ije/13.4.459; ARO T, 1983, EARLY HUM DEV, V9, P49, DOI 10.1016/0378-3782(83)90101-9; BRESLOW NE, 1978, AM J EPIDEMIOL, V108, P299, DOI 10.1093/oxfordjournals.aje.a112623; CZEIZEL A, 1991, Acta Morphologica Hungarica, V39, P229; CZEIZEL A, 1989, MUTAT RES, V212, P3, DOI 10.1016/0027-5107(89)90017-1; CZEIZEL A, 1988, World Health Statistics Quarterly, V41, P219; CZEIZEL A, 1980, ACTA MORPHOL HUNG, V28, P177; CZEIZEL AE, 1993, J MED GENET, V30, P593, DOI 10.1136/jmg.30.7.593; CZEIZEL AE, 1993, TERATOLOGY, V48, P323, DOI 10.1002/tera.1420480405; CZEIZEL AE, 1993, AM J MED GENET, V46, P372, DOI 10.1002/ajmg.1320460406; CZEIZEL AE, 1993, AM J MED GENET, V46, P427, DOI 10.1002/ajmg.1320460416; CZEIZEL AE, 1993, CLIN GENET, V44, P32; CZEIZEL AE, 1992, ACTA MORPHOL HUNG, V40, P49; EVANS JA, 1994, IN PRESS AM J MED; FIRTH HV, 1991, LANCET, V337, P762, DOI 10.1016/0140-6736(91)91374-4; HARLOW SD, 1989, AM J EPIDEMIOL, V33, P159; HOLFORD TR, 1978, AM J EPIDEMIOL, V107, P245, DOI 10.1093/oxfordjournals.aje.a112531; HOYME HE, 1982, J PEDIATR-US, V101, P839, DOI 10.1016/S0022-3476(82)80343-0; KOBOR J, 1988, Orvosi Hetilap, V129, P21; KULLANDER S, 1971, ACTA OBSTET GYN SCAN, V50, P83, DOI 10.3109/00016347109157292; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LOWE CR, 1959, BRIT MED J, V2, P673, DOI 10.1136/bmj.2.5153.673; MACKENZIE SG, 1989, AM J EPIDEMIOL, V129, P65, DOI 10.1093/oxfordjournals.aje.a115125; MASTROIACOVO P, 1991, LANCET, V337, P1091, DOI 10.1016/0140-6736(91)91735-D; MENGES RW, 1970, ENVIRON RES, V3, P285, DOI 10.1016/0013-9351(70)90022-8; OAKLEY A, 1990, J BIOSOC SCI, V22, P477, DOI 10.1017/S0021932000018885; OLSEN J, 1988, SCAND J SOC MED, V16, P49, DOI 10.1177/140349488801600108; SHIONO PH, 1986, TERATOLOGY, V34, P65, DOI 10.1002/tera.1420340109	28	67	71	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 4	1994	308	6942					1473	1476		10.1136/bmj.308.6942.1473	http://dx.doi.org/10.1136/bmj.308.6942.1473			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NQ229	8019281	Green Published			2022-12-24	WOS:A1994NQ22900017
J	DOWNEY, GP; GABRIEL, G; DEERY, ARS; CROW, J; WALKER, PG				DOWNEY, GP; GABRIEL, G; DEERY, ARS; CROW, J; WALKER, PG			MANAGEMENT OF FEMALE PRISONERS WITH ABNORMAL CERVICAL CYTOLOGY	BRITISH MEDICAL JOURNAL			English	Article									ROYAL FREE HOSP,SCH MED,LONDON NW3 2QG,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School								LUESLEY DM, 1990, BRIT MED J, V300, P1690, DOI 10.1136/bmj.300.6741.1690; MOGHISSI KS, 1968, AM J OBSTET GYNECOL, V100, P607, DOI 10.1016/S0002-9378(15)33386-X; WILL M, 1970, Scottish Medical Journal, V15, P219	3	17	18	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 28	1994	308	6941					1412	1413		10.1136/bmj.308.6941.1412	http://dx.doi.org/10.1136/bmj.308.6941.1412			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP420	8019252	Green Published			2022-12-24	WOS:A1994NP42000017
